PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MALI, M; ANDTFOLK, H; MIETTINEN, HM; JALKANEN, M				MALI, M; ANDTFOLK, H; MIETTINEN, HM; JALKANEN, M			SUPPRESSION OF TUMOR-CELL GROWTH BY SYNDECAN-1 ECTODOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MAMMARY EPITHELIAL-CELLS; FIBROBLAST GROWTH; HEPARAN-SULFATE; CARCINOMA-CELLS; MOUSE SKIN; SURFACE; PROTEIN; EXPRESSION; ADHESION; BINDING	Syndecans are integral membrane proteoglycans characterized by the similarity of cytoplasmic and transmembrane domains of the core proteins. Syndecans may regulate cell behavior by participating in matrix recognition and growth factor binding. Using syndecan-1 deletion mutants, we show that the extracellular part of the molecule (ectodomain) can suppress malignant growth, stimulate actin polymerization, and induce epithelioid morphology in mouse mammary tumor Shionogi 115 (S115) cells. Free ectodomain isolated from the culture medium of either syndecan-1-transfected S115 cells or normal murine mammary gland (NMuMG) cells can suppress the growth of S115 tumor cells at nanomolar concentrations. The ectodomain of syndecan-1 inhibited also the growth of other carcinoma cell lines, such as CarB and MCF-7, but no such inhibition was observed for contact-inhibited cell lines, including MH 3T3 cells, NMuMG cells, and human HaCaT keratinocytes. Intact heparan sulfate structure of the ectodomain was required for the suppression because degradation of heparan sulfate chains completely abolished growth inhibition. These results suggest a tumor suppressor activity for the syndecan-1 ectodomain.	UNIV TURKU,CTR BIOTECHNOL,SF-20521 TURKU,FINLAND; UNIV TURKU,DEPT MED BIOCHEM,SF-20520 TURKU,FINLAND	University of Turku; University of Turku								AVIEZER D, 1994, J BIOL CHEM, V269, P114; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUCHMANN A, 1991, CANCER RES, V51, P4097; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; COUCHMAN JR, 1981, CANCER RES, V41, P263; INKI P, 1994, BRIT J CANCER, V70, P319, DOI 10.1038/bjc.1994.300; INKI P, 1991, AM J PATHOL, V139, P1333; INKI P, 1994, EUR J CELL BIOL, V63, P43; INKI P, 1994, J PATHOL, V172, P349, DOI 10.1002/path.1711720410; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KIRJAVAINEN J, 1993, MOL BIOL CELL, V4, P849, DOI 10.1091/mbc.4.8.849; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LEPPA S, 1991, CELL REGUL, V2, P1; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; MALI M, 1993, J BIOL CHEM, V268, P24215; MIETTINEN HM, 1994, J CELL SCI, V107, P1571; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SALMIVIRTA M, 1992, J BIOL CHEM, V267, P17606; SY MS, 1992, J EXP MED, V176, P623, DOI 10.1084/jem.176.2.623; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1992, J CELL SCI, V101, P277; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YATES J, 1981, CANCER RES, V41, P258; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	30	92	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27795	27798						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961703				2022-12-25	WOS:A1994PV77200004
J	TATSUMI, E; TAKAHASHI, N; HIROSE, M				TATSUMI, E; TAKAHASHI, N; HIROSE, M			DENATURED STATE OF OVALBUMIN IN HIGH-CONCENTRATIONS OF UREA AS EVALUATED BY DISULFIDE REARRANGEMENT ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; FOLDING PATHWAY; RIBONUCLEASE-A; HEN OVALBUMIN; CROSS-LINK; PROTEIN; BONDS; STABILITY; CLEAVAGE; LYSOZYME	To investigate the highly denatured state of ovalbumin (molecular mass of 42.7 kDa, four cysteine sulfhydryls and one cystine disulfide) using the disulfide rearrangement approach, we established the peptide-mapping procedure using a cysteine-labeling technique with a fluorescent dye that allows the quantitative analyses for the disulfide-involved half-cystines. Ovalbumin denatured at a low protein concentration in 8-10 M urea, in which the protein showed complete unfolding as evaluated by far-UV CD spectra, was analyzed for the disulfide-involved half cystines using the peptide-mapping procedure. Data clearly showed that the number of free sulfhydryls and intrachain disulfides were four and one, respectively, but that all six half-cystines are labeled with the dye. These results strongly suggested that 15 disulfide isomers that are theoretically possible for a molecule having one disulfide and four sulfhydryls are all generated during the denaturation. The quantitative data for the ratios of the observed labeling values for the six half-cystines, relative to the overall labeling values, were consistent with the view that the distribution of the 15 possible disulfide isomers at equilibrium depends on the number of amino acid residues separating the two half-cystines to the power of -1.9 to -2.0. Essentially, the same non-gaussian chain nature was also observed with kinetic data for sulfhydryl-disulfide exchanges after denaturation of native ovalbumin.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University				Hirose, Masaaki/0000-0003-2672-4384				AMIR D, 1988, BIOCHEMISTRY-US, V27, P8889, DOI 10.1021/bi00425a003; AMIR D, 1992, PROTEINS, V13, P162, DOI 10.1002/prot.340130210; AUNE KC, 1967, J BIOL CHEM, V242, P4486; BIERZYNSKI A, 1982, J MOL BIOL, V162, P173, DOI 10.1016/0022-2836(82)90167-X; CHAN HS, 1990, J CHEM PHYS, V92, P3118, DOI 10.1063/1.458605; CHAN HS, 1991, ANNU REV BIOPHYS BIO, V20, P447, DOI 10.1146/annurev.biophys.20.1.447; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; DARBY NJ, 1993, J MOL BIOL, V232, P873, DOI 10.1006/jmbi.1993.1437; GOTO Y, 1987, J BIOCHEM, V101, P319, DOI 10.1093/oxfordjournals.jbchem.a121916; GREENE RF, 1974, J BIOL CHEM, V249, P5388; Kauzmann W., 1959, SULFUR PROTEINS, P93; KITABATAKE N, 1988, AGR BIOL CHEM TOKYO, V52, P967; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SH, 1984, BIOCHEMISTRY-US, V23, P5504, DOI 10.1021/bi00318a019; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; NERI D, 1992, SCIENCE, V257, P1559, DOI 10.1126/science.1523410; NISBET AD, 1981, EUR J BIOCHEM, V115, P335, DOI 10.1111/j.1432-1033.1981.tb05243.x; PACE CN, 1988, J BIOL CHEM, V263, P11820; POLAND DC, 1965, BIOPOLYMERS, V3, P379, DOI 10.1002/bip.1965.360030404; SORENSEN SPL, 1915, COMPT REND TRAV LAB, V12, P12; TAKAHASHI N, 1990, ANAL BIOCHEM, V188, P359, DOI 10.1016/0003-2697(90)90621-F; TAKAHASHI N, 1992, J BIOL CHEM, V267, P11565; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; Tanford C., 1961, PHYS CHEM MACROMOLEC; THOMPSON EOP, 1978, AUST J BIOL SCI, V31, P433, DOI 10.1071/BI9780433; UEDA T, 1985, BIOCHEMISTRY-US, V24, P6316, DOI 10.1021/bi00343a042; Walsh KA, 1970, METHOD ENZYMOL, V19, P31, DOI DOI 10.1016/0076-6879(70)19005-7; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	29	22	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28062	28067						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961742				2022-12-25	WOS:A1994PV77200046
J	CORBO, L; LEROUX, F; SERGEANT, A				CORBO, L; LEROUX, F; SERGEANT, A			THE EBV EARLY GENE-PRODUCT EB2 TRANSFORMS RODENT CELLS THROUGH A SIGNALING PATHWAY INVOLVING C-MYC	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; LYMPHOCYTE GROWTH TRANSFORMATION; DNA-BINDING; MAX; PROTEINS; TRANSCRIPTION; EXPRESSION; SEQUENCE; ONCOGENE; REQUIRES	Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus associated with several neoplasia. We present evidence here that the protein EB2, an EBV posttranscriptional activator, has transforming properties not only when expressed in established cell lines such as Rat1 or NIH3T3 but also in primary rat fibroblasts (REF). EB2 transformation in Rat1 cells correlates with an increase in the steady-state level of the cellular oncogenic protein c-Myc, and cotransfection of a plasmid expressing Max suppresses the transformation. These results implicate c-Myc in EB2-mediated cell transformation and help define the pathway by which this EBV early protein causes transformation.			CORBO, L (corresponding author), ECOLE NORMALE SUPER LYON,INSERM,U412,UNITE VIROL HUMAINE,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.			Le Roux, Frederique/0000-0002-9112-6199				AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BAICHWALL VR, 1988, ONCOGENE, V2, P416; BILLAUD M, 1993, P NATL ACAD SCI USA, V90, P2739, DOI 10.1073/pnas.90.7.2739; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUISSON M, 1989, J VIROL, V63, P5276, DOI 10.1128/JVI.63.12.5276-5284.1989; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORBO L, 1993, EPSTEINBARR VIRUS AS, V225, P51; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; Hinnebusch A, 1993, CURR OPIN CELL BIOL, V5, P941, DOI 10.1016/0955-0674(93)90073-Y; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JOAB I, 1991, J INFECT DIS, V163, P53, DOI 10.1093/infdis/163.1.53; KAROMILAS AE, 1992, SCIENCE, V257, P1685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KENNEY S, 1989, J VIROL, V63, P3870, DOI 10.1128/JVI.63.9.3870-3877.1989; KIEFF E, 1990, VIROLOGY, P1889; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MANET E, 1989, EMBO J, V8, P1819, DOI 10.1002/j.1460-2075.1989.tb03576.x; MARCU KB, 1992, ANN REV BIOCH, V61, P808; MCLAUCHLAN J, 1992, J VIROL, V66, P6939, DOI 10.1128/JVI.66.12.6939-6945.1992; MIKAELIAN I, 1993, J VIROL, V67, P734; MILLER G, 1990, VIROLOGY, P1921; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PALLESEN G, 1991, J PATHOL, V165, P289, DOI 10.1002/path.1711650404; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PALLESEN G, 1991, BLOOD, V78, P1162; PHELAN A, 1993, P NATL ACAD SCI USA, V90, P9056, DOI 10.1073/pnas.90.19.9056; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SANDRIGOLDIN RM, 1992, GENE DEV, V6, P848, DOI 10.1101/gad.6.5.848; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHIC C, 1982, CELL, V29, P161; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SU IJ, 1991, BLOOD, V77, P799; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WONG KM, 1989, VIROLOGY, V168, P101, DOI 10.1016/0042-6822(89)90408-X; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; ZENG Y, 1982, INT J CANCER, V29, P193	47	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3299	3304						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936654				2022-12-25	WOS:A1994PM65800023
J	LELKES, PI; RAMOS, EM; CHICK, DM; LIU, JD; UNSWORTH, BR				LELKES, PI; RAMOS, EM; CHICK, DM; LIU, JD; UNSWORTH, BR			MICROGRAVITY DECREASES TYROSINE-HYDROXYLASE EXPRESSION IN RAT ADRENALS	FASEB JOURNAL			English	Article						SPACE BIOLOGY; CHROMAFFIN CELLS; CATECHOLAMINES; ADRENAL MEDULLA	DOPAMINE-BETA-HYDROXYLASE; REPEATED IMMOBILIZATION STRESS; MESSENGER-RNA LEVELS; PROTEIN-KINASE-C; MEDULLARY CELLS; SIGNAL-TRANSDUCTION; RESPONSE ELEMENT; GENE-EXPRESSION; FOS; TRANSCRIPTION	During spaceflight, alterations in blood and urinary catecholamine (CA) levels have been observed, yet the cellular/molecular mechanisms leading to these changes are not known. We used molecular, immunological, and biochemical approaches to analyze in situ the expression of catecholamine enzymes in adrenal medullary chromaffin cells of rats flown for 6 days on board Space Shuttle mission STS-54. Exposure to microgravity (10(-6) g) resulted in a 35% inhibition of both the expression and the specific activity of tyrosine hydroxylase (TH), the rate-limiting step in the cascade of CA synthesis. By contrast, the expression, specific activity, and immunoreactivity of other catecholamine-synthesizing enzymes, e.g., phenylethanolamine-N-methyl-transferase (PNMT), were not altered. The total tissue CA contents were reduced, concomitant with a decrease in the epinephrine:norepinephrine ratio. These results are in line with reports of other gravity-sensitive cellular effects and suggest that the inhibition of TH expression might be due to a direct effect of microgravity on PKC-dependent signal transduction pathways in chromaffin cells.	MARQUETTE UNIV,DEPT BIOL,MILWAUKEE,WI 53201	Marquette University	LELKES, PI (corresponding author), UNIV WISCONSIN,SCH MED,SINAI SAMARITAN MED CTR,DEPT MED,CELL BIOL LAB,MILWAUKEE CLIN CAMPUS,MILWAUKEE,WI 53201, USA.		Lelkes, Peter I/S-1751-2019; Lelkes, Peter/HGA-2907-2022					Ausubel F.M, 1992, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V2; BARUCHIN A, 1990, J NEUROCHEM, V54, P1769, DOI 10.1111/j.1471-4159.1990.tb01232.x; COGOLI A, 1993, J LEUKOCYTE BIOL, V53, P569, DOI 10.1002/jlb.53.5.569; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; DEGROOT RP, 1990, J CELL SCI, V97, P33; DEGROOT RP, 1991, AVIAT SPACE ENVIR MD, V62, P37; Ferre F, 1992, PCR Methods Appl, V2, P1; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; GRINDELAND R, 1987, AM J PHYSIOL, V252, pR209, DOI 10.1152/ajpregu.1987.252.2.R209; GRINDELAND RE, 1990, FASEB J, V4, P105, DOI 10.1096/fasebj.4.1.2295371; HOLLEY DC, 1991, AVIAT SPACE ENVIR MD, V62, P953; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; ILYIN EA, 1983, AVIAT SPACE ENVIR MD, V54, pS9; KEIL L, 1992, J APPL PHYSIOL, V73, pS166, DOI 10.1152/jappl.1992.73.2.S166; KELNER KL, 1985, NEUROCHEM INT, V7, P373, DOI 10.1016/0197-0186(85)90128-7; KILBOURNE EJ, 1991, J NEUROSCI METH, V40, P193, DOI 10.1016/0165-0270(91)90068-B; KIM KS, 1993, J BIOL CHEM, V268, P15689; LEACH CS, 1976, AVIAT SPACE ENVIR MD, V47, P402; LEVINE RA, 1984, ANAL BIOCHEM, V143, P205, DOI 10.1016/0003-2697(84)90577-3; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; MCMAHON A, 1992, J NEUROCHEM, V58, P2124, DOI 10.1111/j.1471-4159.1992.tb10954.x; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MERZEY M, 1989, NUCLEIC ACIDS RES, V17, P2125; MINER LL, 1992, J NEUROSCI RES, V33, P10, DOI 10.1002/jnr.490330103; NANKOVA B, 1993, J NEUROCHEM, V61, P776; POLLARD HB, 1979, ANAL BIOCHEM, V99, P281, DOI 10.1016/S0003-2697(79)80007-X; ROSENHECK K, 1987, STIMULUS SECRETION C; SCHMITT DA, 1993, J CELL SCI, V104, P805; STACHOWIAK MK, 1990, BRAIN RES, V510, P277, DOI 10.1016/0006-8993(90)91378-T; STACHOWIAK MK, 1990, ONCOGENE, V5, P69; STACHOWIAK MK, 1990, J BIOL CHEM, V265, P4694; TAKIYYUDDIN MA, 1993, HYPERTENSION, V21, P674, DOI 10.1161/01.HYP.21.5.674; TISCHLER ME, 1992, AM I AERONAUT AUSTRO, V92, P1; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WESSEL TC, 1992, MOL BRAIN RES, V15, P349, DOI 10.1016/0169-328X(92)90128-X; ZHU YS, 1993, MOL PHARMACOL, V44, P328; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	42	16	17	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1177	1182		10.1096/fasebj.8.14.7958625	http://dx.doi.org/10.1096/fasebj.8.14.7958625			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958625				2022-12-25	WOS:A1994PT12800014
J	PLUMMER, SJ; SANTIBANEZKOREF, M; KUROSAKI, T; LIAO, S; NOBLE, B; FAIN, PR; ANTONCULVER, H; CASEY, G				PLUMMER, SJ; SANTIBANEZKOREF, M; KUROSAKI, T; LIAO, S; NOBLE, B; FAIN, PR; ANTONCULVER, H; CASEY, G			A GERMLINE 2.35-KB DELETION OF P53 GENOMIC DNA CREATING A SPECIFIC LOSS OF THE OLIGOMERIZATION DOMAIN INHERITED IN A LI-FRAUMENI-SYNDROME FAMILY	ONCOGENE			English	Article							CANCER-PRONE FAMILY; MUTANT P53; BREAST-CANCER; WILD-TYPE; SPLICING MUTATION; SUPPRESSOR GENE; PROTEINS; BINDING; PHOSPHORYLATION; TRANSACTIVATION	The primary genetic cancer predisposing event in many Li-Fraumeni syndrome families is a germline mutation in the p53 gene. We describe an extended Li-Fraumeni family with a germline mutation in the p53 gene involving a deletion of exon 10. The mutation is a 2.35 kilobase intragenic deletion encompassing exon 10, which results in the specific loss of the entire p53 oligomerization domain. This mutation segregates with the cancer phenotype. A lymphoblastoid cell line developed from a mutation carrier shows accumulation of mutant p53 protein by immunoblotting. However, tumor tissues from two affected carriers are negative by immunohistochemical staining. A major structural alteration specifically involving the oligomerization domain of a germline p53 gene has not been previously described and occurs in a region rarely mutated in sporadic tumors. The oligomerization domain is dispensable for many wild-type p53 functions, including transactivation, sequence-specific DNA binding, and suppression of oncogenic transformation. However, the domain appears to be required for trancriptional repression, and DNA strand reassociation. The identification of this mutation in an LFS family may yield insights into the importance of the oligomerization domain for suppressor function of the p53 tumor suppressor gene.	CLEVELAND CLIN FDN,DEPT CANC BIOL,CLEVELAND,OH 44195; UNIV CALIF IRVINE,DEPT MED,PROGRAM EPIDEMIOL,IRVINE,CA 92717; UNIV UTAH,DEPT MED INFORMAT,SALT LAKE CITY,UT 84108	Cleveland Clinic Foundation; University of California System; University of California Irvine; Utah System of Higher Education; University of Utah					NCI NIH HHS [CA56554] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA056554] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADDISON C, 1990, ONCOGENE, V5, P423; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIRCH JM, 1994, CANCER RES, V54, P1298; BODNER SM, 1992, ONCOGENE, V7, P743; BORRESEN AL, 1992, CANCER RES, V52, P3234; BRAIN R, 1994, ONCOGENE, V9, P1775; BRUGIERES L, 1993, CANCER RES, V53, P452; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELIX CA, 1993, ONCOGENE, V8, P1203; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; GARBER JE, 1991, CANCER RES, V51, P6094; HAINAUT P, 1994, ONCOGENE, V9, P299; HARLOW E, 1988, ANTIBODIES LABORATOR; HORIO Y, 1994, ONCOGENE, V9, P1231; JOLLY KW, 1994, ONCOGENE, V9, P97; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEGROS Y, 1994, ONCOGENE, V9, P2071; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1993, CANCER GENET CYTOGEN, V66, P83, DOI 10.1016/0165-4608(93)90233-C; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MAZOYER S, 1994, ONCOGENE, V9, P1237; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; Reed Michael, 1993, Gene Expression, V3, P95; SAMESHIMA Y, 1992, J NATL CANCER I, V48, P5358; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; TARUNINA M, 1993, ONCOGENE, V8, P3165; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839	50	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3273	3280						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936651				2022-12-25	WOS:A1994PM65800020
J	FREIMARK, BD; FEESER, WS; ROSENFELD, SA				FREIMARK, BD; FEESER, WS; ROSENFELD, SA			MULTIPLE SITES OF THE PROPEPTIDE REGION OF HUMAN STROMELYSIN-1 ARE REQUIRED FOR MAINTAINING A LATENT FORM OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; HUMAN MATRIX METALLOPROTEINASE-3; RHEUMATOID SYNOVIAL FIBROBLASTS; CYSTEINE SWITCH; DIFFERENTIAL EXPRESSION; SCANNING MUTAGENESIS; CATALYTIC DOMAIN; INSULIN-RECEPTOR; TYROSINE KINASE; BETA-SUBUNIT	Latency of matrix metalloproteinase 3 (MMP-3) is regulated by the interaction of a free cysteine residue (Cys-75) in the conserved amino acid sequence Pro-Arg-Cys-Gly-Val-Pro-Asp located in the COOH-terminal portion of the propeptide with a chelated zinc atom in the active site of the catalytic domain, Proteolytic activation of full-length human pro-MMP-3 involves the removal of similar to 35 amino acids hom the NH2-terminal portion of the propeptide, forming a 53-kDa unstable intermediate that undergoes intermolecular autocatalysis to form the 45-kDa mature active enzyme. In this study, we have evaluated the contribution of the NH2-terminal 35 amino acids to the maintenance of latency. Full-length human pro-MMP-3 was expressed in Escherichia coli and refolded to form latent pro-MMP-3 capable of activation by chymotrypsin or aminophenylmercuric acetate. Renaturation of pro-MMP-3 expressed in bacteria with 20 or more amino acids removed from the NH2-terminal region of the propeptide yielded only an active enzyme. COS-7 cells transiently transfected with pro-MMP-3 expression vectors containing the single amino acid substitutions Y20A, L21A, and C75S also secreted active forms of the enzyme. These data suggest that simultaneous interactions of the NH2- and COOH-terminal regions of the propeptide are required for maintenance of the latent form of the enzyme.	DUPONT MERCK PHARMACEUT CO,DEPT INFLAMMATORY DIS RES,WILMINGTON,DE 19880; DUPONT MERCK PHARMACEUT CO,DEPT APPL BIOTECHNOL,WILMINGTON,DE 19880	DuPont; DuPont								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BUCHNER J, 1992, ANAL BIOCHEM, V205, P264; CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KNAUPER V, 1990, EUR J BIOCHEM, V189, P295, DOI 10.1111/j.1432-1033.1990.tb15489.x; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MARTELPELLETIER J, 1984, ARTHRITIS RHEUM, V27, P305, DOI 10.1002/art.1780270310; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; Nagase H, 1992, Matrix Suppl, V1, P421; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OKADA Y, 1986, J BIOL CHEM, V261, P14245; PARK AJ, 1991, J BIOL CHEM, V266, P1584; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; ROSENFELD SA, 1994, GENE, V139, P281, DOI 10.1016/0378-1119(94)90770-6; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1988, J BIOL CHEM, V263, P6742; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	49	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26982	26987						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929438				2022-12-25	WOS:A1994PQ93100061
J	GOULD, GW; JESS, TJ; ANDREWS, GC; HERBST, JJ; PLEVIN, RJ; GIBBS, EM				GOULD, GW; JESS, TJ; ANDREWS, GC; HERBST, JJ; PLEVIN, RJ; GIBBS, EM			EVIDENCE FOR A ROLE OF PHOSPHATIDYLINOSITOL 3-KINASE IN THE REGULATION OF GLUCOSE-TRANSPORT IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE CASCADE; SUBSTRATE SPECIFICITIES; GENE-EXPRESSION; SUGAR-TRANSPORT; GROWTH-FACTORS; MESSENGER-RNA; INSULIN; FIBROBLASTS; INVITRO; TRANSFORMATION	We have used two experimental approaches to examine the possible role of phosphatidylinositol 3-kinase (PI 3-kinase) in the regulation of glucose transport in oocytes isolated from Xenopus laevis. Incubation of oocytes with the PI 3-kinase inhibitor wortmannin inhibited insulin-like growth factor-1-stimulated deoxyglucose uptake. Half-maximal inhibition was observed at concentrations similar to 20 nM. Conversely, we also examined the effects of microinjection of synthetic peptides designed to interact with Src homology 2 domains of the regulatory subunit of PI 3-kinase on deoxyglucose transport in oocytes. We show that a bifunctional synthetic peptide containing two YMXM consensus sequences for binding to SH2 domains stimulated both PI 3-kinase activity and deoxyglucose transport when both tyrosine residues were phosphorylated. However, non-phosphorylated or bisphosphonotyrosine peptides with the identical amino acid sequence failed to stimulate transport or PI 3-kinase activity. Taken together, these data argue strongly for a role for PI 3-kinase in the regulation of glucose transport in oocytes.	PFIZER INC,CENT RES,GROTON,CT 06340; UNIV STRATHCLYDE,DEPT PHYSIOL & PHARMACOL,GLASGOW G1 1XW,LANARK,SCOTLAND	Pfizer; University of Strathclyde	GOULD, GW (corresponding author), UNIV GLASGOW,DEPT BIOCHEM,GLASGOW G12 8QQ,LANARK,SCOTLAND.		Gould, Gwyn/AAF-6721-2019	Gould, Gwyn/0000-0001-6571-2875	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHN NG, 1991, J BIOL CHEM, V266, P4220; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLVILLE CA, 1993, BIOCHEM J, V290, P701, DOI 10.1042/bj2900701; COLVILLE CA, 1993, MEMBRANE PROTEIN EXP, P243; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HAINAUT P, 1991, CELL REGUL, V2, P317, DOI 10.1091/mbc.2.4.317; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; HIRAKI Y, 1989, P NATL ACAD SCI USA, V86, P8252, DOI 10.1073/pnas.86.21.8252; JANICOT M, 1989, P NATL ACAD SCI USA, V86, P2642, DOI 10.1073/pnas.86.8.2642; JIMENEZDEASUA L, 1974, NATURE, V251, P624, DOI 10.1038/251624a0; KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548; KITAGAWA T, 1989, BIOCHIM BIOPHYS ACTA, V980, P100, DOI 10.1016/0005-2736(89)90205-8; KLETZIEN RF, 1974, J BIOL CHEM, V249, P3366; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KRUPKA RM, 1971, BIOCHEMISTRY-US, V10, P1143, DOI 10.1021/bi00783a007; LAMPHERE M, 1993, AM J PHYSIOL, V266, pE486; MERRALL NW, 1993, BIOCHEM J, V295, P351, DOI 10.1042/bj2950351; OKADA T, 1994, J BIOL CHEM, V269, P3563; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; ROLLINS BJ, 1988, J BIOL CHEM, V263, P16523; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P8622; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SKOLNIK EY, 1993, EMBO J, V12, P1937; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS G, 1992, CELL, V68, P1; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WHITE MF, 1994, J BIOL CHEM, V269, P1	35	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26622	26625						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929393				2022-12-25	WOS:A1994PQ93100009
J	HIASA, H; MARIANS, KJ				HIASA, H; MARIANS, KJ			TUS PREVENTS OVERREPLICATION OF ORIC PLASMID DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; REPLICATION FORK MOVEMENT; EXHIBIT POLAR INHIBITION; TERMINUS REGION; PBR322 DNA; BINDING-PROTEIN; TERMINATION SITES; BACILLUS-SUBTILIS; ANTIGEN HELICASE; TOPOISOMERASE-IV	Minichromosome plasmid DNA templates containing oriC and two Ter sites, oriented as they are on the Escherichia coli chromosome, have been used to study the role of Tus in termination of bidirectional replication. In replication reactions reconstituted with purified proteins where it could be demonstrated that each active template was replicating bidirectionally, Tus was required to prevent extensive overreplication. In the presence of Tus, both replication forks terminated DNA synthesis at one or the other Ter site in an apparent stepwise manner. First, the progress of one replication fork was arrested by a properly oriented Tus-Ter complex. Then, either because of steric hindrance resulting from the stalled replication machinery of the first fork or because of the formation of a branched DNA structure, the progression of the second opposing fork was halted at the same site on the DNA template. In the absence of Tus, overreplication required DNA ligase and arose via a template strand-switching mechanism. Thus, the role of Tus in E. coli is more likely to prevent overreplication rather than to ensure accurate termination.			HIASA, H (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM34558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN AA, 1992, J BIOL CHEM, V267, P18612; ASAI T, 1990, EMBO J, V9, P4065, DOI 10.1002/j.1460-2075.1990.tb07628.x; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BIRD RE, 1972, J MOL BIOL, V70, P549, DOI 10.1016/0022-2836(72)90559-1; BOHK JJ, 1983, GENE, V24, P265; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; DEMASSY B, 1987, P NATL ACAD SCI USA, V84, P1759; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIASA H, 1994, J BIOL CHEM, V269, P2093; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HIDAKA M, 1991, J BACTERIOL, V173, P391, DOI 10.1128/jb.173.1.391-393.1991; HILL TM, 1987, P NATL ACAD SCI USA, V84, P1754, DOI 10.1073/pnas.84.7.1754; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HORIUCHI T, 1988, CELL, V54, P515, DOI 10.1016/0092-8674(88)90073-6; KAGUNI JM, 1982, NATURE, V296, P623, DOI 10.1038/296623a0; KHARTRI GS, 1989, CELL, V59, P667; KOBAYASHI T, 1989, EMBO J, V8, P2435, DOI 10.1002/j.1460-2075.1989.tb08374.x; Kornberg A., 1992, DNA REPLICATION, P524; KUEMPEL PL, 1977, P NATL ACAD SCI USA, V74, P3927, DOI 10.1073/pnas.74.9.3927; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LOUARN J, 1979, MOL GEN GENET, V172, P7, DOI 10.1007/BF00276208; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P2304; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PELLETIER AJ, 1989, J BACTERIOL, V171, P1739, DOI 10.1128/jb.171.3.1739-1741.1989; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1993, J BIOL CHEM, V268, P24481; PRESCOTT DM, 1972, P NATL ACAD SCI USA, V69, P2842, DOI 10.1073/pnas.69.10.2842; ROECKLEIN B, 1991, RES MICROBIOL, V142, P169, DOI 10.1016/0923-2508(91)90026-7; SHARMA B, 1992, J BACTERIOL, V174, P7854, DOI 10.1128/JB.174.23.7854-7858.1992; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WEISS AS, 1984, CELL, V39, P683, DOI 10.1016/0092-8674(84)90475-6; WU CA, 1992, J BIOL CHEM, V267, P4030	43	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26959	26968						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929435				2022-12-25	WOS:A1994PQ93100058
J	SCHULTZCHERRY, S; LAWLER, J; MURPHYULLRICH, JE				SCHULTZCHERRY, S; LAWLER, J; MURPHYULLRICH, JE			THE TYPE-1 REPEATS OF THROMBOSPONDIN-1 ACTIVATE LATENT TRANSFORMING GROWTH-FACTOR-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL THROMBOSPONDIN; HEPARIN-BINDING PEPTIDES; PLATELET THROMBOSPONDIN; I REPEATS; MONOCLONAL-ANTIBODIES; COMPLEX-FORMATION; ADHESION; PROTEINS; FIBRONECTIN; PROPERDIN	Thrombospondin (TSP) is complexed with transforming growth factor-beta (TGF-beta) in the alpha-granules of stimulated platelets. TSP stripped of associated TGF-beta activity (sTSP) activates latent TGF-beta secreted by bovine aortic endothelial cells (BAE) in culture. To better understand the interactions of TSP with TGF-beta, we investigated which region of sTSP interacts with TGF-beta. The chymotrypsin-resistant core of TSP, which contains the procollagen-like region and the properdin-like type 1 repeats, activated both latent TGF-beta secreted by BAE and a recombinant form of the small latent TGF-beta complex at levels similar to or better than sTSP. The core fragment bound I-125-TGF-beta in solution and shifted the elution profile of I-125-TGF-beta in gel permeation chromatography. Fusion constructs of the type 1, 2, and 3 repeats and the COOH terminus of TSP1 were tested for their ability to activate latent TGF-beta. Only the type 1 construct, containing the three properdin-like repeats of TSP found in the 50-kDa fragment, activated latent TGF-beta. In addition, a polyclonal antibody against the type 1 construct inhibits activation of latent TGF-beta by intact TSP, suggesting that this region is exposed in the intact molecule. These results show that the type 1 properdin-like repeats of TSP are responsible for activating recombinant and endothelial cell-derived latent TGF-beta and that this site is exposed in intact TSP.	UNIV ALABAMA,DEPT PATHOL,DIV CELLULAR & MOLEC PATHOL,BIRMINGHAM,AL 35294; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	University of Alabama System; University of Alabama Birmingham; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Schultz-Cherry, Stacey/N-2506-2018; Lawler, Jack/AAJ-1379-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050061, R01HL044575, R01HL028749] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44575, HL50061, HL28749] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLENHOFFMANN BL, 1988, MOL CELL BIOL, V8, P4234, DOI 10.1128/MCB.8.10.4234; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CATIMEL B, 1992, BIOCHEM J, V284, P231, DOI 10.1042/bj2840231; DARDIK R, 1989, EUR J BIOCHEM, V185, P581, DOI 10.1111/j.1432-1033.1989.tb15153.x; DARDIK R, 1991, BIOCHEMISTRY-US, V30, P9378, DOI 10.1021/bi00102a035; DEPOLI P, 1989, BLOOD, V73, P976; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HAVERSTICK DM, 1984, BIOCHEMISTRY-US, V23, P5597, DOI 10.1021/bi00318a033; KLAR A, 1992, CELL, V61, P1051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1983, J BIOL CHEM, V258, P2098; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEGRAND C, 1992, BLOOD, V79, P1995; LEUNG LLK, 1982, J CLIN INVEST, V70, P542, DOI 10.1172/JCI110646; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MOORADIAN DL, 1989, J CELL BIOCHEM, V41, P189, DOI 10.1002/jcb.240410404; MOSHER DF, 1990, ANNU REV MED, V41, P85; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; PHAN SH, 1989, BIOCHEM BIOPH RES CO, V163, P56, DOI 10.1016/0006-291X(89)92098-6; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SIPES JM, 1993, J CELL BIOL, V121, P469, DOI 10.1083/jcb.121.2.469; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; VOGEL T, 1993, J CELL BIOCHEM, V53, P1; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214	51	190	205	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26783	26788						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929414				2022-12-25	WOS:A1994PQ93100033
J	WOODFORD, KJ; HOWELL, RM; USDIN, K				WOODFORD, KJ; HOWELL, RM; USDIN, K			A NOVEL K+-DEPENDENT DNA-SYNTHESIS ARREST SITE IN A COMMONLY OCCURRING SEQUENCE MOTIF IN EUKARYOTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; REVERSE-TRANSCRIPTASE; REPLICATION INVITRO; INTERNAL REGIONS; POLYMERASE-ALPHA; STRAND TRANSFER; INSULIN GENE; AMPLIFICATION; COMPONENTS; TEMPLATES	We have found that a strong DNA synthesis arrest site forms in the chicken beta-globin promoter in vitro under physiological conditions. The arrest site is located in a G + C-rich region in which the guanines are located predominately on the top strand and the pyrimidines on the bottom strand. This region is non-palindromic and has no mirror symmetry. Arrest of DNA synthesis is only observed when the G-rich strand of the promoter is used as the template, and shows an absolute requirement for K+. The sequence G(16)CG(GGT)(3) is necessary and sufficient to arrest DNA synthesis. This arrest is template concentration independent and is eliminated by blocking the N7 positions of the last 4 guanine residues in the arrest site. These observations suggest that the basis of the block to chain extension is the formation of an unusual tetraplex-like structure by the template strand. Sequences able to form intrastrand tetraplexes are ubiquitous in eukaryotes. We show that known intrastrand tetraplex-forming sequences arrest DNA synthesis in vitro, suggesting that this may be a general property of DNA tetraplexes. We suggest that the arrest of DNA synthesis by some of these structures may account for some of the high frequency of recombination associated with these loci, perhaps by promoting strand slippage or providing an opportunity for strand exchange.	NIDDKD, GENOM STRUCT & FUNCT SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BARAN N, 1987, MOL CELL BIOL, V7, P2636, DOI 10.1128/MCB.7.7.2636; BELTRAN R, 1993, J MOL BIOL, V230, P966, DOI 10.1006/jmbi.1993.1213; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; Boynton A. L., 1982, IONS CELL PROLIFERAT; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; BUISER RG, 1993, BIOCHIM BIOPHYS ACTA, V1216, P20, DOI 10.1016/0167-4781(93)90033-A; DAY LE, 1981, BIOCHEMISTRY-US, V20, P2091, DOI 10.1021/bi00511a005; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DOLNICK BJ, 1979, J CELL BIOL, V83, P394, DOI 10.1083/jcb.83.2.394; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; GERMINO J, 1981, CELL, V23, P681, DOI 10.1016/0092-8674(81)90431-1; GIOVANNANGELI C, 1993, P NATL ACAD SCI USA, V90, P10013, DOI 10.1073/pnas.90.21.10013; HAMMONDKOSACK MCU, 1993, J MOL ENDOCRINOL, V10, P121, DOI 10.1677/jme.0.0100121; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HOFFMANN JS, 1993, CANCER RES, V53, P2895; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHWI Y, 1989, NUCLEIC ACIDS RES, V17, P4493, DOI 10.1093/nar/17.12.4493; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; LAPIDOT A, 1989, NUCLEIC ACIDS RES, V17, P883, DOI 10.1093/nar/17.3.883; LAU YT, 1988, SCIENCE, V240, P1321, DOI 10.1126/science.3375816; LING GN, 1984, SEARCH PHYSICAL BASI; NICKOL JM, 1983, CELL, V35, P467, DOI 10.1016/0092-8674(83)90180-0; OWERBACH D, 1993, DIABETES, V42, P1708, DOI 10.2337/diabetes.42.12.1708; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PAPANICOLAOU C, 1991, J MOL BIOL, V221, P805, DOI 10.1016/0022-2836(91)80177-V; PATHAK VK, 1992, J VIROL, V66, P3093, DOI 10.1128/JVI.66.5.3093-3100.1992; RAO BS, 1988, NUCLEIC ACIDS RES, V16, P8077, DOI 10.1093/nar/16.16.8077; SCHEIN CH, 1990, BIO-TECHNOL, V8, P308, DOI 10.1038/nbt0490-308; SCHIMKE RT, 1979, COLD SPRING HARB SYM, V43, P1297, DOI 10.1101/SQB.1979.043.01.148; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; SCHIMKE RT, 1977, COLD SPRING HARB SYM, V42, P649, DOI 10.1101/SQB.1978.042.01.067; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TAPPER DP, 1980, CELL, V22, P97, DOI 10.1016/0092-8674(80)90158-0; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; WEAVER DT, 1984, J MOL BIOL, V180, P961, DOI 10.1016/0022-2836(84)90266-3	39	87	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27029	27035						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929444				2022-12-25	WOS:A1994PQ93100067
J	JOST, CR; KURUCZ, I; JACOBUS, CM; TITUS, JA; GEORGE, AJT; SEGAL, DM				JOST, CR; KURUCZ, I; JACOBUS, CM; TITUS, JA; GEORGE, AJT; SEGAL, DM			MAMMALIAN EXPRESSION AND SECRETION OF FUNCTIONAL SINGLE-CHAIN FV MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTORS; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; LIGHT-CHAINS; GLYCOSYLATION SITES; VARIABLE PORTIONS; DISULFIDE BOND; PROTEIN; IMMUNOGLOBULIN	Single chain Fv (sFv) proteins are genetically engineered molecules that consist of the two variable domains of an antibody connected by a polypeptide linker; they contain the antigen binding function of the parental protein in a single 30-kDa polypeptide chain. sFvs are usually produced in bacteria where they are insoluble and therefore require extensive refolding in vitro. In this report we followed the processing of three antibody sFvs (145-2C11 directed against murine CD3 epsilon chain, OKT9 against the human transferrin receptor, and U7.6 against dinitrophenyl groups) by transfected mammalian (COS-7) cells to determine whether the mammalian protein folding machinery can produce and secrete active sFv with high efficiency. The sFvs contained an immunoglobulin light chain leader sequence, which directed them to the endoplasmic reticulum and allowed secretion into the medium. We found that the sFvs were secreted at different rates, with the rate-limiting step of secretion being their exit from the endoplasmic reticulum. We increased the secretion rate of one of the sFvs by introducing an asparagine-linked glycosylation site in FR1 of the heavy chain, and by using tunicamycin (an inhibitor of glycosylation) we found that glycosylated antibody sFvs were secreted faster than their nonglycosylated counterparts. All secreted sFvs specifically bound their antigens; where tested, at least 90% of the secreted sFv was functional. Therefore, mammalian cells can effectively fold and secrete sFv antibody and can provide a convenient system for testing and producing sFv proteins.	NCI, EXPTL IMMUNOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				George, Andrew/0000-0002-2866-0241				BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CO MS, 1993, MOL IMMUNOL, V30, P1361; DAVIS LG, 1986, BASIC METHODS MOL BI, P286; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GEORGE AJT, 1994, J IMMUNOL, V152, P1802; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GODING JW, 1981, J IMMUNOL, V127, P1256; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HOCHMAN J, 1976, BIOCHEMISTRY-US, V15, P2706, DOI 10.1021/bi00657a034; HOCHMAN J, 1973, BIOCHEMISTRY-US, V12, P1130, DOI 10.1021/bi00730a018; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HOLLAND IB, 1990, METHOD ENZYMOL, V182, P132; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Huston J S, 1993, Int Rev Immunol, V10, P195, DOI 10.3109/08830189309061696; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; HUSTON JS, 1991, METHOD ENZYMOL, V203, P46; HWU P, 1993, J EXP MED, V178, P361, DOI 10.1084/jem.178.1.361; INBAR D, 1972, P NATL ACAD SCI USA, V69, P2659, DOI 10.1073/pnas.69.9.2659; JOHNSON S, 1991, METHOD ENZYMOL, V203, P88; KEARSE KP, 1994, J IMMUNOL METHODS, V167, P75, DOI 10.1016/0022-1759(94)90076-0; KNAPPIK A, 1993, BIO-TECHNOL, V11, P77, DOI 10.1038/nbt0193-77; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MELNICK J, 1992, J BIOL CHEM, V267, P21303; NICHOLLS PJ, 1993, J IMMUNOL METHODS, V165, P81, DOI 10.1016/0022-1759(93)90109-K; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SEGAL DM, 1987, METHOD ENZYMOL, V150, P478; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; STANCOVSKI I, 1993, J IMMUNOL, V151, P6577; TARENTINO AL, 1974, J BIOL CHEM, V249, P818; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	42	54	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26267	26273						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929344				2022-12-25	WOS:A1994PQ93000052
J	WAYMAN, GA; IMPEY, S; WU, ZL; KINDSVOGEL, W; PRICHARD, L; STORM, DR				WAYMAN, GA; IMPEY, S; WU, ZL; KINDSVOGEL, W; PRICHARD, L; STORM, DR			SYNERGISTIC ACTIVATION OF THE TYPE-I ADENYLYL-CYCLASE BY CA2+ AND G(S)-COUPLED RECEPTORS IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONAL-STIMULATION; WHOLE CELLS; CALMODULIN; CALCIUM; DOPAMINE; BRAIN; EXPRESSION; RUTABAGA; MEMORY; MUTANT	The type I adenylyl cyclase is directly stimulated by Ca2+ and calmodulin in vivo (Choi, E. J., Wong, S. T., Hinds, T. R. and Storm, D. R. (1992) J. Biol. Chem. 267, 12440-12442; Wu, Z., Wong, S. T., and Storm, D. R. (1993) J. Biol. Chem. 268, 23766-23768). In this study, we examined the sensitivity of the type I adenylyl cyclase expressed in HEK-293 cells to beta-adrenergic agonists or glucagon when intracellular Ca2+ was elevated by Ca2+ ionophore or carbachol. Although previous studies have shown that this enzyme can be directly stimulated by activated G(s) in vitro, we demonstrate that it is not stimulated by G(s)-coupled receptors in vivo. However, the enzyme was stimulated by G(s)-coupled receptors in vivo when it was activated by intracellular Ca2+. For example, the Ca2+ ionophore A23187 stimulated the enzyme 3 +/- 0.5-fold (n = 9) and isoproterenol alone did not stimulate the enzyme, but the combination of the two stimulated type I adenylyl cyclase 13 +/- 2-fold (n = 9) in vivo. Similarly, 500 nM glucagon alone did not stimulate the enzyme but the combination of A23187 and glucagon activated the enzyme 90 +/- 8-fold (n = 4). Synergistic stimulation of type I adenylyl cyclase activity was also obtained with combinations of carbachol and isoproterenol or glucagon. This phenomenon was not observed with a mutant enzyme that is insensitive to Ca2+ and calmodulin, suggesting that conformational changes caused by binding of calmodulin to the type I adenylyl cyclase enhance binding or coupling to activated G(s). These data illustrate that this adenylyl cyclase can couple Ca2+ and neurotransmitter signals to generate optimal cAMP levels, a property of the enzyme that may be important for its role in learning and memory in mammals.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; ZYMOGENET INC,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Zymogenet Inc.					NINDS NIH HHS [NS 20498] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020498] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; DUDAI Y, 1985, J NEUROCHEM, V45, P355, DOI 10.1111/j.1471-4159.1985.tb03996.x; DUDAI Y, 1984, NEUROSCI LETT, V47, P19; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GNEGY M, 1981, MOL PHARMACOL, V19, P256; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HARRISON JK, 1988, J NEUROCHEM, V51, P345, DOI 10.1111/j.1471-4159.1988.tb01045.x; HARRISON JK, 1989, J BIOL CHEM, V264, P15880; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1985, P NATL ACAD SCI USA, V82, P5992, DOI 10.1073/pnas.82.17.5992; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MASURE HR, 1984, BIOCHEM J, V218, P691, DOI 10.1042/bj2180691; NATSUKARI N, 1990, BRAIN RES, V534, P170, DOI 10.1016/0006-8993(90)90126-V; PIASCIK MT, 1981, MOL PHARMACOL, V20, P319; PYNE NJ, 1989, FEBS LETT, V243, P77, DOI 10.1016/0014-5793(89)81221-9; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SALTER RS, 1981, J BIOL CHEM, V256, P9830; SANO M, 1985, BRAIN RES, V345, P337, DOI 10.1016/0006-8993(85)91012-1; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TOSCANO WA, 1979, P NATL ACAD SCI USA, V76, P5582, DOI 10.1073/pnas.76.11.5582; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU ZL, 1993, J BIOL CHEM, V268, P23766; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P; YOVELL Y, 1992, P NATL ACAD SCI USA, V89, P6526, DOI 10.1073/pnas.89.14.6526	38	106	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25400	25405						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929237				2022-12-25	WOS:A1994PQ49100029
J	WILSON, DM; DEUTSCH, WA; KELLEY, MR				WILSON, DM; DEUTSCH, WA; KELLEY, MR			DROSOPHILA RIBOSOMAL-PROTEIN S3 CONTAINS AN ACTIVITY THAT CLEAVES DNA AT APURINIC APYRIMIDINIC SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; APURINIC ENDONUCLEASE; XERODERMA-PIGMENTOSUM; PYRIMIDINE DIMERS; REPAIR; GENE; CDNA; EXPRESSION; CLONING	A rat cDNA-encoding ribosomal protein S3 was used to clone the S3 homolog in Drosophila melanogaster. The Drosophila gene was in turn used to construct fusions between S3 and glutathione S-transferase that were overexpressed in Escherichia coli, purified on affinity columns, and subsequently used for antibody production and biochemical analysis. Antibody specific for S3 was originally tested to determine the subcellular location of S3 by Western (immunoblot) analysis. As expected, the S3 antigen was found associated with purified preparations of ribosomes, but notably the protein was also observed in the nucleus where it was found to be tightly associated with the nuclear matrix. This result, combined with the fact that S3 contains a nuclear localization signal and that the protein shares some homology to a yeast nuclease gene, suggested that S3 might possibly have a role in DNA metabolism. Tests were initially performed to see if S3 contained DNase activity, where it was subsequently determined that the protein specifically cleaved DNA containing an apurinic/apyrimidinic site via a beta-elimination reaction. The DNase activity was inactivated by antibody to S3, indicating that the apurinic/apyrimidinic lyase activity was associated with the Drosophila S3 protein. Taken together, these results suggest that S3 is among a growing class of multifunctional proteins with roles in transcription/translation and DNA repair.	LOYOLA UNIV,STRITCH SCH MED,PROGRAM MOLEC BIOL,MAYWOOD,IL 60153; LOUISIANA STATE UNIV,DEPT BIOCHEM,BATON ROUGE,LA 70803; INDIANA UNIV,SCH MED,WELLS CTR PEDIAT RES,DEPT PEDIAT,PEDIAT ENDOCRINOL SECT,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Loyola University Chicago; Louisiana State University System; Louisiana State University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis			Wilson, David M/AAK-5409-2021	Wilson, David M/0000-0002-8945-0395; Kelley, Mark/0000-0002-6120-9532	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009884] Funding Source: NIH RePORTER; NCRR NIH HHS [RR09884] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ASHBURNER M, 1989, DROSOPHILA LABORATOR, P358; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BANDURSKI RS, 1951, J BIOL CHEM, V193, P405; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRUCKNER RC, 1989, NUCLEIC ACIDS RES, V17, P3145, DOI 10.1093/nar/17.8.3145; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; DECOCK JGR, 1992, MUTAT RES, V293, P11, DOI 10.1016/0921-8777(92)90003-L; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DUKER NJ, 1982, BIOCHEM BIOPH RES CO, V105, P1433, DOI 10.1016/0006-291X(82)90948-2; ELKON KB, 1985, J EXP MED, V162, P459, DOI 10.1084/jem.162.2.459; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FISHER PA, 1982, J CELL BIOL, V92, P674, DOI 10.1083/jcb.92.3.674; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; GATES FT, 1977, J BIOL CHEM, V252, P2802; GRABOWSKI DT, 1992, CARCINOGENESIS, V13, P259, DOI 10.1093/carcin/13.2.259; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HARLOW E, 1988, ANTIBODIES LABORATOR; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; KELLEY MR, 1989, MOL CELL BIOL, V9, P965, DOI 10.1128/MCB.9.3.965; KELLY WG, 1989, CELL, V57, P243, DOI 10.1016/0092-8674(89)90962-8; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KONGSUWAN K, 1985, NATURE, V317, P555, DOI 10.1038/317555a0; KUHNLEIN U, 1976, P NATL ACAD SCI USA, V73, P1169, DOI 10.1073/pnas.73.4.1169; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; MALE R, 1982, NUCLEIC ACIDS RES, V10, P6305, DOI 10.1093/nar/10.20.6305; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MOUNKES LC, 1992, CELL, V71, P925, DOI 10.1016/0092-8674(92)90389-T; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; POGUEGEILE K, 1991, MOL CELL BIOL, V11, P3842, DOI 10.1128/MCB.11.8.3842; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SANCHEZMADRID F, 1981, EUR J BIOCHEM, V114, P609, DOI 10.1111/j.1432-1033.1981.tb05187.x; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; TOLAN DR, 1983, BIOCHIMIE, V65, P427, DOI 10.1016/S0300-9084(83)80062-5; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WATSON KL, 1992, P NATL ACAD SCI USA, V89, P11302, DOI 10.1073/pnas.89.23.11302; WESTERMANN P, 1979, FEBS LETT, V97, P101, DOI 10.1016/0014-5793(79)80061-7; WILSON DM, 1993, NUCLEIC ACIDS RES, V21, P2516, DOI 10.1093/nar/21.10.2516; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443; WU C, 1979, CELL, V16, P797, DOI 10.1016/0092-8674(79)90095-3; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	40	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25359	25364						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929231				2022-12-25	WOS:A1994PQ49100022
J	YE, JP; GHOSH, P; CIPPITELLI, M; SUBLESKI, J; HARDY, KJ; ORTALDO, JR; YOUNG, HA				YE, JP; GHOSH, P; CIPPITELLI, M; SUBLESKI, J; HARDY, KJ; ORTALDO, JR; YOUNG, HA			CHARACTERIZATION OF A SILENCER REGULATORY ELEMENT IN THE HUMAN INTERFERON-GAMMA PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; TRANSCRIPTION FACTOR; NEGATIVE CONTROL; DNA ELEMENT; C-MYC; ENHANCER; BINDS; EXPRESSION; PROTEIN; SITE	Previous analysis of the human interferon-gamma (IFN-gamma promoter indicated that the region of DNA from -251 to -215 (designated here as BE (binding element)) possessed silencer activity, as deletion of this region caused an increase in promoter activity. Based on this finding, we have conducted a series of experiments to characterize BE function and analyze the binding proteins which interact with this region. Transient transfection assays in the Jurkat T cell line revealed that the BE region possesses silencer activity, which is orientation-dependent when reinserted 5' to the IFN-gamma core promoter. However, when the BE region was inserted in front of a heterologous promoter (thymidine kinase (TK)), a mild enhancer activity was observed. Utilizing the electrophoretic mobility shift assay, we have identified two major DNA-protein complexes (designated as S and E complexes) which interact with this region. Mutational analysis indicated that the silencer activity observed with the IFN-gamma promoter correlated with the S complex and the enhancer activity correlated with the E complex. Preliminary characterization of these two DNA-protein complexes has demonstrated the presence of multiple proteins in each complex. We have found that the S protein complex has a recognition sequence similar to the nuclear factor AP2, and we have identified the nuclear factor Yin-Yang 1 (YY1) as one of the proteins in the E complex.	NCI, FREDERICK CANC RES & DEV CTR, EXPTL IMMUNOL LAB, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA; UNIV MISSISSIPPI, MED CTR, DEPT MED, JACKSON, MS 39216 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Mississippi; University of Mississippi Medical Center			Cippitelli, Marco/AAF-4857-2021; Ye, Jianping/N-1998-2017; Young, Howard/A-6350-2008	Cippitelli, Marco/0000-0002-9620-538X; Ye, Jianping/0000-0003-3875-365X; Young, Howard/0000-0002-3118-5111				CHRIVIA JC, 1990, J EXP MED, V172, P661, DOI 10.1084/jem.172.2.661; CICCARONE VC, 1990, J IMMUNOL, V144, P725; CLARK AR, 1989, NUCLEIC ACIDS RES, V17, P10130, DOI 10.1093/nar/17.23.10130; COWELL IG, 1993, TRENDS BIOCHEM SCI, V19, P40; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLANAGAN JR, 1989, MOL CELL BIOL, V9, P739, DOI 10.1128/MCB.9.2.739; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FONG CLW, 1994, NUCLEIC ACIDS RES, V22, P1108, DOI 10.1093/nar/22.6.1108; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1994, ONCOGENE, V9, P1047; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MICHELL PJ, 1987, CELL, V50, P847; MIN LW, 1992, J IMMUNOL, V148, P1913; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; NABEL GJ, 1988, P NATL ACAD SCI USA, V85, P2934, DOI 10.1073/pnas.85.9.2934; NOMIYAMA H, 1993, MOL CELL BIOL, V13, P2787, DOI 10.1128/MCB.13.5.2787; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; RADBOUD JEM, 1993, J LEUKOCYTE BIOL, V54, P545; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q	36	68	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25728	25734						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929277				2022-12-25	WOS:A1994PQ49100074
J	BAUKAL, AJ; HUNYADY, L; CATT, KJ; BALLA, T				BAUKAL, AJ; HUNYADY, L; CATT, KJ; BALLA, T			EVIDENCE FOR PARTICIPATION OF CALCINEURIN IN POTENTIATION OF AGONIST-STIMULATED CYCLIC-AMP FORMATION BY THE CALCIUM-MOBILIZING HORMONE, ANGIOTENSIN-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADRENAL GLOMERULOSA CELLS; PROTEIN-KINASE-C; PHORBOL ESTER TREATMENT; ADENYLATE-CYCLASE; SIGNALING PATHWAYS; EXPRESSION; RECEPTOR; CLONING; GS; METABOLISM	Angiotensin II (AII) receptors are known to interact with two distinct guanine nucleotide binding proteins, G(q/11) and G(i), in rat adrenal glomerulosa cells to activate phospholipase C and to inhibit adenylate cyclase, respectively. However, in cultured bovine glomerulosa cells AII potentiates rather than inhibits the stimulatory effect of adrenocorticotropin (ACTH) on cAMP levels. This effect of AII was partially mimicked by phorbol 12-myristate 13-acetate (PMA) and was partially inhibited by staurosporine or depletion of protein kinase C but was unaffected by pertussis toxin treatment. No potentiation was detectable in disrupted cells or in membrane preparations. In intact glomerulosa cells, treatment with cyclosporin A or FK506 completely inhibited AII- or PMA-induced potentiation of cAMP production without affecting the response to ACTH. In COS-7 cells transfected with the rat AT(1) receptor, AII caused 2-3-fold enhancement of the ACTH-induced cAMP response, an effect that was partially reproduced by PMA. These potentiating actions of AII and PMA were prevented by preincubation with cyclosporin A or FK506, and the latter effect was abolished by rapamycin. These results implicate the Ca2+- and calmodulin-dependent protein phosphatase, calcineurin, in AII-induced enhancement of adenylate cyclase activity in both adrenal glomerulosa and transfected COS-7 cells. The finding that AII enhances ACTH stimulated production of cAMP by a second messenger-mediated mechanism that involves the participation of calcineurin reveals an additional mode of cross-talk between pathways activated by Ca2+-mobilizing and cAMP-generating receptors.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Balla, Tamas/0000-0002-9077-3335				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; BALLA T, 1989, ARCH BIOCHEM BIOPHYS, V270, P398, DOI 10.1016/0003-9861(89)90043-X; BAUKAL AJ, 1990, MOL ENDOCRINOL, V4, P1712, DOI 10.1210/mend-4-11-1712; BEGEOT M, 1988, EUR J BIOCHEM, V174, P317, DOI 10.1111/j.1432-1033.1988.tb14100.x; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BRAMI B, 1987, MOL CELL ENDOCRINOL, V50, P131, DOI 10.1016/0303-7207(87)90085-2; Catt KJ, 1993, CELLULAR MOL BIOL RE, P307; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CLARK AJL, 1992, MOL ENDOCRINOL, V6, P1889, DOI 10.1210/me.6.11.1889; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; GUILLEMETTE G, 1987, BIOCHEM BIOPH RES CO, V142, P15, DOI 10.1016/0006-291X(87)90445-1; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KAWABE J, 1994, J BIOL CHEM, V269, P16554; LONDOS C, 1975, J BIOL CHEM, V250, P3459; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MORIMOTO BH, 1994, J BIOL CHEM, V269, P4065; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; RAINEY WE, 1991, MOL CELL ENDOCRINOL, V81, P33, DOI 10.1016/0303-7207(91)90202-4; SALA GB, 1979, J BIOL CHEM, V254, P3861; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; WARHURST G, 1994, CELL CALCIUM, V15, P162, DOI 10.1016/0143-4160(94)90055-8; WEBER A, 1993, BIOCHEM BIOPH RES CO, V197, P172, DOI 10.1006/bbrc.1993.2456; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	28	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24546	24549						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929124				2022-12-25	WOS:A1994PQ49000008
J	CULVER, GM; CONSAUL, SA; TYCOWSKI, KT; FILIPOWICZ, W; PHIZICKY, EM				CULVER, GM; CONSAUL, SA; TYCOWSKI, KT; FILIPOWICZ, W; PHIZICKY, EM			TRANSFER-RNA SPLICING IN YEAST AND WHEAT-GERM - A CYCLIC PHOSPHODIESTERASE IMPLICATED IN THE METABOLISM OF ADP-RIBOSE 1'',2''-CYCLIC PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA LIGASE; HELA-CELL EXTRACT; 3',5'-PHOSPHODIESTER LINKAGE; INTERVENING SEQUENCES; XENOPUS-LAEVIS; ENDONUCLEASE; MECHANISM; PURIFICATION; PRECURSORS; SUBSTRATE	Adenosine diphosphate (ADP)-ribose 1'',2'' cyclic phosphate (Appr>p) is produced as a result of transfer RNA (tRNA) splicing in the yeast Saccharomyces cerevisiae and probably in other eukaryotes. Endonucleolytic cleavage and ligation result in a mature length tRNA with a 2'-phosphate at the splice junction. This 2'-phosphate is transferred to NAD to produce Appr>p. Metabolism of Appr>p requires hydrolysis of the 1'',2''-cyclic phosphate linkage. We show here that yeast has a unique cyclic phosphodiesterase that can hydrolyze Appr>p, ribose 1,2-cyclic phosphate, and ribose 1,3-cyclic phosphate to the crresponding ribose 1-phosphate derivatives. The cyclic phosphodiesterase is highly specific for Appr>p; there is 20-fold less activity on ribose 1,3-cyclic phosphate and no detectable activity on nucleoside 2',3'-cyclic phosphates. A similar cyclic phosphodiesterase is present in wheat germ. The wheat perm cyclic phosphodiesterase activity co-chromatographs with a 2',3'-cyclic nucleotide 3'-phosphodiesterase that was previously identified and purified. The purified wheat germ enzyme has a distinct preference for Appr>p and ribose cyclic phosphate compared to guanosine 2',3'-cyclic phosphate and shares other biochemical characteristics with the yeast enzyme.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	University of Rochester; Friedrich Miescher Institute for Biomedical Research					NIDCR NIH HHS [NIDR DE07202] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007202] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		APOSTOL BL, 1991, J BIOL CHEM, V266, P7445; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; DRUMMOND GI, 1962, J BIOL CHEM, V237, P3535; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; FILIPOWICZ W, 1983, NUCLEIC ACIDS RES, V11, P1405, DOI 10.1093/nar/11.5.1405; FURNEAUX H, 1983, P NATL ACAD SCI-BIOL, V80, P3933, DOI 10.1073/pnas.80.13.3933; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HELFMAN DM, 1982, J BIOL CHEM, V257, P1044; KALCKAR HM, 1947, J BIOL CHEM, V167, P477; KNAPP G, 1979, CELL, V18, P37, DOI 10.1016/0092-8674(79)90351-9; KONARSKA M, 1982, P NATL ACAD SCI-BIOL, V79, P1474, DOI 10.1073/pnas.79.5.1474; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; LASKI FA, 1983, J BIOL CHEM, V258, P1974; LOWRY OH, 1946, J BIOL CHEM, V162, P421; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; MIRO A, 1989, FEBS LETT, V244, P123, DOI 10.1016/0014-5793(89)81176-7; NEU HC, 1964, J BIOL CHEM, V239, P2927; NISHIKURA K, 1981, J MOL BIOL, V145, P405, DOI 10.1016/0022-2836(81)90212-6; OHTSU E, 1971, METHODS ENZYMOL B, V18, P127; OLAFSON RW, 1969, CAN J BIOCHEM CELL B, V47, P961, DOI 10.1139/o69-151; OTSUKA A, 1981, MOL CELL BIOL, V1, P269, DOI 10.1128/MCB.1.3.269; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PICK L, 1986, J BIOL CHEM, V261, P6694; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; ROSS TS, 1991, J BIOL CHEM, V266, P851; ROSS TS, 1986, J BIOL CHEM, V261, P1119; RUSHIZKY GW, 1963, J BIOL CHEM, V238, P371; SCHWARTZ RC, 1983, J BIOL CHEM, V258, P8374; SOGIN DC, 1976, J NEUROCHEM, V27, P1333, DOI 10.1111/j.1471-4159.1976.tb02612.x; STANGE N, 1988, EMBO J, V7, P3823, DOI 10.1002/j.1460-2075.1988.tb03267.x; STANGE N, 1992, EUR J BIOCHEM, V210, P193, DOI 10.1111/j.1432-1033.1992.tb17408.x; TYC K, 1983, EMBO J, V2, P605, DOI 10.1002/j.1460-2075.1983.tb01470.x; TYC K, 1987, J BIOL CHEM, V262, P12994; UCHIDA T, 1967, BIOCHEM TOKYO, V261, P44; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WESTAWAY SK, 1993, J BIOL CHEM, V268, P2435; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410; ZILLMANN M, 1992, J BIOL CHEM, V267, P10289	46	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24928	24934						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929175				2022-12-25	WOS:A1994PQ49000062
J	HUNYADY, L; BAUKAL, AJ; BALLA, T; CATT, KJ				HUNYADY, L; BAUKAL, AJ; BALLA, T; CATT, KJ			INDEPENDENCE OF TYPE-I ANGIOTENSIN-II RECEPTOR ENDOCYTOSIS FROM G-PROTEIN COUPLING AND SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ADRENAL GLOMERULOSA CELLS; SMOOTH-MUSCLE CELLS; MEDIATED ENDOCYTOSIS; POTENTIAL MECHANISM; CARBOXYL-TERMINUS; INTERNALIZATION; SEQUESTRATION; MUTAGENESIS; GENERATION	The relationship between angiotensin II-induced activation of G proteins and receptor internalization was analyzed by transiently expressing mutant and wild type cDNAs for the rat AT(1a) receptor in COS-7 cells. Pertussis toxin-sensitive G proteins did not appear to play a role in endocytosis since the receptor showed normal internalization kinetics in pertussis toxin-treated cells. Three deletion mutants of the third cytoplasmic loop revealed that the N-terminal part of this region is important for both receptor endocytosis and intracellular signaling. Three point mutations of Asp(74), which has been implicated in signal transduction by the AT(1a) receptor, caused impaired G protein coupling and inositol phosphate responses. However, each of these mutants (D74N, D74H, and D74Y) showed markedly different internalization kinetics. The D74Y mutant showed the greatest impairment of internalization but retained the highest degree of inositol phosphate stimulation. In contrast, the D74N mutant, which showed the most impaired G protein coupling and inositol phosphate responses, had similar internalization kinetics to the wild type receptor. The combined mutant receptor containing the D74N substitution and deletion of residues 221-226 from the third cytoplasmic loop showed no G protein coupling or inositol phosphate response but was internalized about 60% as rapidly as the wild type receptor. These data demonstrate that endocytosis of the AT(1) receptor is independent of agonist-activated signal transduction and indicate that receptor internalization and activation of phospholipase C have different structural requirements.	NICHHD, ENDOCRINOL & REPROD RES BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Balla, Tamas/0000-0002-9077-3335				ANDERSON KM, 1993, AM J PHYSIOL, V264, pC179, DOI 10.1152/ajpcell.1993.264.1.C179; BALLA T, 1991, J BIOL CHEM, V266, P24719; BECK KA, 1991, J BIOL CHEM, V266, P4442; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BIANCHI C, 1986, ENDOCRINOLOGY, V118, P2605, DOI 10.1210/endo-118-6-2605; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BROWN VI, 1991, DNA CELL BIOL, V10, P399, DOI 10.1089/dna.1991.10.399; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CARPENTIER JL, 1992, PROG HISTOCHEM CYTOC, V26, P77, DOI 10.1016/S0079-6336(11)80081-1; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CATT KJ, 1991, J BIOENERG BIOMEMBR, V23, P7; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; CROZAT A, 1986, ENDOCRINOLOGY, V118, P2312, DOI 10.1210/endo-118-6-2312; GRIENDLING KK, 1987, J BIOL CHEM, V262, P14555; HAUSDORFF WP, 1992, ASIA PAC J PHARMACOL, V7, P149; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUNYADY L, 1991, J BIOL CHEM, V266, P2783; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JARD S, 1981, J BIOL CHEM, V256, P2603; MORO O, 1994, J BIOL CHEM, V269, P6651; MORO O, 1993, J BIOL CHEM, V268, P6862; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHULTZ G, 1993, ARZNEIMITTEL-FORSCH, V43-1, P229; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SPAT A, 1991, EXP PHYSIOL, V76, P859, DOI 10.1113/expphysiol.1991.sp003550; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; YAMASAKI H, 1993, MOL ENDOCRINOL, V7, P681, DOI 10.1210/me.7.5.681; YU SS, 1993, J BIOL CHEM, V268, P337; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	35	130	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24798	24804						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929158				2022-12-25	WOS:A1994PQ49000045
J	RANJAN, M; WONG, JM; SHI, YB				RANJAN, M; WONG, JM; SHI, YB			TRANSCRIPTIONAL REPRESSION OF XENOPUS TR-BETA GENE IS MEDIATED BY A THYROID-HORMONE RESPONSE ELEMENT LOCATED NEAR THE START SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC-ACID RECEPTOR; HUMAN GLUCOCORTICOID RECEPTOR; X-RECEPTOR; AMPHIBIAN METAMORPHOSIS; PREINITIATION COMPLEX; GENOMIC STRUCTURE; ONCOGENE PRODUCT; MESSENGER-RNA; EXPRESSION; PROTEIN	We report here the detailed analysis of the promoter of a thyroid hormone receptor (TR) gene that is regulated by the hormone itself. The receptor gene, TR beta A, is one of the two TR beta genes in Xenopus laevis. It has two transcription start sites. The mRNAs derived from one of them are up-regulated by thyroid hormone, whereas those derived from the other are independent of the hormone. We have characterized the hormone inducible promoter using a transient transfection assay in a Xenopus tissue culture cell line (A6). Deletion and mutational analysis identifies the first amphibian thyroid hormone response element (TRE). This TRE consists of near perfect direct repeats of AGGTCA with a 4-base pair spacing similar to mammalian TREs. The TRE forms specific complexes with extracts of A6 cells that have similar sequence specificities as those found for the complexes between mammalian TRs and TREs. However, unlike TREs found in other thyroid hormone-inducible promoters, this TRE is located at the putative transcription start site and mediates transcriptional repression by unliganded TRs. The addition of thyroid hormone at physiological concentrations overcomes the repression and induces further transcriptional activation at higher concentrations. These results suggest a potential mechanism for the regulation of amphibian metamorphosis, a process that is entirely controlled by thyroid hormone.	NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Wong, Jiemin/0000-0002-5311-842X; Shi, Yun-Bo/0000-0002-6330-0639				Ausubel FM., 1988, CURRENT PROTOCOLS MO; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; BUCKBINDER L, 1992, J BIOL CHEM, V267, P25786; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; DUGUID JR, 1990, NUCLEIC ACIDS RES, V18, P2789, DOI 10.1093/nar/18.9.2789; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; Gilbert L, 1981, METAMORPHOSIS PROBLE; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HUCKABY CS, 1987, P NATL ACAD SCI USA, V84, P8380, DOI 10.1073/pnas.84.23.8380; ISHIZUYAOKA A, 1991, IN VITRO CELL DEV B, V27, P853; JELTSCH JM, 1990, J BIOL CHEM, V265, P3967; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KAWAHARA A, 1991, DEVELOPMENT, V112, P933; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHNEIDER MJ, 1991, MOL ENDOCRINOL, V5, P201, DOI 10.1210/mend-5-2-201; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI YB, 1990, GENE DEV, V4, P1107, DOI 10.1101/gad.4.7.1107; SHI YB, 1992, J BIOL CHEM, V267, P733; SHI YB, 1993, J BIOL CHEM, V268, P20312; SHI YB, 1994, BBA-GENE STRUCT EXPR, V1217, P227, DOI 10.1016/0167-4781(94)90042-6; SHI YB, 1994, TRENDS ENDOCRIN MET, V5, P14, DOI 10.1016/1043-2760(94)90116-3; TATA JR, 1991, DEV BIOL, V146, P72, DOI 10.1016/0012-1606(91)90447-B; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG Z, 1993, J BIOL CHEM, V268, P16270; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YEN PM, 1992, J BIOL CHEM, V267, P23248; YU YC, 1991, CELL, V67, P1251; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZONG J, 1990, MOL CELL BIOL, V10, P5580, DOI 10.1128/MCB.10.10.5580	56	161	162	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24699	24705						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929143				2022-12-25	WOS:A1994PQ49000030
J	BEGUIN, P; BEGGAH, AT; CHIBALIN, AV; BURGENERKAIRUZ, P; JAISSER, F; MATHEWS, PM; ROSSIER, BC; COTECCHIA, S; GEERING, K				BEGUIN, P; BEGGAH, AT; CHIBALIN, AV; BURGENERKAIRUZ, P; JAISSER, F; MATHEWS, PM; ROSSIER, BC; COTECCHIA, S; GEERING, K			PHOSPHORYLATION OF THE NA,K-ATPASE ALPHA-SUBUNIT BY PROTEIN KINASE-A AND KINASE-C IN-VITRO AND IN INTACT-CELLS - IDENTIFICATION OF A NOVEL MOTIF FOR PKC-MEDIATED PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; (NA+ + K+)-ATPASE; XENOPUS OOCYTES; INTRACELLULAR-TRANSPORT; FUNCTIONAL EXPRESSION; PRIMARY SEQUENCE; DISTAL NEPHRON; NA/K-ATPASE; NA+,K+-ATPASE; KIDNEY	Na,K-ATPase is a potential target for regulatory phosphorylation by protein kinase A and C (PKA and PKC). To identify the phosphorylation sites, we have mutated the alpha(1)-subunit of Bufo marinus in a highly conservative PKA and in 20 different PKC consensus sequences. The mutants were expressed in Xenopus oocytes and their phosphorylation capacity tested in homogenates upon stimulation of PKA or PKC. While serine 943 (Ser-943) was identified as a unique target site for PKA, none of the PKC consensus serine or threonine residues are implicated in PKC phosphorylation. Controlled trypsinolysis of phosphorylated alpha-subunits of various purified enzyme preparations and of alpha/beta complexes from oocyte homogenates revealed that PKC phosphorylation was exclusively associated with the N terminus. A fusion protein containing the first 32 amino acids of the Bufo alpha-subunit was phosphorylated in vitro and serine and threonine residues (Thr-15 and Ser-16) in this region were identified by site-directed mutagenesis as the PKC phosphorylation sites. Finally, the Bufo alpha-subunit was phosphorylated by protein kinases in transfected COS-7 cells. In intact cells, PKA stimulation induced phospho rylation exclusively on Ser-943 and PKC stimulation mainly on Thr-15 and Ser-16, which are contained in a novel PKC phosphorylation motif.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND; RUSSIAN CARDIOL RES CTR, INST EXPTL CARDIOL, MOSCOW 121552, RUSSIA	University of Lausanne; National Medical Research Center of Cardiology			Jaisser, Frederic/P-4287-2017	Jaisser, Frederic/0000-0001-9051-1901; Chibalin, Alexander/0000-0002-6339-6271				BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BERTORELLO AM, 1993, AM J PHYSIOL, V265, pF743, DOI 10.1152/ajprenal.1993.265.6.F743; BORGHINI I, 1994, P NATL ACAD SCI USA, V91, P6211, DOI 10.1073/pnas.91.13.6211; BURGENERKAIRUZ P, 1991, FEBS LETT, V290, P83, DOI 10.1016/0014-5793(91)81231-V; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; CHIBALIN AV, 1993, J BIOENERG BIOMEMBR, V25, P61, DOI 10.1007/BF00768069; CHIBALIN AV, 1991, BIOL MEMBRANY, V8, P1140; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; FISONE G, 1994, J BIOL CHEM, V269, P9368; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FRYCKSTEDT J, 1992, ACTA PHYSIOL SCAND, V144, P185, DOI 10.1111/j.1748-1716.1992.tb09284.x; FUKUDA Y, 1991, PEDIATR RES, V30, P131, DOI 10.1203/00006450-199108000-00001; GEERING K, 1979, BIOCHIM BIOPHYS ACTA, V566, P157, DOI 10.1016/0005-2744(79)90258-4; GEERING K, 1982, J BIOL CHEM, V257, P338; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GEERING K, 1987, J CELL BIOL, V105, P2613, DOI 10.1083/jcb.105.6.2613; GEERING K, 1985, J BIOL CHEM, V260, P5154; GOOD PJ, 1988, J VIROL, V62, P944, DOI 10.1128/JVI.62.3.944-953.1988; HOOTMAN SR, 1987, AM J PHYSIOL, V252, pG499, DOI 10.1152/ajpgi.1987.252.4.G499; HORISBERGER JD, 1994, NAKATPASE STRUCTURE; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAUNIN P, 1992, J BIOL CHEM, V267, P577; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LATTIMER SA, 1989, AM J PHYSIOL, V256, pE264, DOI 10.1152/ajpendo.1989.256.2.E264; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; LYNCH CJ, 1986, J BIOL CHEM, V261, P4551; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; MORITA K, 1991, NEUROCHEM INT, V19, P81, DOI 10.1016/0197-0186(91)90122-T; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1993, AM J PHYSIOL, V265, pF399, DOI 10.1152/ajprenal.1993.265.3.F399; SILVA P, 1983, J MEMBRANE BIOL, V75, P105, DOI 10.1007/BF01995630; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEMOTO F, 1992, PFLUG ARCH EUR J PHY, V421, P302, DOI 10.1007/BF00374216; TUNG P, 1990, J BIOL CHEM, V265, P3936; VASILETS LA, 1992, J MEMBRANE BIOL, V125, P119; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034; ZAMOFING D, 1987, BIOCHIM BIOPHYS ACTA, V904, P381, DOI 10.1016/0005-2736(87)90388-9	45	171	172	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24437	24445						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929106				2022-12-25	WOS:A1994PQ34600091
J	KARLSSON, A; JOHANSSON, M; ERIKSSON, S				KARLSSON, A; JOHANSSON, M; ERIKSSON, S			CLONING AND EXPRESSION OF MOUSE DEOXYCYTIDINE KINASE - PURE RECOMBINANT MOUSE AND HUMAN ENZYMES SHOW DIFFERENCES IN SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKEMIA-CELLS; NUCLEOSIDE ANALOGS; MOLECULAR-CLONING; METABOLISM; CDNA; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; 2',3'-DIDEOXYCYTIDINE; PHOSPHORYLATION; PURINE; GENE	A cDNA encoding mouse deoxycytidine kinase (dCK) (EC 2.7.1.74) was cloned from a mouse T-cell lambda ZAP cDNA library. An insert of 2.8 kilobases (kb) contained the entire coding sequence of 780 base pairs. The protein coding sequence was 88% homologous at the nucleotide level with human dCK cDNA (Chottiner, E. G., Shewach, D. S., Datta, N. S., Ashcraft, E., Gribbin, D., Ginsburg, D., Fox, I. H., and Mitchell, B. S. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1531-1535). At the amino acid level the homology was greater with only 16 of the 260 amino acids being different. Northern blot analyses revealed a size of 3.4 kb for mouse dCK mRNA as compared with 2.8 kb for human dCK. Part of the 3'-untranslated region was conserved between human and mouse dCK cDNA in contrast to the remainder of the 3'-sequence which was unrelated and about 500 nucleotides longer in mouse dCK cDNA. Mouse dCK cDNA showed cross-hybridization with several bands in EcoRI-digested genomic DNA from seven different mammalian species and chicken but not with yeast DNA. Both mouse and human dCK were cloned into the T5 promotor pQE30 vector system, expressed in Escherichia coli and purified to homogeneity. The kinetic constants for dCyd phosphorylation were similar for the human and mouse enzymes and also similar to what previously has been observed for dCK purified from human tissues. Mouse dCK was less efficient with regard to dAdo, dGuo, and ddCyd phosphorylation as compared with human dCK when using ATP as phosphate donor in a phosphoryl transfer assay.			KARLSSON, A (corresponding author), KAROLINSKA INST,MED NOBEL INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN.		Karlsson, Anna/E-7945-2018	Karlsson, Anna/0000-0001-6843-6685				BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P897, DOI 10.1016/0006-2952(88)90178-5; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; CARSON DA, 1980, J IMMUNOL, V124, P8; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4; HABTEYESUS A, 1991, BIOCHEM PHARMACOL, V42, P1829, DOI 10.1016/0006-2952(91)90522-7; HENGSTSCHLAGER M, 1993, FEBS LETT, V321, P237, DOI 10.1016/0014-5793(93)80116-C; Ives D H, 1978, Methods Enzymol, V51, P337; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KIERDASZUK B, 1990, BIOCHEMISTRY-US, V29, P4109, DOI 10.1021/bi00469a013; LIN PF, 1985, MOL CELL BIOL, V5, P3149, DOI 10.1128/MCB.5.11.3149; MITCHELL BS, 1993, ADV ENZYME REGUL, V33, P61; PLUNKETT W, 1991, PHARMACOL THERAPEUT, V49, P239, DOI 10.1016/0163-7258(91)90057-S; SARUP JC, 1987, BIOCHEMISTRY-US, V26, P590, DOI 10.1021/bi00376a034; SHEWACH DS, 1992, MOL PHARMACOL, V42, P518; SONG JJ, 1993, P NATL ACAD SCI USA, V90, P431, DOI 10.1073/pnas.90.2.431; ULLMAN B, 1988, J BIOL CHEM, V263, P12391; WHITE JC, 1987, CANCER RES, V47, P1820; WHITE JC, 1991, CANCER RES, V51, P2559	20	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24374	24378						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929097				2022-12-25	WOS:A1994PQ34600081
J	CRESSMAN, DE; TAUB, R				CRESSMAN, DE; TAUB, R			PHYSIOLOGICAL TURNOVER OF NUCLEAR FACTOR KAPPA-B BY NUCLEAR PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTOR; REGENERATING LIVER; RAPID PROTEOLYSIS; INHIBITOR; ALPHA; PROTEASOMES; PROMOTER; PATHWAY; COMPLEX; CELLS	Regenerating Liver is a physiologic animal system in which p50/p65 nuclear factor kappa B (NF-KR) DNA binding activity is induced and rapidly disappears in the remnant liver within minutes of partial hepatectomy. The activation of NF-kappa B may contribute to the mechanism by which hepatocytes regulate their mitogenic program during liver regeneration. A p50/NF-kappa B1-p35/RelA heterodimer that contains a proteolyzed amino-terminal DNA binding fragment of p65/RelA is also present in the nuclei of hepatic cells within minutes of partial hepatectomy. In the absence of I kappa B-alpha resynthesis, turnover of NF-kappa B occurs via conversion of p50/NF-kappa B1-p65/RelA to a p50/NF-kappa B1-p35/RelA DNA binding complex. Proteolytic conversion of p65/RelA into p35/RelA and subsequent degradation of p35/RelA account at least in part for the rapid turnover of NF-kappa B in the cell nuclei. Nuclear proteolysis provides a potential mechanism for tightly regulating the level of active NF-kappa B.	UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania								Arias I.M., 1994, LIVER BIOL PATHOBIOL, V3; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD D W, 1989, New Biologist, V1, P83; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; CRESSMAN DE, 1994, IN PRESS J BIOL CHEM, V269; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; ELIASSON E, 1992, J BIOL CHEM, V267, P15765; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOHMANN HP, 1991, MOL CELL BIOL, V11, P259, DOI 10.1128/MCB.11.1.259; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIU JL, 1991, J IMMUNOL, V146, P1685; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; RICE NR, 1993, EMBO J, V12, P5043; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TANAKA K, 1989, J CELL PHYSIOL, V139, P34, DOI 10.1002/jcp.1041390107; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898	25	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26594	26597						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929386				2022-12-25	WOS:A1994PQ93100002
J	ASO, T; CONAWAY, JW; CONAWAY, RC				ASO, T; CONAWAY, JW; CONAWAY, RC			ROLE OF CORE PROMOTER STRUCTURE IN ASSEMBLY OF THE RNA-POLYMERASE-II PREINITIATION COMPLEX - A COMMON PATHWAY FOR FORMATION OF PREINITIATION INTERMEDIATES AT MANY TATA AND TATA-LESS PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE GENE; PURIFIED TRANSCRIPTION FACTORS; MAJOR LATE PROMOTER; INITIATION-FACTOR; BINDING PROTEIN; FACTOR-EPSILON; FACTOR-DELTA; DNA-BINDING; BOX-BINDING; TFIID COMPLEX	Efforts to understand the impact of core promoter architecture on the mechanism of transcription initiation by RNA polymerase II have been hampered by lack of well defined, reconstituted transcription systems responsive both to efficiently transcribed consensus and near consensus TATA box-containing promoters and to considerably weaker TATA-less promoters. In this report, we investigate the influence of core promoter structure on the mechanism of assembly of the RNA polymerase II preinitiation complex using a highly purified, holoTFIID-dependent transcription system that permits sensitive measurement of transcription initiation from a wide variety of TATA and TATA-less promoters in the absence of transactivators. A direct comparison of the requirements for formation of stable preinitiation intermediates at these promoters led to the discovery that, whereas holoTFIID binds avidly to the consensus TATA- and strong initiator-containing adenovirus major late (AdML) promoter to form the first stable intermediate on the pathway leading to formation of the complete preinitiation complex, it binds poorly not only to TATA-less promoters but also to promoters with consensus or near consensus TATA elements. With the exception of the AdML promoter, formation of stable preinitiation intermediates at each of the promoters tested was found to be strongly dependent on RNA polymerase II, holoTFIID, and TFIIB and was stimulated by TFIIF. Based on these observations, we suggest that RNA polymerase II assembles with many TATA and TATA-less promoters by a common pathway.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1994, EMBO J, V13, P435, DOI 10.1002/j.1460-2075.1994.tb06278.x; ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Battey, 1986, BASIC METHODS MOL BI; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; CONAWAY JW, 1990, J BIOL CHEM, V265, P7564; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; EMANUEL PA, 1993, P NATL ACAD SCI USA, V90, P8449, DOI 10.1073/pnas.90.18.8449; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GREENBLATT J, 1992, NATURE, V360, P16, DOI 10.1038/360016a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; KADESCH TR, 1982, J MOL BIOL, V155, P1, DOI 10.1016/0022-2836(82)90489-2; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MONCOLLIN V, 1984, EMBO J, V3, P2363; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SAFER B, 1991, J BIOL CHEM, V266, P10989; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1994, TRANSCRIPTION MECHAN, P27; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VANDYKE MW, 1990, MOL CELL BIOL, V10, P3415, DOI 10.1128/MCB.10.7.3415; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	81	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26575	26583						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929383				2022-12-25	WOS:A1994PQ93000096
J	LOWRY, DF; ROTH, AF; RUPERT, PB; DAHLQUIST, FW; MOY, FJ; DOMAILLE, PJ; MATSUMURA, P				LOWRY, DF; ROTH, AF; RUPERT, PB; DAHLQUIST, FW; MOY, FJ; DOMAILLE, PJ; MATSUMURA, P			SIGNAL-TRANSDUCTION IN CHEMOTAXIS - A PROPAGATING CONFORMATION CHANGE UPON PHOSPHORYLATION OF CHEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOSIGNALING PROTEIN CHEY; BACTERIAL CHEMOTAXIS; RESPONSE REGULATOR; F-19 NMR; ACTIVATION	The CheY protein from Escherichia coli and Salmonella typhimurium are among the best characterized proteins of the receiver domain family of two component signal transduction systems in bacteria. Phosphorylation of CheY plays a central role in bacterial chemo taxis. However, it is not entirely clear how its state of phosphorylation contributes to its function. Genetic evidence suggests that CheY changes its conformation upon phosphorylation. We present evidence for this con formation change by comparing the NMR N-15 - H-1 correlation spectra of CheY.Mg2+ complex and phospho-CheY in the presence of magnesium. Large changes in chemical shift are used as indicators of chemical changes and probable structural changes in the protein backbone. Our observations suggest that significant structural changes occur in CheY upon phosphorylation and that these changes are distinct from the changes produced by magnesium ion binding. In addition to residues Asn-59 and Gly-65 that are immediately adjacent to the site of phosphorylation at Asp-57, a large number of other residues show significant chemical shift changes as a result of phosphorylation. These include Met-17, Val-21, Asn-23, Gly-39, Met-60, Met-63, Asp-64, Leu-66, Glu-67, Leu-68, Leu-69, Met-85, Val-86, Thr-87, Ala-88, Asn-94, Val-107, Lys-109, Thr-112, Ala-113, Ala-114, and Asn-121. These results appear inconsistent with the recent suggestion that phosphorylation produces the same structural changes as magnesium binding (Bell-solell, L., Prieto, J., Serrano, L., and Cell, M. (1994) J. Mel. Biol. 238, 489-495). We find that some regions change overlap with a genetically defined motor binding face. We therefore propose that the conformation switch modulates the interaction of CheY with its target, the flagellar motor. Other regions also change, possibly reflecting the many different functions of CheY homologues.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; UNIV ILLINOIS, DEPT MICROBIOL & IMMUNOL, CHICAGO, IL 60612 USA	University of Oregon; DuPont; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NIAID NIH HHS [AI18985] Funding Source: Medline; NIGMS NIH HHS [GM33677] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033677, R37GM033677] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; BOURRET RB, 1993, J BIOL CHEM, V268, P13089; BRUIX M, 1993, EUR J BIOCHEM, V215, P573, DOI 10.1111/j.1432-1033.1993.tb18068.x; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MOY FJ, 1994, IN PRESS BIOCH; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; STOCK JB, 1992, J BIOL CHEM, V267, P19753; VOLZ K, 1991, J BIOL CHEM, V266, P15511; ZHANG O, 1994, IN PRESS J BIOMOL NM	15	78	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26358	26362						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929354				2022-12-25	WOS:A1994PQ93000064
J	MARTIN, G; CHAUVIN, MF; DUGELAY, S; BAVEREL, G				MARTIN, G; CHAUVIN, MF; DUGELAY, S; BAVEREL, G			NONSTEADY STATE MODEL APPLICABLE TO NMR-STUDIES FOR CALCULATING FLUX RATES IN GLYCOLYSIS, GLUCONEOGENESIS, AND CITRIC-ACID CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY-CORTEX; KREBS CYCLE; METABOLISM; GLUTAMATE; PYRUVATE; LIVER; HEART	We present a mathematical model for calculating most reaction rates of glycolysis, gluconeogenesis and citric acid cycle in mammalian cells. The model also includes cycles such as the ''phosphoenolpyruvate (PEP) --> pyruvate --> oxaloacetate --> PEP'' cycle and the ''pyruvate --> acetyl-CoA --> citrate --> citric acid cycle --> oxaloacetate --> PEP --> pyruvate'' cycle. The model, which does not require steady state conditions, is based on a set of equations, each one describing the fates of a given carbon of a selected intermediate. These fates are expressed as ratios of integrated transfer of this carbon to corresponding carbons in subsequent metabolites. At each bifurcation, the sum of all proportions adds up to 1. Among several calculation routes to determine a proportion value, we chose the one that was based on the most reliable parameter determined experimentally. The data introduced in the model are the micrograms of atom of traced carbon measured on each carbon of a number of products (corrected for natural tracer abundance). These incorporations can be measured by C-13 NMR, gas chromatography-mass spectroscopy, or C-14 counting. Thanks to its flexibility, this model can be applied to data obtained with substrates other than glucose under many experimental conditions.			MARTIN, G (corresponding author), HOP EDOUARD HERRIOT,CTR ETUD METAB SPECT RESONANCE MAGNET,CNRS,EP 18,PAVILLON P,PL ARSONVAL,F-69374 LYON 03,FRANCE.							CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CHAUVIN MF, 1994, J BIOL CHEM, V269, P26025; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P581, DOI 10.1021/bi00376a033; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; KATZ J, 1989, J BIOL CHEM, V264, P12994; KELLEHER JK, 1985, AM J PHYSIOL, V248, pE252, DOI 10.1152/ajpendo.1985.248.2.E252; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; ROGNSTAD R, 1972, J BIOL CHEM, V247, P6047; WATFORD M, 1980, BIOCHEM J, V188, P741, DOI 10.1042/bj1880741	12	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26034	26039						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929314				2022-12-25	WOS:A1994PQ93000018
J	BRAVO, DA; GLEASON, JB; SANCHEZ, RI; ROTH, RA; FULLER, RS				BRAVO, DA; GLEASON, JB; SANCHEZ, RI; ROTH, RA; FULLER, RS			ACCURATE AND EFFICIENT CLEAVAGE OF THE HUMAN INSULIN PRORECEPTOR BY THE HUMAN PROPROTEIN-PROCESSING PROTEASE FURIN - CHARACTERIZATION AND KINETIC-PARAMETERS USING THE PURIFIED, SECRETED SOLUBLE PROTEASE EXPRESSED BY A RECOMBINANT BACULOVIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINIDASE; TYROSINE KINASE FAMILY; HAMSTER OVARY CELLS; SACCHAROMYCES-CEREVISIAE; POINT MUTATION; KEX2 PROTEASE; RECEPTOR; ENDOPROTEASE; CDNA; PRECURSOR	Maturation of the insulin proreceptor in a late Golgi compartment requires cleavage at an Arg-Lys-Arg-Arg processing site, suggesting involvement of furin, a transmembrane serine protease of the Kex2 family of processing enzymes. A genetically engineered secreted, soluble form of human furin (ss-furin), expressed by infection of insect cells with a recombinant baculovirus, was purified to near homogeneity. ss-furin exhibited rapid and efficient cleavage of both isoforms of the human insulin proreceptor in solubilized extracts of cultured mammalian cells expressing preproreceptor cDNA. Proreceptor cleavage occurred at the physiological processing site as judged by the effects of mutations in this site on cleavage by purified ss-furin. Moreover, purified ss-furin exhibited specificity for proreceptor cleavage identical to that of the endogenous insulin proreceptor-processing enzyme. Furin thus displays the properties expected of an insulin proreceptor processing enzyme in that it (i) cleaves the proreceptor efficiently and at the correct site; (ii) exhibits the same specificity in processing variant proreceptors as the endogenous enzyme; (iii) appears to be localized in the correct secretory compartment; and (iv) has the same broad pattern of tissue distribution as the insulin proreceptor.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305	Stanford University; Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, R01DK034926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM039697, R01GM039697] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34926] Funding Source: Medline; NIGMS NIH HHS [GM39697] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGLIKER H, 1993, BIOCHEM J, V293, P75, DOI 10.1042/bj2930075; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; CHIN JE, 1991, J BIOL CHEM, V266, P15587; DARDEVET D, 1991, AM J PHYSIOL, V261, pE562, DOI 10.1152/ajpendo.1991.261.5.E562; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HEDO JA, 1983, J BIOL CHEM, V258, P20; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KOBAYASHI M, 1988, BIOCHEM BIOPH RES CO, V153, P657, DOI 10.1016/S0006-291X(88)81145-8; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; OLSON TS, 1987, J BIOL CHEM, V262, P6816; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PASHMFOROUSH M, 1992, DIABETES S1, V241, P55; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SALZMAN A, 1984, BIOCHEMISTRY-US, V23, P6555, DOI 10.1021/bi00321a043; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; SHIER P, 1989, J BIOL CHEM, V264, P14605; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; Summers MD, 1987, TEXAS AGR EXPT STATI; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; YOKOTA T, 1984, P NATL ACAD SCI-BIOL, V81, P1070, DOI 10.1073/pnas.81.4.1070; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230; ZHANG B, 1991, J BIOL CHEM, V266, P990	44	116	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25830	25837						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929288				2022-12-25	WOS:A1994PQ49100088
J	JOE, YA; PARK, MH				JOE, YA; PARK, MH			STRUCTURAL FEATURES OF THE EIF-5A PRECURSOR REQUIRED FOR POSTTRANSLATIONAL SYNTHESIS OF DEOXYHYPUSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION-FACTOR; HYPUSINE-CONTAINING PROTEIN; SACCHAROMYCES-CEREVISIAE; SEQUENCE DETERMINATION; FACTOR 4D; SPERMIDINE; CDNA; IDENTIFICATION; PURIFICATION; CLEAVAGE	Eukaryotic translation initiation factor 5A (eIF-5A, older nomenclature, eIF-4D) is a highly conserved protein that contains the unusual amino acid hypusine ((epsilon)-(4-amino-2-hydroxybutyl)lysine). The biosynthesis of hypusine occurs posttranslationally in only this protein by modification of a single lysine residue (Lys(50) in the human eIF-5A precursor). The basis for the specificity of this modification with respect to the substrate protein was investigated using fragments of eIF-5A precursor protein, each containing this lysine residue, as substrates for deoxyhypusine synthase, the first enzyme in hypusine synthesis. Proteolytic fragments (5-6 kDa) of ec-eIF-5A (the precursor form of eIF-5A produced in Escherichia coli by expression of the human eIF-5A cDNA) generated by specific cleavage by endoproteinases Arg-C, Asp-N, or Glu-C, did not act as substrates for deoxyhypusine synthesis. A series of truncated forms of the eIF-5A precursor protein generated by expression in E. coli of recombinant deletion constructs from the human eIF-5A cDNA were tested. Truncation of up to 9 amino acid residues (Met(1)-Thr(9)) from the NH, terminus or 64 amino acid residues (Leu(91)-Lys(154)) from the COOH terminus did not significantly decrease the substrate reactivity, but removal of an additional 10 amino acids from either side did, Deletion of 34 amino acid residues (Met(1)-Lys(34)) from the NH2 terminus or of 84 amino acid residues (Asp(71)-Lys(154)) from the carboxyl terminus caused complete loss of substrate property. The results obtained thus far define the minimum domain of the eIF-5A precursor protein required for enzymatic deoxyhypusine synthesis as Phe(30)-Asp(80), which corresponds to a region of high amino acid conservation in this protein throughout the eukaryotic kingdom.	NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; BENNE R, 1978, J BIOL CHEM, V253, P3078; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; CHAMOT D, 1992, NUCLEIC ACIDS RES, V20, P665, DOI 10.1093/nar/20.4.665; GORDON ED, 1987, J BIOL CHEM, V262, P16585; JAKUS J, 1993, J BIOL CHEM, V268, P13151; KANG HA, 1994, J BIOL CHEM, V269, P3934; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; PARK MH, 1983, METHOD ENZYMOL, V94, P458; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1993, BIOFACTORS, V4, P95; PARK MH, 1988, J BIOL CHEM, V263, P15264; PAY A, 1991, PLANT MOL BIOL, V17, P927, DOI 10.1007/BF00037075; RINAUDO MS, 1993, GENE, V137, P303, DOI 10.1016/0378-1119(93)90025-X; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SANDHOLZER U, 1989, FEBS LETT, V246, P94, DOI 10.1016/0014-5793(89)80260-1; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P1578; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; YAN SCB, 1989, TRENDS BIOCHEM SCI, V14, P264, DOI 10.1016/0968-0004(89)90060-1	24	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25916	25921						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929297				2022-12-25	WOS:A1994PQ49100099
J	ALAM, J				ALAM, J			MULTIPLE ELEMENTS WITHIN THE 5' DISTAL ENHANCER OF THE MOUSE HEME OXYGENASE-1 GENE MEDIATE INDUCTION BY HEAVY-METALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOMA-CELLS; TRANSCRIPTION FACTOR; BINDING-PROTEIN; C/EBP FAMILY; CHLORAMPHENICOL ACETYLTRANSFERASE; NUCLEAR-PROTEIN; MAMMALIAN-CELLS; JUN GENE; C-JUN; EXPRESSION	A 268-base pair 5' distal fragment, SX2, which mediates basal level and inducer dependent activation of the mouse heme oxygenase-1 gene, contains two activator protein-1 (AP-1) binding sites (Alam, J., and Zhining, D. (1992) J. Biol. Chem. 267, 21894-21900). Mutation of both AP-1 binding elements diminishes (by 50-70%), but does not abolish, the enhancer activity of SX2 in transient expression assays, suggesting that other sequences contribute to enhancer function. Directly upstream of the AP-1 binding sites are two copies of a sequence motif, TGAGGAAAT, which resemble elements found in cellular and viral genes that are known to interact with the CCAAT/enhancer binding protein (C/EBP) family of transcription factors. These SX2 sequences bind specifically to liver enriched, heat-stable nuclear proteins and confer C/EBP alpha-dependent transactivation of the heterologous chloramphenicol acetyltransferase (CAT) gene. Site-directed mutagenesis of these 9-base pair elements abolishes protein binding and transactivation, establishing these sequences as functional C/EBP binding sites. Stably transfected SX2/CAT fusion genes are induced between 37- and 44-fold in mouse hepatoma, Hepa, cells and between 52- and 111-fold in mouse fibroblast L929 cells in response to CdCl2 treatment. Subfragments of SX2 lacking the AP-1 binding elements do not mediate cadmium dependent activation of the CAT gene, whereas subfragments containing the AP-1 binding elements, but lacking the C/EBP binding sites, exhibit only partial transcriptional activity. Site-directed mutagenesis of one or more of the C/EBP and AP-1 binding sites indicates that each of these elements is required for optimal activity of the SX2 enhancer fragment. The AP-1 binding elements, however, appear to be more important for induction as constructs containing multiple copies of either of the AP-1 binding elements, but not the C/EBP binding sequences, are readily activated by CdCl2. Treatment of Hepa cells with cadmium or heme does not alter the nuclear concentration of AP-1 or C/EBP binding activity.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, NEW ORLEANS, LA 70121 USA	Louisiana State University System	ALAM, J (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN, DEPT MOLEC GENET, 1516 JEFFERSON HIGHWAY, NEW ORLEANS, LA 70121 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43135] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM J, 1992, J BIOL CHEM, V267, P16379; ALAM J, 1994, J BIOL CHEM, V269, P1001; ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ALAM J, 1992, J BIOL CHEM, V267, P21894; ALAM J, 1989, J BIOL CHEM, V264, P6371; ALAM J, 1991, BIOTECHNIQUES, V10, P422; APPLEGATE LA, 1991, CANCER RES, V51, P974; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DAILEY HA, 1987, ANN NY ACAD SCI, V514, P81, DOI 10.1111/j.1749-6632.1987.tb48763.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; LAVROVSKY Y, 1993, BIOCHEM BIOPH RES CO, V196, P336, DOI 10.1006/bbrc.1993.2253; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; Maines M.D., 1992, HEME OXYGENASE CLIN; MAINES MD, 1974, P NATL ACAD SCI USA, V71, P4293, DOI 10.1073/pnas.71.11.4293; MAINES MD, 1976, BIOCHEM J, V154, P125, DOI 10.1042/bj1540125; MITANI K, 1990, BIOCHEM BIOPH RES CO, V166, P1429, DOI 10.1016/0006-291X(90)91026-O; MITANI K, 1993, BIOCHEM J, V290, P819, DOI 10.1042/bj2900819; MULLER RM, 1987, J BIOL CHEM, V262, P6795; NATSUKA S, 1992, BLOOD, V79, P460; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OKINAGA S, 1993, EUR J BIOCHEM, V212, P167, DOI 10.1111/j.1432-1033.1993.tb17647.x; PEI J, 1990, J BIOL CHEM, V265, P14061; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918	51	115	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25049	25056						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929191				2022-12-25	WOS:A1994PQ49000079
J	OU, WJ; KUMAMOTO, T; MIHARA, K; KITADA, S; NIIDOME, T; ITO, A; OMURA, T				OU, WJ; KUMAMOTO, T; MIHARA, K; KITADA, S; NIIDOME, T; ITO, A; OMURA, T			STRUCTURAL REQUIREMENT FOR RECOGNITION OF THE PRECURSOR PROTEINS BY THE MITOCHONDRIAL PROCESSING PEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-ORNITHINE TRANSCARBAMYLASE; ADRENAL-CORTEX MITOCHONDRIA; RAT-LIVER; CYTOCHROME-P-450(SCC) PRECURSOR; PROTEOLYTIC CLEAVAGE; PARTIAL-PURIFICATION; EXTENSION PEPTIDES; YEAST MITOCHONDRIA; ENZYME PRECURSORS; LEADER PEPTIDE	We examined the structural characteristics of the extension peptides responsible for the recognition by the mitochondrial processing peptidase by using pre-adrenodoxin, which has a long extension peptide of 58 amino acid residues, as the substrate. The deletion of various parts of the extension peptide of pre-adrenodoxin indicated that more than 40 amino acid residues and the presence of basic amino acid residues in the distal portion (20-40 amino acid residues upstream of the cleavage site) were necessary for the recognition of the precursor by the peptidase. The processing of pre-adrenodoxin was strongly inhibited by the synthetic peptide corresponding to the middle portion of the extension peptide, whereas the peptide corresponding to the amino-terminal portion exhibited weak inhibition of the processing. The replacement of arginine residues in the middle portion of the extension peptide with neutral amino acids resulted in a great decrease in the processing. We conclude that basic amino acids at a position distal to the cleavage site are necessary for the recognition of the precursor proteins by the processing peptidase and that basic amino acids required for the mitochondrial targeting and those for the recognition by the peptidase are separately located in the extension peptide of pre adrenodoxin.	KYUSHU UNIV,FAC SCI,DEPT CHEM,FUKUOKA 812,JAPAN; KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University			Niidome, Takuro/F-1508-2010	Niidome, Takuro/0000-0002-8070-8708				AOYAGI H, 1987, J BIOCHEM-TOKYO, V102, P813, DOI 10.1093/oxfordjournals.jbchem.a122120; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; FURUYA S, 1987, J BIOCHEM, V102, P821, DOI 10.1093/oxfordjournals.jbchem.a122121; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HURT EC, 1987, J BIOL CHEM, V262, P1420; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; ITO A, 1985, J BIOCHEM-TOKYO, V98, P1571, DOI 10.1093/oxfordjournals.jbchem.a135426; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KALOUSEK F, 1992, EMBO J, V11, P1803; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KITADA S, 1993, BIOCHEM BIOPH RES CO, V190, P289, DOI 10.1006/bbrc.1993.1044; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KRAUS JP, 1988, P NATL ACAD SCI USA, V85, P8905, DOI 10.1073/pnas.85.23.8905; KUMAMOTO T, 1989, J BIOCHEM-TOKYO, V105, P72, DOI 10.1093/oxfordjournals.jbchem.a122622; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCADA PC, 1982, J BIOL CHEM, V257, P3177; MIURA S, 1982, EUR J BIOCHEM, V122, P641; NEUPERT W, 1981, TRENDS BIOCHEM SCI, V6, P1, DOI 10.1016/0968-0004(81)90002-5; OGISHIMA T, 1985, J BIOCHEM, V98, P781, DOI 10.1093/oxfordjournals.jbchem.a135335; OU W, 1986, J BIOCHEM-TOKYO, V100, P1287, DOI 10.1093/oxfordjournals.jbchem.a121835; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5335; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; SAGARA Y, 1984, J BIOCHEM-TOKYO, V96, P1743, DOI 10.1093/oxfordjournals.jbchem.a135007; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; ZWIZINSKI C, 1983, J BIOL CHEM, V258, P3340	42	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24673	24678						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929139				2022-12-25	WOS:A1994PQ49000026
J	OTTERSON, GA; KRATZKE, RA; COXON, A; KIM, YW; KAYE, FJ				OTTERSON, GA; KRATZKE, RA; COXON, A; KIM, YW; KAYE, FJ			ABSENCE OF P16(INK4) PROTEIN IS RESTRICTED TO THE SUBSET OF LUNG-CANCER LINES THAT RETAINS WILDTYPE RB	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; PHOSPHORYLATION; EXPRESSION; INACTIVATION; SUPPRESSION; CARCINOMA; BINDING; GROWTH	Cell cycle dependent phosphorylation of the RB tumor suppressor protein is mediated by a family of G1 cyclin dependent kinases (cdks) and cyclins including the activated cdk4:cyclin D complex. The identification of a cdk4 inhibitor, p16(INK4), as a target for mutations in cultured tumor lines and primary tumors suggested that RB activity may be affected in these cells. We have examined 88 lung cancer lines for p16(INK4) protein expression and have observed a striking inverse correlation between the presence of p16(INK4) and wildtype RB. We demonstrated that only 6/55 (11%) of small cell lung cancer (SCLC) samples had absent p16(INK4) protein, and all 6 belonged to the rare subset of SCLC with wildtype RB expression. Conversely of 48 SCLC samples with absent or mutant RB, all showed detectable levels of p16(INK4) protein. In contrast, we observed that 23/33 (70%) of non-SCLC samples had loss of p16(INK4). Twenty-two of 26 non-SCLC lines with wildtype RB had absent p16(INK4) while 6 of 7 non-SCLC lines with absent or mutant RB had detectable p16(INK4). The inverse correlation of RB and p16(INK4) expression and the absence of p16(INK4) inactivation in RB (-/-) SCLC lines (0/48) confirms a common p16(INK4)/RB growth suppressor pathway in human cancers and provides evidence that p16(INK4), and not an adjacent gene on chromosome 9p, is a specific target for mutational events.	NCI,NAVY ONCOL BRANCH,BETHESDA,MD 20889; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20889	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA			kaye, frederic/E-2437-2011					BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORI T, 1994, CANCER RES, V54, P3396; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OOKAWA K, 1993, ONCOGENE, V8, P2175; OTTERSON GA, 1993, ONCOGENE, V8, P949; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; REISSMANN PT, 1993, ONCOGENE, V8, P1913; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIMIZU E, 1994, ONCOGENE, V9, P2441; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XU HJ, 1991, CANCER RES, V51, P2735; YOKOTA J, 1988, ONCOGENE, V3, P471	31	373	382	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3375	3378						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936665				2022-12-25	WOS:A1994PM65800034
J	FULLER, CM; ISMAILOV, II; KEETON, DA; BENOS, DJ				FULLER, CM; ISMAILOV, II; KEETON, DA; BENOS, DJ			PHOSPHORYLATION AND ACTIVATION OF A BOVINE TRACHEAL ANION CHANNEL BY CA2+-CALMODULIN-DEPENDENT PROTEIN-KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CHLORIDE CHANNEL; CA-2+-DEPENDENT CL CHANNELS; CYSTIC-FIBROSIS AIRWAY; PLANAR LIPID BILAYERS; COLONIC CELLS HT-29; FUNCTIONAL RECONSTITUTION; APICAL MEMBRANE; CALCIUM; CFTR	Secretion of Cl- by epithelial cells is fundamental to the processes of fluid and electrolyte transport by epithelia such as those of the airways, sweat-ducts, and gastrointestinal tract. In the present study, we show that a novel Cl- channel protein, immunoaffinity purified from bovine tracheal apical membrane vesicles, is sensitive to phosphorylation by Ca2+/calmodulin protein kinase II (CaMK II). The channel protein, which migrates with an M(r) of 140,000 under nonreducing conditions, is phosphorylated in vitro by CaMK II in a Ca2+- and calmodulin-dependent manner. When reconstituted into planar lipid bilayers, the protein behaves as an anion-selective, 4,4'-diisothiocyanostilbene- and dithiothreitol-sensitive channel. The open probability of this channel is significantly increased by Ca2+ alone but only at levels of Ca2+ (5-10 mu M) that lie outside the physiological range. Addition of CaMK II to the presumptive cytoplasmic side of the bilayer in the presence of ATP and calmodulin dramatically increased the sensitivity of the channel to free Ca2+, shifting the dose-response curve for Ca2+-dependent channel activation to lower [Ca2+](i) the maximum increase in channel P-o occurring between 0.6 and 1 mu M. The addition of kinase in the absence of ATP or calmodulin or the addition of ATP or calmodulin in the absence of kinase was without effect on channel P-o. Increasing [Ca2+] above 1 mu M decreased channel mean current, causing a flickery block that was maximal at 2 mu M. Increasing [Ca2+] as high as 10 mu M in the presence of kinase did not further alter channel behavior. In contrast to CaMK II, the addition of the catalytic subunit of protein kinase A either alone or together with ATP had no effect on channel P-o. These observations suggest that a novel Ca2+-sensitive anion channel isolated from bovine airway epithelium is regulated by CaMK II phosphorylation.			FULLER, CM (corresponding author), UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BHSB 705,UNIV STN,BIRMINGHAM,AL 35294, USA.		Fuller, Cathy/B-4046-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK042017] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42017] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CHAN HC, 1992, AM J PHYSIOL, V262, pC1237; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; Dubinsky William P., 1992, American Journal of Physiology, V263, pC888; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FINN AL, 1992, AM J PHYSIOL, V263, pC172, DOI 10.1152/ajpcell.1992.263.1.C172; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FULLER CM, 1994, AM J PHYSIOL, V266, pC661, DOI 10.1152/ajpcell.1994.266.3.C661; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GRAY MA, 1994, AM J PHYSIOL, V266, pC213, DOI 10.1152/ajpcell.1994.266.1.C213; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; ISMAILOV II, 1994, IN PRESS KIDNEY INT; LA BQ, 1991, AM J PHYSIOL, V260, pC1217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANGRIDGESMITH JE, 1983, BIOCHIM BIOPHYS ACTA, V731, P318, DOI 10.1016/0005-2736(83)90024-X; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MCMANUS OB, 1991, J BIOENERG BIOMEMBR, V23, P537, DOI 10.1007/BF00785810; MORRIS AP, 1993, AM J PHYSIOL, V264, pC968, DOI 10.1152/ajpcell.1993.264.4.C968; MORRIS AP, 1993, AM J PHYSIOL, V264, pC977, DOI 10.1152/ajpcell.1993.264.4.C977; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; OH YS, 1993, AM J PHYSIOL, V265, pC85, DOI 10.1152/ajpcell.1993.265.1.C85; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PRESTON CL, 1992, AM J PHYSIOL, V263, pC879, DOI 10.1152/ajpcell.1992.263.4.C879; RAN S, 1992, J BIOL CHEM, V267, P20630; RAN S, 1991, J BIOL CHEM, V266, P4782; RAN S, 1992, J BIOL CHEM, V267, P3618; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; REEVES BW, 1994, AM J PHYSIOL, V266, pC741; SAKAKIBARA M, 1986, BIOPHYS J, V50, P319, DOI 10.1016/S0006-3495(86)83465-8; TILLY BC, 1992, J BIOL CHEM, V267, P9470; TSAI LM, 1991, J GEN PHYSIOL, V98, P723, DOI 10.1085/jgp.98.4.723; VALDIVIA HH, 1988, SCIENCE, V242, P1441, DOI 10.1126/science.2462280; VALVERDE MA, 1993, PFLUG ARCH EUR J PHY, V425, P434, DOI 10.1007/BF00374869; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WAGNER JA, 1992, P NATL ACAD SCI USA, V89, P6785, DOI 10.1073/pnas.89.15.6785; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877; YAMAYA M, 1993, AM J PHYSIOL, V265, pL170, DOI 10.1152/ajplung.1993.265.2.L170	47	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26642	26649						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929397				2022-12-25	WOS:A1994PQ93100013
J	SPRINGER, BA; PANTOLIANO, MW; BARBERA, FA; GUNYUZLU, PL; THOMPSON, LD; HERBLIN, WF; ROSENFELD, SA; BOOK, GW				SPRINGER, BA; PANTOLIANO, MW; BARBERA, FA; GUNYUZLU, PL; THOMPSON, LD; HERBLIN, WF; ROSENFELD, SA; BOOK, GW			IDENTIFICATION AND CONCERTED FUNCTION OF 2 RECEPTOR-BINDING SURFACES ON BASIC FIBROBLAST GROWTH-FACTOR REQUIRED FOR MITOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; HEPARIN-BINDING; 3-DIMENSIONAL STRUCTURE; EXTRACELLULAR DOMAIN; SIGNAL TRANSDUCTION; TYROSINE KINASES; AFFINITY; SULFATE; HORMONE; FAMILY	Members of the fibroblast growth factor (FGF) family promote angiogenesis and wound repair, modulate early developmental events and survival of neurons, and have been associated with the pathogenesis of various diseases. FGFs interact with specific FGF receptors (FGFRs) and heparan sulfate proteoglycans on cell surfaces to mediate mitogenesis. Using protein structure-based site-directed mutagenesis of basic FGF (bFGF), we have identified two FGFR binding sites on bFGF which act in concert to initiate signal transduction. Both FGFR binding surfaces are distinct from the heparan sulfate proteoglycan binding domain. The primary, higher affinity, binding interaction comprises a cluster of solvent exposed hydrophobic amino acids (Tyr-24, Tyr-103, Leu-140, and Met-142), and two polar residues (Arg-44 and Asn-101). The hydrophobic contacts dominate the primary binding interaction and provide similar to 75% of the binding affinity. The secondary FGFR binding site on bFGF has an similar to 250-fold lower affinity and is composed of amino acids Lys-110, Tyr-111, and Trp-114 in a surface-exposed type I beta-turn (formerly known as the putative receptor binding loop). Binding of FGFR to both bFGF surfaces in a stoichiometry of 2FGFR:1bFGF is required for growth factor mediated cell proliferation. This represents a mechanism for the fibroblast growth factor/receptor family in which FGF facilitates FGFR dimerization and subsequent signal transduction events as a monomeric ligand.	DUPONT MERCK PHARMACEUT CO,DEPT CRYSTALLOG & BIOPHYS,DUPONT EXPTL STN,WILMINGTON,DE 19880; DUPONT MERCK PHARMACEUT CO,DEPT CARDIOVASC DIS RES,DUPONT EXPTL STN,WILMINGTON,DE 19880; DUPONT MERCK PHARMACEUT CO,DEPT BIOTECHNOL,DUPONT EXPTL STN,WILMINGTON,DE 19880	DuPont; DuPont; DuPont			Thompson, Lester D. R./J-8404-2016	Thompson, Lester D. R./0000-0003-3714-1432				BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEIGE JJ, 1989, P NATL ACAD SCI USA, V86, P3174, DOI 10.1073/pnas.86.9.3174; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; HEATH WF, 1991, BIOCHEMISTRY-US, V30, P5608, DOI 10.1021/bi00236a039; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SQUIRES CH, 1988, J BIOL CHEM, V263, P16297; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	32	133	150	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26879	26884						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929426				2022-12-25	WOS:A1994PQ93100047
J	VITTORIOSO, P; CARATTOLI, A; LONDEI, P; MACINO, G				VITTORIOSO, P; CARATTOLI, A; LONDEI, P; MACINO, G			INTERNAL TRANSLATIONAL INITIATION IN THE MESSENGER-RNA FROM THE NEUROSPORA-CRASSA ALBINO-3 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; AUG SELECTION; LEADER	The ''ribosome scanning model'' for translational initiation predicts that eukaryotic mRNAs should, as a rule, be monocistronic. However, cases have recently been described of eukaryotic mRNAs producing more than one protein through alternative translational initiation at several different AUG codons. The present work reports the occurrence of multiple translational start sites on the mRNA of the Neurospora crassa gene albino-3 (al-3), encoding the carotenoid biosynthetic enzyme geranylgeranyl-pyrophosphate synthase. This was revealed by the molecular analysis of an al-3 mutant carrying a deletion within the coding sequence, which was expected to prevent the synthesis of a functional geranylgeranyl-pyrophosphate synthase because of ribosome frameshifting and premature translational termination. However, the mutants could maintain appreciable geranylgeranyl-pyrophosphate synthase activity through a mechanism operating at the translational level, whereby a fraction of ribosomes initiated protein synthesis from either of two internal in-frame AUG codons located downstream of the deletion, thus producing a shortened but still active version of the geranylgeranyl-pyrophosphate synthase. The results presented indicate that the internal AUG codons are recognized mainly or solely by direct ribosome binding rather than by ''leaky scanning'' from the 5' end of the mRNA.	UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,DIPARTIMENTO BIOPATOL UMANA,SEZ BIOL CELLULARE,I-00161 ROME,ITALY	Sapienza University Rome; University Hospital Sapienza Rome			Carattoli, Alessandra/A-1324-2009	Carattoli, Alessandra/0000-0002-6120-6526; Vittorioso, Paola/0000-0002-4189-5168				CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; HARDING RW, 1981, PLANT PHYSIOL, V68, P745, DOI 10.1104/pp.68.3.745; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWEE L, 1992, J VIROL, V66, P4382, DOI 10.1128/JVI.66.7.4382-4389.1992; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; NELSON MA, 1989, MOL CELL BIOL, V9, P1271, DOI 10.1128/MCB.9.3.1271; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; ROMANO N, 1992, MOL MICROBIOL, V6, P3343, DOI 10.1111/j.1365-2958.1992.tb02202.x; Sambrook J, 1989, MOL CLONING LABORATO; SANDMANN G, 1993, J PHOTOCH PHOTOBIO B, V18, P245, DOI 10.1016/1011-1344(93)80071-G; SCHEPER CG, 1991, J BIOL CHEM, V267, P7269; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; TAHARA SM, 1991, J BIOL CHEM, V266, P3594; VOSS JW, 1991, J BIOL CHEM, V266, P12832	19	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26650	26654						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929398				2022-12-25	WOS:A1994PQ93100014
J	DILIBERTO, PA; KRISHNA, S; KWON, S; HERMAN, B				DILIBERTO, PA; KRISHNA, S; KWON, S; HERMAN, B			ISOFORM-SPECIFIC INDUCTION OF NUCLEAR FREE CALCIUM OSCILLATIONS BY PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CYTOSOLIC FREE CALCIUM; INTRACELLULAR FREE CALCIUM; C-FOS EXPRESSION; INOSITOL TRISPHOSPHATE; CONFOCAL MICROSCOPY; BALB/C-3T3 CELLS; CYTOPLASMIC CA2+; FACTOR RECEPTORS; LIVER NUCLEI	Confocal laser scanning microscopy was used to analyze alterations in nuclear free calcium (Ca-n(2+)) levels induced by platelet-derived growth factor (PDGF) iso forms in BALB/c3T3 fibroblasts loaded with the calcium-sensitive fluorescent indicator Fluo-3. Both AA-PDGF and BB-PDGF caused a transient increase in Ca-n(2+). Analysis of PDGF-induced Ca-n(2+) alterations as a function of time revealed that BB-PDGF stimulation resulted in the generation of Ca-n(2+) oscillations that diminished over time. The frequency of BB-PDGF-stimulated oscillations was modulated by extracellular Ca2+ and could not be mimicked by increasing intracellular inositol 1,4,5-trisphosphate levels in the absence of growth factor stimulation. Caffeine alone had no effect on Ca-n(2+) levels, but exposure of cells to caffeine after BB-PDGF stimulation augmented Ca-n(2+) oscillations, either by increasing the frequency or reinitiating preexisting oscillations. The genesis of these oscillations in Ca-n(2+), appears to be in the region just outside of the nucleus, as perinuclear cytoplasmic free calcium (Ca-i(2+)) increased just prior to Ca-n(2+). In contrast, AA-PDGF stimulation resulted in the generation of one or two irregular, transient Ca-n(2+) spikes. Caffeine pretreatment followed by AA-PDGF stimulation resulted in Ca-n(2+) oscillations very similar to those produced by BB-PDGF alone. Additionally, the AA-PDGF and BB-PDGF isoforms appeared to modulate distinct pools of cellular Ca2+, as BB-PDGF was still capable of inducing Ca-n(2+) oscillations subsequent to prior induction of oscillations by AA-PDGF/caffeine. These PDGF isoform-specific changes in nuclear free Ca2+ could serve as a mechanism by which isoform-specific cellular signaling pathways may be manifested by the growth factors.	UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CELL BIOL LABS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER CANC RES CTR,SCH MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NIA NIH HHS [AG10104] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010104] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLBRITTON NL, 1993, BIOPHYS, V66, P151; ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BERNACKI SH, 1990, OPTICAL MICROSCOPY FOR BIOLOGY, P307; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; CHANDRA S, 1989, P NATL ACAD SCI USA, V86, P1870, DOI 10.1073/pnas.86.6.1870; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; DILIBERTO PA, 1990, J CELL BIOCHEM, V44, P39, DOI 10.1002/jcb.240440104; DILIBERTO PA, 1991, J BIOL CHEM, V266, P12612; DILIBERTO PA, 1992, J BIOL CHEM, V267, P11888; DILIBERTO PA, 1991, RES COMMUN CHEM PATH, V72, P3; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HART CE, 1990, J INVEST DERMATOL, V94, pS53, DOI 10.1111/1523-1747.ep12875065; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HERMAN B, 1987, CELL MOTIL CYTOSKEL, V8, P91, DOI 10.1002/cm.970080202; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HIMPENS B, 1992, AM J PHYSIOL, V263, pC978, DOI 10.1152/ajpcell.1992.263.5.C978; HIMPENS B, 1992, AM J PHYSIOL, V263, pC95, DOI 10.1152/ajpcell.1992.263.1.C95; HIMPENS B, 1993, AM J PHYSIOL, V265, pC966, DOI 10.1152/ajpcell.1993.265.4.C966; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LANINI L, 1992, J BIOL CHEM, V267, P11548; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MOOLENAAR WH, 1986, J EXP BIOL, V124, P359; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NEYLON CB, 1990, AM J PHYSIOL, V259, pC675, DOI 10.1152/ajpcell.1990.259.4.C675; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; PETERSEN OH, 1991, CELL CALCIUM, V12, P135, DOI 10.1016/0143-4160(91)90015-7; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; STRICKER SA, 1992, DEV BIOL, V149, P370, DOI 10.1016/0012-1606(92)90292-O; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TUCKER RW, 1990, EUR J CELL BIOL, V51, P120; TUCKER RW, 1989, J CELL BIOCHEM, V39, P139, DOI 10.1002/jcb.240390206; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; WHARTON W, 1982, J CELL PHYSIOL, V111, P201, DOI 10.1002/jcp.1041110212; WILLIAMS DA, 1987, SCIENCE, V235, P1644, DOI 10.1126/science.3103219; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; ZAGARI M, 1989, J CELL PHYSIOL, V139, P167, DOI 10.1002/jcp.1041390123	55	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26349	26357						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929353				2022-12-25	WOS:A1994PQ93000063
J	HIRSCHBERG, BT; SCHIMERLIK, MI				HIRSCHBERG, BT; SCHIMERLIK, MI			A KINETIC-MODEL FOR OXOTREMORINE-M BINDING TO RECOMBINANT PORCINE M2 MUSCARINIC RECEPTORS EXPRESSED IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; ADENYLATE-CYCLASE; AGONISTS; COMPLEX; SYSTEM; BRAIN	The kinetic mechanism of super high affinity [H-3]oxotremorine M binding to porcine m2 muscarinic receptors expressed in Chinese hamster ovary cells was examined. In cell lines expressing low receptor numbers (10(4) binding sites/cell) and in high expression (10(6) sites/cell) cell lines treated with cholate, [H-3]oxotremorine M association and dissociation kinetics were monophasic. The reciprocal relaxation time for the association reaction was independent of [H-3]oxotremorine M concentration and equaled the dissociation rate constant consistent with a special case for a mechanism involving a protein conformational change followed by ligand binding. Membranes from high expression cell lines and porcine atrial membranes showed complex kinetic behavior. Two kinetic phases were observed for [H-3]oxotremorine M association, and both reciprocal relaxation times were independent of Ligand concentration. The number of kinetic phases and their relative amplitudes seen in dissociation experiments were dependent on whether dissociation was initiated by dilution or by addition of unlabeled ligand(s) as well as on the fractional saturation of the receptor. Computer simulations of the data led to a model consistent with the existence of asymmetric receptor dimers as well as monomers and the ligand-dependent interconversion of fully occupied dimers and monomers.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; OREGON STATE UNIV,CTR ENVIRONM HLTH SCI,CORVALLIS,OR 97331	Oregon State University; Oregon State University								BERNASCONI CF, 1976, RELAXATION KINETICS, P112; Bevington PR, 1969, DATA REDUCTION ERROR; BIRDSALL NJM, 1980, PROC R SOC SER B-BIO, V207, P1, DOI 10.1098/rspb.1980.0011; BURGEN ASV, 1987, BRIT J PHARMACOL, V92, P327, DOI 10.1111/j.1476-5381.1987.tb11327.x; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; GALPER JB, 1987, MOL PHARMACOL, V32, P230; GILLARD M, 1987, MOL PHARMACOL, V32, P100; HARDEN TK, 1983, J PHARMACOL EXP THER, V277, P570; HERRON SG, 1982, BIOCHEMISTRY-US, V21, P515; HULME EC, 1991, BIOCHEM SOC T, V19, P133, DOI 10.1042/bst0190133; JARV J, 1980, J BIOL CHEM, V255, P2649; JARV J, 1979, J BIOL CHEM, V254, P5595; JARV J, 1988, HDB EXP PHARM, V86, P320; LEE TWT, 1986, BIOCHEMISTRY-US, V25, P7009, DOI 10.1021/bi00370a038; MATTERA R, 1985, J BIOL CHEM, V260, P7410; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PETERSON GL, 1984, PREP BIOCHEM, V14, P33, DOI 10.1080/10826068408070612; POTTER LT, 1991, MOL PHARMACOL, V39, P211; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIMERLIK MI, 1989, ANNU REV PHYSIOL, V51, P217, DOI 10.1146/annurev.ph.51.030189.001245; SCHIMERLIK MI, 1980, BIOCHEMISTRY-US, V19, P3407, DOI 10.1021/bi00556a001; TOTA MR, 1987, BIOCHEMISTRY-US, V26, P8175, DOI 10.1021/bi00399a023; WONG HMS, 1986, BIOCHEMISTRY-US, V25, P6995, DOI 10.1021/bi00370a037	25	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26127	26135						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929325				2022-12-25	WOS:A1994PQ93000031
J	MENDOZA, JA; HOROWITZ, PM				MENDOZA, JA; HOROWITZ, PM			BOUND SUBSTRATE POLYPEPTIDES CAN GENERALLY STABILIZE THE TETRADECAMERIC STRUCTURE OF CPN6O AND INDUCE ITS REASSEMBLY FROM MONOMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; MALATE-DEHYDROGENASE; CITRATE SYNTHASE; PROTEIN; CHAPERONIN; GROEL; PURIFICATION; CARBOXYLASE	We demonstrate that the previously observed stabilizing effect by the enzyme rhodanese of the oligomeric structure of Cpn60 is general and can be provided by six other proteins that can interact with Cpn60. All these substrate proteins, which include examples that are monomeric, as well as oligomeric polypeptides in their native states, were shown previously to be assisted in their refolding by the chaperonin. Strikingly, during the disassembly of Cpn60 in the presence of any of the substrate proteins, significant amounts of intermediates were detected. Furthermore, unfolded substrate proteins induce the reassembly of tetradecameric Cpn60 from monomers, and binding of each substrate protein stabilizes Cpn60 quaternary structure.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78240	University of Texas System; University of Texas Health San Antonio					NIGMS NIH HHS [NIGMSE05729, GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P9195; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GREGORY EM, 1971, J BIOL CHEM, V246, P5491; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; LORIMER GH, 1993, PHILOS T R SOC B, V339, P297, DOI 10.1098/rstb.1993.0028; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; Shapiro B., 1970, METHOD ENZYMOL, V17A, P910, DOI 10.1016/0076-6879(71)17305-3; THORNE CJR, 1963, J BIOL CHEM, V238, P1861; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WEST SM, 1990, BIOCHIM BIOPHYS ACTA, V1037, P332, DOI 10.1016/0167-4838(90)90034-D	19	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25963	25965						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929305				2022-12-25	WOS:A1994PQ93000006
J	RUBBO, H; RADI, R; TRUJILLO, M; TELLERI, R; KALYANARAMAN, B; BARNES, S; KIRK, M; FREEMAN, BA				RUBBO, H; RADI, R; TRUJILLO, M; TELLERI, R; KALYANARAMAN, B; BARNES, S; KIRK, M; FREEMAN, BA			NITRIC-OXIDE REGULATION OF SUPEROXIDE AND PEROXYNITRITE-DEPENDENT LIPID-PEROXIDATION - FORMATION OF NOVEL NITROGEN-CONTAINING OXIDIZED LIPID DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; XANTHINE-OXIDASE; MYOCARDIAL-ISCHEMIA; TRYPANOSOMA-CRUZI; PEROXYL RADICALS; OXIDATION; IRON; REPERFUSION; MACROPHAGES; INJURY	Superoxide (O-2(radical-anion)), nitric oxide ((NO)-N-.), and their reaction product peroxynitrite (ONOO-) have all been shown to independently exert toxic target molecule reactions. Because these reactive species are often generated in excess during diverse inflammatory and other pathologic circumstances, we assessed the influence of (NO)-N-. on membrane lipid peroxidation induced by O-2(radical-anion), H2O2, and (OH)-O-. derived from xanthine oxidase (XO) and by ONOO-. Experimental conditions in lipid oxidation systems were adjusted to yield different rates of delivery of (NO)-N-., relative to rates of O-2(radical-anion) and H2O2 generation, by infusion of either (NO)-N-. or via (NO)-N-. released from S-nitroso-N-acetylpenicillamine or S-nitrosoglutathione. Peroxidation of phosphatidylcholine liposomes was assessed by formation of thiobarbituric acid-reactive products and by liquid chromatography-mass spectrometry. Liposomes exposed to XO derived reactive species in the presence of (NO)-N-. exhibited both stimulation and inhibition of lipid peroxidation, depending on the ratio of the rates of reactive oxygen species production and (NO)-N-. introduction into reaction systems. Nitric oxide alone did not induce lipid peroxidation. Linolenic acid emulsions peroxidized by XO-derived reactive species showed similar dose-dependent regulation of lipid peroxidation by (NO)-N-.. Mass spectral analysis of oxidation products showed formation of nitrito-, nitro-, nitrosoperoxo-, and/or nitrated lipid oxidation adducts, demonstrating that (NO)-N-. serves as a potent terminator of radical chain propagation reactions. Electron spin resonance (ESR) analysis of incubation mixtures provided no evidence for formation of paramagnetic iron-lipid-nitric oxide complexes in reaction systems. Peroxynitrite-dependent lipid peroxidation, which predominantly occurs by metal-independent mechanisms, was also inhibited by (NO)-N-.. Peroxynitrite-mediated benzoate hydroxylation was partially inhibited by (NO)-N-., inferring reaction between (NO)-N-. and ONOOH. It is concluded that (NO)-N-. can both stimulate O-2(radical-anion)/H2O2/(OH)-O-.-induced lipid oxidation and mediate oxidant-protective reactions in membranes at higher rates of (NO)-N-. production, with the prooxidant versus antioxidant outcome critically dependent on relative concentrations of individual reactive species. Prooxidant reactions of (NO)-N-. will occur after O-2(radical-anion) reaction with (NO)-N-. to yield potent secondary oxidants such as ONOO- and the antioxidant effects of (NO)-N-. a consequence of direct reaction with alkoxyl and peroxyl radical intermediates during lipid peroxidation, thus terminating lipid radical chain propagation reactions.	UNIV ALABAMA,DEPT ANESTHESIOL,BIRMINGHAM,AL 35233; UNIV ALABAMA,DEPT MOLEC GENET & BIOCHEM,BIRMINGHAM,AL 35233; UNIV ALABAMA,DEPT PEDIAT,BIRMINGHAM,AL 35233; UNIV ALABAMA,DEPT PHARMACOL,BIRMINGHAM,AL 35233; UNIV ALABAMA,CTR COMPREHENS CANC,MASS SPECTROMETRY SHARED FACIL,BIRMINGHAM,AL 35233; UNIV REPUBLICA,FAC MED,DEPT BIOQUIM,11800 MONTEVIDEO,URUGUAY; MED COLL WISCONSIN,BIOPHYS RES INST,MILWAUKEE,WI 53226	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Universidad de la Republica, Uruguay; Medical College of Wisconsin			Freeman, Bruce A/H-9342-2012	Trujillo, Madia/0000-0003-2087-017X; Rubbo, Homero/0000-0002-7897-6551	NHLBI NIH HHS [R01-HL51245, HL 47250, P01-HL48676] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047250, R01HL051245, P01HL048676] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKENS J, 1993, ARCH BIOCHEM BIOPHYS, V305, P516, DOI 10.1006/abbi.1993.1455; AIKENS J, 1992, CHEM RES TOXICOL, V5, P263, DOI 10.1021/tx00026a018; BAKER MS, 1984, ARCH BIOCHEM BIOPHYS, V234, P258, DOI 10.1016/0003-9861(84)90348-5; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BRITIGAN BE, 1990, J BIOL CHEM, V265, P17533; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; COMMONER B, 1970, CANCER RES, V30; CROW JP, 1994, FREE RADICAL BIO MED, V16, P331, DOI 10.1016/0891-5849(94)90034-5; DEE G, 1991, FEBS LETT, V294, P38, DOI 10.1016/0014-5793(91)81338-9; DENICOLA A, 1993, ARCH BIOCHEM BIOPHYS, V304, P279, DOI 10.1006/abbi.1993.1350; FEELISCH M, 1994, NATURE, V368, P62, DOI 10.1038/368062a0; FIELD L, 1978, J CHEM SOC CHEM COMM, V6, P249; FRIDOVICH I, 1985, HARVEY LECT, V79, P51; FRUEBIS J, 1992, P NATL ACAD SCI USA, V89, P10588, DOI 10.1073/pnas.89.22.10588; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GRAHAM A, 1993, FEBS LETT, V330, P181, DOI 10.1016/0014-5793(93)80269-Z; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JESSUP W, 1993, ATHEROSCLEROSIS, V101, P145, DOI 10.1016/0021-9150(93)90111-7; Job P, 1928, ANN CHIM FRANCE, V9, P113; KANNER J, 1992, LIPIDS, V27, P46, DOI 10.1007/BF02537058; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; KAVANAGH BP, 1994, J APPL PHYSIOL, V76, P1324, DOI 10.1152/jappl.1994.76.3.1324; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KING PA, 1992, J AM CHEM SOC, V114, P5430, DOI 10.1021/ja00039a068; KLUG D, 1972, J BIOL CHEM, V247, P4839; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; KON H, 1968, J BIOL CHEM, V243, P4350; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUBES P, 1993, AM J PHYSIOL, V264, pG143, DOI 10.1152/ajpgi.1993.264.1.G143; KUROSE I, 1994, CIRC RES, V74, P376, DOI 10.1161/01.RES.74.3.376; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LEFER DJ, 1993, CIRCULATION, V88, P2337, DOI 10.1161/01.CIR.88.5.2337; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MALORANTA U, 1994, FEBS LETT, V337, P179, DOI 10.1016/0014-5793(94)80269-6; MATHEIS G, 1992, AM J PHYSIOL, V262, pH616, DOI 10.1152/ajpheart.1992.262.2.H616; MCDONALD CC, 1965, J AM CHEM SOC, V87, P3319, DOI 10.1021/ja01093a007; MINOTTI G, 1992, LIPIDS, V27, P219, DOI 10.1007/BF02536182; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203; NAKAZAWA H, 1993, FREE RADICAL BIO MED, V15, P497, DOI 10.1016/0891-5849(93)90284-2; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; PAYNE D, 1993, AM J PHYSIOL, V265, pG189, DOI 10.1152/ajpgi.1993.265.1.G189; PRYOR WA, 1985, J AM CHEM SOC, V107, P211, DOI 10.1021/ja00287a039; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V286, P117, DOI 10.1016/0003-9861(91)90016-C; REIF DW, 1990, ARCH BIOCHEM BIOPHYS, V283, P537, DOI 10.1016/0003-9861(90)90680-W; Ross A.B., 1992, NDRL NIST SOLUTION K; RUBANYI GM, 1991, BIOCHEM BIOPH RES CO, V181, P1392, DOI 10.1016/0006-291X(91)92093-Y; RUBBO H, 1994, ARCH BIOCHEM BIOPHYS, V308, P96, DOI 10.1006/abbi.1994.1014; SCHAICH KM, 1988, LIPIDS, V23, P570, DOI 10.1007/BF02535600; SHERMAN MP, 1991, J PROTOZOOL, V38, pS234; SIEGFRIED MR, 1992, AM J PHYSIOL, V263, pH771, DOI 10.1152/ajpheart.1992.263.3.H771; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; STAMLER JS, 1992, ANAL CHEM, V64, P779, DOI 10.1021/ac00031a014; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; TAMIR S, 1993, CHEM RES TOXICOL, V6, P895, DOI 10.1021/tx00036a021; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; TSAI JHM, 1994, J AM CHEM SOC, V116, P4115, DOI 10.1021/ja00088a072; VOGEL A, 1978, PRACTICAL ORGANIC CH, P417; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; YAMAZAKI I, 1990, J BIOL CHEM, V265, P589; YAO SK, 1992, CIRCULATION, V86, P1302, DOI 10.1161/01.CIR.86.4.1302; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	83	1186	1218	1	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26066	26075						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929318				2022-12-25	WOS:A1994PQ93000023
J	NYKJAER, A; KJOLLER, L; COHEN, RL; LAWRENCE, DA; GARNIWAGNER, BA; TODD, RF; VANZONNEVELD, AJ; GLIEMANN, J; ANDREASEN, PA				NYKJAER, A; KJOLLER, L; COHEN, RL; LAWRENCE, DA; GARNIWAGNER, BA; TODD, RF; VANZONNEVELD, AJ; GLIEMANN, J; ANDREASEN, PA			REGIONS INVOLVED IN BINDING OF UROKINASE-TYPE-1 INHIBITOR COMPLEX AND PROUROKINASE TO THE ENDOCYTIC ALPHA(2)-MACROGLOBULIN RECEPTOR LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN - EVIDENCE THAT THE UROKINASE RECEPTOR PROTECTS PROUROKINASE AGAINST BINDING TO THE ENDOCYTIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; TISSUE-TYPE; ALPHA-2-MACROGLOBULIN RECEPTOR; HEPATIC RECEPTOR; BOUND UROKINASE; SARCOMA-CELLS; DEGRADATION; INTERNALIZATION; LOCALIZATION; DOMAIN	The alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha(2)MR/LRP) binds several ligands, including complex between the two chain urokinase-type plasminogen activator (uPA) and type-1 plasminogen activator inhibitor (PAI-1), and the single chain zymogen pro-urokinase (pro-uPA). We have used truncated variants of uPA and PAI-1 as well as Fab fragments of monoclonal antibodies with known epitopes to identify regions in the uPA PAI-1 complex and in pro-uPA involved in binding to alpha(2)MR/LRP. uPA PAI-1 complex bound with high affinity (EC(50) about 0.4 nM) via contacts in the PAI-1 moiety as well as the uPA serine proteinase domain and the uPAA chain. Pro-uPA bound with lower affinity (EC(50) about 10 nM), and efficient binding to alpha(2)MR/LRP was dependent on contact with both the A chain and the serine proteinase domain. We analyzed the effect of complex formation with the urokinase receptor since this is the primary target for binding of uPA.PAI-1 and pro-uPA at the cell surface, and since it has been demonstrated that urokinase receptor-bound uPA PAI-1 complex is internalized following interaction with alpha(2)MR/LRP (Nykjaer, A., Petersen, C. M., Moller, B., Jensen, P. H., Moestrup, S. K., Holtet, T. L., Etzerodt, M., Thogersen, H. C., Munch, M., Andreasen, P. A., and Gliemann, J. (1992) J. Biol. Chem. 267, 14543-14546). Soluble recombinant urokinase receptor blocked the binding of pro-uPA to alpha(2)MR/LRP but caused only a slight reduction in the affinity for binding of uPA PAI-1. Moreover, pro-uPA bound to the urokinase receptor at the cell surface was not internalized and degraded unless activated to uPA and complexed with PAI-1. We conclude that pro-uPA is protected against degradation via alpha(2)MR/LRP when bound to uPAR due to shielding of a binding contact in the A chain, whereas the affinity of uPAR-bound uPA PAI-1 complex for binding to alpha(2)MR/LRP remains sufficient to allow rapid internalization and degradation.	AARHUS UNIV, DEPT BIOL MOLEC, DK-8000 AARHUS C, DENMARK; UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV AMSTERDAM, DEPT BIOCHEM, 1105 AZ AMSTERDAM, NETHERLANDS	Aarhus University; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; University of Amsterdam	NYKJAER, A (corresponding author), AARHUS UNIV, DEPT BIOCHEM MED, OLE WORMS ALLE, BLDG 170, DK-8000 AARHUS C, DENMARK.		van Zonneveld, Anton Jan/D-8060-2018; Todd, Robert/GWM-4486-2022	van Zonneveld, Anton Jan/0000-0002-1676-7738; Nykjaer, Anders/0000-0001-6422-6736				ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; BACKMAN L, 1985, PARTITIONING AQUEOUS, P267; BASSELDUBY R, 1992, J BIOL CHEM, V267, P9668; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BIANCHI E, 1994, CANCER RES, V54, P861; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CAMANI C, 1994, J BIOL CHEM, V269, P5770; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V885, P49, DOI 10.1016/0167-4889(86)90037-6; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; GRONDAHLHANSEN J, 1987, J INVEST DERMATOL, V88, P28, DOI 10.1111/1523-1747.ep12464827; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC, P58; KEIJER J, 1991, BLOOD, V78, P401; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MIN HY, 1992, J IMMUNOL, V148, P3636; MIZUKAMI IF, 1994, CLIN IMMUNOL IMMUNOP, V71, P96, DOI 10.1006/clin.1994.1057; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; MUNCH M, 1991, FEBS LETT, V281, P181; NYKJAER A, 1994, J IMMUNOL, V152, P505; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; NYKJAER A, 1994, ANN NY ACAD SCI, V737, P483, DOI 10.1111/j.1749-6632.1994.tb44346.x; NYKJAER A, 1992, FEBS LETT, V300, P13, DOI 10.1016/0014-5793(92)80154-9; NYKJAER A, 1990, BIOCHIM BIOPHYS ACTA, V1052, P399, DOI 10.1016/0167-4889(90)90149-8; OLSON D, 1992, J BIOL CHEM, V267, P9129; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1991, ADV CANCER RES, V57, P273; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; STEPHENS RW, 1992, BIOCHEMISTRY-US, V31, P7572, DOI 10.1021/bi00148a019; TODD RF, 1994, IN PRESS LEUKOCYTE T, V5; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405	46	135	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25668	25676						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929271				2022-12-25	WOS:A1994PQ49100067
J	DRAGO, GA; COLYER, J				DRAGO, GA; COLYER, J			DISCRIMINATION BETWEEN 2 SITES OF PHOSPHORYLATION ON ADJACENT AMINO-ACIDS BY PHOSPHORYLATION SITE-SPECIFIC ANTIBODIES TO PHOSPHOLAMBAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INTRACELLULAR CALCIUM; VENTRICULAR MYOCYTES; MONOCLONAL-ANTIBODY; MYOCARDIUM; SEQUENCE; BOVINE; DEPHOSPHORYLATION; CHROMATOGRAPHY; PURIFICATION	A pair of polyclonal antibodies have been produced in rabbits which recognize the two phosphorylated forms of the cardiac muscle protein, phospholamban. The two sites of phosphorylation of this protein are situated on neighboring residues and yet one antibody, PS-16, recognizes the Ser(16) phosphoprotein, while the other, PT-17, recognizes the Thr(17) phosphoprotein. Neither antibody recognizes phospholamban phosphorylated at ''the other site,'' nor do they recognize free phosphoamino acids or dephosphorylated protein. This represents the most demanding test of the technique of phosphorylation site-specific antibody production to date, which these antibodies have satisfied without ambiguity. These antibodies remain specific for phospholamban in the company of other muscle phosphoproteins and will be invaluable in determining the role of each phosphorylation site in the biology of the heart. They also demonstrate the absolute specificity of phosphorylation site-specific antibodies and augur well for the use of this approach in the study of other phosphoproteins.	UNIV LEEDS, DEPT BIOCHEM & MOLEC BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Leeds								BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; BOYETT MR, 1988, J PHYSIOL-LONDON, V407, P77, DOI 10.1113/jphysiol.1988.sp017404; BRIAND JP, 1985, J IMMUNOL METHODS, V78, P59, DOI 10.1016/0022-1759(85)90329-1; CHIU RC, 1990, TRANSFORMED MUSCLE C; COLYER J, 1991, J BIOL CHEM, V266, P17486; Corbin J D, 1974, Methods Enzymol, V38, P287; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; GASSER J, 1988, EUR J BIOCHEM, V176, P535, DOI 10.1111/j.1432-1033.1988.tb14311.x; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; Hudson L, 1989, PRACTICAL IMMUNOLOGY, P348; HUGGINS JP, 1989, BIOCHEM J, V260, P829, DOI 10.1042/bj2600829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CF, 1990, BIOCHEMISTRY-US, V29, P4535, DOI 10.1021/bi00471a005; LINDEMANN JP, 1985, J BIOL CHEM, V260, P4516; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; NAIRN AC, 1982, NATURE, V299, P734, DOI 10.1038/299734a0; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PETERS KA, 1977, BIOCHEMISTRY-US, V16, P5691, DOI 10.1021/bi00645a007; POULTER L, 1993, J BIOL CHEM, V268, P9636; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; WEGENER AD, 1989, J BIOL CHEM, V264, P11468	28	94	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25073	25077						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929194				2022-12-25	WOS:A1994PQ49000083
J	DUCHE, D; BATY, D; CHARTIER, M; LETELLIER, L				DUCHE, D; BATY, D; CHARTIER, M; LETELLIER, L			UNFOLDING OF COLICIN-A DURING ITS TRANSLOCATION THROUGH THE ESCHERICHIA-COLI ENVELOPE AS DEMONSTRATED BY DISULFIDE BOND ENGINEERING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; PRECURSOR PROTEIN; FORMATION INVIVO; UPTAKE SYSTEMS; TOLR PROTEINS; MEMBRANE; IMPORT; EXPORT; ENTRY	Three double cysteine mutants, each possessing a disulfide bond in its pore forming domain, were used to study the translocation of colicin A through the Escherichia coli envelope. These mutated colicins were able to exert their in vivo channel activity only after their disulfide bonds had been reduced by dithiothreitol. In solution, the reduction of the disulfide bonds by dithiothreitol was a slow process whose kinetics depended on the position of the sidulfide bond (t(1/2) varying between 35 and 100 s), This t(1/2) was strongly decreased (t(1/2) = 8-9 s) upon predenaturation of the mutated colicins with urea. The t(1/2) values of reduction of the mutants bound to E. coli-sensitive cells were similar to those of predenatured colicins. This suggested that the interaction of the oxidized double cysteine mutants with the E. coli envelope triggered their unfolding. The disulfide bonds did not prevent but delayed the translocation of the colicins. The amplitude of the delay and the time at which it occurred during translocation depended on the position of the disulfide bond. We could discriminate between the delays accumulated during binding to the receptor and those during the translocation via OmpF and the Tol proteins.	UNIV PARIS 11,BIOMEMBRANES LAB,CNRS,URA 1116,F-91405 ORSAY,FRANCE; CNRS,CTR BIOCHIM & BIOL MOLEC,INGN & DYNAM SYST MEMBRANAIRES LAB,F-13402 MARSEILLE 20,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)				Duche, Denis/0000-0002-4208-6661; Baty, Daniel/0000-0001-8443-4444				BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BATY D, 1988, MOL MICROBIOL, V2, P806; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BENEDETTI H, 1989, J GEN MICROBIOL, V135, P3413; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; BRAUN V, 1993, MOL MICROBIOL, V8, P261, DOI 10.1111/j.1365-2958.1993.tb01570.x; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; DAVIES JK, 1975, J BACTERIOL, V123, P96, DOI 10.1128/JB.123.1.96-101.1975; DUCHE D, 1994, J BIOL CHEM, V269, P6332; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; GUIHARD G, 1994, J BIOL CHEM, V269, P5874; HIRST TR, 1987, J BACTERIOL, V169, P1037, DOI 10.1128/jb.169.3.1037-1045.1987; JASCUR T, 1992, J BIOL CHEM, V267, P13636; KAMPFENKEL K, 1993, J BACTERIOL, V175, P4485, DOI 10.1128/JB.175.14.4485-4491.1993; MAHER PA, 1986, P NATL ACAD SCI USA, V83, P9001, DOI 10.1073/pnas.83.23.9001; MULLER G, 1988, EMBO J, V7, P639, DOI 10.1002/j.1460-2075.1988.tb02858.x; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PUGSLEY AP, 1992, P NATL ACAD SCI USA, V89, P12058, DOI 10.1073/pnas.89.24.12058; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; SUN TP, 1986, J BACTERIOL, V165, P107, DOI 10.1128/jb.165.1.107-115.1986; TANI K, 1990, J BIOL CHEM, V265, P17341; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x	27	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24820	24825						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929161				2022-12-25	WOS:A1994PQ49000048
J	HASAN, S; KODA, T; KAKINUMA, M				HASAN, S; KODA, T; KAKINUMA, M			AN UPSTREAM NF-Y-BINDING SITE IS REQUIRED FOR TRANSCRIPTIONAL ACTIVATION FROM THE HST PROMOTER IN F9 EMBRYONAL CARCINOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-FGF PROTOONCOGENE; TRANSFORMING GENE; STOMACH CANCERS; STEM-CELLS; CLASS-II; EXPRESSION; PROTEINS; DIFFERENTIATION; GROWTH; FAMILY	Expression of hst (k-FGF, FGF-4), a member of the fibroblast growth factor gene family, is restricted to early stages of developing embryos and to embryonal carcinoma cells. In F9, which is a prototype of embryonal carcinoma cells expressing hst, the expression of hst gene is positively regulated by a downstream octamer motif that functions as an enhancer. We have investigated, by chloramphenicol acetyltransferase (CAT) reporter fusion gene analysis in F9, the cis-acting regulatory element within the hst promoter region that interacts with this enhancer. Electrophoretic mobility shift assay and methylation interference analysis showed that the hst promoter contains, in a segment termed Y, the sequence 5'-CTGATTGGCA-3', which closely resembles the consensus binding motif for the CCAAT-binding factor NF-Y. Deletions or mutations in this element substantially reduced expression of hst-CAT constructs. The nuclear factor binding to the Y segment of the hst promoter was indistinguishable from NF-Y, as inferred from interactions with specific anti-NF-Y monoclonal and polyclonal antibodies. We conclude that the expression of the hst gene in F9 is positively regulated by the coordinated interaction between an NF-Y-binding site and an octamer motif.	HOKKAIDO UNIV, INST IMMUNOL SCI, BACTERIAL INFECT SECT, KITA KU, SAPPORO, HOKKAIDO 060, JAPAN; HOKKAIDO UNIV, GRAD SCH ENVIRONM SCI, ENVIRONM MED SECT, SAPPORO, HOKKAIDO 060, JAPAN	Hokkaido University; Hokkaido University			Koda, Toshiaki/F-5268-2011	Koda, Toshiaki/0000-0003-1421-6964				BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; COONEY AJ, 1993, TRANSCRIPTION FACTOR, P49; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; DRUCKER BJ, 1993, MECH DEVELOP, V40, P155, DOI 10.1016/0925-4773(93)90073-7; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HOWE CC, 1981, DEV BIOL, V84, P239, DOI 10.1016/0012-1606(81)90390-0; KODA T, 1987, JPN J CANCER RES, V78, P325; KODA T, 1994, FEBS LETT, V342, P71, DOI 10.1016/0014-5793(94)80587-3; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LI XY, 1992, J BIOL CHEM, V267, P8984; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MARICS I, 1989, ONCOGENE, V4, P335; Maxam A M, 1980, Methods Enzymol, V65, P499; NISWANDER L, 1992, DEVELOPMENT, V114, P755; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SASAKI A, 1991, JPN J CANCER RES, V82, P1191, DOI 10.1111/j.1349-7006.1991.tb01778.x; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOORLEMMER J, 1991, MECH DEVELOP, V36, P75, DOI 10.1016/0925-4773(91)90074-G; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; VELCICH A, 1989, ONCOGENE RES, V5, P31; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X	35	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25042	25048						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929190				2022-12-25	WOS:A1994PQ49000078
J	VIVEKANANDA, J; LIN, A; COALSON, JJ; KING, RJ				VIVEKANANDA, J; LIN, A; COALSON, JJ; KING, RJ			ACUTE INFLAMMATORY INJURY IN THE LUNG PRECIPITATED BY OXIDANT STRESS INDUCES FIBROBLASTS TO SYNTHESIZE AND RELEASE TRANSFORMING GROWTH-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-ALPHA; HUMAN KERATINOCYTES; MESSENGER-RNA; INDUCTION; MACROPHAGES; RECEPTORS; PROTEINS	Although transforming growth factor-alpha (TGF-alpha) is widely distributed in transformed cells and in some normal cells and much is known about its structure and metabolism, there is little information about its physio logical actions. TGF a is not thought to be synthesized by nontransformed fibroblasts, but it is thought to be a mitogen for these and epithelial cells (Derynck, R. (1986) J. Cell. Biochem. 32, 293-304). We report here that fibroblasts obtained from hamsters with oxidant-induced lung injury release TGF-alpha at levels comparable with those reported for transformed cells. In conditioned media, one isoform of 18 kDa was recognized by a monoclonal antibody to mature TGF-alpha; five isoforms ranging from 18 to 42 kDa were recognized in cell lysates. Conditioned media from these fibroblasts stimulated tyrosine phosphorylation of the epidermal growth factor (EGF)/TGF-alpha receptor, competed with radioactive EGF for binding sites on A431 cells, and were mitogenic for mesenchymal and epithelial cells. This mitogenic activity could be almost completely blocked by anti-TGF-alpha. Conditioned media from normal lung fibroblasts exhib ited none of these activities. Using normal lung fibroblasts, we found that TGF-alpha synthesis could be induced in vitro with 25 nmol/ml EGF, suggesting that the induction in vivo may have been due, in part, to a stimulation by EGF (or TGF-alpha) released by other cell types such as alveolar macrophages recruited to the injury site. TGF-alpha is, in general, a mitogen for epithelial cells (Derynck, 1986); more specific to acute injury in the lung, it may affect the proliferation (Ryan, R. M., Mineo-Kuhn, M. M., Kromer, C. M., and Finkelstein, J. N. (1994) Am. J. Physiol. 266, L17-L23) and metabolic activities (Whitsett, J. A., Weaver, T. E., Lieberman, M. A., Clark, J. G., and Daugherty, C. (1987) J. Biol. Chem. 262, 7908-7913) of alveolar epithelial type II cells. This is, we believe, the first report of a fibroblast-derived TGF-alpha induced with oxidant injury If this response was ubiquitously manifested in other tissues, then fibroblast derived TGF-alpha might be an important determinant of the epithelial and mesenchymal hyperplasia commonly observed in tissue repair.	UNIV TEXAS,HLTH SCI CTR,DEPT PHYSIOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043704] Funding Source: NIH RePORTER; NHLBI NIH HHS [NHLBI HL 43704] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON IYR, 1990, AM J PATHOL, V137, P385; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; CROUCH E, 1990, AM J PHYSIOL, V259, pL159, DOI 10.1152/ajplung.1990.259.4.L159; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1986, J CELL BIOCHEM, V32, P293, DOI 10.1002/jcb.240320406; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; JONES MB, 1987, AM REV RESPIR DIS, V135, P997; KORFHAGEN TR, 1994, J CLIN INVEST, V93, P1691, DOI 10.1172/JCI117152; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MINOO P, 1992, AM J PHYSIOL, V263, pL291, DOI 10.1152/ajplung.1992.263.2.L291; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RYAN RM, 1994, AM J PHYSIOL, V266, pL17, DOI 10.1152/ajplung.1994.266.1.L17; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; TATE RM, 1983, AM REV RESPIR DIS, V128, P552, DOI 10.1164/arrd.1983.128.3.552; WHITSETT JA, 1987, J BIOL CHEM, V262, P7908; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; 1972, DHEW NIH73432 PUBL, P167	24	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25057	25061						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929192				2022-12-25	WOS:A1994PQ49000080
J	ZHOU, GC; DENU, JM; WU, L; DIXON, JE				ZHOU, GC; DENU, JM; WU, L; DIXON, JE			THE CATALYTIC ROLE OF CYS(124) IN THE DUAL-SPECIFICITY PHOSPHATASE VHR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; IMMEDIATE-EARLY GENE; VACCINIA VIRUS; MAP KINASE; INTERMEDIATE; ACTIVATION; EXPRESSION; CYSTEINE; ENCODES; CLONING	The recombinant human Vaccinia virus H1-related protein tyrosine phosphatase, (VHR PTPase) possesses intrinsic Tyr and Thr/Ser phosphatase activities. Both activities were abolished by a single amino acid substitution, C124S. When VHR was incubated with a P-32-labeled phosphotyrosine-containing substrate and then rapidly denatured, enzyme-associated P-32 was evident following SDS-polyacrylamide gel electrophoresis. The formation of P-32-labeled protein could be blocked in the presence of an unlabeled substrate. VHR-associated P-32 was sensitive to iodine but insensitive to pyridine and hydroxylamine. The catalytically inactive C124S mutant would not form a P-32-labeled enzyme. Furthermore, VBR phosphatase could be selectively inactivated by the alkylating agent iodoacetate. The inactivation resulted from the specific covalent modification of Cys(124). Collectively these results suggest that a thiol-phosphate enzyme intermediate is formed when Cys(124) of VHR accepts a phosphate from the substrate. Our results also demonstrate that the dual specificity phosphatases and the tyrosine-specific PTPases employ similar catalytic mechanisms.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; WALTHER CANC INST,INDIANAPOLIS,IN 46208	University of Michigan System; University of Michigan; Walther Cancer Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018024, R01DK018849, T32DK007245, R01DK018024] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07245-17, NIDDKD 18024, NIDDKD 18849] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERFELDT S, 1960, ACTA CHEM SCAND, V14, P1980, DOI 10.3891/acta.chem.scand.14-1980; ALESSI DR, 1993, ONCOGENE, V8, P2015; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; Cleland W W, 1979, Methods Enzymol, V63, P103; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FISHER EH, 1991, SCIENCE, V253, P401; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HUNTER T, 1989, ONCOGENES MOL ORIGIN, P149; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; POT DA, 1992, J BIOL CHEM, V267, P140; POT DA, 1991, J BIOL CHEM, V266, P19688; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	30	115	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28084	28090						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961745				2022-12-25	WOS:A1994PV77200049
J	ESNAULT, Y; FELDHEIM, D; BLONDEL, MO; SCHEKMAN, R; KEPES, F				ESNAULT, Y; FELDHEIM, D; BLONDEL, MO; SCHEKMAN, R; KEPES, F			SSS1 ENCODES A STABILIZING COMPONENT OF THE SEC61 SUBCOMPLEX OF THE YEAST PROTEIN TRANSLOCATION APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; POLYPEPTIDE TRANSLOCATION; SECRETORY PROTEINS; INSERTION; RIBOSOMES; PEPTIDES; MUTANTS; HOMOLOG; IMPORT; INVIVO	The yeast SSS1 gene has been isolated as an extragenic high copy suppressor of sec61, a mutant displaying defects in protein translocation into the endoplasmic reticulum (ER). We found that SSS1 is an essential gene required for transfer of secretory precursors through the ER membrane. Here we demonstrate that the SSS1 product (Sss1p) is firmly bound to the ER membrane and exposes its amino-terminal half on the cytosolic side. Only detergent, or an alkali treatment, is effective at extracting Sss1p from the membrane. Coimmunoprecipitation experiments revealed that Sss1p and Sec61p participate in the same multisubunit complex. Cross-linking followed by immunoprecipitation specifically yielded an additional polypeptide of molecular mass 73 kDa. Moreover, Sss1p and Sec61p show mutually stabilizing interactions: Sss1p is destabilized in a sec61 mutant context, and mutated Sec61p is stabilized by Sss1p overproduction. These observations account for the isolation of SSS1 as a dosage-dependent suppressor of sec61. Since the polytopic integral membrane protein Sec61p is adjacent to translocating precursors and to ribosomes, and given the comparable translocation deficiencies of sss1 or sec61 mutants, we propose that Sss1p belongs to the ''Sec61 subcomplex'' that constitutes the pore of the membrane-bound translocation apparatus.	CENS, CEA, DSV, DBCM, SERV BIOCHIM & GENET MOLEC, F-91191 GIF SUR YVETTE, FRANCE; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; INST JACQUES MONOD, CNRS, F-75251 PARIS 05, FRANCE; UNIV PARIS 07, F-75251 PARIS 05, FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; University of California System; University of California Berkeley; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite								BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FELDHEIM D, 1993, MOL BIOL CELL, V4, P931, DOI 10.1091/mbc.4.9.931; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; KURIHARA T, 1993, MOL BIOL CELL, V4, P919, DOI 10.1091/mbc.4.9.919; KUROIWA T, 1993, J BIOCHEM-TOKYO, V114, P541, DOI 10.1093/oxfordjournals.jbchem.a124213; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TOYN J, 1988, EMBO J, V7, P4347, DOI 10.1002/j.1460-2075.1988.tb03333.x; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; VOLLAND C, 1988, J BIOL CHEM, V263, P8294; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335	34	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27478	27485						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961662				2022-12-25	WOS:A1994PV77100052
J	BEAUPARLANT, P; KWAN, I; BITAR, R; CHOU, P; KOROMILAS, AE; SONENBERG, N; HISCOTT, J				BEAUPARLANT, P; KWAN, I; BITAR, R; CHOU, P; KOROMILAS, AE; SONENBERG, N; HISCOTT, J			DISRUPTION OF I-KAPPA-B-ALPHA REGULATION BY ANTISENSE RNA EXPRESSION LEADS TO MALIGNANT TRANSFORMATION	ONCOGENE			English	Article							PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; DNA-BINDING SUBUNIT; TRANSCRIPTIONAL ACTIVATOR; PROTOONCOGENE BCL-3; REL ONCOGENE; P65 SUBUNIT; GENE; INHIBITOR; FAMILY	NF-kappa B transcription factors regulate the expression of a variety of genes involved in immune regulation and cell growth. In most cell types NF-kappa B proteins are localized in an inactive form in the cytoplasm coupled to the inhibitory I kappa B proteins. Viruses, cytokines, lipopolysaccharides and other stimulating agents promote the dissociation of the cytosolic NF-kappa B/I kappa B complexes, via phosphorylation and degradation of I kappa B, resulting in the translocation of DNA binding, NF-kappa B complexes to the nucleus. To further understand the association of I kappa B with cell growth regulation, the effect of ectopic expression of sense and antisense I kappa B genes was examined in NIH3T3 cells. Overexpression of I kappa B alpha antisense RNA but not I kappa B gamma antisense RNA decreased the steady state levels of I kappa B alpha protein, altered NF-kappa B DNA binding and gene activity and, most importantly, induced malignant transformation as measured by saturation density, growth in soft agar and tumorigenicity in nude mice. In contrast, overexpression of I kappa B alpha resulted in decreased saturation density, a battened cellular morphology and decreased NF-kappa B dependent reporter gene activity. These results indicate that overexpression of an I kappa B alpha antisense RNA may disrupt the NF-kappa B/I kappa B autoregulatory loop, leading to cellular transformation. Our results raise the interesting possibility that I kappa B alpha represents a potential tumor suppressor activity.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,TERRY FOX MOLEC ONCOL GRP,MONTREAL H3T 1E2,PQ,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University								Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BULL P, 1989, MOL CELL BIOL, V9, P5239, DOI 10.1128/MCB.9.11.5239; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GERONDAKIS S, 1993, CELL GROWTH DIFFER, V4, P617; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; LANOIX J, 1994, ONCOGENE, V9, P841; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEBEAU MM, 1992, GENOMICS, V14, P529, DOI 10.1016/S0888-7543(05)80261-7; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PEPIN N, 1994, IN PRESS VIROLOGY; PEREZ JR, 1994, P NATL ACAD SCI USA, V91, P5957, DOI 10.1073/pnas.91.13.5957; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rossi John J., 1993, Methods (Orlando), V5, P1, DOI 10.1006/meth.1993.1001; ROULSTON A, 1993, J VIROL, V67, P5235, DOI 10.1128/JVI.67.9.5235-5246.1993; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; WEINBERG RA, 1989, CANCER RES, V49, P3713	49	80	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3189	3197						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936641				2022-12-25	WOS:A1994PM65800010
J	HAFT, CR; KLAUSNER, RD; TAYLOR, SI				HAFT, CR; KLAUSNER, RD; TAYLOR, SI			INVOLVEMENT OF DILEUCINE MOTIFS IN THE INTERNALIZATION AND DEGRADATION OF THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE GLYCOPROTEIN; MANNOSE 6-PHOSPHATE RECEPTOR; TYROSINE KINASE-ACTIVITY; FACTOR-II RECEPTOR; CYTOPLASMIC DOMAIN; JUXTAMEMBRANE REGION; TRANSFERRIN RECEPTOR; BETA-HEXOSAMINIDASE; AMINO-ACIDS; ENDOCYTOSIS	Dileucine motifs have been shown to be involved in trans Golgi sorting, lysosomal targeting, and internalization of a number of proteins. The insulin receptor contains four dileucine pairs in its cytoplasmic domain. To determine if these insulin receptor sequences can serve as lysosomal sorting sequences, chimeric molecules expressing the Tac antigen fused to each isolated insulin receptor motif were constructed. A chimera con taining the juxtamembrane dileucine motif (EKITLL), which closely resembles the sequences originally identified in the gamma- and delta-chains of the T cell receptor (DKQTLL and EVQALL), was shown to sort to lysosomes by immunofluorescence microscopy, as did a chimera expressing the dileucine motif (GGKGLL) found in the tyrosine kinase domain. Chimeras expressing either a second tyrosine kinase domain sequence (HVVRLL) or the carboxyl-terminal sequence (EIVNLL) localized to both lysosomes and the plasma membrane. In contrast, chimeras expressing two other potential sorting signals found in the cytoplasmic tail of the insulin receptor (NARDII and KNGRIL) localized predominantly to the plasma membrane. Exclusively cell surface staining was also seen for a chimera expressing a mutant motif (EKITAA), where the leucine residues were mutated to alanines. When the alanine pair was introduced into the juxtamembrane domain of the intact insulin receptor and the mutant receptor expressed in NM-3T3 cells, we found that the mutation did not impair insulin binding or receptor tyrosine kinase activity. However, the Ala-Ala mutant internalized insulin 5-fold slower than the wild-type receptor. Taken together, these findings suggest that the dileucine motif found in the juxtamembrane domain of the insulin receptor is involved in receptor internalization and that other insulin receptor sequences may mask the potential lysosomal targeting signals in the intact molecule.	NIDDKD, DIABET BRANCH, BETHESDA, MD 20892 USA; NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BACKER JM, 1989, J BIOL CHEM, V264, P1694; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; CAMA A, 1992, J BIOL CHEM, V267, P8383; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHIN JE, 1991, J BIOL CHEM, V266, P15587; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FURUNO K, 1989, J BIOCHEM-TOKYO, V106, P717, DOI 10.1093/oxfordjournals.jbchem.a122922; FURUNO K, 1989, J BIOCHEM-TOKYO, V106, P708, DOI 10.1093/oxfordjournals.jbchem.a122921; GAVIN JR, 1974, P NATL ACAD SCI USA, V71, P84, DOI 10.1073/pnas.71.1.84; HAFT CR, 1994, BIOCHEMISTRY-US, V33, P9143, DOI 10.1021/bi00197a017; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KASUGA M, 1981, P NATL ACAD SCI-BIOL, V78, P6917, DOI 10.1073/pnas.78.11.6917; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LUND KA, 1990, J BIOL CHEM, V265, P15713; MAIN HY, 1994, J BIOL CHEM, V269, P3928; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MYERS MG, 1991, J BIOL CHEM, V266, P10616; OPRESKO LK, 1987, J BIOL CHEM, V262, P4116; PAVLAKIS GN, 1983, P NATL ACAD SCI-BIOL, V80, P397, DOI 10.1073/pnas.80.2.397; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PROIA RL, 1984, J BIOL CHEM, V259, P3350; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; THIES RS, 1990, J BIOL CHEM, V265, P10132; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VEGA MA, 1991, J BIOL CHEM, V266, P16269; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; WEITZ G, 1992, J BIOL CHEM, V267, P10039; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	59	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26286	26294						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929346				2022-12-25	WOS:A1994PQ93000055
J	ODA, K; TAKAHASHI, T; TOKUDA, Y; SHIBANO, Y; TAKAHASHI, S				ODA, K; TAKAHASHI, T; TOKUDA, Y; SHIBANO, Y; TAKAHASHI, S			CLONING, NUCLEOTIDE-SEQUENCE, AND EXPRESSION OF AN ISOVALERYL PEPSTATIN-INSENSITIVE CARBOXYL PROTEINASE GENE FROM PSEUDOMONAS SP-101	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SCYTALIDIUM-LIGNICOLUM M-133; PROTEASE-B; ESCHERICHIA-COLI; PEPSIN; PURIFICATION; INHIBITOR; DNA; INACTIVATION; BACTERIUM	A unique carboxyl proteinase (EC 3.4.23.33), insensitive to the classical inhibitor isovaleryl pepstatin and isolated from Pseudomonas sp. 101 (PCP), is the first example of a prokaryotic enzyme of this class. The gene coding for PCP was cloned, sequenced, and expressed in Escherichia coli. The gene consists of 1,761 base pairs encoding a protein of 587 amino acid residues. The NH2-terminal 215-amino acid preprosequence flanks the 372-amino acid mature protein, which is identical with the primary structure of an authentic PCP determined by chemical methods. E. coli carrying a plasmid containing the cloned wild-type PCP gene produced a 62-kDa protein. This molecule was processed and secreted into the periplasm as a 43-kDa protein, which converted to mature PCP under acidic conditions. This autocatalytic conversion was completely blocked by tyrostatin, a PCP-specific peptidic inhibitor from Kitasatosporia sp. 55. The purified recombinant PCP has the same characteristics as authentic PCP. When several preprosequence deletion mutants were expressed in E. coli, mutant proteins were accumulated as insoluble forms with no proteinase activities. These results suggest that the prepropeptide of PCP plays an essential role in the formation of functional PCP.	SUNTORY LTD, INST FUNDAMENTAL RES, SHIMAMOTO, OSAKA 618, JAPAN	Suntory Holdings Ltd	ODA, K (corresponding author), KYOTO INST TECHNOL, FAC TEXT SCI, DEPT APPL BIOL, SAKYO KU, KYOTO 606, JAPAN.							CHANG WJ, 1976, J BIOCHEM-TOKYO, V80, P975, DOI 10.1093/oxfordjournals.jbchem.a131385; DELANEY R, 1987, J BIOL CHEM, V262, P1461; FRAZEE RW, 1993, J BACTERIOL, V175, P6194, DOI 10.1128/JB.175.19.6194-6202.1993; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HORIUCHI H, 1988, J BACTERIOL, V170, P272, DOI 10.1128/jb.170.1.272-278.1988; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; Kay J., 1985, Aspartic proteinases and their inhibitors, P1; KOBAYASHI H, 1985, AGR BIOL CHEM TOKYO, V49, P2393, DOI 10.1080/00021369.1985.10867083; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAITA T, 1984, J BIOCHEM-TOKYO, V95, P465, DOI 10.1093/oxfordjournals.jbchem.a134628; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORIHARA K, 1979, J BIOCHEM, V85, P661; Morihara K., 1981, PROTEINASES THEIR IN, P213; MURAO S, 1970, AGR BIOL CHEM TOKYO, V34, P1265, DOI 10.1080/00021369.1970.10859764; MURAO S, 1988, AGR BIOL CHEM TOKYO, V52, P1629; MURAO S, 1973, AGR BIOL CHEM TOKYO, V37, P1417, DOI 10.1080/00021369.1973.10860841; MURAO S, 1972, AGR BIOL CHEM TOKYO, V36, P1647, DOI 10.1080/00021369.1972.10860454; Murao S., 1985, ASPARTIC PROTEINASES, P379; ODA K, 1991, ADV EXP MED BIOL, V306, P185; ODA K, 1989, AGR BIOL CHEM TOKYO, V53, P405, DOI 10.1080/00021369.1989.10869302; ODA K, 1976, AGR BIOL CHEM TOKYO, V40, P1221, DOI 10.1080/00021369.1976.10862184; ODA K, 1981, AGR BIOL CHEM TOKYO, V45, P2339, DOI 10.1080/00021369.1981.10864881; ODA K, 1976, AGR BIOL CHEM TOKYO, V40, P859, DOI 10.1080/00021369.1976.10862145; ODA K, 1975, AGR BIOL CHEM TOKYO, V39, P477, DOI 10.1080/00021369.1975.10861610; ODA K, 1986, AGR BIOL CHEM TOKYO, V50, P651, DOI 10.1080/00021369.1986.10867441; ODA K, 1992, BIOCHIM BIOPHYS ACTA, V1120, P208, DOI 10.1016/0167-4838(92)90272-F; ODA K, 1974, AGR BIOL CHEM TOKYO, V38, P2435, DOI 10.1080/00021369.1974.10861522; ODA K, 1987, AGR BIOL CHEM TOKYO, V51, P3073; ODA K, 1987, BIOCHIM BIOPHYS ACTA, V923, P463, DOI 10.1016/0304-4165(87)90055-9; RAJAGOPALAN TG, 1966, J BIOL CHEM, V241, P4295; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TANG J, 1971, J BIOL CHEM, V246, P4510; TANG J, 1973, P NATL ACAD SCI USA, V70, P3437, DOI 10.1073/pnas.70.12.3437; TERASHITA T, 1981, AGR BIOL CHEM TOKYO, V45, P1937, DOI 10.1080/00021369.1981.10864821; TERASHITA T, 1984, AGR BIOL CHEM TOKYO, V48, P1029, DOI 10.1080/00021369.1984.10866245; TONOUCHI N, 1986, NUCLEIC ACIDS RES, V14, P7557, DOI 10.1093/nar/14.19.7557; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSURU D, 1986, J BIOCHEM-TOKYO, V99, P1537, DOI 10.1093/oxfordjournals.jbchem.a135624; TSURU D, 1989, AGR BIOL CHEM TOKYO, V53, P2751, DOI 10.1080/00021369.1989.10869723; UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259; WEST EH, 1988, NUCLEIC ACIDS RES, V16, P9293	47	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26518	26524						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929375				2022-12-25	WOS:A1994PQ93000088
J	PRESTA, L; SHIELDS, R; OCONNELL, L; LAHR, S; PORTER, J; GORMAN, C; JARDIEU, P				PRESTA, L; SHIELDS, R; OCONNELL, L; LAHR, S; PORTER, J; GORMAN, C; JARDIEU, P			THE BINDING-SITE ON HUMAN-IMMUNOGLOBULIN-E FOR ITS HIGH-AFFINITY RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; EPIDERMAL LANGERHANS CELLS; RAT MAST-CELLS; IGE RECEPTOR; CHIMERIC IG; MURINE IGE; ANTIBODIES; PROTEIN; REGION; HUMANIZATION	Immunoglobulin (Ig)E antibodies mediate allergic responses by binding to specific high affinity receptors, Fc epsilon RI, on mast cells and basophils. Previous studies have shown that the principal Fc epsilon RI binding site is located on the third constant domain, Fc epsilon 3, of IgE. Based on a model of the IgE Fc epsilon 3 (which is homologous to the second constant domain of IgG), homology scanning mutagenesis and replacement of individual residues were used to determine the specific amino acids of human IgE involved in binding to human Fc epsilon RI. The amino acids are localized in three loops, which form a putative ridge on the most exposed side of the Fc epsilon 3 domain of IgE and include Arg-408, Ser-411, Lys-415, Glu-452, Arg-465, and Met-469. The preponderance of charged residues suggests that IgE-Fc epsilon RI binding is mediated primarily by electrostatic interaction. Furthermore, it is possible to confer Fc epsilon RI binding to an IgG molecule by introducing these three IgE loops into the IgG C gamma 2 domain.	GENENTECH INC,DEPT IMMUNOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	PRESTA, L (corresponding author), GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080, USA.							AUSTEN KF, 1968, MOL ASPECTS ACUTE AL, P293; BAIRD B, 1993, ACCOUNTS CHEM RES, V26, P428, DOI 10.1021/ar00032a006; BANIYASH M, 1988, MOL IMMUNOL, V25, P705, DOI 10.1016/0161-5890(88)90106-X; BASU M, 1993, J BIOL CHEM, V268, P13118; BENNICH HH, 1978, IMMEDIATE HYPERSENSI, P1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BURT DS, 1987, MOL IMMUNOL, V24, P379, DOI 10.1016/0161-5890(87)90180-5; BURT DS, 1987, EUR J IMMUNOL, V17, P437, DOI 10.1002/eji.1830170323; CAPRON A, 1986, IMMUNOL TODAY, V7, P15, DOI 10.1016/0167-5699(86)90184-2; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CONRAD DH, 1983, J IMMUNOL, V130, P327; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; FLANAGAN JG, 1982, EMBO J, V1, P655, DOI 10.1002/j.1460-2075.1982.tb01223.x; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HELM B, 1989, P NATL ACAD SCI USA, V86, P9465, DOI 10.1073/pnas.86.23.9465; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; HELM BA, 1991, EUR J IMMUNOL, V21, P1543, DOI 10.1002/eji.1830210631; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; JEFFERIS R, 1990, MOL IMMUNOL, V27, P1237, DOI 10.1016/0161-5890(90)90027-W; KABAT EA, 1991, SEQUENCES PROTEINS I, P103; KEEGAN AD, 1991, MOL IMMUNOL, V28, P1149, DOI 10.1016/0161-5890(91)90030-N; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MENDOZA G, 1976, NATURE, V264, P548, DOI 10.1038/264548a0; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MISHELL BB, 1980, SELECTED METHODS CEL, P292; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477; NIO N, 1990, PEPTIDE CHEMISTRY 1989, P203; NISSIM A, 1991, EMBO J, V10, P101, DOI 10.1002/j.1460-2075.1991.tb07925.x; NISSIM A, 1993, J IMMUNOL, V150, P1365; PADLAN EA, 1986, MOL IMMUNOL, V23, P1063, DOI 10.1016/0161-5890(86)90005-2; PRESTA LG, 1993, J IMMUNOL, V151, P2623; ROBERTSON MW, 1988, MOL IMMUNOL, V25, P103, DOI 10.1016/0161-5890(88)90057-0; SCHWARZBAUM S, 1989, EUR J IMMUNOL, V19, P1015, DOI 10.1002/eji.1830190610; SENO M, 1983, NUCLEIC ACIDS RES, V11, P719, DOI 10.1093/nar/11.3.719; SHOPES B, 1990, J IMMUNOL, V145, P3842; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WEETALL M, 1990, J IMMUNOL, V145, P3849; WOOF JM, 1986, MOL IMMUNOL, V23, P319, DOI 10.1016/0161-5890(86)90059-3; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	48	160	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26368	26373						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929356				2022-12-25	WOS:A1994PQ93000066
J	DONG, AC; NAGAI, M; YONEYAMA, Y; CAUGHEY, WS				DONG, AC; NAGAI, M; YONEYAMA, Y; CAUGHEY, WS			DETERMINATION OF THE AMOUNTS AND OXIDATION-STATES OF HEMOGLOBINS-M BOSTON AND M-SASKATOON IN SINGLE ERYTHROCYTES BY INFRARED MICROSPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH-FLAVIN REDUCTASE; SUBUNITS; SPECTROSCOPY; GEOMETRY; HEME	The reduced abnormal subunits of two M-type hemoglobins, Boston (His(alpha 58) --> Tyr) and Saskatoon (His(beta 63) --> Tyr), have been determined in the presence of normal human hemoglobin A by measurement of C-O stretch bands in infrared spectra of carbon monoxide complexes. Use of an infrared microscope coupled to a Fourier transform infrared spectrometer of high sensitivity permitted measurements to be made on as small a hemoglobin mixture as is contained in a single erythrocyte. The abnormal subunits of both Hbs M exhibit bands near 1970 cm(-1) compared with bands near 1951 cm(-1) for the normal subunits. The increase in 1970 cm(-1) band intensity upon erythrocyte reduction with dithionite provided a measure of the extent of abnormal subunit oxidation; in cell suspensions about 60% of the abnormal subunits of Hb M Boston and 80% for Hb M Saskatoon remained reduced. The amount of Hb present as abnormal Hb averaged about 25% for Hb M Boston cells and about 50% for Hb M Saskatoon cells. However, the ratio of Hb M to Hb A in individual cells varied markedly, with the ratio expected to decrease as the cell ages. These results demonstrate the unique utility of infrared microspectroscopy for the study of differences in abnormal Hb status among individual erythrocytes.	COLORADO STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, FT COLLINS, CO 80523 USA; KANAZAWA UNIV, SCH ALLIED HLTH PROFESS, BIOL LAB, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, SCH MED, DEPT BIOCHEM, KANAZAWA, ISHIKAWA 920, JAPAN	Colorado State University; Kanazawa University; Kanazawa University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015980] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-15980] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBEN JO, 1966, HEMES HEMOPROTEINS, P139; ARBANEDAHMANE M, 1985, HEMOGLOBIN, V9, P509, DOI 10.3109/03630268508997029; BAINE RM, 1980, HEMOGLOBIN, V4, P201; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P381; BYCKOVA V, 1971, BIOCHIM BIOPHYS ACTA, V243, P117, DOI 10.1016/0005-2795(71)90045-6; Caughey W. S., 1980, METHODS DETERMINING, P95; CAUGHEY WS, 1969, BIOCHEMISTRY-US, V8, P59, DOI 10.1021/bi00829a009; DONG AC, 1994, METHOD ENZYMOL, V232, P139; DONG AC, 1988, BIOCHEM BIOPH RES CO, V156, P752, DOI 10.1016/S0006-291X(88)80907-0; GERALD PS, 1961, P NATL ACAD SCI USA, V47, P1758, DOI 10.1073/pnas.47.11.1758; GERALD PS, 1958, BLOOD, V13, P936, DOI 10.1182/blood.V13.10.936.936; GERALD PS, 1957, SCIENCE, V126, P300, DOI 10.1126/science.126.3268.300; GIBSON QH, 1966, J BIOL CHEM, V241, P1650; HAYASHI A, 1966, SCIENCE, V152, P207, DOI 10.1126/science.152.3719.207; HAYASHI A, 1968, BIOCHIM BIOPHYS ACTA, V168, P262, DOI 10.1016/0005-2795(68)90149-9; HORLEIN H., 1948, DEUTSCHE MED WOCHENSCHR, V73, P476; HULTQUIST DE, 1971, NATURE-NEW BIOL, V229, P252, DOI 10.1038/newbio229252a0; Kiese M., 1974, METHEMOGLOBINEMIA CO; LAMAR GN, 1980, BIOCHEM BIOPH RES CO, V96, P1172, DOI 10.1016/0006-291X(80)90075-3; LIAN T, 1993, BIOCHEMISTRY-US, V32, P5809, DOI 10.1021/bi00073a013; MAKINO N, 1979, J BIOL CHEM, V254, P862; MOTOKAWA Y, 1964, ARCH BIOCHEM BIOPHYS, V105, P612, DOI 10.1016/0003-9861(64)90058-X; MURAWSKIK, 1965, ARCH BIOCH BIOPHS, V111, P197; NAGAI M, 1980, J BIOL CHEM, V255, P4599; NAGAI M, 1989, BIOCHEMISTRY-US, V28, P2418, DOI 10.1021/bi00432a012; NAGAI M, 1987, ACTA HAEMATOL-BASEL, V78, P95, DOI 10.1159/000205853; NAGAI M, 1991, BIOCHEMISTRY-US, V30, P6495, DOI 10.1021/bi00240a021; NAGAI M, 1985, BIOCHEM BIOPH RES CO, V128, P689, DOI 10.1016/0006-291X(85)90101-9; NISHIKURA K, 1975, J BIOL CHEM, V250, P6679; PISCIOTTA AV, 1959, J LAB CLIN MED, V54, P73; POTTER WT, 1990, BIOCHEMISTRY-US, V29, P6283, DOI 10.1021/bi00478a025; POTTER WT, 1983, BIOCHEM BIOPH RES CO, V116, P719, DOI 10.1016/0006-291X(83)90584-3; PULSINELLI PD, 1973, P NATL ACAD SCI USA, V70, P3870, DOI 10.1073/pnas.70.12.3870; SCOTT EM, 1968, HERED DISORD, P102; SINGER K, 1955, AM J MED, V18, P633, DOI 10.1016/0002-9343(55)90464-2; SUGITA Y, 1971, J BIOL CHEM, V246, P6072; SUZUKI T, 1966, BIOCHIM BIOPHYS ACTA, V127, P280, DOI 10.1016/0304-4165(66)90510-1; YUBISUI T, 1979, J BIOCHEM, V85, P719	38	6	6	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25365	25368						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929232				2022-12-25	WOS:A1994PQ49100023
J	BRENNAN, TV; ANDERSON, JW; JIA, ZC; WAYGOOD, EB; CLARKE, S				BRENNAN, TV; ANDERSON, JW; JIA, ZC; WAYGOOD, EB; CLARKE, S			REPAIR OF SPONTANEOUSLY DEAMIDATED HPR PHOSPHOCARRIER PROTEIN CATALYZED BY THE L-ISOASPARTATE-(D-ASPARTATE) O-METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-CONTAINING PROTEIN; SUGAR PHOSPHOTRANSFERASE SYSTEM; L-ISOASPARTYL RESIDUES; D-ASPARTYL RESIDUES; CARBOXYL METHYLTRANSFERASE; ASPARAGINYL RESIDUES; SPONTANEOUS DEGRADATION; SUCCINIMIDE FORMATION; ESCHERICHIA-COLI; PEPTIDE DEGRADATION	The non-enzymatic deamidation at residues Asn-la and Asn-38 of Escherichia coli phosphocarrier protein, HPr, and the repair of the resulting L-isoaspartyl (or beta-aspartyl) derivatives, HPr-1 and HPr-2, by recombinant human S-adenosylmethionine-dependent L-isoaspartate-(D-aspartate) O-methyltransferase (EC 2.1.1.77) were investigated. HPr is a component of the bacterial phosphoenolpyruvate:sugar phosphotransferase system that is involved in the concomitant translocation and phosphorylation of many hexose sugars. The major products of the deamidation reaction, L-isoaspartyl (or P-aspartyl) residues at positions 12 and 38, were found to be substrates for the L-isoaspartate-(D-aspartate) O-methyltransferase, an enzyme active on a wide variety of peptides and proteins containing these abnormal residues. This enzyme has been shown to catalyze the first step in a process that can convert L-isoaspartyl residues in peptides to normal L-aspartyl residues. The affinity of a recombinant human methyltransferase for HPr-1, a form deamidated at Asn-38, was relatively poor (K-m = 3.6 mM), while a greater affinity was found for HPr-2, a form deamidated at both Asn-12 and Asn-38 (K-m = 197 mu M). When HPr-2 was incubated with S-adenosylmethionine and the methyltransferase, the bulk of the L-isoaspartyl residues at position 12 was converted to L-aspartyl residues, The major by-product was the D-isoaspartyl form. The conversion of L-isoaspartyl residues at position 38 to L-aspartyl residues was less complete, reflecting the lower affinity of the methyltransferase for this site. The phosphohydrolysis activity of the repaired form was found to be midway between the form containing only L-aspartyl residues at positions 12 and 38 and the deamidated HPr-2 form.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON S7N 0W0,SK,CANADA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Saskatchewan					NIGMS NIH HHS [GM26020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON B, 1971, J BIOL CHEM, V246, P7023; ANDERSON JW, 1993, BIOCHEMISTRY-US, V32, P5913, DOI 10.1021/bi00073a025; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; BRENNAN TV, 1993, PROTEIN SCI, V2, P331; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAPASSO S, 1993, J CHEM SOC PERK T 2, P679, DOI 10.1039/p29930000679; CHAZIN WJ, 1989, BIOCHEMISTRY-US, V28, P8646, DOI 10.1021/bi00447a055; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; CLARKE S, 1992, STABILITY PROTEIN PH, P1; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GEIGER T, 1987, J BIOL CHEM, V262, P785; GEORGENASCIMENT.C, 1990, BIOCHEMISTRY-US, V29, P9586; JIA ZC, 1993, J BIOL CHEM, V268, P22490; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1993, NEUROCHEM RES, V18, P87, DOI 10.1007/BF00966926; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1989, ARCH BIOCHEM BIOPHYS, V268, P276, DOI 10.1016/0003-9861(89)90589-4; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI C, 1992, J BACTERIOL, V174, P355, DOI 10.1128/jb.174.2.355-361.1992; LIU DTY, 1992, TRENDS BIOTECHNOL, V10, P364, DOI 10.1016/0167-7799(92)90269-2; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; MACLAREN DC, 1992, BIOCHEM BIOPH RES CO, V185, P277, DOI 10.1016/S0006-291X(05)80987-8; MANNING MC, 1989, PHARM RES-DORDR, V6, P903, DOI 10.1023/A:1015929109894; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MEINWALD YC, 1986, INT J PEPT PROT RES, V28, P79; MURRAY ED, 1984, J BIOL CHEM, V259, P722; MURRAY ED, 1986, J BIOL CHEM, V261, P306; OTA IM, 1989, J BIOL CHEM, V264, P54; OTA IM, 1989, BIOCHEMISTRY-US, V28, P4020, DOI 10.1021/bi00435a058; PARANANDI MV, 1994, J BIOL CHEM, V269, P243; PATEL K, 1990, PHARMACEUT RES, V7, P787, DOI 10.1023/A:1015999012852; PATEL K, 1990, PHARMACEUT RES, V7, P703, DOI 10.1023/A:1015807303766; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SHARMA S, 1993, J BIOL CHEM, V268, P17695; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; WAYGOOD EB, 1985, BIOCHEMISTRY-US, V24, P6938, DOI 10.1021/bi00345a028; YAMADA H, 1985, BIOCHEMISTRY-US, V24, P7953, DOI 10.1021/bi00348a017	43	119	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24586	24595						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929130				2022-12-25	WOS:A1994PQ49000015
J	MARTIN, GEM; SEAMON, KB; BROWN, FM; SHANAHAN, MF; ROBERTS, PE; HENDERSON, PJF				MARTIN, GEM; SEAMON, KB; BROWN, FM; SHANAHAN, MF; ROBERTS, PE; HENDERSON, PJF			FORSKOLIN SPECIFICALLY INHIBITS THE BACTERIAL GALACTOSE H+ TRANSPORT PROTEIN, GALP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSE TRANSPORTER; ESCHERICHIA-COLI; SUGAR-TRANSPORT; CYTOCHALASIN-B; SALMONELLA-TYPHIMURIUM; PHOTOAFFINITY LABEL; HUMAN-ERYTHROCYTES; ARABINOSE; GENE; MEMBRANE	Forskolin is a potent inhibitor of mammalian passive glucose transporters. Here we show that forskolin is a remarkably specific inhibitor of energized D-galactose transport by the GalP sugar-H+ symport protein of Escherichia coli. Surprisingly, it does not inhibit transport of L-arabinose or D-xylose by the related E. coli AraE and XylE transporters, even though the amino acid sequences of their proteins are 30-64% identical to GalP and to the mammalian GLUT family. However, unlike GLUT1, photoactivation of the [H-3]forskolin-GalP complex fails to incorporate radioactivity covalently into the protein, in contrast to the effective incorporation of radioactivity from [H-3]cytochalasin B into both proteins, However, 3-[I-125]iodo-4-azidophenethylamido-7-O- succinyldesacetylforskolin ([I-125]APS-forskolin), which labels GLUT1, is a potent labeling reagent for GalP and, to a lesser extent, for AraE. The appropriate sugar substrates of each transporter protect it against the [I-125]APS-forskolin. Equilibrium binding studies using membranes from an E. coli strain that overexpresses GalP reveal a single set of high affinity binding sites for [H-3]forskolin with a K-d of 1.3-1.4 mu M, probably forming a 1:1 complex, compared with a value of 7.5 mu M for GLUT1. Sugar substrates of GalP and cytochalasin B displace forskolin from the protein. The nonhomologous sugar-H+ symporters for L-rhamnose (RhaT), L-fucose (FucP) and lactose (LacY) in E. coli are insensitive to forskolin. Forskolin and [I-125]APS-forskolin, therefore, constitute novel probes for exploring the structure-activity relationship of the bacterial GalP protein. GalP will provide an excellent model for the human glucose transporters and for elucidating the molecular basis of subtle differences in substrate and inhibitor recognition by individual members of this widespread family of transport proteins.	UNIV LEEDS, DEPT BIOCHEM & MOLEC BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; US FDA, DIV BIOCHEM & BIOPHYS, MOLEC PHARMACOL LAB, BETHESDA, MD 20892 USA; UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CB2 1EW, ENGLAND; SO ILLINOIS UNIV, SCH MED, DEPT PHYSIOL, CARBONDALE, IL 62901 USA	University of Leeds; US Food & Drug Administration (FDA); University of Cambridge; Southern Illinois University System; Southern Illinois University			Henderson, Peter JF/Q-1907-2018	Henderson, Peter/0000-0002-9187-0938	NIDDK NIH HHS [DK 36855] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036855] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1975, J BIOL CHEM, V250, P6032; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BLOCH R, 1973, BIOCHEMISTRY-US, V12, P4799, DOI 10.1021/bi00747a036; CAIRNS MT, 1991, J BIOL CHEM, V266, P8176; CARTERSU C, 1982, J BIOL CHEM, V257, P5419; CHARALAMBOUS BM, 1989, BIOCHEM SOC T, V17, P441; Cleland W W, 1979, Methods Enzymol, V63, P103; DARUWALLA KR, 1981, BIOCHEM J, V200, P611, DOI 10.1042/bj2000611; DAVIS EO, 1984, J BIOL CHEM, V259, P1520; DENT HC, 1993, THESIS U CAMBRIDGE; DEVES R, 1978, BIOCHIM BIOPHYS ACTA, V510, P339, DOI 10.1016/0005-2736(78)90034-2; FUTAI M, 1978, BACTERIAL TRANSPORT, P7; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HENDERSON PJF, 1992, INT REV CYTOL, V137A, P149; HENDERSON PJF, 1977, BIOCHEM J, V162, P309, DOI 10.1042/bj1620309; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; HENDERSON PJF, 1986, METHOD ENZYMOL, V125, P387; HENDERSON PJF, 1977, BIOCHEM J, V168, P15, DOI 10.1042/bj1680015; HORNE P, 1983, BIOCHEM J, V210, P699, DOI 10.1042/bj2100699; JOOST HG, 1988, MOL PHARMACOL, V33, P449; JUNG CY, 1977, J BIOL CHEM, V252, P5456; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KRUPKA RM, 1971, BIOCHEMISTRY-US, V10, P1143, DOI 10.1021/bi00783a007; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LEIVE L, 1965, BIOCHEM BIOPH RES CO, V21, P290, DOI 10.1016/0006-291X(65)90191-9; MACPHERSON AJS, 1983, J BIOL CHEM, V258, P4390; MAIDEN MCJ, 1988, J BIOL CHEM, V263, P8003; MCKEOWN BJ, 1992, THESIS U CAMBRIDGE; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; MUIRY JAR, 1993, BIOCHEM J, V290, P833, DOI 10.1042/bj2900833; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PETRO KR, 1988, THESIS U CAMBRIDGE; ROBBINS AR, 1975, J BACTERIOL, V123, P69, DOI 10.1128/JB.123.1.69-74.1975; ROBBINS AR, 1975, P NATL ACAD SCI USA, V72, P423, DOI 10.1073/pnas.72.2.423; ROBERTS PE, 1992, THESIS U CAMBRIDGE; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SERGEANT S, 1985, J BIOL CHEM, V260, P4677; SHANAHAN MF, 1987, J BIOL CHEM, V262, P5978; TATE CG, 1993, J BIOL CHEM, V268, P26850; TATE CG, 1992, J BIOL CHEM, V267, P6923; WADZINSKI BE, 1988, BIOCHEM J, V255, P983, DOI 10.1042/bj2550983; WADZINSKI BE, 1987, J BIOL CHEM, V262, P17683; WADZINSKI BE, 1990, BIOCHEM J, V272, P151, DOI 10.1042/bj2720151; WALMSLEY AR, 1993, EUR J BIOCHEM, V215, P43, DOI 10.1111/j.1432-1033.1993.tb18005.x; WALMSLEY AR, 1994, EUR J BIOCHEM, V221, P513, DOI 10.1111/j.1432-1033.1994.tb18763.x; WALMSLEY AR, 1994, J BIOL CHEM, V269, P17009; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; WITHOLT B, 1978, BIOCHIM BIOPHYS ACTA, V508, P296, DOI 10.1016/0005-2736(78)90332-2	49	21	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24870	24877						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929167				2022-12-25	WOS:A1994PQ49000054
J	OHASHI, M; HUTTNER, WB				OHASHI, M; HUTTNER, WB			AN ELEVATION OF CYTOSOLIC PROTEIN-PHOSPHORYLATION MODULATES TRIMERIC G-PROTEIN REGULATION OF SECRETORY VESICLE FORMATION FROM THE TRANS-GOLGI NETWORK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; HETEROTRIMERIC G-PROTEIN; ADP-RIBOSYLATION FACTOR; POLYMERIC IMMUNOGLOBULIN RECEPTOR; KINASE-C PHOSPHORYLATION; BREFELDIN-A; GUANINE-NUCLEOTIDE; POTENT INHIBITOR; EGF RECEPTOR; ENDOPLASMIC-RETICULUM	The role of protein phosphorylation in the formation of secretory vesicles from the trans Golgi network (TGN) and in the regulation of this process by TGN-associated trimeric G-proteins was investigated, using a previously established and a novel cell-free system derived from the neuroendocrine cell line PC12. In the absence of exogenous activators of trimeric G-proteins, okadaic acid, an inhibitor of protein serine/threonine phosphatase types 1, 2A, and PPX, had no significant effect on secretory vesicle formation as reconstituted in a postnuclear supernatant. However, okadaic acid antagonized the inhibition of secretory vesicle formation which occurred upon activation of trimeric G-proteins by either aluminum fluoride or guanosine 5'-3-O-(thio)-triphosphate (GTP gamma S). Microcystin LR, a protein phosphatase inhibitor structurally distinct from okadaic acid, also antagonized the trimeric G-protein-mediated inhibition of secretory vesicle formation but, in contrast to okadaic acid, alone was sufficient to stimulate this process. The antagonistic effect of the phosphatase inhibitors was abolished by a broad spectrum protein kinase inhibitor, staurosporine, which alone, however, did not affect vesicle formation. The effect of okadaic acid was promoted by activators of protein kinase C (phorbol myristate acetate) and protein kinase A (cyclic AMP). To investigate the subcellular localization of the phosphoprotein that is involved in the antagonistic effect of protein phosphatase inhibitors, a novel cell-free system was established which reconstitutes the formation of secretory vesicles from TGN membranes supplemented with cytosol. Using this cell-free system, the relevant phosphoprotein was found to reside in the cytosol. In conclusion, our results suggest that serine/threonine protein phosphorylation is not required for secretory vesicle formation from the TGN but modulates, via a cytosolic phosphoprotein, the regulation of this process by TGN-associated trimeric G-proteins.	UNIV HEIDELBERG, INST NEUROBIOL, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg			Huttner, Wieland B./P-4080-2018					ANTONNY B, 1992, J BIOL CHEM, V267, P6710; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; COHEN P, 1985, EUR J BIOCHEM, V151, P439, DOI 10.1111/j.1432-1033.1985.tb09121.x; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FUJITAYAMAGUCHI Y, 1988, BIOCHEM BIOPH RES CO, V157, P955, DOI 10.1016/S0006-291X(88)80967-7; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRIFFITHS G, 1990, J CELL SCI, V96, P691; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LUCOCQ J, 1991, J CELL SCI, V100, P753; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELANCON P, 1993, CURR BIOL, V3, P230, DOI 10.1016/0960-9822(93)90341-K; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; MORGAN A, 1993, EMBO J, V12, P3747, DOI 10.1002/j.1460-2075.1993.tb06052.x; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; OHASHI M, 1991, EXP CELL RES, V197, P168, DOI 10.1016/0014-4827(91)90419-U; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROSA P, 1992, EUR J CELL BIOL, V59, P265; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3409, DOI 10.1073/pnas.86.9.3409; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEELEMORTIMER O, 1993, FEBS LETT, V329, P313, DOI 10.1016/0014-5793(93)80244-O; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STUART RA, 1993, J BIOL CHEM, V268, P4050; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TBOZE SA, 1992, METHOD ENZYMOL, V219, P81; TBOZE SA, 1990, CELL, V60, P837; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331	73	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24897	24905						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929171				2022-12-25	WOS:A1994PQ49000058
J	TAWFIC, S; AHMED, K				TAWFIC, S; AHMED, K			GROWTH STIMULUS-MEDIATED DIFFERENTIAL TRANSLOCATION OF CASEIN KINASE-2 TO THE NUCLEAR MATRIX - EVIDENCE BASED ON ANDROGEN ACTION IN THE PROSTATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRAL PROSTATE; DNA TOPOISOMERASE-II; C-MYC PROTEIN; POLYCLONAL ANTIBODIES; CELLULAR-REGULATION; PHOSPHORYLATION; BINDING; ENZYME; IDENTIFICATION; TRANSCRIPTION	Recently, we documented that a significant amount of nuclear casein kinase 2 (CK2) (a ubiquitous multipotential messenger-independent serine/threonine protein kinase) is associated with the nuclear matrix (NM), where it may be involved in the phosphorylation of several intrinsic proteins (Tawfic, S., and Ahmed, K. (1994) J. Biol. Chem. 269, 7489-7493). Both CK2 and NM have been implicated in cell growth and proliferation. To examine whether CK2 in the NM was regulated in relation to a growth stimulus, we employed androgen action in the prostate as a model of growth control. In rats, androgen deprivation leads to a differential loss of CK2 activity and protein from the NM fraction in the prostate. At 24 h after androgen deprivation, the NM-associated CK2 activity as well as immunoreactive protein decline by about 80%. By comparison, total nuclear CK2 activity decreased by only 37%. Androgen administration to the castrated rats evokes a rapid differential increase in CK2 activity in the NM, so that within 1 h following the androgenic stimulus, the CK2 activity increases by 110% in the NM fraction versus 45% in the total nuclei. We propose that the stimulus-mediated differential translocation of CK2 to NM may play a role in the transduction of growth signal.	DEPT VET AFFAIRS MED CTR, CELLULAR & MOLEC BIOCHEM RES LAB 151, MINNEAPOLIS, MN 55417 USA; DEPT VET AFFAIRS MED CTR, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55417 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55417 USA	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL CANCER INSTITUTE [U01CA015062, R37CA015062, R01CA015062] Funding Source: NIH RePORTER; NCI NIH HHS [CA-15062] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; AHMED K, 1993, CELL MOL BIOL RES, V39, P451; AHMED K, 1987, BIOCHEM ACTION HORM, V14, P237; AHMED K, 1993, P NATL ACAD SCI USA, V90, P4426, DOI 10.1073/pnas.90.10.4426; AHMED K, 1994, CELL MOL BIOL RES, V40, P1; AHMED K, 1971, MOL PHARMACOL, V7, P323; AHMED K, 1992, RECENT ADV CELLULAR, V4, P7; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AURICCHIO F, 1981, BIOCHEM J, V194, P569, DOI 10.1042/bj1940569; BARRACK ER, 1980, J BIOL CHEM, V255, P7265; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BEREZNEY R, 1984, CHROMOSOMAL NONHISTO, V4, P119; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHAN PK, 1986, J BIOL CHEM, V261, P1868; Coffey D.S., 1988, P1081; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; DUMBAR TS, 1989, THESIS U MISSISSIPPI; ENGLISH HF, 1989, PROSTATE, V15, P233, DOI 10.1002/pros.2990150304; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GETZENBERG RH, 1990, MOL ENDOCRINOL, V4, P1336, DOI 10.1210/mend-4-9-1336; GETZENBERG RH, 1991, J CELL BIOCHEM, V47, P289, DOI 10.1002/jcb.240470402; GETZENBERG RH, 1990, ENDOCR REV, V11, P399, DOI 10.1210/edrv-11-3-399; GOLSTEYN EJ, 1989, PROSTATE, V14, P91, DOI 10.1002/pros.2990140203; GOUELI SA, 1990, BIOCHEM INT, V21, P685; GOUELI SA, 1984, ARCH BIOCHEM BIOPHYS, V234, P646, DOI 10.1016/0003-9861(84)90315-1; GOUELI SA, 1980, EUR J BIOCHEM, V113, P45; GOUELI SA, 1991, MOL CELL BIOCHEM, V101, P145; GOUELI SA, 1984, BIOCHEM BIOPH RES CO, V123, P778, DOI 10.1016/0006-291X(84)90297-3; HOTZ MA, 1992, EXP CELL RES, V201, P184, DOI 10.1016/0014-4827(92)90362-C; HOUSLEY PR, 1982, J BIOL CHEM, V257, P8615; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; LIAO S, 1966, P NATL ACAD SCI USA, V55, P1593, DOI 10.1073/pnas.55.6.1593; LIAO S, 1989, J STEROID BIOCHEM, V34, P41, DOI 10.1016/0022-4731(89)90064-2; LORENZ P, 1993, J BIOL CHEM, V268, P2733; MAINWARING WIP, 1983, J STEROID BIOCHEM, V19, P101, DOI 10.1016/S0022-4731(83)80012-0; MCCABE MJ, 1993, BIOCHEM BIOPH RES CO, V194, P944, DOI 10.1006/bbrc.1993.1912; MEEK DW, 1992, BIOCHEM J, V287, P1; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MOUDGIL VK, 1990, BIOCHIM BIOPHYS ACTA, V1055, P243, DOI 10.1016/0167-4889(90)90040-K; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; NICKERSON JA, 1990, EUKARYOTIC NUCLEUS M, V2, P763; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROBITZKI A, 1993, J BIOL CHEM, V268, P5694; SAMUELS DS, 1992, J BIOL CHEM, V267, P11156; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; TAWF, 1994, J BIOL CHEM, V269, P7489; TAWFIC S, 1993, CELL MOL BIOL RES, V39, P43; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WAITZ W, 1991, ONCOGENE, V6, P29; WILLIAMSASHMAN HG, 1979, ENDOCRINOLOGY, V3, P1527; XING YG, 1991, J CELL BIOL, V112, P1055, DOI 10.1083/jcb.112.6.1055; ZINI N, 1992, EXP CELL RES, V200, P460, DOI 10.1016/0014-4827(92)90196-F	71	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24615	24620						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929133				2022-12-25	WOS:A1994PQ49000019
J	MAO, XD; SHUMAN, S				MAO, XD; SHUMAN, S			INTRINSIC RNA (GUANINE-7) METHYLTRANSFERASE ACTIVITY OF THE VACCINIA VIRUS CAPPING ENZYME D1 SUBUNIT IS STIMULATED BY THE D12 SUBUNIT - IDENTIFICATION OF AMINO-ACID-RESIDUES IN THE D1 PROTEIN REQUIRED FOR SUBUNIT ASSOCIATION AND METHYL-GROUP TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ESCHERICHIA-COLI; (GUANINE-7-)METHYLTRANSFERASE COMPLEX; SCANNING MUTAGENESIS; DNA; SEQUENCE; GUANYLYLTRANSFERASE; CATALYSIS; DOMAINS	Vaccinia virus mRNA capping enzyme, a heterodimer of virus-encoded D1 and D12 subunits, catalyzes three steps in the synthesis of the m(7)GpppN cap. By expressing portions of the subunits in bacteria, singly and together, we have localized the RNA (guanine-7) methyltransferase domain to a 305-amino acid carboxyl-terminal segment of the D1 polypeptide (residues 540-844) complexed with the D12 protein. We find that the purified carboxyl D1 protein has a weak intrinsic methyltransferase activity, indicating that the catalytic center resides within this subunit. The basal level of activity can be stimulated 100-fold by addition of purified D12 protein, which is itself catalytically inert. The carboxyl region of D1 forms a heterodimer with the D12 subunit in vivo and in vitro. Analysis of alanine substitution mutants of the D1 protein identifies amino acid residues important for subunit interaction. Our results suggest that subunit heterodimerization is necessary, but not sufficient, for full methyltransferase activity. A mutation of vicinal positions His-682-Tyr-683 that specifically affects catalytic activity but not subunit interaction implicates these residues as constituents of the active site.			MAO, XD (corresponding author), SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT WF, 1991, J BIOL CHEM, V266, P5191; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; CONG PJ, 1993, J BIOL CHEM, V268, P7256; CONG PJ, 1992, J BIOL CHEM, V267, P16424; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HIGMAN MA, 1994, J BIOL CHEM, V269, P14982; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MOSS B, 1976, VIROLOGY, V72, P341, DOI 10.1016/0042-6822(76)90163-X; NILES EG, 1993, J BIOL CHEM, V268, P24986; NILES EG, 1986, VIROLOGY, V153, P96, DOI 10.1016/0042-6822(86)90011-5; PENA L, 1993, VIROLOGY, V193, P319, DOI 10.1006/viro.1993.1128; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; UPTON C, 1991, VIROLOGY, V183, P773, DOI 10.1016/0042-6822(91)91009-6; VENKATESAN S, 1980, J BIOL CHEM, V255, P903	25	77	90	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24472	24479						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929111				2022-12-25	WOS:A1994PQ34600096
J	ARAKAWA, T; HANIU, M; NARHI, LO; MILLER, JA; TALVENHEIMO, J; PHILO, JS; CHUTE, HT; MATHESON, C; CARNAHAN, J; LOUIS, JC; YAN, Q; WELCHER, AA; ROSENFELD, R				ARAKAWA, T; HANIU, M; NARHI, LO; MILLER, JA; TALVENHEIMO, J; PHILO, JS; CHUTE, HT; MATHESON, C; CARNAHAN, J; LOUIS, JC; YAN, Q; WELCHER, AA; ROSENFELD, R			FORMATION OF HETERODIMERS FROM 3 NEUROTROPHINS, NERVE GROWTH-FACTOR, NEUROTROPHIN-3, AND BRAIN-DERIVED NEUROTROPHIC FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; FACTOR FAMILY; RECEPTORS; SIMILARITIES; EXPRESSION; STABILITY; MEMBER; CELLS	Three neurotrophic factors, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and nerve growth factor (NGF) form noncovalent homodimers in solution. Since they are highly homologous proteins, it seemed probable that two monomers of these proteins might associate together to form a heterodimer. This was tested by denaturing the two different proteins together in 6 M guanidine HCl and refolding them in phosphate-buffered saline. When the refolded mixture of BDNF and NT-3 was subjected to Mono S cation exchange chromatography, a new peak was observed eluting between NT-3 and BDNF, which accounted for about 30% of the protein used. This new protein species migrated as a single band upon native gel electrophoresis with mobility between that of the NT-3 homodimer and the BDNF homodimer, indicating that a complex had been formed. Sedimentation equilibrium data show that the dissociation constant of this heterodimer is <3 x 10-(10) M. The heterodimer was stable upon incubation at 37 degrees C in phosphate-buffered saline over 11 days. Having determined that the heterodimer is highly stable, it was subjected to various biological assays. Autophosphorylation assay using TrkB receptor showed that the heterodimer is indistinguishable from the BDNF or NT-3 homodimer in the ability to induce phosphorylation of the receptor. It was also indistinguishable from the homodimers in the neurotrophic activity using chick dorsal root ganglion explant. In the sympathetic neuron survival assay, the heterodimer behaved more similarly to NT-3, whereas in the dopamine uptake assay, it was intermediate between the two homodimers. In addition, the heterodimer was shown to be retrogradely transported in the dorsal root ganglion neurons. A heterodimer between NGF and BDNF is formed but much less effectively than the NT-3 BDNF heterodimer, and it is not stable even at 4 degrees C. These results indicate that BDNF and NT-3 have an intersubunit contact surface for dimerization resembling each other's but different from the contact surface of NGF.			ARAKAWA, T (corresponding author), AMGEN INC,AMGEN CTR,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.		Philo, John S/A-8804-2009	Philo, John S/0000-0003-3418-0356				ACKLIN C, 1993, INT J PEPT PROT RES, V41, P548; ANGLETTI RH, 1971, BIOCHEMISTRY-US, V10, P463; BARBACID M, 1993, ONCOGENE, V8, P2033; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; DECHANT G, 1993, J NEUROSCI, V13, P2610, DOI 10.1523/JNEUROSCI.13-06-02610.1993; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P446; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P229; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; NARHI LO, 1993, J BIOL CHEM, V268, P13309; PHILO J, 1994, J BIOL CHEM, V269, P27840; PHILO JS, 1993, BIOCHEMISTRY-US, V32, P10812, DOI 10.1021/bi00091a036; RADZIEJEWSKI C, 1992, BIOCHEMISTRY-US, V31, P4431, DOI 10.1021/bi00133a007; RADZIEWJEWSKI C, 1993, BIOCHEMISTRY-US, V32, P13350, DOI 10.1021/bi00211a049; ROSENFELD R, 1993, J CHROMATOGR, V632, P29, DOI 10.1016/0021-9673(93)80022-Z; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROTHWELL M, 1977, J BIOL CHEM, V252, P8532; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YAN Q, 1991, SOC NEUR ABSTR	23	26	42	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27833	27839						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961712				2022-12-25	WOS:A1994PV77200013
J	BOYAN, BD; SCHWARTZ, Z; PARKSNYDER, S; DEAN, DD; YANG, FM; TWARDZIK, D; BONEWALD, LF				BOYAN, BD; SCHWARTZ, Z; PARKSNYDER, S; DEAN, DD; YANG, FM; TWARDZIK, D; BONEWALD, LF			LATENT TRANSFORMING GROWTH-FACTOR-BETA IS PRODUCED BY CHONDROCYTES AND ACTIVATED BY EXTRACELLULAR-MATRIX VESICLES UPON EXPOSURE TO 1,25-(OH)(2)D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D METABOLITES; ARACHIDONIC-ACID TURNOVER; MOLECULAR-WEIGHT COMPLEX; CARTILAGE CELLS-INVITRO; RESTING ZONE; ALKALINE-PHOSPHATASE; PLATE CHONDROCYTES; FACTOR-BETA-1 GENE; MESSENGER-RNA; BONE CULTURES	Resting zone and growth zone (GC) costochondral chondrocytes constitutively release latent, but not active, transforming growth factor-beta (TGF-beta) into the culture medium. When exogenous TGF-beta is added to the culture medium, no autocrine effect is observed. However, when 1,25-(OH)(2)D-3 is added, a dose-dependent inhibition of latent TGF-beta release is found. Messenger RNA levels for TGF-beta 1 are unchanged by treatment with either 1,25-(OH)(2)D-3 or TGF-beta 1. Since active growth factor was not observed in the conditioned medium, we tested the hypothesis that latent TGF-beta could be activated in the matrix. GC matrix vesicles, extracellular organelles associated with matrix calcification, were able to activate latent TGF-beta 1 and TGF-beta 2 when preincubated with 1,25-(OH)(2)D-3. In contrast, GC plasma membranes activated latent TGF-beta, and addition of 1,25-(OH)(2)D-3 inhibited this activation. The 1,25-(OH)(2)D-3-dependent decrease in latent TGF-beta in the medium, with no detectable change in mRNA level, and the inhibition of plasma membrane activation of latent TGF-beta by 1,25-(OH)(2)D-3 suggest that 1,25-(OH)(2)D-3 may act through post-transcriptional and/or nongenomic mechanisms. The results also suggest that latent TGF-beta is activated in the matrix and that 1,25-(OH)(2)D-3 regulates this activation by a direct, non-genomic action on the matrix vesicle membrane.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT PERIODONT,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT MED ENDOCRINOL & METAB,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT STRUCT & CELLULAR BIOL,SAN ANTONIO,TX 78284; HEBREW UNIV JERUSALEM,HADASSAH FAC DENT MED,DEPT PERIODONT,JERUSALEM,ISRAEL; ADV TISSUE SCI,LA JOLLA,CA 92037; UNIV WASHINGTON,SCH MED,DEPT DERMATOL,SEATTLE,WA 98195; AUDIE MURPHY VET AFFAIRS MED CTR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Hebrew University of Jerusalem; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	BOYAN, BD (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT ORTHOPAED,SAN ANTONIO,TX 78284, USA.		Bonewald, Lynda/Q-3638-2019	Dean, David/0000-0002-4512-9065	NIDCR NIH HHS [DE08603, DE05937, DE08569] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005937, R01DE008603, P01DE008569] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; BONEWALD LF, 1992, J BIOL CHEM, V267, P8943; BONEWALD LF, 1990, J CELL PHYSIOL, V145, P200, DOI 10.1002/jcp.1041450203; BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312; BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend-5-6-741; BOSKEY AL, 1992, BONE MINER, V17, P257, DOI 10.1016/0169-6009(92)90747-2; BOSKEY AL, 1986, BONE, V7, P277, DOI 10.1016/8756-3282(86)90208-5; BOYAN BD, 1988, ENDOCRINOLOGY, V122, P2851, DOI 10.1210/endo-122-6-2851; BOYAN BD, 1988, BONE, V9, P185, DOI 10.1016/8756-3282(88)90008-7; BOYAN BD, 1989, J BIOL CHEM, V264, P11879; BOYAN BD, 1992, CRIT REV ORAL BIOL M, V3, P15, DOI 10.1177/10454411920030010401; BRETAUDIERE JP, 1984, METHOD ENZYMAT AN, V4, P75; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRABB ID, 1990, J BONE MINER RES, V5, P1105; DALLAS SL, 1994, J BIOL CHEM, V269, P6815; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; DAVIES LG, 1977, BASIC METHODS MOL BI, P143; DEAN DD, 1992, CALCIFIED TISSUE INT, V50, P342, DOI 10.1007/BF00301632; DEAN DD, 1994, CALCIFIED TISSUE INT, V54, P399, DOI 10.1007/BF00305527; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; ECAROTCHARRIER B, 1988, BONE, V9, P147, DOI 10.1016/8756-3282(88)90004-X; EINHORN TA, 1989, J ORTHOPAED RES, V7, P792, DOI 10.1002/jor.1100070604; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITZPATRICK DF, 1969, J BIOL CHEM, V244, P3561; Fourney R.M., 1988, FOCUS, V10, P5; GELB DE, 1990, ENDOCRINOLOGY, V127, P1941, DOI 10.1210/endo-127-4-1941; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GINSBURG I, 1992, INFLAMMATION, V16, P519, DOI 10.1007/BF00918977; HIRSCHMAN A, 1983, CALCIFIED TISSUE INT, V35, P791, DOI 10.1007/BF02405125; JINGUSHI S, 1990, CALCIUM REGULATION B, V10, P298; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KIM SJ, 1989, J BIOL CHEM, V264, P7041; KIM SJ, 1989, J BIOL CHEM, V264, P402; LANGSTON GG, 1990, CALCIFIED TISSUE INT, V47, P230, DOI 10.1007/BF02555924; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Madisen L, 1990, GROWTH FACTORS, V3, P129, DOI 10.3109/08977199009108275; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; OKEEFE R, 1988, J BONE MINER RES, V3, pS67; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; OURSLER MJ, 1994, J BONE MINER RES, V9, P443; PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024; ROSIER RN, 1989, CONNECT TISSUE RES, V20, P295, DOI 10.3109/03008208909023900; SAITO S, 1993, CLIN EXP IMMUNOL, V94, P220, DOI 10.1111/j.1365-2249.1993.tb06004.x; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHWARTZ Z, 1991, J BONE MINER RES, V6, P709; SCHWARTZ Z, 1993, J BIOMED MATER RES, V27, P1029, DOI 10.1002/jbm.820270808; SCHWARTZ Z, 1988, ENDOCRINOLOGY, V123, P2878, DOI 10.1210/endo-123-6-2878; SCHWARTZ Z, 1990, BIOCHIM BIOPHYS ACTA, V1027, P278, DOI 10.1016/0005-2736(90)90319-J; SCHWARTZ Z, 1988, ENDOCRINOLOGY, V122, P2191, DOI 10.1210/endo-122-5-2191; SCHWARTZ Z, 1992, ENDOCRINOLOGY, V130, P2495, DOI 10.1210/en.130.5.2495; SCHWARTZ Z, 1988, J BIOL CHEM, V263, P6023; SCHWARTZ Z, 1989, BONE, V10, P53, DOI 10.1016/8756-3282(89)90147-6; SCHWARTZ Z, 1993, ENDOCRINOLOGY, V132, P1544, DOI 10.1210/en.132.4.1544; SEYEDIN SM, 1986, J BIOL CHEM, V261, P5693; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; SWAIN LD, 1992, BIOCHIM BIOPHYS ACTA, V1136, P45, DOI 10.1016/0167-4889(92)90083-N; SWAIN LD, 1993, BONE, V14, P609, DOI 10.1016/8756-3282(93)90082-L; SYLVIA VL, 1993, J CELL PHYSIOL, V157, P271, DOI 10.1002/jcp.1041570209; SYLVIA VL, 1994, J BONE MINER RES, V9, P1477; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; TWARDZIK DR, 1990, ANN NY ACAD SCI, V593, P276, DOI 10.1111/j.1749-6632.1990.tb16119.x; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WEGEDAHL JE, 1992, METABOLISM, V41, P42; WUTHIER RE, 1985, J BIOL CHEM, V260, P5972; WUTHIER RE, 1973, CLIN ORTHOP RELAT R, V90, P191	69	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28374	28381						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961777				2022-12-25	WOS:A1994PV77200089
J	MOLINARI, M; ANAGLI, J; CARAFOLI, E				MOLINARI, M; ANAGLI, J; CARAFOLI, E			CA2+-ACTIVATED NEUTRAL PROTEASE IS ACTIVE IN THE ERYTHROCYTE-MEMBRANE IN ITS NONAUTOLYZED 80-KDA FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALPAIN-II; BRAIN SPECTRIN; CALCIUM; DEGRADATION; PROTEINASES; DOMAIN; INVOLVEMENT; CALPASTATIN; INHIBITORS; ACTIVATION	The aim of this study was to investigate the process leading to Ca2+-activated neutral protease (CANP) activation in vivo. The unautolyzed form of CANP has been targeted to the erythrocyte membrane by increasing, in a controlled way, the Ca2+ concentration in the cells; this was achieved by incubating erythrocytes with the Ca2+ ionophore A23187 and fixed Ca2+ concentrations. After isolation of the CANP-bearing erythrocyte membrane, we could observe that CANP remained bound to the membrane in the 80-kDa unautolyzed form in the presence of low Ca2+ concentrations (1.75 mu M); under these conditions, the preferred CANP substrates (the Ca2+-ATPase and Band 3) were cleaved. That the cleavage was due to CANP was shown by the finding that the two substrates were not degraded in the presence of a membrane-permeable irreversible CANP inhibitor, Cbz-Leu-Leu-Tyr-CHN2, nor when the free Ca2+ concentration was decreased to sub mu M levels with EDTA. The findings suggest an activation mechanism of CANP based on its translocation to the membrane rather than on its autolysis. In this mechanism, CANP would become reversibly activated on the membrane and would return to the quiescent state after dissociating from it when the cell Ca2+ concentration has returned to the physiological, submicromolar level.	ETH ZURICH, INST BIOCHEM 3, CH-8092 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094; Molinari, Maurizio/0000-0002-7636-5829				ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; BANIK NL, 1987, NEUROCHEM PATHOL, V7, P57, DOI 10.1007/BF02834292; CONG JY, 1989, J BIOL CHEM, V264, P10096; CONG JY, 1993, J BIOL CHEM, V268, P25740; CRAWFORD C, 1993, BIOCHEM J, V296, P135, DOI 10.1042/bj2960135; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; CRAWFORD C, 1990, BIOCHEM J, V265, P575, DOI 10.1042/bj2650575; DAVID LL, 1993, J BIOL CHEM, V268, P1937; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; INOMATA M, 1990, BIOCHEM BIOPH RES CO, V171, P625, DOI 10.1016/0006-291X(90)91192-U; JAMES P, 1989, J BIOL CHEM, V264, P8289; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; PONTREMOLI S, 1988, BIOCHEM BIOPH RES CO, V157, P867, DOI 10.1016/S0006-291X(88)80955-0; PONTREMOLI S, 1985, BIOCHEM INT, V11, P35; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; PONTREMOLI S, 1985, BIOCHIM BIOPHYS ACTA, V831, P335, DOI 10.1016/0167-4838(85)90116-5; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; SALAMINO F, 1993, BIOCHEM J, V290, P191, DOI 10.1042/bj2900191; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SHIMOHAMA S, 1991, BRAIN RES, V558, P105, DOI 10.1016/0006-8993(91)90722-8; SIMAN R, 1990, FID RES FDN, V4, P145; SORIMACHI H, 1990, BIOL CHEM H-S, V371, P171; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; SUZUKI K, 1990, FID RES FDN, V4, P79; Vanaman T. C., 1977, CALCIUM BINDING PROT, P107	30	91	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27992	27995						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961733				2022-12-25	WOS:A1994PV77200036
J	NISHIYAMA, T; MCDONOUGH, AM; BRUNS, RR; BURGESON, RE				NISHIYAMA, T; MCDONOUGH, AM; BRUNS, RR; BURGESON, RE			TYPE-XII AND TYPE-XIV COLLAGENS MEDIATE INTERACTIONS BETWEEN BANDED COLLAGEN-FIBERS IN-VITRO AND MAY MODULATE EXTRACELLULAR-MATRIX DEFORMABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORING FIBRILS; GEL CONTRACTION; VII COLLAGEN; VONWILLEBRAND-FACTOR; GROWTH-FACTOR; IX COLLAGEN; FIBROBLASTS; IDENTIFICATION; FORM; REORGANIZATION	Type XII and XIV collagens are very large molecules containing three extended globular domains derived from the amino terminus of each cu chain and an interrupted triple helix. Both collagens are genetically and immunologically unique and have distinct distributions in many tissues. These collagens localize near the surface of banded collagen fibrils. The function of the molecules is unknown. We have prepared a mixture of native type XII and XIV collagens that is free of contaminating proteins by electrophoretic criteria. In addition, we have purified the collagenase-resistant globular domains of type XII or XIV collagens (XII-NC-3 or XIV-NC-3). In this study, we have investigated the effect of intact type XII and XIV and XII-NC-3 or XIV-NC-3 on the interactions between fibroblasts and type I collagen fibrils. We find that both type XII and XIV collagens promote collagen gel contraction mediated by fibroblasts, even in the absence of serum, The activity is present in the NC-3 domains. The effect is dose-dependent and is inhibited by denaturation. The effect of type XII NC-3 is inhibited by the addition of anti-XII antiserum. To elucidate the mechanism underlying this phenomenon, we examined the effect of XII-NC-3 or XIV-NC-3 on deformability of collagen gels by centrifugal force. XII-NC-3 or XIV-NC-3 markedly promotes gel compression after centrifugation. The effect is also inhibited by denaturation, and the activity of type XII-NC3 is inhibited by the addition of anti-MT antiserum. The results indicate that the effect of XII-NC-3 or XIV-NC-3 on collagen gel contraction by fibroblasts is not due to activation of cellular events but rather results from the increase in mobility of hydrated collagen fibrils within the gel. These studies suggest that collagen types XII and XIV may modulate the biomechanical properties of tissues.	MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Nishiyama, Toshio/C-5434-2013	Nishiyama, Toshio/0000-0002-3459-2636	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035689] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM35689] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHINGER HP, 1990, J BIOL CHEM, V265, P10095; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; GERECKE DR, 1993, J BIOL CHEM, V268, P12177; GORDON MK, 1989, J BIOL CHEM, V264, P19772; GUIDRY C, 1987, J CELL BIOL, V104, P1097, DOI 10.1083/jcb.104.4.1097; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; HEINO J, 1989, J BIOL CHEM, V264, P380; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KOCH M, 1992, EUR J BIOCHEM, V207, P847, DOI 10.1111/j.1432-1033.1992.tb17116.x; KUPPER TS, 1993, FASEB J, V7, P1401, DOI 10.1096/fasebj.7.14.8224612; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LETHIAS C, 1993, J INVEST DERMATOL, V101, P92, DOI 10.1111/1523-1747.ep12360433; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; LUNSTRUM GP, 1991, J CELL BIOL, V113, P963, DOI 10.1083/jcb.113.4.963; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; NISHIYAMA T, 1988, COLLAGEN REL RES, V8, P259; NISHIYAMA T, 1993, MATRIX, V13, P447, DOI 10.1016/S0934-8832(11)80111-3; NISHIYAMA T, 1989, MATRIX, V9, P193, DOI 10.1016/S0934-8832(89)80050-2; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; SCHAFER IA, 1989, EXP CELL RES, V183, P112, DOI 10.1016/0014-4827(89)90422-9; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; TINGSTROM A, 1992, J CELL SCI, V102, P315; TRUEB J, 1992, EUR J BIOCHEM, V207, P549, DOI 10.1111/j.1432-1033.1992.tb17081.x; WATT SL, 1992, J BIOL CHEM, V267, P20093; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	29	132	136	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28193	28199						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961756				2022-12-25	WOS:A1994PV77200064
J	OKAZAKI, T; CHUNG, UI; NISHISHITA, T; EBISU, S; USUDA, S; MISHIRO, S; XANTHOUDAKIS, S; IGARASHI, T; OGATA, E				OKAZAKI, T; CHUNG, UI; NISHISHITA, T; EBISU, S; USUDA, S; MISHIRO, S; XANTHOUDAKIS, S; IGARASHI, T; OGATA, E			A REDOX FACTOR PROTEIN, REF1, IS INVOLVED IN NEGATIVE GENE-REGULATION BY EXTRACELLULAR CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE GENE; ELEMENT-BINDING PROTEIN; RETINOID X-RECEPTOR; DNA-REPAIR ENZYME; TRANSCRIPTIONAL REGULATION; DEOXYRIBONUCLEIC-ACID; THYROID-HORMONE; CYCLIC-AMP; JUN; PHOSPHORYLATION	A rise in extracellular calcium (Ca-e(2+)) suppresses not only secretion of parathyroid hormone (PTH) but also expression of the PTH gene to ensure constant plasma Ca2+ level. A nuclear protein(s) in a wide variety of cells bound to the specific DNA elements (negative Ca2+ responsive elements, nCaREs) in the human PTH gene in sequence-specific and Ca(2+)e concentration-dependent manners. Our Southwestern cloning revealed that a redox factor protein (ref1), which was known to activate several transcription factors via alterations of their redox state, belonged to an nCaRE binding protein. The level of ref1 mRNA as well as of its protein was elevated by an increase in Ca-e(2+) concentration. In gel shift assay, anti-ref1 antibody eliminated formation of the nCaRE-protein complex. We also found that there was another protein(s) interacting with nCaREs and ref1. Further, experiments with an antisense-ref cDNA expression vector introduced into cultured cells suggested that DNA (nCaRE)-ref1 interaction led to Ca-e(2+)-mediated transcriptional suppression. Thus, it is concluded that ref1 possesses transcription repressor activity in addition to its function as a transcriptional auxiliary protein.	UNIV TOKYO,CTR HLTH SERV,BUNKYO KU,TOKYO 113,JAPAN; HIGETA SHOYU CO LTD,RES LAB,CHOSHI,CHIBA 288,JAPAN; INST IMMUNOL,BUNKYO KU,TOKYO 112,JAPAN; CANC INST HOSP,TOSHIMA KU,TOKYO 170,JAPAN; ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	University of Tokyo; Japanese Foundation for Cancer Research	OKAZAKI, T (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,ENDOCRINE GENET UNIT,BUNKYO KU,3-28-6 MEJIRODAI,TOKYO 112,JAPAN.			Mishiro, Shunji/0000-0001-9618-6468				ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CAMPOS RV, 1992, MOL ENDOCRINOL, V6, P1642, DOI 10.1210/me.6.10.1642; CHEN CJ, 1987, ENDOCRINOLOGY, V121, P958, DOI 10.1210/endo-121-3-958; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOGGARD N, 1991, MOL ENDOCRINOL, V5, P1748, DOI 10.1210/mend-5-11-1748; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P3889; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OKAZAKI T, 1991, J BIOL CHEM, V266, P21903; OKAZAKI T, 1988, J BIOL CHEM, V263, P2203; OKAZAKI T, 1992, J CLIN INVEST, V89, P1268, DOI 10.1172/JCI115711; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PRIBNOW D, 1992, MOL ENDOCRINOL, V6, P1003, DOI 10.1210/me.6.7.1003; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SAMBROOK S, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO N, 1990, AM J MED SCI, V299, P309, DOI 10.1097/00000441-199005000-00004; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGT PK, 1989, ADV CANCER RES, V55, P1; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YAMAMOTO M, 1989, J CLIN INVEST, V83, P1053, DOI 10.1172/JCI113946; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	46	132	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27855	27862						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961715				2022-12-25	WOS:A1994PV77200016
J	VANWIJK, KJ; NILSSON, LO; STYRING, S				VANWIJK, KJ; NILSSON, LO; STYRING, S			SYNTHESIS OF REACTION-CENTER PROTEINS AND REACTIVATION OF REDOX COMPONENTS DURING REPAIR OF PHOTOSYSTEM-II AFTER LIGHT-INDUCED INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; CHLAMYDOMONAS-REINHARDTII; D1 PROTEIN; SPECTROSCOPIC CHARACTERIZATION; TRANSLATION INTERMEDIATE; CHLOROPLAST MEMBRANES; KINETIC RESOLUTION; GREEN-ALGA; PHOTOINHIBITION; D1-PROTEIN	The D1 reaction center protein in photosystem II (PSII) has a high turnover rate due to light-induced inactivation of the redox components. We have studied the reactivation kinetics of the redox components of PSII after strong illumination and compared these kinetics with the turnover of the D1 protein and translation kinetics of the plastid-encoded PSII core proteins in Chlamydomonas reinhardtii cells. Repair of PSII was to a large extent dependent on protein translation. During the first hours of repair, D1 translation was highly accelerated as compared to the other PSII core proteins. By addition of protein synthesis inhibitors during the recovery process, it was found that the time from protein synthesis to full reassembly and reactivation of the individual PSII complexes was about 55 +/- 10 min. Inactivation and reactivation of the redox components in PSII were followed by electron spin resonance and electron transport measurements. Combining the data shows that reactivation of the individual components proceeded together or shortly after one another. Thus, no accumulation of any partially active reactivation intermediate occurred. We conclude that the rate-limiting step of the repair cycle of PSII lies in the degradation and synthesis of the PSII reaction center proteins. Once stable synthesis of the PSII core proteins is achieved, reactivation of the redox components occurs very quickly.			VANWIJK, KJ (corresponding author), UNIV STOCKHOLM, DEPT BIOCHEM, ARRHENIUS LABS NAT SCI, S-10691 STOCKHOLM, SWEDEN.		Styring, Stenbjörn/L-8414-2016	Styring, Stenbjörn/0000-0002-2803-9244				ADIR N, 1990, J BIOL CHEM, V265, P12563; ANDERSSON B, 1992, J PHOTOCH PHOTOBIO B, V15, P15, DOI 10.1016/1011-1344(92)87003-R; ANDERSSON B., 1991, CURR TOP BIOENERG, V16, P1; ARNON DI, 1948, PLANT PHYSIOL, V24, P1; ARO EM, 1990, BIOCHIM BIOPHYS ACTA, V1019, P269, DOI 10.1016/0005-2728(90)90204-H; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; ARO EM, 1994, PLANT PHYSIOL, V104, P1033, DOI 10.1104/pp.104.3.1033; BARBATO R, 1992, J CELL BIOL, V119, P325, DOI 10.1083/jcb.119.2.325; BLACK MT, 1986, PHOTOSYNTH RES, V8, P193, DOI 10.1007/BF00037128; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEVITRY C, 1989, J CELL BIOL, V109, P999; ERIKSEN JM, 1992, TOPICS PHOTOSYNTHESI, V11, P101; FALK S, 1990, PHYSIOL PLANTARUM, V78, P173; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; GREER DH, 1986, PLANTA, V168, P253, DOI 10.1007/BF00402971; HUNDAL T, 1990, BIOCHIM BIOPHYS ACTA, V1017, P285; IKEUCHI M, 1992, RES PHOTOSYNTHESIS, V2, P175; INAGAKI N, 1992, FEBS LETT, V300, P5, DOI 10.1016/0014-5793(92)80152-7; KETTUNEN R, 1991, FEBS LETT, V290, P153, DOI 10.1016/0014-5793(91)81247-6; KIM JH, 1993, PLANT PHYSIOL, V103, P181, DOI 10.1104/pp.103.1.181; KIM JM, 1991, J BIOL CHEM, V266, P14931; KIRILOVSKY DL, 1990, BIOCHEMISTRY-US, V29, P8100, DOI 10.1021/bi00487a016; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; LAEMMLI VK, 1975, NATURE, V227, P680; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MICHAELS A, 1990, BIOCHEM BIOPH RES CO, V170, P1082, DOI 10.1016/0006-291X(90)90503-F; NEALE PJ, 1990, PLANT PHYSIOL, V92, P1196, DOI 10.1104/pp.92.4.1196; NEALE PJ, 1991, BIOCHIM BIOPHYS ACTA, V1056, P195, DOI 10.1016/S0005-2728(05)80287-7; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; OHAD I, 1990, J BIOL CHEM, V265, P1972; Okamura MY., 1987, PROGR PHOTOSYNTHESIS, V1, P379; PAKRASI HB, 1992, CURRENT TOPICS PHOTO, V11, P231; PRASIL O, 1992, PHOTOSYSTEMS TOPICS, V11, P220; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; RUTHERFORD AW, 1988, BIOCHIM BIOPHYS ACTA, V932, P171, DOI 10.1016/0005-2728(88)90152-1; SATOH K, 1992, NATO ADV SCI I A-LIF, V226, P375; SATOH K, 1993, PHOTOSYNTHETIC REACT, V1, P289; SCHNETTGER B, 1992, PHOTOSYNTHETICA, V27, P261; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; Seibert M, 1993, PHOTOSYNTHETIC REACT, VI, P319, DOI DOI 10.1016/B978-0-12-208661-8.50016-4; STYRING S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P269, DOI 10.1016/0005-2728(90)90031-X; STYRING S, 1994, PHOTOINHIBITION PHOT, P51; SUNDBY C, 1993, J BIOL CHEM, V268, P25476; TANIGUCHI M, 1993, FEBS LETT, V317, P57, DOI 10.1016/0014-5793(93)81491-H; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANMIEGHEM FJE, 1989, BIOCHIM BIOPHYS ACTA, V977, P207, DOI 10.1016/S0005-2728(89)80073-8; VANWIJK KJ, 1992, BIOCHIM BIOPHYS ACTA, V1100, P207; VANWIJK KJ, 1993, BIOCHIM BIOPHYS ACTA, V1142, P59, DOI 10.1016/0005-2728(93)90084-S; VANWIJK KJ, 1993, PHYSIOL PLANTARUM, V87, P187, DOI 10.1034/j.1399-3054.1993.870210.x; VASS I, 1992, BIOCHEMISTRY-US, V31, P5957, DOI 10.1021/bi00141a002; VASS I, 1991, BIOCHEMISTRY-US, V30, P830, DOI 10.1021/bi00217a037; VERMAAS WFJ, 1988, P NATL ACAD SCI USA, V85, P8477, DOI 10.1073/pnas.85.22.8477; VERMAAS WFJ, 1984, FEBS LETT, V175, P243, DOI 10.1016/0014-5793(84)80744-9; VIRGIN I, 1988, FEBS LETT, V233, P408, DOI 10.1016/0014-5793(88)80472-1	58	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28382	28392						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961778				2022-12-25	WOS:A1994PV77200090
J	COLAMONICI, OR; PORTERFIELD, B; DOMANSKI, P; HANDA, RK; FLEX, S; SAMUEL, CE; PINE, R; DIAZ, MO				COLAMONICI, OR; PORTERFIELD, B; DOMANSKI, P; HANDA, RK; FLEX, S; SAMUEL, CE; PINE, R; DIAZ, MO			LIGAND-INDEPENDENT ANTI-ONCOGENIC ACTIVITY OF THE ALPHA SUBUNIT OF THE TYPE-I INTERFERON RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CELL-LINES; HUMAN-LEUKEMIA; GENES; EXPRESSION; DELETION; CLONING; CDNA; INDUCTION; SYSTEM	Two interferon (IFN) alpha-regulated genes, 1RF1/ISGF2 and PKR/p68 kinase, may function as tumor suppressor genes suggesting that the IFN system may function as a tumor suppressor system. We report that the expression of the alpha subunit of the type I IFN receptor in human K-562 cells had anti-oncogenic effects that include a marked decrease in: (i) cell proliferation rate, (ii) the cell density at which grow th arrest normally occurs, and (iii) the tumorigenicity in nude mice. Furthermore, expression of the alpha subunit in R-562 cells induced erythroid differentiation. While most cytokine receptors become activated after binding their corresponding ligands, the overexpression of the alpha subunit has a physiological effect in the absence of its natural ligand, type I IFNs, suggesting a novel function for this type I IFN receptor subunit. The anti-oncogenic effect of the alpha subunit is mediated by a pathway that does not involve two tumor suppressor genes induced by type I IFNs, the transcriptional regulator IFN response factor-1 and the RNA-dependent protein kinase, or the p135(tyk2) tyrosine kinase that directly associates and phosphorylates the or subunit.	LOYOLA UNIV,INST ONCOL,MAYWOOD,IL 60153; UNIV CALIF SANTA BARBARA,GRAD PROGRAM BIOCHEM & MOLEC BIOL,SANTA BARBARA,CA 93106; PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016	Loyola University Chicago; University of California System; University of California Santa Barbara	COLAMONICI, OR (corresponding author), UNIV TENNESSEE,DEPT PATHOL,BMH RM 576,800 MADISON AVE,MEMPHIS,TN 38163, USA.				NCI NIH HHS [CA49133, CA55079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055079, R01CA049133] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUET M, 1980, NATURE, V284, P459, DOI 10.1038/284459a0; COLAMONICI OR, 1992, BLOOD, V80, P744; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; COLAMONICI OR, 1903, J BIOL CHEM, V268, P10899; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; FUHR JE, 1981, BLOOD CELLS, V7, P389; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MOORE RN, 1984, SCIENCE, V223, P178, DOI 10.1126/science.6606850; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; ONOZAKI K, 1988, J IMMUNOL, V140, P112; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; SEN GC, 1992, J BIOL CHEM, V267, P5017; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VILLEVAL JL, 1983, EXP CELL RES, V146, P428, DOI 10.1016/0014-4827(83)90145-3; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	28	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27275	27279						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961637				2022-12-25	WOS:A1994PV77100022
J	KOVALSKY, OI; GROSSMAN, L				KOVALSKY, OI; GROSSMAN, L			THE USE OF MONOCLONAL-ANTIBODIES FOR STUDYING INTERMEDIATES IN DNA-REPAIR BY THE ESCHERICHIA-COLI UVR(A)BC ENDONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; SITE-SPECIFIC MUTAGENESIS; TURN-HELIX MOTIF; UVRABC ENDONUCLEASE; (A)BC EXCINUCLEASE; DAMAGED DNA; ENZYMATIC-PROPERTIES; SUPERCOILED DOMAINS; PROTEIN COMPLEXES; INCISION REACTION	The Escherichia coli Uvr(A)BC endonuclease acts in a progression of several distinct steps accompanied by changes in the conformation of macromolecular constituents, the overall architecture of the complex, and its stoichiometry. In order to probe these structural changes, we generated monoclonal antibodies (mAbs) to Uvr proteins. The anti-UvrA mAb, A2D1, recognizing the N-terminal zinc-finger region of UvrA, and the anti-UvrB mAb, B2E2, having an epitope within the 43 C-terminal amino acids of UvrB, were purified and further characterized It was found that A2D1 mAb interacts in solution both with UvrA-UvrB and UvrA-DNA complexes in the presence of the requisite ATP. This implies that the N-terminal zinc-finger of UvrA doesn't play a direct role in its interactions with UvrB and DNA. On the other hand, A2D1 does inhibit formation of the UvrB-damaged DNA preincision complex, apparently by preventing UvrB delivery by UvrA. The interaction of B2E2 with UvrA-UvrB and nucleoprotein complexes, including UvrB, suggests that the highly hydrophobic C-terminal domain of UvrB (i) doesn't participate in its interaction with UvrA, (ii) is accessible to this mAb in an intermediate UvrA-UvrB DNA helix-tracking complex, and (iii) seems to be directly involved in the formation of the preincision complex. These conclusions are supported by the finding that the neutralizing effect of A2D1 and B2E2 on the Uvr(A)BC endonuclease is significantly decreased if the preincision complex is preformed prior to mAbs addition.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022846, R01GM022846] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-22846] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG JM, 1990, J BIOL CHEM, V265, P6513; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10891, DOI 10.1093/nar/16.22.10891; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11380; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11388; FRIGUET B, 1989, PROTEIN STRUCTURE PR, P287; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; GROSSMAN L, 1990, MUTAT RES, V236, P213, DOI 10.1016/0921-8777(90)90006-Q; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; IKEDA M, 1993, J BIOL CHEM, V268, P10296; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LIN JJ, 1992, J BIOL CHEM, V267, P17693; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3834, DOI 10.1021/bi00230a005; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; SNOWDEN A, 1991, J MOL BIOL, V220, P19, DOI 10.1016/0022-2836(91)90378-J; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; THIAGALINGAM S, 1993, J BIOL CHEM, V268, P18382; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1992, J BIOL CHEM, V267, P6736; WANG JT, 1993, J BIOL CHEM, V268, P5323; WANG JT, 1994, J BIOL CHEM, V269, P10771; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	41	11	13	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27421	27426						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961654				2022-12-25	WOS:A1994PV77100044
J	UJITA, M; SHINOMURA, T; ITO, K; KITAGAWA, Y; KIMATA, K				UJITA, M; SHINOMURA, T; ITO, K; KITAGAWA, Y; KIMATA, K			EXPRESSION AND BINDING-ACTIVITY OF THE CARBOXYL-TERMINAL PORTION OF THE CORE PROTEIN OF PG-M, A LARGE CHONDROITIN SULFATE PROTEOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; ASPARAGINE-LINKED OLIGOSACCHARIDES; LEUKOCYTE ADHESION MOLECULE-1; ENDOTHELIAL LIGAND; L-SELECTIN; LIMB BUD; CLONING; FIBRONECTIN; VERSICAN; AGGRECAN	PG-M is a large chondroitin sulfate proteoglycan that has been shown to be expressed in the prechondrogenic condensation area of the developing chick limb buds. We previously isolated cDNA clones encoding the core protein of PG-M (Shinomura, T., Nishida, Y., Ito, H., and Kimata, K. (1993) J. Biol. Chem. 268, 14461-14469). The amino acid sequence deduced from the cDNA analysis revealed the presence of two epidermal growth factor-like domains, a C-type lectin-like domain, and a complement regulatory protein (CRP)-like domain at the COOH terminus. The COOH-terminal portion has been expressed as a fusion protein with glutathione S-transferase in Escherichia coli to test its carbohydrate binding activity using affinity chromatography. The purified fusion protein binds to immobilized D-mannose, D-galactose, L-fucose, and N-acetyl-D-glucosamine in a calcium-dependent manner. Furthermore, the fusion protein binds to heparin- or heparan sulfate-Sepharose. To investigate roles of each COOH-terminal domain, we have made a truncated construct which lacks the CRP-like domain and determined if the CRP-like domain is involved in the binding activity. The removal of this domain resulted in the complete loss of both C-type lectin-like and heparin binding activities. The results suggest that a whole set of epidermal growth factor-, lectin-, and CRP-like domains may serve a functional structure for these bindings.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN; NAGOYA UNIV,CTR BIOSCI,NAGOYA,AICHI 46401,JAPAN; NAGOYA UNIV,SCH AGR SCI,GRAD PROGRAM BIOCHEM REGULAT,NAGOYA,AICHI 46401,JAPAN	Aichi Medical University; Nagoya University; Nagoya University								ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; AULTHOUSE AL, 1987, DEV BIOL, V120, P377, DOI 10.1016/0012-1606(87)90240-5; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CHANDRASEKARAN L, 1992, BIOCHEM J, V288, P903, DOI 10.1042/bj2880903; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUNAHASHI M, 1982, ANAL BIOCHEM, V126, P414, DOI 10.1016/0003-2697(82)90537-1; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HAYASHI M, 1982, J BIOL CHEM, V257, P5263; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; KANSAS GS, 1991, J CELL BIOL, V114, P351, DOI 10.1083/jcb.114.2.351; KIJIMOTOOCHIAI S, 1985, ANAL BIOCHEM, V147, P222, DOI 10.1016/0003-2697(85)90031-4; KIMATA K, 1986, J BIOL CHEM, V261, P3517; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; MATSUTANI E, 1982, DEV BIOL, V92, P544, DOI 10.1016/0012-1606(82)90199-3; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; PIGOTT R, 1991, J IMMUNOL, V147, P130; RAUCH U, 1992, J BIOL CHEM, V267, P19536; SALEQUE S, 1993, GLYCOBIOLOGY, V3, P185, DOI 10.1093/glycob/3.2.185; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SHINOMURA T, 1990, DEV GROWTH DIFFER, V32, P243; SHINOMURA T, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P35; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SUZUKI Y, 1993, BIOCHEM BIOPH RES CO, V190, P426, DOI 10.1006/bbrc.1993.1065; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V105, P742, DOI 10.1093/oxfordjournals.jbchem.a122738; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V106, P228, DOI 10.1093/oxfordjournals.jbchem.a122837; TAKASAKI S, 1980, J BIOCHEM-TOKYO, V88, P1587, DOI 10.1093/oxfordjournals.jbchem.a133133; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; WATSON SR, 1991, J CELL BIOL, V115, P235, DOI 10.1083/jcb.115.1.235; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	45	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27603	27609						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961677				2022-12-25	WOS:A1994PV77100069
J	XU, LZ; ZHANG, W; WEBER, IT; HARRISON, RW; PILKIS, SJ				XU, LZ; ZHANG, W; WEBER, IT; HARRISON, RW; PILKIS, SJ			SITE-DIRECTED MUTAGENESIS STUDIES ON THE DETERMINANTS OF SUGAR SPECIFICITY AND COOPERATIVE BEHAVIOR OF HUMAN BETA-CELL GLUCOKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER GLUCOKINASE; TYPE-2 DIABETES-MELLITUS; HEXOKINASE-D GLUCOKINASE; SIGMOIDAL RATE BEHAVIOR; HEPATIC GLUCOKINASE; MECHANISTIC ORIGIN; SLOW TRANSITION; GENE; EXPRESSION; GLUCOSE	The determinants of sugar specificity and cooperative behavior of human beta-cell glucokinase were studied by mutating several active site residues and performing a steady-state kinetic analysis of the purified mutant and wild-type enzymes after their expression in Escherichia coli. Asn-204, Glu-256, and Glu-290 were predicted from molecular modeling to interact with the 3-OH, 4-OH, 2-OH, and 1-OH groups of glucose. Mutation of these residues resulted in enzymes with decreased values of k(cat) and increased values of K-m for glucose, mannose, and 2-deoxyglucose. Lys-56 is also predicted to make an interaction with the side chain of Glu-256 and its mutation increased the K-m for glucose, deoxyglucose, mannose, and fructose by 4-, 4-, 3-, and 10-fold, respectively, and also increased the k(cat) for fructose by 5-fold. The K-i values for N-acetylglucosamine and mannoheptulose for the wild type enzyme were 0.2 and 0.8 mm, respectively, and mutation of glucose binding residues to alanine resulted in an increase of about 3 orders of magnitude in these K-i values. Mutation of residues that directly hydrogen bond glucose hydroxyls (Asn-204, Glu-256, and Glu-290) to alanine resulted in enzymes that did not exhibit cooperative behavior, but mutation of Lys-56 or other residues that do not directly contact glucose had no effect on the Hill coefficient. Only glucose and deoxyglucose exhibited cooperative behavior. The results 1) confirm the predictions of the model that Asn-204, Glu-256, and Glu-290 are important residues involved in catalysis and hydrogen bonding glucose hydroxyl groups, 2) provide evidence for a role of Lys-56 in hexose binding, and 3) are consistent with the cooperative behavior of glucokinase being mediated by interactions of other regions of the protein with the highly conserved active site glucose binding residues.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11780; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Jefferson University				Harrison, Robert/0000-0003-2449-1214	NIDDK NIH HHS [DK 4730A] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; CARDENAS ML, 1984, EUR J BIOCHEM, V145, P163, DOI 10.1111/j.1432-1033.1984.tb08536.x; CARDENAS ML, 1984, BIOCHEM J, V222, P363, DOI 10.1042/bj2220363; CHARLES RS, 1994, DIABETES, V43, P784, DOI 10.2337/diab.43.6.784; CHEIN CT, 1989, BIOCHEM BIOPH RES CO, V165, P817; CORNISHBOWDEN A, 1986, BIOCHEM J, V240, P293, DOI 10.1042/bj2400293; GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932; GRANNER DK, 1990, J BIOL CHEM, V265, P16012; HARRISON RW, 1993, J COMPUT CHEM, V14, P1112, DOI 10.1002/jcc.540140912; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANGE AJ, 1991, BIOCHEM J, V277, P159, DOI 10.1042/bj2770159; Lin K, 1990, Protein Expr Purif, V1, P169, DOI 10.1016/1046-5928(90)90012-N; LIN SX, 1990, J BIOL CHEM, V265, P9670; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; NEET KE, 1990, BIOCHEMISTRY-US, V29, P770, DOI 10.1021/bi00455a026; PETTERSSON G, 1986, BIOCHEM J, V233, P347, DOI 10.1042/bj2330347; PILKIS SJ, 1972, ARCH BIOCHEM BIOPHYS, V149, P349, DOI 10.1016/0003-9861(72)90333-5; PILKIS SJ, J BIOL CHEM, V269, P21925; POLONSKY KS, 1986, J CLIN INVEST, V77, P98, DOI 10.1172/JCI112308; STOFFEL M, 1992, NAT GENET, V2, P153, DOI 10.1038/ng1092-153; STOFFEL M, 1992, P NATL ACAD SCI USA, V89, P7698, DOI 10.1073/pnas.89.16.7698; STORER AC, 1977, BIOCHEM J, V165, P61, DOI 10.1042/bj1650061; STORER AC, 1976, BIOCHEM J, V159, P7, DOI 10.1042/bj1590007; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STURIS J, 1994, DIABETES, V43, P718, DOI 10.2337/diabetes.43.5.718; TAKEDA J, 1993, J BIOL CHEM, V268, P15200; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1	30	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27458	27465						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961659				2022-12-25	WOS:A1994PV77100049
J	ANANT, S; AXENOVICH, SA; MADDEN, SL; RAUSCHER, FJ; SUBRAMANIAN, KN				ANANT, S; AXENOVICH, SA; MADDEN, SL; RAUSCHER, FJ; SUBRAMANIAN, KN			NOVEL REPLICATION INHIBITORY FUNCTION OF THE DEVELOPMENTAL REGULATOR TRANSCRIPTION REPRESSOR PROTEIN WT1 ENCODED BY THE WILMS-TUMOR GENE	ONCOGENE			English	Article							ZINC FINGER PROTEIN; SIMIAN-VIRUS 40; SV40 T-ANTIGEN; RETINOBLASTOMA SUSCEPTIBILITY GENE; DNA-BINDING DOMAIN; FACTOR-A-CHAIN; TRANSCRIPTIONAL ACTIVATOR; CELL-GROWTH; EGR FAMILY; SV40-TRANSFORMED CELLS	The tumor suppressor/developmental regulator protein WT1 encoded by the Wilms' tumor gene is a zinc finger-containing transcription factor which binds to the G + C-rich motif 5'-GCGGGGGCG-3' and represses transcription. Alternatively spliced variants of WT1 (termed + KTS) having an insertion in the zinc finger region are defective for binding to and hence for repression of transcription from promoters containing this motif. Due to the known interactions of two other tumor suppressor proteins with the simian virus 40 (SV40) oncoprotein large tumor antigen (TAg) [which in one case (p53) results in inhibition of the replication initiation activity of TAg], and because of the presence of G+C-rich sequences in the SV40 origin region, we tested the effect of WT1 on TAg- and SV40 origin-dependent DNA replication. WT1 and its alternatively spliced variants were found to be potent inhibitors of replication. Inhibition of replication by WT1 required portions of the N-terminal transcription repression domain and the C-terminal DNA binding domain, while other WT1 sequences needed for transcriptional regulation were dispensable. WT1 neither inhibited the synthesis of TAg nor formed a stable complex with it. Studies of the requirement of cis-active origin sequences in vivo and protein-DNA interactions in vitro indicated that WT1 and its alternatively spliced variants might inhibit replication by their novel binding to the GC box promoter motifs of the SV40 21 bp repeat replication-auxiliary sequence.	UNIV ILLINOIS, COLL MED, DEPT GENET, CHICAGO, IL 60612 USA; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; The Wistar Institute					NCI NIH HHS [CA 52009, CA 47983] Funding Source: Medline; NCRR NIH HHS [S07 RR 05369] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047983, P01CA052009] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005369] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANANT S, 1992, METHOD ENZYMOL, V216, P20; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BERGSMA DJ, 1982, P NATL ACAD SCI-BIOL, V79, P381, DOI 10.1073/pnas.79.2.381; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHANDRASEKHARAPPA SC, 1987, J VIROL, V61, P2973, DOI 10.1128/JVI.61.10.2973-2980.1987; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELUCIA AL, 1986, J VIROL, V57, P138, DOI 10.1128/JVI.57.1.138-144.1986; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HERTZ GZ, 1986, MOL CELL BIOL, V6, P3513, DOI 10.1128/MCB.6.10.3513; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOANG AT, 1992, MOL CELL BIOL, V12, P3087, DOI 10.1128/MCB.12.7.3087; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE NG, 1991, ONCOGENE, V6, P1161; LEECHEN GJ, 1986, MOL CELL BIOL, V6, P3086, DOI 10.1128/MCB.6.9.3086; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1993, ANN NY ACAD SCI, V684, P75, DOI 10.1111/j.1749-6632.1993.tb32272.x; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS JF, 1991, ONCOGENE, V6, P2339; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEVINS JR, 1992, SCIENCE, V258, P424; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Roswell D. F., 1978, METHOD ENZYMOL, V57, P409, DOI [10.1016/0076-6879(78)57038-9, DOI 10.1016/0076-6879(78)57038-9]; Sambrook J, 1989, MOL CLONING LABORATO; SHALLOWAY D, 1980, CELL, V20, P411, DOI 10.1016/0092-8674(80)90627-3; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SZYMANSKI P, 1990, J VIROL, V64, P1360, DOI 10.1128/JVI.64.3.1360-1365.1990; TEGTMEYER P, 1983, J VIROL, V46, P151, DOI 10.1128/JVI.46.1.151-161.1983; TRIFILLIS P, 1990, J VIROL, V64, P1345, DOI 10.1128/JVI.64.3.1345-1347.1990; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG ZY, 1992, J BIOL CHEM, V267, P21999; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	73	12	12	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3113	3126						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936634				2022-12-25	WOS:A1994PM65800003
J	JIANG, HP; LIN, J; SU, ZZ; COLLART, FR; HUBERMAN, E; FISHER, PB				JIANG, HP; LIN, J; SU, ZZ; COLLART, FR; HUBERMAN, E; FISHER, PB			INDUCTION OF DIFFERENTIATION IN HUMAN PROMYELOCYTIC HL-60 LEUKEMIA-CELLS ACTIVATES P21, WAF1/CIP1, EXPRESSION IN THE ABSENCE OF P53	ONCOGENE			English	Article							PROTEIN KINASE-C; GLIOBLASTOMA-MULTIFORME CELLS; CYCLIN-DEPENDENT KINASES; MYELOID-LEUKEMIA; LINE HL-60; TERMINAL DIFFERENTIATION; TRANSFORMED PHENOTYPE; ANTIGENIC PHENOTYPE; GENE-EXPRESSION; RESISTANT	The melanoma differentiation associated gene, mda-6, which is identical to the P53-inducible gene WAF1/CIP1, encodes an M(r) 21,000 protein (p21) that can directly inhibit cell growth by repressing cyclin dependent kinases, mda-6 was identified using subtraction hybridization by virtue of its enhanced expression in human melanoma cells induced to terminally differentiate by treatment with human fibroblast interferon and the anti-leukemic compound mezerein (Jiang and Fisher, 1993). In the present study, we demonstrate that mda-6 (WAF1/CIP1) is an immediate early response gene induced during differentiation of the promyelocytic HL-60 leukemia cell line along the granulocytic or macrophage/monocyte pathway. mda-6 gene expression in HL-60 cells is induced within 1 to 3 h during differentiation along the macrophage/monocyte pathway evoked by 12-0-tetradecanoyl phorbol-13-acetate (TPA) or 1,25-dihydroxyvitamin D3 (Vit D3) or the granulocytic pathway produced by retinoic acid (RA) or dimethylsulfoxide (DMSO). Immunoprecipitation analyses using an anti-p21 antibody indicate a temporal induction of p21 protein following treatment with TPA, DMSO or RA. A relationship between rapid induction of mda-6 gene expression and differentiation is indicated by a delay in this expression in an HL-60 cell variant resistant to TPA-induced growth arrest and differentiation. A similar delay in mda 6 gene expression is not observed in Vit D3 treated TPA-resistant variant cells that are also sensitive to induction of monocytic differentiation. Since HL-60 cells have a null-p53 phenotype, these results demonstrate that p21 induction occurs during initiation of terminal differentiation in a p53-independent manner. In this context, p21 may play a more global role in growth control and differentiation than originally envisioned.	COLUMBIA UNIV, COLL PHYSICIANS & SURGEONS,INST CANC RES, CTR COMPREHENS CANC ,DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYSICIANS & SURGEONS,INST CANC RES, CTR COMPREHENS CANC,DEPT UROL, NEW YORK, NY 10032 USA; ARGONNE NATL LAB, CTR MECHANIST BIOL & BIOTECHNOL, ARGONNE, IL 60439 USA	Columbia University; Columbia University; United States Department of Energy (DOE); Argonne National Laboratory				Collart, Frank/0000-0001-6942-4483	NATIONAL CANCER INSTITUTE [R01CA035675, R01CA043208] Funding Source: NIH RePORTER; NCI NIH HHS [CA43208, CA35675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ANDERSON NL, 1985, CANCER RES, V45, P4955; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER PB, 1984, CANCER RES, V44, P5550; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1991, SERONO SYM, V82, P201; FOON KA, 1982, BLOOD, V60, P1; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GALLAGHER R, 1979, BLOOD, V54, P713; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOMMA Y, 1988, CANCER RES, V48, P2744; HOMMA Y, 1986, P NATL ACAD SCI USA, V83, P7316, DOI 10.1073/pnas.83.19.7316; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; JIANG H, 1994, IN PRESS MOL CELL DI, V2; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1992, INT J ONCOL, V1, P227; JIMENEZ JJ, 1987, SCIENCE, V238, P1278, DOI 10.1126/science.3685979; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LI Y, 1994, ONCOGENE, V9, P2261; LIN J, 1994, INT J ONCOL, V5, P5; LOTAN R, 1993, RETINOIDS ONCOLOGY, P43; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; MICHIELI P, 1994, CANCER RES, V54, P3391; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; MURAO S, 1983, CANCER RES, V43, P4989; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; REDDY PG, 1991, J NATL CANCER I, V83, P1307, DOI 10.1093/jnci/83.18.1307; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SU ZZ, 1991, MOL CARCINOGEN, V4, P231, DOI 10.1002/mc.2940040310; SU ZZ, 1993, CANCER RES, V53, P1929; TANAKA H, 1982, BIOCHEM J, V204, P713, DOI 10.1042/bj2040713; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAXMAN S, 1988, STATUS DIFFERENTIATI, V1; WAXMAN S, 1991, STATUS DIFFERENTIATI, V2; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	50	622	635	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3397	3406						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936668				2022-12-25	WOS:A1994PM65800037
J	JOHNSON, GR; WONG, L				JOHNSON, GR; WONG, L			HEPARAN-SULFATE IS ESSENTIAL TO AMPHIREGULIN-INDUCED MITOGENIC SIGNALING BY THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; FIBROBLAST GROWTH; CELL-SURFACE; EPITHELIAL-CELLS; TYROSINE PHOSPHORYLATION; COLORECTAL TUMORS; FACTOR FAMILY; EXPRESSION; BINDING; PROTEOGLYCANS	Human amphiregulin (AR) is a heparin-binding growth factor which functions by binding to and activating the epidermal growth factor (EGF) receptor tyrosine kinase. AR contains an EGF-like domain (residues 44-84) and a Lys/Arg-rich NH2-terminal extension (residues 1-43). Synthetic peptides corresponding to residues 8-26, 26-44, and 68-84 of AR were tested for their ability to compete for the binding of AR to immobilized heparin. AR(8-26) and AR(68-84) had no significant effect on the binding of AR to heparin, whereas AR(26-44) bound to heparin and blocked the binding of AR to heparin. Both soluble heparin and heparan sulfate inhibited AR-induced mitogenesis in MCF-10A human mammary epithelial cells with an IC50 of 5 and 2 mu g/ml, respectively, whereas soluble chondroitin sulfate had only a slight inhibitory effect. When MCF-10A cells were grown in the presence of chlorate, an inhibitor of sulfation, or exposed to the glycosaminoglycan-degrading enzymes heparitinase or heparinase, the ability of AR to evoke mitogenesis in these cells was lost. Chlorate, heparitinase, or heparinase treatment inhibited AR-induced autophosphorylation of tyrosine residues in the EGF receptor. None of these treatments had any significant effect on EGF-triggered mitogenic signaling by the EGF receptor. These results indicate that extracellular heparan sulfate glycosaminoglycan is essential to AR-induced mitogenic signaling by the EGF receptor tyrosine kinase.			JOHNSON, GR (corresponding author), US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,HFM-511,BLDG 29A,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1992, CANCER RES, V52, P3224; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; EBERT M, 1994, CANCER RES, V54, P3959; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FARLEY JR, 1978, ARCH BIOCHEM BIOPHYS, V185, P376, DOI 10.1016/0003-9861(78)90180-7; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; JOHNSON GR, 1991, BIOCHEM BIOPH RES CO, V180, P481, DOI 10.1016/S0006-291X(05)81090-3; JOHNSON GR, 1993, J BIOL CHEM, V268, P18835; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kenney Nicholas, 1993, Molecular and Cellular Differentiation, V1, P163; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KITADAI Y, 1993, JPN J CANCER RES, V84, P879, DOI 10.1111/j.1349-7006.1993.tb02061.x; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LEJEUNE S, 1993, CANCER RES, V53, P3597; LI SW, 1992, J CELL PHYSIOL, V153, P103, DOI 10.1002/jcp.1041530114; Modrell B, 1992, GROWTH FACTORS, V7, P305, DOI 10.3109/08977199209046413; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OTOTANI N, 1981, CARBOHYD RES, V88, P291, DOI 10.1016/S0008-6215(00)85542-1; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAEKI T, 1992, CANCER RES, V52, P3467; SAEKI T, 1994, INT J ONCOL, V5, P215; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	52	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27149	27154						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929459				2022-12-25	WOS:A1994PQ93100083
J	MOLLA, A; HARRIS, KS; PAUL, AV; SHIN, SH; MUGAVERO, J; WIMMER, E				MOLLA, A; HARRIS, KS; PAUL, AV; SHIN, SH; MUGAVERO, J; WIMMER, E			STIMULATION OF POLIOVIRUS PROTEINASE 3C(PRO)-RELATED PROTEOLYSIS BY THE GENOME-LINKED PROTEIN VPG AND ITS PRECURSOR 3AB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; CYSTEINE PROTEASES; ESCHERICHIA-COLI; SERINE PROTEASES; POLYPEPTIDE 3CD; CELL-FREE; CLEAVAGE; INVITRO; EXPRESSION; REPLICATION	Purified recombinant poliovirus polypeptide 3AB interacts with 3CD(pro) and 3D(pol) as shown by coimmunoprecipitation with anti-3D(pol) antibodies. A consequence of this interaction is an accelerated autoprocessing of 3CD(pro) to produce 3C(pro) and 3D(pol). The activation of 3D(pol) polymerase activity by cleavage of 3CD(pro), a polypeptide that has no polymerase activity, can be shown by template- and primer-dependent poly(U) synthesis. Anti-VPg antibodies (VPg = 3B) added to HeLa translation extracts programmed with poliovirion RNA inhibit cleavage of 3CD(pro) whereas addition of purified 3AB or VPg to these translation reactions increases 3CD(pro) processing. 3AB stimulates also 3C(pro)-related proteolysis of 2BC, a poliovirus-specific, nonstructural processing intermediate. In contrast, 3CD(pro)-specific cleavage of the structural precursor P1 is inhibited by the addition of 3AB as shown by a decrease in the production of VPO and VP3. These data shed new light on a phenomenon in the regulation of expression of poliovirus genetic information: whereas the proteinase 3CD(pro) is needed for processing of the capsid precursor, the cleavage product of this relatively stable precursor is required for RNA replication.	SUNY STONY BROOK, HLTH SCI CTR, SCH MED, DEPT MOLEC GENET & MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [CA-28146] Funding Source: Medline; NIAID NIH HHS [AI-32100, AI-15122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032100, R37AI015122, R01AI015122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, J VIROL, V64, P607, DOI 10.1128/JVI.64.2.607-612.1990; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BLAIR WS, 1993, J VIROL, V67, P2336, DOI 10.1128/JVI.67.4.2336-2343.1993; DORNER AJ, 1981, FEBS LETT, V132, P219, DOI 10.1016/0014-5793(81)81164-7; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P3677, DOI 10.1073/pnas.74.9.3677; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; HAMMERLE T, 1991, J BIOL CHEM, V266, P5412; HANECAK R, 1982, P NATL ACAD SCI-BIOL, V79, P3973, DOI 10.1073/pnas.79.13.3973; HANECAK R, 1984, CELL, V37, P1063, DOI 10.1016/0092-8674(84)90441-0; HARRIS KS, 1992, J VIROL, V66, P7481, DOI 10.1128/JVI.66.12.7481-7489.1992; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; Harris KS, 1990, SEMINARS VIROLOGY, V1, P323; HELLEN CUT, 1991, J VIROL, V65, P4226, DOI 10.1128/JVI.65.8.4226-4231.1991; JORE J, 1988, J GEN VIROL, V69, P1627, DOI 10.1099/0022-1317-69-7-1627; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LAMA J, 1994, J BIOL CHEM, V269, P66; LAWSON MA, 1990, CURR TOP MICROBIOL, V161, P49; LAWSON MA, 1992, VIROLOGY, V191, P309, DOI 10.1016/0042-6822(92)90193-S; LEE CK, 1988, VIROLOGY, V166, P405, DOI 10.1016/0042-6822(88)90511-9; LONG AC, 1989, FEBS LETT, V258, P75, DOI 10.1016/0014-5793(89)81619-9; MOLLA A, 1993, J VIROL, V67, P5932, DOI 10.1128/JVI.67.10.5932-5938.1993; MOLLA A, 1988, J BIOCHEM, V104, P616, DOI 10.1093/oxfordjournals.jbchem.a122521; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; MOLLA A, 1993, J VIROL, V67, P4688, DOI 10.1128/JVI.67.8.4688-4695.1993; NICKLIN MJH, 1987, P NATL ACAD SCI USA, V84, P4002, DOI 10.1073/pnas.84.12.4002; NICKLIN MJH, 1988, J VIROL, V62, P4586, DOI 10.1128/JVI.62.12.4586-4593.1988; NICKLIN MJH, 1986, BIO-TECHNOL, V4, P33, DOI 10.1038/nbt0186-33; ORR DC, 1989, J GEN VIROL, V70, P2931, DOI 10.1099/0022-1317-70-11-2931; PALLAI PV, 1989, J BIOL CHEM, V264, P9738; PALMENBERG AC, 1979, J VIROL, V32, P770, DOI 10.1128/JVI.32.3.770-778.1979; PINCUS SE, 1986, J VIROL, V60, P793, DOI 10.1128/JVI.60.2.793-796.1986; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; SEMLER BL, 1987, J CELL BIOCHEM, V33, P39, DOI 10.1002/jcb.240330105; SEMLER BL, 1981, P NATL ACAD SCI-BIOL, V78, P3464, DOI 10.1073/pnas.78.6.3464; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TOYODA H, 1986, CELL, V45, P761, DOI 10.1016/0092-8674(86)90790-7; TOYODA H, 1987, J VIROL, V61, P2816, DOI 10.1128/JVI.61.9.2816-2822.1987; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; VANDYKE TA, 1980, J VIROL, V35, P732, DOI 10.1128/JVI.35.3.732-740.1980; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; YPMAWONG MF, 1988, VIROLOGY, V166, P265, DOI 10.1016/0042-6822(88)90172-9	47	75	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27015	27020						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929442				2022-12-25	WOS:A1994PQ93100065
J	BROWN, NF; ESSER, V; FOSTER, DW; MCGARRY, JD				BROWN, NF; ESSER, V; FOSTER, DW; MCGARRY, JD			EXPRESSION OF A CDNA FOR RAT-LIVER CARNITINE PALMITOYLTRANSFERASE-I IN YEAST ESTABLISHES THAT CATALYTIC ACTIVITY AND MALONYL-COA SENSITIVITY RESIDE IN A SINGLE POLYPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-SYSTEM; MITOCHONDRIAL OUTER; BINDING; INHIBITORS; MEMBRANES; DEFICIENCY; COMPONENTS; AFFINITY; CLONING; TISSUES	A cDNA encoding full-length carnitine palmitoyltransferase I (CPT I) from rat liver was expressed in Saccharomyces cerevisiae, a system devoid of endogenous CPT activity. The recombinant enzyme was of the expected size (as deduced from immunoblots), membrane-bound, and detergent-labile. It was also potently inhibited by malonyl-CoA, with an I-50 value (concentration causing 50% inhibition) of similar to 5 mu M, similar to that of the native enzyme in rat liver mitochondria. A truncated variant of the enzyme that lacked the amino-terminal 82 residues encompassing the first hydrophobic domain retained catalytic function but was much less sensitive to malonyl-CoA (I-50 > 80 mu M). Deletion of the cDNA segment encoding amino acids 31-148 (which includes both first and second hydrophobic stretches) resulted in no detectable product. The data establish unequivocally that a single polypeptide possesses both catalytic and malonyl-CoA binding domains, as well as the other properties previously attributed by us to native CPT I in mammalian mitochondria, and should thus put to rest the controversy surrounding this issue (Kerner, J., Zaluzec, E., Gage, D., and Bieber, L. L. (1994) J. Biol. Chem. 269, 8209-8219). In addition, the results strengthen the view that one site of interaction of malonyl-CoA with the rat liver enzyme involves the NH2-terminal region of the molecule.	UNIV TEXAS,SW MED CTR,SW MED SCH,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,SW MED SCH,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,SW MED SCH,GIFFORD LABS DIABET RES,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK18573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R37DK018573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONNEFONT JP, 1990, PROG CLIN BIOL RES, V321, P451; BROWN NF, 1994, J BIOL CHEM, V269, P19157; CHUNG CH, 1992, BIOCHEMISTRY-US, V31, P9777, DOI 10.1021/bi00155a034; COOK GA, 1994, J BIOL CHEM, V269, P8803; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; DEMAUGRE F, 1988, PEDIATR RES, V24, P308, DOI 10.1203/00006450-198809000-00006; ESSER V, 1993, J BIOL CHEM, V268, P5817; ESSER V, 1993, J BIOL CHEM, V268, P5810; FOLEY JE, 1992, DIABETES CARE, V15, P773, DOI 10.2337/diacare.15.6.773; GHADIMINEJAD I, 1990, BIOCHEM J, V270, P787, DOI 10.1042/bj2700787; GHADIMINEJAD I, 1991, BIOCHEM J, V277, P611, DOI 10.1042/bj2770611; GHADIMINEJAD I, 1991, BIOCHIM BIOPHYS ACTA, V1083, P166, DOI 10.1016/0005-2760(91)90038-J; GRANTHAM BD, 1986, BIOCHEM J, V233, P589, DOI 10.1042/bj2330589; KASHFI K, 1992, BIOCHEM J, V282, P909, DOI 10.1042/bj2820909; KASHFI K, 1994, BBA-LIPID LIPID MET, V1212, P245, DOI 10.1016/0005-2760(94)90259-3; KERNER J, 1994, J BIOL CHEM, V269, P8209; KOLODZIEJ MP, 1990, BIOCHEM J, V267, P85, DOI 10.1042/bj2670085; KOLODZIEJ MP, 1990, BIOCHEM J, V272, P421, DOI 10.1042/bj2720421; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND H, 1986, BIOCHIM BIOPHYS ACTA, V878, P243, DOI 10.1016/0005-2760(86)90152-9; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1992, PROG CLIN BIOL RES, V375, P47; MILLS SE, 1983, BIOCHEM J, V214, P83, DOI 10.1042/bj2140083; MURTHY MSR, 1987, P NATL ACAD SCI USA, V84, P378, DOI 10.1073/pnas.84.2.378; MURTHY MSR, 1987, BIOCHEM J, V248, P727, DOI 10.1042/bj2480727; MYNATT RL, 1984, BIOCHEM J, V299, P761; PANDE SV, 1986, BIOCHIM BIOPHYS ACTA, V877, P223, DOI 10.1016/0005-2760(86)90298-5; Sambrook J, 1989, MOL CLONING LABORATO; TARONI F, 1992, P NATL ACAD SCI USA, V89, P8429, DOI 10.1073/pnas.89.18.8429; TEIN I, 1994, J PEDIATR-US, V124, P938, DOI 10.1016/S0022-3476(05)83187-7; WEIS BC, 1994, J BIOL CHEM, V269, P18712; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714; WOLDEGIORGIS G, 1992, ARCH BIOCHEM BIOPHYS, V295, P348, DOI 10.1016/0003-9861(92)90527-4	36	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26438	26442						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929364				2022-12-25	WOS:A1994PQ93000076
J	JEZEK, P; OROSZ, DE; MODRIANSKY, M; GARLID, KD				JEZEK, P; OROSZ, DE; MODRIANSKY, M; GARLID, KD			TRANSPORT OF ANIONS AND PROTONS BY THE MITOCHONDRIAL UNCOUPLING PROTEIN AND ITS REGULATION BY NUCLEOTIDES AND FATTY-ACIDS - A NEW LOOK AT OLD HYPOTHESES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; INNER MEMBRANE; PURINE NUCLEOTIDES; LIGHT-SCATTERING; RECONSTITUTION; CONDUCTANCE; UNIPORT; H+; CONTRACTION; ACTIVATION	The uncoupling protein generates heat by catalyzing electrophoretic proton transport across the inner membrane of brown adipose tissue mitochondria. It also transports Cl- and other monovalent anions, and both proton and anion transport are inhibited by purine nucleotides. Several long standing hypotheses bear on specific aspects of Cl- transport, H+ transport, and nucleotide gating mechanisms in uncoupling protein. We reevaluated these hypotheses in mitochondria and liposomes reconstituted with purified uncoupling protein; GDP inhibition is strictly noncompetitive with Cl- and unaffected by either transmembrane electrical potential or fatty acids. The K-m and V-max values for Cl- are independent of pH, arguing against a common binding site for Cl- and OH- ions. Cl- transport was inhibited by fatty acids and stimulated by fatty acid removal, refuting the consensus hypothesis that there is no interaction between fatty acids and anion transport through uncoupling protein. These results support a mechanism in which the transport pathway for anions is identical with the fatty acid binding site and distinct from the nucleotide binding site.	OREGON GRAD INST SCI & TECHNOL, DEPT CHEM BIOCHEM & MOLEC BIOL, PORTLAND, OR 97291 USA; ACAD SCI CZECH REPUBL, INST PHYSIOL, CR-14220 PRAGUE, CZECH REPUBLIC; CASE WESTERN RESERVE UNIV, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Case Western Reserve University			Modriansky, Martin/A-6338-2008; Jezek, Petr/B-9264-2012	Modriansky, Martin/0000-0001-7692-0338; Jezek, Petr/0000-0002-2720-9395; Garlid, Keith/0000-0002-6777-1235	FIC NIH HHS [TW00120] Funding Source: Medline; NIGMS NIH HHS [GM31086] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; CANNON B, 1977, FEBS LETT, V74, P43, DOI 10.1016/0014-5793(77)80748-5; Chinet A, 1978, Experientia Suppl, V32, P25; CUNNINGHAM SA, 1986, EUR J BIOCHEM, V157, P415, DOI 10.1111/j.1432-1033.1986.tb09683.x; DIRESTA DJ, 1986, AM J PHYSIOL, V251, pR787, DOI 10.1152/ajpregu.1986.251.4.R787; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; GARLID KD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P151, DOI 10.1016/0005-2728(90)90237-X; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GARLID KD, 1986, BIOCHIM BIOPHYS ACTA, V853, P187, DOI 10.1016/0304-4173(87)90001-2; JEZEK P, 1988, J BIOENERG BIOMEMBR, V20, P603, DOI 10.1007/BF00768922; JEZEK P, 1990, J BIOL CHEM, V265, P19303; JEZEK P, 1989, AM J PHYSIOL, V257, pC1142, DOI 10.1152/ajpcell.1989.257.6.C1142; JEZEK P, 1990, J BIOL CHEM, V265, P19296; JEZEK P, 1990, J LIPID MEDIATOR, V2, P85; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KLINGENBERG M, 1985, EMBO J, V4, P3087, DOI 10.1002/j.1460-2075.1985.tb04049.x; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; LANOUE KF, 1986, J BIOL CHEM, V261, P298; LOCKE RM, 1982, EUR J BIOCHEM, V129, P373, DOI 10.1111/j.1432-1033.1982.tb07060.x; MURDZAINGLIS DL, 1994, J BIOL CHEM, V269, P7435; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; NEDERGAARD J, 1994, BBA-BIOENERGETICS, V1185, P311, DOI 10.1016/0005-2728(94)90246-1; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NICHOLLS DG, 1976, EUR J BIOCHEM, V62, P223, DOI 10.1111/j.1432-1033.1976.tb10151.x; NICHOLLS DG, 1977, EUR J BIOCHEM, V77, P349, DOI 10.1111/j.1432-1033.1977.tb11674.x; NICHOLLS DG, 1974, EUR J BIOCHEM, V49, P585, DOI 10.1111/j.1432-1033.1974.tb03862.x; NICHOLLS DG, 1984, BIOCHEM SOC T, V12, P388, DOI 10.1042/bst0120388; NICHOLLS DG, 1979, BIOCHIM BIOPHYS ACTA, V549, P1, DOI 10.1016/0304-4173(79)90016-8; OROSZ DE, 1993, ANAL BIOCHEM, V210, P7, DOI 10.1006/abio.1993.1143; RIAL E, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P261; RIAL E, 1983, EUR J BIOCHEM, V137, P197, DOI 10.1111/j.1432-1033.1983.tb07815.x; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; STRIELEMAN PJ, 1985, AM J PHYSIOL, V248, pE699, DOI 10.1152/ajpendo.1985.248.6.E699; STRIELEMAN PJ, 1985, J BIOL CHEM, V260, P3402; WINKLER E, 1994, J BIOL CHEM, V269, P2508; WINKLER E, 1992, EUR J BIOCHEM, V207, P135, DOI 10.1111/j.1432-1033.1992.tb17030.x	37	103	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26184	26190						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929332				2022-12-25	WOS:A1994PQ93000039
J	LEEBLUNDBERG, LMF; MATHIS, SA; HERZIG, MCS				LEEBLUNDBERG, LMF; MATHIS, SA; HERZIG, MCS			ANTAGONISTS OF BRADYKININ THAT STABILIZE A G-PROTEIN-UNCOUPLED STATE OF THE B2 RECEPTOR ACT AS INVERSE AGONISTS IN RAT MYOMETRIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TERNARY COMPLEX MODEL; SMOOTH-MUSCLE CELLS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; MEDIATED INTERNALIZATION; INTRINSIC ACTIVITY; KININ RECEPTORS; BINDING; HYDROLYSIS; ACTIVATION; STIMULATION	Several B2 bradykinin (BK) receptor-specific antagonists including HOE140, NPC17731, and NPC567 exhibited negative intrinsic activity, which was observed as a decrease in basal phosphoinositide hydrolysis in primary cultures of rat myometrial cells, and this response was opposite to that elicited by the agonist BK. The order of potency of the antagonists in attenuating basal activity was essentially the same as that in competing both [H-3]BK and [H-3]NPC17731 for binding to B2 receptors on both intact rat myometrial cells and bovine myometrial membranes. We previously proposed a three-state model for the binding of agonists to G-protein-coupled B2 receptors in bovine myometrial membranes (Leeb-Lundberg, L. M. F and Mathis, S. A. (1990) J. Biol. Chem. 265, 9621-9627). This model was based on the ability of BK to promote the sequential formation of three receptor binding states where formation of the third, equilibrium state was blocked by Gpp(NH)p (guanyl-5'-yl imidodiphosphate) identifying it as the G-protein-coupled state of the receptor. Here, we show that, in contrast to BK, these antagonists bound preferentially to a G-protein uncoupled state of the receptor. These results indicate that B2 receptor antagonists that stabilize a G-protein-uncoupled state of the receptor act as inverse agonists. Furthermore, these results provide strong evidence that endogenous G-protein coupled receptors exhibit spontaneous activity in their natural environment in the absence of agonist occupancy.			LEEBLUNDBERG, LMF (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NIGMS NIH HHS [GM41659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041659, R01GM041659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER EL, 1994, J BIOL CHEM, V269, P11687; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAESTRUP C, 1982, SCIENCE, V216, P1241, DOI 10.1126/science.6281892; BURCH RM, 1992, DUPONT BIOTECH UPDAT, V4, P127; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; Colquhoun D., 1973, DRUG RECEPTORS, P149, DOI [10.1007/978-1-349-00910-7_11, DOI 10.1007/978-1-349-00910-7_11]; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COSTA T, 1992, MOL PHARMACOL, V41, P549; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DERIAN CK, 1986, J BIOL CHEM, V261, P3831; FARMER SG, 1992, ANNU REV PHARMACOL, V32, P511; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HILF G, 1992, EUR J PHARM-MOLEC PH, V225, P245, DOI 10.1016/0922-4106(92)90026-R; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; KARLIN A, 1967, J THEOR BIOL, V16, P306, DOI 10.1016/0022-5193(67)90011-2; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KYLE DJ, 1991, J MED CHEM, V34, P2649, DOI 10.1021/jm00112a047; KYLE DJ, 1991, J MED CHEM, V34, P1230, DOI 10.1021/jm00107a052; KYLE DJ, 1991, BRADYKININ ANTAGONIS, P181; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; MUNOZ CM, 1992, J BIOL CHEM, V267, P303; MURRAY R, 1989, CELL SIGNAL, V1, P173, DOI 10.1016/0898-6568(89)90007-7; REGOLI D, 1980, PHARMACOL REV, V32, P1; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; STEWART JM, 1991, BRADYKININ ANTAGONIS, P51; TILLY BC, 1987, BIOCHEM J, V244, P129, DOI 10.1042/bj2440129; TROPEA MM, 1992, CAN J PHYSIOL PHARM, V70, P1360, DOI 10.1139/y92-191; VAVREK RJ, 1985, PEPTIDES, V6, P161, DOI 10.1016/0196-9781(85)90033-6; YANO K, 1984, J BIOL CHEM, V259, P201	36	83	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25970	25973						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929307				2022-12-25	WOS:A1994PQ93000008
J	LUSITANI, DM; QTAISHAT, N; LABRAKE, CC; YU, RN; DAVIS, J; KELLEY, MR; FUNG, LWM				LUSITANI, DM; QTAISHAT, N; LABRAKE, CC; YU, RN; DAVIS, J; KELLEY, MR; FUNG, LWM			THE FIRST HUMAN ALPHA-SPECTRIN STRUCTURAL DOMAIN BEANS WITH SERINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TETRAMER BINDING-SITE; ERYTHROCYTE SPECTRIN; MEMBRANE SKELETON; BETA-SPECTRIN; I DOMAIN; SEGMENTS; ELLIPTOCYTOSIS; POLYPEPTIDES; SEQUENCE	The 106-amino acid sequence motifs of spectrin have been suggested to fold into stable structural domains, consisting mostly of coiled coils of triple helices. With the advent of molecular biology and biophysical techniques, structural studies of these spectrin 106-amino acid structural domains became approachable. However, one of the difficulties in such an approach is determination of the correct phasing of the structural do mains, which may or may not coincide with the phasing of the sequence motifs. Proper identification of the domain phasing is vital to the construction of stable spectrin domains for molecular studies. A previously published phasing shift for Drosophila alpha-spectrin indicated a downstream phase-shift of 26 amino acids for the structural domain (Winograd, E., Hume, D., and Branton, D. (1991) Proc, Natl. Acad. Sci. U. S. A. 88, 10788-10791). Using this phase-shift, we prepared a recombinant spectrin peptide with the sequence from residue 49 to residue 155 of human erythrocyte alpha-spectrin and found this peptide to be unstable relative to other peptides that we prepared. Using several other recombinant alpha-spectrin peptides and following the protease digestion approach, we digested spectrin peptides with elastase and chymotrypsin and analyzed the amino acid sequence of the digestive products. We provide the first experimental evidence in identifying the first amino acid residue of the first spectrin domain in human erythrocyte alpha-spectrin as residue 52 (Ser).	LOYOLA UNIV,DEPT CHEM,CHICAGO,IL 60626; NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611; INDIANA UNIV,JAMES WHITCOMB RILEY HOSP CHILDREN,SCH MED,WELLS CTR PEDIAT RES,DEPT PEDIAT,INDIANAPOLIS,IN 46202; INDIANA UNIV,JW RILEY HOSP CHILDREN,SCH MED,WELLS CTR PEDIAT RES,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Loyola University Chicago; Northwestern University; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children				Kelley, Mark/0000-0002-6120-9532	NCRR NIH HHS [RR09884] Funding Source: Medline; NHLBI NIH HHS [R01-HL38361] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009884] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038361] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BYERS TJ, 1992, P NATL ACAD SCI USA, V89, P6187, DOI 10.1073/pnas.89.13.6187; DELAUNAY J, 1993, SEMIN HEMATOL, V30, P21; GARBARZ M, 1990, BLOOD, V75, P1691; KAHANA E, 1994, J MOL BIOL, V235, P1271, DOI 10.1006/jmbi.1994.1080; KENNEDY SP, 1994, J BIOL CHEM, V269, P11400; KOTULA L, 1993, J BIOL CHEM, V268, P14788; MACDONALD RI, 1994, P NATL ACAD SCI USA, V91, P1299, DOI 10.1073/pnas.91.4.1299; MARCHESI SL, 1987, J CLIN INVEST, V80, P191, DOI 10.1172/JCI113047; MARCHESI SL, 1989, RED BLOOD CELL MEMBR, P77; MCGUIRE M, 1988, Hematologic Pathology, V2, P1; PALEK J, 1990, SEMIN HEMATOL, V27, P290; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; PARRY DAD, 1991, AIP CONF PROC, V226, P367; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPEICHER DW, 1983, J BIOL CHEM, V258, P4938; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097	22	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25955	25958						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929303				2022-12-25	WOS:A1994PQ93000004
J	OH, BH; AMES, GFL; KIM, SH				OH, BH; AMES, GFL; KIM, SH			STRUCTURAL BASIS FOR MULTIPLE LIGAND SPECIFICITY OF THE PERIPLASMIC LYSINE, ARGININE, ORNITHINE-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; ESCHERICHIA-COLI; TRANSPORT-SYSTEMS; ACTIVE-TRANSPORT; MECHANISM; CHEMOTAXIS; BACTERIA; AFFINITY; LEUCINE	The substrate-binding site of a protein with multiple specificity should satisfy geometric and energetic complementarity for several different substrates. The structural basis of the multiple ligand specificity of the periplasmic lysine-, arginine-, ornithine-binding protein (LAO) was investigated by determining and analyzing the structures of the protein unliganded and liganded with each of the three high-affinity ligands (L-lysine, L-arginine, and L-ornithine) and with one low-affinity ligand (L-histidine). The geometric complementarity is achieved primarily by virtue of the large size of the ligand-binding site which can accommodate the maximum common volume of the four ligands plus three water molecules. The optimization of energetic complementarity is achieved by the relocation of protein-bound water molecules and by the movement of the Asp-11 side chain. The structure of the LAO-histidine complex indicates that the 30-fold reduced affinity of the protein for histidine is primarily due to unavailability of one ionic interaction of the histidine side chain with the protein which is present in the other three complexes.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV STRUCT BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley			Oh, Byung-Ha/C-2061-2011		NIAID NIH HHS [AI30725] Funding Source: Medline; NIDDK NIH HHS [DK12121, DK43747] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043747, R01DK012121, R37DK012121] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1991, J BIOL CHEM, V266, P6209; AMANUMA H, 1976, J BIOCHEM, V79, P1167, DOI 10.1093/oxfordjournals.jbchem.a131172; AMES GFL, 1972, J BIOL CHEM, V247, P4309; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BLOMBACK B, 1967, NATURE, V215, P1445, DOI 10.1038/2151445a0; BRUNGER AT, 1991, X PLOR VERSION 3 0; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DONELLADEANA A, 1990, EUR J BIOCHEM, V194, P773, DOI 10.1111/j.1432-1033.1990.tb19468.x; FURLONG CE, 1987, ESCHERICHIA COLI SAL, P768; Hardy R. W. F., 1979, A treatise on dinitrogen fixation. Inorganic and physical chemistry and biochemistry, P515; HIGGINS CF, 1981, P NATL ACAD SCI-BIOL, V78, P6038, DOI 10.1073/pnas.78.10.6038; KOSHLAND DE, 1988, BIOCHEMISTRY-US, V27, P5835; MA YT, 1992, BIOCHEMISTRY-US, V31, P11772, DOI 10.1021/bi00162a014; Markland F. S., 1971, ENZYMES, V3, P561, DOI 10.1016/S1874-6047(08)60407-2; MILLER DM, 1983, J BIOL CHEM, V258, P3665; NIEHRS C, 1990, J BIOL CHEM, V265, P8525; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; OH BH, 1993, J BIOL CHEM, V268, P11348; OIZUMI J, 1990, BIOCHEM J, V271, P45, DOI 10.1042/bj2710045; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; POWERS JC, 1989, J CELL BIOCHEM, V39, P33, DOI 10.1002/jcb.240390105; PROUD CG, 1991, EUR J BIOCHEM, V195, P1771; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628	29	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26323	26330						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929349				2022-12-25	WOS:A1994PQ93000059
J	PINNER, E; PADAN, E; SCHULDINER, S				PINNER, E; PADAN, E; SCHULDINER, S			KINETIC-PROPERTIES OF NHAB, A NA+/H+ ANTIPORTER FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-VESICLES; PROTON GRADIENT; H+ ANTIPORT; SODIUM; EXPRESSION; GENE; ANT; PH; PROTEINS; CELLS	NhaB, a Na+/H+ antiporter from Escherichia coli, was overproduced, purified, and reconstituted in a functional state, demonstrating that a single polypeptide, the product of the nhaB gene, can catalyze full activity. NhaB is a minor protein that accounts for less than 0.1% of the total membrane protein. The use of proteoliposomes made possible the determination of important kinetic and pharmacological properties in the absence of passive and mediated leaks. The activity of NhaB was found to have some pH dependence; the apparent K-m for Na+ changes by 10-fold from 1.55 mM at pH 8.5 to 16.66 mM at pH 7.2, while the V-max remains constant. It was demonstrated that NhaB is electrogenic and translocates more H+ than Na+ per cycle; the rate of sodium efflux from proteoliposomes was accelerated by a membrane potential, negative inside, and NhaB activity generated a membrane potential as monitored by two techniques. The stoichiometry of NhaB was estimated by a thermodynamic method in which the magnitude of Delta psi generated by NhaB was measured at various Na+ gradients. A kinetic method, in which the electrophoretic movement of Rb-86(+) (in the presence of valinomycin) was monitored in parallel with measurements of NhaB-mediated Na-22(+) uptake, allowed us to determine a stoichiometry of 3H(+)/ 2Na(+). The significance of the existence of two antiporters with different stoichiometries, NhaA and NhaB, active in the same cell, is discussed.			PINNER, E (corresponding author), HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DIV MICROBIAL & MOLEC ECOL,IL-91904 JERUSALEM,ISRAEL.		Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				BASSILANA M, 1984, BIOCHEMISTRY-US, V23, P1015, DOI 10.1021/bi00300a033; BASSILANA M, 1984, BIOCHEMISTRY-US, V23, P5288, DOI 10.1021/bi00317a029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMEL O, 1994, EMBO J, V13, P1981, DOI 10.1002/j.1460-2075.1994.tb06467.x; CASTLE AM, 1986, J BIOL CHEM, V261, P7797; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KARPEL R, 1991, J BIOL CHEM, V266, P21753; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PADAN E, 1993, J BIOENERG BIOMEMBR, V25, P647; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; PAN JW, 1990, J BIOL CHEM, V265, P9247; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1993, J BIOL CHEM, V268, P1729; RAHAVMANOR O, 1992, J BIOL CHEM, V267, P10433; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; Schuldiner S., 1992, ALKALI CATION TRANSP, P25; SHAHAK Y, 1982, FEBS LETT, V150, P27, DOI 10.1016/0014-5793(82)81298-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; WEST IC, 1974, BIOCHEM J, V144, P87, DOI 10.1042/bj1440087; ZILBERSTEIN D, 1979, BIOCHEMISTRY-US, V18, P669, DOI 10.1021/bi00571a018	26	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26274	26279						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929345				2022-12-25	WOS:A1994PQ93000053
J	WANG, JB; JOHNSON, PS; WU, JM; WANG, WF; UHL, GR				WANG, JB; JOHNSON, PS; WU, JM; WANG, WF; UHL, GR			HUMAN KAPPA-OPIATE RECEPTOR 2ND EXTRACELLULAR LOOP ELEVATES DYNORPHINS AFFINITY FOR HUMAN MU/KAPPA CHIMERAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DELTA-OPIOID RECEPTOR; FORMYL PEPTIDE RECEPTOR; LIGAND-BINDING; EXPRESSION; CLONING; DOMAINS; ANTAGONIST; AGONISTS; CDNA	To investigate roles of second extracellular loop sequences in peptide and nonpeptide ligand recognition by human opiate receptors, we have constructed a chimeric receptor in which this domain of the human mu opiate receptor has been replaced with that of the human kappa opiate receptor. The chimeric opiate receptor displays dramatically increased affinity for dynorphin peptides. Affinities for dynorphin A-(1-17), dynorphin A-(1-13), and alpha-neoendorphin increase by up to 250-fold when compared with the wild-type human mu opiate receptor. The chimera maintains recognition of the mu-selective ligands morphine and [D-Ala(2),MePhe(4),Gly-ol(5)] enkephalin and displays no significant changes in affinity for the kappa-selective small molecule ligand U50,488. The chimeric opiate receptor displays evidence for effective G-protein coupling; 100 nM dynorphin A-(1-17) is as effective as 100 nM morphine at inhibiting forskolin-stimulated adenyl cyclase activity through actions at the chimeric receptor. These data suggest that the putative second extracellular loop contributes substantially to the kappa receptor's selectivity in dynorphin ligand recognition.	NIDA,MOLEC NEUROBIOL BRANCH,BALTIMORE,MD 21224; NIDA,INTRAMURAL RES PROGRAM,OFF DIRECTOR,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins University								EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FONG TM, 1992, J BIOL CHEM, V267, P25664; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KNAPP RJ, 1994, LIFE SCI, V54, P463; KONG HY, 1993, J BIOL CHEM, V268, P23055; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; TAKEMORI AE, 1992, ANNU REV PHARMACOL, V32, P239, DOI 10.1146/annurev.pa.32.040192.001323; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736	21	116	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25966	25969						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929306				2022-12-25	WOS:A1994PQ93000007
J	WESTWICK, JK; WEITZEL, C; MINDEN, A; KARIN, M; BRENNER, DA				WESTWICK, JK; WEITZEL, C; MINDEN, A; KARIN, M; BRENNER, DA			TUMOR-NECROSIS-FACTOR-ALPHA STIMULATES AP-1 ACTIVITY THROUGH PROLONGED ACTIVATION OF THE C-JUN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EPIDERMAL GROWTH-FACTOR; SIGNAL-REGULATED KINASE-2; PROTEIN-KINASE; FACTOR RECEPTOR; DNA-BINDING; MOLECULAR-CLONING; GENE-EXPRESSION; TNF RECEPTORS; MAP KINASES	Tumor necrosis factor alpha (TNF alpha) has multiple biological functions including the prolonged activation of the collagenase and c-jun genes, which are regulated via their AP-1 binding sites. We show that incubating human fibroblasts with TNF alpha induces prolonged activation of JNK, the c-Jun kinase, which phosphorylates the transactivation domain of c-Jun. Furthermore, an immune complex kinase assay specifically demonstrates that TNF alpha stimulates the activity of JNK1, the recently described predominant form of JNK. TNF alpha also produces a small and transient increase in extracellular signal-regulated kinase (ERK) activity and no measured increase in Raf-1 kinase activity. On the other hand, epidermal growth factor causes a prolonged activation of Raf-1 kinase and ERK activity and a smaller, more transient activation of JNK, whereas the phorbol ester phorbol 12-myristate 13-acetate causes a small stimulation of Raf-1 kinase and a pronounced stimulation of ERK activity. The activation of JNK by TNF alpha does not correlate with Raf-1 or ERK activity. The kinetics of Raf-1, ERK, and JNK induction by epidermal growth factor, phorbol 12-myristate 13-acetate, or TNF alpha indicate distinct mechanisms of activation in human fibroblasts.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV CALIF SAN DIEGO,SCH MED,PROGRAM MOLEC PATHOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Diego; University of California System; University of California San Diego				Brenner, David/0000-0003-2573-525X	NCI NIH HHS [CA50528] Funding Source: Medline; NIDDK NIH HHS [DK34987] Funding Source: Medline; NIGMS NIH HHS [GM41804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; GARDNER AM, 1993, IN PRESS METHODS ENZ; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HATTORI M, 1993, AM J PHYSIOL, V264, pG95, DOI 10.1152/ajpgi.1993.264.1.G95; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HELLER RA, 1992, CELL, V70, P47; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KALTHOFF H, 1993, J BIOL CHEM, V268, P2762; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIU J, 1994, J BIOL CHEM, V269, P3047; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RIPPE RA, 1990, MOL CELL BIOL, V10, P689, DOI 10.1128/MCB.10.2.689; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YANG ZH, 1993, J BIOL CHEM, V268, P20520; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	61	267	269	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26396	26401						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929360				2022-12-25	WOS:A1994PQ93000070
J	WINDSOR, LJ; BODDEN, MK; BIRKEDALHANSEN, B; ENGLER, JA; BIRKEDALHANSEN, H				WINDSOR, LJ; BODDEN, MK; BIRKEDALHANSEN, B; ENGLER, JA; BIRKEDALHANSEN, H			MUTATIONAL ANALYSIS OF RESIDUES IN AND AROUND THE ACTIVE-SITE OF HUMAN FIBROBLAST-TYPE COLLAGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; CYSTEINE SWITCH; ACTIVATION; PROCOLLAGENASE; THERMOLYSIN; FAMILY; IDENTIFICATION; INHIBITORS; PRINCIPLE; PROTEINS	Mutants in and around the catalytic zinc-binding site of human fibroblast-type collagenase have been expressed in Escherichia coli. Replacement of each of the three zinc ligands, His-199, His-203, and His-209, in the active site sequence: VAAHEXGHXXGXXH, not only destroyed catalytic activity but also led to improper folding of the polypeptide, suggesting that this sequence also serves as a structural zinc-binding site. By comparison, mutation of His-194 immediately preceding this sequence had no measurable effect on catalytic activity or on folding. Replacement of Glu-200 in the active site yielded enzymes that either were completely inactive (E200Q) or had greatly diminished (E200D) catalytic activity. Both Glu-200 mutants, however, were fully capable of forming complexes with tissue inhibitor of metalloproteinases-1 (TIMP-1) after reaction with organomercurials. Formation of complexes with TIMP-1 appear to require a properly folded, but not necessarily catalytically competent, active site. By contrast, complexes with alpha(2)-macroglobulin form only with mutants with a catalytically competent active site. Two mutants identified in this study (E200Q and D212E) appeared to be properly folded but unable to generate any catalytic activity when exposed to either p-aminophenylmercuric acetate, trypsin, or SDS.	UNIV ALABAMA,SCH DENT,DEPT ORAL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,ORAL BIOL RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,DEPT DIAGNOST SCI,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,DEPT RESTORAT DENT,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294; NIDR,BETHESDA,MD 20892	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	WINDSOR, LJ (corresponding author), UNIV ALABAMA,DEPT MOLEC GENET & BIOCHEM,BIRMINGHAM,AL 35294, USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE006028, R01DE009122, P50DE008228] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08228, DE06028, DE09122] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; BIRKEDALHANSEN H, 1982, BIOCHEM BIOPH RES CO, V107, P1173, DOI 10.1016/S0006-291X(82)80120-4; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1976, J BIOL CHEM, V251, P3162; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; GRANT GA, 1987, J BIOL CHEM, V262, P5886; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1990, Biotechniques, V9, P788; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P41, DOI 10.1038/newbio238041a0; Nagase H, 1992, Matrix Suppl, V1, P421; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1992, MATRIX METALLOPROTEI, P5; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	33	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26201	26207						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929334				2022-12-25	WOS:A1994PQ93000042
J	KUMAR, R; KORUTLA, L; ZHANG, KR				KUMAR, R; KORUTLA, L; ZHANG, KR			CELL CYCLE-DEPENDENT MODULATION OF ALPHA-INTERFERON-INDUCIBLE GENE-EXPRESSION AND ACTIVATION OF SIGNALING COMPONENTS IN DAUDI CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-REGULATION; 2'-5'-OLIGOADENYLATE SYNTHETASE; GAMMA-INTERFERON; TYROSINE KINASE; MESSENGER-RNA; A431 CELLS; PROTEIN; BINDING; DIFFERENTIATION; PHOSPHORYLATION	To investigate cell cycle-dependent expression of interferon (IFN)-induced genes and signaling pathways, we examined the modulation of IPN inducible gene expression and p91 activation, and JAK-1 and Tyk-2 kinases' activation in human Burkitt's lymphoma Daudi cells which were synchronized at different points in the cell cycle progression. We observed that each one of 100-, 67-, and 46-kDa 2'-5'-oligoadenylate synthetase (2-5(A)synthetase) proteins had a unique expression pattern in different phases of the cell cycle which was different from the expression of 2-5(A)-synthetase proteins in exponentially growing Daudi cells. The cell cycle-dependent changes in the overall levels of expression of 2-5(A)synthetase proteins correlated well with the induction of expression of 2-5(A)-synthetase mRNA as well as the appearance of IFN stimulatory gene factor-3 and expression and activation of p91 in cells released from the C-1/S block in the absence of exogenous IFN-LU. In addition, cells from the C-1/S phase exhibited increased tyrosine phosphorylation of JAK-1 and Tyk-2 kinases and p91 by IFN-alpha as compared with asynchronized cells. Enhanced stimulation of activation of JAK-1, Tyk-2, and p91 by IFN-alpha was progressively reduced from C-1/S to G(2)/M to pass G(2)/M. These findings demonstrate that the levels of constitutive and inducible expression of IBN-alpha-inducible genes, activation of p91, and tyrosine phosphorylation of JAK-1 and Tyk-2 kinases are differentially influenced by the state of the cell cycle.	PENN STATE UNIV,COLL MED,DEPT MED,HERSHEY,PA 17033; PENN STATE UNIV,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NCI NIH HHS [CA56564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; BANDYOPADHYAY SK, 1992, CELL GROWTH DIFFER, V3, P369; CHEBATH J, 1987, J BIOL CHEM, V262, P3852; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; CREASEY AA, 1983, MOL CELL BIOL, V3, P780, DOI 10.1128/MCB.3.5.780; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KUMAR R, 1988, J VIROL, V62, P3175, DOI 10.1128/JVI.62.9.3175-3181.1988; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR R, 1987, J VIROL, V61, P2727, DOI 10.1128/JVI.61.9.2727-2732.1987; KUMAR R, 1990, J BIOL CHEM, V265, P4578; KUMAR R, 1989, CANCER RES, V49, P5180; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1990, CANCER RES, V50, P2654; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SEN GC, 1992, J BIOL CHEM, V267, P5017; WELLS V, 1985, EXP CELL RES, V159, P27, DOI 10.1016/S0014-4827(85)80034-3; WELLS V, 1988, J INTERFERON RES, V8, P293; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479	32	35	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25437	25441						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929242				2022-12-25	WOS:A1994PQ49100035
J	SATHER, SK; KING, J				SATHER, SK; KING, J			INTRACELLULAR TRAPPING OF A CYTOPLASMIC FOLDING INTERMEDIATE OF THE PHAGE-P22 TAILSPIKE USING IODOACETAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAIL-SPIKE PROTEIN; INCLUSION BODY FORMATION; HEAD FORMATION GROE; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; SALMONELLA PHAGE-P22; MOLECULAR CHAPERONES; RAMAN-SPECTROSCOPY; POLYPEPTIDE-CHAIN; DISULFIDE BONDS	Critical steps in polypeptide chain folding within the bacterial cytoplasm have been difficult to identify. Salmonella cells infected with temperature-sensitive folding mutants of the P22 tailspike protein at restrictive temperature accumulated a metastable folding intermediate with a half-life of 6 min at 39 degrees C. The native trimeric tailspike contains 24 buried cysteines (8/chain) but neither disulfide bonds nor active site cysteines. Eighteen of the 24 cysteines are involved in strong hydrogen bonds (Thomas, G. J., Jr., Becka, R., Sargent, D., Yu, M.-H., and King, J. (1990) Biochemistry 29, 4181-4187). Cyanide and iodoacetamide prevented the folding and association of the restrictive temperature folding intermediate to the native state after shift to permissive temperature. The cytoplasmic folding intermediate was covalently modified by iodoacetamide within infected cells. Chains which had reacted with iodoacetamide were unable to proceed through the folding pathway. Iodoacetamide also reacted with a folding intermediate during the refolding of purified tailspike chains in vitro, inhibiting further folding. No reaction occurred with native tailspike in vivo or in vitro. The target residues in the intermediates were in the carboxyl terminus of the chain and may be a unique set of cysteine residues that are activated during protein folding, but not in the native state.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [NIGMS 17980] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017980, R37GM017980] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MH, 1959, BACTERIOPHAGES; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BEISSINGER M, 1994, IN PRESS PROTEIN PEP; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; BOTSTEIN D, 1973, J MOL BIOL, V80, P669, DOI 10.1016/0022-2836(73)90204-0; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; COPPO A, 1973, J MOL BIOL, V76, P61, DOI 10.1016/0022-2836(73)90081-8; Creighton T. E., 1984, PROTEINS, P242; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; Creighton Thomas E., 1992, P301; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DRAHOS DJ, 1982, J BACTERIOL, V149, P1050, DOI 10.1128/JB.149.3.1050-1063.1982; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FANE B, 1987, GENETICS, V117, P157; FRIGUET B, 1990, J BIOL CHEM, V265, P10347; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GORDON CL, 1994, IN PRESS J BIOL CHEM, V269; GURD FRN, 1967, METHOD ENZYMOL, V11, P532; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; IWASHITA S, 1976, EUR J BIOCHEM, V65, P87, DOI 10.1111/j.1432-1033.1976.tb10392.x; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MEANS GE, 1971, CHEM MODIFICATION PR, P110; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MURIALDO H, 1979, VIROLOGY, V96, P341, DOI 10.1016/0042-6822(79)90094-1; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; REVEL HR, 1980, J VIROL, V33, P366, DOI 10.1128/JVI.33.1.366-376.1980; SARGENT D, 1988, J MOL BIOL, V199, P491, DOI 10.1016/0022-2836(88)90620-1; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SCHWARZ JJ, 1989, J BIOL CHEM, V264, P20112; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; SMITH DH, 1980, GENETICS, V96, P331; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; STERNBERG N, 1973, J MOL BIOL, V76, P1, DOI 10.1016/0022-2836(73)90078-8; STUDIER FW, 1972, SCIENCE, V176, P367, DOI 10.1126/science.176.4033.367; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; THOMAS GJ, 1990, BIOCHEMISTRY-US, V29, P4181, DOI 10.1021/bi00469a022; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; WINSTON F, 1979, J BACTERIOL, V137, P433, DOI 10.1128/JB.137.1.433-439.1979; YU MH, 1988, J BIOL CHEM, V263, P1424; ZWEIG M, 1973, J MOL BIOL, V80, P505, DOI 10.1016/0022-2836(73)90418-X	63	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25268	25276						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929218				2022-12-25	WOS:A1994PQ49100008
J	ABUGO, OO; RIFKIND, JM				ABUGO, OO; RIFKIND, JM			OXIDATION OF HEMOGLOBIN AND THE ENHANCEMENT PRODUCED BY NITROBLUE TETRAZOLIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAL HISTIDINE; NUCLEOPHILIC DISPLACEMENT; COLORIMETRIC ASSAY; AUTOXIDATION; SUPEROXIDE; MECHANISM; OXYHEMOGLOBIN; OXYMYOGLOBIN; MYOGLOBIN; AUTOOXIDATION	The autoxidation of hemoglobin as a function of oxygen pressure and the effect of added nitroblue tetrazolium have been studied. It has been shown that the enhanced autoxidation at intermediate oxygen pressures can only be partially explained by the outer-sphere reaction of oxygen with deoxygenated chains. An additional enhancement associated with the properties of partially oxygenated hemoglobins has been attributed to the mobility on the distal side of the heme which facilitates the nucleophilic displacement of bound oxygen by the distal histidine. Nitroblue tetrazolium, in addition to reacting with the superoxide formed during autoxidation, is shown to oxidize directly both deoxygenated and oxygenated hemoglobin in two steps, proceeding through the one electron reduced intermediate, a tetrazolinyl radical. Even though the oxygenated chains are oxidized by nitroblue tetrazolium, much less overall reduction of nitroblue tetrazolium is observed at high oxygen pressures. This phenomenon is attributed to the reoxidation by oxygen of both the tetrazolinyl radical and the formazan. The reaction with nitroblue tetrazolium is also found to con tribute to enhanced oxidation at intermediate oxygen pressures. This behavior is explained by the two-electron reaction with nitroblue tetrazolium and the oxygen dependence of the various processes involved in the reaction of nitroblue tetrazolium.	NIA, GERONTOL RES CTR, CELLULAR & MOLEC BIOL LAB, MOLEC DYNAM SECT, BALTIMORE, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								Altman F P, 1976, Prog Histochem Cytochem, V9, P1; ANTONINI E, 1965, BIOCHEMISTRY-US, V4, P545, DOI 10.1021/bi00879a026; Auclair C., 1985, CRC HDB METHODS OXYG, P123, DOI DOI 10.1201/9781351072922; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BIELSKI BHJ, 1980, J PHYS CHEM-US, V84, P830, DOI 10.1021/j100445a006; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; Brooks J, 1935, PROC R SOC SER B-BIO, V118, P560, DOI 10.1098/rspb.1935.0072; DICKERSON LD, 1993, J AM CHEM SOC, V115, P3623, DOI 10.1021/ja00062a028; FARBER E, 1956, J HISTOCHEM CYTOCHEM, V4, P254, DOI 10.1177/4.3.254; GEORGE P, 1952, BIOCHEM J, V51, P418, DOI 10.1042/bj0510418; Hanahan D J, 1974, Methods Enzymol, V31, P168; IMAI K, 1982, ALLOSTERIC EFFECTS H, P145; KLUGROTH D, 1973, J AM CHEM SOC, V95, P2786, DOI 10.1021/ja00790a007; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; LEVY A, 1990, BIOCHEMISTRY-US, V29, P9311, DOI 10.1021/bi00492a002; LEVY A, 1992, BIOPHYS J, V61, P750, DOI 10.1016/S0006-3495(92)81879-9; LEVY A, 1985, BIOCHEMISTRY-US, V24, P6050, DOI 10.1021/bi00343a005; LEVY A, 1988, OXY RADICALS MOL BIO, P11; LEVY A, 1991, J INORG BIOCHEM, V43, P327, DOI DOI 10.1016/0162-0134(91)84314-Y; MANSOURI A, 1973, BIOCHEMISTRY-US, V12, P4946, DOI 10.1021/bi00748a020; MISRA HP, 1972, J BIOL CHEM, V247, P6960; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NACHLAS MM, 1957, J HISTOCHEM CYTOCHEM, V5, P420, DOI 10.1177/5.4.420; PENNELL RB, 1964, RED BLOOD CELL COMPR, P37; RIFKIND JM, 1991, FREE RADICAL RES COM, V12-3, P645; RIFKIND JM, 1976, BIOCHEMISTRY-US, V15, P5337, DOI 10.1021/bi00669a021; RIFKIND JM, 1974, BIOCHEMISTRY-US, V13, P2475, DOI 10.1021/bi00709a003; RIFKIND JM, 1993, 6TH INT C BIOIN CHEM, P344; RIFKIND JM, 1992, SURVIVING HYPOXIA ME, P509; RIFKIND JM, 1994, IN PRESS OXYGEN TRAN; RIFKIND JM, 1989, OXYGEN RADICALS BIOL, P157; ROOK GAW, 1985, J IMMUNOL METHODS, V82, P161, DOI 10.1016/0022-1759(85)90235-2; SATOH Y, 1981, J BIOL CHEM, V256, P272; SEIDLER E, 1991, PROG HISTOCHEM CYTOC, V24, P1; SHIKAMA K, 1984, BIOCHEM J, V223, P279, DOI 10.1042/bj2230279; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; SUTTON HC, 1976, BIOCHEM J, V155, P503, DOI 10.1042/bj1550503; THAYER WS, 1990, ARCH BIOCHEM BIOPHYS, V276, P139, DOI 10.1016/0003-9861(90)90020-Y; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; WALLACE WJ, 1974, FEBS LETT, V43, P33, DOI 10.1016/0014-5793(74)81099-9; WALLACE WJ, 1975, BIOCHEM BIOPH RES CO, V62, P561, DOI 10.1016/0006-291X(75)90435-0; WALLACE WJ, 1974, BIOCHEM BIOPH RES CO, V57, P1104, DOI 10.1016/0006-291X(74)90810-9; WEVER R, 1973, BIOCHIM BIOPHYS ACTA, V302, P475, DOI 10.1016/0005-2744(73)90180-0; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493; WINTERBOURN CC, 1985, CRC HDB METHODS OXYG, P277; YUSA K, 1987, BIOCHEMISTRY-US, V26, P6684, DOI 10.1021/bi00395a018; ZHANG L, 1990, 34TH ANN BIOPH SOC M, P2399	47	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24845	24853						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929164				2022-12-25	WOS:A1994PQ49000051
J	MADDELEIN, ML; LIBESSART, N; BELLANGER, F; DELRUE, B; DHULST, C; VANDENKOORNHUYSE, N; FONTAINE, T; WIERUSZESKI, JM; DECQ, A; BALL, S				MADDELEIN, ML; LIBESSART, N; BELLANGER, F; DELRUE, B; DHULST, C; VANDENKOORNHUYSE, N; FONTAINE, T; WIERUSZESKI, JM; DECQ, A; BALL, S			TOWARD AN UNDERSTANDING OF THE BIOGENESIS OF THE STARCH GRANULE - DETERMINATION OF GRANULE-BOUND AND SOLUBLE STARCH SYNTHASE FUNCTIONS IN AMYLOPECTIN SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-GLUCOSE PYROPHOSPHORYLASE; CHLAMYDOMONAS-REINHARDTII; BRANCHING ENZYME; INHIBITION; EXPRESSION; STORAGE; POTATO; MUTANT; GENES	Plant starch synthesis can be distinguished from those of bacterial, fungal, and animal glycogen by the presence of multiple elongation (starch synthases) and branching enzymes. This complexity has precluded genetic assignment of functions to the various soluble starch synthases in the building of amylopectin. In Chlamydomonas, we have recently shown that defects in the major soluble starch synthase lead to a specific decrease in the amount of a subset of amylopectin chains whose length ranges between 8 and 40 glucose residues (Fontaine, T., D'Hulst, C., Maddelein, M.-L., Routier, F., Marianne-Pepin, T., Decq, A., Wieruszeski, J. M., Delrue, B., Van Den Koornhuyse, N., Bossu, J.-P., Fournet, B., and Ball, S. G. (1993) J. Biol. Chem. 268, 16223-16230). We now demonstrate that granule-bound starch synthase, the enzyme that was thought to be solely responsible for amylose synthesis, is involved in amylopectin synthesis. Disruption of the Chlamydomonas granule-bound starch synthase structural gene establishes that synthesis of long chains by this enzyme can become an absolute requirement for amylopectin synthesis in particular mutant backgrounds, In the sole presence of soluble starch synthase I, Chlamydomonas directs the synthesis of a major water-soluble polysaccharide fraction and minute amounts of a new type of highly branched granular material, whose structure is intermediate between those of glycogen and amylopectin. These results lead us to propose that the nature of the elongation enzyme conditions the synthesis of distinct size classes of glucans in all starch fractions.	UNIV SCI & TECH LILLE FLANDRES ARTOIS,CNRS,UMR 111,CHIM BIOL LAB,F-59655 VILLENEUVE DASCQ,FRANCE; ROQUETTE FRERES,F-62136 LESTREM,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille			D'Hulst, Christophe/AAX-2809-2020; Fontaine, thierry/Q-2201-2018; D'HULST, Christophe/B-2072-2012; Fontaine, Thierry/F-8227-2011; MADDELEIN, Marie-Lise/G-5395-2010	D'Hulst, Christophe/0000-0002-5556-9099; Fontaine, thierry/0000-0002-8184-789X; D'HULST, Christophe/0000-0002-5556-9099; Ball, Steven/0000-0003-1629-1650				BABA T, 1987, STARCH-STARKE, V39, P52, DOI 10.1002/star.19870390207; BALL S, 1991, PLANTA, V185, P17, DOI 10.1007/BF00194509; BALL SG, 1990, PLANT SCI, V66, P1, DOI 10.1016/0168-9452(90)90162-H; BANKS W, 1971, CARBOHYD RES, V17, P25, DOI 10.1016/S0008-6215(00)81539-6; CREECH RG, 1965, GENETICS, V52, P1175; DELRUE B, 1992, J BACTERIOL, V174, P3612, DOI 10.1128/JB.174.11.3612-3620.1992; FONTAINE T, 1993, J BIOL CHEM, V268, P16223; GIDLEY MJ, 1985, CARBOHYD RES, V139, P85; Harris E.H., 1989, CHLAMYDOMONAS SOURCE, P399; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; HARRIS EH, 1989, CHLAMYDOMONAS SOURCE, P581; HIZUKURI S, 1986, CARBOHYD RES, V147, P342, DOI 10.1016/S0008-6215(00)90643-8; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; KRISMAN CR, 1985, ANAL BIOCHEM, V147, P491, DOI 10.1016/0003-2697(85)90303-3; KUIPERS AGJ, 1994, PLANT CELL, V6, P43, DOI 10.1105/tpc.6.1.43; LELOIR LF, 1961, J BIOL CHEM, V236, P636; LIN TP, 1988, PLANT PHYSIOL, V88, P1175, DOI 10.1104/pp.88.4.1175; MACDONALD FD, 1985, PLANT PHYSIOL, V78, P849, DOI 10.1104/pp.78.4.849; MANNERS DJ, 1989, CARBOHYD POLYM, V11, P87, DOI 10.1016/0144-8617(89)90018-0; MULLERROBER B, 1992, EMBO J, V11, P1229, DOI 10.1002/j.1460-2075.1992.tb05167.x; NELSON OE, 1962, BIOCHEM BIOPH RES CO, V9, P297, DOI 10.1016/0006-291X(62)90043-8; PARENTE JP, 1985, CARBOHYD RES, V141, P41, DOI 10.1016/S0008-6215(00)90753-5; Preiss J., 1980, MECHANISMS SACCHARID, P161; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; Shannon J., 1984, STARCH CHEM TECHNOLO, P25, DOI 10.1016/B978-0-12-746270-7.50009-4; TAM LW, 1993, GENETICS, V135, P375; THON VJ, 1992, J BIOL CHEM, V267, P15224; TSAI CY, 1966, SCIENCE, V151, P341, DOI 10.1126/science.151.3708.341; VISSER RGF, 1991, MOL GEN GENET, V225, P289, DOI 10.1007/BF00269861	29	84	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25150	25157						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929203				2022-12-25	WOS:A1994PQ49000093
J	WLAD, H; MACCARANA, M; ERIKSSON, I; KJELLEN, L; LINDAHL, U				WLAD, H; MACCARANA, M; ERIKSSON, I; KJELLEN, L; LINDAHL, U			BIOSYNTHESIS OF HEPARIN - DIFFERENT MOLECULAR-FORMS OF O-SULFOTRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							D-GLUCOSAMINYLTRANSFERASE REACTIONS; FIBROBLAST GROWTH-FACTOR; POLYMER-MODIFICATION; SULFATE; PURIFICATION; BINDING; DEPOLYMERIZATION; IDENTIFICATION; ANTITHROMBIN; SEQUENCE	O-Sulfotransferases involved in heparin biosynthesis were purified greater than or equal to 10,000-fold from detergent extracts of mouse mastocytoma tissue by sequential chromatographies on DEAE-Sephacel, heparin-agarose, blue Sepharose, and 3',5'-ADP-Sepharose. The resultant preparation catalyzed the transfer of S-35 from 3'-phosphoadenosyl-5'-phospho-[S-35]sulfate into N,O-desulfated, re;hr-sulfated heparin. Anion-exchange high performance liquid chromatography of disaccharides obtained by deaminative cleavage of the S-35-labeled polysaccharide product revealed O-S-35-sulfation at C-2 of L-iduronic acid and at C-6 of D-glucosamine units. SDS-polyacrylamide gel electrophoresis of semipurified enzyme followed by extraction of gel segments and renaturation of proteins consistently showed two distinct fractions of O-sulfotransferase activity, corresponding to proteins of similar to 20 and similar to 60 kDa. The similar to 60-kDa enzyme(s) catalyzed both the 2-O- and 6-O-sulfotransferase reactions, whereas the similar to 20-kDa fraction promoted iduronosyl 2-O-sulfation only. These results are discussed in relation to previous findings, indicating that some of the enzymes involved in heparin biosynthesis catalyze more than one reaction.	UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN; BIOMED CTR,DEPT VET MED CHEM,S-75123 UPPSALA,SWEDEN	Uppsala University			Kjellen, Lena/F-1362-2011; maccarana, marco/AAB-4764-2021	Maccarana, Marco/0000-0003-3549-8921				BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FURTH J, 1957, P SOC EXP BIOL MED, V95, P824; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; LEVY L, 1962, P SOC EXP BIOL MED, V190, P901; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIND T, 1993, J BIOL CHEM, V268, P20705; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; Lindahl U., 1989, HEPARIN, P159; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RENOSTO F, 1977, ARCH BIOCHEM BIOPHYS, V180, P416, DOI 10.1016/0003-9861(77)90056-X; ROBBINS PW, 1962, METHOD ENZYMOL, V5, P964, DOI 10.1016/S0076-6879(62)05343-4; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885	24	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24538	24541						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929122				2022-12-25	WOS:A1994PQ49000006
J	MA, H; YANG, HQ; TAKANO, E; HATANAKA, M; MAKI, M				MA, H; YANG, HQ; TAKANO, E; HATANAKA, M; MAKI, M			AMINO-TERMINAL CONSERVED REGION IN PROTEINASE-INHIBITOR DOMAIN OF CALPASTATIN POTENTIATES ITS CALPAIN INHIBITORY ACTIVITY BY INTERACTING WITH CALMODULIN-LIKE DOMAIN OF THE PROTEINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASE; ACTIVATED NEUTRAL PROTEASE; 4 REPEATING DOMAINS; ENDOGENOUS INHIBITOR; ESCHERICHIA-COLI; PIG CALPASTATIN; PEPTIDE COMPLEX; THIOL PROTEASE; BINDING; RECOGNITION	Calpastatin is a widely distributed endogenous inhibitor protein specifically acting on calpain (Ca2+-dependent proteinase) and is known to interact with the calmodulin-like domain (CaMLD) of the proteinase in a Ca2+-dependent fashion. The calpastatin molecule consists of four inhibitory domains (domains 1-4) with mutually homologous sequences in three regions designated as A, B, and C. Acidic amphiphilic alpha-helical motifs are found in both regions A and C. We investigated the correlation between the calpain inhibition potency and the ability of calpastatin to bind to recombinant CaMLD of the mu-calpain large subunit using various mutant proteins of pig calastatin domain 1 expressed in Escherichia coli. Substitution of conserved Leu-161 with Pro in region A caused a reduction in activity of both calpain inhibition and CaMLD binding. Additional substitution of Leu-236 with Pro in region C further decreased the calpain inhibitory activity and caused a loss of CaMLD binding ability. The effects of mutation in region C alone on the above activities were smaller than those in region A. Although a mutant of deletion in the entire region B had no calpain inhibitory activity, it retained the CaMLD binding ability. On the other hand, although a region B oligopeptide had a moderate inhibitory activity, it had no CaMLD binding ability. These results suggest that region A has a role in potentiating the inhibitory activity of calpastatin by interacting with CaMLD of calpain to form a tighter complex where region B exerts the inhibitory function,	KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 60601, JAPAN	Kyoto University			Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491				COTTIN P, 1981, FEBS LETT, V136, P221, DOI 10.1016/0014-5793(81)80622-9; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; EMORI Y, 1988, J BIOL CHEM, V263, P2364; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ISHIMA R, 1991, FEBS LETT, V294, P64, DOI 10.1016/0014-5793(91)81344-8; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KAWASAKI H, 1993, ARCH BIOCHEM BIOPHYS, V305, P467, DOI 10.1006/abbi.1993.1448; KAWASAKI H, 1989, J BIOCHEM, V106, P274, DOI 10.1093/oxfordjournals.jbchem.a122844; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WJ, 1992, J BIOL CHEM, V267, P8437; MA H, 1993, J BIOCHEM, V113, P591, DOI 10.1093/oxfordjournals.jbchem.a124088; MAKI M, 1987, FEBS LETT, V223, P174, DOI 10.1016/0014-5793(87)80531-8; MAKI M, 1989, J BIOL CHEM, V264, P18866; MAKI M, 1988, J BIOL CHEM, V263, P10254; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MELLGREN RL, 1990, INTRACELLULAR CALCIU, P1; MURAKAMI T, 1981, J BIOCHEM-TOKYO, V90, P1809, DOI 10.1093/oxfordjournals.jbchem.a133659; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PARR T, 1992, EUR J BIOCHEM, V208, P333, DOI 10.1111/j.1432-1033.1992.tb17191.x; SAKIHAMA T, 1985, P NATL ACAD SCI USA, V82, P6075, DOI 10.1073/pnas.82.18.6075; SHIGETA K, 1984, BIOCHEM INT, V9, P327; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; UEMORI T, 1990, BIOCHEM BIOPH RES CO, V166, P1485, DOI 10.1016/0006-291X(90)91035-Q; YANG HQ, 1994, J BIOL CHEM, V269, P18977	31	59	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24430	24436						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929105				2022-12-25	WOS:A1994PQ34600090
J	ROBINS, P; PAPPIN, DJC; WOOD, RD; LINDAHL, T				ROBINS, P; PAPPIN, DJC; WOOD, RD; LINDAHL, T			STRUCTURAL AND FUNCTIONAL HOMOLOGY BETWEEN MAMMALIAN DNASE-IV AND THE 5'-NUCLEASE DOMAIN OF ESCHERICHIA-COLI DNA-POLYMERASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							5'->3' EXONUCLEASE; 5'-3' EXONUCLEASE; CELLS; IDENTIFICATION; REPLICATION; EXCISION; PROTEINS; REPAIR; SITES; YEAST	A nuclear 42-kDa 5' --> 3'-exonuclease, DNase TV, was found previously in animal tissues. The enzyme has been purified from HeLa cells and shown to possess two catalytic properties characteristic of the 5'-nuclease function of Escherichia coli DNA polymerase I; DNase IV removes single-stranded 5' regions from splayed-arm DNA structures by endonucleolytic incision at the bifurcation point and possesses RNase H activity. Determination of the molecular masses of tryptic and V8 peptides of DNase IV by mass spectrometry identified the enzyme as the human homolog of the Schizosaccharomyces pombe Rad2 protein. The protein sequence retains conserved residues and shows significant homology to the sequences of the 5'-nuclease domain of E. coli DNA polymerase I and related microbial enzymes.	LINCOLNS INN FIELDS LABS,LONDON WC2A 3PX,ENGLAND		ROBINS, P (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.		Wood, Richard/M-6319-2018	Wood, Richard/0000-0002-9495-6892; Pappin, Darryl/0000-0002-8981-8401				CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; COULL J M, 1990, Journal of Protein Chemistry, V9, P259; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; ENGLER MJ, 1983, J BIOL CHEM, V258, P1197; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; GUTMAN PD, 1993, NUCLEIC ACIDS RES, V21, P4406, DOI 10.1093/nar/21.18.4406; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JACQUIER A, 1992, YEAST, V8, P122; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KELLY RB, 1969, NATURE, V224, P495, DOI 10.1038/224495a0; KENNY MK, 1988, J BIOL CHEM, V263, P9801; Kornberg A., 1992, DNA REPLICATION; LINDAHL T, 1971, EUR J BIOCHEM, V18, P415, DOI 10.1111/j.1432-1033.1971.tb01258.x; LINDAHL T, 1969, J BIOL CHEM, V244, P5014; LINDAHL T, 1971, EUR J BIOCHEM, V18, P407, DOI 10.1111/j.1432-1033.1971.tb01257.x; LINDAHL T, 1969, P NATL ACAD SCI USA, V62, P597, DOI 10.1073/pnas.62.2.597; LINDAHL T, 1971, METHODS ENZYMOL D, V21, P148; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MOCK KK, 1992, RAPID COMMUN MASS SP, V6, P233, DOI 10.1002/rcm.1290060402; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; PRICE A, 1992, FEBS LETT, V300, P101, DOI 10.1016/0014-5793(92)80173-E; SAYERS JR, 1990, J BIOL CHEM, V265, P18311; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; UYEMURA D, 1976, J BIOL CHEM, V251, P4085; WAGA S, 1994, J BIOL CHEM, V269, P10923	34	123	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28535	28538						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961795				2022-12-25	WOS:A1994PU16800004
J	ATKINSON, MR; KAMBEROV, ES; WEISS, RL; NINFA, AJ				ATKINSON, MR; KAMBEROV, ES; WEISS, RL; NINFA, AJ			REVERSIBLE URIDYLYLATION OF THE ESCHERICHIA-COLI PII SIGNAL-TRANSDUCTION PROTEIN REGULATES ITS ABILITY TO STIMULATE THE DEPHOSPHORYLATION OF THE TRANSCRIPTION FACTOR NITROGEN REGULATOR-I (NRI OR NTRC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE-SYNTHETASE; CASCADE CONTROL; REMOVING ENZYME; GLNALG OPERON; URIDYLYLTRANSFERASE; PHOSPHORYLATION; GENE; PHOSPHATASE; GLNL; AUTOPHOSPHORYLATION	We have reconstituted the signal transduction system responsible for the negative regulation of the transcription of the Escherichia coli glnA gene, encoding glutamine synthetase, by glutamine. This signal transduction system consists of four proteins: the transcription factor NRI (NtrC), which activates glnA transcription when it is phosphorylated, the kinase/phosphatase protein NRII (NtrB) that directly controls the extent of NRI phosphorylation, the PII signal transduction protein that controls the phosphatase activity of NRII and the uridylyl-transferase/uridylyl-removing (UTase/UR) enzyme that is regulated by glutamine and controls the activity of PII. In the reconstituted system, the removal of uridylyl groups from the PII protein, catalyzed by the UTase/UR protein in the presence of glutamine, resulted in the stimulation of NRI similar to P dephosphorylation. In contrast, the uridylylated form of the PII protein had no discernible effect on NRI phosphorylation. The uridylylation of the trimeric PII protein by the monomeric UTase/LTR protein is a non-cooperative reaction in which the partially modified species accumulated and were readily observed. Partially modified PII trimers were partially active in stimulating the dephosphorylation of NRI similar to P. Thus, both the PII-UTase/UR and PII-NRII interactions display the continuous variability characteristic of rheostats as opposed to the binary variability characteristic of toggle switches.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047460] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47460] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER SP, 1975, J BIOL CHEM, V250, P6264; ATKINSON MR, 1992, J BACTERIOL, V174, P4538, DOI 10.1128/JB.174.14.4538-4548.1992; ATKINSON MR, 1993, J BACTERIOL, V175, P7016, DOI 10.1128/jb.175.21.7016-7023.1993; BLOOM FR, 1978, J BACTERIOL, V134, P569, DOI 10.1128/JB.134.2.569-577.1978; BROWN MS, 1971, P NATL ACAD SCI USA, V68, P2949, DOI 10.1073/pnas.68.12.2949; BUENO R, 1985, J BACTERIOL, V164, P816, DOI 10.1128/JB.164.2.816-822.1985; ENGLEMAN EG, 1978, ARCH BIOCHEM BIOPHYS, V191, P602, DOI 10.1016/0003-9861(78)90398-3; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; FRANCIS SH, 1978, ARCH BIOCHEM BIOPHYS, V191, P590, DOI 10.1016/0003-9861(78)90397-1; GARCIA E, 1983, J BIOL CHEM, V258, P2246; HOLTEL A, 1989, MOL GEN GENET, V217, P474, DOI 10.1007/BF02464920; KAMBEROV ES, 1994, J BIOL CHEM, V269, P28294; KAMBEROV ES, 1994, IN PRESS CELLULAR MO; KAMBEROV ES, 1994, IN PRESS CELL MOL BI; KEENER J, 1988, P NATL ACAD SCI USA, V82, P8453; MACNEIL T, 1982, MOL GEN GENET, V188, P325, DOI 10.1007/BF00332696; MAGASANIK B, 1988, TRENDS BIOCHEM SCI, V13, P475, DOI 10.1016/0968-0004(88)90234-4; NINFA AJ, 1991, J BIOL CHEM, V266, P6888; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; PAHEL G, 1978, J BACTERIOL, V133, P139, DOI 10.1128/JB.133.1.139-148.1978; RHEE SG, 1985, CURR TOP CELL REGUL, V27, P221; SANDERS DA, 1992, J BACTERIOL, V174, P5117, DOI 10.1128/JB.174.15.5117-5122.1992; SON HS, 1987, J BIOL CHEM, V262, P8690; Stadtman ER, 1980, GLUTAMINE METABOLISM, P41; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	26	86	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28288	28293						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961766				2022-12-25	WOS:A1994PV77200077
J	OLSZEWSKI, S; DEENEY, JT; SCHUPPIN, GT; WILLIAMS, KP; CORKEY, BE; RHODES, CJ				OLSZEWSKI, S; DEENEY, JT; SCHUPPIN, GT; WILLIAMS, KP; CORKEY, BE; RHODES, CJ			RAB3A EFFECTOR DOMAIN PEPTIDES INDUCE INSULIN EXOCYTOSIS VIA A SPECIFIC INTERACTION WITH A CYTOSOLIC PROTEIN DOUBLET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SYNAPTIC VESICLES; GUANINE-NUCLEOTIDES; SYNTHETIC PEPTIDE; EXCHANGE PROTEIN; TARGET PROTEIN; KINASE-C; SMG P25A; B-CELLS; SECRETION	A key protein involved in the regulated exocytotic mechanism in neuroendocrine cells is the GTP-binding protein, Rab3A. Rab3A is thought to mediate exocytosis by an interaction of its effector domain with a putative effector protein. we demonstrate here that Rab3A effector domain peptides specifically stimulated insulin exocytosis in electroporated insulin-secreting cells (K-0.5 activation, 6-8 mu M) in a Ca2+-independent manner, although in the presence of Ca2+ insulin exocytosis was further potentiated. By using a I-125-radiolabeled photoactivated cross-linking Rab3A effector domain peptide, we identified a cytosolic protein doublet (REEF-1 and REEP-2), which specifically interacted with the Rab3A effector domain. Competitive inhibition studies revealed this protein-protein interaction to be at a concentration equivalent to that required for Rab3A effector domain peptides to trigger insulin exocytosis (K-i, 6-8 mu M) Furthermore, under basal secretory conditions REEF-1 and -2 were membrane associated, but upon stimulation of exocytosis they were released into a cytosolic fraction. Our results suggest that REEF-I and -2 are part of the regulated exocytotic machinery, and their dissociation upon stimulation of hormone release (likely from a protein complex) may be essential to the mechanism that triggers regulated exocytosis in pancreatic beta-cells.	BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,EP JOSLIN RES LAB,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; BOSTON UNIV,SCH MED,DEPT DIABET & METAB,BOSTON,MA 02118	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Boston University			; Corkey, Barbara/E-7712-2015	Deeney, Jude/0000-0003-0988-9419; Corkey, Barbara/0000-0002-5467-1630	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047919, R37DK035914, R01DK035914, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35914, DK47919, DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; LI GD, 1993, FEBS LETT, V327, P145, DOI 10.1016/0014-5793(93)80159-R; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REGAZZI R, 1992, EUR J BIOCHEM, V208, P729, DOI 10.1111/j.1432-1033.1992.tb17241.x; REGAZZI R, 1989, J BIOL CHEM, V264, P9939; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; RICHMOND J, 1993, FEBS LETT, V326, P124, DOI 10.1016/0014-5793(93)81775-U; ROEP BO, 1990, NATURE, V345, P632, DOI 10.1038/345632a0; SENYSHYN J, 1992, FEBS LETT, V309, P41, DOI 10.1016/0014-5793(92)80735-Y; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STORER AC, 1976, BIOCHEM J, V159, P1; VALLAR L, 1987, J BIOL CHEM, V262, P5049; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WILLIAMS KP, 1993, J BIOL CHEM, V268, P5361; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	42	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27987	27991						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961732				2022-12-25	WOS:A1994PV77200035
J	SIEBENLIST, KR; MOSESSON, MW				SIEBENLIST, KR; MOSESSON, MW			PROGRESSIVE CROSS-LINKING OF FIBRIN GAMMA-CHAINS INCREASES RESISTANCE TO FIBRINOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR-SOLUBLE COMPLEXES; FACTOR-XIII CONCENTRATIONS; DEEP-VEIN THROMBOSIS; CROSSLINKED FIBRIN; ALPHA-2-PLASMIN INHIBITOR; PLASMIC DEGRADATION; SUBUNIT STRUCTURE; LIGHT-SCATTERING; STABILIZING FACTOR; FIBRINOPEPTIDE-B	In the presence of plasma transglutaminase (factor XIIIa) fibrin first undergoes intermolecular covalent cross-linking between its gamma chains to create gamma dimers followed by slower cross-linking among its alpha chains to form alpha polymers. Progressive cross-linking of gamma chain dimers occurs at the slowest rate, resulting in gamma trimers and gamma tetramers (''gamma multimers''). Most studies indicate that cross-linked fibrin clots become resistant to fibrinolysis, but the basis for this event is not clear. In this study, we explored the role of gamma chain multimerization compared with alpha polymerization as causal factors in time-dependent development of resistance to fibrinolysis. Fibrin clots prepared from native (intact) fibrinogen were incubated for up to 120 h at near physiological ionic strength and a factor XIIIa level approximating that in plasma. These clots were lysed by plasmin at rates that were inversely proportional to the level of gamma multimers, which increased progressively with the time of incubation. In contrast, fibrin cross-linked at high ionic strength (a condition under which only gamma dimers and alpha polymers form) or fibrin formed in the absence of factor XIII showed no time dependent decrease in lysis rates. Fibrin cross-linked for a fixed time period with increasing amounts of factor XIIIa contained gamma multimer levels that were proportional to the factor XIIIa concentration and lysed at rates that were inversely proportional to the gamma multimer level. Furthermore, cross-linked fibrin formed from fibrinogen fraction I-9, which has limited potential for alpha polymerization, showed the same reduction in the lysis rate as native cross-linked fibrin. These findings indicate that development of resistance to fibrinolysis of cross-linked fibrin is not measurably dependent upon gamma dimer or alpha polymer formation but develops solely as a function of gamma multimerization.	MARQUETTE UNIV, SCH DENT, DEPT BASIC HLTH SCI, MILWAUKEE, WI 53233 USA	Marquette University	SIEBENLIST, KR (corresponding author), UNIV WISCONSIN, SINAI SAMARITAN MED CTR,SCH MED,WINTER RES BLDG, 836 N 12TH ST, MILWAUKEE CLIN CAMP, MILWAUKEE, WI 53233 USA.				NHLBI NIH HHS [HL-47000] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047000] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKJAERSIG N, 1977, THROMB HAEMOSTASIS, V38, P524, DOI 10.1055/s-0038-1651859; AOKI N, 1993, THROMB HAEMOSTASIS, V70, P376; ASTEDT B, 1974, SURG GYNECOL OBSTET, V139, P387; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; BROMMER EJP, 1992, BLOOD COAGUL FIBRIN, V3, P717, DOI 10.1097/00001721-199212000-00003; CARR ME, 1977, BIOPOLYMERS, V16, P1, DOI 10.1002/bip.1977.360160102; CHEN R, 1969, P NATL ACAD SCI USA, V63, P420, DOI 10.1073/pnas.63.2.420; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; DOOLITTL.RF, 1973, THROMB DIATH HAEMOST, P155; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; FERRY JD, 1952, P NATL ACAD SCI USA, V38, P566, DOI 10.1073/pnas.38.7.566; FINLAYSON J S, 1973, Thrombosis Research, V2, P467, DOI 10.1016/0049-3848(73)90001-7; FINLAYSON JS, 1963, BIOCHEMISTRY-US, V2, P42, DOI 10.1021/bi00901a010; FINLAYSON JS, 1972, J BIOL CHEM, V247, P5220; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOWLER WE, 1981, P NATL ACAD SCI-BIOL, V78, P4872, DOI 10.1073/pnas.78.8.4872; FRANCIS CW, 1987, THROMB HAEMOSTASIS, V57, P110; FRANCIS CW, 1987, J CLIN INVEST, V80, P1459, DOI 10.1172/JCI113226; FRANCIS CW, 1980, BLOOD, V56, P456; FRANCIS CW, 1980, J CLIN INVEST, V66, P1033, DOI 10.1172/JCI109931; FRANCIS CW, 1988, BLOOD, V71, P1361; GAFFNEY PJ, 1983, ANN NY ACAD SCI, V408, P407, DOI 10.1111/j.1749-6632.1983.tb23261.x; GAFFNEY PJ, 1973, BIOCHIM BIOPHYS ACTA, V295, P308, DOI 10.1016/0005-2795(73)90098-6; GAFFNEY PJ, 1980, THROMB RES, V20, P647, DOI 10.1016/0049-3848(80)90153-X; GAFFNEY PJ, 1979, THROMB RES, V14, P85, DOI 10.1016/0049-3848(79)90027-6; GLADNER JA, 1983, THROMB RES, V30, P273, DOI 10.1016/0049-3848(83)90081-6; GORMSEN J, 1967, ARCH BIOCHEM BIOPHYS, V120, P654, DOI 10.1016/0003-9861(67)90531-0; HANTGAN R, 1983, ANN NY ACAD SCI, V408, P344, DOI 10.1111/j.1749-6632.1983.tb23256.x; HANTGAN R, 1980, THROMB HAEMOSTASIS, V44, P119; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; HAVERKATE F, 1975, THROMB DIATH HAEMOST, V34, P584; HAVERKATE F, 1977, THROMB RES, V10, P803, DOI 10.1016/0049-3848(77)90137-2; HENDERSON KW, 1969, BRIT J HAEMATOL, V17, P445, DOI 10.1111/j.1365-2141.1969.tb01392.x; HERMANS J, 1982, SEMIN THROMB HEMOST, V8, P11, DOI 10.1055/s-2007-1005039; HESS H, 1967, 1966 S THROMB THER M, P1; HEWAT EA, 1983, J MOL BIOL, V170, P203, DOI 10.1016/S0022-2836(83)80233-2; ICHINOSE A, 1982, BIOCHIM BIOPHYS ACTA, V706, P158, DOI 10.1016/0167-4838(82)90482-4; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KRAKOW W, 1972, J MOL BIOL, V71, P95, DOI 10.1016/0022-2836(72)90403-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LOEWY AG, 1961, J BIOL CHEM, V236, P2625; LORAND J, 1966, NATURE, V210, P1273, DOI 10.1038/2101273a0; Lorand L., 1970, METHOD ENZYMOL, V19, P770; MARDER VJ, 1977, J LAB CLIN MED, V89, P1018; MATACIC S, 1968, BIOCHEM BIOPH RES CO, V30, P356, DOI 10.1016/0006-291X(68)90750-X; MCDONAGH RP, 1971, BRIT J HAEMATOL, V21, P323, DOI 10.1111/j.1365-2141.1971.tb03444.x; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MIRSHAHI M, 1991, J LAB CLIN MED, V117, P274; Mosesson M W, 1976, Prog Hemost Thromb, V3, P61; MOSESSON MW, 1966, BIOCHEMISTRY-US, V5, P2829, DOI 10.1021/bi00873a008; MOSESSON MW, 1972, J BIOL CHEM, V247, P5223; MOSESSON MW, 1963, J LAB CLIN MED, V62, P663; MOSESSON MW, 1989, P NATL ACAD SCI USA, V86, P1113, DOI 10.1073/pnas.86.4.1113; MOSESSON MW, 1972, J BIOL CHEM, V247, P5210; NIEUWENHUIZEN W, 1982, BIOCHIM BIOPHYS ACTA, V707, P190, DOI 10.1016/0167-4838(82)90349-1; NIEUWENHUIZEN W, 1981, BIOCHIM BIOPHYS ACTA, V667, P321, DOI 10.1016/0005-2795(81)90198-7; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; PIZZO SV, 1973, J BIOL CHEM, V248, P4574; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; PURVES LR, 1978, THROMB RES, V12, P473, DOI 10.1016/0049-3848(78)90318-3; RAMPLING MW, 1978, THROMB RES, V12, P287, DOI 10.1016/0049-3848(78)90299-2; REGANON E, 1978, THROMB HAEMOSTASIS, V40, P368; Robbins K C, 1976, Methods Enzymol, V45, P257; Robbins K. C., 1970, METHOD ENZYMOL, V19, P184; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SAKATA Y, 1984, BLOOD, V63, P1393; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SEAMAN AJ, 1976, ANGIOLOGY, V27, P549, DOI 10.1177/000331977602701001; SHAINOFF JR, 1991, J BIOL CHEM, V266, P6429; SHAINOFF JR, 1983, ANN NY ACAD SCI, V408, P254, DOI 10.1111/j.1749-6632.1983.tb23249.x; SHAINOFF JR, 1979, SCIENCE, V204, P200, DOI 10.1126/science.155308; SHARP JJ, 1972, FEBS LETT, V25, P334, DOI 10.1016/0014-5793(72)80517-9; SIEBENLIST KR, 1992, BIOCHEMISTRY-US, V31, P936, DOI 10.1021/bi00118a040; STRYER L, 1963, NATURE, V197, P793, DOI 10.1038/197793a0; THEISS W, 1983, ANGIOLOGY, V34, P61, DOI 10.1177/000331978303400108; TRANTHANG C, 1984, J CLIN INVEST, V74, P2009, DOI 10.1172/JCI111623; UCHINO R, 1991, FIBRINOLYSIS, V5, P93, DOI 10.1016/0268-9499(91)90049-A; VANGIEZEN JJJ, 1993, BLOOD COAGUL FIBRIN, V4, P869, DOI 10.1097/00001721-199304060-00002; WEBER K, 1969, J BIOL CHEM, V244, P4406; WILLIAMS RC, 1981, J MOL BIOL, V150, P399, DOI 10.1016/0022-2836(81)90555-6; WILLIAMS RC, 1983, ANN NY ACAD SCI, V408, P180, DOI 10.1111/j.1749-6632.1983.tb23244.x	85	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28414	28419						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961782				2022-12-25	WOS:A1994PV77200094
J	GOORMAGHTIGH, E; VIGNERON, L; SCARBOROUGH, GA; RUYSSCHAERT, JM				GOORMAGHTIGH, E; VIGNERON, L; SCARBOROUGH, GA; RUYSSCHAERT, JM			TERTIARY CONFORMATIONAL-CHANGES OF THE NEUROSPORA-CRASSA PLASMA-MEMBRANE H+-ATPASE MONITORED BY HYDROGEN-DEUTERIUM EXCHANGE KINETICS - A FOURIER-TRANSFORM INFRARED-SPECTROSCOPY APPROACH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; SARCOPLASMIC-RETICULUM; CIRCULAR-DICHROISM; E1->E2 TRANSITION; CATALYTIC CYCLE; PROTEINS; BINDING; MODEL	Attenuated total reflection Fourier transform infrared spectroscopy of hydrated films of the Neurospora crassa plasma membrane H+-ATPase has been used to monitor the alpha-helix and beta-sheet contents and amide hydrogen exchange rates of the enzyme in the absence of ligands or locked in several stages of the enzyme catalytic cycle by MgADP, Mg-vanadate, and MgATP-vanadate. No difference larger than 2% was found in the alpha-helix or beta-sheet content of the H+-ATPase in different conformational states. However, when the rate of hydrogen/deuterium exchange monitored by the evolution of the area of amide II and amide II' is decomposed into three components, the number of amide protons characterized by a short exchange rate (1.1 min) falls from 38% of the protein amide protons (or 37% in the presence of Mg2+ alone) to 24-27% in the presence of Mg-vanadate and MgATP-vanadate and to 19% in the presence of MgADP. These results suggest that the conformational changes known to occur when the H+-ATPase interacts with the above ligands are predominantly tertiary structure changes.	UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	GOORMAGHTIGH, E (corresponding author), FREE UNIV BRUSSELS, CHIM PHYS MACROMOLEC INTERFACES LAB, ULB CAMPUS PLAINE, CP 206-2, BD TRIOMPHE, B-1050 BRUSSELS, BELGIUM.			Goormaghtigh, Erik/0000-0002-2071-2262	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024784, R55GM024784] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24784] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; ADDISON R, 1982, J BIOL CHEM, V257, P421; AMORY A, 1982, J BIOL CHEM, V257, P4723; ARRONDO JLR, 1987, J BIOL CHEM, V262, P9037; BARTH A, 1991, BIOCHIM BIOPHYS ACTA, V1057, P115, DOI 10.1016/S0005-2728(05)80091-X; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BROOKER RJ, 1983, J BIOL CHEM, V258, P222; BUCHET R, 1991, BIOCHIM BIOPHYS ACTA, V1068, P201, DOI 10.1016/0005-2736(91)90211-P; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CHADWICK CC, 1987, ARCH BIOCHEM BIOPHYS, V252, P348, DOI 10.1016/0003-9861(87)90041-5; CHETVERIN AB, 1986, J BIOL CHEM, V260, P7817; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; CSERMELY P, 1987, BIOCHEM J, V241, P663, DOI 10.1042/bj2410663; DEMEL RA, 1990, BIOCHIM BIOPHYS ACTA, V1027, P155, DOI 10.1016/0005-2736(90)90079-4; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; FETTIPLACE R, 1980, PHYSIOL REV, V60, P510, DOI 10.1152/physrev.1980.60.2.510; Finkelstein A., 1987, WATER MOVEMENT LIPID; Fringeli U P, 1981, Mol Biol Biochem Biophys, V31, P270; GOORMAGHTIGH E, 1993, BIOCHEMISTRY-US, V32, P6104, DOI 10.1021/bi00074a023; GOORMAGHTIGH E, 1986, J BIOL CHEM, V261, P7466; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; GRESALFI TJ, 1984, J BIOL CHEM, V259, P2622; Harrick N.J., 1967, INTERNAL REFLECTION; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; HENNESSEY JP, 1988, J BIOL CHEM, V263, P3123; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9600, DOI 10.1021/bi00088a012; Kim P S, 1986, Methods Enzymol, V131, P136; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDALA SM, 1988, J BIOL CHEM, V263, P15122; ROSENBERG A, 1986, METHOD ENZYMOL, V127, P630; SCARBOROUGH GA, 1984, J BIOL CHEM, V259, P9109; SCARBOROUGH GA, 1985, MICROBIOL REV, V49, P214, DOI 10.1128/MMBR.49.3.214-231.1985; SCARBOROUGH GA, 1992, MOL ASPECTS MEMBRANE, P117; SCARBOROUGH GA, 1988, METHOD ENZYMOL, V157, P574; SCHINKEL JE, 1985, BIOCHEMISTRY-US, V24, P352, DOI 10.1021/bi00323a018; SMITH R, 1984, ANAL BIOCHEM, V138, P156, DOI 10.1016/0003-2697(84)90784-X; WOODWARD C, 1982, MOL CELL BIOCHEM, V48, P135, DOI 10.1007/BF00421225	41	72	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27409	27413						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961652				2022-12-25	WOS:A1994PV77100042
J	KINDREGAN, HC; ROSENBAUM, SE; OHNO, S; NILES, RM				KINDREGAN, HC; ROSENBAUM, SE; OHNO, S; NILES, RM			CHARACTERIZATION OF CONVENTIONAL PROTEIN-KINASE-C (PKC) ISOTYPE EXPRESSION DURING F9 TERATOCARCINOMA DIFFERENTIATION - OVEREXPRESSION OF PKC-ALPHA ALTERS THE EXPRESSION OF SOME DIFFERENTIATION-DEPENDENT GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; PHORBOL ESTER RECEPTOR; RETINOIC ACID; JUN EXPRESSION; STEM-CELLS; RAT-BRAIN; FOS; INDUCTION; GROWTH; TRANSCRIPTION	F9 teratocarcinoma is a useful model for studying early embryogenesis since these cells can differentiate into primitive or parietal endoderm under the influence of retinoic acid or retinoic acid and cyclic AMP, respectively. We have found that three isoforms of protein kinase C (PKC alpha, -beta, and -gamma) were expressed in undifferentiated stem cells. When the cells were treated with retinoic acid either alone or in the presence of cAMP for 120 h, PKC alpha mRNA and protein levels increased, whereas those of PKC beta and PKC gamma became undetectable. These changes began within 24 h of drug treatment and were complete by 48-72 h. In order to determine the functional significance of the induction of PKC alpha during F9 differentiation, we established two stable transfectants that overexpressed PKC alpha protein between 4- and 5-fold compared to wild type cells. Characterization of these cell lines revealed an altered pattern of expression of some of the markers of F9 differentiation. The clone that had the highest amount of PKC alpha protein constitutively expressed mRNA for type IV collagen and c-Jun, which are not normally expressed until 24-48 h of treatment with differentiation agents. In the other overexpressing clone, these markers were induced much faster than in wild type cells. The growth rate of both overexpressing clones was less than wild type cells, while the expression of the PKC beta protein in these clones was similar to the levels found in differentiated F9 cells. However, other markers of differentiation, including the cellular morphology and levels of pST6-135 and c-myc RNA, responded to agents identically in both wild type and PKC-alpha-overexpressing clones. Therefore, overexpression of PKC alpha is not sufficient to induce full differentiation of F9 cells. However, our data suggest that certain pathways that lead to the expression of differentiation-dependent genes are regulated by PKC alpha protein levels.	YOKOHAMA CITY UNIV,SCH MED,DEPT BIOL MOLEC,KAMAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	Yokohama City University	KINDREGAN, HC (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118, USA.		Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; FINKLESTEIN R, 1988, ONCOGENE RES, V3, P287; GOLDSTEIN B, 1990, J CELL PHYSIOL, V143, P205, DOI 10.1002/jcp.1041430202; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALLAHAN DE, 1991, INT J RADIAT ONCOL, V21, P1677, DOI 10.1016/0360-3016(91)90352-5; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRAFT AS, 1983, J BIOL CHEM, V258, P9178; Kuo J F, 1989, Adv Exp Med Biol, V255, P8; LEVINE RA, 1984, MOL CELL BIOL, V4, P2142, DOI 10.1128/MCB.4.10.2142; MUFSON RA, 1992, J IMMUNOL, V148, P1129; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NIINO YS, 1992, J BIOL CHEM, V267, P6158; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHNO S, 1987, NATURE, V325, P1611; OTTE AP, 1991, SCIENCE, V251, P570, DOI 10.1126/science.1990433; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; POWELL CT, 1992, P NATL ACAD SCI USA, V89, P147, DOI 10.1073/pnas.89.1.147; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROSENBAUM SE, 1992, ARCH BIOCHEM BIOPHYS, V294, P123, DOI 10.1016/0003-9861(92)90145-M; RUBIN E, 1992, CANCER RES, V52, P878; SAMBROOK J, 1989, MOL CLONING LABORATO, P1630; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SNOEK GT, 1986, DEV BIOL, V115, P282, DOI 10.1016/0012-1606(86)90249-6; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SPOSI NM, 1989, MOL CELL BIOL, V9, P2284, DOI 10.1128/MCB.9.5.2284; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1981, CELL, V24, P277, DOI 10.1016/0092-8674(81)90313-5; TAKEBE Y, 1988, MOL CELL BIOL, V8, P446; TANAKA Y, 1992, J BIOCHEM-TOKYO, V111, P265, DOI 10.1093/oxfordjournals.jbchem.a123747; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; YANG-YEN H-F, 1990, New Biologist, V2, P351; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	48	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27756	27761						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961696				2022-12-25	WOS:A1994PV77100092
J	GILLARDON, F; ESCHENFELDER, C; UHLMANN, E; HARTSCHUH, W; ZIMMERMANN, M				GILLARDON, F; ESCHENFELDER, C; UHLMANN, E; HARTSCHUH, W; ZIMMERMANN, M			DIFFERENTIAL REGULATION OF C-FOS, FOSB, C-JUN, JUNB, BCL-2 AND BAX EXPRESSION IN RAT SKIN FOLLOWING SINGLE OR CHRONIC ULTRAVIOLET-IRRADIATION AND IN-VIVO MODULATION BY ANTISENSE OLIGODEOXYNUCLEOTIDE SUPERFUSION	ONCOGENE			English	Article							PROGRAMMED CELL-DEATH; SUNBURN CELL; FOLLICULAR LYMPHOMA; GENE-EXPRESSION; PROTO-ONCOGENE; MESSENGER-RNA; VIRUS TYPE-1; DNA; APOPTOSIS; MOUSE	Single ultraviolet (u.v.) irradiation of mammalian cells in culture evokes the transcriptional activation of various proto-oncogenes, among them members of the fos/jun family which are known to play an important role in cell proliferation and differentiation. u.v. exposure of mammalian skin results in growth arrest and cell death followed by hyperproliferation of epidermal cells. To obtain information in vivo about a possible relationship between u.v.-induced proto-oncogene expression and cellular alterations, me have analysed the expression of c-fos, fosB, c-jun, junB, bcl-2 and bdx in rat epidermis after single and chronic u.v. irradiation. We present data demonstrating that the transcripts of these genes are constitutively expressed in the epidermis and that expression is differentially modulated by u.v. exposure, Single u.v. irradiation causes a rapid and sustained increase in c-jun, junB and c-fos mRNA and a decline in bcl-2 transcripts, whereas expression of bax remained unchanged. c-Fos and c-Jun immunoreactivity was localized throughout the epidermal cell layers 1.5 h after single irradiation, but restricted to basal cells at 48 h suggesting an involvement in both u.v.-induced apoptosis and hyperproliferation. 48 h after chronic exposure a significantly higher induction and a totally different pattern of epidermal proto-oncogene expression was detectable which may be associated with malignancy. Superfusion of rat skin with c-fos antisense oligodeoxynucleotides inhibited the increase in c-Fos immunolabeled epidermal cells 1.5 h after single u.v. irradiation demonstrating that antisense oligodeoxynucleotides are capable of penetrating mammalian skin and modulating the u.v. response in vivo. However, suppression of the early c-Fos activation did not significantly affect the formation of sunburn cells in the u.v.-exposed epidermis. Thus, c-Fos does not seem to play a major role in u.v.-induced apoptosis or other members of the fos/jun family may compensate for a loss in c-Fos.	HOECHST AG, GEN PHARMA RES G838, D-65926 FRANKFURT, GERMANY; UNIV HEIDELBERG, HAUT KLIN, D-69115 HEIDELBERG, GERMANY	Sanofi-Aventis; Ruprecht Karls University Heidelberg	GILLARDON, F (corresponding author), UNIV HEIDELBERG, INST PHYSIOL 2, INF 326, D-69120 HEIDELBERG, GERMANY.			Eschenfelder, Christoph/0000-0003-2766-2488				BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BHALLA K, 1992, BLOOD, V80, P2883; BLOCH W, 1991, BIOCHEMISTRY-US, V30, P2735, DOI 10.1021/bi00225a001; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; BRUNET S, 1990, J PHOTOCH PHOTOBIO B, V6, P431, DOI 10.1016/1011-1344(90)85116-E; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANNO K, 1981, PHOTOCHEM PHOTOBIOL, V34, P203; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dilworth D D, 1992, PCR Methods Appl, V1, P279; DONAWHO CK, 1991, CANCER METAST REV, V10, P177, DOI 10.1007/BF00049413; EPSTEIN JH, 1970, PHOTOCHEM PHOTOBIOL, V12, P57, DOI 10.1111/j.1751-1097.1970.tb06038.x; Ferre F, 1992, PCR Methods Appl, V2, P1; FISHER C, 1991, DEVELOPMENT, V111, P253; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GARMYN M, 1991, LAB INVEST, V65, P471; GILLARDON F, 1991, NEUROSCI LETT, V124, P144, DOI 10.1016/0304-3940(91)90080-D; GRASSILLI E, 1992, BIOCHEM BIOPH RES CO, V188, P1261, DOI 10.1016/0006-291X(92)91367-Y; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANADA K, 1991, J INVEST DERMATOL, V96, P838, DOI 10.1111/1523-1747.ep12474538; HERDEGEN T, 1991, J COMP NEUROL, V312, P1; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1989, CANCER RES, V49, P1687; IYER RP, 1990, J ORG CHEM, V55, P4693, DOI 10.1021/jo00302a039; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KULKA M, 1993, ANTIVIR RES, V20, P115, DOI 10.1016/0166-3542(93)90002-Z; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; MAI S, 1989, J CELL SCI, V94, P609; MARTIN SJ, 1991, INT J RADIAT BIOL, V59, P1001, DOI 10.1080/09553009114550891; MATTEUCCI MD, 1981, J AM CHEM SOC, V103, P3185, DOI 10.1021/ja00401a041; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; OLSEN WM, 1990, J INVEST DERMATOL, V94, P101, DOI 10.1111/1523-1747.ep12873961; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARRISH JA, 1979, DERMATOLOGY GENERAL, P957; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SAKAI M, 1989, CANCER RES, V49, P5633; Sambrook J, 1989, MOL CLONING LABORATO; SHAH G, 1993, CANCER RES, V53, P38; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; UHLMANN E, 1990, CHEM REV, V90, P544; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Weedon D, 1979, Am J Dermatopathol, V1, P133; YOUNG AR, 1987, PHOTODERMATOLOGY, V4, P127; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	59	71	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3219	3225						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936645				2022-12-25	WOS:A1994PM65800014
J	MARIN, MC; HSU, B; MEYN, RE; DONEHOWER, LA; ELNAGGAR, AK; MCDONNELL, TJ				MARIN, MC; HSU, B; MEYN, RE; DONEHOWER, LA; ELNAGGAR, AK; MCDONNELL, TJ			EVIDENCE THAT P53 AND BCL-2 ARE REGULATORS OF A COMMON CELL-DEATH PATHWAY IMPORTANT FOR IN-VIVO LYMPHOMAGENESIS	ONCOGENE			English	Article							WILD-TYPE P53; THYMOCYTE APOPTOSIS; LYMPHOID-TISSUES; BURKITT-LYMPHOMA; PROTEIN; MUTATIONS; GENE; ONCOGENES; HYPERPLASIA; PROGRESSION	Multistep lymphomagenesis involves the deregulation of oncogenes and inactivation of tumor suppressor genes resulting in altered rates of proliferation as well as apoptotic cell death in tumor cells. The contribution of bcl-2 and p53 to the regulation of cell death during lymphomagenesis is assessed using bcl-2-1g, p53 'knockout' (p53 KO), and p53 KO/bcl-2 hybrid mice. PCR-SSCP and DNA sequence analysis demonstrated that p53 somatic mutations are uncommon in lymphomas arising in bcl-2-Ig transgenic mice. Reduction in tumor latency was not observed in p53 KO/bcl-2 hybrid mice compared to p53 KO mice. Furthermore, overexpressed bcl-2 suppressed wild-type p53 associated apoptosis following gamma-radiation. These findings indicate that bcl-2 and p53 serve a suppressor and effector function, respectively, of a common cell death pathway. These findings also suggest that p53 somatic mutations provide no selective advantage during in vivo multistep lymphomagenesis in the context of bcl-2 gene deregulation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL RADIOTHERAPY,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DIV PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine			Marin, Maria C/G-1040-2010; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X	NATIONAL CANCER INSTITUTE [R01CA062597, R01CA054897] Funding Source: NIH RePORTER; NCI NIH HHS [CA62597, CA54897] Funding Source: Medline; NCRR NIH HHS [RR5511] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ASTER JC, 1992, AM J PATHOL, V141, P291; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARPER JW, 1993, CELL, V75, P805; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LIMPENS J, 1991, ONCOGENE, V6, P2271; LOCOCO F, 1993, BLOOD, V82, P2289; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCDONNELL TJ, 1993, TRANSGENE, V1, P47; MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424; MIYASHITA T, 1992, CANCER RES, V52, P5407; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORI N, 1992, BRIT J HAEMATOL, V81, P235, DOI 10.1111/j.1365-2141.1992.tb08213.x; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1992, CANCER METAST REV, V11, P141, DOI 10.1007/BF00048060; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OVERTON WR, 1988, CYTOMETRY, V9, P619, DOI 10.1002/cyto.990090617; SANDER CA, 1993, BLOOD, V82, P1994; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG YS, 1993, ONCOGENE, V8, P3427; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	53	78	81	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3107	3112						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936633				2022-12-25	WOS:A1994PM65800002
J	HANSEN, WJ; LINGAPPA, VR; WELCH, WJ				HANSEN, WJ; LINGAPPA, VR; WELCH, WJ			COMPLEX ENVIRONMENT OF NASCENT POLYPEPTIDE-CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEAT-SHOCK; CHLORAMPHENICOL ACETYLTRANSFERASE; CYTOPLASMIC CHAPERONIN; PROTEINS; ATP; TRANSLOCATION; TRANSLATION; SUBUNITS; TUBULIN; BINDING	Nascent polypeptides enter into high molecular weight complexes with other proteins during chain elongation in vitro and in vivo. The nature of these complexes was investigated using an in vitro translation system programmed with a single mRNA lacking a translational termination codon. Complexes containing nascent polypeptides (molecular mass < 20 kDa), the molecular chaperone hsp 73 and other unidentified proteins can be released from the translationally arrested polysomes by puromycin treatment. The apparent native molecular mass of the nascent chain binding complex was determined to be >700 kDa by gel-filtration analysis. Complexes between the nascent polypeptide and at least hsp 73 appear to be sensitive to (disrupted by) ATP. The presence of ATP also dramatically alters the sensitivity of the nascent polypeptide chains to digestion by exogenous protease. Collectively, our data indicate that there may be a cytoplasmic machinery, including hsp 70, which comprises a nascent polypeptide chain binding complex.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	HANSEN, WJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,BOX 0854,SAN FRANCISCO,CA 94143, USA.			Lingappa, Vishwanath R./0000-0003-0962-6571	NIGMS NIH HHS [R01 GM33551] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033551] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; BUTLER ET, 1982, J BIOL CHEM, V257, P5772; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; LINGAPPA JR, 1994, J CELL BIOL, V125, P99, DOI 10.1083/jcb.125.1.99; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MURRAY IA, 1988, BIOCHEM J, V252, P173, DOI 10.1042/bj2520173; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	26	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26610	26613						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929390				2022-12-25	WOS:A1994PQ93100006
J	NEWTON, DL; NICHOLLS, PJ; RYBAK, SM; YOULE, RJ				NEWTON, DL; NICHOLLS, PJ; RYBAK, SM; YOULE, RJ			EXPRESSION AND CHARACTERIZATION OF RECOMBINANT HUMAN EOSINOPHIL-DERIVED NEUROTOXIN AND EOSINOPHIL-DERIVED NEUROTOXIN-ANTI-TRANSFERRIN RECEPTOR SFV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN FV; RICIN-A-CHAIN; MONOCLONAL-ANTIBODIES; PSEUDOMONAS EXOTOXIN; FUSION PROTEINS; CYTOTOXIC RIBONUCLEASE; OVERLAP EXTENSION; ESCHERICHIA-COLI; IMMUNOTOXINS; BINDING	The gene for the human recombinant eosinophil-derived neurotoxin (rEDN) was synthesized and fused to the gene encoding a single chain antibody (sFv) to the human transferrin receptor (EDNsFv). Both rEDN and EDNsFv were expressed as insoluble proteins in inclusion bodies in Escherichia coli BL21(DE3). Following denaturation and renaturation, EDN and EDNsFv were partially purified by chromatography on heparin-Sepharose. Final purification of EDN was achieved by Sephadex G-100, whereas EDNsFv which contained a g-histidyl residue carboxyl terminus was highly purified using the metal chelate resin, Ni2+-nitriloacetic acid. Whereas the recombinant EDN had ribonuclease activity that was similar to the native protein, the fusion protein had enzymatic activity that was 6-13% that of native EDN. The fusion protein was able to bind to the human transferrin receptor. In contrast to rEDN that had no inherent cytotoxicity to human tumor cells, the EDNsFv fusion protein was cytotoxic to human leukemia cells that express the human transferrin receptor with an IC50, 0.2-1 nM. At 1.3 nM EDNsFv, no cytotoxicity was observed on cells that lack the human transferrin receptor. Free antibody to the human transferrin receptor, E6, inhibited the cytotoxicity of the EDNsFv. Human enzymes may be engineered to acquire cytotoxic properties by fusing them to antibodies. Thus, they may be candidates for the construction of immunofusion proteins that may be less immunogenic than immunotoxins containing bacterial- or plant-derived toxin moieties.	NINCDS, SURG NEUROL BRANCH, BIOCHEM SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; BATRA JK, 1991, MOL CELL BIOL, V11, P2200, DOI 10.1128/MCB.11.4.2200; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BRINKMANN U, 1992, P NATL ACAD SCI USA, V89, P3075, DOI 10.1073/pnas.89.7.3075; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; BUTTERWORTH AE, 1984, ADV PARASIT, V23, P143, DOI 10.1016/S0065-308X(08)60287-0; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; COLCHER D, 1990, JNCI-J NATL CANCER I, V82, P1191, DOI 10.1093/jnci/82.14.1191; COVELL DG, 1986, CANCER RES, V46, P3969; DARZYNKIEWICZ Z, 1988, CELL TISSUE KINET, V21, P169, DOI 10.1111/j.1365-2184.1988.tb00855.x; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GRANTHAM R, 1981, NUCLEIC ACIDS RES, V9, pR43; HEYLIGEN H, 1985, FED PROC, V44, P787; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOOGENBOOM HR, 1990, J IMMUNOL, V144, P3211; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUSTON JS, 1991, METHOD ENZYMOL, V203, P46; JOHNSON S, 1991, METHOD ENZYMOL, V203, P88; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KNAPPIK A, 1993, BIO-TECHNOL, V11, P77, DOI 10.1038/nbt0193-77; MILENIC DE, 1991, CANCER RES, V51, P6363; NEVILLE DM, 1982, IMMUNOL REV, V62, P75, DOI 10.1111/j.1600-065X.1982.tb00390.x; NEWTON DL, 1992, J BIOL CHEM, V267, P19572; NEWTON DL, 1994, J NEUROSCI, V14, P538; NICHOLLS PJ, 1993, J BIOL CHEM, V268, P5302; PAI LH, 1993, EUR J CANCER, V29A, P1606, DOI 10.1016/0959-8049(93)90306-Z; Rybak S.M., 1993, DRUG DELIV, V1, P3; RYBAK SM, 1992, P NATL ACAD SCI USA, V89, P3165, DOI 10.1073/pnas.89.8.3165; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; RYBAK SM, 1991, IMMUNOL ALLERGY CLIN, V11, P359; SAXENA SK, 1992, J BIOL CHEM, V267, P21982; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; SHEALY D, 1990, Journal of Nuclear Medicine, V31, P776; SKERRA A, 1991, PROTEIN ENG, V4, P971, DOI 10.1093/protein/4.8.971; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SOLERRODRIGUEZ AM, 1993, EXP CELL RES, V206, P227, DOI 10.1006/excr.1993.1142; SORRENTINO S, 1992, J BIOL CHEM, V267, P14859; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTHERLAND R, 1987, CANCER RES, V47, P1627; TAI MS, 1990, BIOCHEMISTRY-US, V29, P8024, DOI 10.1021/bi00487a005; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TEPPER RI, 1992, SCIENCE, V257, P548, DOI 10.1126/science.1636093; WU YN, 1993, J BIOL CHEM, V268, P10686; YAMASHITA K, 1986, ARCH BIOCHEM BIOPHYS, V250, P263, DOI 10.1016/0003-9861(86)90725-3; YOKOTA T, 1992, CANCER RES, V52, P3402; YOULE RJ, 1993, CRIT REV THER DRUG, V10, P1	48	78	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26739	26745						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929408				2022-12-25	WOS:A1994PQ93100027
J	FU, DX; SINE, SM				FU, DX; SINE, SM			COMPETITIVE ANTAGONISTS BRIDGE THE ALPHA-GAMMA SUBUNIT INTERFACE OF THE ACETYLCHOLINE-RECEPTOR THROUGH QUATERNARY AMMONIUM-AROMATIC INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; RESIDUES; SITE; IDENTIFICATION; SELECTIVITY; CURARE	We recently demonstrated that conserved tyrosines Tyr(198) of the alpha subunit and Tyr(117) of the gamma subunit of the acetylcholine receptor stabilize binding of the curariform antagonist dimethyl-d-tubocurarine (DMT). To test the hypothesis that DMT interacts directly with these tyrosines, and therefore bridges the alpha-gamma subunit interface, we introduced point mutations into these key positions and expressed one or both mutant subunits in alpha(2) beta gamma(2) acetylcholine receptors in 293 HEK cells. Binding of DMT, measured by competition against the initial rate of I-125-alpha-bungarotoxin binding, shows high affinity for aromatic mutations, reduced affinity for polar mutations, and lowest affinity for arginine mutations. Similar side chain dependences were observed for both Tyr(alpha 198) and Tyr(gamma 117), indicating interaction of these residues with two symmetrical chemical groups in DMT. Two more bisquaternary antagonists, pancuronium and gallamine, show side chain dependences similar to that of DMT, indicating that the primary stabilizing interactions are aromatic-quaternary in both subunits. For the rigid ligands DMT and pancuronium, co-expressing mutant alpha and gamma subunits revealed independent contributions by each determinant, but strict independence was not observed for the flexible ligand gallamine. The free energy contributed by each aromatic quaternary interaction was estimated to be 2-4 kcal/mol, as determined from the free energy difference between aromatic and alkyl hydroxyl mutations. Our results suggest that bis-quaternary competitive antagonists bridge the alpha-gamma subunit interface by fitting into a pocket bounded by tyrosines at positions 198 of the alpha subunit and 117 of the gamma subunit.	MAYO CLIN & MAYO FDN, DEPT PHYSIOL & BIOPHYS, RECEPTOR BIOL LAB, ROCHESTER, MN 55905 USA	Mayo Clinic				Fu, Dax/0000-0002-2663-1316	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031744, R01NS031744] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31744] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; COHEN JB, 1991, J BIOL CHEM, V266, P23354; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; FILATOV GN, 1993, MOL PHARMACOL, V44, P237; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GAO J, 1993, BIOPHYS J, V65, P43, DOI 10.1016/S0006-3495(93)81031-2; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; KAO P, 1986, J BIOL CHEM, V259, P286; LAU FTK, 1994, J MOL BIOL, V236, P1049, DOI 10.1016/0022-2836(94)90011-6; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; PAULING P, 1973, CHEM-BIOL INTERACT, V6, P351, DOI 10.1016/0009-2797(73)90056-2; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1981, J BIOL CHEM, V256, P6692; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107	22	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26152	26157						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929328				2022-12-25	WOS:A1994PQ93000034
J	VENABLE, ME; BLOBE, GC; OBEID, LM				VENABLE, ME; BLOBE, GC; OBEID, LM			IDENTIFICATION OF A DEFECT IN THE PHOSPHOLIPASE-D DIACYLGLYCEROL PATHWAY IN CELLULAR SENESCENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN-DIPLOID FIBROBLASTS; DNA-SYNTHESIS; CELLS; DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; PHOSPHORYLATION; PROLIFERATION; HYDROLYSIS	Normal cells become senescent in culture after a limited number of population doublings becoming unable to respond to mitogens. This raises the possibility of defects in mitogenic signaling pathways in cellular senescence. In contrast to young human diploid fibroblasts (HDF), their senescent counterparts failed to undergo protein kinase C translocation in response to serum stimulation. On the other hand, phorbol 12-myristate 13-acetate was equally active in inducing protein kinase C translocation in young and senescent HDF. This suggested a defect in generation of the endogenous activator of protein kinase C, diacylglycerol. Stimulation of young HDF with serum resulted in 3-4-fold generation of diacylglycerol (DAG). In contrast, senescent cells displayed insignificant DAG: formation in response to serum. The mechanism of DAG generation was investigated next. In young HDF, serum induced a 5-fold activation of the phospholipase D (PLD) pathway as measured by the incorporation of exogenous ethanol into phosphatidylethanol, which is a measure of the transphosphatidylation reaction of PLD. In contrast, PLD in senescent cells was not activated by serum. Since senescent cells demonstrate significant elevations in the level of endogenous ceramide, the impact of ceramide on the PLD/DAG pathway was also investigated. A soluble analog of ceramide, C-6-ceramide, was found to inhibit serum-stimulated DAG accumulation and PLD activation in young cells. These data demonstrate for the first time a defect in PLD activation in cellular senescence and suggest that ceramide may be responsible for the inhibition of this pathway.	DUKE UNIV,MED CTR,DEPT MED,DIV GERIATR,DURHAM,NC 27710; DURHAM VET ADM GERIATR RES EDUC & CLIN CTR,DURHAM,NC 27710	Duke University; Geriatric Research Education & Clinical Center			Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; obeid, lina/0000-0002-0734-0847; Venable, Mark/0000-0003-1708-9163	NATIONAL INSTITUTE ON AGING [T32AG000029] Funding Source: NIH RePORTER; NIA NIH HHS [5T32AG00029] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASOAKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKSFREDERICH KM, 1993, EXP CELL RES, V205, P412, DOI 10.1006/excr.1993.1106; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DETATA V, 1993, EXP CELL RES, V205, P261, DOI 10.1006/excr.1993.1085; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KIM MY, 1991, J BIOL CHEM, V266, P484; KIRKLAND JL, 1992, CLIN BIOCHEM, V25, P61, DOI 10.1016/0009-9120(92)80047-K; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LISCOVITCH M, 1991, BIOCHEM SOC T, V19, P402, DOI 10.1042/bst0190402; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; PREISS J, 1986, J BIOL CHEM, V261, P8597; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SMITH JR, 1992, AM J CLIN NUTR, V55, P1215; STEIN GH, 1986, P NATL ACAD SCI USA, V83, P9030, DOI 10.1073/pnas.83.23.9030; SUBLETTE E, 1993, NEUROSCI LETT, V159, P175, DOI 10.1016/0304-3940(93)90827-8; WADHWA R, 1993, J BIOL CHEM, V268, P22239; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	32	103	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26040	26044						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929315				2022-12-25	WOS:A1994PQ93000019
J	MOLINALOPEZ, JA; GOVANTES, F; SANTERO, E				MOLINALOPEZ, JA; GOVANTES, F; SANTERO, E			GEOMETRY OF THE PROCESS OF TRANSCRIPTION ACTIVATION AT THE SIGMA-54-DEPENDENT NIFH PROMOTER OF KLEBSIELLA-PNEUMONIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; NITROGEN-FIXATION GENES; ESCHERICHIA-COLI; RNA-POLYMERASE; POSITIONAL REQUIREMENTS; ALPHA-SUBUNIT; TOL PLASMID; DNA; PROTEIN; NIFA	The Klebsiella pneumoniae nifH promoter is very strictly controlled by nitrogen availability and highly dependent on sigma 54 and integration host factor (IHF) for expression. This promoter region has been used to examine the role of IHF in the activation of transcription from sigma 54-dependent promoters and to analyze the positional restrictions which may exist for an activation mechanism from distant sites such as this one. By functionally replacing the binding site of MF by sequence-directed curved DNA fragments, it has been shown that the role of IHF in stimulating transcription is structural; it brings the molecules directly involved in the process into close proximity. Unlike other promoter regions with an activation mechanism at a distance, this IHF-dependent promoter requires a precise geometry for efficient transcription. In this sense, it resembles an activation mechanism from near sites. However, alternative functional structures which are very different from the native one can be isolated.	UNIV SEVILLA,FAC BIOL,DEPT GENET,E-41080 SEVILLE,SPAIN	University of Sevilla			Govantes, Fernando/E-4790-2017; Santero, Eduardo/K-6510-2014	Govantes, Fernando/0000-0002-4866-6798; Santero, Eduardo/0000-0002-6111-7160				ABRIL MA, 1993, MOL GEN GENET, V239, P281, DOI 10.1007/BF00281629; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; BUCK M, 1986, NATURE, V320, P374, DOI 10.1038/320374a0; BUCK M, 1987, MOL MICROBIOL, V1, P243, DOI 10.1111/j.1365-2958.1987.tb00518.x; BUCK M, 1987, MOL GEN GENET, V210, P140, DOI 10.1007/BF00337770; CALI BM, 1989, J BACTERIOL, V171, P2666, DOI 10.1128/jb.171.5.2666-2672.1989; CLAVERIEMARTIN F, 1992, J MOL BIOL, V227, P996, DOI 10.1016/0022-2836(92)90516-M; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GILADI H, 1992, J MOL BIOL, V227, P985, DOI 10.1016/0022-2836(92)90514-K; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LEE HS, 1993, P NATL ACAD SCI USA, V90, P2266, DOI 10.1073/pnas.90.6.2266; LEE HS, 1993, J BACTERIOL, V175, P2479, DOI 10.1128/JB.175.8.2479-2482.1993; MACNEIL T, 1978, J BACTERIOL, V134, P821, DOI 10.1128/JB.134.3.821-829.1978; Miller JH., 1972, EXPT MOL GENETICS; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MORETT E, 1988, P NATL ACAD SCI USA, V85, P9401, DOI 10.1073/pnas.85.24.9401; MULLIN DA, 1993, J BACTERIOL, V175, P2067, DOI 10.1128/JB.175.7.2067-2076.1993; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; OW DW, 1983, NATURE, V301, P307, DOI 10.1038/301307a0; POPHAM D, 1991, J BIOL CHEM, V266, P19510; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REITZER LJ, 1989, J BACTERIOL, V171, P5512, DOI 10.1128/jb.171.10.5512-5522.1989; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SANTERO E, 1989, P NATL ACAD SCI USA, V86, P7346, DOI 10.1073/pnas.86.19.7346; SANTERO E, 1992, J MOL BIOL, V227, P602, DOI 10.1016/0022-2836(92)90211-2; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; THONY B, 1989, FEMS MICROBIOL LETT, V63, P341; VALENTINHANSEN P, 1986, EMBO J, V5, P2015, DOI 10.1002/j.1460-2075.1986.tb04458.x; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	41	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25419	25425						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929239				2022-12-25	WOS:A1994PQ49100032
J	BONNER, G; LAFER, EM; SOUSA, R				BONNER, G; LAFER, EM; SOUSA, R			CHARACTERIZATION OF A SET OF T7 RNA-POLYMERASE ACTIVE-SITE MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; BACTERIOPHAGE-T7; DNA; PROCESSIVITY; MUTATIONS	We have evaluated the elongation rates, processivities, and abortive transcription characteristics of a set of T7 RNA polymerase mutants that map to the polymerase active site. The effects of these mutations on transcription are complex: they cause decreases in activity and processivity during both the processive and abortive phases of transcription and exhibit disproportionate decreases in activity and processivity on poly(dA).poly(dT) or poly(dT) versus poly(dG).poly(dC) templates. They also exhibit an increase in the proportion of slippage dependent poly(G) transcript synthesis during the initial stages of transcription. It is shown that these multiple, distinct effects on transcription can be attributed to decreases in the mutant enzymes' phosphodiester bond formation rates. Estimates of the decreases in these rates are derived from the measured transcript elongation rates and processivities of the mutant enzymes.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,PROGRAM MOLEC MED,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio				Lafer, Eileen/0000-0002-0493-6522; Sousa, Rui/0000-0003-4314-121X				ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; BONNER G, 1994, J BIOL CHEM, V269, P25129; DELARUE M, 1990, J PROTEIN ENG, V10, P461; GOLOMB M, 1974, J BIOL CHEM, V249, P2858; GROSS L, 1992, J MOL BIOL, V228, P488, DOI 10.1016/0022-2836(92)90837-A; IKEDA RA, 1987, J BIOL CHEM, V262, P3790; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; McClure W R, 1980, Methods Enzymol, V64, P277; MOOKHTIAR KA, 1991, BIOCHEMISTRY-US, V30, P6305, DOI 10.1021/bi00239a032; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; OLLIS DL, 1985, NATURE, V313, P765; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; OSUMIDAVIS PA, 1994, J MOL BIOL, V237, P5, DOI 10.1006/jmbi.1994.1205; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SANKAR S, 1992, J BIOL CHEM, V267, P10168; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074	22	59	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25120	25128						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929200				2022-12-25	WOS:A1994PQ49000089
J	MACINTYRE, S; SAMOLS, D; DAILEY, P				MACINTYRE, S; SAMOLS, D; DAILEY, P			2 CARBOXYLESTERASES BIND C-REACTIVE PROTEIN WITHIN THE ENDOPLASMIC-RETICULUM AND REGULATE ITS SECRETION DURING THE ACUTE-PHASE RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCURONIDASE; MOLECULAR-CLONING; RAT-LIVER; TRANSMEMBRANE PROTEINS; NUCLEOTIDE-SEQUENCE; HEPATOMA-CELLS; KDEL RECEPTOR; ESTERASE; EGASYN; RETENTION	We have previously reported that C-reactive protein (CRP) is normally synthesized by rabbit hepatocytes at relatively low rates and is retained in the endoplasmic reticulum (ER), apparently by specific interaction with a 60-kDa lumenal ER protein. During the acute phase response to tissue injury, a marked increase in CRP synthesis is associated with a decrease in the CRP binding capacity of the 60-kDa protein, with accompanying rapid secretion of CRP. In the present studies, we purified two 60-kDa ER lumenal glycoproteins (referred to as gp60a and gp60b) capable of binding CRP. gp60b, though present at only 5% the level of gp60a, was found to account for 80% of the total CRP binding capacity. Amino-terminal amino acid sequence analysis and biochemical characterization identified gp60a and gp60b as two microsomal carboxylesterases previously reported by others to contain COOH-terminal ER retention signals (HIEL and HTEL). The CRP binding activities of gp60a and gp60b were found to be independent of their esterase activities. In animals undergoing the acute phase response, the levels of gp60a and gp60b were diminished by about 50%, but the CRP binding capacities were reduced by 4-6-fold for gp60a and 25-30-fold for gp60b. These findings indicate that CRP is normally retained within the ER via interaction with gp60a and gp60b, while during the acute phase response a decrease in the CRP binding affinity of these proteins, particularly gp60b, results in efficient secretion of CRP.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44109 USA	Case Western Reserve University	MACINTYRE, S (corresponding author), CASE WESTERN RESERVE UNIV, METROHLTH MED CTR, DEPT MED, 2500 METROHLTH DR, CLEVELAND, OH 44109 USA.				NIAMS NIH HHS [AR34313] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR034313, R23AR034313] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDRES DA, 1990, J BIOL CHEM, V265, P5952; CANONICO PG, 1977, AM J CLIN NUTR, V30, P1359, DOI 10.1093/ajcn/30.8.1359; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLD AM, 1964, BIOCHEMISTRY-US, V3, P783, DOI 10.1021/bi00894a009; GOTSCHLICH EC, 1965, P NATL ACAD SCI USA, V54, P558, DOI 10.1073/pnas.54.2.558; HU SI, 1986, BIOCHEMISTRY-US, V25, P7834, DOI 10.1021/bi00372a008; HU SI, 1988, J BIOL CHEM, V263, P1500; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORZA G, 1988, J BIOL CHEM, V263, P3486; KREJCI E, 1991, P NATL ACAD SCI USA, V88, P6647, DOI 10.1073/pnas.88.15.6647; KUSHNER I, 1961, J EXP MED, V114, P961, DOI 10.1084/jem.114.6.961; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LEDFORD BE, 1983, J BIOL CHEM, V258, P3304; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LI H, 1990, J BIOL CHEM, V265, P14732; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MACINTYRE SS, 1988, METHOD ENZYMOL, V163, P383; MACINTYRE SS, 1992, J CELL BIOL, V118, P253, DOI 10.1083/jcb.118.2.253; MACINTYRE SS, 1985, J BIOL CHEM, V260, P4169; MATSUSHIMA M, 1991, FEBS LETT, V293, P37, DOI 10.1016/0014-5793(91)81147-Z; MEDDA S, 1985, J BIOL CHEM, V260, P5802; MEDDA S, 1987, CELL, V50, P301, DOI 10.1016/0092-8674(87)90225-X; MENTLEIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P230, DOI 10.1016/0003-9861(84)90064-X; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOVAK EK, 1991, J BIOL CHEM, V266, P6377; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; OVNIC M, 1991, GENOMICS, V9, P344, DOI 10.1016/0888-7543(91)90263-E; OZOLS J, 1989, J BIOL CHEM, V264, P12533; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROBBI M, 1991, J BIOL CHEM, V266, P20498; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SCHEELE G, 1985, J BIOL CHEM, V260, P926; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SHIBATA F, 1993, GENOMICS, V17, P76, DOI 10.1006/geno.1993.1285; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YEO KT, 1985, J BIOL CHEM, V260, P7896; ZHEN LD, 1993, ARCH BIOCHEM BIOPHYS, V304, P402, DOI 10.1006/abbi.1993.1368	52	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24496	24503						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929114				2022-12-25	WOS:A1994PQ34600099
J	MULLER, EGD				MULLER, EGD			DEOXYRIBONUCLEOTIDES ARE MAINTAINED AT NORMAL LEVELS IN A YEAST THIOREDOXIN MUTANT DEFECTIVE IN DNA-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN RIBONUCLEOTIDE REDUCTASE; CELL-CYCLE REGULATION; AMINO-ACID SEQUENCE; RABBIT BONE-MARROW; SACCHAROMYCES-CEREVISIAE; ORNITHINE DECARBOXYLASE; ESCHERICHIA-COLI; BINDING ACTIVITY; GENE; EXPRESSION	Deletion of both thioredoxin genes TRX1 and TRX2 of Saccharomyces cerevisiae reduces the rate of DNA replication. This observation, originally determined by flow cytometry, was confirmed by radiochemical labeling of synchronized cultures. Since thioredoxin is a hydrogen donor to ribonucleotide reductase, a priori the inhibition of DNA synthesis was predicted to be caused by a reduction in the deoxyribonucleotide pools. However, the levels of TTP, dCTP, dATP, and dGTP were either unchanged or slightly greater in the thioredoxin mutant (3.2, 0.91, 1.4, and 1.21 pmol/10(6) cells, respectively) versus the wild-type culture (2.5, 0.91, 1.0, and 0.68 pmol/10(6) cells, respectively). An impact on ribonucleotide reduction was seen by an increased accumulation of RNR1 and RNR2 transcripts in the thioredoxin mutant (4.3-and 6.8-fold, respectively). Increased RNR expression did not reflect a general response of the DNA replication machinery. POL1 (DNA polymerase I) and CDC8 (thymidylate kinase) transcription were unaltered, while histone H2B transcripts actually decreased by half. Two alternative models incorporating these results are discussed. One suggests that thioredoxin reduces a multiprotein complex channeling nucleotides to the replication apparatus. The second proposes that thioredoxin regulates the tempo of DNA replication directly by activating a component of the replication machinery.			MULLER, EGD (corresponding author), UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA.			Muller, Eric/0000-0002-3915-4520	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045448] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45448] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERG A, 1989, J BIOL CHEM, V264, P12249; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BREEDEN L, 1991, GENE DEV, V5, P1183, DOI 10.1101/gad.5.7.1183; BROCKERHOFF SE, 1992, J CELL BIOL, V118, P619, DOI 10.1083/jcb.118.3.619; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; ECKSTEIN H, 1974, Z NATURFORSCH C, VC 29, P272; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; FLAMIGNI F, 1989, BIOCHEM J, V259, P111, DOI 10.1042/bj2590111; FONZI WA, 1987, J BIOL CHEM, V262, P10127; FONZI WA, 1989, J BIOL CHEM, V264, P18110; GAN ZR, 1992, BIOCHEM BIOPH RES CO, V187, P949, DOI 10.1016/0006-291X(92)91289-3; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HARTMAN H, 1993, P NATL ACAD SCI USA, V90, P2271, DOI 10.1073/pnas.90.6.2271; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HARVEY G, 1988, J CELL PHYSIOL, V134, P25, DOI 10.1002/jcp.1041340104; HIMAWAN JS, 1992, P NATL ACAD SCI USA, V89, P9774, DOI 10.1073/pnas.89.20.9774; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOPPER S, 1983, J BIOL CHEM, V258, P3453; HOPPER S, 1989, J BIOL CHEM, V264, P20438; KOHALMI SE, 1991, J MOL BIOL, V220, P933, DOI 10.1016/0022-2836(91)90364-C; LAMMERS M, 1984, EUR J BIOCHEM, V140, P281, DOI 10.1111/j.1432-1033.1984.tb08099.x; LI CG, 1994, NUCLEIC ACIDS RES, V22, P632, DOI 10.1093/nar/22.4.632; LIM CJ, 1985, J BACTERIOL, V161, P799, DOI 10.1128/JB.161.2.799-802.1985; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MATHEWS CK, 1986, EXP CELL RES, V162, P285, DOI 10.1016/0014-4827(86)90335-6; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCFARLAN SC, 1989, EUR J BIOCHEM, V179, P389, DOI 10.1111/j.1432-1033.1989.tb14565.x; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; MULLER EGD, 1989, J BIOL CHEM, V264, P4008; MULLER EGD, 1992, YEAST, V8, P117, DOI 10.1002/yea.320080206; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; NAKAMURA H, 1992, CANCER-AM CANCER SOC, V69, P2091, DOI 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X; OREDSSON SM, 1990, EUR J BIOCHEM, V190, P483, DOI 10.1111/j.1432-1033.1990.tb15599.x; PAYNE SM, 1982, ANAL BIOCHEM, V123, P151, DOI 10.1016/0003-2697(82)90636-4; POGOLOTTI AL, 1982, ANAL BIOCHEM, V126, P335, DOI 10.1016/0003-2697(82)90524-3; POON PP, 1994, J BIOL CHEM, V269, P8341; Reddy G P, 1993, Crit Rev Eukaryot Gene Expr, V3, P255; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; RUSSEL M, 1991, MOL MICROBIOL, V5, P1607, DOI 10.1111/j.1365-2958.1991.tb01907.x; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; SALZ HK, 1994, GENETICS, V136, P1075; Sambrook J, 1989, MOL CLONING LABORATO; SCLAFANI RA, 1984, P NATL ACAD SCI-BIOL, V81, P5821, DOI 10.1073/pnas.81.18.5821; Sherman F., 1986, METHODS YEAST GENETI; SHERWOOD PW, 1993, MOL CELL BIOL, V13, P28, DOI 10.1128/MCB.13.1.28; SIKORSKA M, 1990, BIOCHEM CELL BIOL, V68, P880, DOI 10.1139/o90-130; SRIVASTAVA VK, 1988, MUTAT RES, V200, P45, DOI 10.1016/0027-5107(88)90070-X; TAGAYA Y, 1990, MOL IMMUNOL, V27, P1279; TANAKA K, 1984, ANAL BIOCHEM, V139, P35, DOI 10.1016/0003-2697(84)90386-5; TONISSEN K, 1993, J BIOL CHEM, V268, P22485; WAGA S, 1994, J BIOL CHEM, V269, P10923; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WAWRA E, 1988, J BIOL CHEM, V263, P9908; WETTERAUER B, 1992, J BIOL CHEM, V267, P9895; WIEGAND M, 1989, J STEROID BIOCHEM, V32, P53, DOI 10.1016/0022-4731(89)90013-7; WU Y, 1994, J CELL BIOCHEM, V54, P32, DOI 10.1002/jcb.240540105; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAGLE K, 1990, MOL CELL BIOL, V10, P5553, DOI 10.1128/MCB.10.10.5553; ZHOU Z, 1992, GENETICS, V131, P851; ZHU GF, 1993, MOL CELL BIOL, V13, P1779, DOI 10.1128/MCB.13.3.1779	68	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24466	24471						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929110				2022-12-25	WOS:A1994PQ34600095
J	WANG, TW; LUO, Y; SMALL, GM				WANG, TW; LUO, Y; SMALL, GM			THE POX1 GENE ENCODING PEROXISOMAL ACYL-COA OXIDASE IN SACCHAROMYCES-CEREVISIAE IS UNDER THE CONTROL OF MULTIPLE REGULATORY ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; PROLIFERATION; TRANSCRIPTION; BINDING; PROTEIN; EXPRESSION; GAL4; SITE; ADR1	Transcription of POX1, the gene encoding peroxisomal acyl-CoA oxidase in the yeast Saccharomyces cerevisiae, is controlled by the carbon source given for cell growth. The gene is repressed in glucose, derepressed in glycerol, and induced in oleate. This regulation is controlled by cis-acting elements in the 5' region of the gene, which bind regulatory proteins. By deletion analysis and DNA band shift assays, we have characterized three such elements in the POX1 upstream sequence, two upstream repression sequences and an upstream activating sequence. Each was able to regulate the transcription of a heterologous gene construct iso-l-cyto chrome-c (CYC1)lacZ.	CUNY MT SINAI SCH MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KOVARI L, 1990, MOL CELL BIOL, V10, P5087, DOI 10.1128/MCB.10.10.5087; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; RAO MS, 1987, CARCINOGENESIS, V8, P631; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; Sambrook J, 1989, MOL CLONING LABORATO; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WANG TW, 1992, NUCLEIC ACIDS RES, V20, P3495, DOI 10.1093/nar/20.13.3495; YOO HS, 1989, MOL CELL BIOL, V9, P3231, DOI 10.1128/MCB.9.8.3231	24	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24480	24485						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929112				2022-12-25	WOS:A1994PQ34600097
J	GORDON, CL; SATHER, SK; CASJENS, S; KING, J				GORDON, CL; SATHER, SK; CASJENS, S; KING, J			SELECTIVE IN-VIVO RESCUE BY GROEL/ES OF THERMOLABILE FOLDING INTERMEDIATES TO PHAGE-P22 STRUCTURAL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TAIL-SPIKE PROTEIN; INCLUSION-BODY FORMATION; ESCHERICHIA-COLI; TAILSPIKE PROTEIN; MOLECULAR CHAPERONE; RIBULOSEBISPHOSPHATE CARBOXYLASE; LACTATE-DEHYDROGENASE; SCAFFOLDING PROTEIN; BETA-LACTAMASE	The in vivo conformational substrates of the GroE chaperonins have been difficult to identify, in part because of limited information on in vivo polypeptide chain folding pathways. Temperature-sensitive folding (tsf) mutants have been characterized for the coat protein and tailspike protein of phage P22. These mutations block intracellular folding at restrictive temperature by increasing the lability of folding intermediates without impairing the stability or function of the native state. Overexpression of GroEL/ES suppressed the defects of tsf mutants at 17 sites in the coat protein, by improving folding efficiency rather than assembly efficiency or protein stability. Immunoprecipitation experiments demonstrated that GroEL interacted transiently with newly synthesized mild-type coat protein and that this interaction was prolonged by the tsf mutations. Folding defects of the tailspike polypeptide chains were not suppressed. A fraction of the tsf mutant tailspike chains bound to GroEL but were inefficiently discharged. The results suggest that 1) thermolabile folding intermediates are natural substrates of GroEL/ES; 2) although GroEL may bind such intermediates for many proteins, the chaperoning function is limited to a subset of substrate proteins; and 3) a key reason for the heat-shock response may be to stabilize thermolabile folding intermediates at elevated temperatures.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV UTAH,MED CTR,DEPT CELLULAR VIRAL & MOLEC BIOL,SALT LAKE CITY,UT 84112	Massachusetts Institute of Technology (MIT); Utah System of Higher Education; University of Utah					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017980, R01GM017980] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17980] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANG D, 1991, J BIOL CHEM, V266, P24233; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; BOTSTEIN D, 1973, VIROLOGY, V49, P268; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CASJENS S, 1991, GENETICS, V127, P637; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHRUNYK BA, 1993, J BIOL CHEM, V268, P18053; COPPO A, 1973, J MOL BIOL, V76, P61, DOI 10.1016/0022-2836(73)90081-8; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; DONNELLY CE, 1992, J BACTERIOL, V174, P3133, DOI 10.1128/jb.174.10.3133-3139.1992; EPPLER K, 1991, VIROLOGY, V183, P519, DOI 10.1016/0042-6822(91)90981-G; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GORDON CL, 1993, J BIOL CHEM, V268, P9358; GORDON CL, 1994, GENETICS, V136, P427; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANN REV BIOCH, V62, P49; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KING J, 1978, CELL, V15, P551, DOI 10.1016/0092-8674(78)90023-5; KING J, 1974, NATURE, V251, P112, DOI 10.1038/251112a0; KING J, 1973, J MOL BIOL, V80, P697, DOI 10.1016/0022-2836(73)90205-2; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; REVEL HR, 1980, J VIROL, V33, P366, DOI 10.1128/JVI.33.1.366-376.1980; Sambrook J., 1989, MOL CLONING; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SMITH DH, 1980, GENETICS, V96, P331; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; SUGIHARA J, 1988, BIOCHEMISTRY-US, V27, P2872, DOI 10.1021/bi00408a031; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10658, DOI 10.1021/bi00091a016; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10839, DOI 10.1021/bi00091a040; TRUONG HTN, 1991, BIOCHEMISTRY-US, V30, P10722; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WINSTON F, 1979, J BACTERIOL, V137, P433, DOI 10.1128/JB.137.1.433-439.1979; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029; ZWICKL P, 1990, J STRUCT BIOL, V103, P197, DOI 10.1016/1047-8477(90)90037-D	87	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27941	27951						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961726				2022-12-25	WOS:A1994PV77200029
J	IKEBE, M; IKEBE, R; KAMISOYAMA, H; REARDON, S; SCHWONEK, JP; SANDERS, CR; MATSUURA, M				IKEBE, M; IKEBE, R; KAMISOYAMA, H; REARDON, S; SCHWONEK, JP; SANDERS, CR; MATSUURA, M			FUNCTION OF THE NH2-TERMINAL DOMAIN OF THE REGULATORY LIGHT-CHAIN ON THE REGULATION OF SMOOTH-MUSCLE MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN GIZZARD MUSCLE; VERTEBRATE NON-MUSCLE; PHOSPHORYLATION; CONFORMATION; KINASE; IDENTIFICATION; PROTEOLYSIS; MOLECULES; SEQUENCE; SUBFRAGMENT-1	The role of the NH2-terminal domain of the 20,000-dalton light chain on the regulatory function of smooth muscle myosin was studied by exchanging it in myosin with various mutant forms. The 10 S to 6 S conformational transition as well as the thick filament formation were significantly influenced by the deletion or substitution of the amino acid residues at the NH2-terminal side of the phosphorylation site (Ser(19)). Whereas the deletion of Ser(1)-Thr(10) did not significantly affect these functions, further deletion of Lys(11)-Arg(16) completely abolished the formation of 10 S conformation and induced thick filament formation. Among the residues in this region, Arg(13) and Arg(16) were most important for these functions since substitution of these residues by Glu or Ala significantly altered these functions. Similar substitutions of Lys(11) and Lys(12) also stabilized the 6 S conformation and thick filament formation but less effectively. While the 6 S conformation was stabilized, the deletion of NH2-terminal residues did not activate the actin-activated ATPase activity. This suggests that stabilization of the 6 S conformation is not directly coupled with activation of actomyosin ATPase activity but rather a more defined conformational change around the phosphorylation site is necessary for activation. Such a change also influences the 6 S to 10 S conformation and, therefore, the filament formation. To support this notion, substitution of Lys(11) and Lys(12) by Glu-Glu inhibited the phosphorylation-induced activation of actomyosin ATPase activity.	MEIJI MILK PROD CO LTD,CENT RES INST,TOKYO 189,JAPAN	Central Research Institute of Electric Power Industry - Japan; Meiji Holdings Co., Ltd.	IKEBE, M (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117, P01HL047530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47530, HL37117] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; CROSS RA, 1986, EMBO J, V5, P2637, DOI 10.1002/j.1460-2075.1986.tb04545.x; EVANS RM, 1988, FEBS LETT, V234, P73, DOI 10.1016/0014-5793(88)81306-1; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; Higashihara M, 1989, J BIOL CHEM, V264, P5218; HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1991, J BIOL CHEM, V266, P21339; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P2713, DOI 10.1021/bi00463a014; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKEBE M, 1988, J BIOL CHEM, V263, P6432; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; IKEBE M, 1993, 17TH C INT UN PHYS S, P79; ITO T, 1989, NATURE, V338, P164; KAMISOYAMA H, 1994, BIOCHEMISTRY-US, V33, P840, DOI 10.1021/bi00169a027; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KENDRICKJONES J, 1987, J MOL BIOL, V198, P241, DOI 10.1016/0022-2836(87)90310-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORITA JI, 1991, BIOCHEMISTRY-US, V30, P9539, DOI 10.1021/bi00103a022; ONISHI H, 1983, J BIOCHEM-TOKYO, V94, P1147, DOI 10.1093/oxfordjournals.jbchem.a134459; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; PEARSON RB, 1984, FEBS LETT, V168, P108, DOI 10.1016/0014-5793(84)80216-1; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUZUKI H, 1978, J BIOCHEM, V84, P1529, DOI 10.1093/oxfordjournals.jbchem.a132278; Trybus KM, 1991, CURR OPIN CELL BIOL, V3, P105, DOI 10.1016/0955-0674(91)90172-U; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564	40	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28173	28180						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961753				2022-12-25	WOS:A1994PV77200061
J	LAWSON, TG; GRONROS, DL; WERNER, JA; WEY, AC; DIGEORGE, AM; LOCKHART, JL; WILSON, JW; WINTRODE, PL				LAWSON, TG; GRONROS, DL; WERNER, JA; WEY, AC; DIGEORGE, AM; LOCKHART, JL; WILSON, JW; WINTRODE, PL			THE ENCEPHALOMYOCARDITIS VIRUS 3C PROTEASE IS A SUBSTRATE FOR THE UBIQUITIN-MEDIATED PROTEOLYTIC SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; HEPATITIS-A VIRUS; RETICULOCYTE LYSATE; ESCHERICHIA-COLI; DEGRADATION; CLEAVAGE; PROTEINS; LIGASE; TRANSLATION; EXPRESSION	The encephalomyocarditis virus 3C protease has been shown to be rapidly degraded in infected cells and in vitro in rabbit reticulocyte lysate. The in vitro degradation, at least, is accomplished by a virus-independent, ATP-dependent proteolytic system. Here we identify this proteolytic system as the ubiquitin-mediated system. Incubation of the 3C protease in rabbit reticulocyte or cultured mouse cell lysate preparations, alone or in the presence of added ubiquitin or methylated ubiquitin, resulted in the generation of new higher molecular weight species. These new products were shown to be 3C protease-ubiquitin conjugates by their ability to bind antibodies against both the 3C protease and ubiquitin. Supplemental ubiquitin also stimulated the degradation of the 3C protease in these preparations. Large 3C protease-polyubiquitin conjugates were observed to accumulate in reticulocyte lysate in the presence of adenosine 5'-O-(3-thiotriphosphate), an inhibitor of the 26 S multicatalytic protease. This, combined with the fact that the proteolytic activity could be removed from the lysate by sedimentation, implicates the multicatalytic protease in the degradation of the 3C protease-ubiquitin conjugates. It was also found that the slow rate of degradation of a model polyprotein, which resembles the stable viral 3CD diprotein produced in vivo, is likely due to the fact that the polyprotein is a poor substrate for the ubiquitin conjugating system.			LAWSON, TG (corresponding author), BATES COLL, DEPT CHEM, LEWISTON, ME 04240 USA.				NIAID NIH HHS [1 R15 AI 32666-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI032666] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASCHAUER B, 1991, VIROLOGY, V184, P587, DOI 10.1016/0042-6822(91)90429-F; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BERLETH ES, 1990, BIOCHEM BIOPH RES CO, V171, P705, DOI 10.1016/0006-291X(90)91203-5; BERLETH ES, 1992, J BIOL CHEM, V267, P16403; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; CORDINGLEY MG, 1989, J VIROL, V63, P5037, DOI 10.1128/JVI.63.12.5037-5045.1989; DASSO MC, 1989, NUCLEIC ACIDS RES, V17, P3129, DOI 10.1093/nar/17.8.3129; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; GAUSSMULLER V, 1991, VIROLOGY, V182, P861, DOI 10.1016/0042-6822(91)90630-T; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gray W R, 1972, Methods Enzymol, V25, P121, DOI 10.1016/S0076-6879(72)25010-8; HAAS AL, 1988, UBIQUITIN, P173; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; JEN G, 1982, J VIROL, V43, P250, DOI 10.1128/JVI.43.1.250-261.1982; JIA XY, 1991, J VIROL, V65, P2595, DOI 10.1128/JVI.65.5.2595-2600.1991; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON TG, 1989, J VIROL, V63, P5013, DOI 10.1128/JVI.63.12.5013-5022.1989; OBERST MD, 1993, VIROLOGY, V193, P28, DOI 10.1006/viro.1993.1100; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PALMENBERG AC, 1984, NUCLEIC ACIDS RES, V12, P2969, DOI 10.1093/nar/12.6.2969; PALMENBERG AC, 1979, J VIROL, V32, P770, DOI 10.1128/JVI.32.3.770-778.1979; PARKS GD, 1987, J VIROL, V61, P3680, DOI 10.1128/JVI.61.12.3680-3687.1987; PARKS GD, 1986, J VIROL, V60, P376, DOI 10.1128/JVI.60.2.376-384.1986; PARKS GD, 1989, J VIROL, V60, P1054; RAMABHADRAN TV, 1981, J VIROL, V39, P573, DOI 10.1128/JVI.39.2.573-583.1981; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REISS Y, 1988, J BIOL CHEM, V263, P2693; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS AAM, 1983, J VIROL, V48, P309, DOI 10.1128/JVI.48.1.309-313.1983	46	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28429	28435						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961784				2022-12-25	WOS:A1994PV77200096
J	PETERS, JW; FISHER, K; DEAN, DR				PETERS, JW; FISHER, K; DEAN, DR			IDENTIFICATION OF A NITROGENASE PROTEIN-PROTEIN INTERACTION SITE DEFINED BY RESIDUES 59 THROUGH 67 WITHIN THE AZOTOBACTER-VINELANDII FE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE NITROGENASE; STRUCTURAL GENE-CLUSTER; AMINO-ACID-SEQUENCE; IRON-PROTEIN; ELECTRON-TRANSFER; SUBSTRATE REDUCTION; COMPONENT PROTEINS; CROSS-LINKING; COMPLEX; DINITROGENASE	During nitrogenase catalysis the Fe protein and the MoFe protein associate and dissociate in a MgATP-dependent process involving electron transfer from the Fe protein to the MoFe protein. A docking model, based primarily on the crystal structures of the separate components from Azotobacter vinelandii, was previously proposed in which the g-fold symmetric surface of the homodimeric Fe protein interacts with the exposed surface of a MoFe protein pseudosymmetric alpha beta-unit interface. In this model, a loop, which is included within residues 59 through 67 of the Fe protein primary sequence, is likely to interact with the MoFe protein during component protein docking. In the present study, evidence supporting the component protein docking model was obtained by construction of an A. vinelandii strain that produces a hybrid Fe protein for which residues 59 through 67 have been replaced by the corresponding residues from the Fe protein of Clostridium pasteurianum. Biochemical analyses of the hybrid Fe protein revealed the following features when compared with the unaltered Fe protein. First, the hybrid Fe protein exhibited half the maximum specific activity of the normal Fe protein and was insensitive to inhibition by low levels of NaCl. Second, the hybrid Fe protein activity was hypersensitive to a molar excess of MoFe protein, which also resulted in the uncoupling of MgATP hydrolysis from substrate reduction. Third, stopped-now spectrophotometry experiments showed that during catalysis the hybrid Fe protein dissociates from the MoFe protein at only half the normal rate of Fe protein-MoFe protein dissociation. Thus, the salient feature of the hybrid Fe protein is that it appears to form a relatively tighter complex with the MoFe protein. This property is in line with previous biochemical reconstitution experiments where it was shown that a heterologous mixture of Fe protein hom C. pasteurianum and MoFe protein from A. vinelandii form a tight, inactive complex and supports the proposal that a region defined by residues 59 through 67 within the Fe protein is involved in component protein interaction.	VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM & ANAEROB MICROBIOL, BLACKSBURG, VA 24061 USA	Virginia Polytechnic Institute & State University			Fisher, Karl/A-5956-2013	Fisher, Karl/0000-0003-3539-8939; Peters, John/0000-0001-9117-9568	NIDDK NIH HHS [DK37255] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037255] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRIGLE KE, 1985, GENE, V37, P37, DOI 10.1016/0378-1119(85)90255-0; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; DEITS TL, 1990, J BIOL CHEM, V265, P3859; DILWORTH MJ, 1992, ANAL BIOCHEM, V207, P6, DOI 10.1016/0003-2697(92)90491-O; EADY RR, 1972, BIOCHEM J, V128, P655, DOI 10.1042/bj1280655; EMERICH DW, 1976, P NATL ACAD SCI USA, V73, P4369, DOI 10.1073/pnas.73.12.4369; EMERICH DW, 1978, BIOCHIM BIOPHYS ACTA, V527, P359, DOI 10.1016/0005-2744(78)90350-9; ENNOR AH, 1957, METHOD ENZYMOL, V3, P850, DOI 10.1016/S0076-6879(57)03460-6; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1978, BIOCHEMISTRY-US, V17, P4117, DOI 10.1021/bi00613a002; HAGEMAN RV, 1980, BIOCHIM BIOPHYS ACTA, V591, P63, DOI 10.1016/0005-2728(80)90220-0; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HAUSINGER RP, 1982, J BIOL CHEM, V257, P2483; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; HOWARD JB, 1993, ACS SYM SER, V535, P271; JACOBSON MR, 1990, J BIOL CHEM, V265, P19429; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; JENG DY, 1970, J BIOL CHEM, V245, P2809; KIM J, 1994, BIOCHEMISTRY-US, V33, P389, DOI 10.1021/bi00168a001; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KLUGKIST J, 1986, EUR J BIOCHEM, V155, P33, DOI 10.1111/j.1432-1033.1986.tb09455.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJONES T, 1972, BIOCHIM BIOPHYS ACTA, V283, P339; LOWE DJ, 1990, BIOCHEM J, V272, P621, DOI 10.1042/bj2720621; LOWERY RG, 1989, BIOCHEMISTRY-US, V28, P1206, DOI 10.1021/bi00429a038; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ORMEJOHNSON WH, 1976, IRON SULFUR PROTEINS, P15; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; STRANDBERG GW, 1968, CAN J MICROBIOL, V14, P25, DOI 10.1139/m68-005; THORNELEY RNF, 1984, BIOCHEM J, V224, P903, DOI 10.1042/bj2240903; THORNELEY RNF, 1988, BIOCHEM J, V253, P587, DOI 10.1042/bj2530587; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; THORNELEY RNF, 1975, BIOCHEM J, V145, P391, DOI 10.1042/bj1450391; THORNELEY RNF, 1991, BIOCHEM J, V277, P735, DOI 10.1042/bj2770735; THORNELEY RNF, 1985, MOLYBDENUM ENZYMES, P222; WHERLAND S, 1981, BIOCHEMISTRY-US, V20, P5132, DOI 10.1021/bi00521a006; WILLING A, 1990, J BIOL CHEM, V265, P6596; WILLING AH, 1989, J BIOL CHEM, V264, P8499; WOLLE D, 1992, J BIOL CHEM, V267, P3667; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643	48	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28076	28083						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961744				2022-12-25	WOS:A1994PV77200048
J	WALKER, KW; GILBERT, HF				WALKER, KW; GILBERT, HF			EFFECT OF REDOX ENVIRONMENT ON THE IN-VITRO AND IN-VIVO FOLDING OF RTEM-1 BETA-LACTAMASE AND ESCHERICHIA COLI ALKALINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; BOND FORMATION INVIVO; ENDOPLASMIC-RETICULUM; COLI; CATALYSIS; INVITRO; DSBA; IDENTIFICATION; TEMPERATURE; MUTATIONS	The oxidative folding mechanisms of two Escherichia coli periplasmic proteins, alkaline phosphatase and RTEM-1 beta-lactamase, have been examined in vitro and in vivo. In contrast to eukaryotic proteins, which require a relatively reducing environment for optimal folding rates, both alkaline phosphatase and beta-lactamase fold fastest under very oxidizing conditions. For example, bovine pancreatic ribonuclease exhibits an optimal folding rate in a redox buffer consisting of 1 mM GSH and 0.2 mM GSSG (Lyles, M. M., and Gilbert, H. F (1991) Biochemistry 30, 613-619); however, both E. coli alkaline phosphatase and beta-lactamase exhibit optimal in vitro folding rates at low concentrations of GSH (< 0.4 mM) and very high concentrations of GSSG (4-8 mM). For both bacterial proteins, GSH inhibits oxidative folding. Under optimal redox conditions, the rate-limiting step for the in vitro oxidative folding of alkaline phosphatase depends on the concentration of the protein, consistent with a mechanism involving rapid oxidation followed by slow dimerization. With beta-lactamase, the oxidative folding mechanism involves a competition between disulfide bond formation and folding of the molecule into a catalytically active conformation that buries the 2 reduced cysteines in the core of the enzyme. The effects of including a thiol reductant in the growth medium on the in vivo folding of alkaline phosphatase and beta-lactamase are similar to the effects observed during in vitro folding of these enzymes. The levels of both oxidized proteins are decreased by GSH in the growth medium. However, addition of a disulfide oxidant to the growth medium does not positively affect the production of either enzyme. These observations are consistent with the idea that the oxidative folding mechanisms of E. coli periplasmic proteins and, by inference, proteins of the eukaryotic endoplasmic reticulum have evolved to accommodate constraints placed on the folding reaction by the folding environment, The consequences of differences between the folding mechanisms in eukaryotic and prokaryotic disulfide containing proteins on the expression of eukaryotic proteins in the bacterial periplasm are discussed.	BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; BANEYX F, 1991, J BACTERIOL, V173, P2696, DOI 10.1128/jb.173.8.2696-2703.1991; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BESSEY OA, 1946, J BIOL CHEM, V164, P321; BOWDEN GA, 1990, J BIOL CHEM, V265, P16760; CHALMERS JJ, 1990, APPL ENVIRON MICROB, V56, P104, DOI 10.1128/AEM.56.1.104-111.1990; COLEMAN JE, 1983, ADV ENZYMOL RAMB, V55, P381; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Georgiou G., 1990, RECOMBINANT DNA TECH, P333; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; Gilbert HF, 1994, MECH PROTEIN FOLDING, P104; GRANA D, 1988, GENETICS, V120, P319; GUZMAN LM, 1992, J BACTERIOL, V174, P7716, DOI 10.1128/JB.174.23.7717-7728.1992; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HUTH JR, 1993, J BIOL CHEM, V268, P16472; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; IMITIAZ U, 1993, ANTIMICROB AGENTS CH, V37, P2438; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LANG K, 1988, NATURE, V331, P453, DOI 10.1038/331453a0; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; OLIVER DB, 1987, ESCHERICHIA COLI SAL, P56; PALZKILL T, 1994, MOL MICROBIOL, V12, P217, DOI 10.1111/j.1365-2958.1994.tb01011.x; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; SCHLESINGER MJ, 1965, J BIOL CHEM, V240, P4284; SCHULTZ SC, 1987, PROTEINS, V2, P290, DOI 10.1002/prot.340020405; SOWADSKI JM, 1981, J MOL BIOL, V150, P245, DOI 10.1016/0022-2836(81)90451-4; SUTTER KD, 1992, MOL MICROBIOL, V6, P2201; Thatcher DR, 1994, MECH PROTEIN FOLDING, P229; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WUNDERLICH M, 1993, J BIOL CHEM, V268, P24547; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	37	41	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28487	28493						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961790				2022-12-25	WOS:A1994PV77200104
J	BERGERAT, A; GADELLE, D; FORTERRE, P				BERGERAT, A; GADELLE, D; FORTERRE, P			PURIFICATION OF A DNA TOPOISOMERASE-II FROM THE HYPERTHERMOPHILIC ARCHAEON SULFOLOBUS-SHIBATAE - A THERMOSTABLE ENZYME WITH BOTH BACTERIAL AND EUCARYAL FEATURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HALOPHILIC ARCHAEBACTERIA; REVERSE GYRASE; DROSOPHILA-MELANOGASTER; ANTITUMOR DRUGS; CALF THYMUS; ACIDOCALDARIUS; COMPONENT; HOMOLOGY; CLEAVAGE	A type II DNA topoisomerase has been purified to homogeneity from the hyperthermophilic archaeon Sulfolobus shibatae. The enzyme is composed of two subunits of 60 and 47 kDa. It has a Stokes radius of 69 Angstrom and has a sedimentation coefficient of 7.8 S which gives a calculated native molecular mass of approximately 230 kDa, indicating a heterotetrameric structure. This enzyme is ATP and Mg2+ dependent and can relax both negatively and positively supercoiled DNA, but presents no supercoiling activity. The S. shibatae DNA topoisomerase II is more efficient in decatenation than in relaxation. The optimal temperature for the enzymatic activity is similar to 80 degrees C. This archaeal enzyme is not inhibited by the gyrase inhibitor novobiocin but is sensitive to several inhibitors of eucaryotic DNA topoisomerases of type II such as amsacrines, ellipticine, and the quinolone CP-115,953. Like all prokaryotic DNA topoisomerase II, the S. shibatae DNA topoisomerase II is a heterotetramer but the absence of supercoiling activity, the strong decatenase activity, and the pattern of antibiotic sensitivity of the S. shibatae DNA topoisomerase II is reminiscent of eucaryotic enzymes.			BERGERAT, A (corresponding author), UNIV PARIS 11,INST GENET & MICROBIOL,CNRS,URA 1354,BAT 409,F-91405 ORSAY,FRANCE.							BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; CHARBONNIER F, 1992, J BACTERIOL, V174, P6103, DOI 10.1128/JB.174.19.6103-6108.1992; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; ELIE C, 1989, EUR J BIOCHEM, V178, P619, DOI 10.1111/j.1432-1033.1989.tb14490.x; Forterre P, 1992, Biochem Soc Symp, V58, P99; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GOTO T, 1982, J BIOL CHEM, V257, P5866; GROGAN DW, 1989, J BACTERIOL, V171, P6710, DOI 10.1128/jb.171.12.6710-6719.1989; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HOLMES ML, 1991, J BACTERIOL, V173, P642, DOI 10.1128/jb.173.2.642-648.1991; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; KIKUCHI A, 1986, SYST APPL MICROBIOL, V7, P72, DOI 10.1016/S0723-2020(86)80126-6; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P5498, DOI 10.1073/pnas.78.9.5498; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MELENDY T, 1989, J BIOL CHEM, V264, P1870; MILLER KG, 1981, J BIOL CHEM, V256, P9334; NADAL M, 1994, J BIOL CHEM, V269, P5255; PULLEYBLANK D, 1983, MOL BIOL REP, V9, P191, DOI 10.1007/BF00775367; REECE RJ, 1991, CRC CRIT REV BIOCH M, V26, P235; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; SCHOMBURG U, 1986, EUR J BIOCHEM, V160, P451, DOI 10.1111/j.1432-1033.1986.tb10061.x; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIOUD M, 1988, NUCLEIC ACIDS RES, V16, P1379, DOI 10.1093/nar/16.4.1379; SIOUD M, 1987, EUR J BIOCHEM, V169, P231, DOI 10.1111/j.1432-1033.1987.tb13602.x; SLESAREV AI, 1993, NATURE, V364, P735, DOI 10.1038/364735a0; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WHEELIS ML, 1992, P NATL ACAD SCI USA, V89, P2930, DOI 10.1073/pnas.89.7.2930; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6	47	88	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27663	27669						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961685				2022-12-25	WOS:A1994PV77100079
J	MINEGISHI, N; MINEGISHI, M; TSUCHIYA, S; FUJIE, H; NAGAI, T; HAYASHI, N; YAMAMOTO, M; KONNO, T				MINEGISHI, N; MINEGISHI, M; TSUCHIYA, S; FUJIE, H; NAGAI, T; HAYASHI, N; YAMAMOTO, M; KONNO, T			ERYTHROPOIETIN-DEPENDENT INDUCTION OF HEMOGLOBIN-SYNTHESIS IN A CYTOKINE-DEPENDENT CELL-LINE M-TAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ERYTHROID PROGENITOR CELLS; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; RECEPTOR GENE; GM-CSF; DIFFERENTIATION; INTERLEUKIN-3; ESTABLISHMENT	M-TAT is a cytokine-dependent cell line with the potential to differentiate along the erythroid and megakaryocytic lineages. We cultured M-TAT cells long term (>1 year) in the continuous presence of erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), or stem cell factor (SCF). These long term cultures are referred to as M-TAT/EPO, M-TAT/GM-CSF, and M-TAT/SCF cells, respectively. Hemoglobin concentration and gamma-globin and erythroid delta-aminolevulinate synthase mRNA levels were significantly higher in M-TAT/EPO cells than in M-TAT/GM-CSF cells. When the supplemented cytokine was switched from GM-CSF to EPO, hemoglobin synthesis in M-TAT/GM-CSF cells increased rapidly (within 5 h), and the level of GATA-1 mRNA increased. In contrast, the addition of GM-CSF to the M-TAT/EPO cell culture decreased the amount of hemoglobin, even in the presence of EPO, indicating that the EPO signal for erythroid differentiation is suppressed by GM-CSF. Thus, erythroid development of M-TAT cells is promoted by EPO and suppressed by GM-CSF. These results support the hypothesis that EPO actively influences the programming of gene expression required for erythroid progenitor cell differentiation.	TOHOKU UNIV,SCH MED,DEPT BIOCHEM,AOBA KU,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,INST DEV AGING & CANC,DEPT PEDIAT ONCOL,SENDAI,MIYAGI,JAPAN	Tohoku University; Tohoku University			Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436				BOYER SH, 1992, BLOOD, V80, P2503; BROUDY VC, 1990, BLOOD, V75, P1622; CHIBA S, 1991, BLOOD, V78, P2261; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DAMEN JE, 1993, BLOOD, V82, P2296; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; ENDO K, 1993, BRIT J HAEMATOL, V85, P653, DOI 10.1111/j.1365-2141.1993.tb03205.x; ENGEL JD, 1991, SEMIN HEMATOL, V28, P158; ENVER T, 1988, P NATL ACAD SCI USA, V85, P9091, DOI 10.1073/pnas.85.23.9091; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUIMARAES JE, 1984, EXP HEMATOL, V12, P535; HANAZONO Y, 1993, BLOOD, V81, P3193; HARA K, 1988, EXP HEMATOL, V16, P256; HERMINE O, 1992, BLOOD, V80, P3060; KENNEDY M, 1992, BLOOD, V79, P180; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KOMATSU N, 1993, BLOOD, V82, P456; KOMATSU N, 1991, CANCER RES, V51, P341; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; NAGAIT, 1994, BLOOD, V84, P1074; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; ORKIN SH, 1992, BLOOD, V80, P575; SUDA J, 1986, BLOOD, V67, P1002; UMEMURA T, 1989, BLOOD, V73, P1993; WICKREMA A, 1992, BLOOD, V80, P1940, DOI 10.1182/blood.V80.8.1940.1940; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMOTO M, 1991, J BIOL CHEM, V266, P3317; YAMAMOTO M, 1994, REGULATION HEME PROT, P11; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638; ZON LI, 1992, NUCLEIC ACIDS RES, V20, P1812, DOI 10.1093/nar/20.7.1812; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668	39	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27700	27704						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961690				2022-12-25	WOS:A1994PV77100084
J	PIKULA, S; HAYDEN, JB; AWASTHI, S; AWASTHI, YC; ZIMNIAK, P				PIKULA, S; HAYDEN, JB; AWASTHI, S; AWASTHI, YC; ZIMNIAK, P			ORGANIC ANION-TRANSPORTING ATPASE OF RAT-LIVER .1. PURIFICATION, PHOTOAFFINITY-LABELING, AND REGULATION BY PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; HEREDITARY-CONJUGATED HYPERBILIRUBINEMIA; BILE CANALICULAR MEMBRANE; GLUTATHIONE S-CONJUGATE; DEPENDENT TRANSPORT; MULTIDRUG-RESISTANCE; MUTANT RATS; HUMAN-ERYTHROCYTES; CYSTIC-FIBROSIS; DUBIN-JOHNSON	An ATP-dependent transport system specific for nonbile acid organic anions such as S-(2,4-dinitrophenyl)glutathione is present in the canalicular plasma membrane of hepatocytes. It has been shown recently that transport of these anions by isolated hepatocytes is modulated by the activity of cellular protein kinase C (Roelofsen, H., Ottenhoff, R., Oude Elferink, R. P., and Jansen, P. L. (1991) Biochem. J. 278, 637-641, 1991). Using a series of affinity chromatography steps, we have purified to apparent homogeneity a 90-kDa glycoprotein which has S-(2,4-dinitrophenyl) glutathione dependent ATPase activity As shown by binding to immobilized S-(2,4-dinitrophenyl)glutathione and by photoaffinity labeling with 8-azido-ATP, the binding sites for organic anions and for ATP of the 90-kDa protein are interdependent, a behavior that is consistent with an ATP-dependent pendent transport function. The ATP binding site has been further characterized using a fluorescent ATP analog. The 90-kDa protein was phosphorylated by protein kinase C, and the V-max (but not the K-m) of the S-(2,4-dinitrophenyl)glutathione-dependent ATPase activity increased at least a-fold upon phosphorylation. On the basis of its enzymatic properties, we propose that the 90-kDa protein is identical with the multispecific organic anion transporter (MOAT) of the hepatic canalicular plasma membrane. The size and oligosaccharide content of the 90-kDa protein indicate that it does not belong to the family of mammalian plasma membrane P-glycoproteins.	UNIV ARKANSAS MED SCI HOSP,DEPT MED,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; VET ADM JOHN MCCLELLAN MEM HOSP,LITTLE ROCK,AR 72205; UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston			Awasthi, Sanjay/R-4904-2019	Awasthi, Sanjay/0000-0002-5214-5717; Pikula, Slawomir/0000-0003-4640-3094	NCI NIH HHS [CA-63660] Funding Source: Medline; NIGMS NIH HHS [GM-32304] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032304] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; ARIAS IM, 1993, HEPATOLOGY, V17, P318, DOI 10.1002/hep.1840170225; AWASTHI S, 1994, J CLIN INVEST, V93, P958, DOI 10.1172/JCI117102; AWASTHI YC, 1991, BIOCHEM BIOPH RES CO, V175, P1090, DOI 10.1016/0006-291X(91)91677-5; BALLATORI N, 1992, AM J PHYSIOL, V263, pG617, DOI 10.1152/ajpgi.1992.263.5.G617; BOARD P, 1992, HEPATOLOGY, V15, P722, DOI 10.1002/hep.1840150428; BODMER JG, 1992, TISSUE ANTIGENS, V39, P161, DOI 10.1111/j.1399-0039.1992.tb01932.x; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEVRIES MH, 1989, N-S ARCH PHARMACOL, V340, P588, DOI 10.1007/BF00260615; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; ELFERINK RPJO, 1993, BIOCHEM J, V290, P759, DOI 10.1042/bj2900759; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HOSOKAWA S, 1992, LAB ANIM SCI, V42, P27; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; INOUE M, 1984, J BIOL CHEM, V259, P4998; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; JANSEN PLM, 1987, HEPATOLOGY, V7, P71, DOI 10.1002/hep.1840070116; JANSEN PLM, 1985, HEPATOLOGY, V5, P573, DOI 10.1002/hep.1840050408; KAST C, 1994, J BIOL CHEM, V269, P5179; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KNOWLES AF, 1984, J BIOL CHEM, V259, P919; KOBAYASHI K, 1988, FEBS LETT, V240, P55, DOI 10.1016/0014-5793(88)80339-9; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; KUIPERS F, 1988, J CLIN INVEST, V81, P1593, DOI 10.1172/JCI113493; KUNST M, 1989, BIOCHIM BIOPHYS ACTA, V983, P123, DOI 10.1016/0005-2736(89)90389-1; LABELLE EF, 1986, BIOCHEM J, V238, P443, DOI 10.1042/bj2380443; LABELLE EF, 1988, FEBS LETT, V228, P53, DOI 10.1016/0014-5793(88)80583-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SH, 1990, ANN NY ACAD SCI, V603, P394; LINDWALL G, 1987, J BIOL CHEM, V262, P5151; Meier Peter J., 1993, P587; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; NICOTERA P, 1985, FEBS LETT, V187, P121, DOI 10.1016/0014-5793(85)81226-6; NISHIDA T, 1992, J CLIN INVEST, V90, P2130, DOI 10.1172/JCI116098; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; PIKULA S, 1994, J BIOL CHEM, V269, P27574; ROELOFSEN H, 1991, BIOCHEM J, V278, P637, DOI 10.1042/bj2780637; RUETZ S, 1987, J BIOL CHEM, V262, P11324; SAXENA M, 1992, ARCH BIOCHEM BIOPHYS, V298, P231, DOI 10.1016/0003-9861(92)90117-F; SCHAUB T, 1991, FEBS LETT, V279, P83, DOI 10.1016/0014-5793(91)80256-3; SHARMA R, 1990, BIOCHEM BIOPH RES CO, V171, P155, DOI 10.1016/0006-291X(90)91370-8; SINGHAL SS, 1991, FEBS LETT, V281, P255, DOI 10.1016/0014-5793(91)80405-R; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1994, J BIOL CHEM, V269, P2820; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; THOMAS PJ, 1993, J BIOENERG BIOMEMBR, V25, P11, DOI 10.1007/BF00768063; VINCE R, 1971, J MED CHEM, V14, P402, DOI 10.1021/jm00287a006; ZIMNIAK P, 1992, ARCH BIOCHEM BIOPHYS, V292, P534, DOI 10.1016/0003-9861(92)90027-T; ZIMNIAK P, 1993, HEPATOLOGY, V17, P330, DOI 10.1002/hep.1840170226; ZIMNIAK P, 1993, SEMIN LIVER DIS, V13, P248, DOI 10.1055/s-2007-1007353	59	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27566	27573						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961673				2022-12-25	WOS:A1994PV77100064
J	BACMAN, S; STERINBORDA, L; CAMUSSO, JJ; HUBSCHER, O; ARANA, R; BORDA, ES				BACMAN, S; STERINBORDA, L; CAMUSSO, JJ; HUBSCHER, O; ARANA, R; BORDA, ES			CIRCULATING ANTIBODIES AGAINST NEUROTRANSMITTER RECEPTOR ACTIVITIES IN CHILDREN WITH CONGENITAL HEART-BLOCK AND THEIR MOTHERS	FASEB JOURNAL			English	Article						BETA-ADRENERGIC ANTIBODIES; MUSCARINIC CHOLINERGIC ANTIBODIES; CAMP; ATRIA CONTRACTILITY; BINDING ASSAY	SYSTEMIC LUPUS-ERYTHEMATOSUS; SS-A ANTIGEN; CHAGASIC IGG; BETA-ADRENOCEPTORS; SJOGRENS SYNDROME; AUTOANTIBODIES; DISEASE; BINDING; A/RO; MONOPHOSPHATE	In this work we demonstrated that IgG present in the sera of patients with congenital heart block (CHB) and their mothers could bind and activate beta adrenoceptors and muscarinic cholinergic receptors of neonatal heart. These antibodies were able to inhibit in a noncompetitive manner the binding of [H-3]QNB and [H-3]CGP to muscarinic cholinergic and beta adrenoceptors of purified neonatal rat myocardial membranes, respectively. Moreover, IgG from children with CHB and their mothers could modify biological effects mediated by these neurotransmitter receptors, i.e., heart contractility and cAMP production. Neither binding nor biological effects were obtained using adult instead of neonatal rat atria. Both reactivities (adrenergic and cholinergic) were independent of Ro/SS-A and La/SS-B antibodies and were absent in the sera of normal women of childbearing age and of normal children. It could be concluded that antibodies against cardiac neurotransmitter receptors may be another serum factor (or factors) to be considered in the pathophysiology of the development of CHB.	CEMIC,RA-1414 BUENOS AIRES,DF,ARGENTINA	Centro de Educacion Medica e Investigaciones Clinicas (CEMIC)	BACMAN, S (corresponding author), CONSEJO NACL INVEST CIENT & TECN,CEFYBO,SERRANO 669,RA-1414 BUENOS AIRES,DF,ARGENTINA.							AHEARN JM, 1982, ARTHRITIS RHEUM-US, V25, P1031, DOI 10.1002/art.1780250901; ALEXANDER E, 1992, ARTHRITIS RHEUM-US, V35, P176, DOI 10.1002/art.1780350209; ALEXANDER EL, 1989, J INVEST DERMATOL, V93, P751, DOI 10.1111/1523-1747.ep12284404; ALEXANDER EL, 1982, J RHEUMATOL, V9, P239; ALMON RR, 1974, SCIENCE, V186, P55, DOI 10.1126/science.186.4158.55; BEHAN WMH, 1989, BRIT HEART J, V62, P320; BORDA E, 1984, CLIN EXP IMMUNOL, V57, P679; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; CREMASCHI GA, 1991, IMMUNOPHARMACOLOGY, V22, P195, DOI 10.1016/0162-3109(91)90044-Y; DENG JS, 1987, ARTHRITIS RHEUM, V30, P1232, DOI 10.1002/art.1780301105; DENG JS, 1985, J INVEST DERMATOL, V85, P412, DOI 10.1111/1523-1747.ep12277079; FLEMING JW, 1992, CIRCULATION, V85, P420, DOI 10.1161/01.CIR.85.2.420; FLIEGEL L, 1989, BIOCHIM BIOPHYS ACTA, V982, P1, DOI 10.1016/0005-2736(89)90166-1; FLIER JS, 1976, J CLIN INVEST, V58, P1442, DOI 10.1172/JCI108600; HARBON S, 1971, BIOCHEM BIOPH RES CO, V44, P1496, DOI 10.1016/S0006-291X(71)80255-3; HUNTER F A, 1991, Arthritis and Rheumatism, V34, pS75; IOSA D, 1990, J AUTONOM NERV SYST, V30, P583; KURATA N, 1976, ARTHRITIS RHEUM, V19, P574, DOI 10.1002/art.1780190309; LEE LA, 1985, J INVEST DERMATOL, V85, P143, DOI 10.1111/1523-1747.ep12276566; LEE LA, 1989, J INVEST DERMATOL, V86, P488; LEIROS CP, 1990, P SOC EXP BIOL MED, V195, P356; LIEU T S, 1991, Arthritis and Rheumatism, V34, pS102; LIMAS CJ, 1989, CIRC RES, V64, P97, DOI 10.1161/01.RES.64.1.97; MCCAULIFFE DP, 1990, J CLIN INVEST, V86, P332, DOI 10.1172/JCI114704; MEVORACH D, 1993, ARTHRITIS RHEUM, V36, P259, DOI 10.1002/art.1780360219; PASCUAL J, 1986, BIOCHEM PHARMACOL, V35, P3839, DOI 10.1016/0006-2952(86)90673-8; PASCUAL J, 1987, LIFE SCI, V19, P574; PROVOST TT, 1988, ARCH DERMATOL, V124, P63, DOI 10.1001/archderm.124.1.63; REED BR, 1983, J PEDIATR-US, V103, P889, DOI 10.1016/S0022-3476(83)80707-0; REESSMITH B, 1974, LANCET, V2, P427; ROKEACH LA, 1991, J IMMUNOL, V147, P3031; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT JS, 1983, NEW ENGL J MED, V309, P209, DOI 10.1056/NEJM198307283090403; SONTHEIMER RD, 1982, ANN INTERN MED, V97, P664, DOI 10.7326/0003-4819-97-5-664; STERINBORDA L, 1986, INT J IMMUNOPHARMACO, V8, P581, DOI 10.1016/0192-0561(86)90029-9; STERINBORDA L, 1988, CLIN EXP IMMUNOL, V74, P349; STERINBORDA L, 1991, CLIN IMMUNOL IMMUNOP, V61, P387, DOI 10.1016/S0090-1229(05)80010-8; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TAYLOR PV, 1986, NEW ENGL J MED, V315, P667, DOI 10.1056/NEJM198609113151103; VENTER JC, 1980, SCIENCE, V207, P1361, DOI 10.1126/science.6153472; WATSON RM, 1984, MEDICINE, V63, P362, DOI 10.1097/00005792-198411000-00003; ZAKARIJA M, 1980, ANN INTERN MED, V93, P28, DOI 10.7326/0003-4819-93-1-28	42	24	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1170	1176		10.1096/fasebj.8.14.7958624	http://dx.doi.org/10.1096/fasebj.8.14.7958624			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958624				2022-12-25	WOS:A1994PT12800013
J	LOPEZBOADO, YS; TOLIVIA, J; LOPEZOTIN, C				LOPEZBOADO, YS; TOLIVIA, J; LOPEZOTIN, C			APOLIPOPROTEIN-D GENE INDUCTION BY RETINOIC ACID IS CONCOMITANT WITH GROWTH ARREST AND CELL-DIFFERENTIATION IN HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROSS CYSTIC-DISEASE; MESSENGER-RNA; HUMAN-PLASMA; CHOLESTEROL ACYLTRANSFERASE; INSITU HYBRIDIZATION; TISSUE DISTRIBUTION; PERIPHERAL-NERVE; RESPONSE ELEMENT; FLUID PROTEINS; X-RECEPTOR	We have examined the regulation by retinoic acid of the gene encoding apolipoprotein D (apoD), a human plasma protein belonging to the superfamily of the lipocalins that is produced by a specific subtype of highly differentiated breast carcinomas. Northern blot analysis revealed that all-trans-retinoic acid (RA) strongly induced the accumulation of apoD mRNA in T-47D and ZR-75-1 estrogen receptor-positive human breast cancer cells in a time- and dose-dependent manner, while no inductive effect was observed in estrogen receptor-negative cell lines, including MDA-MB-231 and MDA-MB-435. The effect of RA on apoD expression by T-47D cells was at least 12-fold more potent than the effect of the steroids dihydrotestosterone and dexamethasone, which had been previously described as hormonal up-regulators of apoD expression in these cells. A time course study demonstrated that the induction of apoD mRNA reached a level of 15-fold over the untreated control cells after 48 h of incubation in the presence of a 10(-7) M concentration of RA. A dose-response analysis showed that as little as 10(-13) M RA produced an accumulation of 5-fold over the control, while incubation of the cells in the presence of 10(-5) M RA induced a maximal accumulation of 24-fold over the control untreated cells. The induction of apoD mRNA was independent of the synthesis of proteins de novo, as demonstrated by the fact that the induction was also detected in the presence of cycloheximide. The incubation of the cells in the presence of RA did not affect significantly the stability of apoD mRNA By contrast, treatment of the T-47D cells with RA produced an increase of approximately 8-fold in the rate of transcription of the apoD gene. Furthermore, treatment of the T-47D cells with RA induced the synthesis and secretion to the culture medium of apoD. This increased expression of apoD was accompanied by an inhibition of cell proliferation and a progression through a more differentiated phenotype, suggesting that the mechanisms controlling RA-induced growth arrest, cell differentiation, and apoD synthesis may be directly coordinated in human breast cancer cells.	UNIV OVIEDO, DEPT BIOL FUNC, E-33006 OVIEDO, SPAIN	University of Oviedo			Tolivia, Jorge/A-6950-2008; Tolivia, Jorge/D-2248-2010; Lopez-Otin, Carlos/AAB-2106-2020	Tolivia, Jorge/0000-0001-8984-8849; Lopez-Otin, Carlos/0000-0001-6964-1904				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BALBIN M, 1990, BIOCHEM J, V271, P803, DOI 10.1042/bj2710803; BLANCOVACA F, 1992, J LIPID RES, V33, P1785; BOYLES JK, 1990, J LIPID RES, V31, P2243; BOYLES JK, 1990, J BIOL CHEM, V265, P17805; CHAMBON P, 1993, GENE, V135, P223, DOI 10.1016/0378-1119(93)90069-F; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DE LUCA LM, 1991, FASEB J, V5, P2924; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DIEZITZA I, 1994, AM J PATHOL, V144, P310; DILLEY WG, 1990, BREAST CANCER RES TR, V16, P253, DOI 10.1007/BF01806333; DILORENZO D, 1993, BIOCHEM BIOPH RES CO, V192, P1066, DOI 10.1006/bbrc.1993.1525; DRAYNA D, 1986, J BIOL CHEM, V261, P6535; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FIELDING PE, 1980, P NATL ACAD SCI-BIOL, V77, P3327, DOI 10.1073/pnas.77.6.3327; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; HAAGENSEN DE, 1992, BREAST CANCER RES TR, V23, P77, DOI 10.1007/BF01831479; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOLDER MJ, 1993, INT IMMUNOL, V5, P1059, DOI 10.1093/intimm/5.9.1059; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KOGA M, 1991, J STEROID BIOCHEM, V39, P455, DOI 10.1016/0960-0760(91)90238-Z; LAMBERT J, 1993, BIOCHIM BIOPHYS ACTA, V1172, P190, DOI 10.1016/0167-4781(93)90292-L; LEA OA, 1987, CANCER RES, V47, P6189; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOPEZBOADO YS, 1994, BREAST CANCER RES TR, V29, P247, DOI 10.1007/BF00666478; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MAZOUJIAN G, 1990, ANN NY ACAD SCI, V586, P188, DOI 10.1111/j.1749-6632.1990.tb17806.x; MCCONATH.WJ, 1973, FEBS LETT, V37, P178, DOI 10.1016/0014-5793(73)80453-3; MILNE RW, 1993, CURR OPIN LIPIDOL, V4, P100, DOI 10.1097/00041433-199304000-00005; PEARLMAN WH, 1973, J BIOL CHEM, V248, P5736; Peitsch M C, 1990, New Biol, V2, P197; PROVOST PR, 1991, FEBS LETT, V290, P139, DOI 10.1016/0014-5793(91)81244-3; PROVOST PR, 1990, J LIPID RES, V31, P2057; PROVOST PR, 1991, J LIPID RES, V32, P1959; ROMAN SD, 1992, CANCER RES, V52, P2236; ROMAN SD, 1993, CANCER RES, V53, P5940; SANCHEZ LM, 1992, CANCER RES, V52, P95; SANCHEZ LM, 1992, CLIN CHEM, V38, P695; SAWYER L, 1987, NATURE, V327, P659, DOI 10.1038/327659a0; SILVA JS, 1982, SURGERY, V92, P443; SIMARD J, 1991, CANCER RES, V51, P4336; SIMARD J, 1992, ENDOCRINOLOGY, V130, P1115, DOI 10.1210/en.130.3.1115; SIMARD J, 1990, ENDOCRINOLOGY, V126, P3223, DOI 10.1210/endo-126-6-3223; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH KM, 1990, J LIPID RES, V31, P995; SPREYER P, 1990, EMBO J, V9, P2479, DOI 10.1002/j.1460-2075.1990.tb07426.x; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TOLIVIA J, 1985, J NEUROSCI METH, V13, P305, DOI 10.1016/0165-0270(85)90078-0; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; WEECH PK, 1991, PROG LIPID RES, V30, P259, DOI 10.1016/0163-7827(91)90023-X; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	58	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26871	26878						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929425				2022-12-25	WOS:A1994PQ93100046
J	PESQUERO, JB; LINDSEY, CJ; ZEH, K; PAIVA, ACM; GANTEN, D; BADER, M				PESQUERO, JB; LINDSEY, CJ; ZEH, K; PAIVA, ACM; GANTEN, D; BADER, M			MOLECULAR-STRUCTURE AND EXPRESSION OF RAT BRADYKININ B2 RECEPTOR GENE - EVIDENCE FOR ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHARMACOLOGICAL CHARACTERIZATION; GENOMIC ORGANIZATION; BETA-2-ADRENERGIC RECEPTOR; ANGIOTENSIN RECEPTOR; MAMMALIAN-CELLS; MESSENGER-RNAS; CLONING; SEQUENCE; PROTEIN; LOCALIZATION	Bradykinin is a potent vasodilatory peptide hormone involved in a broad range of physiological actions. While it acts through at least two types of receptors which are named B1 and B2, most of its effects are mediated via activation of the B2 receptor. The gene for this receptor was isolated hom a rat genomic library and shown to span more than 28 kilobases, including four introns. The relative positions of the exons were mapped and all exons, intron-exon boundaries, and 5'- and 3'-flanking regions were sequenced. While the 5'-untranslated region of the mRNA is distributed on all four exons, the coding and the 3'-untranslated region are located entirely on the fourth exon. Characterization of the region upstream to the transcriptional start site detected by primer extension analysis shows that the bradykinin B2 receptor promoter contains no typical TATA or CCAAT boxes. Nevertheless, the promoter sequence was shown to be functional in NG108-15 cells transfected with a construct bearing 1.1 kilobases of 5'-flanking sequence fused to a luciferase reporter gene. Reverse transcription-polymerase chain reaction analysis detected two different bradykinin B2 receptor mRNAs containing or lacking exon 3 in all rat tissues tested, providing evidence for alternative splicing of the 5'-untranslated sequence.	MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY; ESCOLA PAULISTA MED,DEPT BIOPHYS,BR-04034970 SAO PAULO,BRAZIL	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Universidade Federal de Sao Paulo (UNIFESP)			Bader, Michael/K-2124-2013; Pesquero, Joao/C-1470-2012	Pesquero, Joao/0000-0002-4507-632X; Bader, Michael/0000-0003-4780-4164				ASSONBATRES MA, 1994, P NATL ACAD SCI USA, V91, P1318, DOI 10.1073/pnas.91.4.1318; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BURCH RM, 1992, LIFE SCI, V50, P829, DOI 10.1016/0024-3205(92)90201-Y; CHEN K, 1992, MOL BRAIN RES, V14, P20, DOI 10.1016/0169-328X(92)90005-V; CURNOW KM, 1992, MOL ENDOCRINOL, V6, P1113, DOI 10.1210/me.6.7.1113; DALTON S, 1988, EMBO J, V7, P49, DOI 10.1002/j.1460-2075.1988.tb02782.x; DEUSCHLE U, 1989, P NATL ACAD SCI USA, V86, P5400, DOI 10.1073/pnas.86.14.5400; DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870; EGGERICKX D, 1992, BIOCHEM BIOPH RES CO, V187, P1306, DOI 10.1016/0006-291X(92)90445-Q; EMORINE LJ, 1987, P NATL ACAD SCI USA, V84, P6995, DOI 10.1073/pnas.84.20.6995; FARHY RD, 1992, BIOCHEM BIOPH RES CO, V182, P283, DOI 10.1016/S0006-291X(05)80142-1; FARMER SG, 1992, ANNU REV PHARMACOL, V32, P511; FERES T, 1992, BRIT J PHARMACOL, V107, P991, DOI 10.1111/j.1476-5381.1992.tb13396.x; FIOR DR, 1993, AM J PHYSIOL, V265, pH1000, DOI 10.1152/ajpheart.1993.265.3.H1000; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD NP, 1990, J BIOL CHEM, V265, P20455; GOHLKE P, 1994, HYPERTENSION, V23, P411, DOI 10.1161/01.HYP.23.4.411; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARTMAN JC, 1993, J CARDIOVASC PHARM, V21, P996, DOI 10.1097/00005344-199306000-00022; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; HERZOG H, 1993, J BIOL CHEM, V268, P6703; HESS JF, 1994, MOL PHARMACOL, V45, P1; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HIRSCH MR, 1991, FEBS LETT, V287, P197, DOI 10.1016/0014-5793(91)80050-D; HOSODA K, 1992, J BIOL CHEM, V267, P18797; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANGFORD K, 1992, BIOCHEM BIOPH RES CO, V183, P1025, DOI 10.1016/S0006-291X(05)80293-1; LINDSEY CJ, 1989, BRIT J PHARMACOL, V97, P763, DOI 10.1111/j.1476-5381.1989.tb12014.x; LINZ W, 1993, J HYPERTENS, V11, pS96; MADEDDU P, 1994, HYPERTENSION, V23, pI189, DOI 10.1161/01.HYP.23.1_Suppl.I189; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MCINTYRE P, 1993, MOL PHARMACOL, V44, P346; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MIZUNO T, 1992, BIOCHEM J, V287, P305, DOI 10.1042/bj2870305; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURPHY PM, 1993, GENE, V133, P285, DOI 10.1016/0378-1119(93)90653-K; NAKAJIMA M, 1993, BIOCHEM BIOPH RES CO, V197, P393, DOI 10.1006/bbrc.1993.2492; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OMALLEY KL, 1990, BIOCHEMISTRY-US, V29, P1367, DOI 10.1021/bi00458a003; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; POWELL SJ, 1993, GENOMICS, V15, P435, DOI 10.1006/geno.1993.1084; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; REGOLI D, 1980, PHARMACOL REV, V32, P1; REISER G, 1982, BRAIN RES, V239, P191, DOI 10.1016/0006-8993(82)90841-1; REN HZ, 1994, J BIOL CHEM, V269, P3104; RHALEB NE, 1992, EUR J PHARMACOL, V210, P115, DOI 10.1016/0014-2999(92)90661-M; Roberts R A, 1989, Prog Growth Factor Res, V1, P237, DOI 10.1016/0955-2235(89)90013-6; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; RUPP RAW, 1987, NUCLEIC ACIDS RES, V15, P9707, DOI 10.1093/nar/15.23.9707; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLKENS BA, 1991, J CARDIOVASC PHARM, V18, pS26; SEYFRIED CE, 1992, GENOMICS, V13, P832, DOI 10.1016/0888-7543(92)90162-L; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; SNELL PH, 1990, BIOCHEM PHARMACOL, V39, P1921, DOI 10.1016/0006-2952(90)90610-W; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPRENGER H, 1994, J BIOL CHEM, V269, P11065; STERANKA LR, 1989, FASEB J, V3, P2019, DOI 10.1096/fasebj.3.9.2545496; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; TAKEUCHI K, 1993, CIRC RES, V73, P612, DOI 10.1161/01.RES.73.4.612; TIO RA, 1991, BASIC RES CARDIOL, V86, P107, DOI 10.1007/BF02190543; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767	73	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26920	26925						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929432				2022-12-25	WOS:A1994PQ93100053
J	PLOEMEN, JHTM; JOHNSON, WW; JESPERSEN, S; VANDERWALL, D; VANOMMEN, B; VANDERGREEF, J; VANBLADEREN, PJ; ARMSTRONG, RN				PLOEMEN, JHTM; JOHNSON, WW; JESPERSEN, S; VANDERWALL, D; VANOMMEN, B; VANDERGREEF, J; VANBLADEREN, PJ; ARMSTRONG, RN			ACTIVE-SITE TYROSYL RESIDUES ARE TARGETS IN THE IRREVERSIBLE INHIBITION OF A CLASS MU-GLUTATHIONE TRANSFERASE BY 2-(S-GLUTATHIONYL)-3,5,6-TRICHLORO-1,4-BENZOQUINONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASE; CLASS-PI; 3-DIMENSIONAL STRUCTURE; CHEMICAL MODIFICATION; CATALYTIC MECHANISM; CYSTEINE RESIDUES; ISOENZYME 3-3; RAT-LIVER; TETRACHLORO-1,4-BENZOQUINONE; CONJUGATE	The mode of inactivation of glutathione S-transferase isoenzyme 3-3 from rat by the active site-directed inhibitor 2-(S-glutathionyl)-3,5,6-trichloro-1,4-benzoquinone (GSTCBQ) has been investigated by a combination of site specific mutagenesis and mass spectrometric analysis of the sites of reaction of the reagent with the enzyme. This very reactive reagent is shown to target 3 residues in or near the active site, including the hydroxyl groups of Tyr-6 and Tyr-115 and the sulfhydryl group of Cys-114. Although the covalent attachment of one 2-(S-glutathionyl)dichloro-1,4-benzoquinonyl group/active site is sufficient to inactivate the enzyme (<5% residual activity), the 1 mol of reagent appears to be distributed among all three target sites. Mutant enzymes in which the reactive functional groups of these 3 residues have been individually removed remain susceptible to GSTCBQ. Evidence from amino acid sequencing and peptide maps visualized by matrix-assisted laser desorption/ionization mass spectrometry suggests that both Tyr-6 and Tyr-115 are primary targets of the reagent in the native enzyme. Docking of a model of GSTCBQ in a model of the active site derived from the crystal structure of the enzyme indicates that the trichlorobenzoquinonyl group can be positioned so that both tyrosine hydroxyl groups can act as nucleophiles to add to the reagent or alternatively act as electrophiles to assist in the nucleophilic addition of the other. The reaction of GSTCBQ with Cys-114 appears to require a conformation different from that in the crystal structure.	TNO,INST TOXICOL,DEPT BIOL TOXICOL,3700 ZEIST,NETHERLANDS; TNO,INST TOXICOL,DEPT STRUCT ELUCIDAT & INSTRUMENTAL ANAL,3700 ZEIST,NETHERLANDS; UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLLEGE PK,MD 20742	Netherlands Organization Applied Science Research; Netherlands Organization Applied Science Research; University System of Maryland; University of Maryland College Park				Vanderwall, Dana/0000-0003-1076-8788	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030910] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30910] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong R N, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P1; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; ASKELOF P, 1975, BIOCHEM J, V147, P513, DOI 10.1042/bj1470513; BARYCKI JJ, 1993, BIOCHEMISTRY-US, V32, P13002, DOI 10.1021/bi00211a008; BLACK SM, 1991, PHARMACOL THERAPEUT, V51, P139, DOI 10.1016/0163-7258(91)90044-M; CACCURI AM, 1992, ARCH BIOCHEM BIOPHYS, V297, P119, DOI 10.1016/0003-9861(92)90648-G; CHEN WL, 1992, BIOCHEM J, V286, P205, DOI 10.1042/bj2860205; Cleland W W, 1979, Methods Enzymol, V63, P103; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HSIEH JC, 1991, BIOCHEM J, V278, P293, DOI 10.1042/bj2780293; JI X, 1993, BIOCHEMISTRY-US, V32, P12949, DOI 10.1021/bi00211a001; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; KATUSZ RM, 1992, ARCH BIOCHEM BIOPHYS, V298, P667, DOI 10.1016/0003-9861(92)90464-8; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; KONG KH, 1992, BIOCHEM BIOPH RES CO, V184, P194, DOI 10.1016/0006-291X(92)91177-R; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MEYER DJ, 1993, BIOCHEM J, V293, P351, DOI 10.1042/bj2930351; PLOEMEN JHTM, 1991, BIOCHEM PHARMACOL, V41, P1665, DOI 10.1016/0006-2952(91)90167-4; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Smith B J, 1988, Methods Mol Biol, V3, P57, DOI 10.1385/0-89603-126-8:57; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; TEW KD, 1988, CANCER RES, V48, P3622; VANBLADEREN PJ, 1991, PHARMACOL THERAPEUT, V51, P35, DOI 10.1016/0163-7258(91)90040-S; VANOMMEN B, 1988, J BIOL CHEM, V263, P12939; VANOMMEN B, 1989, EUR J BIOCHEM, V181, P423; VANOMMEN B, 1991, BIOCHEM J, V276, P661, DOI 10.1042/bj2760661; WAXMAN DJ, 1990, CANCER RES, V50, P6449; WIDERSTEN M, 1991, FEBS LETT, V293, P156, DOI 10.1016/0014-5793(91)81175-8; ZHANG PH, 1990, BIOPOLYMERS, V29, P159, DOI 10.1002/bip.360290121	38	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26890	26897						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929428				2022-12-25	WOS:A1994PQ93100049
J	AGARWAL, AK; MUNE, T; MONDER, C; WHITE, PC				AGARWAL, AK; MUNE, T; MONDER, C; WHITE, PC			NAD(+)-DEPENDENT ISOFORM OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE - CLONING AND CHARACTERIZATION OF CDNA FROM SHEEP KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							APPARENT MINERALOCORTICOID EXCESS; CORTICOSTEROID 11-BETA-DEHYDROGENASE; EXPRESSION; TISSUE; LOCALIZATION; GENE; PURIFICATION; RECEPTOR; DEFECTS; ENZYME	11 beta-Hydroxysteroid dehydrogenase (11-HSD) catalyzes the conversion of cortisol to cortisone and corticosterone to 11-dehydrocorticosterone. This activity may be required to confer normal ligand specificity upon the mineralocorticoid receptor. Although an isozyme of 11-HSD was previously isolated from rat liver, a different isozyme is apparently expressed in mineralocorticoid target tissues. We isolated a sheep kidney cDNA clone encoding this isozyme by expression screening using Xenopus oocytes. The cDNA is 1.8 kilobase pairs in length and encodes a protein of 427 amino acid residues with a predicted M(r) of 46,700. When expressed in oocytes, this enzyme functions as an NAD(+)-dependent 11 beta-dehydrogenase with very high affinity for steroids, but it has no detectable reductase activity. It is 37% identical in amino acid sequence to an NAD(+)-dependent isozyme of 17 beta-hydroxysteroid dehydrogenase but only 20% identical to the NADP(+)-dependent liver isozyme of 11-HSD. It is expressed at high levels in the kidney and adrenal and at lower levels in the colon. The corresponding gene is present in a single copy in the sheep genome. In humans, this gene is a candidate locus for the syndrome of apparent mineralocorticoid excess, a form of hypertension postulated to result from 11-HSD deficiency in mineralocorticoid target tissues.	NEW YORK HOSP,CORNELL MED CTR,DEPT PEDIAT,NEW YORK,NY 10021; POPULAT COUNCIL,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital; Population Council					NIDDK NIH HHS [DK42169, DK37094] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042169, R01DK037094] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; BROWN RW, 1993, ENDOCRINOLOGY, V132, P2614, DOI 10.1210/en.132.6.2614; CHEN Z, 1993, BIOCHEMISTRY-US, V32, P3342, DOI 10.1021/bi00064a017; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo-123-5-2390; MONDER C, 1989, ENDOCRINOLOGY, V125, P1046, DOI 10.1210/endo-125-2-1046; MONDER C, 1993, VITAM HORM, V47, P187, DOI 10.1016/S0083-6729(08)60447-1; NIKKILA H, 1993, J CLIN ENDOCR METAB, V77, P687, DOI 10.1210/jc.77.3.687; OBEID J, 1992, BIOCHEM BIOPH RES CO, V188, P222, DOI 10.1016/0006-291X(92)92373-6; OBERFIELD SE, 1983, J CLIN ENDOCR METAB, V56, P332, DOI 10.1210/jcem-56-2-332; RUNDLE SE, 1989, ENDOCRINOLOGY, V125, P1700, DOI 10.1210/endo-125-3-1700; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; STEWART PM, 1994, J CLIN ENDOCR METAB, V78, P1529, DOI 10.1210/jc.78.6.1529; TAKAHASHI T, 1992, GENET ANAL-BIOMOL E, V9, P91, DOI 10.1016/1050-3862(92)90004-O; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; ULICK S, 1979, J CLIN ENDOCR METAB, V49, P757, DOI 10.1210/jcem-49-5-757; WU L, 1993, J BIOL CHEM, V268, P12964; YANG K, 1994, J STEROID BIOCHEM, V49, P245, DOI 10.1016/0960-0760(94)90016-7; YANG K, 1992, ENDOCRINOLOGY, V131, P2120, DOI 10.1210/en.131.5.2120	26	251	255	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25959	25962						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929304				2022-12-25	WOS:A1994PQ93000005
J	BIRMAN, S; MORGAN, B; ANZIVINO, M; HIRSH, J				BIRMAN, S; MORGAN, B; ANZIVINO, M; HIRSH, J			A NOVEL AND MAJOR ISOFORM OF TYROSINE-HYDROXYLASE IN DROSOPHILA IS GENERATED BY ALTERNATIVE RNA PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPA-DECARBOXYLASE GENE; CATECHOLAMINE-CONTAINING NEURONS; MULTIPLE MESSENGER-RNAS; NERVOUS-SYSTEM; MELANOGASTER; EXPRESSION; PHOSPHORYLATION; ENZYME; TRANSCRIPTS; DOMAINS	We report that two isoforms of Drosophila tyrosine hydroxylase protein are encoded via alternatively spliced exons. The major isoform (Type II) contains a novel acidic extension of 71 amino acids in the aminoterminal regulatory domain, which is likely to alter the regulatory properties of the tyrosine hydroxylase protein. The minor isoform (Type I) corresponds to the cDNA sequence reported previously (1). We also report the structure of the Drosophila tyrosine hydroxylase (DTH) gene and the diversity and tissue localization of its transcripts. At least three types of DTH mRNA are generated from a single primary transcript through alternative splicing and polyadenylation. Type II mRNA is the most abundant tyrosine hydroxylase transcript in Drosophila and is found predominantly in the hypoderm throughout all stages of development. Type I mRNA is present only in the CNS, where it is the primary form. The DTH transcripts detected in the CNS contain a longer 3'-untranslated region than the transcript expressed in the hypoderm, due to differential polyadenylation. In contrast, the same start site is used for DTH gene transcription in both tissues. These results show unexpected diversity in the DTH transcripts and point out possible mechanisms for differential regulation of tyrosine hydroxylase activity in the CNS and in the hypoderm.			BIRMAN, S (corresponding author), UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22903, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027318] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27318] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1988, BIOCHEM BIOPH RES CO, V151, P1446, DOI 10.1016/S0006-291X(88)80524-2; AKAM ME, 1985, EMBO J, V4, P1689, DOI 10.1002/j.1460-2075.1985.tb03838.x; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BANERJEE SA, 1992, J NEUROSCI, V12, P4460; BEALL CJ, 1987, GENE DEV, V1, P510, DOI 10.1101/gad.1.5.510; BOURDELLES BL, 1991, J BIOL CHEM, V266, P17124; BRAY SJ, 1988, EMBO J, V7, P177, DOI 10.1002/j.1460-2075.1988.tb02798.x; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BROWN ER, 1987, BIOCHEMISTRY-US, V26, P5208, DOI 10.1021/bi00390a046; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BUDNIK V, 1988, J COMP NEUROL, V268, P400, DOI 10.1002/cne.902680309; BUDNIK V, 1986, J NEUROSCI, V6, P3682; BUDNIK V, 1987, J NEUROGENET, V4, P309, DOI 10.3109/01677068709102351; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; D'MELLO SR, 1989, J NEUROSCI RES, V23, P31, DOI 10.1002/jnr.490230105; DAUBNER SC, 1993, PROTEIN SCI, V2, P1452, DOI 10.1002/pro.5560020909; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; EVELETH DD, 1986, EMBO J, V5, P2663, DOI 10.1002/j.1460-2075.1986.tb04549.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HIRSH J, 1981, MOL CELL BIOL, V1, P475, DOI 10.1128/MCB.1.6.475; HIRSH J, 1989, DEV GENET, V10, P232, DOI 10.1002/dvg.1020100312; HOPKINS TL, 1992, ANNU REV ENTOMOL, V37, P273, DOI 10.1146/annurev.en.37.010192.001421; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; ICHIKAWA S, 1990, BIOCHEM BIOPH RES CO, V173, P1331, DOI 10.1016/S0006-291X(05)80933-7; IWATA N, 1992, BIOCHEM BIOPH RES CO, V182, P348, DOI 10.1016/S0006-291X(05)80151-2; JOHNSON WA, 1989, GENE DEV, V3, P676, DOI 10.1101/gad.3.5.676; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KOBAYASHI K, 1988, J BIOCHEM, V103, P907, DOI 10.1093/oxfordjournals.jbchem.a122386; KONRAD KD, 1987, DEV BIOL, V122, P172, DOI 10.1016/0012-1606(87)90343-5; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LEDLEY FD, 1985, BIOCHEMISTRY-US, V24, P3389, DOI 10.1021/bi00335a001; LEVITT M, 1965, J PHARMACOL EXP THER, V148, P1; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIVINGSTONE MS, 1983, NATURE, V303, P67, DOI 10.1038/303067a0; LUNDELL MJ, 1992, DEV BIOL, V154, P84, DOI 10.1016/0012-1606(92)90050-Q; Maniatis T, 1989, DECONTAMINATION DILU; MARKEY KA, 1980, MOL PHARMACOL, V17, P79; MARSH JL, 1980, DEV BIOL, V80, P379, DOI 10.1016/0012-1606(80)90412-1; MARTINEZRAMIREZ AC, 1992, INSECT BIOCHEM MOLEC, V22, P491, DOI 10.1016/0965-1748(92)90145-5; MASTICK GS, 1992, MOL CELL BIOL, V12, P5659, DOI 10.1128/MCB.12.12.5659; MORGAN BA, 1986, EMBO J, V5, P3335, DOI 10.1002/j.1460-2075.1986.tb04648.x; NAGATSU T, 1991, NEUROSCI RES, V12, P315, DOI 10.1016/0168-0102(91)90001-F; NAGATSU T, 1991, COMP BIOCHEM PHYS C, V98, P203; NASSEL DR, 1992, CELL TISSUE RES, V267, P147, DOI 10.1007/BF00318701; NECKAMEYER WS, 1993, J NEUROGENET, V8, P189, DOI 10.3109/01677069309083448; NECKAMEYER WS, 1989, NEURON, V2, P1167, DOI 10.1016/0896-6273(89)90183-9; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; OKUNO S, 1991, J NEUROCHEM, V57, P53, DOI 10.1111/j.1471-4159.1991.tb02098.x; OMALLEY KL, 1987, BIOCHEMISTRY-US, V26, P6910, DOI 10.1021/bi00396a007; ORCHARD I, 1990, J INSECT PHYSIOL, V36, P593, DOI 10.1016/0022-1910(90)90028-E; OWEN MD, 1992, INSECT BIOCHEM MOLEC, V22, P193, DOI 10.1016/0965-1748(92)90159-C; RESTIFO LL, 1990, ADV INSECT PHYSL, V22, P116; RIBEIRO P, 1993, J MOL NEUROSCI, V4, P125, DOI 10.1007/BF02782125; ROSENFELD MG, 1984, SCIENCE, V225, P1315, DOI 10.1126/science.6089345; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLNICK SB, 1986, SCIENCE, V234, P998, DOI 10.1126/science.3095924; SHEN J, 1993, MOL CELL BIOL, V13, P4549, DOI 10.1128/MCB.13.8.4549; STROEHER VL, 1988, MOL CELL BIOL, V8, P4143, DOI 10.1128/MCB.8.10.4143; VALLES AM, 1986, J NEUROSCI, V6, P1482; VIGNY A, 1982, BIOCHEM BIOPH RES CO, V106, P1, DOI 10.1016/0006-291X(82)92049-6; VIGNY A, 1981, J NEUROCHEM, V36, P483, DOI 10.1111/j.1471-4159.1981.tb01618.x; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WRIGHT TRF, 1976, GENETICS, V84, P287; WRIGHT TRF, 1976, GENETICS, V84, P267; WRIGHT TRF, 1987, ADV GENET, V24, P127, DOI 10.1016/s0065-2660(08)60008-5; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	69	65	67	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26559	26567						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929381				2022-12-25	WOS:A1994PQ93000094
J	SHERMAN, JA; MATSON, SW				SHERMAN, JA; MATSON, SW			ESCHERICHIA-COLI DNA HELICASE-I CATALYZES A SEQUENCE-SPECIFIC CLEAVAGE LIGATION REACTION AT THE F-PLASMID ORIGIN OF TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SEX FACTOR; BACTERIAL CONJUGATION; NICKING REACTION; GENE-PRODUCT; PROTEIN; PURIFICATION; ENZYME; FLAC; TRAI	Recent studies have shown that the Escherichia coli F plasmid-encoded traI gene product (TraIp), also known as DNA helicase I, catalyzes the formation of the site- and strand-specific nick that initiates F plasmid DNA transfer. Scission of the phosphodiester bond at the nic site within the origin of transfer (oriT) is accompanied by the covalent attachment of TraIp to the 5'-phosphate of the nicked DNA strand. This mechanism suggests that TraIp may also be capable of catalyzing a DNA ligation reaction using the energy stored in the protein-DNA intermediate. To test this possibility, an in vitro assay was designed that utilized short single-stranded DNA oligonucleotides of different lengths derived from the region within oriT that spanned the nic site. Purified TraIp was capable of efficiently cleaving single-stranded DNA that contained a nic site, and upon cleavage, the protein became covalently linked to the 5-'end of the nic site. When TraIp was incubated with two oligonucleotides of different length that contained the nic site, there was formation of novel recombinant products resulting from a TraIp-catalyzed cleavage/ligation reaction. Furthermore, the cleavage and ligation reactions were both sequence-specific. These data suggest that TraIp plays an important role in the initiation and termination of conjugative DNA transfer.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET & MOLEC BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM 33476] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P431, DOI 10.1111/j.1432-1033.1976.tb10358.x; ACHTMAN M, 1972, J BACTERIOL, V110, P831, DOI 10.1128/JB.110.3.831-842.1972; Ausubel FM, 1994, CURRENT PROTOCOLS MO; DILAURENZIO L, 1992, MOL MICROBIOL, V6, P2951; EISENBERG S, 1977, P NATL ACAD SCI USA, V74, P3198, DOI 10.1073/pnas.74.8.3198; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; GAO Q, 1994, MOL MICROBIOL, V11, P449, DOI 10.1111/j.1365-2958.1994.tb00326.x; Ippen-Ihler K., 1993, BACTERIAL CONJUGATIO, P23; KINGSMAN A, 1978, J MOL BIOL, V122, P287, DOI 10.1016/0022-2836(78)90191-2; KLINE BC, 1971, BIOCHEMISTRY-US, V10, P4975, DOI 10.1021/bi00802a022; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; MATSON SW, 1991, J BIOL CHEM, V266, P16232; MATSON SW, 1993, J BACTERIOL, V175, P2599, DOI 10.1128/JB.175.9.2599-2606.1993; NELSON WC, 1993, J BACTERIOL, V175, P2221, DOI 10.1128/JB.175.8.2221-2228.1993; PANICKER MM, 1992, J BIOL CHEM, V267, P12761; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P11538, DOI 10.1073/pnas.90.24.11538; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P2925, DOI 10.1073/pnas.90.7.2925; REYGERS U, 1991, EMBO J, V10, P2689, DOI 10.1002/j.1460-2075.1991.tb07812.x; SCHERZINGER E, 1993, EUR J BIOCHEM, V217, P929, DOI 10.1111/j.1432-1033.1993.tb18323.x; SILVERMAN P, 1986, BACTERIAL OUTER MEMB, P277; Wilkins B, 1993, BACTERIAL CONJUGATIO, P105; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; WILLETTS N, 1980, ANNU REV GENET, V14, P41, DOI 10.1146/annurev.ge.14.120180.000353	25	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26220	26226						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929337				2022-12-25	WOS:A1994PQ93000045
J	MIZOKAMI, A; CHANG, CS				MIZOKAMI, A; CHANG, CS			INDUCTION OF TRANSLATION BY THE 5'-UNTRANSLATED REGION OF HUMAN ANDROGEN RECEPTOR MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' UNTRANSLATED REGION; MESSENGER-RNA; SECONDARY STRUCTURE; HUMAN TISSUES; GROWTH-FACTOR; GENE; EFFICIENCY; RESISTANCE; FERRITIN; ELEMENT	Androgens and androgen receptor (AR) play important roles in sexual differentiation and prostatic cancer cell proliferation. To investigate the regulation of AR expression, a 2-kilobase pair 5'-flanking region of human AR gene including a 0.6-kilobase pair 5'-untranslated region (5'-UTR) was ligated to a chloramphenicol acetyltransferase (CAT) gene and characterized by CAT assay after transfection into HeLa cells. The results revealed that AR 5'-UTR was absolutely needed for the induction of CAT activity, but could not function as an enhancer for the AR transcription. A further study using a 180 base pairs (+21 to +202 including a stem-loop secondary structure at +109 to +129) within the AR 5'-UTR demonstrated that this region was sufficient to induce more CAT activity without changing the CAT mRNA expression. Taken together, these results strongly suggested that 5'-UTR of AR mRNA plays an essential role in the induction of AR translation, which may represent the first reported translational induction mechanism in the steroid receptor superfamily.	UNIV WISCONSIN,CTR COMPREHENS CANC,DEPT HUMAN ONCOL,MADISON,WI 53792; UNIV WISCONSIN,ENDOCRINOL REPROD PHYSIOL PROGRAM,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					PHS HHS [55639] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHODAK GW, 1992, J UROLOGY, V147, P798, DOI 10.1016/S0022-5347(17)37389-5; FABER PW, 1993, J BIOL CHEM, V268, P9296; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; GALLIE DR, 1988, NUCLEIC ACIDS RES, V16, P883, DOI 10.1093/nar/16.3.883; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KIM SJ, 1992, J BIOL CHEM, V267, P13702; KIMURA N, 1993, J HISTOCHEM CYTOCHEM, V41, P671, DOI 10.1177/41.5.8468448; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MARCELLI M, 1992, J ENDOCRINOL INVEST, V15, P149, DOI 10.1007/BF03348684; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; MIZOKAMI A, 1992, ENDOCRINOL JAPON, V39, P235; MIZOKAMI A, 1994, MOL ENDOCRINOL, V8, P77, DOI 10.1210/me.8.1.77; MOWSZOWICZ I, 1993, MOL ENDOCRINOL, V7, P861, DOI 10.1210/me.7.7.861; MOWSZOWICZ I, 1993, ENDOCR J, V1, P203; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PATEL RC, 1992, J BIOL CHEM, V267, P1159; PIEKARZ RL, 1993, J BIOL CHEM, V268, P7613; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RAO SM, 1993, J BIOL CHEM, V268, P22164; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; ROMEO DS, 1993, MOL ENDOCRINOL, V7, P759, DOI 10.1210/me.7.6.759; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; Sambrook J, 1989, MOL CLONING LABORATO; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; TIMMER RT, 1993, J BIOL CHEM, V268, P9504; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; YOUNG W, 1994, ENDOCRINE, V2, P321	35	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25655	25659						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929269				2022-12-25	WOS:A1994PQ49100065
J	HECK, RW; TANHAUSER, SM; MANDA, R; TU, CK; LAIPIS, PJ; SILVERMAN, DN				HECK, RW; TANHAUSER, SM; MANDA, R; TU, CK; LAIPIS, PJ; SILVERMAN, DN			CATALYTIC PROPERTIES OF MOUSE CARBONIC-ANHYDRASE-V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXIDE HYDRATION ACTIVITY; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; EXPRESSION; MECHANISM; NUCLEOTIDE; ISOENZYME; CLONING	A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH,terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several aminoterminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a pro tein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of k(cat)/K-m at 3 x 10(7) M(-1) s(-1) and k(cat) at 3 x 10(5) s(-1) with an apparent pK(a), for catalysis of 7.4 determined from k(cat)/K-m. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr(64) --> His showed that the unique kinetic properties of CAV are not due to the presence of tyrosine at position 64.	UNIV FLORIDA,COLL MED,DEPT PHARMACOL & THERAPEUT,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMORGUERET M, 1990, NUCLEIC ACIDS RES, V18, P1646, DOI 10.1093/nar/18.6.1646; DATTA PK, 1959, ARCH BIOCHEM BIOPHYS, V81, P124, DOI 10.1016/0003-9861(59)90182-1; DODGSON SJ, 1989, AM J PHYSIOL, V257, pE791, DOI 10.1152/ajpendo.1989.257.6.E791; DODGSON SJ, 1991, CARBONIC ANHYDRASES, P297; ERIKSSON AE, 1988, PROTEINS, V4, P283, DOI 10.1002/prot.340040407; FRASER PJ, 1986, J MOL EVOL, V23, P294, DOI 10.1007/BF02100637; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENDRICK JP, 1989, BIOCHEMISTRY-US, V28, P4056; HEWETTEMMETT D, 1986, ISOZYME B, V19, P13; JEWELL DA, 1991, BIOCHEMISTRY-US, V30, P1484, DOI 10.1021/bi00220a006; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KHALIFAH RG, 1977, BIOCHEMISTRY-US, V16, P2241, DOI 10.1021/bi00629a031; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIANG ZW, 1993, EUR J BIOCHEM, V211, P821, DOI 10.1111/j.1432-1033.1993.tb17614.x; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MAREN TH, 1967, MOL PHARMACOL, V3, P503; NAGAO Y, 1993, P NATL ACAD SCI USA, V90, P7623, DOI 10.1073/pnas.90.16.7623; OHLIGER DE, 1993, FASEB J, V7, pA676; POCKER Y, 1967, BIOCHEMISTRY-US, V6, P668, DOI 10.1021/bi00855a005; SANYAL G, 1982, MOL PHARMACOL, V22, P211; SEGEL IH, 1975, ENZYME KINETICS, P150; SILVERMAN DN, 1982, METHOD ENZYMOL, V87, P732; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; SIMONSSON I, 1982, EUR J BIOCHEM, V123, P29, DOI 10.1111/j.1432-1033.1982.tb06494.x; SIMONSSON I, 1979, EUR J BIOCHEM, V93, P409, DOI 10.1111/j.1432-1033.1979.tb12837.x; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; TWEEDIE S, 1989, BIOCHEM GENET, V27, P17, DOI 10.1007/BF00563015; VENTA PJ, 1985, J BIOL CHEM, V260, P2130	30	54	54	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24742	24746						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929150				2022-12-25	WOS:A1994PQ49000037
J	RAMANATHAN, M; LANTZ, M; MACGREGOR, RD; GAROVOY, MR; HUNT, CA				RAMANATHAN, M; LANTZ, M; MACGREGOR, RD; GAROVOY, MR; HUNT, CA			CHARACTERIZATION OF THE OLIGODEOXYNUCLEOTIDE-MEDIATED INHIBITION OF INTERFERON-GAMMA-INDUCED MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I AND INTERCELLULAR-ADHESION MOLECULE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE OLIGONUCLEOTIDES; ENHANCED EXPRESSION; CELL-LINES; ANTIGENS; ICAM-1; ACTIVATION; ANTIBODIES; MACROPHAGE; ALLOGRAFT; INDUCTION	The major histocompatibility complex (MHC) Class I and II genes and intercellular adhesion molecule-1 (ICAM-1) are regulated by interferon-gamma in a variety of cell types. We have previously shown that the oligodeoxynucleotide 5'-GGG GTT GGT TGT GTT GGG TGT TGT GT-RNH(2) (oligo I) inhibits the interferon-gamma-mediated enhancement of MHC Class I and ICAM-1 proteins in the K562 cell line. We have now investigated the mechanism of action of oligo I and report that it acts by inhibiting the binding of interferon-gamma to cells. We also show that the dose-response curves, the selectivity profile, and the kinetics of oligo I are consistent with this novel mechanism of action. The dose-response curves for oligo I, obtained using antibodies against the MHC Class I heavy chain, beta(2)-microglobulin, or ICAM-1, are almost superimposable at each observation time. MHC Class I induction by 6400 units/ml interferon-alpha or interferon-beta or ICAM-1 enhancement by 800 units/ml tumor necrosis factor-alpha is not inhibited by oligo I. However, the synergistic induction of MHC Class I by mixtures of tumor necrosis factor-alpha and interferon-gamma is inhibited. Oligo I belongs to a class of active oligodeoxynucleotides that inhibits interferon-gamma-induced MHC Class I and ICAM-1 in K562 cells. The activity and potency is sequence-dependent, but remarkably different sequences can have comparable effects. The activity of oligo I in the HeLa S3 cell line inhibits the interferon-gamma-mediated enhancement of both ICAM-1 and MHC Class II DR and the interferon-gamma-mediated reduction in transferrin receptor expression. Thus, oligo I appears to specifically inhibit interferon-gamma-induced changes in protein expression, which is consistent with oligo I acting at an early step(s) in the induction process. Taken together, our results show that oligo I exerts its effects by inhibiting the association of interferon-gamma with the cell surface, which is a novel mechanism of action for oligodeoxynucleotides.	UNIV CALIF SAN FRANCISCO,UNIV CALIF SAN FRANCISCO UNIV CALIF BERKELEY PROG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARM & PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California Berkeley; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Hunt, C. Anthony/0000-0001-9372-6860				CHIANG MY, 1991, J BIOL CHEM, V266, P18162; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FAUSTMAN D, 1991, SCIENCE, V252, P1700, DOI 10.1126/science.1710828; FEDOSEYEVA EV, 1994, TRANSPLANTATION, V52, P606; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; KANBE M, 1992, ANTI-CANCER DRUG DES, V7, P341; LICHTENSTEIN A, 1992, CELL IMMUNOL, V141, P219, DOI 10.1016/0008-8749(92)90141-B; LINDAHL P, 1976, P NATL ACAD SCI USA, V73, P1284, DOI 10.1073/pnas.73.4.1284; NORONHA IL, 1992, TRANSPLANTATION, V54, P1017, DOI 10.1097/00007890-199212000-00015; PACE JL, 1983, J IMMUNOL, V130, P2011; RAMANATHAN M, 1994, TRANSPLANTATION, V52, P612; ROSA FM, 1988, J IMMUNOL, V140, P1660; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; SIEGRIST CA, 1993, EUR J IMMUNOL, V23, P2903, DOI 10.1002/eji.1830231126; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; WONG GHW, 1983, J IMMUNOL, V131, P788	19	30	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24564	24574						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929128				2022-12-25	WOS:A1994PQ49000012
J	SPEAR, DH; ERICSSON, J; JACKSON, SM; EDWARDS, PA				SPEAR, DH; ERICSSON, J; JACKSON, SM; EDWARDS, PA			IDENTIFICATION OF A 6-BASE PAIR ELEMENT INVOLVED IN THE STEROL-MEDIATED TRANSCRIPTIONAL REGULATION OF FARNESYL DIPHOSPHATE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; MOLECULAR-CLONING; PROTEIN-BINDING; RECEPTOR GENE; PROMOTER; PRENYLTRANSFERASE; EXPRESSION; SEQUENCE; PATHWAY	Previous studies identified a 115-base pair (bp) region of the farnesyl diphosphate (FPP) synthase promoter which is involved in the transcriptional regulation of this gene by sterols (Spear, D. H., Kutsunai, S. Y., Correll, C. C., and Edwards, P A. (1992) J. Biol. Chem. 267, 14462-14469). In the current study we fused a 117-bp fragment, containing this region of interest, upstream of the heterologous minimal promoter of the herpes simplex virus thymidine kinase gene linked to the chloramphenicol acetyltransferase (CAT) reporter gene. Chinese hamster ovary (CHO) cells were stably transfected with this fusion gene and incubated in the absence or presence of sterols. Analysis of CAT mRNA by primer extension indicated that transcription of the fusion gene was under sterol-mediated control, Thus, when cellular sterols were present, the CAT mRNA levels were reduced 2-4-fold. To further localize the FPP synthase sterol-responsive element(s), additional promoter-reporter gene constructs containing either deletions or mutations were constructed and transfected into CHO or CV-1 cells. These studies localized a 6-bp region (ATTGGC) that is required for both transcriptional induction in the absence of sterols and transcriptional repression in the presence of sterols. Gel shift and footprinting analyses demonstrated that nuclear proteins isolated from CHO cells bound to six distinct regions of the promoter between nucleotides -293 to -47. Taken together, these results further define both the cis-acting elements controlling normal transcription of the FPP synthase gene and identify a novel sequence involved in sterol regulation.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles			Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	NHLBI NIH HHS [HL 30568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ARCOT SS, 1989, J BIOL CHEM, V264, P2343; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; PANG JH, 1993, J BIOL CHEM, V268, P2909; POULTER CD, 1981, BIOSYNTHESIS ISOPREN, V1, P162; RILLING HC, 1985, STEROLS BILE ACIDS, P17; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SPEAR D, 1993, SRATEGIES MOL BIOL, V6, P10; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	31	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25212	25218						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929210				2022-12-25	WOS:A1994PQ49000102
J	BERNIER, F; LEBLANC, G; LABRIE, F; LUUTHE, V				BERNIER, F; LEBLANC, G; LABRIE, F; LUUTHE, V			STRUCTURE OF HUMAN ESTROGEN AND ARYL SULFOTRANSFERASE GENE - 2 MESSENGER-RNA SPECIES ISSUED FROM A SINGLE-GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; DEHYDROEPIANDROSTERONE SULFOTRANSFERASE; MAMMARY-CANCER; MESSENGER-RNA; HUMAN LIVER; RAT-LIVER; EXPRESSION; CDNA; N-HYDROXY-2-ACETYLAMINOFLUORENE; METABOLISM	Estrone sulfate is the predominant form of estrogens found in the circulation in women and could thus serve as precursor for active estrogens in target tissues by removal of the sulfate group through the action of endogenous steroid sulfatase. Recently, we isolated a cDNA encoding human placental estrogen sulfotransferase that differs fi om brain aryl sulfotransferase only in the 5'-noncoding sequence. To increase our knowledge of the regulation and tissue-specific expression of the sulfotransferase gene, we screened a lambda EMBL3 Library of human leucocyte genomic DNA using the estrogen sulfotransferase cDNA as probe and isolated a clone containing almost the whole gene sequence. Sequencing of the gene indicates that it is included in approximately 7.7 kilobases and contains nine short exons separated by eight introns. The two first exons, named exon la and exon Ib, are noncoding and correspond to the 5'-untranslated sequences of human brain and human placental estrogen sulfotransferase cDNAs, respectively. Transfection of chloramphenicol acetyltransferase reporter gene vectors containing the 5'-flanking sequence upstream from exon la and exon Ib in human adrenal adenocarcinoma cells indicates that both sequences possess promoter activity. The present results thus indicate that brain aryl sulfotransferase and placental human placental estrogen sulfotransferase mRNA species are transcribed from a single gene by alternate exon 1a and exon 1b promoters, respectively. Using DNA from panels of human/rodent somatic cell hybrids and amplification of the gene by polymerase chain reaction, the human placental estrogen sulfotransferase gene was assigned to chromosome 16.	CHUL,RES CTR,MRC,MOLEC ENDOCRINOL GRP,MONTREAL G1V 4G2,PQ,CANADA; UNIV LAVAL,MONTREAL G1V 4G2,PQ,CANADA	Laval University; Laval University			Bernier, Francois/V-7150-2018; Bernier, Francois/AAP-2174-2020					ADAMS JB, 1990, J STEROID BIOCHEM, V36, P695, DOI 10.1016/0022-4731(90)90190-4; BERNIER F, 1994, MOL CELL ENDOCRINOL, V99, pR11, DOI 10.1016/0303-7207(94)90159-7; BERWAER M, 1994, MOL ENDOCRINOL, V8, P635, DOI 10.1210/me.8.5.635; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BUIRCHELL BJ, 1975, J STEROID BIOCHEM, V6, P1489, DOI 10.1016/0022-4731(75)90202-2; COMER KA, 1992, MOL PHARMACOL, V41, P645; DEBAUN JR, 1970, CANCER RES, V30, P577; DEMYAN WF, 1992, MOL ENDOCRINOL, V6, P589, DOI 10.1210/me.6.4.589; DICZFALUSY E, 1969, FOETUS PLACENTA, P191; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; DUMONT M, 1992, J INVEST DERMATOL, V99, P415, DOI 10.1111/1523-1747.ep12616131; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P199; KAREN L, 1987, CURRENT PROTOCOLS MO; KINGSTON RE, 1991, CURRENT PROTOCOLS MO; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LORIAUX DL, 1971, STEROIDS, V18, P463, DOI 10.1016/0039-128X(71)90059-6; MANCINI MA, 1992, ENDOCRINOLOGY, V131, P1541, DOI 10.1210/en.131.3.1541; Maniatis T., 1982, MOL CLONING; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Mulder G.J., 1990, CONJUGATION REACTION, P107; NABESHIMA YI, 1984, NATURE, V308, P333, DOI 10.1038/308333a0; NAGATA K, 1993, J BIOL CHEM, V268, P24720; NASH AR, 1988, AUST J BIOL SCI, V41, P507; OEDA T, 1992, MOL ENDOCRINOL, V6, P1216, DOI 10.1210/me.6.8.1216; OGURA K, 1990, BIOCHEM BIOPH RES CO, V166, P1494, DOI 10.1016/0006-291X(90)91036-R; OTTERNESS DM, 1992, MOL PHARMACOL, V41, P865; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RUDER HJ, 1972, J CLIN INVEST, V51, P1020, DOI 10.1172/JCI106862; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTNER SJ, 1984, J CLIN ENDOCR METAB, V59, P29, DOI 10.1210/jcem-59-1-29; SIMPSON E, 1992, J STEROID BIOCHEM, V41, P409, DOI 10.1016/0960-0760(92)90366-Q; THE VL, 1989, MOL ENDOCRINOL, V3, P1301, DOI 10.1210/mend-3-8-1301; VIGNON F, 1980, ENDOCRINOLOGY, V106, P1079, DOI 10.1210/endo-106-4-1079; WILBORN TW, 1993, MOL PHARMACOL, V43, P70; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V192, P671, DOI 10.1006/bbrc.1993.1467; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V195, P120, DOI 10.1006/bbrc.1993.2018	40	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28200	28205						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961757				2022-12-25	WOS:A1994PV77200065
J	HO, AM; JAIN, J; RAO, A; HOGAN, PG				HO, AM; JAIN, J; RAO, A; HOGAN, PG			EXPRESSION OF THE TRANSCRIPTION FACTOR NFATP IN A NEURONAL CELL-LINE AND IN THE MURINE NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; CIS-ACTING ELEMENT; NUCLEAR FACTOR; CYCLOSPORINE-A; GENE-EXPRESSION; SPINAL-CORD; NF-AT; FOS; PROTEIN; BINDING	The transcription factor NFATp, which has a central role in cytokine gene induction in T cells, was previously thought to be expressed only in T cells and other immune cells. Here we report that NFATp, is also expressed in the rat PC12 pheochromocytoma cell line and in the murine nervous system. Antisera against T cell NFATp recognize proteins of similar apparent molecular weight in T cells, PC12 cells, and murine olfactory bulb. The immunoreactive proteins from PC12 cells and from olfactory bulb bind to an NFAT site of the murine interleukin-2 promoter with the same specificity as T cell NFATp. Immunohistochemical staining localizes NFATp to neurons, specifically to olfactory receptor neurons and to their terminals in the olfactory bulb. The presence of NFATp in the nervous system suggests that it has a role in the transcription of specific neuronal genes in response to increases in cytosolic calcium.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [CA42471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042471, R01CA042471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTIGLI E, 1993, J IMMUNOL, V150, P3284; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4412, DOI 10.1073/pnas.91.10.4412; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TOKUMITSU H, 1993, BIOCHEM BIOPH RES CO, V196, P737, DOI 10.1006/bbrc.1993.2311; VALGEARCHER VE, 1990, J IMMUNOL, V145, P4355; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; YASEEN NR, 1993, J BIOL CHEM, V268, P14285	38	117	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28181	28186						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961754				2022-12-25	WOS:A1994PV77200062
J	ISHIBASHI, S; HAMMER, RE; HERZ, J				ISHIBASHI, S; HAMMER, RE; HERZ, J			ASIALOGLYCOPROTEIN RECEPTOR DEFICIENCY IN MICE LACKING THE MINOR RECEPTOR SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							APOLIPOPROTEIN-E; RAT-LIVER; CELLS; CDNA; HYPERCHOLESTEROLEMIA; CLEARANCE; PROTEINS; SEQUENCE; SURFACE; TRANSFECTION	The asialoglycoprotein receptor is an abundant heterooligomeric endocytic receptor that is predominantly expressed on the sinusoidal surface of the hepatocytes. Proposed physiological and pathophysiological functions ascribed to this hepatic lectin (HL) include the removal of desialylated serum glycoproteins and apoptotic cells, clearance of chylomicron remnants, and a role as a homing receptor for lymphatic and metastatic cells. The assembly of two homologous subunits, HL-1 and HL-2, is required to form functional, high affinity receptors on the cell surface. However, the importance of the individual subunits for receptor transport to the cell surface has been controversial. To explore the significance of the minor HL-2 subunit for receptor expression and function in vivo, we have disrupted the HL-2 gene in mice. Homozygous HL-a-deficient animals are superficially normal. However, HL-1 expression in the liver is greatly reduced, indicating that HL-2 may promote HL-1 stability. Although these mice are completely unable to clear asialoorosomucoid, a high affinity ligand for asialoglycoprotein receptor, they do not accumulate desialylated glycoproteins or lipoproteins in their circulation.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ISHIBASHI, S (corresponding author), UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA.			Hammer, Robert E./0000-0001-5487-7551	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; CROSS AS, 1991, J CLIN INVEST, V88, P2067, DOI 10.1172/JCI115536; DINI L, 1992, FEBS LETT, V296, P174, DOI 10.1016/0014-5793(92)80373-O; DRICKAMER K, 1991, CELL, V67, P1029, DOI 10.1016/0092-8674(91)90278-7; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GEFFEN I, 1992, INT REV CYTOL, V137B, P181; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; GRAEVE L, 1990, J BIOL CHEM, V265, P1216; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; MCPHAUL M, 1987, MOL CELL BIOL, V7, P1841, DOI 10.1128/MCB.7.5.1841; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OZAKI K, 1992, J BIOL CHEM, V267, P9229; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; SAMLOWSKI WE, 1984, CELL IMMUNOL, V88, P309, DOI 10.1016/0008-8749(84)90164-3; SANFORD JP, 1990, BIOCHIM BIOPHYS ACTA, V1087, P259, DOI 10.1016/0167-4781(90)90216-O; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SCHLEPPERSCHAFER J, 1981, EUR J CELL BIOL, V25, P95; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; SPIESS M, 1985, J BIOL CHEM, V260, P1979; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WINDLER E, 1991, BIOCHEM J, V276, P79, DOI 10.1042/bj2760079; YEATMAN TJ, 1989, J SURG RES, V46, P567, DOI 10.1016/0022-4804(89)90021-8; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	36	77	92	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27803	27806						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961705				2022-12-25	WOS:A1994PV77200006
J	JOHNSON, RE; PRAKASH, S; PRAKASH, L				JOHNSON, RE; PRAKASH, S; PRAKASH, L			YEAST DNA-REPAIR PROTEIN RADS THAT PROMOTES INSTABILITY OF SIMPLE REPETITIVE SEQUENCES IS A DNA-DEPENDENT ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; COLORECTAL-CANCER; POLYMERASE-III; MUTATIONS; HOMOLOG	The RAD5 gene of Saccharomyces cerevisiae functions in postreplication repair of ultraviolet damaged DNA, and interestingly, it also has a role in increasing the instability of simple repetitive sequences in the genome. In contrast to DNA mismatch repair genes which function in maintaining constant length of repeat sequences, RADS promotes alterations in the length of repeat sequences. In this work, we purify the RADS protein to near homogeneity from yeast cells and show that it is a single-stranded DNA dependent ATPase. The possible roles of RADS ATPase in postreplication gap filling and in increasing the incidence of length alterations of repeat sequences are discussed.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555; UNIV ROCHESTER,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Texas System; University of Texas Medical Branch Galveston; University of Rochester			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19261] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ARMSTRONG JD, 1994, IN PRESS MUTAT RES; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; HAN HJ, 1993, CANCER RES, V53, P5087; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; HUANG CC, 1981, J BIOL CHEM, V256, P4087; IONOV Y, 1993, NATURE, V363, P553; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MADDOX J, 1994, NATURE, V368, P685, DOI 10.1038/368685a0; MIRONOV NM, 1994, CANCER RES, V54, P41; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790	24	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28259	28262						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961763				2022-12-25	WOS:A1994PV77200073
J	OHNISHI, K; TAKEMORI, T				OHNISHI, K; TAKEMORI, T			MOLECULAR-COMPONENTS AND ASSEMBLY OF MU-SURROGATE LIGHT-CHAIN COMPLEXES IN PRE-B-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN GENE REARRANGEMENT; ANTIGEN-RECEPTOR COMPLEX; HEAVY-CHAIN; LYMPHOCYTES-B; TARGETED DISRUPTION; ALLELIC EXCLUSION; TYROSINE KINASES; BINDING-PROTEIN; MEMBRANE EXON; CROSS-LINKING	We describe the molecular components, subunit assembly, and cell surface expression of mu-chain complexes in mu(+)kappa(-) pre-E cell lines as revealed by two-dimensional gel electrophoresis. The mu-chain complexes of these cell lines contain several previously unreported components, p42(6.4), p39(6.7), p18(8.6), and p14(7.0), in addition to lambda 5, VpreB1, VpreB3 (formerly named 8HS20), MB-1(Ig-alpha), and B29(Ig-P). These new components are not detected in mu(+)kappa(+) immature B cell lines. The mu-chain associates with lambda 5, VpreB3, and p56(5.0) at an early phase of assembly, preceding the association of other molecules. mu-Associated VpreB3 decreased during assembly as the association of VpreB1 became dominant, suggesting that the change in the ratio of these two V-L-like surrogate light chains is involved in the mechanism of assembly. lambda 5, VpreB1, p56(5.0), p32(5.0), p36(5.5), and p14(7.0) were shown to be expressed on the cell surface in association with mu-chain. The association of the other molecules with mu-chain is most likely restricted to the intracellular compartment. An interaction between VpreB1 and VpreB3 was also suggested. These findings might be important for understanding the function of mu-chain complexes in pre-B cells. A possible signaling mechanism of mu/surrogate light chain complexes is discussed.	NATL INST HLTH,DEPT IMMUNOL,SHINJUKU KU,TOKYO 162,JAPAN				Takemori, Toshitada/A-5909-2016					BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, J IMMUNOL, V147, P1575; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DAVIDSON WF, 1984, J IMMUNOL, V133, P744; FRIEDRICH RJ, 1993, J IMMUNOL, V150, P2814; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; ISHIHARA K, 1992, P NATL ACAD SCI USA, V89, P633, DOI 10.1073/pnas.89.2.633; Ishihara K, 1991, Dev Immunol, V1, P149, DOI 10.1155/1991/79721; ISHIHARA K, 1993, J IMMUNOL, V150, P2253; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; KARASUYAMA H, 1993, J EXP MED, V178, P469, DOI 10.1084/jem.178.2.469; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KINCADE PW, 1981, J IMMUNOL, V127, P2262; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LENNY N, 1991, J BIOL CHEM, V266, P20532; MATSUO T, 1993, J IMMUNOL, V150, P3766; MATSUO T, 1991, J IMMUNOL, V146, P1584; MATSUUCHI L, 1992, P NATL ACAD SCI USA, V89, P3404, DOI 10.1073/pnas.89.8.3404; MELCHERS F, 1993, IMMUNOL TODAY, V14, P60, DOI 10.1016/0167-5699(93)90060-X; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NAKAMURA T, 1992, P NATL ACAD SCI USA, V89, P8522, DOI 10.1073/pnas.89.18.8522; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; NISHIMOTO N, 1991, P NATL ACAD SCI USA, V88, P6284, DOI 10.1073/pnas.88.14.6284; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; RATHBUN G, 1993, INT IMMUNOL, V5, P997, DOI 10.1093/intimm/5.8.997; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; RUSCONI S, 1985, NATURE, V314, P330, DOI 10.1038/314330a0; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SHIRASAWA T, 1993, EMBO J, V12, P1827, DOI 10.1002/j.1460-2075.1993.tb05831.x; TAKEMORI T, 1987, EMBO J, V6, P951, DOI 10.1002/j.1460-2075.1987.tb04844.x; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; TSUBATA T, 1992, INT IMMUNOL, V4, P637, DOI 10.1093/intimm/4.6.637; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WARNER NL, 1979, IMMUNOL REV, V48, P197, DOI 10.1111/j.1600-065X.1979.tb00304.x; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P118; YELLENSHAW AJ, 1992, J EXP MED, V176, P129, DOI 10.1084/jem.176.1.129	57	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28347	28353						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961773				2022-12-25	WOS:A1994PV77200085
J	KUMAR, KN; BABCOCK, KK; JOHNSON, PS; CHEN, XY; EGGEMAN, KT; MICHAELIS, EK				KUMAR, KN; BABCOCK, KK; JOHNSON, PS; CHEN, XY; EGGEMAN, KT; MICHAELIS, EK			PURIFICATION AND PHARMACOLOGICAL AND IMMUNOCHEMICAL CHARACTERIZATION OF SYNAPTIC MEMBRANE-PROTEINS WITH LIGAND-BINDING PROPERTIES OF N-METHYL-D-ASPARTATE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 MK-801 BINDING; NMDA-RECEPTOR; GLUTAMATE-RECEPTOR; RAT-BRAIN; COMPETITIVE ANTAGONISTS; PHENCYCLIDINE RECEPTOR; FUNCTIONAL EXPRESSION; HIPPOCAMPAL-NEURONS; MOLECULAR-CLONING; CHANNEL COMPLEX	A method was developed for the solubilization of approximately 50% of proteins in synaptic membranes that have ligand-binding characteristics of N-methyl-D-aspartate (NMDA) receptors. Affinity chromatographic separation of the solubilized proteins through L-glutamate-derivatized matrices and subsequent elution by NMDA-containing buffers led to the purification of four predominant proteins with estimated sizes of 67-70, 53-62, 41-43, and 28-36 kDa. The co purification of NMDA-sensitive L-glutamate binding, dizocilpine-sensitive thienylcyclohexyl piperidine (TCP)-binding, and strychnine-insensitive glycine-binding proteins was achieved by this affinity chromatographic procedure. Glutamate, glycine, and the polyamine spermidine increased both the ''on'' rate and the equilibrium level of [H-3]TCP binding to the isolated proteins. The group of proteins eluted by NMDA from the glutamate-derivatized matrices could be further purified through size exclusion chromatography without loss of ligand binding activity or separation of the NMDA-sensitive glutamate-binding from the dizocilpine-sensitive TCP-binding proteins. Polyclonal and monoclonal antibodies to the cloned NMDA receptor protein NMDAR1 did not react with any proteins in the solubilized membrane proteins or the purified fractions. However, immunoreaction of antibodies raised against a glutamate binding protein and a phosphonoaminocarboxylic acid-binding protein indicated that these are two of the major proteins in the purified fractions. These studies indicate that these two proteins might be components of a complex that has some of the characteristics of NMDA receptors and that neuronal membranes may contain varieties of NMDA-like receptors composed of protein subunits that differ from the NMDAR1 and NMDAR2 receptor proteins.	UNIV KANSAS, DEPT PHARMACOL & TOXICOL, LAWRENCE, KS 66045 USA; UNIV KANSAS, CTR NEUROBIOL & IMMUNOL RES, LAWRENCE, KS 66045 USA; NIDA, MOLEC NEUROBIOL LAB, BALTIMORE, MD 21224 USA; UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA	University of Kansas; University of Kansas; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA004732, R01AA004732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA005472] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA04732] Funding Source: Medline; NIDA NIH HHS [DA 05472] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMBAR I, 1988, J NEUROCHEM, V51, P133, DOI 10.1111/j.1471-4159.1988.tb04846.x; BAKKER MHM, 1991, J NEUROCHEM, V57, P39, DOI 10.1111/j.1471-4159.1991.tb02096.x; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BINPARK K, 1989, ANAL BIOCHEM, V180, P55, DOI 10.1016/0003-2697(89)90086-9; BONHAUS DW, 1988, MOL PHARMACOL, V34, P250; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BROSE N, 1993, J BIOL CHEM, V268, P22663; CHEN JW, 1988, J BIOL CHEM, V263, P417; COTMAN CW, 1987, PSYCHOPHARMACOLOGY 3, P197; CUNNINGHAM MD, 1990, J BIOL CHEM, V265, P7768; EATON MJ, 1990, J BIOL CHEM, V265, P16195; EGGEMAN KT, 1993, NEUROSCI LETT, V158, P173, DOI 10.1016/0304-3940(93)90257-L; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; HARING R, 1986, BIOCHEMISTRY-US, V25, P612, DOI 10.1021/bi00351a015; HENLEY JM, 1992, P NATL ACAD SCI USA, V89, P4806, DOI 10.1073/pnas.89.11.4806; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HONORE T, 1989, EUR J PHARM-MOLEC PH, V172, P239, DOI 10.1016/0922-4106(89)90054-0; HUNTER C, 1992, J NEUROCHEM, V58, P1379, DOI 10.1111/j.1471-4159.1992.tb11353.x; IKIN AF, 1990, BIOCHEMISTRY-US, V29, P2290, DOI 10.1021/bi00461a012; JAVITT DC, 1989, MOL PHARMACOL, V35, P387; JAVITT DC, 1990, MOL PHARMACOL, V37, P603; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KERRY CJ, 1993, MOL PHARMACOL, V44, P142; KUMAR KN, 1991, J BIOL CHEM, V266, P14947; KUMAR KN, 1991, NATURE, V354, P70, DOI 10.1038/354070a0; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LY AM, 1991, BIOCHEMISTRY-US, V30, P4307, DOI 10.1021/bi00231a029; MATTSON MP, 1991, BRAIN RES, V565, P94, DOI 10.1016/0006-8993(91)91740-R; MATTSON MP, 1993, J NEUROSCI, V13, P4575; MCKERNAN RM, 1989, J NEUROCHEM, V52, P777, DOI 10.1111/j.1471-4159.1989.tb02522.x; MCVITTIE LD, 1989, LIFE SCI, V44, P1793, DOI 10.1016/0024-3205(89)90567-5; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; PETRALIA RS, 1994, J NEUROSCI, V14, P667; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; SMIRNOVA T, 1993, SCIENCE, V262, P430, DOI 10.1126/science.8105537; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; WANG H, 1992, NEUROSCIENCE, V46, P793, DOI 10.1016/0306-4522(92)90186-6; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A	41	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27384	27393						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961649				2022-12-25	WOS:A1994PV77100039
J	LAWRENCE, DA; OLSON, ST; PALANIAPPAN, S; GINSBURG, D				LAWRENCE, DA; OLSON, ST; PALANIAPPAN, S; GINSBURG, D			SERPIN REACTIVE CENTER LOOP MOBILITY IS REQUIRED FOR INHIBITOR FUNCTION BUT NOT FOR ENZYME RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL STABILITY; AFFINITY CHROMATOGRAPHY; PROTEINASE-INHIBITORS; SUBSTRATE PROPERTIES; CRYSTAL-STRUCTURE; ALPHA-1-ANTITRYPSIN; ANTITHROMBIN; THROMBOSIS	One feature that distinguishes all of the inhibitory members of the serpin gene family is the presence of a small uncharged residue at the P14 position of the reactive center loop. In this report we examine the effects of mutations at this position, in the serpin, plasminogen activator inhibitor type 1 (PAI-1). Replacement of the native P14 Thr-333 residue by an Arg (Thr-333 --> Arg) resulted in complete loss of inhibitory activity toward tissue-type plasminogen activator and urokinase-type plasminogen activator. Comparison of the binding of the mutant inhibitor and wild type PAI-1 (WTPAI-I) to anhydrotrypsin indicated that the initial interaction of the two inhibitors with proteases was identical. However, whereas WTPAI-1 forms SDS-stable complexes with both plasminogen activators, the mutant PAI-1 was efficiently cleaved as a substrate. Amino-terminal sequence analysis indicated that cleavage of the mutant PAI-I occurred at its reactive center P1-P1' Arg-Met bond. Thermal denaturation studies of native and cleaved PAIs indicated that native Thr-333 --> Arg mutant had a thermal stability identical to active WTPAI-1 and that both proteins became significantly more stable following cleavage by elastase (cleaved at the P4-P3 bond). Finally the function of recombinant PAI-I variants containing 15 of the possible 19 amino acid substitutions at P14 were analyzed. While residue size appeared to have little effect on inhibitory activity, the presence of either a positive or a negative charge at P14, converted PAI-1 to a substrate. Taken together, these results suggest that while insertion of the reactive center loop is not essential for protease binding, it is a necessary second step required for inhibitor function. The presence of a charged residue at P14 can retard this insertion, resulting in conversion of the serpin to a substrate.	UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV ILLINOIS,CTR MOLEC BIOL ORAL DIS,CHICAGO,IL 60612	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	LAWRENCE, DA (corresponding author), UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008572, R29HL039888, R01HL039137, R01HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 39888, HL 39137, HL 08572] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKO H, 1972, BIOCHEM BIOPH RES CO, V47, P1402, DOI 10.1016/0006-291X(72)90228-8; AKO H, 1974, BIOCHEMISTRY-US, V13, P132, DOI 10.1021/bi00698a021; BJORK I, 1992, J BIOL CHEM, V267, P1976; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LAWRENCE DA, 1995, IN PRESS MOL BIOL TH; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MIKUS P, 1993, EUR J BIOCHEM, V218, P1071, DOI 10.1111/j.1432-1033.1993.tb18467.x; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; ROBINSON NC, 1971, BIOCHEMISTRY-US, V10, P2743; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1991, EUR J BIOCHEM, V202, P1147, DOI 10.1111/j.1432-1033.1991.tb16483.x; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; YUNG BY, 1975, BIOCHEM BIOPH RES CO, V65, P927, DOI 10.1016/S0006-291X(75)80474-8; YUNG BYK, 1980, J BIOL CHEM, V255, P9724	45	134	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27657	27662						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961684				2022-12-25	WOS:A1994PV77100078
J	LUO, ZG; FUENTES, ME; TAYLOR, P				LUO, ZG; FUENTES, ME; TAYLOR, P			REGULATION OF ACETYLCHOLINESTERASE MESSENGER-RNA STABILITY BY CALCIUM DURING DIFFERENTIATION FROM MYOBLASTS TO MYOTUBES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; MESSENGER-RNA; CHARGE MOVEMENT; RELEASE CHANNEL; CA-2+ RELEASE; SUBUNIT GENE; MOUSE MUSCLE; CELL-LINE	The expression of acetylcholinesterase (AChE), nicotinic acetylcholine receptors (nAChR), and their corresponding mRNAs increases dramatically during the conversion of myoblasts to myotubes in C2-C12 cells. The increase in expression of nAChR arises from transcriptional activation of the genes encoding the receptor subunits, whereas stabilization of labile transcripts is primarily responsible for enhanced AChE expression. In a search for the signaling pathways responsible for stabilization of the AChE mRNA, we found that ryanodine, synthetic ryanodine receptor antagonists and L-type, but not N-type, Ca2+ channel blockers inhibit the differentiation-induced expression of AChE mRNA, but not the nAChR mRNA. Selective inhibition of increased expression of AChE is also evident. Inhibition by ryanodine and nifedipine is additive suggesting different target sites for the two Ca2+ channel ligands. Ryanodine binding sites can be detected in both myoblasts and myotubes, but they increase substantially during differentiation. Rates of AChE gene transcription are not altered by ryanodine and nifedipine, indicating that decreased Ca2+ availability prevents stabilization of the mRNA normally seen with differentiation. Muscle cells still undergo elongation and fusion in the presence of ryanodine or L-type Ca2+ channel antagonists. Ryanodine block is fully reversible, indicating functional integrity of the cellular expression system after the drug treatment. These findings indicate that intracellular ryanodine-sensitive calcium channels and extracellular L-type Ca2+ channels link to play an important role in stabilizing AChE mRNA and suggest that transient increases in intracellular Ca2+ may be critical for the commitment of AChE expression during myogenesis.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL 0636,LA JOLLA,CA 92093	University of California System; University of California San Diego			Fuentes, Maria/HGA-8617-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 18360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; BALDWIN TJ, 1988, J CELL BIOL, V107, P2271, DOI 10.1083/jcb.107.6.2271; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BUONANNO A, 1986, J BIOL CHEM, V261, P1452; CAFFREY JM, 1989, J NEUROSCI, V9, P3443; CARTAUD J, 1993, EUR J NEUROSCI, V5, P191, DOI 10.1111/j.1460-9568.1993.tb00485.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECKER MM, 1990, J BIOL CHEM, V265, P11796; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; EVANS S, 1987, J BIOL CHEM, V262, P4911; FRAIL DE, 1989, NEURON, V2, P1077, DOI 10.1016/0896-6273(89)90232-8; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; FUENTES ME, 1993, NEURON, V10, P1; GILMAN M, 1989, CURRENT PROTOCOLS MO, V7; GREENBERG ME, 1989, CURRENT PROTOCOLS MO, V9; HAHN S, 1991, ONCOGENE, V6, P2327; HALL ZW, 1993, NEURON S, V10, P99; HASTINGS KEM, 1982, P NATL ACAD SCI-BIOL, V79, P1553, DOI 10.1073/pnas.79.5.1553; HOWE JG, 1986, P NATL ACAD SCI USA, V83, P9006, DOI 10.1073/pnas.83.23.9006; HWANG KS, 1987, BIOCHEM BIOPH RES CO, V142, P674, DOI 10.1016/0006-291X(87)91467-7; INESTROSA NC, 1983, EXP CELL RES, V147, P393, DOI 10.1016/0014-4827(83)90221-5; Janis RA, 1987, ADV DRUG RES, V16, P309; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; LI Y, 1993, J BIOL CHEM, V268, P3563; LU XY, 1994, J BIOL CHEM, V269, P6511; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; NUMA S, 1990, COLD SPRING HARB SYM, V45, P1; OHMURA T, 1990, INT IMMUNOL, V2, P1073, DOI 10.1093/intimm/2.11.1073; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIVIER J, 1987, J BIOL CHEM, V262, P1194; RUBIN LL, 1985, P NATL ACAD SCI USA, V82, P7121, DOI 10.1073/pnas.82.20.7121; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHWARTZ LM, 1985, NATURE, V314, P747, DOI 10.1038/314747a0; SILMAN I, 1978, FEBS LETT, V94, P166, DOI 10.1016/0014-5793(78)80929-6; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YUAN SH, 1991, J CELL BIOL, V112, P289, DOI 10.1083/jcb.112.2.289	47	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27216	27223						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961631				2022-12-25	WOS:A1994PV77100013
J	MCLEAN, RH; NIBLACK, G; JULIAN, B; WANG, T; WYATT, R; PHILLIPS, JA; COLLINS, TS; WINKELSTEIN, J; VALLE, D				MCLEAN, RH; NIBLACK, G; JULIAN, B; WANG, T; WYATT, R; PHILLIPS, JA; COLLINS, TS; WINKELSTEIN, J; VALLE, D			HEMOLYTICALLY INACTIVE C4B COMPLEMENT ALLOTYPE CAUSED BY A PROLINE TO LEUCINE MUTATION IN THE C5-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID 21-HYDROXYLASE GENES; BETA-CHAIN RESIDUE-458; PATHWAY C5 CONVERTASE; 4TH COMPONENT; STRUCTURAL BASIS; SINGLE ARGININE; NULL ALLELES; POLYMORPHISM; DNA; ORGANIZATION	The fourth component of complement (C4) is encoded by two highly homologous genes, C4A and C4B. Only one hemolytically inactive C4A allotype (C4A*6) has been reported. No hemolytically inactive C4B allotype has been described. We report the first hemolytically inactive (hi) allotype of C4B, C4B*1(hi). This unique variant was first recognized by hemolytic overlay assays and confirmed to segregate in the affected pedigree with the major histocompatibility complex haplotype A28,B35,CW4,DR6, C4A3,C4B1(hi), BFF,C2C. By single strand conformational polymorphism, we detected only a migration variant in exon 12 caused by a C to T transition in the second base of codon 459. This mutation results in a leucine substitution for proline (P459L) 1 residue down-stream of a residue known to contribute to the C5-binding site. Allele-specific oligonucleotide analysis of samples demonstrated cosegregation of the mutation with the hemolytically inactive allotype in the affected pedigree. Site-directed mutagenesis and expression studies showed that the P459L mutation causes loss of hemolytic function. C4B*1(hi) is the first example of a circulating C4B protein lacking detectable hemolytic activity and the P459L mutation expands our knowledge of the C5-binding site of C4.	GENE PROOF LABS,NASHVILLE,TN 37205; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; LEBONHEUR CHILDRENS HOSP & MED CTR,DEPT PEDIAT,TENNESSEE CTR HLTH SCI,MEMPHIS,TN 38103; VANDERBILT UNIV,SCH MED,DIV GENET,NASHVILLE,TN 37232; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; Johns Hopkins University; University of Tennessee System; University of Tennessee Health Science Center; Vanderbilt University; Johns Hopkins University	MCLEAN, RH (corresponding author), UNIV MARYLAND,SCH MED,DEPT PEDIAT,DIV PEDIAT NEPHROL N5W70,22 S GREENE ST,BALTIMORE,MD 21201, USA.			Wyatt, Robert/0000-0001-6077-0259	NICHD NIH HHS [HD 28819] Funding Source: Medline; NIDDK NIH HHS [DK 35592, F33 DK08693] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035592, F33DK008693] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSWORTH PJ, 1991, NUCLEIC ACIDS RES, V19, P405, DOI 10.1093/nar/19.2.405; ANDERSON MJ, 1992, J IMMUNOL, V148, P2795; AWDEH ZL, 1979, NATURE, V282, P205, DOI 10.1038/282205a0; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; BELT KT, 1985, IMMUNOGENETICS, V21, P173; BELT KT, 1984, CELL, V36, P907; BRODY LC, 1992, J BIOL CHEM, V267, P3302; CAMPBELL RD, 1988, ANNU REV IMMUNOL, V6, P161, DOI 10.1146/annurev.iy.06.040188.001113; CARROLL MC, 1985, P NATL ACAD SCI USA, V82, P521, DOI 10.1073/pnas.82.2.521; CARROLL MC, 1985, IMMUNOL REV, V87, P39, DOI 10.1111/j.1600-065X.1985.tb01144.x; CARROLL MC, 1990, P NATL ACAD SCI USA, V87, P6868, DOI 10.1073/pnas.87.17.6868; CARROLL MC, 1984, NATURE, V307, P236; DODDS AW, 1985, EMBO J, V4, P2239, DOI 10.1002/j.1460-2075.1985.tb03920.x; EBANKS RO, 1992, J IMMUNOL, V148, P2803; FASANO MB, 1992, J CLIN INVEST, V90, P1180, DOI 10.1172/JCI115978; GAITHER TA, 1974, J IMMUNOL, V113, P574; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; HORTIN GL, 1989, P NATL ACAD SCI USA, V86, P1338, DOI 10.1073/pnas.86.4.1338; ISENMAN DE, 1984, J IMMUNOL, V132, P3019; KIM YU, 1992, J BIOL CHEM, V267, P4171; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; REVEILLE JD, 1985, IMMUNOGENETICS, V21, P299, DOI 10.1007/BF00430796; SCHNEIDER PM, 1986, J CLIN INVEST, V78, P650, DOI 10.1172/JCI112623; WINKELSTEIN JA, 1982, J IMMUNOL, V129, P2598; YAP EPH, 1992, TRENDS GENET, V8, P49, DOI 10.1016/0168-9525(92)90339-6; YU CY, 1987, IMMUNOGENETICS, V25, P383; YU CY, 1986, EMBO J, V5, P2873, DOI 10.1002/j.1460-2075.1986.tb04582.x; YU CY, 1991, J IMMUNOL, V146, P1057; 1992, B WORLD HEALTH ORGAN, V70, P527	30	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27727	27731						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961694				2022-12-25	WOS:A1994PV77100088
J	HAGUE, A; MOORGHEN, M; HICKS, D; CHAPMAN, M; PARASKEVA, C				HAGUE, A; MOORGHEN, M; HICKS, D; CHAPMAN, M; PARASKEVA, C			BCL-2 EXPRESSION IN HUMAN COLORECTAL ADENOMAS AND CARCINOMAS	ONCOGENE			English	Note							PROGRAMMED CELL-DEATH; DNA FRAGMENTATION; APOPTOSIS; PROTEIN; LINES; CANCER; NEUROBLASTOMA; PROTOONCOGENE; RESISTANCE; PROSTATE	As BCL-2 oncoprotein has been implicated as a survival factor in a number of tissues, we examined colorectal tumour specimens and cell lines for BCL-2 expression. BCL-2 protein was expressed in 19/22 adenocarcinomas and 12/13 adenomas. 6/9 carcinoma cell lines and 7/8 adenoma cell lines were also BCL-2 positive. BCL-2 expression was retained in metastases to the regional lymph nodes (3/3 specimens) and in the cell line SW620, derived from a lymph node metastasis. These studies suggest a role for BCL-2 in promoting cell survival of benign and malignant colorectal tumours and that BCL-2 deregulation may be a relatively early event in colorectal carcinogenesis. The retention of BCL-2 expression in the carcinomas and lymph node metastases may explain the resistance of colorectal tumours to chemotherapeutic treatment.	UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,CRC,COLORECTAL TUMOUR BIOL RES GRP,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol								COLOMBEL M, 1993, AM J PATHOL, V143, P390; FEARON ER, 1990, SCIENCE, V247, P47; FISHER TC, 1993, CANCER RES, V53, P3321; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HANADA M, 1993, CANCER RES, V53, P4978; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; IKEGAKI N, 1994, CANCER RES, V54, P6; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MIYASHITA T, 1992, CANCER RES, V52, P5407; OHMORI T, 1993, BIOCHEM BIOPH RES CO, V192, P30, DOI 10.1006/bbrc.1993.1377; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; RAMANI P, 1994, J PATHOL, V172, P273, DOI 10.1002/path.1711720308; REED JC, 1991, CANCER RES, V51, P6529; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1992, INT J CANCER, V52, P785, DOI 10.1002/ijc.2910520519	25	184	185	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3367	3370						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936663				2022-12-25	WOS:A1994PM65800032
J	MANO, H; SATO, K; YAZAKI, Y; HIRAI, H				MANO, H; SATO, K; YAZAKI, Y; HIRAI, H			TEC PROTEIN-TYROSINE KINASE DIRECTLY ASSOCIATES WITH LYN PROTEIN-TYROSINE KINASE THROUGH ITS N-TERMINAL UNIQUE DOMAIN	ONCOGENE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; CELL ANTIGEN RECEPTOR; HEMATOPOIETIC-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; MESSENGER-RNA; GROWTH-FACTOR; SH3 DOMAINS; AMINO-ACIDS; GENE	Most of non-receptor-type protein-tyrosine kinases share common structures, such as N-terminal unique domains, Src homology region (SH)-2 domains, SH-3 domains and kinase domains. Although vast effort has brought some information about the in vivo roles of SH-2, -3 and kinase domains, little is still understood about the function of N-terminal unique domain. By utilizing the glutathione S-transferase (GST)-fusion system, we have investigated the role of N-terminal unique domain of the Tec protein-tyrosine kinase in a mouse IL-3-dependent myeloid cell line. We could reveal that the C-terminal half of the Tec N-terminal unique domain (NTec2 region) can bind to a set of tyrosine-phosphorylated cellular proteins in vitro in an IL-3-dependent manner. Surprisingly, p56/53(Lyn) constitutively binds to the NTec2 region. Among the NTec2-bound Lyn proteins, only-the p56 form seems to be inducibly tyrosine-phosphorylated in response to IL-3. Binding domain of Lyn to the NTec2 region was localized to its SH-3 domain. Tec was also shown to make a stable complex with Lyn in vivo. This is the first report demonstrating the direct association between distinct cytoplasmic protein-tyrosine kinases, especially through N-terminal unique domain.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	University of Tokyo	MANO, H (corresponding author), JICHI MED SCH,DEPT MOLEC BIOL,3311-1 YAKUSHIJI,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOLEN JB, 1993, ONCOGENE, V8, P2025; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KATZAV S, 1989, ONCOGENE, V4, P1129; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MACAULEY A, 1993, ONCOGENE, V8, P117; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Sambrook J, 1989, MOL CLONING LABORATO; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YAMANASHI Y, 1991, CELL REGUL, V2, P979, DOI 10.1091/mbc.2.12.979; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	35	35	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3205	3211						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936643				2022-12-25	WOS:A1994PM65800012
J	KUWABARA, S				KUWABARA, S			PURIFICATION AND PROPERTIES OF PEDITOXIN AND THE STRUCTURE OF ITS PROSTHETIC GROUP, PEDOXIN, FROM THE SEA-URCHIN TOXOPNEUSTES PILEOLUS (LAMARCK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST ATOM BOMBARDMENT; MASS-SPECTROMETRY	A protein toxin, termed peditoxin, containing an active prosthetic group was isolated and purified hom the globiferous pedicellariae of the sea urchin Toxopneustes pileolus (Lamarck). The prosthetic group, called pedoxin, is a small molecular mass substance (206 daltons) with an empirical formula of C10H10N2O3 and is comprised of a heterocyclic lactone structure formed from pyridoxal and glycine. Administered subcutaneously or intramuscularly to mice in sublethal doses, pedoxin markedly reduced basal body temperature and led to sedation and anesthetic coma accompanied by muscular relaxation. At higher doses, it leads to convulsion and death (LD(50) 200 mg/kg). The apoprotein, a cytochrome b-like heme protein called pedin (molecular mass, 10,000 daltons) is itself not toxic, but the purified holoprotein is extremely toxic, causing anaphylaxis-like shock and death in experimental animals at low doses (LD(50) 70 mu g/kg). Small amounts of the prosthetic group added to holoprotein preparations caused the toxicity to be greatly enhanced, suggesting that holoprotein preparations also contain apoprotein capable of being activated by the low molecular weight toxin. The structure of pedoxin was determined to be 3-hydroxy-2-methyl-5-methoxy-4-pyridineformyl-glycyliden ester and was confirmed by total synthesis.	UNIV TOKYO,INST MED SCI,TOKYO 108,JAPAN; UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,YAHATANISHI KU,KITAKYUSHU,FUKUOKA 807,JAPAN	University of Tokyo; University of Occupational & Environmental Health - Japan								ALENDER CHARLES B., 1965, TOXICON, V3, P9, DOI 10.1016/0041-0101(65)90062-0; BACH SJ, 1946, BIOCHEM J, V40, P229, DOI 10.1042/bj0400229; Barthels Philipp, 1906, Zoologischer Anzeiger Leipzig, V29; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BECKEY HD, 1969, PRINCIPLES FIELD ION, P20; BERGMANN M, 1926, PHYSIOL CHEM PHYS M, V152, P282; BOJESEN G, 1986, INT J MASS SPECTROM, V68, P239, DOI 10.1016/0168-1176(86)87050-1; CHILDS B, 1961, PEDIATRICS, V27, P522; Cu?not L., 1891, ARCH BIOL, V11, P313, DOI 10.5038/bin.books.1014; DALGLIESH CE, 1947, J CHEM SOC, P559; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V5, pD7; FEIGEN GA, 1966, TOXICON, V4, P161, DOI 10.1016/0041-0101(66)90046-8; FENSELAU C, 1987, CHEM REV, V87, P501, DOI 10.1021/cr00079a002; FOETTINGER A, 1881, ARCH BIOL, V2, P455; FREDERICQ L, 1924, WINTERSTEINS HDB VER, V2, P36; Fujiwara T., 1935, Annotationes Zoologicae Japonenses, V15, P62; GOWER JL, 1985, BIOMED MASS SPECTROM, V12, P191, DOI 10.1002/bms.1200120502; HAMANN O, 1887, Z NATURWISS, V21, P91; HEYL D, 1948, J AM CHEM SOC, V70, P3429, DOI 10.1021/ja01190a061; HEYL D, 1951, J AM CHEM SOC, V73, P3430, DOI 10.1021/ja01151a126; HOLIDAY ER, 1936, BIOCHEM J, V36, P1794; KATZ AM, 1959, J BIOL CHEM, V234, P2897; KIERNIK E, 1906, ZOOL ANZ, V29, P610; KOUGE K, 1987, B CHEM SOC JPN, V60, P2409, DOI 10.1246/bcsj.60.2409; KUMMLER D, 1975, ORG MASS SPECTROM, V10, P813, DOI 10.1002/oms.1210100918; KUWABARA S, 1975, J BIOL CHEM, V250, P2563; KUWABARA S, 1975, J BIOL CHEM, V250, P2556; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENDES EG, 1936, SCIENCE, V139, P408; MOORE S, 1958, ANAL CHEM, V30, P1185, DOI 10.1021/ac60139a005; MOORE S, 1963, J BIOL CHEM, V238, P235; OSHIMA H, 1951, DOBUTSUGAKU ZASSHI, V27, P605; POSO O, 1908, ZOOL ANZ, V32, P14; Reichensperger A, 1908, Z WISS ZOOL ABT A, V91, P304; ROMANES GJ, 1984, J LINN SOC LOND ZOOL, V17, P131; Sarasin C. F., 1886, ZOOL ANZ, V9, P80; SCHULTEN JR, 1975, METHOD BIOCHEM ANAL, V24, P313; Sladen W P, 1880, ANN MAG NAT HIST, V6, P101, DOI 10.1080/00222938009458904; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; UEXKULL J, 1899, Z BIOL, V19, P335; UEXKULL J, 1899, Z BIOL, V37, P298	41	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26734	26738						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929407				2022-12-25	WOS:A1994PQ93100026
J	MACKMAN, N				MACKMAN, N			PROTEASE INHIBITORS BLOCK LIPOPOLYSACCHARIDE INDUCTION OF TISSUE FACTOR GENE-EXPRESSION IN HUMAN MONOCYTIC CELLS BY PREVENTING ACTIVATION OF C-REL/P65 HETERODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR MESSENGER-RNA; AMP-DEPENDENT MECHANISM; PROCOAGULANT ACTIVITY; MONONUCLEAR PHAGOCYTES; INTRAVASCULAR COAGULATION; THROMBOPLASTIN GENERATION; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; ENDOTOXIN	Tissue factor (TF) is expressed rapidly by human monocytes exposed to bacterial endotoxin (lipopolysaccharide, or LPS). Transcriptional regulation is mediated by binding of c-Rel/p65 heterodimers to a KB-like site in the TF promoter. Nuclear translocation of cytosolic c-Rel/p65 heterodimers and other members of the NF-kappa B/Rel family requires dissociation and proteolytic degradation of the inhibitor protein, I kappa B alpha. The protease inhibitors N-alpha-tosylphenylalanyl chloromethyl ketone (TPCK) and N-alpha-tosyl-L-lysine chloromethyl ketone (TLCK) block activation of NF-kappa B/Rel proteins by preventing degradation of I kappa B alpha. To determine if TPCK and TLCK inhibited LPS induction of TF expression, freshly isolated human monocytes and monocytic THP-1 cells were pretreated with these inhibitors for 30 min before LPS stimulation. Both TPCK and TLCK inhibited LPS induction of TF protein, TF mRNA and TF promoter activity in a dose-dependent manner. These inhibitors specifically prevented degradation of I kappa B alpha and nuclear translocation of c-Rel/p65 heterodimers. In contrast, TPCK and TLCK did not block induction of an immediate early gene encoding the transcription factor, Egr-1. Taken together, these data indicated that inhibiting nuclear translocation of c-Rel/p65 heterodimers prevented LPS induction of TF gene transcription in monocytic cells.			MACKMAN, N (corresponding author), Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, IMM-17, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL-48872] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048872] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMDAHL SM, 1987, THROMB RES, V47, P37, DOI 10.1016/0049-3848(87)90238-6; ANDERSEN OK, 1985, ACTA CHIR SCAND, V151, P205; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CRUTCHLEY DJ, 1991, BLOOD, V78, P382; CRUTCHLEY DJ, 1992, ARTERIOSCLER THROMB, V12, P664, DOI 10.1161/01.ATV.12.6.664; DEPROST D, 1990, MOL PHARMACOL, V38, P562; DRAKE TA, 1993, AM J PATHOL, V142, P1; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERBERT JM, 1993, FEBS LETT, V328, P268, DOI 10.1016/0014-5793(93)80941-M; HERBERT JM, 1992, FEBS LETT, V310, P31, DOI 10.1016/0014-5793(92)81139-D; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NIEMETZ J, 1972, J CLIN INVEST, V51, P307, DOI 10.1172/JCI106815; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; OKAJIMA K, 1991, AM J HEMATOL, V36, P265, DOI 10.1002/ajh.2830360408; OLLIVIER V, 1993, BLOOD, V81, P973; OLLIVIER V, 1993, FEBS LETT, V322, P231, DOI 10.1016/0014-5793(93)81576-L; PARRY GCN, 1994, FASEB J, V8, P5902; PRADIER O, 1993, EUR J IMMUNOL, V23, P2700, DOI 10.1002/eji.1830231048; RAMANI M, 1993, BRIT J HAEMATOL, V85, P462; RAMANI M, 1993, FEBS LETT, V334, P114, DOI 10.1016/0014-5793(93)81693-T; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WARR TA, 1990, BLOOD, V75, P1481	39	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26363	26367						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929355				2022-12-25	WOS:A1994PQ93000065
J	ROSHAK, A; SATHE, G; MARSHALL, LA				ROSHAK, A; SATHE, G; MARSHALL, LA			SUPPRESSION OF MONOCYTE 85-KDA PHOSPHOLIPASE A(2) BY ANTISENSE AND EFFECTS ON ENDOTOXIN-INDUCED PROSTAGLANDIN BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE-A2; ARACHIDONIC-ACID; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; SYNTHASE CYCLOOXYGENASE; HUMAN FIBROBLASTS; SYNOVIAL-FLUID; MACROPHAGES; CELLS; PURIFICATION; EXPRESSION	Studies were conducted to characterize a human monocyte model where the role of the 85-kDa phospholipase A(2) (PLA(2)) in prostanoid formation could be evaluated. The presence of an immunologically related 85-kDa PLA, and type II 14-kDa PLA(2) was demonstrated in human monocytes and their roles examined in lipopolysaccharide (LPS)-induced monocyte prostaglandin E(2) (PGE(2)) formation. Exposure of human monocytes to LPS over 18 h resulted in the up-regulation of the mitogen-inducible cyclooxygenase-a and was accompanied by production and release of prostaglandin E(2) but not leukotriene C-4. This coincided with a 2-fold increase in the 85-kDa PLA(2) protein and activity levels. In contrast, there was no effect on the type II 14-kD-like PLA(2) activity measured in the 100,000 x g particulate fraction nor did LPS induce the release of type II 14-kDa PLA(2) into the medium. Treatment with cycloheximide over 18 h resulted in a time dependent decrease in cytosolic 85-kDa PLA(2) protein and activity (half life = 4 h), but there was no change in the particulate type II 14-kDa-like PLA(2) activity. Monocytes were therefore exposed to an 85-kDa PLA(2) initiation site directed antisense oligonucleotide which specifically decreased the cytosolic 85-kDa PLA(2) protein levels and activity in a concentration-dependent manner. This had no effect on the cyclooxygenase-2 (protein mass or the ability to convert arachidonic acid to PGE(2)) or the particulate fraction sn-2 acylhydrolytic activity but was associated with a decrease in LPS-induced PGE(2) production. Taken together, these data support a role for the cytosolic 85-kDa PLA(2) in LPS induced monocyte PGE(2) formation.	SMITHKLINE BEECHAM PHARMACEUT,DEPT INFLAMMAT & RESP PHARMACOL,UW2532,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline								AMEGADZIE BY, 1993, GENE, V128, P307, DOI 10.1016/0378-1119(93)90580-V; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; CAVAILLON J-M, 1990, Cytokine, V2, P313, DOI 10.1016/1043-4666(90)90061-W; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CROOKE RM, 1991, ANTI-CANCER DRUG DES, V6, P609; CROOKE ST, 1992, BIO-TECHNOL, V10, P882, DOI 10.1038/nbt0892-882; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DENNIS EA, 1983, ENZYMES, V16, P308; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DIEZ E, 1990, J BIOL CHEM, V265, P14654; FU JY, 1990, J BIOL CHEM, V265, P16737; GOPPELTSTRUEBE M, 1992, BIOCHIM BIOPHYS ACTA, V1127, P163, DOI 10.1016/0005-2760(92)90273-X; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; HUMES JL, 1982, J BIOL CHEM, V257, P1591; KADA A, 1989, BIOCHEM BIOPH RES CO, V163, P42; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAI CY, 1988, BIOCHEM BIOPH RES CO, V157, P488, DOI 10.1016/S0006-291X(88)80275-4; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIN L, 1992, P NATL ACAD SCI USA, V89, P6146; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MANSON J, 1990, LYMPHOKINE RES, V9, P35; MARSHALL LA, 1994, J PHARMACOL EXP THER, V268, P709; MARSHALL LA, 1993, BIOCHEM CELL BIOL, V71, P331, DOI 10.1139/o93-050; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MCKEARN TJ, 1979, IMMUNOL REV, V47, P91, DOI 10.1111/j.1600-065X.1979.tb00290.x; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MIRABELLI CK, 1991, ANTI-CANCER DRUG DES, V6, P647; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NAKAGAWA Y, 1989, PROG LIPID RES, V28, P205, DOI 10.1016/0163-7827(89)90013-1; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; RAZ A, 1990, ADV PROSTAG THROMB L, V20, P22; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V248, P1; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; Stadel J. M., 1992, Journal of Molecular Recognition, V5, P145, DOI 10.1002/jmr.300050405; SVENSSON U, 1993, EUR J BIOCHEM, V213, P81, DOI 10.1111/j.1432-1033.1993.tb17736.x; TRINCHIERI G, 1991, IMMUNOL RES, V10, P89, DOI 10.1007/BF02918157; ZON G, 1991, ANTI-CANCER DRUG DES, V6, P539; ZUCALI JR, 1990, PROG LEUC B, V10, P315	43	113	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25999	26005						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929310				2022-12-25	WOS:A1994PQ93000013
J	WEISS, J; INADA, M; ELSBACH, P; CROWL, RM				WEISS, J; INADA, M; ELSBACH, P; CROWL, RM			STRUCTURAL DETERMINANTS OF THE ACTION AGAINST ESCHERICHIA-COLI OF A HUMAN INFLAMMATORY FLUID PHOSPHOLIPASE A(2) IN CONCERT WITH POLYMORPHONUCLEAR LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY-INCREASING PROTEIN; GROUP-II PHOSPHOLIPASE-A2; SYNOVIAL-FLUID; SNAKE-VENOM; PURIFICATION; CELLS; BINDING; GENE; EXPRESSION; BACTERIA	Extracellular 14-kDa phospholipases A(2) (PLA(2)) in inflammatory exudates can contribute to bacterial phospholipid (PL) degradation during phagocytosis of Escherichia coli by polymorphonuclear leukocytes (PMN) and are highly active toward E. coli treated with the bactericidal/permeability-increasing protein (BPI) purified from PMN. PLA(2) activity toward BPI-treated E. coli varies greatly among members of this conserved family of enzymes and apparently depends on a cluster of basic residues in a variable surface region near the NH2 terminus for recognition of this biological target (Weiss, J., Wright, G. W., Bekkers, A. C. A. P. A., van den Bergh, C. J., and Verheij, H. M. (1991) J. Biol. Chem. 266, 4162-4167). We have examined by site specific mutagenesis of a recombinant PLA(2) that is identical to an enzyme in human synovial fluid (containing His-6, Arg-7, Lys-10, and Lys-15 and a global net charge of +15) the role of basic residues in this region in PLA(2), action against PLA-deficient (pldA(-)) E. coli. Substitution of Ser for Arg-7 +/- Gln for Lys-15 caused, respectively, about a 10- and 25-fold reduction in BPI-dependent PLA(2) binding and activity to E. coli, but had no effect on hydrolysis of PL of autoclaved E. coli or dispersions of purified PL. PL degradation during phagocytosis was increased after pretreatment off. coli (or PMN) with wild-type PLA(2) followed by removal of unbound PLA(2). Thus, the PLA(2) binds to cells before phagocytosis followed by internalization of the enzyme along with E. coli and intracellular action. Mutant (e.g. R7S +/- K15Q) PLA(2) show the same BPI-inde pendent binding to E. coli as the wild-type enzyme but 10-30-fold reduced activity during phagocytosis, reflecting lower intracellular activity of these enzymes. Thus, structural determinants first implicated in PLA(2) action toward E. coli treated with purified BPI apparently are also important in the intracellular action of PLA(2) during phagocytosis by PMN.	NYU, SCH MED, DEPT MED, NEW YORK, NY 10016 USA; HOFFMANN LA ROCHE INC, DEPT MOLEC GENET, NUTLEY, NJ 07110 USA	New York University; Roche Holding	WEISS, J (corresponding author), NYU, SCH MED, DEPT MICROBIOL, 550 1ST AVE, NEW YORK, NY 10016 USA.			Weiss, Jerrold/0000-0003-1476-4485	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005472] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18571] Funding Source: Medline; NIDDK NIH HHS [R37 DK 05472] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CROWL R, 1990, ADV EXP MED BIOL, V279, P173; CROWL RM, 1991, J BIOL CHEM, V266, P2647; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEGEUS P, 1983, MOL GEN GENET, V190, P150, DOI 10.1007/BF00330338; DENNIS EA, 1987, DRUG DEVELOP RES, V10, P205, DOI 10.1002/ddr.430100404; ELSBACH P, 1985, J BIOL CHEM, V260, P1618; ELSBACH P, 1988, BIOCHIM BIOPHYS ACTA, V947, P29, DOI 10.1016/0304-4157(88)90018-4; ELSBACH P, 1991, METHOD ENZYMOL, V197, P24; ELSBACH P, 1979, J BIOL CHEM, V254, P1000; ELSBACH P, 1973, J BACTERIOL, V115, P490, DOI 10.1128/JB.115.2.490-497.1973; Elsbach P, 1992, INFLAMMATION BASIC P, P603; ELSBACH P, 1989, CELL ACTIVATION SIGN, P323; FORST S, 1982, J BIOL CHEM, V257, P4055; FORST S, 1986, BIOCHEMISTRY-US, V25, P4309, DOI 10.1021/bi00363a020; FORST S, 1986, BIOCHEMISTRY-US, V25, P8381, DOI 10.1021/bi00374a008; FORST S, 1987, BIOCHIM BIOPHYS ACTA, V920, P221, DOI 10.1016/0005-2760(87)90098-1; GROSS RW, 1992, TRENDS CARDIOVAS MED, V2, P115, DOI 10.1016/1050-1738(92)90016-L; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOMMA H, 1984, J BIOCHEM-TOKYO, V96, P1645, DOI 10.1093/oxfordjournals.jbchem.a134996; INADA M, 1994, J BIOL CHEM, V269, P26338; KINI RM, 1987, J BIOL CHEM, V262, P14402; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LEVIN W, 1992, PROTEIN EXPRES PURIF, V3, P27, DOI 10.1016/1046-5928(92)90052-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNION BA, 1989, J IMMUNOL, V142, P2807; MANNION BA, 1990, J CLIN INVEST, V86, P631, DOI 10.1172/JCI114755; Means G E, 1977, Methods Enzymol, V47, P469; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; OOI CE, 1990, J BIOL CHEM, V265, P15956; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; STONER CR, 1991, J IMMUNOL METHODS, V145, P127, DOI 10.1016/0022-1759(91)90318-A; VANDENBOSCH H, 1992, ADV EXP MED BIOL, V318, P1; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WEISS J, 1991, J BIOL CHEM, V266, P4162; WEISS J, 1982, J CLIN INVEST, V69, P959, DOI 10.1172/JCI110535; WEISS J, 1979, J BIOL CHEM, V254, P1010; WEISS J, 1985, J CLIN INVEST, V76, P206, DOI 10.1172/JCI111947; WEISS J, 1990, PHOSPHOLIPASE A2, P103; WRIGHT GC, 1990, J CLIN INVEST, V85, P1925, DOI 10.1172/JCI114655; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675	51	119	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26331	26337						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929350				2022-12-25	WOS:A1994PQ93000060
J	BUBB, MR; LEWIS, MS; KORN, ED				BUBB, MR; LEWIS, MS; KORN, ED			ACTOBINDIN BINDS WITH HIGH-AFFINITY TO A COVALENTLY CROSS-LINKED ACTIN DIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA-CASTELLANII; POLYMERIZATION; PURIFICATION; GELSOLIN; PROTEIN; MOTIF	Actobindin, a 9.8-kDa protein purified from Acanthamoeba castellanii, contains two actin-binding sites that can simultaneously bind two actin monomers. However, actobindin inhibits actin polymerization to a greater extent than can be explained by its affinity for actin monomers (site specific K-D = 3.3 mu M). This paradox would be resolved if actobindin could interfere with the nucleation phase of polymerization by using both binding sites to bind simultaneously to an actin oligomer because the interaction with oligomer would be thermodynamically favored over that with actin monomer. We now show that a covalently cross-linked actin dimer prepared from cross linked F-actin binds to actobindin with high affinity (apparent K-D = 11 nM) in accordance with theoretical predictions for simultaneous binding of two actin subunits per single actobindin and consistent with the hypothesis that actobindin might bind to native actin oligomers and prevent them from nucleating polymerization. Furthermore, the interaction with cross-linked dimer exhibits specificity in that an isomeric cross-linked actin dimer with more rapid electrophoretic mobility binds weakly to actobindin. However, only this isomeric dimer is produced when cross-linking reagents are added to actin undergoing polymerization in the presence of actobindin. Therefore, if actobindin inhibits polymerization by interacting with a native dimer whose conformation is similar to that of the cross-linked dimer with slower electrophoretic mobility, then actobindin must either block the cross linking sites or convert the dimer to a different conformation.	NHLBI, CELL BIOL LAB, BETHESDA, MD 20892 USA; NIH, NATL CTR RES RESOURCES, BIOMED ENGN & INSTRUMENTAT PROGRAM, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA			Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				BUBB MR, 1991, J BIOL CHEM, V266, P3820; BUBB MR, 1994, J BIOL CHEM, V269, P25592; BUBB MR, 1991, METHOD ENZYMOL, V196, P119; CHATELIER RC, 1987, BIOPHYS CHEM, V28, P121, DOI 10.1016/0301-4622(87)80081-9; DOI Y, 1992, BIOCHEMISTRY-US, V31, P10061, DOI 10.1021/bi00156a028; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; HESTERKAMP T, 1993, EUR J BIOCHEM, V218, P507, DOI 10.1111/j.1432-1033.1993.tb18403.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOOY PK, 1988, J BIOL CHEM, V263, P12836; LAMBOOY PK, 1986, J BIOL CHEM, V261, P7150; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; MILLONIG R, 1988, J CELL BIOL, V106, P785, DOI 10.1083/jcb.106.3.785; MOCKRIN SC, 1981, J BIOL CHEM, V256, P8228; SPUDICH JA, 1971, J BIOL CHEM, V246, P4865; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; ZARBOCK J, 1990, BIOCHEMISTRY-US, V29, P7814, DOI 10.1021/bi00486a006	16	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25587	25591						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929261				2022-12-25	WOS:A1994PQ49100056
J	HADAD, N; ZABLE, AC; ABRAMSON, JJ; SHOSHANBARMATZ, V				HADAD, N; ZABLE, AC; ABRAMSON, JJ; SHOSHANBARMATZ, V			CA2+ BINDING-SITES OF THE RYANODINE RECEPTOR CA2+ RELEASE CHANNEL OF SARCOPLASMIC-RETICULUM - LOW-AFFINITY BINDING SITE(S) AS PROBED BY TERBIUM FLUORESCENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CA-2+ RELEASE; ADENOSINE-TRIPHOSPHATASE; LANTHANIDE IONS; CALCIUM; PURIFICATION; VESICLES	Fluorescence spectroscopy has been used to study the interaction of Tb3+ (as a Ca2+ analog) with the purified ryanodine receptor (RyR)/Ca2+ release channel of skeletal muscle sarcoplasmic reticulum. Tb3+ replaces Ca2+ in both the high- and the low-affinity sites. Occupation of the low-affinity site (inhibitory), but not of the high-affinity Ca2+ binding site (activating), by Tb3+ results in a strong enhanced green fluorescence (at 543 nm) and in an inhibition of ryanodine binding. The Tb3+ concentrations required for half-maximal enhanced fluorescence and inhibition of ryanodine binding were: 22.5 +/- 2.5 mu M (n = 4) and 22.3 +/- 3.1 mu M (n = 2), respectively. Tb3+ appears to bind to the protein at two or more cooperative sites (n(H) = 2.4) and to dissociate from these sites with three different rate constants (K--1,K-1 = 361 +/- 250 min(-1) (n = 6); K--1,K-2 = 0.45 +/- 0.22 min(-1) (n = 11); K--1,K-3 = 0.011 +/- 0.013 min(-1) (n = 7). The enhancement in Tb3+ fluorescence is very fast (K-1 >> 5 x 10(5) M(-1).min(-1)), and it is quenched by EGTA, La3+, or Ca2+ addition. About 20% of the bound Tb3+ was not displaced by EGTA or Ca2+; suggesting its ''occlusion'' in the RyR. This is also reflected in the partially irreversible inhibition of ryanodine binding by Tb3+. Reconstitution of sarcoplasmic reticulum vesicles into a planar bilayer lipid membrane showed that the Ca2+ release channel was activated by submicromolar and inhibited by micromolar concentrations of Tb3+ and La3+. The Tb3+-activated channel showed an enhancement of the open dwell time of the channel. The results suggest that RyR/Ca2+ release channel undergoes conformational changes due to Tb3+ binding to the low-affinity Ca2+ binding site, and this binding results in the closing of the Ca2+ release channel.	BEN GURION UNIV NEGEV, DEPT LIFE SCI, IL-84105 BEER SHEVA, ISRAEL; PORTLAND STATE UNIV, DEPT PHYS, PORTLAND, OR 97202 USA	Ben Gurion University; Portland State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM044337] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R15GM44337-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAPUS C, 1990, J BIOL CHEM, V265, P3726; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; EPSTEIN M, 1977, BIOCHEMISTRY-US, V16, P2449, DOI 10.1021/bi00630a021; Evans C.H, 2013, BIOCH LANTHANIDES, V8; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FURIE BC, 1976, J BIOL CHEM, V251, P3235; FURIE BC, 1975, J BIOL CHEM, V250, P601; GOMEZ JE, 1974, BIOCHEMISTRY-US, V13, P3745, DOI 10.1021/bi00715a020; HIGHSMITH SR, 1983, J BIOL CHEM, V258, P6858; HUTTON WC, 1977, CHEM PHYS LIPIDS, V19, P255, DOI 10.1016/0009-3084(77)90047-0; INUI M, 1987, J BIOL CHEM, V262, P15637; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P95; KILHOFFER MC, 1980, FEBS LETT, V116, P269, DOI 10.1016/0014-5793(80)80660-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MARTIN RB, 1979, Q REV BIOPHYS, V12, P181, DOI 10.1017/S0033583500002754; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SHOSHANBARMATZ V, 1992, BIOCHEM J, V285, P61, DOI 10.1042/bj2850061; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SOLER F, 1992, INT J BIOCHEM, V24, P903, DOI 10.1016/0020-711X(92)90095-I; SONOLKA GE, 1971, BIOCHEMISTRY-US, V10, P4556; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THOMAS DD, 1981, MOL BIOL, V154, P145; YAMAMOTO N, 1982, J BIOCHEM-TOKYO, V92, P485, DOI 10.1093/oxfordjournals.jbchem.a133956; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	36	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24864	24869						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929166				2022-12-25	WOS:A1994PQ49000053
J	SHIMAN, R; GRAY, DW; HILL, MA				SHIMAN, R; GRAY, DW; HILL, MA			REGULATION OF RAT-LIVER PHENYLALANINE-HYDROXYLASE .1. KINETIC-PROPERTIES OF THE ENZYMES IRON AND ENZYME REDUCTION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; MECHANISM; 4-MONOOXYGENASE; ACTIVATION; PHOSPHORYLATION; HYDROPEROXIDES; STATE	Tetrahydropterins react with phenylalanine hydroxylase at a redox site, a regulatory site, and the catalytic site, but neither the properties of nor relationships among these sites are well understood. We have studied the redox site using the fluorescent iron chelators 2,3-dihydroxynaphthalene and bathophenanthroline; these compounds act as site-specific reporter groups for reactions on oxidized and reduced enzyme, respectively. The chelators bind reversibly and specifically to the enzyme's iron with 1:1 stoichiometry, high affinity (K-d values similar to 1 nM), and complete quenching of their own fluorescence. The kinetic behavior of these and other iron chelators indicates that the enzyme's iron is solvent ac cessible and in a hydrophobic pocket of the protein. Both ferrous and ferric chelators inhibit phenylalanine hydroxylase activity. Bathophenanthroline inhibits by binding to Fe2+ on reduced, active enzyme. 2,3-Dihydroxynaphthalene inhibits by binding to Fe3+ on enzyme that is oxidized during catalysis. This oxidation occurs similar to 1/150 enzyme turnovers, and its rate is increased when p-chloro- or p-fluorophenylalanine is used as the reaction substrate. Studies of the reaction of tetrahydrobiopterin (BH4) at the enzyme's redox site showed that BH4 reduces the enzyme more slowly than 6-methyltetrahydropterin under catalytic and non-catalytic conditions. Reduction occurs at a distinct site whose binding determinants and reaction characteristics are different from those of the BH4 regulatory or catalytic sites, and phenylalanine activated enzyme is reduced more rapidly than unactivated enzyme. In reducing phenylalanine activated enzyme, BH4 donates one electron/subunit (1/iron atom); the reduction kinetics suggest a trihydrobiopterin-free radical as a reaction intermediate.			SHIMAN, R (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT BIOCHEM & MOLEC BIOL, HERSHEY, PA 17033 USA.							BAILEY SW, 1978, J BIOL CHEM, V253, P1598; BLOOM LM, 1986, BIOCHEMISTRY-US, V25, P4204, DOI 10.1021/bi00363a006; Cotton F. A., 1988, ADV INORGANIC CHEM; COX DD, 1988, J AM CHEM SOC, V110, P2026, DOI 10.1021/ja00215a002; DEGRAW JI, 1967, J MED CHEM, V10, P64, DOI 10.1021/jm00313a013; DIX TA, 1988, ACCOUNTS CHEM RES, V21, P101, DOI 10.1021/ar00147a002; DIX TA, 1985, BIOCHEMISTRY-US, V24, P5839, DOI 10.1021/bi00342a022; DOSKELAND AP, 1984, J BIOL CHEM, V259, P1242; FISHER DB, 1972, J BIOL CHEM, V247, P5161; FUNK MO, 1976, LIPIDS, V11, P113, DOI 10.1007/BF02532660; GOTTSCHALL DW, 1982, J BIOL CHEM, V257, P845; HILL MA, 1988, J BIOL CHEM, V263, P5646; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P562; KAUFMAN S, 1971, ADV ENZYMOL RAMB, V35, P245; KAUFMAN S, 1961, BIOCHIM BIOPHYS ACTA, V51, P619, DOI 10.1016/0006-3002(61)90632-1; MAROTA JJA, 1984, BIOCHEMISTRY-US, V23, P1303, DOI 10.1021/bi00301a044; MARTINEZ A, 1991, EUR J BIOCHEM, V198, P675, DOI 10.1111/j.1432-1033.1991.tb16066.x; MARTINEZ A, 1990, EUR J BIOCHEM, V193, P211, DOI 10.1111/j.1432-1033.1990.tb19325.x; MILLER MR, 1976, J BIOL CHEM, V251, P3671; MILLER MR, 1975, J BIOL CHEM, V250, P1132; MOAD G, 1979, J AM CHEM SOC, V101, P6068, DOI 10.1021/ja00514a033; PHILLIPS RS, 1984, J BIOL CHEM, V259, P2474; Press W., 1986, NUMERICAL RECIPES; SHIMAN R, 1979, J BIOL CHEM, V254, P1300; SHIMAN R, 1994, J BIOL CHEM, V269, P24647; SHIMAN R, 1990, J BIOL CHEM, V265, P11633; SHIMAN R, 1987, METHOD ENZYMOL, V142, P17; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; SHIMAN R, 1982, J BIOL CHEM, V257, P1213; SHIMAN R, 1971, J BIOL CHEM, V246, P1330; SHIMAN R, 1982, J BIOL CHEM, V257, P839; SHIMAN R, 1985, CHEM BIOCH PTERINS, V2, P179; STORM CB, 1971, J ORG CHEM, V36, P3925; STORM CB, 1968, BIOCHEM BIOPH RES CO, V32, P788, DOI 10.1016/0006-291X(68)90309-4; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; XIA T, 1994, J BIOL CHEM, V269, P24657	37	41	41	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24637	24646						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929135				2022-12-25	WOS:A1994PQ49000022
J	FAN, Z; LU, Y; WU, XP; MENDELSOHN, J				FAN, Z; LU, Y; WU, XP; MENDELSOHN, J			ANTIBODY-INDUCED EPIDERMAL GROWTH-FACTOR RECEPTOR DIMERIZATION MEDIATES INHIBITION OF AUTOCRINE PROLIFERATION OF A431 SQUAMOUS CARCINOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST CANCER; HUMAN-TUMOR CELLS; MONOCLONAL-ANTIBODIES; EGF RECEPTOR; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; TYROSINE KINASE; ACTIVATION; BLOCKADE	We previously reported that anti-epidermal growth factor (EGF) receptor monoclonal antibody (mAb) 225 can block receptor activation and inhibit proliferation of tumor cells bearing EGF receptors. To further explore the mechanism of mAb-mediated growth inhibition, we compared the capacities of bivalent 225 mAb and 225 F(ab')(2), and monovalent 225 Fab' fragment to block ligand binding to EGF receptors, inhibit activation of receptor tyrosine kinase by exogenous and endogenous ligand, produce receptor dimerization, down-regulate receptors, and inhibit proliferation of cultured A431 squamous carcinoma cells. Unlike 225 mAb and 225 F(ab')(2), 225 Fab' fragment was a poor inhibitor of A431 cell proliferation. The weak antiproliferative capacity of 225 Fab' was not due to depletion of active fragment from cultures. When cells were exposed to exogenous EGF, monovalent 225 Fab' remaining in conditioned culture medium could act as well as the bivalent forms of mAb to block binding and tyrosine kinase activation by exogenous EGF. However unlike the bivalent forms, 225 Fab' fragment was unable to induce receptor dimerization and down-regulation, and it lacked the capacity to block autocrine activation of EGF receptors by endogenous ligand. These deficiencies were corrected by addition of rabbit anti-mouse IgG antibody, which also enabled 225 Fab' fragment to inhibit cell proliferation. We conclude that in A431 cells, inhibition of autocrine-stimulated proliferation by anti-EGF receptor mAbs requires antibody bivalency, which provides the capacity to produce EGF receptor dimerization accompanied by receptor down-regulation. These properties may explain the greater efficacy of bivalent mAb and F(ab')(2), compared with monovalent Fab' fragment, in inhibiting proliferation of a variety of malignant and nonmalignant cultured cell lines.	CORNELL UNIV, COLL MED, NEW YORK, NY 10021 USA	Cornell University	FAN, Z (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT MED, RECEPTOR BIOL LAB, 1275 YORK AVE, NEW YORK, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA042060, R37CA042060, U01CA037641, U19CA037641] Funding Source: NIH RePORTER; NCI NIH HHS [CA37641, CA42060] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; ATLAS I, 1992, CANCER RES, V52, P3335; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DERYNCK R, 1987, CANCER RES, V47, P707; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1993, CANCER RES, V53, P4637; FAN Z, 1993, J BIOL CHEM, V268, P21073; GILL GN, 1984, J BIOL CHEM, V259, P7755; HARRIS AL, 1989, CANCER CEL, V7, P353; Hendler F., 1989, P AN M AM SOC CLIN, V8, P223; HOFER DR, 1991, CANCER RES, V51, P2780; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MASUI H, 1984, CANCER RES, V44, P1002; MASUI H, 1986, CANCER RES, V46, P5592; MASUI H, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P394; MASUI H, 1993, J CELL BIOL, V120, P85, DOI 10.1083/jcb.120.1.85; MENDELSOHN J, 1989, CANCER CEL, V7, P359; Mendelsohn J, 1987, Trans Assoc Am Physicians, V100, P173; MENDELSOHN J, 1993, CANCER PRINCIPLES PR, P114; NEAL DE, 1985, LANCET, V1, P366; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; REISS M, 1991, CANCER RES, V51, P6254; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; SAINSBURY JRC, 1985, J CLIN PATHOL, V38, P1225, DOI 10.1136/jcp.38.11.1225; Sato J D, 1983, Mol Biol Med, V1, P511; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Wu Xipu, 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	55	249	261	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27595	27602						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961676				2022-12-25	WOS:A1994PV77100068
J	SMITH, L; SMITH, JB				SMITH, L; SMITH, JB			REGULATION OF SODIUM-CALCIUM EXCHANGER BY GLUCOCORTICOIDS AND GROWTH-FACTORS IN VASCULAR SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOLEMMAL NA+-CA2+ EXCHANGER; ANGIOTENSIN-II; FREE CA-2+; CELLS; EXPRESSION; RAT; DEXAMETHASONE; TRANSCRIPTION; PURIFICATION; RECEPTORS	The findings presented in this paper indicate that glucocorticoids down-regulate Na+-Ca2+ exchanger (NCX) mRNA and activity in aortic myocytes. Serum and purified growth factors reversed NCX down-regulation. Dexamethasone, cortisol, or aldosterone decreased NCX activity by similar to 55% in 24 h. Dexamethasone was >100 times more potent than aldosterone, indicating that a glucocorticoid receptor mediates the down-regulation of NCX activity. Dexamethasone decreased the NCX transcript to similar to 10% of the control level in 24 h without affecting plasma membrane Ca2+ ATPase transcripts. Fetal bovine serum increased NCX mRNA 10-fold in 4 h in dexamethasone-treated cells and restored full NCX activity in 16 h. The increase in NCX mRNA produced by serum required RNA and protein synthesis. Thrombin moderately increased NCX mRNA and partially restored NCX activity in dexamethasone-treated cells. Insulin, platelet-derived growth factor, or epidermal growth factor increased NCX mRNA similarly to thrombin. Tunicamycin, which inhibits N-linked glycosylation, prevented the restoration of NCX activity. These observations suggest that changes in the level of NCX mRNA mediate the opposing influences of glucocorticoids and growth factors on NCX activity. NCX induction by growth stimuli would increase the capacity for Ca2+ efflux and cycling between the cell and the environment.	UNIV ALABAMA,SCH MED,DEPT PHARMACOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NHLBI NIH HHS [HL44408] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044408] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERK BC, 1993, J CELL PHYSIOL, V154, P368, DOI 10.1002/jcp.1041540221; BURNSTEIN KL, 1989, ANNU REV PHYSIOL, V51, P683, DOI 10.1146/annurev.ph.51.030189.003343; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHROUSOS GP, 1988, KIDNEY INT, V34, pS18; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GRUNFELD JP, 1988, KIDNEY INT, V34, pS24; GRUNFELD JP, 1987, HYPERTENSION, V10, P608, DOI 10.1161/01.HYP.10.6.608; HAMMES A, 1994, FASEB J, V8, P428, DOI 10.1096/fasebj.8.6.8168693; HAYASHI T, 1991, AM J PHYSIOL, V261, pC106, DOI 10.1152/ajpcell.1991.261.1.C106; HOECK W, 1989, J BIOL CHEM, V264, P14396; IIJIMA F, 1985, HYPERTENSION, V7, P783, DOI 10.1161/01.HYP.7.5.783; IIJIMA F, 1988, HYPERTENSION DALL SI, V11, pI42; KADOWITZ PJ, 1971, EUR J PHARMACOL, V13, P281, DOI 10.1016/0014-2999(71)90215-9; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KENT RL, 1993, AM J PHYSIOL, V265, pH1024, DOI 10.1152/ajpheart.1993.265.3.H1024; KOFUJI P, 1993, AM J PHYSIOL, V265, pF598, DOI 10.1152/ajprenal.1993.265.4.F598; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1992, J BIOL CHEM, V267, P7828; LIU J, 1992, J ENDOCRINOL, V133, P405, DOI 10.1677/joe.0.1330405; LONGENECKER JP, 1982, J CELL PHYSIOL, V113, P197, DOI 10.1002/jcp.1041130203; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYU RM, 1992, AM J PHYSIOL, V263, pC623; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; NAMBI P, 1992, J BIOL CHEM, V267, P19555; NICOLL DA, 1991, ANN NY ACAD SCI, V639, P181, DOI 10.1111/j.1749-6632.1991.tb17305.x; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NORRIS JS, 1984, BIOCHEM BIOPH RES CO, V122, P124, DOI 10.1016/0006-291X(84)90448-0; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; REEVES JP, 1985, CURR TOP MEMBR TRANS, V25, P77; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUSSO D, 1990, J HYPERTENS, V8, P817; SAKAUE M, 1991, J CLIN INVEST, V88, P385, DOI 10.1172/JCI115315; SATO A, 1992, HYPERTENSION, V19, P109, DOI 10.1161/01.HYP.19.1.109; SMITH JB, 1984, J CELL PHYSIOL, V118, P298, DOI 10.1002/jcp.1041180313; SMITH JB, 1989, AM J PHYSIOL, V256, pC147, DOI 10.1152/ajpcell.1989.256.1.C147; SMITH JB, 1987, J BIOL CHEM, V262, P17455; SMITH JB, 1991, BIOCHEM PHARMACOL, V41, P601, DOI 10.1016/0006-2952(91)90633-G; SMITH JB, 1991, ANN NY ACAD SCI, V639, P505, DOI 10.1111/j.1749-6632.1991.tb17344.x; WEINSTEIN R, 1981, SCIENCE, V212, P818, DOI 10.1126/science.7013068; WHITWORTH JA, 1987, KIDNEY INT, V31, P1213, DOI 10.1038/ki.1987.131	48	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27527	27531						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961668				2022-12-25	WOS:A1994PV77100058
J	BRUNET, A; PAGES, G; POUYSSEGUR, J				BRUNET, A; PAGES, G; POUYSSEGUR, J			CONSTITUTIVELY ACTIVE MUTANTS OF MAP KINASE KINASE (MEK1) INDUCE GROWTH FACTOR-RELAXATION AND ONCOGENICITY WHEN EXPRESSED IN FIBROBLASTS	ONCOGENE			English	Article							PROTEIN-KINASE; HAMSTER FIBROBLASTS; SIGNALING PATHWAYS; NA+/H+ ANTIPORTER; ACTIVATION; CELLS; RAS; PHOSPHATASE; CASCADE; PHOSPHORYLATION	The Mitogen Activated Protein Kinase (MAPK) module operates downstream of Pas to convey cell surface signals to the nucleus via the nuclear translocation of p42/p44 MAPKs. We have previously established that MAPK activation is obligatory and must persist in the G1 phase to allow resting fibroblasts to exit from G0 (Pages et al., Proc. Natl. Acad. Sci.1993, 90, 8319-8323). It remained to be established whether MAPK activation was sufficient to trigger cell proliferation. To this aim, we generated and expressed in Chinese hamster lung fibroblasts, constitutively active mutants of hamster MAP kinase kinase (MAPKK). Three mutants: S218D, S222D and S218D/S222D in which we substituted the Raf1/MAPKKK-dependent regulatory phosphorylation sites by aspartic acid residues, displayed increased basal activity when expressed in fibroblasts. Two of them, S218D and S218D/S222D which have a basal activity higher than serum-stimulated wild type-MAPKK (respectively 2- and 5-fold), induced activation of p42 MAPK in growth factor-deprived cells. Interestingly, only these two mutants led to a growth factor-independent state as judged by early gene transcription (activation of the fos promoter), increased sensitivity to growth factors for reinitiation of DNA synthesis, autonomous cell cycling and rapid tumor formation in nude mice. Therefore we conclude that the downstream elements of the growth factor signalling cascade, MAPKK-MAPK, are both necessary and sufficient to promote growth factor signals and autonomous cell cycling in fibroblasts.	UNIV NICE,CTR BIOCHIM,CNRS,F-06108 NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Pages, Gilles/N-7135-2017					ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUBOIS MF, 1994, IN PRESS EMBO J; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; ELLIS L, 1986, COLD SPRING HARB SYM, V51, P773, DOI 10.1101/SQB.1986.051.01.090; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOTOH Y, 1994, ONCOGENE, V9, P1891; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANGECARTER CA, 1993, SCIENCE, V260, P318; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MORDRET G, 1993, BIOL CELL, V79, P193, DOI 10.1016/0248-4900(93)90138-5; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PEREZRODRIGUEZ R, 1981, J CELL PHYSIOL, V109, P387, DOI 10.1002/jcp.1041090303; PEREZRODRIGUEZ R, 1982, INT J CANCER, V29, P309, DOI 10.1002/ijc.2910290314; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; POYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589	57	226	229	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3379	3387						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936666				2022-12-25	WOS:A1994PM65800035
J	SOANS, C; HOLASH, JA; PASQUALE, EB				SOANS, C; HOLASH, JA; PASQUALE, EB			CHARACTERIZATION OF THE EXPRESSION OF THE CEK8 RECEPTOR-TYPE TYROSINE KINASE DURING DEVELOPMENT AND IN TUMOR-CELL LINES	ONCOGENE			English	Article							NERVOUS-SYSTEM; EPH GENE; PROTEIN; FAMILY; CHICKEN; IDENTIFICATION; HINDBRAIN; MEMBERS; ENCODES; CLONING	Cek8 is a receptor-type tyrosine kinase gene that was identified by screening a 10 day chicken embryo library with a DNA probe corresponding to the related kinase Cek4 (Sajjadi and Pasquale, 1993). Here we report the characterization of the Cek8 protein and its expression in embryonic tissues and tumor cell lines. The 120 kd Cek8 protein is detected early in embryogenesis, is developmentally regulated and preferentially, but not exclusively, expressed in neural tissues. In the stage 24 chick embryo, Cek8 immunoreactivity is prominent in the spinal cord and spinal nerves. At embryonic day 6, Cek8 expression becomes concentrated to the ventral portion of the spinal nerves, suggesting a role in axonogenesis of specific subsets of neurons. Cek8 is expressed in nearly all of the tumor cell lines examined, including cell lines derived from tumors of the central nervous system. Although the phosphorylation on tyrosine of Cek8 during development is moderate or undetectable, Cek8 is substantially phosphorylated on tyrosine (and thus presumably activated) in many of the transformed cell lines. Because of its high frequency of expression in tumor cell lines, Cek8 differs from previously investigated Eph-related kinases. However, as we show, Cek8 is not unique among the Eph-related kinases: another member of the Eph subclass, Cek5, has similar patterns of expression and phosphorylation in tumor cells. Based on its binding to a variety of lectin columns, Cek8 contains complex N-linked oligosaccharides. Cross-linking of Cek8 molecules on the cell surface with wheat germ agglutinin caused their rapid phosphorylation on tyrosine. Autophosphorylation on tyrosine is typically the first step in the activation of a receptor tyrosine kinase by a ligand.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026351, R01HD026351] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA056721] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56721] Funding Source: Medline; NICHD NIH HHS [HD-26351] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BISHOP JM, 1991, CELL, V64, P234; BOHME B, 1993, ONCOGENE, V8, P2857; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOYD AW, 1992, J BIOL CHEM, V267, P3262; CHAN J, 1991, ONCOGENE, V6, P1057; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HARLOW E, 1988, ANTIBODIES LABORATOR; Hazan R., 1993, Molecular Biology of the Cell, V4, p9A; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SUGII S, 1982, CARBOHYD RES, V99, P99, DOI 10.1016/S0008-6215(00)80982-9; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	34	66	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3353	3361						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936661				2022-12-25	WOS:A1994PM65800030
J	CAMPBELL, P; HANNESSON, HH; SANDBACK, D; RODEN, L; LINDAHL, U; LI, JP				CAMPBELL, P; HANNESSON, HH; SANDBACK, D; RODEN, L; LINDAHL, U; LI, JP			BIOSYNTHESIS OF HEPARIN/HEPARAN SULFATE - PURIFICATION OF THE D-GLUCURONYL C-5 EPIMERASE FROM BOVINE LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN; SUBSTRATE; 5-EPIMERASE; CLEAVAGE; PROTEINS; ASSAY	The D-glucuronyl C-5 epimerase involved in the biosynthesis of heparin/heparan sulfate was purified from the high speed supernatant fraction of a homogenate of bovine liver by chromatography on immobilized O-desulfated heparin, red Sepharose, phenyl Sepharose, and concanavalin A-Sepharose. After close to 1 million-fold purification, in 10-15% yield, the product gave a single band on SDS-polyacrylamide gel electrophoresis with silver staining and had a mobility corresponding to an M(r) of similar to 52,000. Since the epimerase assay used in the course of purification was based on release of tritium, as [H-3]H2O, from a [5-H-3]uronyl-labeled substrate, it was important to establish that the purified enzyme did indeed catalyze the actual conversion of D-glucuronyl to L-iduronyl residues. Upon incubation of the purified enzyme with H-3-labeled heparosan N-sulfate, prepared by metabolic labeling (with D-[1-H-3]glucose) of a capsular polysaccharide from Escherichia coli K5 and subsequent chemical partial N-deacetylation and N-sulfation, approximately 30% of the D-glucuronyl residues located between two N-sulfated glucosamine units were converted to L-iduronyl units.	UNIV UPPSALA,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN; UNIV ALABAMA,BIRMINGHAM,AL 35294	Uppsala University; University of Alabama System; University of Alabama Birmingham					NIDCR NIH HHS [DE 08252] Funding Source: Medline; NINDS NIH HHS [NS 27353] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027353] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL P, 1983, ANAL BIOCHEM, V131, P146, DOI 10.1016/0003-2697(83)90146-X; DMITRIEV BA, 1973, CARBOHYD RES, V29, P451, DOI 10.1016/S0008-6215(00)83031-1; HOOK M, 1974, J BIOL CHEM, V249, P3908; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; JACOBSSON I, 1979, BIOCHEM J, V179, P77, DOI 10.1042/bj1790077; JENSEN JW, 1983, CARBOHYD RES, V117, P241, DOI 10.1016/0008-6215(83)88090-2; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY L, 1962, P SOC EXP BIOL MED, V109, P901; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; Lindahl U., 1989, HEPARIN, P159; MALMSTROM A, 1980, J BIOL CHEM, V255, P3878; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PODUSLO JF, 1981, ANAL BIOCHEM, V114, P131, DOI 10.1016/0003-2697(81)90463-2; PRIHAR HS, 1980, BIOCHEMISTRY-US, V19, P495, DOI 10.1021/bi00544a016; SHALTIEL S, 1973, P NATL ACAD SCI USA, V70, P778, DOI 10.1073/pnas.70.3.778; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005	21	34	40	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26953	26958						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929434				2022-12-25	WOS:A1994PQ93100057
J	ISHIGURO, N; OHZONO, T; SHINAGAWA, T; HORIUCHI, M; SHINAGAWA, M				ISHIGURO, N; OHZONO, T; SHINAGAWA, T; HORIUCHI, M; SHINAGAWA, M			A SPONTANEOUS INTERNAL DELETION OF THE C-MYB PROTOONCOGENE ENHANCES TRANSCRIPTIONAL ACTIVATION IN BOVINE T-LYMPHOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; AVIAN-MYELOBLASTOSIS VIRUS; AMINO-TERMINAL REGION; NUCLEOTIDE-SEQUENCE; V-MYB; DIFFERENTIAL EXPRESSION; HEMATOPOIETIC-CELLS; FUNCTIONAL DOMAINS; GENE-EXPRESSION; LEUKEMIA-VIRUS	Three double negative (BoCD4(-), BoCD8(-)) bovine T cell lines, BTL-PC3, BLT-2, and Pr2181, which have been established from bovine lymphosarcomas, were examined for expression and molecular function of bovine c-myb genes. BTL-PC3 expressed 4.0- and 3.6-kilobase c-myb transcripts, and BLT2 and Pr2181 expressed a 3.8-kilobase c-myb message. The c-Myb protein (75 kDa) was detected in Pr2181 but not as a clear band in BLT2, while BTL-PC3 exhibited a 65-kDa c-Myb band in immunoprecipitation tests with anti-Myb antiserum. Nucleotide sequences for c-myb cDNA clones from BTL-PC3 and BLT2 indicated that the predicted bovine wild-type c-Myb from BLT2 consists of 640 amino acids whereas that from BTL-PC3 consists of 555 amino acids lacking 85 internal amino acids. This deleted DNA region (255 base pairs consisting of 85 amino acids) corresponds to the human genomic exon 9 encoding a negative regulatory domain in the c-myb gene. Upon cotransfections with reporter plasmids containing myb binding sites, the internally deleted c-Myb exhibited a 3-fold higher transcriptional activity than the wild-type c-Myb in chloramphenicol acetyltransferase assays. These results indicate that internal DNA deletion in the c-myb gene is directly involved in the enhancement of transcriptional activation in bovine T lymphoma cells.			ISHIGURO, N (corresponding author), OBIHIRO UNIV AGR & VET MED,DEPT VET PUBL HLTH,OBIHIRO,HOKKAIDO 080,JAPAN.							ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDER TP, 1987, J IMMUNOL, V139, P3822; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BROWN KE, 1992, J BIOL CHEM, V267, P4625; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DUDEK H, 1989, ONCOGENE, V4, P1061; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P266; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; ISHIGURO N, 1993, AM J VET RES, V54, P2010; ISHIGURO N, 1985, J BACTERIOL, V164, P977, DOI 10.1128/JB.164.3.977-982.1985; ISHIGURO N, 1990, GENE, V91, P281, DOI 10.1016/0378-1119(90)90101-V; ISHIGURO N, 1994, VET IMMUNOL IMMUNOP, V41, P1, DOI 10.1016/0165-2427(94)90053-1; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KIMURA S, 1968, JPN J MICROBIOL, V12, P293, DOI 10.1111/j.1348-0421.1968.tb00398.x; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NOMURA T, 1993, J BIOL CHEM, V268, P21914; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1990, MOL CELL BIOL, V10, P2715, DOI 10.1128/MCB.10.6.2715; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; TAKAI T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P105, DOI 10.1016/0167-4781(90)90029-2; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEUCHI N, 1992, IMMUNOGENETICS, V35, P89, DOI 10.1007/BF00189517; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043	56	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26822	26829						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929419				2022-12-25	WOS:A1994PQ93100039
J	CHAMBERS, RS; DAHMUS, ME				CHAMBERS, RS; DAHMUS, ME			PURIFICATION AND CHARACTERIZATION OF A PHOSPHATASE FROM HELA-CELLS WHICH DEPHOSPHORYLATES THE C-TERMINAL DOMAIN OF RNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGEST SUBUNIT; PROTEIN PHOSPHATASES; PHOSPHORYLATION; TRANSCRIPTION; PROMOTER; KINASE; INITIATION; SPECIFICITY; ENCODES; INVITRO	The repetitive C-termin al domain (CTD) of RNA polymerase (RNAP) II is extensively phosphorylated concomitant with the initiation of transcription and must be dephosphorylated before RNAP LT: can begin another round of transcription. A CTD phosphatase was purified more than 7,500-fold from a HeLa cell extract. SDS-polyacrylamide gel electrophoresis shows a predominant protein of 205 kDa and a less abundant protein of 150 kDa co-eluting with the CTD phosphatase activity. Sedimentation and gel filtration analysis suggest that CTD phosphatase has an elongated structure with a M(r) of 200,000. This enzyme is a type 2C phosphatase in that it requires Mg2+ for activity and is resistant to okadaic acid. CTD phosphatase appears to processively dephosphorylate the CTD and is specific in that it does not dephosphorylate phosphorylase a, the alpha or beta subunits of phosphorylase kinase or RNAP II phosphorylated with casein kinase II. CTD phosphatase dephosphorylates RNAP IIO purified from calf thymus or generated in vitro by two previously described CTD kinases. These results suggest that CTD phosphatase has the properties expected for a protein phosphatase that catalyzes the conversion of RNAP IIO to RNAP IIA and may play a key role in the transcription cycle of RNAP II.	UNIV CALIF DAVIS,DIV BIOL SCI,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NIGMS NIH HHS [GM33300] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHAMBON P, 1974, ENZYMES, P261; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CORDEN JL, 1992, TRANSCRIPTIONAL REGU, P81; DAHMUS ME, 1994, TRANSCRIPTION MECHAN, P243; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; DVIR A, 1993, J BIOL CHEM, V268, P10440; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KANG ME, 1993, J BIOL CHEM, V268, P25033; KIM WY, 1986, J BIOL CHEM, V261, P14219; KIM YH, 1993, J BIOL CHEM, V268, P18513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; NEWSHOLME P, 1992, BIOCHEM J, V283, P845, DOI 10.1042/bj2830845; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PATO MD, 1990, ARCH BIOCHEM BIOPHYS, V276, P116, DOI 10.1016/0003-9861(90)90017-S; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PERUSKI LF, 1993, ADV PROTEIN PHOSPHAT, V7, P9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEWART AA, 1981, EUR J BIOCHEM, V115, P197; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHANG J, 1991, J BIOL CHEM, V266, P2290	39	124	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26243	26248						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929341				2022-12-25	WOS:A1994PQ93000049
J	CHAUVIN, MF; MEGNINCHANET, F; MARTIN, G; LHOSTE, JM; BAVEREL, G				CHAUVIN, MF; MEGNINCHANET, F; MARTIN, G; LHOSTE, JM; BAVEREL, G			THE RABBIT KIDNEY TUBULE UTILIZES GLUCOSE FOR GLUTAMINE SYNTHESIS - A C-13 NMR-STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CITRIC-ACID-CYCLE; NUCLEAR MAGNETIC-RESONANCE; RAT-BRAIN INVIVO; KREBS CYCLE; METABOLISM; LIVER; GLUCONEOGENESIS; SPECTROSCOPY; PYRUVATE; CARBON	The metabolism of variously labeled [C-13]- and [C-14]glucoses, used at a physiological concentration (5 mM), has been studied in isolated rabbit kidney tubules both in the absence and the presence of NH4Cl. When present as sole exogenous substrate, glucose was metabolized at high rates and converted not only into CO2 and lactate but also, in contrast to a previous conclusion of Krebs (Krebs, H. A. (1935) Biochem. J. 29, 1951-1969), into glutamine. Absolute fluxes through enzymes of glycolysis and gluconeogenesis and of enzymes of three different cycles operating simultaneously were assessed by using a novel model describing reactions of glucose metabolism in conjunction with the C-13 MMR and, to a lesser extent, the radioactive data obtained. The presence of NH4Cl (5 mM) caused a large stimulation of glucose removal and a large increase in lactate, glutamine, and glycerol 3-phosphate accumulation. Under this condition, the stimulation of glutamine synthesis was accompanied not by an activation of citrate synthesis but by an inhibition of flux through alpha-ketoglutarate dehydrogenase. The resulting depletion of citric acid cycle intermediates was compensated by anaplerosis at the level of pyruvate carboxylase. The ''futile'' cycle involving oxaloacetate, phosphoenolpyruvate and pyruvate, which was intense in the presence of glucose alone, was greatly stimulated by the addition of NH4Cl.	HOP EDOUARD HERRIOT, CTR ETUD METAB SPECT RESONANCE MAGNET, CNRS, EP 18, F-69374 LYON 03, FRANCE; INSERM, U350, UNITE BIOPHYS MOLEC, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)			Chanet, Frédérique Megnin/M-1983-2018					[Anonymous], METHODS ENZYMATIC AN; BAVEREL G, 1980, BIOCHEM J, V188, P873, DOI 10.1042/bj1880873; BAVEREL G, 1979, BIOCHEM J, V184, P599, DOI 10.1042/bj1840599; BAVEREL G, 1978, KIDNEY INT, V14, P567, DOI 10.1038/ki.1978.165; BURCH HB, 1982, J BIOL CHEM, V257, P3676; CANIONI P, 1983, BIOCHEMISTRY-US, V22, P4974, DOI 10.1021/bi00290a015; CERDAN S, 1990, J BIOL CHEM, V265, P12916; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; COHEN SM, 1981, P NATL ACAD SCI-BIOL, V78, P60, DOI 10.1073/pnas.78.1.60; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P581, DOI 10.1021/bi00376a033; COHEN SM, 1981, J BIOL CHEM, V256, P3428; COHEN SM, 1979, P NATL ACAD SCI USA, V76, P4808, DOI 10.1073/pnas.76.10.4808; DAMIAN AC, 1970, AM J PHYSIOL, V218, P1249, DOI 10.1152/ajplegacy.1970.218.5.1249; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; DUGELAY S, 1991, BIOCHIM BIOPHYS ACTA, V1075, P191, DOI 10.1016/0304-4165(91)90251-B; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; GUDER WG, 1980, INT J BIOCHEM, V42, P529; GUDER WG, 1992, HDB PHYSL 8, V2, P2119; GULLANS SR, 1984, J MEMBRANE BIOL, V78, P257, DOI 10.1007/BF01925973; HOWARTH OW, 1978, PROG NUCL MAG RES SP, V12, P1, DOI 10.1016/0079-6565(78)80001-6; JANICKI RH, 1969, AM J PHYSIOL, V216, P1107, DOI 10.1152/ajplegacy.1969.216.5.1107; JANS AWH, 1989, BIOCHEM J, V263, P231, DOI 10.1042/bj2630231; KALDERON B, 1987, FEBS LETT, V213, P209, DOI 10.1016/0014-5793(87)81493-X; KATZ J, 1989, J BIOL CHEM, V264, P12994; KELLEHER JK, 1985, AM J PHYSIOL, V248, pE252, DOI 10.1152/ajpendo.1985.248.2.E252; Krebs HA, 1932, H-S Z PHYSIOL CHEM, V210, P33, DOI 10.1515/bchm2.1932.210.1-2.33; KREBS HA, 1963, BIOCHEM J, V89, P398, DOI 10.1042/bj0890398; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1951; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MARTIN G, 1994, J BIOL CHEM, V269, P26034; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; RICHTERICH RW, 1958, AM J PHYSIOL, V195, P316, DOI 10.1152/ajplegacy.1958.195.2.316; ROGNSTAD R, 1972, J BIOL CHEM, V247, P6047; Ross BD, 1982, METABOLIC COMPARTMEN, P363; ROTHMAN DL, 1992, P NATL ACAD SCI USA, V89, P9603, DOI 10.1073/pnas.89.20.9603; ROTHMAN DL, 1985, P NATL ACAD SCI USA, V82, P1633, DOI 10.1073/pnas.82.6.1633; SHAKA AJ, 1983, J MAGN RESON, V52, P335, DOI 10.1016/0022-2364(83)90207-X; WATFORD M, 1980, BIOCHEM J, V188, P741, DOI 10.1042/bj1880741	40	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26025	26033						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929313				2022-12-25	WOS:A1994PQ93000017
J	SUN, LZ; WU, GF; WILLSON, JKV; ZBOROWSKA, E; YANG, JH; RAJKARUNANAYAKE, I; WANG, J; GENTRY, LE; WANG, XF; BRATTAIN, MG				SUN, LZ; WU, GF; WILLSON, JKV; ZBOROWSKA, E; YANG, JH; RAJKARUNANAYAKE, I; WANG, J; GENTRY, LE; WANG, XF; BRATTAIN, MG			EXPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA TYPE-II RECEPTOR LEADS TO REDUCED MALIGNANCY IN HUMAN BREAST-CANCER MCF-7 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA-CELLS; ATHYMIC MICE; C-MYC; INHIBITION; FACTOR-BETA-1; PROLIFERATION; TUMORIGENICITY; CLONING; FORMS; DIFFERENTIATION	The role of transforming growth factor (TGF) beta type II receptor in reversing the malignant phenotype of human breast cancer MCF-7 cells was examined. MCF-7 cells were insensitive to TGF beta(1) and expressed undetectable levels of cell surface TGF beta type I receptor (RI) and type II receptor (RII) by cross-linking with I-125-TGF beta(1). Stable transfection of a RII expression vector yielded 3 transfectants with varying levels of exogenous RII mRNA and protein levels. Expression of RII also increased TGF beta(1) binding to RI in all 3 clones. Proliferation of RII-positive clones was inhibited by exogenous TGF beta(1) in a dose-dependent manner, whereas the control clones remained TGF beta-insensitive. The RII transfectants were growth arrested in monolayer culture at saturation densities which were 41-66% of that of the Neo controls. They also showed reduced clonogenicity in soft-agarose. Tumorigenicity in ovariectomized, estrogen-supplemented nude mice was delayed in transfectants with low RII levels. Transfectants expressing high levels of RII showed a large reduction in tumorigenicity as well as a longer delay in tumor formation. Tumor growth was associated with loss of exogenous RII expression in transfectants. The results indicate that when systems for TGF beta signal transduction are intact, reconstitution of the TGF beta receptor system can lead to reversion of malignancy in cells lacking RII.	MED COLL OHIO,DEPT BIOCHEM & MOLEC BIOL,TOLEDO,OH 43614; CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Case Western Reserve University; Duke University			, LuZhe/AAW-4095-2021		NATIONAL CANCER INSTITUTE [R01CA038173, R01CA050457, R01CA060848, R37CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [CA38173, CA50457, CA60848] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1988, CANCER RES, V48, P3898; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BRATTAIN MG, 1993, ADV MOL CELL BIOL BI, V7, P35; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHANG HL, 1993, CANCER RES, V53, P4391; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTARDIS MM, 1988, J STEROID BIOCHEM, V30, P311, DOI 10.1016/0022-4731(88)90113-6; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOSES HL, 1992, MOL REPROD DEV, V32, P179, DOI 10.1002/mrd.1080320215; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; MURPHY CS, 1991, COLD SPRING HARB SYM, V56, P129; OSBORNE CK, 1987, BREAST CANCER RES TR, V9, P111, DOI 10.1007/BF01807363; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SING GK, 1990, CELL GROWTH DIFFER, V1, P549; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; TWARDZIK DR, 1989, J NATL CANCER I, V81, P1182, DOI 10.1093/jnci/81.15.1182; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P186; ZUGMAIER G, 1991, CANCER RES, V51, P3590	42	307	319	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26449	26455						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929366				2022-12-25	WOS:A1994PQ93000078
J	TOYOFUKU, T; KURZYDLOWSKI, K; NARAYANAN, N; MACLENNAN, DH				TOYOFUKU, T; KURZYDLOWSKI, K; NARAYANAN, N; MACLENNAN, DH			IDENTIFICATION OF SER(38) AS THE SITE IN CARDIAC SARCOPLASMIC-RETICULUM CA2+-ATPASE THAT IS PHOSPHORYLATED BY CA2+ CALMODULIN-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; CA-2+-ATPASE; ATPASE; MUSCLE; PHOSPHOLAMBAN; EXPRESSION; CALCIUM; DOMAIN; MUTAGENESIS; AFFINITY	In previous studies (Xu, A., Hawkins, C., and Narayanan, N. (1993) J. Biol. Chem. 268, 8394-8397), the Ca2+-ATPase of cardiac muscle sarcoplasmic reticulum (SERCA2) was shown to be phosphorylated by Ca2+/calmodulin-dependent protein kinase II (CaM kinase) on a serine residue, likely to be either Ser(38), Ser(167), or Ser(531). SERCA2 and SERCA2 mutants S38A, S167A, and S531A were expressed in HEK-293 cells and tested for phosphorylation with CaM kinase. Mutant S38A was not phosphorylated, while mutants S167A and S531A were phosphorylated, suggesting that Ser(38) is the site of CaM kinase phosphorylation in SERCA2. This conclusion was supported by the observation that phosphorylation of SERCA2 and mutants S167A and S531A by CaM kinase increased the V-max for Ca2+ transport, while the V-max for Ca2+ transport by mutant S38A was unaffected by exposure to a phosphorylation reaction mix. SERCA1, containing a potential CaM kinase phosphorylation site at Ser(167) and two SERCA1 mutants, K35R plus H38S and T532S, in which potential CaM kinase sites were created, were not phosphorylated by CaM kinase, and V-max for Ca2+ transport was unaffected by exposure to a phosphorylation reaction mix. Thus phosphorylation of Ser(38) in SERCA2 results in a unique activation of V-max for Ca2+ transport, providing a potential regulatory mechanism for Ca2+ removal from cardiac and other tissues in which SERCA2 is expressed.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ON, CANADA; UNIV WESTERN ONTARIO, DEPT PHYSIOL, LONDON N6A 5C1, ON, CANADA	University of Toronto; Western University (University of Western Ontario)								BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; BURK SE, 1989, J BIOL CHEM, V264, P18561; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; TADA M, 1988, METHOD ENZYMOL, V157, P107; THOMLISON RJ, 1990, CHILD MALTREATMENT : EXPANDING OUR CONCEPT OF HELPING, P127; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; XU A, 1993, J BIOL CHEM, V268, P8394	25	115	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26492	26496						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929371				2022-12-25	WOS:A1994PQ93000084
J	BAKER, RT; SMITH, SA; MARANO, R; MCKEE, J; BOARD, PG				BAKER, RT; SMITH, SA; MARANO, R; MCKEE, J; BOARD, PG			PROTEIN EXPRESSION USING COTRANSLATIONAL FUSION AND CLEAVAGE OF UBIQUITIN - MUTAGENESIS OF THE GLUTATHIONE-BINDING SITE OF HUMAN PI-CLASS GLUTATHIONE-S-TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURE; FUNCTIONAL-ANALYSIS; HUMAN-LIVER; PURIFICATION; RESOLUTION; CLONING; COMPLEX	Expression of cloned genes in prokaryotes such as Escherichia coli is a widely used technique in both basic research and biotechnology. Despite the availability of several E. coli expression vector systems, adequate levels of expression may not be achieved. Expressing proteins as fusions to the highly conserved eukaryotic protein ubiquitin has been reported by several investigators to enhance protein yield in both bacterial and eukaryotic systems. We have modified this technique by the co-expression in E. coli of a ubiquitin-fusion protein and the Saccharomyces cerevisiae ubiquitin-specific protease Ubp2. This allows the co-translational cleavage of engineered ubiquitin-fusion proteins expressed in E. coli. This system was used to express a human Pi class glutathione S-transferase (GST) GSTP1 as well as two mutant GSTP1 derivatives, Trp(39)-->Cys and Gln(52)-->Glu. The yield of these enzymes was improved 40-fold by using the ubiquitin-fusion/co-translational cleavage technique, and no uncleaved product was detected. The Trp(39)-->Cys mutant was totally devoid of GST activity, while the activity of the Gln(52)-->Glu mutant was reduced to 6% of wild type GSTP1-1. As both of the mutated residues map within the glutathione binding site, the reduced GST activity is consistent with a marked reduction in glutathione binding ability.			BAKER, RT (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,MOLEC GENET GRP,POB 334,CANBERRA,ACT 2601,AUSTRALIA.		Marano, Robert/A-3552-2015	Marano, Robert/0000-0001-9565-3167				ALIN P, 1985, FEBS LETT, V182, P319, DOI 10.1016/0014-5793(85)80324-0; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BOARD P, 1993, J BIOL CHEM, V268, P15655; BOARD PG, 1987, BIOCHEM J, V248, P937, DOI 10.1042/bj2480937; BORA PS, 1991, J BIOL CHEM, V266, P16774; BROSIUS J, 1987, METHOD ENZYMOL, V153, P54; BUTT TR, 1989, P NATL ACAD SCI USA, V86, P2540, DOI 10.1073/pnas.86.8.2540; DANIELSON UH, 1985, BIOCHEM J, V231, P263, DOI 10.1042/bj2310263; ECKER DJ, 1989, J BIOL CHEM, V264, P7715; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Habig W H, 1981, Methods Enzymol, V77, P398; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; KONG KH, 1991, BIOCHEM BIOPH RES CO, V181, P748, DOI 10.1016/0006-291X(91)91254-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MANOHARAN TH, 1992, J BIOL CHEM, V267, P18940; MONIA BP, 1989, J BIOL CHEM, V264, P4093; NISHIHIRA J, 1992, BIOCHEM BIOPH RES CO, V185, P1069, DOI 10.1016/0006-291X(92)91735-9; PENNINGTON CJ, 1992, BIOCHEMISTRY-US, V31, P2912; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SABIN EA, 1989, BIO-TECHNOL, V7, P705, DOI 10.1038/nbt0789-705; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; SMITH DB, 1988, MOL BIOCHEM PARASIT, V27, P249, DOI 10.1016/0166-6851(88)90044-8; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKI T, 1987, ANN HUM GENET, V51, P95, DOI 10.1111/j.1469-1809.1987.tb01051.x; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; UHLEN M, 1990, METHOD ENZYMOL, V185, P129; WIDERSTEIN M, 1992, BIOCHEM J, V285, P377, DOI 10.1042/bj2850377; YOO Y, 1989, J BIOL CHEM, V264, P17078	36	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25381	25386						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929235				2022-12-25	WOS:A1994PQ49100026
J	FUJINAMI, K; TANAHASHI, N; TANAKA, K; ICHIHARA, A; CEJKA, Z; BAUMEISTER, W; MIYAWAKI, M; SATO, T; NAKAGAWA, H				FUJINAMI, K; TANAHASHI, N; TANAKA, K; ICHIHARA, A; CEJKA, Z; BAUMEISTER, W; MIYAWAKI, M; SATO, T; NAKAGAWA, H			PURIFICATION AND CHARACTERIZATION OF THE 26-S PROTEASOME FROM SPINACH LEAVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; RABBIT RETICULOCYTE LYSATE; MOLECULAR-WEIGHT PROTEASES; UBIQUITIN-LIGATED PROTEINS; PROTEOLYTIC COMPLEX; DEPENDENT PROTEOLYSIS; ELECTRON-MICROSCOPY; MULTIPLE FORMS; HIGHER-PLANT; ATP	The 26 S proteasome complex catalyzing ATP-dependent breakdown of ubiquitin-ligated proteins was purified from spinach leaves 60 near homogeneity by chromatography on DEAE-cellulose, gel filtration on Biogel A-1.5, and glycerol density gradient centrifugation. The purified enzyme was shown to degrade multi-ubiquitinated, but not unmodified, lysozymes in an ATP-dependent fashion coupled with ATPase activity supplying energy for proteolysis and isopeptidase activity to generate free ubiquitin. By nondenaturing electrophoresis, the purified enzyme was separated into two distinct forms of the 26 S complex, named 26 S alpha and 26 S beta proteasomes, with different electrophoretic mobilities, The 26 S proteasome was found to consist of multiple polypeptides with molecular masses of 23-35 and 39-115 kDa, which were thought to be those of a 20 S proteasome with multicatalytic proteinase activity and an associated regulatory part with ATPase and deubiquitinating activities, respectively. The subunit multiplicity of the spinach 26 S proteasome closely resembled that of rat liver with minor differences in certain components. No sulfhydryl bond was involved in the assembly of this multicomponent polypeptide complex. Electron microscopy showed that the 26 S proteasome complex had a ''caterpillar''-like shape, consisting of four central protein layers, assumed to be the 20 S proteasome, with asymmetric V-shaped layers at each end. These structural and functional characteristics of the spinach 26 S proteasome showed marked similarity to those of the mammalian 26 S proteasomes reported recently, suggesting that the 26 S proteasome is widely distributed in eukaryotic cells and is of general importance for catalyzing the soluble energy- and ubiquitin-dependent proteolytic pathway.	CHIBA UNIV,FAC HORT,DEPT AGR CHEM,MATSUDO,CHIBA 271,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Chiba University; Tokushima University; Max Planck Society								ARMON T, 1990, J BIOL CHEM, V265, P20723; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FRANK J, 1982, J MOL BIOL, V161, P1134; GOLDBERG AL, 1992, EUR J BIOCHEM, V205, P9; HATFIELD PM, 1989, BIOCHEMISTRY-US, V28, P735, DOI 10.1021/bi00428a048; HEGERL R, 1991, FEBS LETT, V283, P117, DOI 10.1016/0014-5793(91)80567-M; HEGERL R, 1982, ULTRAMICROSCOPY, V9, P109, DOI 10.1016/0304-3991(82)90233-9; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1987, J BIOL CHEM, V262, P8303; IKAI A, 1991, FEBS LETT, V292, P21, DOI 10.1016/0014-5793(91)80824-M; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NAKAGAWA H, 1985, PLANT CELL REP, V4, P148, DOI 10.1007/BF00571303; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; OZAKI M, 1992, J BIOL CHEM, V267, P21678; PETERS JM, 1991, EUR J CELL BIOL, V56, P422; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SAXTON WO, 1979, ULTRAMICROSCOPY, V4, P343, DOI 10.1016/S0304-3991(79)80044-3; SKODA B, 1992, PLANT PHYSIOL, V99, P1515, DOI 10.1104/pp.99.4.1515; TAMURA T, 1991, FEBS LETT, V292, P154, DOI 10.1016/0014-5793(91)80856-X; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; VIERSTRA RD, 1988, BIOCHEMISTRY-US, V27, P3290, DOI 10.1021/bi00409a025; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050	38	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25905	25910						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929295				2022-12-25	WOS:A1994PQ49100097
J	ALI, H; RICHARDSON, RM; TOMHAVE, ED; DUBOSE, RA; HARIBABU, B; SNYDERMAN, R				ALI, H; RICHARDSON, RM; TOMHAVE, ED; DUBOSE, RA; HARIBABU, B; SNYDERMAN, R			REGULATION OF STABLY TRANSFECTED PLATELET-ACTIVATING-FACTOR RECEPTOR IN RBL-2H3 CELLS - ROLE OF MULTIPLE G-PROTEINS AND RECEPTOR PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; C5A CHEMOATTRACTANT RECEPTORS; GAMMA-SUBUNITS; POLYMORPHONUCLEAR NEUTROPHILS; BETA-2-ADRENERGIC RECEPTOR; DEPENDENT PHOSPHORYLATION; INDUCED DESENSITIZATION; DISTINCT PATHWAYS; ADENYLATE-CYCLASE; PERTUSSIS TOXIN	Platelet activating factor (PAF) interacts with cell surface receptors to mediate inflammatory responses. To determine the mechanisms of PAF receptor regulation, we constructed epitope-tagged human PAF receptor cDNA (ET-PAFR) and generated stable transfectants in a rat basophilic cell line (RBL-2H3 cells). The expressed receptors displayed ligand binding and functional properties similar to the native receptors in neutrophils. PAF-stimulated intracellular Ca2+ mobilization was not inhibited by pertussis toxin (PTx), whereas phosphoinositide hydrolysis and secretion were blocked by similar to 40%. The PTx-resistant secretion mediated by PAF was, however, inhibited by guanosine 5'-O-(2-thiodiphosphate) in permeabilized RBL-2H3 cells, indicating a role for PTx-insensitive G protein. In contrast to the PAF receptor, responses mediated by formylpeptide and C5a chemoattractants were inhibited by PTx. PAF stimulated a dose- and time dependent phosphorylation of its receptor. ET-PAFR was also phosphorylated by phorbol la-myristate 13-acetate (PMA) and dibutyryl cyclic AMP. Staurosporine caused complete inhibition of ET-PAFR phosphorylation by PMA but only partial inhibition by PAF Receptor phosphorylation by PAF and PMA correlated with desensitization as measured by a decrease in both PAF-stimulated GTPase activity in membranes and Ca2+ mobilization in intact cells. Phosphorylation of ET-PAFR by dibutyryl cyclic AMP was not, however, associated with desensitization. These data demonstrate that a single PAF receptor population interacts with multiple G proteins to mediate its biological responses. Moreover, ET-PAFR, unlike the formylpeptide or C5a receptors, is phosphorylated by at least three kinases (most likely protein kinases A and C and a receptor kinase). The functional consequences of cellular activation by various chemoattractants may depend upon the G protein to which their receptor is coupled.	DUKE UNIV, MED CTR, DEPT IMMUNOL, DURHAM, NC 27710 USA	Duke University	ALI, H (corresponding author), DUKE UNIV, MED CTR, DEPT MED, BOX 3680, DURHAM, NC 27710 USA.		Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NCI NIH HHS [CA-29589] Funding Source: Medline; NIDCR NIH HHS [DE-03738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALI H, 1993, J BIOL CHEM, V268, P24247; ALI H, 1990, J BIOL CHEM, V265, P745; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BATES MD, 1993, J BIOL CHEM, V268, P14757; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CAMUSSI G, 1981, IMMUNOLOGY, V42, P191; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; HAGA K, 1992, J BIOL CHEM, V267, P2222; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HOMMA H, 1988, ARCH BIOCHEM BIOPHYS, V262, P32, DOI 10.1016/0003-9861(88)90165-8; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1988, J BIOL CHEM, V263, P3225; HWANG SB, 1991, ANN NY ACAD SCI, V629, P217; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLEIN P, 1987, J BIOL CHEM, V262, P358; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; KROEGEL C, 1989, BIOCHEM BIOPH RES CO, V162, P511, DOI 10.1016/0006-291X(89)92027-5; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LAD PM, 1985, BIOCHEM BIOPH RES CO, V129, P632, DOI 10.1016/0006-291X(85)91938-2; MURPHY PM, 1990, J IMMUNOL, V145, P2227; NACCACHE PH, 1985, BIOCHEM BIOPH RES CO, V130, P677, DOI 10.1016/0006-291X(85)90470-X; NACCACHE PH, 1986, J LEUKOCYTE BIOL, V40, P533, DOI 10.1002/jlb.40.5.533; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; OFLAHERTY JT, 1992, BIOCHEM J, V288, P241, DOI 10.1042/bj2880241; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SHUKLA SD, 1989, MOL PHARMACOL, V35, P409; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; STADEL JM, 1983, P NATL ACAD SCI-BIOL, V80, P3173, DOI 10.1073/pnas.80.11.3173; TARDIF M, 1993, J IMMUNOL, V150, P3534; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; UKENA D, 1988, FEBS LETT, V228, P285, DOI 10.1016/0014-5793(88)80017-6; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	46	133	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24557	24563						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929127				2022-12-25	WOS:A1994PQ49000011
J	WOSCHOLSKI, R; DHAND, R; FRY, MJ; WATERFIELD, MD; PARKER, PJ				WOSCHOLSKI, R; DHAND, R; FRY, MJ; WATERFIELD, MD; PARKER, PJ			BIOCHEMICAL-CHARACTERIZATION OF THE FREE CATALYTIC P110-ALPHA AND THE COMPLEXED HETERODIMERIC P110-ALPHA-CENTER-DOT-P85-ALPHA - FORMS OF THE MAMMALIAN PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; PHOSPHOINOSITIDE 3-KINASE; SIGNALING COMPLEXES; SH2 DOMAINS; PROTEIN; EXPRESSION; SUBUNIT; CLONING; P85; PHOSPHORYLATION	The regulatory (p85 alpha) and catalytic (p110 alpha) subunits of the mammalian phosphatidylinositol 3-kinase have been expressed in insect cells using the baculovirus system. The free catalytic subunit p110 alpha and the coexpressed heterodimeric complex of p85 alpha and p110 alpha were purified and their enzymological properties compared, While many kinetic parameters were similar, the coexpressed complex was found to have a 20-fold higher K-m for ATP in comparison with the free catalytic subunit p110 alpha using phosphatidylinositol 4,5-bisphosphate as a substrate; no significant difference was detectable when phosphatidylinositol was used. Reconstitution of the p110 alpha.p85 alpha complex in vitro showed that it had the properties of the free p110 alpha and not the p110 alpha.p85 alpha in vivo complex. Therefore, a post-translational modification dependent upon the presence of the regulatory subunit p85 alpha rather than the physical subunit interaction itself is responsible for the observed properties of the lipid kinase activity of the p110 alpha.p85 alpha complex. Phosphatase treatment of the purified lipid kinase complex reduced the high K-m for ATP, suggesting that a phosphorylation of the heterodimeric complex (p85 alpha.p110 alpha) caused this effect. This mode of regulation is discussed in the context of lipid kinase activation in vivo.	IMPERIAL CANC RES FUND, PROT PHOSPHORYLAT LAB, LONDON WC2A 3PX, ENGLAND; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; INST CANC RES, HADDOW LABS, SUTTON SM2 5NG, SURREY, ENGLAND; UNIV LONDON UNIV COLL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research; University of London; Institute of Cancer Research - UK; University of London; University College London			Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933; Fry, Michael/0000-0001-8518-1370				BACKER JM, 1993, J BIOL CHEM, V268, P8204; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRY MJ, 1993, PROTEIN SCI, V2, P1785, DOI 10.1002/pro.5560021102; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KODAKI T, 1994, EUR J BIOCHEM, V219, P775, DOI 10.1111/j.1432-1033.1994.tb18557.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; ROCHE S, 1994, BIOCHEM J, V301, P703, DOI 10.1042/bj3010703; RUIZLARREA F, 1993, BIOCHEM J, V290, P609, DOI 10.1042/bj2900609; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHIBASAKI F, 1993, BIOCHEM J, V289, P227, DOI 10.1042/bj2890227; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25067	25072						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929193				2022-12-25	WOS:A1994PQ49000082
J	COFFIELD, JA; CONSIDINE, RV; JEYAPAUL, J; MAKSYMOWYCH, AB; ZHANG, RD; SIMPSON, LL				COFFIELD, JA; CONSIDINE, RV; JEYAPAUL, J; MAKSYMOWYCH, AB; ZHANG, RD; SIMPSON, LL			THE ROLE OF TRANSGLUTAMINASE IN THE MECHANISM OF ACTION OF TETANUS TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE ANALYSIS; AMINO-ACID-SEQUENCE; NEUROTOXIN TYPE-A; NEUROTRANSMITTER RELEASE; CLOSTRIDIAL NEUROTOXINS; INHIBITS EXOCYTOSIS; ENCODING GENE; LIGHT CHAIN; BOTULINUM; SYNAPTOBREVIN	Tetanus toxin is a zinc-dependent metalloendoprotease that cleaves synaptobrevin, a polypeptide found in the membranes of synaptic vesicles. This action is thought to account for toxin-induced blockade of transmitter release. However, Facchiano and Luini (Facchiano, F., and Luini, A. (1992) J. Biol Chem. 267, 13267-13271) have proposed that tetanus toxin can stimulate transglutaminase, and Facchiano et al. (Facchiano, F., Benfenati, F., Valtorta, F., and Luini, A. (1993) J. Biol Chem. 268, 4588-4591) have further proposed that the stimulated enzyme produces cross-linking of synapsin. These actions might also account for toxin-induced blockade of exocytosis. Therefore, a series of experiments were performed to evaluate the possibility that tetanus toxin exerts its effects via transglutaminase. The results indicated that clostridial neurotoxins were poor substrates for the cross-linking effects of transglutaminase, and transglutaminase was a poor substrate for the proteolytic actions of tetanus toxin. In addition, at concentrations relevant to blockade of exocytosis, clostridial neurotoxins did not act on intact cells to stimulate transglutaminase, nor did they act on the isolated enzyme to stimulate cross-linking of putrescine and dimethylcasein. When used as competitive inhibitors of endogenous transglutaminase substrates, glycine methyl ester and monodansylcadaverine did not block toxin action. Furthermore, concentrations of calcium that were too low to support transglutaminase activity did not prevent toxin action. The data suggest that stimulation of transglutaminase is not the principal mechanism by which tetanus toxin blocks exocytosis in nerve cells.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009472, R01NS022153] Funding Source: NIH RePORTER; NIDDK NIH HHS [1-F32-DK08888-01] Funding Source: Medline; NINDS NIH HHS [NINCDS NS-22153, 1-F32-NS09472-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; BARSIGIAN C, 1988, J BIOL CHEM, V263, P14015; BINZ T, 1990, NUCLEIC ACIDS RES, V18, P5556, DOI 10.1093/nar/18.18.5556; BINZ T, 1990, J BIOL CHEM, V265, P9153; BITTNER MA, 1989, J NEUROCHEM, V53, P966, DOI 10.1111/j.1471-4159.1989.tb11800.x; BLAUSTEIN MP, 1988, HDB EXPT PHARM, V83, P275; BUNGAY PJ, 1984, BIOCHEM J, V219, P819, DOI 10.1042/bj2190819; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; FACCHIANO F, 1992, J BIOL CHEM, V267, P13267; FACCHIANO F, 1993, J BIOL CHEM, V268, P4588; FAIRWEATHER NF, 1986, NUCLEIC ACIDS RES, V14, P7809, DOI 10.1093/nar/14.19.7809; HABERMANN E, 1986, CURR TOP MICROBIOL, V129, P93; HAUSER D, 1990, NUCLEIC ACIDS RES, V18, P4924, DOI 10.1093/nar/18.16.4924; KURAZONO H, 1992, J BIOL CHEM, V267, P14721; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MCGEE R, 1978, P NATL ACAD SCI USA, V75, P1314, DOI 10.1073/pnas.75.3.1314; PASTUSZKO A, 1986, J NEUROCHEM, V46, P499, DOI 10.1111/j.1471-4159.1986.tb12996.x; POULET S, 1992, BIOCHEM BIOPH RES CO, V183, P107, DOI 10.1016/0006-291X(92)91615-W; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SENNER A, 1985, ENDOCRINOLOGY, V117, P237; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; THOMPSON DE, 1990, EUR J BIOCHEM, V189, P73, DOI 10.1111/j.1432-1033.1990.tb15461.x; WHELAN SM, 1992, EUR J BIOCHEM, V204, P657, DOI 10.1111/j.1432-1033.1992.tb16679.x; WHELAN SM, 1992, APPL ENVIRON MICROB, V58, P2345, DOI 10.1128/AEM.58.8.2345-2354.1992	25	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24454	24458						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929108				2022-12-25	WOS:A1994PQ34600093
J	DING, L; SETO, BL; AHMED, SA; COLEMAN, WG				DING, L; SETO, BL; AHMED, SA; COLEMAN, WG			PURIFICATION AND PROPERTIES OF THE ESCHERICHIA-COLI K-12 NAD-DEPENDENT NUCLEOTIDE DIPHOSPHOSUGAR EPIMERASE, ADP-L-GLYCERO-D-MANNOHEPTOSE 6-EPIMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE GALACTOSE 4-EPIMERASE; RFAD GENE; BINDING; BIOSYNTHESIS; ENZYME; EXPRESSION; ADENOSINE; MECHANISM; REDUCTION; SUBSTRATE	The Escherichia coli K-12 NAD-dependent nucleotide-diphosphosugar epimerase, ADP-L-glycero-D-mannoheptose 6-epimerase, catalyzes the conversion of ADP-D-glycero-D-mannoheptose to ADP-L-glycero-D-mannoheptose. ADP-L-glycero-D-mannoheptose is a key intermediate of lipopolysaccharide inner core biosynthesis in several genera of Gram-negative bacteria. Sedimentation equilibrium and sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the purified epimerase revealed that the native enzyme has a molecular mass of 240 kDa and a subunit molecular weight of 37,000 +/- 3,000. Lectin binding studies of the purified epimerase indicated that the protein is glycosylated. There was 1 mol of tightly bound NAD(+) per enzyme subunit. Variable but small fractions of purified preparations of epimerase are highly fluorescent and contain NADH. The native enzyme can be resolved into apoenzyme and NAD(+) by acidic ammonium sulfate precipitation. The catalytic activity can be reconstituted with the addition of NAD(+) to the apoenzyme. Optimum pH range for enzyme activity is broad, between 5.5 and 9.5. It exhibits a temperature optimum at 42 degrees C. The K-m and V-max for the substrate is 0.1 mM and 46 mu mol 30 min(-1) mg(-1), respectively. The native enzyme displays UV and fluorescence spectra that are consistent with the presence of enzyme bound NAD(+). CD spectra of the holoepimerase indicate 11% alpha-helical and 36% beta-sheet structures.	NIDDK, BIOCHEM PHARMACOL LAB, PHARMACOL SECT, BETHESDA, MD 20892 USA; NIDDK, BIOCHEM PHARMACOL LAB, ENZYME STRUCT & FUNCT SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ATTRI AK, 1983, ANAL BIOCHEM, V133, P142, DOI 10.1016/0003-2697(83)90235-X; BAUER AJ, 1992, PROTEINS, V12, P372, DOI 10.1002/prot.340120409; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIOTTI MM, 1957, METHOD ENZYMOL, V3, P896; COLEMAN WG, 1992, PSEUDOMONAS : MOLECULAR BIOLOGY AND BIOTECHNOLOGY, P161; COLEMAN WG, 1979, J BACTERIOL, V139, P899, DOI 10.1128/JB.139.3.899-910.1979; COLEMAN WG, 1983, J BIOL CHEM, V258, P1985; EIDELS L, 1974, J BIOL CHEM, V249, P5642; FLENTKE GR, 1990, BIOCHEMISTRY-US, V29, P2430, DOI 10.1021/bi00461a029; GINSBURG V, 1962, J BIOL CHEM, V237, P497; GLASER L, 1972, ENZYMES, V6, P355; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; GORNALL AG, 1949, J BIOL CHEM, V177, P751; KALCKAR HM, 1970, P NATL ACAD SCI USA, V65, P113; KONTROHR T, 1981, J BIOL CHEM, V256, P7715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MAXWELL ES, 1960, J BIOL CHEM, V235, P308; MCPHIE P, 1993, BIOCHEMISTRY-US, V32, P7460, DOI 10.1021/bi00080a017; MINTON AP, 1986, COMPUT APPL BIOSCI, V2, P167; NELSESTU.GL, 1971, J BIOL CHEM, V246, P7533; PEGUES JC, 1990, J BACTERIOL, V172, P4652, DOI 10.1128/jb.172.8.4652-4660.1990; PORTER DJT, 1992, J BIOL CHEM, V267, P3205; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; SHARON N, 1989, LECTINS; SWANSON BA, 1993, BIOCHEMISTRY-US, V32, P13231, DOI 10.1021/bi00211a035; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WEE TG, 1973, J BIOL CHEM, V248, P33; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILSON DB, 1964, J BIOL CHEM, V239, P2469; WINER AD, 1959, J BIOL CHEM, V234, P1149; WINER AD, 1959, J BIOL CHEM, V234, P1155	32	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24384	24390						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929099				2022-12-25	WOS:A1994PQ34600083
J	YUAN, CJ; HUANG, CYF; GRAVES, DJ				YUAN, CJ; HUANG, CYF; GRAVES, DJ			OXIDATION AND SITE-DIRECTED MUTAGENESIS OF THE SULFHYDRYL-GROUPS OF A TRUNCATED GAMMA-CATALYTIC SUBUNIT OF PHOSPHORYLASE-KINASE - FUNCTIONAL AND STRUCTURAL EFFECTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURE; CONSERVED FEATURES; PEPTIDE INHIBITOR; IDENTIFICATION; BINDING; DOMAINS; FAMILY	A truncated form of the gamma subunit of phosphorylase kinase is inactivated by CU2+ with the formation of two intra-molecular disulfide bonds. The formation of a disulfide bond between Cys-36 and Cys-172 (semioxidized form) results in approximately 50% loss of specific activity because the K-m for MgATP is about 10-fold higher. The second disulfide bond is between Cys-184 and Cys-197 and causes further loss of activity. Eight Cys mutants, i.e. C36S, C36A, C42S, C138S, C172S, C184S, C184A, and C197S, were expressed and purified. Kinetic studies suggest that Cys-36 is important for interaction at the nucleotide site because of its hydrophobicity. With Cys-184 mutants, C184S and C184A, tyrosyl phosphorylation of angiotensin II is affected much more than serine kinase activity. The loss of tyrosine kinase activity is related to a lowered activity with Mn2+. With Mn2+, angiotensin II is a competitive inhibitor with respect to seryl kinase activity of C184S. With Mg2+, however, angiotensin II is a noncompetitive inhibitor. We suggest that metal ions influence the conformation of truncated gamma and that the protein substrate binding region containing Cys-184 is important for the dual specificity of this kinase.	IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA	Iowa State University				Huang, Chi-Ying F/0000-0003-4898-4937	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM009587] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-09587] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRON ESG, 1951, ADV ENZYMOL REL S BI, V11, P201; BARRON ESG, 1947, BIOCHEM J, V41, P62, DOI 10.1042/bj0410062; BLACK SD, 1991, ANAL BIOCHEM, V193, P72, DOI 10.1016/0003-2697(91)90045-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN KFJ, 1982, J BIOL CHEM, V257, P5939; CHAN KFJ, 1984, CALCIUM CELL FUNCTIO, V5, P1; CHANG JY, 1983, BIOCHEM J, V211, P163, DOI 10.1042/bj2110163; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; HALL PK, 1992, BIOCHIM BIOPHYS ACTA, V1121, P325, DOI 10.1016/0167-4838(92)90164-9; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUANG CYF, 1993, MOL CELL BIOCHEM, V128, P7, DOI 10.1007/BF01076753; JAMES P, 1991, J BIOL CHEM, V266, P7087; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KEE SM, 1987, J BIOL CHEM, V262, P9448; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LANDGRAF W, 1991, J BIOL CHEM, V266, P16305; LEWIS CT, 1993, J BIOL CHEM, V268, P1628; MALENCIK DA, 1982, CALCIUM CELL FUNCTIO, V3, P161; PAUDEL HK, 1991, J BIOL CHEM, V266, P16524; PICKETTGIES CA, 1986, ENZYMES, V175, P396; SILVA EFD, 1987, FEBS LETT, V220, P36, DOI 10.1016/0014-5793(87)80871-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WEHLAN HA, 1993, FASEB J, V7, pA1161; YUAN CJ, 1993, J BIOL CHEM, V268, P17683; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	30	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24367	24373						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929096				2022-12-25	WOS:A1994PQ34600080
J	BRADYKALNAY, SM; TONKS, NK				BRADYKALNAY, SM; TONKS, NK			IDENTIFICATION OF THE HOMOPHILIC BINDING-SITE OF THE RECEPTOR PROTEIN-TYROSINE-PHOSPHATASE PTP-MU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; IMMUNOGLOBULIN SUPERFAMILY; RECOGNITION MOLECULE; EXTRACELLULAR REGION; HOMOPHILIC BINDING; IG SUPERFAMILY; NG-CAM; FAMILY; LOCALIZATION; EXPRESSION	The receptor-type protein tyrosine phosphatase PTP mu comprises an extracellular segment containing a MAM domain, an immunoglobulin domain and four fibronectin type III repeats, a transmembrane segment, and two intracellular PTP domains. We have previously shown that PTP mu binds homophilically, i.e. PTP mu on the surface of one cell binds to PTP mu on an apposing cell, and that the extracellular segment alone is sufficient for homophilic binding. In this study we report that in MvLu cells PTP mu is proteolytically processed into two noncovalently associated fragments, one comprising most of the extracellular segment (similar to 100 kDa) and the other containing predominantly the transmembrane and intracellular portions (similar to 100 kDa). We have also identified the hemophilic binding site within the extracellular segment. We have generated, expressed, and purified various fragments of the extracellular segment of PTP mu and have used fluorescent beads (Covaspheres) coated with these fragments in three binding assays: (i) measurement of bead aggregation, (ii) binding of beads to surfaces of dishes coated with purified PTP mu or (iii) binding to MvLu cells. Only beads coated with recombinant fragments that contained the immunoglobulin domain underwent aggregation or bound to surfaces displaying PTP mu, suggesting that neither the MAM domain nor the fibronectin type III repeats bound homophilically in these assays. The fragment containing the Ig domain alone bound as well as any other Ig domain-containing fragment, suggesting that the Ig domain is both necessary and sufficient for homophilic binding under these conditions.			BRADYKALNAY, SM (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.				NCI NIH HHS [CA53840, 5T32CA09311] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840, T32CA009311] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; Brady-Kalnay S, 1994, ADV PROTEIN PHOSPHAT, V8, P241; BRADYKALNAY SM, 1993, MOL CELL BIOCHEM, V128, P131, DOI 10.1007/BF01076764; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; COLE GJ, 1986, J CELL BIOL, V103, P1739, DOI 10.1083/jcb.103.5.1739; FAISSNER A, 1985, EMBO J, V4, P3105, DOI 10.1002/j.1460-2075.1985.tb04052.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GRUMET M, 1991, J CELL BIOL, V113, P1399, DOI 10.1083/jcb.113.6.1399; GRUMET M, 1994, J BIOL CHEM, V269, P12142; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HE HT, 1986, EMBO J, V5, P2489, DOI 10.1002/j.1460-2075.1986.tb04526.x; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KAYYEM JF, 1992, J CELL BIOL, V118, P1259, DOI 10.1083/jcb.118.5.1259; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; SAP J, 1994, MOL CELL BIOL, V14, P1; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; Tonks N K, 1993, Semin Cell Biol, V4, P373, DOI 10.1006/scel.1993.1044; VOLKMER H, 1992, J CELL BIOL, V118, P149, DOI 10.1083/jcb.118.1.149; YU Q, 1992, ONCOGENE, V7, P1051; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	31	101	103	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28472	28477						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961788				2022-12-25	WOS:A1994PV77200102
J	KO, KWS; OHNISHI, T; YOKOYAMA, S				KO, KWS; OHNISHI, T; YOKOYAMA, S			TRIGLYCERIDE TRANSFER IS REQUIRED FOR NET CHOLESTERYL ESTER TRANSFER BETWEEN LIPOPROTEINS IN PLASMA BY LIPID TRANSFER PROTEIN - EVIDENCE FOR A HETERO-EXCHANGE TRANSFER MECHANISM DEMONSTRATED BY USING NOVEL MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEIN; DEFICIENT PLASMA; APOLIPOPROTEINS; PURIFICATION; INHIBITION; RABBIT; ASSOCIATION; INVITRO	In order to investigate the role of lipid transfer protein (LTP) in plasma lipoprotein metabolism, monoclonal antibodies (mAbs) have been raised against LTP isolated from rabbit plasma. mAbs 2-8G and 3-9F inhibited both [H-3]cholesteryl ester (CE) and [H-3]triglyceride (TG) transfer from low density lipoprotein (LDL) to high density lipoprotein (HDL) mediated by LTP. Although 3-9F cross-reacted with human LTP, 2-8G was species specific for rabbit LTP. mAb 14-8H inhibited only [H-3]TG but not [H-3]CE transfer and was cross-reactive with human LTP. mAbs 2-8G and 3-9F interfered with association of LTP with lipid microemulsions, again 2-8G with species specificity, whereas 14-8H did not affect LTP-microemulsion binding. Thus, mAbs 3-9F and 14-8H were used for further study in human plasma. By total inhibition of CE and TG transfer by 3-9F, LTP was shown to be responsible for net mass transfer of neutral Lipids between Lipoprotein classes in plasma, namely of CE from HDL to very low density lipoprotein (VLDL) and TG from VLDL to LDL and HDL. Selective inhibition of TG transfer by mAb 14-8H was also able to inhibit such net neutral lipid transfer. Such effect of these antibodies was demonstrated more remarkably in the presence of cholesterol esterification. Thus, TG transfer activity of LTP was shown to be required for net CE transfer, suggesting that net neutral Lipid transfer in plasma between lipoproteins occurred mainly by a hetero-exchange mechanism. Inhibition of net neutral lipid transfer in plasma did not affect cholesterol esterification occurring predominantly on HDL. Consequently, mAb inhibition of TG transfer in plasma leads to CE accumulation in HDL. It is possible that hyperalphalipoproteinemia may be induced by a mutation in LTP that causes a selective defect in TG transfer activity.	UNIV ALBERTA,HERITAGE MED RES CTR 303,DEPT MED,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA	University of Alberta; University of Alberta								BARTER PJ, 1979, ATHEROSCLEROSIS, V34, P67, DOI 10.1016/0021-9150(79)90107-2; BARTER PJ, 1980, J LIPID RES, V21, P238; FRANCIS GA, 1991, BIOCHIM BIOPHYS ACTA, V1084, P159, DOI 10.1016/0005-2760(91)90215-4; FUKASAWA M, 1992, J BIOCHEM-TOKYO, V111, P696, DOI 10.1093/oxfordjournals.jbchem.a123821; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; HESLER CB, 1988, J BIOL CHEM, V263, P5020; HOPKINS GJ, 1980, METABOLISM, V29, P546, DOI 10.1016/0026-0495(80)90080-3; HOPKINS GJ, 1982, METABOLISM, V31, P78, DOI 10.1016/0026-0495(82)90048-8; IHM J, 1982, J LIPID RES, V23, P1328; KO KWS, 1993, BIOCHEMISTRY-US, V32, P6729, DOI 10.1021/bi00077a028; KURASAWA T, 1985, J BIOCHEM, V98, P1499, DOI 10.1093/oxfordjournals.jbchem.a135418; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILNER TG, 1991, BIOCHIM BIOPHYS ACTA, V1082, P71, DOI 10.1016/0005-2760(91)90301-W; MORTON RE, 1985, J BIOL CHEM, V260, P2593; MORTON RE, 1982, J LIPID RES, V23, P1058; MORTON RE, 1983, J BIOL CHEM, V258, P1751; NAGASHIMA M, 1988, J LIPID RES, V29, P1643; NISHIKAWA O, 1986, J BIOCHEM, V99, P295, DOI 10.1093/oxfordjournals.jbchem.a135473; OHNISHI T, 1993, BIOCHEMISTRY-US, V32, P5029, DOI 10.1021/bi00070a009; OHNISHI T, 1994, BIOCHEMISTRY-US, V33, P6093, DOI 10.1021/bi00186a008; OHNISHI T, 1990, J LIPID RES, V31, P397; OHNISHI T, 1994, BIOCHEMISTRY-US, V33, P4533, DOI 10.1021/bi00181a014; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; SWENSON TL, 1989, J BIOL CHEM, V264, P14318; TAJIMA S, 1983, J BIOL CHEM, V258, P73; TALL A, 1987, J CLIN INVEST, V79, P1217, DOI 10.1172/JCI112940; TALL AR, 1993, J LIPID RES, V34, P1255; WANG S, 1991, BIOCHEMISTRY-US, V30, P3484, DOI 10.1021/bi00228a019; WANG SK, 1993, J BIOL CHEM, V268, P1955; WHITLOCK ME, 1989, J CLIN INVEST, V84, P129, DOI 10.1172/JCI114132; YEN FT, 1989, J CLIN INVEST, V83, P2018, DOI 10.1172/JCI114112	34	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28206	28213						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961758				2022-12-25	WOS:A1994PV77200066
J	URA, K; WOLFFE, AP; HAYES, JJ				URA, K; WOLFFE, AP; HAYES, JJ			CORE HISTONE ACETYLATION DOES NOT BLOCK LINKER HISTONE BINDING TO A NUCLEOSOME INCLUDING A XENOPUS-BOREALIS 5-S RIBOSOMAL-RNA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHROMATIN; HYPERACETYLATION; DNA; PARTICLE; TRANSITIONS; EXPRESSION; TAILS	We demonstrate that acetylation of core histone tails does not significantly impair the ability of linker histones to bind preferentially and asymmetrically to a defined sequence mononucleosome core reconstituted in vitro. Thus a simple inhibition mechanism cannot explain models whereby acetylation is causal for the observed reduction in the linker histone content in chromatin. Other models to explain this correlation are discussed.	NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; ANNUNZIATO AT, 1988, CHROMOSOMA, V96, P132, DOI 10.1007/BF00331045; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; BAUER WR, 1994, J MOL BIOL, V236, P685, DOI 10.1006/jmbi.1994.1180; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; DIMITROV S, 1993, DEV BIOL, V160, P214, DOI 10.1006/dbio.1993.1299; DIMITROV S, 1986, FEBS LETT, V197, P217, DOI 10.1016/0014-5793(86)80329-5; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; IMAI BS, 1986, J BIOL CHEM, V261, P8784; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIBERTINI LJ, 1988, BIOPHYS J, V53, P477, DOI 10.1016/S0006-3495(88)83126-6; MCGHEE JD, 1983, NUCLEIC ACIDS RES, V11, P4065, DOI 10.1093/nar/11.12.4065; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PANYIM S, 1969, BIOCHEMISTRY-US, V8, P3972, DOI 10.1021/bi00838a013; PERRY CA, 1991, EXP CELL RES, V196, P337, DOI 10.1016/0014-4827(91)90269-Z; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; ROBERGE M, 1991, FEBS LETT, V288, P215, DOI 10.1016/0014-5793(91)81037-9; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; THOMA F, 1979, J CELL BIOL, V83, P407; TURNER BM, 1991, J CELL SCI, V99, P13; van Holde KE., 1989, SPRINGER SERIES MOL; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; WOLFFE A, 1992, CHROMATIN STRUCTURE	37	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27171	27174						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961624				2022-12-25	WOS:A1994PV77100005
J	WATERS, KM; NTAMBI, JM				WATERS, KM; NTAMBI, JM			INSULIN AND DIETARY FRUCTOSE INDUCE STEAROYL-COA DESATURASE-1 GENE-EXPRESSION IN LIVER OF DIABETIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; POST-TRANSCRIPTIONAL REGULATION; MALIC ENZYME-SYNTHESIS; PYRUVATE-KINASE GENE; RAT-LIVER; MESSENGER-RNA; INVIVO; CELLS; ACID	The transcription and mRNA levels of murine liver stearoyl-CoA desaturase 1 (SCD1) are induced 11- and 45-fold, respectively, by feeding fasted normal mice with a fat-free, high carbohydrate diet (Ntambi, J. M. (1992) J. Biol. Chem. 267, 10925-10930). In this study, we used streptozotocin-induced diabetic mice to study the regulatory role of carbohydrate and insulin on expression of the SCD1 gene in liver. Fructose administration to fasted diabetic mice induced a 2-fold increase in SCD1 mRNA within 6 h and a 23-fold increase within 24 h. Similarly, insulin administration to diabetic mice induced SCD1 mRNA from 4-fold within 4 h to 22-fold within 24 h. Insulin plus fructose, however, achieved full induction, with a 45-fold increase of SCD1 mRNA and a 10-fold increase in SCD1 transcription within 24 h. Additionally, the effect of insulin on SCD1 mRNA was inhibited 75% with dibutyryl-cAMP and theophylline administration and 70% by cycloheximide administration. Synthesis of liver albumin mRNA showed little change upon dietary manipulation or insulin treatment. Our data demonstrate that insulin and dietary fructose or a metabolite of fructose positively regulate the expression of the SCD1 gene in mouse liver.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Waters, Katrina/0000-0003-4696-5396	NIDDK NIH HHS [DK42825] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042825] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN RC, 1966, J BIOL CHEM, V241, P5467; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DETOMAS ME, 1973, BIOCHIM BIOPHYS ACTA, V306, P149, DOI 10.1016/0005-2760(73)90220-8; DIORON B, 1994, J BIOL CHEM, V269, P10213; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; GELLHORN A, 1964, BIOCHIM BIOPHYS ACTA, V84, P167, DOI 10.1016/0926-6542(64)90073-3; GELLHORN A, 1965, ANN NY ACAD SCI, V131, P344, DOI 10.1111/j.1749-6632.1965.tb34802.x; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; JUMP DB, 1990, MOL ENDOCRINOL, V4, P1655, DOI 10.1210/mend-4-11-1655; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KASTURI I, 1982, J BIOL CHEM, V257, P12224; KATSURADA A, 1989, BIOCHIM BIOPHYS ACTA, V1004, P103, DOI 10.1016/0005-2760(89)90219-1; KATSURADA A, 1988, BIOCHIM BIOPHYS ACTA, V950, P113, DOI 10.1016/0167-4781(88)90003-6; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; MUNNICH A, 1987, J BIOL CHEM, V262, P17065; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NOGUCHI T, 1982, EUR J BIOCHEM, V128, P583; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PRASAD MR, 1979, J BIOL CHEM, V254, P997; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SZEPESI B, 1972, LIFE SCI 2-BIOCH GEN, V11, P113, DOI 10.1016/0024-3205(72)90143-9; THIEDE MA, 1985, J BIOL CHEM, V260, P4459; THIEDE MA, 1986, J BIOL CHEM, V261, P3230; WEINER FR, 1991, J BIOL CHEM, V266, P23525; ZIEGLER M, 1988, J IMMUNOL, V14, P4144	30	105	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27773	27777						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961698				2022-12-25	WOS:A1994PV77100095
J	YUDKOFF, M; NELSON, D; DAIKHIN, Y; ERECINSKA, M				YUDKOFF, M; NELSON, D; DAIKHIN, Y; ERECINSKA, M			TRICARBOXYLIC-ACID CYCLE IN RAT-BRAIN SYNAPTOSOMES - FLUXES AND INTERACTIONS WITH ASPARTATE-AMINOTRANSFERASE AND MALATE ASPARTATE SHUTTLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL GLUTAMINE UTILIZATION; AMINO-ACIDS; OXIDATIVE-METABOLISM; MITOCHONDRIA; TRANSPORT; CHROMATOGRAPHY; DERIVATIVES; GLUCOSE; ENZYMES; ATP	The flux through different segments of the tricarboxylic acid cycle was measured in rat brain synaptosomes with gas chromatography-mass spectrometry using either deuterated glutamine or [C-13]aspartate. The flux between 2-oxoglutarate and oxaloacetate was estimated to be 3.14 and 4.97 nmol/min/mg protein with and without glucose, respectively. These values were 3-5-fold faster than the flux between oxaloacetate and a 2-oxoglutarate (0.92 nmol/min per mg protein) measured in the presence of glucose. The pattern of intermediates labeling suggests that the overall rate-controlling reaction involves either citrate synthase or pyruvate dehydrogenase but not 2-oxoglutarate or isocitrate dehydrogenase. The enrichment in [3,3,4,4-H-2(4)]glutamate from [2,3,3,4,4-H-2(5)]glutamine was as rapid as in [2,3,3,4,4-H-2(5)]glutamate, which indicates that the aspartate aminotransferase reaction is severalfold faster than the flux through the tricarboxylic acid cycle. [C-13]Aspartate was rapidly converted to [C-13]malate, suggesting that in intact synaptosomes aspartate entry into the mitochondrion is very slow. The finding that aspartate is taken up by mitochondria as malate, along with the observed high enrichment in [3-H-2]malate (from [2,3,3,4,4-H-2(5)]glutamine), is consistent with the substantial synaptosomal activity of the malate/aspartate shuttle.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104; CHILDRENS HOSP,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027889, R01NS028329] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 27889, NS 28329] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENUCK M, 1971, J NEUROCHEM, V18, P1555, DOI 10.1111/j.1471-4159.1971.tb00017.x; Biemann K., 1962, ORGANIC CHEM APPL, P223; BOOTH RFG, 1980, J NEUROCHEM, V34, P17, DOI 10.1111/j.1471-4159.1980.tb04616.x; BOOTH RFG, 1978, BIOCHEM J, V176, P365, DOI 10.1042/bj1760365; BRAND MD, 1974, BIOCHEM J, V140, P205, DOI 10.1042/bj1400205; BRUICE PY, 1978, J AM CHEM SOC, V100, P4793, DOI 10.1021/ja00483a027; CHEESEMAN AJ, 1988, J NEUROCHEM, V50, P1559, DOI 10.1111/j.1471-4159.1988.tb03044.x; COOPER AJ, 1983, CHEM REV, V83, P321, DOI 10.1021/cr00055a004; COOPER AJL, 1987, PHYSIOL REV, V67, P440, DOI 10.1152/physrev.1987.67.2.440; DAGANI F, 1987, J NEUROCHEM, V49, P1229, DOI 10.1111/j.1471-4159.1987.tb10015.x; DENNIS SC, 1976, BIOCHEM J, V156, P323, DOI 10.1042/bj1560323; DUFFY TE, 1972, J NEUROCHEM, V19, P959, DOI 10.1111/j.1471-4159.1972.tb01417.x; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; ERECINSKA M, 1994, J NEUROCHEM, V63, P1033; ERECINSKA M, 1990, PROG NEUROBIOL, V35, P245, DOI 10.1016/0301-0082(90)90013-7; ERECINSKA M, 1993, J NEUROCHEM, V60, P1696, DOI 10.1111/j.1471-4159.1993.tb13393.x; ERECINSKA M, 1988, J NEUROCHEM, V51, P892, DOI 10.1111/j.1471-4159.1988.tb01826.x; ERECINSKA M, 1990, J NEUROCHEM, V54, P2057, DOI 10.1111/j.1471-4159.1990.tb04911.x; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; FITZPATRICK SM, 1983, J NEUROCHEM, V41, P1370, DOI 10.1111/j.1471-4159.1983.tb00835.x; GARFINKEL D, 1966, J BIOL CHEM, V241, P3918; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Hansford R.G., 1980, CURR TOP BIOENERG, VVolume 10, P217, DOI 10.1016/B978-0-12-152510-1.50012-2; HSSEL B, 1994, J NEUROCHEM, V62, P2187; JARRETT HW, 1986, ANAL BIOCHEM, V153, P189, DOI 10.1016/0003-2697(86)90079-5; KAUPPINEN RA, 1987, BIOCHIM BIOPHYS ACTA, V930, P173, DOI 10.1016/0167-4889(87)90029-2; Krebs H.A., 1970, PYRIDINE NUCL DEPEND, P413; LANOUE KF, 1971, METABOLISM, V20, P119, DOI 10.1016/0026-0495(71)90087-4; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; MASON GF, 1992, J CEREBR BLOOD F MET, V12, P434, DOI 10.1038/jcbfm.1992.61; MAWHINNEY TP, 1986, J CHROMATOGR, V358, P231, DOI 10.1016/S0021-9673(01)90333-4; MILLER AL, 1973, J NEUROCHEM, V20, P1393, DOI 10.1111/j.1471-4159.1973.tb00251.x; MINN A, 1977, J NEUROCHEM, V29, P873, DOI 10.1111/j.1471-4159.1977.tb10731.x; Palmieri F, 1971, EXPERIMENTIA       S, V18, P505; RATNAKUMARI L, 1989, NEUROCHEM RES, V14, P221, DOI 10.1007/BF00971314; SHUG AL, 1994, LIFE SCI, V54, P567, DOI 10.1016/0024-3205(94)90008-6; VANDENBE.CJ, 1971, BIOCHEM J, V123, P211, DOI 10.1042/bj1230211; YUDKOFF M, 1989, J NEUROCHEM, V53, P632, DOI 10.1111/j.1471-4159.1989.tb07380.x	38	115	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27414	27420						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961653				2022-12-25	WOS:A1994PV77100043
J	CHAN, WK; CHU, RY; JAIN, S; REDDY, JK; BRADFIELD, CA				CHAN, WK; CHU, RY; JAIN, S; REDDY, JK; BRADFIELD, CA			BACULOVIRUS EXPRESSION OF THE AH RECEPTOR AND AH RECEPTOR NUCLEAR TRANSLOCATOR - EVIDENCE FOR ADDITIONAL DIOXIN-RESPONSIVE ELEMENT-BINDING SPECIES AND FACTORS REQUIRED FOR SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TRANSCRIPTIONAL REGULATION; INDUCIBLE EXPRESSION; GENE-EXPRESSION; BASAL LEVEL; LIGAND; IDENTIFICATION; CLONING; DOMAIN; HSP90	In an effort to facilitate the structural and biochemical cal analyses of the Ah receptor (AKR) and the Ah receptor nuclear translocator (ARNT), a baculovirus system was developed to express microgram-milligram quantities of the human version of these proteins. To simplify purification, a polyhistidine tag was cloned at their C termini so that the recombinant proteins could be specifically adsorbed to nickel-nitriloacetic acid-Sepharose. Expression studies revealed that approximately 23% of the overexpressed AHR was recovered in cell extracts with the remaining 77% forming insoluble aggregates. ARNT was found to be more soluble, with 90% recovery from cell extracts and only 10% aggregation. Photoaffinity labeling and gel shift assays demonstrated that the recombinant proteins bound ligand, heterodimerized, and recognized their cognate ''dioxin response element'' (DRE) in a manner similar to their native counterparts. Coexpression of the AHR and ARNT in Sf9 cells resulted in the in vivo generation of heterodimers that bound the DRE in the absence of ligand. Studies with the nickel-nitriloacetic acid-purified recombinant proteins demonstrated that the AHR and ARNT could bind DRE only when reconstituted with a heat-sensitive factor(s) present in soluble extracts from a variety of cell types. Use of these proteins also demonstrated the existence of at least three AHR-dependent DRE-binding species, suggesting that the AHR can bind to DRE in at least three distinct conformations.	NORTHWESTERN UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611	Northwestern University; Northwestern University				jain, sanjay/0000-0003-2804-127X	NIEHS NIH HHS [ES-05703] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005703, R29ES005703, R37ES005703] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; ALVARES K, 1992, P NATL ACAD SCI USA, V89, P4908, DOI 10.1073/pnas.89.11.4908; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P3; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DENISON MS, 1991, ARCH BIOCHEM BIOPHYS, V284, P158, DOI 10.1016/0003-9861(91)90278-Q; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; GASIEWICZ TA, 1987, J BIOL CHEM, V262, P2116; GONZALEZ FJ, 1984, MOL PHARMACOL, V26, P117; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; ISREAL DI, 1983, J BIOL CHEM, V258, P10390; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; MANCHESTER DK, 1987, CANCER RES, V47, P4861; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MERCHANT M, 1992, ARCH BIOCHEM BIOPHYS, V292, P250, DOI 10.1016/0003-9861(92)90076-9; MITSUI K, 1993, J BIOL CHEM, V268, P24415; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; PAPOULAS O, 1992, J BIOL CHEM, V267, P10470; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1986, J BIOL CHEM, V261, P6352; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x	38	40	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26464	26471						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929368				2022-12-25	WOS:A1994PQ93000080
J	HILFIKER, H; GUERINI, D; CARAFOLI, E				HILFIKER, H; GUERINI, D; CARAFOLI, E			CLONING AND EXPRESSION OF ISOFORM-2 OF THE HUMAN PLASMA-MEMBRANE CA2+ ATPASE - FUNCTIONAL-PROPERTIES OF THE ENZYME AND ITS SPLICING PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; MESSENGER-RNAS; CA-2+ PUMP; MOLECULAR CHARACTERIZATION; LIMITED PROTEOLYSIS; PEPTIDE COMPLEX; RAT-BRAIN; CALMODULIN; BINDING; DOMAINS	Full-length cDNAs for the three human plasma membrane Ca2+ pump isoforms 2 (PMCA2) differently spliced at the A site were constructed and transferred to baculovirus. The corresponding proteins were expressed after infection in Sf9 insect cells. The proteins were expressed at high levels and retained the canonical properties of the plasma membrane Ca2+ pump. The alternative splicing process failed to produce functional differences detectable with the methods used. The Ca2+-dependent ATPase activity of the PMCA2 pumps had a 5-10-fold higher affinity for calmodulin than the PMCA4 pump expressed in the same system. Experiments on the formation of the phosphoenzyme intermediate from ATP revealed that the PMCA2 pumps had higher affinity for ATP than did the PMCA4 counterpart. The response of the two pump types to activating acidic phospholipids was the same.	ETH ZENTRUM,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BRANDT P, 1992, GENOMICS, V14, P484, DOI 10.1016/S0888-7543(05)80246-0; BRANDT P, 1992, J BIOL CHEM, V267, P4376; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; CARAFOLI E, 1994, IN PRESS FASEB J; CARIDE AJ, 1988, BIOCHEM J, V255, P663; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; HEIM R, 1992, J BIOL CHEM, V267, P24476; HEINKOFF S, 1984, GENE, V28, P351; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KESSLER F, 1990, J BIOL CHEM, V265, P16012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LATIF F, 1993, CANCER RES, V53, P861; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG MG, 1994, CYTOGENET CELL GENET, V67, P41, DOI 10.1159/000133794; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	38	102	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26178	26183						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929331				2022-12-25	WOS:A1994PQ93000038
J	RUBLEVSKAYA, I; MAINES, MD				RUBLEVSKAYA, I; MAINES, MD			INTERACTION OF FE-PROTOPORPHYRIN-IX AND HEME ANALOGS WITH PURIFIED RECOMBINANT HEME OXYGENASE-2, THE CONSTITUTIVE ISOZYME OF THE BRAIN AND TESTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; CARBON-MONOXIDE; MESSENGER-RNA; BILIVERDIN REDUCTASE; ZINC-PROTOPORPHYRIN; HEAT-SHOCK; LIVER; EXPRESSION; CDNA; PROTEIN	Heme oxygenase-2 (HO-2) is the predominant form of heme oxygenase in the brain and testes. The enzyme is not readily amenable to isolation from mammalian tissues and has not been characterized for its kinetic properties and interaction with metalloporphyrins. Presently a rat HO-2 cDNA (Rotenberg, M. O., and Maines, M. D. (1990) J. Biol. Chem. 265, 7501-7506) was used to generate a construct with a neutral hydrophobicity profile at its COOH terminus for expression of nearly full-length HO-2 protein in Escherichia coli. The procedures used for HO-1 were of no utility in purification of HO-2. A multistep protocol developed for isolation of HO-2 resulted in a homogeneous protein with a specific activity up to 6,500 nmol of bilirubin/mg/h. Based on SDS-polyacrylamide gel electrophoresis and Western blot analyses, the protein had an apparent molecular mass of similar to 34 kDa. HO-2 binds Fe-protoporphyrin (heme) at near molar unity to give a complex with the absorption maximum at 403 nm. The Soret band has a blue shift to 430 nm when heme iron is reduced, with distinct alpha and beta bands at 485 and 550 nm, respectively. The Soret band of the CO complex of ferrous heme.HO-2 is at 420 nm, and alpha and beta bands are at 540 and 572 nm, respectively. The apparent K-m for Fe-protoporphyrin is 0.33 mu M, with a V-max of 0.45 mmol of bilirubin/mg/h. Zn-protoporphyrin is a strong mixed inhibitor of enzyme activity, whereas Co-protoporphyrin is a poor competitive inhibitor of activity. When HO-2 was preincubated (10 min at 4 degrees C) with Feprotoporphyrin, the cobalt complex did not inhibit enzyme activity, whereas the Zn-protoporphyrin effectively inhibited activity. Calorimetric measurements suggest that HO-2/heme interaction involves one type of association producing a single heat absorption peak upon melting of the complex and that the unfolding is not reversible. The association increases the enthalpy of HO-2 (130 kcal/mol versus 184 kcal/mol) and increases the stability to heat denaturation by 9 degrees C. Heat duration of zinc complex involves at least two stages of unfolding.	UNIV ROCHESTER,SCH MED,DEPT BIOPHYS,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,DEPT ENVIRONM MED,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NIEHS NIH HHS [ES04066, ES03968, ES01247] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247, R01ES004066, R01ES003968] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BRAGGINS PE, 1986, BIOCHEM BIOPH RES CO, V141, P528, DOI 10.1016/S0006-291X(86)80205-4; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CRUSE I, 1988, J BIOL CHEM, V263, P3348; DRUMMOND GS, 1981, P NATL ACAD SCI-BIOL, V78, P6466, DOI 10.1073/pnas.78.10.6466; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; EVANS CO, 1991, BIOCHEM J, V273, P659, DOI 10.1042/bj2730659; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; HAMORI CJ, 1989, J PEDIATR GASTR NUTR, V8, P110, DOI 10.1097/00005176-198901000-00020; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; KAGEYAMA H, 1988, CANCER RES, V48, P4795; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINES MD, 1975, J BIOL CHEM, V250, P4171; MAINES MD, 1993, MOL CELL NEUROSCI, V4, P389, DOI 10.1006/mcne.1993.1049; MAINES MD, 1977, BIOCHEMISTRY-US, V16, P419, DOI 10.1021/bi00622a012; MAINES MD, 1974, P NATL ACAD SCI USA, V71, P4293, DOI 10.1073/pnas.71.11.4293; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1981, BIOCHIM BIOPHYS ACTA, V673, P339, DOI 10.1016/0304-4165(81)90465-7; MAINES MD, 1986, J BIOL CHEM, V261, P411; MAINES MD, 1992, HEME OXYGENASE CLIN, P1; MARK JA, 1992, PEDIATR RES, V32, P324, DOI 10.1203/00006450-199209000-00016; MCCOUBREY WK, 1993, ARCH BIOCHEM BIOPHYS, V302, P402, DOI 10.1006/abbi.1993.1231; MCCOUBREY WK, 1992, ARCH BIOCHEM BIOPHYS, V295, P13, DOI 10.1016/0003-9861(92)90481-B; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; MULLER RM, 1987, J BIOL CHEM, V262, P6795; Privalov P L, 1986, Methods Enzymol, V131, P4; ROTENBERG MO, 1990, J BIOL CHEM, V265, P7501; ROTENBERG MO, 1991, ARCH BIOCHEM BIOPHYS, V290, P336, DOI 10.1016/0003-9861(91)90549-X; SCOPES R, 1982, PROTEIN PURIFICATION, P21; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; SUN Y, 1990, J BIOL CHEM, V265, P8212; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAKSHEL GM, 1988, ARCH BIOCHEM BIOPHYS, V260, P732, DOI 10.1016/0003-9861(88)90503-6; TRAKSHEL GM, 1986, J BIOL CHEM, V261, P1131; TRAKSHEL GM, 1991, BIOCHEM J, V275, P159, DOI 10.1042/bj2750159; TRAKSHEL GM, 1989, J BIOL CHEM, V264, P1323; VALAES T, 1994, PEDIATRICS, V93, P1; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WEBER CM, 1994, J NEUROCHEM, V63, P953; WILKS A, 1993, J BIOL CHEM, V268, P22357; WU ML, 1993, BIOCHEMISTRY-US, V32, P7216, DOI 10.1021/bi00079a018; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; YOSHIDA T, 1974, J BIOCHEM, V75, P1187, DOI 10.1093/oxfordjournals.jbchem.a130494; YOSHIDA T, 1978, J BIOL CHEM, V253, P8479; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	53	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26390	26395						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929359				2022-12-25	WOS:A1994PQ93000069
J	PUIG, A; GILBERT, HF				PUIG, A; GILBERT, HF			ANTI-CHAPERONE BEHAVIOR OF BIP DURING THE PROTEIN DISULFIDE ISOMERASE-CATALYZED REFOLDING OF REDUCED DENATURED LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; CHAIN-BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; PEPTIDE-BINDING; 3-DIMENSIONAL STRUCTURE; MAMMALIAN-CELLS; BOND FORMATION; HEAT-SHOCK; YEAST	Folding catalysts of the endoplasmic reticulum (ER), such as protein disulfide isomerase (PDI), accelerate the slow chemical steps, such as disulfide bond formation, that accompany protein folding. Molecular chaperones of the ER, notably the heavy chain-binding protein, BiP (grp78), bind and release unfolded proteins in an ATP-dependent fashion. In vitro, the fate of reduced, denatured lysozyme is dependent on whether the substrate interacts first with BiP or PDI. Depending on the ratio of PDI to substrate and order in which the components of the reaction are mixed, PDI can exhibit a foldase/ chaperone activity, which increases the rate and extent of lysozyme refolding, or it can function as an anti-chaperone that promotes the formation of inactive, disulfide linked lysozyme aggregates (Puig, A., and Gilbert, H. F. (1994) J. Biol. Chem. 269, 7764-7771). Reduced, denatured lysozyme, but not the native protein, interacts with BiP and efficiently stimulates its peptide-dependent ATPase activity. When present at substoichiometric amounts, BiP, like PDI, facilitates the formation of large, inactive lysozyme aggregates that are non-covalently associated with BiP. BiP and PDI compete for a limited number of sites in these insoluble aggregates. If Bip is present at a high molar excess, the chaperone binds unfolded lysozyme and inhibits its aggregation by maintaining it in a soluble, yet inactive, conformation, both in the presence or absence of ATP. Increasing concentrations of BiP decrease the extent, but not the initial rate, of refolding, suggesting that Bip and PDI compete for unfolded lysozyme and that the BiP-lysozyme complex is not a very good substrate for PDI either in the presence or absence of ATP. Depending on the BiP and PDI concentrations, unfolded lysozyme may either be efficiently refolded into the native conformation in a PDI-catalyzed reaction, or it may form both soluble and insoluble BiP-lysozyme complexes. In vitro, PDI- and BiP-facilitated aggregation, as well as the competition of the two proteins for substrate, reproduces many of the features of the quality control system of the ER.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FRIEDMAN PJ, 1992, EMBO J, V11, P63; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HUTH JR, 1992, J BIOL CHEM, V267, P21396; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KIM PS, 1993, J BIOL CHEM, V268, P4873; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEMANTIA M, 1993, CELL, V74, P899; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OTSU M, 1994, J BIOL CHEM, V269, P6874; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SHIELDS D, 1978, J BIOL CHEM, V253, P3753; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WETLAUFER DB, 1974, LYSOZYME, P269; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	45	46	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25889	25896						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929293				2022-12-25	WOS:A1994PQ49100095
J	DUCKWORTH, WC; BENNETT, RG; HAMEL, FG				DUCKWORTH, WC; BENNETT, RG; HAMEL, FG			A DIRECT INHIBITORY EFFECT OF INSULIN ON A CYTOSOLIC PROTEOLYTIC COMPLEX CONTAINING INSULIN-DEGRADING ENZYME AND MULTICATALYTIC PROTEINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTE LYSATE; RAT HEPATOMA-CELLS; DROSOPHILA-MELANOGASTER; DEGRADATION PRODUCTS; ISOLATED HEPATOCYTES; RECEPTOR-BINDING; MAMMALIAN-CELLS; SKELETAL-MUSCLE; PROTEASE; PURIFICATION	The insulin degrading enzyme (IDE) and the multicatalytic proteinase (MCP) can be isolated as components of a cytosolic proteolytic complex. IDE is the primary enzyme involved in cellular degradation of insulin, and insulin has been shown to interact with cytosolic IDE. MCP is believed to be important in nonubiquitin pathways of cellular protein degradation. Insulin has a dose- and time-dependent inhibitory effect on MCP degradation of N-succinyl-Leu-Leu-Val-Tyr 7-amido-4-methylcoumarin (LLVY), a substrate for MCP. Proinsulin also inhibits LLVY degradation in a dose dependent manner. The effect of insulin is immediate as measured in a continuously monitored assay of LLVY degradation. purification of the IDE MCP complex using a variety of approaches, including affinity and conventional chromatography, retains the insulin effect on LLVY degradation as long as the complex remains intact. After ion-exchange chromatography, which separates IDE and MCP, insulin no longer has an inhibitory effect. Recombination of purified IDE and MCP does not restore the effect of insulin, but inclusion of additional components from the ion exchange column does. These results support the existence of a functional cytosolic complex that contains IDE and MCP. Insulin interacts with IDE and alters the activity of MCP, suggesting a functional relationship between these two components and a mechanism for an intracellular action of insulin.			DUCKWORTH, WC (corresponding author), UNIV NEBRASKA, MED CTR, VET AFFAIRS MED CTR, 600 S 42ND ST, OMAHA, NE 68198 USA.							AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; AMSTERDAM A, 1993, P NATL ACAD SCI USA, V90, P99, DOI 10.1073/pnas.90.1.99; BASKIN FK, 1973, EUR J BIOCHEM, V37, P489, DOI 10.1111/j.1432-1033.1973.tb03010.x; BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9; BRUCK C, 1982, J IMMUNOL METHODS, V53, P313, DOI 10.1016/0022-1759(82)90178-8; BURGHEN GA, 1972, ENDOCRINOLOGY, V91, P633, DOI 10.1210/endo-91-3-633; DRAZNIN B, 1982, J BIOL CHEM, V257, P1988; DUCKWORT.WC, 1972, P NATL ACAD SCI USA, V69, P3698, DOI 10.1073/pnas.69.12.3698; DUCKWORTH WC, 1987, BIOCHEM BIOPH RES CO, V147, P615, DOI 10.1016/0006-291X(87)90975-2; DUCKWORTH WC, 1989, AM J PHYSIOL, V256, pE208, DOI 10.1152/ajpendo.1989.256.2.E208; DUCKWORTH WC, 1988, ENDOCRINOLOGY, V123, P2701, DOI 10.1210/endo-123-6-2701; DUCKWORTH WC, 1988, ENDOCR REV, V9, P319, DOI 10.1210/edrv-9-3-319; DUCKWORTH WC, 1974, DIABETES, V23, P536, DOI 10.2337/diab.23.6.536; FRANK BH, 1983, DIABETES, V32, P705, DOI 10.2337/diab.32.8.705; GARCIA JV, 1988, BIOCHEMISTRY-US, V27, P4237, DOI 10.1021/bi00412a006; GARCIA JV, 1989, J CELL BIOL, V108, P177, DOI 10.1083/jcb.108.1.177; HAMEL FG, 1991, DIABETES, V40, P436, DOI 10.2337/diabetes.40.4.436; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; HARADA S, 1993, ENDOCRINOLOGY, V132, P2293, DOI 10.1210/en.132.6.2293; HARI J, 1987, ENDOCRINOLOGY, V120, P829, DOI 10.1210/endo-120-2-829; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOFMANN CA, 1983, J BIOL CHEM, V258, P1774; HOUGH R, 1987, J BIOL CHEM, V262, P8303; ISHIURA S, 1985, FEBS LETT, V189, P119, DOI 10.1016/0014-5793(85)80854-1; KAYALAR C, 1990, J CELL BIOCHEM, V44, P137, DOI 10.1002/jcb.240440303; KOLB HJ, 1980, H-S Z PHYSIOL CHEM, V361, P1029, DOI 10.1515/bchm2.1980.361.2.1029; KUEHN L, 1990, FEBS LETT, V261, P274, DOI 10.1016/0014-5793(90)80570-9; KUEHN L, 1992, ARCH BIOCHEM BIOPHYS, V295, P55, DOI 10.1016/0003-9861(92)90487-H; KUO WL, 1991, MOL ENDOCRINOL, V5, P1467, DOI 10.1210/mend-5-10-1467; KUO WL, 1993, ENDOCRINOLOGY, V132, P604, DOI 10.1210/en.132.2.604; LI D, 1992, J BIOL CHEM, V267, P2414; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MCGUIRE MJ, 1988, BIOCHIM BIOPHYS ACTA, V967, P195, DOI 10.1016/0304-4165(88)90009-8; MILLER DS, 1988, SCIENCE, V240, P506, DOI 10.1126/science.2451860; MIRSKY IA, 1957, RECENT PROG HORM RES, V13, P429; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PEAVY DE, 1985, J BIOL CHEM, V260, P3989; PEAVY DE, 1984, ENDOCRINOLOGY, V114, P753, DOI 10.1210/endo-114-3-753; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1993, BIOCHEM J, V291, P1; STOPPELLI MP, 1988, P NATL ACAD SCI USA, V85, P3469, DOI 10.1073/pnas.85.10.3469; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; YOKONO K, 1982, ENDOCRINOLOGY, V111, P1102, DOI 10.1210/endo-111-4-1102	45	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24575	24580						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929129				2022-12-25	WOS:A1994PQ49000013
J	OLAH, ME; JACOBSON, KA; STILES, GL				OLAH, ME; JACOBSON, KA; STILES, GL			ROLE OF THE 2ND EXTRACELLULAR LOOP OF ADENOSINE RECEPTORS IN AGONIST AND ANTAGONIST BINDING - ANALYSIS OF CHIMERIC A(1)/A(3)-ADENOSINE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MOLECULAR-CLONING; LIGAND-BINDING; HUMAN BRAIN; ADENOSINE-A1-RECEPTOR CDNA; NEUROKININ-1 RECEPTOR; HIGH-AFFINITY; RAT-BRAIN; EXPRESSION; A1	Adenosine receptor (AR) agonists and antagonists are similar to 100-fold and 100,000-fold, respectively, more potent at the bovine A(1)AR as compared to the rat A(3)AR. To determine regions of ARs involved in ligand recognition, chimeric receptors composed of bovine A(1)AR and rat A(3)AR sequence were constructed and their ligand binding properties examined following expression in COS-7 cells. Substitutions of the second extracellular loop or a region encompassing transmembrane domains 6 and 7 of the A(1)AR into the A(3)AR resulted in enhanced affinities of both agonists and antagonists compared to wild-type A(3)AR. The region of the second extracellular loop of the A(1)AR responsible for this effect was identified as the distal eleven amino acids of the loop. Replacement of this segment of the A(3)AR with that of the A(1)AR in combination with the regions encompassing transmembrane domains 6 and 7 resulted in a 50,000-fold increase in the K-d for antagonist radioligand, [H-3]1,3-dipropyl-8-cyclopentylxanthine. Agonist affinity at this chimeric was over 100-fold greater than that displayed by wild-type A(3)AR. Thus, multiple regions of ARs including a segment of the second extracellular loop are involved in ligand recognition, and considerable overlap exists in structural features required for agonist and antagonist binding.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; NIDDK, BIOORGAN CHEM LAB, BETHESDA, MD 20892 USA	Duke University; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035134, P50HL017670] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 DK999999, Z01 DK031117-20] Funding Source: Medline; NHLBI NIH HHS [NHLBI RO1HL35134, NHLBI P50HL17670] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRINGTON WW, 1989, J BIOL CHEM, V264, P13157; BEAVEN MA, 1994, TRENDS PHARMACOL SCI, V15, P13, DOI 10.1016/0165-6147(94)90124-4; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOUDHARY MS, 1992, MOL PHARMACOL, V42, P627; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DUDLEY MW, 1993, DRUG DEVELOP RES, V28, P237, DOI 10.1002/ddr.430280309; FINK JS, 1992, MOL BRAIN RES, V14, P186, DOI 10.1016/0169-328X(92)90173-9; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FURLONG TJ, 1992, MOL BRAIN RES, V15, P62, DOI 10.1016/0169-328X(92)90152-2; GETHER U, 1994, MOL PHARMACOL, V45, P500; GUAN XM, 1992, MOL PHARMACOL, V41, P695; HUANG RRC, 1994, MOL PHARMACOL, V45, P690; IJzerman A P, 1992, Drug Des Discov, V9, P49; KLOTZ KN, 1988, J BIOL CHEM, V263, P17522; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LIBERT F, 1992, BIOCHEM BIOPH RES CO, V187, P919, DOI 10.1016/0006-291X(92)91285-X; LINDEN J, 1993, MOL PHARMACOL, V44, P524; MACKENZIE RG, 1993, FEBS LETT, V323, P59, DOI 10.1016/0014-5793(93)81448-9; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; OLAH ME, 1992, J BIOL CHEM, V267, P10764; OLAH ME, 1994, MOL PHARMACOL, V45, P978; OLAH ME, 1994, J BIOL CHEM, V269, P18016; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PIERCE KD, 1992, BIOCHEM BIOPH RES CO, V187, P86, DOI 10.1016/S0006-291X(05)81462-7; POLLOCK NJ, 1992, J BIOL CHEM, V267, P17780; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; RUDOLPHI KA, 1992, TRENDS PHARMACOL SCI, V13, P439, DOI 10.1016/0165-6147(92)90141-R; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SALVATORE CA, 1993, P NATL ACAD SCI USA, V90, P10365, DOI 10.1073/pnas.90.21.10365; SCHWABE U, 1985, N-S ARCH PHARMACOL, V330, P212, DOI 10.1007/BF00572436; STEHLE JH, 1992, MOL ENDOCRINOL, V6, P384, DOI 10.1210/me.6.3.384; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; TOWNSENDNICHOLSON A, 1994, J BIOL CHEM, V269, P2373; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; TUCKER AL, 1992, FEBS LETT, V297, P107, DOI 10.1016/0014-5793(92)80338-H; VANGALEN PJM, 1992, MED RES REV, V12, P423, DOI 10.1002/med.2610120502; WANG CD, 1991, MOL PHARMACOL, V40, P168; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; XIE YB, 1990, J BIOL CHEM, V265, P21411; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	46	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24692	24698						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929142				2022-12-25	WOS:A1994PQ49000029
J	BERNSTEIN, R; DEJONG, J; ROEDER, RG				BERNSTEIN, R; DEJONG, J; ROEDER, RG			CHARACTERIZATION OF THE HIGHLY CONSERVED TFIIA SMALL-SUBUNIT FROM DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR-IIA; TATA-BINDING PROTEIN; GENE-TRANSCRIPTION; INITIATION-FACTORS; IDENTIFICATION; ACTIVATION; PURIFICATION; COACTIVATORS; PROMOTER	TPIIA is a general transcription factor that modulates class II transcription initiation in vitro by functionally and physically interacting with TFIID or the derived TATA-binding protein (TBP). TFIIA was previously purified from human, bovine, rat, and yeast sources and has recently been identified in association with TFIID in Drosophila. Here, we report the cloning of a cDNA encoding the 12.5-kDa subunit of TFIIA from Drosophila melanogaster (dTFIIA-S) and the identification of a partial dTFIIA-S gene in Drosophila virilis. The deduced amino acid sequence of dTFIIA-S indicates a high degree of homology to the small TFIIA subunit from yeast and to a partial TFIIA-S cDNA identified in rice. A hybrid TFIIA consisting of recombinant dTFIIA-S and the recombinant human TFIIA/alpha gene product mimics natural TFIIA activity in a TBP-dependent DNA binding assay. The promoter complex formed with this hybrid TFIIA depends upon the TATA element and can be efficiently incorporated into a higher order preinitiation complex upon addition of TFIIB. The presence of dTFIIA-S within the TBP-TFIIA-promoter complex was demonstrated using anti-dTFIIA-S antiserum. Finally, the ability of recombinant dTFIIA-S to reconstitute transcriptionally active TFIIA was demonstrated in a well defined human transcription system.			BERNSTEIN, R (corresponding author), ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA.				NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI127379] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1993, PEPTIDE RES, V6, P62; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; Coulombe Benoit, 1992, Gene Expression, V2, P99; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GE H, 1994, J BIOL CHEM, V269, P17136; GE H, 1994, IN PRESS CELL; HARLOW E, 1988, ANTIBODIES LABORATOR; HEBERLEIN U, 1990, P NATL ACAD SCI USA, V87, P5916, DOI 10.1073/pnas.87.15.5916; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; INOSTROZA JA, 1992, CELL, V70, P477; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MA D, 1993, GENE DEV, V7, P2235; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSENBERG AHH, 1987, GENE, V56, P155; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	39	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24361	24366						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929095				2022-12-25	WOS:A1994PQ34600079
J	GARRITSEN, A; SIMONDS, WF				GARRITSEN, A; SIMONDS, WF			MULTIPLE DOMAINS OF G-PROTEIN-BETA CONFER SUBUNIT SPECIFICITY IN BETA-GAMMA-INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; LIMITED PROTEOLYSIS; COILED-COIL; TRANSDUCIN; ASSOCIATION; PRENYLATION; EXPRESSION; ANTIBODIES; DIMERS; CELLS	The expression and assembly of particular combinations of beta and gamma subunit isoforms into beta gamma heterodimers may contribute to the specificity of signal transduction mediated by heterotrimeric guanine nucleotide binding regulatory proteins. Using a transient transfection paradigm to examine selectivity in beta gamma heterodimer formation, we find that gamma(1) interacts with beta(1) but not with beta(2), while both beta subunits interact with gamma(2) and that a beta(2)/beta(1) chimera containing the N-terminal 41 residues of beta(2) retained a beta(1), phenotype. These results confirm previous reports and imply that a structure or structures between residues 42 and 340 in the C-terminal region of the beta subunit imparts the ability to distinguish between gamma chains. Extending this chimeric approach to further localize the regions of beta important for selectivity between gamma subunits, we find that the region of beta(1) or beta(2) between residue 215 and the C terminus is sufficient to confer the parental phenotype. Additional mutants implicate multiple regions of beta, including discrete residues in the variable connecting segments joining conserved elements of the fifth and sixth GH-WD repeats toward the C terminus of beta. These findings suggest a multidomain interaction between beta and gamma.	NIDDK,METAB DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; CLARK KL, 1993, MOL CELL BIOL, V13, P1; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIETRICH A, 1992, FEBS LETT, V313, P220, DOI 10.1016/0014-5793(92)81195-R; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NEER EJ, 1993, NAT GENET, V5, P3, DOI 10.1038/ng0993-3; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Spiegel A. M., 1994, G PROTEINS; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571	33	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24418	24423						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929103				2022-12-25	WOS:A1994PQ34600088
J	SVEJSTRUP, JQ; FEAVER, WJ; LAPOINTE, J; KORNBERG, RD				SVEJSTRUP, JQ; FEAVER, WJ; LAPOINTE, J; KORNBERG, RD			RNA-POLYMERASE TRANSCRIPTION FACTOR IIH HOLOENZYME FROM YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-LOOP MUTATION; SACCHAROMYCES-CEREVISIAE; FACTOR-B; CTD KINASE; DNA-REPAIR; PURIFICATION; INITIATION; SUPPRESSOR; COMPONENT; CLONING	An RNA polymerase transcription factor IIH holoenzyme (holoTFIIH) has been resolved to near homogeneity from Saccharomyces cerevisiae. HoloTFIIH comprises the five-subunit core transcription factor described previously (Feaver, W. J., Svejstrup, J. Q., Bardwell, A. J., Bardwell, L., Buratowski, S., Gulyas, K. D., Donahue, T. F., Friedberg, E. C. and Kornberg, R. D. (1993) Cell 75, 1379-1387) and in addition, SSL2 and three further, as yet unidentified, polypeptides. HoloTFIIH possesses C-terminal repeat domain kinase activity and, together with other pure yeast transcription proteins, enables RNA polymerase II transcription in a fully defined system. By contrast, core TFIIH is inert in both C-terminal repeat domain kinase and reconstituted transcription assays.	STANFORD UNIV,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305	Stanford University				Svejstrup, Jesper/0000-0003-4964-6147	NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; HENRY NL, 1992, J BIOL CHEM, V267, P23388; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; NAUMOVSKI L, 1983, P NATL ACAD SCI-BIOL, V80, P4818, DOI 10.1073/pnas.80.15.4818; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	29	80	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28044	28048						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961739				2022-12-25	WOS:A1994PV77200043
J	BLONDEL, O; BELL, GI; MOODY, M; MILLER, RJ; GIBBONS, SJ				BLONDEL, O; BELL, GI; MOODY, M; MILLER, RJ; GIBBONS, SJ			CREATION OF AN INOSITOL 1,4,5-TRISPHOSPHATE-SENSITIVE CA2+ STORE IN SECRETORY GRANULES OF INSULIN-PRODUCING CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; BETA-CELLS; RECEPTOR; CA-2+; TRISPHOSPHATE; LOCALIZATION; CA-2+-ATPASE; NEURONS; RELEASE	A rapid rise in the cytosolic free Ca2+ concentration due to influx of extracellular Ca2+ or mobilization from intracellular stores is the primary trigger for exocytosis from secretory cells. Our understanding as to the precise role of Ca2+ mobilization has been complicated by the presence of several types of Ca2+ stores in most cells. We now demonstrate that overexpression of the type 3 inositol 1,4,5-trisphosphate (IP2) receptor in insulin-secreting beta TC-3 cells results in the creation of a unique IP3-sensitive Ca2+ pool, restricted to the insulin secretory granules of these cells.	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago				Gibbons, Simon/0000-0001-5311-5993				ANDERSSON T, 1982, BIOMED RES-TOKYO, V3, P29, DOI 10.2220/biomedres.3.29; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIDEN TJ, 1992, BIOCHEM J, V285, P541, DOI 10.1042/bj2850541; BINDOKAS VP, 1993, NEUROPHARMACOLOGY, V32, P1213, DOI 10.1016/0028-3908(93)90015-U; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; CUNNINGHAM AM, 1993, NEUROSCIENCE, V57, P339, DOI 10.1016/0306-4522(93)90067-P; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MARANTO AR, 1994, J BIOL CHEM, V269, P1223; NICAISE G, 1992, BIOL CELL, V75, P89, DOI 10.1016/0248-4900(92)90128-N; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; UYAMA Y, 1992, BRIT J PHARMACOL, V106, P208, DOI 10.1111/j.1476-5381.1992.tb14316.x; YOO SH, 1990, J BIOL CHEM, V265, P13446; ZAWALICH WS, 1988, DIABETES, V37, P137, DOI 10.2337/diabetes.37.2.137	23	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27167	27170						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961623				2022-12-25	WOS:A1994PV77100004
J	GERHARDINGER, C; TANEDA, S; MARION, MS; MONNIER, VM				GERHARDINGER, C; TANEDA, S; MARION, MS; MONNIER, VM			ISOLATION, PURIFICATION, AND CHARACTERIZATION OF AN AMADORI PRODUCT BINDING-PROTEIN FROM A PSEUDOMONAS SP SOIL STRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION END-PRODUCTS; EXPERIMENTAL DIABETES-MELLITUS; MONOCLONAL-ANTIBODY; CELL-SURFACE; AMINOGUANIDINE; COMPLICATIONS; PENTOSIDINE; OXIDASE; QUANTITIES; SEQUENCE	Sugars react nonenzymatically with protein amino groups to form a ketoamine adduct (Amadori product), which leads to the formation of advanced glycation endproducts. These compounds are involved in the development of tissue modifications such as cross-linking and fluorescence in diabetes and aging. Searching for an en zyme to reverse protein glycation, we isolated a Pseudomonas sp. soil strain growing selectively on the Amadori product epsilon-fructosyl-aminocaproate. An Amadori product binding protein (ABP) was purified from the bacterial extract by single-step affinity chromatography on glycated lysine-Sepharose. The protein, a monomer of 45 kDa, did not bind to unglycated or NaBH4-reduced glycated lysine-Sepharose suggesting specificity for the Amadori compound. The concentration dependent binding of glycated aminocaproate showed saturation with K-d = 1.49 mu M and B-max = 17.63 nnol/mg of protein corresponding to 0.8 mol/mol of protein. The binding of epsilon-[C-14]fructosyl-aminocaproate to the protein was inhibited by other glucose-derived Amadori products, but not by free sugars, unglycated amines, or ribated lysine. The sequence of the first 16 NH2-terminal amino acids and a GenBank search revealed that ABP is a novel protein. Its synthesis was inducible by growth of the organism in Amadori product. Immunoblotting studies showed that ABP is not found in cell extracts from other prokaryotes, yeast, or liver homogenate and does not bind Amadori products in glycated proteins. ABP has no enzymatic activity toward glycated substrates and may thus have transport or permease function for glycated amino acids.	CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106	Case Western Reserve University			Monnier, Vincent M/B-1371-2009		NATIONAL EYE INSTITUTE [R01EY007099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005601] Funding Source: NIH RePORTER; NEI NIH HHS [EY 07099] Funding Source: Medline; NIA NIH HHS [AG 05601] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHMED MU, 1986, J BIOL CHEM, V261, P4889; ANRAKU Y, 1968, J BIOL CHEM, V243, P3116; BEISSWENGER PJ, 1993, J CLIN INVEST, V92, P212, DOI 10.1172/JCI116552; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CERAMI A, 1979, METABOLISM, V28, P421; EAGON RG, 1971, CAN J BIOCHEM CELL B, V49, P1031, DOI 10.1139/o71-151; ELLIS EN, 1991, METABOLISM, V40, P1016, DOI 10.1016/0026-0495(91)90122-D; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FINOT PA, 1969, HELV CHIM ACTA, V52, P1488, DOI 10.1002/hlca.19690520609; GERHARDINGER C, 1994, DIABETES, V43, P161; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; GUYMON LF, 1973, J BACTERIOL, V117, P1261; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HODGE JE, 1953, J AGR FOOD CHEM, V1, P928, DOI 10.1021/jf60015a004; HORIUCHI T, 1991, AGR BIOL CHEM TOKYO, V55, P333, DOI 10.1080/00021369.1991.10870584; HORIUCHI T, 1989, AGR BIOL CHEM TOKYO, V53, P103, DOI 10.1080/00021369.1989.10869245; HOSHINO T, 1980, J BACTERIOL, V141, P1055, DOI 10.1128/JB.141.3.1055-1063.1980; IDO Y, 1990, DIABETES S1, V39, pA93; KAETZEL CS, 1984, BIOCHEM J, V219, P917, DOI 10.1042/bj2190917; KRANTZ S, 1993, BIOCHIM BIOPHYS ACTA, V1177, P15, DOI 10.1016/0167-4889(93)90151-E; KU V, 1993, BIOCHEM BIOPH RES CO, V193, P1131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; MONNIER VM, 1981, PROG FOOD NUTR SCI, V5, P315; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; OXLUND H, 1992, DIABETOLOGIA, V35, P19, DOI 10.1007/BF00400847; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Resmini P., 1990, ITAL J FOOD SCI, V3, P173; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHULMAN M, 1978, Nature (London), V276, P269; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; TANEDA S, 1993, CLIN CHEM, V40, P1766; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; WATANABE N, 1990, AGR BIOL CHEM TOKYO, V54, P1063, DOI 10.1080/00021369.1990.10870059; YAGIHASHI S, 1992, DIABETES, V41, P47, DOI 10.2337/diabetes.41.1.47; [No title captured]	40	20	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27297	27302						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961640				2022-12-25	WOS:A1994PV77100026
J	HOLTZ, JK; TOPAL, MD				HOLTZ, JK; TOPAL, MD			LOCATION OF PUTATIVE BINDING AND CATALYTIC SITES OF NAEI BY RANDOM MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORI ENDONUCLEASE; RESTRICTION ENDONUCLEASE; RECOGNITION SITES; CRYSTAL-STRUCTURE; CLEAVAGE CENTER; DNA; SPERMIDINE; GLU-111	Endonuclease NaeI is a prototype for an unusual group of type II restriction endonucleases that must bind two DNA recognition sequences to cleave DNA. The naeIR gene, expressed from a Ptac promotor construct, was toxic to Escherichia coli in the absence of NaeI-sequence specific methylases. The naeIR gene was mu tagenized with N-methyl-N'-nitrosoguanidine; four classes of NaeI variants were isolated in the absence of protecting methylase activity. Class I variants (T60I, E70K) lacked detectable cleavage activity, but displayed good sequence-specific DNA binding. Class II variants (D95N, G141D) displayed 1-5% of the wild-type cleavage activity and normal DNA binding, Class III variants (G131E, G131R, G155D, G245E) displayed significantly attenuated cleavage and binding activities. Class IV variants (G197D, G214/A219T, G236S, L241P, G245E, G245R, G250E, G270E) lacked both cleavage and binding activities. These results imply two amino acids (Thr-60, Glu-70) essential for catalysis. In addition, two domains are indicated in NaeI: one (Thr-60 to Gly-155) mediates substrate binding and catalysis, the other (Gly-197 to Gly-270) may mediate binding of the activating DNA sequence. Our results are compared with the active site residues of EcoRI, EcoRV, and BamHI.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, SCH MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PATHOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine								BAXTER BK, 1993, BIOCHEMISTRY-US, V32, P8291, DOI 10.1021/bi00083a033; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; FOSTER PL, 1991, METHOD ENZYMOL, V204, P114; GABBARA S, 1992, J BIOL CHEM, V267, P18623; Heitman J, 1993, Genet Eng (N Y), V15, P57; HEITMAN J, 1992, BIOESSAYS, V14, P445, DOI 10.1002/bies.950140704; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KING K, 1989, J BIOL CHEM, V264, P11807; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; McClelland M, 1985, Nucleic Acids Res, V13 Suppl, pr201; Miller J.H., 1972, EXPT MOL GENETICS; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; Sambrook J, 1989, MOL CLONING LABORATO; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; TARON CH, 1994, IN PRESS GENE; THIELKING V, 1992, BIOCHEMISTRY-US, V31, P3727, DOI 10.1021/bi00130a001; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816; XU SY, 1991, J BIOL CHEM, V266, P4425; YANG CC, 1992, BIOCHEMISTRY-US, V31, P9657, DOI 10.1021/bi00155a019	23	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27286	27290						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961638				2022-12-25	WOS:A1994PV77100024
J	COX, AD; BRTVA, TR; LOWE, DG; DER, CJ				COX, AD; BRTVA, TR; LOWE, DG; DER, CJ			R-RAS INDUCES MALIGNANT, BUT NOT MORPHOLOGIC, TRANSFORMATION OF NIH3T3 CELLS	ONCOGENE			English	Article							C-MYC; PROTEIN-KINASE; EXPRESSION; ONCOGENES; GROWTH; BCL-2; GENE; ACTIVATION; PRODUCT; GTPASES	Although previous studies have not identified transforming properties of the Ras-related protein R-Ras, two recent observations have prompted our further evaluation of R-Ras function. First, we observed that mutant forms of the closely related R-Ras2/TC21 protein (similar to 70% identity) exhibited the same potent transforming activity as oncogenic Ras proteins. Second, R-Ras association with Bcl-2 suggested a possible role for R-Ras in apoptotic growth control. Therefore, we have performed a detailed analysis of R-Ras transforming potential in NIH3T3 cells. Whereas expression of a mutant R-Ras protein (38V; analogous to the 12V activating Ras mutation) did not induce morphologic transformation of NIH3T3 cells, R-Ras(38V)-expressing cells proliferated in low serum, formed colonies in soft agar, and formed progressive tumors in nude mice. Like Ras-transformed cells, R-Ras(38V)-transformed cells exhibited constitutively activated mitogen activated protein kinases. Furthermore, R-Ras(38V) stimulated transcriptional activation of Ras-responsive promoter elements, and this activity (and transformation) was blocked by Raf dominant negative proteins, Finally, whereas co-expression of Bcl-2 did not cause significant alteration in wild type or mutant R-Ras transforming activity, coexpression of v-Myc and R-Ras(38V) induced a striking morphologic transformation of NIH3T3 cells. Taken together, these observations suggest that aberrant R-Ras function may stimulate malignant transformation, in the absence of morphologic transformation, via up-regulation of part of the Ras signal transduction pathway.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC 27599; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Roche Holding; Genentech	COX, AD (corresponding author), UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599, USA.			Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA61951, CA52070, CA42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042978, R29CA061951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; COX AD, 1994, METHOD ENZYMOL, V238, P277; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SELF AJ, 1993, ONCOGENE, V8, P655; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G	36	114	117	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3281	3288						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936652				2022-12-25	WOS:A1994PM65800021
J	LUBEC, G; WENINGER, M; ANDERSON, SR				LUBEC, G; WENINGER, M; ANDERSON, SR			RACEMIZATION AND OXIDATION STUDIES OF HAIR PROTEIN IN THE HOMO-TIROLENSIS	FASEB JOURNAL			English	Article						O-TYROSINE; DI-TYROSINE; DATING; TEMPERATURE; RADIATION	ASPARTIC-ACID; AMINO-ACIDS	Amino acids contained in fossil materials show an increasing extent of racemization with age, postulating time and temperature as the two major variables. The recent discovery of the Home tirolensis made possible a comparison between racemization rates of the amino acids found in hair at identical ages (5200 years of age) but at different diagenetic temperatures (''Ginger,'' found in the hot, dry sand of Egypt; H. tirolensis, found on a glacier of the Otztaler Alps). The rate of racemization was higher in the H. tirolensis, which is surprising and in contrast to current concepts. Ortho-tyrosine and di-tyrosine, parameters for OH-radical attack, were also higher in the H. tirolensis, suggesting a role for free OH-radical involvement in the racemization process.	OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA	Oregon State University	LUBEC, G (corresponding author), UNIV VIENNA, DEPT PEDIAT, WAHRINGER GURTEL 18-20, A-1090 VIENNA, AUSTRIA.			Lubec, Gert/0000-0002-6333-9461				BADA JL, 1982, INTERDISCIPL SCI REV, V7, P30, DOI 10.1179/030801882789801304; BADA JL, 1980, EARTH-SCI REV, V16, P21, DOI 10.1016/0012-8252(80)90003-3; BADA JL, 1975, NATURWISSENSCHAFTEN, V62, P71, DOI 10.1007/BF00592179; BARMAN TE, 1974, ENZYME HDB S, V1, P463; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BOGL KW, 1989, APPL RADIAT ISOTOPES, V40, P1203, DOI 10.1016/0883-2889(89)90064-6; Bonani G., 1992, MANN EIS, V187, P108; FUJII N, 1991, BIOMED RES-TOKYO, V12, P315, DOI 10.2220/biomedres.12.315; GETOFF N, 1992, Amino Acids (Vienna), V2, P195, DOI 10.1007/BF00805942; GOODFRIEND GA, 1992, NATURE, V357, P399, DOI 10.1038/357399a0; HELFMAN PM, 1976, NATURE, V262, P279, DOI 10.1038/262279b0; KAMPEL D, 1990, AMINO ACIDS CHEM BIO, P1164; LUBEC G, 1993, AMINO ACIDS, V4, P1, DOI 10.1007/BF00805796; LUBEC G, 1987, J ARCHAEOL SCI, V14, P113, DOI 10.1016/0305-4403(87)90001-X; MASTERS PM, 1979, J AGR FOOD CHEM, V27, P507, DOI 10.1021/jf60223a035; Meier W., 1988, Beta-gamma, V1, P34; TIEFENBRUNNER F, 1992, MANN EIS, V1, P100; WEINER S, 1980, NATURE, V287, P820, DOI 10.1038/287820a0	18	34	36	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1994	8	14					1166	1169		10.1096/fasebj.8.14.7958623	http://dx.doi.org/10.1096/fasebj.8.14.7958623			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958623				2022-12-25	WOS:A1994PT12800012
J	SCHLUTER, V; MEYER, M; HOFSCHNEIDER, PH; KOSHY, R; CASELMANN, WH				SCHLUTER, V; MEYER, M; HOFSCHNEIDER, PH; KOSHY, R; CASELMANN, WH			INTEGRATED HEPATITIS-B VIRUS-X AND 3' TRUNCATED PRES/S-SEQUENCES DERIVED FROM HUMAN HEPATOMAS ENCODE FUNCTIONALLY ACTIVE TRANSACTIVATORS	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; CELLULAR FLANKING SEQUENCES; LONG TERMINAL REPEAT; NF-KAPPA-B; TRANS-ACTIVATION; GENE-EXPRESSION; MAMMALIAN-CELLS; DNA INTEGRATION; VIRAL ENHANCERS; LIVER-CANCER	The hepatitis B virus (HBV) frequently integrates into hepatocellular genomic DNA during viral infection. Transcriptional transactivators encoded by integrated HBV X and 3' truncated preS/S sequences are known to stimulate gene expression from homologous and heterologous promoters. Here we demonstrate that 21 of 26 (81%) hepatocellular carcinoma tissues/cell lines contain coding sequences for at least one of the two known transactivators. Pour integrated X and three preS/S transactivator sequences contained in five isolates from three hepatoma primary tissues or cell lines were used as examples to prove functionality of the encoded transactivators, In one case, where both X and preS/S sequences were present, dissection of X and preS/S transactivator sequences showed independent functionality. The investigation of X- and preS/S-specific RNA and protein expression revealed the existence of. carboxyterminally truncated viral-cellular fusion proteins that were able to stimulate gene expression from the c-fos proto-oncogene promoter five- to ten-fold. These results demonstrate that structurally intact HBV transactivator sequences are integrated in the majority of HBV-associated HCCs/hepatoma cell lines. In all tested examples integrated DNAs had retained functionality as transactivators. This data thereby support indirectly the hypothesis of a possible involvement of HBV transactivators in liver cell proliferation and hepatocarcinogenesis.	MAX PLANCK INST BIOCHEM,DEPT VIRUS RES,D-82152 MARTINSRIED,GERMANY; UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT MED 2,D-81366 MUNICH,GERMANY	Max Planck Society; University of Munich								ARII M, 1992, ONCOGENE, V7, P397; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BUDKOWSKA A, 1986, J MED VIROL, V20, P111, DOI 10.1002/jmv.1890200204; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO KB, 1986, VIROLOGY, V154, P405, DOI 10.1016/0042-6822(86)90467-8; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; DIAMANTIS ID, 1992, J HEPATOL, V15, P400, DOI 10.1016/0168-8278(92)90077-3; FAUSTO N, 1989, LAB INVEST, V60, P4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEITELSON MA, 1989, GASTROENTEROLOGY, V98, P1071; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; GERBES AL, 1993, J HEPATOL, V19, P312, DOI 10.1016/S0168-8278(05)80587-2; GEY GO, 1952, CANCER RES, V12, P264; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAEF E, 1994, ONCOGENE, V9, P81; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HILGER C, 1991, J VIROL, V65, P4284, DOI 10.1128/JVI.65.8.4284-4291.1991; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; HINO O, 1989, J VIROL, V63, P2638, DOI 10.1128/JVI.63.6.2638-2643.1989; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; KAM W, 1982, VIRAL HEPATITIS, P809; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOCH S, 1984, NUCLEIC ACIDS RES, V17, P6871; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LAUER U, 1994, HEPATOLOGY, V19, P23, DOI 10.1002/hep.1840190106; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MATSUMOTO H, 1988, INT J CANCER, V42, P1, DOI 10.1002/ijc.2910420102; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; MEYER M, 1992, HEPATOLOGY, V15, P665, DOI 10.1002/hep.1840150419; MIZUSAWA H, 1985, P NATL ACAD SCI USA, V82, P208, DOI 10.1073/pnas.82.1.208; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NATOLI G, 1992, VIROLOGY, V187, P663, DOI 10.1016/0042-6822(92)90469-6; OGATA N, 1990, HEPATOLOGY, V11, P1017, DOI 10.1002/hep.1840110617; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUADE K, 1992, J GEN VIROL, V73, P179, DOI 10.1099/0022-1317-73-1-179; RITTER SE, 1991, VIROLOGY, V182, P841, DOI 10.1016/0042-6822(91)90626-M; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAUL Y, 1984, J VIROL, V51, P776, DOI 10.1128/JVI.51.3.776-787.1984; SHIH CH, 1987, J VIROL, V61, P3491, DOI 10.1128/JVI.61.11.3491-3498.1987; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SLAGLE BL, 1991, CANCER RES, V51, P49; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; Szmuness W, 1978, Prog Med Virol, V24, P40; TAKADA S, 1990, J VIROL, V64, P822, DOI 10.1128/JVI.64.2.822-828.1990; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TOKINO T, 1991, J VIROL, V65, P6761, DOI 10.1128/JVI.65.12.6761-6764.1991; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG WL, 1991, CANCER RES, V51, P4971; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YAGINUMA K, 1985, P NATL ACAD SCI USA, V82, P4458, DOI 10.1073/pnas.82.13.4458; YAGINUMA K, 1987, J VIROL, V61, P1808, DOI 10.1128/JVI.61.6.1808-1813.1987; YAMAMOTO S, 1993, BIOCHEM BIOPH RES CO, V192, P111, DOI 10.1006/bbrc.1993.1388; YAMAMOTO S, 1993, BIOCHEM BIOPH RES CO, V197, P1209, DOI 10.1006/bbrc.1993.2605; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990; ZHOU YZ, 1988, J VIROL, V62, P4224, DOI 10.1128/JVI.62.11.4224-4231.1988	74	104	110	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3335	3344						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936659				2022-12-25	WOS:A1994PM65800028
J	HARRIS, KS; XIANG, WK; ALEXANDER, L; LANE, WS; PAUL, AV; WIMMER, E				HARRIS, KS; XIANG, WK; ALEXANDER, L; LANE, WS; PAUL, AV; WIMMER, E			INTERACTION OF POLIOVIRUS POLYPEPTIDE 3CD(PRO) WITH THE 5'-TERMINI AND 3'-TERMINI OF THE POLIOVIRUS GENOME - IDENTIFICATION OF VIRAL AND CELLULAR COFACTORS NEEDED FOR EFFICIENT BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RNA-SYNTHESIS; PROTEIN-SYNTHESIS; NONCODING REGION; REPLICATION; PRECURSOR; INVITRO; 3CD; POLYMERASE; CLEAVAGE	Poliovirus proteinase 3CD(pro) by itself is not an RNA-binding protein. Two cellular proteins have been purified from HeLa cells (p50 and p36) which interact with purified 3CD(pro) but only p36-3CD(pro) bind to the 5'-terminal 110 nucleotides of polioviral RNA genome, an RNA segment whose secondary structure resembles a cloverleaf. The identity of these factors was determined by microsequencing tryptic digests of the purified proteins. Host protein p50 is the eukaryotic elongation factor EF-1 alpha, and p36 an N-terminal fragment thereof. p36, referred to as host factor, did not appear to interact with purified 3C(pro) or 3D(pol). Significantly, the formation of a 3CD(pro)-cloverleaf complex was also observed in the presence of purified poliovirus polypeptide 3AB, the precursor of VPg. 3AB by itself does not stably bind to the cloverleaf. Competition experiments have demonstrated that the RNA-protein interactions are specific for the full-length cloverleaf. UV cross-linking studies were employed to examine the protein components of the cloverleaf ribonucleoproteins. RNA footprinting was used to determine the site on the cloverleaf where the viral and cellular factors bind. Finally, we have discovered that 3AB-3CD(pro) also interacts with the 3'-terminal sequence of poliovirus RNA. In contrast to the 5'-terminal cloverleaf, the 3'-terminal RNA can bind 3AB in the absence of other proteins. A model for initiation of poliovirus RNA synthesis is presented.	SUNY STONY BROOK,HLTH SCI CTR,SCH MED,DEPT MOLEC GENET & MICROBIOL,STONY BROOK,NY 11794; HARVARD UNIV,MICROCHEM FACIL,CAMBRIDGE,MA 02138	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University					NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015122, R01AI032100, R01AI015122] Funding Source: NIH RePORTER; NCI NIH HHS [CA-28146] Funding Source: Medline; NIAID NIH HHS [AI-15122, AI-32100] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDINO R, 1990, J VIROL, V64, P607, DOI 10.1128/JVI.64.2.607-612.1990; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; BERNSTEIN HD, 1986, J VIROL, V60, P1040, DOI 10.1128/JVI.60.3.1040-1049.1986; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; CUI T, 1993, J BIOL CHEM, V268, P26093; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIACHETTI C, 1992, J VIROL, V66, P6045, DOI 10.1128/JVI.66.10.6045-6057.1992; HAMMERLE T, 1992, J VIROL, V66, P6028; HARRIS KS, 1992, J VIROL, V66, P7481, DOI 10.1128/JVI.66.12.7481-7489.1992; Harris KS, 1990, SEMINARS VIROLOGY, V1, P323; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; IIZUKA N, 1987, VIROLOGY, V156, P64, DOI 10.1016/0042-6822(87)90436-3; JACOBSON SJ, 1993, J VIROL, V67, P2961, DOI 10.1128/JVI.67.6.2961-2971.1993; JORE J, 1988, J GEN VIROL, V69, P1627, DOI 10.1099/0022-1317-69-7-1627; LAMA J, 1994, J BIOL CHEM, V269, P66; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LARSEN GR, 1981, J VIROL, V37, P328, DOI 10.1128/JVI.37.1.328-335.1981; LEONG LEC, 1993, J BIOL CHEM, V268, P25735; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MIRZAYAN C, 1994, VIROLOGY, V199, P176, DOI 10.1006/viro.1994.1110; MOLLA A, 1994, J BIOL CHEM, V269, P27015; NICKLIN MJH, 1988, J VIROL, V62, P4586, DOI 10.1128/JVI.62.12.4586-4593.1988; NOMOTO A, 1977, NATURE, V268, P208, DOI 10.1038/268208a0; PILIPENKO EV, 1992, NUCLEIC ACIDS RES, V20, P1739, DOI 10.1093/nar/20.7.1739; RIVERA VM, 1988, VIROLOGY, V165, P42, DOI 10.1016/0042-6822(88)90656-3; SARNOW P, 1986, P NATL ACAD SCI USA, V83, P571, DOI 10.1073/pnas.83.3.571; SEMLER BL, 1983, VIROLOGY, V126, P624, DOI 10.1016/S0042-6822(83)80018-X; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TOYODA H, 1987, J VIROL, V61, P2816, DOI 10.1128/JVI.61.9.2816-2822.1987; TRONO D, 1988, J VIROL, V62, P2291, DOI 10.1128/JVI.62.7.2291-2299.1988; WIMMER E, 1982, CELL, V28, P199, DOI 10.1016/0092-8674(82)90335-X; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; YPMAWONG MF, 1988, VIROLOGY, V166, P265, DOI 10.1016/0042-6822(88)90172-9	39	223	229	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27004	27014						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929441				2022-12-25	WOS:A1994PQ93100064
J	JOKINEN, EV; LANDSCHULZ, KT; WYNE, KL; HO, YK; FRYKMAN, PK; HOBBS, HH				JOKINEN, EV; LANDSCHULZ, KT; WYNE, KL; HO, YK; FRYKMAN, PK; HOBBS, HH			REGULATION OF THE VERY-LOW-DENSITY LIPOPROTEIN RECEPTOR BY THYROID-HORMONE IN RAT SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; LDL RECEPTOR; LIPASE GENE; SEQUENCE; EXPRESSION; PROTEIN; CELLS; HYPOTHYROIDISM; ADIPOSE; RABBIT	A new member of the low density lipoprotein receptor gene family that binds and internalizes very low density lipoprotein (VLDL) particles was previously cloned and characterized from the rabbit and human. The physiological role of this putative VLDL receptor is not known, but its tissue distribution and ligand specificity suggest a possible role in the delivery of triglycerides to peripheral tissue. To learn more about the potential function of this receptor, we measured the changes in VLDL receptor mRNA and protein in various tissues following dietary or hormonal manipulation of rats. No significant changes in the VLDL receptor mRNA or protein were seen after a 48-h fast and subsequent to refeeding. A striking change in receptor mRNA and protein was ob served in skeletal muscle of hypothyroid and hyperthyroid rats. In hypothyroid rats, the amount of immunodetectable VLDL receptor was reduced by 80%, while in the hyperthyroid animals it was increased by 300%. These maneuvers did not affect VLDL receptor mRNA or protein levels in adipose tissue or heart. The changes in VLDL receptor mRNA in muscle were opposite to those observed with lipoprotein lipase. These studies suggest that the VLDL receptor plays a role in a metabolic process in muscle that is regulated by thyroid hormone.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	JOKINEN, EV (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20948] Funding Source: Medline; NIGMS NIH HHS [GM 08014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAULT D, 1992, GENE, V121, P237, DOI 10.1016/0378-1119(92)90127-B; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN JC, 1992, GENOMICS, V14, P153, DOI 10.1016/S0888-7543(05)80298-8; COOPER DA, 1989, BIOCHIM BIOPHYS ACTA, V1008, P92, DOI 10.1016/0167-4781(89)90174-7; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ERNEBACK S, 1988, GENE AMST, V64, P97; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; GILL TJ, 1989, SCIENCE, V245, P269, DOI 10.1126/science.2665079; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; HERZ J, 1990, J BIOL CHEM, V265, P21355; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; KAJINAMI K, 1988, ARTERIOSCLEROSIS, V8, P187, DOI 10.1161/01.ATV.8.2.187; KIEFFER JD, 1974, ACTA ENDOCRINOL-COP, V76, P495; KIRCHGESSNER TG, 1989, J BIOL CHEM, V264, P1473; KOIVISTO PVI, 1992, ARTERIOSCLER THROMB, V12, P584, DOI 10.1161/01.ATV.12.5.584; KOVANEN PT, 1979, ENDOCRINOLOGY, V104, P610, DOI 10.1210/endo-104-3-610; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KUBISTA V, 1971, EUR J BIOCHEM, V18, P553, DOI 10.1111/j.1432-1033.1971.tb01276.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMAX RB, 1992, J ENDOCRINOL, V133, P375, DOI 10.1677/joe.0.1330375; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; Mayrand P E, 1992, Appl Theor Electrophor, V3, P1; MCALLISTER RM, 1991, AM J PHYSIOL, V260, pE272, DOI 10.1152/ajpendo.1991.260.2.E272; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; REICHL D, 1973, CLIN SCI MOL MED, V45, P313, DOI 10.1042/cs0450313; SAFFARI B, 1992, J LIPID RES, V33, P241; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TORCZYNSKI R, 1983, NUCLEIC ACIDS RES, V11, P4879, DOI 10.1093/nar/11.14.4879; VANMIDDLESWORTH L, 1992, ENDOCRINOLOGY, V106, P1686; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	40	125	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26411	26418						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929362				2022-12-25	WOS:A1994PQ93000072
J	MUCHOWSKI, PJ; ZHANG, L; CHANG, ER; SOULE, HR; PLOW, EF; MOYLE, M				MUCHOWSKI, PJ; ZHANG, L; CHANG, ER; SOULE, HR; PLOW, EF; MOYLE, M			FUNCTIONAL INTERACTION BETWEEN THE INTEGRIN ANTAGONIST NEUTROPHIL INHIBITORY FACTOR AND THE I-DOMAIN OF CD11B/CD18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT RECEPTOR TYPE-3; MONOCLONAL-ANTIBODIES; VONWILLEBRAND-FACTOR; CELLULAR ADHESION; RECOGNITION SITE; MAC-1; FIBRINOGEN; MONOCYTES; BINDING; LFA-1	Neutrophil inhibitory factor (NIF) is a hookworm-derived glycoprotein ligand of the integrin CD11b/ CD18 that inhibits human neutrophil function (Moyle, M., Foster, D. L., McGrath, D. E., Brown, S. M., Laroche, A., De Meutter, J., Stanssens, P., Bogowitz, C. A., Fried, V. A., Ely, J. A., Soule, H. R., and Vlasuk, G. P. (1994) J. Biol. Chem. 269, 10008-10015). Here, we present evidence that recombinant NIF (rNIF) associates with the similar to 200-amino acid residue I domain of CD11b/CD18 and that this interaction is essential for inhibition of neutrophil function by NIF. First, radiolabeled rNIF binds to a recombinant glutathione S-transferase fusion protein that contains the CD11b I domain. This high affinity interaction has a partial dependence on divalent cations. The association of rNIF with the CD11b I domain is specific because I-125-rNIF does not bind either a glutathione S-transferase fusion protein that contains the I domain of the integrin CD11a/CD18 or recombinant glutathione S-transferase without the I domain. Second, the CD11b I domain fusion protein effectively competes with CD11b/ CD18 on human neutrophils for I-125-rNIF binding. Third, the CD11b I domain fusion protein blocks the inhibition of certain neutrophil functions by rNIF, including adhesion of neutrophils to human endothelial cell monolayers and adhesion dependent release of hydrogen peroxide from neutrophils. Specificity is demonstrated by the inability of the CD11a I domain fusion protein to block either rNIF binding to neutrophils or rNIF activity. Fourth, rNIF blocks the interaction between neutrophils and fibrinogen, a CD11b/CD18 ligand that is also thought to bind the I domain of CD11b. In contrast, rNIF does not appear to block the binding of factor X to CD11b/CD18 on neutrophils. These results suggest that CD11b/CD18 has multiple distinct binding sites for its cognate ligands, including, but not limited to, the I domain. NIF interferes with the binding of a subset of these CD11b/CD18 ligands in a highly selective manner.	CORVAS INT INC,SAN DIEGO,CA 92121; CLEVELAND CLIN FDN,CTR THROMBOSIS & VASC BIOL,DEPT MOLEC CARDIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038292] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38292] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; ARNAOUT MA, 1993, CURR OPIN HEMATOL, V1, P113; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; COLOMBATTI A, 1991, BLOOD, V77, P2305; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; KAMATA T, 1994, J BIOL CHEM, V269, P9659; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MURRAY MJ, 1983, MOL CELL BIOL, V3, P32, DOI 10.1128/MCB.3.1.32; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	21	121	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26419	26423						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929363				2022-12-25	WOS:A1994PQ93000073
J	OTOOLE, GA; TRZEBIATOWSKI, JR; ESCALANTESEMERENA, JC				OTOOLE, GA; TRZEBIATOWSKI, JR; ESCALANTESEMERENA, JC			THE COBC GENE OF SALMONELLA-TYPHIMURIUM CODES FOR A NOVEL PHOSPHATASE INVOLVED IN THE ASSEMBLY OF THE NUCLEOTIDE LOOP OF COBALAMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-B12 BIOSYNTHETIC GENES; PROSTATIC ACID-PHOSPHATASE; SITE-DIRECTED MUTAGENESIS; PHOSPHOGLYCERATE MUTASE; SEQUENCE-ANALYSIS; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; TETRACYCLINE RESISTANCE; ESCHERICHIA-COLI; MUTANTS; CLONING	We report the identification of a new locus, designated cobC, involved in the assembly of the nucleotide loop of cobalamin in Salmonella typhimurium. The cobC gene has been mapped, cloned, and sequenced. DNA sequence analysis suggested that cobC is divergently transcribed from the adjacent cobD gene and suggests that the regulatory region of these genes overlap. The cobC gene codes for a predicted polypeptide of 26 kDa with striking homology to phosphoglycerate mutase, fructose-2,6-bisphosphatase, and acid phosphatase enzymes. In vitro experiments demonstrated that CobC dephosphorylated the cobalamin biosynthetic intermediate N-1-(5 phospho-alpha-D-ribosyl)-5,6-dimethylbenzimidazole to generate N-1-alpha-D-ribosyl-5,6-dimethylbenzimidazole. In vivo data showed that the lack of cobC function blocks the synthesis of cobalamin from its precursors cobinamide and 5,6-dimethylbenzimidazole, i.e. it prevents the assembly of the nucleotide loop of cobalamin. Additionally, exogenous N-1-alpha-D-ribosyl-5,6-dimethylbenzimidazole rescues the defect of a cobC mutant. We propose that cobC codes for a novel phosphatase whose primary role is in cobalamin biosynthesis. A model for the sequence of biosynthetic steps that as semble the nucleotide loop of cobalamin in S. typhimurium is presented.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [R01 GM040313, GM40313] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040313, R37GM040313] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BENSON NR, 1992, J BACTERIOL, V174, P1673, DOI 10.1128/jb.174.5.1673-1681.1992; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; BROWN KL, 1984, INORG CHEM, V23, P1463, DOI 10.1021/ic00178a032; CAMERON B, 1991, J BACTERIOL, V173, P6066, DOI 10.1128/jb.173.19.6066-6073.1991; CASTELLAESCOLA J, 1989, BIOCHEM BIOPH RES CO, V165, P1345, DOI 10.1016/0006-291X(89)92751-4; CHANG GW, 1975, NATURE, V254, P150, DOI 10.1038/254150a0; COLOSIA AD, 1987, BIOCHEM BIOPH RES CO, V143, P1092, DOI 10.1016/0006-291X(87)90364-0; CROUZET J, 1990, J BACTERIOL, V172, P5980, DOI 10.1128/jb.172.10.5980-5990.1990; DAVIES WD, 1982, NUCLEIC ACIDS RES, V10, P4045, DOI 10.1093/nar/10.13.4045; DAVIS RW, 1980, MANUAL GENETIC ENG A; ESCALANTESEMERENA JC, 1992, J BACTERIOL, V174, P24, DOI 10.1128/jb.174.1.24-29.1992; ESCALANTESEMERENA JC, 1987, J BACTERIOL, V169, P2251, DOI 10.1128/jb.169.5.2251-2258.1987; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; FRIEDMAN.HC, 1965, J BIOL CHEM, V240, P413; FYFE JA, 1969, J BIOL CHEM, V244, P1659; GRABAU C, 1992, J BACTERIOL, V174, P2138, DOI 10.1128/JB.174.7.2138-2144.1992; HICKEY ME, 1973, ARCH BIOCHEM BIOPHYS, V153, P423; JETER RM, 1987, J BACTERIOL, V169, P3189, DOI 10.1128/jb.169.7.3189-3198.1987; JOHNSON MG, 1992, J BIOL CHEM, V267, P13302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; Maniatis T., 1982, MOL CLONING; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MCTIGUE JJ, 1978, BIOCHIM BIOPHYS ACTA, V523, P407, DOI 10.1016/0005-2744(78)90043-8; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; OTOOLE GA, 1993, J BACTERIOL, V175, P6328, DOI 10.1128/JB.175.19.6328-6336.1993; OTOOLE GA, 1993, J BACTERIOL, V175, P3317, DOI 10.1128/jb.175.11.3317-3326.1993; PARAVICINI G, 1992, BIOCHEMISTRY-US, V31, P7126, DOI 10.1021/bi00146a014; ROOF DM, 1988, J BACTERIOL, V170, P3855, DOI 10.1128/jb.170.9.3855-3863.1988; ROTH JR, 1993, J BACTERIOL, V175, P3303, DOI 10.1128/jb.175.11.3303-3316.1993; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SCHMIEGER H, 1973, MOL GEN GENET, V120, P181, DOI 10.1007/BF00267246; SCHMIEGER H, 1971, MOL GEN GENET, V100, P378; SHANSKE S, 1987, J BIOL CHEM, V262, P14612; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUH SJ, 1993, GENE, V129, P93, DOI 10.1016/0378-1119(93)90701-4; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1990, CURRENT PROTOCOLS MO; TAULER A, 1990, J BIOL CHEM, V265, P15617; TAYLOR RT, 1973, ENZYMES; TRZEBIATOWSKI JR, 1994, J BACTERIOL, V176, P3568, DOI 10.1128/JB.176.12.3568-3575.1994; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; WHITE PJ, 1992, J BACTERIOL, V174, P434, DOI 10.1128/jb.174.2.434-440.1992	47	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26503	26511						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929373				2022-12-25	WOS:A1994PQ93000086
J	OUTRAM, SV; OWEN, MJ				OUTRAM, SV; OWEN, MJ			THE HELIX-LOOP-HELIX CONTAINING TRANSCRIPTION FACTOR USF ACTIVATES THE PROMOTER OF THE CD2 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE THY-1 GENE; NON-TATA PROMOTER; PROTEIN-KINASE-C; TRANSGENIC MICE; FUNCTIONAL DOMAINS; SURFACE-ANTIGENS; ZIPPER PROTEIN; EXPRESSION; MAX; MYC	T cell development within the thymus involves the ordered expression of a number of tissue-specific components such as the CD2 gene. Control of expression of this gene is regulated by a well characterized 3' enhancer together with a promoter and upstream elements. The CD2 promoter is typical of a group of T cell-specific promoters that lack a TATA box and use multiple sites for initiation of transcription. An ''E box'' motif CACGTG, located just upstream from the most 5' initiation start site, was found to contribute a major effect to the level of basal transcription of a reporter gene. Analysis of the proteins in T cell extracts that bound to this site revealed that the bHLH-LZ protein USF was the major component. A functional role for USF was established in transient transfection experiments. Thus, this protein restored full promoter activity following repression caused by cotransfection with the E box binding bHLH-LZ protein Max. Taken together, these results indicate that an E box motif is critical to expression of the CD2 gene during T cell development and that the HLH protein USF acts as a transcriptional activator of the CD2 promoter.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CANN AJ, 1988, ONCOGENE, V3, P123; CANTRELL DA, 1988, EUR J IMMUNOL, V18, P1391, DOI 10.1002/eji.1830180914; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CLEVERS HC, 1988, P NATL ACAD SCI USA, V85, P8156, DOI 10.1073/pnas.85.21.8156; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISANTO JP, 1993, EUR J IMMUNOL, V23, P320, DOI 10.1002/eji.1830230203; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KRENSKY AM, 1983, J IMMUNOL, V131, P611; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; MONOSTORI E, 1991, IMMUNOLOGY, V74, P369; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MURAGUCHI A, 1992, INT IMMUNOL, V4, P841, DOI 10.1093/intimm/4.8.841; OWEN MJ, 1988, EUR J IMMUNOL, V18, P187, DOI 10.1002/eji.1830180129; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHANBERG LE, 1991, P NATL ACAD SCI USA, V88, P603, DOI 10.1073/pnas.88.2.603; SEN J, 1989, EUR J IMMUNOL, V19, P1297, DOI 10.1002/eji.1830190722; Sirito Mario, 1992, Gene Expression, V2, P231; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; TUNNACLIFFE A, 1987, EMBO J, V6, P2953, DOI 10.1002/j.1460-2075.1987.tb02600.x; TUNNACLIFFE A, 1986, EMBO J, V5, P1245, DOI 10.1002/j.1460-2075.1986.tb04353.x; WOTTON D, 1993, J BIOL CHEM, V268, P17975; WOTTON D, 1989, P NATL ACAD SCI USA, V86, P4195, DOI 10.1073/pnas.86.11.4195; YAGITA H, 1989, P NATL ACAD SCI USA, V86, P645, DOI 10.1073/pnas.86.2.645; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	46	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26525	26530						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929376				2022-12-25	WOS:A1994PQ93000089
J	WONG, AKC; DELAFAILLE, MAC; WIRTH, DF				WONG, AKC; DELAFAILLE, MAC; WIRTH, DF			IDENTIFICATION OF A CIS-ACTING GENE REGULATORY ELEMENT FROM THE LEMDR1 LOCUS OF LEISHMANIA-ENRIETTI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRYPANOSOMA-BRUCEI; LARGEST SUBUNIT; STABLE TRANSFECTION; EXPRESSION SITE; MESSENGER-RNAS; PROMOTER; DNA; SEQUENCES; PROTEIN	The goal of this work is to identify those elements which control gene expression in the parasitic protozoan, Leishmania enriettii. To date there has been no report of a transcriptional controlling element identified in this parasite. In the present study, we have found that a region of the lemdr1 locus of L. enriettii can down-regulate the steady state mRNA level of the reporter neomycin phosphotransferase gene when it is placed in an extrachromosomal expression vector, pALTneo. Through deletion analysis, we have mapped a putative regulatory sequence to the flanking region upstream of the lemdr1 gene. This cis regulatory element is shown to control gene expression in an orientation-dependent and position independent manner. By performing nuclear run on analysis, we have demonstrated that this element mainly exerts its effect at the transcriptional level by determining the strandedness of transcription on the pALTneo vector. The identification of this novel cis regulatory element should further our understanding of the transcriptional process in Leishmania and other related trypanosomatids.	HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI027872, R01AI027872, R01AI021365] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27872, AI-21365] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHARONI A, 1993, NUCLEIC ACIDS RES, V21, P5221, DOI 10.1093/nar/21.22.5221; ALY R, 1993, GENE, V127, P155, DOI 10.1016/0378-1119(93)90714-E; BELLOFATTO V, 1991, P NATL ACAD SCI USA, V88, P6711, DOI 10.1073/pnas.88.15.6711; BENAMAR MF, 1991, NUCLEIC ACIDS RES, V19, P5857, DOI 10.1093/nar/19.21.5857; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CHOW LMC, 1993, MOL BIOCHEM PARASIT, V60, P195, DOI 10.1016/0166-6851(93)90131-G; CHUNG HMM, 1993, MOL CELL BIOL, V13, P3734, DOI 10.1128/MCB.13.6.3734; DELAFAILLE MAC, 1992, J BIOL CHEM, V267, P23839; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; DIETRICH P, 1993, GENE, V125, P103, DOI 10.1016/0378-1119(93)90753-P; DONELSON JE, 1990, PARASITOL TODAY, V6, P327, DOI 10.1016/0169-4758(90)90177-6; EVERS R, 1989, CELL, V56, P585, DOI 10.1016/0092-8674(89)90581-3; FANTONI A, 1994, MOL CELL BIOL, V14, P2021, DOI 10.1128/MCB.14.3.2021; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GRONDAL EJM, 1989, EMBO J, V8, P3383, DOI 10.1002/j.1460-2075.1989.tb08502.x; HEHL A, 1994, P NATL ACAD SCI USA, V91, P370, DOI 10.1073/pnas.91.1.370; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HUANG J, 1991, EMBO J, V10, P3877, DOI 10.1002/j.1460-2075.1991.tb04957.x; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KAPOTAS N, 1993, NUCLEIC ACIDS RES, V21, P4067, DOI 10.1093/nar/21.17.4067; KOCK J, 1988, NUCLEIC ACIDS RES, V16, P8753, DOI 10.1093/nar/16.18.8753; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LIU X, 1992, P NATL ACAD SCI USA, V89, P4991, DOI 10.1073/pnas.89.11.4991; PERRY K, 1991, EXPERIENTIA, V47, P118, DOI 10.1007/BF01945412; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN DR, 1991, EMBO J, V10, P3379, DOI 10.1002/j.1460-2075.1991.tb04902.x; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; WEBB JR, 1993, J BIOL CHEM, V268, P13994; WILSON ME, 1993, J BIOL CHEM, V268, P15731; WONG AKC, 1994, MOL BIOCHEM PARASIT, V64, P75, DOI 10.1016/0166-6851(94)90136-8; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153	41	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26497	26502						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929372				2022-12-25	WOS:A1994PQ93000085
J	URBAN, RJ; SHUPNIK, MA; BODENBURG, YH				URBAN, RJ; SHUPNIK, MA; BODENBURG, YH			INSULIN-LIKE GROWTH-FACTOR-I INCREASES EXPRESSION OF THE PORCINE P-450 CHOLESTEROL SIDE-CHAIN CLEAVAGE GENE THROUGH A GC-RICH DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC-OVARY-SYNDROME; FOLLICLE-STIMULATING-HORMONE; MESSENGER-RIBONUCLEIC-ACID; SWINE GRANULOSA-CELLS; BOX-BINDING-PROTEINS; HUMAN SOMATOMEDIN-C; TUMOR-CELLS; DEVELOPMENTAL REGULATION; PRIMARY CULTURES; PROMOTER REGION	The promoter/regulatory region of the porcine P-450 cholesterol side chain cleavage (P450scc) gene was cloned from a porcine genomic library. This gene contains a GC-rich region (-130-100) that mediates insulinlike growth factor I (IGF-I) and cAMP stimulation of gene expression in porcine granulosa cells. Stimulation of gene expression by cAMP occurs in 6 h, while IGF-I stimulation occurs in 24-48 h. This region is also responsive to insulin but not fibroblast growth factor. The effects of IGF-I and cAMP on gene expression in porcine granulosa cells are additive. In Y1 adrenal cells, the same region is responsive to cAMP but not to IGF-I. Gel shift assays using an oligonucleotide of this region and nuclear extract protein from porcine granulosa and Y1 adrenal cells identified three DNA protein complexes (C-1-C-3). The binding activity of the complexes did not change with IGF-I or forskolin treatment of granulosa cells. Mutational analysis results were consistent with IGF-I regulating gene expression through the C-2 DNA protein complex. Moreover, this complex binds differently in gel shift assay to mutant oligonucleotides with porcine and Y1 and nuclear extract protein. We conclude that IGF-I stimulates porcine P450scc gene expression through a distinct, cell-specific protein complex binding to a GC-rich domain.	UNIV VIRGINIA,DEPT INTERNAL MED,DIV ENDOCRINOL,CHARLOTTESVILLE,VA 22908	University of Virginia	URBAN, RJ (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV ENDOCRINOL,3142 MRB,1060,GALVESTON,TX 77555, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028393] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038942] Funding Source: NIH RePORTER; NCRR NIH HHS [2S07 RR05427-30] Funding Source: Medline; NICHD NIH HHS [HD28393] Funding Source: Medline; NIDDK NIH HHS [DK 38942] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADASHI EY, 1985, ENDOCRINOLOGY, V116, P2135, DOI 10.1210/endo-116-6-2135; ADASHI EY, 1993, ANN NY ACAD SCI, V687, P10; ADASHI EY, 1985, ENDOCR REV, V6, P400, DOI 10.1210/edrv-6-3-400; AHLGREN R, 1990, J BIOL CHEM, V265, P3313; ALEMANY J, 1992, BIOCHEM BIOPH RES CO, V183, P659, DOI 10.1016/0006-291X(92)90533-Q; ALEMANY J, 1990, P NATL ACAD SCI USA, V87, P3353, DOI 10.1073/pnas.87.9.3353; Arber W., 1983, LAMBDA; BARNES R, 1989, ANN INTERN MED, V110, P386, DOI 10.7326/0003-4819-110-5-386; BEGEOT M, 1993, J BIOL CHEM, V268, P17317; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERGH C, 1991, ACTA ENDOCRINOL-COP, V125, P177, DOI 10.1530/acta.0.1250177; BRASIER AR, 1991, METHODS NEUROSCI, V5, P108; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; CIARALDI TP, 1992, J CLIN ENDOCR METAB, V75, P577, DOI 10.1210/jc.75.2.577; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FUNKENSTEIN B, 1984, J BIOL CHEM, V259, P8572; GOLDRING NB, 1987, ENDOCRINOLOGY, V120, P1942, DOI 10.1210/endo-120-5-1942; GUO IC, 1994, J BIOL CHEM, V269, P6362; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HATEY F, 1992, J STEROID BIOCHEM, V43, P869, DOI 10.1016/0960-0760(92)90314-9; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; INOUE H, 1988, EUR J BIOCHEM, V171, P435, DOI 10.1111/j.1432-1033.1988.tb13808.x; JOHN ME, 1984, P NATL ACAD SCI-BIOL, V81, P5628, DOI 10.1073/pnas.81.18.5628; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KAMIKUBO K, 1990, MOL ENDOCRINOL, V4, P2021, DOI 10.1210/mend-4-12-2021; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KAZER RR, 1990, J CLIN ENDOCR METAB, V71, P958, DOI 10.1210/jcem-71-4-958; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KNOLL BJ, 1983, NUCLEIC ACIDS RES, V11, P6733, DOI 10.1093/nar/11.19.6733; LAATIKAINEN T, 1993, ANN NY ACAD SCI, V687, P90; LARA HE, 1993, ENDOCRINOLOGY, V133, P2690, DOI 10.1210/en.133.6.2690; LAUBER ME, 1993, MOL CELL ENDOCRINOL, V94, P235, DOI 10.1016/0303-7207(93)90172-G; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; MULHERON GW, 1989, NUCLEIC ACIDS RES, V17, P1773, DOI 10.1093/nar/17.4.1773; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OONK RB, 1990, J BIOL CHEM, V265, P22392; REIN M S, 1982, Biology of Reproduction, V26, p113A; RICE DA, 1990, J BIOL CHEM, V265, P11713; RICH CB, 1993, BIOCHEM BIOPH RES CO, V196, P1316, DOI 10.1006/bbrc.1993.2396; ROSENBAUM D, 1993, AM J PHYSIOL, V264, pE197, DOI 10.1152/ajpendo.1993.264.2.E197; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMMER BP, 1985, METHOD ENZYMOL, V109, P350; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SIMPSON ER, 1990, MOL CELL ENDOCRINOL, V70, pC25, DOI 10.1016/0303-7207(90)90151-W; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; URBAN RJ, 1990, ENDOCRINOLOGY, V127, P2481, DOI 10.1210/endo-127-5-2481; URBAN RJ, 1991, ENDOCRINOLOGY, V128, P2000, DOI 10.1210/endo-128-4-2000; VELDHUIS JD, 1985, BIOCHEM BIOPH RES CO, V130, P234, DOI 10.1016/0006-291X(85)90407-3; VELDHUIS JD, 1985, ENDOCRINOLOGY, V116, P1235, DOI 10.1210/endo-116-4-1235; VELDHUIS JD, 1986, ENDOCRINOLOGY, V119, P530, DOI 10.1210/endo-119-2-530; VELDHUIS TD, 1984, BIOCHEM BIOPH RES CO, V120, P144, DOI 10.1016/0006-291X(84)91425-6; VOSS JW, 1993, MOL ENDOCRINOL, V7, P1551, DOI 10.1210/me.7.12.1551; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOLFE BL, 1993, J BIOL CHEM, V268, P12418; WONG M, 1989, J BIOL CHEM, V264, P12867	65	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25761	25769						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929280				2022-12-25	WOS:A1994PQ49100079
J	PORTER, DJT				PORTER, DJT			REACTION OF 5-ETHYNYLURACIL WITH RAT-LIVER XANTHINE-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM-BASED INACTIVATION; DIHYDROPYRIMIDINE DEHYDROGENASE; THYMINE HYDROXYLASE; 5-FLUOROURACIL; CONVERSION	5-Ethynyluracil is a time-dependent and tight binding inhibitor of xanthine oxidase. The maximal value of the first-order rate constant for onset of inhibition is 0.01 s(-1), and the concentration of 5-ethynyluracil which gives one-half of this value is 190 mu M. Because the t(1/2) for formation of active enzyme from inhibited enzyme is greater than 30 h in the absence of NADH inhibition of xanthine oxidase by 5-ethynyluracil is functionally irreversible. One equivalent of 5-[2-C-14]ethynyluracil/equivalent of active enzyme is required for complete inhibition. Allopurinol (100 mu M), a potent inhibitor of xanthine oxidase, and cyanide (5 mM), an inactivator of the enzyme, do not abolish the binding of 5-[2-C-14]ethynyluracil to the enzyme. Because radiolabel is released from 5-[2-C-14]ethynyluracil-treated enzyme by treatment with 6 M guanidine HCl, a stable covalent bond is not formed between the inhibitor and the enzyme. However, the radiolabel released from inhibited enzyme is not 5-ethynyluracil. Moreover, NADH restores catalytic activity to the inhibited enzyme and displaces the radiolabel as 5-acetyluracil. Thermal denaturation of 5-ethynyluracil-inhibited xanthine oxidase results in the release of approximately equal amounts of 5-acetyluracil and a more hydrophilic product. Consequently, the 5-ethynyluracil-xanthine oxidase complex yields different degradation products of 5-ethynyluracil under different denaturation conditions. Seven uracil analogues with B-substituents were tested as time dependent inhibitors of xanthine oxidase. 5-Ethynyluracil is the only uracil analogue that potently inhibited xanthine oxidase. The reactivity of these uracil derivatives with sulfite was also determined. 5-Ethynyluracil is many fold more susceptible to nonenzymatic nucleophilic addition of sulfite than are the other analogues. Thus, the potency of these uracil analogues as inhibitors of xanthine oxidase is related to the nonenzymatic reactivity of the analogues with sulfite.			PORTER, DJT (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,3030 CORNWALLIS RD,RES TRIANGLE PK,NC 27709, USA.							ALSTON TA, 1987, BIOCHEMISTRY-US, V26, P4082, DOI 10.1021/bi00387a051; BACCANARI DP, 1993, P NATL ACAD SCI USA, V90, P11064, DOI 10.1073/pnas.90.23.11064; BARR PJ, 1983, BIOCHEMISTRY-US, V22, P1696, DOI 10.1021/bi00276a027; CAO SS, 1994, CANCER RES, V54, P1507; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P3330; DESGRANGES C, 1986, CANCER RES, V46, P1094; EDMONDSON D, 1972, J BIOL CHEM, V247, P1597; ELION GB, 1966, ANN RHEUM DIS, V25, P608, DOI 10.1136/ard.25.Suppl_6.608; ENGERSON TD, 1987, J CLIN INVEST, V79, P1564, DOI 10.1172/JCI112990; HARRIS BE, 1990, CANCER RES, V50, P197; HAYATSU H, 1975, J ORG CHEM, V40, P3862, DOI 10.1021/jo00914a009; HILLE R, 1981, PHARMACOL THERAPEUT, V14, P249, DOI 10.1016/0163-7258(81)90063-2; IKEGAMI T, 1986, ARCH BIOCHEM BIOPHYS, V247, P254, DOI 10.1016/0003-9861(86)90582-5; IVANETICH KM, 1992, PROG NUCLEIC ACID RE, V42, P127, DOI 10.1016/S0079-6603(08)60575-9; KRENITSKY TA, 1986, ARCH BIOCHEM BIOPHYS, V247, P108, DOI 10.1016/0003-9861(86)90539-4; POMALES R, 1965, BIOCHIM BIOPHYS ACTA, V95, P505, DOI 10.1016/0005-2787(65)90196-6; PORTER DJT, 1994, BIOCHEM PHARMACOL, V47, P1165, DOI 10.1016/0006-2952(94)90388-3; PORTER DJT, 1992, J BIOL CHEM, V267, P5236; RORK GS, 1975, J AM CHEM SOC, V97, P5559, DOI 10.1021/ja00852a040; RORK GS, 1975, J AM CHEM SOC, V97, P5566, DOI 10.1021/ja00852a041; SAITO T, 1989, J BIOL CHEM, V264, P10015; SEDOR FA, 1975, J AM CHEM SOC, V97, P5572, DOI 10.1021/ja00852a042; SPECTOR T, 1993, BIOCHEM PHARMACOL, V46, P2243, DOI 10.1016/0006-2952(93)90615-4; THORNBURG LD, 1993, BIOCHEMISTRY-US, V32, P14034, DOI 10.1021/bi00213a037; THORNBURG LD, 1989, J AM CHEM SOC, V111, P7632, DOI 10.1021/ja00201a064; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6	26	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27932	27940						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961725				2022-12-25	WOS:A1994PV77200028
J	RAO, Y; ZHAO, XN; SIU, CH				RAO, Y; ZHAO, XN; SIU, CH			MECHANISM OF HOMOPHILIC BINDING MEDIATED BY THE NEURAL CELL-ADHESION MOLECULE NCAM - EVIDENCE FOR ISOLOGOUS INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; MONOCLONAL-ANTIBODY EPITOPES; MEMBRANE-SPANNING REGION; N-CAM; DICTYOSTELIUM-DISCOIDEUM; HOMOPHILIC BINDING; NEURITE OUTGROWTH; SKELETAL-MUSCLE; FUNCTIONAL DETERMINANTS; EXTRACELLULAR DOMAIN	We have previously shown that a decapeptide sequence between Lys-243 and Glu-252 (KYSFNYDGSE) in the third immunoglobulin (Ig) like domain of chick neural cell adhesion molecule NCAM is directly involved in NCAM-to-NCAM binding. To identify the domain that interacts with this decapeptide sequence, the Ig-like domain 3 of NCAM was expressed in bacteria and the refolded protein was assayed for its NCAM binding activity. Covaspheres conjugated with domain 3 protein bound to a substratum coated with either NCAM or the domain 3 protein, suggesting that NCAM-NCAM binding is mediated by interactions between domain 3 sequences on apposing molecules. Further studies were carried out using a cell-to-substratum binding assay. Mouse L cells stably transformed with different deletion constructs of NCAM were assayed for their ability to attach to substratum coated with different peptide conjugates. The results indicated that a site in NCAM Ig-like domain 3 bound specifically to the decapeptide sequence. To identify this site, cells expressing mutant NCAMs with alterations in the amino acid sequence of the homophilic binding site were subjected to the same cell-to substratum assay. Mutant NCAMs that had lost their homophilic binding activity also failed to attach to the peptide substrate. Taken together, these results suggest that the NCAM homophilic binding site interacts isologously with the same sequence on apposing molecules.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ON, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5G 1L6, ON, CANADA	University of Toronto; University of Toronto								BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLE GJ, 1985, J CELL BIOL, V100, P1192, DOI 10.1083/jcb.100.4.1192; COLMAN PM, 1976, J MOL BIOL, V100, P257, DOI 10.1016/S0022-2836(76)80062-9; COVAULT J, 1987, J CELL BIOL, V105, P2479, DOI 10.1083/jcb.105.6.2479; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEISENHOFER J, 1976, H-S Z PHYSIOL CHEM, V357, P1421, DOI 10.1515/bchm2.1976.357.2.1421; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; FRELINGER AL, 1986, J CELL BIOL, V103, P1729, DOI 10.1083/jcb.103.5.1729; GLOCKSHUBER R, 1992, BIOCHEMISTRY-US, V31, P1270, DOI 10.1021/bi00120a002; GRUMET M, 1982, NATURE, V295, P693, DOI 10.1038/295693a0; HALL AK, 1985, DEV BIOL, V110, P39, DOI 10.1016/0012-1606(85)90061-2; HE HT, 1986, EMBO J, V5, P2489, DOI 10.1002/j.1460-2075.1986.tb04526.x; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; HOCHMAN J, 1976, BIOCHEMISTRY-US, V15, P2706, DOI 10.1021/bi00657a034; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KAMBOJ RK, 1989, CELL, V59, P615, DOI 10.1016/0092-8674(89)90007-X; KAMBOJ RK, 1988, J CELL BIOL, V107, P1835, DOI 10.1083/jcb.107.5.1835; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; MATSUNAGA T, 1987, SCAND J IMMUNOL, V25, P485, DOI 10.1111/j.1365-3083.1987.tb02220.x; MOORE SE, 1987, J CELL BIOL, V105, P1377, DOI 10.1083/jcb.105.3.1377; MURRAY BA, 1986, J CELL BIOL, V102, P189, DOI 10.1083/jcb.102.1.189; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PECK D, 1993, J CELL BIOL, V123, P1587, DOI 10.1083/jcb.123.6.1587; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; POLJAK RJ, 1972, NATURE-NEW BIOL, V235, P137, DOI 10.1038/newbio235137a0; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RECNY MA, 1990, J BIOL CHEM, V265, P8542; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; RUTISHAUSER U, 1982, P NATL ACAD SCI-BIOL, V79, P685, DOI 10.1073/pnas.79.2.685; RUTISHAUSER U, 1983, J CELL BIOL, V97, P145, DOI 10.1083/jcb.97.1.145; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Sambrook J, 1989, MOL CLONING LABORATO; SANDIG M, 1994, J BIOL CHEM, V269, P14841; SANTONI MJ, 1988, J NEUROSCI RES, V20, P304, DOI 10.1002/jnr.490200304; SIU CH, 1990, DEV GENET, V11, P377, DOI 10.1002/dvg.1020110509; SIU CH, 1987, J CELL BIOL, V105, P2523, DOI 10.1083/jcb.105.6.2523; SMALL SJ, 1988, NEURON, V1, P1007, DOI 10.1016/0896-6273(88)90158-4; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THIERY JP, 1977, J BIOL CHEM, V252, P6841; THOMPSON J, 1989, GENE DEV, V3, P348, DOI 10.1101/gad.3.3.348; THOR G, 1986, NEUROSCI LETT, V66, P121, DOI 10.1016/0304-3940(86)90176-X; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	66	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27540	27548						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961669				2022-12-25	WOS:A1994PV77100060
J	DARBON, JM; DEVAULT, A; TAVIAUX, S; FESQUET, D; MARTINEZ, AM; GALAS, S; CAVADORE, JC; DOREE, M; BLANCHARD, JM				DARBON, JM; DEVAULT, A; TAVIAUX, S; FESQUET, D; MARTINEZ, AM; GALAS, S; CAVADORE, JC; DOREE, M; BLANCHARD, JM			CLONING, EXPRESSION AND SUBCELLULAR-LOCALIZATION OF THE HUMAN HOMOLOG OF P40(MO15) CATALYTIC SUBUNIT OF CDK-ACTIVATING KINASE	ONCOGENE			English	Article							MATURATION-PROMOTING FACTOR; CYCLIN-DEPENDENT KINASES; PROTEIN-KINASE; CELL-CYCLE; TYROSINE KINASE; FISSION YEAST; NEGATIVE REGULATION; CDC25 PROTEIN; S-PHASE; PHOSPHORYLATION	Transitions of the cell cycle are controlled by cyclin-dependent protein kinases (cdks) whose phosphorylation on the Thr residue included in the conserved sequence YTHEVV dramatically increases the activity. A kinase responsible for this specific phosphorylation, called CAK for cdk-activating kinase, has been recently purified from starfish and Xenopus oocytes and shown to contain the MO15 gene product as a catalytic subunit. In the present paper, we have cloned the human homolog of Xenopus p40(MO15) by probing a HeLa cell cDNA library with degenerate oligonucleotides deduced from Xenopus and starfish MO15 sequences. Human and Xenopus MO15 displayed a strong homology showing 86% identity with regard to amino acid sequences. Northern blot analysis of RNA extracts from a series of human tissues as well as from cultured rodent fibroblasts revealed a unique 1.4 kb MO15 mRNA. No variation in the amount of MO15 transcript or protein was found along the entire course of the fibroblast cell cycle. Fluorescence in situ hybridization on human lymphocyte metaphases showed two distinct chromosomal locations of human MO15 gene at 5q12-q13 and 2q22-q24. By using gene tagging and mammalian cell transfection, we demonstrate that the KRKR motif located at the carboxy terminal end of MO15 is required for nuclear targeting of the protein. Mutation of KRKR to NGER retains MO15 in the cytoplasmic compartment, whilst the wild-type protein is detected exclusively in the nucleus. Interestingly, we demonstrate that the nuclear targeting of MO15 is necessary to confer the protein its CAK activity. In contrast to the wild-type, the NLS-mutated MO15 expressed in Xenopus oocytes is unable to generate CAK as long as the nuclear envelope is not broken. The nuclear localization of both the MO15 gene product and CAK activity may imply that cdks activation primarily occurs in the cell nucleus.	CNRS, UMR 9942, F-34033 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS)	DARBON, JM (corresponding author), CNRS, INSERM, U249, UPR 9008, BP 5051, F-34033 MONTPELLIER, FRANCE.		Fesquet, didier/M-9750-2019; Fesquet, Didier/A-1490-2009; martinez, Anne-marie/R-2751-2017	Fesquet, didier/0000-0001-5657-9689; martinez, Anne-marie/0000-0001-8562-7627				BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; CLARKE PR, 1991, J CELL SCI, V100, P409; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS NL, 1990, NUCLEIC ACIDS RES, V18, P3015, DOI 10.1093/nar/18.10.3015; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Hunt T, 1991, Semin Cell Biol, V2, P213; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOSAK M, 1984, NUCLEIC ACIDS RES, V12, P857; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LABBE JC, 1994, IN PRESS EMBO J; LASKEY RA, 1993, CELL, V74, P585, DOI 10.1016/0092-8674(93)90505-K; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; LORCA T, 1992, J CELL SCI, V102, P55; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ONOE S, 1993, BIOMED RES-TOKYO, V14, P441, DOI 10.2220/biomedres.14.441; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0	60	48	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3127	3138						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936635				2022-12-25	WOS:A1994PM65800004
J	SUGIMOTO, T; SAITO, M; MOCHIZUKI, S; WATANABE, Y; HASHIMOTO, S; KAWASHIMA, H				SUGIMOTO, T; SAITO, M; MOCHIZUKI, S; WATANABE, Y; HASHIMOTO, S; KAWASHIMA, H			MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF A CDNA-ENCODING THE HUMAN V-1B VASOPRESSIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADENOHYPOPHYSIS; BINDING-SITES; PITUITARY; BRAIN; AUTORADIOGRAPHY; LOCALIZATION; ANTAGONISTS; SPECIFICITY; OXYTOCIN; ACIDS	Arginine vasopressin modulates the release of adrenocorticotropic hormone, beta-endorphin, and prolactin from the anterior pituitary. Release is mediated by the V-1b receptor through the mobilization of intracellular Ca2+ by phosphatidylinositol hydrolysis. In contrast to its well characterized peripheral actions, such as antidiuresis, contraction of vascular smooth muscle, and stimulation of hepatic glycogenolysis, the exact site and mechanism of vasopressin action in the pituitary remain unclear. This is largely due to a lack of information on the molecular identity and exact localization of the V-1b receptor. This lack prompted us to try to isolate this receptor subtype. Here we report the molecular cloning and functional expression of a complementary DNA encoding the human V-1b receptor. The deduced 424-amino acid sequence of the receptor has highest overall homology with the V-1a, V-2, and oxytocin receptors, with homologies of 45, 39, and 45%, respectively. The receptor expressed in COS-1 cells has a single binding site for arginine vasopressin with a K-d of 0.17 +/- 0.04 nM. It binds various agonists and antagonists of vasopressin with affinities distinct hom those of V-1a and V-2 receptors but consistent with those anticipated for the V-1b receptor on the basis of the pharmacological studies. Furthermore, arginine vasopressin evoked calcium-dependent chloride current in Xenopus oocytes transfected with the receptor, which was not affected by a V-1a/V-2 antagonist. In contrast, the current evoked in oocytes transfected with V-1a receptor was abolished by the antagonist. Northern blot analysis revealed that the receptor expression is restricted to the pituitary. These data clearly indicate that the cloned cDNA encodes the V-1b receptor.	YAMANOUCHI INST DRUG DISCOVERY RES,MOLEC MED RES LABS,TSUKUBA,IBARAKI 305,JAPAN									ANTONI FA, 1984, NEUROENDOCRINOLOGY, V39, P186, DOI 10.1159/000123976; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BUCKINGHAM JC, 1987, J ENDOCRINOL, V113, P389, DOI 10.1677/joe.0.1130389; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLEMENTS JA, 1986, ENDOCR REV, V7, P449, DOI 10.1210/edrv-7-4-449; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; JARD S, 1986, MOL PHARMACOL, V30, P171; JARD S, 1987, AM J PHYSIOL, V253, pF41, DOI 10.1152/ajprenal.1987.253.1.F41; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KJAER A, 1993, ACTA ENDOCRINOL-COP, V129, P489; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LASZLO FA, 1991, PHARMACOL REV, V43, P73; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MIYAKE A, 1994, BIOCHEM PHARMACOL, V47, P1339; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; OSTROWSKI NL, 1992, ENDOCRINOLOGY, V131, P533, DOI 10.1210/en.131.1.533; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; PHILLIPS PA, 1988, NEUROSCIENCE, V27, P749, DOI 10.1016/0306-4522(88)90180-7; PITTEL Z, 1994, MOL PHARMACOL, V45, P61; REN HZ, 1994, P NATL ACAD SCI USA, V91, P4864, DOI 10.1073/pnas.91.11.4864; RYMOND V, 1985, FEBS LETT, V182, P196; SCHWARTZ J, 1991, ENDOCRINOLOGY, V129, P1107, DOI 10.1210/endo-129-2-1107; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; TRIBOLLET E, 1988, BRAIN RES, V442, P105, DOI 10.1016/0006-8993(88)91437-0	28	293	308	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27088	27092						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929452				2022-12-25	WOS:A1994PQ93100075
J	FUKUDOME, K; ESMON, CT				FUKUDOME, K; ESMON, CT			IDENTIFICATION, CLONING, AND REGULATION OF A NOVEL ENDOTHELIAL-CELL PROTEIN-C ACTIVATED PROTEIN-C RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; AMINO-ACID SEQUENCES; C4B-BINDING PROTEIN; PURPURA FULMINANS; ESCHERICHIA-COLI; GROWTH-FACTOR; THROMBOMODULIN; ANTICOAGULANT; DEFICIENCY; ACTIVATION	Human protein C and activated protein C are shown to bind to endothelium specifically, selectively and saturably (K-d = 30 nM, 7000 sites per cell) in a Ca2+ dependent fashion. Expression cloning revealed a 1.3-kilobase pair cDNA that coded for a novel type 1 transmembrane glycoprotein capable of binding protein C. This protein appears to be a member of the CD1/major histocompatibility complex superfamily. Like thrombomodulin, the receptor involved in protein C activation, the endothelial cell protein C receptor function and message are both down-regulated by exposure of endothelium to tumor necrosis factor. Identification of endothelial cell protein C receptor as a member of the CD1/major histocompatibility complex superfamily provides insights into the role of protein C in regulating the inflammatory response.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center								BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BALK SP, 1991, J IMMUNOL, V146, P768; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; DAHLBACK B, 1992, BIOCHEMISTRY-US, V31, P12769, DOI 10.1021/bi00166a009; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DITTMAN WA, 1990, BLOOD, V75, P329; DITTMAN WA, 1991, TRENDS CARDIOVAS MED, V1, P331, DOI 10.1016/1050-1738(91)90070-U; DREYFUS M, 1991, NEW ENGL J MED, V325, P1565, DOI 10.1056/NEJM199111283252207; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1992, TRENDS CARDIOVAS MED, V2, P214, DOI 10.1016/1050-1738(92)90027-P; GERSON WT, 1993, PEDIATRICS, V91, P418; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREY S, 1993, TRANSPLANT P, V25, P2913; GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221; HOGG PJ, 1992, J BIOL CHEM, V267, P703; KAISHO T, 1994, P NATL ACAD SCI USA, V91, P5325, DOI 10.1073/pnas.91.12.5325; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEDBETTER JA, 1985, J IMMUNOL, V134, P4250; LENTZ SR, 1991, BLOOD, V77, P543; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; OLSEN PH, 1992, BIOCHEMISTRY-US, V31, P746, DOI 10.1021/bi00118a016; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTHBARTH K, 1993, J CELL SCI, V104, P19; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; STERN DM, 1986, J BIOL CHEM, V261, P713; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	41	436	456	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26486	26491						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929370				2022-12-25	WOS:A1994PQ93000083
J	MANGUS, DA; JANG, SH; JAEHNING, JA				MANGUS, DA; JANG, SH; JAEHNING, JA			RELEASE OF THE YEAST MITOCHONDRIAL RNA-POLYMERASE SPECIFICITY FACTOR FROM TRANSCRIPTION COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; TERNARY COMPLEXES; GENE-EXPRESSION; SIGMA-FACTORS; PROMOTER; PURIFICATION; INITIATION; PROTEINS; BINDING	The yeast mitochondrial RNA polymerase is composed of two nuclear encoded subunits, a catalytic core (Rpo41p), which resembles the enzymes from bacteriophage T7 and T3, and a specificity factor required for promoter recognition (Mtf1p), which is similar to members of the eubacterial sigma factor family. Using mitochondrial RNA polymerase reconstituted from highly purified subunits, we have determined that Rpo41p and Mtf1p interact to form a holoenzyme in solution prior to DNA binding and promoter recognition. We analyzed the composition of the polymerase during and after the initiation of transcription and found that, like the eubacterial a factors, Mtf1p is released after initiation and is available to catalyze transcription on a second template. By analyzing gel mobility shift complexes of the RNA polymerase and DNA at different stages of the transcription reaction, we found that both subunits were associated with DNA prior to initiation and after the formation of two phosphodiester bonds. After the formation of a 13-nucleotide transcript, Mtf1p is no longer associated with Rpo41p on the DNA. These data establish that Mtf1p is functionally as well as structurally similar to eubacterial sigma factors.	INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405; INDIANA UNIV,INST MOLEC & CELLULAR BIOL,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036692] Funding Source: NIH RePORTER; NIAID NIH HHS [KO4 AI 00874] Funding Source: Medline; NIGMS NIH HHS [R01 GM 36692] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; BISWAS TK, 1987, J BIOL CHEM, V262, P13690; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURGESS RR, 1971, METHOD ENZYMOL, V21, P500; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DEZAMAROCZY M, 1986, GENE, V47, P155, DOI 10.1016/0378-1119(86)90060-0; ENGBAEK F, 1976, MOL GEN GENET, V143, P291, DOI 10.1007/BF00269405; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GRIMES GW, 1974, SCIENCE, V185, P630, DOI 10.1126/science.185.4151.630; Guthrie C, 1991, METHODS ENZYMOL, V194; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HARLOW E, 1988, ANTIBODIES LABORATOR; HELMANN JD, 1994, ANN REV BIOCH, P1; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; JAEHNING JA, 1991, SCIENCE, V253, P859, DOI 10.1126/science.1876846; JANG SH, 1991, J BIOL CHEM, V266, P22671; JANG SH, 1994, TRANSCRIPTION, P171; KELLY JL, 1986, J BIOL CHEM, V261, P348; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISOWSKY T, 1988, MOL GEN GENET, V214, P218, DOI 10.1007/BF00337714; MALIK S, 1987, NUCLEIC ACIDS RES, V15, P8521, DOI 10.1093/nar/15.20.8521; MANGUS DA, 1994, FUNCTIONAL ANAL YEAS; MANGUS DA, 1994, IN PRESS METHODS ENZ; MARCZYNSKI GT, 1989, MOL CELL BIOL, V9, P3193, DOI 10.1128/MCB.9.8.3193; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MCALLISTER WT, 1993, MOL MICROBIOL, V10, P1, DOI 10.1111/j.1365-2958.1993.tb00897.x; PARTHUN MR, 1990, J BIOL CHEM, V265, P209; RANISH JA, 1991, J BIOL CHEM, V266, P19320; RIEMEN G, 1993, MOL GEN GENET, V237, P49, DOI 10.1007/BF00282783; Sambrook J, 1989, MOL CLONING LABORATO; SCHINKEL AH, 1987, J BIOL CHEM, V262, P12785; SCHINKEL AH, 1988, EMBO J, V7, P3255, DOI 10.1002/j.1460-2075.1988.tb03192.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; ULERY TL, 1994, MOL CELL BIOL, V14, P1160, DOI 10.1128/MCB.14.2.1160; ULERY TL, 1993, COORDINATED REGULATI; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WILCOXEN SE, 1988, J BIOL CHEM, V263, P12346; WINKLEY CS, 1985, J BIOL CHEM, V260, P4214; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	45	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26568	26574						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929382				2022-12-25	WOS:A1994PQ93000095
J	KASHIWAYA, Y; SATO, K; TSUCHIYA, N; THOMAS, S; FELL, DA; VEECH, RL; PASSONNEAU, JV				KASHIWAYA, Y; SATO, K; TSUCHIYA, N; THOMAS, S; FELL, DA; VEECH, RL; PASSONNEAU, JV			CONTROL OF GLUCOSE-UTILIZATION IN WORKING PERFUSED RAT-HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUX CONTROL COEFFICIENTS; SKELETAL-MUSCLE HEXOKINASE; METABOLIC CONTROL ANALYSIS; TRICARBOXYLIC-ACID CYCLE; FRUCTOSE 2,6-BISPHOSPHATE; DICTYOSTELIUM-DISCOIDEUM; TRANSPORTER GLUT4; LIVER CELLS; GLYCOLYSIS; KINETICS	Metabolic control analyses of glucose utilization were performed for four groups of working rat hearts perfused with Krebs-Henseleit buffer containing 10 mu M glucose only, or with the addition of 4 mM D-beta-hydroxybutyrate/1 mM acetoacetate, 100 ana insulin (0.05 unit/ml), or both. Net glycogen breakdown occurred in the glucose group only and was converted to net glycogen synthesis in the presence of all additions. The flux of [2-H-3]glucose through P-glucoisomerase (EC 5.3.1.9) was reduced with ketones, elevated with insulin, and unchanged with the combination. Net glycolytic flux was reduced in the presence of ketones and the combination. The flux control coefficients were determined for the portion of the pathway involving glucose transport to the branches of glycogen synthesis and glycolysis. Major control was divided between the glucose transporter and hexokinase (EC 2.7.1.1) in the glucose group. The distribution of the control was slightly shifted to hexokinase with ketones, and control at the glucose transport step was abolished in the presence of insulin. Analysis of the pathway from 3-P-glycerate to pyruvate determined that the major control was shared by enolase (EC 4.2.1.1) and pyruvate kinase (EC 2.7.1.40) in the glucose group. Addition of ketones, insulin, or the combination shifted the control to P-glycerate mutase (EC 5.4.2.1) and pyruvate kinase. These results illustrate that the control of the metabolic flux in glucose metabolism of rat heart is not exerted by a single enzyme but variably distributed among enzymes depending upon substrate availability, hormonal stimulation, or other changes of conditions.	NIAAA, ROCKVILLE, MD 20852 USA; OXFORD BROOKES UNIV, SCH BIOL & MOLEC SCI, OXFORD OX3 0BP, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Oxford Brookes University			Fell, David A/B-2109-2009	Fell, David A/0000-0001-6669-2247				ALBE KR, 1992, J BIOL CHEM, V267, P3106; BRAND MD, 1988, BIOCHEM J, V255, P535; Brown DH., 1961, ENZYMES, V5, P207; BROWN GC, 1990, EUR J BIOCHEM, V188, P321, DOI 10.1111/j.1432-1033.1990.tb15406.x; BURNS JA, 1985, TRENDS BIOCHEM SCI, V10, P16, DOI 10.1016/0968-0004(85)90008-8; CASAZZA JP, 1986, J BIOL CHEM, V261, P690; CHEUNG JY, 1978, AM J PHYSIOL, V234, pE70, DOI 10.1152/ajpendo.1978.234.1.E70; CLARK MG, 1978, INT J BIOCHEM, V9, P17, DOI 10.1016/0020-711X(78)90131-3; CORNELL NW, 1979, J BIOL CHEM, V254, P6522; DEPRE C, 1993, J BIOL CHEM, V268, P13274; ESTABROOK RW, 1958, J BIOL CHEM, V233, P1014; FELL DA, 1985, EUR J BIOCHEM, V148, P555, DOI 10.1111/j.1432-1033.1985.tb08876.x; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; GANSON NJ, 1985, J BIOL CHEM, V260, P2099; GLIEMANN J, 1983, CURR TOP MEMBR TRANS, V18, P339; GOLDBERG RN, 1989, J BIOL CHEM, V264, P9901; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GROEN AK, 1986, BIOCHEM J, V237, P379, DOI 10.1042/bj2370379; GUYNN RW, 1974, J BIOL CHEM, V249, P3248; Haldane JBS, 1930, ENZYMES, P74; HESTRIN S, 1949, J BIOL CHEM, V179, P943; HOFMEYR JHS, 1991, EUR J BIOCHEM, V200, P223, DOI 10.1111/j.1432-1033.1991.tb21071.x; HUTTER OF, 1961, J PHYSIOL-LONDON, V157, P335, DOI 10.1113/jphysiol.1961.sp006726; KACSER H, 1981, GENETICS, V97, P639; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KAHANA SE, 1960, J BIOL CHEM, V235, P2178; Katz J, 1976, Curr Top Cell Regul, V10, P237; KIM YA, 1992, AM J PHYSIOL, V262, pE344, DOI 10.1152/ajpendo.1992.262.3.E344; KOLTER T, 1992, BIOCHEM BIOPH RES CO, V189, P1207, DOI 10.1016/0006-291X(92)92333-S; KREBS EG, 1959, J BIOL CHEM, V234, P2867; KREBS HA, 1961, BIOCHEM J, V80, P225, DOI 10.1042/bj0800225; KREBS HA, 1961, ARCH INTERN MED, V107, P51, DOI 10.1001/archinte.1961.03620010055010; KRUCKEBERG AL, 1989, BIOCHEM J, V261, P457, DOI 10.1042/bj2610457; Langendorff O., 1895, PFLUGERS ARCH, V61, P291, DOI [10.1007/BF01812150, 10.1007/bf01812150, DOI 10.1007/BF01812150]; LAWSON JWR, 1987, J BIOL CHEM, V262, P3165; LAWSON JWR, 1976, GLUCONEOGENESIS ITS, P481; LEVINE R, 1949, J BIOL CHEM, V179, P985; LOWRY OH, 1964, J BIOL CHEM, V239, P31; LOWRY OH, 1964, J BIOL CHEM, V239, P18; LUECK JD, 1974, J BIOL CHEM, V249, P1341; Lundsgaard E., 1939, UPSALA LAK FOREN FOR, V45, P143; MASUDA T, 1990, J BIOL CHEM, V265, P20321; MCQUATE JT, 1959, J BIOL CHEM, V234, P2151; Michaelis L, 1913, BIOCHEM Z, V49, P333; MILNER Y, 1964, ISRAEL J CHEM, V2, P316; MORGAN HE, 1964, J BIOL CHEM, V239, P369; NAJJAR VA, 1962, ENZYMES, V6, P161; NEELY JR, 1967, AM J PHYSIOL, V212, P804; NEELY JR, 1967, AM J PHYSIOL, V212, P815; NEELY JR, 1972, BIOCHEM J, V128, P147, DOI 10.1042/bj1280147; PAGE RA, 1991, BIOCHEM J, V278, P659, DOI 10.1042/bj2780659; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; PASSONNEAU JV, 1975, J BIOL CHEM, V250, P2287; PILKIS SJ, 1981, J BIOL CHEM, V256, P3171; PLOUG T, 1987, AM J PHYSIOL, V253, pE12, DOI 10.1152/ajpendo.1987.253.1.E12; QUANT PA, 1993, TRENDS BIOCHEM SCI, V18, P26; REGEN DM, 1984, J THEOR BIOL, V111, P635, DOI 10.1016/S0022-5193(84)80259-3; REN JM, 1993, J BIOL CHEM, V268, P16113; REN JM, 1994, J BIOL CHEM, V269, P14396; ROSE ZB, 1970, ANAL BIOCHEM, V35, P177, DOI 10.1016/0003-2697(70)90023-0; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22912; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SMALL JR, 1993, BIOCHEM J, V296, P423, DOI 10.1042/bj2960423; SOLA MM, 1993, J BIOL CHEM, V268, P19352; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; TEWARI YB, 1991, BIOPHYS CHEM, V40, P59, DOI 10.1016/0301-4622(91)85029-P; THOMAS S, 1993, BIOCHEM J, V292, P351, DOI 10.1042/bj2920351; TORRES NV, 1986, BIOCHEM J, V234, P169, DOI 10.1042/bj2340169; UYEDA K, 1981, J BIOL CHEM, V256, P8394; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P897, DOI 10.1042/bj1920897; VEECH RL, 1969, BIOCHEM J, V115, P837, DOI 10.1042/bj1150837; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VEECH RL, 1994, IN PRESS ALCOHOL CLI; VEECH RL, 1975, FRONTIERS PINEAL PHY, P177; VELOSO D, 1973, J BIOL CHEM, V248, P4811; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WESTERHOFF HV, 1992, CURR TOP CELL REGUL, V33, P361; WESTERHOFF HV, 1984, BIOSCIENCE REP, V4, P1, DOI 10.1007/BF01120819; WHEELER TJ, 1988, J BIOL CHEM, V263, P19447; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514	82	253	257	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25502	25514						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929251				2022-12-25	WOS:A1994PQ49100044
J	OLAH, Z; LEHEL, C; ANDERSON, WB; EIDEN, MV; WILSON, CA				OLAH, Z; LEHEL, C; ANDERSON, WB; EIDEN, MV; WILSON, CA			THE CELLULAR RECEPTOR FOR GIBBON APE LEUKEMIA-VIRUS IS A NOVEL HIGH-AFFINITY SODIUM-DEPENDENT PHOSPHATE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; AMINO-ACID TRANSPORTER; MURINE RETROVIRUSES; NUCLEOTIDE-SEQUENCE; NEUROSPORA-CRASSA; SURFACE RECEPTOR; GENE ENCODES; CELLS; INFECTION; SYSTEM	The primate type C retrovirus gibbon ape leukemia virus (GaLV) has been shown to use a widely expressed, multiple membrane-spanning protein of unknown function as its cell surface receptor on human cells (GLVR1) (Johann, S. V., Gibbons, J. J., and O'Hara, B. (1992) J. Virol. 66, 1635-1640; O'Hara, B., Johann, S. V., Klinger, H. P., Blair, D. G., Rubinson, H., Dunni, K. J., Sass, P., Vitek, S. M., and Robins, T. (1990) Cell Growth Diff. 1, 119-127). Here we present evidence that the receptor for GaLV (GLVR1) functions as a sodium dependent transporter of inorganic phosphate. GLVR1 is shown to have approximately 3-4-fold higher affinity for phosphate than other mammalian phosphate transporters described to date. Productive infection of GLVR1-expressing cells by GaLV, but not other retroviruses, results in the complete blockade of GLVR1-specific uptake of inorganic phosphate. Since productive infection of cells with GaLV is generally not cytotoxic, it is likely that more than one phosphate transporter exists on the cell surface. Our data suggest that GLVR1 represents a sodium-dependent phosphate transporter that differs from other mammalian phosphate transporters in structure, affinity for phosphate, and function.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; NIMH,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BIBER J, 1993, RENAL PHYSIOL BIOCH, V16, P37; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; EGLITIS MA, 1993, J VIROL, V67, P4572; ESCOUBET B, 1991, AM J PHYSIOL, V260, pF235, DOI 10.1152/ajprenal.1991.260.2.F235; JOHANN SV, 1993, J VIROL, V67, P6733, DOI 10.1128/JVI.67.11.6733-6736.1993; JOHANN SV, 1992, J VIROL, V66, P1635, DOI 10.1128/JVI.66.3.1635-1640.1992; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LIFSON JD, 1989, IMMUNOL REV, V109, P93, DOI 10.1111/j.1600-065X.1989.tb00021.x; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MANN BJ, 1989, GENE, V83, P281, DOI 10.1016/0378-1119(89)90114-5; MCLACHLIN JR, 1993, VIROLOGY, V195, P1, DOI 10.1006/viro.1993.1340; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLER AD, 1984, J VIROL, V49, P214, DOI 10.1128/JVI.49.1.214-222.1984; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; OHARA B, 1990, CELL GROWTH DIFFER, V1, P119; OLAH Z, 1993, BIOCHIM BIOPHYS ACTA, V1176, P333, DOI 10.1016/0167-4889(93)90063-U; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; REIN A, 1982, VIROLOGY, V120, P251, DOI 10.1016/0042-6822(82)90024-1; SICILIANO RF, 1988, CELL, V54, P561; SITBON M, 1990, J VIROL, V64, P2135, DOI 10.1128/JVI.64.5.2135-2140.1990; SOMMERFELT MA, 1990, VIROLOGY, V176, P58, DOI 10.1016/0042-6822(90)90230-O; TAILOR CS, 1993, J VIROL, V67, P6737, DOI 10.1128/JVI.67.11.6737-6741.1993; WANG H, 1992, J BIOL CHEM, V267, P23617; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; WILSON CA, 1994, J GEN VIROL, V75, P1901, DOI 10.1099/0022-1317-75-8-1901; WILSON CA, 1994, J VIROL METHODS, V48, P109, DOI 10.1016/0166-0934(94)90093-0	32	163	166	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25426	25431						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929240				2022-12-25	WOS:A1994PQ49100033
J	DELARIA, K; FIORENTINO, L; WALLACE, L; TAMBURINI, P; BROWNELL, E; MULLER, D				DELARIA, K; FIORENTINO, L; WALLACE, L; TAMBURINI, P; BROWNELL, E; MULLER, D			INHIBITION OF CATHEPSIN L-LIKE CYSTEINE PROTEASES BY CYTOTOXIC T-LYMPHOCYTE ANTIGEN-2-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASES; CELLS; PRECURSOR; PEPTIDES; BINDING	The protein sequence of cytotoxic T-lymphocyte antigen-2 beta (CTLA-2 beta) is 36% identical to the proregion of mouse cathepsin L (Denizot, F., Brunet, J. F., Roustan, P., Harper, K., Suzan, M., Luciani, M. F., Mattei, M. G., and Golstein, P. (1989) Eur. J. Immunol. 19, 631-635). Here we report the expression, purification, and characterization of recombinant murine CTLA-2 beta. The protein was purified by consecutive pel-filtration, anion exchange, and reverse-phase (C4) chromatography. Purified CTLA-2 beta exists in solution primarily as a dimer but also as a disulfide-linked tetramer as judged by size exclusion chromatography. Circular dichroism studies suggest that the dimeric form of the protein contains 8% alpha-helix, 67% beta-sheet, and 21% random coil and also indicates that there is a conformational change upon formation of the tetramer. The protein is a competitive inhibitor of certain cysteine proteases including papain (K-i = 25 nM), cathepsins L (K-i = 24 nM) and H (IC50 = 67 nM) but not cathepsin B. CTLA-2 beta forms a noncovalent complex with cathepsin L and has a stoichiometry of binding to papain of 1 mol. of CTLA-2 beta/mol of papain. There is no homology between CTLA-2 beta and any of the known cysteine protease inhibitors, including the kininogens and cystatins. Therefore, CTLA-2 beta represents a novel Glass of cysteine protease inhibitor that is specific for the cathepsin L family of proteases.	MILES INC,DIV PHARMACEUT,W HAVEN,CT 06516									AOYAMA A, 1990, P NATL ACAD SCI USA, V87, P8296, DOI 10.1073/pnas.87.21.8296; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; DALETFUMERON V, 1991, J CHROMATOGR-BIOMED, V568, P55, DOI 10.1016/0378-4347(91)80340-I; DENIZOT F, 1989, EUR J IMMUNOL, V19, P631, DOI 10.1002/eji.1830190409; DIXON M, 1979, ENZYMES, P365; EVIN G, 1984, P NATL ACAD SCI-BIOL, V81, P48, DOI 10.1073/pnas.81.1.48; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; FUSEK M, 1991, FEBS LETT, V287, P160, DOI 10.1016/0014-5793(91)80040-A; GABRIJELCIC D, 1992, EUR J CLIN CHEM CLIN, V30, P69; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; MACIEWICZ RA, 1991, BIOMED BIOCHIM ACTA, V50, P561; Segundo B S, 1982, Biochim Biophys Acta, V707, P74; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; VANNOORDEN CJF, 1987, ADV BIOSCI, V65, P27	19	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25172	25177						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929206				2022-12-25	WOS:A1994PQ49000096
J	EMORI, Y; SAIGO, K				EMORI, Y; SAIGO, K			CALPAIN LOCALIZATION CHANGES IN COORDINATION WITH ACTIN-RELATED CYTOSKELETAL CHANGES DURING EARLY EMBRYONIC-DEVELOPMENT OF DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASE; CA-2+-ACTIVATED NEUTRAL PROTEASE; MICROTUBULE-ASSOCIATED PROTEINS; HOMEO BOX GENES; ENDOGENOUS INHIBITOR; BINDING PROTEINS; F-ACTIN; MOLECULAR-CLONING; THIOL PROTEASE; LARGE SUBUNIT	Calpain, a calcium-dependent intracellular protease, was identified in Drosophila melanogaster. Drosophila calpain has an amino acid sequence highly homologous to those of mammalian calpains and exhibits a distinct domain structure consisting of cysteine protease and calcium-binding domains. Specific antibodies raised against a recombinant calpain fragment were used to identify the localization of calpain in developing Drosophila embryos. Calpain was first detected near the anterior pole and in posterior region of the embryo just after fertilization. The anterior calpain disappeared during the cleavage cycles. On the other hand, the posterior calpain moved to the posterior pole when polar buds were formed, and condensed just below the pole cells. At cleavage cycles 8 and 9, when nuclei reached the egg surface, calpain was localized between the nuclei at the surface beneath the precleavage furrows. Co-staining experiments with anti-actin antibody revealed that calpain condenses specifically at the edge of and between actin caps that underlie the plasma membrane immediately above each nucleus. These results indicate that calpain is involved in the dynamic changes in the embryonic cytoskeleton, especially actin-related structures, during early embryogenesis prior to cellularization.			EMORI, Y (corresponding author), UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, HONGO 7-3-1, TOKYO 113, JAPAN.							AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Dustin P., 1984, MICROTUBULES; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; EMORI Y, 1986, J BIOL CHEM, V261, P9465; EMORI Y, 1988, J BIOL CHEM, V263, P2364; EMORI Y, 1985, NATURE, V315, P773, DOI 10.1038/315773a0; ENGELS WR, 1986, FOCUS, V8, P6; FREEMAN M, 1986, CELL, V46, P457, DOI 10.1016/0092-8674(86)90666-5; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HIGASHIJIMA S, 1992, GENE DEV, V6, P1005, DOI 10.1101/gad.6.6.1005; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; IBNSOUDA S, 1993, DEVELOPMENT, V119, P471; IMAJOH S, 1988, BIOCHEMISTRY-US, V27, P8122, DOI 10.1021/bi00421a022; KARR TL, 1986, J CELL BIOL, V102, P1494, DOI 10.1083/jcb.102.4.1494; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER KG, 1985, COLD SPRING HARB SYM, V50, P79, DOI 10.1101/SQB.1985.050.01.012; MILLER KG, 1989, J CELL BIOL, V109, P2963, DOI 10.1083/jcb.109.6.2963; MINAMI Y, 1987, J BIOCHEM-TOKYO, V101, P889, DOI 10.1093/oxfordjournals.jbchem.a121956; MURACHI T, 1989, BIOCHEM INT, V18, P263; ODA A, 1993, J BIOL CHEM, V268, P12603; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; PINTER M, 1988, BIOCHEM J, V253, P467, DOI 10.1042/bj2530467; PINTER M, 1992, BIOCHEMISTRY-US, V31, P8201, DOI 10.1021/bi00150a012; POSTNER MA, 1992, J CELL BIOL, V119, P1205, DOI 10.1083/jcb.119.5.1205; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SCHEJTER ED, 1993, CELL, V75, P373, DOI 10.1016/0092-8674(93)80078-S; SCHEJTER ED, 1992, COLD SPRING HARB SYM, V57, P653, DOI 10.1101/SQB.1992.057.01.071; SCHEJTER ED, 1993, ANNU REV CELL BIOL, V9, P67, DOI 10.1146/annurev.cellbio.9.1.67; SIMPSON L, 1990, DEVELOPMENT, V110, P851; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; SULLIVAN W, 1993, DEVELOPMENT, V118, P1245; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WARN RM, 1984, J CELL BIOL, V98, P156, DOI 10.1083/jcb.98.1.156; WARN RM, 1985, J CELL BIOL, V100, P1010, DOI 10.1083/jcb.100.4.1010; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005	44	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25137	25142						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929201				2022-12-25	WOS:A1994PQ49000091
J	FERNANDEZMORENO, MA; MARTINEZ, E; CABALLERO, JL; ICHINOSE, K; HOPWOOD, DA; MALPARTIDA, F				FERNANDEZMORENO, MA; MARTINEZ, E; CABALLERO, JL; ICHINOSE, K; HOPWOOD, DA; MALPARTIDA, F			DNA-SEQUENCE AND FUNCTIONS OF THE ACTVI REGION OF THE ACTINORHODIN BIOSYNTHETIC GENE-CLUSTER OF STREPTOMYCES-COELICOLOR A3(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN ALCOHOL DEHYDROGENASES; ACID BETA-OXIDATION; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ANTIBIOTIC ACTINORHODIN; MOLECULAR-CLONING; CDNA-CLONING; CLASS-I; MULTIFUNCTIONAL ENZYME; POLYKETIDE SYNTHASE	Six open reading frames (ORFs) were identified by DNA sequencing of 5.7 kilobase pairs at the left end of the act cluster (the so-called ''actVI region''), in the order: ORFB, ORFA, ORF1, ORF2, ORF3, ORF4, ORF1-4 are transcribed rightward and in the same direction as the ORFs of the actVA region which lies to the right of the actVI region, whereas ORFA and ORFB run in the opposite direction. By complementation of mutants and gene disruption of the wild type strain, the two previously genetically characterized actVI mutations were assigned to ORF1. Although disruption of ORFB and ORF4, using phi C31 derivatives, did not cause any obvious change in actinorhodin production, defects in actinorhodin synthesis were obtained by insertional inactivation of ORFA, ORF1, ORF2, or ORF3. RNA analysis within the ORF1/ORFA intergenic region showed overlapping divergent promoters, at least one of which is under the control of the actII-ORF4 gene product, the transcriptional activator of the act cluster. Data base searches with the deduced products of ORFB and ORF3 failed to show any significant similarities with other known proteins. The deduced product of ORFA strongly resembles those of genes of unknown function from Saccharopolyspora hirsuta and Streptomyces roseofulvus, located within polyketide synthase clusters. The ORF1 product strongly resembles beta-hydroxyacyl-CoA dehydrogenases of bacteria and mammals and the ORF2 and ORF4 products resemble each other and enoyl reductases from bacteria, animals, and plants, with a highly conserved cofactor-binding domain. These findings strongly suggest that the actVI region is involved in catalyzing reduction processes that determine the two stereochemical configurations at C-3/C-15 during actinorhodin biosynthesis. A scheme is proposed for the middle steps of the biosynthesis, that is formation of the pyran ring, leading to the benzoisochromanequinone structure.	UNIV AUTONOMA MADRID,CSIC,CTR NACL BIOTECNOL,E-28049 MADRID,SPAIN; JOHN INNES INST,JOHN INNES CTR PLANT SCI RES,NORWICH NR4 7UH,NORFOLK,ENGLAND	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Fernandez-Moreno, Miguel Angel/K-4425-2017; Ichinose, Koji/GON-5032-2022; Malpartida, Francisco/D-2563-2009; Caballero, José L./L-2067-2014	Fernandez-Moreno, Miguel Angel/0000-0002-3461-0726; Ichinose, Koji/0000-0003-3734-4336; Caballero, José L./0000-0002-2678-4849				AMMENDOLA S, 1992, BIOCHEMISTRY-US, V31, P12514, DOI 10.1021/bi00164a031; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BARTEL PL, 1990, J BACTERIOL, V172, P4816, DOI 10.1128/jb.172.9.4816-4826.1990; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432-1033.1992.tb16603.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; BIBB MJ, 1986, 6TH INT S ACT BIOL, P25; BITAR KG, 1980, FEBS LETT, V116, P196, DOI 10.1016/0014-5793(80)80642-9; BROCKMAN H, 1966, LIEBIGS ANN CHEM, V698, P3575; BROWN NL, 1983, BIOCHEMISTRY-US, V22, P4089, DOI 10.1021/bi00286a015; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHATER KF, 1982, GENE, V19, P21, DOI 10.1016/0378-1119(82)90185-8; CHATER KF, 1983, GENE, V26, P67, DOI 10.1016/0378-1119(83)90037-9; COLE SP, 1987, J ANTIBIOT, V40, P340, DOI 10.7164/antibiotics.40.340; DANIELSSON O, 1992, BIOCHEMISTRY-US, V31, P3751, DOI 10.1021/bi00130a004; DENNIS ES, 1985, NUCLEIC ACIDS RES, V13, P727, DOI 10.1093/nar/13.3.727; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; ESTONIUS M, 1990, EUR J BIOCHEM, V194, P593, DOI 10.1111/j.1432-1033.1990.tb15657.x; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; FERNANDEZMORENO MA, 1991, CELL, V66, P769, DOI 10.1016/0092-8674(91)90120-N; FUJII I, 1991, BIOCHEM INT, V25, P1043; GONZALEZ P, 1993, BIOCHEM BIOPH RES CO, V191, P902, DOI 10.1006/bbrc.1993.1302; GORSTALLMAN CP, 1981, J ORG CHEM, V46, P455, DOI 10.1021/jo00315a046; GRAMAJO HC, 1993, MOL MICROBIOL, V7, P837, DOI 10.1111/j.1365-2958.1993.tb01174.x; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOOG JO, 1993, EUR J BIOCHEM, V213, P31, DOI 10.1111/j.1432-1033.1993.tb17731.x; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; ISHII N, 1987, J BIOL CHEM, V262, P8144; JANSSEN GR, 1993, GENE, V124, P133, DOI 10.1016/0378-1119(93)90774-W; JENDROSSEK D, 1988, J BACTERIOL, V170, P5248, DOI 10.1128/jb.170.11.5248-5256.1988; JORNVALL H, 1987, EUR J BIOCHEM, V167, P195, DOI 10.1111/j.1432-1033.1987.tb13323.x; KAISER R, 1990, BIOCHEMISTRY-US, V29, P8365, DOI 10.1021/bi00488a024; LEGOUILL C, 1993, MOL GEN GENET, V240, P146, DOI 10.1007/BF00276894; MALPARTIDA F, 1986, MOL GEN GENET, V205, P66, DOI 10.1007/BF02428033; MALPARTIDA F, 1984, NATURE, V309, P462, DOI 10.1038/309462a0; Maniatis T., 1982, MOL CLONING; MATHUR M, 1992, J BIOL CHEM, V267, P19388; Maxam A M, 1980, Methods Enzymol, V65, P499; MULDERS JWM, 1988, J BIOL CHEM, V263, P15462; MURRAY MG, 1986, ANAL BIOCHEM, V158, P165, DOI 10.1016/0003-2697(86)90605-6; NAKAYAMA N, 1984, J BIOL CHEM, V259, P97; OKI T, 1981, J ANTIBIOT, V34, P783, DOI 10.7164/antibiotics.34.783; PARK DH, 1991, J BIOL CHEM, V266, P13296; PERSSON B, 1993, EUR J BIOCHEM, V216, P49, DOI 10.1111/j.1432-1033.1993.tb18115.x; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; RODICIO MR, 1985, GENE, V34, P283, DOI 10.1016/0378-1119(85)90137-4; RUDD BAM, 1979, J GEN MICROBIOL, V114, P35, DOI 10.1099/00221287-114-1-35; RUSSELL PR, 1983, J BIOL CHEM, V258, P143; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO S, 1992, J BIOCHEM-TOKYO, V111, P8, DOI 10.1093/oxfordjournals.jbchem.a123722; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SHEN B, 1993, BIOCHEMISTRY-US, V32, P6656, DOI 10.1021/bi00077a019; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SNIPES CE, 1979, J AM CHEM SOC, V101, P701, DOI 10.1021/ja00497a036; STROHL WR, 1992, NUCLEIC ACIDS RES, V20, P961, DOI 10.1093/nar/20.5.961; SUMMERS RG, 1993, J BACTERIOL, V175, P7571, DOI 10.1128/JB.175.23.7571-7580.1993; TSUZUKI K, 1986, J ANTIBIOT, V39, P1343, DOI 10.7164/antibiotics.39.1343; VAN DER STRAETEN D, 1991, FEBS LETT, V295, P39, DOI 10.1016/0014-5793(91)81379-M; WEHNER EP, 1993, MOL GEN GENET, V237, P351, DOI 10.1007/BF00279438; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WRIGHT F, 1992, GENE, V113, P55, DOI 10.1016/0378-1119(92)90669-G; WRIGHT LF, 1976, J GEN MICROBIOL, V96, P289, DOI 10.1099/00221287-96-2-289; XIE Y, 1989, PLANT MOL BIOL, V13, P53, DOI 10.1007/BF00027335; YANG XYH, 1991, BIOCHEMISTRY-US, V30, P6788, DOI 10.1021/bi00241a023; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG IG, 1981, EUR J BIOCHEM, V116, P165, DOI 10.1111/j.1432-1033.1981.tb05314.x; YOUNGLESON JS, 1989, J BACTERIOL, V171, P6800, DOI 10.1128/jb.171.12.6800-6807.1989; ZHANG HL, 1990, J ORG CHEM, V55, P1682, DOI 10.1021/jo00292a053	79	85	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24854	24863						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929165				2022-12-25	WOS:A1994PQ49000052
J	LIN, JH; MCLEAN, K; MORSER, J; YOUNG, TA; WYDRO, RM; ANDREWS, WH; LIGHT, DR				LIN, JH; MCLEAN, K; MORSER, J; YOUNG, TA; WYDRO, RM; ANDREWS, WH; LIGHT, DR			MODULATION OF GLYCOSAMINOGLYCAN ADDITION IN NATURALLY EXPRESSED AND RECOMBINANT HUMAN THROMBOMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-CATALYZED ACTIVATION; HUMAN SOLUBLE THROMBOMODULIN; RABBIT THROMBOMODULIN; PROTEIN-C; COFACTOR ACTIVITY; ANTITHROMBIN-III; FACTOR-V; BINDING; SITE; IDENTIFICATION	The two major glycoforms of full-length human thrombomodulin (TM), one with (TM(CS+)) and one without (TM(CS-)) chondroitin sulfate (CS) were analyzed on Western blots of primary and transformed cells and in cells expressing recombinant TM. TM on the surface of Chinese hamster ovary and COS-7 cells is solely TM(CS-). Primary arterial endothelial cells (HAEC and HPAEC) express a greater fraction of TM with CS attached than venous cells (HUVEC). Human lung carcinoma cells (A549) express more TM(CS+) than primary cells and recombinant TM on human melanoma cells (CHL-1) occurs in two very high molecular weight forms of TM(CS+). We explored this variation in TM(CS+) with soluble recombinant TM in several cell lines and analyzed the ambiguous CS addition site in human TM by site-directed mutagenesis. Mutation of Ser(474) to Ala blocks CS addition in Chinese hamster ovary and COS-7 cells but not CHL-1 cells which add CS to Ser(472) and Ser(474). Structure of the O-link domain affects partitioning into TM(CS+) since substituting with the decorin CS addition sequence, substituting all Ser and Thr except Ser(474) with Ala, and deleting around the potential beta-turn all increase the ratio of TM(CS+) to TM(CS-). A combination of the decorin substitution and deletion of the remaining O-link domain yields the most TM(CS+).	BERLEX BIOSCI INC,DEPT PROT BIOCHEM & BIOPHYS,RICHMOND,CA 94804; BERLEX BIOSCI INC,DEPT CARDIOVASC RES,RICHMOND,CA 94804; BERLEX BIOSCI INC,DEPT MOLEC BIOL,RICHMOND,CA 94804									ARITOMI M, 1993, THROMB HAEMOSTASIS, V70, P418; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOURIN MC, 1989, THROMB RES, V54, P27; BOURIN MC, 1990, BIOCHEM J, V270, P419, DOI 10.1042/bj2700419; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BOURIN MC, 1986, P NATL ACAD SCI USA, V83, P5924, DOI 10.1073/pnas.83.16.5924; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; ENJYOJI K, 1991, J BIOCHEM-TOKYO, V109, P890, DOI 10.1093/oxfordjournals.jbchem.a123476; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON NL, 1982, J BIOL CHEM, V257, P859; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GERLITZ B, 1993, BIOCHEM J, V295, P131, DOI 10.1042/bj2950131; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; Harper J. R., 1987, BIOL PROTEOGLYCANS, P345; LIU LW, 1994, J BIOL CHEM, V269, P11807; MANN DM, 1990, J BIOL CHEM, V265, P5317; Marval E., 1992, Sangre (Saragossa), V37, P355; MORGAN AC, 1981, HYBRIDOMA, V1, P27, DOI 10.1089/hyb.1.1981.1.27; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; PARKINSON JF, 1992, BIOCHEM J, V283, P151, DOI 10.1042/bj2830151; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1992, BIOCHEM BIOPH RES CO, V185, P567, DOI 10.1016/0006-291X(92)91662-A; PARKINSON JF, 1990, BIOCHEM BIOPH RES CO, V169, P177, DOI 10.1016/0006-291X(90)91451-W; PREISSNER KT, 1987, BIOCHEMISTRY-US, V26, P2521, DOI 10.1021/bi00383a018; PREISSNER KT, 1990, J BIOL CHEM, V265, P4915; SPIRO RC, 1989, J BIOL CHEM, V264, P1779; SURUKI K, 1987, EMBO J, V6, P1891; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655; YE J, 1993, J BIOL CHEM, V268, P2373; ZUSHI M, 1991, J BIOL CHEM, V266, P19886	32	73	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25021	25030						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929188				2022-12-25	WOS:A1994PQ49000076
J	MATTSSON, JP; SCHLESINGER, PH; KEELING, DJ; TEITELBAUM, SL; STONE, DK; XIE, XS				MATTSSON, JP; SCHLESINGER, PH; KEELING, DJ; TEITELBAUM, SL; STONE, DK; XIE, XS			ISOLATION AND RECONSTITUTION OF A VACUOLAR-TYPE PROTON PUMP OF OSTEOCLAST MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE ACIDIFICATION; H+-ATPASE; TRANSLOCATING COMPLEX; SUBUNIT; BONE; INHIBITORS; ISOFORMS	A vacuolar-type proton-translocating ATPase was extracted from ruffled membranes of chicken osteoclasts with 1% polyoxyethylene 9-lauryl ether (C(12)E(9)) and was purified 13-fold by glycerol gradient centrifugation. The isolated pump appears by sodium dodecyl sulfate-polyacrylamide gel electrophoresis to have a subunit composition similar to that of the clathrin-coated vesicle proton pump, in that subunits of apparent molecular masses of 116, 71, 57, 40, 39, 33, and 17 kDa are present in the osteoclast pump preparation. In addition, the 116-, 71-, 57-, and 40-kDa components were shown to crossreact with specific antisera generated against the ho mologous subunits of the clathrin coated vesicle proton pump. The isolated osteoclast H+-ATPase was reconstituted into liposomes prepared from purified lipids (phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and cholesterol) by a cholate-dilution, freeze thaw method. Proton transport catalyzed by the reconstituted pump was inhibited by bafilomycin A(1) (10 nM) and N-ethyhnaleimide (1 mM) but was insensitive to vanadate. We propose that osteoclast-mediated bone resorption is effected by a vacuolar-type proton pump with functional and structural similarities to that isolated from clathrin-coated vesicles.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOLEC TRANSPORT,DALLAS,TX 75235; AB HASSLE,DEPT CELL BIOL,S-43183 MOLNDAL,SWEDEN; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,JEWISH HOSP ST LOUIS,DEPT PATHOL,ST LOUIS,MO 63110	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Schlesinger, Paul H/C-6049-2012	Teitelbaum, Steven/0000-0002-4054-6679	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 42370] Funding Source: Medline; NIDCR NIH HHS [DE 05413] Funding Source: Medline; NIDDK NIH HHS [DK 33627] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEKKER PJ, 1990, J BONE MINER RES, V5, P569, DOI 10.1002/jbmr.5650050606; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1990, BIOCHEM BIOPH RES CO, V171, P920, DOI 10.1016/0006-291X(90)90771-E; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BLAIR HC, 1991, AM J PHYSIOL, V260, pC1315, DOI 10.1152/ajpcell.1991.260.6.C1315; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; KANE MP, 1991, J BIOL CHEM, V267, P447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTSSON J, 1991, BIOCHIM BIOPHYS ACTA, V1146, P106; MATTSSON JP, 1991, BIOCHIM BIOPHYS ACTA, V1065, P261, DOI 10.1016/0005-2736(91)90238-4; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P261; PENG SB, 1994, J BIOL CHEM, V269, P17262; PENG SB, 1993, J BIOL CHEM, V268, P23519; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1988, KIDNEY INT, V33, P403; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; Vaes G., 1988, CLIN ORTHOP RELAT R, V231, P239; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1989, J BIOL CHEM, V264, P18870; XIE XS, 1983, J BIOL CHEM, V258, P4834; XIE XS, 1986, P NATL ACAD SCI USA, V83, P8913, DOI 10.1073/pnas.83.23.8913; XIE XS, 1988, J BIOL CHEM, V263, P9859	29	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24979	24982						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929181				2022-12-25	WOS:A1994PQ49000068
J	PRALONG, WF; SPAT, A; WOLLHEIM, CB				PRALONG, WF; SPAT, A; WOLLHEIM, CB			DYNAMIC PACING OF CELL-METABOLISM BY INTRACELLULAR CA2+ TRANSIENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; ADRENAL GLOMERULOSA CELLS; INDUCED INSULIN-SECRETION; MITOCHONDRIAL FREE CA2+; RAT HEPATOCYTES; CYTOSOLIC CA2+; FREE CALCIUM; GLUCOSE; OSCILLATIONS; ISLETS	During cell activation, Ca2+, by stimulating the NADH-producing mitochondrial dehydrogenases, triggers the generation of reducing equivalents whereby ATP production is sustained. In cell populations, [Ca2+] changes in the mitochondrial matrix were demonstrated to parallel rapidly those in the cytosol ([Ca2+](i)). There is still no indication as to whether metabolic activation follows oscillatory patterns similar to those of [Ca2+](i). Therefore, changes in NAD(P)H were monitored in single pancreatic beta-cells, adrenal glomerulosa cells, and liver cells during oscillatory [Ca2+](i) transients, Rapid NAD(P)H and [Ca2+](i) oscillations with similar frequency and sensitive both to changes in glucose concentration and to extracellular Ca2+ removal were identified in a subpopulation of pancreatic beta-cells in primary culture. Furthermore, Ca2+-dependent oscillatory NAD(P)H formation could be evoked by the pulsatile application of depolarizing [K+], demonstrating the pacing effect of increased [Ca2+](i) on beta-cell metabolism. In adrenal glomerulosa cells, angiotensin II, a physiological stimulator of aldosterone production, could be shown to elicit the oscillatory formation of mitochondrial NAD(P)H through frequency modulation of [Ca2+](i) transients. In contrast to the two former endocrine cell types, in hepatocytes, [Arg(8)]vasopressin and epinephrine caused the amplitude modulation of NAD(P)H formation. Taken together, these results provide unprecedented evidence for a cell-specific pacing of metabolism by [Ca2+](i) transients coordinated with cell activation and function.	SEMMELWEIS UNIV MED, SCH MED, DEPT PHYSIOL, H-1444 BUDAPEST, HUNGARY	Semmelweis University	PRALONG, WF (corresponding author), UNIV GENEVA, CTR MED, DEPT MED, DIV CLIN BIOCHEM, CH-1211 GENEVA, SWITZERLAND.		Spat, Andras/AAE-9981-2019					ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BALABAN RS, 1982, AM J PHYSIOL, V242, pC172, DOI 10.1152/ajpcell.1982.242.3.C172; BERGSTEN P, 1993, DIABETES, V42, P670, DOI 10.2337/diabetes.42.5.670; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; COHEN E, 1979, SCIENCE, V204, P862; CRIVELLO JF, 1982, ENDOCRINOLOGY, V111, P469, DOI 10.1210/endo-111-2-469; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GILON P, 1993, J BIOL CHEM, V268, P22265; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; KAWANISHI T, 1991, J BIOL CHEM, V266, P20062; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCCORMACK JG, 1989, BIOCHIM BIOPHYS ACTA, V973, P420, DOI 10.1016/S0005-2728(89)80384-6; MEDA P, 1984, Q J EXP PHYSIOL CMS, V69, P719; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MURPHY E, 1980, J BIOL CHEM, V255, P6600; OPARA EC, 1988, PANCREAS, V3, P484, DOI 10.1097/00006676-198808000-00019; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; PRALONG WF, 1992, P NATL ACAD SCI USA, V89, P132, DOI 10.1073/pnas.89.1.132; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; REBER BFX, 1990, BIOCHIM BIOPHYS ACTA, V1018, P190, DOI 10.1016/0005-2728(90)90246-Z; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SPAT A, 1991, EXP PHYSIOL, V76, P859, DOI 10.1113/expphysiol.1991.sp003550; THELER JM, 1992, J BIOL CHEM, V267, P18110; THORN P, 1992, PFLUG ARCH EUR J PHY, V422, P173, DOI 10.1007/BF00370417; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	34	164	166	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27310	27314						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961642				2022-12-25	WOS:A1994PV77100028
J	SZALLASI, Z; SMITH, CB; BLUMBERG, PM				SZALLASI, Z; SMITH, CB; BLUMBERG, PM			DISSOCIATION OF PHORBOL ESTERS LEADS TO IMMEDIATE REDISTRIBUTION TO THE CYTOSOL OF PROTEIN-KINASES C-ALPHA AND C-DELTA IN MOUSE KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ISOZYMES; BINDING; CELLS; ACTIVATION; MEMBRANE; GROWTH; BRAIN	We have measured the dissociation rate of phorbol 12-myristate 13-acetate (PMA), a potent tumor promoter, phorbol 12,13-dibutyrate (PDBu), a weak tumor promoter, and 12-deoxyphorbol 13-phenylacetate (dPP), an antitumor promoter, from intact mouse keratinocytes. PDBu and dPP showed a very rapid release from the cells (t(1/2) = 1 min), whereas PMA showed a slower release (t(1/2) = 9 min). Western blot analysis of the amounts of protein kinase C alpha (PKC alpha) and PHC delta in the soluble fraction and the Triton X-100-soluble particulate fraction revealed that translocation of both isozymes from the soluble to the particulate fraction was reversible when the phorbol esters were washed off. Washes of 5-15 min resulted in complete redistribution of the PKC isozymes when the cells were previously treated with 1 mu M dPP or 1 mu M PDBu for 5 min. In the case of treatment with 100 or 10 nar PMA, the redistribution required a longer time; nevertheless, the PHC isozymes returned to the soluble fraction within 60 min. Longer initial treatments with PMA dPP, and PDBu (up to 60 min) translocated PHC in a very similar, completely reversible fashion. We conclude that in this cell line phorbol esters do not induce the conversion of PHC isozymes to an integral membrane state.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Szallasi, Zoltan/0000-0001-5395-7509				ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BAZZI MD, 1988, BIOCHEM BIOPH RES CO, V152, P336, DOI 10.1016/S0006-291X(88)80719-8; DEISHER TA, 1993, BIOCHEM BIOPH RES CO, V193, P1283, DOI 10.1006/bbrc.1993.1764; DUNPHY WG, 1981, CANCER RES, V41, P2640; HA KS, 1993, J BIOL CHEM, V268, P10534; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KILEY SC, 1994, CARCINOGENESIS, V15, P319, DOI 10.1093/carcin/15.2.319; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LEE MH, 1989, J BIOL CHEM, V264, P14797; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; SCRIBNER JD, 1972, EUR J CANCER, V8, P617, DOI 10.1016/0014-2964(72)90142-9; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1993, CANCER RES, V53, P2507	22	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27159	27162						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961621				2022-12-25	WOS:A1994PV77100002
J	KAMPS, MP; WRIGHT, DD				KAMPS, MP; WRIGHT, DD			ONCOPROTEIN E2A-PBX1 IMMORTALIZES A MYELOID PROGENITOR IN PRIMARY MARROW CULTURES WITHOUT ABROGATING ITS FACTOR-DEPENDENCE	ONCOGENE			English	Article							T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; GROWTH-FACTOR-INDEPENDENCE; HOMEOBOX GENE; PRE-B; CHROMOSOMAL TRANSLOCATIONS; TRANSGENIC MICE; PROTEIN; EXPRESSION	E2A-PBX1 is a chimeric homeobox oncogene formed by the t(1;19) translocation of human pre-B cell acute lymphoblastic leukemia (ALL). Tn a previous study, we found that retroviral expression of E2A-Phx1 in the marrow of reconstituted mice induced the formation of acute myeloid leukemia (AML) in vivo. Here, we report that E2A-Pbx1 can also immortalize myeloid progenitors in vitro, and that the outgrowth of immortalized myeloblasts is evident only in the presence of the myeloid lymphokine, granulocyte-macrophage colony stimulating factor (GM-CSF). When cultured in the presence of GM-CSP, responsive myeloblasts from normal marrow exhibit concurrent proliferation and differentiation, and undergo terminal differentiation into non-mitotic neutrophils and macrophages within 4 weeks. Infection of identical cultures with a retrovirus encoding E2A-Pbx1 produces a rapid outgrowth of myeloid progenitors that express high levels of E2A-Pbx1 protein. A small fraction of myeloblasts in each population exhibited limited differentiation to neutrophils, and all populations of myeloblasts retained a strict dependence on GM-CSF for both survival and proliferation. This data suggests that the function of E2A-Pbx1 in leukemias is to strongly retard differentiation without affecting growth-factor dependence.			KAMPS, MP (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,LA JOLLA,CA 92093, USA.				NATIONAL CANCER INSTITUTE [R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [5 RO1 CA 56876-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACKWOOD EM, 1991, COLD SPRING HARB SYM, V56, P109; BLATT C, 1992, CELL GROWTH DIFFER, V3, P671; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1984, BLOOD, V63, P721; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DUBE ID, 1991, BLOOD, V78, P2996; ERICKSON P, 1992, BLOOD, V80, P1825; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MOUTHON MA, 1993, BLOOD, V81, P647; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OVAL J, 1992, LEUKEMIA, V6, P446; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; READING CL, 1993, BLOOD, V81, P3083; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VOGT M, 1986, MOL CELL BIOL, V6, P3545, DOI 10.1128/MCB.6.10.3545; VOGT M, 1987, ONCOGENE RES, V2, P49; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1	39	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3159	3166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936638				2022-12-25	WOS:A1994PM65800007
J	FALLON, RJ; DANAHER, M; SAXENA, A				FALLON, RJ; DANAHER, M; SAXENA, A			THE ASIALOGLYCOPROTEIN RECEPTOR IS ASSOCIATED WITH A TYROSINE KINASE IN HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOCYTOSIS; PURIFICATION; SEQUENCE	The asialoglycoprotein (ASGP) receptor undergoes constitutive endocytosis in HepG2 cells, which is regulated by tyrosine kinase activity (Fallen, R. J., Danaher, M., Saylors, R. L., and Saxena, A (1994) J. Biol. Chem. 269, 11011-11017). In this study we show that the receptor copurifies with a tyrosine kinase activity, as defined by tyrosine phosphorylation of an exogenous substrate (reduced carboxyamidomethylated and maleylated lysozyme). Analysis of cells transfected with one subunit of the ASGP receptor showed that signals in the cytoplasmic domain of the H1 subunit are sufficient for receptor kinase association. In addition, receptor kinase association is not dependent on the single cytoplasmic tyrosine at position 5. Analysis of the components of anti-ASGP receptor immunoprecipitates revealed the presence of a 127-kDa protein (p127), which becomes phosphorylated on tyrosine upon addition of gamma-[P-32]ATP and which is capable of binding ATP. p127 was also demonstrated in anti-transferrin receptor immunoprecipitates but not in immunoprecipitates of a resident membrane protein, human HLA. In conclusion, these data demonstrate that the ASGP receptor, a protein that participates in constitutive, rapid endocytosis, is associated with a cellular tyrosine kinase.	CARDINAL GLENNON MEM HOSP CHILDREN, PEDIAT RES INST, ST LOUIS, MO 63110 USA		FALLON, RJ (corresponding author), ST LOUIS UNIV, SCH MED, DEPT PEDIAT, 1465 S GRAND BLVD, ST LOUIS, MO 63104 USA.				NIDDK NIH HHS [DK42081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042081] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; EISEMAN E, 1992, NATURE, V355, P78; FALLON RJ, 1994, J BIOL CHEM, V269, P11011; FALLON RJ, 1990, J BIOL CHEM, V265, P3401; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P96; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; SMYTHE E, 1992, METHOD ENZYMOL, V219, P223; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; SPIESS M, 1985, J BIOL CHEM, V260, P1979; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILEY HS, 1991, J BIOL CHEM, V263, P13159	19	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26626	26629						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929394				2022-12-25	WOS:A1994PQ93100010
J	MALCOLM, KC; ROSS, AH; QIU, RG; SYMONS, M; EXTON, JH				MALCOLM, KC; ROSS, AH; QIU, RG; SYMONS, M; EXTON, JH			ACTIVATION OF RAT-LIVER PHOSPHOLIPASE-D BY THE SMALL GTP-BINDING PROTEIN RHOA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADP-RIBOSYLATION; REGULATORY PROTEIN; NADPH OXIDASE; TOXIN; MECHANISM; GDI; PHOSPHATIDYLCHOLINE; ACCUMULATION; PURIFICATION; HYDROLYSIS	Stimulation of phospholipase D by guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) in rat liver plasma membranes indicates the involvement of GTP-binding proteins. We used RhoGDI, an inhibitor of GDP dissociation from small GTP-binding proteins of the Rho family, to determine the involvement of these proteins. Incuba tion, and subsequent washing, of plasma membranes with RhoGDI dose-dependently diminished GTP gamma S-stimulated phospholipase D activity, as determined by accumulation of phosphatidylethanol in the presence of ethanol. Incubation with RhoGDI also caused a rapid and dose dependent appearance of RhoA in the wash, which was associated with the inhibition of phospholipase D. RhoGDI also rapidly extracted Cdc42 from membranes, but Rad was not extracted. Full reconstitution of GTP gamma S-stimulated phospholipase D in RhoGDI-washed membranes was achieved with recombinant RhoA. There was partial reconstitution with Rac1 and no enhancement with Cdc42 or ADP-ribosylation factor. The response to RhoA was dose-dependent (EC(50) = 0.5 mu M). ADP-ribosylation of RhoA by Clostridium botulinum C3 exoenzyme did not affect its ability to recover GTP gamma S-stimulated phospholipase D activity in RhoGDI-washed membranes. These findings support a role for GTP-binding proteins of the Rho family in the activation of membrane-associated phospholipase D and implicate RhoA as the major protein involved.	VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; ONYX PHARMACEUT,RICHMOND,CA 94806	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University				Malcolm, Kenneth/0000-0002-8097-6059				BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1988, J BIOL CHEM, V263, P16744; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GUSTAVSSON L, 1994, J BIOL CHEM, V269, P849; HART MJ, 1994, J BIOL CHEM, V269, P62; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; KANAHO Y, 1991, FEBS LETT, V279, P249, DOI 10.1016/0014-5793(91)80160-5; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MORII N, 1991, J BIOL CHEM, V266, P7646; MORII N, 1992, J BIOL CHEM, V267, P20921; MOSS J, 1993, CELL SIGNAL, V5, P367, DOI 10.1016/0898-6568(93)90076-X; OLSEN SC, 1991, J BIOL CHEM, V266, P17236; PRPIC V, 1984, J BIOL CHEM, V259, P1382; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SONG JG, 1993, BIOCHEM J, V294, P711, DOI 10.1042/bj2940711; SUGIYAMA T, 1994, BIOCHEM J, V298, P479, DOI 10.1042/bj2980479; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	40	270	271	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25951	25954						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929302				2022-12-25	WOS:A1994PQ93000003
J	NASTRI, HG; KNIGHT, KL				NASTRI, HG; KNIGHT, KL			IDENTIFICATION OF RESIDUES IN THE L1 REGION OF THE RECA PROTEIN WHICH ARE IMPORTANT TO RECOMBINATION OR COPROTEASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; SINGLE-STRANDED-DNA; NUCLEOSIDE TRIPHOSPHATE; LEXA CLEAVAGE; MUTAGENESIS; REPRESSOR; MUTANTS; REPAIR; ACTIVATION; INDUCTION	Using a combinatorial cassette mutagenesis procedure we have introduced a large number of single and multiple amino acid substitutions into an area of the RecA protein defined by residues 152-159. This sequence overlaps the disordered loop 1 region (L1) in the RecA crystal structure which has been hypothesized to be involved in DNA binding. Assays for recombinational DNA repair and LexA coprotease activities identify Glu(154) as the only one of these 8 residues which is critical to RecA function. Several other mutations observed at nearby residues support the identity of Glu(154) as the most important of the 14 residues in the area defined by Pro(151) to, Met(164). In addition, Gly(157) and Glu(158) appear to be hot spots for the occurrence of mutation-induced constitutive coprotease activity.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044772] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 44772] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BRYANT FR, 1988, J BIOL CHEM, V263, P8716; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; COX MM, 1991, MOL MICROBIOL, V5, P1295, DOI 10.1111/j.1365-2958.1991.tb00775.x; EGELMAN EH, 1989, SCIENCE, V245, P404, DOI 10.1126/science.2667137; ENNIS DG, 1993, J BACTERIOL, V175, P7373, DOI 10.1128/JB.175.22.7373-7382.1993; FREITAG NE, 1991, J BIOL CHEM, V266, P7058; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; KNIGHT KL, 1988, BIOCHEMISTRY-US, V27, P2088, DOI 10.1021/bi00406a041; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P538; LAVERY PE, 1992, J BIOL CHEM, V267, P20648; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LEVINSON A, 1984, Journal of Molecular and Applied Genetics, V2, P507; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LITTLE JW, 1993, J BACTERIOL, V175, P4943, DOI 10.1128/JB.175.16.4943-4950.1993; LIU SK, 1993, J BACTERIOL, V175, P6518, DOI 10.1128/jb.175.20.6518-6529.1993; LOGAN KM, 1993, J MOL BIOL, V232, P1048, DOI 10.1006/jmbi.1993.1459; MCENTEE K, 1981, P NATL ACAD SCI-BIOL, V78, P6061, DOI 10.1073/pnas.78.10.6061; MEAH YS, 1993, J BIOL CHEM, V268, P23991; Miller J.H., 1992, SHORT COURSE BACTERI, P150; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; PETERSON KR, 1988, J BACTERIOL, V170, P1; PHIZICKY EM, 1981, CELL, V25, P259, DOI 10.1016/0092-8674(81)90251-8; QUILLARDET P, 1982, MOL GEN GENET, V188, P37, DOI 10.1007/BF00332993; REIDHAAROLSON JF, 1991, METHOD ENZYMOL, V208, P564; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Sambrook J, 1989, MOL CLONING LABORATO; SKIBA MC, 1994, J BIOL CHEM, V269, P3823; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TESSMAN ES, 1985, J BACTERIOL, V163, P677, DOI 10.1128/JB.163.2.677-687.1985; TESSMAN ES, 1985, J BACTERIOL, V163, P688, DOI 10.1128/JB.163.2.688-695.1985; WANG TCV, 1986, J BACTERIOL, V168, P940, DOI 10.1128/jb.168.2.940-946.1986; WANG WB, 1988, J BACTERIOL, V170, P4823, DOI 10.1128/jb.170.10.4823-4827.1988; WANG WB, 1986, J BACTERIOL, V168, P901, DOI 10.1128/jb.168.2.901-910.1986; WANG WB, 1988, J BACTERIOL, V170, P4816, DOI 10.1128/jb.170.10.4816-4822.1988; WEISEMANN JM, 1988, DNA-J MOLEC CELL BIO, V7, P389, DOI 10.1089/dna.1.1988.7.389; YU X, 1993, J MOL BIOL, V231, P29, DOI 10.1006/jmbi.1993.1254; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	41	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26311	26322						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929348				2022-12-25	WOS:A1994PQ93000058
J	SIVAKUMAR, B; JAHOOR, F; BURRIN, DG; FRAZER, EM; REEDS, PJ				SIVAKUMAR, B; JAHOOR, F; BURRIN, DG; FRAZER, EM; REEDS, PJ			FRACTIONAL SYNTHESIS RATES OF RETINOL-BINDING PROTEIN, TRANSTHYRETIN, AND A NEW PEPTIDE MEASURED BY STABLE-ISOTOPE TECHNIQUES IN NEONATAL PIGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL MEMBRANE-RECEPTOR; LIVER PARENCHYMAL-CELLS; VITAMIN-A; CALORIE MALNUTRITION; PREALBUMIN CONCENTRATIONS; PLASMA; METABOLISM; COMPLEX; TRANSPORT; TURNOVER	Our objective was to develop a stable isotopic method to measure the synthesis rates of retinol-binding protein (RBP) and transthyretin (TTR). Both proteins were isolated from human and pig plasma by sequential immunoprecipitation and purified by SDS-polyacrylamide gel electrophoresis under denaturing conditions. Both human and pig anti RBP precipitates contained a peptide (TTR2) that had a molecular mass that was similar but not identical to that of TTR subunit. The N-terminal amino acid sequence of porcine TTR2 was highly but not completely homologous with porcine TTR. Human TTR2 showed no homology with TTR but was completely ho mologous with an internal sequence of human fibrinogen alpha chain. To measure the fractional rates of synthesis (FRS) of these peptides, six infant pigs were infused with [H-2(3)]leucine at a constant rate for 6 h, and the amount of [H-2(3)]leucine incorporated into the proteins was measured by negative chemical ionization gas chromatography-mass spectrometry. The plateau isotope ratio of plasma very low density lipoprotein apoB-100-bound leucine was used to estimate the isotopic enrichment of hepatic protein synthetic precursor pool. The mean FRS (% h +/- S.E.) of TTR (1.97 +/- 0.13) and RBP (3.89 +/- 0.07) were significantly different. The FRS of TTR2 was low (0.31 +/- 0.19) relative to that of RBP and TTR. Thus, three different peptides with different turnover rates seem to be involved in the transport of retinol.			SIVAKUMAR, B (corresponding author), BAYLOR COLL MED,DEPT PEDIAT,USDA ARS,CHILDRENS NUTR RES CTR,1100 BATES ST,HOUSTON,TX 77030, USA.		Burrin, Douglas/AID-0081-2022	Burrin, Douglas/0000-0002-8792-3339				BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BAVIK CO, 1993, J BIOL CHEM, V268, P20540; CLAWITTER J, 1990, J BIOL CHEM, V265, P3248; COSTA PMP, 1993, SCAND J IMMUNOL, V38, P177, DOI 10.1111/j.1365-3083.1993.tb01710.x; FARER LS, 1962, ENDOCRINOLOGY, V70, P686, DOI 10.1210/endo-70-5-686; FURLAN M, 1988, FIBRINOEN FIBRIN STA, P18; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HUANG CC, 1972, J COMP BIOCH PHYSL B, V42, P57; INGENBLEEK Y, 1975, METABOLISM, V24, P633, DOI 10.1016/0026-0495(75)90143-2; JAHOOR F, 1994, AM J PHYSIOL, V267, pR221, DOI 10.1152/ajpregu.1994.267.1.R221; LARGE S, 1980, BRIT J NUTR, V43, P393, DOI 10.1079/BJN19800107; MALABA L, 1993, BIOCHEM J, V291, P187, DOI 10.1042/bj2910187; MOTIL KJ, 1989, J APPL PHYSIOL, V66, P370, DOI 10.1152/jappl.1989.66.1.370; MUTO Y, 1972, J BIOL CHEM, V247, P2542; MUTO Y, 1973, J LIPID RES, V14, P525; MUTO Y, 1972, J BIOL CHEM, V247, P2533; ONG DE, 1979, J BIOL CHEM, V254, P8733; PATTERSON BW, 1991, J LIPID RES, V32, P1063; Peterson P A, 1974, Vitam Horm, V32, P181; PETERSON PA, 1971, EUR J CLIN INVEST, V1, P437, DOI 10.1111/j.1365-2362.1971.tb00555.x; REEDS PJ, 1992, J NUTR, V122, P457; SCHIREIBER G, 1993, COMP BIOCH PHYSL B, V105, P317; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SMITH FR, 1973, AM J CLIN NUTR, V26, P982, DOI 10.1093/ajcn/26.9.982; SMITH FR, 1975, AM J CLIN NUTR, V28, P732, DOI 10.1093/ajcn/28.7.732; SZIALAGYI AK, 1993, ELECTROPHORESIS, V14, P1079; VAHLQUIS.A, 1973, J BIOL CHEM, V248, P4040; VAHLQUIS.A, 1973, EUR J CLIN INVEST, V3, P352, DOI 10.1111/j.1365-2362.1973.tb00362.x; VAHLQUIST A, 1972, SCAND J CLIN LAB INV, V30, P349, DOI 10.3109/00365517209080270; VANBENNEKUM AM, 1993, BIOCHEMISTRY-US, V32, P1727, DOI 10.1021/bi00058a005	30	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26196	26200						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929333				2022-12-25	WOS:A1994PQ93000041
J	ZHUO, SQ; CLEMENS, JC; STONE, RL; DIXON, JE				ZHUO, SQ; CLEMENS, JC; STONE, RL; DIXON, JE			MUTATIONAL ANALYSIS OF A SER/THR PHOSPHATASE - IDENTIFICATION OF RESIDUES IMPORTANT IN PHOSPHOESTERASE SUBSTRATE-BINDING AND CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ESCHERICHIA-COLI K-12; NUCLEOTIDE-SEQUENCE; GENE; EXPRESSION; 5'-NUCLEOTIDASE; SUBUNIT; CLONING; ENZYME; BACTERIOPHAGE-T4	The Ser/Thr phosphoprotein phosphatases (PPases) display similarities in amino acid sequence and biochemical properties. Most members of this family require transition metal ions for activity. The smallest family member, the bacteriophage lambda PPase (lambda-PPase), has been successfully overexpressed in Escherichia coli, purified, and characterized (Zhuo, S., Clemens, J. C., Hakes, D. J., Barford, D., and Dixon, J. E. (1993) J. Biol. Chem. 268, 17754-17761). Site-directed mutagenesis has now been employed to define amino acid residues in lambda-PPase required for metal ion binding and catalysis. Conservative amino acid substitutions at residues Asp(20), His(22), ASp(49), His(76), and Glu(77) affected lambda-PPase catalysis and metal ion binding, whereas substitutions at residues Arg(53) and Arg(73) affected catalysis and substrate binding. Each of these residues is invariant in all phosphoprotein phosphatases, suggesting that these residues may play important roles in binding and catalysis in all of the PPases. Computer-assisted sequence alignment further revealed that lambda-PPase residues Asp(20), His(22), Asp(49), His(76), Arg(53), and Arg(73) lie within three larger regions of PPase sequence identity with the consensus sequence (DXH-(similar to 25)-GDXXD-(similar to 25)-GNHD/E). This motif can be found in a wide variety of phosphoesterases unrelated to the PPases and defines structural and catalytic features utilized by a diverse group of enzymes for the hydrolysis of phosphate esters.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; WALTHER CANC INST,INDIANAPOLIS,IN 46208	University of Michigan System; University of Michigan; Walther Cancer Institute					NIDDK NIH HHS [NIDDKD 18024] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018024, R01DK018024] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLOU LM, 1986, ENZYMES, V17; BARKER HM, 1990, GENOMICS, V7, P159, DOI 10.1016/0888-7543(90)90536-4; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BLANCHINROLAND S, 1986, MOL GEN GENET, V205, P515, DOI 10.1007/BF00338091; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; BURNS DM, 1986, NUCLEIC ACIDS RES, V14, P4325, DOI 10.1093/nar/14.10.4325; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; Cohen P, 1978, Curr Top Cell Regul, V14, P117; COHEN PTW, 1988, GENE, V69, P131, DOI 10.1016/0378-1119(88)90385-X; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; Dixon N. E., 1983, ZINC ENZYMES; Eadie GS, 1942, J BIOL CHEM, V146, P85; GOOSEN N, 1989, J BACTERIOL, V171, P447, DOI 10.1128/jb.171.1.447-455.1989; GRAM H, 1985, EMBO J, V4, P257, DOI 10.1002/j.1460-2075.1985.tb02344.x; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KOOISTRA J, 1991, J BACTERIOL, V173, P3644, DOI 10.1128/JB.173.12.3644-3655.1991; KOONIN EV, 1994, PROTEIN SCI, V3, P356; KREBS EG, 1986, ENZYMES, V17; KUMANO M, 1986, MOL GEN GENET, V202, P173, DOI 10.1007/BF00331633; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1986, J BACTERIOL, V165, P1002, DOI 10.1128/jb.165.3.1002-1010.1986; MISUMI Y, 1990, EUR J BIOCHEM, V191, P563, DOI 10.1111/j.1432-1033.1990.tb19158.x; NAOM IS, 1989, NUCLEIC ACIDS RES, V17, P8033, DOI 10.1093/nar/17.20.8033; OCHIAI EI, 1987, GENERAL PRINCIPLES B; POSAS F, 1992, J BIOL CHEM, V267, P11734; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAMAO Y, 1991, J BIOCHEM-TOKYO, V109, P24, DOI 10.1093/oxfordjournals.jbchem.a123345; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; ZHUO S, 1993, J BIOL CHEM, V268, P17754; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	41	150	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26234	26238						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929339				2022-12-25	WOS:A1994PQ93000047
J	DIKOV, MM; SPRINGMAN, EB; YEOLA, S; SERAFIN, WE				DIKOV, MM; SPRINGMAN, EB; YEOLA, S; SERAFIN, WE			PROCESSING OF PROCARBOXYPEPTIDASE-A AND OTHER ZYMOGENS IN MURINE MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-I; TOXIC LYMPHOCYTES-T; NATURAL-KILLER-CELLS; LEUCINE METHYL-ESTER; SERINE-PROTEASE; MOLECULAR-CLONING; CARBOXYPEPTIDASE-A; CYTOTOXIC LYMPHOCYTES; SECRETORY GRANULES; CATHEPSIN-G	By cDNA sequence analyses the proteases found within the secretory granules of immune/inflammatory cells appear to be translated initially as zymogens, but by amino-terminal sequencing they are stored within the granules in an active form. We now show that murine mast cell carboxypeptidase A (MC-CPA) is produced in a zymogen form (MC-pro-CPA) that is present at similar to 0.5% of the level of MC-CPA. MC-pro-CPA is an inactive precursor of MC-CPA and is located within the secretory granules of the mast cells. We have identified one mast cell line, KiSV-MC9, that produces MC-pro-CPA yet cannot process it to the active form despite the fact that these cells can process prochymase and protryptase to their active forms, indicating that a separate mechanism exists for activation of the serine proteases. We show that dipeptidylpeptidase-I is involved in the processing of murine mast cell prochymase and procathepsin G, but does not process MC-pro-CPA or protryptase. Thus, mast cell carboxypeptidase, tryptase, and chymase zymogens are each processed to their active forms by different mechanisms.	VANDERBILT UNIV,SCH MED,DEPT MED,DIV ALLERGY,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,DIV CLIN PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, T32GM007569] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31273] Funding Source: Medline; NIGMS NIH HHS [GM15431, GM07569] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMADOR E, 1963, CLIN CHEM, V9, P391; ANGLIKER H, 1989, BIOCHEM J, V262, P63, DOI 10.1042/bj2620063; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P561; BROWN GR, 1993, J IMMUNOL, V150, P4733; CAUGHEY GH, 1990, BIOCHEMISTRY-US, V29, P5166, DOI 10.1021/bi00473a024; CAUGHEY GH, 1990, NEUTRAL PROTEASES MA, P67; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COLE KR, 1991, BIOCHEMISTRY-US, V30, P648, DOI 10.1021/bi00217a009; DEYOUNG MB, 1987, ARCH BIOCHEM BIOPHYS, V254, P222, DOI 10.1016/0003-9861(87)90098-1; EVERITT MT, 1980, FEBS LETT, V110, P292, DOI 10.1016/0014-5793(80)80095-0; GERSHENFELD HK, 1986, SCIENCE, V232, P854, DOI 10.1126/science.2422755; GOLDSTEIN SM, 1987, J IMMUNOL, V139, P2724; GOLDSTEIN SM, 1989, J CLIN INVEST, V83, P1630, DOI 10.1172/JCI114061; GREEN GDJ, 1981, J BIOL CHEM, V256, P1923; GUASCH A, 1992, J MOL BIOL, V224, P141, DOI 10.1016/0022-2836(92)90581-4; HADDAD P, 1990, GENE, V87, P265, DOI 10.1016/0378-1119(90)90311-E; HAMMEL I, 1993, VIRCHOWS ARCH B, V64, P83, DOI 10.1007/BF02915099; HENKART PA, 1987, J IMMUNOL, V139, P2398; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; JENNE D, 1988, P NATL ACAD SCI USA, V85, P4814, DOI 10.1073/pnas.85.13.4814; JENNE D, 1988, J IMMUNOL, V140, P318; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; JENNE DE, 1989, BIOCHEMISTRY-US, V28, P7953, DOI 10.1021/bi00445a060; JOHNSON RG, 1990, FEBS LETT, V120, P75; KAMADA MM, 1989, J IMMUNOL, V142, P609; KINOSHITA A, 1991, J BIOL CHEM, V266, P19192; KRAHENBUHL O, 1988, J IMMUNOL, V141, P3471; KURIBAYASHI M, 1993, J BIOCHEM-TOKYO, V113, P441, DOI 10.1093/oxfordjournals.jbchem.a124064; LAGUNOFF D, 1983, EXP CELL RES, V144, P353, DOI 10.1016/0014-4827(83)90414-7; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P2266; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; MALLORY PA, 1975, BIOCHEMISTRY-US, V14, P722, DOI 10.1021/bi00675a012; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCGUIRE MJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P280, DOI 10.1016/0003-9861(92)90519-3; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MEIER M, 1990, BIOCHEMISTRY-US, V29, P4042, DOI 10.1021/bi00469a003; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1988, J BIOL CHEM, V263, P12783; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; REYNOLDS DS, 1993, ROLE MAST CELL HLTH, P247; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARID J, 1989, J BIOL CHEM, V264, P1022; SAYERS TJ, 1994, J IMMUNOL, V152, P2289; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER NM, 1988, ARCH BIOCHEM BIOPHYS, V262, P232, DOI 10.1016/0003-9861(88)90185-3; SCHECHTER NM, 1986, J IMMUNOL, V137, P962; SCHECHTER NM, 1990, J IMMUNOL, V145, P2652; SCHWARTZ LB, 1982, J IMMUNOL, V128, P1128; SCHWARTZ LB, 1990, NEUTRAL PROTEASES MA, P90; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1991, P NATL ACAD SCI USA, V88, P5984, DOI 10.1073/pnas.88.14.5984; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; SERAFIN WE, 1993, J ALLERGY CLIN IMMUN, V91, P255; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMYTH MJ, 1992, J BIOL CHEM, V267, P24418; SMYTH MJ, 1993, J IMMUNOL, V151, P6195; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; SPRINGMAN EB, 1994, BIOL MAST CELL PROTE; TCHEKNEVA E, 1994, J IMMUNOL, V152, P5912; THIELE DL, 1990, J EXP MED, V172, P183, DOI 10.1084/jem.172.1.183; THIELE DL, 1990, P NATL ACAD SCI USA, V87, P83, DOI 10.1073/pnas.87.1.83; URATA H, 1990, J BIOL CHEM, V265, P22348; URATA H, 1993, J BIOL CHEM, V268, P24318; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; VENSEL WH, 1971, BIOCHIM BIOPHYS ACTA, V250, P395, DOI 10.1016/0005-2744(71)90196-3; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; ZUNINO SJ, 1990, J IMMUNOL, V144, P2001	86	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25897	25904						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929294				2022-12-25	WOS:A1994PQ49100096
J	MOSSIER, B; TOGEL, M; FUCHS, K; SIEGHART, W				MOSSIER, B; TOGEL, M; FUCHS, K; SIEGHART, W			IMMUNOAFFINITY PURIFICATION OF GAMMA-AMINOBUTYRIC ACID(A) (GABA(A)) RECEPTORS CONTAINING GAMMA(1)-SUBUNITS - EVIDENCE FOR THE PRESENCE OF A SINGLE TYPE OF GAMMA-SUBUNIT IN GABA(A) RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BENZODIAZEPINE RECEPTORS; RAT-BRAIN; ALPHA-SUBUNIT; MESSENGER-RNAS; EXISTENCE; HETEROGENEITY; PHARMACOLOGY; POPULATIONS	Two polyclonal antibodies were raised against the gamma 1-subunit of gamma-aminobutyric acid(A) (GABA(A)) receptors. One of these antibodies could be used for the immunopurification of GABA(A) receptors containing gamma(1)-subunits. These receptors exhibited [H-3]muscimol and [H-3]flunitrazepam binding, and their benzodiazepine binding properties were dramatically different from those of receptors precipitated by anti-gamma(2)- or anti-gamma(3)-antibodies. Western blot analysis of the immunopurified GABA(A) receptors indicated that the gamma(1)-subunit exhibits an apparent molecular mass of 45-51 kDa. Furthermore, in addition to gamma(1)-subunits, beta(2/3)-, alpha(1)-, alpha(2)-, alpha(3)- and alpha(5)-subunits could be detected in immunoaffinity column eluates from total brain. In contrast, gamma(2)- or gamma(3)-subunits could not be identified in GABA(A) receptors immunopurified by anti-gamma(1)-antibodies. Similarly, gamma(1)- and gamma(3)-subunits or gamma(1)- and gamma(2)-subunits could not be identified in GABA(A) receptors purified by anti-gamma(2)- or anti-gamma(3)-antibodies, respectively. These data seem to indicate that GABA(A) receptors contain only a single type of gamma-subunit.	UNIV VIENNA,PSYCHIAT CLIN,DEPT BIOCHEM PSYCHIAT,A-1090 VIENNA,AUSTRIA	University of Vienna			Sieghart, Werner/A-4877-2013	Sieghart, Werner/0000-0002-0443-0302				BENKE D, 1991, J BIOL CHEM, V266, P4478; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DREXLER G, 1986, J IMMUNOL METHODS, V95, P117, DOI 10.1016/0022-1759(86)90325-X; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; FUCHS K, 1989, NEUROSCI LETT, V97, P329, DOI 10.1016/0304-3940(89)90619-8; KHAN ZU, 1993, J NEUROCHEM, V60, P961, DOI 10.1111/j.1471-4159.1993.tb03243.x; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; MERTENS S, 1993, J BIOL CHEM, V268, P5965; NAYEEM N, 1994, J NEUROCHEM, V62, P815; POLLARD S, 1993, J BIOL CHEM, V268, P3753; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; Sambrook J, 1989, MOL CLONING LABORATO; SIEGHART W, 1992, TRENDS PHARMACOL SCI, V13, P446, DOI 10.1016/0165-6147(92)90142-S; SIEGHART W, 1993, J NEUROCHEM, V60, P93, DOI 10.1111/j.1471-4159.1993.tb05826.x; SIEGHART W, 1992, CELL SIGNAL, V4, P231, DOI 10.1016/0898-6568(92)90062-D; Silviotti L, 1991, PROG NEUROBIOL, V36, P35; TOGEL M, 1994, J BIOL CHEM, V269, P12993; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WISDEN W, 1992, J NEUROSCI, V12, P1040; YMER S, 1990, EMBO J, V9, P3261, DOI 10.1002/j.1460-2075.1990.tb07525.x; ZEZULA J, 1991, FEBS LETT, V284, P15, DOI 10.1016/0014-5793(91)80750-W	23	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25777	25782						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929282				2022-12-25	WOS:A1994PQ49100081
J	MUDGETT, MB; CLARKE, S				MUDGETT, MB; CLARKE, S			HORMONAL AND ENVIRONMENTAL RESPONSIVENESS OF A DEVELOPMENTALLY-REGULATED PROTEIN REPAIR L-ISOASPARTYL METHYLTRANSFERASE IN WHEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID; ASPARTYL RESIDUES; CARBOXYL METHYLTRANSFERASE; SPONTANEOUS DEGRADATION; GENE-EXPRESSION; SUBCELLULAR-DISTRIBUTION; ASPARAGINYL RESIDUES; OSMOTIC-STRESS; MESSENGER-RNAS; EM POLYPEPTIDE	The L-isoaspartyl protein methyltransferase (EC 2.1.1.77) has been proposed to be involved in the repair of spontaneously damaged proteins by facilitating the conversion of abnormal L-isoaspartyl residues to normal L-aspartyl residues. Based on the abundance of this enzyme in the seeds of a variety of plants and its unique substrate specificity, it has been hypothesized that it functions to prevent the accumulation of abnormal aspartyl residues in the proteins of aging seeds that can limit the viability of the embryo or its chances for germination. In this work, we show that the expression of the L-isoaspartyl methyltransferase is under developmental regulation in the winter wheat, Triticum aestivum. Methyltransferase mRNA and active enzyme are first detected in seeds during the late stages (III-IV) of caryopsis development. As mature seeds germinate, methyltransferase mRNA levels decline and are nearly undetectable by 72 h post-imbibition. Enzyme activity remains constant for 24 h post-imbibition and then decreases rapidly following the reduction of its corresponding mRNA. Methyltransferase activity is very low or undetectable in wheat seedlings, including leaf and root tissues. We show, however, that the L-isoaspartyl methyltransferase can be induced in vegetative tissues in response to hormone treatment and environmental stress. Abscisic acid, a phytohormone involved in seed development and desiccation tolerance, induces both methyltransferase mRNA and enzyme activity in 4-day-old wheat seedlings. Dehydration and salt stress also induce its transcription and enzymatic activity in seedlings. The ability of a plant to regulate methyltransferase activity in its seeds and vegetative tissues in response to desiccation, aging, and environmental stress may allow the plant to efficiently repair protein damage associated with these physiological changes.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	MUDGETT, MB (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90024, USA.				NIGMS NIH HHS [GM 26020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JW, 1967, PHYTOCHEMISTRY, V6, P1047, DOI 10.1016/S0031-9422(00)86061-6; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; BARTEN DM, 1990, LIFE SCI, V47, P181, DOI 10.1016/0024-3205(90)90319-M; BERGE SK, 1989, MOL BASIS PLANT DEV, P193; BLACK M, 1991, ABSCISIC ACID PHYSL, P99; BOSTOCK RM, 1992, PLANT PHYSIOL, V98, P1356, DOI 10.1104/pp.98.4.1356; Bray E. A, 1991, ABSCISIC ACID PHYSL, P81; BRENNAN TV, 1993, PROTEIN SCI, V2, P331; Chandler P. M., 1988, J CELL BIOCHEM     S, V12, P143; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; COHEN A, 1990, PLANTA, V182, P27, DOI 10.1007/BF00239979; CUMING AC, 1984, EUR J BIOCHEM, V145, P351, DOI 10.1111/j.1432-1033.1984.tb08561.x; DILIBERTO EJ, 1976, J NEUROCHEM, V26, P1159, DOI 10.1111/j.1471-4159.1976.tb07001.x; DURE L, 1989, PLANT MOL BIOL, V12, P475, DOI 10.1007/BF00036962; Dure L. III, 1993, Control of plant gene expression., P325; GALAU GA, 1986, PLANT MOL BIOL, V7, P155, DOI 10.1007/BF00021327; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GALUS A, 1994, ARCH BIOCHEM BIOPHYS, V312, P524, DOI 10.1006/abbi.1994.1341; GEIGER T, 1987, J BIOL CHEM, V262, P785; GEORGENASCIMENTO C, 1990, BIOCHEMISTRY-US, V29, P9584, DOI 10.1021/bi00493a012; GOLDBERG RB, 1989, CELL, V56, P149, DOI 10.1016/0092-8674(89)90888-X; GOMEZ J, 1988, NATURE, V334, P262, DOI 10.1038/334262a0; GRZELCZAK ZF, 1982, CAN J BIOCHEM CELL B, V60, P389, DOI 10.1139/o82-046; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; GUILTINAN MJ, 1990, SCIENCE, V250, P20131; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; LADINO CA, 1992, J CELL PHYSIOL, V153, P297, DOI 10.1002/jcp.1041530209; LANE BG, 1991, FASEB J, V5, P2893, DOI 10.1096/fasebj.5.14.1752357; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI C, 1992, P NATL ACAD SCI USA, V89, P9885, DOI 10.1073/pnas.89.20.9885; LITTS JC, 1987, NUCLEIC ACIDS RES, V15, P3607, DOI 10.1093/nar/15.8.3607; LOWENSON JD, 1991, GERONTOLOGY, V37, P128; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MIZOBUCHI M, 1994, J NEUROCHEM, V62, P322; MORRIS PC, 1990, EUR J BIOCHEM, V190, P625, DOI 10.1111/j.1432-1033.1990.tb15618.x; MUDGETT MB, 1993, BIOCHEMISTRY-US, V32, P11100, DOI 10.1021/bi00092a020; MUNDY J, 1990, P NATL ACAD SCI USA, V87, P1406, DOI 10.1073/pnas.87.4.1406; MUNDY J, 1988, EMBO J, V7, P2279, DOI 10.1002/j.1460-2075.1988.tb03070.x; OCONNOR CM, 1989, GAMETE RES, V22, P307, DOI 10.1002/mrd.1120220308; OCONNOR CM, 1987, J BIOL CHEM, V262, P10398; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; PLA M, 1989, PLANT MOL BIOL, V13, P385, DOI 10.1007/BF00015550; Quatrano R. S., 1986, Oxford Surveys of Plant Molecular and Cell Biology, V3, P467; QUATRANO RS, 1992, CONTROL PLANT GENE E, P69; ROGERS SO, 1983, AM J BOT, V70, P308, DOI 10.2307/2443277; ROMANIK EA, 1992, GENE, V118, P217, DOI 10.1016/0378-1119(92)90191-Q; Sambrook J, 1989, MOL CLONING LABORATO; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; TRIVEDI L, 1982, EUR J BIOCHEM, V128, P349; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; WILLIAMSON JD, 1985, EUR J BIOCHEM, V152, P501, DOI 10.1111/j.1432-1033.1985.tb09224.x; WILLIAMSON JD, 1988, PLANT PHYSIOL, V86, P208, DOI 10.1104/pp.86.1.208; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.pp.39.060188.002255	59	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25605	25612						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929264				2022-12-25	WOS:A1994PQ49100059
J	PAN, P; JAKOB, CA; SANDMEIER, E; CHRISTEN, P; GEHRING, H				PAN, P; JAKOB, CA; SANDMEIER, E; CHRISTEN, P; GEHRING, H			MODULATION OF THE ACTIVITY OF MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE H352C BY THE REDOX STATE OF THE ENGINEERED INTERDOMAIN DISULFIDE BOND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; ENZYME; MUTAGENESIS; EXCHANGE	Molecular modeling suggested that the large and small domain of mitochondrial aspartate aminotransferase might be linked by an engineered disulfide bond that could be expected to interfere with ligand-induced and syncatalytic changes in conformation and thus to assist in the elucidation of their significance for the catalytic mechanism. His-352, which is situated in the small domain close to Cys-166 of the large domain, was replaced with a cysteine residue by oligonucleotide-directed mutagenesis. Aspartate aminotransferase H352C, that had not been exposed to reducing conditions, in part contained a disulfide bond between Cys-166 and Cys-352. Exposure to a reducing agent cleaved the cross-link completely and produced an enzyme derivative with 8% of the activity of the wild type enzyme. Cu2+-mediated autoxidation resulted in complete formation of the disulfide bond and a decrease in enzymic activity to 2%. Independently of the redox state of the disulfide bond, the H352C substitution seems to shift the equilibrium from the open toward the closed conformation of the enzyme. This change in conformation was accompanied by an increase in the binding affinity for both the amino and oxo acid substrate by one order of magnitude. Apparently, 1-2 kcal/mol of the binding energy of the substrates are no longer diverted to shift the conformational equilibrium toward the closed conformation. The k(cat)/K-m values were unchanged or even increased in the reduced form of the mutant enzyme and only slightly decreased in its oxidized form, Both the disulfide-independent decrease in enzymic activity, as observed in reduced aspartate aminotransferase H352C and also in two other mutant enzymes (C166H/H352C and H352Q), and the redox-dependent modulation of activity indicate that unhindered domain movements are essential for full catalytic competence of aspartate aminotransferase.	UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND	University of Zurich								Christen P, 1982, Methods Biochem Anal, V28, P151, DOI 10.1002/9780470110485.ch3; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GEHRING H, 1978, J BIOL CHEM, V253, P3158; HOHENESTER E, 1994, J MOL BIOL, V236, P963, DOI 10.1016/0022-2836(94)90001-9; Jocelyn P. C., 1972, BIOCH SH GROUP, P94; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MALASHKEVICH VN, 1993, BIOCHEMISTRY-US, V32, P13451, DOI 10.1021/bi00212a010; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MEER L, 1984, CHEM BIOL ASPECTS  B, P277; PAN P, 1994, BIOCHEMISTRY-US, V33, P2757, DOI 10.1021/bi00176a003; PEDERSEN AO, 1980, EUR J BIOCHEM, V106, P291; PERRY LJ, 1986, BIOCHEMISTRY-US, V25, P733, DOI 10.1021/bi00351a034; PFISTER K, 1985, J BIOL CHEM, V260, P1414; PICOT D, 1991, EUR J BIOCHEM, V196, P329, DOI 10.1111/j.1432-1033.1991.tb15821.x; SANDMEIER E, 1980, J BIOL CHEM, V255, P284; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; STERK M, 1994, EUR J BIOCHEM, V219, P993, DOI 10.1111/j.1432-1033.1994.tb18582.x; ZIAK M, 1993, EUR J BIOCHEM, V211, P475, DOI 10.1111/j.1432-1033.1993.tb17573.x	21	5	5	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25432	25436						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929241				2022-12-25	WOS:A1994PQ49100034
J	NAKAMURA, H; IZUMOTO, Y; KAMBE, H; KURODA, T; MORI, T; KAWAMURA, K; YAMAMOTO, H; KISHIMOTO, T				NAKAMURA, H; IZUMOTO, Y; KAMBE, H; KURODA, T; MORI, T; KAWAMURA, K; YAMAMOTO, H; KISHIMOTO, T			MOLECULAR-CLONING OF COMPLEMENTARY-DNA FOR A NOVEL HUMAN HEPATOMA-DERIVED GROWTH-FACTOR - ITS HOMOLOGY WITH HIGH-MOBILITY GROUP-1 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL-PROTEINS; CELLS; EXPRESSION; SEQUENCE; HMG1; NUCLEAR; LOCALIZATION; AMPHOTERIN; AUTOCRINE; HMG-I(Y)	A novel hepatoma-derived growth factor was purified from the conditioned medium of human hepatoma-derived cell line, HuH-7, by the assay of [H-3]thymidine incorporation into Swiss 3T3 cells. Molecular cloning of a complementary DNA from the cDNA Library of HuH-7 cells was done on the basis of the N-terminal amino acid sequence. This protein was acid- and heat-labile heparin-binding protein and inactivated by reducing condition. The cDNA is 2.4 kilobase pairs long, and the deduced amino acid sequence from cDNA contained 240 amino acids without a signal peptide-like N-terminal hydrophobic sequence. Heparin column-eluted fraction of the conditioned medium of Cos-7 cells transfected by the cDNA stimulated the DNA synthesis. Northern blot analysis revealed its ubiquitous expression in several tumor-derived cell lines, as well as in normal tissues. The primary sequence shares homology with the high mobility group (HMG)-1 protein (23.4% amino acid identity and 35.6% similarity). However, its hydrophobic profile was distinct from that of HMG-1 except for the C-terminal acidic region, and it contained no apparent HMG box motif. Immunofluorescence study showed that it is localized in the cytoplasma of hepatoma cells. These findings suggest that this factor is a novel heparin-binding protein, with mitogenic activity for fibroblasts.	SEKISUI CHEM CO LTD,CHEM RES INST,BIOTECHNOL RES LAB,SHIMAMOTO,OSAKA 618,JAPAN	Sekisui Chemical Co Ltd	NAKAMURA, H (corresponding author), OSAKA UNIV,SCH MED,DEPT MED 3,YAMADA OKA 2-2,SUITA,OSAKA 565,JAPAN.		Kishimoto, Tadamitsu/C-8470-2009					AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BIANCHI ME, 1992, NUCLEIC ACIDS MOL BI, V6, P112; BONNEANDREA C, 1984, EMBO J, V3, P1193, DOI 10.1002/j.1460-2075.1984.tb01950.x; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; DANG CV, 1989, J BIOL CHEM, V264, P18019; EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; HAMADA H, 1985, BIOCHEMISTRY-US, V24, P1428, DOI 10.1021/bi00327a022; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JAVAHERIAN K, 1979, NUCLEIC ACIDS RES, V6, P3569, DOI 10.1093/nar/6.11.3569; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUEHL L, 1985, J BIOL CHEM, V260, P361; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MOSEVITSKY MI, 1989, EUR J BIOCHEM, V185, P303, DOI 10.1111/j.1432-1033.1989.tb15116.x; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NAKAMURA H, 1989, CLIN CHIM ACTA, V183, P273, DOI 10.1016/0009-8981(89)90361-6; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; RAECK GR, 1982, NATURE, V300, P76; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRAKAWA H, 1990, BIOCHEMISTRY-US, V29, P4419, DOI 10.1021/bi00470a022; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; VERTIANEN EJ, 1988, FEBS LETT, V288, P445; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; YE RD, 1988, J BIOL CHEM, V263, P4869	37	182	202	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25143	25149						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929202				2022-12-25	WOS:A1994PQ49000092
J	TACHIBANA, T; IMAMOTO, N; SEINO, H; NISHIMOTO, T; YONEDA, Y				TACHIBANA, T; IMAMOTO, N; SEINO, H; NISHIMOTO, T; YONEDA, Y			LOSS OF RCC1 LEADS TO SUPPRESSION OF NUCLEAR-PROTEIN IMPORT IN LIVING CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; CHROMOSOME CONDENSATION; KARYOPHILIC PROTEINS; SYNTHETIC PEPTIDES; DNA-REPLICATION; 2 STEPS; TRANSPORT; REGULATOR; MITOSIS; TRANSLOCATION	The role of RCC1-Ran/TC4 in nuclear protein import was examined in living cells using a temperature-sensitive RCC1 mutant cell line, tsBN2, and tsBN2 transformed with a RCC1 cDNA lacking the nuclear localization sequence domain, Delta 8-29. Substrate, containing a small number of SV40 T antigen nuclear localization sequence peptides, injected into the cytoplasm of tsBN2 cells cultured at the non-permissive temperature of 39.5 degrees C did not accumulate efficiently in the nucleus. When the same substrate was injected into the cytoplasm of heterokaryons of tsBN2 and wild type BHK21 cells, import efficiency into the tsBN2 nuclei was not restored. Import into the BHK21 nuclei gradually decreased after fusion. In contrast, import efficiency into tsBN2 nuclei gradually recovered after fusion with tsBN2 cells transformed with Delta 8-29 in which functional RCC1 was diffusely distributed in both the nuclei and cytoplasm. Substrate did not accumulate in the nuclei of digitonin-permeabilized tsBN2 cells cultured at 39.5 degrees C even in the presence of normal cytosol. These results suggest that loss of RCC1 function leads to the decline of import competence of the nucleus and accumulation of a factor in the cytoplasm that suppresses nuclear import. These results indicate that the RCC1-Ran/TC4 system may regulate nuclear import.	OSAKA UNIV, SCH MED, DEPT ANAT & CELL BIOL, SUITA, OSAKA 565, JAPAN; KYUSHU UNIV, GRAD SCH MED SCI, DEPT BIOL MOLEC, MAIDASHI, FUKUOKA 812, JAPAN	Osaka University; Kyushu University			Imamoto, Naoko/A-7458-2015	Imamoto, Naoko/0000-0002-2886-3022				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OKADA Y, 1993, METHOD ENZYMOL, V221, P18, DOI 10.1016/0076-6879(93)21005-S; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; SEINO H, 1992, J CELL SCI, V102, P393; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3	32	105	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24542	24545						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929123				2022-12-25	WOS:A1994PQ49000007
J	WILLUHN, J; SCHMITTWREDE, HP; GREVEN, H; WUNDERLICH, F				WILLUHN, J; SCHMITTWREDE, HP; GREVEN, H; WUNDERLICH, F			CDNA CLONING OF A CADMIUM-INDUCIBLE MESSENGER-RNA ENCODING A NOVEL CYSTEINE-RICH, NONMETALLOTHIONEIN 25-KDA PROTEIN IN AN ENCHYTRAEID EARTHWORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEINS; ELECTROPHORESIS; TRANSLATION; SEQUENCE	Cadmium accumulation and its effect on gene expression have been investigated at sublethal cadmium concentrations in the soil oligochaete Enchytraeus buch-holzi. This worm is capable of accumulating cadmium to large amounts, which coincides with the induction of a mRNA isolated as a cDNA clone by differential screening of a cDNA library constructed from cadmium-treated enchytraeids. The cDNA clone designated CRP1 is 1474 base pairs in length and contains a 753-base pair open reading frame, encoding a novel Cys-rich non-metallothionein protein. In vitro translation of the in vitro transcribed CRP1 results in a protein with a molecular mass of 25 kDa and an pi of approximately 7.5. These values are consistent with those predicted from the deduced amino acid sequence. The CRP protein contains 27% Cys, most of them arranged in Cys-X-Cys and Cys-Cys segments. The sequence is also characterized by a 31-amino-acid motif, which is tandemly repeated along the sequence. Northern blot analysis reveals that the CRP gene is not constitutively expressed in untreated worms, but rather it is rapidly induced by cadmium. The CRP gene may be a promising candidate gene for monitoring bioavailable cadmium at subtoxic levels in terrestric environments.	UNIV DUSSELDORF, INST ZOOL, DIV PARASITOL, D-40225 DUSSELDORF, GERMANY; UNIV DUSSELDORF, BIOL MED FORSCHUNGSZENTRUM, D-40225 DUSSELDORF, GERMANY; UNIV DUSSELDORF, INST ZOOL, DIV MORPHOL & CELL BIOL, D-40225 DUSSELDORF, GERMANY	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf			Schmitt-Wrede, Hans-Peter/ABD-6206-2021					ATWATER JA, 1990, ANNU REV GENET, V24, P519; BRADY FO, 1982, TRENDS BIOCHEM SCI, V7, P143, DOI 10.1016/0968-0004(82)90206-7; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FRAZIER JM, 1985, COMP BIOCHEM PHYS C, V80, P257, DOI 10.1016/0742-8413(85)90052-0; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KASPRZAK K, 1982, PEDOBIOLOGIA, V23, P217; KIMURA M, 1991, METHOD ENZYMOL, V205, P114; KOJIMA Y, 1991, METHOD ENZYMOL, V205, P8; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASTOWSKIPERRY D, 1985, J BIOL CHEM, V260, P1527; LITCHFIELD JT, 1949, J PHARMACOL EXP THER, V96, P99; MENZER RE, 1991, TOXICOLOGY, P890; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; POSTHUMA L, 1993, COMP BIOCHEM PHYS C, V106, P11, DOI 10.1016/0742-8413(93)90251-F; RAMSEIER S, 1990, MOL CELL BIOCHEM, V97, P137; ROEMBKE J, 1989, HYDROBIOLOGIA, V180, P235, DOI 10.1007/BF00027556; Ruther U., 1990, Acta Biologica Benrodis, V2, P125; Sambrook J, 1989, MOL CLONING LABORATO; STONE H, 1985, COMP BIOCHEM PHYS C, V80, P9, DOI 10.1016/0742-8413(85)90126-4; WEIGMANN G, 1991, WATER AIR SOIL POLL, V57-8, P655, DOI 10.1007/BF00282929; Westheide W., 1991, P497	28	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24688	24691						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929141				2022-12-25	WOS:A1994PQ49000028
J	ELICEIRI, BP; BROWN, DD				ELICEIRI, BP; BROWN, DD			QUANTITATION OF ENDOGENOUS THYROID-HORMONE RECEPTOR-ALPHA AND RECEPTOR-BETA DURING EMBRYOGENESIS AND METAMORPHOSIS IN XENOPUS-LAEVIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRIIODOTHYRONINE RECEPTORS; AMPHIBIAN METAMORPHOSIS; BINDING-CAPACITY; TRANSLATIONAL CONTROL; TADPOLE ERYTHROCYTES; GENE-EXPRESSION; ASSAY PROCEDURE; RAT; PROTEINS; CELLS	Greater than 90% of the endogenous thyroid hormone receptor proteins TR alpha and TR beta in tissues of Xenopus laevis comigrate with their respective in vitro synthesized counterparts, and these major components are not phosphorylated detectably. Maternally inherited TR alpha protein is stable through early embryogenesis during a time in which there is no detectable TR alpha mRNA synthesis. At stage 35 when TR alpha mRNA is first detectable, the inherited TR alpha protein is present at about 100 molecules/cell. TR alpha protein subsequently increases to levels of about 1500 and 6000 molecules/cell in tail and head regions, respectively, in stage 52 tadpoles. Even though TR alpha mRNA gradually increases during metamorphosis (from stage 52 to 62), TR alpha protein remains constant, suggesting strongly that post-transcriptional events control the ultimate levels of TR alpha protein. In contrast, there is no detectable TR beta protein (less than 100 molecules/cell) throughout embryogenesis until stage 52. Both TR beta mRNA and protein rise along with the increase in endogenous thyroid hormone, reaching a maximum at the climax of metamorphosis, when TR beta protein exceeds TR alpha protein in concentration. As with TR alpha protein, TR beta protein in tail is consistently about one-fourth that of TR beta protein in the head region. The number of TR alpha protein molecules in extracts of premetamorphic tadpoles and cultured cells grown in the absence of thyroid hormone fully accounts for all of the sites to which I-125-T-3 bind. We interpret this to mean that TR alpha protein must be a necessary, if not sufficient, component in the pathway toward metamorphosis triggered by thyroid hormone and required for the phenomenon of competence in tissues and cells.			ELICEIRI, BP (corresponding author), CARNEGIE INST WASHINGTON,BALTIMORE,MD 21210, USA.			Eliceiri, Brian/0000-0003-1811-1916				BANKER DE, 1993, MOL CELL BIOL, V13, P7540, DOI 10.1128/MCB.13.12.7540; BENOIT R, 1982, P NATL ACAD SCI-BIOL, V79, P917, DOI 10.1073/pnas.79.3.917; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BROWN TA, 1990, J BIOL CHEM, V265, P10025; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P294; DAWID IB, 1965, J MOL BIOL, V12, P581, DOI 10.1016/S0022-2836(65)80313-8; DENNER LA, 1990, J BIOL CHEM, V265, P16458; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GALTON VA, 1985, ENDOCRINOLOGY, V116, P99, DOI 10.1210/endo-116-1-99; GALTON VA, 1984, ENDOCRINOLOGY, V114, P735, DOI 10.1210/endo-114-3-735; GALTON VA, 1983, THYROID  HORMONE ACT, P445; GLINEUR C, 1989, ONCOGENE, V4, P1247; Gudernatsch JF, 1912, ARCH ENTWICKLUNG ORG, V35, P457, DOI 10.1007/BF02277051; HARLOW E, 1988, ANTIBODIES LABORATOR; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOROWITZ ZD, 1988, PHOTOAFFINITY LABELI, P212; INOUE A, 1983, ANAL BIOCHEM, V134, P176, DOI 10.1016/0003-2697(83)90280-4; KANAMORI A, 1993, P NATL ACAD SCI USA, V90, P6013, DOI 10.1073/pnas.90.13.6013; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KAWAHARA A, 1991, DEVELOPMENT, V112, P933; KIKUYAMA S, 1993, INT REV CYTOL, V145, P105, DOI 10.1016/S0074-7696(08)60426-X; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KROTOSKI DM, 1985, J EXP ZOOL, V233, P443, DOI 10.1002/jez.1402330313; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; MACHUCA I, 1992, MOL CELL ENDOCRINOL, V87, P105, DOI 10.1016/0303-7207(92)90238-2; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; OPPENHEIMER JH, 1972, J CLIN ENDOCR METAB, V35, P330, DOI 10.1210/jcem-35-2-330; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; PUDNEY M, 1973, EXPERIENTIA, V29, P466, DOI 10.1007/BF01926785; RODD C, 1992, ENDOCRINOLOGY, V131, P2559, DOI 10.1210/en.131.6.2559; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHWARTZ HL, 1992, J BIOL CHEM, V267, P11794; SHI YB, 1992, J BIOL CHEM, V267, P733; SHI YB, 1994, TRENDS ENDOCRIN MET, V5, P14, DOI 10.1016/1043-2760(94)90116-3; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P7767, DOI 10.1073/pnas.91.16.7767; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STULTS NL, 1989, ANAL BIOCHEM, V180, P114, DOI 10.1016/0003-2697(89)90097-3; TAGAMI T, 1993, ENDOCRINOLOGY, V132, P275, DOI 10.1210/en.132.1.275; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; WANG Z, 1993, J BIOL CHEM, V268, P16270; Weber R, 1967, BIOCH ANIMAL DEV, P227; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WEISS RE, 1992, ANNU REV MED, V43, P363, DOI 10.1146/annurev.med.43.1.363; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YOSHIZATO K, 1975, NATURE, V254, P705, DOI 10.1038/254705a0	58	126	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24459	24465						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929109				2022-12-25	WOS:A1994PQ34600094
J	SNYDER, PM; MCDONALD, FJ; STOKES, JB; WELSH, MJ				SNYDER, PM; MCDONALD, FJ; STOKES, JB; WELSH, MJ			MEMBRANE TOPOLOGY OF THE AMILORIDE-SENSITIVE EPITHELIAL SODIUM-CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; POTASSIUM CHANNEL; NA+ CHANNEL; EXPRESSION; NEURODEGENERATION; PROTEINS; CLONING	The amiloride-sensitive epithelial sodium channel (ENaC) is involved in fluid and electrolyte absorption across a number of epithelia, and cloning of several ENaC subunits has begun to facilitate investigation of the structure, function, and regulation of this channel. Analysis of the amino acid sequence has revealed two potential membrane-spanning domains, but little else is known about the structure of ENaC. To investigate the membrane topology of one subunit, alpha rENaC, we used in vitro transcription, translation, and translocation into microsomal membranes. This generated a glycosylated protein of 93 kDa. Sequence analysis also revealed eight potential sites for N-glycosylation, six of which were found to be glycosylated (Asn(190), Asn(259), Asn(320), Asn(339) Asn(424), and Asn(538)), indicating that they are extracellular. The C terminus was localized as intracellular based on antibody recognition and protease sensitivity of a tagged epitope at the C terminus. The N terminus was also found to be intracellular, based on its protease sensitivity. Similar results were obtained by expression in Xenopus oocytes. Together, these results support a model of alpha rENaC consisting of an intracellular N terminus and C terminus, a large N-glycosylated extracellular domain, and two membrane-spanning domains that each pass once through the plasma membrane. Because of their sequence similarity, it is likely that this structure is shared by other ENaC subunits and possibly the degenerins of Caenorhabditis elegans as well.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DIV NEPHROL,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Iowa				Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007344] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07344] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; Canessa C. M., 1993, Journal of the American Society of Nephrology, V4, P864; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247	20	194	195	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24379	24383						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929098				2022-12-25	WOS:A1994PQ34600082
J	HARNISH, DC; MALIK, S; KARATHANASIS, SK				HARNISH, DC; MALIK, S; KARATHANASIS, SK			ACTIVATION OF APOLIPOPROTEIN AI GENE-TRANSCRIPTION BY THE LIVER-ENRICHED FACTOR HNF-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NUCLEAR FACTOR-III; I GENE; SYNERGISTIC INTERACTIONS; CONTROL EXPRESSION; PROMOTER ELEMENTS; BINDING PROTEINS; MESSENGER-RNA; B GENE; C-III	Liver-specific expression of the apolipoprotein AI (apoA-I) gene is controlled by the coordinate action of transcription factors bound to three sites (A, B, and C) located within a powerful liver-specific enhancer which spans the -222 to -110 region upstream of the apoA-I gene transcription start site (+1). Sites A and C bind various members of the nuclear receptor superfamily including the Liver-enriched factor HNF-4. In the current report, enhancer derivatives with mutagenized protein-binding sites were tested for their ability to stimulate the apoA-I basal promoter in hepatoblastoma HepG2 cells. The results revealed that occupation of both sites A and B, but not C is essential for high level expression. Electrophoretic mobility shift assays showed that in HepG2 cells site B is occupied by the liver-enriched factor HNF-3 beta. Binding of HNF-3 beta to site B transactivates the apoA-I basal promoter in hepatic and nonhepatic cells. HNF-3 beta binding and transactivation were dependent upon the close proximity of two HNF-3 beta binding motifs within site B. Furthermore, HNF-3 beta and HNF-4, bound to their cognate sites within the apoA-I enhancer exhibited strong synergy in transactivation of the apoA-I basal promoter in nonhepatic cells, highlighting the central role of HNF-3 beta in liver-specific transcription of the apoA-I gene. It is concluded that cooperative binding of HNF-3 beta to site B and synergistic interactions between HNF-4 and HNF-3 beta bound to their cognate sites in the apoA-I enhancer may play a fundamental role in apoA-I gene expression in liver.	AMER CYANAMID CO,LEDERLE LABS,DEPT CARDIOVASC MOLEC BIOL,PEARL RIVER,NY 10965									APOSTOLOPOULOS JJ, 1988, BIOCHEM BIOPH RES CO, V154, P997, DOI 10.1016/0006-291X(88)90238-0; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COSTA RH, 1991, NUCLEIC ACIDS RES, V19, P4139, DOI 10.1093/nar/19.15.4139; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DREWES T, 1991, NUCLEIC ACIDS RES, V19, P6383, DOI 10.1093/nar/19.23.6383; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; ETTINGER WH, 1994, ARTERIOSCLER THROMB, V14, P8, DOI 10.1161/01.ATV.14.1.8; FREEDMAN A, 1989, GENE DEV, V3, P1314; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GE RW, 1994, J BIOL CHEM, V269, P13185; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; KARATHANASIS SK, 1992, MONOGR HUM GENET, V14, P140; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEMAIGRE FP, 1993, J BIOL CHEM, V268, P19896; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MOLOWA DT, 1992, BIOCHEMISTRY-US, V31, P2539, DOI 10.1021/bi00124a014; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PETROPOULOS I, 1991, J BIOL CHEM, V266, P24220; POTTER JJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P360, DOI 10.1016/0003-9861(92)90529-6; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; TAM SP, 1986, P NATL ACAD SCI USA, V83, P3111, DOI 10.1073/pnas.83.10.3111; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WU AL, 1979, J BIOL CHEM, V254, P7316; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469	49	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28220	28226						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961760				2022-12-25	WOS:A1994PV77200068
J	KISHIMOTO, I; YOSHIMASA, T; SUGA, S; OGAWA, Y; KOMATSU, Y; NAKAGAWA, O; ITOH, H; NAKAO, K				KISHIMOTO, I; YOSHIMASA, T; SUGA, S; OGAWA, Y; KOMATSU, Y; NAKAGAWA, O; ITOH, H; NAKAO, K			NATRIURETIC PEPTIDE CLEARANCE RECEPTOR IS TRANSCRIPTIONALLY DOWN-REGULATED BY BETA(2)-ADRENERGIC STIMULATION IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GUANYLATE-CYCLASE; CARDIAC MYOCYTES; GENE-EXPRESSION; ALPHA-HUMAN; A RECEPTOR; ATRIAL; POLYPEPTIDE; BRAIN; HYPERTROPHY	Three natriuretic peptide receptors (the ANP-A, ANP-B, and clearance (C) receptors) have been reported. The regulation of these receptors by catecholamines was examined in cultured rat vascular smooth muscle cells. Treatment with norepinephrine decreased the maximum I-125-ANP binding. The competitive binding assay with des[Gln(18),Ser(19),Gly(20),Leu(21),Gly(22)]ANP-(4-23)-NH2 (C-ANF-4-23), a specific ligand for the C receptor, revealed that the decrease in the I-125-ANP binding by norepinephrine was caused by the down-regulation of the C receptor. Isoproterenol also down-regulated the C receptor in a time- and dose-dependent manner. The catecholamine-induced downregulation of the C receptor was antagonized by a beta(2)-selective adrenergic antagonist, ICI 118,551 but not by an alpha(1)-, alpha(2)-, or beta(1)-adrenergic antagonist. Forskolin, NaF and, 8-bromo-cyclic AMP also decreased the C receptor density. The isoproterenol-induced decrease in the C receptor level was further confirmed by affinity crosslinking and Western blot analysis. Northern blot analysis revealed that isoproterenol and 8-bromo-cyclic AMP decreased the steady-state level of C receptor mRNA. By contrast, neither the ANP-A receptor nor the ANP-B receptor mRNA level was affected by 8-bromo-cyclic AMP. The nuclear run-on assay showed that the transcriptional rate of the C receptor gene was decreased by isoproterenol, whereas those of the ANP-A and ANP-B receptor genes were unchanged. Isoproterenol attenuated the clearance of exogenously added ANP and augmented the ANP-stimulated intracellular cyclic GMP production to the same extent as the selective occupancy of the C receptor with C-ANF-(4-23), suggesting that the isoproterenol-induced enhancement of responsiveness to ANP could result not from the sensitization of the ANP-A or ANP-B receptor but from the down-regulation of the C receptor, which leads to the attenuated clearance of ANP. These findings suggest that the beta(2)-adrenergic receptor stimulation down-regulates the C receptor through the decrease in the transcriptional rate of the C receptor gene and that the activation of the sympathetic nervous system augments the biological responsiveness to natriuretic peptides by attenuating their metabolic clearance in vascular walls.	KYOTO UNIV,FAC MED,DEPT MED,DIV 2,SAKYO KU,KYOTO 606,JAPAN	Kyoto University				Ogawa, Yoshihiro/0000-0002-0834-2836				BRAUNWALD E, 1992, HEART DISEASE, P408; CHABRIER PE, 1988, J BIOL CHEM, V263, P13199; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797; DOERNER D, 1988, NEURON, V1, P693, DOI 10.1016/0896-6273(88)90168-7; FULLER F, 1988, J BIOL CHEM, V263, P9395; HIRATA Y, 1989, EUR J PHARMACOL, V164, P603, DOI 10.1016/0014-2999(89)90273-2; HIRATA Y, 1988, BIOCHEM BIOPH RES CO, V152, P1097, DOI 10.1016/S0006-291X(88)80397-8; HOSODA K, 1992, J BIOL CHEM, V267, P18797; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; JIANG H, 1992, J BIOL CHEM, V267, P1015; KATO J, 1991, J BIOL CHEM, V266, P14681; KISHIMOTO I, 1993, AM J PHYSIOL, V265, pH1373, DOI 10.1152/ajpheart.1993.265.4.H1373; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KUCHEL O, 1987, LIFE SCI, V40, P1545, DOI 10.1016/0024-3205(87)90119-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MUKOYAMA M, 1988, HYPERTENSION, V12, P117, DOI 10.1161/01.HYP.12.2.117; MUKOYAMA M, 1990, NEW ENGL J MED, V323, P757; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAO K, 1992, J HYPERTENS, V10, P907; NAKAO K, 1984, BIOCHEM BIOPH RES CO, V124, P815, DOI 10.1016/0006-291X(84)91030-1; NEEDLEMAN P, 1985, HYPERTENSION, V7, P469, DOI 10.1161/01.HYP.7.4.469; NUGLOZEH E, 1990, AM J PHYSIOL, V259, pF130, DOI 10.1152/ajprenal.1990.259.1.F130; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; POTTER LR, 1992, J BIOL CHEM, V267, P14531; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SHIMONAKA M, 1987, J BIOL CHEM, V262, P5510; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUGA S, 1992, HYPERTENSION, V19, P762, DOI 10.1161/01.HYP.19.6.762; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; SUGA SI, 1992, CIRC RES, V71, P34, DOI 10.1161/01.RES.71.1.34; SUGAWARA A, 1988, J CLIN INVEST, V81, P1962, DOI 10.1172/JCI113544	42	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28300	28308						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961768				2022-12-25	WOS:A1994PV77200079
J	BOGGARAM, V; MARGANA, RK				BOGGARAM, V; MARGANA, RK			DEVELOPMENTAL AND HORMONAL-REGULATION OF SURFACTANT PROTEIN-C (SP-C) GENE-EXPRESSION IN FETAL LUNG - ROLE OF TRANSCRIPTION AND MESSENGER-RNA STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC GLOBIN GENE; ADULT ERYTHROID-CELLS; MESSENGER-RNA; SP-A; PULMONARY SURFACTANT; RAT LUNG; RABBIT LUNG; HALF-LIFE; SP-B; GLUCOCORTICOIDS	Pulmonary surfactant protein C (SP-C) gene expression is developmentally and hormonally regulated in fetal lung. In the present study we investigated the role of transcriptional and posttranscriptional mechanisms in the developmental, cAMP, and dexamethasone induction of SP-C mRNA. We found that developmental induction of SP-C mRNA was not coincident with induction of SP-C gene transcription. SP-C mRNA levels reached similar to 90% of levels in adult lung on day 24 of gestation, whereas SP-C gene transcription was only similar to 4% of level in adult lung and did not increase until day 28 of gestation (term in rabbit = 31 days). Treatment of fetal lung tissues in vitro with dibutyryl cyclic AMP (Bt(2)cAMP) and dexamethasone increased SP-C mRNA accumulation by different mechanisms. Increase in SP-C mRNA accumulation by Bt(2)cAMP was the result of increased SP-C gene transcription, whereas increased SP-C mRNA accumulation by dexamethasone was due to stabilization of RNA. In control tissues the SP-C mRNA half-life (t(1/2)) was 11.2 h, and after dexamethasone treatment it increased to 30 h. These data show that both transcriptional and mRNA stabilization mechanisms regulate induction of SP-C gene expression during fetal lung development and by cAMP and dexamethasone in fetal lung in vitro.			BOGGARAM, V (corresponding author), UNIV TEXAS, CTR HLTH, DEPT BIOL MOLEC, POB 2003, TYLER, TX 75710 USA.							ACARREGUI MJ, 1990, ENDOCRINOLOGY, V127, P1105, DOI 10.1210/endo-127-3-1105; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALCORN JL, 1993, MOL ENDOCRINOL, V7, P1072, DOI 10.1210/me.7.8.1072; AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; AVIV H, 1976, CELL, V8, P495, DOI 10.1016/0092-8674(76)90217-8; BOGGARAM V, 1988, J BIOL CHEM, V263, P19060; BOGGARAM V, 1992, AM J PHYSIOL, V263, pL634, DOI 10.1152/ajplung.1992.263.6.L634; BOGGARAM V, 1989, J BIOL CHEM, V264, P11421; BOGGARAM V, 1991, MOL ENDOCRINOL, V5, P414, DOI 10.1210/mend-5-3-414; BOGGARAM V, 1994, AM J RESP CRIT CARE, V149, pA523; Brawerman G., 1993, CONTROL MESSENGER RN, P149; CONNELLY IH, 1991, ENDOCRINOLOGY, V129, P2583, DOI 10.1210/endo-129-5-2583; COX A, 1989, NUCLEIC ACIDS RES, V17, P10439, DOI 10.1093/nar/17.24.10439; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DELEON V, 1983, DEV BIOL, V98, P400, DOI 10.1016/0012-1606(83)90369-X; DURHAM PL, 1993, ANAT REC, V237, P365, DOI 10.1002/ar.1092370310; DURHAM PL, 1992, EXP LUNG RES, V18, P775, DOI 10.3109/01902149209031707; FEI HH, 1993, BIOTECHNIQUES, V15, P838; FISHER JH, 1991, AM J RESP CELL MOL, V5, P63, DOI 10.1165/ajrcmb/5.1.63; FLOROS J, 1991, AM J RESP CELL MOL, V4, P449, DOI 10.1165/ajrcmb/4.5.449; GENOVESE C, 1990, MOL IMMUNOL, V27, P733, DOI 10.1016/0161-5890(90)90082-B; GINDER GD, 1984, P NATL ACAD SCI-BIOL, V81, P3954, DOI 10.1073/pnas.81.13.3954; GLAUBER JG, 1991, MOL CELL BIOL, V11, P4690, DOI 10.1128/MCB.11.9.4690; GOERKE J, 1986, HDB PHYSL RESPIRATOR, V3, P47; HOD Y, 1988, J BIOL CHEM, V263, P7747; KALINA M, 1992, AM J RESP CELL MOL, V6, P594, DOI 10.1165/ajrcmb/6.6.594; KIKKAWA Y, 1968, AM J PATHOL, V52, P177; KING RJ, 1985, ANNU REV PHYSIOL, V47, P775, DOI 10.1146/annurev.ph.47.030185.004015; KROCZEK RA, 1990, ANAL BIOCHEM, V184, P90, DOI 10.1016/0003-2697(90)90017-4; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LILEY HG, 1989, J CLIN INVEST, V83, P1191, DOI 10.1172/JCI114000; LODISH HF, 1976, CELL, V7, P59, DOI 10.1016/0092-8674(76)90255-5; MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/annurev.ph.53.030191.002215; MENDELSON CR, 1986, J BIOL CHEM, V261, P9938; ODOM MW, 1990, AM J PHYSIOL, V259, pL283, DOI 10.1152/ajplung.1990.259.4.L283; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PETEREC SM, 1994, AM J PHYSIOL, V267, pL9, DOI 10.1152/ajplung.1994.267.1.L9; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; POSSMAYER F, 1990, AM REV RESPIR DIS, V142, P749, DOI 10.1164/ajrccm/142.4.749; POSSMAYER F, 1988, AM REV RESPIR DIS, V138, P990, DOI 10.1164/ajrccm/138.4.990; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SCHELLHASE DE, 1989, PEDIATR RES, V26, P167, DOI 10.1203/00006450-198909000-00001; SCHELLHASE DE, 1991, AM J RESP CELL MOL, V4, P304, DOI 10.1165/ajrcmb/4.4.304; SIMONET WS, 1989, J BIOL CHEM, V264, P569; SNYDER JM, 1981, DEV BIOL, V85, P129, DOI 10.1016/0012-1606(81)90242-6; SNYDER JM, 1991, ANAT REC, V229, P73, DOI 10.1002/ar.1092290109; VELETZA SV, 1992, AM J PHYSIOL, V262, pL684, DOI 10.1152/ajplung.1992.262.6.L684; VENKATESH VC, 1993, AM J RESP CELL MOL, V8, P222, DOI 10.1165/ajrcmb/8.2.222; WHITSETT JA, 1987, J BIOL CHEM, V262, P15618; WILLIAMS DL, 1993, CONTROL MESSENGER RN, P161; WOHLFORDLENANE CL, 1992, AM J RESP CELL MOL, V6, P225, DOI 10.1165/ajrcmb/6.2.225	54	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27767	27772						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961697				2022-12-25	WOS:A1994PV77100094
J	KENNEDY, TA; SMITH, CJ; MARNETT, LJ				KENNEDY, TA; SMITH, CJ; MARNETT, LJ			INVESTIGATION OF THE ROLE OF CYSTEINES IN CATALYSIS BY PROSTAGLANDIN ENDOPEROXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H SYNTHASE; TYROSYL RADICALS; CYCLOOXYGENASE CATALYSIS; COMPLEMENTARY-DNA; BINDING-SITES; HEME-BINDING; OXIDATION; KINETICS; ASPIRIN; BIOSYNTHESIS	The importance of cysteine residues in the cyclooxygenase activity of prostaglandin endoperoxide synthase (PGHS) was investigated using cysteine-specific reagents and site-directed mutagenesis. N-(7-Dimethylamino-4-methyl-3-coumarinyl)maleimide (DACM), a hydrophobic maleimide, inactivated both cyclooxygenase and peroxidase activities of apoPGHS in a time-dependent manner but did not affect holoPGHS. Heme titration experiments indicated that modification of apoPGHS with DACM prevented heme binding. Peptide mapping revealed that DACM modified Cys(313), Cys(512), and Cys(540). N-Ethylmaleimide inactivated cyclooxygenase and peroxidase activities of holoPGHS in a time-dependent manner but did not affect apoPGHS. Peptide mapping demonstrated that N-ethylmaleimide reacted primarily with Cys(313) in holoPGHS and with Cys(540) in apoPGHS. Each of the 3 cysteines was changed to serine by site-directed mutagenesis, and the mutant proteins were expressed in COS-1 cells. The C512S mutant converted arachidonic acid to products to the same extent as wildtype PGHS. In contrast, the C313S and C540S mutants converted arachidonic acid to products to the extent of 10% of wild-type PGHS. These results indicate that Cys(313), Cys(512), and Cys(540) are not essential for cyclooxygenase activity but that alteration of Cys(540) Or Cys(313) dramatically decreases enzyme activity. Both residues are well removed from the cyclooxygenase and peroxidase active sites so our findings reveal that subtle changes, such as substitution of a single oxygen for sulfur atom as far as 30 Angstrom from the heme prosthetic group, can significantly alter enzyme activity.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, AB HANCOCK JR MEM LAB CANC RES, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT CHEM, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University					NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAKOVIC M, 1994, BIOCHEMISTRY-US, V33, P6475, DOI 10.1021/bi00187a013; BAKOVIC M, 1993, BIOCHEMISTRY-US, V32, P833, DOI 10.1021/bi00054a014; BARNETT J, 1993, EICOSANOIDS OTHER BI, P139; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; CHEN YNP, 1989, FASEB J, V3, P2294, DOI 10.1096/fasebj.3.11.2506093; DAVIES MJ, 1993, FREE RADICAL RES COM, V18, P353, DOI 10.3109/10715769309147502; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FARAGGI M, 1990, BIOCHEM BIOPH RES CO, V166, P867, DOI 10.1016/0006-291X(90)90890-Y; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; Howard JA, 1972, ADV FREE RADICAL CHE, V4, P49; INGOLD KU, 1969, ACCOUNTS CHEM RES, V2, P1, DOI 10.1021/ar50013a001; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KENNEDY TA, 1993, EICOSANOIDS OTHER BI, P161; KULMACZ RJ, 1984, J BIOL CHEM, V259, P6358; KULMACZ RJ, 1989, PROSTAGLANDINS, V38, P277, DOI 10.1016/0090-6980(89)90133-0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASSMANN G, 1993, ARCH BIOCHEM BIOPHYS, V300, P132, DOI 10.1006/abbi.1993.1018; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MOBASHERY S, 1988, BIOCHEMISTRY-US, V27, P3691, DOI 10.1021/bi00410a025; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; ODENWALLER R, 1990, METHOD ENZYMOL, V187, P479; OTTO JC, 1993, J BIOL CHEM, V268, P18234; PEDERSEN JZ, 1993, FEBS LETT, V325, P53, DOI 10.1016/0014-5793(93)81412-S; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SCHONEICH C, 1992, ARCH BIOCHEM BIOPHYS, V292, P456, DOI 10.1016/0003-9861(92)90016-P; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Smyth DG, 1960, J AM CHEM SOC, V82, P4600, DOI 10.1021/ja01502a039; SMYTH DG, 1964, BIOCHEM J, V91, P589, DOI 10.1042/bj0910589; TSAI AL, 1994, J BIOL CHEM, V269, P5085; TSAI AL, 1992, J BIOL CHEM, V267, P17753; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WELLS I, 1993, BIOCHEMISTRY-US, V32, P2710, DOI 10.1021/bi00061a032; YAMAMOTO K, 1977, ANAL BIOCHEM, V79, P83, DOI 10.1016/0003-2697(77)90381-5; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	48	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27357	27364						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961646				2022-12-25	WOS:A1994PV77100035
J	WALKER, RK; KRISHNASWAMY, S				WALKER, RK; KRISHNASWAMY, S			THE ACTIVATION OF PROTHROMBIN BY THE PROTHROMBINASE COMPLEX - THE CONTRIBUTION OF THE SUBSTRATE-MEMBRANE INTERACTION TO CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-V; FACTOR-XA; PHOSPHOLIPID-VESICLES; ACTIVE-SITE; COFACTOR DEPENDENCE; BLOOD-COAGULATION; ENZYME COMPLEXES; ALPHA-THROMBIN; BINDING-SITE; MEIZOTHROMBIN	The conversion of prothrombin to thrombin requires the cleavage of two peptide bonds and is catalyzed by the prothrombinase complex composed of factors Xa and Va assembled on a membrane surface. Presteady-state kinetic studies of the effects of membranes on the proteolytic reaction were undertaken using model membranes composed of phosphatidylcholine and phosphatidylserine (PCPS). The concentration of PCPS was varied to alter the concentration of free phospholipid available for substrate binding without influencing the concentration of membrane-assembled prothrombinase. In fluorescence stopped-flow measurements, increasing concentrations of PCPS resulted in an increase in the rate of product formation. Assessment of bond cleavage by sodium dodecyl sulfate-polyacrylamide gel electrophoresis following rapid chemical quench using I-125-prothrombin revealed that the activation reaction proceeded through the ordered cleavage at Arg(323)-Ile(324) followed by cleavage at Arg(274)-Thr(275) at all concentrations of PCPS. Increasing the PCPS concentration resulted in a large increase in the Arg(323)-Ile(324) cleavage reaction with a much smaller effect on the subsequent cleavage at Arg(274)-Thr(275), thereby leading to an increase in the extent of accumulation of the intermediate, meizothrombin. Fluorescence stopped flow and rapid chemical quench measurements were also conducted using prethrombin 2 plus fragment 1.2 or meizothrombin as substrates to assess the influence of PCPS on the individual cleavage reactions. The rate of cleavage at Arg(323)-Ile(324) by prothrombinase was increased similar to 60-fold with increasing PCPS, whereas the cleavage at Arg(274)-Thr(275) was increased by a factor of similar to 5. These differential effects of PCPS on the two cleavage reactions adequately explain changes in the extent of accumulation of meizothrombin during prothrombin activation. Proteolytic removal of the membrane binding fragment 1 domain of the substrates, meizothrombin and prethrombin 2-fragment 1.2, had no effect on the cleavage at Arg(274)-Thr(275) at saturating PCPS but completely eliminated the membrane-dependent rate enhancement for cleavage at Arg(323)-Ile(324). Thus, membrane binding by the substrate is essential for the first cleavage reaction at Arg(323)-Ile(324), which leads to the conversion of prothrombin to meizothrombin, In contrast, the substrate-membrane interaction mediated by the fragment 1 domain has no detectable effect on the second cleavage reaction at Arg(274)-Thr(275) which is required for the conversion of meizothrombin to thrombin.	EMORY UNIV,DEPT MED,DIV HEMATOL ONCOL,ATLANTA,GA 30322	Emory University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047465, R01HL052883] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52883, HL-47465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BOVILL EG, 1993, THROMB HAEMOSTASIS, V69, P779; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; DAVID GS, 1972, BIOCHEM BIOPH RES CO, V48, P464, DOI 10.1016/S0006-291X(72)80074-3; DOYLE MF, 1993, METHOD ENZYMOL, V222, P299; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1974, J BIOL CHEM, V249, P7798; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; GITEL SN, 1973, P NATL ACAD SCI USA, V70, P1344, DOI 10.1073/pnas.70.5.1344; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4492, DOI 10.1021/bi00852a046; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; Jesty J, 1976, Methods Enzymol, V45, P95; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; Mason J T, 1978, Ann N Y Acad Sci, V308, P29, DOI 10.1111/j.1749-6632.1978.tb22012.x; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PAPAHADJOPOULOS D, 1964, BIOCHIM BIOPHYS ACTA, V90, P436, DOI 10.1016/0304-4165(64)90220-X; PUSEY ML, 1983, BIOCHEM BIOPH RES CO, V114, P526, DOI 10.1016/0006-291X(83)90812-4; RIEMSLAG JWG, 1992, BIOCHEMISTRY-US, V31, P10000; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; ROSING J, 1980, J BIOL CHEM, V255, P274; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; SEGEL IH, 1975, ENZYME KINETICS, P606; TANS G, 1994, J BIOL CHEM, V269, P15969; TANS G, 1991, J BIOL CHEM, V266, P21864; TANS G, 1986, NEW COMPREHENSIVE BI, V13, P59; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WALKER RK, 1993, J BIOL CHEM, V268, P13920; WALKER RK, 1990, FASEB J, V7, pA1191	52	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27441	27450						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961657				2022-12-25	WOS:A1994PV77100047
J	MARQUARDT, B; FRITH, D; STABEL, S				MARQUARDT, B; FRITH, D; STABEL, S			SIGNALING FROM TPA TO MAP KINASE REQUIRES PROTEIN-KINASE-C, RAF AND MEK - RECONSTITUTION OF THE SIGNALING PATHWAY IN-VITRO	ONCOGENE			English	Article							PHORBOL ESTER; GROWTH-FACTORS; ONCOGENIC P21(RAS); RAT-1 FIBROBLASTS; THREONINE KINASE; IN-VITRO; ACTIVATION; PHOSPHORYLATION; CELLS; TYROSINE	The phorbol ester PMA/TPA (phorbol 12-myristate 13-acetate) is a potent tumor promoter which mimicks distinct intracellular signalling events triggered by activated growth factor receptors, e.g. the activation of MAP kinases. The largest known family of TPA-binding proteins comprise members of the protein kinase C (PKC) family although other TPA-binding proteins outside the PKC family have recently been identified. In this report we addressed the mechanism and the pathway by which TPA induces the activation Of MAPkinases. Using recombinant proteins and in vitro phosphorylation reactions we identified the components in the signal transduction pathway from TPA to MAPkinase and we show that the activation of MAPkinase by TPA requires the presence of protein kinase C, c-raf and the MAPkinase activator MEK. We also find that the activation of raf autophosphorylation in vitro correlates with the ability of Raf to signal to MAPkinase. Thus the activation of Raf by PKC apparently can trigger the same signalling pathway as oncogenic Raf or Raf activation by vas in combination with tyrosine phosphorylation.	MAX PLANCK GESELL,MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY; UNIV LONDON IMPERIAL COLL SCI & TECHNOL,LONDON SW7 2AY,ENGLAND	Max Planck Society; Imperial College London								ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; ADEREM A, 1992, PROTEIN KINASE C CUR, P255; AHMED S, 1993, J BIOL CHEM, V268, P10709; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BLUMBERG PM, 1981, CRC CR REV TOXICOL, V8, P199, DOI 10.3109/10408448109109658; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CHUNG DL, 1992, P NATL ACAD SCI USA, V89, P1993, DOI 10.1073/pnas.89.5.1993; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HARLOW E, 1988, ANTIBODIES LABORATOR; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARQUARDT B, 1992, GENE, V120, P297, DOI 10.1016/0378-1119(92)90109-3; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PFEIFER AMA, 1989, P NATL ACAD SCI USA, V86, P10075, DOI 10.1073/pnas.86.24.10075; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SOZERI O, 1992, ONCOGENE, V7, P2259; Stabel S., 1993, INTRACELLULAR MESSEN, P167; STABEL S, 1993, METH NEUROSCI, V18, P154; STITH BJ, 1987, EXP CELL RES, V169, P514, DOI 10.1016/0014-4827(87)90211-4; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUMMERS MD, 1987, TEXAS EXP STATION B, V1555; TOBE K, 1991, J BIOL CHEM, V266, P24793; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARNER LC, 1993, ONCOGENE, V8, P3249; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	56	162	162	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3213	3218						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936644				2022-12-25	WOS:A1994PM65800013
J	MOSNER, J; DEPPERT, W				MOSNER, J; DEPPERT, W			P53 AND MDM2 ARE EXPRESSED INDEPENDENTLY DURING CELLULAR PROLIFERATION	ONCOGENE			English	Article							WILD-TYPE P53; AUTOREGULATORY FEEDBACK LOOP; TUMOR-SUPPRESSOR PROTEIN; A MOUSE CELLS; DNA-REPLICATION; CYCLE CONTROL; GROWTH-REGULATION; NUCLEAR ANTIGEN; NORMAL 3T3; GENE	We analysed p53 expression during proliferation of serum stimulated Swiss mouse 3T3 cells and of concanavalin A stimulated mouse spleen lymphocytes and correlated it to rate of DNA synthesis and to expression of PCNA. We also analysed mdm2 gene expression, as rising p53 levels during proliferation might require MDM2 protein expression to functionally antagonize p53 mediated growth inhibition. p53 protein synthesis closely paralleled DNA synthesis and PCNA expression, suggesting a direct involvement of p53 in cellular DNA synthesis. mdm2 expression in 3T3 cells could not be correlated with p53 expression and DNA synthesis and was not detected at all in stimulated lymphocytes. We conclude that p53 and mdm2 expression during proliferation are not functionally related and that mdm2 expression is not required for proliferation.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY	Heinrich Pette Institute; University of Hamburg								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BASERGA R, 1991, J CELL SCI, V98, P433; BOYUM A, 1968, SCAND J CLIN LAB INV, V97, P76; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1990, ONCOGENE, V5, P1701; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FEINBERG AP, 1983, ANAL BIOCHEM, V136, P6; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FRITSCHE M, 1993, ONCOGENE, V8, P307; FROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1992, ONCOGENE, V7, P661; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PERRY ME, 1993, CURR OPIN CELL BIOL, V5, P1378; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SHOHAT O, 1987, ONCOGENE, V1, P277; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STURZBECHER HW, 1994, ONCOL REP, V1, P301; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	53	39	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3321	3328						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936657				2022-12-25	WOS:A1994PM65800026
J	MURTY, VVVS; LI, RG; HOULDSWORTH, J; BRONSON, DL; REUTER, VE; BOSL, GJ; CHAGANTI, RSK				MURTY, VVVS; LI, RG; HOULDSWORTH, J; BRONSON, DL; REUTER, VE; BOSL, GJ; CHAGANTI, RSK			FREQUENT ALLELIC DELETIONS AND LOSS OF EXPRESSION CHARACTERIZE THE DCC GENE IN MALE GERM-CELL TUMORS	ONCOGENE			English	Article							SUPPRESSOR GENE; CYTOGENETIC ANALYSIS; HETEROZYGOSITY; CHROMOSOME-18; CARCINOMAS; CANCER; 18Q21	The DCC tumor suppressor gene has been shown to be frequently deleted or its expression reduced or absent in colorectal, gastro-intestinal, pancreatic, prostatic, and breast carcinomas, and glioblastomas. By allelotype analysis using the DCC-flanking polymorphic marker D18S5 we have previously shown that allelic deletions at 18q21 occur in 40% of male germ cell tumors (Murty et al., 1994). In order to further understand the role of DCC gene in germ cell tumorigenesis, we evaluated deletions by loss of heterozygosity (LOH) and mRNA expression by RT-PCR in tumor tissues and cell lines. Analysis of 61 paired normal-tumor DNAs using the probes D18S5, JOSH 4.4 (a polymorphism within the DCC locus) and a (CA)(n) polymorphism in an intron of DCC revealed that 45% of GCTs had allelic deletions. In addition, two homozygous deletions were found in the DCC gene among 91 (61 used in the LOH analysis and an additional 30) tumor DNAs when screened with the cDNA probes (pDCC 1,65, pDCC 1.9 and pDCC 1.0). By RT-PCR analysis of four normal testes, nine GCT cell lines and 14 tumor tissues, DCC gene expression was detected in all four normal testes, while four (45%) GCT cell lines and one (7%) tumor specimen showed lack of expression. In addition, DCC expression was highly reduced in three (21%) tumor tissues. The high frequency of LOH at 18q21 was characteristic of seminomas as well as all subsets of non-seminomas in primary as well as metastatic states. Frequent allelic loss in all histologic subsets, homozygous deletions, and loss of expression of DCC suggest that suppression of this gene's function is an early event in GCT development.	MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,CYTOGENET SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR,NEW YORK,NY 10021; UNIV MINNESOTA,DEPT UROL SURG,MINNEAPOLIS,MN 55455	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Minnesota System; University of Minnesota Twin Cities	MURTY, VVVS (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.				NCI NIH HHS [CA-08748, CA-05826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA005826, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHAGANTI RSK, 1994, LANCET, V343, P1130, DOI 10.1016/S0140-6736(94)90235-6; CHAGANTI RSK, 1993, UROL CLIN N AM, V20, P55; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DAVIES PO, 1993, DEV BIOL, V3, P179; DEVILEE P, 1991, ONCOGENE, V6, P311; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GAO X, 1993, CANCER RES, V53, P2723; HOHNE MW, 1992, CANCER RES, V52, P2616; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; MURTY VVVS, 1994, ONCOGENE, V9, P2245; PORFIRI E, 1993, BLOOD, V81, P2696; RISINGER JI, 1992, HUM MOL GENET, V1, P657, DOI 10.1093/hmg/1.8.657-a; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; SCHECK AC, 1993, CANCER RES, V53, P5605; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; UCHINO S, 1992, CANCER RES, V52, P3099	20	46	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3227	3231						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936646				2022-12-25	WOS:A1994PM65800015
J	WU, K; SALAS, PJI; YEE, L; FREGIEN, N; CARRAWAY, KL				WU, K; SALAS, PJI; YEE, L; FREGIEN, N; CARRAWAY, KL			TISSUE AND TUMOR EXPRESSION OF A CELL-SURFACE GLYCOPROTEIN COMPLEX CONTAINING AN INTEGRAL MEMBRANE GLYCOPROTEIN ACTIVATOR OF P185(NEU)	ONCOGENE			English	Article							MAMMARY ADENOCARCINOMA CELLS; GROWTH FACTOR-ALPHA; EGF RECEPTOR; DIFFERENTIATION FACTOR; SIGNAL TRANSDUCTION; SIALOMUCIN COMPLEX; NEU ONCOGENE; TRANSFORMATION; HEREGULIN; PRECURSOR	Ascites 13762 rat mammary adenocarcinoma cells contain an abundant heterodimeric cell surface glycoprotein complex. It is composed of a transmembrane subunit and a sialomucin subunit and is the product of a single gene. The transmembrane subunit has two EGF-like domains and activates the proto-oncogene receptor kinase p185(neu). Southern blot comparisons of the ascites tumor and rat liver demonstrated the presence of the gene encoding the complex in normal tissues and showed an amplification of about fivefold in the ascites tumor. Polymerase chain reaction assays showed the presence of mRNA for the complex in rat brain and lung, but not in liver, pancreas, placenta,intestine, kidney, ovary and uterus. Northern blot analyses showed that the 9 kb transcript for the complex is expressed at an approximately 500-fold higher level in the ascites cells than in rat brain. Immunocytochemical studies using antiserum directed against the transmembrane subunit showed its presence in bronchial epithelium, brain ependymal and neurons of four day old animals and in the endoderm and neuronal cells of embryos. Similar immunocytochemical studies showed the presence of the transmembrane subunit in some human breast tumors. These results suggest that the gene encoding this complex is regulated in a tissue-specific manner, is overexpressed in some tumors and may play a role in tumor progesssion.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101; MT SINAI MED CTR,MIAMI BEACH,FL 33140	University of Miami; University of Miami; Mount Sinai Medical Center			Salas, Pedro J./AAS-9455-2021	Salas, Pedro/0000-0002-7411-1366	NCI NIH HHS [CA 52498, CA 14395] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052498, P30CA014395] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BUCK RL, 1979, ARCH BIOCHEM BIOPHYS, V198, P12, DOI 10.1016/0003-9861(79)90390-4; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1992, J CELL SCI, V103, P299; CODINGTON JF, 1983, BIOMEMBRANE, V11, P207; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Favaloro J, 1980, Methods Enzymol, V65, P718; GOSPODAROWICZ D, 1976, ANNU REV BIOCHEM, V45, P531, DOI 10.1146/annurev.bi.45.070176.002531; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOWARD SC, 1980, BIOCHIM BIOPHYS ACTA, V631, P79, DOI 10.1016/0304-4165(80)90055-0; HUGGINS JW, 1980, CANCER RES, V40, P1873; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Maniatis T., 1982, MOL CLONING; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MERCOLA M, 1988, DEVELOPMENT, V102, P451; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PETO R, 1975, BRIT J CANCER, V32, P411, DOI 10.1038/bjc.1975.242; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1986, CANCER RES, V46, P4543; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STECK PA, 1983, EXP CELL RES, V147, P255, DOI 10.1016/0014-4827(83)90208-2; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; WU K, 1994, J BIOL CHEM, V269, P11950; YU DH, 1991, ONCOGENE, V6, P1991	42	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3139	3147						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936636				2022-12-25	WOS:A1994PM65800005
J	ARGENT, RH; ROBERTS, LM; WALES, R; ROBERTUS, JD; LORD, JM				ARGENT, RH; ROBERTS, LM; WALES, R; ROBERTUS, JD; LORD, JM			INTRODUCTION OF A DISULFIDE BOND INTO RICIN-A CHAIN DECREASES THE CYTOTOXICITY OF THE RICIN HOLOTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIRABILIS ANTIVIRAL PROTEIN; DIPHTHERIA-TOXIN; A-CHAIN; ENDOPLASMIC-RETICULUM; EUKARYOTIC RIBOSOMES; ENGINEERED DISULFIDE; SUBSTANTIAL INCREASE; GALACTOSE BINDING; ESCHERICHIA-COLI; IDENTIFICATION	Wild type ricin A chain (RTA) contains two cysteine residues (Cys(171) and Cys(259)). Cys(259) forms the interchain disulfide bond of ricin holotoxin with Cys(4) of ricin B chain (RTB). We have used site-directed mutagenesis of RTA cDNA to convert Cys(171) to Ser and to introduce a disulfide bond into RTA by converting Ser(215) and Met(255) to Cys residues. Mutant RTA was expressed in Escherichia coli and directed to the oxidizing environment of the periplasmic space where the Cys(215)-Cys(255) disulfide bond was formed. The disulfide-containing RTA mutant had an in vitro catalytic activity similar to that of an identical form of recombinant RTA that lacked the S215C and M255C mutations. In the presence of glutathione and protein disulfide isomerase, this RTA variant reassociated with RTB to form ricin holotoxin. Incubation of this holotoxin with increasing concentrations of dithiothreitol showed that the interchain disulfide bond joining RTA and RTB was more readily reduced than the intrachain disulfide bond in RTA. Ricin in which the RTA moiety contained the disulfide bond was 15-18-fold less cytotoxic to HeLa or Vero cells than ricin in which the RTA did not contain the stabilizing disulfide crosslink. Since these ricin molecules had identical RTB cell binding and RTA catalytic activities, we suggest that the observed reduction in cytotoxicity caused by the introduced disulfide bond resulted from a constraint on the unfolding of RTA, indicating that such unfolding is necessary for the membrane translocation of RTA during its entry into the cytosol.	UNIV WARWICK, DEPT BIOL SCI, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND; UNIV TEXAS, DEPT CHEM, AUSTIN, TX 78712 USA	University of Warwick; University of Texas System; University of Texas Austin								BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAN HS, 1989, J CHEM PHYS, V90, P492, DOI 10.1063/1.456500; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FALNES PO, 1994, J BIOL CHEM, V269, P8402; Gibson T.J., 1984, THESIS U CAMBRIDGE; HABUKA N, 1991, J BIOL CHEM, V266, P23558; HABUKA N, 1989, J BIOL CHEM, V264, P6629; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KATZIN BJ, 1991, PROTEINS, V10, P251, DOI 10.1002/prot.340100309; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; MACER DRJ, 1988, J CELL SCI, V91, P61; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MAY MJ, 1989, EMBO J, V8, P301, DOI 10.1002/j.1460-2075.1989.tb03377.x; MEKADA E, 1981, J BIOL CHEM, V256, P1225; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; NEWTON DL, 1992, J BIOL CHEM, V267, P11917; OHARE M, 1987, FEBS LETT, V216, P73, DOI 10.1016/0014-5793(87)80759-7; PACE CN, 1988, J BIOL CHEM, V263, P11820; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PERRY LJ, 1986, BIOCHEMISTRY-US, V25, P733, DOI 10.1021/bi00351a034; RICHARDSON J, 1984, ADV PROTEIN CHEM, V34, P223; Robertus J, 1991, Semin Cell Biol, V2, P23; SANDVIG K, 1984, J CELL BIOL, V98, P963, DOI 10.1083/jcb.98.3.963; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; WALES R, 1991, J BIOL CHEM, V266, P19172; WALES R, 1992, EXP CELL RES, V203, P1, DOI 10.1016/0014-4827(92)90032-4; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z	32	51	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26705	26710						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929403				2022-12-25	WOS:A1994PQ93100022
J	DIX, DR; BRIDGHAM, JT; BRODERIUS, MA; BYERSDORFER, CA; EIDE, DJ				DIX, DR; BRIDGHAM, JT; BRODERIUS, MA; BYERSDORFER, CA; EIDE, DJ			THE FET4 GENE ENCODES THE LOW-AFFINITY FE(II) TRANSPORT PROTEIN OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT IRON TRANSPORT; TRANSFERRIN-BOUND IRON; FERRIC REDUCTASE; ESCHERICHIA-COLI; UPTAKE SYSTEM; YEAST; MEMBRANE; CELLS; DNA; TRANSFORMATION	Previous studies on Fe(II) uptake in Saccharomyces cerevisiae suggested the presence of two uptake systems with different affinities for this substrate. We demonstrate that the FET3 gene is required for high affinity uptake but not for the low affinity system. This requirement has enabled a characterization of the low affinity system. Low affinity uptake is time-, temperature-, and concentration-dependent and prefers Fe(II) over Fe(III) as substrate. We have isolated a new gene, FET4, that is required for low affinity uptake, and our results suggest that FET4 encodes an Fe(II) transporter protein. FET4's predicted amino acid sequence contains six potential transmembrane domains. Overexpressing FET4 increased low affinity uptake, whereas disrupting this gene eliminated that activity. In contrast, overexpressing FET4 decreased high affinity activity, while disrupting FET4 increased that activity. Therefore, the high affinity system may be regulated to compensate for alterations in low affinity activity. These analyses, and the analysis of the iron-dependent regulation of the plasma membrane Fe(III) reductase, demonstrate that the low affinity system is a biologically relevant mechanism of iron uptake in yeast. Furthermore, our results indicate that the high and low affinity systems are separate uptake pathways.	UNIV MINNESOTA, DEPT BIOCHEM & MOLEC BIOL, DULUTH, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth					NIGMS NIH HHS [GM48139] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048139] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Borson N D, 1992, PCR Methods Appl, V2, P144; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKER DJ, 1983, J BACTERIOL, V155, P616, DOI 10.1128/JB.155.2.616-622.1983; EGYED A, 1988, BRIT J HAEMATOL, V68, P483, DOI 10.1111/j.1365-2141.1988.tb04241.x; EIDE D, 1992, J BIOL CHEM, V267, P20774; EVANS SL, 1986, J BACTERIOL, V168, P1096, DOI 10.1128/jb.168.3.1096-1099.1986; FUHRMANN GF, 1968, BIOCHIM BIOPHYS ACTA, V163, P325, DOI 10.1016/0005-2736(68)90117-X; GRUSAK MA, 1990, PLANT PHYSIOL, V94, P1353, DOI 10.1104/pp.94.3.1353; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; INMAN RS, 1993, J BIOL CHEM, V268, P8521; JOHNSON W, 1991, INFECT IMMUN, V59, P2376, DOI 10.1128/IAI.59.7.2376-2381.1991; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; LIU HP, 1992, GENETICS, V132, P665; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; NEILANDS JB, 1987, IRON TRANSPORT MICRO, P24; NORRIS PR, 1977, J GEN MICROBIOL, V99, P317, DOI 10.1099/00221287-99-2-317; NUNEZ MT, 1992, J BIOL CHEM, V267, P11490; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; OSHIRO S, 1993, J BIOL CHEM, V268, P21586; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; ROMHELD V, 1983, PLANT PHYSIOL, V71, P949, DOI 10.1104/pp.71.4.949; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; Sherman F., 1986, METHODS YEAST GENETI; STURROCK A, 1990, J BIOL CHEM, V265, P3139; THORSTENSEN K, 1988, J BIOL CHEM, V263, P8844; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; Winkelmann G, 1987, IRON TRANSPORT MICRO; WRIGHT TL, 1986, J BIOL CHEM, V261, P909	41	255	263	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26092	26099						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929320				2022-12-25	WOS:A1994PQ93000026
J	ERICSON, ML; SUNDSTROM, M; SANSOM, DM; CHARRON, DJ				ERICSON, ML; SUNDSTROM, M; SANSOM, DM; CHARRON, DJ			MUTUALLY EXCLUSIVE BINDING OF PEPTIDE AND INVARIANT CHAIN TO MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II ANTIGENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; STAPHYLOCOCCAL ENTEROTOXIN-A; ALPHA-BETA-HETERODIMERS; HLA-DR MOLECULES; SURFACE EXPRESSION; ENDOPLASMIC-RETICULUM; MHC MOLECULES; MICE LACKING; GAMMA-CHAIN; PROTEIN	The invariant chain is a membrane protein associated with the major histocompatibility complex class II antigens both intra- and extracellularly. The extracellular portion of the human invariant chain (Ii) was expressed in Escherichia coli as a fusion protein with a polyhistidine tail and purified by metal affinity chromatography. The recombinant Ii was used as a ligand to probe binding to the cell surface of Chinese hamster ovary cells stably transfected with human class II alpha and beta genes of the DR4 isotype. We show that recombinant Ii inhibits peptide loading on class II polypeptides and also the converse; the presence of peptide in the antigen groove prevents binding of fluorescein conjugated Ii. Moreover, blocking of Ii binding by peptide did not require a transition of the class II dimers to an SDS stable state. A monoclonal antibody, L243, known to bind to (or close to) the peptide pocket of the class II molecule likewise blocked Ii-fluorescein binding. Further, we investigated whether or not the Ii, a variety of bacterial superantigens or the CD4 molecule, have overlapping binding sites on the class II heterodimer. Of the class II ligands tested, reduced binding was detected for the Staphylococcus superantigen type SEB on cells precincubated with soluble Ii while the binding of the other ligands was either unchanged or marginally changed. These data clarify by a direct biochemical approach the binding characteristics of Ii in comparison with other class II Ligands.	INST BIOMED CORDELIERS,IMMUNOGENET HUMAINE LAB,INSERM,U396,F-75006 PARIS,FRANCE; KAROLINSKA INST,CTR STRUCT BIOCHEM,S-10401 STOCKHOLM,SWEDEN; BATH INST RHEUMATOL DIS,BATH BA1 1HD,AVON,ENGLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Karolinska Institutet				Sansom, David/0000-0001-6506-3115				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BONNEROT C, 1994, EMBO J, V13, P934, DOI 10.1002/j.1460-2075.1994.tb06338.x; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; CHEN BP, 1990, J EXP MED, V172, P779, DOI 10.1084/jem.172.3.779; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; CLAESSONWELSH L, 1986, J IMMUNOL, V136, P484; CLEMENTS VK, 1992, J IMMUNOL, V149, P2391; FISCHER H, 1989, J IMMUNOL, V142, P3151; FLEISCHER B, 1991, J IMMUNOL, V146, P11; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; FREISEWINKEL IM, 1993, P NATL ACAD SCI USA, V90, P9703, DOI 10.1073/pnas.90.20.9703; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; JENSEN PE, 1992, J EXP MED, V176, P793, DOI 10.1084/jem.176.3.793; JONES PP, 1978, IMMUNOCHEMISTRY, V16, P51; KARP DR, 1992, P NATL ACAD SCI USA, V89, P9657, DOI 10.1073/pnas.89.20.9657; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOCH N, 1989, TRENDS BIOCHEM SCI, V14, P383, DOI 10.1016/0968-0004(89)90013-3; KOCH N, 1991, J IMMUNOL, V147, P2643; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LOSS GE, 1993, J IMMUNOL, V150, P3187; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MAX H, 1993, HUM IMMUNOL, V38, P193, DOI 10.1016/0198-8859(93)90540-H; MOLLICK JA, 1989, SCIENCE, V244, P817, DOI 10.1126/science.2658055; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NUCHTERN JG, 1990, NATURE, V343, P75; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; REAY PA, 1992, EMBO J, V11, P2829, DOI 10.1002/j.1460-2075.1992.tb05350.x; REYES VE, 1991, J IMMUNOL, V146, P3877; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROCHE PA, 1992, EMBO J, V11, P2841, DOI 10.1002/j.1460-2075.1992.tb05351.x; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SADEGHNASSERI S, 1992, IMMUNOL TODAY, V13, P43, DOI 10.1016/0167-5699(92)90131-P; SANSOM DM, 1993, IMMUNOLOGY, V80, P242; SCHOLL PR, 1989, J IMMUNOL, V143, P2583; SETTE A, 1992, J IMMUNOL, V148, P844; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VIGUIER M, 1990, P NATL ACAD SCI USA, V87, P7170, DOI 10.1073/pnas.87.18.7170; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	65	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26531	26538						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929377				2022-12-25	WOS:A1994PQ93000090
J	TEPEL, M; KUHNAPFEL, S; THEILMEIER, G; TEUPE, C; SCHLOTMANN, R; ZIDEK, W				TEPEL, M; KUHNAPFEL, S; THEILMEIER, G; TEUPE, C; SCHLOTMANN, R; ZIDEK, W			FILLING STATE OF INTRACELLULAR CA2+ POOLS TRIGGERS TRANS PLASMA-MEMBRANE NA+ AND CA2+ INFLUX BY A TYROSINE KINASE-DEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE NA+; CAPACITATIVE CALCIUM ENTRY; PAROTID ACINAR-CELLS; SMOOTH-MUSCLE CELLS; HUMAN PLATELETS; TUMOR PROMOTER; CYCLOPIAZONIC ACID; THAPSIGARGIN; STORES; CA-2+	The relations between the filling state of intracellular calcium stores that are regulated by the endoplasmic Ca2+-ATPase and trans plasma membrane sodium and calcium influx were investigated. The effects of specific inhibition of endoplasmic Ca2+-ATPase by thapsigargin, cyclopiazonic acid, and 2,5 di-(tert-butyl)-1,4-benzohydroquinone (BHQ) on cytosolic free sodium concentration ([Na+](i)) and cytosolic free calcium concentration ([Ca2+](i)) were evaluated in lymphocytes from healthy subjects using the fluorescent dyes sodium-binding benzofuran isophthalate and fura2. The specific inhibition of endoplasmic Ca2+-ATPase by thapsigargin, cyclopia tonic acid, or BHQ increased lymphocytic [Na+](i) and [Ca2+](i). The thapsigargin-induced [Na+](i) increase was abolished in the absence of external sodium, indicating that thapsigargin induced a trans plasma membrane sodium influx. In the absence of external calcium the thapsigargin-induced [Ca2+](i) increase was significantly reduced, whereas the thapsigargin induced [Na+](i) increase remained the same. This finding indicates that the filling state of intracellular calcium pools rather than the elevation of [Ca2+](i) per se regulates the plasma membrane permeability for sodium in lymphocytes. The inhibition of the tyrosine kinase by genistein inhibited the thapsigargin-induced increases of both [Na+](i) and [Ca2+](i) in lymphocytes. The present study shows that the filling state of intracellular thapsigargin-sensitive calcium pools regulates trans plasma membrane sodium and calcium influx via a tyrosine kinase-dependent pathway.			TEPEL, M (corresponding author), UNIV MUNSTER,MED POLIKLIN,D-48129 MUNSTER,GERMANY.		Tepel, Martin/GRS-9581-2022	Tepel, Martin/0000-0002-0086-0997				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BALASUBRAMANYAM M, 1993, AM J PHYSIOL, V265, pC321, DOI 10.1152/ajpcell.1993.265.2.C321; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BORIN M, 1990, J BIOL CHEM, V265, P19543; BORIN ML, 1993, AM J PHYSIOL, V264, pC1513, DOI 10.1152/ajpcell.1993.264.6.C1513; BRUNE B, 1991, J BIOL CHEM, V266, P19232; DEAN NM, 1989, BIOCHEM BIOPH RES CO, V165, P258; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; ISHIDA T, 1993, J HYPERTENS, V11, P1089, DOI 10.1097/00004872-199310000-00013; ISHIKAWA S, 1993, BIOCHEM BIOPH RES CO, V194, P287, DOI 10.1006/bbrc.1993.1817; KIMURA M, 1993, J PHYSIOL-LONDON, V464, P1; LEE KM, 1993, J BIOL CHEM, V268, P9945; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MARKS F, 1991, CARCINOGENESIS, V12, P1491, DOI 10.1093/carcin/12.8.1491; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MONTERO M, 1990, BIOCHEM J, V271, P535, DOI 10.1042/bj2710535; NASMITH PE, 1987, FEBS LETT, V221, P95, DOI 10.1016/0014-5793(87)80359-9; OKADA K, 1991, AM J PHYSIOL, V261, pF1007; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PEPER RJ, 1968, J LAB CLIN MED, V72, P842; PRITCHARD K, 1989, CLIN SCI, V76, P631, DOI 10.1042/cs0760631; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RADRIAMAMPITA C, 1993, NATURE, V364, P809; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TEPEL M, 1992, J HYPERTENS, V10, P991; TEPEL M, 1991, BIOCHEM BIOPH RES CO, V177, P991, DOI 10.1016/0006-291X(91)90636-L; TEPEL M, 1994, HYPERTENSION S1, V23, P198; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911	36	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26239	26242						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929340				2022-12-25	WOS:A1994PQ93000048
J	DOI, T; KURASAWA, M; HIGASHINO, K; IMANISHI, T; MORI, T; NAITO, M; TAKAHASHI, K; KAWABE, Y; WADA, Y; MATSUMOTO, A; KODAMA, T				DOI, T; KURASAWA, M; HIGASHINO, K; IMANISHI, T; MORI, T; NAITO, M; TAKAHASHI, K; KAWABE, Y; WADA, Y; MATSUMOTO, A; KODAMA, T			THE HISTIDINE INTERRUPTION OF AN ALPHA-HELICAL COILED-COIL ALLOSTERICALLY MEDIATES A PH-DEPENDENT LIGAND DISSOCIATION FROM MACROPHAGE SCAVENGER RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; EPIDERMAL GROWTH-FACTOR; LEUCINE ZIPPER; CHOLESTEROL DEPOSITION; MOLECULAR FLYPAPER; INSULIN-RECEPTOR; RAT-LIVER; ENDOCYTOSIS; BINDING; ATHEROSCLEROSIS	Macrophage scavenger receptors uptake modified low density lipoproteins (LDLs) through receptor mediated endocytosis. In the alpha-helical coiled coil domain, 2 histidines (His(168) and His(260)) disrupt leucine or isoleucine heptad repeats. Substitution of His(168) or/and His(260) to leucine had no effect on AcLDL binding activities, However, the His(260)-replaced receptors had their ligand degradation activities diminished. Cell surface ligand release experiments under acidic pH clarified that His(260) mutants lost their ligand dissociation activities at 37 degrees C. Furthermore, immunoelectron microscopic experiments using anti-scavenger receptor antibody showed that the His(260) replaced receptors were not able to release gold-labeled AcLDL in endosomes. Here we propose an allosterical ligand dissociation mechanism by His(260) in macrophage scavenger receptors.	KUMAMOTO UNIV,SCH MED,DEPT PATHOL 2,KUMAMOTO 860,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	Kumamoto University; University of Tokyo	DOI, T (corresponding author), OSAKA UNIV,FAC PHARMACEUT SCI,SUITA,OSAKA 565,JAPAN.			Kawabe, Yoshiki/0000-0002-6465-7146				ACTON S, 1993, J BIOL CHEM, V268, P3530; ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P741, DOI 10.1177/10.6.741; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; DIPAOLA M, 1984, J BIOL CHEM, V259, P9163; DOI T, 1993, J BIOL CHEM, V268, P2126; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; EMI M, 1993, J BIOL CHEM, V268, P2120; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANDLEY DA, 1981, P NATL ACAD SCI-BIOL, V78, P368, DOI 10.1073/pnas.78.1.368; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; KRUPP MN, 1982, J BIOL CHEM, V257, P1372; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORI T, 1994, IN PRESS LAB INVEST; MUEHLPFORDT H, 1982, Experientia (Basel), V38, P1127; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PASTAN I, 1983, TRENDS BIOCHEM SCI, V8, P250, DOI 10.1016/0968-0004(83)90351-1; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TERASAKI T, 1989, J PHARMACOL EXP THER, V251, P351; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WOODS JW, 1986, J CELL BIOL, V103, P277, DOI 10.1083/jcb.103.1.277	39	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25598	25604						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929263				2022-12-25	WOS:A1994PQ49100058
J	AOTA, S; NOMIZU, M; YAMADA, KM				AOTA, S; NOMIZU, M; YAMADA, KM			THE SHORT AMINO-ACID-SEQUENCE PRO-HIS-SER-ARG-ASN IN HUMAN FIBRONECTIN ENHANCES CELL-ADHESIVE FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BINDING DOMAIN; III MODULE; POLYMERASE; REGIONS; PROTEIN; RGD	Synergistic sites in the central cell-adhesive domain of fibronectin (FN) substantially enhance cell adhesion mediated by the alpha(5) beta(1) integrin receptor for fibronectin. We characterized a critical minimal sequence needed for synergistic activity using site directed mutagenesis and homology scanning using intramolecular chimeras. The minimal cell-binding domain of FN consisting of the 9th and 10th type III FN repeat was expressed in an Escherichia coli expression system. This protein retained high biological activity when assayed using a competitive inhibition assay for FN-mediated adhesion of baby hamster kidney or HT-1080 cells. In contrast, a construct consisting of the 8th and 10th repeat displayed very low biological activity. By replacing various portions of the 8th repeat with homologous 9th repeat segments, we mapped the synergistic region to the center of the 9th repeat. When a very short peptide sequence, Pro-His-Ser-Arg-Asn (PHSRN), from the 9th repeat was substituted for the homologous pentapeptide site in the 8th repeat sequence, the recombinant protein showed markedly enhanced activity. Further mutagenesis analysis suggested that the arginine residue of this pentapeptide sequence is important for function. We also identified a weaker adjacent synergy region other than the PHSRN region, Epitope mapping of an anti-FN monoclonal antibody that inhibits FN-mediated adhesion identified the same critical regions. A synthetic peptide containing the PHSRN sequence showed neither competitive inhibitory activity in solution nor synergy with a soluble RGD-containing peptide. However, when the same synthetic peptide was positioned via a covalent bond at the corresponding site of the normally inactive 8th repeat, it mediated an enhancement of adhesive activity. These results identify a pentapeptide site that synergistically enhances the cell-adhesive activity of the FN RGD sequence.	NIDR,DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Yamada, Kenneth/0000-0003-1512-6805				AOTA S, 1991, J BIOL CHEM, V266, P15938; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; Hynes RO, 1990, FIBRONECTINS; KIMIZUKA F, 1991, J BIOL CHEM, V266, P3045; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Mosher DF, 1989, FIBRONECTIN; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; ROBEY FA, 1989, ANAL BIOCHEM, V177, P373, DOI 10.1016/0003-2697(89)90068-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3	22	528	536	1	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24756	24761						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929152				2022-12-25	WOS:A1994PQ49000039
J	IYPE, LE; WOOD, EA; INMAN, RB; COX, MM				IYPE, LE; WOOD, EA; INMAN, RB; COX, MM			RUVA AND RUVB PROTEINS FACILITATE THE BYPASS OF HETEROLOGOUS DNA INSERTIONS DURING RECA PROTEIN-MEDIATED DNA STRAND EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RUVA; HOLLIDAY JUNCTIONS; BRANCH MIGRATION; BINDING-PROTEIN; NUCLEOSIDE TRIPHOSPHATE; PARTIAL DENATURATION; ATP HYDROLYSIS; M13 VECTORS; RECOMBINATION; REPAIR	RecA protein mediated DNA strand exchange between circular single stranded DNA and linear duplex DNA readily bypasses short (up to 100 base pairs) heterologous inserts in one of the DNA substrates. Larger heterologous inserts are bypassed with decreasing efficiency, and inserts larger than 200 base pairs substantially block RecA-mediated DNA strand exchange. The RuvA and RuvB proteins dramatically facilitate the bypass of larger heterologous inserts. When the RuvA and RuvB proteins are added to an ongoing RecA protein-mediated strand exchange reaction, interior heterologous inserts of 1 kilobase pair are bypassed at significant frequencies. The RuvA, RuvB, and RecA proteins are all required for this activity. Bypass occurs only when homologous sequences are present on both sides of the insert. When the heterologous insert is positioned at either end of the linear duplex substrate, the RuvA and RuvB proteins do not significantly increase product formation in RecA protein-mediated DNA strand exchange reactions. The results suggest an important role for RuvA and RuvB in the bypass of DNA structural barriers during recombinational DNA repair.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison								BEDALE WA, 1993, J BIOL CHEM, V268, P15004; BEDALE WA, 1991, J BIOL CHEM, V266, P6499; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; COX MM, 1991, MOL MICROBIOL, V5, P1295, DOI 10.1111/j.1365-2958.1991.tb00775.x; COX MM, 1987, DNA REPLICATION RECO, P597; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DASGUPTA C, 1982, P NATL ACAD SCI-BIOL, V79, P762, DOI 10.1073/pnas.79.3.762; Davis R., 1980, ADV BACTERIAL GENETI; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; HAHN TR, 1988, J BIOL CHEM, V263, P7431; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1989, MOL GEN GENET, V219, P328, DOI 10.1007/BF00261196; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; JAIN SK, 1992, J BIOL CHEM, V267, P4215; JAIN SK, 1994, J BIOL CHEM, V269, P20653; JWANG BR, 1992, P NATL ACAD SCI USA, V89, P7596, DOI 10.1073/pnas.89.16.7596; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KIM JI, 1992, J BIOL CHEM, V267, P16438; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LICHTEN M, 1984, P NATL ACAD SCI-BIOL, V81, P7180, DOI 10.1073/pnas.81.22.7180; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LIVNEH Z, 1982, P NATL ACAD SCI-BIOL, V79, P3171, DOI 10.1073/pnas.79.10.3171; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SHINAGAWA H, 1991, BIOCHIMIE, V73, P505, DOI 10.1016/0300-9084(91)90120-P; SHURVINTON CE, 1982, MOL GEN GENET, V185, P352, DOI 10.1007/BF00330811; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAYLOR AF, 1992, CELL, V69, P1063, DOI 10.1016/0092-8674(92)90626-N; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WEST SC, 1992, MOL MICROBIOL, V6, P2755, DOI 10.1111/j.1365-2958.1992.tb01454.x; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149	68	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24967	24978						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929180				2022-12-25	WOS:A1994PQ49000067
J	LEMBERGER, T; STAELS, B; SALADIN, R; DESVERGNE, B; AUWERX, J; WAHLI, W				LEMBERGER, T; STAELS, B; SALADIN, R; DESVERGNE, B; AUWERX, J; WAHLI, W			REGULATION OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA GENE BY GLUCOCORTICOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACYL-COA OXIDASE; FATTY-ACIDS; RESPONSE ELEMENT; CLOFIBRIC ACID; ENZYME GENE; IDENTIFICATION; INDUCTION; DEXAMETHASONE; SUPERFAMILY; EXPRESSION	This study demonstrates that the expression of the peroxisome proliferator-activated receptor alpha (PPAR alpha) is regulated by glucocorticoid hormones in hepatocytes. Hydrocortisone, dexamethasone, and triamcinolone stimulated PPAR alpha mRNA synthesis in a dose-dependent manner in primary rat hepatocyte cultures. This glucocorticoid stimulation was inhibited by RU 486, a specific glucocorticoid antagonist. Moreover, in contrast to glucocorticoid hormones, the mineralocorticoid aldosterone had only a weak effect, suggesting that the hormonal stimulation of PPAR alpha was mediated by the glucocorticoid receptor. The induction was not prevented by cycloheximide treatment of the hepatocytes, indicating that it was mediated by preexisting glucocorticoid receptor. Finally, the RNA synthesis inhibitor actinomycin D abolished the stimulatory effect of dexamethasone, and nuclear run-on analysis showed an increase of PPAR alpha transcripts after hormonal induction. Thus, the PPAR alpha gene is an early response gene of glucocorticoids that control its expression at the transcriptional level.	UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND; INST PASTEUR,DEPT ATHEROSCLEROSE,BIOL REGULAT EUCARYOTES LAB,F-59019 LILLE,FRANCE	University of Lausanne; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Staels, Bart/N-9497-2016; Wahli, Walter/I-3194-2019; Lemberger, Thomas/A-7301-2008; Wahli, Walter/B-1398-2009; Auwerx, Johan/ABE-9307-2021; Desvergne, Beatrice/C-8892-2016	Staels, Bart/0000-0002-3784-1503; Lemberger, Thomas/0000-0002-2499-4025; Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X; Auwerx, Johan/0000-0002-5065-5393				AMRI EZ, 1991, J LIPID RES, V32, P1457; AUWERX J, 1992, HORM RES, V38, P269, DOI 10.1159/000182557; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DESVERGNE B, 1994, INDUCIBLE GENE EXPRE, V1, P142; DIVERTIE GD, 1991, DIABETES, V40, P1228, DOI 10.2337/diabetes.40.10.1228; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FAIN JN, 1965, J BIOL CHEM, V240, P3522; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; RODRIGUEZ JC, 1994, IN PRESS J BIOL CHEM, V269; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SORENSEN HN, 1993, BIOCHIM BIOPHYS ACTA, V1171, P263, DOI 10.1016/0167-4781(93)90064-K; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; ZHU Y, 1993, J BIOL CHEM, V258, P26817	28	210	219	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24527	24530						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929119				2022-12-25	WOS:A1994PQ49000003
J	SCHIRCH, D; VILLAR, E; MARAS, B; BARRA, D; SCHIRCH, V				SCHIRCH, D; VILLAR, E; MARAS, B; BARRA, D; SCHIRCH, V			DOMAIN-STRUCTURE AND FUNCTION OF 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE BINDING-PROTEIN; RAT-LIVER; PURIFICATION; HYDROLASE; METABOLISM; RESOLUTION; CYTOSOL	10-Formyltetrahydrofolate dehydrogenase catalyzes the NADP(+)-dependent oxidation of 10-formyltetrahydrofolate to CO2 and tetrahydrofolate. Previous studies have shown that the enzyme binds the physiological pentaglutamate form of tetrahydrofolate product so tightly that it remains bound during size exclusion chromatography (Cook, R. J., and Wagner, C. (1982) Biochemistry 21, 4427-4434). In addition to the dehydrogenase activity, the enzyme from rat liver has been reported to exhibit both 10-formyltetrahydrofolate hydrolase and aldehyde dehydrogenase activities (Cook, R. J., Lloyd, R. S., and Wagner, C. (1991) J. Biol. Chem. 266, 4965-4973). We have purified the enzyme from rabbit liver and found that it catalyzes the same three reactions with similar kinetic constants and that it is a 99-kDa homotetramer, as reported previously for the rat and pig enzymes. Previous studies have suggested that the enzyme is composed of three domains and has separate folate binding sites for the dehydrogenase and hydrolase activities. We have investigated the domain structure of the rabbit enzyme. Differential scanning calorimetry reveals two thermal transitions, indicating the presence of two independently folded domains. The pentaglutamate form of tetrahydrofolate and NADP(+) each stabilize one of the thermal transitions, showing that these ligands bind to separate domains. Limited proteolytic digestions by several proteases cleave the enzyme in a linker region between the two domains. After proteolytic cleavage, the domains no longer remain associated and do not catalyze the 10-formyltetrahydrofolate dehydrogenase reaction. Isolation and characterization of the intact domains revealed that the N-terminal domain only catalyzes the NADP(+)-independent 10-formyltetrahydrofolate hydrolase activity and the C-terminal domain only catalyzes the NADP(+)-dependent aldehyde dehydrogenase activity. The kinetic constants of these isolated domains are similar to those of the intact enzyme. Binding studies on the native enzyme using fluorescence and isothermal titration calorimetry indicated that the enzyme binds one molecule of tetrahydrofolate and two molecules of NADP(+) per tetramer. Dissociation constants for both ligands were also determined by these methods.	VIRGINIA COMMONWEALTH UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, RICHMOND, VA 23298 USA; UNIV SALAMANCA, DEPT BIOQUIM & BIOL MOLEC, E-37007 SALAMANCA, SPAIN; UNIV ROMA LA SAPIENZA, CNR, DIPARTIMENTO SCI BIOCHIM, I-00185 ROME, ITALY; UNIV ROMA LA SAPIENZA, CNR, CTR BIOL MOLEC, I-00185 ROME, ITALY	Virginia Commonwealth University; University of Salamanca; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Maras, Bruno/A-2020-2010; Barra, Donatella/D-1236-2011		NIGMS NIH HHS [GM 28143] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagshaw C. R., 1987, SPECTROPHOTOMETRY SP, P91; BARLOWE C K, 1988, Biofactors, V1, P171; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; CASE GL, 1988, J BIOL CHEM, V263, P10204; CHEN MS, 1973, J BIOL CHEM, V248, P3631; COOK RJ, 1991, J BIOL CHEM, V266, P4965; COOK RJ, 1982, BIOCHEMISTRY-US, V21, P4427, DOI 10.1021/bi00261a036; Dawson R.M., 1986, DATA BIOCH RES, P130; ECKFELDT J, 1976, J BIOL CHEM, V251, P236; KREBS HA, 1976, BIOCHEM J, V158, P341, DOI 10.1042/bj1580341; KUTZBACH C, 1971, METHODS ENZYMOL B, V18, P793; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; REAM JE, 1992, BIOCHEMISTRY-US, V31, P5528, DOI 10.1021/bi00139a015; RIOSORLANDI EM, 1986, BIOCHIM BIOPHYS ACTA, V871, P24, DOI 10.1016/0167-4838(86)90129-9; RYAN LD, 1974, ARCH BIOCHEM BIOPHYS, V160, P279, DOI 10.1016/S0003-9861(74)80035-4; SANNY CG, 1985, ALCOHOL CLIN EXP RES, V9, P255, DOI 10.1111/j.1530-0277.1985.tb05746.x; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SCRUTTON MC, 1979, BIOCHEM J, V177, P833, DOI 10.1042/bj1770833; STOVER P, 1992, ANAL BIOCHEM, V202, P82, DOI 10.1016/0003-2697(92)90210-X; TEMPLE C, 1980, CHEM BIOCH FOLATES, V1, P61; WEBB JL, 1963, ENZYMES METABOL INH, V1, P71	25	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24728	24735						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929148				2022-12-25	WOS:A1994PQ49000035
J	TAKEUCHI, A; MIYAMOTO, T; HAYASHI, H; TOMITA, M; ONOZAKI, K				TAKEUCHI, A; MIYAMOTO, T; HAYASHI, H; TOMITA, M; ONOZAKI, K			PURIFICATION AND CHARACTERIZATION OF A HUMAN ERYTHROCYTE-DERIVED GROWTH-FACTOR WITH A WIDE TARGET-CELL SPECTRUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; GRADIENT GEL-ELECTROPHORESIS; NON-DENATURED PROTEINS; POTENTIATING ACTIVITY; PROMOTING ACTIVITY; MOLECULAR-WEIGHTS; TISSUE INHIBITOR; STOKES RADII; LINES; PLATELETS	A cell extract from human erythrocytes promoted the growth of a wide variety of cell types, namely human and mouse myeloid cells, human and mouse T cells, human B cells, human melanoma cells, mouse transformed fibroblast cells, mouse mastocytoma cells, human lung fibroblast cells, and mouse bone marrow fibroblast/stroma-like cells. The growth-promoting activity was acid- and heat labile and sensitive to proteases, indicating the proteinaceous nature of the molecule. The activity was also lost upon exposure to 2-mercaptoethanol. The novel growth-promoting factor, termed basic growth factor because of its fundamental effect and a wide target cell spectrum, was purified by sequential anion-exchange, hydrophobic, gel filtration, hydroxylapatite, and reverse-phase high performance liquid chromatographies. The purified factor has an apparent molecular mass of 53 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing and nonreducing conditions. The factor migrated at 270 kDa on native gradient polyacrylamide gel electrophoresis. Therefore, the factor consists of a homopolymer of a single polypeptide chain. The purified factor promoted the growth of the same cell types as the cell extract, except for bone marrow cells.	NAGOYA CITY UNIV,FAC PHARMACEUT SCI,DEPT HYG CHEM,MIZUHO KU,NAGOYA,AICHI 467,JAPAN; SHOWA UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,SHINAGAWA KU,TOKYO 143,JAPAN	Nagoya City University; Showa University								ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; AVALOS BR, 1988, BLOOD, V71, P1720; BALKWILL FR, 1989, IMMUNOL TODAY, V10, P299, DOI 10.1016/0167-5699(89)90085-6; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; FRAEFEL W, 1986, 2ND P S CYT KYOT, V2, P293; GAFFNEY EV, 1986, J LEUKOCYTE BIOL, V39, P409, DOI 10.1002/jlb.39.4.409; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; JAEGER KH, 1958, KLIN WOCHENSCHR, V36, P441, DOI 10.1007/BF01478732; KODAMA S, 1989, MATRIX, V9, P1; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; MIYAMOTO T, 1994, IN PRESS BIOCH MOL B; MIYAURA C, 1988, FEBS LETT, V234, P17, DOI 10.1016/0014-5793(88)81293-6; MORINAGA Y, 1989, J IMMUNOL, V143, P3538; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; ONOZAKI K, 1985, J IMMUNOL, V135, P3962; ONOZAKI K, 1988, J IMMUNOL, V140, P112; Riede U N, 1975, Med Welt, V26, P122; ROTHE GM, 1982, ELECTROPHORESIS, V3, P43, DOI 10.1002/elps.1150030108; ROTHE GM, 1982, ELECTROPHORESIS, V3, P33, DOI 10.1002/elps.1150030107; RUFF MR, 1980, J IMMUNOL, V125, P1671; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; STANLEY ER, 1980, MONONUCLEAR PHAGOCYT, P417; TAKEUCHI A, 1993, CANCER RES, V53, P1871; TAMATANI T, 1989, J BIOCHEM-TOKYO, V105, P55, DOI 10.1093/oxfordjournals.jbchem.a122619; TSUTSUI T, 1984, JPN J PHARMACOL, V34, P471, DOI 10.1254/jjp.34.471; WELUGUS HG, 1983, J BIOL CHEM, V258, P12259; WESTBROOK CA, 1984, J BIOL CHEM, V259, P9992	36	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24935	24940						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929176				2022-12-25	WOS:A1994PQ49000063
J	TIELENS, AGM; VANDENHEUVEL, JM; VANMAZIJK, HJ; WILSON, JE; SHOEMAKER, CB				TIELENS, AGM; VANDENHEUVEL, JM; VANMAZIJK, HJ; WILSON, JE; SHOEMAKER, CB			THE 50-KDA GLUCOSE 6-PHOSPHATE-SENSITIVE HEXOKINASE OF SCHISTOSOMA-MANSONI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN HEXOKINASE; C-TERMINAL HALVES; FRUCTOSE 2,6-BISPHOSPHATE; ENERGY-METABOLISM; SUGAR KINASES; PROTEINS; ENZYME; SITE; PHOSPHOFRUCTOKINASE; BINDING	Hexokinase has been purified from adult Schistosoma mansoni worms and the activity shown to be associated with a single protein species having an M(r) about 50,000. This protein is recognized on Western blots probed with antisera against rat Type I hexokinase or against a recombinant S. mansoni hexokinase that had been expressed in Escherichia coli using a previously cloned cDNA. An 18-residue N-terminal sequence determined for the purified S. mansoni hexokinase is identical to that deduced from the nucleotide sequence of the cDNA, consistent with the view that the cloned cDNA encodes the hexokinase characterized in the present study. The S. mansoni enzyme has a relatively low K-m (approximate to 60 mu M) for glucose and is sensitive to inhibition (competitive versus ATP, K-i approximate to 50 mu M) by its product, glucose 6-phosphate (Glc-6-P). With these kinetic properties and 50 kDa molecular mass, S. mansoni hexokinase resembles the ancestral hexokinase predicted to have given rise, by gene duplication and fusion, to the present day 100-kDa Glc-6-P-sensitive mammalian hexokinases. The schistosomal hexokinase represents the first 50-kDa Glc-6-P-sensitive hexokinase whose sequence has been obtained. The schistosomal hexokinase does not bind to mitochondria, consistent with its lack of a hydrophobic segment at the N terminus which is required for binding of the mammalian Type I and II isoenzymes to mitochondria. The marked Crabtree effect exhibited by S. mansoni cercariae may be at least partly attributed to the expression of rather high levels of a hexokinase having a high affinity for glucose but only a moderate sensitivity to product inhibition by Glc-6-P.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115	Michigan State University; Harvard University; Harvard T.H. Chan School of Public Health	TIELENS, AGM (corresponding author), UNIV UTRECHT,VET BIOCHEM LAB,POB 80176,3508 TD UTRECHT,NETHERLANDS.			Tielens, Aloysius/0000-0002-5485-1105	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI028499, R01AI028499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009910] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28499] Funding Source: Medline; NINDS NIH HHS [NS09910] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARORA KK, 1993, J BIOL CHEM, V268, P18259; ARORA KK, 1991, J BIOL CHEM, V266, P5359; BAIJAL M, 1992, ARCH BIOCHEM BIOPHYS, V298, P271, DOI 10.1016/0003-9861(92)90123-E; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BORK P, 1993, PROTEIN SCI, V2, P31; BUEDING E, 1950, J GEN PHYSIOL, V33, P475, DOI 10.1085/jgp.33.5.475; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; CHOU AC, 1974, ARCH BIOCHEM BIOPHYS, V165, P628, DOI 10.1016/0003-9861(74)90290-2; Colowick SP., 1973, ENZYMES, V9, P1, DOI DOI 10.1016/S1874-6047(08)60113-4; EIGENBRODT E, 1985, REGULATION CARBOHYDR, V2, P141; ELLISON WR, 1975, J BIOL CHEM, V250, P1864; ELLISON WR, 1974, BIOCHEM BIOPH RES CO, V57, P1214, DOI 10.1016/0006-291X(74)90826-2; GRIFFIN LD, 1991, GENOMICS, V11, P1014, DOI 10.1016/0888-7543(91)90027-C; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; HARRISON RW, 1985, THESIS YALE U NEW HA; HOREMANS AMC, 1991, PARASITOLOGY, V102, P259, DOI 10.1017/S0031182000062570; HOREMANS AMC, 1992, MOL BIOCHEM PARASIT, V51, P73, DOI 10.1016/0166-6851(92)90202-U; HUE L, 1993, ADV ENZYME REGUL, V33, P97; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNANI M, 1992, BIOCHEM J, V285, P193, DOI 10.1042/bj2850193; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOCHIZUKI Y, 1981, COMP BIOCHEM PHYS B, V70, P745, DOI 10.1016/0305-0491(81)90011-0; MOCHIZUKI Y, 1977, J BIOCHEM, V81, P1849, DOI 10.1093/oxfordjournals.jbchem.a131646; PAYNE MA, 1991, J BIOL CHEM, V266, P8891; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; POLAKIS PG, 1985, ARCH BIOCHEM BIOPHYS, V236, P328, DOI 10.1016/0003-9861(85)90633-2; REES BB, 1989, J BIOL CHEM, V264, P15410; ROSE IA, 1974, ARCH BIOCHEM BIOPHYS, V164, P729, DOI 10.1016/0003-9861(74)90086-1; SANGSTER NC, 1987, COMP BIOCHEM PHYS B, V88, P317, DOI 10.1016/0305-0491(87)90122-2; SENER A, 1988, J BIOL CHEM, V263, P1904; SKELLY PJ, 1993, MOL BIOCHEM PARASIT, V60, P93, DOI 10.1016/0166-6851(93)90032-S; SOLS A, 1954, J BIOL CHEM, V210, P581; SRINIVASAN NG, 1990, MOL BIOCHEM PARASIT, V38, P151, DOI 10.1016/0166-6851(90)90215-8; VANOORDT BEP, 1985, MOL BIOCHEM PARASIT, V16, P117, DOI 10.1016/0166-6851(85)90080-5; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P3483; WHITE TK, 1990, ARCH BIOCHEM BIOPHYS, V277, P26, DOI 10.1016/0003-9861(90)90545-A; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; WHITE TK, 1987, ARCH BIOCHEM BIOPHYS, V259, P402, DOI 10.1016/0003-9861(87)90506-6; WILKIN JP, 1977, J NEUROCHEM, V24, P1034; WILSON JE, 1994, IN PRESS REV PHYSL B; YANAGAWA HA, 1978, INSECT BIOCHEM, V8, P293, DOI 10.1016/0020-1790(78)90040-9	42	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24736	24741						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929149				2022-12-25	WOS:A1994PQ49000036
J	HARRISON, PT; DAVIS, W; NORMAN, JC; HOCKADAY, AR; ALLEN, JM				HARRISON, PT; DAVIS, W; NORMAN, JC; HOCKADAY, AR; ALLEN, JM			BINDING OF MONOMERIC IMMUNOGLOBULIN-G TRIGGERS FC-GAMMA-RI-MEDIATED ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CROSS-LINKING; HIGH-AFFINITY; TYROSINE PHOSPHORYLATION; CELL-LINE; ASIALOGLYCOPROTEIN RECEPTOR; LYSOSOMOTROPIC AMINES; HEPATOMA-CELLS; IGE RECEPTOR; U937 CELLS; INTERNALIZATION	Cross-linking of leukocyte Fe receptors specific for IgG (Fc gamma Rs) by multivalent IgG complexes triggers a wide range of immune functions. Many of these responses can also be stimulated in vitro using anti-Fc gamma R monoclonal antibody-containing complexes. This observation has suggested that cross-linking is the key event and that binding of IgG, which in itself does not elicit a response, is functionally passive. However, in this study we show that binding of monomeric IgG to the human high affinity receptor, Fc gamma RI, is itself sufficient to permit the receptor to enter an internalization-recycling pathway, which has a small intracellular pool. Unoccupied Fc gamma RI is not internalized and recycled in this manner. This finding may be explained by the previous observation that there is a physical association between Fc gamma RI and the cytoskeletal component, actin-binding protein (non-muscle filamin; ABP-280), which is disrupted upon IgG binding. Thus, in the absence of IgG, Fc gamma RI may be physically excluded from the endocytic pathway by tethering to the cytoskeleton. The role of cross-linking is to divert Fc gamma RI-IgG complexes from the recycling pathway, causing their retention and subsequent degradation within the cell. In contrast to Fc gamma RII-mediated endocytosis, intracellular accumulation of cross-linked Fc gamma RI-IgG complexes is not sensitive to inhibition by genistein, suggesting that the process is independent of tyrosine kinase activity.	UNIV CAMBRIDGE,PHYSIOL LAB,CAMBRIDGE CB2 3EG,ENGLAND	University of Cambridge				Harrison, Patrick/0000-0002-2319-0949; NORMAN, Jim/0000-0002-0098-3014				AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GHAZIZADEH S, 1994, J IMMUNOL, V152, P30; GUYRE PM, 1989, J IMMUNOL, V143, P1650; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HIEBSCH RR, 1991, J BIOL CHEM, V266, P20323; JONES DH, 1985, J CELL BIOL, V100, P558, DOI 10.1083/jcb.100.2.558; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KRUTMANN J, 1990, J IMMUNOL, V145, P1337; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; MELLMAN I, 1984, J CELL BIOL, V98, P1163, DOI 10.1083/jcb.98.4.1163; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; PFEFFERKORN LC, 1989, J BIOL CHEM, V264, P14112; RANKIN BM, 1993, J IMMUNOL, V150, P605; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; STROUS GJ, 1985, J CELL BIOL, V101, P531, DOI 10.1083/jcb.101.2.531; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VANDEWINKEL JGJ, 1990, SCAND J IMMUNOL, V31, P315; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	27	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24396	24402						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929100				2022-12-25	WOS:A1994PQ34600085
J	YEO, EJ; KAZLAUSKAS, A; EXTON, JH				YEO, EJ; KAZLAUSKAS, A; EXTON, JH			ACTIVATION OF PHOSPHOLIPASE C-GAMMA IS NECESSARY FOR STIMULATION OF PHOSPHOLIPASE-D BY PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR-BETA-SUBUNIT; INOSITOL-LIPID HYDROLYSIS; PROTEIN-KINASE-C; SWISS 3T3 CELLS; SIGNAL TRANSDUCTION; PHOSPHATIDYLCHOLINE BREAKDOWN; TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; MITOGENIC SIGNAL; FIBROBLASTS	Platelet-derived growth factor (PDGF) stimulates phosphatidylcholine hydrolysis via phospholipase D (PLD) in several tissues. To determine whether PLD activation is dependent on phosphoinositide hydrolysis by phospholipase C (PLC), we measured the formation of phosphatidylbutanol (PtdBut), in TRMP cells overexpressing wild type or various mutant PDGF receptors. Both PLC and PLD were stimulated by PDGF in cells expressing wild type receptors whereas they were not in cells expressing kinase-deficient (R634) receptors. These data indicate that tyrosine phosphorylation is required for activation of both PLC and PLD. Mutation of Tyr-1021 of the PDGF receptor to Phe caused loss of PDGF stimulation of both PLC and PLD. On the other hand, a mutant PDGF receptor that was able to bind PLC gamma 1 but not other signaling proteins (including the Ras GTPase-activating protein, phosphatidylinositol 3-kinase, and a SH2-containing phosphotyrosine phosphatase (Syp)) restored the stimulatory effect of PDGF on PLC and PLD. Furthermore, receptors in which association with the GTPase-activating protein, phosphatidylinositol S-kinase, or Syp was individually restored were unable to mediate PDGF stimulation of PLC or PLD. These data indicate that these other signal transduction proteins are not involved in the activation of PLD by PDGF Treatment of the cells with the protein kinase C inhibitor, Ro-31-8220, and depletion of cellular protein kinase C by pretreatment with 4 beta-phorbol 12-myristate 13-acetate resulted in loss of PLD activation by PDGF indicating a PKC-dependent mechanism. In summary, these results indicate that activation of PLC gamma 1 and protein kinase C are necessary for the stimulation of PLD by PDGF and provide no evidence for alternative mechanisms.	VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOLEC BIOPHYS,NASHVILLE,TN 37232; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; National Jewish Health					NCI NIH HHS [CA 55063, CA 58187] Funding Source: Medline; NIGMS NIH HHS [GM 48339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058187, R29CA055063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED A, 1994, AM J PHYSIOL, V266, pC206, DOI 10.1152/ajpcell.1994.266.1.C206; BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; HA KS, 1993, J BIOL CHEM, V268, P10534; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KONDO T, 1994, CLIN EXP HYPERTENS, V16, P17, DOI 10.3109/10641969409068581; KUMADA T, 1994, BIOCHEM BIOPH RES CO, V199, P792, DOI 10.1006/bbrc.1994.1299; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PARIS S, 1988, J BIOL CHEM, V263, P12893; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; PRICE BD, 1989, BIOCHEM J, V264, P509, DOI 10.1042/bj2640509; SIMPSON CMF, 1987, NEUROCHEMISTRY PRACT, P193; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; Zhang Wei, 1992, Neurological Research, V14, P397	36	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27823	27826						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961710				2022-12-25	WOS:A1994PV77200011
J	FOURNIER, T; MEJDOUBI, N; LAPOUMEROULIE, C; HAMELIN, J; ELION, J; DURAND, G; PORQUET, D				FOURNIER, T; MEJDOUBI, N; LAPOUMEROULIE, C; HAMELIN, J; ELION, J; DURAND, G; PORQUET, D			TRANSCRIPTIONAL REGULATION OF RAT ALPHA(1)-ACID GLYCOPROTEIN GENE BY PHENOBARBITAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEPATOCYTE-STIMULATING FACTOR; PLASMA-PROTEIN GENES; ACUTE-PHASE PROTEINS; TUMOR NECROSIS FACTOR; ALPHA-1-ACID GLYCOPROTEIN; NADPH-CYTOCHROME-P-450 OXIDOREDUCTASE; LIVER CYTOCHROME-P-450; MICROSOMAL-ENZYMES; CYTOKINE-RESPONSE; MESSENGER-RNA	Phenobarbital induces gene transcription of both cytochrome P450IIB (the barbiturate inducible cytochrome P450 in mammals) and alpha(1)-acid glycoprotein, one of the major acute-phase proteins in rats and humans. Analysis of the 5'-regulatory sequences of cytochrome P450IIB and alpha(1)-acid glycoprotein genes in rats revealed the presence of a consensus sequence of 10 base pairs, termed the phenobarbital-responsive element or Barbie box, located in a region extending from positions -136 to -127 from the transcription start site of the alpha(1)-acid glycoprotein gene. A 17-base pair oligonucleotide probe specific for alpha(1)-acid glycoprotein and including the consensus sequence showed, in mobility shift assays, slight binding to liver nuclear protein from untreated animals. This binding was strongly and specifically increased with protein extracts from phenobarbital-treated rats. Transfection of rat primary hepatocytes with the pAGPcat construct induced basal expression of chloramphenicol acetyltransferase activity, which was increased by phenobarbital and dexamethasone treatment of cells. Induction of chloramphenicol acetyltransferase activity by phenobarbital was abolished when hepatocytes were transfected by constructs with a mutation or deletion of the Barbie box sequence. These results strongly suggest that the Barbie box sequence is involved in alpha(1)-acid glycoprotein gene regulation by phenobarbital.	UNITE FORMAT & RECH PHARM,UA 1595,BIOCHIM GEN LAB,F-92290 CHATENAY MALABRY,FRANCE; HOP ROBERT DEBRE,INSERM,U120,F-75019 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Fournier, Thierry C/E-5836-2016; Elion, Jacques/A-1048-2014; HAMELIN, Jocelyne JH/R-4590-2018; Lapoumeroulie, Claudine/P-3515-2018; MEJDOUBI-CHAREF, Najet/R-4683-2018	Elion, Jacques/0000-0002-8407-1783; HAMELIN, Jocelyne JH/0000-0003-4222-0792; LAPOUMEROULIE, Claudine/0000-0001-6665-3598				ADESNIK M, 1981, J BIOL CHEM, V256, P340; ADESNIK M, 1986, CRIT REV BIOCHEM MOL, V19, P247, DOI 10.3109/10409238609084657; ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; BAUMANN H, 1989, J BIOL CHEM, V264, P8046; BAUMANN H, 1989, IN VITRO CELL DEV B, V25, P115; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BERTAUX O, 1992, EUR J BIOCHEM, V203, P655, DOI 10.1111/j.1432-1033.1992.tb16595.x; BERTINI R, 1989, J LEUKOCYTE BIOL, V46, P254, DOI 10.1002/jlb.46.3.254; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONNEY AH, 1967, PHARMACOL REV, V19, P317; CONNEY AH, 1982, CANCER RES, V42, P4875; DANNAN GA, 1986, J BIOL CHEM, V261, P728; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; FRANCIS VNK, 1986, NUCLEIC ACIDS RES, V14, P2497, DOI 10.1093/nar/14.6.2497; GAULDIE J, 1989, ANN NY ACAD SCI, V557, P46; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GAULDIE J, 1988, MONOKINES OTHER NONL, P15; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HARDWICK JP, 1983, J BIOL CHEM, V258, P8081; HE JS, 1991, J BIOL CHEM, V266, P7864; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; KLEIN ES, 1987, J BIOL CHEM, V262, P520; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KULKARNI AB, 1985, J BIOL CHEM, V260, P5386; KUSHNER I, 1987, DIS MARKERS, V5, P1; KUTT H, 1989, ANTIEPILEPTIC DRUGS; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P626; OMIECINSKI CJ, 1985, J BIOL CHEM, V260, P3247; PORTER TD, 1990, BIOCHEMISTRY-US, V29, P9814, DOI 10.1021/bi00494a009; PROWSE KR, 1989, J LEUKOCYTE BIOL, V45, P55, DOI 10.1002/jlb.45.1.55; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; SHAW GC, 1993, J BIOL CHEM, V268, P2997; STANLEY LA, 1988, EUR J BIOCHEM, V174, P31, DOI 10.1111/j.1432-1033.1988.tb14058.x; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; SUJITA K, 1990, BIOCHEM BIOPH RES CO, V168, P1217, DOI 10.1016/0006-291X(90)91158-O; VANNICE JL, 1984, P NATL ACAD SCI-BIOL, V81, P4241, DOI 10.1073/pnas.81.14.4241; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333; WILLIAMS JF, 1991, BIOCHEM BIOPH RES CO, V178, P1049, DOI 10.1016/0006-291X(91)90998-M; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965	52	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27175	27178						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961625				2022-12-25	WOS:A1994PV77100006
J	ODONNELL, JK; BIRCH, P; PARSONS, CT; WHITE, SP; OKABE, J; MARTIN, MJ; ADAMS, C; SUNDARAPANDIYAN, K; MANJULA, BN; ACHARYA, AS; LOGAN, JS; KUMAR, R				ODONNELL, JK; BIRCH, P; PARSONS, CT; WHITE, SP; OKABE, J; MARTIN, MJ; ADAMS, C; SUNDARAPANDIYAN, K; MANJULA, BN; ACHARYA, AS; LOGAN, JS; KUMAR, R			INFLUENCE OF THE CHEMICAL NATURE OF SIDE-CHAIN AT BETA-108 OF HEMOGLOBIN A ON THE MODULATION OF THE OXYGEN-AFFINITY BY CHLORIDE-IONS - LOW-OXYGEN AFFINITY VARIANTS OF HUMAN HEMOGLOBIN EXPRESSED IN TRANSGENIC PIGS - HEMOGLOBINS PRESBYTERIAN AND YOSHIZUKA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; BLOOD SUBSTITUTE; HUMAN DEOXYHEMOGLOBIN; X-RAY; IDENTIFICATION; RESOLUTION; SWINE	Hemoglobin A (HbA) and two low oxygen affinity variants of HbA, Hb(Presbyterian) and Hb(Yoshizuka), were produced in transgenic pigs and purified to homogeneity by ion-exchange chromatography. These two variants contain either lysine (Hb(Presbyterian)) or aspartic acid (Hb(Yoshizuka)) instead of the normal asparagine residue at position beta 108 in HbA. Transgenic pigs expressed these variants at a level up to 11% and were healthy. Both Hb(Presbyterian) and Hb(Yoshizuka) exhibited low O-2 affinity (P-50 of 21.2 and 18.9, respectively, compared with control HbA value of 11.8 in 0.1 M NaCl, pH 7.5) and retained normal cooperativity with Hill coefficients of 2.9 and 2.5, respectively. Hb(Presbyterian) exhibited Bohr effect comparable with HbA. In contrast, Hb(Yoshizuka) had a diminished response to changes in pH. Thus the structural basis of reduced O-2 affinity of these variants appears to be distinct: the consequence of mutation at beta 108 is a function of the chemical nature of the side chain. This is further confirmed by the sensitivity of the O-2 affinity of the variants to the presence of Cl-. The O-2 affinity of Hb(Yoshizuka) is insensitive to changes in Cl- concentration, whereas the O-2 affinity of Hb(Presbyterian) exhibited a pronounced and dramatic chloride effect. In fact, P-50 of Hb(Presbyterian) was identical to that of HbA at very low Cl- concentrations, and the P-50 increased to >40 at 0.5 M Cl-. The chloride effect was completely abolished when Hb(Presbyterian) was stabilized at the 2,3-diphosphoglycerate pocket by interdimeric cross-linking. Molecular modeling studies demonstrate that in Hb(Presbyterian), Cl- can bridge the epsilon-amino group of Lys(beta 108) with either the guanidino group of Arg(beta 104) or the epsilon-amino group of Lys(alpha 99), resulting in the stabilization of the ''T'' structure. The utility of these low O-2 affinity hemoglobins as cell-free oxygen carriers is discussed.	DNX BIOTHERAPEUT INC,PRINCETON,NJ 08540; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV HEMATOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NHLBI NIH HHS [HL-38665] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM DJ, 1992, BIOCHEMISTRY-US, V31, P9141, DOI 10.1021/bi00153a005; ALTER BP, 1980, BRIT J HAEMATOL, V44, P527, DOI 10.1111/j.1365-2141.1980.tb08706.x; BENESCH R, 1967, BIOCHEM BIOPH RES CO, V26, P162, DOI 10.1016/0006-291X(67)90228-8; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bohr C, 1904, SKAND ARCH PHYSIOL, V16, P402, DOI 10.1111/j.1748-1716.1904.tb01382.x; BONAVENTURA C, 1994, BIOPHYS J, V66, pA270; BONAVENTURA J, 1976, J BIOL CHEM, V251, P7563; BUNN HF, 1993, AM J HEMATOL, V42, P112, DOI 10.1002/ajh.2830420122; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CHIANCONE E, 1975, EUR J BIOCHEM, V55, P385, DOI 10.1111/j.1432-1033.1975.tb02173.x; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; GACON G, 1977, FEBS LETT, V82, P243, DOI 10.1016/0014-5793(77)80593-0; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; HANSCOMBE O, 1989, GENE DEV, V3, P1572, DOI 10.1101/gad.3.10.1572; HOFFMAN SJ, 1991, BIOTECHNOLOGY, V9, P57; HUISMAN THJ, 1987, J CHROMATOGR-BIOMED, V418, P277, DOI 10.1016/0378-4347(87)80012-9; IMAMURA T, 1969, J CLIN INVEST, V48, P2341, DOI 10.1172/JCI106200; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P4111, DOI 10.1021/bi00131a030; KEIPERT PE, 1989, TRANSFUSION, V29, P768, DOI 10.1046/j.1537-2995.1989.29990070179.x; KELLY RM, 1994, BIOPHYS J, V66, pA70; LOGAN JS, 1993, METHOD ENZYMOL, V231, P435; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; MANITIS T, 1982, MOL CLONING LABORATO; MANJULA BM, 1994, ARTIF CELLS BLOOD SU, V2, P747; MOOPENN WF, 1978, FEBS LETT, V92, P53, DOI 10.1016/0014-5793(78)80720-0; NIGEN AM, 1980, J BIOL CHEM, V255, P5525; ODONNELL JK, 1993, CANCER DETECT PREV, V17, P307; ODONNELL S, 1979, J BIOL CHEM, V254, P2204; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; POYART C, 1980, J BIOL CHEM, V255, P9465; RAO MJ, 1994, ARTIF CELL BLOOD SUB, V22, P695, DOI 10.3109/10731199409117900; Riggs A., 1981, Methods in Enzymology, V76, P5; ROLLEMA HS, 1975, J BIOL CHEM, V250, P1333; ROSSIFANELLI A, 1961, J BIOL CHEM, V236, P391; SCHMIDTNEILSEN K, 1958, AM J PHYSIOL, V195, P424, DOI 10.1152/ajplegacy.1958.195.2.424; SHARMA A, 1993, BIOTECHNOLOGY, V12, P55; SHEN TJ, 1993, P NATL ACAD SCI USA, V90, P8108, DOI 10.1073/pnas.90.17.8108; SWANSON ME, 1992, BIO-TECHNOL, V10, P557, DOI 10.1038/nbt0592-557; UENO H, 1992, J PROTEIN CHEM, V11, P177, DOI 10.1007/BF01025223; UENO H, 1993, J PROTEIN CHEM, V12, P561, DOI 10.1007/BF01025120; VANBEEK GGM, 1980, EUR J BIOCHEM, V105, P353; [No title captured]	44	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27692	27699						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961689				2022-12-25	WOS:A1994PV77100083
J	FERNANDEZ, B; BALBOA, MA; SOLISHERRUZO, JA; BALSINDE, J				FERNANDEZ, B; BALBOA, MA; SOLISHERRUZO, JA; BALSINDE, J			PHOSPHATIDATE-INDUCED ARACHIDONIC-ACID MOBILIZATION IN MOUSE PERITONEAL-MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PLATELET-ACTIVATING-FACTOR; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; STIMULATED PHOSPHOLIPASE-A2 ACTIVATION; RAT KUPFFER CELLS; HUMAN-NEUTROPHILS; EXTRACELLULAR CALCIUM; MESANGIAL CELLS; FATTY-ACIDS; MOBILIZING PHOSPHOLIPASE-A2	Phosphatidate (PA) is synthesized by a variety of cells in response to physiological agonists. Addition of PA vesicles to [H-3]arachidonic acid (AA)-labeled macrophages was found to induce the release of radiolabel in a dose- and time-dependent manner. This effect correlated with the uptake of PA by the macrophages and appeared to be attributable to PA itself and not to a PA metabolite. In parallel with AA release, PA induced a rapid increase in lysophosphatidylcholine in cells prelabeled with [C-14]glycerol. Down-regulation of protein kinase C by long term exposure of the cells to phorbol myristate acetate or cell treatment with the protein kinase C inhibitor staurosporine did not affect the PA response. Also, removal of external calcium or cell treatment with the calmodulin antagonist trifluoperazine did not affect PA-induced AA release, while inhibiting the responses to zymosan, phorbol 12-myristate 13-acetate, and ionophore A23187. PA-induced AA release was not affected by intracellular calcium depletion by treatment with quin2/AM in the presence of EGTA. When assayed toward an AA-containing substrate, PA was able to enhance phospholipase A(2) activity from cell homogenates in the absence of calcium. The dose dependence and magnitude of the PA effect correlated with those observed for PA-induced AA release in whole cells. Inclusion of ATP in the assay mixture did not affect the activity of the PA-stimulated phospholipase A. These findings suggest a role for PA in the cascade of events leading to AA release in macrophages through Ca2+-independent stimulation of an AA-selective phospholipase A.	HOSP UNIV DOCE OCTUBRE,CTR INVEST,E-28041 MADRID,SPAIN	Hospital Universitario 12 de Octubre			Balsinde, Jesús/C-7833-2018; Balboa, María A./V-9493-2018	Balsinde, Jesús/0000-0002-4157-6714; Balboa, María A./0000-0002-2130-5298				ADEREM AA, 1986, J EXP MED, V163, P139, DOI 10.1084/jem.163.1.139; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BALBOA MA, 1992, J EXP MED, V176, P9, DOI 10.1084/jem.176.1.9; BALSINDE J, 1992, BIOCHIM BIOPHYS ACTA, V1136, P75, DOI 10.1016/0167-4889(92)90087-R; BALSINDE J, 1991, J BIOL CHEM, V266, P18726; BALSINDE J, 1990, J IMMUNOL, V144, P4298; BALSINDE J, 1994, EUR J BIOCHEM, V221, P1013, DOI 10.1111/j.1432-1033.1994.tb18818.x; BALSINDE J, 1988, J BIOL CHEM, V263, P1929; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; BUCKLEY BJ, 1991, BIOCHEM J, V280, P281, DOI 10.1042/bj2800281; BURSTEN SL, 1991, J BIOL CHEM, V266, P20732; CHAO W, 1992, J BIOL CHEM, V267, P6725; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; DIETER P, 1988, EUR J BIOCHEM, V177, P61, DOI 10.1111/j.1432-1033.1988.tb14345.x; DIEZ E, 1990, BIOCHIM BIOPHYS ACTA, V1047, P83, DOI 10.1016/0005-2760(90)90264-X; DIVIRGILIO F, 1984, NATURE, V310, P691, DOI 10.1038/310691a0; DUYSTER J, 1992, J CELL BIOCHEM, V48, P288, DOI 10.1002/jcb.240480309; EMILSSON A, 1986, BIOCHIM BIOPHYS ACTA, V876, P533, DOI 10.1016/0005-2760(86)90041-X; ENGLISH D, 1991, BLOOD, V77, P2746; FERNANDEZ B, 1990, FEBS LETT, V268, P107, DOI 10.1016/0014-5793(90)80984-Q; FERNANDEZ B, 1991, BIOCHEM BIOPH RES CO, V180, P1036, DOI 10.1016/S0006-291X(05)81170-2; FERNANDEZ B, 1992, EICOSANOIDS, V5, P115; FERNANDEZ B, 1993, BIOCHIM BIOPHYS ACTA, V1176, P169, DOI 10.1016/0167-4889(93)90193-S; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; HALENDA SP, 1989, BIOCHEMISTRY-US, V28, P7356, DOI 10.1021/bi00444a031; HOFFMAN T, 1991, J IMMUNOL, V146, P692; INSEL PA, 1991, BIOCHEM SOC T, V19, P329, DOI 10.1042/bst0190329; JALINK K, 1990, J BIOL CHEM, V265, P12232; JONES GA, 1993, J BIOL CHEM, V268, P20845; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KESTER M, 1993, J CELL PHYSIOL, V156, P317, DOI 10.1002/jcp.1041560214; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; KRAUSE H, 1991, BIOCHEM BIOPH RES CO, V175, P532, DOI 10.1016/0006-291X(91)91597-6; KROLL MH, 1989, J CELL PHYSIOL, V139, P558, DOI 10.1002/jcp.1041390315; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; MAHONEY EM, 1980, J BIOL CHEM, V255, P4910; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; OHTSUKA T, 1989, J BIOCHEM-TOKYO, V106, P259, DOI 10.1093/oxfordjournals.jbchem.a122841; PFANNKUCHE HJ, 1989, BIOCHEM J, V260, P471, DOI 10.1042/bj2600471; QIAN Z, 1991, FASEB J, V5, P315, DOI 10.1096/fasebj.5.3.2001791; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RAAFLAUB J, 1956, Methods Biochem Anal, V3, P301; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SATO T, 1992, J BIOCHEM-TOKYO, V112, P756, DOI 10.1093/oxfordjournals.jbchem.a123971; SCHATZMUNDING M, 1991, EUR J BIOCHEM, V197, P487, DOI 10.1111/j.1432-1033.1991.tb15936.x; SCHATZMUNDING M, 1992, EUR J BIOCHEM, V204, P705, DOI 10.1111/j.1432-1033.1992.tb16685.x; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; STEWART SJ, 1991, CELL REGUL, V2, P841, DOI 10.1091/mbc.2.10.841; SVENSSON U, 1993, EUR J BIOCHEM, V213, P81, DOI 10.1111/j.1432-1033.1993.tb17736.x; SVENSSON U, 1991, EUR J BIOCHEM, V200, P699, DOI 10.1111/j.1432-1033.1991.tb16234.x; TAMURA M, 1993, ARCH BIOCHEM BIOPHYS, V305, P477, DOI 10.1006/abbi.1993.1450; TOU JS, 1991, BIOCHEM J, V280, P625, DOI 10.1042/bj2800625; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; WEBER C, 1993, EUR J IMMUNOL, V23, P852, DOI 10.1002/eji.1830230413; WEISS BA, 1991, J BIOL CHEM, V266, P2126; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; WIJKANDER J, 1989, BIOCHIM BIOPHYS ACTA, V1010, P78, DOI 10.1016/0167-4889(89)90187-0; WIJKANDER J, 1992, FEBS LETT, V311, P299, DOI 10.1016/0014-5793(92)81124-5; XING MZ, 1992, J BIOL CHEM, V267, P25966; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	71	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26711	26716						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929404				2022-12-25	WOS:A1994PQ93100023
J	ELIASSON, R; PONTIS, E; ECKSTEIN, F; REICHARD, P				ELIASSON, R; PONTIS, E; ECKSTEIN, F; REICHARD, P			INTERACTIONS OF 2'-MODIFIED AZIDOANALOGS AND HALOANALOGS OF DEOXYCYTIDINE 5'-TRIPHOSPHATE WITH THE ANAEROBIC RIBONUCLEOTIDE REDUCTASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2'-AZIDO-2'-DEOXYURIDINE 5'-DIPHOSPHATE; LACTOBACILLUS-LEICHMANNII; DIPHOSPHATE REDUCTASE; INACTIVATION; MECHANISM; GENE; ACTIVATION; GENERATION; CLONING	The anaerobic Escherichia coli ribonucleotide reductase (class III reductase) responsible for the synthesis of the deoxyribonucleotides required for anaerobic DNA replication contains an oxygen-sensitive glycyl radical (Gly-681) suggesting involvement of radical chemistry in catalysis. The amino acid sequence of this enzyme completely differs from that of earlier described aerobic class I (prototype, aerobic E. coli) and class II (proto type, Lactobacillus leichmanii) reductases that use radical chemistry but employ other means for radical generation. Here, we study the interaction between the anaerobic E. coli reductase with the 5'-triphosphates of 2'-chloro-2'-deoxycytidine, 2'-fluoro-2'-deoxycytidine, and 2'-azido-2' deoxycytidine (N3CTP), which are mechanism-based inhibitors of class I and II reductases and, on interaction with these enzymes, decompose to base, inorganic di(tri)phosphate and 2'-methylene-3(2H)-furanone. Also, with the anaerobic E. coli reductase, the 2'-substituted nucleotides act as mechanism-based inhibitors and decompose. N3CTP scavenges the glycyl radical of the enzyme similar to the interaction of N3CDP with the tyrosyl radical of class I enzymes. However we found no evidence for a new transient radical species as is the case with class I enzymes. Our results suggest that the chemistry at the nucleotide level for the reduction of ribose by class III enzymes is similar to the chemistry employed by class I and II enzymes.	KAROLINSKA INST, INST MED NOBEL, DEPT BIOCHEM 1, MBB, S-17177 STOCKHOLM, SWEDEN; MAX PLANCK INST EXPTL MED, CHEM ABT, W-3400 GOTTINGEN, GERMANY	Karolinska Institutet; Max Planck Society								ASHLEY GW, 1988, BIOCHEMISTRY-US, V27, P7841, DOI 10.1021/bi00420a038; ATOR M, 1984, J AM CHEM SOC, V106, P1886, DOI 10.1021/ja00318a082; ATOR MA, 1985, BIOCHEMISTRY-US, V24, P7214, DOI 10.1021/bi00346a029; AURUP H, 1992, BIOCHEMISTRY-US, V31, P9636, DOI 10.1021/bi00155a016; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; HARDER J, 1992, J BIOL CHEM, V267, P25548; HARRIS G, 1987, BIOCHEMISTRY-US, V26, P1895, DOI 10.1021/bi00381a017; HARRIS G, 1984, BIOCHEMISTRY-US, V23, P5214, DOI 10.1021/bi00317a020; HOBBS J, 1972, BIOCHEMISTRY-US, V11, P4336, DOI 10.1021/bi00773a021; LOWE PN, 1982, BIOORG CHEM, V11, P55, DOI 10.1016/0045-2068(82)90048-7; LUDWIG J, 1989, J ORG CHEM, V54, P631, DOI 10.1021/jo00264a024; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SALOWE S, 1993, BIOCHEMISTRY-US, V32, P12749, DOI 10.1021/bi00210a026; SALOWE SP, 1987, BIOCHEMISTRY-US, V26, P3408, DOI 10.1021/bi00386a024; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; STUBBE J, 1983, J BIOL CHEM, V258, P1619; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; THELANDER L, 1976, J BIOL CHEM, V251, P1398	23	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26116	26120						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929323				2022-12-25	WOS:A1994PQ93000029
J	LEWIS, RE; VOLLE, DJ; SANDERSON, SD				LEWIS, RE; VOLLE, DJ; SANDERSON, SD			PHORBOL ESTER STIMULATES PHOSPHORYLATION ON SERINE-1327 OF THE HUMAN INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PROTEIN-KINASE; BETA-SUBUNIT; HEPATOMA-CELLS; INTACT-CELLS; PHOSPHATIDYLINOSITOL 3'-KINASE; THREONINE PHOSPHORYLATION; SIGNALING COMPLEXES; CARBOXYL-TERMINUS; GROWTH-FACTORS	Phorbol esters stimulate the phosphorylation of the insulin receptor on discrete serine and threonine residues in intact cells. Phosphorylation of the insulin receptor cytoplasmic domain on serine, threonine, and tyrosine residues regulates receptor tyrosine kinase activity and signaling. In these studies, we demonstrate that phorbol ester treatment of intact COS-1 cells transiently expressing the human insulin receptor stimulates phosphorylation of serine 1327 within the carboxyl-terminal tail of the insulin receptor beta subunit. Phosphopeptide maps of wild-type (Ser(1327)) and mutant (Ala(1327)) human insulin receptors revealed the absence of a single phosphopeptide in the Ala(1327) receptors when compared with wild-type receptors from phorbol ester treated cells. Phosphoamino acid analysis revealed phosphoserine within the phosphopeptide from wildtype receptors that is absent in the Ala(1327) receptor. The synthetic peptide 1327S (KRSYEEHIPYTHMNGGKK) corresponding to amino acids 1325-1342 of the human insulin receptor is phosphorylated on serine by protein kinase C. After digestion with trypsin, the phosphorylated synthetic peptide comigrated with the serine-phosphorylated peptide isolated from wild-type insulin receptors that was absent from the Ala(1327) mutant. Ser(1327) is proximal to autophosphorylation sites Tyr(1328) and Tyr(1334). The potential effects of serine phosphorylation at position 1327 on subsequent phosphorylation of these tyrosines by the insulin receptor kinase were examined using synthetic peptides. The chemically modified peptide 1327S(P) was synthesized with the stoichiometric addition of phosphate to the side chain hydroxyl of a serine corresponding to position 1327 of the insulin receptor. Kinetic analysis revealed that the addition of phosphate to the serine improved substrate recognition by the insulin receptor tyrosine kinase almost a-fold. The average K-m was 1.44 mM for the peptide 1327S(P) versus 2.64 mM for peptide 1327S. However, when compared with the unphosphorylated control peptide, 1327S, the serine-phosphorylated peptide 1327S(P) also reduced the V-max of the insulin receptor tyrosine kinase 53%. Radiosequence analysis revealed that the chemical addition of phosphate to the serine in peptide 1327S(P) inhibited insulin receptor-catalyzed phosphorylation of the tyrosine on 1327S(P) corresponding to Tyr(1334) but not of the tyrosine corresponding to Tyr(1328). These data suggest that the juxtaposition of a serine phosphorylation site adjacent to receptor tyrosine phosphorylation sites provides the potential for regulation of insulin receptor autophosphorylation and signaling through its carboxyl-terminal tail.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC & ALLIED DIS, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT BIOCHEM & MOLEC BIOL, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT PHARMACEUT SCI, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center			Lewis, Robert E./H-3404-2019		NCI NIH HHS [CA36727] Funding Source: Medline; NIDDK NIH HHS [DK41896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABERNATHY JL, 1992, TECHNIQUES PROTEIN C, V3, P277; ADASHI EY, 1993, ANN NY ACAD SCI, V687, P10; AHN J, 1993, J BIOL CHEM, V268, P16839; AHN JC, 1993, J BIOL CHEM, V268, P7571; ANDERSON CM, 1991, J BIOL CHEM, V266, P21760; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; BEGUM N, 1993, J BIOL CHEM, V268, P7917; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHIN JE, 1993, J BIOL CHEM, V268, P6338; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COGHLAN MP, 1993, BIOCHEM BIOPH RES CO, V193, P371, DOI 10.1006/bbrc.1993.1633; DURONIO V, 1990, ENDOCRINOLOGY, V127, P481, DOI 10.1210/endo-127-1-481; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FISCHER PM, 1991, INT J PEPT PROT RES, V38, P491; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; GRIMES RW, 1992, ENDOCRINOLOGY, V131, P553, DOI 10.1210/en.131.2.553; HEIDENREICH K, 1994, BIOL CHEM H-S, V375, P99, DOI 10.1515/bchm3.1994.375.2.99; JACOBS S, 1986, J BIOL CHEM, V261, P934; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P6211, DOI 10.1073/pnas.80.20.6211; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5766, DOI 10.1021/bi00073a007; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5773, DOI 10.1021/bi00073a008; KOSHIO O, 1989, FEBS LETT, V254, P22, DOI 10.1016/0014-5793(89)81001-4; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEVINE BA, 1991, J BIOL CHEM, V266, P12369; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LIU F, 1994, BIOCHEM J, V298, P471, DOI 10.1042/bj2980471; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PANG DT, 1985, J BIOL CHEM, V260, P7131; PILLAY TS, 1991, FEBS LETT, V288, P206, DOI 10.1016/0014-5793(91)81035-7; PILLAY TS, 1991, BIOCHEM BIOPH RES CO, V179, P962, DOI 10.1016/0006-291X(91)91912-V; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1991, J BIOL CHEM, V266, P21804; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAVARE JM, 1992, BIOCHEM BIOPH RES CO, V188, P86, DOI 10.1016/0006-291X(92)92353-Y; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WOLFE L, 1992, J BIOL CHEM, V267, P9749; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; YU KT, 1984, J BIOL CHEM, V259, P5277; YU KT, 1986, J BIOL CHEM, V261, P4715; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	66	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26259	26266						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929343				2022-12-25	WOS:A1994PQ93000051
J	WANG, ZM; CHOUDHARY, A; LEDVINA, PS; QUIOCHO, FA				WANG, ZM; CHOUDHARY, A; LEDVINA, PS; QUIOCHO, FA			FINE-TUNING THE SPECIFICITY OF THE PERIPLASMIC PHOSPHATE-TRANSPORT RECEPTOR - SITE-DIRECTED MUTAGENESIS, LIGAND-BINDING, AND CRYSTALLOGRAPHIC STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; PROTEIN-STRUCTURE; ACTIVE-TRANSPORT; HYDROGEN-BONDS; PHOS-GENE; REFINEMENT; DIPOLES; CHARGES	Phosphorous, primarily in the form of phosphate, is a critical nutrient for the life of a cell. We have previously determined the 1.7-Angstrom resolution structure of the phosphate-binding protein, an initial receptor for the high-affinity phosphate active transport system or permease in Escherichia coli (Luecke, H., and Quiocho, F.A. (1990) Nature 347, 402-406). This structure is the first to reveal the key role of hydrogen bonding interactions in conferring the high specificity of the permease, a specificity also shared by other phosphate transport systems. Both monobasic and dibasic phosphates are recognized by the phosphate-binding protein with Asp(56) playing a key role. Here we report site-directed mutagenesis, ligand binding, and crystallographic studies of the binding protein which show that introduction of one additional Asp by mutagenesis of the Thr(141) in the ligand-binding site restricts binding to only the monobasic phosphate.	BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; BAYLOR COLL MED, STRUCT & COMPUTAT BIOL & MOLEC BIOPHYS PROGRAM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine								ANDERSEN AB, 1989, INFECT IMMUN, V57, P2481, DOI 10.1128/IAI.57.8.2481-2488.1989; AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; Brunger A.T., 1992, XPLOR VERSION 31; CHANG ZY, 1994, J BIOL CHEM, V269, P1956; Clare Speakman J., 1972, STRUCTURE BONDING, P141; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FURLONG CE, 1987, ESCHERICHIA COLI SAL, P768; HE JJ, 1993, PROTEIN SCI, V2, P1643, DOI 10.1002/pro.5560021010; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; JACOBSON BL, 1988, J MOL BIOL, V204, P783, DOI 10.1016/0022-2836(88)90369-5; KUBENA BD, 1986, J BIOL CHEM, V261, P7995; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MAGOTA K, 1984, J BACTERIOL, V157, P909, DOI 10.1128/JB.157.3.909-917.1984; MEDVECZKY N, 1970, BIOCHIM BIOPHYS ACTA, V211, P158, DOI 10.1016/0005-2736(70)90090-8; MEDVECZKY N, 1971, BIOCHIM BIOPHYS ACTA, V241, P494, DOI 10.1016/0005-2736(71)90048-4; NEU HC, 1965, J BIOL CHEM, V240, P3685; PARDEE AB, 1966, J BIOL CHEM, V241, P5886; PARDEE AB, 1966, J BIOL CHEM, V241, P3962; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SAWYER L, 1982, NATURE, V295, P79, DOI 10.1038/295079a0; SHARMA SD, 1992, MICROELECTRON RELIAB, V32, P1657, DOI 10.1016/0026-2714(92)90261-I; SURIN BP, 1984, J BACTERIOL, V157, P772, DOI 10.1128/JB.157.3.772-778.1984; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004	29	61	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25091	25094						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929197				2022-12-25	WOS:A1994PQ49000086
J	XIA, T; GRAY, DW; SHIMAN, R				XIA, T; GRAY, DW; SHIMAN, R			REGULATION OF RAT-LIVER PHENYLALANINE-HYDROXYLASE .3. CONTROL OF CATALYSIS BY (6R)-TETRAHYDROBIOPTERIN AND PHENYLALANINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; ACTIVATION; 4-MONOOXYGENASE; PURIFICATION; METABOLISM; MECHANISM; INVITRO; PTERINS; INVIVO	Effects of phenylalanine and di and tetrahydropterins on presteady-state and steady-state catalytic behavior of rat liver phenylalanine hydroxylase are analyzed. From this and previous work (Shiman, R, Xia, T., Hill, M., and Gray, D. (1994) J. Biol. Chem. 269, 24647-24656), which analyzed binding of the same compounds to the enzyme in the absence of catalysis, a model of phenylalanine hydroxylase regulation is proposed. The mechanism appears novel in that 1) one substrate, phenylalanine, is a positive effector (activator), 2) a second substrate, (6R)-tetrahydrobiopterin (BH4), is a negative effector that blocks phenylalanine activation by forming an inactive BH4 enzyme complex, and 3) the BH4-enzyme complex sequesters BH4 and controls its metabolic availability. Reaction progress curves showing regulatory effects of BH4, 7,8-dihydrobiopterin (BH2), and phenylalanine are fit by the model with high precision. Data are presented that the high affinity pterin-binding site on unactivated phenylalanine hydroxylase is the pterin site that regulates catalysis. Occupancy of this site by BH4 or BH2 causes non-cooperative, linear inhibition of phenylalanine activation of the enzyme. All inhibitory effects of BH4 appear due to its binding at the pterin regulatory site on unactivated enzyme. BH2 inhibits by binding at the active site as well as the pterin regulatory site. 6-Methyltetrahydropterin also appears to bind at the pterin regulatory site, but its effect is only seen at high phenylalanine concentrations. Using kinetic constants measured in this and earlier work, quantitative effects of phenylalanine and BH4 regulation on the rate of the phenylalanine hydroxylase reaction in vitro and in vivo are calculated. The effects of formation of the BH4 enzyme complex on free BH4 concentration, on enzyme activity, and on regulation of the rate of phenylalanine hydroxylation in liver are discussed.	PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT BIOCHEM & MOLEC BIOL, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								ABITA JP, 1976, J BIOL CHEM, V251, P5310; BLAU N, 1988, ANNU REV NUTR, V8, P185; DONLON J, 1978, J BIOL CHEM, V253, P6657; DOSKELAND AP, 1987, BIOCHEM J, V242, P867, DOI 10.1042/bj2420867; DOSKELAND AP, 1984, J BIOL CHEM, V259, P1242; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P562; KAUFMAN S, 1971, ADV ENZYMOL RAMB, V35, P245; LAZARUS RA, 1983, J BIOL CHEM, V258, P960; LAZARUS RA, 1981, BIOCHEMISTRY-US, V20, P6834, DOI 10.1021/bi00527a015; LAZARUS RA, 1982, J AM CHEM SOC, V104, P6871, DOI 10.1021/ja00388a106; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NIELSEN KH, 1969, EUR J BIOCHEM, V9, P497, DOI 10.1111/j.1432-1033.1969.tb00636.x; PARNIAK MA, 1988, J BIOL CHEM, V263, P1223; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P3836, DOI 10.1021/bi00312a007; Press W., 1986, NUMERICAL RECIPES; SHIMAN R, 1979, J BIOL CHEM, V254, P1300; SHIMAN R, 1990, J BIOL CHEM, V265, P11633; SHIMAN R, 1987, METHOD ENZYMOL, V142, P17; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; SHIMAN R, 1982, J BIOL CHEM, V257, P1213; SHIMAN R, 1985, CHEM BIOCH PTERINS, V2, P179; SMITH GK, 1991, J NUTR BIOCH, V2, P411; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STORM CB, 1971, J ORG CHEM, V36, P3925; VEECH RL, 1979, J BIOL CHEM, V254, P6538; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	28	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24657	24665						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929137				2022-12-25	WOS:A1994PQ49000024
J	DUDEN, R; HOSOBUCHI, M; HAMAMOTO, S; WINEY, M; BYERS, B; SCHEKMAN, R				DUDEN, R; HOSOBUCHI, M; HAMAMOTO, S; WINEY, M; BYERS, B; SCHEKMAN, R			YEAST BETA-COAT AND BETA'-COAT PROTEINS (COP) - 2 COATOMER SUBUNITS ESSENTIAL FOR ENDOPLASMIC RETICULUM-TO-GOLGI PROTEIN TRAFFIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; TRANSPORT VESICLE FORMATION; INTEGRAL MEMBRANE-PROTEIN; CLATHRIN-COATED VESICLES; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; VESICULAR TRANSPORT; SHOWS HOMOLOGY; SEC13P COMPLEX	To understand better the role of non-clathrin coat proteins in membrane traffic, we have cloned and characterized two essential genes encoding subunits of the yeast coatomer, SEC26 and SEC27. Sec26p is a 109-kDa protein that shares 43% sequence identity with mammalian beta-coat protein (beta-COP). Sec26p depleted cells accumulate endoplasmic reticulum (ER) forms of secretory precursor proteins, and growth ceases after a dramatic accumulation of ER membranes. Sec26p overproduction partially suppresses sec27-1, a new mutant that shows a temperature-sensitive defect in ER-to-Golgi transport. The SEC27 gene was cloned, and the sequence predicts a 99.4-kDa protein with 45% sequence identity to mammalian beta'-COP. Our sequence data support a two-domain model for the SEC27 protein: a conserved amino-terminal domain, composed of five WD-40 repeats similar to those found in beta-subunits of trimeric G proteins, and a less conserved carboxyl-terminal domain. Genetic interactions connect sec27-1 and sec21-1 (coatomer gamma subunit) with the ARF1 and ARF2 genes and with the SEC22, BET1, and BOS1 genes, which encode membrane proteins involved in ER-to-Golgi transport.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA; UNIV WASHINGTON, DEPT GENET SK-50, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Colorado System; University of Colorado Boulder; University of Washington; University of Washington Seattle			Duden, Rainer/C-8917-2011					BARLOWE C, 1993, J BIOL CHEM, V268, P873; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; REXACH M, 1994, IN PRESS J CELL BIOL; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RIPOCHE J, 1994, P NATL ACAD SCI USA, V91, P1878, DOI 10.1073/pnas.91.5.1878; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WHITNEY JA, 1993, MOL BIOL CELL S, V4, pA455; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745	56	120	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24486	24495						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929113				2022-12-25	WOS:A1994PQ34600098
J	BROWNAUGSBURGER, P; BROEKELMANN, T; MECHAM, L; MERCER, R; GIBSON, MA; CLEARY, EG; ABRAMS, WR; ROSENBLOOM, J; MECHAM, RP				BROWNAUGSBURGER, P; BROEKELMANN, T; MECHAM, L; MERCER, R; GIBSON, MA; CLEARY, EG; ABRAMS, WR; ROSENBLOOM, J; MECHAM, RP			MICROFIBRIL-ASSOCIATED GLYCOPROTEIN BINDS TO THE CARBOXYL-TERMINAL DOMAIN OF TROPOELASTIN AND IS A SUBSTRATE FOR TRANSGLUTAMINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN-ASSOCIATED MICROFIBRILS; MARFAN-SYNDROME; PROTEIN; GENE; MAGP; LOCALIZATION; VITRONECTIN; FIBRILLIN; SEQUENCE; PRODUCT	Microfibril-associated glycoprotein (MAGP) is an integral component of microfibrillar structures that play a critical role in the organization of elastic fibers in the extracellular matrix. To study possible molecular interactions between MAGP and other elastic fiber components, we have generated native MAGP using a baculovirus expression system and tested its ability to associate with tropoelastin and fibrillin. MAGP produced by SF9 cells underwent processing similar to the mammalian protein, including correct cleavage of the signal peptide and sulfation of tyrosine residues. When tested in solid-phase binding assays, native MAGP specifically bound to tropoelastin but not fibrillin-1. Binding to tropoelastin was divalent cation-independent and was completely blocked by reduction and alkylation of either protein. Antibody inhibition studies indicated that the carboxyl terminus of tropoelastin mediated its interaction with MAGP. In addition to binding to elastin, MAGP was also a substrate for transglutaminase, which might explain its propensity to form high molecular weight aggregates that cannot be dissociated with reduction or denaturation, Together, the results of this study provide new insights into the functional relationship between microfibrillar proteins and have important implications for understanding elastic fiber assembly.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; UNIV ADELAIDE, DEPT PATHOL, ADELAIDE, SA 5001, AUSTRALIA; UNIV PENN, DEPT DENT MED, PHILADELPHIA, PA 19104 USA	Washington University (WUSTL); Washington University (WUSTL); University of Adelaide; University of Pennsylvania					NHLBI NIH HHS [HL-41926, HL-26499] Funding Source: Medline; NIAMS NIH HHS [AR-41474] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041926, R01HL026499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041474] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; BASHIR MM, 1994, BIOCHEMISTRY-US, V33, P593, DOI 10.1021/bi00168a026; BROWN PL, 1992, BIOCHEM BIOPH RES CO, V186, P549, DOI 10.1016/S0006-291X(05)80843-5; CHEN YP, 1993, J BIOL CHEM, V268, P27381; DAHLBACK K, 1989, J INVEST DERMATOL, V92, P727, DOI 10.1111/1523-1747.ep12721619; DAVIS EC, 1994, J CELL SCI, V107, P727; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; GIBSON MA, 1987, IMMUNOL CELL BIOL, V65, P345, DOI 10.1038/icb.1987.39; HINEK A, 1993, J BIOL CHEM, V268, P1405; INDIK Z, 1990, GENES EXTRACELLULAR, P221; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; MECHAM RP, 1987, METHOD ENZYMOL, V144, P232; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PROSSER IW, 1991, CONNECT TISSUE RES, V25, P265, DOI 10.3109/03008209109029162; PROSSER IW, 1984, AUST J EXP BIOL MED, V62, P485, DOI 10.1038/icb.1984.46; Ross R, 1977, Adv Exp Med Biol, V79, P7; SCHWARTZ E, 1985, J HISTOCHEM CYTOCHEM, V33, P268, DOI 10.1177/33.4.3980980; TOMASINIJOHANSSON BR, 1993, MATRIX, V13, P203, DOI 10.1016/S0934-8832(11)80004-1; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	25	103	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28443	28449						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961786				2022-12-25	WOS:A1994PV77200098
J	CLARK, BJ; WELLS, J; KING, SR; STOCCO, DM				CLARK, BJ; WELLS, J; KING, SR; STOCCO, DM			THE PURIFICATION, CLONING, AND EXPRESSION OF A NOVEL LUTEINIZING HORMONE-INDUCED MITOCHONDRIAL PROTEIN IN MA-10 MOUSE LEYDIG TUMOR-CELLS - CHARACTERIZATION OF THE STEROIDOGENIC ACUTE REGULATORY PROTEIN (STAR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL-CORTEX CELLS; SIDE-CHAIN CLEAVAGE; DIAZEPAM BINDING INHIBITOR; STEROL CARRIER PROTEIN-2; CONTACT SITES; CYCLIC-AMP; ADRENOCORTICOTROPIC HORMONE; BENZODIAZEPINE RECEPTOR; ACTIVATOR POLYPEPTIDE; POLYACRYLAMIDE GELS	The acute response of steroidogenic cells to trophic hormone stimulation is the mobilization of cholesterol hom cellular stores to the mitochondrial outer membrane and the transfer of this cholesterol to the mitochondrial inner membrane where the first enzymatic step in steroidogenesis occurs. The transfer of cholesterol across the mitochondrial membranes is dependent upon de novo protein synthesis, and this is the regulated step in the process. Although the newly synthesized regulatory protein(s) have yet 60 be identified, we previously have proposed a candidate protein which we identified in MA-10 cells that is synthesized in response to luteinizing hormone stimulation and that is localized to the mitochondria. In the present study, we report the isolation of a cDNA that encodes this luteinizing hormone-induced protein. Analysis of the cDNA and protein sequences reveals this is a novel protein. Importantly, we demonstrate for the first time that expression of the protein in MA-10 cells in the absence of hormone stimulation is sufficient 60 induce steroid production. We conclude that this protein is required in the acute regulation of steroidogenesis and propose to call this protein the Steroidogenic Acute Regulatory protein (StAR).			CLARK, BJ (corresponding author), TEXAS TECH UNIV, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, LUBBOCK, TX 79430 USA.		King, Steven/AAN-1385-2021	Clark, Barbara/0000-0003-1558-1904	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017481, R01HD017481, F32HD007688] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 17481, HD 07688] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERTA JA, 1989, J BIOL CHEM, V264, P2368; ALMAHBOBI G, 1992, EXP CELL RES, V200, P361, DOI 10.1016/0014-4827(92)90184-A; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARDAIL D, 1991, J BIOL CHEM, V266, P7978; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AS, 1992, MOL CELL ENDOCRINOL, V83, P1, DOI 10.1016/0303-7207(92)90189-D; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; COOKE BA, 1975, BIOCHEM J, V150, P413, DOI 10.1042/bj1500413; CRIVELLO JF, 1980, J BIOL CHEM, V255, P8144; DAVIS WW, 1968, J BIOL CHEM, V243, P5153; Deutscher M, 1990, METHODS ENZYMOLOGY, V182; ELLIOTT ME, 1993, ENDOCRINOLOGY, V133, P1669, DOI 10.1210/en.133.4.1669; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; FERGUSON JJ, 1963, J BIOL CHEM, V238, P2754; FREEMAN DA, 1987, J BIOL CHEM, V262, P13061; GARNIER M, 1993, ENDOCRINOLOGY, V132, P444, DOI 10.1210/en.132.1.444; GARREN LD, 1965, P NATL ACAD SCI USA, V53, P1443, DOI 10.1073/pnas.53.6.1443; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GREEN EG, 1991, J STEROID BIOCHEM, V40, P421, DOI 10.1016/0960-0760(91)90211-M; HALL PF, 1992, J STEROID BIOCHEM, V43, P769, DOI 10.1016/0960-0760(92)90306-4; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; HAYNES RC, 1959, J BIOL CHEM, V234, P1421; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; JEFCOATE CR, 1974, EUR J BIOCHEM, V42, P539, DOI 10.1111/j.1432-1033.1974.tb03369.x; JEFCOATE CR, 1986, ENDOCR RES, V12, P315, DOI 10.3109/07435808609035444; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; JEFCOATE CR, 1987, J STEROID BIOCHEM, V27, P721, DOI 10.1016/0022-4731(87)90142-7; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KARABOYAS GC, 1965, BIOCHEMISTRY-US, V4, P462, DOI 10.1021/bi00879a014; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KRUEGER RJ, 1983, J BIOL CHEM, V258, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MENDELSON C, 1975, BIOCHIM BIOPHYS ACTA, V411, P222, DOI 10.1016/0304-4165(75)90302-5; MERTZ LM, 1989, ENDOCR RES, V15, P101, DOI 10.1080/07435808909039091; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEDERSEN RC, 1987, SCIENCE, V236, P188, DOI 10.1126/science.3563495; PEDERSEN RC, 1983, P NATL ACAD SCI-BIOL, V80, P1882, DOI 10.1073/pnas.80.7.1882; PON LA, 1986, J BIOL CHEM, V261, P3309; PON LA, 1986, ENDOCR RES, V12, P429, DOI 10.3109/07435808609035449; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; PYTHON CP, 1993, ENDOCRINOLOGY, V132, P1489, DOI 10.1210/en.132.4.1489; REDDY SV, 1993, BIOTECHNIQUES, V15, P444; RESKO JA, 1974, ENDOCRINOLOGY, V94, P128, DOI 10.1210/endo-94-1-128; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALA GB, 1979, J BIOL CHEM, V254, P3861; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; SIMBENI R, 1990, J BIOL CHEM, V265, P281; SIMPSON ER, 1972, EUR J BIOCHEM, V28, P442, DOI 10.1111/j.1432-1033.1972.tb01931.x; STOCCO DM, 1993, ENDOCRINOLOGY, V133, P2827, DOI 10.1210/en.133.6.2827; STOCCO DM, 1993, J STEROID BIOCHEM, V46, P337, DOI 10.1016/0960-0760(93)90223-J; STOCCO DM, 1991, ENDOCRINOLOGY, V128, P1918, DOI 10.1210/endo-128-4-1918; STOCCO DM, 1988, BIOCHEM J, V249, P95, DOI 10.1042/bj2490095; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; STOCCO DM, 1992, J STEROID BIOCHEM, V43, P319, DOI 10.1016/0960-0760(92)90167-H; STOCCO DM, 1990, CELL SIGNAL, V2, P161, DOI 10.1016/0898-6568(90)90019-7; STOCCO DM, 1993, ENDOCRINOLOGY, V132, P959, DOI 10.1210/en.132.3.959; STONE D, 1954, ARCH BIOCHEM BIOPHYS, V51, P457, DOI 10.1016/0003-9861(54)90501-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANAMERONGEN A, 1989, BIOCHIM BIOPHYS ACTA, V1004, P36, DOI 10.1016/0005-2760(89)90209-9; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x	71	961	991	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28314	28322						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961770				2022-12-25	WOS:A1994PV77200081
J	GUO, W; JORGENSEN, AO; CAMPBELL, KP				GUO, W; JORGENSEN, AO; CAMPBELL, KP			CHARACTERIZATION AND ULTRASTRUCTURAL-LOCALIZATION OF A NOVEL 90-KDA PROTEIN UNIQUE TO SKELETAL-MUSCLE JUNCTIONAL SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; PURIFIED RYANODINE RECEPTOR; DEPENDENT CA-2+ CHANNEL; DIHYDROPYRIDINE RECEPTOR; 1,4-DIHYDROPYRIDINE RECEPTOR; BIOCHEMICAL-CHARACTERIZATION; GLYCOPROTEIN TRIADIN; TRANSVERSE TUBULES; FOOT PROTEIN; KINASE	Monoclonal antibodies were used to identify and characterize a novel 90 kDa protein that was specifically localized to the junctional sarcoplasmic reticulum of rabbit skeletal muscle. Biochemical experiments show that the 90 kDa protein is an integral membrane protein of the junctional face membrane and is a substrate for the intrinsic protein kinase in triads. Immunofluorescence staining of serial transverse sections of skeletal muscle with a monoclonal antibody to the 90 kDa protein showed preferential staining of type II ''fast'' fibers. Specific labeling was confined to the interphase between the A- and I-bands, where the triad structure is localized. Immunoelectron microscopical labeling further indicates that the 90 kDa protein, like the ryanodine receptor/Ca2+-release channel and triadin, is confined to the terminal cisternae of the sarcoplasmic reticulum. Western blot analysis with a combination of monoclonal antibodies against the 90 kDa protein shows that it is specifically expressed in skeletal muscle but not in cardiac muscle or brain. Similarly, specific immunofluorescence labeling to the 90 kDa protein was not detected in ventricular myocytes or vascular smooth muscle cells. The junctional localization and phosphorylation of this protein suggest that it may play an important regulatory or structural role in the skeletal muscle triad junction.	UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, HHMI, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA; UNIV TORONTO, DEPT ANAT, TORONTO M5S 1A8, ON, CANADA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Toronto				Campbell, Kevin/0000-0003-2066-5889				BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; CALA SE, 1993, J BIOL CHEM, V268, P2969; CAMPBELL KP, 1980, J MEMBRANE BIOL, V56, P241, DOI 10.1007/BF01869479; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CAMPBELL KP, 1982, J BIOL CHEM, V257, P1238; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; EISENBERG BR, 1983, HDB PHYSL, P75; FLUCHER BE, 1990, NEURON, V5, P339, DOI 10.1016/0896-6273(90)90170-K; FOSSET M, 1983, J BIOL CHEM, V258, P6086; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; IMAGAWA T, 1987, J BIOL CHEM, V262, P8333; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1988, METHOD ENZYMOL, V157, P490; JORGENSEN AO, 1979, J CELL BIOL, V80, P372, DOI 10.1083/jcb.80.2.372; JORGENSEN AO, 1987, J HISTOCHEM CYTOCHEM, V35, P723, DOI 10.1177/35.7.2953782; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; JORGENSEN AO, 1990, J CELL BIOL, V110, P1173, DOI 10.1083/jcb.110.4.1173; JORGENSEN AO, 1983, J CELL BIOL, V97, P1573, DOI 10.1083/jcb.97.5.1573; KAWAMOTO RM, 1986, J CELL BIOL, V103, P1405, DOI 10.1083/jcb.103.4.1405; KIM DH, 1986, J BIOL CHEM, V261, P1674; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KNUDSON CM, 1989, J BIOL CHEM, V264, P10795; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEDDY JJ, 1993, BIOCHEM J, V295, P849, DOI 10.1042/bj2950849; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MacLennan D., 1983, CALCIUM CELL FUNCT, V4, P151; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1975, BIOCHIM BIOPHYS ACTA, V389, P51, DOI 10.1016/0005-2736(75)90385-5; MITCHELL RD, 1983, J BIOL CHEM, V258, P9867; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROSEMBLATT M, 1981, J BIOL CHEM, V256, P8140; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TUANA BS, 1984, J BIOL CHEM, V259, P6979; VOLPE P, 1992, P NATL ACAD SCI USA, V89, P6142, DOI 10.1073/pnas.89.13.6142; WADA I, 1991, J BIOL CHEM, V266, P19599; WANG JX, 1992, NATURE, V359, P739, DOI 10.1038/359739a0	49	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28359	28365						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961775				2022-12-25	WOS:A1994PV77200087
J	KOSAKO, H; GOTOH, Y; NISHIDA, E				KOSAKO, H; GOTOH, Y; NISHIDA, E			MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IS REQUIRED FOR THE MOS-INDUCED METAPHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE THREONINE KINASE; MAMMALIAN SOMATIC-CELLS; PHASE MAP KINASE; XENOPUS-OOCYTES; SIGNAL TRANSDUCTION; ONCOGENE PRODUCT; MEIOTIC MATURATION; SKELETAL-MUSCLE; FROG OOCYTES; GENE-PRODUCT	The product of the c-mos proto-oncogene functions not only as an initiator of oocyte maturation but also as a component of cytostatic factor that causes the natural arrest of the unfertilized egg at the second meiotic metaphase. It has been shown that Mos can phosphorylate and activate mitogen-activated protein (MAP) kinase kinase (MAPKK) in vitro, leading to activation of MAP kinase. In this study, by using an anti-MAPKK antibody that can specifically inhibit Xenopus MAPKK activity, we have shown that MAPKK mediates the cytostatic factor activity of Mos. Coinjection of this anti-MAPKK antibody with the bacterially expressed Mos protein into a two cell embryo prevented the Mos-induced cleavage arrest as well as the Mos-induced MAP kinase activation. The analysis of individual embryos indicated that the degree of the cleavage arrest was correlated with the extent of the MAP kinase activation in the Mos- and the Mos/antibody-injected embryos. These observations suggest the involvement of a signal transmission pathway consisting of Mos, MAPKK and MAP kinase in the metaphase arrest.	KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOLEC BIOL,SAKYO KU,KYOTO 60601,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOCHEM & BIOPHYS,TOKYO 113,JAPAN	Kyoto University; University of Tokyo								Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ASHWORTH A, 1992, ONCOGENE, V7, P2555; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	57	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28354	28358						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961774				2022-12-25	WOS:A1994PV77200086
J	EGLI, CM; BRAUS, GH				EGLI, CM; BRAUS, GH			UNCOUPLING OF MESSENGER-RNA 3' CLEAVAGE AND POLYADENYLATION BY EXPRESSION OF A HAMMERHEAD RIBOZYME IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA POLYADENYLATION; SACCHAROMYCES-CEREVISIAE; POLY(A) POLYMERASE; 3'-END FORMATION; DNA FRAGMENT; SITE; INVITRO; SEQUENCE; GENE; END	An artificial messenger RNA containing a derivative of a tobacco ringspot virus ribozyme was expressed in the bakers' yeast Saccharomyces cerevisiae. This mRNA was able to cleave itself efficiently in vivo. Using this system, the two steps of mRNA 3' processing, i.e. cleavage and the addition of a poly(A) tail, can be separated in yeast in vivo. The ribozyme cleaved transcript was shown to be polyadenylated. The poly(A) tail length was similar to the poly(A) tail length of an endogenous yeast mRNA. Therefore, cleavage of the precursor RNA at the polyadenylation site and the addition of adenosine residues to the 5' product require independent cellular machineries in yeast and can be separately analyzed. This is in contrast to higher eukaryotes where both processes are coupled.	UNIV ERLANGEN NURNBERG,INST MICROBIOL BIOCHEM & GENET,D-91058 ERLANGEN,GERMANY; ETH ZURICH,INST MICROBIOL,CH-8092 ZURICH,SWITZERLAND	University of Erlangen Nuremberg; Swiss Federal Institutes of Technology Domain; ETH Zurich			Braus, Gerhard/ABC-6293-2021; Braus, Gerhard H/G-3999-2012	Braus, Gerhard/0000-0002-3117-5626; Braus, Gerhard H/0000-0002-3117-5626				ABE A, 1990, EMBO J, V9, P3691, DOI 10.1002/j.1460-2075.1990.tb07581.x; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BRAUS G, 1985, ARCH MICROBIOL, V142, P383, DOI 10.1007/BF00491908; BUTLER JS, 1988, SCIENCE, V242, P1270, DOI 10.1126/science.2848317; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; FAHRNER K, 1980, NUCLEIC ACIDS RES, V8, P5725, DOI 10.1093/nar/8.23.5725; FAVOLORO J, 1980, METHOD ENZYMOL, V65, P718; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GERSTEL B, 1992, MOL MICROBIOL, V6, P2339, DOI 10.1111/j.1365-2958.1992.tb01409.x; GIEBEL LB, 1990, NUCLEIC ACIDS RES, V18, P4947, DOI 10.1093/nar/18.16.4947; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GRONER B, 1975, BIOCHEMISTRY-US, V13, P5378; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HENIKOFF S, 1983, CELL, V33, P607, DOI 10.1016/0092-8674(83)90441-5; HUMPHREY T, 1988, TRENDS GENET, V4, P243, DOI 10.1016/0168-9525(88)90028-5; HYMAN LE, 1991, MOL CELL BIOL, V11, P2004, DOI 10.1128/MCB.11.4.2004; IRNIGER S, 1992, MOL CELL BIOL, V12, P2322, DOI 10.1128/MCB.12.5.2322; IRNIGER S, 1991, MOL CELL BIOL, V11, P3060, DOI 10.1128/MCB.11.6.3060; IRNIGER S, 1993, CURR GENET, V23, P201, DOI 10.1007/BF00351496; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MIOZZARI G, 1978, J BACTERIOL, V153, P163; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; RAVE N, 1979, NUCLEIC ACIDS RES, V6, P3559, DOI 10.1093/nar/6.11.3559; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; SADHALE PP, 1992, MOL CELL BIOL, V12, P4262, DOI 10.1128/MCB.12.10.4262; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YU K, 1989, MOL CELL BIOL, V9, P2431, DOI 10.1128/MCB.9.6.2431; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; ZITOMER RS, 1976, J BIOL CHEM, V251, P6320	46	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27378	27383						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961648				2022-12-25	WOS:A1994PV77100038
J	HAMAGUCHI, I; IWAMA, A; YAMAGUCHI, N; SAKANO, S; MATSUDA, Y; SUDA, T				HAMAGUCHI, I; IWAMA, A; YAMAGUCHI, N; SAKANO, S; MATSUDA, Y; SUDA, T			CHARACTERIZATION OF MOUSE NONRECEPTOR TYROSINE KINASE GENE, HYL	ONCOGENE			English	Note							RAT-BRAIN; PROTEIN; MICE; FYN; LOCALIZATION; FAMILY; CSK	We previously reported a novel human non-receptor tyrosine kinase gene, HYL (hematopoietic consensus tyrosine-lacking kinase) (Sakano et al., 1994), which consists of each of the SH2 (src homology 2), SH3 and tyrosine kinase catalytic domains. HYL has unique structural features shared with CSK (C-terminal Src kinase). Recently it has also been reported that matk (Bennett et al., 1994) and Ctk (Klages et al., 1994) are isolated as novel kinases with structural similarity to CSK. Comparisons of cDNA sequence indicate the HYL, matk and Ctk are the same gene. We further characterized the mouse HYL genomic structure and HYL mRNA expression in mouse brain. The mouse HYL gene is distributed over 5.8 kb and is composed of 12 exons; The exon-intron organization is almost identical with that of human CSK. The mouse HYL gene was assigned to the R-positive C1 band of chromosome 10 by fluorescent in situ hybridization. RNA in situ hybridization demonstrated the broad distribution of HYL mRNA expression in various neuronal cells. Especially, strong signals were detected in Purkinje cells, pyramidal cells in the hippocampus, granule cells in the dentate gyrus, and mitral cells in the olfactory bulb, indicating that mRNA expression of HYL in brain is very similar to that of SRC-family kinases. These findings establish close relationship between the HYL and CSK genes and also suggest that HYL may play an important role in signal transduction through SRC-family kinases in the central nervous system.	KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,DEPT CELL DIFFERENTIAT,KUMAMOTO 860,JAPAN; ASAHI CHEM IND CO LTD,FUNDAMENTAL RES LAB LIFE SCI,FUJI 416,SHIZUOKA,JAPAN; NATL INST RADIOL SCI,DIV GENET,CHIBA 263,JAPAN	Kumamoto University; National Institutes for Quantum Science & Technology			Suda, Toshio/H-6761-2013	Suda, Toshio/0000-0001-7540-1771				BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BOLEN JB, 1993, ONCOGENE, V8, P2025; BRAUNINGER A, 1993, ONCOGENE, V8, P1365; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; COOKE M P, 1989, New Biologist, V1, P66; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SAKANO S, 1994, ONCOGENE, V9, P1115; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SOMSSICH IE, 1989, GENETIC VARIANTS STR, P580; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TAYLOR BA, 1993, MAMM GENOME, V4, pS154, DOI 10.1007/BF00360836; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAGI T, 1993, ONCOGENE, V8, P3343; ZHAO YH, 1991, ONCOGENE, V6, P1725	25	16	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3371	3374						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936664				2022-12-25	WOS:A1994PM65800033
J	SUZUKI, T; HIRAI, H; YOSHIDA, M				SUZUKI, T; HIRAI, H; YOSHIDA, M			TAX PROTEIN OF HTLV-1 INTERACTS WITH THE REL HOMOLOGY DOMAIN OF NF-KAPPA-B P65 AND C-REL PROTEINS BOUND TO THE NF-KAPPA-B BINDING-SITE AND ACTIVATES TRANSCRIPTION	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANS-ACTIVATION; GENE-EXPRESSION; PRECURSOR P105; TRANSACTIVATOR; ENHANCER; PROMOTER; P40X	Tax protein of human T cell leukemia virus type 1 (HTLV-1) enhances transcription of several cellular genes through activation of a specific enhancer, the NF-kappa B binding site. We found previously that Tax binds to NF-kappa B p50, which is a member of the Rel/NF-kappa B family proteins, and associates with the DNA sequence of the NF-kappa B binding site. In the present study, we tested other NF-kappa B family proteins and found that NF-kappa B p65 and c-Rel proteins also bind to Tax and that their complexes with Tax bind to the DNA sequence of the NF-kappa B binding site. The Tax binding site on NF-kappa B p50 is the Rel homology domain, which is conserved in the Rel/NF-kappa B family proteins. The formations of these complexes by Tax mutants were well correlated with their transactivating capacities. In F9 embryonic carcinoma cells, Tax enhanced transcription synergistically with NF-kappa B p65 or c-Rel. Thus Tax interacts with the Rel homology domain of Rel/NF-kappa B family proteins which bind to the NF-kappa B binding site and activates transcription.	UNIV TOKYO,INST MED SCI,DEPT CELL & MOLEC BIOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BAUERLE PA, 1988, CELL, V53, P211; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GESSAIN A, 1985, LANCET, V2, P407; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KIYOKAWA T, 1984, JPN J CANCER RES, V75, P747; LANOIX J, 1994, ONCOGENE, V9, P841; Leonardo MJ, 1998, CELL, V58, P227; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; MARUYAMA M, 1987, CELL, V48, P493; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; OSAME M, 1986, LANCET, V1, P1031; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; WATANABE M, 1993, ONCOGENE, V8, P2949; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	36	92	95	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3099	3105						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936632				2022-12-25	WOS:A1994PM65800001
J	KUUSK, V; MCINTIRE, WS				KUUSK, V; MCINTIRE, WS			INFLUENCE OF MONOVALENT CATIONS ON THE ULTRAVIOLET-VISIBLE SPECTRUM OF TRYPTOPHAN TRYPTOPHYLQUINONE-CONTAINING METHYLAMINE DEHYDROGENASE FROM BACTERIUM W3A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; PARACOCCUS-DENITRIFICANS; ACTIVE-SITE; OBLIGATE METHYLOTROPH; QUINONE COFACTOR; PURIFICATION; PROTEINS; ENZYME; SELECTIVITY; CONSTANTS	The influence of the monovalent cations on the UV-visible spectra of the methylamine dehydrogenase (MADH) from bacterium W3A1 was investigated. The spectra for the oxidized and 1- and 2-electron-reduced forms, unperturbed by bound cations, were obtained for the enzyme, and the extinction coefficients for these forms were determined. The binding of the following cations was investigated: Li+, Na+, K+, Rb+, Cs+, NH4+, (CH3N+, and (CH3N+. It was shown that each cation produced unique spectral changes, some of which were pH-dependent. Except for NH4+, all spectral changes produced by binding of the monovalent cations can be explained by assuming two different binding sites in MADH (type I and type II sites). Na+ and K+ displayed monophasic binding to the type II site, (CH3)(3)NH+ and (CH3N+ displayed monophasic binding to the type I site, and Li+, Rb+, and Cs+ displayed either monophasic or biphasic binding to one or both sites depending on pH. The pH dependence for binding to the two sites is different, i.e. plots of log(K-d) versus pH have negative slopes approximate to 1 for the type II site, whereas the negative slope is significantly less than 1 (0.6-0.8) for the type I site. This difference leads to pH-dependent changes in spectral features produced by binding of Li+, Rb+, and Cs+. The spectral changes seen during titrations with NH4+ were unlike those seen for any other cation. The binding of NH4+ was biphasic, and the spectra produced in each phase were unaffected by pH. It is assumed that this cation binds to the tryptophan tryptophylquinone cofactor to produce the iminoquinone in the first phase and then binds to the type I monovalent cation binding site in the second phase. It is suggested that binding of NH4+ (and CH3NH3+) to the type I site is a prelude to binding to the cofactor.	VET AFFAIRS MED CTR,DIV MOLEC BIOL 151S,SAN FRANCISCO,CA 94121; NO CALIF INST RES EDUC,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143	US Department of Veterans Affairs; Veterans Health Administration (VHA); Northern California Institute for Research & Education; University of California System; University of California San Francisco; University of California System; University of California San Francisco								BACKES G, 1991, BIOCHEMISTRY-US, V30, P9201, DOI 10.1021/bi00102a011; BADGER J, 1994, BIOPHYS J, V66, P286, DOI 10.1016/S0006-3495(94)80795-7; BASHFORD D, 1993, BIOCHEMISTRY-US, V32, P8045, DOI 10.1021/bi00082a027; BURROWS AL, 1991, EUR J BIOCHEM, V199, P73, DOI 10.1111/j.1432-1033.1991.tb16093.x; CHEN LY, 1991, FEBS LETT, V287, P163, DOI 10.1016/0014-5793(91)80041-Z; CHISTOSERDOV AY, 1991, J BACTERIOL, V173, P5901, DOI 10.1128/jb.173.18.5901-5908.1991; DAVIDSON VL, 1990, BIOCHEMISTRY-US, V29, P10786, DOI 10.1021/bi00500a010; EDMONDSON DE, 1973, FEBS LETT, V64, P255; EISENMAN G, 1987, ANNU REV BIOPHYS BIO, V16, P205; Eisenman G., 1961, S MEMBRANE TRANSPORT, P163; HINTON JF, 1986, BIOPHYS J, V50, P539, DOI 10.1016/S0006-3495(86)83492-0; HUIZINGA EG, 1992, BIOCHEMISTRY-US, V31, P9789, DOI 10.1021/bi00155a036; HUSAIN M, 1987, BIOCHEMISTRY-US, V26, P4139, DOI 10.1021/bi00387a059; HUSAIN M, 1987, J BACTERIOL, V169, P1712, DOI 10.1128/jb.169.4.1712-1717.1987; ITOH S, 1992, J AM CHEM SOC, V114, P7294, DOI 10.1021/ja00044a050; KANKARE JJ, 1970, ANAL CHEM, V42, P1322, DOI 10.1021/ac60294a012; KENNEY WC, 1983, BIOCHEMISTRY-US, V22, P3858, DOI 10.1021/bi00285a022; KIRUKHIN MY, 1990, METHOD ENZYMOL, V188, P247; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; LAWTON SA, 1985, BIOCHEM J, V228, P719, DOI 10.1042/bj2280719; Malinowski ER., 1991, FACTOR ANAL CHEM, V2; MATSUMOTO T, 1978, BIOCHIM BIOPHYS ACTA, V522, P291, DOI 10.1016/0005-2744(78)90063-3; MCINTIRE WS, 1991, BIOCHEMISTRY-US, V30, P125, DOI 10.1021/bi00215a019; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MCINTIRE WS, 1987, J BIOL CHEM, V262, P11012; MCINTIRE WS, 1987, APPL ENVIRON MICROB, V53, P2183, DOI 10.1128/AEM.53.9.2183-2188.1987; MCWHIRTER RB, 1989, PQQ AND QUINOPROTEINS, P259; MEHTA RJ, 1977, CAN J MICROBIOL, V23, P402, DOI 10.1139/m77-059; MILLER C, 1993, SCIENCE, V261, P1692, DOI 10.1126/science.8397443; SHIRAI S, 1978, J BIOCHEM, V83, P1599, DOI 10.1093/oxfordjournals.jbchem.a132071; SLEATH PR, 1985, J AM CHEM SOC, V107, P3328, DOI 10.1021/ja00297a044; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; VELLIEUX FMD, 1986, EUR J BIOCHEM, V154, P383, DOI 10.1111/j.1432-1033.1986.tb09409.x; YAMASHITA MM, 1990, P NATL ACAD SCI USA, V87, P5648, DOI 10.1073/pnas.87.15.5648	35	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26136	26143						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929326				2022-12-25	WOS:A1994PQ93000032
J	PAUL, MF; ACKERMANN, S; YUE, J; ARSELIN, G; VELOURS, J; TZAGOLOFF, A				PAUL, MF; ACKERMANN, S; YUE, J; ARSELIN, G; VELOURS, J; TZAGOLOFF, A			CLONING OF THE YEAST ATP3 GENE CODING FOR THE GAMMA-SUBUNIT OF F1 AND CHARACTERIZATION OF ATP3 MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-MEMBRANE SYSTEM; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; OXIDATIVE-PHOSPHORYLATION; SEQUENCE-ANALYSIS; EPSILON-SUBUNIT; STRUCTURAL GENE; COUPLING FACTOR; BETA-SUBUNIT	Saccharomyces cerevisiae pet mutants, of complementation group G115, are deficient in mitochondrial ATPase and have properties indicative of defective F-1. In this study we show that C287/LU1, a mutant belonging to group G115, is complemented by the yeast nuclear ATP3 gene coding for the gamma-subunit of the mitochondrial F-1- ATPase. The amino-terminal sequence of the mature gamma-subunit matches the sequence encoded by ATP3 starting with the 34th amino acid confirming the identity of the gene, and earlier evidence indicating that this F-1 component is synthesized as a precursor with a long amino-terminal extension. The properties of the mitochondrial ATPase have been studied in C287/LU1 with an Ala(273) --> Val substitution in the carboxyl-terminal region of the gamma-subunit and in W303 Delta ATP3, a mutant lacking the gamma-subunit as a result of a deletion in ATP3. Both strains have negligible ATPase activity but near normal concentrations of the alpha- and beta-subunits of F-1. In W303 Delta ATP3, the subunits do not form a stable F-1 oligomer nor are they firmly associated with F-0. This is not true of C287/LU1, which was found to assemble an F-1-F-0 complex. These data indicate that the yeast gamma-subunit has dual functions, one in catalysis of ATP hydrolysis/synthesis and the second in assembly/stability of F-1.	INST BIOCHIM & GENET CELLULAIRE, F-33077 BORDEAUX, FRANCE		PAUL, MF (corresponding author), COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022174, R01HL022174] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ARSELIN G, 1991, J BIOL CHEM, V266, P723; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; COX GB, 1992, MOL MECHANISMS BIOEN, P283; DUNN SD, 1980, J BIOL CHEM, V255, P113; DYER MR, 1989, BIOCHEMISTRY-US, V28, P3670, DOI 10.1021/bi00435a008; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V79, P1231, DOI 10.1016/0006-291X(77)91138-X; GUELIN E, 1993, J BIOL CHEM, V268, P161; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; KANAZAWA H, 1983, ARCH BIOCHEM BIOPHYS, V223, P521, DOI 10.1016/0003-9861(83)90617-3; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIN AS, 1980, P NATL ACAD SCI-BIOL, V77, P3998, DOI 10.1073/pnas.77.7.3998; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; Maniatis T., 1982, MOL CLONING; MASON JG, 1990, PLANT MOL BIOL, V14, P1007, DOI 10.1007/BF00019397; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NORAIS N, 1991, J BIOL CHEM, V266, P16541; NORTHROP FD, 1985, J MOL BIOL, V184, P677; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SARASTE M, 1981, NUCLEIC ACIDS RES, V9, P5287, DOI 10.1093/nar/9.20.5287; SCHATZ G, 1968, J BIOL CHEM, V243, P2192; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; Tzagoloff A, 1979, Methods Enzymol, V55, P351; TZAGOLOFF A, 1971, J BIOL CHEM, V246, P7328; VELOURS J, 1988, EUR J BIOCHEM, V170, P637, DOI 10.1111/j.1432-1033.1988.tb13745.x; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480	44	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26158	26164						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929329				2022-12-25	WOS:A1994PQ93000035
J	JACOB, KK; STANLEY, FM				JACOB, KK; STANLEY, FM			THE INSULIN AND CAMP RESPONSE ELEMENTS OF THE PROLACTIN GENE ARE OVERLAPPING SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ACTING ELEMENTS; PROXIMAL REGION; THYROID-HORMONE; EXPRESSION; TRANSCRIPTION; PROMOTER; BINDING; DNA; CELLS; BASAL	Prolactin gene expression is affected by numerous signals, but many of the promoter elements required for these responses have not been clearly identified. This report identifies sequences within the prolactin gene promoter that are required for the responses to cAMP and insulin. The cAMP response element, -101 to -92 shares a 6 of 8 base pair homology with previously identified cAMP response elements. Mutation of this element also results in a >100-fold decrease in basal prolactin gene expression. This is characteristic of cAMP response elements, but the importance of this element to basal prolactin gene transcription was previously unrecognized. The insulin response element, -97 to -67, is not homologous to previously reported insulin response elements and mediates the 10-fold increases in prolactin gene expression due to insulin observed in GH cells. These elements also function to mediate insulin and cAMP responses from the heterologous Delta MTV-CAT reporter plasmid. Together, insulin and cAMP increase prolactin gene expression additively. The clustering of these elements may provide clues to the independent and possible coordinate regulation by these effecters.	NYU,MED CTR,DEPT MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University; New York University				Stanley, Frederick/0000-0002-3684-2168	NIDDK NIH HHS [DK 43365] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043365] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANCROFT FC, 1981, FUNCTIONALLY DIFFERE, P47; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; DEMDEN MC, 1992, MOL ENDOCRINOL, V6, P581, DOI 10.1210/me.6.4.581; FLUG F, 1987, J BIOL CHEM, V262, P6373; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAZRIN N, 1990, P NATL ACAD SCI USA, V87, P5273; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; PEERS B, 1991, J BIOL CHEM, V266, P18127; PEERS B, 1992, EUR J BIOCHEM, V210, P53, DOI 10.1111/j.1432-1033.1992.tb17389.x; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; STANLEY F, 1988, J BIOL CHEM, V263, P13444; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WEBER JL, 1984, MOL CELL BIOCHEM, V65, P171; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237	27	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25515	25520						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929252				2022-12-25	WOS:A1994PQ49100045
J	KERY, V; BUKOVSKA, G; KRAUS, JP				KERY, V; BUKOVSKA, G; KRAUS, JP			TRANSSULFURATION DEPENDS ON HEME IN ADDITION TO PYRIDOXAL 5'-PHOSPHATE - CYSTATHIONINE BETA-SYNTHASE IS A HEME PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOPROTEIN H-450; CULTURED-CELLS; HUMAN-LIVER; RAT-LIVER; ENZYMES; LIGAND; CDNA; ADENOSYLMETHIONINE; ADENOSYLETHIONINE; CYTOCHROME-P-450	The first committed step of transsulfuration is catalyzed by cystathionine beta-synthase (CBS), a known pyridoxal 5'-phosphate (PLP) enzyme. The inferred amino acid sequences of rat liver CBS and rat liver hemoprotein H-450 are identical. We now confirm the presence of heme b in rat and human liver CBS. Heme almost entirely accounts for the visible spectrum of CBS rather than PLP. Human CBS, expressed in Escherichia coli, acquires heme b from the host bacteria. delta-Aminolevulinate supplementation during bacterial growth increases both the heme saturation and the specific activity of the homogeneous enzyme more than 3-fold. 1 mol of the 63-kDa CBS subunit binds 1 mol of each (heme and PLP). The presence of heme is required for PLP binding, and the amount of PLP bound is limited by the heme content. Removal of PLP, but not heme, from CBS is reversible. These findings suggest that heme is functionally incorporated into CBS only during protein folding. This report describes the first instance of an enzyme that depends upon both heme and PLP for its function.	UNIV COLORADO,SCH MED,DEPT PEDIAT,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT CELLULAR & STRUCT BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								Adams E, 1979, Methods Enzymol, V62, P407; ADAMS E, 1969, ANAL BIOCHEM, V31, P484, DOI 10.1016/0003-2697(69)90291-7; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; BRAUNSTEIN AE, 1976, BIOCHIMIE, V58, P5, DOI 10.1016/S0300-9084(76)80351-3; BUKOVSKA G, 1994, IN PRESS PROTEIN EXP; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; DOSS M, 1971, H-S Z PHYSIOL CHEM, V352, P725, DOI 10.1515/bchm2.1971.352.1.725; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8958; FINKELSTEIN JD, 1984, BIOCHEM BIOPH RES CO, V118, P14, DOI 10.1016/0006-291X(84)91060-X; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; GRABOWSKI R, 1993, TRENDS BIOCHEM SCI, V18, P297, DOI 10.1016/0968-0004(93)90040-T; HASEGAWA T, 1984, J BIOCHEM-TOKYO, V96, P265, DOI 10.1093/oxfordjournals.jbchem.a134822; ISHIHARA S, 1990, J BIOCHEM-TOKYO, V108, P899, DOI 10.1093/oxfordjournals.jbchem.a123310; KIM IC, 1982, J BIOL CHEM, V257, P1063; KIM IC, 1976, BIOCHEMISTRY-US, V15, P4925, DOI 10.1021/bi00667a027; KIMURA H, 1971, J BIOCHEM-TOKYO, V69, P711, DOI 10.1093/oxfordjournals.jbchem.a129520; Kozich Viktor, 1992, Human Mutation, V1, P113, DOI 10.1002/humu.1380010206; KRAUS J, 1978, J BIOL CHEM, V253, P6523; KRAUS JP, 1993, HUM MOL GENET, V2, P1633, DOI 10.1093/hmg/2.10.1633; KRAUS JP, 1983, ARCH BIOCHEM BIOPHYS, V222, P44, DOI 10.1016/0003-9861(83)90500-3; LIPSON MH, 1980, ARCH BIOCHEM BIOPHYS, V204, P486, DOI 10.1016/0003-9861(80)90060-0; MORINO Y, 1984, METHOD ENZYMOL, V106, P116; MORRISON M, 1965, ANAL BIOCHEM, V12, P77, DOI 10.1016/0003-2697(65)90144-2; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; OMURA T, 1984, J BIOCHEM-TOKYO, V96, P1491, DOI 10.1093/oxfordjournals.jbchem.a134978; ROPER MD, 1992, ARCH BIOCHEM BIOPHYS, V298, P514, DOI 10.1016/0003-9861(92)90443-Z; SCHELLHORN HE, 1988, J BACTERIOL, V170, P78, DOI 10.1128/jb.170.1.78-83.1988; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SKOVBY F, 1984, J BIOL CHEM, V259, P588; SONO M, 1982, J BIOL CHEM, V257, P8308; SWAROOP M, 1992, J BIOL CHEM, V267, P11455	32	153	159	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25283	25288						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929220				2022-12-25	WOS:A1994PQ49100010
J	KUNG, C; HAYES, E; MANN, KG				KUNG, C; HAYES, E; MANN, KG			A MEMBRANE-MEDIATED CATALYTIC EVENT IN PROTHROMBIN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-V; GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR VA; PHOSPHOLIPID-VESICLES; PHASE-TRANSITIONS; ACTIVE-SITE; FACTOR-XA; PHOSPHATIDYLCHOLINE LIPOSOMES; FLUORESCENCE DEPOLARIZATION; COFACTOR DEPENDENCE	Prothrombinase assembly takes place on the surface of unsaturated phosphatidylcholine (PC), phosphatidyl-serine (PS) membranes in the presence of Ca2+, through the rapid association of membrane-bound factor Va and factor Xa. The present study uses saturated PCPS (75:25, w/w) vesicles to study prothrombinase assembly and catalytic properties in order to differentiate the influences of the membrane upon catalyst assembly, substrate delivery, and peptide bond cleavage. In contrast to studies using unsaturated phospholipid, prothrombin activation studies using saturated PCPS (75:25, w/w) (C14:0, C16:0, and C18:0) revealed up to a 20-fold decrease in prothrombinase activity. C18:0 membranes support at least 50% of the prothrombinase binding capacity (K-dVa-Xa = 1 nM and n(Va-Xa) = 1.1) of C18:1 PCPS (75:25, w/w). Thus, the 95% loss in activity cannot be explained by gross alterations in catalyst concentration or assembly. Stopped-flow studies with saturated lipids demonstrate that factor Va, factor Xa, and prothrombin have decreased k(on) values. Compensatory changes in k(off) leave the K-d values for these protein-lipid interactions almost unchanged relative to unsaturated PCPS. The profoundly decreased activation rate on saturated phospholipid membranes as compared to unsaturated phospholipids is in part due to slowed substrate/enzyme delivery caused by the saturated lipids. However, studies using prethrombin-1 and C18:0 PCPS (75:25, w/w) also revealed a 15-fold decrease in activity for preassembled prothrombinase. Although there was a slight change in K-m (+2-fold), the major cause of the decrease is an 18-fold decrease in k(cat). Similar differences for K-m and k(cat) values were obtained for prothrombin. Substrate delivery is thus only partially responsible for the diminished prothrombinase activity observed with saturated phospholipids. Since the activity of prothrombinase is decreased for both prothrombin and, prethrombin-1 principally by reducing k(cat), it appears that catalyst formation on saturated phospholipids somehow compromises the proteolytic activity of the enzyme complex. This implies that the phospholipid bilayer serves not merely as a surface for condensing the proteins but also as a functional element of the prothrombinase enzyme.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405	University of Vermont					NHLBI NIH HHS [P01HL46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BUTENAS S, 1992, BIOCHEMISTRY-US, V31, P5399, DOI 10.1021/bi00138a023; COOPER RA, 1978, BIOCHEMISTRY-US, V17, P327, DOI 10.1021/bi00595a021; CUTSFORTH GA, 1989, BIOCHEMISTRY-US, V28, P7453, DOI 10.1021/bi00444a045; CUTSFORTH GA, 1991, THROMB HAEMOSTASIS, V65, P8582; DOMBROSE FA, 1979, J BIOL CHEM, V254, P5027; Fersht A., 1985, ENZYME STRUCTURE MEC; GERADS I, 1990, BIOCHEMISTRY-US, V29, P7967, DOI 10.1021/bi00486a027; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; Gomori G, 1942, J LAB CLIN MED, V27, P955; GOVERSRIEMSLAG JWP, 1992, BIOCHEMISTRY-US, V31, P10000, DOI 10.1021/bi00156a020; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; Jesty J, 1976, Methods Enzymol, V45, P95; JONES ME, 1985, THROMB RES, V39, P711, DOI 10.1016/0049-3848(85)90255-5; JONES ME, 1986, BIOCHEMISTRY-US, V25, P567, DOI 10.1021/bi00351a009; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KRIEG UC, 1987, BIOCHEMISTRY-US, V26, P103, DOI 10.1021/bi00375a015; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPE PD, 1984, J BIOL CHEM, V259, P9959; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LECOMPTE MF, 1987, J BIOL CHEM, V262, P1935; LECOMPTE MF, 1994, J BIOL CHEM, V269, P1905; LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4529, DOI 10.1021/bi00665a030; LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4521, DOI 10.1021/bi00665a029; LENTZ BR, 1989, BIOCHEMISTRY-US, V28, P7459; MALHOTRA OP, 1985, J BIOL CHEM, V260, P279; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MANN KG, 1990, BLOOD, V76, P755; MANN KG, 1987, PROTEASES BIOL CONTR, P235; MAYER LD, 1983, BIOCHIM BIOPHYS ACTA, V734, P48, DOI 10.1016/0005-2736(83)90073-1; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; ODEGAARD BH, 1987, J BIOL CHEM, V262, P11237; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; PEI G, 1993, J BIOL CHEM, V268, P3226; ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002; ROSING J, 1988, BIOCHEMISTRY-US, V27, P9048, DOI 10.1021/bi00425a025; ROSING J, 1993, J BIOL CHEM, V268, P21130; SEELIG A, 1977, BIOCHEMISTRY-US, V16, P45, DOI 10.1021/bi00620a008; Shattil S J, 1978, Prog Hemost Thromb, V4, P59; STUBBS CD, 1983, ESSAYS BIOCHEM, V19, P1; TANS G, 1979, EUR J BIOCHEM, V95, P449, DOI 10.1111/j.1432-1033.1979.tb12984.x; TENDIAN SW, 1990, BIOCHEMISTRY-US, V29, P6720, DOI 10.1021/bi00480a023; TOWBIN H, 1979, P NATL ACAD SCI USA, V19, P665; TRACY PB, 1986, BIOCH PLATELETS, P295; WALKER RK, 1993, J BIOL CHEM, V268, P13920; WEI GJ, 1982, BIOCHEMISTRY-US, V21, P1949, DOI 10.1021/bi00537a039; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536; WILLIAMS EB, 1993, METHOD ENZYMOL, V222, P503; WU JR, 1991, BIOPHYS J, V60, P70, DOI 10.1016/S0006-3495(91)82031-8	65	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25838	25848						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929289				2022-12-25	WOS:A1994PQ49100089
J	POWELL, WS; GRAVELLE, F; GRAVEL, S				POWELL, WS; GRAVELLE, F; GRAVEL, S			PHORBOL-MYRISTATE ACETATE STIMULATES THE FORMATION OF 5-OXO-6,8,11,14-EICOSATETRAENOIC ACID BY HUMAN NEUTROPHILS BY ACTIVATING NADPH OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD POLYMORPHONUCLEAR LEUKOCYTES; ARACHIDONIC-ACID; INHIBITOR DIPHENYLENEIODONIUM; STRUCTURAL-ANALYSIS; METABOLISM; LEUKOTRIENE; TRANSFORMATION; CYTOKINEPLASTS; MECHANISM; CALCIUM	We have shown previously that human neutrophil microsomes contain a highly specific dehydrogenase which, in the presence of NADP(+), converts 5S-hydroxy-6,8,11,14-eicosatetraenoic acid (5S-HETE) to its 5-oxo metabolite, 5-oxo-ETE, a potent agonist of these cells. However, intact neutrophils convert SS-HETE principally to its psi-oxidation product, 5,20-diHETE, and to only small amounts of 5-oxo-ETE. Phorbol myristate acetate (PMA) dramatically shifts the metabolism of 5S-HETE by intact cells so that 5-oxo-ETE is the major metabolite. The objective of this investigation was to determine the mechanism for the stimulatory effect of PMA on 5-oxo-ETE formation. The possibility that oxidants released in response to PMA nonenzymatically oxidized 5S-HETE was ruled out, since PMA did not appreciably stimulate the formation of 5-oxo-ETE from 5R-HETE. On the other hand, inhibition of NADPH oxidase either by diphenylene iodonium or by mild heating nearly completely prevented the stimulatory effect of PMA on the formation of 5-oxo-ETE. The possibility that this effect was mediated by superoxide seems unlikely, since it was still observed, although somewhat attenuated, in the presence of superoxide dismutase. Moreover, superoxide generated by another mechanism (xanthine/xanthine oxidase) did not appreciably affect the formation of 5-oxo-ETE by neutrophils, However, phenazine methosulfate, which can nonenzymatically convert NADPH to NADP(+), mimicked the effect of PMA on 5-oxo-ETE formation by intact neutrophils. It is concluded that PMA acts by activating NADPH oxidase, resulting in conversion of NADPH to NADP(+), which enhances the formation of 5-oxo-ETE and reduces the formation of 5,20-diHETE. Serum-treated zymosan has an effect on the metabolism of 5S-HETE similar to that of PMA in that it also stimulates the formation of 5-oxo-ETE and inhibits that of 5,20 diHETE.			POWELL, WS (corresponding author), MCGILL UNIV,DEPT MED,RESP HLTH NETWORK CTR EXELLENCE,MEAKINS CHRISTIE LABS,3626 ST URBAIN ST,MONTREAL H2X 2P2,PQ,CANADA.		Powell, William/AAE-9000-2020	Powell, William/0000-0002-8507-4038				BORGEAT P, 1981, PROSTAG LEUKOTR ESS, V6, P557, DOI 10.1016/0161-4630(81)90117-8; BORGEAT P, 1979, J BIOL CHEM, V254, P7865; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; COLLETTE J, 1956, J AM CHEM SOC, V78, P3819, DOI 10.1021/ja01596a070; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DAVIS G, 1983, BIOCHIM BIOPHYS ACTA, V724, P456, DOI 10.1016/0005-2728(83)90106-8; DYETT DE, 1986, J CLIN INVEST, V77, P34, DOI 10.1172/JCI112297; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; ERICKSON RW, 1992, J CLIN INVEST, V89, P1587, DOI 10.1172/JCI115753; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GIBIAN MJ, 1987, ANAL BIOCHEM, V163, P343, DOI 10.1016/0003-2697(87)90234-X; GOETZL EJ, 1980, J IMMUNOL, V125, P1789; GORDON JA, 1989, AM J PHYSIOL, V256, pC1, DOI 10.1152/ajpcell.1989.256.1.C1; HANSSON G, 1981, FEBS LETT, V130, P107, DOI 10.1016/0014-5793(81)80676-X; JUBIZ W, 1982, J BIOL CHEM, V257, P6106; MAAS RL, 1982, J BIOL CHEM, V257, P7056; MALAWISTA SE, 1985, INFLAMMATION, V9, P99, DOI 10.1007/BF00915416; MALAWISTA SE, 1986, BLOOD CELLS, V12, P167; MALAWISTA SE, 1982, J CELL BIOL, V95, P960, DOI 10.1083/jcb.95.3.960; MULLER M, 1992, INFECT IMMUN, V60, P2536, DOI 10.1128/IAI.60.6.2536-2540.1992; NACCACHE PH, 1984, J CELL PHYSIOL, V118, P13, DOI 10.1002/jcp.1041180104; OFLAHERTY JT, 1988, J IMMUNOL, V140, P4323; OFLAHERTY JT, 1986, J IMMUNOL, V137, P3277; OFLAHERTY JT, 1993, BIOCHEM BIOPH RES CO, V192, P129, DOI 10.1006/bbrc.1993.1391; PALMBLAD J, 1981, BLOOD, V58, P658; POWELL WS, 1994, BIOCHEMISTRY-US, V33, P3927, DOI 10.1021/bi00179a019; POWELL WS, 1984, J BIOL CHEM, V259, P3082; POWELL WS, 1993, J BIOL CHEM, V268, P9280; POWELL WS, 1992, J BIOL CHEM, V267, P19233; POWELL WS, 1987, ANAL BIOCHEM, V164, P117, DOI 10.1016/0003-2697(87)90375-7; POWELL WS, 1993, J LEUKOCYTE BIOL S, V137; RAGAN CI, 1977, BIOCHEM J, V163, P605, DOI 10.1042/bj1630605; RICHARDS CF, 1986, BIOCHIM BIOPHYS ACTA, V875, P569, DOI 10.1016/0005-2760(86)90079-2; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SERHAN CN, 1989, BIOCHIM BIOPHYS ACTA, V1004, P158, DOI 10.1016/0005-2760(89)90264-6; SMITH PJ, 1961, NATURE, V190, P84, DOI 10.1038/190084a0; SOBERMAN RJ, 1987, J BIOL CHEM, V262, P12421; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; YEA CM, 1990, BIOCHEM J, V265, P95, DOI 10.1042/bj2650095	41	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25373	25380						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929234				2022-12-25	WOS:A1994PQ49100025
J	BOOTMAN, MD; CHEEK, TR; MORETON, RB; BENNETT, DL; BERRIDGE, MJ				BOOTMAN, MD; CHEEK, TR; MORETON, RB; BENNETT, DL; BERRIDGE, MJ			SMOOTHLY GRADED CA2+ RELEASE FROM INOSITOL 1,4,5-TRISPHOSPHATE-SENSITIVE CA2+ STORES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; ADRENAL CHROMAFFIN CELLS; CALCIUM RELEASE; HELA-CELLS; 1,4,5-TRISPHOSPHATE RECEPTOR; PERMEABILIZED HEPATOCYTES; INTRACELLULAR STORES; NONEXCITABLE CELLS; POSSIBLE MECHANISM; CA-2+ RELEASE	Stimulation of cells with Ca2+-mobilizing hormones often leads to the generation of temporally and spatially complex changes in the intracellular Ca2+ ion concentration ([Ca2+](i)). To understand the mechanisms regulating Ca2+ release from intracellular stores more clearly, we investigated the ability of histamine to release Ca2+ stores under different experimental conditions, using video imaging of single Fura-2-loaded HeLa cells. In Ca2+-free medium, stepwise increases in histamine concentration released an increasing proportion of the intracellular Ca2+ pool. This pattern of Ca2+-release is analogous to the ''quantal'' release of Ca2+ previously observed using permeabilized cells. Quantal Ca2+ release was observed at both 20 and 37 degrees C and was not due to inactivation or desensitization of the Ca2+ release mechanism, since application of histamine in a pulsatile manner, which avoided desensitization of the Ca2+-release mechanism, still produced a quantal response. In Ca2+-containing medium at both 20 and 37 degrees C, stepwise increases in histamine concentration evoked [Ca2+](i) responses where the amplitude was smoothly graded in direct proportion to the histamine concentration. Similar smoothly graded responses were observed from HeLa cells in Ca2+-free medium. These data indicate that hormone-evoked Ca2+ release from intracellular stores is limited by the hormone concentration, and that the mechanisms underlying complex [Ca2+](i) signals do not lead to an all-or-none release of Ca2+ from the entire intracellular Ca2+ pool. We suggest that the hormone-sensitive intracellular Ca2+ pool is composed of functionally discrete units that are recruited by agonists in a concentration-dependent manner.			BOOTMAN, MD (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, BABRAHAM INST, MOLEC SIGNALLING LAB, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1992, J BIOL CHEM, V267, P17722; BIZZARRI C, 1994, EUR J BIOCHEM, V219, P837, DOI 10.1111/j.1432-1033.1994.tb18565.x; BOOTMAN M, 1994, CURR BIOL, V4, P169, DOI 10.1016/S0960-9822(94)00041-2; BOOTMAN MD, 1994, MOL CELL ENDOCRINOL, V98, P157, DOI 10.1016/0303-7207(94)90134-1; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; CHEEK TR, 1994, BIOCHEM J, V301, P879, DOI 10.1042/bj3010879; CHEEK TR, 1993, J BIOL CHEM, V268, P27076; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20850; GIOVANNARDI S, 1992, EXP CELL RES, V202, P398, DOI 10.1016/0014-4827(92)90092-M; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; KALTHOF B, 1993, J PHYSIOL-LONDON, V466, P245; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; MACGLASHAN D, 1989, J CELL BIOL, V109, P123, DOI 10.1083/jcb.109.1.123; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1994, MOL CELL ENDOCRINOL, V98, P147, DOI 10.1016/0303-7207(94)90133-3; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NELSON TE, 1990, FEBS LETT, V263, P292, DOI 10.1016/0014-5793(90)81396-6; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; OLDERSHAW KA, 1992, J BIOL CHEM, V267, P16312; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PIETRI F, 1990, J BIOL CHEM, V265, P17478; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROUXEL FP, 1992, J BIOL CHEM, V267, P20017; SAUVE R, 1987, J MEMBRANE BIOL, V96, P199, DOI 10.1007/BF01869302; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SITSAPESAN R, 1994, J MEMBRANE BIOL, V137, P215; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; TILLY BC, 1990, J CELL BIOL, V110, P1211, DOI 10.1083/jcb.110.4.1211; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435	58	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24783	24791						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929156				2022-12-25	WOS:A1994PQ49000043
J	FITZPATRICK, VD; VANDLEN, RL				FITZPATRICK, VD; VANDLEN, RL			AGONIST SELECTIVITY DETERMINANTS IN SOMATOSTATIN RECEPTOR SUBTYPE-I AND SUBTYPE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; PROTEIN-COUPLED RECEPTORS; DELTA-OPIOID RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; AMINO TERMINUS; BRAIN; BINDING; IDENTIFICATION; SPECIFICITY	The biological activities of the peptide hormone somatostatin are mediated through a recently identified family of G-protein-linked receptors. A number of somatostatin analogs have been characterized with selective affinities for particular somatostatin receptor subtypes. Using one such molecule (MK-678), we have delineated receptor regions that determine analog selectivity in the murine Type 1 and Type 2 somatostatin receptors. We find that the regions about the second and third extracellular loops of these two receptors contain the determinants for MK-678 selectivity and affinity	GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BELL GI, 1993, TRENDS NEUROSCI, V16, P34, DOI 10.1016/0166-2236(93)90050-V; BREDER CD, 1992, J NEUROSCI, V12, P3920; BRUNO JF, 1993, ENDOCRINOLOGY, V133, P2561, DOI 10.1210/en.133.6.2561; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; CHAPMAN V, 1992, NEUROPEPTIDES, V23, P147, DOI 10.1016/0143-4179(92)90115-D; CHEN Y, 1993, MOL PHARMACOL, V44, P8; DENOBLE VJ, 1989, BRAIN RES, V482, P42, DOI 10.1016/0006-8993(89)90540-4; ENGLAND BP, 1991, FEBS LETT, V279, P87, DOI 10.1016/0014-5793(91)80257-4; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FITZGERALD LW, 1989, BRAIN RES, V505, P246, DOI 10.1016/0006-8993(89)91450-9; FONG TM, 1992, J BIOL CHEM, V267, P25664; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GETHER U, 1993, J BIOL CHEM, V268, P7893; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; HULME EC, 1993, CELL SIGNAL, V5, P687, DOI 10.1016/0898-6568(93)90030-P; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; KAUPMANN K, 1993, FEBS LETT, V331, P53, DOI 10.1016/0014-5793(93)80296-7; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; MANNI A, 1992, BIOTHERAPY, V4, P31, DOI 10.1007/BF02171707; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAYNOR K, 1993, J PHARMACOL EXP THER, V265, P67; RAYNOR K, 1993, MOL PHARMACOL, V44, P385; RAYNOR K, 1993, MOL PHARMACOL, V43, P838; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; RENSDOMIANO S, 1992, J NEUROCHEM, V58, P1987, DOI 10.1111/j.1471-4159.1992.tb10938.x; ROSSOWSKI WJ, 1993, BIOCHEM BIOPH RES CO, V197, P366, DOI 10.1006/bbrc.1993.2488; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; VANETTI M, 1992, FEBS LETT, V311, P290, DOI 10.1016/0014-5793(92)81122-3; VEBER DF, 1984, LIFE SCI, V34, P1371, DOI 10.1016/0024-3205(84)90009-2; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; YASUDA K, 1992, J BIOL CHEM, V267, P20422	44	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24621	24626						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929134				2022-12-25	WOS:A1994PQ49000020
J	KACA, W; ROTH, RI; LEVIN, J				KACA, W; ROTH, RI; LEVIN, J			HEMOGLOBIN, A NEWLY RECOGNIZED LIPOPOLYSACCHARIDE (LPS)-BINDING PROTEIN THAT ENHANCES LPS BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMA-FREE HEMOGLOBIN; LIPID-A; BIS(3,5-DIBROMOSALICYL) FUMARATE; BACTERIAL LIPOPOLYSACCHARIDES; ALPHA-CHAINS; POLYMYXIN-B; TOXICITY; BINDING; SUBSTITUTE; COMPLEMENT	Cell-free hemoglobin (Hb) is a purified preparation of human hemoglobin that is being developed as a resuscitation fluid. In vivo administration of hemoglobin has resulted in significant toxicity, due in part to contamination with bacterial endotoxin (lipopolysaccharide (LPS)). To better understand this toxicity, we have studied the interaction between Hb and LPS. Mixtures of each of three different Hb preparations (cross-linked alpha alpha Hb, cross-linked carbon monoxy-alpha alpha HbCO, and noncross-linked (native) HbA(o)) and LPS (Escherichia coli O26:B6 or Proteus mirabilis S1959) were examined by several independent methods for evidence of Hb.LPS complex formation, Binding assays in microtiter plates demonstrated saturable binding of LPS to immobilized Hb, with a k(D) of 3.1 x 10(-8) M. finding of LPS to Hb also was demonstrated with a radiolabeled LPS photoaffinity probe. Ultrafiltration of Hb/LPS mixtures by 300- and 100-kDa cut-off membranes showed that the majority of LPS in these mixtures (87-97 and 64-72%, respectively) was detected in the filtrates, in contrast to the lack of filterability of LPS in the absence of Rb. Density centrifugation demonstrated that LPS co-migrated with each of the three Hbs, whereas unbound LPS had a distinctly greater sedimentation velocity than Hb or Hb.LPS complexes. Nondenaturing polyacrylamide gel electrophoresis demonstrated that in the presence of Bb, LPS migrated into the gel and co-electrophoresed with Hb, whereas LPS alone did not appreciably enter the gel. Finally, precipitation by ethanol of each of the three Hb preparations was increased in the presence of LPS compared with precipitation in the absence of LPS. Interaction of LPS with each of the three Hb preparations was also associated with altered biological activity of LPS, as shown by enhancement of LPS activation of Limulus amebocyte lysate. Therefore, our data provide several lines of independent evidence for Hb.LPS complex formation and indicated that LPS exhibited altered physical characteristics and enhanced biological activity in the presence of Hb.	VET ADM MED CTR, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco				Kaca, Wieslaw/0000-0002-8734-7191	NIDDK NIH HHS [NIDDK DK 43102] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043102] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKHREM AA, 1989, BIOCHIM BIOPHYS ACTA, V992, P191, DOI 10.1016/0304-4165(89)90009-3; AMBERSON WR, 1949, J APPL PHYSIOL, V1, P469, DOI 10.1152/jappl.1949.1.7.469; BRANDT JL, 1951, BLOOD, V6, P1152, DOI 10.1182/blood.V6.11.1152.1152; CHAPMAN KW, 1992, BIOMAT ARTIF CELL IM, V20, P415, DOI 10.3109/10731199209119661; CHATTERJEE R, 1986, J BIOL CHEM, V261, P9929; CHRISTENSEN SM, 1988, J BIOCHEM BIOPH METH, V17, P145; DAVID SA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P269, DOI 10.1016/0005-2760(92)90006-H; DAWIDSON I, 1988, CRIT CARE MED, V16, P606, DOI 10.1097/00003246-198806000-00008; DEVENUTO F, 1982, SURG GYNECOL OBSTET, V155, P342; FEOLA M, 1988, CIRC SHOCK, V25, P275; FEOLA M, 1988, SURG GYNECOL OBSTET, V166, P211; FREUDENBERG MA, 1980, INFECT IMMUN, V28, P373; GALANOS C, 1971, EUR J BIOCHEM, V19, P143, DOI 10.1111/j.1432-1033.1971.tb01298.x; GALANOS C, 1972, EUR J BIOCHEM, V31, P230, DOI 10.1111/j.1432-1033.1972.tb02524.x; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; HESS JR, 1991, J APPL PHYSIOL, V70, P1639, DOI 10.1152/jappl.1991.70.4.1639; HOMMA R, 1982, ENDOTOXINS THEIR DET, P310; KACA W, 1987, ARCH IMMUNOL THER EX, V35, P431; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; LITWIN MS, 1963, ANN SURG, V157, P485, DOI 10.1097/00000658-196304000-00001; MARKS DH, 1989, MIL MED, V154, P180; MARRA MN, 1992, J IMMUNOL, V148, P532; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; Nowotny A., 1979, BASIC EXERCISES IMMU, P171; OHNO N, 1989, J BIOL CHEM, V264, P4434; RADZIEJEWSKALEB.J, 1989, EUR J BIOCHEM, V193, P573; REMILLARD JF, 1987, DETECTION BACTERIAL, P197; ROTH RI, 1994, METHOD ENZYMOL, V231, P75; ROTH RI, 1994, BLOOD, V83, P2860, DOI 10.1182/blood.V83.10.2860.2860; ROTH RI, 1993, INFECT IMMUN, V61, P1033, DOI 10.1128/IAI.61.3.1033-1039.1993; ROTH RI, 1993, TRANSFUSION, V33, P919, DOI 10.1046/j.1537-2995.1993.331194082383.x; SAVITSKY JP, 1978, CLIN PHARMACOL THER, V23, P73; SEHGAL LR, 1984, SURGERY, V95, P433; SIDORCZYK Z, 1983, EUR J BIOCHEM, V137, P15, DOI 10.1111/j.1432-1033.1983.tb07789.x; SMITH CD, 1990, BIOMATER ARTIF CELL, V18, P251, DOI 10.3109/10731199009117305; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; ULEVITCH RJ, 1978, IMMUNOCHEMISTRY, V15, P157, DOI 10.1016/0161-5890(78)90144-X; ULEVITCH RJ, 1978, J CLIN INVEST, V62, P1313, DOI 10.1172/JCI109252; VANDEGRIFF KD, 1989, J BIOL CHEM, V264, P17824; WAINWRIGHT NR, 1990, INT CONGR SER, V923, P315; WEBER G, 1992, INFECT IMMUN, V60, P1062; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WHITE CT, 1986, J LAB CLIN MED, V108, P121; WHITE CT, 1986, J LAB CLIN MED, V108, P132; WINSLOW R M, 1991, Biomaterials Artificial Cells and Immobilization Biotechnology, V19, P503; WINSLOW RM, 1989, RED CELL, P305; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068	49	121	126	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25078	25084						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929195				2022-12-25	WOS:A1994PQ49000084
J	KIMURA, K; NOZAKI, N; SAIJO, M; KIKUCHI, A; UI, M; ENOMOTO, T				KIMURA, K; NOZAKI, N; SAIJO, M; KIKUCHI, A; UI, M; ENOMOTO, T			IDENTIFICATION OF THE NATURE OF MODIFICATION THAT CAUSES THE SHIFT OF DNA TOPOISOMERASE-II-BETA TO APPARENT HIGHER MOLECULAR-WEIGHT FORMS IN THE M-PHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CASEIN KINASE-II; MITOTIC CHROMOSOMES; PHORBOL ESTER; PHOSPHORYLATION; CONDENSATION; CELLS; LOCALIZATION; EXPRESSION; ISOFORMS; EXTRACTS	Human cell lines express two genetically distinct isoforms of DNA topoisomerase (topo II) II: topo II alpha (p170) and topo II beta (p180). We detected a higher molecular weight form with an apparent molecular mass of about 190 kDa in M phase-arrested HeLa cells (Kimura, K., Saijo, M., Ui, M., and Enomoto, T. (1994) J. Biol, Chem. 269, 1173-1176). In this study we confirmed, using anti-topo II alpha and topo II beta monoclonal antibodies, that this higher molecular weight form is topo II beta and consists of doublet bands around 190 kDa. We confirmed that the doublet bands constituted an M phase-specific phenomenon and were not an artifact of the procedure used to accumulate mitotic cells. Digesting the immunoprecipitated materials from mitotic cell extracts with alkaline phosphatase resulted in the disappearance of the doublet bands and the appearance of the 180-kDa band with the concomitant disappearance of P-32 label in the region of the doublet bands. Neither heat-inactivated alkaline phosphatase nor phosphodiesterase affected the doublet bands and the P-32 label. Topo II beta in interphase cells was also phosphorylated, but the shift in apparent molecular weight was very slight after alkaline phosphatase digestion. Analysis of the labeled phosphoamino acids present in topo II beta from M phase and logarithmically growing cells indicated that phosphorylation occurred mainly on serine and fairly on threonine residues in both topo II beta isoforms. These results indicated that topo II beta is phosphorylated at specific sites in M phase, resulting in the formation of the doublet bands.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,TOKYO 113,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	University of Tokyo			Saijo, Masayuki/L-2697-2019					ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; CAPRANICO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P43, DOI 10.1016/0167-4781(92)90050-A; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEVORE RF, 1992, CANCER RES, V52, P2156; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KIMURA K, 1994, J BIOL CHEM, V269, P1173; NEGRI C, 1992, EXP CELL RES, V200, P452, DOI 10.1016/0014-4827(92)90195-E; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TSUTSUI K, 1993, J BIOL CHEM, V268, P19076; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; ZINI N, 1992, EXP CELL RES, V200, P460, DOI 10.1016/0014-4827(92)90196-F	35	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24523	24526						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929118				2022-12-25	WOS:A1994PQ49000002
J	PRUSS, D; REEVES, R; BUSHMAN, FD; WOLFFE, AP				PRUSS, D; REEVES, R; BUSHMAN, FD; WOLFFE, AP			THE INFLUENCE OF DNA AND NUCLEOSOME STRUCTURE ON INTEGRATION EVENTS DIRECTED BY HIV INTEGRASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-HYPERSENSITIVE SITES; TRANSFER-RNA GENE; RETROVIRAL INTEGRATION; ESCHERICHIA-COLI; B-DNA; TRANSCRIPTION COMPLEXES; PREFERRED TARGETS; KINETOPLAST DNA; SEQUENCE; CHROMATIN	DNA copies of the human immunodeficiency virus (HIV) genome integrate nonrandomly into the chromosomal DNA of the host cell. In this report, we investigate the molecular basis of this selectivity using the virus-encoded HIV integrase to direct integration of a synthetic HIV long terminal repeat substrate into either DNA molecules of known structure or previously defined nucleosomal complexes. We find that the structure of the target greatly influences the site of integration, and, moreover, DNA curvature, flexibility, and rigidity in solution all influence the frequency of integration. Importantly, for DNA with all of these properties, the distortion of the double helix directed by association with the histone proteins promotes the integration reaction and alters the distribution of sites that are selected for integration. We suggest that both intrinsic DNA structure and the folding of DNA into chromosomal structures will exert a major influence on target site selection for integration of the viral genome.	SALK INST BIOL STUDIES,INFECT DIS LAB,LA JOLLA,CA 92014	Salk Institute	PRUSS, D (corresponding author), NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892, USA.							AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; BOSSI L, 1984, CELL, V39, P643, DOI 10.1016/0092-8674(84)90471-9; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BRUKNER I, 1993, NUCLEIC ACIDS RES, V21, P1025, DOI 10.1093/nar/21.4.1025; BRUTLAG DL, 1980, ANNU REV GENET, V14, P121, DOI 10.1146/annurev.ge.14.120180.001005; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; BURKHOFF AM, 1988, NATURE, V331, P445; BUSHMAN FD, 1992, P NATL ACAD SCI USA, V89, P3458, DOI 10.1073/pnas.89.8.3458; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; CHUPRINA VP, 1985, FEBS LETT, V186, P98, DOI 10.1016/0014-5793(85)81347-8; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; GOODSELL DS, 1993, P NATL ACAD SCI USA, V90, P2930, DOI 10.1073/pnas.90.7.2930; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HOGAN ME, 1987, NATURE, V328, P554, DOI 10.1038/328554a0; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; HUIBREGTSE JM, 1987, MOL CELL BIOL, V7, P3212, DOI 10.1128/MCB.7.9.3212; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; JI H, 1993, CELL, V73, P1007, DOI 10.1016/0092-8674(93)90278-X; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KITAMURA Y, 1992, P NATL ACAD SCI USA, V89, P5532, DOI 10.1073/pnas.89.12.5532; KUNKEL GR, 1981, NUCLEIC ACIDS RES, V9, P6869, DOI 10.1093/nar/9.24.6869; LAMOND AI, 1983, NATURE, V305, P248, DOI 10.1038/305248a0; LIBERTINI LJ, 1980, NUCLEIC ACIDS RES, V8, P3517, DOI 10.1093/nar/8.16.3517; LOSA R, 1990, NUCLEIC ACIDS RES, V18, P3495, DOI 10.1093/nar/18.12.3495; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MORSE RH, 1992, MOL CELL BIOL, V12, P4015, DOI 10.1128/MCB.12.9.4015; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, P NATL ACAD SCI USA, V89, P9237, DOI 10.1073/pnas.89.19.9237; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; RAMSAY N, 1984, EMBO J, V3, P2605, DOI 10.1002/j.1460-2075.1984.tb02181.x; RHODES D, 1981, NATURE, V292, P378, DOI 10.1038/292378a0; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANDMEYER SB, 1990, ANNU REV GENET, V24, P1499; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5293; THOMAS GH, 1988, EMBO J, V7, P7291; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; TRAVERS AA, 1993, CURR BIOL, V3, P898, DOI 10.1016/0960-9822(93)90231-C; VALENZUELA P, 1977, NATURE, V267, P641, DOI 10.1038/267641a0; VARMUS HE, 1985, RNA TUMOR VIRUSES, V1; VARMUS HE, 1985, RNA TUMOR VIRUSES, V2; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; YAO J, 1991, BIOCHEMISTRY-US, V30, P8408, DOI 10.1021/bi00098a019; YAO J, 1990, P NATL ACAD SCI USA, V87, P7603, DOI 10.1073/pnas.87.19.7603	65	150	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25031	25041						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929189				2022-12-25	WOS:A1994PQ49000077
J	GRAVEN, KK; TROXLER, RF; KORNFELD, H; PANCHENKO, MV; FARBER, HW				GRAVEN, KK; TROXLER, RF; KORNFELD, H; PANCHENKO, MV; FARBER, HW			REGULATION OF ENDOTHELIAL-CELL GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE EXPRESSION BY HYPOXIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; NITRIC-OXIDE; TRANSCRIPTIONAL ENHANCER; DNA GLYCOSYLASE; SKELETAL-MUSCLE; PROTEIN; BINDING; IDENTIFICATION; STRESS; INDUCTION	Exposure of endothelial cells (EC) to hypoxia results in the increased expression of a distinct set of proteins with molecular masses of 56, 47, 39, 36, and 34 kDa. Their induction appears to be unique to EC and the stress of decreased oxygen tension. To understand the mechanism(s) and significance of the up-regulation of these proteins we have identified the 36-kDa protein by limited amino-terminal amino acid sequencing. The 21-amino acid sequence from the bovine protein exhibited 90.5% identity with the human sequence of the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Northern blot analysis showed that the time course and extent of EC GAPDH mRNA up-regulation correlated with the increase in 36-kDa protein synthesis. Nuclear runoff analysis demonstrated that this increase in GAPDH expression is regulated, in part, at the transcriptional level; however, the increase in the rate of transcription did not account for the entire mRNA accumulation, suggesting that GAPDH, like other hypoxia-regulated proteins, is posttranscriptionally regulated. Subcellular fractionation of hypoxic EC showed up-regulation of the 36-kDa protein in the cytoplasmic fraction and, to a lesser extent, in the nuclear fraction. The up-regulation of GAPDH in EC may be related to their relative hypoxia tolerance. Alternatively, the upregulation of GAPDH in EC during hypoxia may be related to the potential nonglycolytic functions of this enzyme.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University	GRAVEN, KK (corresponding author), BOSTON UNIV,SCH MED,CTR PULM,80 E CONCORD ST,K-603,BOSTON,MA 02118, USA.		Kornfeld, Hardy/AAS-2903-2021	Farber, Harrison/0000-0002-0297-7902; Panchenko, Maria/0000-0001-6247-6598	NHLBI NIH HHS [HL-44846, HL-45537] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045537, R01HL044846] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN RW, 1987, J BIOL CHEM, V262, P649; ANDERSON GR, 1989, J BIOL CHEM, V264, P14885; BECK I, 1991, J BIOL CHEM, V266, P15563; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN T, 1993, CURRENT PROTOCOLS MO; CASWELL AH, 1985, J BIOL CHEM, V260, P6892; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWAN DB, 1993, J BIOL CHEM, V268, P26904; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P200; FARBER HW, 1991, CIRC RES, V68, P1446, DOI 10.1161/01.RES.68.5.1446; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GRAVEN KK, 1993, J CELL PHYSIOL, V157, P544, DOI 10.1002/jcp.1041570314; GREENBERG ME, 1993, CURRENT PROTOCOLS MO; HEACOCK CS, 1986, INT J RADIAT ONCOL, V12, P1287, DOI 10.1016/0360-3016(86)90155-0; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; HODOR P, 1989, MICROCIRC ENDOTH LYM, V5, P485; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; LAUNAY JF, 1989, BIOCHIM BIOPHYS ACTA, V996, P103, DOI 10.1016/0167-4838(89)90101-5; LEE SL, 1987, CIRC RES, V60, P653, DOI 10.1161/01.RES.60.5.653; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MANSUR NR, 1993, NUCLEIC ACIDS RES, V21, P993, DOI 10.1093/nar/21.4.993; MCDONALD B, 1993, P NATL ACAD SCI USA, V90, P11122, DOI 10.1073/pnas.90.23.11122; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MEJEAN C, 1989, BIOCHEM J, V264, P671, DOI 10.1042/bj2640671; MERTENS S, 1990, AM J PHYSIOL, V258, pH689, DOI 10.1152/ajpheart.1990.258.3.H689; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MIZZEN LA, 1988, J CELL BIOL, V106, P1105, DOI 10.1083/jcb.106.4.1105; MORGENEGG G, 1986, J NEUROCHEM, V47, P54; OGAWA S, 1991, P NATL ACAD SCI USA, V88, P9897, DOI 10.1073/pnas.88.21.9897; PAGLIARO L, 1992, J CELL BIOL, V118, P859, DOI 10.1083/jcb.118.4.859; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; PERUCHO M, 1977, EUR J BIOCHEM, V81, P557, DOI 10.1111/j.1432-1033.1977.tb11982.x; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; ROLLET E, 1992, BIOCHEM BIOPH RES CO, V185, P116, DOI 10.1016/S0006-291X(05)80963-5; RYAZANOV AG, 1988, EUR J BIOCHEM, V171, P301, DOI 10.1111/j.1432-1033.1988.tb13790.x; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SCHUSTER SJ, 1989, BLOOD, V73, P13; SCIANDRA JJ, 1984, P NATL ACAD SCI-BIOL, V81, P4843, DOI 10.1073/pnas.81.15.4843; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SULLIVAN DT, 1985, J BIOL CHEM, V260, P4345; TABOR S, 1993, CURRENT PROTOCOLS MO; TSAI IH, 1982, J BIOL CHEM, V257, P1438; VASS K, 1988, ACTA NEUROPATHOL, V77, P128; WANG CS, 1980, ARCH BIOCHEM BIOPHYS, V205, P136, DOI 10.1016/0003-9861(80)90092-2; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WEBSTER KA, 1988, CAN J ZOOL, V66, P1046, DOI 10.1139/z88-155; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382; ZIMMERMAN LH, 1991, J CLIN INVEST, V87, P908, DOI 10.1172/JCI115097	53	134	135	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24446	24453						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929107				2022-12-25	WOS:A1994PQ34600092
J	CHAPMAN, ER; AN, S; BARTON, N; JAHN, R				CHAPMAN, ER; AN, S; BARTON, N; JAHN, R			SNAP-25, A T-SNARE WHICH BINDS TO BOTH SYNTAXIN AND SYNAPTOBREVIN VIA DOMAINS THAT MAY FORM COILED COILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; INTEGRAL MEMBRANE-PROTEIN; SYNAPTIC VESICLES; LEUCINE ZIPPER; FUSION; PALMITOYLATION; YEAST; CDNA; IDENTIFICATION; MACHINERY	The membrane proteins SNAP-25, syntaxin, and synaptobrevin (vesicle associated membrane protein) have recently been implicated as central elements of an exocytotic membrane fusion complex in neurons. Here we report that SNAP-25 binds directly to both syntaxin and synaptobrevin. The SNAP-25-binding domain of syntaxin lies between residues 199 and 243, within the region previously shown to mediate synaptobrevin binding (Calakos, N., Bennett, M. K., Peterson, K. E., and Scheller, R. H. (1994) Science 263, 1146-1149). The syntaxin-binding domain of SNAP-25 encompasses most of the amino-terminal half of SNAP-25, including its putative palmitoylation sites. Truncation of the carboxyl-terminal 9 residues of SNAP-25, which yields a fragment corresponding to that generated by botulinum neurotoxin A, diminishes the interaction of SNAP-25 with synaptobrevin, but not with syntaxin. Sequence analysis revealed that the regions that mediate the interaction between SNAP-25 and syntaxin contain heptad repeats characteristic of certain classes of alpha-helices. Similar repeats are also present at the carboxyl terminus of SNAP-25 and in synaptobrevin. These domains have a moderate to high probability of forming coiled coils. We conclude that SNAP-25 can interact with both syntaxin and synaptobrevin and that binding may be mediated by alpha-helical domains that form intermolecular coiled-coil structures.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University; Yale University	CHAPMAN, ER (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,BOYER CTR MOLEC MED,RM 247,NEW HAVEN,CT 06511, USA.			Jahn, Reinhard/0000-0003-1542-3498; Chapman, Edwin/0000-0001-9787-8140				BARK IC, 1993, J MOL BIOL, V233, P67, DOI 10.1006/jmbi.1993.1485; BARK IC, 1994, GENE AMST, V132, P291; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HESS DT, 1992, J NEUROSCI, V12, P4634; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; INOUE A, 1992, J BIOL CHEM, V267, P10613; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCMAHON H, 1993, NATURE, V364, P356; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; RISINGER C, 1993, J BIOL CHEM, V268, P24408; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPRING J, 1993, TRENDS BIOCHEM SCI, V18, P124, DOI 10.1016/0968-0004(93)90018-I; SUDHOF TC, 1993, CELL, V75, P1; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803	44	262	265	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27427	27432						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961655				2022-12-25	WOS:A1994PV77100045
J	SHACHAR, I; RABINOVICH, E; KEREM, A; BARNUN, S				SHACHAR, I; RABINOVICH, E; KEREM, A; BARNUN, S			THIOL-REDUCING AGENTS AND CALCIUM PERTURBANTS ALTER INTRACELLULAR SORTING OF IMMUNOGLOBULIN-M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CHAIN BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; LYMPHOCYTES-B; SECRETORY PROTEINS; HEAVY-CHAINS; IGM; DEGRADATION; RECEPTOR; CELL	The secretory form of IgM (sIgM) undergoes developmentally regulated intracellular sorting and transport, as demonstrated by the distinct assembly patterns and intracellular fate exhibited by its mu heavy chain (mu s) In the 38C B lymphocytes, mu s-containing monomers are retained and degraded intracellularly, whereas in the 38C-derived D2 hybridoma, mu s-containing polymers are secreted. Here we show that sorting of sIgM is impaired in the presence of the thiol-reducing agent beta-mercaptoethanol or when cellular calcium sequestration is perturbed either with the Ca2+ ionophore A23187 or with thapsigargin, an inhibitor of endoplasmic reticulum Ca2+-ATPase. Under these conditions, sIgM evades retention/degradation in the 38C cells, resulting in its enhanced secretion. Conversely, in the D2 cells, secretion is strongly attenuated, and sIgM is partly degraded. Both cell types secrete unusually processed sIgM, which is completely resistant to endoglycosidase H, unlike the partially sensitive sIgM secreted in the usual manner, indicating terminal glycosylation of all carbohydrate moieties of mu s. Moreover, secretion is no longer restricted to fully assembled polymeric sIgM, and in both cell types under Ca2+ perturbation preferentially hemimeric and monomeric assembly intermediates are detected in the medium. Our results suggest that the intracellular fate of sIgM is collectively determined by several sorting events that confer sIgM retention/degradation, ensure sIgM secretion from D2 cells, and prevent the arrival of assembly intermediates to the cell surface. All of these sorting events appear to require high Ca2+ concentration and oxidizing thiol redox state, the conditions that prevail in the lumen of the endoplasmic reticulum. Thus, thiol and calcium are implicated as modulators of intracellular traffic.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University								AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AMITAY R, 1991, J BIOL CHEM, V266, P12568; AMITAY R, 1992, J BIOL CHEM, V267, P20694; ANDREWS SB, 1988, P NATL ACAD SCI USA, V85, P1682, DOI 10.1073/pnas.85.5.1682; BAUMANN O, 1991, P NATL ACAD SCI USA, V88, P741, DOI 10.1073/pnas.88.3.741; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRENCKLE R, 1980, ARCH BIOCHEM BIOPHYS, V201, P160, DOI 10.1016/0003-9861(80)90499-3; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DAHMS NM, 1986, J BIOL CHEM, V261, P3186; DAVIS AC, 1989, MOL IMMUNOL, V26, P147, DOI 10.1016/0161-5890(89)90096-5; DAVIS AC, 1988, EUR J IMMUNOL, V18, P1001, DOI 10.1002/eji.1830180705; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MACER DRJ, 1988, J CELL SCI, V91, P61; MELNICK J, 1992, J BIOL CHEM, V267, P21303; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RABINOVICH E, 1993, J BIOL CHEM, V268, P24145; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SHACHAR I, 1992, J BIOL CHEM, V267, P24241; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; VONFIGURA K, 1986, ANN REV BIOCH, V55, P67; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	53	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27344	27350						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961645				2022-12-25	WOS:A1994PV77100033
J	SCHREIBERAGUS, N; CHIN, L; CHEN, K; TORRES, R; THOMSON, CT; SACCHETTINI, JC; DEPINHO, RA				SCHREIBERAGUS, N; CHIN, L; CHEN, K; TORRES, R; THOMSON, CT; SACCHETTINI, JC; DEPINHO, RA			EVOLUTIONARY RELATIONSHIPS AND FUNCTIONAL CONSERVATION AMONG VERTEBRATE MAX-ASSOCIATED PROTEINS - THE ZEBRA FISH HOMOLOG OF MXI1	ONCOGENE			English	Article							C-MYC ONCOGENE; INDUCED TERMINAL DIFFERENTIATION; DNA-BINDING; LEUCINE ZIPPER; N-MYC; RAS COTRANSFORMATION; MUTATIONAL ANALYSIS; MESSENGER-RNAS; CELL-CYCLE; EXPRESSION	In mammals, current evidence supports the view that Myc-responsive activities are regulated in part through an intracellular balance between levels of transcriptionally-active Myc/Max heterodimers and those of transcriptionally-inert Max/Max, Mad/Max-and Mxil/Max complexes. To gain insight into the roles of Mad and Mxi1 in cellular growth and differentiation and to fortify key structure-function relationships from an evolutionary standpoint, low stringency hybridization screens were used to identify potential homologs of these Max-associated proteins in the zebra fish genome. A single class of cDNA clones that cross-hybridized both to human mad and mxi1 probes was shown to encode a putative protein with significantly greater homology to mammalian Mxi1 than to Mad, particularly in the basic and helix-loop-helix (bHLH) regions. The high degree of structural relatedness between vertebrate Mxi1 proteins apparent in molecular;modelling studies was consistent with the findings that the HLH/leucine zipper (LZ) region of zMxi1 exhibited the same profile of. dimerization specificities as its mammalian counterpart in the two-hybrid system and that zmxi1 could, like human mxi1 (Lahoz et al., 1994), suppress the oncogenic potential of mouse c-myc in a mammalian cell. Finally, a comparison of steady-state zc-myc and zmxi1 mRNA levels during zebra fish embryogenesis demonstrated (i) high levels of zc-myc relative to zmxi1 mRNA during initiation of organogenesis, a period characterized by intense growth and active differentiation and (ii) rising levels of zmxi1 mRNA during progression towards the terminally differentiated state. These contrasting patterns of developmental expression together with the capacity of zmxi1 to repress myc-induced transformation support a model for the regulation, by Max-associated proteins, of Myc functions in the control of normal cell development and neoplastic growth.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CA09173-14] Funding Source: Medline; NIGMS NIH HHS [T32 GM07128, GM45859] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007128, R01GM045859] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHISHOLM O, 1992, ONCOGENE, V7, P1827; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GUTHRIE C, 1992, METHOD ENZYMOL, V194, P1; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HISAOKA K. KENNETH, 1960, JOUR MORPHOL, V107, P205, DOI 10.1002/jmor.1051070206; HISAOKA KENICHI KENNETH, 1958, J MORPH, V102, P311, DOI 10.1002/jmor.1051020205; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; KING MW, 1993, CELL GROWTH DIFFER, V4, P85; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARUYAMA K, 1987, ONCOGENE, V1, P361; Maxam A M, 1980, Methods Enzymol, V65, P499; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Nei M., 1987, MOL EVOLUT GENET, P293; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; REDDY CD, 1992, ONCOGENE, V7, P2085; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROSSANT J, 1992, GENE DEV, V6, P1, DOI 10.1101/gad.6.1.1; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	69	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3167	3177						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936639				2022-12-25	WOS:A1994PM65800008
J	TORTORA, G; PEPE, S; BIANCO, C; BALDASSARRE, G; BUDILLON, A; CLAIR, T; CHOCHUNG, YS; BIANCO, AR; CIARDIELLO, F				TORTORA, G; PEPE, S; BIANCO, C; BALDASSARRE, G; BUDILLON, A; CLAIR, T; CHOCHUNG, YS; BIANCO, AR; CIARDIELLO, F			THE RI-ALPHA-SUBUNIT OF PROTEIN-KINASE-A CONTROLS SERUM DEPENDENCY AND ENTRY INTO CELL-CYCLE OF HUMAN MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article							TISSUE-SPECIFIC EXTINGUISHER; AMP BINDING-PROTEINS; I REGULATORY SUBUNIT; AMINO-ACID SEQUENCE; C-HA-RAS; GROWTH-INHIBITION; MOLECULAR-CLONING; MAMMALIAN-CELLS; DOWN-REGULATION; HL-60 LEUKEMIA	MCP-10A, a nontransformed mammary epithelial cell line, requires a mixture of hormones and growth factors for optimal cell proliferation. In this report we show that when MCF-10A cells are cultured in serum free medium they become quiescent and accumulate in G(0)/G(1) phases of the cell cycle. Following addition of complete medium to quiescent cells, MCF-10A cells enter into the S phase within 15-18h and resume the cell cycle distribution of proliferating cells within 24 h. Measurement of RI alpha subunit of the cAMP-dependent protein kinase (PKA) shows a 10- to 15-fold increase in protein levels at 6 h following complete medium addition, thus preceding cell entry into the S phase. Retroviral vector-mediated overexpression of RI alpha, but not of RII beta or C alpha subunits of PKA, enables MCF-10A cells to grow in serum-free medium. In addition, RI alpha downregulation by specific antisense oligodeoxynucleotide treatment or following infection with a retroviral vector containing the RI alpha cDNA in antisense orientation determines growth arrest of proliferating MCF-10A cells and is able to partially block S phase entry of quiescent MCF-10A cells following complete medium addition. These results suggest that RI alpha/PKAI is involved in the control of cell cycle progression of mammary epithelial cells at a G(1) to S transition border, and that its overexpression is able to overcome serum and growth factors requirement for cell proliferation.	NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TORTORA, G (corresponding author), UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,CATTEDRA ONCOL MED,I-80131 NAPLES,ITALY.		Budillon, Alfredo/K-4763-2016; Baldassarre, Gustavo/K-1350-2016; Tortora, Giampaolo/AAA-1252-2019	Budillon, Alfredo/0000-0002-6330-6053; Baldassarre, Gustavo/0000-0002-9750-8825; Ciardiello, Fortunato/0000-0002-3369-4841; Tortora, Giampaolo/0000-0002-1378-4962				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BYUS CV, 1977, NATURE, V268, P63, DOI 10.1038/268063a0; CERESETO A, 1993, P AM ASSOC CANC RES, V34, P175; CHOCHUNG YS, 1991, PHARMACOL THERAPEUT, V50, P1, DOI 10.1016/0163-7258(91)90071-S; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CIARDIELLO F, 1990, J BIOL CHEM, V265, P1016; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1993, INT J CANCER, V53, P438, DOI 10.1002/ijc.2910530315; CIARDIELLO F, 1994, ONCOGENE, V9, P291; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DEAN PN, 1980, CELL TISSUE KINET, V13, P299, DOI 10.1111/j.1365-2184.1980.tb00468.x; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MILLER WR, 1993, BREAST CANCER RES TR, V26, P89, DOI 10.1007/BF00682703; MILLER WR, 1990, BRIT J CANCER, V61, P263, DOI 10.1038/bjc.1990.48; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PEPE S, 1994, CYTOMETRY, V15, P73, DOI 10.1002/cyto.990150112; RIABOWOL KT, 1992, BIOCHEM CELL BIOL, V70, P1064, DOI 10.1139/o92-151; ROHLFF C, 1993, J BIOL CHEM, V268, P5774; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SOULE HD, 1990, CANCER RES, V50, P6075; TAGLIAFERRI P, 1988, J BIOL CHEM, V263, P409; TAIT L, 1990, CANCER RES, V50, P6087; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TORTORA G, 1993, CELL GROWTH DIFFER, V4, P359; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; TORTORA G, 1990, J BIOL CHEM, V265, P18067; TORTORA G, 1989, FEBS LETT, V242, P363, DOI 10.1016/0014-5793(89)80502-2; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	39	72	73	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3233	3240						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936647				2022-12-25	WOS:A1994PM65800016
J	CHEN, QM; KINCH, MS; LIN, TH; BURRIDGE, K; JULIANO, RL				CHEN, QM; KINCH, MS; LIN, TH; BURRIDGE, K; JULIANO, RL			INTEGRIN-MEDIATED CELL-ADHESION ACTIVATES MITOGEN-ACTIVATED PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE KINASE; MAP KINASE; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; GROWTH-FACTOR; GENE-EXPRESSION; PHOSPHORYLATION; RECEPTOR; FIBRONECTIN; INVITRO	Integrins can function as signal-transducing receptors capable of modulating cell growth and gene expression (Juliano, R. L., and Haskill, S. (1993) J. Cell Biol. 120, 577-585; Hynes, R. O. (1992) Cell 69, 11-25). An early event in integrin signaling in fibroblasts and other cells involves activation of pp125(FAK), a cytoplasmic tyrosine kinase (Hanks, S. K., Calalb, M. B., Harper, M. C., and Patel, S. K. (1992) Proc. Natl. Acad. Sci. U. S. A, 89, 8487-8491; Schaller, M. D., Borgman, C. A., Cobb, B. S., Vines, R. R., Reynolds, A. B., and Parsons, J. T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5192-5196). Here we report a novel aspect of integrin-mediated signal transduction. We demonstrate that adhesion of cells to substrata coated with extracellular matrix proteins, or with a synthetic peptide containing the RGD sequence, can cause activation of mitogen-activated protein (MAP) kinases in 3T3 or REF52 fibroblasts. Activation of MAP kinases seems to depend on integrin engagement rather than simply on cell attachment. Thus, MAP kinases are activated when cells adhere to substrata coated with the integrin ligands fibronectin or laminin, but not when cells adhere to poly-D-lysine, a nonspecific adhesion-promoting polypeptide. Treatment of cells with cytochalasin D, an inhibitor of actin microfilament assembly, almost completely blocks adhesion-induced MAP kinase activation, indicating a critical role for the cytoskeleton. In REF52 cells, we have observed that activation of MAP kinases is accompanied by redistribution of the protein to the nucleus, suggesting that the activated kinases may impinge on factors regulating gene expression. Thus, integrin-mediated cell adhesion seems a sufficient stimulus to cause activation and nuclear translocation of MAP kinases. This may have important implications for the regulation of cell growth and differentiation by the extracellular matrix.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Kinch, Michael/0000-0003-3939-3756				AHN NG, 1991, J BIOL CHEM, V266, P4220; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COHEN P, 1992, CELL, V71, P335; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DHAWAN J, 1990, J BIOL CHEM, V265, P9015; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FRANKI N, 1992, AM J PHYSIOL, V263, pC995, DOI 10.1152/ajpcell.1992.263.5.C995; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MORTARINI R, 1992, CANCER RES, V52, P4499; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHREINER C, 1991, CANCER RES, V51, P1738; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SYMINGTON BE, 1992, J BIOL CHEM, V267, P25744; VARNER JA, 1992, MOL BIOL CELL, V3, pA232; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	37	610	616	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26602	26605						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929388				2022-12-25	WOS:A1994PQ93100004
J	OETJEN, E; DIEDRICH, T; EGGERS, A; ECKERT, B; KNEPEL, W				OETJEN, E; DIEDRICH, T; EGGERS, A; ECKERT, B; KNEPEL, W			DISTINCT PROPERTIES OF THE CAMP-RESPONSIVE ELEMENT OF THE RAT INSULIN-I GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLET CELLS; PROTEIN-PROTEIN INTERACTIONS; TRANSCRIPTION FACTOR-II; DNA-BINDING PROTEINS; GLUCAGON GENE; CYCLIC-AMP; MEMBRANE DEPOLARIZATION; NUCLEAR FACTORS; CYCLOSPORINE-A; FACTOR CREB	The cAMP response element (CRE)-binding transcription factor CREB can mediate induction of gene transcription in response to calcium as well as to cAMP. Since the rat insulin I gene 5'-flanking region contains a CRE with an octamer-like motif (TGACGTCC), CREB binding and cAMP/calcium responsiveness of the insulin CRE were investigated. In an electrophoretic mobility shift assay and in Southwestern blot experiments, bacterially expressed recombinant CREB bound to the insulin CRE as it did to the rat glucagon and rat somatostatin gene CREs. However, in nuclear extracts of the pancreatic islet cell Line HIT, protein complexes binding to the insulin CRE did not contain proteins with CREB-like immunoreactivity, although these bound to the glucagon and somatostatin CREs. When reporter fusion genes were transfected into HIT cells, the isolated insulin CRE increased basal activity and mediated transcriptional activation by cAMP. However, cAMP stimulation of transcription through the insulin CRE was weak when compared with the response through the glucagon and somatostatin CREs. Furthermore, the insulin CRE did not confer responsiveness to membrane depolarization and calcium influx, in contrast to the glucagon and somatostatin CREs. These results demonstrate that the functional properties of the rat insulin I gene CRE are different from those of the rat glucagon and somatostatin CREs which may be explained by a distinct pattern of nuclear protein binding and suggest the existence of post-translational mechanisms that decrease the binding of cellular CREB to the insulin CRE.	UNIV GOTTINGEN,DEPT BIOCHEM PHARMACOL,D-37070 GOTTINGEN,GERMANY	University of Gottingen								ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK DL, 1991, TRENDS NEUROSCI, V14, P411, DOI 10.1016/0166-2236(91)90033-Q; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUCKER DJ, 1991, ENDOCRINOLOGY, V128, P394, DOI 10.1210/endo-128-1-394; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EFRAT S, 1991, J BIOL CHEM, V266, P11141; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GIDDINGS SJ, 1989, J BIOL CHEM, V264, P9462; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; HABENER JF, 1991, ENDOCRINE PANCREAS, P53; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAMMONDS P, 1987, FEBS LETT, V213, P149, DOI 10.1016/0014-5793(87)81481-3; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; IMAI E, 1993, J BIOL CHEM, V268, P5353; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LEVY J, 1975, BIOCHEM PHARMACOL, V24, P235, DOI 10.1016/0006-2952(75)90282-8; LIU F, 1993, J BIOL CHEM, V268, P6714; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILLER CP, 1993, MOL CELL BIOL, V13, P7080, DOI 10.1128/MCB.13.11.7080; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1990, J BIOL CHEM, V265, P1465; POWERS AC, 1989, J BIOL CHEM, V264, P10048; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHATZ H, 1972, ACTA ENDOCRINOL-COP, V26, P237; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SCHWANINGER M, 1993, N-S ARCH PHARMACOL, V348, P541; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; VANNGUYEN T, 1990, J NEUROSCI, V10, P2825; WOLLHEIM CB, 1990, BIOCHEM SOC T, V18, P111, DOI 10.1042/bst0180111	55	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27036	27044						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929445				2022-12-25	WOS:A1994PQ93100068
J	RUCKMAN, J; RINGQUIST, S; BRODY, E; GOLD, L				RUCKMAN, J; RINGQUIST, S; BRODY, E; GOLD, L			THE BACTERIOPHAGE-T4 REGB RIBONUCLEASE - STIMULATION OF THE PURIFIED ENZYME BY RIBOSOMAL-PROTEIN-S1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; ENDONUCLEOLYTIC CLEAVAGE; BINDING-SITE; QBETA REPLICASE; EXPRESSION; ENDORIBONUCLEASE; POLYMERASE; REGION; DECAY	Infection of Escherichia coli by bacteriophage T4 induces a mRNA ribonuclease activity that shows specificity for cleavage within the sequence GGAG. Substrates of the activity in vivo include a number of phage mRNAs that are cleaved at GGAGs within the Shine/Dalgarno domains of their translation initiation regions. Induction of the ribonuclease depends on the product of the T4 gene regB. We describe here the overproduction and extensive purification of the RegB protein. RegB precisely co-purifies with an activity that cleaves within the sequence GGAG in oligonucleotide and polynucleotide RNAs and is therefore likely to constitute the sequence-specific catalytic component of the observed activity. We further report that the low cleavage rate observed with our preparations of purified RegB is substantially increased (1-2 orders of magnitude) by the addition of E. coli ribosomal protein S1. We discuss the implications of this observation for the mechanism of action of the RegB ribonuclease in vitro and in vivo.	UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA; CNRS, CTR GENET MOLEC, F-91190 GIF SUR YVETTE, FRANCE	University of Colorado System; University of Colorado Boulder; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay					NIGMS NIH HHS [GM-19963, GM-28685] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019963, R01GM028685, R37GM019963] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1989, EMBO J, V8, P3401, DOI 10.1002/j.1460-2075.1989.tb08504.x; BEAR DG, 1976, P NATL ACAD SCI USA, V73, P1824, DOI 10.1073/pnas.73.6.1824; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; CANNISTRARO VJ, 1986, J MOL BIOL, V192, P257, DOI 10.1016/0022-2836(86)90363-3; DEUTSCHER MP, 1984, P NATL ACAD SCI-BIOL, V81, P4290, DOI 10.1073/pnas.81.14.4290; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; DRAPER DE, 1978, J MOL BIOL, V122, P339; DUBE SK, 1970, NATURE, V226, P820, DOI 10.1038/226820a0; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EILAM Y, 1971, BIOCHEMISTRY-US, V10, P1489, DOI 10.1021/bi00784a034; GAVRILOVA LP, 1966, J MOL BIOL, V16, P473, DOI 10.1016/S0022-2836(66)80186-9; GESTELAND RF, 1966, J MOL BIOL, V18, P356, DOI 10.1016/S0022-2836(66)80253-X; Higgins CF, 1992, CURR OPIN GENET DEV, V2, P739, DOI 10.1016/S0959-437X(05)80134-0; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; INOUYE H, 1974, EUR J BIOCHEM, V45, P109, DOI 10.1111/j.1432-1033.1974.tb03535.x; JACOB WF, 1987, P NATL ACAD SCI USA, V84, P4757, DOI 10.1073/pnas.84.14.4757; KAMEN R, 1972, EUR J BIOCHEM, V31, P44, DOI 10.1111/j.1432-1033.1972.tb02498.x; Kennell D, 1986, MAXIMIZING GENE EXPR, P101; KING TC, 1987, ESCHERICHIA COLI SAL, P703; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCPHEETERS DS, 1986, NUCLEIC ACIDS RES, V14, P5813, DOI 10.1093/nar/14.14.5813; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; NELSON MA, 1982, MOL GEN GENET, V188, P60, DOI 10.1007/BF00332996; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; PORTIER C, 1987, EMBO J, V6, P2165, DOI 10.1002/j.1460-2075.1987.tb02484.x; REGNIER P, 1991, J MOL BIOL, V217, P283, DOI 10.1016/0022-2836(91)90542-E; RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x; RUCKMAN J, 1989, New Biologist, V1, P54; RUCKMAN JL, 1993, THESIS U COLORADO BO; Sambrook J, 1989, MOL CLONING LABORATO; SANSON B, 1993, J MOL BIOL, V233, P429, DOI 10.1006/jmbi.1993.1522; SCHMEISSNER U, 1984, J MOL BIOL, V176, P39, DOI 10.1016/0022-2836(84)90381-4; SHINEDLING S, 1987, T4 NEWS, V1, P4; SINGER BS, 1991, GENE, V106, P1, DOI 10.1016/0378-1119(91)90558-S; SMITH FL, 1969, COLD SPRING HARB SYM, V34, P91, DOI 10.1101/SQB.1969.034.01.014; STEITZ JA, 1975, P NATL ACAD SCI USA, V72, P4734, DOI 10.1073/pnas.72.12.4734; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; THOMAS JO, 1978, J MOL BIOL, V123, P163, DOI 10.1016/0022-2836(78)90319-4; UZAN M, 1988, P NATL ACAD SCI USA, V85, P8895, DOI 10.1073/pnas.85.23.8895; VALERIE K, 1986, NUCLEIC ACIDS RES, V14, P8637, DOI 10.1093/nar/14.21.8637; VENKATESH TV, 1993, J BACTERIOL, V175, P1844, DOI 10.1128/JB.175.6.1844-1846.1993; WAHBA AJ, 1974, J BIOL CHEM, V249, P3314; Wiberg J. S., 1983, BACTERIOPHAGE T4, P193	49	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26655	26662						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929399				2022-12-25	WOS:A1994PQ93100015
J	SCHULTZCHERRY, S; RIBEIRO, S; GENTRY, L; MURPHYULLRICH, JE				SCHULTZCHERRY, S; RIBEIRO, S; GENTRY, L; MURPHYULLRICH, JE			THROMBOSPONDIN BINDS AND ACTIVATES THE SMALL AND LARGE FORMS OF LATENT TRANSFORMING GROWTH-FACTOR-BETA IN A CHEMICALLY-DEFINED SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MOLECULAR-WEIGHT COMPLEX; HAMSTER OVARY CELLS; ENDOTHELIAL-CELLS; TGF-BETA; MANNOSE 6-PHOSPHATE; FACTOR-BETA-1 PRECURSOR; HUMAN-PLATELETS; RECOMBINANT; PROLIFERATION	Transforming growth factor-beta (TGF-beta) is a potent growth regulatory protein normally secreted by cells in a latent form. Primary regulation of TGF-beta activity occurs through factors which control the processing of the latent to the biologically active molecule. Thrombospondin (TSP), a platelet alpha-granule and extracellular matrix protein, forms specific complexes with active TGF-beta in platelet releasate and activates endogenous latent TGF-beta secreted by endothelial cells via a cell- and protease-independent mechanism. In order to better understand TSP-mediated activation of cell-secreted latent TGF-beta, we examined the consequences of interactions of the large (platelet-derived) and small (recombinant) forms of latent TGF-beta with TSP in a chemically defined system. Data from these studies show that interactions between TSP and both forms of latent TGF-beta result in the generation of biologically active TGF-beta as assayed by the ability of NRK-49F cells to form colonies in soft agar, by the ability to compete for binding to TGF-beta receptors on endothelial cells, and by an enzyme linked immunosorbent assay selective for the active form of TGF-beta. Activation of latent TGF-beta by TSP stripped of associated TGF-beta activity (sTSP) is time- and concentration-dependent, but temperature-independent. The mechanism whereby sTSP activates latent TGF-beta appears to involve the direct binding of sTSP to the latent molecule as shown by gel permeation chromatography. In addition, a polyclonal antibody specific for the amino-terminal region of the latency-associated peptide (amino acids 81-94) inhibits sTSP-mediated activation of latent TGF-beta in both the chemically defined system and in endothelial cell conditioned medium. These data and the observation that similar concentrations of sTSP activate latent TGF-beta in both the chemically defined system and in the endothelial cell system indicate that there is a common mechanism by which TSP activates the small, large, and endothelial cell-derived latent TGF-beta complexes. The ability of TSP to convert latent TGF-beta to biologically active TGF-beta suggests that TSP is a major regulatory factor in the control of TGF-beta activity.	UNIV ALABAMA, DEPT PATHOL, DIV MOLEC & CELLULAR PATHOL, BIRMINGHAM, AL 35294 USA; MED COLL OHIO, DEPT BIOCHEM & MOLEC BIOL, TOLEDO, OH 43699 USA	University of Alabama System; University of Alabama Birmingham			Schultz-Cherry, Stacey/N-2506-2018		NATIONAL CANCER INSTITUTE [R01CA060848] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044575, R01HL050061] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60848] Funding Source: Medline; NHLBI NIH HHS [HL44575, HL50061] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLENHOFFMANN BL, 1988, MOL CELL BIOL, V8, P4234, DOI 10.1128/MCB.8.10.4234; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; BARNARD JA, 1990, BIOCHEM BIOPH RES CO, V163, P56; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; BRUNNER AM, 1988, MOL CELL BIOL, V8, P2229, DOI 10.1128/MCB.8.5.2229; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; HUBER D, 1991, BIOCHEM J, V277, P165, DOI 10.1042/bj2770165; JULLIEN P, 1989, INT J CANCER, V43, P886, DOI 10.1002/ijc.2910430525; KESKIOJA J, 1987, J CELL BIOCHEM, V33, P95, DOI 10.1002/jcb.240330204; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MASSAGUE J, 1992, CANCER SURV, V12, P81; MILLER DM, 1992, MOL ENDOCRINOL, V6, P694, DOI 10.1210/me.6.5.694; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOSHER DF, 1990, ANNU REV MED, V41, P85; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; OKADA F, 1989, FEBS LETT, V242, P240, DOI 10.1016/0014-5793(89)80477-6; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; PHAN SH, 1989, BIOCHEM BIOPH RES CO, V163, P56, DOI 10.1016/0006-291X(89)92098-6; PIRCHER R, 1986, BIOCHEM BIOPH RES CO, V136, P30, DOI 10.1016/0006-291X(86)90872-7; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SATO Y, 1993, J CELL BIOL, V123, P1249, DOI 10.1083/jcb.123.5.1249; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SHA X, 1989, MOL ENDOCRINOL, V3, P1090, DOI 10.1210/mend-3-7-1090; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646	45	243	251	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26775	26782						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929413				2022-12-25	WOS:A1994PQ93100032
J	ARORA, N; WILLIAMSON, LC; LEPPLA, SH; HALPERN, JL				ARORA, N; WILLIAMSON, LC; LEPPLA, SH; HALPERN, JL			CYTOTOXIC EFFECTS OF A CHIMERIC PROTEIN CONSISTING OF TETANUS TOXIN LIGHT-CHAIN AND ANTHRAX TOXIN LETHAL FACTOR IN NONNEURONAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; PROTECTIVE ANTIGEN; NEUROTRANSMITTER RELEASE; ESCHERICHIA-COLI; SPINAL-CORD; INHIBITS EXOCYTOSIS; BOTULINUM TOXINS; HEAVY-CHAIN; CYCLIC-AMP; FUSION	The light chain of tetanus toxin is a zinc endoprotease that inhibits neurotransmitter release by selective proteolysis of the synaptic vesicle-associated protein synaptobrevin/vesicle-associated membrane protein. Cellubrevin is a homologue of synaptobrevin that is found in most cell types and is also a substrate for tetanus toxin. The lack of receptors for tetanus toxin on most cell types has made studies of tetanus toxin action in non-neuronal cells difficult. To characterize tetanus toxin effects in non-neuronal cells, a fusion protein consisting of the 254 amino-terminal amino acids of lethal factor (LF) of anthrax toxin and tetanus toxin light chain (LC) was prepared. This protein (LF-LC) inhibited evoked glycine release from primary spinal cord neurons at concentrations between 1.0 and 100 ng/ml. LF-LC was cytotoxic to RAW 264.7, ANA-1 cells (mouse macrophage cell lines), and Chinese hamster ovary cells in a dose-dependent manner. These effects required the presence of protective antigen, the receptor binding component of anthrax toxin. In contrast, LF-LC was not cytotoxic to RBL-2H3, Vero, or mouse hybridoma cell lines. Mutagenesis of conserved amino acids (His(237) and Glu(234)) in the zinc-binding motif of LC resulted in fusion proteins having no biological activity. LF LC did not inhibit regulated secretion of serotonin in RBL-2H3 cells or constitutive secretion in any non-neuronal cell lines as measured in several different assays. We suggest that the cytotoxic effects of LF-LC result from inhibition of a specific intracellular membrane fusion event mediated by cellubrevin.	US FDA, CTR BIOL EVALUAT & RES, DIV BACTERIAL PROD, BETHESDA, MD 20892 USA; NIDR, MICROBIAL ECOL LAB, BETHESDA, MD 20892 USA; NICHHD, DEV NEUROBIOL LAB, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; ARORA N, 1993, J BIOL CHEM, V268, P3334; ARORA N, 1992, J BIOL CHEM, V267, P15542; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BITTNER MA, 1989, J NEUROCHEM, V53, P966, DOI 10.1111/j.1471-4159.1989.tb11800.x; CAIN CC, 1992, J BIOL CHEM, V267, P11681; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; EISEL U, 1993, EMBO J, V12, P3365, DOI 10.1002/j.1460-2075.1993.tb06010.x; ESCUYER V, 1991, INFECT IMMUN, V59, P3381, DOI 10.1128/IAI.59.10.3381-3386.1991; EZZELL JW, 1992, J GEN MICROBIOL, V138, P543, DOI 10.1099/00221287-138-3-543; FAIRWEATHER NF, 1986, NUCLEIC ACIDS RES, V14, P7809, DOI 10.1093/nar/14.19.7809; GOTTESMAN S, 1990, METHOD ENZYMOL, V185, P119; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HABIG WH, 1986, J NEUROCHEM, V47, P930; HALPERN JL, 1989, INFECT IMMUN, V57, P18, DOI 10.1128/IAI.57.1.18-22.1989; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; HARRISSMITH PW, 1958, J GEN MICROBIOL, V19, P91, DOI 10.1099/00221287-19-1-91; HELTING TB, 1979, J BIOL CHEM, V254, P728; HO JL, 1985, J INFECT DIS, V152, P922, DOI 10.1093/infdis/152.5.922; HOGY B, 1992, TOXICON, V30, P63, DOI 10.1016/0041-0101(92)90502-V; HOHNEZELL B, 1993, FEBS LETT, V336, P175, DOI 10.1016/0014-5793(93)81635-D; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KENIMER JG, 1983, INFECT IMMUN, V42, P942, DOI 10.1128/IAI.42.3.942-948.1983; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KLIMPEL KR, 1993, ANN M AM SOC MICROBI; KURAZONO H, 1992, J BIOL CHEM, V267, P14721; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1988, METHOD ENZYMOL, V165, P103; Leppla SH, 1988, BACTERIAL PROTEIN TO, P111; LINK E, 1993, J BIOL CHEM, V268, P18423; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LITWACK G, 1955, P SOC EXP BIOL MED, V89, P401; MAEYAMA K, 1988, J IMMUNOL, V140, P3919; MATSUDA M, 1974, BIOCHEM BIOPH RES CO, V57, P1257, DOI 10.1016/0006-291X(74)90831-6; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MOCHIDA S, 1989, FEBS LETT, V253, P47, DOI 10.1016/0014-5793(89)80926-3; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MORRIS NP, 1980, J BIOL CHEM, V255, P6071; NOVAK JM, 1992, J BIOL CHEM, V267, P17186; ODA T, 1993, J BIOL CHEM, V268, P12596; PITZURRA L, 1989, INFECT IMMUN, V57, P2452, DOI 10.1128/IAI.57.8.2452-2456.1989; PITZURRA L, 1993, INFECT IMMUN, V61, P3605, DOI 10.1128/IAI.61.9.3605-3610.1993; RANSOM BR, 1977, J NEUROPHYSIOL, V40, P1132, DOI 10.1152/jn.1977.40.5.1132; ROA M, 1985, J BIOL CHEM, V260, P6827; SANDERS D, 1992, N-S ARCH PHARMACOL, V346, P358; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, EMBO J, V11, P3577, DOI 10.1002/j.1460-2075.1992.tb05441.x; SMITH H, 1962, J GEN MICROBIOL, V29, P517, DOI 10.1099/00221287-29-3-517; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STECHER B, 1992, BIOCHEM J, V283, P899, DOI 10.1042/bj2830899; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WILLIAMSON LC, 1992, J NEUROCHEM, V59, P2148; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WRIGHT JF, 1992, J BIOL CHEM, V267, P9053; [No title captured]; [No title captured]	58	47	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26165	26171						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929330				2022-12-25	WOS:A1994PQ93000036
J	CASTEELS, P; ROMAGNOLO, J; CASTLE, M; CASTEELSJOSSON, K; ERDJUMENTBROMAGE, H; TEMPST, P				CASTEELS, P; ROMAGNOLO, J; CASTLE, M; CASTEELSJOSSON, K; ERDJUMENTBROMAGE, H; TEMPST, P			BIODIVERSITY OF APIDAECIN-TYPE PEPTIDE ANTIBIOTICS - PROSPECTS OF MANIPULATING THE ANTIBACTERIAL SPECTRUM AND COMBATING ACQUIRED-RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HONEYBEE APIS-MELLIFERA; ANTIMICROBIAL ACTIVITY; SALMONELLA-TYPHIMURIUM; SARCOPHAGA-PEREGRINA; PROTEIN; MEMBRANE; ANALOGS; BACTENECINS; DEFENSINS; MAGAININS	Insects have a unique repertoire of peptide antibiotics but, to date, prospects of clinical applications are not clear. Apidaecin, a small peptide isolated from honeybees, inhibits viability of Gram-negative bacteria; lethal activity is near immediate, independent of a conventional ''lytic'' mechanism, and involves stereoselective recognition of target molecules. Here we report structural analysis of 14 naturally occurring apidaecin-type peptides and the existence of evolutionarily conserved (''constant'') regions. By detailed analysis of activities against clinically relevant bacteria, we demonstrate that the diversity of the intervening (''variable'') regions confers specificity to the antibacterial spectrum of each homolog. As a result, apidaecin homolog-based antibiograms (using 16 peptides) differ markedly between bacterial strains, contrasting the most between Yersinia enterocolitica and Campylobacter jejuni. Furthermore, in at least one instance, acquired resistance to apidaecin could be negated by minor substitutions in the variable regions. The delineation in a short peptide of constant and variable regions, responsible for, respectively, general antibacterial capacity and specificity of the antibacterial spectrum, is unprecedented. Taken together, we provide evidence that antibacterial spectra of apidaecin-type peptides can be manipulated, and that, in some cases, resistance can be countered and perhaps prevented. The current findings will guide rational design of second generation peptide antibiotics for clinical trials.	CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Cornell University	CASTEELS, P (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.			Erdjument-Bromage, Hediye/0000-0003-0224-3594				AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; AMSTERDAM D, 1991, ANTIBIOTICS LABORATO; ANDREU D, 1985, BIOCHEMISTRY-US, V24, P1683, DOI 10.1021/bi00328a017; BESSALLE R, 1990, FEBS LETT, V274, P151, DOI 10.1016/0014-5793(90)81351-N; Borror DJ, 1981, INTRO STUDY INSECTS; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULET P, 1993, J BIOL CHEM, V268, P14893; CASTEELS P, 1994, BIOCHEM BIOPH RES CO, V199, P339, DOI 10.1006/bbrc.1994.1234; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1990, EUR J BIOCHEM, V187, P381, DOI 10.1111/j.1432-1033.1990.tb15315.x; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; CASTEELS P, 1990, THESIS GHENT STATE U; CASTEELSJOSSON K, 1993, EMBO J, V12, P1569, DOI 10.1002/j.1460-2075.1993.tb05801.x; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; DELORENZO V, 1985, ANTIMICROB AGENTS CH, V27, P666, DOI 10.1128/AAC.27.4.666; ERDJUMENTBROMAG.H, 1993, TECHNIQUES PROTEIN C, V4, P419; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; HARLOW E, 1988, ANTIBODIES LABORATOR; HENZEL WJ, 1990, ANAL BIOCHEM, V187, P228, DOI 10.1016/0003-2697(90)90448-I; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOLDEN C, 1989, SCIENCE, V246, P754, DOI 10.1126/science.2814497; Holt J., 1994, BERGEYS MANUAL DETER; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; KEPPI E, 1989, ARCH INSECT BIOCHEM, V10, P229, DOI 10.1002/arch.940100306; KONISKY J, 1982, ANNU REV MICROBIOL, V36, P125, DOI 10.1146/annurev.mi.36.100182.001013; LEE S, 1986, BIOCHIM BIOPHYS ACTA, V862, P211, DOI 10.1016/0005-2736(86)90485-2; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LI ZQ, 1988, FEBS LETT, V231, P299, DOI 10.1016/0014-5793(88)80837-8; MATSUYAMA K, 1990, J BIOCHEM-TOKYO, V108, P128, DOI 10.1093/oxfordjournals.jbchem.a123151; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; OHTA M, 1992, ANTIMICROB AGENTS CH, V36, P1460, DOI 10.1128/AAC.36.7.1460; OKADA M, 1985, BIOCHEM J, V229, P453, DOI 10.1042/bj2290453; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; STEINER H, 1988, BIOCHIM BIOPHYS ACTA, V939, P260, DOI 10.1016/0005-2736(88)90069-7; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; VILJANEN P, 1988, INFECT IMMUN, V56, P2324, DOI 10.1128/IAI.56.9.2324-2329.1988; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597	43	78	94	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26107	26115						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929322				2022-12-25	WOS:A1994PQ93000028
J	HANFORD, DS; THUERAUF, DJ; MURRAY, SF; GLEMBOTSKI, CC				HANFORD, DS; THUERAUF, DJ; MURRAY, SF; GLEMBOTSKI, CC			BRAIN NATRIURETIC PEPTIDE IS INDUCED BY ALPHA(1)-ADRENERGIC AGONISTS AS A PRIMARY RESPONSE GENE IN CULTURED RAT CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ADRENERGIC STIMULATION; MESSENGER-RNA STABILITY; IMMEDIATE-EARLY GENE; C-FOS; VENTRICULAR CARDIOCYTES; RECEPTOR ACTIVATION; ENDOTHELIAL-CELLS; GROWTH-FACTORS; ATRIAL; EXPRESSION	To better understand the molecular basis for increased atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) expression during overload-induced cardiac hypertrophy, we studied the induction of the genes in primary myocardial cells by the alpha(1)-adrenergic agonist, phenylephrine (PE), a potent hypertrophic agent. PE augmented the transcription of both genes to similar extents, although the time course of mRNA accumulation differed. Increases in ANF mRNA were evident only after 6-8 h of PE exposure, when transcript levels were 2-4-fold over control. However, similar increases in BNP mRNA were observed as soon as 1 h of PE exposure. Moreover, while ANF mRNA levels continued to increase through 24 h of PE treatment, maximal levels of BNP mRNA (8-10-fold over control) were observed at 4 h, after which transcript levels declined to about 3-fold over control. The early induction of the BNP mRNA by PE was independent of protein synthesis, whereas the late induction of both genes required protein synthesis. Interestingly, the early BNP induction was only partially blocked by the transcription inhibitor, actinomycin D, indicating that, in part, the inductive effects of PE might be the result of transcript stabilization. Indeed, the BNP transcript, which was shown to possess a half-life of less than 1 h in control cells, was stabilized by the addition of PE, while the ANF transcript possessed a half-life of at least 24 h under all conditions. These data indicate that the induction of BNP by alpha(1)-adrenergic agonists has characteristics of both a primary and secondary response gene, while ANF is a typical secondary response gene. Moreover, alpha(1)-adrenergic stimulation enhances BNP expression through both transcriptional activation and transcript stabilization, while ANF expression is enhanced primarily transcriptionally.	SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, INST MOLEC BIOL, SAN DIEGO, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46345] Funding Source: Medline; NINDS NIH HHS [NS-25037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARA FM, 1993, NUCLEIC ACIDS RES, V21, P4803, DOI 10.1093/nar/21.20.4803; ARGENTIN S, 1991, J BIOL CHEM, V266, P23315; BELASCO J, 1993, CONTROL MRNA STABILI; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; EMORI T, 1993, ENDOCRINOLOGY, V133, P2474, DOI 10.1210/en.133.6.2474; FALVEY E, 1991, FASEB J, V5, P309, DOI 10.1096/fasebj.5.3.2001790; GARDNER DG, 1988, J CLIN INVEST, V82, P1275, DOI 10.1172/JCI113726; GLEMBOTSKI CC, 1993, J BIOL CHEM, V268, P20646; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOLT EH, 1994, J NEUROCHEM, V62, P1239; HORIO T, 1993, METABOLISM, V42, P94, DOI 10.1016/0026-0495(93)90178-Q; HUANG LY, 1993, J BIOL CHEM, V268, P25769; HUGHES P, 1993, NEUROSCIENCE, V57, P319, DOI 10.1016/0306-4522(93)90065-N; ITOH H, 1989, BIOCHEM BIOPH RES CO, V161, P732, DOI 10.1016/0006-291X(89)92661-2; ITOH H, 1992, HYPERTENSION, V19, P758, DOI 10.1161/01.HYP.19.6.758; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KANGAWA K, 1984, NATURE, V312, P152, DOI 10.1038/312152a0; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KOHNO M, 1992, AM HEART J, V123, P1382, DOI 10.1016/0002-8703(92)91049-7; KOHNO M, 1992, AM J MED, V92, P29, DOI 10.1016/0002-9343(92)90011-Y; KOHNO M, 1993, AM J PHYSIOL, V265, pE673, DOI 10.1152/ajpendo.1993.265.5.E673; KOJIMA M, 1989, BIOCHEM BIOPH RES CO, V159, P1420, DOI 10.1016/0006-291X(89)92268-7; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; LAPOINTE MC, 1993, MOL ENDOCRINOL, V7, P1284, DOI 10.1210/me.7.10.1284; LAPOINTE MC, 1990, HYPERTENSION, V15, P20, DOI 10.1161/01.HYP.15.1.20; MANTYMAA P, 1993, ENDOCRINOLOGY, V133, P1470, DOI 10.1210/en.133.3.1470; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; MUKOYAMA M, 1990, NEW ENGL J MED, V323, P757; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SEHGAL PB, 1978, BIOCHEM PHARMACOL, V27, P2475, DOI 10.1016/0006-2952(78)90313-1; SEI CA, 1991, J BIOL CHEM, V266, P15910; SEIDMAN CE, 1988, P NATL ACAD SCI USA, V85, P4104, DOI 10.1073/pnas.85.11.4104; SEILHAMER JJ, 1989, BIOCHEM BIOPH RES CO, V165, P650, DOI 10.1016/S0006-291X(89)80015-4; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STEINHELPER ME, 1993, CIRC RES, V72, P984, DOI 10.1161/01.RES.72.5.984; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; SUZUKI E, 1992, CIRC RES, V71, P1039, DOI 10.1161/01.RES.71.5.1039; TAKAHASHI T, 1992, CIRC RES, V71, P9, DOI 10.1161/01.RES.71.1.9; THIBAULT G, 1992, AM J PHYSIOL, V263, pR301, DOI 10.1152/ajpregu.1992.263.2.R301; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445	61	72	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26227	26233						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929338				2022-12-25	WOS:A1994PQ93000046
J	LALONDE, JM; LEVENSON, MA; ROE, JJ; BERNLOHR, DA; BANASZAK, LJ				LALONDE, JM; LEVENSON, MA; ROE, JJ; BERNLOHR, DA; BANASZAK, LJ			ADIPOCYTE LIPID-BINDING PROTEIN COMPLEXED WITH ARACHIDONIC-ACID - TITRATION CALORIMETRY AND X-RAY CRYSTALLOGRAPHIC STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS; PROGRAM	The association of the adipocyte lipid-binding protein (ALBP) with arachidonic acid (all cis, 20:4 Delta(5,8,11,14)) and oleic acid (cis, 18:1 Delta(9)) has been examined by titration calorimentry. In addition, the crystal structure of ALBP with bound arachidonic acid has also been obtained. Crystallographic analysis of the arachidonic acid.ALBP complex along with the previously reported oleic acid-ALBP structure (Xu, Z., Bernlohr, D. A., and Banaszak, L. J. (1993) J. Biol. Chem. 268, 7874-7884) provides a framework for the molecular examination of protein-lipid association. Isothermal titration calorimetry revealed high affinity association of both unsaturated fatty acids with the protein. The calorimetric data yielded the following thermodynamic parameters for arachidonic acid: K-d= 4.4 mu M, n = 0.8, Delta G = -7370 cal/mol, Delta H = -6770 cal/mol, and T Delta S = +600 cal/mol. For oleic acid, the thermodynamic parameters were K-d = 2.4 mu M, n = 0.9, Delta G = -7770 cal/mol, Delta H = -6050 cal/mol, and T Delta S = +1720 cal/mol. The identification of thermodynamically dominating enthalpic factors for both fatty acids are consistent with the crystallographic studies demonstrating the interaction of the fatty acid carboxylate with a combination of Arg(106), Arg(126), and Tyr(128). The crystallographic refinement of the protein-arachidonate complex was carried out to 1.6 Angstrom with the resultant R factor of 0.19. Within the cavity of the crystalline binding protein, the arachidonate was found in a hairpin conformation. The conformation of the bound ligand is consistent with acceptable torsional angles and the four cis double bonds in arachidonate. These results demonstrate that arachidonate is a ligand for ALBP. They provide thermodynamic and structural data concerning the physical basis for protein-lipid interaction and suggest that intracellular lipid-binding proteins may mediate the biological effects of polyunsaturated fatty acids in vivo.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,COLL BIOL SCI,DEPT BIOCHEM,ST PAUL,MN 55108; UNIV MINNESOTA,COLL BIOL SCI,INST HUMAN GENET,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIGMS NIH HHS [GM13925] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013925] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSSON S, 1962, ACTA CRYSTALLOGR, V15, P1261, DOI 10.1107/S0365110X62003321; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; BUELT MK, 1990, BIOCHEMISTRY-US, V29, P7408, DOI 10.1021/bi00484a008; ERNST J, 1979, Z NATURFORSCH B, V34, P706, DOI 10.1515/znb-1979-0512; HYMAN BT, 1982, BIOCHIM BIOPHYS ACTA, V713, P375, DOI 10.1016/0005-2760(82)90256-9; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LALONDE JM, 1994, BIOCHEMISTRY-US, V33, P4885, DOI 10.1021/bi00182a017; MEAD JF, 1986, LIPIDS CHEM BIOCH NU, P44; REID T, 1991, J BIOL CHEM, V266, P16580; RICH MR, 1993, BIOCHIM BIOPHYS ACTA, V1178, P87, DOI 10.1016/0167-4889(93)90113-4; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SERRERO G, 1992, ENDOCRINOLOGY, V131, P2545, DOI 10.1210/en.131.6.2545; SHA RS, 1993, J BIOL CHEM, V268, P7885; TEBBEYPW, 1994, J BIOL CHEM, V269, P639; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; XU ZH, 1993, J BIOL CHEM, V268, P7874; XU ZH, 1991, J BIOL CHEM, V266, P14367	20	91	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25339	25347						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929228				2022-12-25	WOS:A1994PQ49100019
J	SONVEAUX, N; CONRATH, K; CAPIAU, C; BRASSEUR, R; GOORMAGHTIGH, E; RUYSSCHAERT, JM				SONVEAUX, N; CONRATH, K; CAPIAU, C; BRASSEUR, R; GOORMAGHTIGH, E; RUYSSCHAERT, JM			THE TOPOLOGY OF THE S-PROTEIN IN THE YEAST-DERIVED HEPATITIS-B SURFACE-ANTIGEN PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFLECTION INFRARED-SPECTROSCOPY; SECONDARY STRUCTURE; ENVELOPE PROTEINS; VIRUS; ORIENTATION; SEQUENCE; EPITOPES; CARRIER	Hepatitis B surface antigen particles are highly immunogenic and have been shown to provide a suitable support for the presentation of foreign epitopes. More information about the topology of their constitutive protein, the S (small envelope) protein, is a prerequisite to any rational attempt to replace region of this protein with foreign epitopes without modifying the assembly of the particle. The topology of the S protein within the lipid membrane was investigated here by combining extensive proteolysis of the external protein domains with proteinase K and (FTIR-ATR). The proteolytic hydrolysis of the S protein and the identification of the digestion products allowed characterization of the membrane-protected regions of the protein. FTIR spectra of the digested hepatitis B particles revealed that the peptides associated with the particles are rich in cu-helix structure. The kinetic of H-2/H exchange provided evidence that a large fraction of the native S protein is poorly accessible to the aqueous medium.	FREE UNIV BRUSSELS,CHIM PHYS MACROMOLEC INTERFACES LAB,B-1050 BRUSSELS,BELGIUM; SMITHKLINE BEECHAM BIOL,B-1330 RIXENSART,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; GlaxoSmithKline				Goormaghtigh, Erik/0000-0002-2071-2262				AGGERBECK LP, 1985, VIROLOGY, V141, P155, DOI 10.1016/0042-6822(85)90192-8; BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; DELPEYROUX F, 1988, J VIROL, V62, P1836, DOI 10.1128/JVI.62.5.1836-1839.1988; DELPEYROUX F, 1986, SCIENCE, V233, P472, DOI 10.1126/science.2425433; DELPEYROUX F, 1990, J VIROL, V64, P6090, DOI 10.1128/JVI.64.12.6090-6100.1990; DEMEUTTER J, 1989, BIOCHIM BIOPHYS ACTA, V1006, P147; DUMONT ME, 1985, J MEMBRANE BIOL, V88, P233, DOI 10.1007/BF01871088; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; EBLE BE, 1986, MOL CELL BIOL, V6, P1454, DOI 10.1128/MCB.6.5.1454; FRINGELI UP, 1981, MEMBRANE SPECTROSCOP, P270; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GOORMAGHTIGH E, 1987, BIOCHEMISTRY-US, V26, P1789, DOI 10.1021/bi00380a043; GOORMAGHTIGH E, 1993, BIOCHEMISTRY-US, V32, P6104, DOI 10.1021/bi00074a023; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; GOORMAGHTIGH E, 1991, EUR J BIOCHEM, V195, P421, DOI 10.1111/j.1432-1033.1991.tb15721.x; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; Guerrero E., 1988, VIRAL HEPATITIS LIVE, P606; HARFORD N, 1987, POSTGRAD MED J, V63, P65; HAUSER P, 1987, POSTGRAD MED J, V63, P83; HEERMANN KH, 1984, J VIROL, V52, P396, DOI 10.1128/JVI.52.2.396-402.1984; HOWARD CR, 1988, VIRAL HEPATITIS LIVE, P1094; IONESCUMATIU I, 1983, J IMMUNOL, V130, P1947; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0; MICHEL ML, 1993, RES VIROLOGY, V144, P263, DOI 10.1016/S0923-2516(06)80038-5; MICHEL ML, 1988, P NATL ACAD SCI USA, V85, P7957, DOI 10.1073/pnas.85.21.7957; PETERSON DL, 1982, J BIOL CHEM, V257, P414; PETERSON DL, 1987, BIOESSAYS, V6, P258, DOI 10.1002/bies.950060604; PETERSON DL, 1981, J BIOL CHEM, V256, P6975; PETRE J, 1987, POSTGRAD MED J, V63, P70; RUTGERS T, 1988, BIO-TECHNOL, V6, P1065, DOI 10.1038/nbt0988-1065; SCHLIENGER K, 1992, J VIROL, V66, P2570, DOI 10.1128/JVI.66.4.2570-2576.1992; STIRK HJ, 1992, INTERVIROLOGY, V33, P148, DOI 10.1159/000150244; SUSI H, 1967, J BIOL CHEM, V242, P5460; TIOLLAIS P, 1984, ADV HEPATITIS RES, P9; UEDA K, 1991, J VIROL, V65, P3521, DOI 10.1128/JVI.65.7.3521-3529.1991; VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0; VANDEKERCKHOVE J, 1985, EUR J BIOCHEM, V152, P9, DOI 10.1111/j.1432-1033.1985.tb09157.x; VANDENBUSSCHE G, 1992, BIOCHEMISTRY-US, V31, P9169, DOI 10.1021/bi00153a008	41	24	26	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25637	25645						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929267				2022-12-25	WOS:A1994PQ49100063
J	BOMMINENI, VR; CHOWDHURY, NR; WU, GY; WU, CH; FRANKI, N; HAYS, RM; CHOWDHURY, JR				BOMMINENI, VR; CHOWDHURY, NR; WU, GY; WU, CH; FRANKI, N; HAYS, RM; CHOWDHURY, JR			DEPOLYMERIZATION OF HEPATOCELLULAR MICROTUBULES AFTER PARTIAL-HEPATECTOMY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE DELIVERY; RAT HEPATOCYTES; INVIVO; RECEPTOR; TRANSPORT; DYNEIN; LIVER; TRANSLOCATION; PERSISTENCE; ENDOCYTOSIS	Asialoglycoproteins (ASG) are internalized by hepatocytes by ASG receptor (ASGR)-mediated endocytosis. We have shown previously that when a plasmid DNA, pAlb(9-12)CAT (expressing chloramphenicol acetyltransferase driven by an albumin promoter enhancer), was complexed with an ASG-polylysine conjugate and injected intravenously in rats, 80% of the DNA was internalized by the liver. In normal recipient rats, over 95% of the internalized DNA was degraded in 4 h; the plasmid was undetectable after 48 h. In contrast, when 66% hepatectomy was performed 20 min after DNA administration, the internalized DNA persisted for several weeks in cytoplasmic vesicles (Chowdhury, N. R., Wu, C. H., Wu, B. Y., Yerneni, P. C., Bommineni, V.R., and Chowdhury, J. R. (1993) J. Biol. Chem. 268, 11265-11271). Since microtubules are required for the translocation of ligand-containing endosomes to lysosomes, the site of ligand degradation, we hypothesized that persistence of the endocytosed DNA might be related to changes in microtubular structure and function. To test this hypothesis, we examined hepatocellular microtubules by immunofluorescence confocal microscopy. Liver from untreated rats or sham-operated controls showed a network of fibrillar microtubules throughout the cytoplasm. The extent of the microtubular network was substantially reduced 3-6 h after 66% hepatectomy. By 24 h, microtubules had regenerated. Intraportal infusion of cycloheximide (250 mg/kg body weight) 15 min before 66% hepatectomy, prevented microtubular disruption, indicating that protein synthesis is required for this process. Immunotransblot analysis showed that hepatic alpha-tubulin concentration remained unchanged through microtubular disassembly and subsequent reassembly, which is consistent with conservation and reutilization of tubulin released by depolymerization of microtubules.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DIV GASTROINTESTINAL & LIVER DIS,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV NEPHROL,BRONX,NY 10461; UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV GASTROENTEROL,FARMINGTON,CT 06030	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Connecticut					NIDDK NIH HHS [R01-DK 46057, R01-DK 39137] Funding Source: Medline; PHS HHS [R01 03858] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046057, R01DK039137] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RD, 1985, J CELL BIOL, V100, P1736, DOI 10.1083/jcb.100.5.1736; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM W, 1990, NATURE, V346, P318; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; HIROKAWA N, 1989, CELL MOVEMENT KINESI, V2, P383; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; OKA JA, 1983, BIOCHIM BIOPHYS ACTA, V763, P368, DOI 10.1016/0167-4889(83)90098-8; PORTER ME, 1989, ANNU REV CELL BIOL, V5, P119; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; SCHMID K, 1967, BIOCHEM J, V104, P361, DOI 10.1042/bj1040361; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOLLMAN YR, 1985, HEPATOLOGY, V5, P798, DOI 10.1002/hep.1840050515; WAYNFORTH HB, 1980, EXPT SURGICAL TECHNI, P137; Weigel P H, 1993, Subcell Biochem, V19, P125; WHITEHEAD PH, 1966, BIOCHIM BIOPHYS ACTA, V124, P209, DOI 10.1016/0304-4165(66)90336-9; WILSON JM, 1992, J BIOL CHEM, V267, P11483; WILSON JM, 1992, J BIOL CHEM, V267, P963; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1991, J BIOL CHEM, V266, P14338	28	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25200	25205						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929209				2022-12-25	WOS:A1994PQ49000100
J	KURATA, S				KURATA, S			POTENTIAL OF AZIDOTHYMIDINE TO ACTIVATE THE HIV-1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; INVITRO; 2',3'-DIDEOXYNUCLEOSIDES; INFECTIVITY; INHIBITION; TRIAL; DNA	Azidothymidine (AZT) has been used for treatment of acquired immunodeficiency syndrome (AIDS), but a recent concord trial showed that it is ineffective for suppressing the development of AIDS. In this study, the effects of AZT on three cell lines transformed by pCD12 plasmid (human immunodeficiency virus-1 (HIV-1) promoter-chloramphenicol acetyltransferase) were examined. Results showed that AZT has the potential to activate the HIV-1 promoter.			KURATA, S (corresponding author), TOKYO MED & DENT UNIV,MED RES INST,DEPT BIOCHEM GENET,TOKYO 113,JAPAN.							ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V176, P87, DOI 10.1016/0006-291X(91)90893-C; KURATA SI, 1993, FEBS LETT, V320, P201; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MITSUYA H, 1987, P NATL ACAD SCI USA, V84, P2033, DOI 10.1073/pnas.84.7.2033; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; RICKMAN DD, 1987, NEW ENGL J MED, V317, P192; SANDRIGOLDIN RM, 1981, MOL CELL BIOL, V1, P743, DOI 10.1128/MCB.1.8.743; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327	17	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24553	24556						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929126				2022-12-25	WOS:A1994PQ49000010
J	SANTOS, MJ; KAWADA, ME; ESPEEL, M; FIGUEROA, C; ALVAREZ, A; HIDALGO, U; METZ, C				SANTOS, MJ; KAWADA, ME; ESPEEL, M; FIGUEROA, C; ALVAREZ, A; HIDALGO, U; METZ, C			CHARACTERIZATION OF HUMAN PEROXISOMAL MEMBRANE-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; ACYL-COA OXIDASE; ZELLWEGER SYNDROME; BINDING PROTEINS; TARGETING SIGNAL; BIOGENESIS; MEMBER; POLYPEPTIDES; LOCALIZATION; FIBROBLASTS	The peroxisomal membrane appears to play a crucial role in transporting proteins into the organelle. Some human genetic disorders involving peroxisome biogenesis, such as Zellweger syndrome, may be caused by genetic defects of the import machinery located in the peroxisomal membrane. In order to characterize the proteins of the human peroxisomal membrane, we isolated peroxisomes from human liver. We obtained their membranes using various procedures and analyzed their proteins by SDS-polyacrylamide gel electrophoresis and silver staining. We compared the protein composition of peroxisomal membranes with membranes derived from mitochondria and microsomes. The main peroxisomal membrane proteins (PMPs) have apparent molecular masses of 147, 112, 95, 87, 81, 79, 74, 69(70), 53-52 (double band), 47, 45, 43, 37, 31, 28, 22, and 17 kDa. The following PMPs of 147, 112, 79, 69(70), 53-52 (double band), 47, 43, 31, 28, 22, and 17 kDa fit the criteria for integral membrane proteins. We then produced rabbit polyclonal and mouse monoclonal antibodies that recognized some human PMPs. One of these antibodies detected mainly PMP43. We used this antiserum to evaluate the presence and subcellular distribution of the PMP43 in fibroblasts derived from patients affected by Zellweger syndrome. These results represent new information about the protein composition of the human peroxisomal membrane and provide biological tools for further characterization of the human PMPs and their genes in normal and pathological conditions.	STATE UNIV GHENT,DEPT ANAT HISTOL & EMBRYOL,B-9000 GHENT,BELGIUM	Ghent University	SANTOS, MJ (corresponding author), PONTIFICIA UNIV CATOLICA CHILE,FAC BIOL SCI & MED,DEPT CELL & MOLEC BIOL,CASILLA 114-D,SANTIAGO,CHILE.		Figueroa, Christian C./A-1170-2008	Figueroa, Christian C./0000-0001-9218-5564; Alvarez Rojas, Alejandra/0000-0002-8129-9280; Metz, Claudia/0000-0002-5093-3066				ALVAREZ A, 1992, ANAL BIOCHEM, V206, P147, DOI 10.1016/S0003-2697(05)80025-9; BALFE A, 1990, PEDIATR RES, V27, P304, DOI 10.1203/00006450-199003000-00023; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BERGMEYER HU, 1963, METHDOS ENZYMATIC AN, P452; BERTHET J, 1951, BIOCHEM J, V50, P174, DOI 10.1042/bj0500174; BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; BOWERS WE, 1967, J CELL BIOL, V32, P339, DOI 10.1083/jcb.32.2.339; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUL S, 1988, J CLIN INVEST, V81, P1702; CAUSERET C, 1993, BIOL CELL, V77, P89, DOI 10.1016/S0248-4900(05)80178-9; DELVALLE R, 1988, BIOCHEM BIOPH RES CO, V156, P1353, DOI 10.1016/S0006-291X(88)80781-2; DUDUVA C, 1967, ENZYME CYTOLOGY, P1; FUJIKI Y, 1989, AGR BIOL CHEM TOKYO, V53, P591; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; GOODMAN JM, 1986, J BIOL CHEM, V261, P3464; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; HARTL FU, 1987, ARCH BIOCHEM BIOPHYS, V255, P109, DOI 10.1016/0003-9861(87)90300-6; HASHIMOTO T, 1986, J BIOCHEM-TOKYO, V100, P301, DOI 10.1093/oxfordjournals.jbchem.a121716; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; IMANAKA T, 1991, BIOCHIM BIOPHYS ACTA, V1062, P264, DOI 10.1016/0005-2736(91)90401-S; KALDI K, 1993, FEBS LETT, V315, P217, DOI 10.1016/0014-5793(93)81167-X; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KAMIJO K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P323, DOI 10.1016/0167-4781(92)90510-7; LABARCA P, 1986, J MEMBRANE BIOL, V94, P285, DOI 10.1007/BF01869724; Lazarow PB, 1989, CURR OPIN CELL BIOL, V1, P630, DOI 10.1016/0955-0674(89)90026-4; Lazarow Paul B., 1993, Trends in Cell Biology, V3, P89, DOI 10.1016/0962-8924(93)90079-G; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LAZAROW PB, 1989, METABOLIC BASIS INHE, P1470; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LEIGHTON F, 1969, J CELL BIOL, V41, P521, DOI 10.1083/jcb.41.2.521; LEMMENS M, 1989, BIOCHIM BIOPHYS ACTA, V984, P351, DOI 10.1016/0005-2736(89)90302-7; MAKITA T, 1990, ACTA HISTOCHEM CYTOC, V23, P601, DOI 10.1267/ahc.23.601; MANNAERTS GP, 1993, BIOCHIMIE, V75, P147, DOI 10.1016/0300-9084(93)90072-Z; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; ROELS F, 1979, J HISTOCHEM CYTOCHEM, V27, P1471, DOI 10.1177/27.11.92501; ROSCHER AA, 1989, PEDIATR RES, V26, P67, DOI 10.1203/00006450-198907000-00019; SANTOS MJ, 1992, J CELL PHYSIOL, V151, P103, DOI 10.1002/jcp.1041510115; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SCHUTGENS RBH, 1986, EUR J PEDIATR, V144, P430, DOI 10.1007/BF00441734; SELLINGER OZ, 1960, BIOCHEM J, V74, P450, DOI 10.1042/bj0740450; SHIMIZU S, 1992, J BIOCHEM-TOKYO, V112, P733, DOI 10.1093/oxfordjournals.jbchem.a123967; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SMALL GM, 1988, J INHERIT METAB DIS, V11, P358, DOI 10.1007/BF01800425; SMALL GM, 1985, BIOCHEM J, V227, P205, DOI 10.1042/bj2270205; SUBRAMANI S, 1992, J MEMBRANE BIOL, V125, P99; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; VERHEYDEN K, 1992, BIOCHIM BIOPHYS ACTA, V1109, P48, DOI 10.1016/0005-2736(92)90185-O; WIEMER EAC, 1989, EUR J CELL BIOL, V50, P407; WILSON GN, 1991, BIOCHEM MED METAB B, V46, P235, DOI 10.1016/0885-4505(91)90071-R; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872	57	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24890	24896						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929170				2022-12-25	WOS:A1994PQ49000057
J	SCHWARTZ, HL; LAZAR, MA; OPPENHEIMER, JH				SCHWARTZ, HL; LAZAR, MA; OPPENHEIMER, JH			WIDESPREAD DISTRIBUTION OF IMMUNOREACTIVE THYROID-HORMONE BETA-2 RECEPTOR (TR-BETA-2) IN THE NUCLEI OF EXTRAPITUITARY RAT-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 MESSENGER-RNA; BINDING-CAPACITY; LYMPHOID-TISSUES; NERVOUS-SYSTEM; EXPRESSION; PROTEIN; LOCALIZATION; OCT-2	Messenger RNA for thyroid hormone receptor (TR) isoforms alpha 1 and beta 1 are widely distributed in rat tissues. Until recently, TR beta 2 mRNA was believed to be limited to the pituitary and the assumption was made that TR beta 2 protein was similarly restricted. We determined the distribution of TR beta 2 protein in selected adult and fetal rat tissues using three anti-TR beta 2 antisera directed to different amino acid sequences of the distinctive A/B domain of TR beta 2. The proportion of total nuclear binding capacity cleared by each antiserum was determined by saturation analysis. 10-20% of total binding capacity in adult brain, liver, kidney, and heart was immunoprecipitated by each antiserum. Use of specific antibodies to TR beta 1 and TR alpha 1 showed these isoforms accounted for the remainder of total T-3 binding. Fetal liver and brain, however, contained only TR alpha 1. Immunohistochemical analysis of the adult tissues showed TR beta 2 present in nuclei. Reverse transcription polymerase chain reaction detected low levels of TR beta 2 mRNA in the adult tissues. We infer that TR beta 2 accounts for a significant fraction of TR in adult rat tissues despite the low levels of its mRNA.	UNIV MINNESOTA,CTR HLTH,DEPT MED,DIABET ENDOCRINOL & METAB SECT,TYROID RES UNIT,MINNEAPOLIS,MN 55455; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104	University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania			Lazar, Mitchell A/AAF-3738-2019		NIADDK NIH HHS [AM19-812] Funding Source: Medline; NIDDK NIH HHS [DK43806] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM019812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043806, R37DK043806] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; CHLEQDESCHAMPS CM, 1993, BLOOD, V81, P293; COOK CB, 1992, ENDOCRINOLOGY, V130, P1077, DOI 10.1210/en.130.2.1077; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GOLDSBOROUGH AS, 1993, NUCLEIC ACIDS RES, V21, P127, DOI 10.1093/nar/21.1.127; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; INOUE A, 1983, ANAL BIOCHEM, V134, P176, DOI 10.1016/0003-2697(83)90280-4; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KONDO E, 1992, BLOOD, V80, P2044; LECHAN RM, 1993, ENDOCRINOLOGY, V132, P2461, DOI 10.1210/en.132.6.2461; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; SCHWARTZ HL, 1992, J BIOL CHEM, V267, P11794; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STRAIT KA, 1991, P NATL ACAD SCI USA, V88, P3887, DOI 10.1073/pnas.88.9.3887; SUZUKI N, 1993, NUCLEIC ACIDS RES, V21, P245, DOI 10.1093/nar/21.2.245; WOOD JN, 1992, J BIOL CHEM, V267, P17787; YEN PM, 1992, ENDOCRINOLOGY, V130, P1539, DOI 10.1210/en.130.3.1539	18	82	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24777	24782						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929155				2022-12-25	WOS:A1994PQ49000042
J	SHAPER, NL; HARDUINLEPERS, A; SHAPER, JH				SHAPER, NL; HARDUINLEPERS, A; SHAPER, JH			MALE GERM-CELL EXPRESSION OF MURINE BETA-4-GALACTOSYLTRANSFERASE - A 796-BASE PAIR GENOMIC REGION, CONTAINING 2 CAMP-RESPONSIVE ELEMENT (CRE)-LIKE ELEMENTS, MEDIATES MALE GERM CELL-SPECIFIC EXPRESSION IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; MESSENGER-RNA; BETA-GALACTOSIDASE; TRANSCRIPTION FACTORS; MOUSE; PROMOTER; GENE; TESTIS; SPERM; BETA-1,4-GALACTOSYLTRANSFERASE	In murine somatic cells, transcription of the single gene encoding beta 4-galactosyltransferase results in two transcripts of 4.1 and 3.9 kilobases (kb), as a consequence of the use of two transcriptional start sites that are located on exon one separated by 200 base pairs (bp). In early male germ cell development, spermatogonia use only the 4.1-kb start site to yield a transcript that is identical to its somatic cell counterpart. As these cells enter meiosis, there is a switch from the use of this somatic cell start site to the exclusive use, beginning in pachytene spermatocytes, of a male germ cell-specific start site. Germ cell specific transcripts are distinguished from their somatic counterparts by an additional similar to 560 nucleotides of 5'-untranslated sequence that is located immediately upstream and contiguous with the transcriptional start site defined for the 4.1-kb mRNA (Harduin-Lepers, A., Shaper, N. L., Mahoney, J. A., and Shaper, J. H. (1992) Glycobiology 2, 361-368). This observation predicts the use of a different upstream male germ cell-specific promoter. In this study we show that a 796-bp fragment containing 543 bp of genomic sequence upstream of the germ cell specific transcriptional start site and 253 bp of flanking downstream sequence, directs expression of the reporter gene, beta-galactosidase, exclusively to the pachytene spermatocytes and round spermatids of transgenic mice. This pattern of cell type-specific expression of the transgene is comparable with that of the endogenous beta 4-galactosyltransferase gene.	JOHNS HOPKINS UNIV,CTR ONCOL,SCH MED,CELL STRUCT & FUNCT LAB,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University			Harduin-Lepers, Anne/O-7503-2017	Harduin-Lepers, Anne/0000-0002-1233-3799	NCI NIH HHS [CA45799] Funding Source: Medline; NICHD NIH HHS [NICHD P30 HD06268-19] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD006268] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA045799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; CHENG A, 1994, CELL BIOL, V125, P867; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GALCHEVAGARGOVA Z, 1993, MOL ENDOCRINOL, V7, P979, DOI 10.1210/me.7.8.979; GEBARA MM, 1992, MOL CELL BIOL, V12, P1422, DOI 10.1128/MCB.12.4.1422; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HARDUINLEPERS A, 1992, GLYCOBIOLOGY, V2, P361, DOI 10.1093/glycob/2.4.361; HOGAN B, 1986, MANIPULATING MOUSE E, P174; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; IANNELLO RC, 1993, J BIOL CHEM, V268, P22581; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; LALLI E, 1994, J BIOL CHEM, V269, P17359; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; OKO R, 1993, J CELL BIOL, V123, P809, DOI 10.1083/jcb.123.4.809; QUERALT R, 1993, GENE, V133, P197, DOI 10.1016/0378-1119(93)90638-J; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SHUR BD, 1982, J CELL BIOL, V95, P567, DOI 10.1083/jcb.95.2.567; TAKAKUBO F, 1992, EXP CELL RES, V199, P39, DOI 10.1016/0014-4827(92)90459-L; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; THOREY IS, 1992, DEV DYNAM, V195, P100, DOI 10.1002/aja.1001950204; TOUSSAINT C, 1994, J BIOL CHEM, V269, P13318; VANDERHOORN FA, 1992, P NATL ACAD SCI USA, V89, P703, DOI 10.1073/pnas.89.2.703; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; WASSARMAN PM, 1985, COLD SPRING HARB SYM, V50, P11, DOI 10.1101/SQB.1985.050.01.004; WILKIE TM, 1986, DEV BIOL, V118, P9, DOI 10.1016/0012-1606(86)90068-0; YOUNG DC, 1993, ANAL BIOCHEM, V215, P24, DOI 10.1006/abio.1993.1549; ZAMBROWICZ BP, 1994, BIOL REPROD, V50, P65, DOI 10.1095/biolreprod50.1.65; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071; ZINN SA, 1991, J BIOL CHEM, V266, P23850	44	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25165	25171						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929205				2022-12-25	WOS:A1994PQ49000095
J	TZAHAR, E; LEVKOWITZ, G; KARUNAGARAN, D; YI, L; PELES, E; LAVI, S; CHANG, D; LIU, NL; YAYON, A; WEN, DZ; YARDEN, Y				TZAHAR, E; LEVKOWITZ, G; KARUNAGARAN, D; YI, L; PELES, E; LAVI, S; CHANG, D; LIU, NL; YAYON, A; WEN, DZ; YARDEN, Y			ERBB-3 AND ERBB-4 FUNCTION AS THE RESPECTIVE LOW AND HIGH-AFFINITY RECEPTORS OF ALL NEU DIFFERENTIATION FACTOR HEREGULIN ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN-BREAST; MAMMARY-TUMORS; LIGAND; HEREGULIN; PROTEIN; CANCER; MEMBER; FAMILY; HER4/P180(ERBB4)	Neu differentiation factor (NDF or heregulin) elevates tyrosine phosphorylation of the ErbB-2 receptor tyrosine kinase, and it was, therefore, thought to function as a ligand of this receptor. However, several lines of evidence raised the possibility that the interaction between NDF and ErbB-2 involves another molecule, which belongs to the family of epidermal growth factor receptors. To address this question we constructed soluble chimeric proteins between alkaline phosphatase and the extracellular domains of ErbB-2 and either ErbB-3 or ErbB-4, two newly recognized members of the epidermal growth factor receptor family. Using the soluble proteins we found that beta isoforms of NDF specifically bind to the ErbB-3 and ErbB-4 receptors but not to the soluble ErbB-2 protein, When ectopically expressed in monkey fibroblasts, the full-length ErbB-3 and ErbB-4 receptors conferred specific binding to NDF. In these cells ErbB-3 displayed lower ligand binding affinity than ErbB-4, but like the latter receptor it preferred to bind the beta isoform over the alpha class of NDFs. These results indicate that both ErbB-3 and ErbB-4 function as physiological receptors of all NDF isoforms and suggest that a still unknown ligand of ErbB-2 exists.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Weizmann Institute of Science; Amgen			Karunagaran, Devarajan/A-8148-2010; YARDEN, YOSEF/K-1467-2012; Levkowitz, Gil/AAB-9441-2019	Karunagaran, Devarajan/0000-0001-9331-8947; Levkowitz, Gil/0000-0002-3896-1881; Peles, Elior/0000-0002-3325-0597				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BACUS SS, 1993, CANCER RES, V53, P5251; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LONARDO F, 1990, New Biologist, V2, P992; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2187; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027	31	260	282	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25226	25233						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929212				2022-12-25	WOS:A1994PQ49000104
J	YAHI, N; SABATIER, JM; NICKEL, P; MABROUK, K; GONZALEZSCARANO, F; FANTINI, J				YAHI, N; SABATIER, JM; NICKEL, P; MABROUK, K; GONZALEZSCARANO, F; FANTINI, J			SURAMIN INHIBITS BINDING OF THE V3 REGION OF HIV-1 ENVELOPE GLYCOPROTEIN GP120 TO GALACTOSYLCERAMIDE, THE RECEPTOR FOR HIV-1 GP120 ON HUMAN COLON EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; SURFACE EXPRESSION; INFECTION; TYPE-1; LINES; CERAMIDE; INVITRO; GLYCOSPHINGOLIPIDS; LYMPHOCYTES	The infection of human colonic epithelial cells HT-29 by human immunodeficiency virus type 1 (HIV-1) occurs independently of CD4, the main HIV-1 receptor ex pressed on lymphocytes and macrophages. Recent studies from our group have shown that HT-29 cells express the glycosphingolipid galactosylceramide (GalCer), a potential alternative receptor for the HIV-1 envelope glycoprotein gp120. The binding of recombinant gp120 to GalCer was blocked by monoclonal antibodies directed against the third variable region (V3) of gp120 suggesting that the V3 domain was implicated in GalCer recognition. In the present report, we show that suramin, a polysulfonyl naphtylurea known to inhibit retroviral reverse transcriptases in vitro, blocks HIV-1 infection in HT-29 cells. The effect is dose dependent, with a half-maximal inhibition (IC50) achieved for a suramin concentration of 54 mu g/ml. Since [H-3]suramin was not significantly internalized into HT-29 cells during our infection assay (i.e. 2 h), we have considered the possibility that the drug could act at an extracellular step of the HIV-1 cycle. Using a high performance thin layer chromatography binding assay, we show that suramin inhibits binding of HIV-1 gp120 to purified GalCer with an IC50 of 25 mu g/ml. Suramin does not bind to GalCer, since preincubation of GalCer with suramin did not prevent the subsequent attachment of gp120. Using a solid-phase assay, we show that [SH]suramin specifically binds to recombinant gp120 and that this binding could be blocked by a monoclonal antibody specific for the conserved GPGRAF motif of the V3 domain of gp120. We also demonstrate that [H-3]suramin binds to multibranched synthetic GPGRAF peptides that block HIV-1 infection in HT-29 cells. Binding of [H-3]suramin to V3 peptides is specific and inhibited by unlabeled suramin (IC50 of 28 mu g/ml). In contrast, the suramin derivative NF036, that is unable to bleak HIV-1 infection in HT-29 cells, does not inhibit the binding of [H-3]suramin to V3 peptides. Taken together, these results suggest that suramin blocks HIV-1 infection in HT-29 cells because it binds to the V3 domain of gp120 and hence prevents the interaction between gp120 and the GalCer receptor.	UNIV BONN,INST PHARMAZEUT,W-5300 BONN 1,GERMANY; UNIV PENN,MED CTR,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MICROBIOL,PHILADELPHIA,PA 19104	University of Bonn; University of Pennsylvania; University of Pennsylvania	YAHI, N (corresponding author), FAC MED NORD,CNRS,URA 1455,BD PIERRE DRAMARD,F-13916 MARSEILLE 20,FRANCE.			SABATIER, Jean-Marc/0000-0002-9040-5647; Fantini, Jacques/0000-0001-8653-5521				ADACHI A, 1987, J VIROL, V61, P209, DOI 10.1128/JVI.61.1.209-213.1987; AMERONGEN HM, 1991, J ACQ IMMUN DEF SYND, V4, P760; ASMUTH DM, 1994, AIDS, V8, P205, DOI 10.1097/00002030-199402000-00008; BAGHDIGUIAN S, 1993, CANCER LETT, V75, P151, DOI 10.1016/0304-3835(93)90057-G; BAGHDIGUIAN S, 1991, CANCER LETT, V60, P213, DOI 10.1016/0304-3835(91)90116-Y; BARNETT SW, 1991, VIROLOGY, V182, P902; BATINIC D, 1992, J BIOL CHEM, V267, P6664; BHAT S, 1991, P NATL ACAD SCI USA, V88, P7131, DOI 10.1073/pnas.88.16.7131; BJORK S, 1987, J BIOL CHEM, V262, P6758; BOURINBAIAR AS, 1993, EUR J PHARMACOL, V230, P15, DOI 10.1016/0014-2999(93)90404-6; COOK DG, 1994, VIROLOGY, V201, P206, DOI 10.1006/viro.1994.1287; COOK DG, 1994, METHODS MOL GENET, V4, P86; DECLERCQ E, 1993, ADV VIRUS RES, V42, P1, DOI 10.1016/S0065-3527(08)60082-2; DECLERCQ E, 1979, CANCER LETT, V8, P9, DOI 10.1016/0304-3835(79)90017-X; DECLERCQ E, 1987, ANTIVIR RES, V7, P1, DOI 10.1016/0166-3542(87)90034-9; FANTINI J, 1993, P NATL ACAD SCI USA, V90, P2700, DOI 10.1073/pnas.90.7.2700; FANTINI J, 1993, CR ACAD SCI III-VIE, V316, P1381; FANTINI J, 1990, INT J CANCER, V45, P554, DOI 10.1002/ijc.2910450330; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HARROP HA, 1994, AIDS, V8, P183, DOI 10.1097/00002030-199402000-00005; HEISE C, 1991, GASTROENTEROLOGY, V100, P1521, DOI 10.1016/0016-5085(91)90648-5; HOLGERSSON J, 1991, J BIOCHEM-TOKYO, V110, P120, DOI 10.1093/oxfordjournals.jbchem.a123530; JENTSCH KD, 1987, J GEN VIROL, V68, P2183, DOI 10.1099/0022-1317-68-8-2183; KOTLER DP, 1991, AM J PATHOL, V139, P823; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LEVY JA, 1989, AM J GASTROENTEROL, V84, P787; MAYER KH, 1986, AM J MED, V80, P357, DOI 10.1016/0002-9343(86)90706-0; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; MITSUYA H, 1984, SCIENCE, V226, P172, DOI 10.1126/science.6091268; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; MOYER MP, 1991, J LEUKOCYTE BIOL, V49, P499, DOI 10.1002/jlb.49.5.499; OMARY MB, 1991, AIDS, V5, P275, DOI 10.1097/00002030-199103000-00005; PHILLIPS DM, 1992, VIROLOGY, V186, P261, DOI 10.1016/0042-6822(92)90080-9; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; SMITH PD, 1992, GASTROENTEROL CLIN N, V21, P331; STEIN CA, 1993, CANCER RES, V53, P2239; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TUCKER SP, 1993, ADV VIRUS RES, V42, P187, DOI 10.1016/S0065-3527(08)60086-X; YAHI N, 1992, J VIROL, V66, P4848, DOI 10.1128/JVI.66.8.4848-4854.1992; YAHI N, 1992, EUR J IMMUNOL, V22, P2495, DOI 10.1002/eji.1830221005	40	75	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24349	24353						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929093				2022-12-25	WOS:A1994PQ34600077
J	LIU, J; LAUE, TM; CHOI, HU; TANG, LH; ROSENBERG, L				LIU, J; LAUE, TM; CHOI, HU; TANG, LH; ROSENBERG, L			THE SELF-ASSOCIATION OF BIGLYCAN FROM BOVINE ARTICULAR-CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; MOLECULAR-WEIGHT; I BIGLYCAN; PG-I; DECORIN; FIBRONECTIN; ADHESION; TENDON; FIBROBLASTS; PROTEIN	Biglycan is a small dermatan sulfate proteoglycan present in the extracellular matrix of a variety of connective tissues. Sedimentation velocity and equilibrium studies were carried out to determine the monomer molecular weight of biglycan in denaturing solvents and to define the oligomeric states of biglycan in physiologic solvents in the presence and absence of Zn2+. In 6 M guanidine chloride, biglycan is a monomer with s(20,w)(0) = 2.9 S and M(z) = 93,100 (where M(z) is z-average molecular weight). In 0.15 m NaCl, 50 mM Tris, pH 7.5, in the absence of divalent metal ions, and at concentrations above 1 mg/ml, biglycan is predominantly dimer (s(20,w)(0) = 4.8 S). Under these same conditions in solvent containing 5 mM Zn2+, biglycan exists predominantly as a hexamer, with s(20,w)(0) = 9.4 S and M(z) approximate to 600,000. In either case, the oligomers dissociate reversibly. In order to determine whether the glycosaminoglycan chains or the core protein was responsible for self-association, sedimentation velocity and sedimentation equilibrium studies were conducted on the isolated components. Dermatan sulfate chains prepared from biglycan, examined in both denaturing and physiologic solvents, show no significant difference in molecular weight (M(z) approximate to 22,000), whether or not the solvents contain Zn2+. However, biglycan core protein strongly self-associated in physiologic solvents. Thus, the self-association of biglycan appears to be mediated by the core protein and not by its glycosaminoglycan chains.	UNIV NEW HAMPSHIRE,DEPT BIOCHEM & MOLEC BIOL,DURHAM,NH 03824; MONTEFIORE MED CTR,ORTHOPAED RES LAB,BRONX,NY 10467	University System Of New Hampshire; University of New Hampshire; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine			Laue, Tom/AAI-5136-2020	Laue, Tom/0000-0003-3571-9368	NIAMS NIH HHS [AR21498, AR34614] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR034614, R37AR021498] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARAKAWA T, 1987, J BIOL CHEM, V262, P7484; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; CANN JR, 1970, INTERACTING MACROMOL, P93; CHOI HU, 1989, J BIOL CHEM, V264, P2876; COSTER L, 1987, J BIOL CHEM, V262, P3809; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; FISHER LW, 1989, J BIOL CHEM, V264, P4571; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KAWAHARA K, 1966, J BIOL CHEM, V241, P3228; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Laue T. M., 1992, ANAL ULTRACENTRIFUGA, P63; LAUE TM, 1994, PROG COLL POL SCI S, V94, P74; LAUE TM, 1992, SHORT COLUMN EQUILIB; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; LIU J, 1993, THESIS U NEW HAMPSHI; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; PERLMANN GE, 1948, J AM CHEM SOC, V70, P2719, DOI 10.1021/ja01188a027; ROARK DE, 1969, ANN NY ACAD SCI, V164, P245, DOI 10.1111/j.1749-6632.1969.tb14043.x; ROSENBERG L, 1993, DERMATAN SULPHATE PR, P225; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCOTT PG, 1989, MATRIX, V9, P284, DOI 10.1016/S0934-8832(89)80004-6; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; VOGEL KG, 1986, J BIOL CHEM, V261, P1334; VOGEL KG, 1985, J BIOL CHEM, V260, P9298; VOGEL KG, 1987, J BIOL CHEM, V262, P13607; WASTESON A, 1971, BIOCHEM J, V122, P477, DOI 10.1042/bj1220477; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YPHANTIS DA, 1960, ANN NY ACAD SCI, V88, P586, DOI 10.1111/j.1749-6632.1960.tb20055.x	32	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28366	28373						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961776				2022-12-25	WOS:A1994PV77200088
J	MORDENTE, A; SANTINI, SA; MIGGIANO, GAD; MARTORANA, GE; PETITTI, T; MINOTTI, G; GIARDINA, B				MORDENTE, A; SANTINI, SA; MIGGIANO, GAD; MARTORANA, GE; PETITTI, T; MINOTTI, G; GIARDINA, B			THE INTERACTION OF SHORT-CHAIN COENZYME-Q ANALOGS WITH DIFFERENT REDOX STATES OF MYOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENTIAL PROTECTIVE MECHANISM; VITAMIN-E; LIPID-PEROXIDATION; FERRYL-MYOGLOBIN; REPERFUSION INJURY; UBIQUINOL HOMOLOGS; MOLECULAR-OXYGEN; RAT-HEART; TROLOX-C; REDUCTION	Two equivalent oxidation of metmyoglobin (Mb(III)) by hydrogen peroxide (H2O2) yields an oxoferryl moiety (Mb(IV)) plus a protein radical which presumably originates from the conversion of tyrosines to tyrosyl radicals (.Mb(IV)). In the absence of electron donors, Mb(III) oxidation is followed by (i) heme degradation or (ii) tyrosyl radical-dependent reactions, such as irreversible dimerization or covalent binding of the heme group to the apoprotein. Moreover, the oxidizing equivalents of H2O2-activated Mb(III) promote the peroxidative decomposition of polyunsaturated fatty acids. In this study, water soluble short chain coenzyme Q analogs (CoQ(1)H(2) and CoQ(2)H(2)) were found to reduce the oxoferryl moiety, preventing heme degradation and regenerating Mb(III) and, more slowly, Mb(II)O(2). CoQ(1)H(2) and CoQ(2)H(2) were also found to reduce tyrosyl radicals generated by UV irradiation of tyrosine solutions. Accordingly, CoQ(1)H(2) and CoQ(2)H(2) effectively prevented tyrosyl radical-dependent reactions such as the dimerization of sperm whale myoglobin and heme-apoprotein covalent binding in horse heart myoglobin. By competing for the oxidizing equivalents of hypervalent myoglobin, CoQ(1)H(2) and CoQ(2)H(2) also prevented the peroxidation of arachidonic acid. Collectively, these studies suggest that the proposed function of coenzyme Q as a naturally occurring antioxidant might well relate to its ability of reducing H2O2-activated myoglobin. Coenzyme Q should therefore mitigate cardiac or muscular dysfunctions that are caused by an abnormal generation of H2O2.	UNIV CATTOLICA SACRO CUORE, SCH MED, INST PHARMACOL, I-00168 ROME, ITALY; UNIV CATTOLICA SACRO CUORE, SCH MED, INST CHEM & CLIN CHEM, I-00168 ROME, ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	MORDENTE, A (corresponding author), UNIV CATTOLICA SACRO CUORE, SCH MED, INST BIOL CHEM, LARGO F VITO 1, I-00168 ROME, ITALY.		Petitti, Tommasangelo/J-5023-2012; Mordente, Alvaro/AAB-7290-2019; Petitti, Tommasangelo/AAN-1884-2021	Petitti, Tommasangelo/0000-0002-5585-9475; Minotti, Giorgio/0000-0002-5678-6175; MORDENTE, Alvaro/0000-0003-3260-9796				ABERG F, 1992, ARCH BIOCHEM BIOPHYS, V295, P230, DOI 10.1016/0003-9861(92)90511-T; ARDUINI A, 1992, FREE RADICAL BIO MED, V13, P449, DOI 10.1016/0891-5849(92)90185-J; ARDUINI A, 1990, ARCH BIOCHEM BIOPHYS, V281, P41, DOI 10.1016/0003-9861(90)90410-Z; ARDUINI A, 1990, FREE RADICAL BIO MED, V9, P511, DOI 10.1016/0891-5849(90)90130-B; Ascoli F, 1981, Methods Enzymol, V76, P72; BENDAHAN D, 1992, NEUROLOGY, V42, P1203, DOI 10.1212/WNL.42.6.1203; BEYER RE, 1990, FREE RADICAL BIO MED, V8, P545, DOI 10.1016/0891-5849(90)90154-B; Buege J A, 1978, Methods Enzymol, V52, P302; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; EDDY L, 1990, AM J PHYSIOL, V259, pC995, DOI 10.1152/ajpcell.1990.259.6.C995; FORSMARK P, 1991, FEBS LETT, V285, P39, DOI 10.1016/0014-5793(91)80720-N; GALARIS D, 1989, ARCH BIOCHEM BIOPHYS, V273, P497, DOI 10.1016/0003-9861(89)90509-2; GALARIS D, 1989, BIOCHEM BIOPH RES CO, V160, P1162, DOI 10.1016/S0006-291X(89)80125-1; GALARIS D, 1989, FREE RADICAL BIO MED, V6, P473, DOI 10.1016/0891-5849(89)90039-7; GIULIVI C, 1992, ARCH BIOCHEM BIOPHYS, V299, P302, DOI 10.1016/0003-9861(92)90279-6; GIULIVI C, 1993, ARCH BIOCHEM BIOPHYS, V303, P152, DOI 10.1006/abbi.1993.1266; GREENBERG SM, 1988, MED CLIN N AM, V72, P243, DOI 10.1016/S0025-7125(16)30792-1; GRISHAM M B, 1985, Journal of Free Radicals in Biology and Medicine, V1, P227, DOI 10.1016/0748-5514(85)90122-9; HOLLER TP, 1989, ANAL BIOCHEM, V180, P326, DOI 10.1016/0003-2697(89)90440-5; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; JANIG GR, 1984, BIOCHIM BIOPHYS ACTA, V787, P8, DOI 10.1016/0167-4838(84)90102-X; KAGAN VE, 1990, FREE RADICAL BIO MED, V9, P117, DOI 10.1016/0891-5849(90)90114-X; KANNER J, 1985, ARCH BIOCHEM BIOPHYS, V237, P314, DOI 10.1016/0003-9861(85)90282-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDI L, 1991, FREE RADICAL RES COM, V14, P1, DOI 10.3109/10715769109088935; LENAZ G, 1992, BIOCHEM CELL BIOL, V70, P504, DOI 10.1139/o92-078; MATSUSHIMA T, 1992, J THORAC CARDIOV SUR, V103, P945; MINOTTI G, 1993, CHEM RES TOXICOL, V6, P134, DOI 10.1021/tx00032a001; MITSOS SE, 1988, LAB INVEST, V59, P824; MORDENTE A, 1992, BIOCHIM BIOPHYS ACTA, V1100, P235, DOI 10.1016/0167-4838(92)90477-U; MORDENTE A, 1993, CLIN INVESTIGATOR, V71, pS92; MUKAI K, 1992, J BIOL CHEM, V267, P22277; NOHL H, 1992, FREE RADICAL RES COM, V16, P409, DOI 10.3109/10715769209049191; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; RADI R, 1991, J BIOL CHEM, V266, P22028; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; ROMERO FJ, 1992, J BIOL CHEM, V267, P1680; RYAN TP, 1992, CRIT REV TOXICOL, V22, P119, DOI 10.3109/10408449209146308; SHIMOMURA Y, 1991, BIOCHEM BIOPH RES CO, V176, P349, DOI 10.1016/0006-291X(91)90931-V; STOCKER R, 1993, BIOCHIM BIOPHYS ACTA, V1158, P15, DOI 10.1016/0304-4165(93)90090-U; TAKAHASHI T, 1993, LIPIDS, V28, P803, DOI 10.1007/BF02536234; TEW D, 1988, J BIOL CHEM, V263, P17880; TURNER JJO, 1991, BIOCHEM J, V277, P833, DOI 10.1042/bj2770833; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; WAZAWA T, 1992, BIOPHYS J, V63, P544, DOI 10.1016/S0006-3495(92)81608-9; WU F, 1994, BBA-MOL BASIS DIS, V1225, P158, DOI 10.1016/0925-4439(94)90073-6; YU L, 1986, BIOCHIM BIOPHYS ACTA, V848, P305, DOI 10.1016/0005-2728(86)90204-5	47	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27394	27400						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961650				2022-12-25	WOS:A1994PV77100040
J	NASSAR, GM; MORROW, JD; ROBERTS, LJ; LAKKIS, FG; BADR, KF				NASSAR, GM; MORROW, JD; ROBERTS, LJ; LAKKIS, FG; BADR, KF			INDUCTION OF 15-LIPOXYGENASE BY INTERLEUKIN-13 IN HUMAN BLOOD MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RETICULOCYTE LIPOXYGENASE; ATHEROSCLEROTIC LESIONS; CYTOKINE PRODUCTION; GENE-EXPRESSION; MESSENGER-RNA; CELL FUNCTION; ACID; MACROPHAGES; OXYGENATION	15-lipoxygenase (15-LO) catalyzes hydroperoxidation of fatty acids, a reaction of potential relevance to inflammation, membrane remodeling, and atherosclerosis. In human leukocytes, 15-lipoxygenation of arachidonic acid produces 15-(S)hydroxyeicosatetraenoic acid and lipoxin A4, which suppress white cell chemotaxis, adherence, and activation, and antagonize proinflammatory leukotrienes. Interleukin (IL)-13, produced by T-helper subset 2 (TH-2) lymphocytes, specifically and potently induced 15-LO gene expression and enzyme activity in human monocytes. Among other TH-2 lymphokines, this induction of 15-LO is shared by IL-4 but not by IL-10. Interferon-gamma, a product of TH-1 lymphocytes, blocked IL-13-mediated induction of 15-LO. The induction of the anti-inflammatory 15-LO pathway by IL-13 reveals a new facet of IL-13 biology that supports its role as a cytokine with potential to down-regulate inflammatory pathways. The contrasting effects of interferon-gamma and IL-13 on 15-LO induction demonstrate mechanisms by which T-lymphocyte subsets may modulate macrophage/monocyte function in inflammation or atherosclerosis.	EMORY UNIV,DEPT MED,DIV RENAL,ATLANTA,GA 30033; VET AFFAIRS MED CTR,ATLANTA,GA 30033; VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Vanderbilt University; Vanderbilt University			Nassar, George/T-2400-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43883] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADR KF, 1992, J AM SOC NEPHROL, V3, P907; BADR KF, 1992, KIDNEY INT, V42, pS101; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOTTA F, 1994, J BIOL CHEM, V269, P12403; CONARD DJ, 1992, P NATL ACAD SCI USA, V89, P217; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FISHER DB, 1992, KIDNEY INT, V41, P1155; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; FORDHUTCHINSON AW, 1991, EICOSANOIDS, V4, P65; KATOH T, 1994, KIDNEY INT, V46, P341, DOI 10.1038/ki.1994.280; KLAUSNER JM, 1990, CANCER-AM CANCER SOC, V66, P2357, DOI 10.1002/1097-0142(19901201)66:11<2357::AID-CNCR2820661118>3.0.CO;2-J; KUHN H, 1990, J BIOL CHEM, V265, P18351; LAKKIS FG, 1993, BIOCHEM BIOPH RES CO, V197, P612, DOI 10.1006/bbrc.1993.2523; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MESLIER N, 1992, AM J RESP CELL MOL, V6, P93, DOI 10.1165/ajrcmb/6.1.93; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURRAY JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P514, DOI 10.1016/0003-9861(88)90156-7; NIGMAN S, 1990, J CELL PHYSL, V143, P512; Papayianni A., 1993, Journal of the American Society of Nephrology, V4, P627; POWRIE F, 1993, IMMUNOL TODAY, V14, P270, DOI 10.1016/0167-5699(93)90044-L; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SIGAL E, 1990, J BIOL CHEM, V265, P5113; SPARROW CP, 1988, J LIPID RES, V29, P745; WONG HL, 1993, J EXP MED, V177, P775, DOI 10.1084/jem.177.3.775; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959	36	206	209	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27631	27634						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961680				2022-12-25	WOS:A1994PV77100073
J	CUERVO, AM; TERLECKY, SR; DICE, JF; KNECHT, E				CUERVO, AM; TERLECKY, SR; DICE, JF; KNECHT, E			SELECTIVE BINDING AND UPTAKE OF RIBONUCLEASE-A AND GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE BY ISOLATED RAT-LIVER LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN TRANSLOCATION; AUTOPHAGIC VACUOLE; PRECURSOR PROTEIN; DEGRADATION; MITOCHONDRIA; IMPORT; PROTEOLYSIS; MECHANISMS; MEMBRANE	Ribonuclease A (RNase A) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are selectively taken up and degraded by isolated rat liver lysosomes by very similar processes. The uptake and degradation of both of these proteins are stimulated by the heat shock cognate protein of 73 kDa and ATP/Mg2+. Both binding and uptake of RNase A and GAPDH by lysosomes are saturable, and uptake of RNase A and GAPDH requires a protease-sensitive component within the lysosomal membrane. GAPDH competes for binding and uptake of RNase A by lysosomes and vice versa while another protein, ovalbumin, does not compete. RNase S-peptide (amino acids 1-20 of RNase A) also competes for RNase A binding and uptake by lysosomes, while RNase S-protein (amino acids 21-124 of RNase A) does not compete. The uptake of RNase A by lysosomes appears to involve an intermediate step in which approximately 2 kDa of the polypeptide's COOH terminus remains outside lysosomes while the remainder is inside the lysosomal lumen.	FDN VALENCIANA INVEST BIOMED,INST INVEST CITOL,E-46010 VALENCIA,SPAIN; TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111	Tufts University			Knecht, Erwin/K-2432-2014; Knecht, Erwin/A-9366-2014	Knecht, Erwin/0000-0002-7208-3832; Cuervo, Ana Maria/0000-0002-0771-700X	NIA NIH HHS [AG06116] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006116, R37AG006116] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHLBERG J, 1982, LAB INVEST, V47, P523; ANIENTO F, 1993, J BIOL CHEM, V268, P10463; BACKER JM, 1983, P NATL ACAD SCI-BIOL, V80, P2166, DOI 10.1073/pnas.80.8.2166; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BUEHNER M, 1974, J MOL BIOL, V90, P25, DOI 10.1016/0022-2836(74)90254-X; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; DETER RL, 1971, J CELL BIOL, V48, P473, DOI 10.1083/jcb.48.3.473; Dice J F, 1990, Semin Cell Biol, V1, P449; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DOHERTY FJ, 1989, BIOCHEM J, V263, P47, DOI 10.1042/bj2630047; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; Marzella L, 1987, LYSOSOMES THEIR ROLE, P319; MORIMOTO T, 1983, METHOD ENZYMOL, V97, P408; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PAK YK, 1990, J BIOL CHEM, V265, P14298; Pfeifer U., 1987, LYSOSOMES THEIR ROLE, P3; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; SCHATZ G, 1993, PROTEIN SCI, V2, P141; Seglen P O, 1990, Semin Cell Biol, V1, P441; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; UENO T, 1991, J BIOL CHEM, V266, P18995; VARGAS JL, 1990, EUR J BIOCHEM, V188, P99, DOI 10.1111/j.1432-1033.1990.tb15376.x; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229	35	107	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26374	26380						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929357				2022-12-25	WOS:A1994PQ93000067
J	HUANG, S; FORTUNE, KP; WANK, SA; KOPIN, AS; GARDNER, JD				HUANG, S; FORTUNE, KP; WANK, SA; KOPIN, AS; GARDNER, JD			MULTIPLE AFFINITY STATES OF DIFFERENT CHOLECYSTOKININ RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; FUNCTIONAL EXPRESSION; GASTRIN RECEPTOR; ANTAGONIST RADIOLIGAND; MOLECULAR-CLONING; PARIETAL-CELLS; CCK; BINDING; BRAIN; L365,260	We transfected COS cells with cDNA for rat cholecystokinin-A (CCK-A) and different CCK-B receptors and measured binding of I-125-CCK-8, [H-3]L-364,718 and [H-3]L-365,260 to characterize the different affinity states for each type of CCH receptor. Rat CCK-A and CCK-B receptors, canine CCK-B receptors and canine mutant CCK-B (M-CCK-B) receptors in which the leucine in position 355 was replaced by valine each existed in three differ ent affinity states for CCK-8, high affinity, low affinity, and very ion: affinity. In rat CCK-A and probably CCK-B receptors, most were in the very low affinity state, whereas with canine CCK-B and M-CCK-B receptors, most were in the low affinity state. Studies with CCK receptor agonists, CCK-8, gastrin, and CCK-JMV-180, in conjunction with CCK receptor antagonists, L-364,718 and L-365,260, showed a different pattern of affinities for these ligands at the different CCK receptors. Thus, each transfected CCK receptor can exist in three different affinity states for CCK-8 and has a characteristic pattern of interaction with different ligands. This ability to exist in multiple affinity states is an intrinsic property of the CCK receptor molecule itself.	ST LOUIS UNIV,HLTH SCI CTR,DEPT INTERNAL MED,ST LOUIS,MO 63104; NIDDK,DIGEST DIS BRANCH,BETHESDA,MD 20892; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GASTROENTEROL,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,CTR GASTROENTEROL RES ABSORPY,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,CTR SECRETORY PROC DIGEST DIS,BOSTON,MA 02111	Saint Louis University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University					NHLBI NIH HHS [HL23632] Funding Source: Medline; NIEHS NIH HHS [ES00210] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; CHANG RSL, 1989, MOL PHARMACOL, V35, P803; CHANG RSL, 1986, MOL PHARMACOL, V30, P212; HUANG SC, 1989, AM J PHYSIOL, V257, pG169, DOI 10.1152/ajpgi.1989.257.1.G169; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LEE YM, 1993, J BIOL CHEM, V268, P8164; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; PRESTI ME, 1993, AM J PHYSIOL, V264, pG399, DOI 10.1152/ajpgi.1993.264.3.G399; ROCHE S, 1991, AM J PHYSIOL, V260, pG182, DOI 10.1152/ajpgi.1991.260.2.G182; SOLL AH, 1984, J CLIN INVEST, V73, P1434, DOI 10.1172/JCI111348; TALKAD VD, 1994, P NATL ACAD SCI USA, V91, P1868, DOI 10.1073/pnas.91.5.1868; TALKAD VD, 1994, IN PRESS BIOCH BIOPH; VINAYEK R, 1993, BIOCHIM BIOPHYS ACTA, V1176, P183, DOI 10.1016/0167-4889(93)90195-U; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; YU DH, 1987, AM J PHYSIOL, V253, pG793, DOI 10.1152/ajpgi.1987.253.6.G793	19	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26121	26126						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929324				2022-12-25	WOS:A1994PQ93000030
J	VALCARCE, C; HOLMGREN, A; STENFLO, J				VALCARCE, C; HOLMGREN, A; STENFLO, J			CALCIUM-DEPENDENT INTERACTION BETWEEN GAMMA-CARBOXYGLUTAMIC ACID-CONTAINING AND N-TERMINAL EPIDERMAL GROWTH FACTOR-LIKE MODULES IN FACTOR-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-IX; BOVINE FACTOR-X; BLOOD-COAGULATION FACTOR; EGF-LIKE DOMAIN; STUART FACTOR; CONTAINING REGION; BINDING-SITE; CA2+ BINDING; LIGHT CHAIN; FACTOR-VA	The N-terminal epidermal growth factor (EGF)-like module in factor X binds a single ca(2+) with low affinity (K-d = 2.2 mM). When it is linked to the gamma-carboxyglutamic acid (Gla)-containing module, however, the affinity increases approximately 20-fold (K-d = 120 mu M), indicating an interaction between the two modules and making the site in the N-terminal EGF-like module essentially saturated at physiological Ca2+ concentrations. We have now used the thioredoxin system to probe Ca2+-induced conformational changes and interaction between modules in the light chain of factor X. Thioredoxin, in conjunction with thioredoxin reductase and NADPH, allows direct measurements of the rate and extent of disulfide bond reduction. Most disulfide bonds accessible to the reducing agent were found to be located in the light chain of the protein. Moreover, those disulfide bonds that were resistant to reduction by thioredoxin in the presence of Ca2+, but were readily reduced in the absence of the metal ion, were located in the N-terminal EGF-like module and in the Gla module, whereas disulfide bonds in the C-terminal EGF-like module appeared to be equally accessible whether Ca2+ was present or not. Comparison of the rate of disulfide bond reduction in the isolated modules with that in mixtures of modules indicated that a Ca2+-dependent interaction occurred between the Gla and the N-terminal EGF-like module. This interaction was mediated by the C-terminal alpha-helical part of the Gla module. The affinity between the modules was low and could not be determined accurately owing to competing equilibria, presumably Ca2+ dependent aggregation of the isolated Gla module. By comparing the rates of disulfide bond reduction in Gla module containing fragments before and after decarboxylation of Gla, we could demonstrate that Ca2+ binding to sites in the Gla module as well as to the single site in the EGF-like module contribute to the interaction between the two modules.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; KAROLINSKA INST,MED NOBEL INST BIOCHEM,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN	Lund University; Karolinska Institutet								BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BARON M, 1992, PROTEIN SCI, V1, P81; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ENFIELD DL, 1980, BIOCHEMISTRY-US, V19, P659, DOI 10.1021/bi00545a009; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4882, DOI 10.1021/bi00776a002; FUNG MR, 1984, NUCLEIC ACIDS RES, V12, P4481, DOI 10.1093/nar/12.11.4481; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GIANNELLI F, 1993, NUCLEIC ACIDS RES, V21, P3075, DOI 10.1093/nar/21.13.3075; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATUREJ, V351, P84; HARLOS K, 1987, NATURE, V330, P82, DOI 10.1038/330082a0; HENRIKSEN RA, 1975, ARCH BIOCHEM BIOPHYS, V170, P149, DOI 10.1016/0003-9861(75)90106-X; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; JACKSON CM, 1972, BIOCHEMISTRY-US, V11, P4873, DOI 10.1021/bi00776a001; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LIN SW, 1990, J BIOL CHEM, V265, P144; MANN KG, 1990, BLOOD, V76, P1; MEDVED LV, 1994, BIOCHEMISTRY-US, V33, P478, DOI 10.1021/bi00168a012; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1993, J BIOL CHEM, V268, P22531; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SAVIDGE G, 1979, THROMB RES, V16, P587, DOI 10.1016/0049-3848(79)90204-4; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; STENFLO J, 1976, J BIOL CHEM, V251, P355; Stenflo J., 1994, MOL BASIS BLOOD DIS, P565; SUGO T, 1986, J BIOL CHEM, V261, P5116; SUGO T, 1984, J BIOL CHEM, V259, P5705; TITANI K, 1975, P NATL ACAD SCI USA, V72, P3082, DOI 10.1073/pnas.72.8.3082; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; VALCARCE C, 1994, METHDOS ENZYMOL, V222, P416; VYSOTCHIN A, 1993, J BIOL CHEM, V268, P8436; [No title captured]	39	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26011	26016						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929311				2022-12-25	WOS:A1994PQ93000015
J	TOURNIER, JM; POLETTE, M; HINNRASKY, J; BECK, J; WERB, Z; BASBAUM, C				TOURNIER, JM; POLETTE, M; HINNRASKY, J; BECK, J; WERB, Z; BASBAUM, C			EXPRESSION OF GELATINASE-A, A MEDIATOR OF EXTRACELLULAR-MATRIX REMODELING, BY TRACHEAL GLAND SEROUS CELLS IN CULTURE AND IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; IV COLLAGENASE; TISSUE INHIBITOR; MONOCLONAL-ANTIBODIES; MAMMARY-GLAND; METALLOPROTEINASES; PROTEIN; DEGRADATION; PROGELATINASE; LOCALIZATION	Tracheal gland morphogenesis and gland hypertrophy in disease involve the penetration of epithelial cells into the submucosa, a process that requires digestion of the basal lamina and the surrounding extracellular matrix. We observed that bovine tracheal gland cells invaded collagen substrates and were inhibited from doing so in the presence of a metalloproteinase inhibitor GM6001. The gland cells, but not bovine tracheal surface epithelial cells, secreted a 72-kDa metalloproteinase. The purified enzyme could be activated with 4-aminophenylmercuric acetate and converted to an active 65-kDa form that was far more effective in degrading denatured collagen (gelatin) than nondenatured type I and IV collagens and was ineffective in degrading intact interstitial collagen fibers. At 25 degrees C, the initial rate of degradation of acid-solubilized type I collagen was approximately 50 mg of type I collagen cleaved per min per mg of enzyme, whereas acid-solubilized type IV collagen was degraded at approximately 250 mg cleaved per min per mg of enzyme. In contrast, at the same temperature, heat-denatured type I collagen was degraded 1000-fold more rapidly, while heat-denatured type IV collagen was cleaved 50-fold more rapidly, The activity of the enzyme was maximal at pH 7-8 and was completely abolished by the metalloproteinase inhibitors EDTA and 1,10-phenanthroline. In immunoblots, the enzyme was recognized by an antibody directed against human gelatinase A, the 72-kDa gelatinase. The purified enzyme disrupted the distribution pattern of type IV collagen in the gland basal lamina, as well as of interstitial collagen in the underlying stromal tissue, as shown in tissue sections by immunocytochemistry. Using an antibody directed against the purified enzyme, we also showed by immunocytochemistry that the gelatinase was present in tracheal tissue and was specifically located at the periphery of some tracheal gland acini. Northern blots showed higher concentrations of gelatinase A mRNA in glands than in epithelium microdissected from adult cow tracheas, These data indicate that gelatinase A is a specialized product of the tracheal gland epithelial cell, a cell type normally invasive as part of its developmental program; the enzyme may play an important role in normal gland development and disease-associated hypertrophy.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; INSERM,U314,F-51092 REIMS,FRANCE	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Institut National de la Sante et de la Recherche Medicale (Inserm)			POLETTE, Myriam/P-5147-2016; Tournier, Jean-Marie/P-5667-2016	POLETTE, Myriam/0000-0001-8173-3246	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43762, HL24136] Funding Source: Medline; NIDCR NIH HHS [DE10306] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASBAUM CB, 1981, CELL TISSUE RES, V220, P481, DOI 10.1007/BF00216752; BENALI R, 1993, AM J PHYSIOL, V8, pL183; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOWES D, 1977, THORAX, V32, P163, DOI 10.1136/thx.32.2.163; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHER U., 1961, THORAX, V16, P219, DOI 10.1136/thx.16.3.219; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CRAIG FM, 1991, BIOCHIM BIOPHYS ACTA, V1074, P243, DOI 10.1016/0304-4165(91)90159-E; CURRY VA, 1992, BIOCHEM J, V285, P143, DOI 10.1042/bj2850143; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; FINKBEINER WE, 1988, AM J PATHOL, V131, P290; FINKBEINER WE, 1986, IN VITRO CELL DEV B, V22, P561, DOI 10.1007/BF02623514; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; HOYHTYA M, 1988, FEBS LETT, V233, P109, DOI 10.1016/0014-5793(88)81365-6; INFELD MD, 1993, AM J RESP CELL MOL, V8, P69, DOI 10.1165/ajrcmb/8.1.69; JACQUOT J, 1990, FEBS LETT, V269, P65, DOI 10.1016/0014-5793(90)81119-9; JEFFERY PK, 1992, EUR RESPIR J, V5, P93; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB D, 1969, BRIT MED J, V1, P33, DOI 10.1136/bmj.1.5635.33; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LIM M, 1993, PEDIATR PULM S, V9, P183; MACKAY AR, 1990, CANCER RES, V50, P5997; MACKAY AR, 1990, J BIOL CHEM, V265, P21929; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MEYRICK B, 1977, MUCUS HLTH DISEASE, V2, P61; MOLL UM, 1990, CANCER RES, V50, P6162; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; NAGASE H, 1991, BIOCHEM SOC T, V19, P715, DOI 10.1042/bst0190715; NILES R, 1988, IN VITRO CELL DEV B, V24, P457; OVERALL C, 1991, J CELL BIOL, V115, P139; PETERKOFSKY B, 1982, METHOD ENZYMOL, V82, P453; REID L, 1963, BRIT J EXP PATHOL, V44, P437; REID LM, 1954, LANCET, V1, P275; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; SALONEN J, 1991, MATRIX, V11, P43, DOI 10.1016/S0934-8832(11)80226-X; SCHULTZ GS, 1992, INVEST OPHTH VIS SCI, V33, P3325; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; TALHOUK RS, 1991, DEVELOPMENT, V112, P439; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TOS M, 1968, Anatomischer Anzeiger, V123, P376; TOURNIER JM, 1992, AM J RESP CELL MOL, V6, P461, DOI 10.1165/ajrcmb/6.5.461; TOURNIER JM, 1990, AM REV RESPIR DIS, V141, P1280, DOI 10.1164/ajrccm/141.5_Pt_1.1280; TOURNIER JM, 1991, AM REV RESPIR DIS, V143, P403; WERB Z, 1975, BIOCHEM J, V151, P645, DOI 10.1042/bj1510645; WERB Z, 1993, TXB RHEUMATOLOGY, P248; WU R, 1985, J CELL PHYSIOL, V125, P167, DOI 10.1002/jcp.1041250202	52	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25454	25464						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929245				2022-12-25	WOS:A1994PQ49100038
J	CHANG, HCJ; LINDQUIST, S				CHANG, HCJ; LINDQUIST, S			CONSERVATION OF HSP90 MACROMOLECULAR COMPLEXES IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; STEROID-RECEPTORS; POLYACRYLAMIDE GELS; CELLULAR PROTEINS; INDUCIBLE GENE; PEP4 GENE; YEAST; COMPONENT; BINDING; KINASE	In higher eukaryotic cells, the Hsp90 chaperone protein is found in complexes with other proteins, in addition to the substrate protein. These other proteins include Hsp70, p60, and several peptidyl-prolyl cis trans isomerases (immunophilins). We utilized affinity chromatography to investigate whether Hsp82, the Hsp90 of Saccharomyces cerevisiae, is found in similar complexes in that organism. Six histidine residues were fused to the N terminus of Hsp82 to yield a fusion protein (Hsp82(FP)) with affinity for a nickel-ion matrix. Hsp82(FP) was shown to have wild type function. In addition, when mammalian substrates of Hsp90 (glucocorticoid receptor and p60(v-src)) were expressed in yeast cells, these proteins bound to the affinity matrix only when isolated from cells containing Hsp82(FP). Yeast homologs of Hsp70 (in particular, members of the Ssa subfamily), p60 (Sti1), and a 45-kDa immunophilin homolog were also isolated; in this manner, by virtue of their specific, stable association with Hsp82. Thus, Hsp90 functions as part of a highly conserved macromolecular complex in eukaryotes.	UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago			Foreman, Hui-Chen (Jane)/GMW-4448-2022	Foreman, Hui-Chen (Jane)/0000-0001-9640-9780				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; CRAIG EA, 1990, STRESS PROTEINS BIOL; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; GASSER CS, 1990, P NATL ACAD SCI USA, V87, P9519, DOI 10.1073/pnas.87.24.9519; INGOLIA TD, 1982, MOL CELL BIOL, V2, P1388, DOI 10.1128/MCB.2.11.1388; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; PRATT WB, 1992, J STEROID BIOCHEM, V41, P223, DOI 10.1016/0960-0760(92)90348-M; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RICKEY C, 1990, MOL BIOL REP, V9, P2; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TAI PKK, 1993, BIOCHEMISTRY-US, V32, P8842, DOI 10.1021/bi00085a015; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOELLMY R, 1983, J BIOL CHEM, V258, P3516; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	48	139	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24983	24988						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929182				2022-12-25	WOS:A1994PQ49000069
J	KRUTH, HS; SKARLATOS, SI; GAYNOR, PM; GAMBLE, W				KRUTH, HS; SKARLATOS, SI; GAYNOR, PM; GAMBLE, W			PRODUCTION OF CHOLESTEROL-ENRICHED NASCENT HIGH-DENSITY-LIPOPROTEINS BY HUMAN MONOCYTE-DERIVED MACROPHAGES IS A MECHANISM THAT CONTRIBUTES TO MACROPHAGE CHOLESTEROL EFFLUX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN-E; HYPERLIPIDEMIC RABBIT; A-I; ATHEROSCLEROSIS; METABOLISM; TRANSPORT; SECRETION; VESICLES; PLAQUES; ATHEROGENESIS	Atherosclerotic lesions have a lipid core containing crystals and liposomes enriched in unesterified cholesterol as well as numerous monocyte-macrophages enriched in cholesteryl ester. Sufficient amounts of plasma-derived high density lipoproteins (HDL) may not reach and efficiently remove the cholesterol deposited in lesion macrophages or in the lipid core of lesions. We examined the potential of human monocyte-macrophages to produce nascent HDL and to solubilize cholesterol derived from interaction of monocyte-macrophages with lipoprotein and non-lipoprotein sources of cholesterol. Monocyte-macrophages produced discoidal (25 +/- 6 nm long and 6 +/- 1 nm wide (mean +/- S.D.)) and vesicular (89 +/- 41 nm in diameter) lipoprotein particles following and during enrichment of macrophages with cholesterol from acetylated low density lipoprotein (AcLDL) or cholesterol crystals. During cholesterol enrichment, discoidal particles progressively accumulated in the medium for up to 6 days. In contrast, vesicles did not increase past 2 days of incubation. Both the discoidal and vesicular lipoprotein particles had a peak density of about 1.09-1.10 g/ml, The discoidal particles contained apolipoprotein E (apoE), whereas the vesicles contained a major protein constituent with a molecular mass of 22,000 daltons. The vesicles did not contain detectable apoE and the 22,000-dalton protein was not the 22,000-dalton thrombolytic fragment of apoE. Following cholesterol enrichment of macrophages with AcLDL or cholesterol crystals, macrophages excreted much of their accumulated cholesterol, even in the absence of exogenously added cholesterol accepters. Most of this excreted cholesterol was recovered from the culture medium and was carried in the apoE discoidal particles that showed cholesterol enrichment up to a 2:1 unesterified cholesterol to phospholipid molar ratio. The findings suggest that sufficient production of these nascent HDL by macrophages within atherosclerotic lesions should facilitate removal of cellular and extracellular cholesterol, even in the absence of plasma-derived HDL.	OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA	Oregon State University	KRUTH, HS (corresponding author), NHLBI, EXPTL ATHEROSCLEROSIS SECT, BLDG 10, RM 5N-113, BETHESDA, MD 20892 USA.							BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BASU SK, 1982, J BIOL CHEM, V257, P9788; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; CHAO FF, 1994, J LIPID RES, V35, P71; CHAO FF, 1990, AM J PATHOL, V136, P169; DORY L, 1985, J LIPID RES, V26, P519; FALK E, 1992, CIRCULATION, V86, P30; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUSTER V, 1992, CIRCULATION, V86, P1; GAMBLE W, 1978, J LIPID RES, V19, P1068; GERRITY RG, 1981, AM J PATHOL, V103, P181; GUO LSS, 1982, J LIPID RES, V23, P543; GUYTON JR, 1990, EUR HEART J, V11, P20, DOI 10.1093/eurheartj/11.suppl_E.20; GUYTON JR, 1989, AM J PATHOL, V134, P705; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERSCOVITZ H, 1992, J LIPID RES, V33, P791; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; KATZ SS, 1980, J BIOL CHEM, V255, P9753; KOO C, 1985, J BIOL CHEM, V260, P1934; KRUL ES, 1982, FEBS LETT, V139, P259, DOI 10.1016/0014-5793(82)80865-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENICH C, 1988, J LIPID RES, V29, P755; LIN CT, 1986, J CLIN INVEST, V78, P947, DOI 10.1172/JCI112685; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1984, CHEM PHYS LIPIDS, V34, P307, DOI 10.1016/0009-3084(84)90004-5; MATSUURA JE, 1991, J LIPID RES, V32, P581; MORA R, 1990, J LIPID RES, V31, P1793; NAKAMURA H, 1992, ELECTRON MICROSC REV, V5, P129, DOI 10.1016/0892-0354(92)90008-E; PITAS RE, 1987, J BIOL CHEM, V262, P14352; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; ROBENEK H, 1988, ARTERIOSCLEROSIS, V8, P57, DOI 10.1161/01.ATV.8.1.57; ROHEIM PS, 1986, AM J CARDIOL, V57, pC3, DOI 10.1016/0002-9149(86)91020-9; SCHMITZ G, 1988, ARTERIOSCLEROSIS, V8, P46, DOI 10.1161/01.ATV.8.1.46; SIMIONESCU N, 1986, AM J PATHOL, V123, P109; Skarlatos S.I., 1992, J TISSUE CULT METHOD, V14, P113, DOI [10.1007/BF01409100, DOI 10.1007/BF01409100]; SOMJEN GJ, 1986, BIOCHIM BIOPHYS ACTA, V879, P14, DOI 10.1016/0005-2760(86)90260-2; SWANEY JB, 1985, CHEM PHYS LIPIDS, V37, P317, DOI 10.1016/0009-3084(85)90086-6; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WOLF AV, 1979, HDB CHEM PHYSICS, P227	44	82	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24511	24518						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929116				2022-12-25	WOS:A1994PQ34600101
J	LEES, JF; BULLEID, NJ				LEES, JF; BULLEID, NJ			THE ROLE OF CYSTEINE RESIDUES IN THE FOLDING AND ASSOCIATION OF THE COOH-TERMINAL PROPEPTIDE OF TYPE-I AND TYPE-III PROCOLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYNTHESIS; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; TRIPLE HELICES; COLLAGEN; PROTEIN; CHAIN; MUTATIONS; CONSERVATION; BIOSYNTHESIS	Procollagen chains assemble in a type-specific manner forming either homo- or heterotrimers. The molecular mechanisms underlying procollagen chain selectivity are unknown, although it is thought that the C-propeptide (COOH-terminal propeptide) is responsible for directing chain recognition and assembly. To define the processes involved in chain selection we reconstituted the initial stages of procollagen folding and assembly in a cell-free system. Using human pro-alpha 1(III) and pro-alpha 2(I) chains as prototypes of chains that are either capable or incapable of forming homotrimeric molecules, respectively, we constructed two minigenes p alpha 1(III)Delta 1 and p(alpha 2(I)Delta 1) that lacked most of the triple helical domains. The minigenes were transcribed in vitro and translated in a rabbit reticulocyte lysate supplemented with microsomal membranes under conditions that favored disulfide bond formation. Both pro-alpha 1(III)Delta 1 and pro-alpha 2(I)Delta 1 chains formed intrachain disulfide bonds within the C-propeptide. However, only pro-alpha 1(III)Delta 1 chains were able to self-associate forming homotrimers stabilized by interchain disulfide bonds. The C-propeptide of the pro-alpha 1(III) chain contains 8 cysteine residues (Cys-1-8). We used a site-directed mutagenesis to investigate the role of specific cysteine residues in trimer formation and found that substitution of serine for Cys-1, Cys-2, Cys-3, and Cys-4 prevented interchain disulfide bonding and trimerization. Furthermore, mutations in Cys-1 and Cys-4 also prevented intrachain disulfide bond formation within the C-propeptide. The C-propeptide of the pro-alpha 2(I) chain contains only 7 cysteine residues, lacking cysteine at position 2. Substitution of the existing Ser residue with Cys did not produce a homotrimeric phenotype, indicating that additional recognition signals are required to determine chain selection.			LEES, JF (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,2205 STOPFORD BLDG,OXFORD RD,MANCHESTER M13 9PT,LANCS,ENGLAND.			Bulleid, Neil/0000-0002-9839-5279	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALAKOKKO L, 1989, BIOCHEM J, V260, P509, DOI 10.1042/bj2600509; BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BULLEID NJ, 1992, BIOCHEM J, V286, P275, DOI 10.1042/bj2860275; BULLEID NJ, 1988, BIOCHEM J, V254, P805, DOI 10.1042/bj2540805; BYERS PH, 1975, P NATL ACAD SCI USA, V72, P3009, DOI 10.1073/pnas.72.8.3009; CHESSLER SD, 1993, J BIOL CHEM, V268, P18218; CHUNG E, 1974, SCIENCE, V183, P1200, DOI 10.1126/science.183.4130.1200; COPELAND CS, 1988, CELL, V53, P167; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HARALSON MA, 1980, P NATL ACAD SCI-BIOL, V77, P5206, DOI 10.1073/pnas.77.9.5206; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; Kielty Cay M., 1993, P103; KOIVU J, 1987, FEBS LETT, V212, P229, DOI 10.1016/0014-5793(87)81350-9; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KUIVANIEMI H, 1988, BIOCHEM J, V252, P633, DOI 10.1042/bj2520633; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUKENS LN, 1976, J BIOL CHEM, V251, P3530; MADRI JA, 1979, AM J PATHOL, V94, P323; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; MILLER EJ, 1971, BIOCHEM BIOPH RES CO, V42, P1024, DOI 10.1016/0006-291X(71)90006-4; NIYIBIZI C, 1984, J BIOL CHEM, V259, P4170; OLSEN BR, 1982, NEW TRENDS BASEMENT, P225; PETERS T, 1982, J BIOL CHEM, V257, P8847; PROCKOP DJ, 1990, ANN NY ACAD SCI, V580, P330, DOI 10.1111/j.1749-6632.1990.tb17942.x; RAMIREZ F, 1989, COLLAGEN, V4, P22; SCHEELE G, 1982, J BIOL CHEM, V257, P1227; SONDERFELDFRESKO S, 1988, J BIOL CHEM, V263, P13463; Traub W, 1971, Adv Protein Chem, V25, P243, DOI 10.1016/S0065-3233(08)60281-8; WEIL D, 1987, NUCLEIC ACIDS RES, V15, P181, DOI 10.1093/nar/15.1.181	38	58	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24354	24360						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929094				2022-12-25	WOS:A1994PQ34600078
J	STOFFEL, RH; RANDALL, RR; PREMONT, RT; LEFKOWITZ, RJ; INGLESE, J				STOFFEL, RH; RANDALL, RR; PREMONT, RT; LEFKOWITZ, RJ; INGLESE, J			PALMITOYLATION OF G-PROTEIN-COUPLED RECEPTOR KINASE, GRK6 - LIPID MODIFICATION DIVERSITY IN THE GRK FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; GAMMA-SUBUNITS; SF9 CELLS; EXPRESSION; PHOSPHORYLATION; ISOPRENYLATION; IDENTIFICATION; RHODOPSIN; CLONING	GRK6, a 66-kDa serine/threonine protein kinase, is a recently identified member of the G protein-coupled receptor kinase (GRK) family. GRKs are involved in the phosphorylation of seven-transmembrane receptors, a process mediating desensitization of signal transduction. An important feature of these enzymes is their membrane-associated nature, which for some members is stimulus dependent. The structural basis for this membrane association previously has been shown in different members of the GRK family to include isoprenylation, G protein beta gamma-binding domains, and basic regions to provide electrostatic interactions with phospholipids. We provide evidence that another mechanism includes fatty acid acylation. GRK6, but not other GRKs tested, incorporated tritium after incubation with [H-3]palmitate in Sf9 and in COS-7 cells overexpressing the kinase. The incorporated radioactivity was released from the protein by neutral hydroxylamine, indicating the presence of a thioester bond, and was confirmed as palmitic acid by high performance liquid chromatography analysis. Site-directed mutagenesis defined the region of palmitate attachment as a cluster of 3 cysteines (Cys(561), Cys(562), and Cys(565)) the carboxyl-terminal domain of the kinase, consistent with the location of the membrane targeting domains of GRKs 1, 2, 3, and 5. Palmitoylation of GRK6 appears essential for membrane association, since palmitoylated kinase was found only in the membrane fraction. This lipid modification provides a structural basis for potential regulation of the subcellular distribution of GRK6 through acylation/deacylation cycles.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University; Howard Hughes Medical Institute; Duke University			Lefkowitz, Robert/AAW-2649-2021	Premont, Richard/0000-0002-8053-5026	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; CAMP LA, 1993, J BIOL CHEM, V268, P22566; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JAMES G, 1990, METHODS COMPANION ME, P270; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Sambrook J, 1989, MOL CLONING LABORATO; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; UVCHINNIKOV YA, 1988, FEBS LETT, V230, P1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	31	119	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27791	27794						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961702				2022-12-25	WOS:A1994PV77200003
J	THOMAS, CE; OHLWEILER, DF; KALYANARAMAN, B				THOMAS, CE; OHLWEILER, DF; KALYANARAMAN, B			MULTIPLE MECHANISMS FOR INHIBITION OF LOW-DENSITY-LIPOPROTEIN OXIDATION BY NOVEL CYCLIC NITRONE SPIN TRAPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERCHOLESTEROLEMIC WATANABE RABBITS; HERITABLE HYPERLIPIDEMIC RABBIT; SUPEROXIDE-DISMUTASE; PROBUCOL; ATHEROSCLEROSIS; COPPER; ANTIOXIDANTS; PEROXIDATION; CHOLESTEROL; MACROPHAGES	Oxidation of low density Lipoproteins (LDL) may be a critical atherogenic event owing to the diverse array of biologic effects attributed to modified LDL, Recently, we and others have demonstrated that the lipophilic nitrone spin trap alpha-phenyl-N-tert-butyl nitrone (PBN) can inhibit Cu2+-dependent LDL oxidation while the related, more hydrophilic analog alpha-(4-pyridyl-1-oxide)-N-tert-butyl nitrone is ineffective. Because the inhibitory activity of PBN is relatively weak as compared to hydrophobic phenolic antioxidants, we have synthesized a number of cyclic analogues of PBN that encompass a wide range of hydrophobicity and examined their ability to inhibit LDL oxidation in vitro. Formation of a six-membered ring by a bond formed from one methyl of the tert-butyl group to the aromatic ring yielded MDL 101,002, which was 3- and 24-fold more active than PBN against Cu2+ and 2,2'-azobis-2-amidinopropane hydrochloride-dependent oxidation, respectively. The effect of aromatic substituents was examined and, in general, activity positively correlated with hydrophobicity, particularly with Cu2+. Electron spin resonance (ESR) spectroscopy demonstrated that the PBN adduct in oxidized LDL is composed of a mobile component (exposed to the LDL aqueous phase) and an immobilized component, localized in the lipid-protein interface or in the bulk lipid. The most active cyclic nitrones exhibited only highly immobilized adducts, suggesting they are buried within the particle. Studies with MDL 105,185 (which is a chloro-substituted nitrone containing a seven-membered ring rather than six-membered as for MDL 101,002) demonstrated radical trapping in both the lipid and apoprotein fractions. Compounds in which a spirocyclohexyl ring was substituted for the gem-dimethyl methylene (MDL 102,832 and 101,694) formed hydrophobic Cu2+ complexes that were observed in the lipid fraction by ESR. This result was confirmed by fractionation of LDL oxidation reaction mixtures and spectrophotometric quantitation of associated Cu2+. Th, ability to bind Cu2+ was dependent upon the presence of the spirocyclohexyl ring. These data demonstrate that cyclic nitrones can inhibit LDL oxidation at exceedingly low concentrations by multiple mechanisms: 1) trapping of lipid-derived radicals, 2) trapping of apoprotein B-derived radicals, and 3) binding of Cu2+ ions. It is suggested that this new class of highly potent spin traps may be used as effective radical traps in free radical biology and medicine.	MED COLL WISCONSIN,BIOPHYS RES INST,MILWAUKEE,WI 53226	Medical College of Wisconsin	THOMAS, CE (corresponding author), MERRELL DOW PHARMACEUT INC,RES INST,2110 E GALBRAITH RD,CINCINNATI,OH 45215, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047250] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01008] Funding Source: Medline; NHLBI NIH HHS [HL47250] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700; CARDIN AD, 1984, METHOD PHARMACOL, V5, P146; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; Carr A. A., 1994, US Patent, Patent No. [5,292,746, 5292746]; ERICKSON MC, 1992, ARCH BIOCHEM BIOPHYS, V292, P427, DOI 10.1016/0003-9861(92)90012-L; GAZIANO JM, 1990, CIRCULATION, V82, P201; HANNA PM, 1992, ARCH BIOCHEM BIOPHYS, V296, P640, DOI 10.1016/0003-9861(92)90620-C; JACKSON RL, 1993, MED RES REV, V13, P161, DOI 10.1002/med.2610130204; JEWETT SL, 1989, EUR J BIOCHEM, V180, P569, DOI 10.1111/j.1432-1033.1989.tb14683.x; KALYANARAMAN B, 1991, FEBS LETT, V280, P17, DOI 10.1016/0014-5793(91)80194-8; KALYANARAMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1168, P220, DOI 10.1016/0005-2760(93)90128-V; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KU G, 1992, J BIOL CHEM, V267, P14183; LEHR HA, 1991, J CLIN INVEST, V88, P9, DOI 10.1172/JCI115309; LIAO F, 1991, J CLIN INVEST, V87, P2253, DOI 10.1172/JCI115261; MAKINO K, 1990, BIOCHEM BIOPH RES CO, V172, P1073, DOI 10.1016/0006-291X(90)91556-8; MAO SJT, 1991, ARTERIOSCLER THROMB, V11, P1266, DOI 10.1161/01.ATV.11.5.1266; MAO SJT, 1991, J MED CHEM, V34, P298, DOI 10.1021/jm00105a046; MCLEAN LR, 1989, BIOCHEMISTRY-US, V28, P321, DOI 10.1021/bi00427a043; MCLEAN LR, 1992, J BIOL CHEM, V267, P12291; RESSOUCHE E, 1993, J AM CHEM SOC, V115, P3610, DOI 10.1021/ja00062a026; ROSENFELD ME, 1991, J CLIN INVEST, V87, P90, DOI 10.1172/JCI115006; SIMPSON JA, 1990, FREE RADICAL RES COM, V10, P303, DOI 10.3109/10715769009149899; SIMPSON JA, 1992, BIOCHEM J, V282, P621, DOI 10.1042/bj2820621; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; THOMAS CE, 1992, BIOCHIM BIOPHYS ACTA, V1128, P50, DOI 10.1016/0005-2760(92)90256-U; THOMAS CE, 1994, J LIPID RES, V35, P417; THOMAS CE, 1994, J LIPID RES, V35, P610; VERLANGIERI AJ, 1992, J AM COLL NUTR, V11, P131; Weindruch R., 1993, FREE RADICALS AGING, P269	31	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28055	28061						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961741				2022-12-25	WOS:A1994PV77200045
J	ZHANG, HY; KOMANO, H; FULLER, RS; GANDY, SE; FRAIL, DE				ZHANG, HY; KOMANO, H; FULLER, RS; GANDY, SE; FRAIL, DE			PROTEOLYTIC PROCESSING AND SECRETION OF HUMAN BETA-AMYLOID PRECURSOR PROTEIN IN YEAST - EVIDENCE FOR A YEAST SECRETASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PREPRO-ALPHA-FACTOR; SACCHAROMYCES-CEREVISIAE; KEX2 PROTEASE; ALZHEIMERS-DISEASE; CLEAVAGE; GLYCOSYLATION; LOCALIZATION; SUBUNITS; RELEASE; PEPTIDE	Human beta-amyloid precursor protein (APP), the transmembrane precursor of the Alzheimer's disease beta-amyloid peptide, was expressed in the yeast Saccharomyces cerevisiae by fusion to prepro-alpha-factor, From analysis of protease deficient yeast strains, the fusion protein underwent partial processing by Kex2 protease to generate full-length APP and a fraction of the molecules were degraded in the vacuole. A soluble APP ectodomain fragment bearing lumenal but not cytosolic epitopes was released into the media, indicating cleavage by a ''membrane protein-solubilizing proteinase'' or ''secretase'' activity. Yeast cells contained a C-terminal APP fragment that co-migrated with authentic C-terminal fragment derived from alpha-secretase cleavage of full-length APP in human cells. The N-terminal sequence of immunoaffinity purified C-terminal APP fragment from yeast was identical to that reported in mammalian and insect cells. These results demonstrate the existence of a secretase activity in yeast. Furthermore, this yeast secretase activity may be related to an APP processing activity present in metazoan cells.	ABBOTT LABS,DEPT CORP MOLEC BIOL,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064; STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,PROGRAM NEUROSCI,NEW YORK,NY 10021	Abbott Laboratories; Stanford University; Cornell University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039697, R55GM039697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R55AG011508, R01AG011508] Funding Source: NIH RePORTER; NIA NIH HHS [AG11508] Funding Source: Medline; NIGMS NIH HHS [GM39697] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODOVITZ S, 1994, IN PRESS J NEUROCHEM; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; BRAKE AJ, 1990, METHOD ENZYMOL, V185, P408; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P7080, DOI 10.1073/pnas.80.23.7080; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FRAIL DE, 1993, MOL PHARMACOL, V44, P1113; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GANDY S, 1992, TRENDS PHARMACOL SCI, V13, P108, DOI 10.1016/0165-6147(92)90039-9; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; PRICE DL, 1993, P NATL ACAD SCI USA, V90, P6381, DOI 10.1073/pnas.90.14.6381; RAMABHADRAN TV, 1993, J BIOL CHEM, V268, P2009; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Rose MD., 1990, METHODS YEAST GENETI; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; WANG R, 1991, J BIOL CHEM, V266, P16960; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x	29	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27799	27802						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961704				2022-12-25	WOS:A1994PV77200005
J	ORNELASSOARES, A; DELENCASTRE, H; DEJONGE, BLM; TOMASZ, A				ORNELASSOARES, A; DELENCASTRE, H; DEJONGE, BLM; TOMASZ, A			REDUCED METHICILLIN RESISTANCE IN A NEW STAPHYLOCOCCUS-AUREUS TRANSPOSON MUTANT THAT INCORPORATES MURAMYL DIPEPTIDES INTO THE CELL-WALL PEPTIDOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTIONAL INACTIVATION; STRAIN; TN551	Screening of a new Tn551 library constructed in the background of a highly methicillin-resistant Staphylococcus aureus strain identified a new insertion site located on the SmaI B-fragment of the chromosome that reduced the minimal inhibitory concentration of the parent (1600 mu g/ml) to 25-50 mu g/ml in the mutant and caused heterogeneous expression of resistance and abnormality in peptidoglycan composition (absence of the unsubstituted pentapeptide and incorporation of alanylglutamate- and alanylisoglutamate-containing muropeptides). There was an accumulation of large amounts of the UDP-linked muramyl dipeptide in the cytoplasmic wall precursor pool of the mutant. Reduced (heterogeneous) antibiotic resistance and all the biochemical abnormalities were reproduced in genetic backcrosses by transduction with phage 80 alpha. Mutant RUSA235 appears to be impaired in the biosynthesis of the staphylococcal cell wall precursor muropeptide before the lysine addition step. We propose to provisionally call the gene inactivated in this mutant femF.	ROCKEFELLER UNIV, MICROBIOL LAB, NEW YORK, NY 10021 USA; UNIV NOVA LISBOA, INST TECNOL QUIM & BIOL, P-2780 OEIRAS, PORTUGAL	Rockefeller University; Universidade Nova de Lisboa			DeJonge, Boudewijn/AAR-6717-2020	Tomasz, Alexander/0000-0003-1520-1983; Ornelas-Soares, Antonio/0000-0002-2080-2858; /0000-0001-6816-8932	NIAID NIH HHS [R01 AI16794] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGERBACHI B, 1983, J BACTERIOL, V154, P479; BERGERBACHI B, 1992, ANTIMICROB AGENTS CH, V36, P1367, DOI 10.1128/AAC.36.7.1367; BERGERBACHI B, 1990, MOL BIOL STAPHYLOCOC, P509; CHATTERJ.AN, 1972, J BACTERIOL, V11, P220, DOI 10.1128/JB.111.1.220-230.1972; DEJONGE BLM, 1993, J BACTERIOL, V175, P2779, DOI 10.1128/JB.175.9.2779-2782.1993; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11255; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DELENCASTRE H, 1991, ANTIMICROB AGENTS CH, V35, P632, DOI 10.1128/AAC.35.4.632; DELENCASTRE H, 1994, J ANTIMICROB CHEMOTH, V33, P7, DOI 10.1093/jac/33.1.7; DELENCASTRE H, 1994, EUR J CLIN MICROBIOL, V13, P64, DOI 10.1007/BF02026129; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; GHUYSEN JM, 1966, METHOD ENZYMOL, V8, P684; GOOD CM, 1972, J BACTERIOL, V11, P231, DOI 10.1128/JB.111.1.231-241.1972; GUSTAFSON J, 1994, J BACTERIOL, V176, P1460, DOI 10.1128/jb.176.5.1460-1467.1994; HANDWERGER S, 1994, J BACTERIOL, V176, P260, DOI 10.1128/JB.176.1.260-264.1994; HARTMAN BJ, 1986, ANTIMICROB AGENTS CH, V29, P85, DOI 10.1128/AAC.29.1.85; KORNBLUM J, 1986, EUR J CLIN MICROBIOL, V5, P714, DOI 10.1007/BF02013311; MATTHEWS P, 1990, ANTIMICROB AGENTS CH, V34, P1777, DOI 10.1128/AAC.34.9.1777; ORNELASSOARES A, 1993, J BIOL CHEM, V268, P26268; OSHIDA T, 1992, J BACTERIOL, V174, P4952, DOI 10.1128/JB.174.15.4952-4959.1992; PATTEE PA, 1981, J BACTERIOL, V145, P479, DOI 10.1128/JB.145.1.479-488.1981; Sambrook J, 1989, MOL CLONING LABORATO; TOMASZ A, 1990, MOL BIOL STAPHYLOCOC, P565	23	55	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27246	27250						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961632				2022-12-25	WOS:A1994PV77100017
J	BRAUCHLE, M; ANGERMEYER, K; HUBNER, G; WERNER, S				BRAUCHLE, M; ANGERMEYER, K; HUBNER, G; WERNER, S			LARGE INDUCTION OF KERATINOCYTE GROWTH-FACTOR EXPRESSION BY SERUM GROWTH-FACTORS AND PRO-INFLAMMATORY CYTOKINES IN CULTURED FIBROBLASTS	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; NECROSIS FACTOR-ALPHA; POLYMORPHONUCLEAR LEUKOCYTES; CELL GROWTH; MACROPHAGES; SECRETION; CLONING; FAMILY; PDGF	We have recently demonstrated a large induction of keratinocyte growth factor expression in dermal fibroblasts during wound healing. To identify possible mediators of KGF induction, we have now analysed the regulation of KGF expression in vitro in cultured murine and human fibroblasts. Here we demonstrate that KGF mRNA and protein expression is low in quiescent fibroblasts but is strongly induced upon serum stimulation. This induction can be mediated by at least two different intracellular pathways involving protein kinase C or cAMP-dependent kinases. Our finding that induction of KGF expression by serum is independent of de novo protein synthesis demonstrates, that KGF is the product of a primary response gene. The stimulatory effect of serum on KGF expression is likely to be a combinatorial effect of different mitogens, since several purified serum growth factors also stimulated KGF expression but to a lesser extent compared to serum. Furthermore, we also found a strong KGF induction by interleukin-1 beta, tumor necrosis factor-alpha and interleukin-6, cytokines which are released by polymorphonuclear leukocytes and activated macrophages during wound healing. These data suggest that serum which is released upon hemorrhage as well as pro-inflammatory cytokines might be responsible for the KGF induction in vivo during skin repair.	MAX PLANCK INST BIOCHEM,VIRUS FORSCH ABT,D-82152 MARTINSRIED,GERMANY	Max Planck Society				Werner, Sabine/0000-0001-7397-8710				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCO NA, 1990, BLOOD, V75, P2049; Clark RAF, 1991, PHYSL BIOCH MOL BIOL, P576; DINARELLO CA, 1991, CYTOKINE HDB, P47; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LINDEMANN A, 1989, J CLIN INVEST, V83, P1308, DOI 10.1172/JCI114016; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; LORD PCW, 1991, J CLIN INVEST, V87, P1312, DOI 10.1172/JCI115134; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1991, SCIENCE, V251, P335; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TOSATO G, 1988, SCIENCE, V239, P502, DOI 10.1126/science.2829354; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WERNER S, 1991, ONCOGENE, V6, P2137; WERNER S, IN PRESS J INVEST DE; Wong H. L., 1989, HUMAN MONOCYTES, P383; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	30	191	193	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3199	3204						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936642				2022-12-25	WOS:A1994PM65800011
J	HARADA, H; KONDO, T; OGAWA, S; TAMURA, T; KITAGAWA, M; TANAKA, N; LAMPHIER, MS; HIRAI, H; TANIGUCHI, T				HARADA, H; KONDO, T; OGAWA, S; TAMURA, T; KITAGAWA, M; TANAKA, N; LAMPHIER, MS; HIRAI, H; TANIGUCHI, T			ACCELERATED EXON SKIPPING OF IRF-1 MESSENGER-RNA IN HUMAN MYELODYSPLASIA/LEUKEMIA - A POSSIBLE MECHANISM OF TUMOR-SUPPRESSOR INACTIVATION	ONCOGENE			English	Article							REGULATORY FACTOR-I; ACUTE NONLYMPHOCYTIC LEUKEMIA; INTERFERON-INDUCIBLE GENES; POLYMERASE CHAIN-REACTION; CELL LUNG-CARCINOMA; PRE-MESSENGER-RNA; P53 GENE; IFN-BETA; RETINOBLASTOMA ANTIONCOGENE; TRANSCRIPTIONAL ACTIVATOR	The transcription factor IRF-1 has been shown to function as a tumor suppressor. Here we report that a significant proportion of the IRF-1 mRNA detected in normal human hematopoietic cells and cultured cell lines lacks exon 2 (containing the AUG initiation codon) and 3 as a result of exon skipping. Surprisingly, when we examined the bone marrow and peripheral mononuclear cells from patients with myelodysplastic syndrome (MDS) or leukemia secondary to MDS, we could still detect the exon-skipped form but little or none of the intact IRF-1 mRNA. This appears to be the result of accelerated exon skipping since we could find no mutations within the exons and splicing junctions from these patients. The exon-skipped form of IRF-1 lacking exons 2 and 3 displayed neither DNA binding nor tumor suppressive activities. Thus this accelerated exon skipping may cause the inactivation of IRF-1 and thereby contribute to the development of human hematopoietic malignancies.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	Osaka University; University of Tokyo			Harada, Hisashi/H-2815-2019; Kondo, Takeshi/G-2103-2012	Harada, Hisashi/0000-0001-5993-1289; Kondo, Takeshi/0000-0001-7455-5824; Tanaka, Nobuyuki/0000-0002-6373-2220; Kitagawa, Motoo/0000-0003-1036-840X				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; BOULTWOOD J, 1993, BLOOD, V82, P2611; CHA Y, 1993, DNA CELL BIOL, V11, P605; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; FOTI A, 1990, BRIT J HAEMATOL, V76, P143, DOI 10.1111/j.1365-2141.1990.tb07849.x; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GALLAGHER R, 1979, BLOOD, V54, P713; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; ITOH S, 1989, NUCLEIC ACIDS RES, V17, P8372, DOI 10.1093/nar/17.20.8372; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; KAELIN WG, 1991, ORIGINS OF HUMAN CANCER, P423; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEBEAU MM, 1989, CANCER CEL, V7, P53; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MAKINO R, 1990, Technique (Philadelphia), V2, P295; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MORI N, 1990, ONCOGENE, V5, P1713; NIMER SD, 1987, BLOOD, V70, P1705; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; PEDERSEN B, 1991, LEUKEMIA, V5, P566; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; SAMESHIMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P697, DOI 10.1016/S0006-291X(05)80091-9; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; SUGIMOTO K, 1993, BLOOD, V81, P3022; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANAKA N, 1991, IN PRESS CANCER LETT; UEGAKI K, 1993, PROTEIN ENG, V6, P195, DOI 10.1093/protein/6.2.195; VANDENBERGHE H, 1985, CANCER GENET CYTOGEN, V17, P189, DOI 10.1016/0165-4608(85)90016-0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	69	126	128	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3313	3320						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936656				2022-12-25	WOS:A1994PM65800025
J	HULTMAN, P; JOHANSSON, U; TURLEY, SJ; LINDH, U; ENESTROM, S; POLLARD, KM				HULTMAN, P; JOHANSSON, U; TURLEY, SJ; LINDH, U; ENESTROM, S; POLLARD, KM			ADVERSE IMMUNOLOGICAL EFFECTS AND AUTOIMMUNITY INDUCED BY DENTAL AMALGAM AND ALLOY IN MICE	FASEB JOURNAL			English	Article						MERCURY; SILVER; FIBRILLARIN; ANTINUCLEAR ANTIBODIES; IMMUNE COMPLEX DEPOSITS	IMMUNE-COMPLEX DEPOSITS; CELL-STIMULATORY FACTOR; MERCURIC-CHLORIDE; ANTINUCLEAR ANTIBODIES; MURINE SUSCEPTIBILITY; AUTOANTIBODY PROFILES; LYMPHOCYTES-T; HEAVY-METALS; B-CELLS; FILLINGS	Dental amalgam fillings are the most important source of mercury exposure in the general population, but their potential to cause systemic health consequences is disputed. In this study, inbred mice genetically susceptible to mercury-induced immune aberrations were used to examine whether dental amalgam may interfere with the immune system and cause autoimmunity. Female SJL/N mice were implanted in the peritoneal cavity with 8-100 mg silver amalgam or silver alloy for 10 weeks or 6 months. Chronic hyperimmunoglobulinemia, serum IgG autoantibodies targeting the nucleolar protein fibrillarin, and systemic immune-complex deposits developed in a time- and dose-dependent manner after implantation of amalgam or alloy. Splenocytes from mice implanted with amalgam or alloy showed an increased expression of class II molecules. The functional capacity of splenic T and B cells was affected in a dose-dependent way: 10 weeks of low-dose and 6 months of high-dose amalgam implantation strongly increased mitogen-induced T and B cell proliferation, whereas 10 weeks of high-dose implantation decreased the proliferation. Not only mercury but also silver accumulated in the spleen and kidneys after amalgam implantation. In conclusion, dental amalgam implantation in a physiological body milieu causes chronic stimulation of the immune system with induction of systemic autoimmunity in genetically sensitive mice. Implantation of silver alloy not containing mercury also induced autoimmunity, suggesting that other elements, especially silver, have the potential to induce autoimmunity in genetically susceptible vertebrates. Accumulation of heavy metals, from dental amalgam and other sources, may lower the threshold of an individual metal to elicit immunological aberrations. We hypothesize that under appropriate conditions of genetic susceptibility and adequate body burden, heavy metal exposure from dental amalgam may contribute to immunological aberrations, which could lead to overt autoimmunity.	SCRIPPS RES INST, DEPT EXPTL MED, WM KECK AUTOIMMUNE DIS CTR, LA JOLLA, CA 92037 USA; UPPSALA UNIV, CTR METAL BIOL, UPPSALA, SWEDEN	Scripps Research Institute; Uppsala University	HULTMAN, P (corresponding author), LINKOPING UNIV, DEPT PATHOL, LINKOPING, SWEDEN.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR040770] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32155] Funding Source: Medline; NIAMS NIH HHS [AR 40770] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMOWICZ D, 1990, EUR J IMMUNOL, V20, P469, DOI 10.1002/eji.1830200303; APOSHIAN HV, 1992, FASEB J, V6, P2472, DOI 10.1096/fasebj.6.7.1563599; ATEN J, 1988, AM J PATHOL, V133, P127; BARR RD, 1990, E AFR MED J, V67, P381; Berlin M, 1992, Lakartidningen, V89, P2918; BIGAZZI PE, 1992, CLIN IMMUNOL IMMUNOP, V65, P81, DOI 10.1016/0090-1229(92)90210-F; BOLEWSKA J, 1990, J ORAL PATHOL MED, V19, P39, DOI 10.1111/j.1600-0714.1990.tb00779.x; BROWN LJ, 1991, J AM DENT ASSOC, V122, P73, DOI 10.14219/jada.archive.1991.0258; BRUNE D, 1984, SCAND J DENT RES, V92, P165; BURLINGAME RW, 1990, J IMMUNOL METHODS, V134, P187, DOI 10.1016/0022-1759(90)90380-E; DANSCHER G, 1990, EXP MOL PATHOL, V52, P291, DOI 10.1016/0014-4800(90)90070-T; DIETER MP, 1983, TOXICOL APPL PHARM, V68, P218, DOI 10.1016/0041-008X(83)90006-6; DUBEY C, 1991, CLIN EXP IMMUNOL, V86, P118; EGGLESTON DW, 1984, J PROSTHET DENT, V51, P617, DOI 10.1016/0022-3913(84)90404-9; EGGLESTON DW, 1987, J PROSTHET DENT, V58, P704, DOI 10.1016/0022-3913(87)90424-0; Eybl V, 1992, Arch Toxicol Suppl, V15, P160; FURCHNER JE, 1968, HEALTH PHYS, V15, P505, DOI 10.1097/00004032-196812000-00005; GAWORSKI CL, 1978, TOXICOL APPL PHARM, V46, P305, DOI 10.1016/0041-008X(78)90076-5; GLEICHMANN E, 1989, ARCH TOXICOL, V63, P257, DOI 10.1007/BF00278639; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; HAHN LJ, 1990, FASEB J, V4, P3256, DOI 10.1096/fasebj.4.14.2227216; HAHN LJ, 1989, FASEB J, V3, P2641, DOI 10.1096/fasebj.3.14.2636872; HANSON M, 1991, EXPERIENTIA, V47, P9, DOI 10.1007/BF02041243; Hickel R, 1991, Dtsch Zahnarztl Z, V46, P542; HULTMAN P, 1989, J CLIN LAB IMMUNOL, V28, P143; HULTMAN P, 1988, CLIN EXP IMMUNOL, V71, P269; HULTMAN P, 1993, CLIN IMMUNOL IMMUNOP, V68, P9, DOI 10.1006/clin.1993.1088; HULTMAN P, 1987, CLIN EXP IMMUNOL, V67, P283; HULTMAN P, 1989, CLIN EXP IMMUNOL, V78, P470; HULTMAN P, 1989, BRIT J EXP PATHOL, V70, P227; HULTMAN P, 1992, CLIN IMMUNOL IMMUNOP, V65, P98, DOI 10.1016/0090-1229(92)90212-7; HULTMAN P, 1991, FOOD CHEM TOXICOL, V29, P633, DOI 10.1016/0278-6915(91)90146-X; HULTMAN P, 1994, CLIN EXP IMMUNOL, V96, P285; LANGWORTH S, 1988, SWED DENT J, V12, P69; LANGWORTH S, 1993, SCAND J WORK ENV HEA, V19, P405, DOI 10.5271/sjweh.1454; LAWRENCE DA, 1981, TOXICOL APPL PHARM, V57, P439, DOI 10.1016/0041-008X(81)90241-6; Lentz D L, 1989, Am J Dent, V2, P171; MACKERT JR, 1991, J AM DENT ASSOC, V122, P49, DOI 10.14219/jada.archive.1991.0095; MADRENAS J, 1991, KIDNEY INT, V39, P273, DOI 10.1038/ki.1991.33; MAGOS L, 1987, ARCH TOXICOL, V60, P422, DOI 10.1007/BF00302384; MCCABE MJ, 1990, J IMMUNOL, V145, P671; MCCLUSKEY RT, 1983, PATHOLOGY KIDNEY, P301; NYLANDER M, 1987, SWED DENT J, V11, P179; OCHEL M, 1991, J IMMUNOL, V146, P3006; PIETSCH P, 1989, INT ARCH ALLER A IMM, V90, P47, DOI 10.1159/000234999; POLLARD KM, 1993, 3RD P INT WORKSH MOL, P65; REARDON CL, 1987, IMMUNOBIOLOGY, V175, P455, DOI 10.1016/S0171-2985(87)80073-6; REIMER G, 1988, ARTHRITIS RHEUM, V31, P525, DOI 10.1002/art.1780310409; REUTER R, 1989, P NATL ACAD SCI USA, V86, P237, DOI 10.1073/pnas.86.1.237; ROGER J, 1992, EUR J DERMAT, V2, P168; RUBIN RL, 1986, MANUAL CLIN LABORATO, P744; RUNGBY J, 1987, ARCH TOXICOL, V61, P40, DOI 10.1007/BF00324546; SCHRALLHAMMERBENKLER K, 1992, ACTA DERM-VENEREOL, V72, P294; Skare I, 1992, Lakartidningen, V89, P1299; SNAPP KR, 1989, J DENT RES, V68, P780, DOI 10.1177/00220345890680050501; SNYDER CA, 1991, J TOXICOL ENV HEALTH, V34, P127, DOI 10.1080/15287399109531553; TURLEY SJ, 1993, BIOCHIM BIOPHYS ACTA, V1216, P119, DOI 10.1016/0167-4781(93)90046-G; WATANABE C, 1993, B ENVIRON CONTAM TOX, V51, P24; Wilhelm M, 1991, Dtsch Zahnarztl Z, V46, P544; ZDOLSEK J, 1994, IN PRESS IMMUNOPHARM; 1989, J AM DENT ASSOC, V120, P395; [No title captured]; 1991, ENV HLTH CRITERIA, V118	63	64	67	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1183	1190		10.1096/fasebj.8.14.7958626	http://dx.doi.org/10.1096/fasebj.8.14.7958626			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958626				2022-12-25	WOS:A1994PT12800015
J	WEIH, F; CARRASCO, D; BRAVO, R				WEIH, F; CARRASCO, D; BRAVO, R			CONSTITUTIVE AND INDUCIBLE REL NF-KAPPA-B ACTIVITIES IN MOUSE THYMUS AND SPLEEN	ONCOGENE			English	Article							DORSOVENTRAL PATTERN-FORMATION; C-REL; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; SIGNAL TRANSDUCTION; PROTEIN SUBUNITS; LYMPHOID-CELLS; P65 SUBUNIT; GENE; FAMILY	We have studied the expression of members of the rel family of transcription factors and ikba in mouse thymus and spleen by in situ hybridization. Our results show that the vel genes have different temporal and spatial patterns of expression suggesting distinct roles in these lymphoid tissues. The Rel/NF-kappa B proteins and I kappa B alpha in thymus and spleen were also analysed by Western blotting and electrophoretic mobility shift assays. Although RelB protein is present at significantly lower levels in thymus and spleen extracts when compared to RelA, in both tissues the predominant kappa B-binding activity consists of p50/RelB and p52/RelB heterodimers and only very little binding of RelA-containing complexes to kappa B sites was detected. Significant binding of c-Rel complexes was only found in spleen extracts. Treatment of thymus and spleen extracts with deoxycholate (DOC), however, results in a strong increase in binding to kappa B sites of both RelA and c-Rel complexes. In contrast, binding of RelB complexes is not induced after DOC treatment. Our results suggest a differential role of Rel/NF-kappa B complexes in mouse thymus and spleen with RelB heterodimers representing the constitutive kappa B-binding activity, whereas RelA and c-Rel complexes most likely are involved in inducible kappa B-binding and gene activation.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								AGGER R, 1992, J LEUKOCYTE BIOL, V52, P34, DOI 10.1002/jlb.52.1.34; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; CARRASCO D, 1994, IN PRESS DEVELOPMENT; CARRASCO D, 1994, CELL BIOL LABORATORY; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; COLIGAN JE, 1992, CURRENT PROTOCOLS IM; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DOBRANSKI P, 1994, IN PRESS EMBO J; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1992, CANCER SURV, V15, P69; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; IP YT, 1992, J CELL SCI, P33; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; METCALF D, 1971, FRONTIERS BIOL HEMAT, P172; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NIEUWENHUIS P, 1976, CELL IMMUNOL, V23, P254, DOI 10.1016/0008-8749(76)90191-X; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; Orkin SH, 1990, CURR OPIN CELL BIOL, V2, P1003, DOI 10.1016/0955-0674(90)90149-9; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; RYSECK RP, 1994, IN PRESS IMMEDIATE E; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STREBEL K, 1986, J VIROL, V57, P983, DOI 10.1128/JVI.57.3.983-991.1986; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TEWARI M, 1992, NUCLEIC ACIDS RES, V20, P607, DOI 10.1093/nar/20.3.607; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523	73	122	123	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3289	3297						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936653				2022-12-25	WOS:A1994PM65800022
J	POMBO, CM; BONVENTRE, JV; AVRUCH, J; WOODGETT, JR; KYRIAKIS, JM; FORCE, T				POMBO, CM; BONVENTRE, JV; AVRUCH, J; WOODGETT, JR; KYRIAKIS, JM; FORCE, T			THE STRESS-ACTIVATED PROTEIN-KINASES ARE MAJOR C-JUN AMINO-TERMINAL KINASES ACTIVATED BY ISCHEMIA AND REPERFUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOONCOGENE EXPRESSION; CEREBRAL-ISCHEMIA; GENE-EXPRESSION; RENAL ISCHEMIA; GERBIL BRAIN; MAP KINASES; PHOSPHORYLATION; FOS; TRANSCRIPTION; TYROSINE	The signal transduction pathways that mediate activation of trans acting factors controlling an organ's response to ischemia are unknown. The stress-activated protein kinases (SAPKs), a subfamily of the extracellular signal-regulated kinases (ERKs), phosphorylate c-Jun within the amino-terminal transactivation domain and are activated in response to a variety of cellular stresses. We determined whether SAPKs are activated in response to ischemia, an extreme, albeit common, pathophysiologic stress. Rats underwent 40 min of renal ischemia followed by reperfusion for 0, 5, 20, or 90 min. SAPKs were immunoprecipitated from kidney lysates and kinase activity assayed with recombinant GST-c-Jun(1-135), containing the amino-terminal transactivation domain of c-Jun as substrate. SAPKs were not activated by ischemia alone, but reperfusion for as little as 5 min was associated with a 4.6-fold increase in kinase activity. Kinase activity was increased 7.6-fold at 20 min following reperfusion and remained elevated at 90 min of reperfusion (4.9-fold). In contrast, activity of the related ERR-1 and -2 was increased only 1.3-fold and only at the 5-min reperfusion time point. When SAPKs were immunodepleted from kidney extracts prior to incubation of the extracts with agarose-coupled GST-c-Jun(1-135), it was found that SAPKs accounted for the majority of the amino-terminal c-Jun kinase activity of kidney at 5 min following reperfusion. In Madin-Darby canine kidney epithelial cells, ATP repletion, following ATP depletion induced by chemical anoxia, was associated with a 9-15-fold activation of SAPKs with a similar time course of activation to that seen in the kidney after ischemia and reperfusion. In conclusion, the SAPKs are markedly activated very early after reperfusion of ischemic kidney and following ATP repletion of anoxic cells in culture. We propose that this activation of SAPKs may trigger part of the kidney's early genetic response to ischemia, possibly by enhancing trans acting activity of c-Jun.	MASSACHUSETTS GEN HOSP, MED SERV, CARDIAC UNIT, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, MED SERV, DIABET UNIT, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, MED SERV, RENAL UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02114 USA; PRINCESS MARGARET HOSP, ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre			Pombo, Celia M/L-4479-2014; Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Pombo, Celia M/0000-0003-2541-9468; Force, Thomas/0000-0002-0450-8659	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041513, K08DK001986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046577, R29GM046577] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01986, DK41513] Funding Source: Medline; NIGMS NIH HHS [GM46577] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; ARMSTRONG S, 1994, CARDIOVASC RES, V28, P72, DOI 10.1093/cvr/28.1.72; ASSELIN C, 1989, ONCOGENE RES, V5, P67; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BONIECE IR, 1993, J NEUROSCI, V13, P4220; BONVENTRE JV, 1991, CELL REGUL, V2, P251, DOI 10.1091/mbc.2.3.251; BONVENTRE JV, 1993, KIDNEY INT, V43, P1160, DOI 10.1038/ki.1993.163; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; CAMPOSGONZALEZ R, 1992, J NEUROCHEM, V59, P1955, DOI 10.1111/j.1471-4159.1992.tb11032.x; CARDELL M, 1993, J NEUROCHEM, V61, P1308, DOI 10.1111/j.1471-4159.1993.tb13623.x; CHURN SB, 1993, BIOCHEM BIOPH RES CO, V193, P934, DOI 10.1006/bbrc.1993.1715; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; HANSON SK, 1994, STROKE, V25, P446; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KELLY KJ, 1994, P NATL ACAD SCI USA, V91, P812, DOI 10.1073/pnas.91.2.812; KINDY MS, 1991, J MOL NEUROSCI, V2, P217; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; MAIESE K, 1993, J NEUROSCI RES, V36, P77, DOI 10.1002/jnr.490360109; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; PARRATT JR, 1994, TRENDS PHARMACOL SCI, V15, P19, DOI 10.1016/0165-6147(94)90129-5; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; ROSENBERG ME, 1991, KIDNEY INT, V39, P1156, DOI 10.1038/ki.1991.146; SAFIRSTEIN R, 1990, KIDNEY INT, V37, P1515, DOI 10.1038/ki.1990.143; SHACKELFORD DA, 1993, J NEUROCHEM, V61, P738; SHERIDAN AM, 1993, AM J PHYSIOL, V265, pF342, DOI 10.1152/ajprenal.1993.265.3.F342; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; WEBSTER KA, 1994, CIRC RES, V74, P679, DOI 10.1161/01.RES.74.4.679; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214	42	248	259	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26546	26551						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929379				2022-12-25	WOS:A1994PQ93000092
J	DANCIS, A; HAILE, D; YUAN, DS; KLAUSNER, RD				DANCIS, A; HAILE, D; YUAN, DS; KLAUSNER, RD			THE SACCHAROMYCES-CEREVISIAE COPPER TRANSPORT PROTEIN (CTR1P) - BIOCHEMICAL, CHARACTERIZATION, REGULATION BY COPPER, AND PHYSIOLOGICAL-ROLE IN COPPER UPTAKE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; WILSON DISEASE GENE; IRON UPTAKE; METALLOTHIONEIN GENE; FERRIC REDUCTASE; YEAST; EXPRESSION; METABOLISM; MUTANTS; ENCODES	The CTR1 gene of Saccharomyces cerevisiae encodes a protein required for high affinity copper uptake. The protein is expressed on the plasma membrane, is heavily glycosylated with O-linkages, and exists as an oligomer in vivo. The transcript abundance is strongly regulated by copper availability, being induced by copper deprivation and repressed by copper excess. Regulation occurs at very low, nontoxic levels of available copper and is independent of ACE1, the trans-inducer of yeast metallothionein. Expression of Ctr1p is limiting for copper uptake, since overexpression from a 2 mu high copy number plasmid increases copper uptake. Mutations in CTR1 result in altered cellular responses to extracellular copper, demonstrating a physiologic role for CTR1 in the delivery of copper to the cytosol. A copper dependent reporter gene construct, CUP1-lacZ, is not expressed in CTR1 mutants to the same level as in wild-type strains, and Cu,Zn superoxide dismutase activity is deficient in these mutants. The growth arrest that occurs in CTR1 mutants grown aerobically in copper-deficient media is attributable to the defect in Cu,Zn superoxide dismutase activity.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHANG EC, 1991, J BIOL CHEM, V266, P4417; CHELLY J, 1993, NAT GENET, V5, P317, DOI 10.1038/ng1293-317; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; EIDE D, 1992, J BIOL CHEM, V267, P20774; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRECO MA, 1990, J BACTERIOL, V172, P317, DOI 10.1128/JB.172.1.317-325.1990; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; Halliwell B, 1988, FREE RADICALS BIOL M; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KEPES F, 1988, J BIOL CHEM, V263, P9155; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Kosman Daniel J., 1994, V11, P1; KRAMER RA, 1984, P NATL ACAD SCI-BIOL, V81, P367, DOI 10.1073/pnas.81.2.367; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Lesuisse Emmanuel, 1994, V11, P149; LIN CM, 1993, J GEN MICROBIOL, V139, P1605, DOI 10.1099/00221287-139-7-1605; LINDER MC, 1991, BIOCH COPPER, P1; LIU XF, 1992, J BIOL CHEM, V267, P18298; Miller J.H., 1972, EXPT MOL GENETICS; NIELANDS JB, 1987, IRON TRANSPORT MICRO, P3; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; OSHUMI Y, 1988, J BACTERIOL, V170, P2676; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; SHERMAN F, 1989, LABORATORY COURSE MA; SIKORSKI RS, 1989, GENETICS, V122, P19; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YANG WM, 1991, MOL CELL BIOL, V11, P3676, DOI 10.1128/MCB.11.7.3676; ZHOU PB, 1993, BIOFACTORS, V4, P105	44	355	362	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25660	25667						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929270				2022-12-25	WOS:A1994PQ49100066
J	MACCOLL, R; LAM, I; CHOI, CY; KIM, J				MACCOLL, R; LAM, I; CHOI, CY; KIM, J			EXCITON SPLITTING IN PHYCOERYTHRIN-545	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE ANALYSIS; C-PHYCOCYANIN; ENERGY-TRANSFER; AGMENELLUM-QUADRUPLICATUM; CRYPTOMONAD BILIPROTEINS; FORSTER TRANSFER; ALLOPHYCOCYANIN; LOCALIZATION; FLUORESCENCE; RESOLUTION	Phycoerythrin 545 is a biliprotein having a polypep tide structure of alpha(2) beta(2) and each alpha and beta polypeptide has chromophores. Circular dichroism (CD) and absorption spectroscopy in the visible region together with various biochemical protocols have been used to study these chromophores. The CD spectrum exhibits overlapping positive and negative bands. Exciton splitting between closely-spaced pairs of chromophores produces a CD spectrum that has positive and negative bands of equal rotational strengths, a conservative spectrum. Alternatively, any positive or negative band could arise from a single chromophore, The results of this study demonstrate that exciton splitting is the likely cause of the negative and corresponding positive bands. The CD spectra of the separated alpha and beta polypeptides, under conditions where the polypeptide structure is denatured, have no negative bands. When the polypeptides are allowed to refold individually, the chromophores on the beta polypeptide regain a combination of negative and positive CD bands. The spectrum of the alpha polypeptide shows no evidence of exciton splitting under these refolding conditions. In another approach, urea is added to the protein in low concentrations, which result in changes in the conformation and perhaps association of the protein. A difference CD spectrum of native protein minus protein in 0.8 M urea shows a spectrum characteristic of exciton splitting. Moveover, the remaining CD spectra in 0.8, 1.6, or 2.4 M urea still show the possibility of further exciton splitting, but at slightly different wavelengths from the spectrum that is deleted by 0.8 M urea. This finding may suggest that there are two types of exciton splitting.	SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12201	State University of New York (SUNY) System; State University of New York (SUNY) Albany	MACCOLL, R (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,BOX 509,ALBANY,NY 12201, USA.							BECK WF, 1992, J PHYS CHEM-US, V96, P4658, DOI 10.1021/j100190a094; CSATORDAY K, 1988, PHOTOCHEM PHOTOBIOL, V47, P285, DOI 10.1111/j.1751-1097.1988.tb02728.x; CSATORDAY K, 1984, BIOCHEMISTRY-US, V23, P6466, DOI 10.1021/bi00321a029; DEBRECZENY MP, 1993, J PHYS CHEM-US, V97, P9852, DOI 10.1021/j100140a050; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GANTT E, 1971, J CELL BIOL, V48, P280, DOI 10.1083/jcb.48.2.280; GANTT E, 1979, BIOCH PHYSL PROTOZOA, V1, P121; GILLBRO T, 1993, BIOCHIM BIOPHYS ACTA, V1140, P321, DOI 10.1016/0005-2728(93)90072-N; GODOVAC-ZIMMERMANN J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P117, DOI 10.1016/0167-4838(92)90432-D; GUARDFRIAR D, 1986, PHOTOCHEM PHOTOBIOL, V43, P81, DOI 10.1111/j.1751-1097.1986.tb05594.x; HOLZWARTH AR, 1991, PHYSIOL PLANTARUM, V83, P518, DOI 10.1111/j.1399-3054.1991.tb00129.x; HUANG C, 1987, BIOCHEMISTRY-US, V26, P243, DOI 10.1021/bi00375a033; JUNG J, 1980, BIOCHEMISTRY-US, V19, P24, DOI 10.1021/bi00542a005; KNOX RS, 1993, PHOTOCHEM PHOTOBIOL, V57, P40, DOI 10.1111/j.1751-1097.1993.tb02252.x; LANGER E, 1980, Z NATURFORSCH C, V35, P367; LICHTLE C, 1992, BIOL CELL, V74, P187, DOI 10.1016/0248-4900(92)90024-U; LUDWIG M, 1989, J CELL BIOL, V108, P875, DOI 10.1083/jcb.108.3.875; MACCOLL R, 1983, ARCH MICROBIOL, V135, P194, DOI 10.1007/BF00414479; MACCOLL R, 1992, J LUMIN, V51, P21, DOI 10.1016/0022-2313(92)90015-2; MACCOLL R, 1983, J BIOL CHEM, V258, P4327; MACCOLL R, 1981, ARCH BIOCHEM BIOPHYS, V208, P42, DOI 10.1016/0003-9861(81)90121-1; MACCOLL R, 1980, BIOCHEMISTRY-US, V19, P2817, DOI 10.1021/bi00553a043; MacColl R., 1987, PHYCOBILIPROTEINS; MALAK H, 1991, BIOCHIM BIOPHYS ACTA, V1059, P165, DOI 10.1016/S0005-2728(05)80201-4; MCKAY RML, 1992, J PHYCOL, V28, P64, DOI 10.1111/j.0022-3646.1992.00064.x; MUCKLE G, 1977, Z NATURFORSCH C, V32, P957; REITH M, 1990, PLANT MOL BIOL, V15, P585, DOI 10.1007/BF00017833; SAUER K, 1988, BIOCHIM BIOPHYS ACTA, V936, P157, DOI 10.1016/0005-2728(88)90232-0; SCHEER H, 1977, Z NATURFORSCH C, V32, P513; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; SHARKOV AV, 1992, CHEM PHYS LETT, V191, P633, DOI 10.1016/0009-2614(92)85601-6; SHARKOV AV, 1992, 1921 P SOC PHOT INST, P136; SPEARBERNSTEIN L, 1989, J PHYCOL, V25, P412, DOI 10.1111/j.1529-8817.1989.tb00245.x; WEDEMAYER GJ, 1992, J BIOL CHEM, V267, P7315; XIE XL, 1992, P SOC PHOTO-OPT INS, V1640, P690; Zuber H, 1987, LIGHT REACTIONS, P197	38	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25465	25469						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929246				2022-12-25	WOS:A1994PQ49100039
J	LAI, TS; ACHYUTHAN, KE; SANTIAGO, MA; GREENBERG, CS				LAI, TS; ACHYUTHAN, KE; SANTIAGO, MA; GREENBERG, CS			CARBOXYL-TERMINAL TRUNCATION OF RECOMBINANT FACTOR-XIII A-CHAINS - CHARACTERIZATION OF MINIMUM STRUCTURAL REQUIREMENT FOR TRANSGLUTAMINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XIII; ESCHERICHIA-COLI; HUMAN-PLASMA; BINDING; FIBRIN; SITES; EXPRESSION; PURIFICATION; SUBSTRATE; SEQUENCE	A series of truncation mutants lacking 218, 229, 250, and 269 amino acid residues from the carboxyl terminus of blood coagulation factor XIII A-chains (FXIII A), designated as Delta K513, Delta A502, Delta Y481, and Delta K462, respectively, were expressed in Escherichia coli to define the minimum structure required for transglutaminase activity. Delta K513 and Delta A502 displayed a 3.8-4.7 fold reduction in the K-cat with no change in the K-m for the glutamine substrate and a 2-fold increase in the K-m of the primary amine substrate. There was no detectable transglutaminase activity for either thrombin-activated Delta Y481 or Delta K462. The rate of ammonia release of thrombin-activated Delta K513 and Delta A502 was reduced 6- and 4-fold, respectively, whereas ammonia release was not detected for the Delta Y481 and Delta 462 mutants. The K-act for calcium ions of the Delta K513 mutant was similar to recombinant FXIIIa, whereas, it was increased by similar to 3-fold for the Delta A502 mutant. The rate of fibrin gamma-chain dimer formation for the Delta K513 and Delta A502 mutants was reduced by similar to 19-fold. Delta K462 did not bind to fibrin, while all of the other thrombin-cleaved mutants were bound. In conclusion, these results documented that the carboxyl-terminal calcium binding domain (Asp(468)-Glu(495)) was important for FXIIIa to adopt the correct conformation to ensure that efficient catalysis occurred.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University; Duke University				, Thung-Shen/0000-0002-8791-9698	NHLBI NIH HHS [HL28391, HL38245] Funding Source: Medline; NIAMS NIH HHS [AR39162] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038245, P60HL028391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039162] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHYUTHAN KE, 1993, J BIOL CHEM, V268, P21284; ACHYUTHAN KE, 1988, J BIOL CHEM, V263, P14296; ACHYUTHAN KE, 1994, ANAL BIOCHEM, V219, P43, DOI 10.1006/abio.1994.1229; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; BOARD PG, 1990, THROMB HAEMOSTASIS, V63, P235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; CHUNG SI, 1972, J BIOL CHEM, V247, P2798; FICKENSCHER K, 1991, THROMB HAEMOSTASIS, V65, P535; FOLK JE, 1967, J BIOL CHEM, V242, P1838; FOLK JE, 1967, J BIOL CHEM, V242, P2615; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GREENBERG CS, 1988, BIOCHEM J, V256, P1013, DOI 10.1042/bj2561013; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; HETTASCH JM, 1993, BLOOD, V82, P276; HORNYAK TJ, 1991, BIOCHEMISTRY-US, V30, P6175, DOI 10.1021/bi00239a014; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; LAI TS, 1994, PROTEIN EXPRES PURIF, V5, P125, DOI 10.1006/prep.1994.1019; LAI TS, 1992, CIRCULATION, V86, P465; LEWIS BA, 1978, BIOCHEM J, V169, P397, DOI 10.1042/bj1690397; LORAND L, 1962, NATURE, V194, P1148, DOI 10.1038/1941148a0; Lorand L, 1980, Prog Hemost Thromb, V5, P245; MARY A, 1988, ARCH BIOCHEM BIOPHYS, V216, P112; McDonagh J, 1987, HEMOSTASIS THROMBOSI, P289; MIRAGLIA CC, 1985, ANAL BIOCHEM, V144, P165, DOI 10.1016/0003-2697(85)90099-5; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; SCHWARTZ ML, 1971, J BIOL CHEM, V246, P5851; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019	38	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24596	24601						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929131				2022-12-25	WOS:A1994PQ49000016
J	ORTIZ, JA; GILGOMEZ, G; CASAROLIMARANO, RP; VILARO, S; HEGARDT, FG; HARO, D				ORTIZ, JA; GILGOMEZ, G; CASAROLIMARANO, RP; VILARO, S; HEGARDT, FG; HARO, D			TRANSFECTION OF THE KETOGENIC MITOCHONDRIAL 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A SYNTHASE CDNA INTO MEV-1 CELLS CORRECTS THEIR AUXOTROPHY FOR MEVALONATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-LIVER; GENE-EXPRESSION; INTESTINE; COA	A somatic cell mutant of the Chinese hamster ovary (CHO)-K1 (called Mev-1), auxotrophic for mevalonate by virtue of a complete lack of detectable cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase activity, was transfected with a plasmid containing the cDNA for ketogenic mitochondrial HMG-CoA synthase under the control of SV40 early promoter. The resulting stable cell line (Mev-SM) was able to grow in the absence of mevalonate. Analysis by Western blot showed that the new cell line strongly expressed mitochondrial HMG-CoA synthase protein. Immunocytochemical studies using specific antibodies against mitochondrial HMG-CoA synthase showed that the protein was located exclusively inside the mitochondria. The prototroph cell line Mev-SM can incorporate labeled ac etate into cholesterol in the absence of mevalonate. These results show that the new cell, line may circumvent the lack of cytosolic HMG-CoA synthase activity by producing cholesterol-convertible HMG-CoA inside the mitochondria.	UNIV BARCELONA,SCH PHARM,DEPT BIOCHEM & MOLEC BIOL,E-08028 BARCELONA,SPAIN; UNIV BARCELONA,SCH BIOL,CELL BIOL UNIT,E-08028 BARCELONA,SPAIN	University of Barcelona; University of Barcelona			Casaroli-Marano, Ricardo Pedro/D-4535-2014; Gil-Gomez, G/H-6307-2014; Haro, Diego/I-4623-2015	Casaroli-Marano, Ricardo Pedro/0000-0003-1812-9323; Gil-Gomez, G/0000-0002-9790-7308; Haro, Diego/0000-0001-9147-0486; Ortiz, Jose A./0000-0003-0505-3032				AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; BEISIEGEL U, 1982, J BIOL CHEM, V257, P3150; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3108; DASHTI N, 1979, BIOCHEM MED METAB B, V22, P365, DOI 10.1016/0006-2944(79)90024-3; ERICSSON J, 1993, BIOCHIMIE, V75, P167, DOI 10.1016/0300-9084(93)90074-3; FOLCH J, 1951, J BIOL CHEM, V191, P833; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; LOWE DM, 1985, BIOCHEM J, V232, P37, DOI 10.1042/bj2320037; PIGNATARO OP, 1983, MOL CELL ENDOCRINOL, V33, P53, DOI 10.1016/0303-7207(83)90056-4; ROYO T, 1993, J LIPID RES, V34, P867; RUNQUIST M, 1994, J BIOL CHEM, V269, P5804; Sambrook J, 1989, MOL CLONING LABORATO; SCHNITZERPOLOKO.R, 1981, J BIOL CHEM, V257, P472; SCHNITZERPOLOKOFF R, 1987, J CELL BIOCHEM, V35, P93, DOI 10.1002/jcb.240350203; SERRA D, 1993, ARCH BIOCHEM BIOPHYS, V301, P445, DOI 10.1006/abbi.1993.1169; THUMELIN S, 1993, BIOCHEM J, V292, P493, DOI 10.1042/bj2920493; WILLIAMS.DH, 1968, BIOCHEM J, V108, P353, DOI 10.1042/bj1080353	17	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28523	28526						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961793				2022-12-25	WOS:A1994PU16800001
J	DANESCH, U; WEBER, PC; SELLMAYER, A				DANESCH, U; WEBER, PC; SELLMAYER, A			ARACHIDONIC-ACID INCREASES C-FOS AND EGR-1 MESSENGER-RNA IN 3T3 FIBROBLASTS BY FORMATION OF PROSTAGLANDIN E(2) AND ACTIVATION OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; EPIDERMAL GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; SIGNAL TRANSDUCTION; GENE-TRANSCRIPTION; MESSENGER-RNA; PHORBOL ESTER; ADENYLATE-CYCLASE; HUMAN MONOCYTES; EXPRESSION	Studying Swiss 3T3 fibroblasts, we report that arachidonic acid strongly stimulates mRNA levels of the growth-associated immediate early genes c-fos and Egr-1. Structurally related compounds like arachidonic acid methyl ester, arachidonyl alcohol, or eicosatetraynoic acid are ineffective, indicating a specific role of free unesterified arachidonic acid or an arachidonic acid metabolite in c-fos and Egr-1 mRNA accumulation. Blocking the conversion of arachidonic acid to prostaglandins by inhibiting cyclooxygenase abolishes arachidonic acid induced accumulation of c-fos and Egr-1 mRNA. Inhibition of the lipoxygenase or cytochrome P-450 epoxygenase pathways has no significant effect on arachidonic acid-induced c-fos and Egr-1 mRNA levels, indicating that prostaglandin synthesis is necessary for the increase in c-fos and Egr-1 mRNA. Reversed phase high performance liquid chromatography revealed prostaglandin E(2) (PGE(2)) as the major arachidonic acid metabolite in Swiss 3T3 fibroblasts. When added to the cells, PGE(2) stimulates c-fos and Egr-1 mRNA levels to the same degree as arachidonic acid, Also, the inhibition of arachidonic acid-stimulated c-fos and Egr-1 mRNA accumulation by indomethacin is reversed by PGE(2). Contrary to reports that PGE(2) caused an increase in cAMP levels in Swiss 3T3 fibroblasts, we found that arachidonic acid and PGE(2) only minimally increase cAMP levels as compared with untreated cells. In contrast, inhibition of protein kinase C by calphostin C and chelerythrine or down-regulation with phorbol 12-myristate 13 acetate drastically reduces PGE(2) and arachidonic acid induced c-fos and Egr-1 mRNA levels. These data indicate that arachidonic acid exerts its stimulatory effect on c-fos and Egr-1 mRNA via synthesis of PGE(2) and subsequent activation of protein kinase C, probably through a PGE(2) receptor coupled to phospholipase C.	UNIV MUNICH,KREISLAUFKRANKHEITEN,KLINIKUM INNENSTADT,INST PROPHYLAXE & EPIDEMIOL,D-80336 MUNICH,GERMANY	University of Munich								BELL RM, 1991, J BIOL CHEM, V266, P4661; BLACK FM, 1990, BIOCHEM J, V266, P661, DOI 10.1042/bj2660661; BUTCHER RD, 1993, CANCER RES, V53, P3405; CLARKE SD, 1993, PROG LIPID RES, V32, P139, DOI 10.1016/0163-7827(93)90013-M; COWLEN MS, 1992, CANCER RES, V52, P6912; DAMRON DS, 1993, J BIOL CHEM, V268, P27335; DANESCH U, 1992, J BIOL CHEM, V267, P7185; DAVIES P, 1992, INFLAMMATION BASIC P, P123; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DOOLAN CM, 1994, BRIT J PHARMACOL, V111, P509, DOI 10.1111/j.1476-5381.1994.tb14766.x; GUSOVSKY F, 1991, MOL PHARMACOL, V40, P633; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; KACICH RL, 1988, MOL ENDOCRINOL, V2, P73, DOI 10.1210/mend-2-1-73; NAOR Z, 1991, MOL CELL ENDOCRINOL, V80, pC181, DOI 10.1016/0303-7207(91)90135-F; NEGISHI M, 1989, J BIOL CHEM, V264, P3916; NOLAN RD, 1988, MOL PHARMACOL, V33, P650; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; ROLAPLESZCZYNSKI M, 1992, BLOOD, V80, P1004; SAKATA A, 1987, J IMMUNOL, V138, P4353; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SHIER WT, 1980, P NATL ACAD SCI-BIOL, V77, P137, DOI 10.1073/pnas.77.1.137; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; STANKOVA J, 1992, BIOCHEM J, V282, P625; STONE RM, 1990, BLOOD, V76, P1225; SUMIDA C, 1993, PROSTAG LEUKOTR ESS, V48, P117, DOI 10.1016/0952-3278(93)90019-S; TEBBEY PW, 1992, BIOCHIM BIOPHYS ACTA, V1171, P27, DOI 10.1016/0167-4781(92)90136-N; TOMASKA L, 1993, J BIOL CHEM, V268, P5317; ZOR U, 1991, BIOCHIM BIOPHYS ACTA, V1091, P385, DOI 10.1016/0167-4889(91)90204-B	35	100	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27258	27263						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961634				2022-12-25	WOS:A1994PV77100019
J	DESROSIERS, C; FERNANDEZ, CA; DAVID, F; BRUNENGRABER, H				DESROSIERS, C; FERNANDEZ, CA; DAVID, F; BRUNENGRABER, H			REVERSIBILITY OF THE MITOCHONDRIAL ISOCITRATE DEHYDROGENASE REACTION IN THE PERFUSED-RAT-LIVER - EVIDENCE FROM ISOTOPOMER ANALYSIS OF CITRIC-ACID CYCLE INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KREBS CYCLE; HEPATIC GLUCONEOGENESIS; METABOLISM	The reversal of the mitochondrial isocitrate dehydrogenase reaction was investigated in rat livers perfused with [U-C-13(5)]glutamate or [U-C-13(5)]glutamine. The mass isotopomer distribution of citric acid cycle intermediates extracted from the livers was determined by gas chromatography-mass spectrometry. Citrate was enriched in an isotopomer containing five C-13. The formation of this isotopomer can only be explained by the reversal of the isocitrate dehydrogenase reaction. Calculation of kinetic parameters from the mass isotopomer data reveals a rapid interconversion of isocitrate and alpha-ketoglutarate. This interconversion results in an isotopic exchange between carbon 6 of citrate and mitochondrial CO2 that can affect the calculation of citric acid cycle kinetic parameters. Thus, the reversal of the isocitrate dehydrogenase reaction should be included in isotope labeling models of the citric acid cycle.	CASE WESTERN RESERVE UNIV, DEPT NUTR, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT BIOMED ENGN, CLEVELAND, OH 44106 USA; UNIV MONTREAL, DEPT NUTR, MONTREAL H3C 3J7, PQ, CANADA	Case Western Reserve University; Case Western Reserve University; Universite de Montreal			Rosiers, Christine Des/O-6285-2014		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35543] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; DALZIEL K, 1968, BIOCHEM J, V110, P223, DOI 10.1042/bj1100223; DALZIEL K, 1975, ENZYMES, V13, P1; DESROSIERS C, 1994, 1994 P S INT FED AUT, P354; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; ESENMO E, 1992, AM J PHYSIOL, V263, pE36, DOI 10.1152/ajpendo.1992.263.1.E36; Fansler B., 1969, METHODS ENZYMOL, V13, P26; FERNANDEZ CA, 1994, 1994 P S INT FED AUT, P3657; GABRIEL JL, 1986, METABOLISM, V35, P661, DOI 10.1016/0026-0495(86)90175-7; Haft DE, 1965, J BIOL CHEM, V240, P613; HANSFORD RG, 1975, J BIOL CHEM, V250, P8361; HEATH DF, 1985, BIOCHEM J, V227, P851, DOI 10.1042/bj2270851; HOEK JB, 1988, BIOCHEM J, V254, P1; KATZ J, 1993, J BIOL CHEM, V268, P25509; KELLEHER JK, 1985, AM J PHYSIOL, V248, pE252, DOI 10.1152/ajpendo.1985.248.2.E252; LANDAU BR, 1993, AM J PHYSIOL, V265, pE636, DOI 10.1152/ajpendo.1993.265.4.E636; Lee W. N. P., 1989, J BIOL CHEM, V264, P13002; LEE WNP, 1993, J BIOL CHEM, V268, P25522; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; NICHOLLS DG, 1969, BIOCHEM J, V114, P215, DOI 10.1042/bj1140215; PLAUT GWE, 1967, BIOCHEM BIOPH RES CO, V28, P628, DOI 10.1016/0006-291X(67)90360-9; REYNOLDS CH, 1978, BIOCHEM J, V171, P733, DOI 10.1042/bj1710733; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; ROSIERS CD, 1988, ANAL BIOCHEM, V173, P96, DOI 10.1016/0003-2697(88)90165-0; ROSIERS CD, 1991, J BIOL CHEM, V266, P1574; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; SMITH CM, 1979, EUR J BIOCHEM, V97, P283, DOI 10.1111/j.1432-1033.1979.tb13113.x; Veech R L, 1981, Curr Top Cell Regul, V18, P151; WANDERS RJA, 1981, EUR J BIOCHEM, V116, P609, DOI 10.1111/j.1432-1033.1981.tb05379.x	29	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27179	27182						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961626				2022-12-25	WOS:A1994PV77100007
J	MANT, A; NIELSEN, VS; KNOTT, TG; MOLLER, BL; ROBINSON, C				MANT, A; NIELSEN, VS; KNOTT, TG; MOLLER, BL; ROBINSON, C			MULTIPLE MECHANISMS FOR THE TARGETING OF PHOTOSYSTEM-I SUBUNIT-F, SUBUNIT-H, SUBUNIT-K, SUBUNIT-L, AND SUBUNIT-N INTO AND ACROSS THE THYLAKOID MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; ENTIRE PRECURSOR POLYPEPTIDES; CHLOROPHYLL A/B-PROTEIN; HORDEUM-VULGARE L; TRANSIT PEPTIDE; CDNA CLONE; NUCLEOTIDE-SEQUENCE; PROTON GRADIENT; PSI-K; BARLEY	The photosystem I (PSI) complex in higher plants contains eight nuclear-encoded subunits, of which two (PSI-F and -N) are synthesized with bipartite presequences containing cleavable thylakoid transfer sequences. Previous studies on four other chloroplast proteins bearing bipartite presequences have shown that they are transported across the thylakoid membrane by two distinct mechanisms. One mechanism is Delta pH dependent and hence sensitive to uncouplers, whereas the other is inhibited by azide. We show that PSI-F is targeted by the latter pathway, since its translocation across the thylakoid membrane is inhibited by azide but not by nigericin. Translocation is furthermore unaffected by the presence of high concentrations of the lumenal 23-kDa photosystem II (PSII) protein, which is known to be transported by the Delta pH dependent pathway. In contrast, translocation of PSI-N across the thylakoid membrane is completely blocked by saturating concentrations of pre-23-kDa protein. Three proteins are now known to be synthesized with thylakoid transfer signals in both higher plants and cyanobacteria (PSI-F, plastocyanin, and the 33-kDa PSII protein), and all three are transported by the azide-sensitive, possibly sec-dependent pathway. In contrast, PSI-N and the 23-kDa and 16-kDa PSII proteins (transported by the Delta pH-driven pathway in higher plants) are all absent in cyanobacteria. These data suggest that the Delta pH-dependent translocation mechanism for these proteins may also have arisen relatively recently during the evolution of the chloroplast. Three additional PSI proteins (PSI-H, -K, and -L) are synthesized in the cytosol with stroma-targeting presequences and hence integrate into the thylakoid membrane by means of information in the mature proteins. We show that the integration mechanisms are insensitive to azide in each case, and nigericin causes only a slight inhibition of integration in each case. We therefore suggest that these proteins are targeted into the thylakoid membrane by a separate pathway(s).	ROYAL VET & AGR UNIV, DEPT PLANT BIOL, PLANT BIOCHEM LAB, DK-1871 FREDERIKSBERG C, DENMARK	University of Copenhagen	MANT, A (corresponding author), UNIV WARWICK, DEPT BIOL SCI, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND.		Møller, Birger Lindberg/GQI-1792-2022; Møller, Birger Lindberg/H-2657-2014	Møller, Birger Lindberg/0000-0002-3252-3119; Møller, Birger Lindberg/0000-0002-3252-3119; Mant, Alexandra/0000-0001-7169-209X				ANDERSEN B, 1993, PIGMENT PROTEIN COMP, P383; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; CHITNIS PR, 1987, PLANT MOL BIOL, V10, P3, DOI 10.1007/BF00014181; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; FRANZEN LG, 1989, MOL GEN GENET, V219, P137; GAVEL Y, 1991, FEBS LETT, V282, P41, DOI 10.1016/0014-5793(91)80440-E; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HE WZ, 1992, FEBS LETT, V308, P298, DOI 10.1016/0014-5793(92)81297-Y; HENRY R, 1994, J BIOL CHEM, V269, P10189; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; HULFORD A, 1994, J BIOL CHEM, V269, P3251; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KJAERULFF S, 1993, J BIOL CHEM, V268, P18912; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; KNOETZEL J, 1993, PLANT MOL BIOL, V22, P337, DOI 10.1007/BF00014940; KNOTT TG, 1994, J BIOL CHEM, V269, P7843; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KUHN A, 1988, EUR J BIOCHEM, V177, P267, DOI 10.1111/j.1432-1033.1988.tb14372.x; KUWABARA T, 1987, P NATL ACAD SCI USA, V84, P8230, DOI 10.1073/pnas.84.23.8230; LAGOUTTE B, 1988, FEBS LETT, V232, P275, DOI 10.1016/0014-5793(88)80752-X; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; MOULD RM, 1991, J BIOL CHEM, V266, P17286; MOULD RM, 1991, J BIOL CHEM, V266, P12189; MUNCH S, 1988, CURR GENET, V14, P511, DOI 10.1007/BF00521277; NIELSEN VS, 1994, J BIOL CHEM, V269, P3762; OKKELS JS, 1988, FEBS LETT, V237, P108, DOI 10.1016/0014-5793(88)80181-9; OKKELS JS, 1992, PLANT MOL BIOL, V18, P989, DOI 10.1007/BF00019215; OKKELS JS, 1991, J BIOL CHEM, V266, P6767; OKKELS JS, 1989, FEBS LETT, V250, P575, DOI 10.1016/0014-5793(89)80799-9; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; STEPPUHN J, 1988, FEBS LETT, V237, P218, DOI 10.1016/0014-5793(88)80205-9; THEG SM, 1989, J BIOL CHEM, V264, P6730; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P1165; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; ZILBER AL, 1992, PLANT PHYSIOL, V99, P901, DOI 10.1104/pp.99.3.901	45	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27303	27309						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961641				2022-12-25	WOS:A1994PV77100027
J	SLOAN, IS; HOROWITZ, PM; CHIRGWIN, JM				SLOAN, IS; HOROWITZ, PM; CHIRGWIN, JM			RAPID SECRETION BY A NONCLASSICAL PATHWAY OF OVEREXPRESSED MAMMALIAN MITOCHONDRIAL RHODANESE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATHEPSIN-D; MOLECULAR CHAPERONES; LIVER RHODANESE; PROTEINS; CELL; EXPRESSION; CDNA; THIOREDOXIN; MEMBRANES; SEQUENCE	Rhodanese is a small (33 kDa) monomeric sulfurtransferase which is synthesized on cytoplasmic ribosomes and imported into the mitochondrial matrix without cleavage of its amino terminus. When we transfected mammalian cell lines with rhodanese cDNA under the control of an efficient viral promoter, up to 40% of the overexpressed protein was secreted into the medium. This secretion was not the result of cell lysis, did not occur via the endoplasmic reticulum, and did not require the amino-terminal mitochondrial import signal. Addition of a carboxyl-terminal peptide extension did not block secretion, nor did a number of inhibitors of cellular sorting processes. Rhodanese polypeptide is known to associate with chaperonin proteins. In the absence of available mitochondrial import sites, such a complex in the cytoplasm of transfected cells could deliver unfolded rhodanese to export pores on the inner surface of the plasma membrane. This mechanism could contribute to the nonclassical secretion of cytoplasmically synthesized interleukins, growth factors, and lectins.	UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV ENDOCRINOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; AUDIE L MURPHY MEM VET ADM MED CTR,RES SERV,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 05729] Funding Source: Medline; NIGMS NIH HHS [GM 25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGGARAM V, 1985, BIOCHEM BIOPH RES CO, V130, P407, DOI 10.1016/0006-291X(85)90431-0; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FENTON WA, 1984, J BIOL CHEM, V259, P6616; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; Kuchler Karl, 1993, Trends in Cell Biology, V3, P421, DOI 10.1016/0962-8924(93)90030-5; KUDLICKI W, 1994, J BIOL CHEM, V269, P16549; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; Linstedt R., 1993, J BIOL CHEM, V268, P11750; McNeil Paul L., 1993, Trends in Cell Biology, V3, P302, DOI 10.1016/0962-8924(93)90012-P; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; REDDY SV, 1993, BIOTECHNIQUES, V15, P444; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; SACHDEV D, 1991, ADV EXP MED BIOL, V306, P335; Sambrook J, 1989, MOL CLONING LABORATO; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; TARENTINO A, 1991, LABORATORY METHODS V, P299; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; WEILAND KL, 1991, BIOCHEM J, V275, P227, DOI 10.1042/bj2750227; WENG L, 1978, J BIOL CHEM, V253, P8109; WESTLEY J, 1983, FUND APPL TOXICOL, V3, P377, DOI 10.1016/S0272-0590(83)80008-6; Westley J, 1981, Methods Enzymol, V77, P285; WIENHUES U, 1992, BIOESSAYS, V14, P17, DOI 10.1002/bies.950140105; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447	46	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27625	27630						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961679				2022-12-25	WOS:A1994PV77100072
J	CHEN, XR; WRIGHT, KL; BERKOWITZ, EA; AZIZKHAN, JC; TING, JPY; LEE, DC				CHEN, XR; WRIGHT, KL; BERKOWITZ, EA; AZIZKHAN, JC; TING, JPY; LEE, DC			PROTEIN INTERACTIONS AT SP1-LIKE SITES IN THE TGF-ALPHA PROMOTER AS VISUALIZED BY IN-VIVO GENOMIC FOOTPRINTING	ONCOGENE			English	Article							GROWTH-FACTOR-ALPHA; LIVER EPITHELIAL-CELLS; CHEMICALLY TRANSFORMED INVITRO; HUMAN-BREAST-CANCER; MESSENGER-RNA; TRANSCRIPTION FACTOR; TRANSGENIC MICE; ANTERIOR-PITUITARY; DEVELOPMENTAL EXPRESSION; HUMAN KERATINOCYTES	Transcription from the rat TGP alpha promoter initiates at two predominant sites (-188 and -58) in a G+C-rich region that does not contain TATA or CAAT motifs. Previous studies using transfected reporter constructs implicated the transcription factor Sp1 in active expression from the promoter, particularly from the -58 site (Chen et al., 1992; Shin et al., 1992). In the present report we have examined the functionality of two adjacent clusters of Sp1-like recognition sites that are located in the upstream portion of the promoter from -300 to -273. A double-stranded oligonucleotide, which spanned this region and contained the putative Sp1 elements, demonstrated similar gel-mobility shifts in the presence of both crude HeLa cells nuclear extract and pure Sp1 protein. Mutations that simultaneously altered several of the overlapping Sp1 elements significantly reduced the gel-mobility shift activity of this oligonncleotide probe and, when introduced into the promoter templates, inhibited transcription in vitro from the proximal -188 start site. To confirm the binding of protein to these sites in cells, we carried out an in vivo genomic footprinting analysis of this portion of the TGF alpha promoter in normal and transformed rat liver epithelial cell lines that express the endogenous gene at varying levels. This analysis revealed clear evidence of protein/DNA interaction at Sp1-like sites in the -300 and -273 region in cells actively expressing the gene but not in a normal, parental cell. line that expressed very low levels of TGF alpha mRNA. Collectively, these results corroborate the functional importance of Sp1 binding elements in the -300 to -273 region, and together with previous findings, indicate that two clusters of Sp1 binding sites respectively determine levels of transcription from the -188 and -58 start sites. Our additional finding that Sp1 mRNA and protein were present at similar levels in normal and transformed cells that expressed the endogenous TGF alpha gene at markedly different levels, suggests that the activity of the TGF alpha promoter could be regulated via the accessibility of Sp1 protein.	UNIV N CAROLINA, SCH MED, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL CANCER INSTITUTE [R01CA048185, R01CA043793] Funding Source: NIH RePORTER; NCI NIH HHS [CA-48185, CA-43793] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BORGUNDVAAG B, 1992, ENDOCRINOLOGY, V130, P3453, DOI 10.1210/en.130.6.3453; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHEN XR, 1992, ONCOGENE, V7, P1805; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1987, CANCER RES, V47, P707; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GODWIN AK, 1990, ONCOGENE, V5, P1231; HAMBURGER AW, 1993, P SOC EXP BIOL MED, V202, P64; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KOHDA D, 1989, BIOCHEMISTRY-US, V28, P953, DOI 10.1021/bi00429a005; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU C, 1988, CANCER RES, V48, P850; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; LYNCH MJ, 1993, CANCER RES, V53, P4041; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCKNIGHT GS, 1977, ANAL BIOCHEM, V78, P86, DOI 10.1016/0003-2697(77)90011-2; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUELLER SG, 1991, MOL ENDOCRINOL, V5, P1439, DOI 10.1210/mend-5-10-1439; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; MURAKAMI H, 1993, CANCER RES, V53, P1719; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RAYMOND VW, 1989, CANCER RES, V49, P3608; ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; SEROOGY KB, 1993, J NEUROCHEM, V60, P1777, DOI 10.1111/j.1471-4159.1993.tb13403.x; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; TAKAGI H, 1993, CANCER RES, V53, P4329; TSAO MS, 1985, CANCER RES, V45, P5139; TSAO MS, 1985, CANCER RES, V45, P5134; TWARDZIK DR, 1982, SCIENCE, V216, P894, DOI 10.1126/science.6177040; TWARDZIK DR, 1983, VIROLOGY, V124, P201, DOI 10.1016/0042-6822(83)90307-0; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WILCOX JN, 1988, J NEUROSCI, V8, P1901; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZIPFEL PA, 1993, CELL GROWTH DIFFER, V4, P637; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	67	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3179	3187						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936640				2022-12-25	WOS:A1994PM65800009
J	PRONCZUK, A; KHOSLA, P; HAYES, KC				PRONCZUK, A; KHOSLA, P; HAYES, KC			DIETARY MYRISTIC, PALMITIC, AND LINOLEIC CHOLESTEROLEMIA IN GERBILS	FASEB JOURNAL			English	Article						FATTY ACIDS; PLASMA CHOLESTEROL; REGRESSION ANALYSIS; THRESHOLD	LOW-DENSITY-LIPOPROTEIN; ESSENTIAL FATTY-ACID; PLASMA-CHOLESTEROL; LDL-CHOLESTEROL; SERUM-LIPIDS; METABOLISM; MONKEYS; REQUIREMENT; SATURATION; RECEPTOR	Previous studies with cebus monkeys and review of published human data indicated that 85% to 90% of the variation in plasma cholesterol (TC) could be explained on the basis of dietary myristic (14:0) and linoleic (18:2) acid intake in the absence of cholesterol, and that 16:0 contributed to cholesterolemia as dietary cholesterol was increased. Because monkeys are a limited resource, a more convenient, sensitive model was sought for investigating these dietary fatty acid and plasma lipid relationships. Accordingly this report describes the results of multiple regression analysis bf the TC response to dietary fatty acids based on 319 young, male Mongolian gerbils fed a total of 59 purified diets supplying about 40% energy as fat from single or blended fat sources. Gerbils (6-16 animals per dietary group) were fed purified diets (21 with 0.01 to 0.08% cholesterol and 38 cholesterol-free) for 4-week periods. When cholesterol-free diets were fed, dietary 14:0 and 18:2 together accounted for 89% of the observed variation in TC. Although 14:0 consumption increased TC in a linear manner, the independent ability of 18:2 to lower cholesterol was nonlinear and exhibited a threshold effect at 5-6% dietary energy above which further lowering of TC was less remarkable. In gerbils consuming cholesterol-supplemented diets, 87% of the observed variation in TC could be accounted for by a regression equation that included 14:0, palmitic acid (16:0), and a log function of 18:2 plus dietary cholesterol itself. These results demonstrate the applicability of gerbils for such studies and confirm previous observations in monkeys and humans that dietary 14:0 and 18:2 are the main fatty acids modulating plasma cholesterol under normocholesterolemic circumstances when consuming low-cholesterol diets and lipoprotein metabolism is normal) whereas 16:0 also appears modestly hypercholesterolemic when LDL receptors are compromised (i.e., when dietary cholesterol or certain metabolic factors have encumbered lipoprotein metabolism).	BRANDEIS UNIV,FOSTER BIOMED RES LAB,WALTHAM,MA 02254	Brandeis University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049128] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49128] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRONTESTEWART B, 1956, LANCET, V1, P521; CHRISTOPHE A, 1978, ARCH INT PHYSL BIOCH, V86, P414; DAUMERIE CM, 1992, P NATL ACAD SCI USA, V89, P10797, DOI 10.1073/pnas.89.22.10797; DIFRANCESCO I, 1990, ACTA CARDIOL, V45, P233; DUPONT J, 1990, J AM COLL NUTR, V9, P272; FIELDING CJ, 1992, FASEB J, V6, P3162, DOI 10.1096/fasebj.6.13.1327930; FUNGWE TV, 1992, J LIPID RES, V33, P179; GRUNDY SM, 1989, J NUTR, V119, P529, DOI 10.1093/jn/119.4.529; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HAYES KC, 1991, AM J CLIN NUTR, V53, P491, DOI 10.1093/ajcn/53.2.491; HAYES KC, 1992, FASEB J, V6, P2600, DOI 10.1096/fasebj.6.8.1592210; HAYES KC, 1992, J NUTR, V122, P374, DOI 10.1093/jn/122.2.374; HAYES KC, 1994, IN PRESS J NUTR BIOC; HAYES KC, 1990, NEW ENGL J MED, V321, P402; Hegsted D. M., 1991, Health effects of dietary fatty acids., P50; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; HEGSTED DM, 1967, J LIPID RES, V8, P210; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; IP C, 1985, CANCER RES, V45, P1997; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; KEYS A, 1957, LANCET, V2, P959; KHOSLA P, 1993, BIOCHIM BIOPHYS ACTA, V1210, P13, DOI 10.1016/0005-2760(93)90043-9; KHOSLA P, 1992, AM J CLIN NUTR, V55, P51, DOI 10.1093/ajcn/55.1.51; KHOSLA P, 1991, BIOCHIM BIOPHYS ACTA, V1083, P46, DOI 10.1016/0005-2760(91)90123-Y; Khosla P, 1993, Metabolism, V42, P915, DOI 10.1016/0026-0495(93)90070-5; KRISETHERTON PM, 1993, METABOLISM, V42, P121, DOI 10.1016/0026-0495(93)90182-N; KRITCHEVSKY D, 1988, NUTR REV, V46, P177, DOI [10.1111/j.1753-4887.1988.tb05419.x, 10.1301/nr.2004.may.177-203]; Lands W. E. M., 1991, Health effects of dietary fatty acids., P21; LEPAGE G, 1986, J LIPID RES, V27, P114; MATTSON FH, 1985, J LIPID RES, V26, P194; MCGANDY RB, 1970, AM J CLIN NUTR, V23, P1288; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MERCER NJH, 1979, LIPIDS, V14, P1009, DOI 10.1007/BF02533438; MUKHERJEE S, 1969, J ATHEROSCLER RES, V10, P51, DOI 10.1016/S0368-1319(69)80081-5; NG TKW, 1992, J AM COLL NUTR, V11, P383; NICOLOSI RJ, 1981, ATHEROSCLEROSIS, V38, P359, DOI 10.1016/0021-9150(81)90052-6; NICOLOSI RJ, 1990, ARTERIOSCLEROSIS, V10, P119, DOI 10.1161/01.ATV.10.1.119; PRONCZUK A, 1991, LIPIDS, V26, P213, DOI 10.1007/BF02543974; RASSIAS G, 1991, EUR J CLIN NUTR, V45, P315; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; SUNDRAM K, 1994, AM J CLIN NUTR, V59, P841, DOI 10.1093/ajcn/59.4.841; THOLSTRUP T, 1994, AM J CLIN NUTR, V59, P371, DOI 10.1093/ajcn/59.2.371; WEINGAND KW, 1990, CLIN CHEM, V36, P575; ZOCK PL, 1994, ARTERIOSCLER THROMB, V14, P567, DOI 10.1161/01.ATV.14.4.567; 1989, IMPLICATIONS REDUCIN	45	47	57	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1994	8	14					1191	1200		10.1096/fasebj.8.14.7958627	http://dx.doi.org/10.1096/fasebj.8.14.7958627			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PT128	7958627				2022-12-25	WOS:A1994PT12800016
J	BARROW, RT; PARKER, ET; KRISHNASWAMY, S; LOLLAR, P				BARROW, RT; PARKER, ET; KRISHNASWAMY, S; LOLLAR, P			INHIBITION BY HEPARIN OF THE HUMAN BLOOD-COAGULATION INTRINSIC PATHWAY FACTOR-X ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT HEPARIN; PORCINE FACTOR-VIII; FACTOR-IXA; PHOSPHOLIPID-VESICLES; DERMATAN SULFATE; MEMBRANE-SURFACE; COFACTOR-II; THROMBIN; BINDING; PURIFICATION	The effect of heparin and other glycosaminoglycans on the activation of factor X by the phospholipid membrane-bound human factor IXa-factor VIIIa complex (intrinsic fXase) was studied. Standard heparin inhibited purified intrinsic fXase by 50% at approximately 0.08 unit/ml (0.4 mu g/ml), which is below the normal range of heparin concentrations achieved during antithrombotic therapy (0.2-0.7 unit/ml). Kinetic and binding experiments revealed that heparin behaves as a partial noncompetitive inhibitor. The inhibition constant of heparin with low affinity for antithrombin was indistinguishable from heparin with high affinity for antithrombin (K-i = 20 nM). Additionally, ''low molecular weight'' heparin, which also is used as an antithrombotic drug, was a potent inhibitor of intrinsic fXase (K-i = 60 nM). Dermatan sulfate inhibited intrinsic fXase much more weakly than standard heparin (IC50 = 80 mu g/ml). The IC50 of the other mammalian glycosaminoglycans, chondroitin sulfate, keratan sulfate, and hyaluronic acid, were greater than 100 mu g/ml. Purified prothrombinase and extrinsic fXase were not inhibited by heparin. We propose that part of the antithrombotic action of heparin and low molecular weight heparin is due to antithrombin-independent inhibition of intrinsic fXase and that heparin with low affinity for antithrombin may be useful as an antithrombotic agent.	EMORY UNIV,DEPT MED,ATLANTA,GA 30322	Emory University					NHLBI NIH HHS [HL46215, HL47465] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046215, R01HL047465] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARROW RT, 1994, J BIOL CHEM, V269, P593; Bevington P. R., 1969, DATA REDUCTION ERROR; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BREYER HG, 1991, SEMIN THROMB HEMOST, V17, P336, DOI 10.1055/s-2007-1002631; Brinkhous KM, 1939, AM J PHYSIOL, V125, P683, DOI 10.1152/ajplegacy.1939.125.4.683; BROZE GJ, 1993, BLOOD, V82, P1679; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DOL F, 1989, BLOOD, V74, P1577; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; HOLMER E, 1989, HEPARIN CHEM BIOL PR, P575; JORGENSEN LN, 1993, BRIT J SURG, V80, P689, DOI 10.1002/bjs.1800800607; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3807; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; Lundblad R L, 1976, Methods Enzymol, V45, P156; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; OFOSU FA, 1982, THROMB RES, V28, P487, DOI 10.1016/0049-3848(82)90165-7; OLSON ST, 1991, J BIOL CHEM, V266, P6342; PRANDONI P, 1992, BRIT J SURG, V79, P505, DOI 10.1002/bjs.1800790610; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SEGEL IH, 1974, ENZYME KINETICS BEHA, P100; THOMAS DP, 1981, THROMB HAEMOSTASIS, V46, P185; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433	36	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26796	26800						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929416				2022-12-25	WOS:A1994PQ93100035
J	CHEN, ZG; LI, Y; CHEN, E; HALL, DL; DARKE, PL; CULBERSON, C; SHAFER, JA; KUO, LC				CHEN, ZG; LI, Y; CHEN, E; HALL, DL; DARKE, PL; CULBERSON, C; SHAFER, JA; KUO, LC			CRYSTAL-STRUCTURE AT 1.9-ANGSTROM RESOLUTION OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE	L-735,524 is a potent, orally bioavailable inhibitor of human immunodeficiency virus (HIV) protease currently in a Phase II clinical trial. We report here the three-dimensional structure of L-735,524 complexed to HIV-2 protease at 1.9-Angstrom resolution, as well as the structure of the native HIV-2 protease at 2.5-Angstrom resolution. The structure of HIV-2 protease is found to be essentially identical to that of HIV-1 protease. In the crystal lattice of the HIV-2 protease complexed with L-735,524, the inhibitor is chelated to the active site of the homodimeric enzyme in one orientation. This feature allows an unambiguous assignment of protein-ligand interactions from the electron density map. Both Fourier and difference Fourier maps reveal clearly the closure of the flap domains of the protease upon L-735,524 binding. Specific interactions between the enzyme and the inhibitor include the hydroxy group of the hydroxyaminopentane amide moiety of L-735,524 ligating to the carboxyl groups of the essential Asp-25 and Asp-25' enzymic residues and the amide oxygens of the inhibitor hydrogen bonding to the backbone amide nitrogen of Ile-50 and Ile-50' via an intervening water molecule. A second bridging water molecule is found between the amide nitrogen N2 of L-735,524 and the carboxyl oxygen of Asp 29'. Although other hydrogen bonds also add to binding, an equally significant contribution to affinity arises from hydrophobic interactions between the protease and the inhibitor throughout the pseudo-symmetric S1/S1', S2/S2', and S3/S3' regions of the enzyme. Except for its pyridine ring, all lipophilic moieties (t-butyl, indanyl, benzyl, and piperidyl) of L-735,524 are rigidly defined in the active site.			CHEN, ZG (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,DEPT BIOL CHEM,W POINT,PA 19486, USA.							ARGOS P, 1979, BIOCHEMISTRY-US, V18, P4951, DOI 10.1021/bi00589a025; CRAIG JC, 1993, ANTIVIR CHEM CHEMOTH, V4, P335, DOI 10.1177/095632029300400605; DIANZANI F, 1993, ANTIVIR CHEM CHEMOTH, V4, P329, DOI 10.1177/095632029300400604; GHOSH AK, 1994, J MED CHEM, V37, P2506, DOI 10.1021/jm00042a002; JACOBSEN H, 1993, J CELL BIOCH E S, V17, P90; MULICHAK AM, 1993, J BIOL CHEM, V268, P13103; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2; TONG L, 1993, P NATL ACAD SCI USA, V90, P8387, DOI 10.1073/pnas.90.18.8387; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096	10	159	165	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26344	26348						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929352				2022-12-25	WOS:A1994PQ93000062
J	GONZALEZRUBIO, C; JIMENEZCLAVERO, MA; FONTAN, G; LOPEZTRASCASA, M				GONZALEZRUBIO, C; JIMENEZCLAVERO, MA; FONTAN, G; LOPEZTRASCASA, M			THE INHIBITORY EFFECT OF FACTOR-J ON THE ALTERNATIVE COMPLEMENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C3 NEPHRITIC FACTOR; BOUND C3B; FACTOR-B; AMPLIFICATION CONVERTASE; 3RD COMPONENT; SIALIC-ACID; FACTOR-H; ACTIVATION; RECOGNITION; BETA-1H	Factor J (FJ) is a cationic glycoprotein with inhibitory activity in C1, the first component of the classical complement pathway. This study demonstrates that FJ is able to regulate the activity of the alternative complement pathway. FJ inhibits the generation of fluid phase and cell-bound alternative pathway C3 convertase, C3b,Bb (C3-cleaving enzyme). Thus, FJ interferes with the generation of alternative pathway C3 convertase when sheep erythrocytes bearing antibody and activated C3 and C4 (EAC4b,3b) are incubated with the individual complement components, factors B, D, and P. FJ accelerates the decay of C3 convertase with a time course similar to that of factor H, and when both regulators are present together, the decay of enzyme activity is faster than when they are added separately. Furthermore, FJ is able to inhibit the cleavage of C3 by factor B in a fluid-phase assay. FJ prevents the initiation of alternative pathway activation in ''more stabilized systems'' with well known activators of alternative pathway C3 convertase such as C3 nephritic factor (an autoantibody against alternative pathway C3 convertase), cobra venom factor, and rabbit erythrocytes. In these systems, FJ has no effect on C3 convertase stabilized by rabbit erythrocytes or cobra venom factor. In contrast, FJ promotes the dissociation of C3 convertase stabilized by C3 nephritic factor, but with much lower efficiency than in preventing initiation. Direct interac tion of FJ with individual components of C3 convertase was shown by a solid-phase binding assay using plates coated with C3, C3b, B, Bb, or FJ. FJ inhibitory activity in the alternative pathway can be modulated by polyanions like heparin. FJ-mediated inhibition in the alternative complement pathway can be modified by surface interactions, as occurs during alternative pathway C3 convertase activation. Thus, when FJ is adsorbed by and eluted from hydroxylapatite and reverse phase columns, its inhibitory effect on more stabilized systems is lost. This loss of inhibitory activity is fully reversed when FJ is rechromatographed on heparin-Sepharose or Sepharose columns. Taking into account these data, FJ may be included in the group of highly charged molecules that inhibit the activation of classical and alternative complement pathways (i.e. eosinophil major basic protein, protamine, and heparin).	HOSP LA PAZ,UNIDAD INMUNOL,E-28046 MADRID,SPAIN	Hospital Universitario La Paz			López-Trascasa, Margarita/L-2699-2014; Jimenez-Clavero, Miguel Angel/E-3048-2010	López-Trascasa, Margarita/0000-0001-8594-282X; Jimenez-Clavero, Miguel Angel/0000-0003-2125-9743				CARRENO MP, 1989, EUR J IMMUNOL, V19, P2145, DOI 10.1002/eji.1830191126; CYONG JC, 1982, J EXP MED, V155, P587, DOI 10.1084/jem.155.2.587; DAHA MR, 1976, J IMMUNOL, V116, P1; Edens E, 1993, COMPLEMENT PROFILES, V1, P96; FEARON DT, 1977, P NATL ACAD SCI USA, V74, P1683, DOI 10.1073/pnas.74.4.1683; FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971; FISHELSON Z, 1987, MOL IMMUNOL, V24, P987, DOI 10.1016/0161-5890(87)90011-3; GIGLI I, 1969, J EXP MED, V129, P679, DOI 10.1084/jem.129.4.679; HORSTMANN RD, 1985, J IMMUNOL, V134, P1101; HUDSON L, 1989, PRACTICAL IMMUNOLOGY, P34; HUDSON L, 1989, PRACTICAL IMMUNOLOGY, P49; Jimenez-Clavero M. A., 1993, Molecular Immunology, V30, P21, DOI 10.1016/0161-5890(93)90242-4; JIMENEZCLAVERO MA, 1994, CLIN BIOCHEM, V27, P169, DOI 10.1016/0009-9120(94)90051-5; JOINER KA, 1988, ANNU REV MICROBIOL, V42, P201, DOI 10.1146/annurev.mi.42.100188.001221; KAZATCHKINE MD, 1979, J EXP MED, V150, P1202, DOI 10.1084/jem.150.5.1202; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; KERR MA, 1981, METHOD ENZYMOL, V80, P102; KOSKI CL, 1985, J IMMUNOL, V134, P1810; LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIS JD, 1984, J BIOL CHEM, V259, P2685; LESAVRE PH, 1979, J IMMUNOL, V123, P529; LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498; Liszewski M. Kathryn, 1993, P917; LOPEZTRASCASA M, 1989, J BIOL CHEM, V264, P16214; LOPEZTRASCASA M, 1987, J IMMUNOL METHODS, V98, P77, DOI 10.1016/0022-1759(87)90438-8; MANGHAM DC, 1993, J CLIN PATHOL, V46, P517, DOI 10.1136/jcp.46.6.517; NAGAKI K, 1978, INT ARCH ALLER A IMM, V57, P221, DOI 10.1159/000232106; NICHOLSON-WELLER A, 1991, Complement and Inflammation, V8, P198; NILSSON UR, 1965, J EXP MED, V122, P277, DOI 10.1084/jem.122.2.277; OHI H, 1990, J IMMUNOL METHODS, V131, P71, DOI 10.1016/0022-1759(90)90234-M; PANGBURN MK, 1989, J IMMUNOL, V142, P2759; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416; PANGBURN MK, 1980, J IMMUNOL, V124, P977; PANGBURN MK, 1984, SPRINGER SEMIN IMMUN, V7, P163, DOI 10.1007/BF01893019; ROOS MH, 1982, NATURE, V298, P854, DOI 10.1038/298854a0; SAHU A, 1993, MOL IMMUNOL, V30, P679, DOI 10.1016/0161-5890(93)90079-Q; SAKAI K, 1973, J IMMUNOL, V110, P1010; SANCHEZCORRAL P, 1989, J IMMUNOL METHODS, V122, P105, DOI 10.1016/0022-1759(89)90340-2; SANCHEZCORRAL P, 1990, MOL IMMUNOL, V27, P891, DOI 10.1016/0161-5890(90)90156-T; SEGURADO OG, 1992, CLIN EXP IMMUNOL, V87, P410; VOGEL CW, 1985, DEV COMP IMMUNOL, V9, P311, DOI 10.1016/0145-305X(85)90122-3; VOGEL CW, 1984, J IMMUNOL METHODS, V73, P203, DOI 10.1016/0022-1759(84)90045-0; WEILER JM, 1988, J IMMUNOL, V140, P1605; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; WEILER JM, 1983, IMMUNOPHARMACOLOGY, V6, P245, DOI 10.1016/0162-3109(83)90024-3	47	6	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26017	26024						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929312				2022-12-25	WOS:A1994PQ93000016
J	CHEFALO, PJ; YANG, JM; RAMAIAH, KVA; GEHRKE, L; CHEN, JJ				CHEFALO, PJ; YANG, JM; RAMAIAH, KVA; GEHRKE, L; CHEN, JJ			INHIBITION OF PROTEIN-SYNTHESIS IN INSECT CELLS BY BACULOVIRUS-EXPRESSED HEME-REGULATED EIF-2-ALPHA KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; CONTROLLED TRANSLATIONAL REPRESSOR; ALPHA-SUBUNIT; FACTOR EIF-2; HELA-CELLS; PHOSPHORYLATION; GCN2; YEAST; FACTOR-2-ALPHA; ACTIVATION	To study further the regulation of the hems-regulated eIF-2 alpha kinase (HRI), we have produced functional wild type HRI using the baculovirus expression system. The amount of recombinant HRI protein expressed in insect cells is approximately 10 times higher than levels in reticulocytes. Baculovirus-expressed HRI (BV-HRI) is indistinguishable from HRI purified from rabbit reticulocytes, It is active both as an autokinase and an eIF-2 alpha kinase. BV-HRI is regulated by heme in vitro as well as in intact insect cells. Coexpression of the wild type HRI with the inactive K199R HRI, S51A eIF-2 alpha, or interleukin-1 beta (IL-1 beta) results in diminished expression of these proteins. Expression of wild type HRI also results in severe inhibition of general protein synthesis in Sf9 cells when compared with cells expressing K199R HRI or IL-beta. In addition, the guanine nucleotide exchange activity of eIF-2B is suppressed in Sf9 cells expressing wild type HRI but not in cells expressing the K199R HRI or IL-1 beta. Furthermore, expression of wild type HRI is increased by coexpression with the nonphosphorylatable S51A eIF-2 alpha or by the addition of hemin, which inhibits HRI activity. These results provide evidence that translational regulation by phosphorylation of eIF-2 alpha and sequestration of eIF-2B can operate in insect cells.	MIT,HARVARD MIT DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139	Harvard University; Massachusetts Institute of Technology (MIT)				Ramaiah, Kolluru/0000-0002-3478-5294	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042504] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK016272] Funding Source: Medline; NIGMS NIH HHS [GM42504, R01 GM042504] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BOAL TR, 1993, BIOCHIM BIOPHYS ACTA, V1176, P257, DOI 10.1016/0167-4889(93)90053-R; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P315, DOI 10.1073/pnas.88.2.315; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHEN JJ, 1993, TRANSLATIONAL REGULA, V2, P349; CHOI SY, 1992, J BIOL CHEM, V267, P286; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; CROSBY JS, 1994, MOL CELL BIOL, V14, P3906, DOI 10.1128/MCB.14.6.3906; DEALDANA CRV, 1993, P NATL ACAD SCI USA, V90, P7215; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DUNCAN R, 1985, J BIOL CHEM, V260, P5486; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; FAGARD R, 1981, P NATL ACAD SCI-BIOL, V78, P866, DOI 10.1073/pnas.78.2.866; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GROSS M, 1978, BIOCHIM BIOPHYS ACTA, V520, P650, DOI 10.1016/0005-2787(78)90150-8; GROSS M, 1987, BIOCHIM BIOPHYS ACTA, V908, P123, DOI 10.1016/0167-4781(87)90051-0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JACKSON RJ, 1985, BIOCHIM BIOPHYS ACTA, V826, P224, DOI 10.1016/0167-4781(85)90010-7; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KIMBALL SR, 1990, J BIOL CHEM, V265, P16794; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LONDON IM, 1987, ENZYMES, V18, P359; MAO XH, 1992, J BIOL CHEM, V267, P20444; MATTS RL, 1984, J BIOL CHEM, V259, P6708; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MURTHARIEL P, 1993, J BIOL CHEM, V268, P12946; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; QU SM, 1994, GENE, V140, P239, DOI 10.1016/0378-1119(94)90550-9; RAMAIAH KVA, 1994, MOL CELL BIOL, V14, P4546, DOI 10.1128/MCB.14.7.4546; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; THOMIS DC, 1992, P NATL ACAD SCI USA, V89, P10837, DOI 10.1073/pnas.89.22.10837; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; YANG JM, 1992, J BIOL CHEM, V267, P20519	45	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25788	25794						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929284				2022-12-25	WOS:A1994PQ49100083
J	DEY, S; DOU, DX; ROSEN, BP				DEY, S; DOU, DX; ROSEN, BP			ATP-DEPENDENT ARSENITE TRANSPORT IN EVERTED MEMBRANE-VESICLES OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ARSENATE RESISTANCE; ANION PUMP; TRANSLOCATING ATPASE; ARSB PROTEIN; MOLECULAR CHARACTERIZATION; EXPRESSION; OPERON; CONSTRUCTION; SYSTEMS; CLONING	Resistance to toxic oxyanions of arsenic and antimony in Escherichia coli results from active efflux of these anions out of the cell. Extrusion is an active process mediated by an ATP-dependent pump composed of two types of subunits, the integral membrane ArsB protein and the catalytic ArsA subunit. An in vitro assay for transport in everted membrane vesicles of E. coli was developed, Uptake of (AsO2-)-As-73, by everted vesicles was time- and temperature-dependent and required both pump subunits. Transport required ATP; no other nucleotide, including GTP, CTP, UTP, or the nonhydrolyzable analog adenosine 5'-O-(thiotriphosphate), could substitute for ATP. Protonophores, ionophores, or inhibitors of other types of ion-motive ATPases did not inhibit arsenite uptake. The sulfhydryl reagent N-ethylmaleimide was a potent inhibitor of ATP-dependent arsenite accumulation in vesicles. The apparent K-m values for ATP and arsenite were approximately 2 and 0.1 mM, respectively. Antimonite, the most potent activator of the ArsA ATPase, inhibited arsenite uptake with an apparent K-i of 10 mu M.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NIAID NIH HHS [AI19793] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; ANGOV E, 1988, J BACTERIOL, V170, P459, DOI 10.1128/jb.170.1.459-462.1988; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHEN CM, 1986, J BIOL CHEM, V261, P5030; DEY S, 1994, IN PRESS MOL BIOCH P; DEY S, 1994, IN PRESS ARCH BIOCH; DOU DX, 1992, J BIOL CHEM, V267, P25768; FRANCISCO MJDS, 1989, MOL MICROBIOL, V3, P15, DOI 10.1111/j.1365-2958.1989.tb00098.x; HEDGES RW, 1973, J BACTERIOL, V115, P459, DOI 10.1128/JB.115.1.459-460.1973; HSU CM, 1989, J BIOL CHEM, V264, P17349; KAUR P, 1992, PLASMID, V27, P29, DOI 10.1016/0147-619X(92)90004-T; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MOBLEY HLT, 1983, MOL GEN GENET, V191, P421, DOI 10.1007/BF00425757; MOBLEY HLT, 1982, P NATL ACAD SCI-BIOL, V79, P6119, DOI 10.1073/pnas.79.20.6119; ODEN KL, 1994, MOL MICROBIOL, V12, P301, DOI 10.1111/j.1365-2958.1994.tb01018.x; OUELLETTE M, 1991, RES MICROBIOL, V142, P737, DOI 10.1016/0923-2508(91)90089-S; OWOLABI JB, 1990, J BACTERIOL, V172, P2367, DOI 10.1128/jb.172.5.2367-2371.1990; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERLIN DS, 1986, ARCH BIOCHEM BIOPHYS, V248, P53, DOI 10.1016/0003-9861(86)90400-5; REAY PF, 1977, ANAL BIOCHEM, V78, P557, DOI 10.1016/0003-2697(77)90117-8; ROSEN BP, 1992, ANN NY ACAD SCI, V671, P257, DOI 10.1111/j.1749-6632.1992.tb43801.x; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; ROSEN BP, 1990, PHILOS T ROY SOC B, V326, P455, DOI 10.1098/rstb.1990.0024; SANFRANCISCO MJD, 1990, NUCLEIC ACIDS RES, V18, P619; TISA LS, 1990, J BIOENERG BIOMEMBR, V22, P493, DOI 10.1007/BF00762959; TISA LS, 1990, J BIOL CHEM, V265, P190; WANG HF, 1993, BIOCHEM BIOPH RES CO, V192, P1093, DOI 10.1006/bbrc.1993.1529; WANG ZL, 1993, TOXICOL APPL PHARM, V118, P80, DOI 10.1006/taap.1993.1012; WU JH, 1992, J BIOL CHEM, V267, P12570	33	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25442	25446						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929243				2022-12-25	WOS:A1994PQ49100036
J	HABIB, T; HERRERA, R; DECKER, SJ				HABIB, T; HERRERA, R; DECKER, SJ			ACTIVATORS OF PROTEIN-KINASE-C STIMULATE ASSOCIATION OF SHC AND THE PEST TYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NUCLEOTIDE EXCHANGE FACTOR; SIGNAL TRANSDUCTION; CELLS; PHOSPHORYLATION; GRB2; RECEPTOR; RAS; EXPRESSION; TRANSFORMATION; CLONING	Using the yeast two-hybrid system, complementary DNA clones were isolated from a HeLa cell library encoding proteins that interacted with p52(shc). One of these clones encoded the non-catalytic, COOH-terminal half of the cytosolic protein tyrosine phosphatase PTP-PEST. Expression of truncated forms of p52(shc) in the two hybrid system revealed that the amino terminal half of p52(shc) was sufficient for interaction with PTP-PEST. The p52 and p66 forms of Shc, but not the p46 form, bound to a glutathione S-transferase fusion protein containing the region of PTP-PEST isolated from the two-hybrid screen. Similarly, when HeLa cell lysates were immunoprecipitated with PTP-PEST antiserum, p52(shc) and p66(shc) proteins, but not p46(shc), co-precipitated. Shc-PTP-PEST complex formation was stimulated 6-8 fold by the protein kinase C activator phorbol 12-myristate 13-acetate, while epidermal growth factor and serum had no effect. Phorbol 12-myristate 13-acetate also stimulated phosphorylation of p52(shc) and p66(shc). The muscarinic agonist carbachol (also an activator of protein kinase C) stimulated complex formation 3-5-fold in SH-SY5Y neuroblastoma cells. These results suggest a role for PTP-PEST in G protein receptor signaling and in cross-talk between G protein receptor and tyrosine kinase receptor pathways.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,ANN ARBOR,MI 48106; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL,ANN ARBOR,MI 48104	Pfizer; University of Michigan System; University of Michigan								BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DECKER SJ, 1989, J BIOL CHEM, V264, P17641; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LAMBERT DG, 1990, BIOCHEM J, V265, P555, DOI 10.1042/bj2650555; OFFERMANNS S, 1993, BIOCHEM J, V294, P545, DOI 10.1042/bj2940545; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Rose M. D., 1990, METHODS YEAST GENETI, P155; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; TURNER NA, 1994, BIOCHEM J, V297, P407, DOI 10.1042/bj2970407; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; YANG Q, 1993, J BIOL CHEM, V268, P6622	32	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25243	25246						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929214				2022-12-25	WOS:A1994PQ49100003
J	TAN, SY; ASO, T; CONAWAY, RC; CONAWAY, JW				TAN, SY; ASO, T; CONAWAY, RC; CONAWAY, JW			ROLES FAR BOTH THE RAP30 AND RAP74 SUBUNITS OF TRANSCRIPTION FACTOR IIF IN TRANSCRIPTION INITIATION AND ELONGATION BY RNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SIGMA-70; MAJOR LATE PROMOTER; PREINITIATION COMPLEX; FUNCTIONAL-PROPERTIES; ACCURATE INITIATION; FACTOR-SII; CHAIN ELONGATION; FACTOR-EPSILON; FACTOR-DELTA; MINIMAL SET	Mammalian transcription factor IIF (TFIIF) is a heterodimer composed of similar to 30-kDa (RAP30) and similar to 70-kDa (RAP74) subunits. TFIIF has been shown to bind RNA polymerase II and control the activity of the enzyme in both the initiation and elongation stages of transcription. Although previous studies have established a role for RAP30 in assembly of the preinitiation complex and in transcription initiation, information on the function of RAP74 in these processes has been lacking. Using a highly purified transcription system and assays that permit sensitive measurement of the contributions of both RAP30 and RAP74 to TFIIF function, we have investigated the roles of these TFIIF subunits in transcription initiation and elongation. Results of template competition experiments indicate that both RAP30 and RAP74 contribute to the formation of stable preinitiation intermediates containing RNA polymerase II. Investigation of the role of TFIIF in transcription initiation indicates that both RAP30 and RAP74 function in synthesis of the first few phosphodiester bonds of nascent transcripts and in formation of Sarkosyl-resistant preinitiation intermediates. Finally, kinetic experiments indicate that both RAP30 and RAP74 function in TFIIF-mediated stimulation of the rate of RNA chain elongation by RNA polymerase II.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1994, EMBO J, V13, P435, DOI 10.1002/j.1460-2075.1994.tb06278.x; ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; CAI H, 1987, J BIOL CHEM, V262, P298; CHANG CH, 1993, J BIOL CHEM, V268, P20482; CONAWAY JW, 1990, J BIOL CHEM, V265, P7564; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GREENBLATT J, 1991, TRENDS BIOCHEM SCI, V16, P408, DOI 10.1016/0968-0004(91)90165-R; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HENRY NL, 1992, J BIOL CHEM, V267, P23388; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KASH SF, 1993, MOL CELL BIOL, V13, P2718, DOI 10.1128/MCB.13.5.2718; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KITAJIMA S, 1990, NUCLEIC ACIDS RES, V18, P4843, DOI 10.1093/nar/18.16.4843; KORNBERG RD, 1993, TRANSCRIPTION MECHAN; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MOTE J, 1994, J MOL BIOL, V236, P725, DOI 10.1006/jmbi.1994.1185; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PUGH BF, 1992, J BIOL CHEM, V267, P679; REINBERG D, 1987, J BIOL CHEM, V262, P331; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1994, TRANSCRIPTION MECHAN, P27; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; TAN S, IN PRESS P NATL ACAD; TAN SY, 1994, BIOTECHNIQUES, V16, P824; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027	67	86	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25684	25691						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929273				2022-12-25	WOS:A1994PQ49100069
J	COLLIECJOUAULT, S; SHWORAK, NW; LIU, J; DEAGOSTINI, AI; ROSENBERG, RD				COLLIECJOUAULT, S; SHWORAK, NW; LIU, J; DEAGOSTINI, AI; ROSENBERG, RD			CHARACTERIZATION OF A CELL MUTANT SPECIFICALLY DEFECTIVE IN THE SYNTHESIS OF ANTICOAGULANTLY ACTIVE HEPARAN-SULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; PROTEOGLYCANS; GROWTH	We have investigated the characteristics of clonal L cell mutant VI-7 that has previously been demonstrated to exhibit reduced levels of cell surface proteoglycans containing heparan sulfate (HS) with regions of defined monosaccharide sequence that interact with antithrombin (HSact) (de Agostini, A. L., Lau, H. K., Leone, C., Youssoufian, H., and Rosenberg, R. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9784-9788). Pulse labeling revealed that the synthesis of HSact in mutant cells, as compared to wild-type cells, was reduced by 5-7-fold, which is identical to the previously observed reduction in cell surface-bound antithrombin. This alteration is independent of growth state since production of HSact by mutant cells, as compared to wild type cells, is decreased to a similar extent in exponentially growing and post-confluent cultures. The synthetic defect was specific for HSact since production of total HS and chondroitin sulfate by mutant cells, as compared to wild-type cells, was identical in magnitude. The synthetic abnormality is not due to an alteration in core protein since complementation was not observed when mutant cells were stably transfected with the epitope-tagged ryudocan cDNA which can initiate HSact production. Structural analyses revealed that HS from mutant cells, as compared to wild-type cells, exhibited normal molecular weight, extent and distribution of sulfate, and disaccharide composition, which indicate that the mutation did not affect HS biosynthetic enzymes. Together, the data suggest that mutant VI-7 is defective in a regulatory component which directly or indirectly coordinates HS biosynthetic enzymes to specifically generate the defined monosaccharide sequence of HSact.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215; UNIV HOSP GENEVA,DEPT OBSTET & GYNAECOL,CH-1211 GENEVA 14,SWITZERLAND	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Geneva			Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634; Colliec-Jouault, Sylvia/0000-0002-2449-5410	NHLBI NIH HHS [HL-33014, HL-41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, P01HL033014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; Esko J D, 1986, Methods Enzymol, V129, P237; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	16	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24953	24958						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929178				2022-12-25	WOS:A1994PQ49000065
J	CURRIE, PD; SULLIVAN, DT				CURRIE, PD; SULLIVAN, DT			STRUCTURE AND EXPRESSION OF THE GENE ENCODING PHOSPHOFRUCTOKINASE (PFK) IN DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIOSEPHOSPHATE ISOMERASE GENE; FLIGHT-MUSCLE; DNA; SEQUENCE; 6-PHOSPHOFRUCTO-1-KINASE; DUPLICATION; TRANSCRIPTS; ISOZYMES; CLONING; INTRONS	The gene from Drosophila melanogaster that encodes phosphofructokinase has been isolated and its structure and expression characterized. Southern blots of genomic DNA, comparison of multiple clones, and in situ hybridization to salivary gland chromosomes indicate that the Drosophila genome contains a single copy of the gene which encodes phosphofructokinase (PFK) that is located at cytogenetic position 46D/E on the polytene map. Analysis of the gene structure reveals a single coding region that spans 6.5 kilobase pairs and is composed of eight exons and seven introns. Three developmentally regulated transcripts are generated through the use of alternative polyadenylation sites. Transcription initiation occurs at a single site. The pattern of transcript accumulation during development is similar to other genes of Drosophila which encode enzymes of the glycolytic pathway. Deficiency analysis of the 46D/E region has identified a lethal complementation group associated with reduced PFK activity, thereby establishing the vital role of PFK function in Drosophila.	SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13244; UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,DEV BIOL UNIT,OXFORD OX1 3PS,ENGLAND	Syracuse University; University of Oxford				Currie, Peter/0000-0001-8874-8862	NIGMS NIH HHS [GM26830] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026830] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; CURRIE P, 1994, IN PRESS GENETICS; DUNAWAY GA, 1983, MOL CELL BIOCHEM, V52, P75; DUNAWAY GA, 1974, ARCH BIOCHEM BIOPHYS, V162, P620, DOI 10.1016/0003-9861(74)90224-0; ENGELS WR, 1986, FOCUS, V8, P6; FRIEDMAN S, 1985, COMPREHENSIVE INSECT, V10, P53; GO M, 1987, COLD SPRING HARB SYM, V52, P915, DOI 10.1101/SQB.1987.052.01.100; GO M, 1993, METHODS IN PROTEIN SEQUENCE ANALYSIS, P229; GOLDSTEIN ES, 1993, 34TH ANN DROS RES C; HEINISCH J, 1989, GENE, V78, P309; HEINISCH J, 1991, CURR GENET, V20, P167, DOI 10.1007/BF00312781; HONG GF, 1982, J MOL BIOL, V158, P539, DOI 10.1016/0022-2836(82)90213-3; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KHOJA SM, 1990, INSECT BIOCHEM, V20, P443, DOI 10.1016/0020-1790(90)90025-P; KIM J, 1992, MOL CELL BIOL, V12, P773, DOI 10.1128/MCB.12.2.773; KOPPERSCHLAGER G, 1977, EUR J BIOCHEM, V81, P317, DOI 10.1111/j.1432-1033.1977.tb11954.x; LEITE A, 1988, J BIOL CHEM, V263, P17527; LISSEMORE JL, 1987, PLANT MOL BIOL, V8, P485, DOI 10.1007/BF00017994; Maniatis T, 1989, DECONTAMINATION DILU; MARCHIONNI M, 1986, CELL, V46, P133, DOI 10.1016/0092-8674(86)90867-6; MCKNIGHT GL, 1986, CELL, V46, P143, DOI 10.1016/0092-8674(86)90868-8; MORELLE G, 1988, FOCUS, V11, P7; MUNNEKE LR, 1985, BIOCHEM GENET, V23, P847, DOI 10.1007/BF00499933; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; ROSELLIREHFUSS L, 1992, MOL GEN GENET, V235, P213, DOI 10.1007/BF00279363; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SHAWLEE R, 1992, J BIOL CHEM, V267, P3959; SHAWLEE RL, 1991, MOL GEN GENET, V230, P225, DOI 10.1007/BF00290672; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOREY KB, 1985, INSECT BIOCHEM, V15, P663, DOI 10.1016/0020-1790(85)90130-1; UYEDA K, 1979, ADV ENZYMOL, V48, P192; VAISANEN PA, 1992, DNA CELL BIOL, V11, P461, DOI 10.1089/dna.1992.11.461; VALAITIS AP, 1992, INSECT BIOCHEM MOLEC, V22, P481, DOI 10.1016/0965-1748(92)90144-4; VONKALM L, 1989, P NATL ACAD SCI USA, V86, P5021; WALKER PR, 1969, BIOCHEM J, V111, P365, DOI 10.1042/bj1110365; WEGENER G, 1986, BIOCHEM J, V236, P925, DOI 10.1042/bj2360925; WINTERROWD CA, 1991, MOL BIOCHEM PARASIT, V48, P17	40	15	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24679	24687						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929140				2022-12-25	WOS:A1994PQ49000027
J	KAWABE, J; EBINA, T; ISMAIL, S; KITCHEN, DB; HOMCY, CJ; ISHIKAWA, Y				KAWABE, J; EBINA, T; ISMAIL, S; KITCHEN, DB; HOMCY, CJ; ISHIKAWA, Y			A NOVEL PEPTIDE INHIBITOR OF ADENYLYL-CYCLASE (AC) - A PEPTIDE FROM TYPE-V AC DIRECTLY INHIBITS AC CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC CHOLINERGIC RECEPTOR; SYNTHETIC PEPTIDES; PROTEIN; EXPRESSION; CLONING; RHODOPSIN; TRANSDUCIN; SEQUENCE; CHANNEL; BINDING	Peptides derived from various regions of type V adenylyl cyclase (AC) were studied to determine their effect on AC catalytic activity. Out of 10 examined, only one peptide, peptide 2 (Lys(425)-Cys(444)), significantly inhibited both basal and stimulated (forskolin or GTP gamma S (guanosine 5'-O-thiotriphosphate)) type VAC catalytic activity overexpressed in CMT cells. The sequence of this peptide was taken from the first cytoplasmic domain of type VAC, which has a high sequence homology to other AC isoforms. Competition studies performed between the peptide and the substrate ATP showed that the inhibition was noncompetitive. Mutation or truncation of the peptide designed to destroy its secondary structure totally negated the inhibitory effect. This peptide also inhibited the catalytic activity of purified types II and VAC, as well as that of various cells, including S49 cyc(-) cells. Our data indicate that the peptide directly interacts with AC to inhibit catalytic activity; this provides new information regarding regions of the enzyme involved in its catalytic activation.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,PEARL RIVER,NY 10965	Columbia University; Columbia University				Kitchen, Douglas/0000-0001-8988-759X	NHLBI NIH HHS [HL38070] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038070] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GARBERS DL, 1992, CELL, V71, P1; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; ISHIKAWA Y, 1992, NUCLEIC ACIDS RES, V20, P4367, DOI 10.1093/nar/20.16.4367; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KATSUSHIKA S, 1993, J BIOL CHEM, V268, P2273; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MONTAL MO, 1993, FEBS LETT, V320, P261, DOI 10.1016/0014-5793(93)80599-P; OBLATTMONTAL M, 1993, J BIOL CHEM, V268, P14601; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; RARICK HM, 1992, SCIENCE, V256, P1033; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555, P1; TAKEMOTO DJ, 1986, BIOCHEM J, V235, P309, DOI 10.1042/bj2350309; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	31	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24906	24911						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929172				2022-12-25	WOS:A1994PQ49000059
J	LEMKUIL, DC; NETTESHEIM, D; SHAW, CF; PETERING, DH				LEMKUIL, DC; NETTESHEIM, D; SHAW, CF; PETERING, DH			REACTION OF CD-7-METALLOTHIONEIN WITH CIS-DICHLORODIAMINE PLATINUM(II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBULE CELLS; METALLOTHIONEIN; RESISTANCE; CISPLATIN; SENSITIVITY; BINDING	The reaction of Cd-7-metallothionein with cis-dichlorodiammine platinum (II) has been examined in titration and kinetic experiments. Titrations followed by Cd-111 MMR spectroscopy and analysis of cadmium and platinum in the products indicated that platinum displaced cadmium in approximate 1:1 fashion, producing Pt-7-metallothionein. According to NMR analysis, the overall reaction involved cooperative exchange of platinum for Cd-111 in each domain of the protein. There was a modest preference for the reaction of the drug with the Cd,containing P-domain of the protein. The product had an apparent molecular weight that was nearly the same as that of Cd-7-metallothionein as determined by Sephadex G-75 chromatography. Kinetic analysis also supported a cooperative displacement mechanism. The reaction was biphasic; neither step could be identified solely with the reaction of one cluster as indicated by the biphasic reaction of the Cd-4-containing alpha-domain with the platinum complex.	UNIV WISCONSIN, DEPT CHEM, MILWAUKEE, WI 53201 USA	University of Wisconsin System; University of Wisconsin Milwaukee					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004026] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-04026] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDREWS PA, 1987, CANCER CHEMOTH PHARM, V19, P149; ARMITAGE IM, 1982, FED PROC, V41, P2974; BAKKA A, 1981, TOXICOL APPL PHARM, V61, P215, DOI 10.1016/0041-008X(81)90411-7; BLUMENTHAL SS, 1990, AM J PHYSIOL, V258, pF1625, DOI 10.1152/ajprenal.1990.258.6.F1625; BONGERS J, 1988, J INORG BIOCHEM, V34, P55, DOI 10.1016/0162-0134(88)85017-7; BONGERS J, 1991, INORG CHEM, V30, P515, DOI 10.1021/ic00003a032; BUHLER RHO, 1974, FEBS LETT, V39, P229, DOI 10.1016/0014-5793(74)80057-8; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; KAEGI JH, 1961, J BIOL CHEM, V236, P2435; KASAHARA K, 1991, CANCER RES, V51, P3237; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; KOROPATNICK J, 1990, SOMAT CELL MOLEC GEN, V16, P529, DOI 10.1007/BF01233093; KRAKER A, 1985, BIOCHEM BIOPH RES CO, V130, P786, DOI 10.1016/0006-291X(85)90485-1; LEMKUIL D, 1991, J INORG BIOCHEM, V43, P604; LI TY, 1981, BIOCHEM J, V193, P441, DOI 10.1042/bj1930441; MCPARTLIN EM, 1969, ACTA CRYSTALL B-STRU, VB 25, P1659, DOI 10.1107/S0567740869004481; MINKEL DT, 1980, BIOCHEM J, V191, P475, DOI 10.1042/bj1910475; Otvos J. D., 1989, COMMENTS INORG CHEM, V9, P1, DOI DOI 10.1080/02603598908035801; PATTANAIK A, 1992, J BIOL CHEM, V267, P16121; Petering D. H., 1984, ANTICANCER INTERFERO, P203; PETERING DH, 1993, METALLOTHIONEIN, V3, P329; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; SAFIRSTEIN R, 1987, INT J ANDROL, V10, P325, DOI 10.1111/j.1365-2605.1987.tb00200.x; SAVAS MM, 1991, INORG CHEM, V30, P581, DOI 10.1021/ic00003a049; SHAW CF, 1990, INORG CHEM, V29, P403, DOI 10.1021/ic00328a012; TAY LK, 1988, CANCER RES, V48, P2538	26	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24792	24797						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929157				2022-12-25	WOS:A1994PQ49000044
J	LI, JZ; ROBERTS, RM				LI, JZ; ROBERTS, RM			STRUCTURE-FUNCTION-RELATIONSHIPS IN THE INTERFERON-TAU (IFN-TAU) - CHANGES IN RECEPTOR-BINDING AND IN ANTIVIRAL AND ANTIPROLIFERATIVE ACTIVITIES RESULTING FROM SITE-DIRECTED MUTAGENESIS PERFORMED NEAR THE CARBOXYL-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVINE TROPHOBLAST PROTEIN-1; HUMAN-LEUKOCYTE INTERFERON; 3-DIMENSIONAL CRYSTAL-STRUCTURE; ALPHA RECEPTOR; GAMMA-CHAIN; ENDOMETRIAL RECEPTORS; INTERESTROUS INTERVAL; ESTROUS-CYCLE; PREGNANCY; SHEEP	The interferons-tau (IFN-tau) are Type I IFN, 172 amino acids in length, which are produced by the trophoblast of ruminant ungulate species and whose only known function is in triggering maternal responses to pregnancy. These IFN have the normal antiviral and antiproliferative activities exhibited by other Type I IFN, such as IFN-alpha and -beta, and are predicted to have similar structures based on five alpha-helices (A-E). A series of ovine IFN-tau variants was prepared with alterations in the carboxyl terminal region in residues not expected to interact directly with the Type I receptor. Replacement of IIe(143) with Thr in helix E significantly lowered receptor binding affinity to about 5% of control values, reduced antiviral activity to about 13% of control values, and abolished antiproliferative activity completely. Deletion of the terminal 11 residues from the carboxyl termini of these 172 amino acid IFN also reduced antiviral activities (similar to 5% of control) and antiproliferative proteins (1-2% of control), but had only slight negative influence on receptor binding. Deletion of Lys(160), but not its replacement with Ala, had similar consequences to deleting the entire 11-amino acid carboxyl terminus. These studies show that mutations can be introduced into IFN-tau that influence antiviral and antiproliferative activities differentially and that the carboxyl tail of the molecule is important for signal transduction but not for primary receptor binding.	UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA; UNIV MISSOURI, DEPT ANIM SCI, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021896, R01HD021896] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21896] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAZER FW, 1992, P SOC EXP BIOL MED, V199, P373, DOI 10.3181/00379727-199-43371A; BOSVELD J, 1989, BIOCHEM BIOPH RES CO, V164, P22, DOI 10.1016/0006-291X(89)91677-X; BRENNAN GL, 1983, BIOTECHNIQUES, V1, P78; CHANG NT, 1983, ARCH BIOCHEM BIOPHYS, V221, P585, DOI 10.1016/0003-9861(83)90179-0; CHEETHAM BF, 1991, ANTIVIR RES, V15, P27, DOI 10.1016/0166-3542(91)90038-S; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; FISH EN, 1992, J INTERFERON RES, V12, P257, DOI 10.1089/jir.1992.12.257; FLORES I, 1991, J BIOL CHEM, V266, P19875; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GODKIN JD, 1982, J REPROD FERTIL, V65, P141, DOI 10.1530/jrf.0.0650141; GODKIN JD, 1984, ENDOCRINOLOGY, V114, P120, DOI 10.1210/endo-114-1-120; HANSEN TR, 1989, J INTERFERON RES, V9, P215, DOI 10.1089/jir.1989.9.215; Hertzog P. J., 1993, Journal of Interferon Research, V13, pS140; HU RQ, 1993, J BIOL CHEM, V268, P12591; KLEMANN SW, 1990, MOL ENDOCRINOL, V4, P1506, DOI 10.1210/mend-4-10-1506; KNICKERBOCKER JJ, 1989, BIOL REPROD, V40, P361, DOI 10.1095/biolreprod40.2.361; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LEAMAN DW, 1992, J INTERFERON RES, V12, P1, DOI 10.1089/jir.1992.12.1; LEVY WP, 1981, P NATL ACAD SCI-BIOL, V78, P6186, DOI 10.1073/pnas.78.10.6186; LI JZ, 1994, J BIOL CHEM, V269, P13544; MARTAL J, 1990, J ENDOCRINOL, V127, pR5, DOI 10.1677/joe.0.127R005; MITSUI Y, 1993, PHARMACOL THERAPEUT, V58, P93, DOI 10.1016/0163-7258(93)90068-O; MURGOLO NJ, 1993, PROTEINS, V17, P62, DOI 10.1002/prot.340170109; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; OLSEN MK, 1989, J BIOTECHNOL, V9, P179, DOI 10.1016/0168-1656(89)90107-7; ORTALDO JR, 1984, P NATL ACAD SCI-BIOL, V81, P4926, DOI 10.1073/pnas.81.15.4926; OTT TL, 1993, THERIOGENOLOGY, V40, P757, DOI 10.1016/0093-691X(93)90211-M; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; PONTZER CH, 1990, P NATL ACAD SCI USA, V87, P5945, DOI 10.1073/pnas.87.15.5945; ROBERTS RM, 1992, ENDOCR REV, V13, P432, DOI 10.1210/er.13.3.432; RUBINSTEIN M, 1986, CRIT REV BIOCHEM MOL, V21, P249, DOI 10.3109/10409238609113613; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SATTAYASAI N, 1991, J INTERFERON RES, V11, P41, DOI 10.1089/jir.1991.11.41; SCHALUEFRANCIS TK, 1991, J REPROD FERTIL, V91, P347, DOI 10.1530/jrf.0.0910347; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SENDA T, 1992, EMBO J, V11, P3193, DOI 10.1002/j.1460-2075.1992.tb05396.x; SHAFFERMAN A, 1987, J BIOL CHEM, V262, P6227; SHARROCKS AD, 1992, NUCLEIC ACIDS RES, V20, P1147, DOI 10.1093/nar/20.5.1147; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Stewart H J, 1989, J Reprod Fertil Suppl, V37, P127; STEWART HJ, 1987, J ENDOCRINOL, V115, pR13, DOI 10.1677/joe.0.115R013; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VALLET JL, 1988, J REPROD FERTIL, V84, P493, DOI 10.1530/jrf.0.0840493; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; ZAVYALOV VP, 1989, IMMUNOL LETT, V22, P173, DOI 10.1016/0165-2478(89)90186-7	53	27	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24826	24833						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929162				2022-12-25	WOS:A1994PQ49000049
J	VANRENTERGHEM, B; BROWNING, MD; MALLER, JL				VANRENTERGHEM, B; BROWNING, MD; MALLER, JL			REGULATION OF MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION BY PROTEIN KINASE-A AND KINASE-C IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE THREONINE KINASE; MAP KINASE; XENOPUS-OOCYTES; P34CDC2 KINASE; S6 KINASE; SIGNAL-TRANSDUCTION; MEIOTIC MATURATION; RAPID STIMULATION; CATALYTIC SUBUNIT	Previously pp(60v-src), cyclin A, p39(mos), and maturation-promoting factor (composed of Cdc2 and cyclin B) have been shown to activate mitogen-activated protein kinase (MAPK) and MAPK kinase (MEK) in cell-free extracts of Xenopus oocytes. The pp60(v-src) pathway is dependent on a functional Pas signal whereas the cyclin/ maturation promoting factor pathway is not. Here we show that protein kinase C (PKC) is also able to stimulate MAPK in a Pas-dependent manner, but PKC is not necessary for signaling by pp60(v-src). In addition, preincubation of extracts with cAMP-dependent protein kinase (PKA) blocks stimulation of MAPK by cyclin, p21(V12ras) PKC, or pp60(v-src), by at least 50%, but stimulation by c-Mos is unaffected. Furthermore, inhibition of endogenous PKA by the heat-stable PKA inhibitor is sufficient to stimulate MAPK activity in these extracts in the absence of protein synthesis and without dependence on a functional Pas protein. These results suggest that independent pp60(v-src) and PKC pathways converge at Pas and that PKA acts to block MAPK activation by both Ras-dependent and -independent signals.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIAAA NIH HHS [AA03527] Funding Source: Medline; NIA NIH HHS [AG04418] Funding Source: Medline; NIDDK NIH HHS [DK28353] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA003527] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; ALEXANDROPOULOS K, 1993, ONCOGENE, V8, P803; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORNSLAEGER EA, 1986, DEV BIOL, V114, P453, DOI 10.1016/0012-1606(86)90209-5; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CAROLL MP, 1994, J BIOL CHEM, V269, P1249; CONRAD KE, 1992, ONCOGENE, V7, P1279; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DAAR I, 1993, J CELL BIOL, V120, P1197, DOI 10.1083/jcb.120.5.1197; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOHMANN P, 1993, CELL PROLIFERAT, V26, P195, DOI 10.1111/j.1365-2184.1993.tb00019.x; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; HUCHON D, 1981, MOL CELL ENDOCRINOL, V22, P211, DOI 10.1016/0303-7207(81)90092-7; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KAMATA T, 1990, MOL CELL BIOL, V10, P880, DOI 10.1128/MCB.10.3.880; KASAKO H, 1992, EMBO J, V11, P2903; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KROOK A, 1993, MOL CELL BIOL, V13, P1471, DOI 10.1128/MCB.13.3.1471; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LISSOOS TW, 1993, J BIOL CHEM, V268, P25132; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; Maller J L, 1980, Curr Top Cell Regul, V16, P271; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEIJER L, 1989, DEV BIOL, V133, P58, DOI 10.1016/0012-1606(89)90296-0; MOLLOY S, 1992, EXP CELL RES, V201, P494, DOI 10.1016/0014-4827(92)90299-N; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBERWETTER JM, 1993, MOL ENDOCRINOL, V7, P915, DOI 10.1210/me.7.7.915; ORI M, 1992, MOL CELL BIOL, V12, P939; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RIME H, 1992, DEV BIOL, V151, P105, DOI 10.1016/0012-1606(92)90217-5; SAHARA S, 1992, BIOCHEM BIOPH RES CO, V182, P105, DOI 10.1016/S0006-291X(05)80118-4; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SELVA E, 1993, J BIOL CHEM, V268, P2250; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SMITH MR, 1992, J IMMUNOL, V149, P1304; SOZERI O, 1992, ONCOGENE, V7, P2259; SPIVACK JG, 1985, MOL CELL BIOL, V5, P3629, DOI 10.1128/MCB.5.12.3629; STITH BJ, 1987, EXP CELL RES, V169, P514, DOI 10.1016/0014-4827(87)90211-4; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS J, 1991, J BIOL CHEM, V266, P10906; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANRENTERGHEM B, 1993, J BIOL CHEM, V268, P19935; WOODROW MA, 1993, J IMMUNOL, V150, P3853; WOTTON D, 1993, J BIOL CHEM, V268, P17975; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	82	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24666	24672						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929138				2022-12-25	WOS:A1994PQ49000025
J	ZHI, G; HERRING, BP; STULL, JT				ZHI, G; HERRING, BP; STULL, JT			STRUCTURAL REQUIREMENTS FOR PHOSPHORYLATION OF MYOSIN REGULATORY LIGHT-CHAIN FROM SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SUBSTRATE-SPECIFICITY; SYNTHETIC PEPTIDES; BASIC RESIDUES; SEQUENCE; BINDING; SITE	Site-directed and chimeric mutations of myosin regulatory light chains were used to identify residues important for phosphorylation of Ser(19) by smooth muscle myosin light chain kinase. Arg(16) and hydrophobic residues C-terminal of Ser(19) in smooth muscle light chain were important substrate determinants in the intact protein. However, changes in the kinetic properties with mutations in the light chain were substantially smaller than results reported with structurally similar synthetic peptide substrates. These results together with the low V-max value for short peptide substrates containing the consensus phosphorylation sequence suggest that there may be additional sites of interactions between the kinase and protein substrate. Chimeras of skeletal and smooth muscle light chains were constructed with exchanges at the N terminus and subdomains I, II, III, and IV. Analysis of results obtained on the kinetic properties for phosphorylation showed that subdomains I and II contribute to high V-max values. Thus, a region distant from the consensus phosphorylation sequence in smooth muscle light chain is also an important substrate determinant for myosin light chain kinase.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296, R01HL026043, R37HL026043] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 26043, HL 06296] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLBURN JC, 1988, J BIOL CHEM, V263, P19166; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HERRING BP, 1992, J BIOL CHEM, V267, P25945; HERRING BP, 1990, J BIOL CHEM, V265, P1724; HERRING BP, 1990, J BIOL CHEM, V265, P16588; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KEMP BE, 1985, J BIOL CHEM, V260, P3355; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1990, PEPTIDES PROTEIN PHO; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KUMAR CC, 1989, BIOCHEMISTRY-US, V28, P4027, DOI 10.1021/bi00435a059; MAEDA K, 1990, NUCLEIC ACIDS RES, V18, P6687, DOI 10.1093/nar/18.22.6687; MICHNOFF CH, 1986, J BIOL CHEM, V261, P8320; NUNNALLY MH, 1985, J BIOL CHEM, V260, P1020; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SELLERS JR, 1987, ENZYMES, P381; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STULL JT, 1986, ENZYMES, V17, P113; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	33	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24723	24727						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929147				2022-12-25	WOS:A1994PQ49000034
J	AINSZTEIN, AM; PURICH, DL				AINSZTEIN, AM; PURICH, DL			STIMULATION OF TUBULIN POLYMERIZATION BY MAP-2 - CONTROL BY PROTEIN-KINASE C-MEDIATED PHOSPHORYLATION AT SPECIFIC SITES IN THE MICROTUBULE-BINDING REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER NEUROFIBRILLARY TANGLES; TAU-PROTEIN; RAT-BRAIN; INVITRO; DOMAIN; NEUROFILAMENTS; SEQUENCE; QUANTITATION; POLYMERASE; MECHANISM	Microtubule-associated protein-2 (MAP-2) is extensively phosphorylated on serine and threonine residues, and such modifications affect various cellular processes, including microtubule dynamics. Although MAP-2 phosphorylation has been studied both in vitro and in vivo, nothing is known about the exact location of phosphorylated sites influencing the strength of MAP-2 for microtubules, we focused on understanding the effect of protein kinase C phosphorylation on MTBR binding to taxol-stabilized microtubules. We used bacterially expressed MAP-2 MTBR, containing newly introduced CNBr-cleavable methionyl residues, as well as mass spectrometry and site-specific mutagenesis to locate and confirm assignments of critical phosphorylation sites. We report on the localization and role of phosphoryls on two specific residues (Ser-1703 and Ser-1711) in terms of kinase-mediated control of MTBR-stimulated tubulin polymerization. Ser-1703 is situated in the so-called first inter-repeat, and Ser-1711 is located in the second nonidentical repeat. Upon more extensive protein kinase C action, microtubule binding can be abolished by phosphorylation at Ser-1728, but this effect is conditionally dependent on the phosphorylation state at Ser-1703 and/or Ser-1711. Our results suggest that in vivo binding of MAP-2 to microtubules may be controlled by protein kinase C action at these residues, and the strategy presented in this report may facilitate future studies with other kinases.	UNIV FLORIDA, HLTH SCI CTR, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044823] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44823] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AAMODT EJ, 1984, BIOCHEMISTRY-US, V23, P6023, DOI 10.1021/bi00320a019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT R, 1994, J BIOL CHEM, V269, P11776; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CHAIT BT, 1993, SCIENCE, V262, P89, DOI 10.1126/science.8211132; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DAMMERMAN M, 1989, J NEUROSCI RES, V24, P487, DOI 10.1002/jnr.490240405; DEANS NL, 1992, BIOCHEM J, V286, P243, DOI 10.1042/bj2860243; EIPPER BA, 1972, P NATL ACAD SCI USA, V69, P2283, DOI 10.1073/pnas.69.8.2283; FLYNN G, 1987, BIOCHEM BIOPH RES CO, V148, P1453, DOI 10.1016/S0006-291X(87)80295-4; FLYNN G, 1987, J BIOL CHEM, V262, P15443; GOLDENRING JR, 1985, J NEUROCHEM, V45, P900, DOI 10.1111/j.1471-4159.1985.tb04078.x; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GOODMAN DBP, 1970, P NATL ACAD SCI USA, V67, P652, DOI 10.1073/pnas.67.2.652; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSHI M, 1988, EUR J BIOCHEM, V174, P225, DOI 10.1111/j.1432-1033.1988.tb14086.x; JAMESON L, 1981, P NATL ACAD SCI-BIOL, V78, P3413, DOI 10.1073/pnas.78.6.3413; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KARR TL, 1979, J BIOL CHEM, V254, P6107; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; KOSIK KS, 1988, J NEUROCHEM, V51, P587, DOI 10.1111/j.1471-4159.1988.tb01079.x; KRISTOPEIT SM, 1984, THROMB RES, V36, P133, DOI 10.1016/0049-3848(84)90335-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATUS A, 1990, J PHYSIOL-PARIS, V84, P131; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAFFAELLI N, 1992, FEBS LETT, V296, P21, DOI 10.1016/0014-5793(92)80394-V; RAPPAPOR.L, 1972, FEBS LETT, V26, P349, DOI 10.1016/0014-5793(72)80609-4; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; SOIFER D, 1972, BIOCHIM BIOPHYS ACTA, V271, P182, DOI 10.1016/0005-2795(72)90146-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEURKAUF WE, 1983, J BIOL CHEM, V258, P7883; TSUYAMA S, 1987, J BIOL CHEM, V262, P10886; VALLEE R, 1980, FED PROC, V39, P1818; VALLEE RB, 1977, J BIOL CHEM, V252, P377; WALLIS KT, 1993, J BIOL CHEM, V268, P15158; WHITE HD, 1980, J BIOL CHEM, V255, P486; WICHE G, 1989, BIOCHEM J, V259, P1; WIDMER HR, 1993, J NEUROCHEM, V60, P2111, DOI 10.1111/j.1471-4159.1993.tb03496.x; YAMAUCHI PS, 1987, J BIOL CHEM, V262, P3369	46	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28465	28471						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961787				2022-12-25	WOS:A1994PV77200101
J	DELEPELAIRE, P				DELEPELAIRE, P			PRTD, THE INTEGRAL MEMBRANE ATP-BINDING CASSETTE COMPONENT OF THE ERWINIA-CHRYSANTHEMI METALLOPROTEASE SECRETION SYSTEM, EXHIBITS A SECRETION SIGNAL-REGULATED ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HEMOLYSIN; MULTIDRUG-RESISTANCE; CLONING VEHICLES; OUTER-MEMBRANE; PROTEIN; CONSTRUCTION; PURIFICATION; PLASMIDS; DOMAIN; HLYB	We have overproduced, partially purified, and characterized PrtD, the ATP-binding cassette (ABC) integral membrane component from the metalloproteases secretion system of the Gram-negative phytopathogenic bacterium Erwinia chrysanthemi. These metalloproteases are secreted independently of the general export pathway encoded by the sec genes. They are secreted via a C-terminal secretion signal and by a secretion apparatus composed of two inner membrane proteins, PrtD and PrtE, and one outer membrane protein PrtF. PrtD is specifically labeled by 8-azido-ATP both in whole membrane vesicles and upon purification. The purified protein displays a low level of P-type ATPase activity. This activity is almost completely and specifically inhibited by the cognate C-terminal secretion signal of the PrtG and PrtB metalloproteases (half inhibition at 0.1 mu M) but not by a C-terminal secretion signal of a protein not secreted by the Prt translocator. A mutant PrtD protein bearing a point mutation in the ATP binding site (conserved lysine 370 of the Walker A box changed to arginine) has also been purified. It displays a lower level of ATPase activity which correlates with the lower level of secretion of the metalloproteases by a strain expressing this mutated protein.			DELEPELAIRE, P (corresponding author), INST PASTEUR,UNITE PHYSIOL CELLULAIRE,CNRS,URA 1300,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DELEPELAIRE P, 1990, J BIOL CHEM, V265, P17118; DELEPELAIRE P, 1991, MOL MICROBIOL, V5, P2427, DOI 10.1111/j.1365-2958.1991.tb02088.x; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; GHIGO JM, 1994, J BIOL CHEM, V269, P8979; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HUGHES C, 1992, BIOESSAYS, V14, P519, DOI 10.1002/bies.950140804; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOFFE S, 1994, J BACTERIOL, V176, P5372; LETOFFE S, 1990, EMBO J, V9, P1375, DOI 10.1002/j.1460-2075.1990.tb08252.x; LETOFFE S, 1994, IN PRESS P NATL ACAD; Maniatis T., 1982, MOL CLONING; MESSING J, 1991, GENE, V100, P3, DOI 10.1016/0378-1119(91)90344-B; Miller J.H., 1972, EXPT MOL GENETICS; MORBACH S, 1993, J BIOL CHEM, V268, P18617; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; SPRATT BG, 1986, GENE, V41, P337, DOI 10.1016/0378-1119(86)90117-4; THOMAS WD, 1992, J BACTERIOL, V174, P6771, DOI 10.1128/JB.174.21.6771-6779.1992; WANDERSMAN C, 1992, TRENDS GENET, V8, P317, DOI 10.1016/0168-9525(92)90264-5; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFF N, 1994, BIOCHEMISTRY-US, V33, P6792, DOI 10.1021/bi00188a007	30	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27952	27957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961727				2022-12-25	WOS:A1994PV77200030
J	CHEN, HS; PERDEW, GH				CHEN, HS; PERDEW, GH			SUBUNIT COMPOSITION OF THE HETEROMERIC CYTOSOLIC ARYL-HYDROCARBON RECEPTOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; NUCLEAR TRANSLOCATOR PROTEIN; AH-RECEPTOR; GLUCOCORTICOID RECEPTORS; 59-KILODALTON PROTEIN; STEROID-RECEPTORS; DIOXIN RECEPTOR; EXISTS; COMPONENT; HSP90	In a previous cross-linking study we have shown that the cytosolic aryl hydrocarbon receptor (AhR) complex has a heterotetrameric structure (Perdew, G. H. (1992) Biochem. Biophys. Res. Commun. 182, 55-62). In this report, both cross linked and [S-35]methionine-labeled Hepa 1c1c7 cytosol were used to characterize the subunit composition of the AhR complex by immunoprecipitation with an AhR polyclonal antibody followed by immunochemical analysis using antibodies against the AhR and 90-kDa heat shock protein (hsp90). Results indicated that the four subunits found in cross linking experiments were composed of three species: the AhR ligand binding subunit, hsp90, and an unknown 43-kDa protein. The stoichiometry of hsp90 present in each AhR complex was determined in two separate experiments: 1) from cross-linking experiments, stoichiometry was determined by quantitative immunoblotting with anti-AhR and anti-hsp90 antibodies followed by quantitation with I-125-counterantibody on protein blots; 2) using S-35-labeled Hepa 1 cytosol, the hsp90/AhR stoichiometry was determined by immunopurifying receptor complexes, and the amount of S-35-labeled AhR and hsp90 was assessed. The stoichiometry values obtained were 2.4 and 1.72 mol of hsp90/mol of AhR using each experimental approach, respectively.	PURDUE UNIV,DEPT FOODS & NUTR,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIEHS NIH HHS [ES-04869] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004869, R29ES004869] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; KELLEY PM, 1982, MOL CELL BIOL, V2, P267, DOI 10.1128/MCB.2.3.267; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; MOORE SK, 1989, J BIOL CHEM, V264, P5343; NEMOTO T, 1990, J BIOL CHEM, V265, P2268; PERDEW GH, 1993, EXP CELL RES, V209, P350, DOI 10.1006/excr.1993.1320; PERDEW GH, 1992, BIOCHEM BIOPH RES CO, V182, P55, DOI 10.1016/S0006-291X(05)80111-1; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PERDEW GH, 1994, ANAL BIOCHEM, V220, P214, DOI 10.1006/abio.1994.1323; PROBST MR, 1993, MOL PHARMACOL, V44, P511; PROKIPCAK RD, 1989, ARCH BIOCHEM BIOPHYS, V274, P648, DOI 10.1016/0003-9861(89)90480-3; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; REHBERGER P, 1992, P NATL ACAD SCI USA, V89, P8001, DOI 10.1073/pnas.89.17.8001; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SINGH SS, 1993, ARCH BIOCHEM BIOPHYS, V305, P170, DOI 10.1006/abbi.1993.1407; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436	29	128	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27554	27558						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961671				2022-12-25	WOS:A1994PV77100062
J	CHUANG, LM; HAUSDORFF, SF; MYERS, MG; WHITE, MF; BIRNBAUM, MJ; KAHN, CR				CHUANG, LM; HAUSDORFF, SF; MYERS, MG; WHITE, MF; BIRNBAUM, MJ; KAHN, CR			INTERACTIVE ROLES OF RAS, INSULIN-RECEPTOR SUBSTRATE-1, AND PROTEINS WITH SRC HOMOLOGY-2 DOMAINS IN INSULIN SIGNALING IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; SH3 DOMAINS; BETA-SUBUNIT; MAP KINASE; ACTIVATION; BINDING; DISTINCT; TRANSDUCTION	Insulin receptor substrate-1 (IRS-1) serves as the major immediate substrate of insulin/insulin-like growth factor (IGF)-1 receptors and following tyrosine phosphorylation binds to specific Src homology-2 (SH2) domain-containing proteins including the p85 subunit of phosphatidylinositol (PI) 3-kinase and GRB2, a molecule believed to link IRS-1 to the Ras pathway. To investigate how these SH2-containing signaling molecules interact to regulate insulin/IGF-1 action, IRS-1, glutathione S-transferase (GST)-SH2 domain fusion proteins and Ras proteins were microinjected into Xenopus oocytes. We found that pleiotropic insulin actions are mediated by IRS-1 through two independent, but convergent, pathways involving PI 3-kinase and GRB2. Thus, microinjection of GST-fusion proteins of either p85 or GRB2 inhibited IRS-1-dependent activation of mitogen-activated protein (MAP) and S6 kinases and oocyte maturation, although only the GST-SH2 of p85 reduced insulin-stimulated PI 3-kinase activation. Co-injection of a dominant negative Ras (S17N) with IRS-1 inhibited insulin-stimulated MAP and S6 kinase activation. Microinjection of activated [Arg(12),Thr(59)]Ras increased basal MAP and S6 kinase activities and sensitized the oocytes to insulin-stimulated maturation without altering insulin-stimulated PI 3-kinase. The Ras-enhanced oocyte maturation response, but not the elevated basal level of MAP and S6 kinase, was partially blocked by the SH2-p85, but not SH2-GRB2. These data strongly suggest that IRS-1 can mediate many of insulin's actions on cellular enzyme activation and cell cycle progression requires binding and activation of multiple different SH2-domain proteins.	HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DEPT MED,DIV RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021; Chuang, Lee-Ming/AAF-3324-2019	Kahn, Ronald/0000-0002-7583-9228; CHUANG, LEE-MING/0000-0003-0978-2662; Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK 33201, DK 43808, DK 39519] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039519, R01DK043808, R01DK033201] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CAMPA MJ, 1992, P NATL ACAD SCI USA, V89, P7654, DOI 10.1073/pnas.89.16.7654; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELLICI G, 1992, CELL, V70, P93; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1994, J BIOL CHEM, V269, P12503; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1993, J BIOL CHEM, V268, P11167; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1989, J CELL BIOCHEM, V39, P429, DOI 10.1002/jcb.240390409; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597	50	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27645	27649						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961682				2022-12-25	WOS:A1994PV77100076
J	PENG, SB; ZHANG, Y; CRIDER, BP; WHITE, AE; FRIED, VA; STONE, DK; XIE, XS				PENG, SB; ZHANG, Y; CRIDER, BP; WHITE, AE; FRIED, VA; STONE, DK; XIE, XS			RECONSTITUTION OF THE RECOMBINANT 70-KDA SUBUNIT OF THE CLATHRIN-COATED VESICLE H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON TRANSLOCATING COMPLEX; VACUOLAR ATPASE; ADENOSINE-TRIPHOSPHATASE; TONOPLAST ATPASE; BETA-SUBUNIT; CLONED GENES; A-SUBUNIT; IDENTIFICATION; PROTEIN; 5'-TRIPHOSPHATE	Vacuolar-type proton pumps are complex heterooligomers. When dissociated into subcomplexes and subunits, the partial reactions of ATP hydrolysis and transmembranous proton flow can be assigned to isolated domains. Data suggest that the molecular site of ATP hydrolysis resides within the 70-kDa subunit but that ATPase activity likely requires at least three additional subunits of 58, 40, and 33 kDa (Xie, X.-S., and Stone, D. K. (1988) J. Biol. Chem. 263, 9859-9867). We have now cloned and sequenced the 70-kDa subunit from bovine brain and have expressed the protein in insect Sf9 (Spodoptera frugiperda) cells with a recombinant baculovirus. When purified, the protein has no significant ATPase activity but can be photoaffinity labeled with [alpha(32)P]ATP and UV irradiation with an apparent K-d of 35 mu M. When reconstituted with biochemically prepared 58-, 40-, and 33-kDa polypeptides, the recombinant 70-kDa)a subunit restores Ca2+-activated ATP hydrolysis to a specific activity of 0.6 mu mol P-i.mg protein(-1).min(-1), thus demonstrating that ATP hydrolysis in vacuolar-type proton pumps is dependent upon both the 70-kDa subunit as well as multi-subunit interactions.			PENG, SB (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOLEC TRANSPORT,DALLAS,TX 75235, USA.				NIDDK NIH HHS [DK-33627] Funding Source: Medline; NINDS NIH HHS [NS-29542] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029542] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALPERN RA, 1990, KIDNEY, P318; ALSHAWI MK, 1990, J BIOL CHEM, V265, P5595; BERRIOS M, 1983, J BIOL CHEM, V258, P4548; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GU HH, 1993, J BIOL CHEM, V268, P7372; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; Innis MA, 1990, PCR PROTOCOLS GUIDE; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDALA S, 1986, J BIOL CHEM, V261, P2850; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; PAN YX, 1991, FEBS LETT, V293, P89, DOI 10.1016/0014-5793(91)81158-5; PENG SB, 1994, J BIOL CHEM, V269, P11356; PENG SB, 1993, J BIOL CHEM, V268, P23519; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1988, KIDNEY INT, V33, P403; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; Summers MD, 1987, TEXAS AGR EXPT STATI; SUN SZ, 1987, J BIOL CHEM, V262, P14790; TAKASE K, 1993, J BIOL CHEM, V268, P11610; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1994, J BIOL CHEM, V269, P25809; XIE XS, 1988, J BIOL CHEM, V263, P9859; XIE XS, 1993, J BIOL CHEM, V268, P25063; XIE XS, 1989, J BIOL CHEM, V264, P1710; YUE VT, 1977, BIOCHEMISTRY-US, V16, P4678, DOI 10.1021/bi00640a023; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	40	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27778	27782						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961699				2022-12-25	WOS:A1994PV77100096
J	PIKULA, S; HAYDEN, JB; AWASTHI, S; AWASTHI, YC; ZIMNIAK, P				PIKULA, S; HAYDEN, JB; AWASTHI, S; AWASTHI, YC; ZIMNIAK, P			ORGANIC ANION-TRANSPORTING ATPASE OF RAT-LIVER .2. FUNCTIONAL RECONSTITUTION OF ACTIVE-TRANSPORT AND REGULATION BY PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; DEPENDENT TRANSPORT; GLUTATHIONE; ACID; SECRETION; PROTEIN	We have previously purified to homogeneity from rat liver plasma membranes a 90-kDa glycoprotein with S-(2,4-dinitrophenyl)glutathione-stimulated ATPase activity and other properties which identify it as the multispecific organic anion transporter (MOAT) specific for the transport into bile of non-bile acid organic anions (Pikula, S., Hayden, J. B., Awasthi, S., Awasthi, Y. C., and Zimniak, P. (1994) J. Biol. Chem. 269, 27566-27573). In the present communication, we report the functional reconstitution of this protein into artificial proteoliposomes. The reconstituted protein catalyzed time and concentration-dependent up take of S-(2,4-dinitrophenyl) glutathione into the vesicles, The transport required the presence of ATP. Phosphorylation of the 90-kDa protein by protein kinase C prior to reconstitution more than tripled the V-max of transport but did not change the K-m for S-(2,4-dinitrophenyl)glutathione. The protein created and, at steady state, maintained a more than 200-fold and 500-fold S-(2,4-dinitrophenyl)glutathione gradient across the membrane for the unphosphorylated and phosphorylated form, respectively. The transport activity of the 90-kDa protein is sufficient to account for the hepatic secretory maximum of non-bile acid organic anions in the rat.	UNIV ARKANSAS MED SCI HOSP,DEPT MED,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; VET ADM JOHN MCCLELLAN MEM HOSP,LITTLE ROCK,AR 72205; UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555; POLISH ACAD SCI,M NENCKI INST EXPTL BIOL,WARSAW,POLAND	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences			Awasthi, Sanjay/R-4904-2019	Pikula, Slawomir/0000-0003-4640-3094; Awasthi, Sanjay/0000-0002-5214-5717	NATIONAL CANCER INSTITUTE [R29CA063660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032304] Funding Source: NIH RePORTER; NCI NIH HHS [CA-63660] Funding Source: Medline; NIGMS NIH HHS [GM-32304] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; BALLATORI N, 1992, AM J PHYSIOL, V263, pG617, DOI 10.1152/ajpgi.1992.263.5.G617; BALLATORI N, 1989, AM J PHYSIOL, V256, pG22, DOI 10.1152/ajpgi.1989.256.1.G22; Boyer J.L., 1986, PHYSL MEMBRANE DISOR, P609; DUX L, 1987, J BIOL CHEM, V262, P6439; ENGELMAN DM, 1969, NATURE, V223, P1279, DOI 10.1038/2231279a0; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HINKLE PC, 1991, BIOCHEMISTRY-US, V30, P3576, DOI 10.1021/bi00228a031; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; KUIPERS F, 1989, J LIPID RES, V30, P1835; KUIPERS F, 1992, AM J PHYSIOL, V262, pG267, DOI 10.1152/ajpgi.1992.262.2.G267; LABELLE EF, 1986, BIOCHEM J, V238, P443, DOI 10.1042/bj2380443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Meier Peter J., 1993, P587; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; PIKULA S, 1994, J BIOL CHEM, V269, P27566; ROELOFSEN H, 1991, BIOCHEM J, V278, P637, DOI 10.1042/bj2780637; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; VINCE R, 1971, J MED CHEM, V14, P402, DOI 10.1021/jm00287a006; ZIMNIAK P, 1993, HEPATOLOGY, V17, P330, DOI 10.1002/hep.1840170226; ZIMNIAK P, 1993, SEMIN LIVER DIS, V13, P248, DOI 10.1055/s-2007-1007353	25	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27574	27579						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961674				2022-12-25	WOS:A1994PV77100065
J	RUSINOL, AE; CUI, Z; CHEN, MH; VANCE, JE				RUSINOL, AE; CUI, Z; CHEN, MH; VANCE, JE			A UNIQUE MITOCHONDRIA-ASSOCIATED MEMBRANE-FRACTION FROM RAT-LIVER HAS A HIGH-CAPACITY FOR LIPID-SYNTHESIS AND CONTAINS PRE-GOLGI SECRETORY PROTEINS INCLUDING NASCENT LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; ROUGH ENDOPLASMIC-RETICULUM; PERMEABILIZED ANIMAL-CELLS; LOW-DENSITY LIPOPROTEINS; SUBCELLULAR-LOCALIZATION; PHOSPHOLIPID-SYNTHESIS; PLASMA-MEMBRANE; TRANSPORT; INTERMEDIATE; COMPLEX	An endoplasmic reticulum-like membrane fraction, termed the ''mitochondria-associated membrane'' (MAM), that co-isolates with mitochondria from rat liver has been characterized. One potential function of the MAM is as a membrane bridge between the endoplasmic reticulum and mitochondria that may be involved in transfer of phospholipids between these two organelles (Vance, J. E. (1990) J. Biol. Chem. 265, 7248-7256). A polyclonal antibody directed against a peptide corresponding to the C terminus of phosphatidylethanolamine N-methyltransferase-2, a specific marker protein of the MAM (Cui, Z., Vance, J. E., Chen, M. H., Voelker, D. R., and Vance, D. E. (1993) J. Biol. Chem. 268, 16655-16663), was used in immunofluorescence and immunogold electron microscopy localization studies in rat hepatocytes. Immunoreactive protein was clustered in regions of the cell that did not correspond to the bulk of endoplasmic reticulum. A second potential role for the MAM, as a component of the secretory pathway that supplies lipids for assembly into very low density lipoproteins, has been examined. The MAM contains enzymes of similar, or higher, specific activities to those enzymes in the endoplasmic reticulum for the synthesis of phospholipids, triacylglycerols, cholesterol, and cholesteryl esters. Specific activities of diacylglycerol acyltransferase, acyl coenzyme A:cholesterol acyltransferase, and phosphatidylserine synthase (base exchange enzyme) are enriched 2.2-3.4-fold in the MAM compared with endoplasmic reticulum. In addition, the microsomal triacylglycerol transfer protein, which is required for the assembly/secretion of apolipoprotein B containing lipoproteins, was present in the MAM. Nascent apolipoprotein B-containing lipoproteins were isolated from the lumen of the MAM. These lipoproteins had the same average density and composition as nascent apolipoprotein B-containing lipoproteins isolated from heavy and light endoplasmic reticulum fractions, from the Golgi, and lipoproteins newly secreted by cultured rat hepatocytes. The MAM is a pre-Golgi compartment of the secretory route, as shown by pulse-chase studies with apolipoprotein B and albumin, as well as the sensitivity of luminal apolipoprotein B to endoglycosidase H.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT MED,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,SURG MED RES INST,EDMONTON T6G 2S2,AB,CANADA	University of Alberta; University of Alberta; University of Alberta; University of Alberta								ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; BARANSKA J, 1989, BIOCHIM BIOPHYS ACTA, V619, P258; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; CUI Z, 1993, J BIOL CHEM, V268, P16655; FRANKE WW, 1971, PROTOPLASMA, V73, P35, DOI 10.1007/BF01286409; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEORGE R, 1990, BIOCHEM CELL BIOL, V68, P674, DOI 10.1139/o90-097; GIEROW P, 1989, BIOCHEM J, V262, P55, DOI 10.1042/bj2620055; HAJRA AK, 1986, METHOD ENZYMOL, V122, P50; HAMILTON RL, 1991, J LIPID RES, V32, P529; HASHIMOTO S, 1980, J BIOL CHEM, V255, P8678; HEIDER JG, 1983, J LIPID RES, V24, P1127; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HOWELL KE, 1982, J CELL BIOL, V92, P833, DOI 10.1083/jcb.92.3.833; HUSSAIN MM, 1989, BIOCHIM BIOPHYS ACTA, V1101, P90; JANERO DR, 1983, J BIOL CHEM, V258, P4496; KARSTEN U, 1972, ANAL BIOCHEM, V46, P135, DOI 10.1016/0003-2697(72)90405-8; KATZ J, 1983, BIOCHEM J, V214, P795, DOI 10.1042/bj2140795; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRE DJ, 1971, PROTOPLASMA, V73, P43, DOI 10.1007/BF01286410; MOSES RL, 1982, VIRCHOWS ARCH B, V41, P95, DOI 10.1007/BF02890274; PICKETT CB, 1980, EXP CELL RES, V128, P343, DOI 10.1016/0014-4827(80)90070-1; REINHART MP, 1987, J BIOL CHEM, V262, P9649; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; SARASTE J, 1991, J CELL SCI, V100, P415; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHORE GC, 1977, J CELL BIOL, V72, P714, DOI 10.1083/jcb.72.3.714; THOMAS J, 1980, BIOCHEM J, V190, P485, DOI 10.1042/bj1900485; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANGOLDE LM, 1974, BIOCHIM BIOPHYS ACTA, V360, P179, DOI 10.1016/0005-2760(74)90168-4; VANGOLDE LM, 1971, BIOCHIM BIOPHYS ACTA, V249, P318, DOI 10.1016/0005-2736(71)90109-X; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; VOELKER DR, 1991, BIOCH LIPIDS LIPOPRO, P489; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; YAO ZM, 1989, J BIOL CHEM, V264, P11373; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	52	353	358	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27494	27502						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961664				2022-12-25	WOS:A1994PV77100054
J	SKAUGEN, M; NISSENMEYER, J; JUNG, G; STEVANOVIC, S; SLETTEN, K; ABILDGAARD, CIM; NES, IF				SKAUGEN, M; NISSENMEYER, J; JUNG, G; STEVANOVIC, S; SLETTEN, K; ABILDGAARD, CIM; NES, IF			IN-VIVO CONVERSION OF L-SERINE TO D-ALANINE IN A RIBOSOMALLY SYNTHESIZED POLYPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; OPIOID-PEPTIDES; SKIN; EPIDERMIN; LANTIBIOTICS; PURIFICATION; BIOSYNTHESIS; PREPEPTIDE; DERMORPHIN; PHASE	In the course of characterizing the bacteriocin lactocin S and its encoding gene, we discovered three alanine for-serine substitutions which, apparently, is a violation of the genetic code. Subsequent chiral analysis of lactocin S hydrolysates revealed a correlation between D-alanine content and the three substitutions, implying a conversion of L-serine to D-alanine in lactocin S maturation. In order to explain this observation, we suggest a sequence of events initiated by the dehydration of serine, which is common in the biosynthesis of the lanthi- onine-containing polycyclic lantibiotics (Schnell, N., Entian, K.-D., Schneider, U., Gotz, F., Zahner, H., Hellner, R. & Jung, G. (1988) Nature 333, 276-278; Jung, G. (1991) Angew. Chem. Int. Ed. Engl. 30, 1051-1068; Bierbaum, G. and Sahl, H.-G. (1993) Zentralbl. Bakteriol. 278, 1-22) and completed by the stereospecific reduction of dehydroalanine residues. The occurrence of non-lanthionine a-carbon stereoinversion in lactocin S maturation substantiates the hypothetical alpha-epimerization scheme originally put forward by Bycroft (Bycroft, B. W. (1969) Nature 224, 595-597), and we propose a revision of this model to accommodate the lactocin S-type stereoinversion. Lactocin S is the first prokaryotic exception to the rule that only L-amino acids are included in ribosomally synthesized peptides.	UNIV OSLO, INST BIOCHEM, N-0317 OSLO, NORWAY; UNIV TUBINGEN, INST ORGAN CHEM, W-7400 TUBINGEN 1, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY; UNIV OSLO, CTR BIOTECHNOL, N-0317 OSLO, NORWAY	University of Oslo; Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Oslo	SKAUGEN, M (corresponding author), AGR UNIV NORWAY, MICROBIAL GENE TECHNOL LAB, POB 5051, N-1432 AS, NORWAY.		Nissen-Meyer, Jon/A-5581-2008; Nissen-Meyer, Jon/Y-8727-2019					ALLGAIER H, 1986, EUR J BIOCHEM, V160, P9, DOI 10.1111/j.1432-1033.1986.tb09933.x; BIERBAUM G, 1993, ZBL BAKT-INT J MED M, V278, P1; BROCCARDO M, 1981, BRIT J PHARMACOL, V73, P625, DOI 10.1111/j.1476-5381.1981.tb16797.x; BYCROFT BW, 1969, NATURE, V224, P595, DOI 10.1038/224595a0; FRANK H, 1977, J CHROMATOGR SCI, V15, P174, DOI 10.1093/chromsci/15.5.174; Graeffe T, 1991, NISIN NOVEL LANTIBIO, P260; GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073; GROSS E, 1973, H-S Z PHYSIOL CHEM, V354, P810; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JUNG G, 1991, ANGEW CHEM INT EDIT, V30, P1051, DOI 10.1002/anie.199110513; KATZ E, 1977, BACTERIOL REV, V41, P449, DOI 10.1128/MMBR.41.2.449-474.1977; KELLNER R, 1988, EUR J BIOCHEM, V177, P53, DOI 10.1111/j.1432-1033.1988.tb14344.x; KUPKE T, 1993, FEMS MICROBIOL LETT, V112, P43, DOI 10.1016/0378-1097(93)90535-A; KUSTERS E, 1984, CHROMATOGRAPHIA, V18, P287, DOI 10.1007/BF02259079; MEYER HE, 1994, IN PRESS ANAL BIOCH; MIGNOGNA G, 1993, EMBO J, V12, P4829, DOI 10.1002/j.1460-2075.1993.tb06172.x; MOR A, 1992, TRENDS BIOCHEM SCI, V17, P481, DOI 10.1016/0968-0004(92)90333-5; MORTVEDT CI, 1990, J GEN MICROBIOL, V136, P1601, DOI 10.1099/00221287-136-8-1601; MORTVEDT CI, 1991, APPL ENVIRON MICROB, V57, P1829; MULDERS JWM, 1991, EUR J BIOCHEM, V201, P581, DOI 10.1111/j.1432-1033.1991.tb16317.x; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; Sahl H. G., 1991, NISIN NOVEL LANTIBIO, P347; Sambrook J, 1989, MOL CLONING LABORATO; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SLETTEN K, 1974, EUR J BIOCHEM, V41, P117, DOI 10.1111/j.1432-1033.1974.tb03251.x; WEIL HP, 1990, EUR J BIOCHEM, V194, P217, DOI 10.1111/j.1432-1033.1990.tb19446.x	28	114	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27183	27185						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961627				2022-12-25	WOS:A1994PV77100008
J	FISCELLA, M; ZAMBRANO, N; ULLRICH, SJ; UNGER, T; LIN, D; CHO, B; MERCER, WE; ANDERSON, CW; APPELLA, E				FISCELLA, M; ZAMBRANO, N; ULLRICH, SJ; UNGER, T; LIN, D; CHO, B; MERCER, WE; ANDERSON, CW; APPELLA, E			THE CARBOXY-TERMINAL SERINE-392 PHOSPHORYLATION SITE OF HUMAN P53 IS NOT REQUIRED FOR WILD-TYPE ACTIVITIES	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; CELL-CYCLE CONTROL; MUTANT P53; GENE AMPLIFICATION; GROWTH ARREST; BINDING-SITE; DNA; TRANSCRIPTION; EXPRESSION	Wild-type p53 functions in the G1 DNA damage checkpoint pathway by activating gene transcription and preventing cell cycle progression. Others reported that mutation of the serine 386 codon in mouse p53 abolished its ability to suppress growth. Serine 386 of murine p53 and the homologous residue of human p53, serine 392, are phosphorylated in vivo and can be phosphorylated in vitro by casein kinase II (CKII). We constructed mutants that changed serine 392 of human p53 to alanine (p53-S392A) or aspartic acid (p53S392D); cotransfection of both these mutants with a reporter gene carrying a p53-responsive element into the p53-null Saos-2 cell line activated transcription as well as did wild-type p53. Furthermore, both mutants blocked cell cycle progression after transient transfection in these cells. A stable derivative of the T98G human glioblastoma cell line was established that expressed p53-S392A in response to dexamethasone. Overexpression of this mutant activated transcription of the endogenous waf1 (also called cip1) and mdm2 genes to the same extent as wild-type p53 and also produced growth arrest. Finally, p53-S392A and p53-S392D suppressed foci formation by activated ras and adenovirus EIA oncogenes as efficiently as did wild-type p53. Thus, unlike mutants that altered the serine 15 phosphorylation site, elimination of the serine 392 phosphorylation site had no discernible effect on p53 function. We conclude that neither phosphorylation nor RNA attachment to serine 392 are required for human p53's ability to suppress cell growth or to activate transcription in vivo.	NCI,CELL BIOL LAB,BETHESDA,MD 20892; NCI,TUMOR VIRUS BIOL LAB,BETHESDA,MD 20892; AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD 20855; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); American Red Cross; Jefferson University; United States Department of Energy (DOE); Brookhaven National Laboratory			Zambrano, Nicola/B-9352-2014	Zambrano, Nicola/0000-0001-9395-3481	NATIONAL CANCER INSTITUTE [R01CA055541, R01CA054140] Funding Source: NIH RePORTER; NCI NIH HHS [CA55541, CA54140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADDISON C, 1990, ONCOGENE, V5, P423; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FISCELLA M, 1993, ONCOGENE, V8, P1519; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARPER JW, 1993, CELL, V75, P805; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SEGAWA K, 1993, ONCOGENE, V8, P543; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER P, 1994, INT J ONCOL, V4, P491; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	67	68	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3249	3257						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936649				2022-12-25	WOS:A1994PM65800018
J	SCHUUR, ER; RABINOVICH, JM; BALUDA, MA				SCHUUR, ER; RABINOVICH, JM; BALUDA, MA			DISTRIBUTION OF ALTERNATIVELY SPLICED CHICKEN C-MYB EXON 9A AMONG HEMATOPOIETIC TISSUES	ONCOGENE			English	Note							AVIAN-MYELOBLASTOSIS VIRUS; DIFFERENTIAL EXPRESSION; CELLS; GENE; IDENTIFICATION; PROTOONCOGENE; TRANSCRIPTS; ONCOGENES	The role of the c-myb proto-oncogene in cellular differentiation may be regulated in part by alternative splicing of its mRNAs. Previously, two forms of alternative splicing of the chicken c-myb gene between exons 9 and 10 were described: one form utilizes the entire 360 base pair (bp) exon 9A while a second form utilizes exon 9A' which consists of the 3' 150 bp of exon 9A. In this study the distribution among chicken hematopoietic tissues of these two forms of alternative splicing was determined by Northern blot analysis using a probe specific for exon 9A. RNA species of 4.2 kilobases (kb) and 4.4 kb which contain exon 9A' or exon 9A, respectively, were detected in each tissue tested. Quantitative analysis of the major 4.0 kb c-myb species and the c-myb species containing exon 9A and exon 9A' revealed that cells from yolk sac contained both the highest absolute and the highest relative levels of alternatively spliced c-myb mRNA, presumably because of the preponderance of immature erythroid cells in these preparations.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SCHUUR, ER (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA010197] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDER TP, 1987, J IMMUNOL, V139, P3822; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DUDEK H, 1989, ONCOGENE, V4, P1061; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KIM WK, 1988, ONCOGENE RES, V3, P147; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; ROMANOFF AL, 1960, AVIAN EMBRYO, P575; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SCHUUR ER, 1991, ONCOGENE, V6, P1409; SCHUUR ER, 1991, ONCOGENE, V6, P1923; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	27	5	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3363	3365						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936662				2022-12-25	WOS:A1994PM65800031
J	BAKKENIST, CJ; COTTERILL, S				BAKKENIST, CJ; COTTERILL, S			THE 50-KDA PRIMASE SUBUNIT OF DROSOPHILA-MELANOGASTER DNA-POLYMERASE-ALPHA - MOLECULAR CHARACTERIZATION OF THE GENE AND FUNCTIONAL ANALYSIS OF THE OVEREXPRESSED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE ESSENTIAL GENE; CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; CALF THYMUS; BINDING; EXPRESSION; EMBRYOS; TRANSCRIPTION; REPLICATION	The gene encoding the 50-kDa subunit of Drosophila melanogaster DNA polymerase alpha has been cloned. A comparison of the predicted polypeptide sequence of the Drosophila protein with the equivalent subunits from mouse and yeast suggests that they are closely related and defines three conserved regions which are likely to be important for enzyme activity. The expression patterns of both the 50-kDa protein and its transcript (a single RNA message of 1.6 kilobases) throughout development are consistent with a role of the protein in DNA replication. When overexpressed and purified the 50-kDa subunit displays DNA primase activity. The products of the reaction, mainly oligoribonucleotides 12-14 nucleotides in length, plus dimers and some trimers, are similar to those synthesized by either the intact DNA polymerase alpha, or the biochemically isolated primase heterodimer. The isolated primase also shows similar sensitivity to antibodies, magnesium and monovalent cations, and the same nucleotide requirements as complexed forms of the primase. The isolated subunit, however, is more thermally labile, suggesting a role for the additional subunits in DNA polymerase alpha in stabilizing the primase activity of the 50-kDa primase subunit.	CHART,MARIS CURIE RES INST,OXTED RH8 0TL,SURREY,ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,LONDON SW7 2AZ,ENGLAND	Imperial College London								BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; COPELAND WC, 1993, J BIOL CHEM, V268, P26179; COTTERILL S, 1987, J BIOL CHEM, V262, P16100; COTTERILL S, 1987, J BIOL CHEM, V262, P16105; COTTERILL SM, 1992, NUCLEIC ACIDS RES; DEAROLF CR, 1989, NATURE, V341, P340, DOI 10.1038/341340a0; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; FOIANI M, 1989, J BIOL CHEM, V264, P2189; HIROSE F, 1993, J BIOL CHEM, V268, P2092; HOCHULI E, 1990, GENETIC ENG PRINCIPL, P12; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; Kornberg A., 1991, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LUCCHINI G, 1987, EMBO J, V6, P737, DOI 10.1002/j.1460-2075.1987.tb04815.x; MELOV S, 1992, J CELL SCI, V102, P847; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; PLEVANI P, 1987, NUCLEIC ACIDS RES, V15, P7975; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; SAMBROOK J, 1990, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOCANALE C, 1993, J BIOL CHEM, V268, P1343; SHEAFF RJ, 1993, BIOCHEMISTRY-US, V32, P3027, DOI 10.1021/bi00063a014; STUBER D, 1990, EUR J IMMUNOL, V20, P819, DOI 10.1002/eji.1830200416; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872	34	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26759	26766						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929411				2022-12-25	WOS:A1994PQ93100030
J	YIN, TG; TSANG, MLS; YANG, YC				YIN, TG; TSANG, MLS; YANG, YC			JAK1 KINASE FORMS COMPLEXES WITH INTERLEUKIN-4 RECEPTOR AND 4PS/INSULIN RECEPTOR SUBSTRATE-1-LIKE PROTEIN AND IS ACTIVATED BY INTERLEUKIN-4 AND INTERLEUKIN-9 IN T-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE PHOSPHORYLATION; GAMMA-CHAIN; CELL-LINE; HEMATOPOIETIC-CELLS; IL-2 RECEPTOR; CLONING; MURINE	Interleukin (IL)-4 and IL-9 regulate the proliferation of T lymphocytes through interactions with their receptors, Previous studies have shown that unknown tyrosine kinases are involved in the proliferative signaling triggered by IL-4 and IL-9. Here we show that IL-4 and IL-9 induce overlapping (170, 130, and 125 kilodalton (kDa)) and distinct (45 and 88/90 kDa, respectively) protein tyrosine phosphorylation in T lymphocytes. We further identify the 170-kDa tyrosine-phosphorylated protein as 4PS/insulin receptor substrate-1-like (IRS-1L) protein and 130-kDa protein as JAK1 kinase. Furthermore, we demonstrate for the first time that JAK1 forms complexes with the IL-4 receptor and 4PS/IRS-1L protein following ligand-receptor interaction. In addition, we demonstrate that IL-9, but not IL-4, induced tyrosine phosphorylation of Stat 91 transcriptional factor. The overlapping and distinct protein tyrosine phosphorylation and activation of the same JAK1 kinase in T lymphocytes strongly suggests that IL-4 and IL-9 share the common signal transduction pathways and that the specificity for each cytokine could be achieved through the unique tyrosine-phosphorylated proteins triggered by individual cytokines.	INDIANA UNIV,SCH MED,MED CTR,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,MED CTR,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; INDIANA UNIV,MED CTR,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; RES & DEV SYST,MINNEAPOLIS,MN 55413	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043105] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK43105] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARTGETSINGER LS, 1993, CELL, V74, P237; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DASILVA L, 1994, J BIOL CHEM, V269, P18267; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; MIYAZAWA K, 1992, BLOOD, V80, P1685; MORIA AO, 1988, MOL CELL BIOL, V8, P2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; PAUL WE, 1991, BLOOD, V77, P1859; RENAULD JC, 1993, ADV IMMUNOL, V54, P79, DOI 10.1016/S0065-2776(08)60533-7; RENAULD JC, 1992, P NATL ACAD SCI USA, V89, P5690, DOI 10.1073/pnas.89.12.5690; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YIN TG, 1994, EXP HEMATOL, V22, P467	35	124	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26614	26617						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929391				2022-12-25	WOS:A1994PQ93100007
J	FURUKAWA, Y; TERUI, Y; SAKOE, K; OHTA, M; SAITO, M				FURUKAWA, Y; TERUI, Y; SAKOE, K; OHTA, M; SAITO, M			THE ROLE OF CELLULAR TRANSCRIPTION FACTOR E2F IN THE REGULATION OF CDC2 MESSENGER-RNA EXPRESSION AND CELL-CYCLE CONTROL OF HUMAN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA-SUSCEPTIBILITY GENE; COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; LINE JOSK-I; PROTEIN-KINASE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; CHROMATIN STRUCTURE; MAMMALIAN-CELLS; PRODUCT	cdc2 mRNA transcripts were detected in immature bone marrow cells and became undetectable along with differentiation. Peripheral blood resting cells did not express cdc2 mRNA,but it was induced in T-lymphocytes when the cells reentered the cell cycle in response to specific mitogens. In contrast, cdc2 mRNA could not be induced in granulocytes and monocytes even after the culture with the appropriate stimulants. In order to investigate the mechanism of the regulation of cdc2 mRNA expression in hematopoietic cells, we isolated the 5'-flanking sequence of the cdc2 gene and found the putative E2F binding site at the position of nucleotides -124 to -117. The binding of E2F at this region was detected by a gel-retardation assay and DNaseI footprinting in phytohemagglutinin stimulated T-lymphocytes, which was coincident with the expression of cdc2 mRNA. E2F binding was not observed in both granulocytes and monocytes. Transient chloramphenicol acetyltransferase assay revealed that the region containing E2F binding site had a strong promoter activity, and introduction of the mutation at the E2F binding site resulted in a significant loss of the activity. E2F-1 and DP-1 mRNAs were not detectable in granulocytes, monocytes and resting T-lymphocytes but were induced after the mitogenic stimulation of T-lymphocytes. The induction of E2F activity preceded the appearance of cdc8 mRNA, which is consistent with the role of E2F in the regulation of cdc2 mRNA expression. These results suggest that cdc2 mRNA expression is related to the cell cycling of normal human hematopoietic cells and that E2F plays some roles in the regulation of its expression.	JICHI MED SCH,INST HEMATOL,DIV HEMOPOIESIS,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	Jichi Medical University			Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				AGLIETTA M, 1989, J CLIN INVEST, V83, P551, DOI 10.1172/JCI113917; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BRUMLEY RL, 1991, NUCLEIC ACIDS RES, V19, P4121, DOI 10.1093/nar/19.15.4121; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHODOSH LA, 1992, SHORT PROTOCOLS MOL, P12; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKACZ B, 1986, EMBO J, V5, P369, DOI 10.1002/j.1460-2075.1986.tb04221.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORS L, 1990, NUCLEIC ACIDS RES, V18, P2793, DOI 10.1093/nar/18.9.2793; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FURUKAWA Y, 1987, CANCER RES, V47, P2589; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; Hunt T, 1991, Semin Cell Biol, V2, P213; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KITAGAWA S, 1984, J CLIN INVEST, V73, P1062, DOI 10.1172/JCI111291; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KU DH, 1993, J BIOL CHEM, V268, P2255; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; LUBBERT M, 1991, BLOOD, V78, P345; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OGAWA M, 1993, BLOOD, V81, P2844; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SUDA T, 1983, J CELL PHYSIOL, V117, P308, DOI 10.1002/jcp.1041170305; SUZUKI K, 1989, J EXP MED, V169, P1895, DOI 10.1084/jem.169.6.1895; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; YUO A, 1992, BLOOD, V79, P1553	64	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26249	26258						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929342				2022-12-25	WOS:A1994PQ93000050
J	NISHIMURA, M; FEDOROV, S; UYEDA, K				NISHIMURA, M; FEDOROV, S; UYEDA, K			GLUCOSE-STIMULATED SYNTHESIS OF FRUCTOSE 2,6-BISPHOSPHATE IN RAT-LIVER - DEPHOSPHORYLATION OF FRUCTOSE 6-PHOSPHATE,2-KINASE-FRUCTOSE 2,6-BISPHOSPHATASE AND ACTIVATION BY A SUGAR-PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AD-LIBITUM; PHOSPHORYLATION; HEPATOCYTES; GLYCOLYSIS; CYCLE; METABOLISM; MECHANISM; 2-KINASE; BINDING; LEVEL	The effect of glucose on hepatic fructose (Fru) 2,6-P-2 in starved rats was investigated. When livers were perfused with high glucose (40 mM), hexose-P in the liver increased immediately reaching the maximum within in 2 min, but Fru 2,6-P-2 after a lag period of 4 min increased linearly. The activation of Fru 6-P,2-kinase and inactivation of Fru 2,6-Pase also showed a similar lag period. Determination of the phosphate contents of the bifunctional enzyme after 10 min of glucose perfusion revealed that 90% of the enzyme was in the dephospho form while only 10% of the control liver enzyme was dephosphorylated. Comparison of crude extracts of liver perfused with either high glucose or normal glucose (5.6 mM) showed that high glucose livers contained 50% higher protein phosphatase activity, which dephosphorylated the bifunctional enzyme. Subcellular fractionation of the ex tract showed that activation of the protein phosphatase occurred in the cytosol. Desalting of the cytosolic fraction resulted in a 50% loss of the protein phosphatase activity. The low molecular weight activator in the cytosol was isolated, and by various chemical and enzymatic methods it was identified as xylulose 5-P. The activation of protein phosphatase by xylulose 5-P showed a highly sigmoidal saturation curve. The rate of formation of xylulose 5-P in the perfused liver showed a lag period of approximately 2 min, and after 4 min its concentration reached 10 mu M, the minimum concentration necessary for the activation of the protein phosphatase. We conclude that the mechanism of glucose-induced Fru 2,6-P-2 synthesis was not due to increased Fru 6-P as generally thought but occurred as a result of dephosphorylation of Fru 6-P,2-kinase:Fru 2,6-Pase. Moreover, the dephosphorylation was enhanced by increased xylulose 5-P, which activated a specific protein phosphatase. The results suggest a mechanism for coordinated regulation of glycolysis and the pentose shunt pathway that is mediated by xylulose 5-P.	DEPT VET AFFAIRS MED CTR,DALLAS,TX 75216; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75216	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ABE Y, 1994, IN PRESS BIOCHEMISTR; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCHIAZZO H, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P383, DOI 10.1073/pnas.65.2.383; BUSTOS R, 1989, FEBS LETT, V251, P143, DOI 10.1016/0014-5793(89)81444-9; CASAZZA JP, 1986, J BIOL CHEM, V261, P690; CASAZZA JP, 1986, BIOCHEM J, V236, P635, DOI 10.1042/bj2360635; Corbin J D, 1974, Methods Enzymol, V38, P287; ELMAGHRABI MR, 1982, P NATL ACAD SCI-BIOL, V79, P315, DOI 10.1073/pnas.79.2.315; FILLAT C, 1993, ARCH BIOCHEM BIOPHYS, V300, P564, DOI 10.1006/abbi.1993.1078; FRANCOIS J, 1987, EUR J BIOCHEM, V164, P369, DOI 10.1111/j.1432-1033.1987.tb11067.x; FURUYA E, 1982, P NATL ACAD SCI-BIOL, V79, P325, DOI 10.1073/pnas.79.2.325; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; HUE L, 1981, J BIOL CHEM, V256, P8900; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; HUE L, 1984, BIOCHEM J, V224, P779, DOI 10.1042/bj2240779; Hue L, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P247; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KATZ J, 1978, J BIOL CHEM, V253, P4530; KHYM JX, 1975, CLIN CHEM, V21, P1245; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lowry O. H., 1972, FLEXIBLE SYSTEM ENZY, P146; MALAISSE WJ, 1982, DIABETES, V31, P90, DOI 10.2337/diabetes.31.1.90; NEELY P, 1981, DIABETES, V30, P1062, DOI 10.2337/diabetes.30.12.1062; NORDLIE RC, 1980, J BIOL CHEM, V255, P1834; OGAWA A, 1993, BIOCHEM MOL BIOL INT, V30, P83; RICHARDS CS, 1980, BIOCHEM BIOPH RES CO, V109, P394; Roach P. J., 1986, ENZYMES, VXVII, P499; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P41; STALMANS W, 1987, Diabetes Metabolism Reviews, V3, P127; STALMANS W, 1976, CURR TOP CELL REGUL, V11, P51; THOMAS H, 1986, ANAL BIOCHEM, V154, P50, DOI 10.1016/0003-2697(86)90494-X; THOMAS H, 1986, FED PROC, V45, P1013; TOMINAGA N, 1993, J BIOL CHEM, V268, P15951; UYEDA K, 1978, J BIOL CHEM, V253, P8319; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V103, P362, DOI 10.1016/0006-291X(81)91701-0; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P887, DOI 10.1042/bj1920887	38	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26100	26106						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929321				2022-12-25	WOS:A1994PQ93000027
J	ONEAL, KD; YULEE, LY				ONEAL, KD; YULEE, LY			DIFFERENTIAL SIGNAL-TRANSDUCTION OF THE SHORT, NB2, AND LONG PROLACTIN RECEPTORS - ACTIVATION OF INTERFERON REGULATORY FACTOR-I AND CELL-PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; STIMULATING FACTOR-RECEPTOR; FACTOR-I; LYMPHOMA-CELLS; ERYTHROPOIETIN RECEPTOR; TYROSINE KINASE; CYTOPLASMIC REGION; GENE-EXPRESSION; BETA-CHAIN; T-CELLS	An Nb2 prolactin receptor (PRL-R) cDNA has been cloned from the PRL-dependent Nb2-11C cell line, and the protein-coding region is identical to that of the PRL-R isolated from the PRL-independent cell line Nb2-Sp. Short, Nb2, and long forms of the PRL-R were analyzed for signal transduction to the immediate-early gene, interferon regulatory factor-1 (IRF-1) and for cellular proliferation. Receptor and IRF-1-CAT reporter constructs were transiently cotransfected into the interleukin-3 dependent cell lines FDC-P1 and BaF3. The Nb2 PRL-R induced IRF-1-CAT 14.3-fold on addition of PRL, while the long PRL-R induced IRF-1-CAT 5.6-fold in FDC-P1 cells. The short PRL-R did not activate the IRF-1 promoter. Stable transfectants were also generated by selecting for growth in PRL. Only the Nb2 and long forms were able to convert the IL-3-dependent cells to PRL-dependence. IRF-1-CAT was induced in these cell lines by the Nb2 PRL-R 10- to 12-fold and long PRL-R 3- to 3.5-fold. Overall, the Nb2 form is more efficient than the long form by about 3-fold at inducing IRF-1-CAT. A PRL dose-response growth curve showed that the Nb2 form requires 20-fold less PRL for half maximal growth than the long form. A PRL dose-response for IRF-1-CAT activity gave similar results, indicating a tight correlation between IRF-1 induction and cell proliferation. These results show that the short PRL-R does not signal to IRF-1 or for growth, and that the Nb2 PRL-R signals more efficiently than the long PRL-R.	BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NIDDK NIH HHS [R01-DK44625] Funding Source: Medline; NIMH NIH HHS [F30-MH10343] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH010343] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ALI S, 1991, J BIOL CHEM, V266, P20110; ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASHKENAZI A, 1987, BIOCHEM INT, V14, P1065; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; COLOSI P, 1993, J BIOL CHEM, V268, P12617; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELSHOLTZ HP, 1986, BIOCHEM CELL BIOL, V64, P381, DOI 10.1139/o86-053; FRIESEN HG, 1991, PROG NEUROENDOCRINIM, V4, P1; FUH G, 1993, J BIOL CHEM, V268, P5376; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GAGNERAULT MC, 1993, J IMMUNOL, V150, P5673; GALA RR, 1993, ENDOCRINOLOGY, V133, P1617, DOI 10.1210/en.133.4.1617; GELLER DA, 1993, SURGERY, V114, P235; GERTLER A, 1985, ENDOCRINOLOGY, V116, P1636, DOI 10.1210/endo-116-4-1636; GOUT PW, 1980, CANCER RES, V40, P2433; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; JAHN GA, 1991, ENDOCRINOLOGY, V128, P2976, DOI 10.1210/endo-128-6-2976; KURAMOCHI S, 1990, J MOL BIOL, V216, P567, DOI 10.1016/0022-2836(90)90384-X; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MORI H, 1991, INT IMMUNOL, V3, P149, DOI 10.1093/intimm/3.2.149; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAGANO M, 1994, J BIOL CHEM, V269, P13337; ONEAL KD, 1991, MOL CELL ENDOCRINOL, V82, P127, DOI 10.1016/0303-7207(91)90023-L; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PELLEGRINI I, 1992, MOL ENDOCRINOL, V6, P1023, DOI 10.1210/me.6.7.1023; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1994, J BIOL CHEM, V269, P5364; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SCHWARZ LA, 1992, MOL CELL ENDOCRINOL, V86, P103, DOI 10.1016/0303-7207(92)90180-E; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STEVENS AM, 1994, MOL ENDOCRINOL, V8, P345, DOI 10.1210/me.8.3.345; STEVENS AM, 1992, MOL ENDOCRINOL, V6, P2236, DOI 10.1210/me.6.12.2236; TOO CKL, 1990, ENDOCRINOLOGY, V126, P1368, DOI 10.1210/endo-126-3-1368; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087; ZHANG R, 1990, BIOCHEM BIOPH RES CO, V168, P415, DOI 10.1016/0006-291X(90)92337-Y; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	60	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26076	26082						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929319				2022-12-25	WOS:A1994PQ93000024
J	SUH, TT; NERLOV, C; DANO, K; DEGEN, JL				SUH, TT; NERLOV, C; DANO, K; DEGEN, JL			THE MURINE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DNA-POLYMERASE; MESSENGER-RNA; CELLULAR RECEPTOR; BOUND UROKINASE; BINDING-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; POLY(DC-DA) SEQUENCE; ENDOTHELIAL-CELLS; MOUSE GENOME; MEMBRANE	The murine urokinase-type plasminogen activator receptor (uPAR) gene has been isolated and its complete nucleotide sequence established. The gene is organized into seven exons comprising 9.5% of the 13,207-base pair region that spans the interval between the transcription initiation and polyadenylation sites. The region upstream of the transcription initiation site lacks TATA- or CCAAT-like elements but is flanked by a G+C-rich region, which contains a number of potential regulatory elements including Sp1 and AP1 binding motifs. The close association of both Sp1 and AP1 sites within the proximal promoter region is consistent with the observation that the murine uPAR gene is inducible by phorbol esters. The major functional domains of the encoded protein, including the signal peptide, three cysteine-rich internal repeats, and the glycolipid anchor attachment motif, are encoded by separate exons. Based on the organization of the murine uPAR gene and the distribution of protein domains within the exons in the Ly-6 family of genes, it appears that the uPAR gene evolved secondarily to two internal duplication events within a Ly-6-like ancestral gene. The cloned and sequenced murine uPAR gene will be a valuable tool in understanding the regulation and biological roles of uPAR in that it will permit detailed studies of gene expression and uPAR-dependent processes in vitro, as well as the generation of both gain-of-function and loss-of-function mutants in transgenic mice.	CHILDRENS HOSP RES FDN,DIV BASIC SCI RES,TCHRF 2025,CINCINNATI,OH 45229; RIGSHOSP,FINSEN LAB,DK-2100 COPENHAGEN 0,DENMARK	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Rigshospitalet; University of Copenhagen								ALBRECHT JC, 1992, VIROLOGY, V190, P527, DOI 10.1016/0042-6822(92)91247-R; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLAKE CCF, 1978, NATURE, V273, P267, DOI 10.1038/273267a0; BLASI F, 1990, CELL DIFFER DEV, V32, P247, DOI 10.1016/0922-3371(90)90037-W; BOTHWELL A, 1988, J IMMUNOL, V140, P2815; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CASEY JR, 1994, BLOOD, V84, P1151; COLLEN D, 1987, MOL BASIS BLOOD DISE, P662; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; DEGEN SJF, 1986, J BIOL CHEM, V261, P6972; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P8270, DOI 10.1021/bi00399a038; DOOLITTLE WF, 1978, NATURE, V272, P581, DOI 10.1038/272581a0; ELLIS V, 1991, SEMIN THROMB HEMOST, V17, P194, DOI 10.1055/s-2007-1002609; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN S, 1990, IMMUNOGENETICS, V31, P104, DOI 10.1007/BF00661220; FUSE N, 1990, EUR J BIOCHEM, V193, P629, DOI 10.1111/j.1432-1033.1990.tb19380.x; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; HAMADA H, 1984, MOL CELL BIOL, V4, P2622, DOI 10.1128/MCB.4.12.2622; HAMADA H, 1984, MOL CELL BIOL, V4, P2610, DOI 10.1128/MCB.4.12.2610; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; HTUN H, 1984, P NATL ACAD SCI-BIOL, V81, P7288, DOI 10.1073/pnas.81.23.7288; HURST HC, 1984, NUCLEIC ACIDS RES, V12, P4313, DOI 10.1093/nar/12.10.4313; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; INGOLIA TD, 1981, NUCLEIC ACIDS RES, V9, P1627, DOI 10.1093/nar/9.7.1627; KALB VF, 1983, NUCLEIC ACIDS RES, V11, P2177, DOI 10.1093/nar/11.7.2177; KING D, 1986, MOL CELL BIOL, V6, P209, DOI 10.1128/MCB.6.1.209; KRAMEROV DA, 1979, NUCLEIC ACIDS RES, V6, P697, DOI 10.1093/nar/6.2.697; KRAYEV AS, 1982, NUCLEIC ACIDS RES, V10, P7461, DOI 10.1093/nar/10.23.7461; KRISTENSEN P, 1991, J CELL BIOL, V115, P1763, DOI 10.1083/jcb.115.6.1763; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; LAFYATIS R, 1991, NUCLEIC ACIDS RES, V19, P6419, DOI 10.1093/nar/19.23.6419; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; LUND LR, 1991, J BIOL CHEM, V266, P5177; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOLLER LB, 1992, EUR J BIOCHEM, V208, P493, DOI 10.1111/j.1432-1033.1992.tb17213.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PETRANKA JG, 1992, P NATL ACAD SCI USA, V89, P7876, DOI 10.1073/pnas.89.17.7876; PLOUG M, 1993, J BIOL CHEM, V268, P17539; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; PULLEYBLANK DE, 1985, CELL, V42, P271, DOI 10.1016/S0092-8674(85)80122-7; PYKE C, 1991, AM J PATHOL, V138, P1059; PYKE C, 1993, FEBS LETT, V326, P69, DOI 10.1016/0014-5793(93)81763-P; RYSKOV AP, 1983, NUCLEIC ACIDS RES, V11, P6541, DOI 10.1093/nar/11.18.6541; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1989, J BIOL CHEM, V264, P6447; TONE M, 1992, J MOL BIOL, V227, P971, DOI 10.1016/0022-2836(92)90239-G; UNKELESS JC, 1974, J EXP MED, V139, P834, DOI 10.1084/jem.139.4.834; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; WILLIAMS AF, 1988, IMMUNOGENETICS, V27, P265, DOI 10.1007/BF00376121	73	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25992	25998						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929309				2022-12-25	WOS:A1994PQ93000012
J	WEIS, BC; COWAN, AT; BROWN, N; FOSTER, DW; MCGARRY, JD				WEIS, BC; COWAN, AT; BROWN, N; FOSTER, DW; MCGARRY, JD			USE OF A SELECTIVE INHIBITOR OF LIVER CARNITINE PALMITOYLTRANSFERASE-I (CPT-I) ALLOWS QUANTIFICATION IF ITS CONTRIBUTION TO TOTAL CPT-I ACTIVITY IN RAT-HEART - EVIDENCE THAT THE DOMINANT CARDIAC CPT-I ISOFORM IS IDENTICAL TO THE SKELETAL-MUSCLE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; MALONYL-COA; MITOCHONDRIAL; TISSUES; CLONING; SENSITIVITY; EXPRESSION; SYSTEM; FORM	It has recently been established that rat heart mitochondria contain two isoforms of carnitine palmitoyltransferase I (CPT I), the minor 88-kDa variant being identical to liver CPT I (L-CPT I) and the dominant 82-kDa form resembling the skeletal muscle enzyme (M-CPT I) (Weis, B. C., Esser, V., Foster, D. W., and McGarry, J. D. (1994) J. Biol. Chem. 269, 18712-18715). To quantify the functional contribution of L-CPT I to overall CPT I activity in heart mitochondria a selective inhibitor of the former was needed. The dinitrophenol analog of 2[6-(4-chlorophenoxy)hexyl] oxirane a carboxylic acid (etomoxir) (DNP-Et) was found to have this property. When liver and skeletal muscle mitochondria were exposed to DNP-Et in the presence of ATP and CoASH, the DNP-Et-CoA formed completely inhibited liver CPT I while leaving the muscle enzyme unaffected. Similar treatment of heart mitochondria blocked only the L-CPT I component. This had the effect of shifting the apparent K-m for carnitine from similar to 200 to similar to 500 mu M and the I-50 value for malonyl-CoA (the concentration needed to suppress enzyme activity by 50%) from similar to 0.18 to similar to 0.06 mu M, i.e. the heart system now behaved exactly the same as that from skeletal muscle. Taking the K-m for carnitine of L-CPT I and M-CPT I to be 30 and 500 mu M, respectively, it could be calculated that the former contributes similar to 2% to the total CPT I in heart. When the 82-kDa CPT I isoforms of heart and skeletal muscle were labeled with [H-3]etomoxir and then exposed to trypsin, the fragmentation patterns obtained were identical and quite distinct from that given by CPT I from liver. We conclude that (i) DNP-Et, unlike other agents of the oxirane carboxylic acid class, has remarkable inhibitory selectivity for L-CPT I over M-CPT I; (ii) the previously puzzling observation that rat heart CPT I displays kinetic characteristics intermediate between those of the enzymes from liver and skeletal muscle is entirely accounted for by the low level expression of L-CPT I in the cardiac myocyte; and (iii) the dominant 82-kDa CPT I isoform in heart is identical to the muscle enzyme. The data reaffirm that, in contrast to CPT II, CPT I exists in at least two isoforms and that both are present in rat heart.	UNIV TEXAS, SW MED CTR, SW MED SCH, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, SW MED SCH, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, SW MED SCH, GIFFORD LABS DIABET RES, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R37DK018573] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18573] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; CHUNG CH, 1992, BIOCHEMISTRY-US, V31, P9777, DOI 10.1021/bi00155a034; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; DEMAUGRE F, 1991, J CLIN INVEST, V87, P859, DOI 10.1172/JCI115090; ESSER V, 1993, J BIOL CHEM, V268, P5817; ESSER V, 1993, J BIOL CHEM, V268, P5810; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; FOLEY JE, 1992, DIABETES CARE, V15, P773, DOI 10.2337/diacare.15.6.773; KERNER J, 1994, J BIOL CHEM, V269, P8209; KOLODZIEJ MP, 1992, BIOCHEM J, V282, P415, DOI 10.1042/bj2820415; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MURTHY MSR, 1990, BIOCHEM J, V268, P599, DOI 10.1042/bj2680599; SADDIK M, 1993, J BIOL CHEM, V268, P25836; SAGGERSON D, 1992, ADV ENZYME REGUL, V32, P285; SAGGERSON ED, 1981, FEBS LETT, V129, P229, DOI 10.1016/0014-5793(81)80171-8; WEIS BC, 1994, J BIOL CHEM, V269, P18712; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714; WOLF HPO, 1982, DIABETOLOGIA, V22, P456, DOI 10.1007/BF00282590	20	109	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26443	26448						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929365				2022-12-25	WOS:A1994PQ93000077
J	FURUHASHI, M; ANDO, H; BIELINSKA, M; PIXLEY, MR; SHIKONE, T; HSUEH, AJW; BOIME, I				FURUHASHI, M; ANDO, H; BIELINSKA, M; PIXLEY, MR; SHIKONE, T; HSUEH, AJW; BOIME, I			MUTAGENESIS OF CYSTEINE RESIDUES IN THE HUMAN GONADOTROPIN ALPHA-SUBUNIT - ROLES OF INDIVIDUAL DISULFIDE BONDS IN SECRETION, ASSEMBLY, AND BIOLOGIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LUTEINIZING-HORMONE LH; HAMSTER OVARY CELLS; GLYCOPROTEIN HORMONES; RECEPTOR-BINDING; BETA-SUBUNIT; MAMMALIAN-CELLS; EXPRESSION; SEQUENCE; LUTROPIN	Human chorionic gonadotropin (hCG) is a member of a family of heterodimeric glycoprotein hormones that contain a common alpha subunit but differ in their hormone specific beta subunits. Site-directed mutagenesis was used to examine the role of the five disulfide bonds in the alpha subunit on the folding, assembly with the hCG beta subunit, and in cases where dimer formation occurred, receptor binding and signal transduction. Cysteine residues in the disulfide bonds formed by cysteines 7-31, 10-60, 28-82, 59-87, and 32-84 (Lapthorn, A., Harris, D. Littlejohn, A., Lustbader, J. Canfield, R., Machin, K., Morgan, F., and Isaacs, N. (1994) Nature 369, 455-461) were converted to alanine, and these mutants were transfected alone or together with the wild-type hCG beta gene into Chinese hamster ovary cells. The a Cys-10, 28, 60, 82, and 84 mutants were not secreted and in most cases were degraded at a faster rate than the native subunit. In addition, these mutants failed to assemble with the hCG beta subunit. Mutants with alterations at alpha Cys-7, 31, 32, 59, or 87 were secreted and combined with the beta subunit. Heterodimers containing a 7-31 double mutant bound to human lutropin-chorionic gonadotropin receptor expressed in transfected human fetal kidney cells, and stimulated cAMP comparable to wild-type hCG. Dimers containing the beta subunit with either single mutant alpha 59, alpha 87, alpha 32, or the alpha 59-87 double mutant showed much lower affinity for the receptor than wild-type hCG. These results suggest that disulfide bonds associated with alpha 7, alpha 31, alpha 59, alpha 87, and alpha 32 are not essential for the alpha subunit to fold into a form that will combine with the hCG beta subunit and to produce a biologically active dimer. This contrasts with observations of the hCG beta subunit where all the disulfide bonds are required for efficient combination and folding (Suganuma, N., Mat zuk, M., and Boime, I. (1989) J. Biol. Chem. 264, 19302-19307). In addition, the lack of secretion of some mutants reflects previous observations that proteins which do not fold correctly are rapidly degraded. Thus, alpha subunit mutants which fold properly are secreted and can form heterodimers.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; STANFORD UNIV,DEPT GYNECOL & OBSTET,DIV REPROD BIOL,STANFORD,CA 94305	Washington University (WUSTL); Stanford University					NICHD NIH HHS [HD-92922, HD-23398] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023398] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; BIELINSKA M, 1990, Journal of Cell Biology, V111, p330A; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CORLESS CL, 1987, J BIOL CHEM, V262, P14197; CORLESS CL, 1985, ENDOCRINOLOGY, V117, P1699, DOI 10.1210/endo-117-4-1699; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EHRLICH PH, 1985, AM J REPROD IM MIC, V8, P48; FENG P, 1990, J BIOL CHEM, V265, P2022; GIUDICE LC, 1979, J BIOL CHEM, V254, P1164; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOSHINA H, 1982, P NATL ACAD SCI-BIOL, V79, P7649, DOI 10.1073/pnas.79.24.7649; HUTH JR, 1992, J BIOL CHEM, V267, P21396; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEINUNG MC, 1991, P NATL ACAD SCI USA, V88, P9707, DOI 10.1073/pnas.88.21.9707; LUSTBADER J, 1987, J BIOL CHEM, V262, P14204; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATZUK MM, 1989, J CELL BIOL, V109, P1429, DOI 10.1083/jcb.109.4.1429; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MISE T, 1980, J BIOL CHEM, V255, P8516; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RAO MC, 1977, ENDOCRINOLOGY, V101, P512, DOI 10.1210/endo-101-2-512; REED DK, 1991, J BIOL CHEM, V266, P14251; RUDDON RW, 1981, J BIOL CHEM, V256, P1389; Ryan R. J., 1990, GLYCOPROTEIN HORMONE, P71; RYAN RJ, 1987, RECENT PROG HORM RES, V43, P383; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; WEINER RS, 1991, ENDOCRINOLOGY, V128, P1485, DOI 10.1210/endo-128-3-1485; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585	37	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25543	25548						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929256				2022-12-25	WOS:A1994PQ49100049
J	CAZENAVE, C; FRANK, P; TOULME, JJ; BUSEN, W				CAZENAVE, C; FRANK, P; TOULME, JJ; BUSEN, W			CHARACTERIZATION AND SUBCELLULAR-LOCALIZATION OF RIBONUCLEASE-H ACTIVITIES FROM XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-RNA HYBRIDS; ESCHERICHIA-COLI; CALF THYMUS; REVERSE TRANSCRIPTASES; SUBSTRATE-SPECIFICITY; SEROLOGICAL ANALYSIS; MESSENGER-RNAS; MITOCHONDRIA; REPLICATION; TRANSLATION	Ribonuclease H activities present in fully grown Xenopus oocytes were investigated by using either liquid assays or renaturation gel assays. Whereas the test in solution detected an apparently unique class I ribonuclease H activity, the activity gels did not detect this enzyme but another one with the molecular weight expected for a class II ribonuclease H. The ribonuclease HI was found to be primarily concentrated in the germinal vesicle, but around 5% of this activity was detected in the cytoplasm and may correspond to the activity involved in antisense oligonucleotide-mediated destruction of messenger RNAs. The concentration of this class I ribonuclease H in oocytes is similar to that in somatic cells. The class II ribonuclease H remained undetectable by the test in solution because its activity was cryptic. On activity gel, a polypeptide with the apparent molecular mass of 32 kDa, expected for a ribonuclease HII, was found to be concentrated in mitochondria although no RNase H activity could be detected by using the liquid assay. Based on sedimentation studies, we hypothesize that the apparent absence of RNase H activity in solution could be the result of the association of this 32-kDa polypeptide with other polypeptides, or possibly nucleic acids, to form a multimer of, until now, unknown function.	UNIV TUBINGEN,LEHRSTUHL ALLGEMEINE GENET,INST BIOL,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen	CAZENAVE, C (corresponding author), UNIV BORDEAUX 2,INSERM,U386,LAB MOLEC BIOPHYS,146 RUE LEO SAIGNAT,F-33076 BORDEAUX,FRANCE.			Toulme, Jean-jacques/0000-0002-8432-5034				BENARTZI H, 1993, J BIOL CHEM, V268, P16465; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; BERTRAND JR, 1989, BIOCHEM BIOPH RES CO, V164, P311, DOI 10.1016/0006-291X(89)91719-1; BOIZIAU C, 1991, NUCLEIC ACIDS RES, V19, P1113, DOI 10.1093/nar/19.5.1113; BOUWMEESTER T, 1994, ONCOGENE, V9, P1029; BRUN G, 1981, EUR J BIOCHEM, V118, P407; BUSEN W, 1977, EUR J BIOCHEM, V74, P203, DOI 10.1111/j.1432-1033.1977.tb11382.x; BUSEN W, 1975, EUR J BIOCHEM, V52, P179, DOI 10.1111/j.1432-1033.1975.tb03985.x; BUSEN W, 1980, J BIOL CHEM, V255, P9434; BUSEN W, 1982, J BIOL CHEM, V257, P7106; BUSEN W, 1995, IN PRESS RIBONUCLEAS; CATHALA G, 1979, J BIOL CHEM, V254, P7353; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P4717, DOI 10.1093/nar/15.12.4717; CAZENAVE C, 1993, BIOCHIMIE, V75, P113, DOI 10.1016/0300-9084(93)90032-N; CAZENAVE C, 1991, ANTISENSE NUCLEIC AC; CHASE JW, 1972, DEV BIOL, V27, P504, DOI 10.1016/0012-1606(72)90189-3; COHEN HJ, 1972, J BIOL CHEM, V247, P7759; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COTE J, 1993, SCIENCE, V261, P765, DOI 10.1126/science.7688144; CROUCH R J, 1990, New Biologist, V2, P771; Crouch R. J., 1982, NUCLEASES, P211; CROUCH RJ, 1995, IN PRESS RIBONUCLEAS; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DRUMMOND DR, 1985, NUCLEIC ACIDS RES, V13, P7375, DOI 10.1093/nar/13.20.7375; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EDER PS, 1993, BIOCHIMIE, V75, P123, DOI 10.1016/0300-9084(93)90033-O; EDER PS, 1991, J BIOL CHEM, V266, P6472; FRANK P, 1993, BIOCHEM BIOPH RES CO, V196, P1552, DOI 10.1006/bbrc.1993.2428; FRANK P, 1991, THESIS U TUBINGEN GE; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; GURDON JB, 1974, CONTROL GENE EXPRESS; HAUSEN P, 1970, EUR J BIOCHEM, V14, P278, DOI 10.1111/j.1432-1033.1970.tb00287.x; HENRY CM, 1973, BIOCHEM BIOPH RES CO, V50, P603, DOI 10.1016/0006-291X(73)91287-4; IBORRA F, 1979, J BIOL CHEM, V254, P920; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Langdon RG, 1966, METHODS ENZYMOL, V9, DOI DOI 10.1016/0076-6879(66)09030-X; LASKEY RA, 1979, BR SOC DEV BIOL S, V4, P65; LEWIN B, 1990, GENES, V4; MARINOS E, 1985, CELL DIFFER DEV, V16, P139, DOI 10.1016/0045-6039(85)90527-5; MILLER HI, 1973, J BIOL CHEM, V248, P2621; MOELLING K, 1971, NATURE, V234, P240; OCUINN G, 1973, BIOCHIM BIOPHYS ACTA, V324, P78, DOI 10.1016/0005-2787(73)90253-0; OGAWA T, 1984, P NATL ACAD SCI-BIOL, V81, P1040, DOI 10.1073/pnas.81.4.1040; RONG YW, 1990, BIOCHEMISTRY-US, V29, P383, DOI 10.1021/bi00454a012; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SARNGADHARAN MG, 1975, J BIOL CHEM, V250, P365; SAWAI Y, 1978, BIOCHEM BIOPH RES CO, V84, P313, DOI 10.1016/0006-291X(78)90172-9; SAWAI Y, 1977, LIFE SCI, V21, P1351, DOI 10.1016/0024-3205(77)90018-2; SAWAI Y, 1978, BIOCHIM BIOPHYS ACTA, V518, P181, DOI 10.1016/0005-2787(78)90128-4; SEIDEL CW, 1994, NUCLEIC ACIDS RES, V22, P1456, DOI 10.1093/nar/22.8.1456; SOLARI A, 1982, NUCLEIC ACIDS RES, V14, P4397; SORIANO L, 1974, NUCLEIC ACIDS RES, V1, P1085, DOI 10.1093/nar/1.9.1085; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; Stick R, 1989, MOL BIOL FERTILIZATI, P153; STRAVIANOPOULOS J, 1978, P NATL ACAD SCI USA, V75, P4140; VONWIRTH H, 1989, EUR J BIOCHEM, V184, P321, DOI 10.1111/j.1432-1033.1989.tb15022.x; VONWIRTH H, 1991, EXPERIENTIA, V47, P92, DOI 10.1007/BF02041264; WANG H, 1993, J BIOL CHEM, V268, P18951; WYERS F, 1973, EUR J BIOCHEM, V35, P270, DOI 10.1111/j.1432-1033.1973.tb02835.x; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	64	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25185	25192						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929207				2022-12-25	WOS:A1994PQ49000098
J	GORDON, MK; FOLEY, JW; BIRK, DE; FITCH, JM; LINSENMAYER, TF				GORDON, MK; FOLEY, JW; BIRK, DE; FITCH, JM; LINSENMAYER, TF			TYPE-V COLLAGEN AND BOWMANS MEMBRANE - QUANTITATION OF MESSENGER-RNA IN CORNEAL EPITHELIUM AND STROMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; EMBRYONIC CHICKEN CORNEA; MONOCLONAL-ANTIBODIES; EXTRACELLULAR MATRICES; MESSENGER-RNA; XII COLLAGEN; I COLLAGEN; INVITRO; LOCALIZATION; ORGANIZATION	Bowman's membrane is an acellular matrix of the cornea which lies between the epithelial basal lamina and the corneal stroma. By immunoelectron microscopy, we have determined that types I and V collagen are components of the collagen fibrils in Bowman's membrane of the chick cornea. Although these same components are found in the fibrils of the stroma, the fibrils of Bowman's membrane are smaller in diameter and less uniform than those of the stroma. At early stages of development, the corneal epithelium synthesizes the types I and II collagen of the primary stroma. We therefore asked whether it might also be capable of synthesizing the type V collagen found in Bowman's membrane at later stages of development. Our results, using competitive polymerase chain reaction to quantitate mRNA from avian corneal cells, indicate that the amount of alpha 1(V) collagen mRNA present in epithelia, relative to alpha 2(I) collagen mRNA, is greater than that in stromal fibroblasts. We postulate that this enables the epithelium to synthesize a higher ratio of type V to type I collagen than the stroma and that this proportionally higher amount of type V might account for the ultrastructural appearance of the fibrils in Bowman's membrane.			GORDON, MK (corresponding author), TUFTS UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,136 HARRISON AVE,BOSTON,MA 02111, USA.		Birk, David/I-4072-2012	Birk, David/0000-0002-4865-9088	NATIONAL EYE INSTITUTE [R01EY005191, R01EY009056, R37EY005191, R01EY005129] Funding Source: NIH RePORTER; NEI NIH HHS [EY05129, EY05191, EY09056] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BIRK DE, 1986, INVEST OPHTH VIS SCI, V27, P1470; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Chomczynski P, 1993, BIOTECHNIQUES, V15, P536; DUBLET B, 1991, J BIOL CHEM, V266, P6853; FITCH JM, 1988, INVEST OPHTH VIS SCI, V29, P1125; FITCH JM, 1984, P NATL ACAD SCI-BIOL, V81, P2791, DOI 10.1073/pnas.81.9.2791; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; HAY ED, 1969, MONOGRAPHS DEV BIOL, P1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; LINSENMAYER TF, 1990, INVEST OPHTH VIS SCI, V31, P1271; LINSENMAYER TF, 1979, P NATL ACAD SCI USA, V76, P3703, DOI 10.1073/pnas.76.8.3703; LINSENMAYER TF, 1984, INVEST OPHTH VIS SCI, V25, P41; LINSENMAYER TF, 1983, J CELL BIOL, V96, P124, DOI 10.1083/jcb.96.1.124; LINSENMAYER TF, 1977, P NATL ACAD SCI USA, V74, P39, DOI 10.1073/pnas.74.1.39; Maniatis T, 1989, DECONTAMINATION DILU; MARCHANT JK, 1991, P NATL ACAD SCI USA, V88, P1560, DOI 10.1073/pnas.88.4.1560; MCLAUGHLIN JS, 1989, J CELL SCI, V94, P371; MIRSKY AE, 1949, NATURE, V163, P666, DOI 10.1038/163666a0; MODESTI A, 1984, EUR J CELL BIOL, V35, P246; NINOMIYA Y, 1984, P NATL ACAD SCI-BIOL, V81, P3014, DOI 10.1073/pnas.81.10.3014; PANABIERES F, 1984, BIOCHEM BIOPH RES CO, V118, P767, DOI 10.1016/0006-291X(84)91461-X; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; SWASDISON S, 1992, MATRIX, V11, P56; TSENG SCG, 1982, J BIOL CHEM, V257, P2627; VANDERREST M, 1982, EUR J BIOCHEM, V125, P491, DOI 10.1111/j.1432-1033.1982.tb06709.x; VONDERMARK K, 1982, COLLAGEN REL RES, V2, P541	34	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24959	24966						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929179				2022-12-25	WOS:A1994PQ49000066
J	GULLBERG, U; LINDMARK, A; NILSSON, E; PERSSON, AM; OLSSON, I				GULLBERG, U; LINDMARK, A; NILSSON, E; PERSSON, AM; OLSSON, I			PROCESSING OF HUMAN CATHEPSIN-G AFTER TRANSFECTION TO THE RAT BASOPHILIC MAST-CELL TUMOR LINE RBL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-I; LYSOSOMAL-ENZYMES; POLYMORPHONUCLEAR LEUKOCYTES; NEUTROPHIL ELASTASE; MYELOID CELLS; GRANULES; BIOSYNTHESIS; SPECIFICITY; PROTEINASES; ACTIVATION	The azurophil granules of neutrophil granulocytes contain neutral proteases such as leukocyte elastase and cathepsin G. These are synthesized as inactive precursors, but following proteolytic processing, they are stored in granules as active enzymes. We describe the establishment of a transgenic cellular model for expression of the human myeloid serine protease cathepsin G. The cDNA for preprocathepsin G was stably expressed in the rat basophilic/mast cell line RBL-1 and the translation product was characterized by use of biosynthetic labeling followed by immunoprecipitation, SDS-polyacrylamide gel electrophoresis, and fluorography. Conversion into complex form of an asparagine-linked carbohydrate unit of approximately 3.5 kDa was shown, as judged by the products obtained upon treatment with endoglycosidase H and N-glycanase. Proteolytic processing of 32.5 kDa procathepsin G into a 31-kDa form, within 1-2 h after synthesis, was demonstrated by pulse-chase experiments. Further processing into a 30-kDa form also occurred to a minor extent. The processed forms were enzymatically active, as judged by affinity for the serine protease inhibitors diisopropylfluorophosphate phosphate and aprotinin. Translocation of processed forms of cathepsin G to high density fractions, indicating targeting of the protease to granules, was demonstrated by subcellular fractionation. The weak base NH4Cl was shown to delay the processing and enzymatic activation of cathepsin G, whereas the monovalent ionophore monensin completely inhibited both events. Our data demonstrate that human cathepsin G transfected to rat RBL-1 cells, is proteolytically processed into enzymatically active forms and that subcellular transfer to granular organelles occurs. As the processing of transgenic human cathepsin G corresponds to that of endogenous protease of myeloid cells, the model should provide new unique possibilities to further characterize the activation and granular targeting of myeloid serine proteases.	LUND UNIV,DEPT MED,DIV HEMATOL,S-22185 LUND,SWEDEN	Lund University								BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BROWN GR, 1993, J IMMUNOL, V150, P4733; Elsbach P, 1992, INFLAMMATION BASIC P, P603; GABAY JE, 1993, CURR OPIN IMMUNOL, V5, P97, DOI 10.1016/0952-7915(93)90087-9; GANZ T, 1993, BLOOD, V82, P641; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; HULTBERG B, 1976, BIOCHEM J, V155, P599, DOI 10.1042/bj1550599; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LINDMARK A, 1994, J LEUKOCYTE BIOL, V55, P50, DOI 10.1002/jlb.55.1.50; LINDMARK A, 1990, BLOOD, V76, P2374; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NAUSEEF WM, 1988, EUR J HAEMATOL, V40, P97; OLSSON I, 1974, BLOOD, V44, P235, DOI 10.1182/blood.V44.2.235.235; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; SALVESEN G, 1991, BIOMED BIOCHIM ACTA, V50, P665; SINAH S, 1987, P NATL ACAD SCI USA, V84, P2228; URATA H, 1993, J BIOL CHEM, V268, P24318; VALORE EV, 1992, BLOOD, V79, P1538; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WATOREK W, 1993, BIOL CHEM H-S, V374, P885	27	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25219	25225						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929211				2022-12-25	WOS:A1994PQ49000103
J	KAO, J; HOUCK, K; FAN, Y; HAEHNEL, I; LIBUTTI, SK; KAYTON, ML; GRIKSCHEIT, T; CHABOT, J; NOWYGROD, R; GREENBERG, S; KUANG, WJ; LEUNG, DW; HAYWARD, JR; KISIEL, W; HEATH, M; BRETT, J; STERN, DM				KAO, J; HOUCK, K; FAN, Y; HAEHNEL, I; LIBUTTI, SK; KAYTON, ML; GRIKSCHEIT, T; CHABOT, J; NOWYGROD, R; GREENBERG, S; KUANG, WJ; LEUNG, DW; HAYWARD, JR; KISIEL, W; HEATH, M; BRETT, J; STERN, DM			CHARACTERIZATION OF A NOVEL TUMOR-DERIVED CYTOKINE - ENDOTHELIAL-MONOCYTE ACTIVATING POLYPEPTIDE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR-PERMEABILITY FACTOR; NEUTROPHIL CHEMOTACTIC FACTOR; NECROSIS-FACTOR CACHECTIN; VONWILLEBRAND ANTIGEN-II; MONONUCLEAR PHAGOCYTES; STIMULATED SECRETION; INTERLEUKIN 1-ALPHA; MOLECULAR-CLONING; MAMMARY-TUMOR; TISSUE FACTOR	Endothelial-monocyte activating polypeptide II (EMAP II) was initially identified in the supernatant of murine methylcholanthrene A-induced fibrosarcomas (Meth A) by its capacity to activate host effector cells (Kao, J., Ryan, J., Brett, J., Chen, J., Shen, H., Fan, Y-G., Godman, G., Familletti, P., Wang, F., Pan, Y-C., Stern, D., and Clauss, M. (1992) J. Biol. Chem. 267, 20239-20247). Based on the NH2-terminal protein sequence, a full-length cDNA has been cloned which indicates that the precursor of EMAP II is a unique, leaderless, single polypeptide chain with predicted molecular mass approximate to 34 kDa and that the mature form released by Meth A cells corresponds to approximate to 20 kDa. Purified recombinant mature EMAP II (EMAP II, approximate to 20 kDa form) activated endothelial cells with resulting elevation of cytosolic free calcium concentration, release of von Willebrand factor, induction of tissue factor, and expression of the adhesion molecules E-selectin and P-selectin. Neutrophils exposed to EMAP II demonstrated elevated cytosolic free calcium concentration, peroxidase generation, and chemotaxis. EMAP II also activated mononuclear phagocytes elevating cytosolic free calcium concentration, inducing tumor necrosis factor-alpha (TNF) and tissue factor, and stimulating chemotaxis. Systemic infusion of EMAP II into C3H/HeJ or Balb/c mice was associated with systemic toxicity, pulmonary congestion, and the appearance of TNF, interleukin-1 and -6 in the plasma. A single intratumor injection of EMAP II into Meth A sarcomas induced acute thrombohemorrhage and partial tumor regression. Local injection of EMAP II into a tumor resistant to the effects of TNF murine mammary carcinoma, rendered it sensitive to subsequently administered TNF, which resulted in acute thrombohemorrhage and partial regression. These data suggest that recombinant EMAP II, a tumor-derived cytokine, has properties of a proinflammatory mediator with the capacity to prime the tumor vasculature for a locally destructive process.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT ANESTHESIA,NEW YORK,NY 10032; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT RECOVERY SCI,S SAN FRANCISCO,CA 94080; UNIV NEW MEXICO,SCH MED,DEPT PATHOL,BLOOD SYST RES FDN LAB,ALBUQUERQUE,NM 87131	Columbia University; Columbia University; Columbia University; Roche Holding; Genentech; Roche Holding; Genentech; University of New Mexico	KAO, J (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHYSIOL,P&S 11-518,630 W 168TH ST,NEW YORK,NY 10032, USA.		Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249	NHLBI NIH HHS [HL42507, HL42833, HL02641] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042833, K08HL002641, R01HL042507] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHER A, 1987, J IMMUNOL, V138, P963; BIBBY MC, 1989, J NATL CANCER I, V81, P216, DOI 10.1093/jnci/81.3.216; BIRCH KA, 1992, J CELL BIOL, V118, P1501, DOI 10.1083/jcb.118.6.1501; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BRAUNSCHWEIGER PG, 1990, CANCER RES, V50, P4709; BRETT J, 1993, AM J PATHOL, V143, P1699; BROZNA JP, 1990, SEMIN THROMB HEMOST, V16, P326, DOI 10.1055/s-2007-1002685; CARRE P, 1991, J CLIN INVEST, V68, P1802; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHENSUE SW, 1991, AM J PATHOL, V138, P395; CLAUSS M, 1990, J BIOL CHEM, V265, P7078; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONSTANTINIDIS I, 1989, CANCER RES, V49, P6379; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; FAY PJ, 1986, SCIENCE, V232, P995, DOI 10.1126/science.3486471; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOLDBLUM SE, 1985, J APPL PHYSIOL, V59, P1978, DOI 10.1152/jappl.1985.59.6.1978; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Jaffe EA, 1984, BIOL ENDOTHELIAL CEL, P1; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P9774; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KARPATI RM, 1991, J IMMUNOL, V146, P2043; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOGA S, 1992, J CLIN INVEST, V90, P1007, DOI 10.1172/JCI115913; KONDO S, 1987, BLOOD, V70, P1947; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1992, NEURON, V8, P1045, DOI 10.1016/0896-6273(92)90126-X; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; LO SK, 1992, J CLIN INVEST, V89, P981, DOI 10.1172/JCI115681; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MENEGAZZI R, 1992, J LEUKOCYTE BIOL, V52, P619, DOI 10.1002/jlb.52.6.619; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; MOVAT HZ, 1987, AM J PATHOL, V129, P463; NAWROTH P, 1988, J EXP MED, V168, P637, DOI 10.1084/jem.168.2.637; OLD LJ, 1961, CANCER RES, V21, P1281; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OUTZEN HC, 1985, J NATL CANCER I, V75, P917, DOI 10.1093/jnci/75.5.917; POBER JS, 1993, J IMMUNOL, V150, P5114; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; REGEHR WG, 1992, J NEUROSCI, V12, P4202; RETROSEN D, 1986, J CELL BIOL, V103, P2379; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; Sambrook J, 1989, MOL CLONING LABORATO; SAUDER DN, 1984, J IMMUNOL, V132, P828; SCHMIDT JA, 1990, PEPTIDE GROWTH FACTO, P473; SCOTT JP, 1981, BLOOD, V58, P1075; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHEN H, 1993, BLOOD, V81, P2767; STRIETER RM, 1992, AM J PATHOL, V141, P1279; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TIJBURG P, 1992, CIRCULATION S1, V86, P1627; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; TWENTYMAN PR, 1980, JNCI-J NATL CANCER I, V64, P595; VAAGE J, 1985, CANCER RES, V45, P659; WAGNER DD, 1991, MAYO CLIN PROC, V66, P621, DOI 10.1016/S0025-6196(12)60522-9; WATANABE N, 1988, CANCER RES, V48, P2179; WEAST RC, 1966, HDB CHEM PHYSICS; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	74	152	170	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25106	25119						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929199				2022-12-25	WOS:A1994PQ49000088
J	OMURA, TH; NOGUCHI, A; JOHANNS, CA; JEFFREY, JJ; PARTRIDGE, NC				OMURA, TH; NOGUCHI, A; JOHANNS, CA; JEFFREY, JJ; PARTRIDGE, NC			IDENTIFICATION OF A SPECIFIC RECEPTOR FOR INTERSTITIAL COLLAGENASE ON OSTEOBLASTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENIC-SARCOMA CELLS; BONE-RESORBING AGENTS; PLASMINOGEN-ACTIVATOR; PARATHYROID-HORMONE; UROKINASE RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; FIBROBLAST COLLAGENASE; MEDIATED ENDOCYTOSIS; BINDING-SITE; PROTEIN	We have previously shown that the rat osteoblastic cell line UMR 106-01 responds to parathyroid hormone treatment by secreting interstitial collagenase. Secreted collagenase reaches a maximal concentration 12-24 h after parathyroid hormone stimulation, but then declines to undetectable levels by 96 h. Neither spontaneous nor cell-mediated extracellular degradation could account for this disappearance, since the enzyme maintained stability in both fresh and conditioned media. Instead, a cell-mediated binding mechanism was suggested by the rapid and saturable removal of exogenous purified rat collagenase at 37 degrees C. Binding studies using I-125-collagenase at 4 degrees C indicated a saturable receptor of a single class and 12,000 receptors per cell (K-d = 5 x 10(-9) M). A time course revealed specific receptor-mediated binding within 10 min and equilibrium by 60 min, while dissociation experiments further demonstrated reversibility, The kinetics of I-125-collagenase binding are characterized by the association (k(1) = 4 x 10(6) M(-1) min(-1)) and dissociation (k(-1) = 2 x 10(-3) min(-1)) rate constants. The receptor was shown to be specific for rat collagenase since a host of related and unrelated proteins failed to compete for binding. Internalization studies revealed maximal intracellular accumulation at 30 min and complete degradation by 90 min, suggesting this receptor functions in these osteoblastic cells to eliminate extracellular collagenase.	ST LOUIS UNIV, MED CTR, SCH MED, DEPT PHARMACOL & PHYSIOL SCI, ST LOUIS, MO 63104 USA; CARDINAL GLENNON MEM HOSP CHILDREN, PEDIAT RES INST, ST LOUIS, MO 63110 USA; ALBANY MED COLL, DEPT MED, DIV HEMATOL, ALBANY, NY 12208 USA	Saint Louis University; Albany Medical College				Partridge, Nicola/0000-0002-5406-4814	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005291, R37HD005291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040661] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40661] Funding Source: Medline; NICHD NIH HHS [HD05291] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1993, J BIOL CHEM, V268, P13002; CAWSTON TE, 1981, BIOCHEM J, V195, P159, DOI 10.1042/bj1950159; CHAMBERS TJ, 1985, CELL TISSUE RES, V241, P671; CIVITELLI R, 1989, ENDOCRINOLOGY, V124, P2928, DOI 10.1210/endo-124-6-2928; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DELAISSE JM, 1988, ENDOCRINOLOGY, V123, P264, DOI 10.1210/endo-123-1-264; DIETRICH JW, 1976, ENDOCRINOLOGY, V98, P943, DOI 10.1210/endo-98-4-943; EECKHOUT Y, 1977, BIOCHEM J, V166, P21, DOI 10.1042/bj1660021; EMONARD HP, 1992, CANCER RES, V52, P5845; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAMILTON JA, 1985, ENDOCRINOLOGY, V116, P2186, DOI 10.1210/endo-116-6-2186; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; JEFFREY JJ, 1990, J CELL PHYSIOL, V143, P396, DOI 10.1002/jcp.1041430226; KRISTENSEN T, 1989, FEBS LETT, V255, P275; MALLYA SK, 1990, BIOCHEMISTRY-US, V29, P10628, DOI 10.1021/bi00499a008; MOLL UM, 1990, CANCER RES, V50, P6995; MONSKY WL, 1993, CANCER RES, V53, P3159; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; PARTRIDGE NC, 1980, FEBS LETT, V115, P139, DOI 10.1016/0014-5793(80)80744-7; PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo-120-5-1956; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; PARTRIDGE NC, 1989, MOL ENDOCRINOL, V3, P232, DOI 10.1210/mend-3-2-232; PARTRIDGE NC, 1993, FRONTIERS OF OSTEOSARCOMA RESEARCH, P269; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1991, ADV CANCER RES, V57, P273; PUCCINELLI JM, 1991, J CELL PHYSIOL, V147, P505, DOI 10.1002/jcp.1041470317; ROSWIT WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P285, DOI 10.1016/0003-9861(83)90032-2; ROSWIT WT, 1992, ARCH BIOCHEM BIOPHYS, V292, P402, DOI 10.1016/0003-9861(92)90009-L; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; THOMSON BM, 1989, BIOCHIM BIOPHYS ACTA, V1014, P125, DOI 10.1016/0167-4889(89)90024-4; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801	44	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24994	24998						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929184				2022-12-25	WOS:A1994PQ49000071
J	RAVICHANDRAN, V; SERES, T; MORIGUCHI, T; THOMAS, JA; JOHNSTON, RB				RAVICHANDRAN, V; SERES, T; MORIGUCHI, T; THOMAS, JA; JOHNSTON, RB			S-THIOLATION OF GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE INDUCED BY THE PHAGOCYTOSIS-ASSOCIATED RESPIRATORY BURST IN BLOOD MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; AUTO-ADP-RIBOSYLATION; DISULFIDE EXCHANGE; HYDROGEN-PEROXIDE; HUMAN-NEUTROPHILS; SUPEROXIDE ANION; OXIDATIVE-METABOLISM; REVERSIBLE OXIDATION; CREATINE-KINASE; SKELETAL-MUSCLE	Chemical oxidants can induce the covalent binding of low molecular weight thiols to reactive sulfhydryls on proteins (S-thiolation), We found that stimulation of the respiratory burst of human blood monocytes resulted in S-thiolation of several proteins, most prominently one of 38 kDa. This purified protein was identified as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by enzyme activity, immunoblotting, and amino acid analysis. After stimulation of the respiratory burst, S-thiolation of GAPDH gradually increased, and cytosol GAPDH activity decreased; so that at 60 min, GAPDH activity was reduced by similar to 40%, Activity was restored by the addition of the sulfhydryl-reducing agent dithioerythritol. H2O2 appeared to be particularly important in mediating S-thiolation during the respiratory burst. Exposure of monocytes to H2O2 induced concentration-dependent S-thiolation of GAPDH and a concomitant decrease in enzyme activity. The addition of respiratory burst stimuli to lymphocytes, which lack a full respiratory burst, had no effect on GAPDH S-thiolation or activity; but H2O2 induced S-thiolation of lymphocyte GAPDH and inhibition of enzyme activity. Stimulation of monocytes from three patients with chronic granulomatous disease resulted in no respiratory burst, S-thiolation of GAPDH, or inactivation of GAPDH activity. The thiols covalently bound to purified S-thiolated GAPDH were removed by dithioerythritol and were identified as glutathione and cysteine; glutathione was predominant. These results indicate that during the respiratory burst in monocytes, low molecular weight thiols can bind to specific cytosolic proteins, including GAPDH. It is possible that S-thiolation of cytosolic proteins serves to modulate cellular metabolic events during phagocytosis.	YALE UNIV,SCH MED,DEPT PEDIAT IMMUNOL,NEW HAVEN,CT 06520; IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Yale University; Iowa State University					NIAID NIH HHS [AI 24782] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024782] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RW, 1987, J BIOL CHEM, V262, P649; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BAEHNER RL, 1977, BLOOD, V50, P327; BIRKETT DJ, 1973, MOL PHARMACOL, V9, P209; BRODIE AE, 1987, BIOCHEM BIOPH RES CO, V148, P120, DOI 10.1016/0006-291X(87)91084-9; CAPPEL RE, 1989, J BIOL CHEM, V264, P9180; CASWELL AH, 1985, J BIOL CHEM, V260, P6892; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; COLLISON MW, 1987, BIOCHIM BIOPHYS ACTA, V928, P121, DOI 10.1016/0167-4889(87)90112-1; CONSTANTINIDES SM, 1969, J BIOL CHEM, V244, P5695; DIMMELER S, 1993, J IMMUNOL, V150, P2964; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; ERNEST MJ, 1974, J BIOL CHEM, V249, P5011; ERNST V, 1978, P NATL ACAD SCI USA, V75, P4110, DOI 10.1073/pnas.75.9.4110; FINKEL TH, 1987, J BIOL CHEM, V262, P12589; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; HARRIS JI, 1976, ENZYMES, V13, P1; HARRIS JJ, 1963, BIOCHEM J, V89, P60; HAZUM E, 1979, NATURE, V282, P626, DOI 10.1038/282626a0; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; JOHNSTON RB, 1976, J EXP MED, V143, P1551, DOI 10.1084/jem.143.6.1551; JOHNSTON RB, 1978, J EXP MED, V148, P115; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P283; MAKINEN AL, 1989, J BIOL CHEM, V264, P12148; MARZULLO G, 1980, SCIENCE, V208, P1171, DOI 10.1126/science.6246583; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEREDITH MJ, 1983, ANAL BIOCHEM, V131, P504, DOI 10.1016/0003-2697(83)90205-1; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MILLER RM, 1990, ARCH BIOCHEM BIOPHYS, V276, P355, DOI 10.1016/0003-9861(90)90732-E; MUKHERJEE SP, 1979, BIOCHIM BIOPHYS ACTA, V568, P224, DOI 10.1016/0005-2744(79)90289-4; NAMBOODIRI MAA, 1979, BIOCHEM BIOPH RES CO, V91, P1166, DOI 10.1016/0006-291X(79)92002-3; NATHAN CF, 1979, J EXP MED, V149, P100, DOI 10.1084/jem.149.1.100; NELSON RD, 1979, INFECT IMMUN, V23, P282, DOI 10.1128/IAI.23.2.282-286.1979; OHNO Y, 1985, J BIOL CHEM, V260, P8438; OLIVER CN, 1985, CELLULAR REGULATION, P320; PABST MJ, 1982, J IMMUNOL, V128, P123; PAJARES MA, 1992, J BIOL CHEM, V267, P17598; Pontremoli S, 1970, CURRENT TOPICS CELLU, V2, P173; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; REED PW, 1969, J BIOL CHEM, V244, P2459; ROKUTAN K, 1991, J IMMUNOL, V147, P260; ROOS D, 1980, AGENTS ACTIONS, V10, P528, DOI 10.1007/BF02024158; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SASADA M, 1980, J EXP MED, V152, P85, DOI 10.1084/jem.152.1.85; SHIMAZU T, 1978, J BIOL CHEM, V253, P7376; Sies H., 1985, OXIDATIVE STRESS, V1, P73, DOI DOI 10.1016/B978-0-12-642760-8.50008-9; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SMIT MJ, 1992, AGENTS ACTIONS, V36, P58, DOI 10.1007/BF01991229; THOMAS JA, 1990, ADV EXP MED BIOL, V283, P95; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	57	152	154	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25010	25015						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929187				2022-12-25	WOS:A1994PQ49000074
J	SHIMAN, R; XIA, T; HILL, MA; GRAY, DW				SHIMAN, R; XIA, T; HILL, MA; GRAY, DW			REGULATION OF RAT-LIVER PHENYLALANINE-HYDROXYLASE .2. SUBSTRATE-BINDING AND THE ROLE OF ACTIVATION IN THE CONTROL OF ENZYMATIC-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDYLATE SYNTHETASE; FILTER ASSAY; AMINO-ACIDS; MECHANISM; SITE; 4-MONOOXYGENASE; PURIFICATION; IRON	Activation by phenylalanine and reduction by the cofactor (GR)-tetrahydrobiopterin (BH4) are required for formation of active liver phenylalanine hydroxylase. This work describes effects of the activation and redox state on substrate and effector recognition of this enzyme, it establishes relationships among the pterin and phenylalanine binding sites on the different forms of the enzyme, and it provides a quantitative description of the enzyme's presumptive regulatory and catalytic sites. BH4, 7,8-dihydrobiopterin (BH2), 6-methyltetrahydropterin, and 5-deaza-6-methyltetrahydropterin were found to bind to unactivated phenylalanine hydroxylase with a stoichiometry of 1/enzyme subunit and with hyperbolic kinetics; all appear to compete for the same binding site on the enzyme, and all appear to bind in the proximity of, but not to, the enzyme's non-heme iron. In the transition from unactivated to activated enzyme, phenylalanine and pterin binding is modified, a new site for phenylalanine is formed, and the pterin site is replaced by a site of greatly decreased affinity for BH4 and BH2, one which does not appear to recognize the dihydroxypropyl side chain of BH4 and BH2. The pterin- and phenylalanine binding sites on activated phenylalanine hydroxylase appear to be part of the enzyme's active site. Despite large effects on substrate binding, neither chelator binding ability nor solvent accessibility of the iron are affected by activation; activation appears to affect the nearby environment of the enzyme's iron but not the iron itself. Studies of oxidized and reduced phenylalanine hydroxylase indicate that the redox state is not a major determinant of pterin and phenylalanine association with enzyme.			SHIMAN, R (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT BIOCHEM & MOLEC BIOL, HERSHEY, PA 17033 USA.							ABITA JP, 1984, J BIOL CHEM, V259, P4560; AHMED F, 1985, ANAL BIOCHEM, V145, P151, DOI 10.1016/0003-2697(85)90341-0; BAILEY SW, 1978, J BIOL CHEM, V253, P1598; DIX TA, 1988, ACCOUNTS CHEM RES, V21, P101, DOI 10.1021/ar00147a002; DIX TA, 1985, BIOCHEMISTRY-US, V24, P5839, DOI 10.1021/bi00342a022; HAAVIK J, 1986, EUR J BIOCHEM, V160, P1, DOI 10.1111/j.1432-1033.1986.tb09932.x; HILL MA, 1988, J BIOL CHEM, V263, P5646; KAUFMAN S, 1971, ADV ENZYMOL RAMB, V35, P245; KAUFMAN S, 1982, J BIOL CHEM, V257, P4667; LFEIDERER W, 1985, CHEM BIOCH PTERINS, V2, P88; MAROTA JJA, 1984, BIOCHEMISTRY-US, V23, P1303, DOI 10.1021/bi00301a044; MARTINEZ A, 1991, EUR J BIOCHEM, V198, P675, DOI 10.1111/j.1432-1033.1991.tb16066.x; MILLER MR, 1976, J BIOL CHEM, V251, P3671; MOAD G, 1979, J AM CHEM SOC, V101, P6068, DOI 10.1021/ja00514a033; NAKATA H, 1980, BIOCHIM BIOPHYS ACTA, V614, P313, DOI 10.1016/0005-2744(80)90221-1; Parsons S M, 1979, Methods Enzymol, V59, P322; PEMBER SO, 1987, BIOCHEMISTRY-US, V26, P4477, DOI 10.1021/bi00388a045; PHILLIPS RS, 1984, J BIOL CHEM, V259, P271; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P3836, DOI 10.1021/bi00312a007; PRESS WH, 1986, NUMERICAL RECIPES AR, P523; RENSON J, 1961, BIOCHEM BIOPH RES CO, V6, P20, DOI 10.1016/0006-291X(61)90177-2; SANTI DV, 1974, BIOCHEMISTRY-US, V13, P467, DOI 10.1021/bi00700a011; SHIMAN R, 1979, J BIOL CHEM, V254, P1300; SHIMAN R, 1990, J BIOL CHEM, V265, P11633; SHIMAN R, 1987, METHOD ENZYMOL, V142, P17; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; SHIMAN R, 1982, J BIOL CHEM, V257, P1213; SHIMAN R, 1994, J BIOL CHEM, V269, P24637; SHIMAN R, 1980, J BIOL CHEM, V255, P29; SHIMAN R, 1985, CHEM BIOCH PTERINS, V2, P179; STORM CB, 1971, J ORG CHEM, V36, P3925; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; XIA T, 1994, J BIOL CHEM, V269, P24657	34	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24647	24656						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929136				2022-12-25	WOS:A1994PQ49000023
J	STAHL, B; VONMOLLARD, GF; WALCHSOLIMENA, C; JAHN, R				STAHL, B; VONMOLLARD, GF; WALCHSOLIMENA, C; JAHN, R			GTP CLEAVAGE BY THE SMALL GTP-BINDING PROTEIN RAB3A IS ASSOCIATED WITH EXOCYTOSIS OF SYNAPTIC VESICLES INDUCED BY ALPHA-LATROTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED NERVE-TERMINALS; SMG P25A; GLUTAMATE RELEASE; SECRETORY PATHWAY; MEMBRANE-PROTEIN; EXCHANGE PROTEIN; SEC4 PROTEIN; RAS; TRANSPORT; SYNAPTOSOMES	Neurotransmitter release from presynaptic nerve terminals is a highly regulated form of exocytosis. Small GTP-binding proteins of the Rab family have been proposed to act as central regulators in this process that cycle between a GTP- and GDP-bound form. Previous work has shown that the synaptic vesicle protein Rab3A undergoes a membrane association-dissociation cycle that is associated with neurotransmitter release. Using isolated nerve terminals as our model system, we have now analyzed the GDP/GTP status of Rab3A. Synaptic vesicle-bound Rab3A was almost exclusively in the GTP form whereas cytosolic Rab3A contained only GDP. Approximately equal amounts of GTP and GDP were found in the pool of Rab3A localized to a membrane fraction containing plasma membrane-synaptic vesicle complexes. In contrast to Rab3A, Rab5 (an endosomal G-protein) was predominantly GDP-bound in all analyzed compartments. To analyze whether Rab3A-bound GTP is cleaved during exocytosis, synaptosomes were stimulated with alpha-latrotoxin, the active component of black widow spider venom. This resulted in massive exocytosis. A significant increase of the GDP/GTP ratio of Rab3A was observed under these conditions that was not due to a nonspecific loss of high energy nucleotides. Our findings suggest that cleavage of Rab3A-bound GTP is a crucial step in regulated exocytosis of synaptic vesicles.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06504; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University; Yale University			von Mollard, Gabriele Fischer/A-3935-2012; von Mollard, Gabriele Fischer/O-9778-2019	von Mollard, Gabriele Fischer/0000-0003-3236-1401; von Mollard, Gabriele Fischer/0000-0003-3236-1401; Jahn, Reinhard/0000-0003-1542-3498	NCI NIH HHS [P01 CA 46128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1993, J BIOL CHEM, V268, P22247; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KAUPPINEN RA, 1988, NEUROSCIENCE, V27, P175, DOI 10.1016/0306-4522(88)90228-X; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCMAHON HT, 1990, J NEUROCHEM, V55, P2039, DOI 10.1111/j.1471-4159.1990.tb05793.x; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NANBERG E, 1993, J BIOL CHEM, V268, P18187; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; SCOTT ID, 1980, BIOCHEM J, V192, P873, DOI 10.1042/bj1920873; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017	45	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24770	24776						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929154				2022-12-25	WOS:A1994PQ49000041
J	PARK, MH; WOLFF, EC; LEE, YB; FOLK, JE				PARK, MH; WOLFF, EC; LEE, YB; FOLK, JE			ANTIPROLIFERATIVE EFFECTS OF INHIBITORS OF DEOXYHYPUSINE SYNTHASE - INHIBITION OF GROWTH OF CHINESE-HAMSTER OVARY CELLS BY GUANYL DIAMINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-4D; MURINE LEUKEMIA-CELLS; POSTTRANSLATIONAL FORMATION; SACCHAROMYCES-CEREVISIAE; HYPUSINE MODIFICATION; AMINO-ACID; PROTEIN; POLYAMINES; SPERMIDINE; IDENTIFICATION	Certain guanyl diamines are effective inhibitors of deoxyhypusine synthase (Jakus, J., Wolff, E. C., Park, M. H., and Folk, J. E. (1993) J. Biol. Chem. 268, 18151-13159), the first enzyme involved in the biosynthesis of the unusual amino acid hypusine (N-epsilon-(4-amino-2-hydroxybutyl)lysine). Evidence that hypusine is implicated in cell growth prompted this study of the cellular effects of these inhibitors. In Chinese hamster ovary (CHO) cells, inhibition of hypusine biosynthesis followed by progressive arrest in cellular proliferation was observed with both N-mono- and N,N'-bisguanyl derivatives of 1,6-diaminohexane, 1,7-diaminoheptane and 1,8-diaminooctane. Cells treated with these compounds showed no significant change in polyamine distribution, suggesting that the observed growth inhibition is not mediated through an interference with polyamine metabolism. N-1-guanyl-1,7-diaminoheptane, the most potent inhibitor of deoxyhypusine synthase both in vitro and in cells, exhibited the highest antiproliferative activity toward CHO cells. No early cytotoxic effects were observed with this inhibitor, and its antiproliferative activity appeared to be reversible. Transport studies showed that N-1-guanyl-1,7-diaminoheptane is actively taken up by the polyamine transport system. Mutant CHO cells defective in polyamine transport were found to be resistant to growth inhibition by this compound. The findings suggest that the antiproliferative effect of N-1-guanyl-1,7-diaminoheptane is exerted intracellularly through inhibition of hypusine synthesis.			PARK, MH (corresponding author), NIDR,CELLULAR DEV & ONCOL LAB,ENZYME CHEM SECT,BLDG 30,RM 211,30 CONVENT DR,MSC 4330,BETHESDA,MD 20892, USA.							ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; BYERS TL, 1987, AM J PHYSIOL, V252, pC663, DOI 10.1152/ajpcell.1987.252.6.C663; BYERS TL, 1993, BIOCHEM J, V290, P115, DOI 10.1042/bj2900115; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; CHEN KY, 1983, BIOCHIM BIOPHYS ACTA, V756, P395, DOI 10.1016/0304-4165(83)90350-1; CLARKE DD, 1959, ARCH BIOCHEM BIOPHYS, V79, P338, DOI 10.1016/0003-9861(59)90413-8; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; COOPER HL, 1982, CELL, V29, P791, DOI 10.1016/0092-8674(82)90441-X; DUNCAN RF, 1986, J BIOL CHEM, V261, P2903; FOLK JE, 1980, J BIOL CHEM, V255, P3695; GERNER EW, 1986, BIOCHEM J, V239, P379, DOI 10.1042/bj2390379; GRETTIE DP, 1978, ADV POLYAMINE RES, V2, P13; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; KANG HA, 1994, J BIOL CHEM, V269, P3934; MANDEL JL, 1978, J CELL PHYSIOL, V97, P335, DOI 10.1002/jcp.1040970308; MCKAY AF, 1959, J AM CHEM SOC, V81, P4328, DOI 10.1021/ja01525a057; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; PARK MH, 1983, METHOD ENZYMOL, V94, P458; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1993, BIOFACTORS, V4, P95; PARK MH, 1988, J BIOL CHEM, V263, P15264; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; PARK MH, 1987, J BIOL CHEM, V262, P12730; PORTER CW, 1993, CANCER RES, V53, P581; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Seiler N., 1987, INHIBITION POLYAMINE, P49; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TORRELIO BM, 1987, BIOCHEM BIOPH RES CO, V145, P1335, DOI 10.1016/0006-291X(87)91584-1; TORRELIO BM, 1984, EXP CELL RES, V154, P454, DOI 10.1016/0014-4827(84)90169-1; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1990, J BIOL CHEM, V265, P4793	35	137	143	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27827	27832						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961711				2022-12-25	WOS:A1994PV77200012
J	MA, QF; WADLEIGH, D; CHI, TH; HERSCHMAN, H				MA, QF; WADLEIGH, D; CHI, TH; HERSCHMAN, H			THE DROSOPHILA TIS11-HOMOLOG ENCODES A DEVELOPMENTALLY CONTROLLED GENE	ONCOGENE			English	Article							TETRADECANOYL PHORBOL ACETATE; PRIMARY RESPONSE GENE; SWISS 3T3 CELLS; NUCLEOTIDE EXCHANGE; TYROSINE KINASE; SEQUENCE; PROTEIN; RECEPTOR; GRB2; RAS	We previously identified a murine primary response gene family containing three members; TIS11, TIS11B and TIS11D. Using degenerate oligonucleotides derived from conserved regions of the mouse TIS11 family cDNAs as primers and Drosophila genomic DNA as template for polymerase chain reaction amplification, we have identified a fly TIS11 homologue called DTIS11. The DTIS11 protein shares 90% sequence identity with the murine TIS11B and TIS11D proteins, over a 74 amino acid region that contains two CX(8)CX(5)CX(3)H repeated motifs separated by 18 amino acids. DTIS11 maps to region 11B(14-16) on the X-chromosome. Northern blot and in situ hybridization show that a maternal 3 kb message is present in embryos of early developmental stages. A 6 kb DTIS11 mRNA subsequently appears. In KC embryonal cells, both a strong 3 kb message and a less intense 6 kb message are present. The larger (6 kb) message is modestly induced in KC cells by both forskolin and tetradecanoyl phorbol acetate, and is stabilized by cycloheximide.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DOE,DEPT BIOL CHEM,STRUCT BIOL & MOLEC MED LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; United States Department of Energy (DOE); University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24797] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BARNARD RC, 1993, NUCLEIC ACIDS RES, V21, P3580, DOI 10.1093/nar/21.15.3580; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GOMPERTS M, 1990, ONCOGENE, V5, P1081; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KANEDA N, 1992, GENE, V118, P289, DOI 10.1016/0378-1119(92)90202-Z; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI WS, 1990, J BIOL CHEM, V265, P16556; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM RW, 1987, ONCOGENE, V1, P263; MA QF, 1991, ONCOGENE, V6, P1277; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580	31	36	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3329	3334						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936658				2022-12-25	WOS:A1994PM65800027
J	DEY, NB; BOUNELIS, P; FRITZ, TA; BEDWELL, DM; MARCHASE, RB				DEY, NB; BOUNELIS, P; FRITZ, TA; BEDWELL, DM; MARCHASE, RB			THE GLYCOSYLATION OF PHOSPHOGLUCOMUTASE IS MODULATED BY CARBON SOURCE AND HEAT-SHOCK IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SARCOPLASMIC-RETICULUM; RESERVE CARBOHYDRATE; TREHALOSE; YEAST; PHOSPHOPROTEIN; ACCEPTOR; GLUCOSYLPHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE; TRANSPORT	Phosphoglucomutase is the acceptor for UDP-glucose:glycoprotein glucose-1-phosphotransferase and contains Glc in a phosphodiester linkage to O-linked Man. In this study, we have characterized the glycosylation of phosphoglucomutase by Saccharomyces cerevisiae in response to heat shock and growth in media containing carbon sources other than Glc. Phosphoglucomutase synthesized under these conditions is underglucosylated relative to that synthesized during logarithmic growth in Glc. The underglucosylation results in increased UDP-glucose:glycoprotein glucose-1-phosphotransferase acceptor activity in in vitro assays and a newly appearing less negatively charged form of phosphoglucomutase resolvable by anion exchange chromatography. Utilizing a yeast strain in which phosphoglucomutase is overexpressed via a multicopy plasmid, metabolic labeling of the enzyme with [S-35]Met and [H-3]Man increased in response to heat shock, whereas [H-3]Glc labeling decreased. The glucosylation state of phosphoglucomutase was also compared in cells grown in media containing various carbon sources and was found to be lowest in cells utilizing Gal as the sole carbon source compared with Glc or;lactate. In mammalian cells, the glucosylation of phosphoglucomutase has been shown to be sensitive to changes in cytoplasmic Ca2+ and to correlate with a change in its membrane association. The change in phosphoglucomutase's oligosaccharide in Saccharomyces cerevisiae may be important to alterations in its distribution under conditions of nutrient deprivation or metabolic stress.	UNIV ALABAMA,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	DEY, NB (corresponding author), UNIV ALABAMA,DEPT CELL BIOL,BASIC HLTH SCI BLDG,RM 690,BIRMINGHAM,AL 35294, USA.			Bedwell, David/0000-0002-6605-818X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK042017, P01DK038518] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06714] Funding Source: Medline; NIDDK NIH HHS [DK 38518, DK 42017] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTFIELD PV, 1987, FEBS LETT, V225, P259, DOI 10.1016/0014-5793(87)81170-5; BENEDETTI A, 1985, BIOCHIM BIOPHYS ACTA, V816, P267, DOI 10.1016/0005-2736(85)90494-8; BOLES E, 1994, EUR J BIOCHEM, V220, P83, DOI 10.1111/j.1432-1033.1994.tb18601.x; CAPUTTO R, 1950, J BIOL CHEM, V184, P333; DOUGLAS HC, 1961, BIOCHIM BIOPHYS ACTA, V52, P209, DOI 10.1016/0006-3002(61)90924-6; EILAM Y, 1985, J GEN MICROBIOL, V131, P623; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOTTIGER T, 1987, J BACTERIOL, V169, P5518, DOI 10.1128/jb.169.12.5518-5522.1987; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KIM DH, 1986, J BIOL CHEM, V261, P1674; LEE YS, 1992, J BIOL CHEM, V267, P21080; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; MARCHASE RB, 1987, BIOCHIM BIOPHYS ACTA, V916, P157, DOI 10.1016/0167-4838(87)90103-8; MARCHASE RB, 1990, ARCH BIOCHEM BIOPHYS, V280, P122, DOI 10.1016/0003-9861(90)90526-5; MARCHASE RB, 1993, J BIOL CHEM, V268, P8341; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; OH D, 1990, MOL CELL BIOL, V10, P1415, DOI 10.1128/MCB.10.4.1415; QUICK CB, 1974, EUR J BIOCHEM, V42, P511, DOI 10.1111/j.1432-1033.1974.tb03366.x; RAY WJ, 1972, CARBOXYLATION DECARB, P407; Rose MD., 1990, METHODS YEAST GENETI; SATIR BH, 1990, J CELL BIOL, V111, P901, DOI 10.1083/jcb.111.3.901; SRISOMSAP C, 1989, J BIOL CHEM, V264, P20540; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEYNA NA, 1994, J NEUROCHEM, V62, P456; WIEMKEN A, 1990, ANTON LEEUW INT J G, V58, P209, DOI 10.1007/BF00548935; WINKLER K, 1991, FEBS LETT, V291, P269, DOI 10.1016/0014-5793(91)81299-N; WOLF BA, 1986, J BIOL CHEM, V261, P6284	28	26	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27143	27148						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929458				2022-12-25	WOS:A1994PQ93100082
J	BUBB, MR; KNUTSON, JR; PORTER, DK; KORN, ED				BUBB, MR; KNUTSON, JR; PORTER, DK; KORN, ED			ACTOBINDIN INDUCES THE ACCUMULATION OF ACTIN DIMERS THAT NEITHER NUCLEATE POLYMERIZATION NOR SELF-ASSOCIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA-CASTELLANII; MONOMERIC ACTIN; FLUORESCENCE; BINDING; DIFFUSION; SPECTROSCOPY; INHIBITION	Actobindin purified from Acanthamoeba castellanii inhibits the nucleation, but not the elongation, phase of actin polymerization. Previously, we had speculated that actobindin, which can simultaneously bind two actin monomers (Bubb, M. R., Lewis, M. S., and Kern, E. D. (1991) J. Biol. Chem. 266, 3820-3826), might preferentially interact with small oligomers and inhibit their ability to elongate (Lambooy, P. K., and Kern, E. D. (1988) J. Biol. Chem. 263, 12836-12843). In the accompanying paper (Bubb, M. R., Lewis, M. S., and Kern, E. D. (1994) J. Biol. Chen. 269, 25587-25591), we show that under non-polymerizing conditions, actobindin binds to covalently cross-linked actin dimers with higher affinity than to two actin monomers, The sedimentation velocity and fluorescence anisotropy experiments described in this paper show that actobindin prevents the formation of actin oligomers larger than an actin dimer under conditions in which, in the absence of actobindin, actin rapidly polymerizes to F-actin with no detectable small oligomers. Moreover, the molar concentration of actin dimer formed in the presence of actobindin can exceed the total actobindin concentration. These results indicate that actobindin does not form a stable complex with native actin dimer but, rather, causes the accumulation of dimers that are unable to nucleate polymerization or self-associate.	NHLBI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ATTRI AK, 1991, J BIOL CHEM, V266, P6815; BUBB MR, 1991, J BIOL CHEM, V266, P3820; BUBB MR, 1994, J BIOL CHEM, V269, P25587; CLAGUE MJ, 1991, BIOCHEMISTRY-US, V30, P5491, DOI 10.1021/bi00236a023; CREETH J. M., 1967, PROGR BIOPHYS MOL BIOL, V17, P217, DOI 10.1016/0079-6107(67)90008-9; DELATORRE JG, 1988, DYNAMIC PROPERTIES B, P3; FECHHEIMER M, 1993, J CELL BIOL, V123, P1, DOI 10.1083/jcb.123.1.1; GOLDBERG RJ, 1953, J PHYS CHEM-US, V57, P194, DOI 10.1021/j150503a014; HARVEY SC, 1977, ARCH BIOCHEM BIOPHYS, V179, P391, DOI 10.1016/0003-9861(77)90126-6; HOLLIDAY LS, 1993, BIOCHEM BIOPH RES CO, V196, P569, DOI 10.1006/bbrc.1993.2287; KABSCH W, 1992, ANNU REV BIOPH BIOM, V21, P49, DOI 10.1146/annurev.biophys.21.1.49; KAWASAKI Y, 1976, BIOCHIM BIOPHYS ACTA, V446, P166, DOI 10.1016/0005-2795(76)90108-2; KIRKWOOD JG, 1954, J POLYM SCI, V12, P1, DOI 10.1002/pol.1954.120120102; KNUTSON JR, 1982, BIOCHEMISTRY-US, V21, P4671, DOI 10.1021/bi00262a024; KNUTSON JR, 1983, CHEM PHYS LETT, V102, P501, DOI 10.1016/0009-2614(83)87454-5; LAMBOOY PK, 1988, J BIOL CHEM, V263, P12836; LAMBOOY PK, 1986, J BIOL CHEM, V261, P7150; LEWIS MS, 1963, BIOCHEMISTRY-US, V2, P34, DOI 10.1021/bi00901a008; MIHASHI K, 1975, FEBS LETT, V52, P8, DOI 10.1016/0014-5793(75)80625-9; MIHASHI K, 1964, ARCH BIOCHEM BIOPHYS, V107, P441, DOI 10.1016/0003-9861(64)90300-5; MONTAGUE C, 1983, J MUSCLE RES CELL M, V4, P95, DOI 10.1007/BF00711960; MURAMATSU N, 1988, ANAL BIOCHEM, V168, P345, DOI 10.1016/0003-2697(88)90328-4; RIGLER R, 1973, Q REV BIOPHYS, V6, P139, DOI 10.1017/S003358350000113X; SCHACHMAN HK, 1959, ULTRACENTRIFUGATION, P75; TAWADA K, 1978, EUR J BIOCHEM, V88, P411, DOI 10.1111/j.1432-1033.1978.tb12463.x; TOBACMAN LS, 1982, J BIOL CHEM, V257, P4166; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; WEGENER WA, 1979, J CHEM PHYS, V70, P622, DOI 10.1063/1.437541	28	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25592	25597						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929262				2022-12-25	WOS:A1994PQ49100057
J	CUI, Z; HOUWELING, M; VANCE, DE				CUI, Z; HOUWELING, M; VANCE, DE			SUPPRESSION OF RAT HEPATOMA-CELL GROWTH BY EXPRESSION OF PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIVER; PHOSPHATIDYLCHOLINE; METHYLTRANSFERASE; PROTEINS	The expression of rat liver phosphatidylethanolamine N-methyltransferase-2 (PEMT2) in McA-RH7777 rat hepatoma cells resulted in the unexpected inhibition of cell growth. There was a strict correlation (r = 0.973) between the level of expression of the enzyme activity and the generation time for hepatoma cell division. Expression of other foreign proteins via the same vector did not inhibit McA-RH7777 cell growth; thus, retardation of cell division was specific for the methyltransferase. Addition of 1 mu M 3-deazaadenosine, which causes inhibition of phosphatidylethanolamine methylation, reversed the PEMT2-mediated inhibition of cell division. Transfection of a line of Chinese hamster ovary cells with PEMT2 had no effect on the division of these cells. Induction of hepatic tumors in rats with N-nitrosodiethylamine coincided with a striking decrease in methyltransferase activity and immunoreactive protein in the tumor nodules. Thus, data from studies in cell culture and intact rats suggest a regulatory role for PEMT2 in hepatocyte cell growth and possibly in the development of liver cancer.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA	University of Alberta; University of Alberta								BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7; CUI Z, 1993, J BIOL CHEM, V268, P16655; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; FOLCH J, 1957, J BIOL CHEM, V226, P497; GRISHAM JW, 1962, CANCER RES, V22, P842; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PELECH SL, 1983, CAN J BIOCHEM CELL B, V61, P1147, DOI 10.1139/o83-147; PRITCHARD PH, 1982, J BIOL CHEM, V257, P6362; RIDGWAY ND, 1992, METHOD ENZYMOL, V209, P366; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; TANG H, 1992, MOL CELL BIOCHEM, V109, P83; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vance D E, 1981, Methods Enzymol, V71 Pt C, P576; VOELKER DR, 1991, MICROBIOL REV, V55, P543, DOI 10.1128/MMBR.55.4.543-560.1991; YAO ZM, 1991, J BIOL CHEM, V266, P3300	18	51	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24531	24533						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929120				2022-12-25	WOS:A1994PQ49000004
J	HARDY, TA; HUANG, DQ; ROACH, PJ				HARDY, TA; HUANG, DQ; ROACH, PJ			INTERACTIONS BETWEEN CAMP-DEPENDENT AND SNF1 PROTEIN-KINASES IN THE CONTROL OF GLYCOGEN ACCUMULATION IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; REGULATORY SUBUNIT; ADENYLATE-CYCLASE; CATABOLITE REPRESSION; INVERTASE EXPRESSION; NUTRIENT LIMITATION; GLUCOSE REPRESSION; POLYUBIQUITIN GENE; BRANCHING ENZYME; ESCHERICHIA-COLI	The synthesis of glycogen in Saccharomyces cerevisiae is stimulated by nutrient limitation and requires both glycogen synthase and the glycogen branching enzyme. Of the two glycogen synthase genes present in yeast, GSY2 appears to be more important for the accumulation of glycogen upon entry into stationary phase. In cells grown on glucose, GSY2 mRNA levels increased approximately 10-fold during the transition from logarithmic to stationary phase. Growth of cells in glycerol, however, resulted in constitutive expression of GSY2 mRNA and the corresponding protein, GS-2, suggestive of glucose repression of GSY2. Mutants defective in the SNF1 gene, which encodes a protein kinase important in glucose repression mechanisms, are known not to accumulate glycogen. A modest 2-4-fold decrease in total GS-2 level was observed, and upon entry into stationary phase, the enzyme was blocked in the inactive, phosphorylated state in snf1 strains. The GS-2 protein is thought to be regulated by covalent phosphorylation of three COOH-terminal sites (Hardy, T.A., and Roach, P. J. (1993) J. Biol. Chem. 268, 23799-23805), removal of which results in constitutively active glycogen synthase that bypasses phosphorylation controls. Expression of COOH-terminally truncated GS-2 in snf1 cells restored glycogen accumulation, and so we propose that the SNF1 kinase controls the phosphorylation state of GS-2. Cyclic AMP pathways also exert control over glycogen accumulation. In bcy1 cells, which have constitutively active cyclic AMP-dependent protein kinase, greatly reduced levels of both GS-2 message and protein were observed. With wild type GSY2 placed under control of the ADH1 promoter, bcy1 cells did not accumulate glycogen despite increased GS-2. Overexpression of truncated GS-2, however, resulted in definite though reduced glycogen accumulation; the glycogen synthesized was structurally distinct from wild type with properties characteristic of less branched polysaccharide. We conclude that the cAMP pathway controls both the expression and the phosphorylation state of GS-2. Furthermore, other factor(s) necessary for glycogen biosynthesis, such as the branching enzyme GLC3, must also be under negative control by the cAMP pathway. The results demonstrate interactive controls of GS-2 by the cAMP-dependent and SNF1 protein kinases.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis					NIDDK NIH HHS [DK 42576] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042576] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BISSINGER PH, 1989, MOL CELL BIOL, V9, P1309, DOI 10.1128/MCB.9.3.1309; BOORSTEIN WR, 1990, EMBO J, V9, P2543, DOI 10.1002/j.1460-2075.1990.tb07435.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNON JF, 1994, GENETICS, V136, P485; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CANNON JF, 1990, J BIOL CHEM, V265, P11897; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHESTER VE, 1968, J GEN MICROBIOL, V51, P47, DOI 10.1099/00221287-51-1-49; CIRIACY M, 1977, MOL GEN GENET, V154, P213, DOI 10.1007/BF00330840; DENIS CL, 1983, J BIOL CHEM, V258, P1165; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; ERASO P, 1984, EUR J BIOCHEM, V141, P195, DOI 10.1111/j.1432-1033.1984.tb08174.x; ESTRUCH F, 1990, NUCLEIC ACIDS RES, V18, P6959, DOI 10.1093/nar/18.23.6959; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FENG ZH, 1991, J BIOL CHEM, V266, P23796; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P551, DOI 10.1111/j.1432-1033.1988.tb14134.x; FRANCOIS J, 1987, EUR J BIOCHEM, V164, P369, DOI 10.1111/j.1432-1033.1987.tb11067.x; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; HADFIELD C, 1986, GENE, V45, P149, DOI 10.1016/0378-1119(86)90249-0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARDY TA, 1993, J BIOL CHEM, V268, P23799; HUBBARD EJA, 1992, GENETICS, V130, P71; HWANG PK, 1989, MOL CELL BIOL, V9, P1659, DOI 10.1128/MCB.9.4.1659; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; POLAKIS ES, 1965, BIOCHEM J, V97, P284, DOI 10.1042/bj0970284; POSAS F, 1991, FEBS LETT, V279, P341, DOI 10.1016/0014-5793(91)80183-4; REIMANN EM, 1993, ADV PROTEIN PHOSPHAT, V7, P173; ROTHMANDENES LB, 1970, P NATL ACAD SCI USA, V66, P967, DOI 10.1073/pnas.66.3.967; ROWEN DW, 1992, MOL CELL BIOL, V12, P22, DOI 10.1128/MCB.12.1.22; RUSSELL M, 1993, MOL BIOL CELL, V4, P757, DOI 10.1091/mbc.4.7.757; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULLER HJ, 1991, J BACTERIOL, V173, P2045, DOI 10.1128/jb.173.6.2045-2052.1991; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TANAKA K, 1988, EMBO J, V7, P495, DOI 10.1002/j.1460-2075.1988.tb02837.x; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; THON VJ, 1992, J BIOL CHEM, V267, P15224; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; ZIMMERMANN FK, 1977, MOL GEN GENET, V151, P95, DOI 10.1007/BF00446918	53	109	109	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27907	27913						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961723				2022-12-25	WOS:A1994PV77200024
J	PHILIPSON, LH; ROSENBERG, MP; KUZNETSOV, A; LANCASTER, ME; WORLEY, JF; ROE, MW; DUKES, ID				PHILIPSON, LH; ROSENBERG, MP; KUZNETSOV, A; LANCASTER, ME; WORLEY, JF; ROE, MW; DUKES, ID			DELAYED RECTIFIER K+ CHANNEL OVEREXPRESSION IN TRANSGENIC ISLETS AND BETA-CELLS ASSOCIATED WITH IMPAIRED GLUCOSE RESPONSIVENESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INSULIN-SECRETING CELLS; SINGLE PANCREATIC-ISLETS; POTASSIUM CHANNEL; ELECTRICAL-ACTIVITY; CYTOPLASMIC CA2+; B-CELLS; OSCILLATIONS; EXPRESSION; LINES; MICE	Glucose stimulation of pancreatic beta-cell insulin secretion is closely coupled to alterations in ion channel conductances and intracellular Ca2+ ([Ca2+](i)). To further examine this relationship after augmentation of voltage-dependent K+ channel expression, transgenic mice were produced which specifically overexpress a human insulinoma-derived, tetraethylammonium (TEA)-insensitive delayed rectifier K+ channel in their pancreatic beta-cells as shown by immunoblot of isolated islets and immunohistochemical analysis of pancreas sections. Whole-cell current recordings confirmed the presence of high amplitude TEA-resistant K+ currents in transgenic islet cells, whose expression correlated with hyperglycemia and hypoinsulinemia. Stable overexpression of the channel in insulinoma cells attenuated glucose-activated increases in [Ca2+](i) and prevented the induction of TEA-dependent [Ca2+](i) oscillations. These results, employing the first ion channel transgenic mouse, demonstrate the importance of membrane potential regulation in excitation-secretion coupling in the pancreatic beta-cells.	GLAXO INC,RES INST,DEPT PHARMACOL,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT CELL PHYSIOL,RES TRIANGLE PK,NC 27709	GlaxoSmithKline; GlaxoSmithKline	PHILIPSON, LH (corresponding author), UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044840] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44840] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ATTALI B, 1993, J BIOL CHEM, V268, P24283; ATWATER I, 1983, CELL CALCIUM, V4, P451, DOI 10.1016/0143-4160(83)90021-0; BOYD AE, 1992, J CELL BIOCHEM, V48, P234, DOI 10.1002/jcb.240480303; COOK DL, 1984, NATURE, V312, P446; DAMBRA R, 1990, ENDOCRINOLOGY, V126, P2815, DOI 10.1210/endo-126-6-2815; DUKES ID, 1994, J BIOL CHEM, V269, P10979; DUKES ID, 1993, AM J PHYSIOL, V264, pE348, DOI 10.1152/ajpendo.1993.264.3.E348; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; ERICKSON RP, 1985, BIOSCIENCE REP, V5, P1087, DOI 10.1007/BF01119630; FATHERAZI S, 1991, J MEMBRANE BIOL, V120, P105, DOI 10.1007/BF01872393; GILON P, 1993, J BIOL CHEM, V268, P22265; HELLMAN B, 1992, BIOCHIM BIOPHYS ACTA, V1113, P295, DOI 10.1016/0304-4157(92)90003-S; HENQUIN JC, 1990, PFLUG ARCH EUR J PHY, V416, P568, DOI 10.1007/BF00382691; KEAHEY HH, 1989, DIABETES, V38, P188, DOI 10.2337/diabetes.38.2.188; MADSEN OD, 1985, ENDOCRINOLOGY, V113, P2135; MEDA P, 1982, J CELL BIOL, V92, P221, DOI 10.1083/jcb.92.1.221; ORCI L, 1973, EXPERIENTIA, V29, P1015, DOI 10.1007/BF01930436; OSBORN L, 1987, MOL CELL BIOL, V7, P326, DOI 10.1128/MCB.7.1.326; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; PHILIPSON LH, 1993, BIOCHIM BIOPHYS ACTA, V1153, P111, DOI 10.1016/0005-2736(93)90282-5; PLANT TD, 1988, J PHYSIOL-LONDON, V404, P731, DOI 10.1113/jphysiol.1988.sp017316; ROE MW, 1993, J BIOL CHEM, V268, P9953; ROJAS E, 1994, ENDOCRINOLOGY, V134, P1771, DOI 10.1210/en.134.4.1771; RORSMAN P, 1989, J GEN PHYSIOL, V91, P243; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SATIN LS, 1989, J MEMBRANE BIOL, V112, P213, DOI 10.1007/BF01870952; SATIN LS, 1989, PFLUG ARCH EUR J PHY, V414, P1, DOI 10.1007/BF00585619; SHERMAN A, 1991, BIOPHYS J, V59, P547, DOI 10.1016/S0006-3495(91)82271-8; SMITH PA, 1990, J GEN PHYSIOL, V95, P1041, DOI 10.1085/jgp.95.6.1041; SNYDERS DJ, 1992, MOL PHARMACOL, V41, P322; WORLEY JF, 1994, J BIOL CHEM, V269, P14359	33	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27787	27790						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961701				2022-12-25	WOS:A1994PV77200002
J	CHEN, ZQ; CRIPPEN, K; GULATI, S; BANERJEE, R				CHEN, ZQ; CRIPPEN, K; GULATI, S; BANERJEE, R			PURIFICATION AND KINETIC MECHANISM OF A MAMMALIAN METHIONINE SYNTHASE FROM PIG-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; COBALAMIN; DISEASE; HOMOCYSTEINEMIA; BINDING; STATE	Porcine hepatic methionine synthase has been purified to near homogeneity. The enzyme is isolated in two forms which were purified similar to 9,000- and similar to 7,000-fold and were obtained in 0.9 and 2.5% overall yield, respectively. The mammalian enzyme from pig liver is a large monomelic protein with a molecular mass of 151-155 bDa. It is characterized by the absence of any metals other than cobalt which is associated with the cofactor, cobalamin. This enzyme, like the methionine synthase from Escherichia coli is dependent on S-adenosylmethionine for activity. The steady state kinetic studies demonstrate that the reaction operates via an ordered sequential mechanism in which binding of CH3-H-4- folate precedes homocysteine, and methionine is released prior to H-4-folate.	UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68583	University of Nebraska System; University of Nebraska Lincoln			Crippen, Kent/AAI-3712-2020	Crippen, Kent/0000-0002-8981-2376	NIDDK NIH HHS [DK45776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045776, R29DK045776] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P11101, DOI 10.1021/bi00502a013; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRATTSTROM LE, 1984, STROKE, V15, P1012, DOI 10.1161/01.STR.15.6.1012; BURKE GT, 1971, BIOCHEMISTRY-US, V10, P3079; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; DRUMMOND JT, 1993, BIOCHEMISTRY-US, V32, P9290, DOI 10.1021/bi00087a005; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FRASCA V, 1988, BIOCHEMISTRY-US, V27, P8458, DOI 10.1021/bi00422a025; GIANNOTTI C, 1982, ELECTRONIC SPECTRA B, P394; HATCH FT, 1961, J BIOL CHEM, V236, P1095; JONES JB, 1977, COMMUN SOIL SCI PLAN, V8, P349, DOI 10.1080/00103627709366727; MANGUM JH, 1971, BIOCHEMISTRY-US, V10, P3765, DOI 10.1021/bi00796a019; MATTHEWS RG, 1986, METHIONINE BIOSYNTHE, P697; MELLMAN IS, 1977, P NATL ACAD SCI USA, V74, P916, DOI 10.1073/pnas.74.3.916; ROSENBERG LE, 1983, METABOLIC BASIS INHE, P474; SCHRAUZER GN, 1968, J AM CHEM SOC, V90, P2441, DOI 10.1021/ja01011a054; SMITH MR, 1984, THESIS B YOUNG U; TAYLOR RT, 1967, J BIOL CHEM, V242, P1502; UTLEY CS, 1985, J BIOL CHEM, V260, P3656; WILCKEN DEL, 1983, METABOLISM, V32, P363, DOI 10.1016/0026-0495(83)90045-8; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350	22	55	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27193	27197						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961628				2022-12-25	WOS:A1994PV77100010
J	HEIN, L; ISHII, K; COUGHLIN, SR; KOBILKA, BK				HEIN, L; ISHII, K; COUGHLIN, SR; KOBILKA, BK			INTRACELLULAR TARGETING AND TRAFFICKING OF THROMBIN RECEPTORS - A NOVEL MECHANISM FOR RESENSITIZATION OF A G-PROTEIN-COUPLED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; CELLS; MEMBRANE; INTERNALIZATION; ACTIVATION; MICROSCOPY; CYCLASE	The receptor for the protease thrombin is a member of the G protein-coupled receptor family, but is activated by a unique proteolytic mechanism. The irreversibility of this proteolytic mechanism and the fact that the ligand is tethered to its receptor raise special questions about inactivation of cleaved receptors and recovery of thrombin responsiveness. We compared the intracellular trafficking of the thrombin receptor to that of the beta(2)-adrenergic receptor in transfected Rat1 fibroblasts. In unstimulated cells almost all beta(2) receptors were located on the plasma membrane; by contrast, part of a cell's thrombin receptors were found in an intracellular membrane compartment which co-localized with Golgi markers. Stimulation by agonist caused internalization and subsequent recycling of the beta(2)-adrenergic receptor, but most activated thrombin receptors were internalized and targeted to lysosomes. The intracellular pool of thrombin receptors found in unstimulated cells was protected from activation by thrombin, but was translocated to the plasma membrane upon activation of cell surface thrombin receptors. Replenishment of plasma membrane thrombin receptors correlated with recovery of thrombin responsiveness. These observations reveal a novel trafficking mechanism for resensitizing the thrombin receptor as opposed to the internalization/recycling pathway of other G protein-coupled receptors.	STANFORD UNIV,SCH MED,BECKMAN CTR B157,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DIV CARDIOVASC MED,STANFORD,CA 94305; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; Stanford University; Stanford University; University of California System; University of California San Francisco				Kobilka, Brian/0000-0001-5958-3990	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAFFY G, 1994, J BIOL CHEM, V269, P8483; BRASS LF, 1991, J BIOL CHEM, V266, P958; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V66, P184; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NIGGLI E, 1990, CELL CALCIUM, V11, P121, DOI 10.1016/0143-4160(90)90065-3; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P1909; Sambrook J, 1989, MOL CLONING LABORATO; SENGELOV H, 1994, BIOCHEM J, V299, P473, DOI 10.1042/bj2990473; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YU SS, 1993, J BIOL CHEM, V268, P337; ZONZASTROW M, 1993, J BIOL CHEM, V268, P763	24	214	217	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27719	27726						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961693				2022-12-25	WOS:A1994PV77100087
J	DE, A; BOYADJIEVA, NI; PASTORCIC, M; REDDY, BV; SARKAR, DK				DE, A; BOYADJIEVA, NI; PASTORCIC, M; REDDY, BV; SARKAR, DK			CYCLIC-AMP AND ETHANOL INTERACT TO CONTROL APOPTOSIS AND DIFFERENTIATION IN HYPOTHALAMIC BETA-ENDORPHIN NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICOTROPIN-RELEASING FACTOR; PROOPIOMELANOCORTIN GENE-EXPRESSION; ADENYLATE-CYCLASE; PRENATAL ETHANOL; ALCOHOL DEPENDENCE; ANTERIOR-PITUITARY; BINDING-PROTEIN; FEMALE RATS; CELL-DEATH; EXPOSURE	In this study we have determined the role of cyclic AMP on the function and differentiation of beta-endorphin (beta-EP) neurons in rat fetal hypothalamic cell cultures. Addition of Bt(2)cAMP or the cAMP elevating agent, forskolin, in cultures, dose and time dependently increased beta-endorphin secretion. The increased beta-EP secretion after Bt(2)cAMP or forskolin treatment was associated with proopiomelanocortin gene expression, enhanced neurite growth, and increased neuronal viability. Determination of internucleosomal cleavage of DNA by agarose gel electrophoresis revealed that apoptosis occurred in hypothalamic neurons during the first 6-8 days in culture. Addition of Bt(2)cAMP during this developmental period inhibited DNA degradation in hypothalamic neurons. Furthermore, incubation with various doses of ethanol, which is known to reduce intracellular levels of Bt(2)cAMP, increased DNA degradation in these cells. Ethanol-induced DNA degradation was blocked by concomitant incubation with Bt(2)cAMP. Histochemical identification of apoptotic cells following ethanol and Bt(2)cAMP treatments further revealed that apoptosis occurred in beta-EP neurons during the developmental period, and that ethanol increased and Bt(2)cAMP reduced apoptotic beta-EP cell numbers. These results suggest that ethanol neurotoxicity on beta-EP neurons during early neuronal differentiation involves an apoptotic process and that the cAMP signaling system plays an important role in controlling apoptosis and differentiation of the beta-EP neuronal system.	WASHINGTON STATE UNIV, DEPT VET & COMPARAT ANAT PHARMACOL & PHYSIOL, PULLMAN, WA 99164 USA	Washington State University			Sarkar, Dipak K/O-7942-2017	Sarkar, Dipak K/0000-0003-3237-9871	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008757] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA08757] Funding Source: Medline; NINDS NIH HHS [NS05130] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel E. L., 1984, FETAL ALCOHOL SYNDRO; ADAMS ML, 1991, ALCOHOL CLIN EXP RES, V15, P685, DOI 10.1111/j.1530-0277.1991.tb00580.x; ALTSHULER HL, 1980, LIFE SCI, V26, P679, DOI 10.1016/0024-3205(80)90257-X; AMALRIC M, 1987, PSYCHOPHARMACOLOGY, V91, P14, DOI 10.1007/BF00690919; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BLUM M, 1989, METHOD ENZYMOL, V168, P618; BOUTILLIER AL, 1992, J BIOL CHEM, V267, P23520; BOUTILLIER AL, 1991, MOL ENDOCRINOL, V5, P1301, DOI 10.1210/mend-5-9-1301; CHARNESS ME, 1989, EXPERIENTIA, V45, P418, DOI 10.1007/BF01952023; CHARNESS ME, 1988, BIOCHEM BIOPH RES CO, V155, P138, DOI 10.1016/S0006-291X(88)81060-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMPTON MM, 1986, ENDOCRINOLOGY, V118, P38, DOI 10.1210/endo-118-1-38; DANIEL V, 1973, P NATL ACAD SCI USA, V70, P76, DOI 10.1073/pnas.70.1.76; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; FROEHLICH JC, 1990, PHARMACOL BIOCHEM BE, V35, P385, DOI 10.1016/0091-3057(90)90174-G; Goldstein DB, 1983, PHARM ALCOHOL; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; GRUOL DJ, 1989, MOL ENDOCRINOL, V3, P2119, DOI 10.1210/mend-3-12-2119; HANDA RJ, 1985, LIFE SCI, V37, P1683, DOI 10.1016/0024-3205(85)90295-4; HUNT WA, 1981, FED PROC, V40, P2077; HYNIE S, 1980, ACTA PHARMACOL TOX, V47, P58; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; KORNET M, 1991, PSYCHOPHARMACOLOGY, V104, P367, DOI 10.1007/BF02246038; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEVIN N, 1991, FRONT NEUROENDOCRIN, V12, P1; LEVIN N, 1989, ENDOCRINOLOGY, V125, P2957, DOI 10.1210/endo-125-6-2957; LUNDBLAD JR, 1988, ENDOCR REV, V9, P135, DOI 10.1210/edrv-9-1-135; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MCGIVERN RF, 1986, PSYCHONEUROENDOCRINO, V11, P105, DOI 10.1016/0306-4530(86)90036-3; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEZEY E, 1985, BRAIN RES, V328, P341, DOI 10.1016/0006-8993(85)91046-7; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; ODONOHUE TL, 1982, PEPTIDES, V3, P353, DOI 10.1016/0196-9781(82)90098-5; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; PASTORCIC M, 1986, MOL CELL BIOL, V6, P2784, DOI 10.1128/MCB.6.8.2784; PRATT RM, 1975, P NATL ACAD SCI USA, V72, P874, DOI 10.1073/pnas.72.3.874; RABIN RA, 1981, J PHARMACOL EXP THER, V216, P129; RAIZADA MK, 1990, AM J PHYSIOL, V258, pC109, DOI 10.1152/ajpcell.1990.258.1.C109; REDDY BV, 1993, ALCOHOL CLIN EXP RES, V17, P1261, DOI 10.1111/j.1530-0277.1993.tb05239.x; REDEI E, 1989, ALCOHOL CLIN EXP RES, V13, P439, DOI 10.1111/j.1530-0277.1989.tb00350.x; RIVIER C, 1984, J PHARMACOL EXP THER, V229, P127; Robison G A, 1970, Adv Biochem Psychopharmacol, V3, P11; ROSSIER J, 1977, P NATL ACAD SCI USA, V74, P5162, DOI 10.1073/pnas.74.11.5162; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SAITO T, 1985, J NEUROCHEM, V44, P1037, DOI 10.1111/j.1471-4159.1985.tb08722.x; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANDMAN CA, 1981, PHARMACOL THERAPEUT, V13, P39, DOI 10.1016/0163-7258(81)90066-8; SARKAR DK, 1990, ENDOCRINOLOGY, V126, P349, DOI 10.1210/endo-126-1-349; SARKAR DK, 1985, ENDOCRINOLOGY, V116, P2080, DOI 10.1210/endo-116-5-2080; SARKAR DK, 1988, NEUROENDOCRINE CONTR, P47; SCHMIDT M J, 1970, Developmental Psychology, V3, P53, DOI 10.1002/dev.420030108; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SPANAGEL R, 1991, PSYCHOPHARMACOLOGY, V104, P51, DOI 10.1007/BF02244553; STREISSGUTH AP, 1989, ANN NY ACAD SCI, V562, P145, DOI 10.1111/j.1749-6632.1989.tb21013.x; TAYLOR AN, 1986, ALCOHOL, V3, P255, DOI 10.1016/0741-8329(86)90034-0; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WALKER C, 1983, J IMMUNOL, V130, P1770; WAND GS, 1991, ALCOHOL CLIN EXP RES, V15, P705, DOI 10.1111/j.1530-0277.1991.tb00583.x; Ward I L, 1983, Monogr Neural Sci, V9, P169; WEINBERG J, 1989, ALCOHOL CLIN EXP RES, V13, P73, DOI 10.1111/j.1530-0277.1989.tb00287.x; WIDMAIER EP, 1989, ENDOCRINOLOGY, V124, P583, DOI 10.1210/endo-124-2-583; WILCOX JN, 1986, J NEUROSCI RES, V16, P89, DOI 10.1002/jnr.490160109; YANG ZY, 1993, J NEUROENDOCRINOL, V5, P371, DOI 10.1111/j.1365-2826.1993.tb00497.x; Zagon I S, 1983, Monogr Neural Sci, V9, P159	66	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26697	26704						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929402				2022-12-25	WOS:A1994PQ93100021
J	ZHANG, ZT; HARMS, E; VANETTEN, RL				ZHANG, ZT; HARMS, E; VANETTEN, RL			ASP(129) OF LOW-MOLECULAR-WEIGHT PROTEIN-TYROSINE-PHOSPHATASE IS INVOLVED IN LEAVING GROUP PROTONATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE HEART; ACID-PHOSPHATASE; EXPRESSION; INTERMEDIATE; DEPENDENCE; CLONING	Site-directed mutagenesis was used to explore the functions of a number of acidic residues of bovine low molecular weight protein tyrosine phosphatase. Residues Asp-129, Asp-56, and Asp-92 were mutated to Ala or Asn. The mutant enzymes D56A, D56N, and D92A showed no significant changes in V-max values, although they did exhibit significantly altered K-m values. In contrast, the D129A mutant enzyme exhibited a greater than 2000-fold reduction in V-max, using p-nitrophenyl phosphate as a substrate. The V-max values of D129A also exhibited a leaving group dependence, an altered solvent isotope effect of V-max(H)/V-max(D) of 0.78, and a lack of dependence on the presence of alternative phosphate acceptor alcohols, all properties that distinguish this mutant from wild type enzyme. The differences are due to a change of the rate-limiting step of the catalytic reaction. Asp-129 is concluded to be the proton donor to the leaving group in the phosphorylation step, and its mutation to alanine results in a reduced V-max value and a change in the rate-limiting step of the catalysis from dephosphorylation to phosphorylation. Mechanistic considerations suggest that other phosphotyrosyl phosphatases having cysteine at the active site may be expected to have a similar requirement for a proton donor.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA; PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus				zhang, zhongtao/0000-0002-1910-4753				BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BROCKLEHURST K, 1988, BIOCHEM J, V250, P761, DOI 10.1042/bj2500761; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; COOK PF, 1991, ENZYME MECHANISM ISO, P202; DAVIS JP, 1994, J BIOL CHEM, V269, P8734; DAVIS JP, 1994, BIOCHEMISTRY-US, V33, P1278, DOI 10.1021/bi00171a031; GUAN KL, 1991, J BIOL CHEM, V266, P17026; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGAN TM, 1994, BIOCHEMISTRY-US, V33, P11087, DOI 10.1021/bi00203a005; LUTZ RA, 1985, CLIN CHEM, V31, P656; OSTANIN K, 1993, J BIOL CHEM, V268, P20778; RAUGEI G, 1991, BIOCHEM INT, V23, P317; SAINI MS, 1981, J BIOL CHEM, V256, P453; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; WO YYP, 1992, J BIOL CHEM, V267, P10856; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; ZHANG ZY, 1991, BIOCHEMISTRY-US, V30, P8954, DOI 10.1021/bi00101a006; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; ZHANG ZY, 1990, THESIS PURDUE U W LA	23	62	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25947	25950						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929301				2022-12-25	WOS:A1994PQ93000002
J	ZHANG, C; LAMBERT, MP; BUNCH, C; BARBER, K; WADE, WS; KRAFFT, GA; KLEIN, WL				ZHANG, C; LAMBERT, MP; BUNCH, C; BARBER, K; WADE, WS; KRAFFT, GA; KLEIN, WL			FOCAL ADHESION KINASE EXPRESSED BY NERVE-CELL LINES SHOWS INCREASED TYROSINE PHOSPHORYLATION IN RESPONSE TO ALZHEIMERS A-BETA PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMYLOID PLAQUE CORE; EXTRACELLULAR-MATRIX; PROTEIN; DISEASE; DIFFERENTIATION; NEUROTOXICITY; INVITRO; NEUROPEPTIDES; PURIFICATION; FIBRONECTIN	A beta is a 39-43-amino acid peptide that accumulates as extracellular aggregates in Alzheimer's disease-afflicted brain tissue. Contact between these aggregates and neurons is potentially pathogenic, although little is known about the cellular transduction mechanisms. We have investigated the impact of A beta aggregates on the neuronal control of protein tyrosine phosphorylation, which underlies signal transduction for multiple families of growth factor and adhesion receptors. Added to cultures of rat and human nerve cell lines, A beta aggregates evoked a non-desensitizing increase (1.3-3.6-fold) in tyrosine phosphorylation in a band at 118 kDa. The 118-kDa protein was determined by immunoprecipitation to be pp125(FAK), not previously documented in cells of neuronal lineage. Immunoblots with anti-focal adhesion kinase (FAK) showed that A beta aggregates had no effect on FAK protein levels. The increase in FAK tyrosine phosphorylation occurred at doses of A beta aggregates that evoked lactate dehydrogenase release; evoked tyrosine phosphorylation preceded the first detectable lactate dehydrogenase release by 4 h. Like degeneration, the FAK response was dependent on A beta aggregation and neuronal differentiation. Since tyrosine phosphorylation of FAK is essential to its activity as a transduction component of integrin-, peptide-, and lysophosphatidic acid-mediated signaling, the data establish a link between A beta aggregates and signal transduction pathways implicated in diverse cell functions including neurite outgrowth, control of the cell cycle, and apoptosis.	NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208; ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064	Northwestern University; Abbott Laboratories								ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CARRI NG, 1992, INT J DEV NEUROSCI, V10, P393, DOI 10.1016/0736-5748(92)90029-Y; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; GHISO J, 1992, BIOCHEM J, V288, P1053, DOI 10.1042/bj2881053; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOREVIC PD, 1986, J NEUROPATH EXP NEUR, V45, P647, DOI 10.1097/00005072-198611000-00004; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; IQBAL K, 1991, MOL NEUROBIOL, V5, P399, DOI 10.1007/BF02935561; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KOSIK K, 1992, NEUROBIOL AGING, V13, P535, DOI 10.1016/0197-4580(92)90052-Y; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LAMBERT MP, 1994, IN PRESS J NEUROSCI; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MANESS PF, 1986, J NEUROSCI RES, V16, P127, DOI 10.1002/jnr.490160113; MANESS PF, 1992, DEV NEUROSCI-BASEL, V14, P257, DOI 10.1159/000111670; MARX J, 1992, SCIENCE, V257, P1336, DOI 10.1126/science.257.5075.1336-a; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; REID DM, 1993, NEUROSCIENCE, V56, P529, DOI 10.1016/0306-4522(93)90353-H; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7845; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; WALLAAS SI, 1988, BRAIN RES, V427, P215; WATT FM, 1993, J CELL SCI, V106, P175; WHITSON JS, 1990, NEUROSCI LETT, V110, P319, DOI 10.1016/0304-3940(90)90867-9; WHITSON JS, 1989, SCIENCE, V243, P1488, DOI 10.1126/science.2928783; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	44	97	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25247	25250						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929215				2022-12-25	WOS:A1994PQ49100004
J	CASELLI, A; CAMICI, G; MANAO, G; MONETI, G; PAZZAGLI, L; CAPPUGI, G; RAMPONI, G				CASELLI, A; CAMICI, G; MANAO, G; MONETI, G; PAZZAGLI, L; CAPPUGI, G; RAMPONI, G			NITRIC-OXIDE CAUSES INACTIVATION OF THE LOW-MOLECULAR-WEIGHT PHOSPHOTYROSINE PROTEIN PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC ACID-PHOSPHATASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; TYROSINE PHOSPHATASES; S-NITROSYLATION; PURIFICATION; SEQUENCE; RECEPTOR; LIVER	The low M(r) phosphotyrosine protein phosphatase (PTPase) and Yersinia enterocolitica PTPase are inactivated by nitric oxide-generating compounds. Inorganic phosphate, a competitive inhibitor, protects the enzymes from inactivation, suggesting that the action of NO is directed to the active sites. Low M(r) PTPase from bovine liver lost two out of eight thiol groups present in the molecule during the inactivation with sodium nitro prusside and with other NO-producing compounds. The mass spectrometric analyses of tryptic fragments of the enzyme, performed after chemical modification of the NO-unreacted thiol groups, demonstrated that NO caused the oxidation of Cys-12 and Cys-17 to form an S-S bond. A similar reaction was described previously for the reaction of NO with N-methyl-D-aspartate receptor. The NO-inactivated low M(r) PTPase was reactivated by treating the inactive enzyme with thiol-containing reagents. Since all members of the PTPase family have the same reaction mechanism and possess a conserved active site motif that contains an essential cysteine residue, the findings on low M(r) and Yersinia PTPases are potentially interesting for all PTPases, an enzyme class that is involved in a number of important biological processes.	UNIV FLORENCE,DIPARTIMENTO SCI BIOCHIM,I-50134 FLORENCE,ITALY; UNIV FLORENCE,DIPARTIMENTO FARMACOL PRECLIN & CLIN,I-50134 FLORENCE,ITALY	University of Florence; University of Florence			Caselli, Anna/O-7512-2014; Camici, Giovanni/H-1631-2018	Caselli, Anna/0000-0001-8140-3415; Camici, Giovanni/0000-0002-0523-0695				BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bates JN, 1990, BIOCHEM PHARMACOL, V42, P157, DOI DOI 10.1016/0006-2952(91)90406-U; BOIVIN P, 1986, BIOCHEM BIOPH RES CO, V134, P557, DOI 10.1016/S0006-291X(86)80456-9; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; CAMICI G, 1989, J BIOL CHEM, V264, P2560; CASELLI A, 1994, J PROTEIN CHEM, V13, P107, DOI 10.1007/BF01891998; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHERNOFF J, 1985, ARCH BIOCHEM BIOPHYS, V240, P135, DOI 10.1016/0003-9861(85)90016-5; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; DISSING J, 1991, J BIOL CHEM, V266, P20619; FAULSTICH H, 1993, ANAL BIOCHEM, V208, P357, DOI 10.1006/abio.1993.1061; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; MANAO G, 1992, J PROTEIN CHEM, V11, P333, DOI 10.1007/BF01024871; MANAO G, 1991, 6TH P NAT M PROT 91, P96; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATAN C, 1992, FASEB J, V6, P3051; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; RUGGIERO M, 1993, FEBS LETT, V326, P294, DOI 10.1016/0014-5793(93)81811-D; SHEKELS LL, 1992, PROTEIN SCI, V1, P710, DOI 10.1002/pro.5560010603; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; SU XD, 1994, FEBS LETT, V343, P107, DOI 10.1016/0014-5793(94)80299-8; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WAHEED A, 1988, BIOCHEMISTRY-US, V27, P4265, DOI 10.1021/bi00412a010	28	135	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24878	24882						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929168				2022-12-25	WOS:A1994PQ49000055
J	HIASA, H; MARIANS, KJ				HIASA, H; MARIANS, KJ			FIS CANNOT SUPPORT ORIC DNA-REPLICATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; HISTONE-LIKE PROTEINS; PBR322 DNA; ENZYMATIC REPLICATION; ORIGIN; INITIATION; HU; BINDING; STRAND; IHF	The effects of the histone like proteins, HU, IHF, and Fis on DNA replication have been examined in vitro using the oriC and pBR322 DNA replication systems. In the oriC system, although low concentrations of HU and IHF stimulated DNA replication, no stimulation was observed upon the addition of Fis. On the contrary, high concentrations of Fis inhibited oriC DNA replication completely. The inhibitory effect of Fis could be overcome when HU, IHF, or RNA polymerase were also present in the reaction mixtures. Unwinding of duplex DNA at the origin correlated with the elevated level of DNA replication. In contrast, only inhibition, rather than stimulation, was observed when these proteins were added to the pBR322 DNA replication system. Thus, the observed dependence on Fis of oriC DNA replication in vivo cannot be attributed to a positive effect on localized DNA unwinding.			HIASA, H (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM 34558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAI T, 1990, EMBO J, V9, P4065, DOI 10.1002/j.1460-2075.1990.tb07628.x; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BONNEFOY E, 1992, EMBO J, V11, P4489, DOI 10.1002/j.1460-2075.1992.tb05550.x; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CROOKE E, 1991, RES MICROBIOL, V142, P127, DOI 10.1016/0923-2508(91)90019-7; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FILUTOWICZ M, 1990, New Biologist, V2, P818; FILUTOWICZ M, 1992, J BACTERIOL, V174, P398, DOI 10.1128/jb.174.2.398-407.1992; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P2093; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HWANG DS, 1992, J BIOL CHEM, V267, P23087; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1992, J BIOL CHEM, V267, P2209; HWANG DS, 1992, J BIOL CHEM, V267, P23083; KANO Y, 1992, GENE AMST, V126, P93; KORNBERG A, 1992, DNA REPLICATION, P523; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; POLACZEK P, 1990, New Biologist, V2, P265; PRENTKI P, 1987, EMBO J, V6, P2479, DOI 10.1002/j.1460-2075.1987.tb02529.x; ROTH A, 1994, IN PRESS BIOCHIMIE P; SKARSTAD K, 1993, J BIOL CHEM, V268, P5365; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SKARSTAD K, 1993, DNA REPLICATION CELL, V43, P15; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WU CA, 1992, J BIOL CHEM, V267, P4030; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	40	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24999	25003						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929185				2022-12-25	WOS:A1994PQ49000072
J	MOLLARD, P; THELER, JM; GUERINEAU, N; VACHER, P; CHIAVAROLI, C; SCHLEGEL, W				MOLLARD, P; THELER, JM; GUERINEAU, N; VACHER, P; CHIAVAROLI, C; SCHLEGEL, W			CYTOSOLIC CA2+ OF EXCITABLE PITUITARY-CELLS AT RESTING POTENTIALS IS CONTROLLED BY STEADY-STATE CA2+ CURRENTS SENSITIVE TO DIHYDROPYRIDINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; PANCREATIC BETA-CELLS; ACTIVATED CALCIUM CHANNELS; ADRENAL CHROMAFFIN CELLS; ELECTRICAL-ACTIVITY; BOVINE LACTOTROPHS; CA-2+; GLUCOSE; TRANSIENTS; DOPAMINE	Different elements of voltage-gated Ca2+ influx and their role for cytosolic-free Ca2+, [Ca2+](i), were studied in cells of the pituitary line GH3B6. Single cell monitoring of [Ca2+](i) with the fluorescent probe indo-1, as well as fast on-line ratio [Ca2+](i) imaging with fura-2, were combined with electrophysiological recordings using the perforated patch configuration of the patch clamp technique. [Ca2+](i) signals are generated by Ca2+ influx both during action potentials and in between. Steady state Ca2+ influx at resting potentials (-60 to -40 mV) was voltage-gated and sensitive to the dihydropyridine antagonist PN 200-110. Ca2+ influx could be demonstrated in physiological conditions as inward Ca2+ currents of maximally 10 pA, which were triggered when stepping up the holding voltage beyond a narrow threshold around -50 mV. Inward currents were well correlated with [Ca2+](i) elevations (R = -0.8; p < 0.001). It is concluded that dihydropyridine-sensitive, low threshold voltage-gated steady state Ca2+ currents, which may be tonically activated at resting potentials, provide for [Ca2+](i) signaling in excitable endocrine cells in a mode that parallels the modulation of Ca2+ influx during action potentials.	UNIV GENEVA, DEPT MED, RECH MED FDN, CH-1211 GENEVA, SWITZERLAND; UNIV BORDEAUX 2, NEUROPHYSIOL LAB, CNRS, URA 1200, F-33076 BORDEAUX, FRANCE; UNIV GENEVA, DIV BIOCHIM CLIN, CH-1211 GENEVA, SWITZERLAND	University of Geneva; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of Geneva			Vacher, Pierre/N-2243-2018	VACHER, Pierre/0000-0003-3503-7981; Guerineau, Nathalie/0000-0003-2517-4210				AKERMAN SN, 1991, ENDOCRINOLOGY, V129, P475, DOI 10.1210/endo-129-1-475; ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; ARMSTRONG DL, 1991, ANN NY ACAD SCI, V635, P26, DOI 10.1111/j.1749-6632.1991.tb36478.x; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; CHIAVAROLI C, 1992, EUR J PHARM-MOLEC PH, V227, P173, DOI 10.1016/0922-4106(92)90125-F; COHEN CJ, 1987, J PHYSIOL-LONDON, V387, P195, DOI 10.1113/jphysiol.1987.sp016570; CORCUFF JB, 1993, J BIOL CHEM, V268, P22313; DEAN PM, 1970, J PHYSIOL-LONDON, V210, P255, DOI 10.1113/jphysiol.1970.sp009207; DOUGLAS WW, 1978, J PHYSIOL-LONDON, V285, P171, DOI 10.1113/jphysiol.1978.sp012565; DUFY B, 1979, SCIENCE, V204, P509, DOI 10.1126/science.107590; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUERINEAU N, 1991, ENDOCRINOLOGY, V129, P409, DOI 10.1210/endo-129-1-409; GUERINEAU N, 1990, FEBS LETT, V276, P111, DOI 10.1016/0014-5793(90)80520-S; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; ISRAEL JM, 1987, J PHYSIOL-LONDON, V390, P1, DOI 10.1113/jphysiol.1987.sp016682; KIDOKORO Y, 1975, NATURE, V258, P741, DOI 10.1038/258741a0; Lussier B. T., 1993, Society for Neuroscience Abstracts, V19, P1333; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MOLLARD P, 1991, EUR J PHARM-MOLEC PH, V206, P271, DOI 10.1016/0922-4106(91)90109-U; MOLLARD P, 1988, ENDOCRINOLOGY, V123, P721, DOI 10.1210/endo-123-2-721; MOLLARD P, 1989, BIOCHEM BIOPH RES CO, V164, P1045, DOI 10.1016/0006-291X(89)91775-0; NOWYCKY MC, 1985, P NATL ACAD SCI USA, V82, P2178, DOI 10.1073/pnas.82.7.2178; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; OZAWA S, 1981, BRAIN RES, V209, P240, DOI 10.1016/0006-8993(81)91188-4; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; SCHERUBL H, 1991, P ROY SOC B-BIOL SCI, V245, P127, DOI 10.1098/rspb.1991.0098; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; TALO A, 1990, J GEN PHYSIOL, V96, P1085, DOI 10.1085/jgp.96.5.1085; THELER JM, 1992, J BIOL CHEM, V267, P18110; THELER JM, 1991, J RECEPTOR RES, V11, P627, DOI 10.3109/10799899109066431; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WINIGER BP, 1988, BIOCHEM J, V255, P161, DOI 10.1042/bj2550161; ZOREC R, 1991, J GEN PHYSIOL, V97, P473, DOI 10.1085/jgp.97.3.473	40	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25158	25164						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929204				2022-12-25	WOS:A1994PQ49000094
J	NIIDOME, T; KITADA, S; SHIMOKATA, K; OGISHIMA, T; ITO, A				NIIDOME, T; KITADA, S; SHIMOKATA, K; OGISHIMA, T; ITO, A			ARGININE RESIDUES IN THE EXTENSION PEPTIDE ARE REQUIRED FOR CLEAVAGE OF A PRECURSOR BY MITOCHONDRIAL PROCESSING PEPTIDASE - DEMONSTRATION USING SYNTHETIC PEPTIDE AS A SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-ORNITHINE TRANSCARBAMYLASE; MALATE-DEHYDROGENASE; PROTEOLYTIC CLEAVAGE; PARTIAL-PURIFICATION; TRANSIT PEPTIDE; LEADER PEPTIDE; SIGNAL PEPTIDE; PROTEASE; PROTEINS; IMPORT	Mitochondrial processing peptidase (MPP) specifically recognizes a large variety of mitochondrial precursor proteins and correctly cleaves off the extension peptides. To determine the structure common to all the extension peptides that is required for specific recognition by MPP, we synthesized various oligopeptides of different chain lengths and amino acid sequences, based on the amino acid sequence of the extension peptide of pre-malate dehydrogenase, and determined kinetic parameters of the cleavage reactions. The minimal length of peptides for effective cleavage was 16 amino acid residues consisting of 11 and 5 residues from the cleavage site to the amino- and carboxyl-terminal sides, respectively. Two sets of basic amino acids in the peptide, the distal arginine residue at position -10 and the proximal ones at positions -3 and -2 relative to the cleavage site, were necessary for effective hydrolysis. Of these two, the residue at position -2 was more important for effective cleavage than the one at position -3 and could not be replaced by a lysine residue. The replacement of the distal arginine by lysine had no effect on the cleavage. Our study demonstrates that use of peptides with the proper length is essential for performing kinetic analyses on the cleavage reaction by MPP and that an arginine residue at position -2 to the cleavage site is necessary for the recognition and cleavage of the extension peptide.	KYUSHU UNIV, FAC SCI, DEPT CHEM, HIGASHI KU, FUKUOKA 812, JAPAN	Kyushu University			Niidome, Takuro/F-1508-2010	Niidome, Takuro/0000-0002-8070-8708				ATHERTON E, 1981, J CHEM SOC PERK T 1, P538, DOI 10.1039/p19810000538; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; CHU TW, 1987, J BIOL CHEM, V262, P12806; CHU TW, 1987, J BIOL CHEM, V262, P15759; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; FUJII N, 1987, CHEM PHARM BULL, V35, P3880; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; JOH T, 1987, BIOCHEMISTRY-US, V26, P2515, DOI 10.1021/bi00383a017; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KRAUS JP, 1988, P NATL ACAD SCI USA, V85, P8905, DOI 10.1073/pnas.85.23.8905; MCADA PC, 1982, J BIOL CHEM, V257, P3177; MIURA S, 1982, EUR J BIOCHEM, V122, P641; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROSENBERG LE, 1986, ANN NY ACAD SCI, V488, P99; SAGARA Y, 1984, J BIOCHEM-TOKYO, V96, P1743, DOI 10.1093/oxfordjournals.jbchem.a135007; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; YANG M, 1991, J BIOL CHEM, V266, P6416; YEMM EW, 1955, ANALYST, V80, P209, DOI 10.1039/an9558000209; ZWIZINSKI C, 1983, J BIOL CHEM, V258, P3340	28	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24719	24722						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929146				2022-12-25	WOS:A1994PQ49000033
J	AGUIRRE, KM; MCCORMICK, RJ; SCHWARZBAUER, JE				AGUIRRE, KM; MCCORMICK, RJ; SCHWARZBAUER, JE			FIBRONECTIN SELF-ASSOCIATION IS MEDIATED BY COMPLEMENTARY SITES WITHIN THE AMINO-TERMINAL ONE-THIRD OF THE MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; MATRIX ASSEMBLY DOMAIN; CELL-BINDING DOMAIN; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODY; IONIC-STRENGTH; I COLLAGEN; FRAGMENT; RECEPTOR; MODULES	The formation of a fibrillar fibronectin (FN) extracellular matrix requires self-association of FN dimers. In this report, we show that the major sites for self-association are the amino-terminal repeats I-1-5 and the first type III repeats. Recombinant FNs and fragments were generated by baculovirus expression of cysteine-rich domains and by bacterial expression of type III repeats as fusion proteins with maltose binding protein. When recombinant polypeptides were immobilized on microtiter wells, FN bound to 70-kDa amino-terminal fragment and to fusion proteins containing repeats III1-2 and III1-6 but not to other type III repeats. Similar results were obtained with a gel overlay assay. finding was concentration-dependent and saturable. The amino-terminal binding site for III1-2 was further localized to repeats I-1-5. Therefore, at least two different sites for FN-FN interaction reside near the amino terminus of the molecule. A model for the regulation of FN matrix assembly is proposed based on intramolecular interactions between these amino terminal sites.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University				Schwarzbauer, Jean/0000-0003-1012-7593	NCI NIH HHS [CA44627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BARRY ELR, 1989, J BIOL CHEM, V264, P4179; BENECKY MJ, 1990, BIOCHEMISTRY-US, V29, P3082, DOI 10.1021/bi00464a027; BUSHUEV VN, 1985, FEBS LETT, V189, P276, DOI 10.1016/0014-5793(85)81039-5; CHERNOUSOV MA, 1987, FEBS LETT, V217, P124, DOI 10.1016/0014-5793(87)81255-3; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; EHRISMANN R, 1981, J BIOL CHEM, V256, P4056; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; ERICKSON HP, 1983, J BIOL CHEM, V258, P4539; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GOSWAMI BB, 1991, BIOTECHNIQUES, V10, P626; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; HOMANDBERG GA, 1986, BIOCHEMISTRY-US, V25, P6917, DOI 10.1021/bi00370a027; ICHIHARATANAKA K, 1992, FEBS LETT, V299, P155, DOI 10.1016/0014-5793(92)80236-A; INGHAM KC, 1988, J BIOL CHEM, V263, P4624; KHAN MY, 1990, BIOCHEM J, V270, P33, DOI 10.1042/bj2700033; KOTELIANSKY VE, 1981, EUR J BIOCHEM, V119, P619, DOI 10.1111/j.1432-1033.1981.tb05652.x; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; MCDONALD JA, 1982, J CELL BIOL, V92, P485, DOI 10.1083/jcb.92.2.485; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; ROCCO M, 1987, EMBO J, V6, P2343, DOI 10.1002/j.1460-2075.1987.tb02510.x; ROCCO M, 1984, FEBS LETT, V178, P327, DOI 10.1016/0014-5793(84)80627-4; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; SCHWARZBAUER JE, 1993, MOL BIOL CELL, V4, P941, DOI 10.1091/mbc.4.9.941; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SJOBERG B, 1987, ARCH BIOCHEM BIOPHYS, V255, P347, DOI 10.1016/0003-9861(87)90402-4; SOTTILE J, 1993, BIOCHEMISTRY-US, V32, P1641, DOI 10.1021/bi00057a031; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; WU CY, 1993, J BIOL CHEM, V268, P21883	42	137	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27863	27868						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961716				2022-12-25	WOS:A1994PV77200017
J	HELAAKOSKI, T; VEIJOLA, J; VUORI, K; REHN, M; CHOW, LT; TAILLONMILLER, P; KIVIRIKKO, KI; PIHLAJANIEMI, T				HELAAKOSKI, T; VEIJOLA, J; VUORI, K; REHN, M; CHOW, LT; TAILLONMILLER, P; KIVIRIKKO, KI; PIHLAJANIEMI, T			STRUCTURE AND EXPRESSION OF THE HUMAN GENE FOR THE ALPHA-SUBUNIT OF PROLYL 4-HYDROXYLASE - THE 2 ALTERNATIVELY SPLICED TYPES OF MESSENGER-RNA CORRESPOND TO 2 HOMOLOGOUS EXONS THE SEQUENCES OF WHICH ARE EXPRESSED IN A VARIETY OF TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; HORMONE-BINDING-PROTEIN; BETA-SUBUNIT; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; YEAST; DNA; POLYPEPTIDE; RESIDENT; CLONES	Prolyl 4-hydroxylase, an alpha(2) beta(2) tetramer, plays a central role in collagen synthesis as it catalyzes the formation of 4-hydroxyproline residues by the hydroxylation of proline in X-Pro-Gly sequences. We report here that the human gene for the catalytically important alpha subunit is more than 69 kilobase pairs and consists of 16 exons. The exons that encode solely protein sequences vary from 54 to 240 base pairs (bp), and the introns vary from 750 to more than 16,000 bp. The 133 bp of 5'-untranslated sequences of the mRNA are coded by two exons, and these sequences contain inverted repeats with a potential for stem-loop formation, which may be involved in translational control of the expression of this gene. The 5'-flanking region contains a TATA motif at -29 relative to the major transcription site but no CCAAT motif. The 5'-flanking region and the downstream sequences contain several motifs that may act as binding sites for various transcription factors. Evidence has previously been reported for a mutually exclusive alternative splicing of RNA transcripts of this gene. The present data indicate that the mutually exclusive sequences found in the mRNAs are coded by two consecutive, homologous 71-bp exons 9 and 10. These exons are identical in their first 5 bp and the overall identity between them is 61% at the nucleotide level and 58% at the level of the coded amino acids. Both types of mRNA were found to be expressed in all of the tissues studied, but in some tissues the type coding for exon 9 or 10 sequences was more abundant than the other type.	UNIV OULU, DEPT MED BIOCHEM, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA	University of Oulu; University of Oulu; University of Rochester; Washington University (WUSTL)				Pihlajaniemi, Taina/0000-0002-1664-9045	NCI NIH HHS [CA36200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; BASSUK JA, 1989, P NATL ACAD SCI USA, V86, P7382, DOI 10.1073/pnas.86.19.7382; Blanchard M M, 1993, PCR Methods Appl, V2, P234; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHENG SY, 1987, J BIOL CHEM, V262, P11221; CHOW LT, 1981, ELECTRON MICROS, V1, P139; DURSO M, 1993, CLONING YAC VECTORS, P50; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; KAO WWY, 1988, CONNECT TISSUE RES, V18, P157, DOI 10.3109/03008208809016805; KERE J, 1992, GENOMICS, V14, P241, DOI 10.1016/S0888-7543(05)80212-5; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1990, ANN NY ACAD SCI, V580, P132, DOI 10.1111/j.1749-6632.1990.tb17925.x; KOIVU J, 1987, J BIOL CHEM, V262, P6447; Maniatis T., 1982, MOL CLONING; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PAJUNEN L, 1989, AM J HUM GENET, V45, P829; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PIHLAJANIEMI T, 1987, METHOD ENZYMOL, V145, P213; POUSTKA A, 1984, P NATL ACAD SCI-BIOL, V81, P4129, DOI 10.1073/pnas.81.13.4129; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TASANEN K, 1988, J BIOL CHEM, V263, P16218; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800	34	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27847	27854						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961714				2022-12-25	WOS:A1994PV77200015
J	HUTCHISON, KA; DITTMAR, KD; PRATT, WB				HUTCHISON, KA; DITTMAR, KD; PRATT, WB			ALL OF THE FACTORS REQUIRED FOR ASSEMBLY OF THE GLUCOCORTICOID RECEPTOR INTO A FUNCTIONAL HETEROCOMPLEX WITH HEAT-SHOCK PROTEIN-90 ARE PREASSOCIATED IN A SELF-SUFFICIENT PROTEIN-FOLDING STRUCTURE, A FOLDOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGESTERONE-RECEPTOR; HSP90; COMPLEX; EXISTS; HSP70; RECONSTITUTION; ASSOCIATION; CYTOSOL; HSP56	The hormone-binding domain of the glucocorticoid receptor must be bound to heat shock protein (hsp) 90 for it to have a high-affinity steroid binding conformation. We have recently demonstrated that hsp70 is required for cell-fi ee assembly of the receptor hsp90 complex and concomitant activation of steroid binding activity (Hutchison, K.A, Dittmar, K. D., Czar, M. J., and Pratt, W. B. (1994) J. Biol. Chem. 269, 5043-5049). hsp90 and hsp70 are known to exist together in a cytosolic complex containing several other proteins, and in this work we ask if all of the factors required for proper receptor folding and heterocomplex assembly are preassociated in this multiprotein complex. The multiprotein complex was immunoadsorbed to protein A-agarose from rabbit reticulocyte lysate using the 3G3 monoclonal IgM directed against hsp90. When this immunopellet is mixed with immunadsorbed mouse glucocorticoid receptor and incubated at 30 degrees C with ATP/Mg2+ and KCl, the receptor is converted to the steroid binding conformation. When the immunoadsorbed multiprotein hsp90 complex is washed extensively, it loses a weakly bound protein (not hsp70 or hsp90) that is required for receptor activation. This protein factor is contained in a Centricon C-100 filtrate of lysate which reconstitutes the receptor activating activity of the washed hsp90 complex. The hsp90 complex can be released from the 3G3 antibody, and in the presence of the protein factor in the Centricon C-100 filtrate it converts the receptor into a functional heterocomplex with hsp90. The results support the proposal that the various components of reticulocyte lysate that are required to refold the glucocorticoid receptor to the steroid binding state are preassociated with each other, acting as a self-sufficient protein folding machine.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031573, R01DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; YEM AW, 1992, J BIOL CHEM, V267, P2868	18	88	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27894	27899						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961721				2022-12-25	WOS:A1994PV77200022
J	TREMETHICK, DJ				TREMETHICK, DJ			HIGH-MOBILITY GROUP PROTEIN-14 AND PROTEIN-17 CAN SPACE NUCLEOSOMAL PARTICLES DEFICIENT IN HISTONES H2A AND H2B CREATING A TEMPLATE THAT IS TRANSCRIPTIONALLY ACTIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; RNA POLYMERASE-II; CHROMATIN STRUCTURE; CHROMOSOMAL-PROTEINS; DNA; INVITRO; CORE; BINDING; COMPLEX; HMG-17	Recently, using a well defined nucleosomal assembly system, we demonstrated that high mobility group proteins (HMGs) 14 and 17 can organize nucleosomes into a regular array with a nucleosomal repeat length of 160-165 base pairs in vitro. Interestingly, such a short repeat length has been described for lower eukaryotes and for active chromatin. To begin to investigate how these proteins may prevent the close packing of nucleosomes, assembly reactions were carried out in which the relative amounts of HMGs 14 and 17, histones H2A and H2B, and the N1/N2-(H3, H4) complex were varied in assembly reactions. Under conditions in which histones H2A and H2B were Limiting and in the absence of HMGs 14 and 17, micrococcal nuclease digestion of the assembled product produced a ladder of DNA fragments that was much less well defined and which included DNA that was associated with subnucleosomal structures. The apparent repeat length for this chromatin template was around 125 base pairs. Most interestingly, when HMGs 14 and 17 were added to this assembly reaction, ''nucleosome-like'' structures were reassembled as shown by the restoration of a regular, well defined ladder of DNA fragments upon micrococcal nuclease digestion. The apparent repeat length increased from 125 to approximately 145 base pairs. Analysis of the protein composition of chromatin formed in the presence or absence of HMGs 14 and 17 reveals that HMGs 14 and 17 might be able to substitute for a histone H2A-H2B dimer in a H2A/H2B-deficient nucleosome. The ability to form a regularly spaced nucleosomal template is also lost when excess HMGs 14 and 17 are used in assembly reactions. Spacing can be restored by the addition of poly(glutamate,alanine), a chemical polymer of negative charge, which may indicate that carrier proteins (specific or nonspecific) may be required for the proper incorporation of all chromatin assembly components into chromatin in vivo. Finally, although the mechanism of action is not known, HMGs 14 and 17 can partially overcome inhibition of initiation of transcription caused by the formation of nucleosomal particles deficient in histones H2A and H2B.			TREMETHICK, DJ (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,POB 334,CANBERRA,ACT 2601,AUSTRALIA.			Tremethick, David/0000-0001-5274-8078				ALBRIGHT SC, 1980, J BIOL CHEM, V255, P3673; ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BRAWLEY JV, 1992, BIOCHEMISTRY-US, V31, P364, DOI 10.1021/bi00117a008; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; COOK GR, 1986, J BIOL CHEM, V261, P6185; CRIPPA MP, 1992, J MOL BIOL, V228, P442, DOI 10.1016/0022-2836(92)90833-6; CRIPPA MP, 1993, EMBO J, V12, P3855, DOI 10.1002/j.1460-2075.1993.tb06064.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DREW HR, 1993, J MOL BIOL, V230, P824, DOI 10.1006/jmbi.1993.1204; EINICK L, 1985, EXP CELL RES, V156, P295; ESPEL E, 1987, BIOCHIM BIOPHYS ACTA, V909, P190, DOI 10.1016/0167-4781(87)90077-7; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; GODDE JS, 1992, J MOL BIOL, V226, P1009, DOI 10.1016/0022-2836(92)91049-U; GONZALEZ PJ, 1990, J BIOL CHEM, V265, P8225; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HAYES JJ, 1994, IN PRESS P NATL ACAD; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1993, PHILOS T ROY SOC B, V339, P263, DOI 10.1098/rstb.1993.0024; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; MARDIAN JKW, 1980, SCIENCE, V209, P1534, DOI 10.1126/science.7433974; PRUSS D, 1993, BIOCHEMISTRY-US, V32, P6810, DOI 10.1021/bi00078a002; SASI R, 1982, J BIOL CHEM, V257, P1448; SEALE RL, 1983, BIOCHEMISTRY-US, V22, P5008, DOI 10.1021/bi00290a020; SHICK VV, 1985, J MOL BIOL, V185, P329, DOI 10.1016/0022-2836(85)90407-3; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; THOMAS JO, 1976, FEBS LETT, V66, P274, DOI 10.1016/0014-5793(76)80521-2; TREMETHICK DJ, 1992, J BIOL CHEM, V267, P15041; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; TREMETHICK DJ, 1993, J BIOL CHEM, V268, P11389; VILLEPONTEAU B, 1992, BIOCHEMISTRY-US, V31, P1554, DOI 10.1021/bi00120a037; WEISBROD S, 1981, CELL, V23, P391, DOI 10.1016/0092-8674(81)90134-3; WOLFFE A P, 1990, New Biologist, V2, P211; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	38	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28436	28442						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961785				2022-12-25	WOS:A1994PV77200097
J	HAATAJA, S; TIKKANEN, K; NILSSON, U; MAGNUSSON, G; KARLSSON, KA; FINNE, J				HAATAJA, S; TIKKANEN, K; NILSSON, U; MAGNUSSON, G; KARLSSON, KA; FINNE, J			OLIGOSACCHARIDE-RECEPTOR INTERACTION OF THE GAL-ALPHA-1-4GAL BINDING ADHESIN OF STREPTOCOCCUS-SUIS - COMBINING SITE ARCHITECTURE AND CHARACTERIZATION OF 2 VARIANT ADHESIN SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ERYTHROCYTES; MANNOSE; TOXIN; VEROTOXIN-1; GALABIOSE; BACTERIA; PROTEINS; LECTINS; ANTIGEN	The sugar binding specificities of two groups of Streptococcus suis, a pig pathogen that causes meningitis also in man, were determined. Both the group represented by a recently characterized strain inhibitable by galactose and N-acetylgalactosamine (type P-N) and the group inhibitable by galactose (type P-O) were found by hemagglutination and solid-phase binding inhibition experiments to recognize the disaccharide Gal alpha 1-4Gal of the P-1 and P-k blood group antigens. Both types preferred the disaccharide in terminal position. P-N showed some, whereas P-O showed almost no, binding to the globoside oligosaccharide containing an additional GalNAc beta 1-3 residue. The complete hydrogen bonding patterns were determined by using deoxy and other synthetic derivatives of the receptor disaccharide, and the constructed models of the interactions were compared with that of Escherichia coli PapG(396) adhesin. The essential hydroxyls for binding were the HO-4', HO-6', HO-2, and HO-3 hydroxyls on the beta' alpha-side of the Gal alpha 1-4Gal molecule. Type P, adhesin also formed weak interactions with the hydroxyls HO-6 and HO-3'. The mechanism differed from that of E. coli, which binds to a cluster of five hydroxyls (HO-6, HO-2', HO-3', HO-4', and HO-6') and thus to a different part of the receptor disaccharide. These results represent the first example of the comparison of the saccharide receptor hydrogen bonding patterns of two bacterial organisms of different origin and show that the same saccharide may be recognized by two different binding mechanisms.	UNIV TURKU,INST BIOMED,DEPT CHEM,SF-20520 TURKU,FINLAND; UNIV KUOPIO,DEPT BIOCHEM & BIOTECHNOL,SF-70211 KUOPIO,FINLAND; LUND UNIV,LUND INST TECHNOL,S-22100 LUND,SWEDEN; GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN	University of Turku; University of Eastern Finland; Lund University; University of Gothenburg	HAATAJA, S (corresponding author), UNIV TURKU,INST BIOMED,DEPT MED BIOCHEM,SF-20520 TURKU,FINLAND.		Haataja, Sauli/AAR-5103-2020; Nilsson, Ulf J./L-3219-2014; Finne, Jukka/B-6881-2008	Nilsson, Ulf J./0000-0001-5815-9522; Finne, Jukka/0000-0002-8076-3344				ANGSTROM J, 1986, ARCH BIOCHEM BIOPHYS, V251, P440, DOI 10.1016/0003-9861(86)90350-4; ANIANSSON G, 1990, MICROB PATHOGENESIS, V8, P315, DOI 10.1016/0882-4010(90)90090-D; ARENDS JP, 1988, REV INFECT DIS, V10, P131; BHATTACHARYYA L, 1988, EUR J BIOCHEM, V176, P207, DOI 10.1111/j.1432-1033.1988.tb14270.x; BOYD B, 1993, J EXP MED, V177, P1745, DOI 10.1084/jem.177.6.1745; BURKERT U, 1982, YIU MONOGRAPH, V177; DAHMEN J, 1984, CARBOHYD RES, V129, P63, DOI 10.1016/0008-6215(84)85299-4; DEGRANDIS S, 1989, J BIOL CHEM, V264, P12520; FIRON N, 1982, BIOCHEM BIOPH RES CO, V105, P1426, DOI 10.1016/0006-291X(82)90947-0; FRANCOISGERARD C, 1979, BIOCHEM J, V177, P679, DOI 10.1042/bj1770679; FRICK IM, 1992, P NATL ACAD SCI USA, V89, P8532, DOI 10.1073/pnas.89.18.8532; Gray G R, 1978, Methods Enzymol, V50, P155; HAATAJA S, 1993, J BIOL CHEM, V268, P4311; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; KIHLBERG J, 1989, J AM CHEM SOC, V111, P6364, DOI 10.1021/ja00198a056; KORHONEN TK, 1985, ENTEROBACTERIAL SURF, P301; KURL DN, 1989, INFECT IMMUN, V57, P384, DOI 10.1128/IAI.57.2.384-389.1989; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; MARCUS DM, 1976, P NATL ACAD SCI USA, V73, P3263, DOI 10.1073/pnas.73.9.3263; MATROSOVICH MN, 1989, FEBS LETT, V252, P1, DOI 10.1016/0014-5793(89)80879-8; NILSSON U, 1994, ACTA CHEM SCAND, V48, P356, DOI 10.3891/acta.chem.scand.48-0356; NILSSON U, 1994, CARBOHYD RES, V252, P137; NILSSON U, 1994, CARBOHYD RES, V252, P117; NOWICKI B, 1985, FEMS MICROBIOL LETT, V26, P35; PAULSEN H, 1988, CARBOHYD RES, V175, P163, DOI 10.1016/0008-6215(88)80168-X; Race RR., 1975, BLOOD GROUPS MAN; SIHVONEN L, 1988, ACTA VET SCAND, V29, P9; Stahl E., 1962, DUNNSCHICHTCHROMATOG; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; STROMBERG N, 1991, P NATL ACAD SCI USA, V88, P9340, DOI 10.1073/pnas.88.20.9340; SVENSSON G, 1986, CARBOHYD RES, V146, P29, DOI 10.1016/0008-6215(86)85021-2; YIU SCK, 1992, ANAL BIOCHEM, V202, P188, DOI 10.1016/0003-2697(92)90226-W	35	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27466	27472						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961660				2022-12-25	WOS:A1994PV77100050
J	KINANE, TB; FINDER, JD; KAWASHIMA, A; BROWN, D; ABBATE, M; SHANG, C; FREDERICKS, WJ; RAUSCHER, FJ; SUKHATME, VP; ERCOLANI, L				KINANE, TB; FINDER, JD; KAWASHIMA, A; BROWN, D; ABBATE, M; SHANG, C; FREDERICKS, WJ; RAUSCHER, FJ; SUKHATME, VP; ERCOLANI, L			GROWTH OF LLC-PK1 RENAL-CELLS IS MEDIATED BY EGR-1 UP-REGULATION OF G-PROTEIN ALPHA-I-2 PROTOONCOGENE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; MULTICELLULAR DEVELOPMENT; SIGNAL TRANSDUCTION; GENE PROMOTER; SUBUNIT; IDENTIFICATION; DICTYOSTELIUM; PRODUCT; DIFFERENTIATION; LOCALIZATION	The early growth response zinc finger transcription factor (EGR-1) and the heterotrimeric guanine nucleotide binding protein encoded by the protooncogene G alpha i-2 each play pivotal roles in signaling pathways that control cell growth and differentiation. The G alpha i-2 gene 5'-flanking region contains a putative binding site (5'-CGCCCCCGC-3') for EGR-1 that may allow it to be a target gene for EGR-1 mitogenic signaling. We now demonstrate in LLC-PK1 renal cells the temporal expression of EGR-1 protein by immunoblotting and immunocytochemistry coincident with the maximal activation of the G alpha i-2 gene during cell growth. To determine whether G alpha i-2 or EGR-1 influence epithelial cell growth, LLC-PK1 cells were transiently transfected with plasmids encoding cDNAs for G alpha i-2 (pRSV G alpha i-2) or EGR-1 (pRSV EGR-1) driven by a viral Rous sarcoma promoter enhancer to overexpress each protein. Following transfection, cell growth was examined in media containing either 10 or 0.1% fetal bovine serum. Only cells transfected with plasmids encoding G alpha i-2 and EGR-1 had growth rates greater than that of serum replete cohorts. To assess whether EGR-1 was contributing to the transcriptional activation of the G alpha i-2 gene, cells were cotransfected with pRSV EGR-1 and plasmids encoding firefly luciferase reporter genes fused to 5'-flanking areas of the G alpha i-2 gene containing either the EGR-1 binding site or a mutated EGR-1 binding site (5'-AAAAACCGC-3'). A 320% enhancement of G alpha i-2 transcription was found only in LLC-PK1 cells following their transfection with plasmids that contained both the EGR-1 binding site and overexpressed EGR-1 protein. Utilizing mobility shift assays, which compared nuclear extracts from cells before and after cell polarization, a probe containing the EGR-1 motif detected induced nuclear protein complexes during transcriptional activation of the G alpha i-2 gene. An anti-EGR-1 antibody specifically retarded the mobility of the induced nuclear complexes, indicating that the EGR-1 protein was a component of these complexes. These data provide direct evidence for a novel mitogenic signaling pathway coupling proximal signaling events that activate EGR-1 gene expression to a target protooncogene G alpha i-2 that is participatory for growth and differentiation in renal cells.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,RENAL UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PEDIAT,PEDIAT PULM UNIT,BOSTON,MA 02114; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,RENAL UNIT,BOSTON,MA 02114	The Wistar Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Sukhatme, Vikas/W-2776-2019; Finder, Jonathan/AAB-2651-2021	Shang, Charles/0000-0003-4450-9557	NIDDK NIH HHS [F32 DK-08838, DK-02271, DK-42543] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008838, R01DK042543, K08DK002271] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1990, CRIT REV BIOCHEM MOL, V25, P225, DOI 10.3109/10409239009090610; BONVENTRE JV, 1991, CELL REGUL, V2, P251, DOI 10.1091/mbc.2.3.251; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HOLTZMAN EJ, 1991, J BIOL CHEM, V266, P1763; HOLTZMAN EJ, 1993, J BIOL CHEM, V268, P3964; KINANE TB, 1993, J BIOL CHEM, V268, P24669; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MOXHAM CM, 1992, SCIENCE, V258, P1373; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; OUELLETE AJ, 1990, J CLIN INVEST, V85, P755; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; WATKINS DC, 1993, SCIENCE, V260, P991	30	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27503	27509						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961665				2022-12-25	WOS:A1994PV77100055
J	MACMILLAN, DK; HILL, E; SALA, A; SIGAL, E; SHUMAN, T; HENSON, PM; MURPHY, RC				MACMILLAN, DK; HILL, E; SALA, A; SIGAL, E; SHUMAN, T; HENSON, PM; MURPHY, RC			EOSINOPHIL 15-LIPOXYGENASE IS A LEUKOTRIENE A(4) SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; POLYMORPHONUCLEAR LEUKOCYTES; MAMMALIAN LIPOXYGENASES; MEMBRANE ASSOCIATION; A4-SYNTHASE ACTIVITY; GAS-CHROMATOGRAPHY; 5-LIPOXYGENASE; CELLS; PURIFICATION; 12-LIPOXYGENASE	5-Lipoxygenase is the first committed enzyme in the leukotriene biosynthetic pathway and is known to catalyze not only the first oxygenation of arachidonate to form 5(S)-hydroperoxyeicosatetraenoic acid (5(S)-HPETE), but also dehydration of this intermediate into leukotriene A(4) (LTA(4)) by an activity termed leukotriene A(4) synthase. Inhibition of cytosolic B-lipoxygenase prepared from human blood granulocytes with zileuton (100 mu m) was virtually complete, but LTA(4) synthase activity was only inhibited by 47%. Structural characterization of eicosanoids synthesized in these preparations revealed an abundance of 15-lipoxygenase metabolites including 15-HETE when arachidonate was used as substrate and 5(S),15(S)-dihydroxy-6,8,11,13(E,E,Z,Z) satetraenoic acid when 5(S)-HPETE was used as substrate. When neutrophils were prepared that contained less than 1% eosinophil contamination, zileuton was found to almost completely inhibit all 5-lipoxygenase, as well as LTA(4) synthase products. Immunochemical analysis of the supernatants from purified neutrophils and eosinophils confirmed the previous observation that neutrophils do not express 15-lipoxygenase. Incubation of 5(S)-HPETE with recombinant mammalian 15-lipoxygenase resulted in the formation of B-trans-LTB(4) and 6-trans-12-epi-LTB(4) as LTA(4) products, as well as the 12 lipoxygenase product 5(S),12(S) diHPETE. The mechanism of action of 15-lipoxygenase acting as an LTA(4) synthase is proposed to involve removing the pro-R hydrogen atom at carbon-10 of 5(S)-HPETE, which is antarafacial to the hydroperoxy group to yield LTA(4).	NATL JEWISH CTR IMMUNOL & RESP MED, DENVER, CO 80206 USA; SYNTEX INC, DISCOVERY RES, PALO ALTO, CA 94303 USA	National Jewish Health; Syntex Corporation			Sala, Angelo/H-5478-2019; Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515; MacMillan, Denise/0000-0002-8424-6651; Sala, Angelo/0000-0001-9290-0257	NHLBI NIH HHS [HL34303] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALAZY M, 1986, ANAL CHEM, V58, P1098, DOI 10.1021/ac00297a026; BORGEAT P, 1988, PROSTAGLANDINS, V35, P723, DOI 10.1016/0090-6980(88)90145-1; BORGEAT P, 1979, J BIOL CHEM, V254, P2643; CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; HADA T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P89, DOI 10.1016/0005-2760(91)90128-5; HASLETT C, 1985, AM J PATHOL, V119, P101; HILL E, 1992, J BIOL CHEM, V267, P22048; HILL E, 1994, IN PRESS ADV PROSTAG; KUHN H, 1993, BIOCHIM BIOPHYS ACTA, V1169, P80, DOI 10.1016/0005-2760(93)90085-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAAS RL, 1982, J BIOL CHEM, V257, P7056; MCGUIRE J, 1985, J BIOL CHEM, V260, P8316; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MORITA E, 1990, SCAND J IMMUNOL, V32, P497, DOI 10.1111/j.1365-3083.1990.tb03190.x; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; MURPHY RC, 1992, TREATISE PULMONARY T, V1, P427; NADEL JA, 1991, J CLIN INVEST, V87, P1139, DOI 10.1172/JCI115110; RADMARK O, 1984, BIOCHIM BIOPHYS ACTA, V792, P324, DOI 10.1016/0005-2760(84)90200-5; REDDANNA P, 1990, METHOD ENZYMOL, V187, P268; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCOTT WA, 1982, J EXP MED, V155, P1148, DOI 10.1084/jem.155.4.1148; SHIMIZU T, 1986, P NATL ACAD SCI USA, V83, P4175, DOI 10.1073/pnas.83.12.4175; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V150, P376, DOI 10.1016/0006-291X(88)90531-1; SIGAL E, 1990, J BIOL CHEM, V265, P5113; SIGAL E, 1991, AM J PHYSIOL, V260, pL13, DOI 10.1152/ajplung.1991.260.2.L13; SIGAL E, 1988, J BIOL CHEM, V263, P5328; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SOK DE, 1983, BIOCHEM BIOPH RES CO, V110, P273, DOI 10.1016/0006-291X(83)91291-3; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; VANDERDONK EMM, 1992, BIOCHIM BIOPHYS ACTA, V1128, P14, DOI 10.1016/0005-2760(92)90252-Q; VANDERHOEK JY, 1984, J BIOL CHEM, V259, P6752; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; WALSTRA P, 1987, BIOCHEM BIOPH RES CO, V149, P258, DOI 10.1016/0006-291X(87)91633-0; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WISEMAN JS, 1987, BIOCHEMISTRY-US, V26, P5684, DOI 10.1021/bi00392a016; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	38	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26663	26668						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929400				2022-12-25	WOS:A1994PQ93100016
J	NORREGAARD, A; VILSEN, B; ANDERSEN, JP				NORREGAARD, A; VILSEN, B; ANDERSEN, JP			TRANSMEMBRANE SEGMENT M3 IS ESSENTIAL TO THAPSIGARGIN SENSITIVITY OF THE SARCOPLASMIC-RETICULUM CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CA2+ TRANSPORT ATPASE; FUNCTIONAL CONSEQUENCES; ALPHA-SUBUNIT; AMINO-ACIDS; CA-2+-ATPASE; INHIBITION; NA+,K+-ATPASE; PHOSPHORYLATION; MUTATIONS; DOMAIN	Five different chimeric fusion proteins between the sarcoplasmic reticulum Ca2+-ATPase and the rat kidney alpha 1 isoform of the Na+,K+-ATPase were expressed in COS-1 cells and analyzed functionally. In two chimeras, the only Na+,K+-ATPase-derived part consisted of the region corresponding to the third transmembrane segment. These proteins phosphorylated from ATP in the presence of a high Ca2+ concentration and from P-i in the absence of Ca2+, but the phosphorylation displayed strongly reduced sensitivity to inhibition by thapsigargin. In two other chimeras, the N-terminal two-thirds of the molecule were derived from Na+,K+-ATPase, except the region containing the fourth transmembrane segment. These proteins were unable to phosphorylate from ATP but phosphorylated from P-i, the latter reaction being insensitive to inhibition by thapsigargin. In the last chimera, the N-terminal two-thirds of the molecule were derived from Na+,K+-ATPase, except the region corresponding to both the third and the fourth transmembrane segments. This chimera phosphorylated from P-i in a reaction that was fully sensitive to inhibition by thapsigargin. It can be concluded that the third transmembrane segment is indispensable to thapsigargin sensitivity of the Ca2+-ATPase and most likely, therefore, constitutes a major binding region for thapsigargin.	AARHUS UNIV,INST PHYSIOL,DANISH BIOMEMBRANE RES CTR,DK-8000 AARHUS C,DENMARK	Aarhus University				Andersen, Jens Peter/0000-0003-0654-4300; Vilsen, Bente/0000-0002-4727-9382				ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; DEMEIS L, 1992, FEBS LETT, V299, P33, DOI 10.1016/0014-5793(92)80093-V; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; NORREGAARD A, 1993, FEBS LETT, V336, P248, DOI 10.1016/0014-5793(93)80813-A; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Witcome M., 1992, BIOCHEM J, V283, P525	22	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26598	26601						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929387				2022-12-25	WOS:A1994PQ93100003
J	KAWAMURA, K; WATANABE, K; SUZUKI, T; YAMAKAWA, T; KAMIYAMA, T; NAKAGAWA, H; TSURUFUJI, S				KAWAMURA, K; WATANABE, K; SUZUKI, T; YAMAKAWA, T; KAMIYAMA, T; NAKAGAWA, H; TSURUFUJI, S			CDNA CLONING AND EXPRESSION OF A NOVEL HUMAN DESMOCOLLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; TUMOR-NECROSIS-FACTOR; DESMOSOMAL CADHERINS; CYTOPLASMIC DOMAINS; HUMAN KERATINOCYTES; CHEMOTACTIC FACTOR; ACTIVATING FACTOR; MESSENGER-RNA; FAMILY; TYPE-1	We have cloned a human cDNA encoding for a novel transmembrane protein from a bladder carcinoma cell line (HT-1376) cDNA library. Sequence analysis of this clone revealed an open reading frame of 2,691 bases encoding a protein of 896 amino acids. Sequence comparison showed that this clone has significant homology to desmocollins, intercellular adhesion molecules belonging to the cadherin superfamily. This protein consists of a signal peptide of 30 amino acids, a precursor segment of 105 amino acids, and a mature protein of 761 amino acids. We expressed this cDNA clone in COS1 cells and found that the predicted cell adhesion molecule remained in the membrane fraction. Antibodies recognizing the predicted mature adhesion molecule of the protein stained antigens along the cell boundaries of both HT-1376 cells and normal human keratinocytes resembling the pattern of desmosome localization. These findings suggest that our clone might be a new member of the desmocollin family, and we have tentatively called this clone human desmocollin type 4.	INST CYTOSIGNAL RES INC,SHINAGAWA KU,TOKYO 140,JAPAN; TOYAMA MED & PHARMACEUT UNIV,FAC PHARMACEUT SCI,SUGITANI,TOYAMA 93001,JAPAN	University of Toyama								ANSEL J, 1990, J INVEST DERMATOL, V94, P101; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN SM, 1983, J BIOL CHEM, V258, P2621; COLDITZ I, 1989, AM J PATHOL, V134, P755; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; COWIN P, 1984, J CELL SCI, V70, P41; COWIN P, 1983, NATURE, V302, P148, DOI 10.1038/302148a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAWKRODGER DJ, 1987, J INVEST DERMATOL, V88, P3469; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; KAPLAN G, 1986, P NATL ACAD SCI USA, V83, P3469, DOI 10.1073/pnas.83.10.3469; KING IA, 1993, GENOMICS, V18, P185, DOI 10.1006/geno.1993.1453; KOCH PJ, 1992, P NATL ACAD SCI USA, V89, P353, DOI 10.1073/pnas.89.1.353; KUPPER TS, 1986, J EXP MED, V164, P2095, DOI 10.1084/jem.164.6.2095; MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; NICKOLOFF BJ, 1991, AM J PATHOL, V138, P129; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; PARKER AE, 1991, J BIOL CHEM, V266, P10438; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZ MA, 1990, ANNU REV CELL BIOL, V6, P461, DOI 10.1146/annurev.cb.06.110190.002333; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THEIS DG, 1993, INT J DEV BIOL, V37, P101; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; TURCK M, 1964, J CLIN INVEST, V41, P1760; WADA KN, 1990, NUCLEIC ACIDS RES, V18, P2367, DOI 10.1093/nar/18.suppl.2367; WATANABE K, 1987, BIOCHEM BIOPH RES CO, V149, P989, DOI 10.1016/0006-291X(87)90506-7; WATANABE K, 1989, J BIOL CHEM, V264, P19559; WATANABE K, 1991, EXP MOL PATHOL, V55, P30, DOI 10.1016/0014-4800(91)90016-Q; YOSHIDA C, 1982, CELL, V28, P217, DOI 10.1016/0092-8674(82)90339-7; YOSHIDANORO C, 1984, DEV BIOL, V101, P19, DOI 10.1016/0012-1606(84)90112-X	35	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26295	26302						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929347				2022-12-25	WOS:A1994PQ93000056
J	TSANEVA, IR; WEST, SC				TSANEVA, IR; WEST, SC			TARGETED VERSUS NON-TARGETED DNA HELICASE ACTIVITY OF THE RUVA AND RUVB PROTEINS OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; SYNTHETIC HOLLIDAY JUNCTIONS; BRANCH MIGRATION; FUNCTIONAL INTERACTIONS; GENETIC-RECOMBINATION; RECA PROTEIN; K-12 REVEALS; REPAIR; RESOLUTION; INVITRO	The RuvA and RuvB proteins of Escherichia coli promote the branch migration of Holliday junctions in vitro. To understand the relationship between branch migration and the intrinsic 5' --> 3' DNA helicase activity of RuvAB, the requirements and substrate specificity of the helicase reaction have been studied in more detail. We find that RuvAB-mediated DNA unwinding and branch migration reactions show similar requirements for Mg2+ and ATP and are inhibited to a similar extent by ADP and ATP gamma S (adenosine 5'-O-(3-thiotriphosphate)). The helicase activity, measured by the dissociation of a short fragment from circular single-stranded DNA, requires both RuvA and RuvB and is stimulated by subsaturating concentrations of single-strand binding protein (SSB). In contrast, saturating concentrations of SSB are inhibitory. Using substrates that contain a DNA junction, which permits the specific binding of RuvA, we find that the RuvA and RuvB proteins promote two types of helicase reactions: nonspecific reactions, which are sensitive to inhibition by stoichiometric amounts of SSB, and junction-targeted reactions, which are not inhibited by SSB. Using three-armed structures, we observe that junction-targeted reactions display a polarity and result in asymmetric product formation. Junction-specific binding and the subsequent initiation of DNA unwinding are Likely to represent early steps in the process of branch migration.	IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND					West, Stephen/0000-0001-8848-9418				BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; DUNDERDALE HJ, 1994, CURR OPIN GENET DEV, V4, P221, DOI 10.1016/S0959-437X(05)80048-6; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P250; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; RADDING CM, 1991, J BIOL CHEM, V266, P5355; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; WEST SC, 1981, NATURE, V290, P29, DOI 10.1038/290029a0; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P	43	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26552	26558						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929380				2022-12-25	WOS:A1994PQ93000093
J	CAZAUBON, SM; RAMOSMORALES, F; FISCHER, S; SCHWEIGHOFFER, F; STROSBERG, AD; COURAUD, PO				CAZAUBON, SM; RAMOSMORALES, F; FISCHER, S; SCHWEIGHOFFER, F; STROSBERG, AD; COURAUD, PO			ENDOTHELIN INDUCES TYROSINE PHOSPHORYLATION AND GRB2 ASSOCIATION OF SHC IN ASTROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P42/MITOGEN-ACTIVATED PROTEIN-KINASE; SIGNAL TRANSDUCTION; MAP KINASE; RAS; ACTIVATION; RAF-1; RECEPTORS; INTERACTS; PATHWAY; FAMILY	While the mitogen-activated protein kinase (MAPK) pathway coupled to receptor tyrosine kinases has been largely clarified, little is known about MAPK activation mediated by heterotrimeric G protein coupled receptors. In a previous study, it has been shown that endothelin-1 (ET-1) signaling through heterotrimeric G protein-coupled receptors stimulates MAPK activity in primary cultures of astrocytes (Cazaubon, S., Parker, P. J., Strosberg, A. D., and Couraud, P. O. (1993) Biochem. J. 293, 381-386). To clarify the molecular mechanism responsible for this response, involvement of the adapter proteins, Shc and Grb2, has now keen investigated. It is shown here that in these cells, ET-1 stimulates tyrosine phosphorylation of Shc, resulting in its stable association with Grb2 but not with Grb3-3, a Grb2 isoform with partially deleted SH2 domain. These results demonstrate that tyrosine-phosphorylated She specifically interacts with the SH2 domain of Grb2. This response was rapid and transient, showing a maximum at 10 min and declining at 60 min. Interestingly, direct activation of G proteins by fluoroaluminate mimics the ET-1 effect. In addition, a shift to a higher apparent molecular mass of Raf-1 kinase, likely reflecting its hyperphosphorylation, was also detected in ET-1-treated cells. These data strongly suggest that ET-1-induced MAPK activation is a G protein-coupled pathway that involves Shc, Grb2, and probably Raf-1. In conclusion, the Shc-Grb2 complex may be involved in the activation of the MAPK pathway, not only by several receptor tyrosine kinases but also by heterotrimeric G protein-coupled receptors, such as ET-1 receptors.	HOP COCHIN,ONCOL CELLULAIRE & MOLEC LAB,INSERM,U363,F-75014 PARIS,FRANCE; RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,VITRY ALFORVILLE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	CAZAUBON, SM (corresponding author), UNIV PARIS 07,INST COCHIN GENET MOLEC,IMMUNOPHARMACOL MOLEC LAB,CNRS,UPR 0415,22 RUE MECHAIN,F-75014 PARIS,FRANCE.		Ramos-Morales, Francisco/C-5734-2008	Ramos-Morales, Francisco/0000-0002-1151-4547				AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; COURAUD PO, 1991, EUR J PHARM-MOLEC PH, V206, P191, DOI 10.1016/S0922-4106(05)80018-5; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DURIEUTRAUTMANN O, 1993, J CELL PHYSIOL, V155, P104, DOI 10.1002/jcp.1041550114; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LADENHEIM RG, 1993, J NEUROCHEM, V60, P260, DOI 10.1111/j.1471-4159.1993.tb05846.x; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MARIN P, 1991, J NEUROCHEM, V56, P1270, DOI 10.1111/j.1471-4159.1991.tb11421.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WINITZ S, 1993, J BIOL CHEM, V268, P19196	34	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24805	24809						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929159				2022-12-25	WOS:A1994PQ49000046
J	FISCHER, I; SAPIRSTEIN, VS				FISCHER, I; SAPIRSTEIN, VS			MOLECULAR-CLONING OF PLASMOLIPIN - CHARACTERIZATION OF A NOVEL PROTEOLIPID RESTRICTED TO BRAIN AND KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; MESSENGER-RNA; RAT-BRAIN; NUCLEOTIDE-SEQUENCES; COATED VESICLES; LIPID BILAYERS; NERVOUS-SYSTEM; BASIC-PROTEIN; GENE FAMILY; EXPRESSION	Plasmolipin is an 18-kDa proteolipid protein found in kidney and brain, where it is restricted to the apical surface of tubular epithelial cells and to mammalian myelinated tracts, respectively (Sapirstein, V. S., Nolan, C. E., Stadler, I. I., and Fischer, I, (1992) J. Neurosci. Res. 31, 96-102; Cochary, E. F., Bizzozero, O. A., Sapirstein, V. S., Nolan, C. E., and Fischer, I. (1990) J. Neurochem. 55, 602-610). Addition of plasmolipin to lipid bilayers induces the formation of ion channels, which are voltage-dependent and K+-selective (Tosteson, M. T., and Sapirstein, V. S. (1981) J. Membr. Biol 63, 77-84). The present study describes the isolation and cloning of plasmolipin cDNA that includes the sequence of the complete coding region of the protein, the analysis of plasmolipin mRNA expression and a proposed model for its membrane structure. Northern blot analysis 1) shows that plasmolipin is encoded by a 1.7-kilobase mRNA, 2) confirms that the distribution of plasmolipin is restricted to kidney and brain, and 3) indicates that the expression of plasmolipin mRNA in cultured oligodendrocytes increases with cell maturation consistent with changes in the level of the protein. Restriction enzyme digestion of DNA followed by Southern blot analysis indicates that plasmolipin is encoded by a single gene. Sequence analysis of plasmolipin cDNA shows an open reading frame encoding a 157-amino acid protein of 17.4 kDa. The deduced amino acid sequence confirms the hydrophobic nature and high helical content of the protein and predicts a structure with four transmembrane domains similar to several other small hydrophobic proteins implicated in ion movement. The proposed model for membrane topology shows an enrichment of hydroxyl groups within two of the transmembrane domains and places cysteine residues near the extracellular membrane surface. Examination of protein sequence data bases reveals little overall homology with other proteins including proteolipids; however, three of the four transmembrane segments of plasmolipin show strong similarity with known membrane transport proteins. These results indicate that plasmolipin is an unique proteolipid protein that may participate in ion transport events specific to select membrane domains.	NATHAN S KLINE INST PSYCHIAT RES,DIV NEUROBIOL,ORANGEBURG,NY 10962; MED COLL PENN,DEPT ANAT & NEUROBIOL,PHILADELPHIA,PA 19129; NYU,DEPT PSYCHIAT,NEW YORK,NY 10016	Nathan Kline Institute for Psychiatric Research; Drexel University; New York University			Fischer, Itzhak/D-1080-2012	Fischer, Itzhak/0000-0003-3187-8740; Fischer, Ilene/0000-0003-1517-7143	NINDS NIH HHS [NS 24894] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024894] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997; ANDERSEN OS, 1992, PHYSIOL REV, V72, pS89, DOI 10.1152/physrev.1992.72.suppl_4.S89; ARAI H, 1987, J BIOL CHEM, V262, P11006; ASANO T, 1988, BIOCHEM BIOPH RES CO, V154, P1204, DOI 10.1016/0006-291X(88)90268-9; BIRMAN S, 1990, FEBS LETT, V261, P303, DOI 10.1016/0014-5793(90)80577-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COCHARY EF, 1990, J NEUROCHEM, V55, P602, DOI 10.1111/j.1471-4159.1990.tb04176.x; COCKLE SA, 1978, BIOCHEMISTRY-US, V17, P630, DOI 10.1021/bi00597a011; CRANDALL JE, 1989, J NEUROCHEM, V53, P1910, DOI 10.1111/j.1471-4159.1989.tb09261.x; DEFERRA F, 1985, CELL, V43, P721, DOI 10.1016/0092-8674(85)90245-4; DIEHL HJ, 1986, P NATL ACAD SCI USA, V83, P9807, DOI 10.1073/pnas.83.24.9807; EYTAN GD, 1977, J BIOL CHEM, V252, P3208; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FISCHER I, 1990, J NEUROSCI RES, V27, P112, DOI 10.1002/jnr.490270117; FISCHER I, 1991, J NEUROSCI RES, V28, P81, DOI 10.1002/jnr.490280108; FISCHER I, 1986, J NEUROCHEM, V47, P2132; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; FUJITA Y, 1986, J BIOL CHEM, V261, P3744; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HOSHINO T, 1990, J BACTERIOL, V172, P5531, DOI 10.1128/jb.172.10.5531-5539.1990; HUDSON LD, 1990, ANN NY ACAD SCI, V605, P155, DOI 10.1111/j.1749-6632.1990.tb42390.x; Innis M S, 1992, Biotechnology, V24, P6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI S, 1991, J BIOL CHEM, V266, P16078; LEES MB, 1979, BIOCHIM BIOPHYS ACTA, V559, P209, DOI 10.1016/0304-4157(79)90002-9; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MAZET JL, 1984, BIOPHYS J, V45, P263, DOI 10.1016/S0006-3495(84)84153-3; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RUSSELL L, 1991, DNA CELL BIOL, V10, P581, DOI 10.1089/dna.1991.10.581; SAFAEI R, 1989, J NEUROCHEM, V52, P1871, DOI 10.1111/j.1471-4159.1989.tb07270.x; SAFAEI R, 1989, J MOL NEUROSCI, V1, P189, DOI 10.1007/BF02918906; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SAPIRSTEIN VS, 1992, J NEUROSCI RES, V32, P593, DOI 10.1002/jnr.490320415; SAPIRSTEIN VS, 1983, BIOCHEMISTRY-US, V22, P3330, DOI 10.1021/bi00283a005; SAPIRSTEIN VS, 1993, J NEUROSCI RES, V35, P83, DOI 10.1002/jnr.490350110; SAPIRSTEIN VS, 1992, J NEUROSCI RES, V31, P96, DOI 10.1002/jnr.490310114; SAPIRSTEIN VS, 1994, J NEUROSCI RES, V37, P348, DOI 10.1002/jnr.490370307; SAPIRSTEIN VS, 1991, NEUROCHEM RES, V16, P123, DOI 10.1007/BF00965699; SAPIRSTEIN VS, 1992, J NEUROCHEM, V58, P1372, DOI 10.1111/j.1471-4159.1992.tb11352.x; SHIMOYAMA Y, 1989, J CELL BIOL, V109, P1787, DOI 10.1083/jcb.109.4.1787; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TINGBEALL HP, 1979, J MEMBRANE BIOL, V51, P33, DOI 10.1007/BF01869342; TOSTESON MT, 1981, J MEMBRANE BIOL, V63, P77, DOI 10.1007/BF01969448; WAWRZYNOW A, 1992, ARCH BIOCHEM BIOPHYS, V298, P620, DOI 10.1016/0003-9861(92)90457-8; YAN YM, 1993, NEURON, V11, P423, DOI 10.1016/0896-6273(93)90147-J	55	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24912	24919						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929173				2022-12-25	WOS:A1994PQ49000060
J	KIM, HH; SIERKE, SL; KOLAND, JG				KIM, HH; SIERKE, SL; KOLAND, JG			EPIDERMAL GROWTH FACTOR-DEPENDENT ASSOCIATION OF PHOSPHATIDYLINOSITOL 3-KINASE WITH THE ERBB3 GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; RECEPTOR TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; SH2 DOMAIN PROTEINS; EGF RECEPTOR; CATALYTIC SUBUNIT; HUMAN-BREAST; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; CARCINOMA-CELLS	The ErbB3 protein is a member of the ErbB subfamily of receptor protein tyrosine kinases. In the present study, the mechanism by which the ErbB3 protein is phosphorylated and the signal-transducing functions of this phosphorylated protein were investigated. When phosphorylated by the epidermal growth factor receptor in vitro, the ErbB3 protein strongly associated with the regulatory p85 subunit and the catalytic activity of phosphatidylinositol (PI) 3-kinase. The association of PI 3-kinase with ErbB3 in human breast cancer cells was found to be correlated with the constitutive phosphorylation of ErbB3 on tyrosine residues. In MDA-MB-468 breast cancer cells in which the ErbB3 protein is not constitutively phosphorylated, stimulation with epidermal growth factor led to the phosphorylation of ErbB3 on tyrosine residues and the formation of a functional signal transduction complex involving the ErbB3 protein and PI 3-kinase. These results suggest that the ErbB3 protein can be phosphorylated on tyrosine residues by a cross-phosphorylation mechanism and that the phosphorylated ErbB3 protein can couple other growth factor receptor protein tyrosine kinases to the PI 3-kinase pathway in a manner similar to the insulin receptor substrate 1 protein.	UNIV IOWA, COLL MED, DEPT PHARMACOL, IOWA CITY, IA 52242 USA	University of Iowa				Koland, John/0000-0002-5028-4297	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044684, P30DK025295, R29DK044684] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-25295, DK-44684] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; COCHET C, 1991, J BIOL CHEM, V266, P637; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; GULLICK WJ, 1990, INT J CANCER, P55; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1988, ONCOGENE, V3, P665; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAJKUMAR T, 1993, J PATHOL, V170, P271, DOI 10.1002/path.1711700309; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAINSBURY JRC, 1987, LANCET, V1, P1398; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SIERKE SL, 1993, BIOCHEMISTRY-US, V32, P10102, DOI 10.1021/bi00089a028; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	65	181	198	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24747	24755						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929151				2022-12-25	WOS:A1994PQ49000038
J	WU, RY; GILL, GN				WU, RY; GILL, GN			LIM DOMAIN RECOGNITION OF A TYROSINE-CONTAINING TIGHT TURN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; LIGAND-INDUCED INTERNALIZATION; INSULIN-RECEPTOR; JUXTAMEMBRANE REGION; PROTEIN; GENE; MOTIF; ENDOCYTOSIS; SEQUENCE; BINDING	Endocytosis of cell surface receptors requires sequence ''codes'' consisting of tight turn structures with an essential Tyr or Phe residue. To determine mechanisms through which cells recognize this information, we utilized exon 16 of the human insulin receptor in the two-hybrid system to isolate a novel 455-amino acid cytoplasmic protein that contains two LIM domains within its carboxyl terminus. Mutational analyses indicate that one of the Cys-rich Zn2+ binding LIM domains specifically recognizes active but not inactive endocytic codes contained in exon 16. These findings suggest that LIM domain structures in proteins provide molecular recognition of Tyr-containing tight turn structures.	UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, DIV ENDOCRINOL METAB 0650, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [P01 CA58689] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BERHANU P, 1991, MOL ENDOCRINOL, V5, P1827, DOI 10.1210/mend-5-12-1827; CADENA DL, 1994, J BIOL CHEM, V269, P260; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SCHIEST RH, 1986, CURR GENET, V16, P339; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; THIES RS, 1990, J BIOL CHEM, V265, P10132; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Welchman Gordon, 1982, HUT 6 STORY BREAKING; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	112	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25085	25090						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929196				2022-12-25	WOS:A1994PQ49000085
J	PIMENTELMUINOS, FX; MAZANA, J; FRESNO, M				PIMENTELMUINOS, FX; MAZANA, J; FRESNO, M			REGULATION OF INTERLEUKIN-2 RECEPTOR-ALPHA CHAIN EXPRESSION AND NUCLEAR FACTOR-CENTER-DOT-KAPPA-B ACTIVATION BY PROTEIN-KINASE-C IN T-LYMPHOCYTES - AUTOCRINE ROLE OF TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-2 RECEPTOR; GENE-EXPRESSION; CYCLOSPORINE-A; TRANSCRIPTION FACTORS; BINDING-PROTEINS; SIGNAL TRANSDUCTION; CELL ACTIVATION; ENHANCER; INDUCTION; REL	The regulation of interleukin-2 receptor alpha chain (IL-2R alpha) expression and nuclear factor (NF) activation by protein kinase C (PKC) in resting T cells, has been studied. Treatment of human resting T cells with phorbol esters strongly induced the expression of IL-2R alpha and the activation of NF.kappa B. This activation was due to the translocation of p65 and c-Rel NF.kappa B proteins from cytoplasmic stores to the nucleus, where they bound the kappa B sequence of the IL-2R alpha promoter either as p50.p65 or as p50.c-Rel heterodimers. Interestingly, all of those events were largely indirect and mediated by endogenously secreted tumor necrosis factor alpha (TNF alpha), as they were strongly inhibited by a neutralizing anti-TNF alpha monoclonal antibody. Furthermore, cyclosporin A, which blocked TNF alpha production induced by PKC, strongly inhibited IL-2R alpha and NF.kappa B activation. The addition of either TNF alpha or IL-2 partially recovered cyclosporin A-induced IL-2R alpha inhibition, but only TNF alpha completely recovered NF.kappa B activation. Those results indicate that, in resting T cells, PKC activation has only a triggering role, whereas the endogenously secreted TNF alpha plays an essential role in the quantitative control of the expression of IL-2R alpha chain or NF.kappa B activation.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			; Pimentel-Muinos, Felipe/K-4557-2014	Fresno Escudero, Manuel/0000-0002-9223-5477; Pimentel-Muinos, Felipe/0000-0002-0258-2855				Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ARIMA N, 1992, J IMMUNOL, V149, P83; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEPPER JM, 1985, P NATL ACAD SCI USA, V82, P4230, DOI 10.1073/pnas.82.12.4230; DEPPER JM, 1984, J IMMUNOL, V133, P3054; ENGLISH BK, 1991, J BIOL CHEM, V266, P7108; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FREIMUTH WW, 1989, J IMMUNOL, V143, P3064; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GOSH S, 1990, CELL, V62, P1019; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HEMAR A, 1990, EUR J IMMUNOL, V20, P2629, DOI 10.1002/eji.1830201216; HEMAR A, 1991, NEW BIOL, V3, P1097; HSIOUCHI L, 1993, CURR OPIN CELL BIOL, V5, P477; JAMIESON C, 1991, J IMMUNOL, V147, P416; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEE JC, 1987, J IMMUNOL, V139, P1935; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LIN BB, 1990, MOL CELL BIOL, V10, P850, DOI 10.1128/MCB.10.2.850; Lorre K, 1992, Eur Cytokine Netw, V3, P321; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MUNOZFERNANDEZ MA, 1990, EUR J IMMUNOL, V20, P605; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; REED JC, 1986, J IMMUNOL, V137, P150; ROMAN D, 1990, New Biologist, V2, P642; Sambrook J, 1989, MOL CLONING LABORATO; SCHEURICH P, 1987, J IMMUNOL, V138, P1786; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STEFFEN M, 1988, J IMMUNOL, V140, P2621; SUNG SSJ, 1988, J EXP MED, V167, P937, DOI 10.1084/jem.167.3.937; SZAMEL M, 1993, EUR J IMMUNOL, V23, P3072, DOI 10.1002/eji.1830231205; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WELTE K, 1984, J EXP MED, V160, P1690; WERNER C, 1977, TISSUE ANTIGENS, V9, P227; YOKOTA S, 1988, J IMMUNOL, V140, P531	59	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24424	24429						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929104				2022-12-25	WOS:A1994PQ34600089
J	THEVENOD, F; ANDERIE, I; SCHULZ, I				THEVENOD, F; ANDERIE, I; SCHULZ, I			MONOCLONAL-ANTIBODIES AGAINST MDR1 P-GLYCOPROTEIN INHIBIT CHLORIDE CONDUCTANCE AND LABEL A 65KDA PROTEIN IN PANCREATIC ZYMOGEN GRANULE MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNELS; CYSTIC-FIBROSIS GENE; RAT EXOCRINE PANCREAS; RESISTANT HUMAN-CELLS; PLASMA-MEMBRANE; ACINAR-CELLS; CHO-CELLS; TRANSPORT; LOCALIZATION; SECRETION	The regulation of Cl- and cation conductances by the nonhydrolyzabIe ATP analog adenosine 5'-(beta,gamma-methylene)triphosphate (AMP-PCP) was characterized in isolated zymogen granules (ZG) from pancreatic acinar cells. ZG were purified from rat pancreas homogenate by Percoll gradient centrifugation. Cl- conductance was assayed by suspending ZG in isotonic KCl buffer and measuring osmotic lysis induced by maximal permeabilization of ZG membranes (ZGM) for K+ with the K+ ionophore valinomycin (Val). This resulted in influx of K+ through the artificial pathway and of Cl- through endogenous channels. To measure cation conductances ZG (pH(i) approximate to 6) were suspended in pH 7 buffered isotonic monovalent cation acetate salts. The pH gradient was converted into an outside-directed H+ diffusion potential by maximally increasing H+ conductance of ZGM with the protonophore carbonyl cyanide p-chlorophenylhydrazone. Osmotic lysis of ZG was induced by H+ diffusion potential driven influx of monovalent cations through endogenous channels and non-ionic diffusion of the counterion acetate. In the absence of Val, ZG were stable in KCl buffer up to 2 h. AMP-PCP enhanced osmotic lysis approximate to 4-fold compared to control, due to activation of Cl- conductance by AMP-PCP and K+ influx through an AMP-PCP-insensitive nonselective cation pathway, which could be blocked by 0.1 mM Ba2+, 0.5 mM quinine, or 0.2 mM flufenamate. In addition, a K+ and Rb+ selective cation conductance was found which was completely blocked by 0.5 mM AMP-PCP or 0.5 mM quinine. AMP-PCP induced C1(-) conductance was strongly inhibited by two monoclonal antibodies against MDR1 P-glycoprotein (JSB-1 and 0219; 5-10 mu g/ml), but not by a monoclonal antibody against the cystic fibrosis transmembrane conductance regulator (M3A7; 5 mu g/ml) or by mouse IgG. The AMP-PCP insensitive nonselective cation conductance was not blocked by monoclonal antibodies against MDR1 P-glycoprotein (MDR1). Immunoblot studies of ZG membranes revealed the presence of a major immunoreactive protein band of approximate to 65 kDa with both monoclonal antibodies against MDR1, but no protein of the approximate size of MDR1 (approximate to 170 kDa) was detected. We propose that the C1(-) channel or a regulator of the channel, that is activated by the non-hydrolyzable ATP analog AMP-PCP in ZG membranes, is a member of the ATP binding cassette superfamily of transporters and may have homology to MDR1 P-glycoprotein.			THEVENOD, F (corresponding author), UNIV SAARLAND,FAC MED,DEPT PHYSIOL 2,D-66421 HOMBURG,GERMANY.							ALTENBERG GA, 1994, J BIOL CHEM, V269, P7145; ALTENBERG GA, 1994, CANCER RES, V54, P618; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEGAULT B, 1993, BIOCHIM BIOPHYS ACTA, V1152, P319, DOI 10.1016/0005-2736(93)90264-Z; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; DELISLE RC, 1986, AM J PHYSIOL, V250, pG489, DOI 10.1152/ajpgi.1986.250.4.G489; FINN AL, 1989, P NATL ACAD SCI USA, V86, P7649, DOI 10.1073/pnas.86.19.7649; FULLER CM, 1989, PFLUG ARCH EUR J PHY, V413, P385, DOI 10.1007/BF00584488; FULLER CM, 1989, PFLUG ARCH EUR J PHY, V415, P29, DOI 10.1007/BF00373138; GASSER KW, 1988, AM J PHYSIOL, V254, pG93, DOI 10.1152/ajpgi.1988.254.1.G93; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOGELEIN H, 1990, BIOCHIM BIOPHYS ACTA, V1027, P191, DOI 10.1016/0005-2736(90)90084-2; GOGELEIN H, 1990, FEBS LETT, V268, P79, DOI 10.1016/0014-5793(90)80977-Q; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRAY MA, 1990, BIOCHIM BIOPHYS ACTA, V1029, P33, DOI 10.1016/0005-2736(90)90433-O; Hille B., 1992, IONIC CHANNELS EXCIT, P130; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KAWAI K, 1994, BIOCHEM BIOPH RES CO, V198, P804, DOI 10.1006/bbrc.1994.1115; KIMURA T, 1985, AM J PHYSIOL, V250, pG698; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LING V, 1974, J CELL PHYSIOL, V83, P103, DOI 10.1002/jcp.1040830114; MARTY A, 1984, J PHYSIOL-LONDON, V357, P293, DOI 10.1113/jphysiol.1984.sp015501; MARUYAMA Y, 1983, NATURE, V302, P827, DOI 10.1038/302827a0; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RANDRIAMAMPITA C, 1988, PFLUG ARCH EUR J PHY, V411, P53, DOI 10.1007/BF00581646; RASOLA A, 1994, J BIOL CHEM, V269, P1432; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHEPER RJ, 1988, INT J CANCER, V42, P389, DOI 10.1002/ijc.2910420314; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THEVENOD F, 1992, ANAL BIOCHEM, V202, P54, DOI 10.1016/0003-2697(92)90205-L; THEVENOD F, 1990, BIOCHEM J, V272, P119, DOI 10.1042/bj2720119; THEVENOD F, 1992, J MEMBRANE BIOL, V129, P253; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LM, 1991, J GEN PHYSIOL, V98, P723, DOI 10.1085/jgp.98.4.723; VALVERDE MA, 1993, PFLUG ARCH EUR J PHY, V425, P552, DOI 10.1007/BF00374885; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WILLINGHAM MC, 1987, J HISTOCHEM CYTOCHEM, V35, P1451, DOI 10.1177/35.12.2890686	52	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24410	24417						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929102				2022-12-25	WOS:A1994PQ34600087
J	SIEBERT, A; LOTTSPEICH, F; NELSON, N; BETZ, H				SIEBERT, A; LOTTSPEICH, F; NELSON, N; BETZ, H			PURIFICATION OF THE SYNAPTIC VESICLE-BINDING PROTEIN PHYSOPHILIN - IDENTIFICATION AS 39-KDA SUBUNIT OF THE VACUOLAR H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON PUMP; ADENOSINE-TRIPHOSPHATASE; TRANSMITTER SECRETION; PRESYNAPTIC MEMBRANE; NERVE-TERMINALS; SYNAPTOPHYSIN; MEDIATOPHORE; RELEASE; ELECTROPHORESIS; IDENTIFICATION	Physophilin is a 36-kDa polypeptide originally identified in synaptic plasma membrane fractions, which binds to synaptic vesicles and has been implicated in vesicle docking and/or exocytosis during neurotransmitter release. Here we report on the purification, amino acid sequence analysis, and subcellular localization of physophilin. Physophilin was enriched from detergent extracts of crude synaptic plasma membranes by a combination of cation exchange and lentil-lectin chromatography. Sequence analysis of peptides generated after sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that physophilin is identical to the 39-kDa subunit (Ac39) of the vacuolar H+-ATPase. This was confirmed further by Western blot analysis with an Ac39-specific antiserum and by vesicle binding assays with recombinant Ac39 protein. Subcellular fractionation showed that Ac39 is enriched in synaptic vesicles, with lesser amounts being present in synaptic plasma membrane fractions. These results argue against a docking role of physophilin/Ac39 in synaptic vesicle exocytosis.	MAX PLANCK INST BRAIN RES,NEUROCHEM ABT,D-60528 FRANKFURT 71,GERMANY; MAX PLANCK INST BIOCHEM,BINDEGEWEBSFORSCH ABT,D-82152 MARTINSRIED,GERMANY; ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110	Max Planck Society; Max Planck Society								ADACHI I, 1990, J BIOL CHEM, V265, P967; ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ALDER J, 1992, NEURON, V9, P759, DOI 10.1016/0896-6273(92)90038-F; ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BIRMAN S, 1990, FEBS LETT, V261, P303, DOI 10.1016/0014-5793(90)80577-6; BROCHIER G, 1993, BIOL CELL, V78, P145, DOI 10.1016/0248-4900(93)90125-X; DERMIETZEL R, 1989, FEBS LETT, V253, P1, DOI 10.1016/0014-5793(89)80917-2; ECKERSKORN C, 1989, CHROMATOGRAPHIA, V28, P92, DOI 10.1007/BF02290390; FLOOR E, 1990, J NEUROCHEM, V55, P1663, DOI 10.1111/j.1471-4159.1990.tb04954.x; FORGAC M, 1992, J EXP BIOL, V172, P155; HEUSER JE, 1981, J CELL BIOL, V88, P564, DOI 10.1083/jcb.88.3.564; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; ISRAEL M, 1987, J NEUROCHEM, V49, P975, DOI 10.1111/j.1471-4159.1987.tb00989.x; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON E, 1986, ANAL BIOCHEM, V155, P243, DOI 10.1016/0003-2697(86)90432-X; LEITCH B, 1990, EXP CELL RES, V190, P218, DOI 10.1016/0014-4827(90)90189-H; LEROY C, 1992, EUR J NEUROSCI, V5, P1539; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON N, 1991, TRENDS PHARMACOL SCI, V12, P71, DOI 10.1016/0165-6147(91)90501-I; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NELSON N, 1993, J PHYSIOLOGY-PARIS, V87, P171, DOI 10.1016/0928-4257(93)90028-R; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; THOMAS L, 1990, J CELL BIOL, V111, P2041, DOI 10.1083/jcb.111.5.2041; WANG SY, 1988, J BIOL CHEM, V263, P17638; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; WOLF ME, 1989, J NEUROSCI, V9, P94; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XIE XS, 1986, J BIOL CHEM, V261, P2492	47	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28329	28334						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961771				2022-12-25	WOS:A1994PV77200083
J	WHITTERS, EA; MCGEE, TP; BANKAITIS, VA				WHITTERS, EA; MCGEE, TP; BANKAITIS, VA			PURIFICATION AND CHARACTERIZATION OF A LATE GOLGI COMPARTMENT FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; YEAST SECRETORY PATHWAY; MEMBRANE-PROTEIN; SUBCELLULAR ORGANIZATION; GUANOSINE DIPHOSPHATASE; KEX2 PROTEASE; GENE-PRODUCT; TRANSPORT; APPARATUS; COMPLEX	We have devised a method for obtaining highly enriched membranes of a late yeast Golgi compartment, operationally defined by their containing the Kex2p protease, and generated four hybridoma cell Lines that produced monoclonal antibodies directed against distinct Golgi membrane proteins (GMPs) (GMP(36), GMP(51), GMP(77), and GMP(95)). Immunofluorescence and subcellular fractionation data indicated that, of the four GMPs analyzed, only GMP(51) exhibited essentially an absolute colocalization with Kex2p. Also, as in the case of Kex2p, retention of GMP(51) in yeast Golgi membranes was dependent on clathrin function. In contrast, the remaining three GMPs exhibited substantial, but not absolute, colocalization with Kex2p. The collective data are most consistent with a model where GMP(36), GMP(77), and GMP(95) are present in all Kex2p-containing membranes, but Kex2p is present in only a subpopulation of membranes that contain these GMPs, thereby suggesting that either these particular GMPs exhibit overlapping distributions in compartments of the yeast Golgi complex or are also present in non-Golgi compartments. These findings are not consistent with the view that resident yeast Golgi proteins are generally restricted to a specific Golgi subcompartment, but they are consistent with the view that Golgi compartmental identity is determined by the relative mixtures of Golgi proteins that reside within individual cisternae.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham				McGee, Todd/0000-0002-3901-1001	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044530] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44530] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CUNNINGHAM KW, 1989, YEAST, V5, P25, DOI 10.1002/yea.320050105; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; Franzusoff A, 1992, Semin Cell Biol, V3, P309, DOI 10.1016/1043-4682(92)90018-Q; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HARLOW E, 1988, ANTIBODIES LAB MANUA, P121; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MONTELARO RC, 1987, ELECTROPHORESIS, V8, P432, DOI 10.1002/elps.1150080912; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PAYNE GS, 1989, SCIENCE, V245, P1358, DOI 10.1126/science.2675311; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P358; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROSE M, 1992, CELL, V57, P1211; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHEKMAN R, 1985, ANNU REV CELL BIOL, V1, P115, DOI 10.1146/annurev.cellbio.1.1.115; SEEGER M, 1992, J CELL BIOL, V118, P531, DOI 10.1083/jcb.118.3.531; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351	42	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28106	28117						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961747				2022-12-25	WOS:A1994PV77200052
J	AMATAYAKULCHANTLER, S; QIAN, SW; GAKENHEIMER, K; BOTTINGER, EP; ROBERTS, AB; SPORN, MB				AMATAYAKULCHANTLER, S; QIAN, SW; GAKENHEIMER, K; BOTTINGER, EP; ROBERTS, AB; SPORN, MB			[SER(77)] TRANSFORMING GROWTH-FACTOR-BETA-1 - SELECTIVE BIOLOGICAL-ACTIVITY AND RECEPTOR-BINDING IN MINK LUNG EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; II RECEPTOR; CRYSTAL-STRUCTURE; CLONING; KINASE; SUPERFAMILY; GROWTH-FACTOR-BETA-2; IDENTIFICATION; EXPRESSION; TGF-BETA-1	Transforming growth factor-beta 1 (TGF-beta 1) is a homodimeric protein stabilized by a single disulfide bridge between Cys(77) on the respective monomers and two paired complementary hydrophobic interfaces between the two subunits. A TGF-beta 1 mutant with Cys(77) replaced by serine has been expressed in stably transfected Chinese hamster ovary cells and purified to homogeneity. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis confirms that the sole interchain disulfide bond in TGF-beta 1 has been eliminated. It is 20% as potent as native TGF-beta 1 in the induction of plasminogen activator inhibitor-1 promoter expression in mink lung epithelial cells (Mv1Lu), although it is less than 1% as potent as native TGF-beta 1 in inhibition of growth in the same cell line. The mutant acts as a full agonist in both bioassays. [Ser(77)]TGF-beta 1 binds to soluble type II receptors and competes with native TGF-beta 1 in sandwich-enzyme-linked immunosorbent assays; however, in Mv1Lu cells, the mutant shows preferential cross-linking to type I rather than type II receptors. [Ser(77)]TGF-beta 1 is a useful tool for understanding the different ligand-receptor complexes and numerous biological activities of this multifunctional cytokine.			AMATAYAKULCHANTLER, S (corresponding author), NCI,CHEMOPREVENT LAB,BLDG 41,RM C-629,BETHESDA,MD 20892, USA.							ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1152, DOI 10.1021/bi00055a021; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DAOPIN S, 1992, SCIENCE, V255, P306; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HUSKENHINDI P, 1994, J BIOL CHEM, V269, P19380; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; KONDAIAH P, 1988, J BIOL CHEM, V263, P18313; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASON AJ, 1994, MOL ENDOCRINOL, V8, P325, DOI 10.1210/me.8.3.325; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; PARKS WP, 1976, CELL, V8, P87, DOI 10.1016/0092-8674(76)90189-6; QIAN SW, 1992, P NATL ACAD SCI USA, V89, P6290, DOI 10.1073/pnas.89.14.6290; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROBERTSON DM, 1992, ENDOCRINOLOGY, V130, P1680, DOI 10.1210/en.130.3.1680; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SPORN MB, 1990, CELL REGUL, V1, P875, DOI 10.1091/mbc.1.12.875; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	35	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27687	27691						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961688				2022-12-25	WOS:A1994PV77100082
J	HIRATSUKA, T				HIRATSUKA, T			NUCLEOTIDE-INDUCED CLOSURE OF THE ATP-BINDING POCKET IN MYOSIN SUBFRAGMENT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; ADENOSINE-TRIPHOSPHATASE; SPATIAL PROXIMITY; CROSS-LINKING; FLUORESCENCE; PROTEINS; DOMAINS; ACTIN; THIOL; SITE	The hydrophobic fluorescent dye 3-[4-(3-phenyl-2-pyrazolin-1-yl)benzene-1 sulfonylamido]phenylboronic acid (PPBA) stoichiometrically binds to myosin subfragment-1 (S-1) with a dissociation constant (K-d) of 26 mu M. Upon addition of nucleotides to the complex of S-1 with PPBA, the PPBA-binding site is converted to a more firm hydrophobic pocket accompanied by a large ffuorescence change. For the complex formed with ATP, binding of the dye is competitive with respect to ATP with a K-i of 0.8 mu M. This competition was confirmed by the result that the K-d value of S-1 with ATP was increased 3.3-fold by the addition of PPBA. The dye bound to S-1 senses ATP hydrolysis but has no effect on the binding of actin to S-1. Measurements of acrylamide fluorescence quenching of the complexes have revealed that the Stern-Volmer quenching constant of the dye is reduced by a factor of 2.7 during ATP hydrolysis. These results together with the fluorescent properties of the complexes suggest that the ATP-binding pocket of S-1 is closed and/or tightened during ATP hydrolysis.			HIRATSUKA, T (corresponding author), ASAHIKAWA MED COLL,DEPT CHEM,ASAHIKAWA,HOKKAIDO 078,JAPAN.							BRAND L, 1967, BIOCHEMISTRY-US, V6, P3510, DOI 10.1021/bi00863a024; CHANCE B, 1957, ARCH BIOCHEM BIOPHYS, V71, P130, DOI 10.1016/0003-9861(57)90015-2; CHAUSSEPIED P, 1986, P NATL ACAD SCI USA, V83, P2037, DOI 10.1073/pnas.83.7.2037; COLLINS JH, 1975, J BIOL CHEM, V250, P5915; DRYDEN DTF, 1992, EUR J BIOCHEM, V208, P115, DOI 10.1111/j.1432-1033.1992.tb17164.x; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EINARSSON R, 1974, EUR J BIOCHEM, V49, P41, DOI 10.1111/j.1432-1033.1974.tb03809.x; Fiske CH, 1925, J BIOL CHEM, V66, P375; GALLOP PM, 1982, SCIENCE, V217, P166, DOI 10.1126/science.6178158; HIRATSUKA T, 1986, BIOCHEMISTRY-US, V25, P2101, DOI 10.1021/bi00356a039; HIRATSUKA T, 1987, BIOCHEMISTRY-US, V26, P3168, DOI 10.1021/bi00385a034; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14949; HIRATSUKA T, 1988, BIOCHEMISTRY-US, V27, P4110, DOI 10.1021/bi00411a030; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18786; HUBER R, 1979, TRENDS BIOCHEM SCI, V4, P271, DOI 10.1016/0968-0004(79)90298-6; JANIN J, 1983, PROG BIOPHYS MOL BIO, V42, P21, DOI 10.1016/0079-6107(83)90003-2; KATO A, 1980, BIOCHIM BIOPHYS ACTA, V624, P13, DOI 10.1016/0005-2795(80)90220-2; LARSSONRAZNIKIEWICZ M, 1978, BIOCHIM BIOPHYS ACTA, V523, P94, DOI 10.1016/0005-2744(78)90012-8; LU RC, 1986, P NATL ACAD SCI USA, V83, P6392, DOI 10.1073/pnas.83.17.6392; MADSEN NB, 1983, BIOCHEMISTRY-US, V22, P4460, DOI 10.1021/bi00288a017; MUELLER H, 1962, BIOCHEM J, V85, P431, DOI 10.1042/bj0850431; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; PERRY SV, 1955, METHOD ENZYMOL, V2, P582, DOI 10.1016/S0076-6879(55)02258-1; PFISTER K, 1978, P NATL ACAD SCI USA, V75, P145, DOI 10.1073/pnas.75.1.145; PICOT D, 1991, EUR J BIOCHEM, V196, P329, DOI 10.1111/j.1432-1033.1991.tb15821.x; RAJASEKHARAN KN, 1989, J BIOL CHEM, V264, P10810; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REES MK, 1967, J BIOL CHEM, V242, P4449; REISLER E, 1974, BIOCHEMISTRY-US, V13, P3837, DOI 10.1021/bi00716a001; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STEITZ TA, 1982, CIBA F S, V93, P25; SUTOH K, 1988, BIOCHEMISTRY-US, V27, P2964, DOI 10.1021/bi00408a045; VARLEY PG, 1991, J MOL BIOL, V220, P531, DOI 10.1016/0022-2836(91)90028-5; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WELLS JA, 1982, METHOD ENZYMOL, V85, P93; WERBER MM, 1972, BIOCHEMISTRY-US, V11, P2872, DOI 10.1021/bi00765a021; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007	39	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27251	27257						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961633				2022-12-25	WOS:A1994PV77100018
J	SOLCA, FF; LURIE, DI; DILTZ, CD; JOHNSON, RS; KUMAR, S; RUBEL, EW; FISCHER, EH				SOLCA, FF; LURIE, DI; DILTZ, CD; JOHNSON, RS; KUMAR, S; RUBEL, EW; FISCHER, EH			IDENTIFICATION AND PURIFICATION OF A CHICKEN BRAIN NEUROGLIA-ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPSE-SPECIFIC PROTEIN; REACTIVE ASTROCYTES; TYROSINE-PHOSPHATASE; F1-20 PROTEIN; TAU-PROTEIN; EXPRESSION; CELLS; MICROGLIA; DISEASE; BINDING	The identification, purification, and biochemical characterization of specific markers for neuroglial cells in the central nervous system is an essential step toward a better understanding of the function of glial cells. This manuscript reports the identification and purification of a neuroglia-associated protein (NAP-185) with an apparent molecular mass of 185 kDa. While its expression is not restricted to the brain, it was first identified in a specific subpopulation of glial cells when chick brain stem sections were analyzed with an affinity-purified rabbit antiserum raised against the catalytic domain of the T-cell protein tyrosine phosphatase. This 185-kDa antigen was purified to apparent homogeneity and confirmed to be responsible for the neuroglial staining observed. In spite of its immunological relation to T-cell protein tyrosine phosphatase, purified NAP-185 failed to display tyrosine phosphatase activity. The primary sequence of five NAP-185-derived peptides shows that this protein has not yet been characterized and that it is possibly related to AP180, a clathrin-associated protein.	UNIV WASHINGTON,VIRGINIA MERRILL BLOEDEL HEARING RES CTR,DEPT OTOLARYNGOL HEAD & NECK SURG,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	SOLCA, FF (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195, USA.			Lurie, Diana/0000-0002-4486-4869	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07902] Funding Source: Medline; NIGMS NIH HHS [GM42508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS PC, 1987, ANAL BIOCHEM, V161, P524, DOI 10.1016/0003-2697(87)90484-2; ANNAERT WG, 1993, J NEUROCHEM, V60, P1746, DOI 10.1111/j.1471-4159.1993.tb13399.x; [Anonymous], [No title captured]; BARK IC, 1994, P NATL ACAD SCI USA, V91, P4621, DOI 10.1073/pnas.91.11.4621; BARRES BA, 1991, J NEUROSCI, V11, P3685; BLACK JA, 1988, GLIA, V1, P169, DOI 10.1002/glia.440010302; BORN DE, 1985, J COMP NEUROL, V231, P435, DOI 10.1002/cne.902310403; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CANCILLA PA, 1993, ASTROCYTES PHARM FUN, P383; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; GARD AL, 1993, ASTROCYTES PHARM FUN, P331; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; KAWAJA MD, 1991, NEURON, V7, P1019, DOI 10.1016/0896-6273(91)90346-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LOWE J, 1989, J PATHOL, V159, P143, DOI 10.1002/path.1711590209; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; LURIE DI, 1994, J COMP NEUROL, V346, P276, DOI 10.1002/cne.903460207; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; MYERS KJ, 1993, J IMMUNOL, V151, P2252; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PEARCE B, 1993, ASTROCYTES PHARM FUN, P47; Prochiantz A, 1988, Ann N Y Acad Sci, V540, P52, DOI 10.1111/j.1749-6632.1988.tb27051.x; ROTT O, 1993, J IMMUNOL, V150, P87; SHIGEMATSU K, 1992, J NEUROSCI RES, V31, P443, DOI 10.1002/jnr.490310306; SOUSA R, 1992, J NEUROSCI, V12, P2130; THOMASREETZ AC, 1994, FASEB J, V8, P209, DOI 10.1096/fasebj.8.2.7907072; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022; ZHOU SB, 1992, J NEUROSCI, V12, P2144	35	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27559	27565						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961672				2022-12-25	WOS:A1994PV77100063
J	ALBAGLI, O; SOUDANT, N; FERREIRA, E; DHORDAIN, P; DEWITTE, F; BEGUE, A; FLOURENS, A; STEHELIN, D; LEPRINCE, D				ALBAGLI, O; SOUDANT, N; FERREIRA, E; DHORDAIN, P; DEWITTE, F; BEGUE, A; FLOURENS, A; STEHELIN, D; LEPRINCE, D			A MODEL FOR GENE EVOLUTION OF THE ETS-1 ETS-2 TRANSCRIPTION FACTORS BASED ON STRUCTURAL AND FUNCTIONAL HOMOLOGIES	ONCOGENE			English	Article							PU.1 REGULATES EXPRESSION; ETS PROTO-ONCOGENE; DNA-BINDING; ACTIVATION DOMAINS; V-ETS; C-ETS-1 LOCUS; PROTEINS; FAMILY; PROMOTER; CELLS	The chicken c-ets-l locus encodes two transcription factors, p54(c-ets-1) and p68(c-ets-1) that differ in their N-termini, encoded respectively by the I-54 and alpha beta exons. p68(c-ets-1) equivalents are only found in birds and reptiles while p54(c-ets-1) is widely conserved in vertebrates, from amphibians to mammals. Thus, the classical view concerning the evolution of the c-ets-1 gene has been to consider that I-54 is of ancient origin whereas alpha and beta, which provide an additional activating domain in p68(c-ets-1), would have been acquired much more recently. Sequencing the alpha and beta exons in various species pinpointed a highly conserved region of 13 amino acids which is rich in acidic and hydrophobic residues, a feature of some other transactivating domains. Strikingly, this subdomain is also present in the otherwise unrelated N-terminal activating region of p58(c-ets-2) and was thus named BEC for Ets-1-Beta/Ets-2-Conserved sequence. Moreover, the two N-termini share the BEC sequence at a homologous position in their highly similar genomic organization indicating a common origin. This structural homology underlies a functional similarity since fusion of the heterologous GAL4 DNA-binding domain with either of the two isolated domains demonstrates that BEC is essential in both cases for the transactivating activity. The function of the alpha beta domain in the context of p68(c-ets-1) also strictly depends on the presence of the BEC sequence. Finally, the whole N-terminus of p58(c-ets-2) can functionally substitute for its counterpart in p68(c-ets-1) further demonstrating that p68(c-ets-1) and p58(c-ets-2) are structurally and functionally more closely related than previously thought. Besides, we also found BEC in the N-terminus of the Drosophila pointed gene which may be considered as closely related to the uncommitted 'ets1/2' common ancestor. These data demonstrate that the alpha and beta exons are not a recent and specific acquisition but stem, like the p58(c-ets-2) N-terminus, from the invertebrate unduplicated 'ets 1/2' gene. This work unravels a new model for the ets-1/ets-2 gene's evolution, based for the first time on both structural and functional evidences. Accordingly, p68(c-ets-1) and p58(c-ets-2) are the direct descendants of the ancestral 'ets1/2' gene whereas I-54 may have been acquired as a second promoter in the c-ets-1 gene after the duplication. Indeed, I-54 is not found in the Drosophila pointed gene. The high degree of similarity, and hence of functional redundancy, between p68(c-ets-1) and p58(c-ets-2) may have led to the rapid divergence (and even loss in mammals) of alpha and beta during evolution whereas I-54, which provided a novel function unique to c-ets-1, was maintained within the presently widespread p54(c-ets-1) version.	INST PASTEUR,CNRS,URA 1160,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Leprince, Dominique/0000-0002-1999-0775				ALBAGLI O, 1992, ONCOGENE, V7, P1435; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; COFFER P, 1994, ONCOGENE, V9, P911; Crepieux Pascale, 1993, Gene Expression, V3, P215; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GEGONNE A, 1992, NEW BIOL, V4, P512; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOPP TP, 1983, MOL IMMUNOL, V20, P483, DOI 10.1016/0161-5890(83)90029-9; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JAWORSKI CJ, 1989, NATURE, V337, P752, DOI 10.1038/337752a0; JENNINGS CGB, 1992, DEV BIOL, V150, P121, DOI 10.1016/0012-1606(92)90012-6; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAGET MP, 1993, NUCLEIC ACIDS RES, V21, P5987, DOI 10.1093/nar/21.25.5987; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LI X, 1993, NATURE, V367, P83; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAHL HL, 1993, J BIOL CHEM, V268, P5014; QUEVA C, 1993, ONCOGENE, V8, P2511; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RAO VN, 1993, ONCOGENE, V8, P2167; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VENKATESH LK, 1993, J VIROL, V67, P3868, DOI 10.1128/JVI.67.7.3868-3876.1993; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1990, ONCOGENE, V5, P1521; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WOLFF CM, 1991, CELL GROWTH DIFFER, V2, P447; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	59	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3259	3271						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936650				2022-12-25	WOS:A1994PM65800019
J	STEINMAN, RA; HOFFMAN, B; IRO, A; GUILLOUF, C; LIEBERMANN, DA; ELHOUSEINI, ME				STEINMAN, RA; HOFFMAN, B; IRO, A; GUILLOUF, C; LIEBERMANN, DA; ELHOUSEINI, ME			INDUCTION OF P21 (WAF-1/CIP1) DURING DIFFERENTIATION	ONCOGENE			English	Article							LEUKEMIA-CELL LINE; SUSCEPTIBILITY GENE-PRODUCT; TUMOR-SUPPRESSOR GENE; C-MYC; TERMINAL DIFFERENTIATION; SODIUM-BUTYRATE; DOWN-REGULATION; HL-60 CELLS; P53 PROTEIN; EXPRESSION	The recently cloned protein, p21 (WAF1/CIP1) is a downstream effector of p53, and mediates growth arrest by inhibiting the action of G1 cyclin-dependent kinases. Since cellular differentiation is frequently characterized by G1 arrest, we examined whether p21 upregulation occurs in differentiation. We show that p21 expression is triggered by multiple differentiation-inducing agents in hematopoietic and hepatoma cells through a p53-independent pathway. The dramatic rise in p21 levels occurs as an immediate early response to differentiation inducers. The induction of p21 is coupled to the expression of early differentiation markers, and is uncoupled from apoptosis. Finally, evidence is presented that p21 expression is uncoupled from G1 arrest in the presence of deregulated c-myc.	UNIV PITTSBURGH,SCH MED,PITTSBURGH CANC INST,PITTSBURGH,PA 15213; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	STEINMAN, RA (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT MED,PITTSBURGH,PA 15213, USA.			El-Houseini, Motawa/0000-0003-4873-8429	NATIONAL CANCER INSTITUTE [R01CA051162, R01CA043618] Funding Source: NIH RePORTER; NCI NIH HHS [IRO1CA51162, IRO1CA43618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTOUN GR, 1991, LEUKEMIA RES, V15, P1029, DOI 10.1016/0145-2126(91)90108-6; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHANG KS, 1991, LEUKEMIA, V5, P205; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; DANOVA M, 1990, LEUKEMIA RES, V14, P417, DOI 10.1016/0145-2126(90)90027-7; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDIERY WS, 1993, CELL, V75, P817; ELDIERY WS, 1994, CANCER RES, V54, P1169; FISCHKOFF SA, 1990, LEUKEMIA, V4, P302; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HARPER JW, 1993, CELL, V75, P805; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; KITAGAWA M, 1993, ONCOGENE, V8, P2425; KIYOKAWA H, 1993, P NATL ACAD SCI USA, V90, P6746, DOI 10.1073/pnas.90.14.6746; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MEIER RW, 1991, BIOCHEM BIOPH RES CO, V176, P1345, DOI 10.1016/0006-291X(91)90434-9; MICHIELI P, 1994, CANCER RES, V54, P3391; MOLLINEDO F, 1993, BIOCHEM J, V294, P137, DOI 10.1042/bj2940137; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NEVINS JR, 1992, SCIENCE, V258, P424; OBERG F, 1993, J IMMUNOL, V150, P3487; OBERG F, 1991, P NATL ACAD SCI USA, V88, P5567, DOI 10.1073/pnas.88.13.5567; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; SAITO H, 1991, INT J CANCER, V48, P291, DOI 10.1002/ijc.2910480223; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SEN S, 1993, LEUKEMIA RES, V17, P639, DOI 10.1016/0145-2126(93)90068-V; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SILVENNOINEN O, 1990, BIOCHEM BIOPH RES CO, V168, P959, DOI 10.1016/0006-291X(90)91122-9; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; STEINMAN RA, 1994, BLOOD, V83, P119; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TKATCH LS, 1994, UNPUB J LEUK BIOL; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEN A, 1992, P SOC EXP BIOL MED, V199, P291; YEN A, 1992, EUR J CELL BIOL, V57, P210; YEN A, 1993, CANCER RES, V53, P3085	49	611	619	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3389	3396						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936667				2022-12-25	WOS:A1994PM65800036
J	ZHENG, DQ; VAYSSIERE, JL; PETIT, PX; LECOEUR, H; SPATZ, A; MIGNOTTE, B; FEUNTEUN, J				ZHENG, DQ; VAYSSIERE, JL; PETIT, PX; LECOEUR, H; SPATZ, A; MIGNOTTE, B; FEUNTEUN, J			APOPTOSIS IS ANTAGONIZED BY LARGE T-ANTIGENS IN THE PATHWAY TO IMMORTALIZATION BY POLYOMAVIRUSES	ONCOGENE			English	Article							WILD-TYPE P53; CELL-CYCLE CONTROL; SIMIAN VIRUS-40; EMBRYO FIBROBLASTS; HAMSTER POLYOMAVIRUS; THYMOCYTE APOPTOSIS; GROWTH ARREST; PROTEIN; TRANSFORMATION; BINDING	The viability of rat embryo cells immortalized by thermosensitive mutants of SV40 or polyoma Large T antigen is impaired at the non-permissive temperature thus demonstrating that the immortal phenotype is dominantly maintained by Large T antigens. We have observed that exposing these cells to the restrictive temperature not only induces growth arrest but also causes apoptotic cell death. We present evidence supporting the model that polyomaviruses may indeed establish immortality by antagonizing the lethal effects of tumor suppressor genes via physical interactions between their products and Large T antigens. In the case of SV40-immortalized cells REtsAF, shift-up to 39.5 degrees C dissociates Large T antigen/p53 complexes releasing wild-type p53 molecules capable of inducing apoptotic cell death. In polyomavirus-immortalized cells, apoptosis may result from an alternative pathway mediated by other unidentified negatively acting molecules.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE; INST PASTEUR,UNITE ONCOL VIRALE,F-75015 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			SPATZ, ALAN/B-8645-2009; Feunteun, Jean/AAZ-1267-2020; Petit, Patrice X./A-3692-2009; Petit, patrice/AAF-6774-2020; PETIT, Patrice/A-4453-2008; Mignotte, Bernard/A-3499-2009	SPATZ, ALAN/0000-0003-3020-1420; Petit, Patrice X./0000-0002-5038-9101; Mignotte, Bernard/0000-0002-8512-8518; Feunteun, Jean/0000-0003-1212-9189				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOUTEBROZE L, 1993, ONCOGENE, V8, P685; GOUTEBROZE L, 1992, J VIROL, V66, P2495, DOI 10.1128/JVI.66.4.2495-2504.1992; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JONKER RR, 1993, NATO ASI SERIES H, V67, P355; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEREM BS, 1983, NATURE, V304, P88, DOI 10.1038/304088a0; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUHAR SG, 1991, ONCOGENE, V6, P1499; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MIGNOTTE B, 1990, ONCOGENE, V5, P1529; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1985, EMBO J, V4, P2941, DOI 10.1002/j.1460-2075.1985.tb04027.x; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STRANGE R, 1992, DEVELOPMENT, V115, P49; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAYSSOERE JL, 1994, UNPUB COMMITMENT APO; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANAI N, 1994, EXP CELL RES, V211, P296, DOI 10.1006/excr.1994.1090; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHU J, 1981, J VIROL, V65, P6872; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	44	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3345	3351						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936660				2022-12-25	WOS:A1994PM65800029
J	CASTELEIN, H; GULICK, T; DECLERCQ, PE; MANNAERTS, GP; MOORE, DD; BAES, MI				CASTELEIN, H; GULICK, T; DECLERCQ, PE; MANNAERTS, GP; MOORE, DD; BAES, MI			THE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR REGULATES MALIC ENZYME GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; BETA-OXIDATION PATHWAY; A-I GENE; THYROID-HORMONE; RESPONSE ELEMENT; FATTY-ACIDS; CLOFIBRIC ACID; RXR-ALPHA; SUPERFAMILY; RAT	A new regulatory element for peroxisome proliferator activated receptor (PPAR)/retinoid X receptor (RXR) heterodimers was found in the promoter of the melic enzyme gene. Similar to previously characterized peroxisome proliferator response elements (PPREs), it consists of a direct repeat of sequences related to the half-site consensus AGGTCA with an interspacing of 1 base pair. Specific binding of PPAR/RXR heterodimers to this element was demonstrated. Furthermore, this sequence conferred ciprofibrate responsiveness of a reporter through the homologous malic enzyme or heterologous thymidine kinase promoters. This PPRE presumably mediates the transcriptional effects of peroxisome proliferators on malic enzyme expression. The presence of a PPRE in the promoter of this lipogenic enzyme suggests a broader function for the PPAR in the regulation of lipid metabolism.	CATHOLIC UNIV LEUVEN,FAC PHARMACEUT SCI,CLIN CHEM LAB,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,FAC MED,PHARMACOL LAB,B-3000 LOUVAIN,BELGIUM; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114	KU Leuven; KU Leuven; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Baes, Myriam/0000-0002-2525-2269				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BRENT GA, 1989, J BIOL CHEM, V264, P178; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASTELEIN H, 1993, FEBS LETT, V332, P24, DOI 10.1016/0014-5793(93)80474-9; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HAWKINS JM, 1987, DRUG METAB REV, V18, P441, DOI 10.3109/03602538708994130; HERTZ R, 1991, BIOCHEM J, V274, P745, DOI 10.1042/bj2740745; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	39	145	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26754	26758						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929410				2022-12-25	WOS:A1994PQ93100029
J	SCHLICHTING, I; YANG, XJ; MILES, EW; KIM, AY; ANDERSON, KS				SCHLICHTING, I; YANG, XJ; MILES, EW; KIM, AY; ANDERSON, KS			STRUCTURAL AND KINETIC-ANALYSIS OF A CHANNEL-IMPAIRED MUTANT OF TRYPTOPHAN SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SALMONELLA-TYPHIMURIUM; MECHANISM	Substrate channeling is a process by which two sequential enzymes interact to transfer a metabolite (or intermediate) from one enzyme active site to the next without allowing free diffusion of the metabolite. Channeling is thought to play an important role in metabolic regulation and cellular modulation of enzymatic activities. Although there are numerous examples of sequential enzyme pairs in glycolysis and other biosynthetic pathways that are thought to exhibit channeling, this is as yet controversial. Tryptophan synthase is considered the best example for an enzyme displaying channeling behavior between subunits. Tryptophan synthase is an alpha(2) beta(2) tetrameric enzyme complex, which catalyzes the last two steps in the biosynthesis of L-tryptophan. The alpha subunit catalyzes the cleavage of indole-3-glycerol phosphate to indole and glyceraldehyde-3-phosphate; the beta subunit catalyzes the condensation of indole with serine to form tryptophan, in a reaction mediated by pyridoxal phosphate. The inability to trap free indole in the steady-state reaction and analysis of the kinetics of single turnover reactions have led to the postulate that indole may pass directly from the alpha to the beta site without diffusion through solution (Demoss, J. A. (1962) Biochim. Biophys. Acta 62, 279-293; Matchett, W. M. (1974) J. Biol. Chem. 249, 4041-4049). The crystal structure of tryptophan synthase from Salmonella typhimurium has provided additional support for substrate channeling by elucidating a 25-Angstrom hydrophobic tunnel connecting the two catalytic sites (Hyde, C. C., Ahmed, S. A., Padlan, E. A., Miles, E. W., and Davies, D. R. (1988) J. Biol. Chem. 263, 17857-17871). The structure suggests that mutation of a residue lining the tunnel to a more bulky residue might impede or block the passage of indole during catalysis thus enabling detection of indole during a single enzyme turnover. A mutant of tryptophan synthase has been prepared in which one of the residues lining the tunnel, beta Cys-170, has been replaced with a bulkier tryptophan residue. Kinetic and structural analyses of the beta C170W mutant by rapid chemical quench methods and x-ray crystallographic analysis show both the transient formation of indole and the obstruction of the tunnel, thus providing direct evidence for the substrate channeling mechanism.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; MAX PLANCK INST MED RES,BIOPHYS ABT,D-69120 HEIDELBERG,GERMANY; NIH,BETHESDA,MD 20892	Yale University; Max Planck Society; National Institutes of Health (NIH) - USA			Schlichting, Ilme/I-1339-2013		NIGMS NIH HHS [GM45343] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045343] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED SA, 1985, J BIOL CHEM, V260, P3716; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; DEMOSS JA, 1962, BIOCHIM BIOPHYS ACTA, V62, P279, DOI 10.1016/0006-3002(62)90041-0; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; MATCHETT WH, 1974, J BIOL CHEM, V249, P4041; YANOFSKY C, 1958, BIOCHIM BIOPHYS ACTA, V28, P640, DOI 10.1016/0006-3002(58)90533-X	11	28	28	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26591	26593						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929385				2022-12-25	WOS:A1994PQ93100001
J	BETTS, L; SPREMULLI, LL				BETTS, L; SPREMULLI, LL			ANALYSIS OF THE ROLE OF THE SHINE-DALGARNO SEQUENCE AND MESSENGER-RNA SECONDARY STRUCTURE ON THE EFFICIENCY OF TRANSLATIONAL INITIATION IN THE EUGLENA-GRACILIS CHLOROPLAST ATPH MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; PROTEIN-SYNTHESIS INVITRO; RIBOSOME-BINDING-SITE; MESSENGER-RNA; ESCHERICHIA-COLI; PHENOTYPIC SELECTION; MICROCOCCUS-LUTEUS; SYNTHASE SUBUNITS; BACILLUS-SUBTILIS; RECOGNITION	Chloroplast mRNAs in Euglena gracilis fall into two classes. One class has a Shine-Dalgarno sequence 5' to the AUG start codon while the other group of mRNAs does not have any conserved sequence elements near the start codon. The chloroplast mRNA encoding the atpH gene has been selected as an example of a message which has a Shine-Dalgarno sequence (GGAGUU) located in the initiation region. Mutations in the Shine-Dalgarno sequence result in 2-5-fold reductions in the efficiency of the message in initiation complex formation depending on the precise mutation. Secondary structure mapping of the initiation region of the atpH mRNA suggests that a number of mRNA conformations are present in an equilibrium mixture. Mutations in the Shine-Dalgarno sequence had little effect on the overall structure of the mRNA Directed mutations which place the Shine-Dalgarno sequence into a region of higher secondary structure drastically reduce the activity of the message. The monocistronic form of the atpH mRNA has a 5'-untranslated leader region slightly over 70 nucleotides in length. Deletions in the leader suggest that a minimum length of 10 bases 5' to the start codon is important for activity in initiation. The presence of the full leader increased efficiency in initiation about 2-fold compared to messages with leaders 25-40 residues in length.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024963] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24963] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONHAMSMITH PC, 1989, NUCLEIC ACIDS RES, V17, P2057, DOI 10.1093/nar/17.5.2057; BONI IV, 1991, NUCLEIC ACIDS RES, V19, P155, DOI 10.1093/nar/19.1.155; BORISOVA GP, 1979, NUCLEIC ACIDS RES, V6, P1761, DOI 10.1093/nar/6.5.1761; COX GB, 1987, J BACTERIOL, V169, P2945, DOI 10.1128/jb.169.7.2945-2949.1987; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; DESMIT MH, 1994, J MOL BIOL, V235, P173, DOI 10.1016/S0022-2836(05)80024-5; DRAGER R, 1993, THESIS U ARIZONA; DRAGER RG, 1993, CURR GENET, V23, P271, DOI 10.1007/BF00351506; FARWELL MA, 1991, J BACTERIOL, V173, P3514, DOI 10.1128/jb.173.11.3514-3522.1991; FARWELL MA, 1992, MOL MICROBIOL, V6, P3375, DOI 10.1111/j.1365-2958.1992.tb02205.x; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRAVES MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P192, DOI 10.1016/0003-9861(83)90516-7; GREN EJ, 1984, BIOCHIMIE, V66, P1, DOI 10.1016/0300-9084(84)90188-3; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; KOO JS, 1994, J BIOL CHEM, V269, P7501; KOO JS, 1994, J BIOL CHEM, V269, P7494; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LOOMAN AC, 1986, NUCLEIC ACIDS RES, V14, P5481, DOI 10.1093/nar/14.13.5481; LOWMAN HB, 1986, J BIOL CHEM, V261, P5396; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x; RUF M, 1988, FEBS LETT, V240, P41, DOI 10.1016/0014-5793(88)80336-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ VP, 1990, J MOL BIOL, V211, P427, DOI 10.1016/0022-2836(90)90363-Q; SHELNESS GS, 1985, J BIOL CHEM, V260, P8637; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; STEEGE DA, 1982, J BIOL CHEM, V257, P430; STEITZ JA, 1969, NATURE, V224, P957, DOI 10.1038/224957a0; SUTTLE DP, 1973, BIOCHEM BIOPH RES CO, V51, P376, DOI 10.1016/0006-291X(73)91268-0; VELLANOWETH RL, 1992, MOL MICROBIOL, V6, P1105, DOI 10.1111/j.1365-2958.1992.tb01548.x; WANG CC, 1989, NUCLEIC ACIDS RES, V17, P9735, DOI 10.1093/nar/17.23.9735; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	38	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26456	26463						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929367				2022-12-25	WOS:A1994PQ93000079
J	NOLAN, DP; REVELARD, P; PAYS, E				NOLAN, DP; REVELARD, P; PAYS, E			OVEREXPRESSION AND CHARACTERIZATION OF A GENE FOR A CA2+-ATPASE OF THE ENDOPLASMIC-RETICULUM IN TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; MEMBRANE CA-2+-TRANSPORTING ATPASE; AMINO-ACID-SEQUENCE; SARCOPLASMIC-RETICULUM; PLASMA-MEMBRANE; MOLECULAR-CLONING; CALCIUM HOMEOSTASIS; SCHIZOSACCHAROMYCES-POMBE; ADENOSINE-TRIPHOSPHATASE; SKELETAL-MUSCLE	Procyclic forms of Trypanosoma brucei were stably transformed with an expression vector containing a gene for a P-type ATPase (tba1) cloned from T. brucei genomic DNA. Transformation with this gene resulted specifically in a 4-5-fold increase in the cellular Ca2+-ATPase activity. Subcellular fractionation studies revealed this increase to be enriched in the microsomal fraction. There was no detectable change in the plasma membrane Ca2+-ATPase activity of the transformants. Western blot analysis of subcellular fractions using antibodies raised against the recombinant tba1 gene product also demonstrated a significant enrichment of a protein with a M(r) of 115,000 in the microsomal fraction of transformed cells. This protein was not detected in purified plasma membranes. Significantly, the increased Ca2+-ATPase activity possessed a high affinity for Ca2+. The activity was sensitive to the classical P-type ATPase inhibitor vanadate, anti-tba1 antibodies, as well as low concentrations of thapsigargin, a specific inhibitor of endoplasmic reticulum Ca2+-ATPases. Taken together, these data demonstrated that the tba1 gene codes for a high affinity Ca2+-ATPase of the endoplasmic reticulum, with properties similar to those reported for the sarcoplasmic/endoplasmic reticulum family of Ca2+ pumps from higher eukaryotes. In addition, these results have identified the tba1 gene product as potentially important element, in conjunction with the mitochondrial membrane potential and the plasma membrane Ca2+ pump, in the pathways of cellular Ca2+ homeostasis in these protozoans.	UNIV BRUSSELS,DEPT MOLEC BIOL,B-1640 RHODE ST GENESE,BELGIUM					Nolan, Derek/0000-0002-3742-4304				Andersen JP, 1990, CURR OPIN CELL BIOL, V2, P722, DOI 10.1016/0955-0674(90)90116-V; BENAIM J, 1993, BIOCHEM J, V296, P759; BOWLES DJ, 1982, FEBS LETT, V139, P17, DOI 10.1016/0014-5793(82)80477-8; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARAFOLI E, 1991, ANNU REV PHYSIOL, V53, P531, DOI 10.1146/annurev.physiol.53.1.531; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1990, J BIOL CHEM, V265, P18848; DOLAN MT, 1986, J CELL SCI, V80, P123; DUNN MJ, 1989, PROTEIN PURIFICATION, P13; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GHISLAIN M, 1990, J BIOL CHEM, V265, P18400; GHISLAIN M, 1991, J BIOL CHEM, V266, P18276; GREEB J, 1989, J BIOL CHEM, V264, P18569; HARLOW E, 1988, ANTIBODIES LABORATOR; JACKSON DG, 1985, BIOCHEM J, V230, P195, DOI 10.1042/bj2300195; JACKSON DG, 1993, J BIOL CHEM, V268, P8085; LEBERER E, 1986, EUR J BIOCHEM, V156, P489, DOI 10.1111/j.1432-1033.1986.tb09607.x; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; LOTERSZTAJN S, 1981, J BIOL CHEM, V256, P1209; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACARA IG, 1980, TRENDS BIOCHEM SCI, V5, P92, DOI 10.1016/0968-0004(80)90256-X; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; Maniatis T., 1982, MOL CLONING; Martell A. E., 1971, SPECIAL PUBLICATION, V17; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MCLAUGHLIN J, 1985, MOL BIOCHEM PARASIT, V15, P189, DOI 10.1016/0166-6851(85)90119-7; MEADE JC, 1989, MOL BIOCHEM PARASIT, V33, P81, DOI 10.1016/0166-6851(89)90045-5; MEADE JC, 1991, MOL BIOCHEM PARASIT, V45, P29, DOI 10.1016/0166-6851(91)90024-Z; METZ DC, 1992, J BIOL CHEM, V267, P20620; MORENO SNJ, 1992, J BIOL CHEM, V267, P6020; NOLAN DP, 1992, EUR J BIOCHEM, V209, P207, DOI 10.1111/j.1432-1033.1992.tb17278.x; OKOROKOV LA, 1993, EUR J BIOCHEM, V216, P573, DOI 10.1111/j.1432-1033.1993.tb18176.x; OPPERDOES FR, 1981, MOL BIOCHEM PARASIT, V4, P291, DOI 10.1016/0166-6851(81)90062-1; OPPERDOES FR, 1977, EUR J BIOCHEM, V76, P21, DOI 10.1111/j.1432-1033.1977.tb11566.x; OPPERDOES FR, 1981, MOL BIOCHEM PARASIT, V4, P311, DOI 10.1016/0166-6851(81)90063-3; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; PRADOFIGUEROA M, 1994, MOL BIOCHEM PARASIT, V63, P255, DOI 10.1016/0166-6851(94)90061-2; REVELARD P, 1991, MOL BIOCHEM PARASIT, V46, P241, DOI 10.1016/0166-6851(91)90048-B; ROLIN S, 1990, EXP PARASITOL, V71, P350, DOI 10.1016/0014-4894(90)90041-A; RUBEN L, 1992, EXP PARASITOL, V74, P332, DOI 10.1016/0014-4894(92)90157-6; RUBEN L, 1991, J BIOL CHEM, V266, P24351; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SACHS G, 1991, Current Opinion in Cell Biology, V3, P685, DOI 10.1016/0955-0674(91)90042-W; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SIDDIQUI AA, 1990, MOL BIOCHEM PARASIT, V40, P95, DOI 10.1016/0166-6851(90)90083-X; SILLEN LG, 1971, SPECIAL PUBLICATION, V26; SIMONIDES WS, 1990, ANAL BIOCHEM, V191, P321, DOI 10.1016/0003-2697(90)90226-Y; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; STEIGER RF, 1980, EUR J BIOCHEM, V105, P163, DOI 10.1111/j.1432-1033.1980.tb04486.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; VERCESI AE, 1993, J BIOL CHEM, V268, P8564; VERCESI AE, 1992, MOL BIOCHEM PARASIT, V56, P251, DOI 10.1016/0166-6851(92)90174-I; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VOORHEIS HP, 1981, EUR J BIOCHEM, V116, P471, DOI 10.1111/j.1432-1033.1981.tb05360.x; VOORHEIS HP, 1977, BIOCHEM J, V180, P11; WANG T, 1979, BIOCHEM BIOPH RES CO, V91, P356, DOI 10.1016/0006-291X(79)90626-0; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976	76	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26045	26051						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929316				2022-12-25	WOS:A1994PQ93000020
J	PTAK, C; PRENDERGAST, JA; HODGINS, R; KAY, CM; CHAU, V; ELLISON, MJ				PTAK, C; PRENDERGAST, JA; HODGINS, R; KAY, CM; CHAU, V; ELLISON, MJ			FUNCTIONAL AND PHYSICAL CHARACTERIZATION OF THE CELL-CYCLE UBIQUITIN-CONJUGATING ENZYME CDC34 (UBC3) - IDENTIFICATION OF A FUNCTIONAL DETERMINANT WITHIN THE TAIL THAT FACILITATES CDC34 SELF-ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; GENE-PRODUCTS; RAD6 PROTEIN; SYSTEM; DOMAIN; E2; DEGRADATION; EXPRESSION	Like several other ubiquitin-conjugating enzymes, the yeast cell cycle enzyme CDC34 (UBCS) has a carboxyl terminal extension or tail. These tails appear to carry out unique functions that can vary from one ubiquitin-conjugating enzyme to the next. Using biophysical techniques we have determined that the tail of CDC34 constitutes a highly structured and extended domain. Although the tail of CDC34 is the largest tail identified to date (125 residues), we have found that only 39 residues lying adjacent to the catalytic domain are necessary and sufficient for full cell cycle function and that this region fulfills a novel function that may be common to the tails of other ubiquitin-conjugating enzymes. Cross-linking studies demonstrate that this region facilitates a physical interaction between CDC34 monomers in vitro. Furthermore, phenotypic analysis of various CDC34 derivatives expressed in different cdc34 mutant strains indicates that this region facilitates the same interaction in vivo. Based on these findings, it appears that the cell cycle function of CDC34 is dependent upon the ability of CDC34 monomers to interact with one another and that this interaction is mediated by a small region of the CDC34 tail. The similarity of this region with sequences contained within the tails of the UBC1 and UBC6 enzymes suggests that these tails may function in a similar manner.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,AB,CANADA; WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201	University of Alberta; Wayne State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047604] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47604] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Chervenka C. H., 1969, MANUAL METHODS ANAL; COOK WJ, 1992, J BIOL CHEM, V267, P16467; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; GIROD PA, 1993, J BIOL CHEM, V268, P955; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JENTSCH S, 1990, TRENDS BIOL SCI, V15, P105; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; PICKART CM, 1985, J BIOL CHEM, V260, P1573; SCHACHMAN HK, 1959, ULTRACENTRIFUGATION, P236; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; Sherman F., 1981, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tanford C., 1961, PHYSICAL CHEM MACROM, P317; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K	29	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26539	26545						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929378				2022-12-25	WOS:A1994PQ93000091
J	BENOV, LT; FRIDOVICH, I				BENOV, LT; FRIDOVICH, I			ESCHERICHIA-COLI EXPRESSES A COPPER-CONTAINING AND ZINC-CONTAINING SUPEROXIDE-DISMUTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOBACTERIUM-LEIOGNATHI; CAULOBACTER-CRESCENTUS; GENE-TRANSFER; BRUCELLA-ABORTUS; BACTERIOCUPREIN; BACTERIUM; PONYFISH; CLONING; MUTANTS; ENZYME	A mutant of Escherichia coli, unable to produce manganese- or iron-containing superoxide dismutase (SOD), was found to contain modest levels of an SOD that was judged to be a copper and zinc-containing SOD on the basis of inhibition by cyanide and inactivation by either H2O2 or diethyldithiocarbamate. Moreover, the diethyldithiocarbamate-inactivated enzyme could be reactivated with Cu(II), and this reconstituted enzyme, like the native enzyme, was unaffected by EDTA and was inhibited by cyanide. This enzyme was, furthermore, selectively released by osmotic shock, in keeping with a periplasmic localization, and it was strongly induced during aerobic growth. This enzyme was also present in the SOD-competent parental strain. Failure to detect it previously can be attributed to its periplasmic localization, thermal lability, sensitivity to pH, and to its relative paucity. It will now be interesting to explore the phenotypic consequences imposed by the absence of this SOD.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; MED UNIV STARA ZAGORA, DEPT BIOPHYS, BU-6000 STARA ZAGORA, BULGARIA	Duke University; Trakia University			Benov, Ludmil/AAD-3714-2020	Benov, Ludmil/0000-0002-0205-0146	FIC NIH HHS [1 F05 TW04975] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004975] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BANNISTER JV, 1985, P NATL ACAD SCI USA, V82, P149, DOI 10.1073/pnas.82.1.149; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BEAUCHAMP CO, 1973, BIOCHIM BIOPHYS ACTA, V317, P50, DOI 10.1016/0005-2795(73)90198-0; BECK BL, 1990, BIOCHEMISTRY-US, V29, P372, DOI 10.1021/bi00454a010; BRICKER BJ, 1990, INFECT IMMUN, V58, P2935, DOI 10.1128/IAI.58.9.2935-2939.1990; BUTLER J, 1975, BIOCHIM BIOPHYS ACTA, V408, P215, DOI 10.1016/0005-2728(75)90124-3; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CORNISHBOWDEN A, 1985, EUR J BIOCHEM, V151, P333, DOI 10.1111/j.1432-1033.1985.tb09105.x; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; HIRATA F, 1975, J BIOL CHEM, V250, P5960; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; KANEMATSU S, 1978, ARCH BIOCHEM BIOPHYS, V185, P473, DOI 10.1016/0003-9861(78)90191-1; KLUG D, 1972, J BIOL CHEM, V247, P4839; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LANGFORD PR, 1992, J GEN MICROBIOL, V138, P517, DOI 10.1099/00221287-138-3-517; LEUNISSEN JAM, 1986, J MOL EVOL, V23, P250, DOI 10.1007/BF02115581; LUNN CA, 1982, J BIOL CHEM, V257, P1424; MARTIN JP, 1981, J BIOL CHEM, V256, P6080; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MISRA HP, 1979, J BIOL CHEM, V254, P1623; PUGET K, 1974, BIOCHEM BIOPH RES CO, V58, P830, DOI 10.1016/S0006-291X(74)80492-4; PUGET K, 1974, BIOCHIMIE, V56, P1255, DOI 10.1016/S0300-9084(74)80019-2; RAJAGOPALAN KV, 1985, CRC HDB METHODS OXYG, P21; STEFFENS GJ, 1983, H-S Z PHYSIOL CHEM, V364, P675, DOI 10.1515/bchm2.1983.364.1.675; STEINMAN HM, 1990, J BACTERIOL, V172, P2901, DOI 10.1128/jb.172.6.2901-2910.1990; STEINMAN HM, 1987, J BIOL CHEM, V262, P1882; STEINMAN HM, 1982, J BIOL CHEM, V257, P283; STEINMAN HM, 1985, J BACTERIOL, V162, P1255, DOI 10.1128/JB.162.3.1255-1260.1985; STEINMAN HM, 1993, J BACTERIOL, V175, P1198, DOI 10.1128/JB.175.4.1198-1202.1993; TATUM FM, 1992, INFECT IMMUN, V60, P2863, DOI 10.1128/IAI.60.7.2863-2869.1992; Tsuchihashi M, 1923, BIOCHEM Z, V140, P63; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582	34	169	171	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25310	25314						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929223				2022-12-25	WOS:A1994PQ49100014
J	BOREN, J; RUSTAEUS, S; OLOFSSON, SO				BOREN, J; RUSTAEUS, S; OLOFSSON, SO			STUDIES ON THE ASSEMBLY OF APOLIPOPROTEIN-B-100-CONTAINING AND APOLIPOPROTEIN-B-48-CONTAINING VERY-LOW-DENSITY LIPOPROTEINS IN MCA-RH7777 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; HEP G2 CELLS; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; RAT-LIVER; APO-B-100-CONTAINING LIPOPROTEINS; APO-B; GROWTH-HORMONE; SECRETION; LINE	The mechanisms by which apolipoprotein B-100 (apoB-100) and apoB-48 assemble lipoproteins have been studied in the McA-RH7777 cell line. After incubation for 2 h with 360 mu M oleic acid, the McA-RH7777 cells secreted apoB-100 mainly on very low density lipoprotein (VLDL) particles, as judged from sucrose gradient and sequential ultracentrifugation. ApoB-48 was secreted on both VLDL and on denser, high density lipoprotein (HDL)-like lipoproteins. Both apoB-48 and apoB-100 occurred on VLDL particles in the luminal content of the total microsomal fraction. In addition, both proteins were present on denser particles, in particular, those that banded in the HDL region. The denser particles containing apoB-48 were secreted from the cells, whereas those containing apoB-100 were retained in the cell and degraded. Pulse-chase experiments showed that apoB-100 on VLDL was present in the secretory pathway already after a labeling period as short as 3 min. Thus, this particle was the first apoB-100 containing lipoprotein that could be detected in the microsomal fraction of the cell. The assembly of labeled apoB-100 VLDL was acutely (within min) and completely blocked by cycloheximide, if the cycloheximide was added after the pulse labeling period. If, on the other hand, a 15-min chase was introduced after the labeling period, there was no effect of cycloheximide on the assembly of apoB-100 VLDL. A 15-min chase is enough to allow the pulse-labeled apoB nascent polypeptides to be completed to apoB-100. These results indicated that the assembly of apoB-100 containing VLDL is dependent upon ongoing protein biosynthesis during the time when the nascent polypeptide elongate. After this period, the assembly and secretion of the particles are independent of ongoing protein biosynthesis. The first apoB-48-containing particle seen in the luminal content of the microsomal fraction was the HDL-like particle. Pulse-chase experiments as well as experiments with different lengths of the radioactive pulse indicated that the formation of apoB-48-containing VLDL was delayed compared with the formation of the apoB-48-containing HDL-like particle and also in relation to the assembly of the different apoB-100-containing particles, including VLDL. After a 30-min pulse with [S-35]methionine followed by a 120-min chase the secretory pathway of the cell was depleted of almost all lipoproteins except the HDL-like apoB-48-containing particle. During a new chase of 180 min in the presence of oleic acid, this HDL-like particle was to a large degree converted to apoB-48-containing VLDL. This conversion was partially inhibited by cycloheximide. Thus, contrary to apoB-100 VLDL the formation of apoB-48 VLDL was influenced by cycloheximide after the completion of the apolipoprotein. Together these results indicated that apoB-48 VLDL is formed in at least two steps. The first step is the formation of a precursor HDL-like particle. This HDL particle is then converted, in a second step, to apoB-48 VLDL.	GOTHENBURG UNIV,DEPT BIOCHEM MED,S-41390 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,WALLENBERG LAB,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg; University of Gothenburg								ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1991, PROG LIPID RES, V30, P205, DOI 10.1016/0163-7827(91)90017-Y; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1993, BIOCHEM SOC T, V21, P487, DOI 10.1042/bst0210487; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIDSON NO, 1990, MOL ENDOCRINOL, V4, P779, DOI 10.1210/mend-4-5-779; FAINARU M, 1977, METABOLISM, V26, P999, DOI 10.1016/0026-0495(77)90017-8; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GLICKMAN RM, 1986, P NATL ACAD SCI USA, V83, P5296, DOI 10.1073/pnas.83.14.5296; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KANE JP, 1980, P NATL ACAD SCI-BIOL, V77, P2465, DOI 10.1073/pnas.77.5.2465; LAU PP, 1991, J BIOL CHEM, V266, P20550; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LEVY E, 1987, J LIPID RES, V28, P1263; OLOFSSON SO, 1980, BIOCHEMISTRY-US, V19, P1059, DOI 10.1021/bi00547a002; PELHAM HRB, 1989, BIOCHEM SOC T, V17, P795, DOI 10.1042/bst0170795; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; SCOTT J, 1989, MOL BIOL MED, V6, P65; SJOBERG A, 1992, ENDOCRINOLOGY, V130, P3356, DOI 10.1210/en.130.6.3356; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; TANABE S, 1993, CELL DEV BIOL, V25, P1129; THRIFT RN, 1986, J LIPID RES, V27, P236; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WINDMUELLER HG, 1985, J LIPID RES, V26, P70; YAO ZM, 1991, J BIOL CHEM, V266, P3300	35	189	190	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25879	25888						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929292				2022-12-25	WOS:A1994PQ49100094
J	MORGAN, PJ; HYMAN, SC; BYRON, O; ANDREW, PW; MITCHELL, TJ; ROWE, AJ				MORGAN, PJ; HYMAN, SC; BYRON, O; ANDREW, PW; MITCHELL, TJ; ROWE, AJ			MODELING THE BACTERIAL PROTEIN TOXIN, PNEUMOLYSIN, IN ITS MONOMERIC AND OLIGOMERIC FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-MEMBRANES; STREPTOLYSIN-O; STREPTOCOCCUS-PNEUMONIAE; PERFRINGOLYSIN-O	Pneumolysin is a member of the family of related bacterial thiol-activated toxins, which share structural similarities and a proposed common cytolytic mechanism. Currently the molecular mechanism of membrane damage caused by these toxins remains a matter of controversy. A prerequisite for defining this mechanism is a detailed knowledge of the monomeric and oligomeric pneumolysin structures. We present for the first time details of the monomeric structure of a thiol-activated toxin, pneumolysin. Electron microscope images of metal-shadowed pneumolysin monomers show an asymmetric molecule composed of four domains. We have studied the conformation of pneumolysin monomer by low resolution hydrodynamic bead modeling procedures. The bead model dimensions and shape are derived solely from the electron micrographs. The bead model has been evaluated in terms of the predicted solution properties, which in turn have been compared to the experimental values of the sedimentation coefficient, s(20,w)(0), obtained by analytical ultracentrifugation and the intrinsic viscosity, [eta]. Pneumolysin oligomers, observed as ring- and are-shaped structures, were also examined by electron microscopy. Metal shadowing and negative staining methods were used to establish the overall dimensions of the oligomer and were used to produce a morphological model for the oligomer, incorporating monomer subunits based on the hydrodynamic bead model.	UNIV LEICESTER, DEPT BIOCHEM, NCMH, LEICESTER LE1 7RH, LEICS, ENGLAND; UNIV LEICESTER, SCH BIOL SCI, ELECTRON MICROSCOPE LABS, LEICESTER LE1 7RH, LEICS, ENGLAND	University of Leicester; University of Leicester	MORGAN, PJ (corresponding author), UNIV LEICESTER, DEPT MICROBIOL & IMMUNOL, POB 148, UNIV RD, LEICESTER LE1 9HN, LEICS, ENGLAND.		Andrew, Peter W/G-7526-2012	Byron, Olwyn/0000-0001-7857-4520; Mitchell, Timothy/0000-0002-8309-5556				Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; AUSTRIAN R, 1981, REV INFECT DIS, V3, P183; BERRY AM, 1989, INFECT IMMUN, V57, P2037, DOI 10.1128/IAI.57.7.2037-2042.1989; BHAKDI S, 1985, INFECT IMMUN, V47, P52; COWELL JL, 1978, BIOCHIM BIOPHYS ACTA, V507, P230, DOI 10.1016/0005-2736(78)90419-4; DELATORRE JG, 1981, Q REV BIOPHYS, V14, P81, DOI 10.1017/S0033583500002080; DELATORRE JG, 1989, ROY SOC CH, V74, P3; DOURMASHKIN RR, 1966, AM J MED, V41, P699, DOI 10.1016/0002-9343(66)90031-3; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; HARRIS RW, 1991, J BIOL CHEM, V266, P6936; KLUG A, 1969, NOBEL S, V11, P425; MITCHELL TJ, 1989, BIOCHIM BIOPHYS ACTA, V1007, P67, DOI 10.1016/0167-4781(89)90131-0; MITSUI K, 1979, BIOCHIM BIOPHYS ACTA, V558, P307, DOI 10.1016/0005-2736(79)90265-7; MORGAN PJ, 1993, BIOCHEM J, V296, P671, DOI 10.1042/bj2960671; MORGAN PJ, 1994, BACTERIAL PROTEIN S, V24, P333; NIEDERMEYER W, 1985, TOXICON, V23, P425, DOI 10.1016/0041-0101(85)90026-1; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; ROCCO M, 1993, PROTEIN SCI, V2, P2154, DOI 10.1002/pro.5560021215; ROTTEM S, 1982, J BACTERIOL, V152, P888; ROWE AJ, 1984, TECHNIQUES PROTEIN E, P29; SAUNDERS FK, 1989, INFECT IMMUN, V57, P2547, DOI 10.1128/IAI.57.8.2547-2552.1989; SEKIYA K, 1993, J BACTERIOL, V175, P5953, DOI 10.1128/JB.175.18.5953-5961.1993; SZUCHET-DERECHIN S., 1966, European Polymer Journal, V2, P115, DOI 10.1016/0014-3057(66)90067-X; TANFORD C, 1955, J PHYS CHEM-US, V59, P798, DOI 10.1021/j150530a027; TANFORD C, 1963, PHYSICAL CHEM MACROM; TRANUMJENSEN J, 1978, SCAND J IMMUNOL, V7, P45, DOI 10.1111/j.1365-3083.1978.tb00425.x; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x	28	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25315	25320						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929224				2022-12-25	WOS:A1994PQ49100015
J	CALAKOS, N; SCHELLER, RH				CALAKOS, N; SCHELLER, RH			VESICLE-ASSOCIATED MEMBRANE-PROTEIN AND SYNAPTOPHYSIN ARE ASSOCIATED ON THE SYNAPTIC VESICLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEUROTRANSMITTER RELEASE; TRANSMITTER SECRETION; VAMP FAMILY; RAT-BRAIN; SYNAPTOBREVIN; GENES; TETANUS; FUSION; CDNA; LOCALIZATIONS	The synaptic vesicle membrane protein VAMP ((v) under bar esicle-(a) under bar ssociated (m) under bar embrane (p) under bar rotein or synaptobrevin) has been implicated in synaptic vesicle docking and fusion. Synaptophysin (p38), also a synaptic vesicle membrane protein, has four transmembrane domains and may function as a gap junction-like pore or channel. Here we report evidence for a direct interaction between VAMP and synaptophysin using chemical cross-linking followed by the identification of immunoreactive protein complexes. A prominent complex of 56 kDa was found to consist of VAMP and synaptophysin. Furthermore, we demonstrate that this VAMP-synaptophysin complex is enriched in the synaptic vesicle fraction of rat brain, is independent of detergent solubilization, and is present in PC12 cells subjected to in vivo cross-linking.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT CELLULAR & MOLEC PHYSIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University								ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ALDER J, 1992, NEURON, V9, P759, DOI 10.1016/0896-6273(92)90038-F; ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BRAUN JEA, 1994, J BIOL CHEM, V269, P5328; BUCKLEY KM, 1987, J CELL BIOL, V105, P2447, DOI 10.1083/jcb.105.6.2447; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FYKSE EM, 1993, J NEUROSCI, V13, P4997; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HUTTNER WB, 1983, J CELL BIOL, V96, P1373; JOHNSTON PA, 1990, J BIOL CHEM, V265, P8869; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; ZHONG CZ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P235, DOI 10.1016/0167-4781(92)90495-L	33	194	198	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24534	24537						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929121				2022-12-25	WOS:A1994PQ49000005
J	JOHNSON, JL; TOFT, DO				JOHNSON, JL; TOFT, DO			A NOVEL CHAPERONE COMPLEX FOR STEROID-RECEPTORS INVOLVING HEAT-SHOCK PROTEINS, IMMUNOPHILINS, AND P23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN PROGESTERONE-RECEPTOR; ROUS-SARCOMA VIRUS; GLUCOCORTICOID RECEPTOR; FK506-BINDING PROTEIN; 59-KILODALTON PROTEIN; MONOCLONAL-ANTIBODIES; POLYCLONAL ANTIBODY; FK506 BINDING; HSP90; COMPONENT	In the absence of hormone, the avian progesterone receptor exists in a large multiprotein complex that is inactive but able to bind and respond to progestins. This inactive complex can be reconstituted in vitro by incubation of receptor monomer in rabbit reticulocyte lysate in the presence of ATP and magnesium. This results in receptor binding to the two heat shock proteins, hsp90 and hsp70, the FK506 binding-proteins, FKBP54 and FKBP52, the cyclosporin A-binding protein, cyclophilin-40, and the recently characterized protein p23. Immune isolation of p23 from rabbit reticulocyte lysate in the absence of receptor reveals an ATP-dependent complex containing the major proteins associated with steroid receptors. Depletion of p23 from lysate prevents the assembly of progesterone receptor complexes, and the addition of purified p23 restores this activity, indicating that the p23 protein complex is an essential precursor to the formation of progesterone receptor complexes.	MAYO CLIN & MAYO GRAD SCH MED,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic					NICHD NIH HHS [HD09140] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALNEMRI ES, 1993, P NATL ACAD SCI USA, V90, P6839, DOI 10.1073/pnas.90.14.6839; BIHAN SL, 1993, BIOCHEM BIOPH RES CO, V195, P600; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NADEAU K, 1992, PROTEIN SCI, V1, P970, DOI 10.1002/pro.5560010802; NING YM, 1993, J BIOL CHEM, V268, P6073; NYGARD O, 1991, J BIOL CHEM, V266, P16425; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; ROSE DW, 1989, J BIOL CHEM, V264, P6239; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; SULLIVAN WP, 1985, BIOCHEMISTRY-US, V24, P4214, DOI 10.1021/bi00336a060; TAI PKK, 1993, BIOCHEMISTRY-US, V32, P8842, DOI 10.1021/bi00085a015; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0	50	209	213	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24989	24993						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929183				2022-12-25	WOS:A1994PQ49000070
J	RIBAS, JC; FUJIMURA, T; WICKNER, RB				RIBAS, JC; FUJIMURA, T; WICKNER, RB			ESSENTIAL RNA-BINDING AND PACKAGING DOMAINS OF THE GAG-POL FUSION PROTEIN OF THE L-A DOUBLE-STRANDED-RNA VIRUS OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROTAVIRUS NONSTRUCTURAL PROTEIN; HEPATITIS-B VIRUS; CONSENSUS SEQUENCE; VIRAL-RNA; YEAST; EXPRESSION; INVITRO; ENCAPSIDATION; REPLICATION; POLYMERASE	The crucial process in the assembly of the L-A double-stranded RNA virus is the recognition of its (+) single-stranded RNA by the Gag-Pol protein. The Pol region of this protein has RNA binding activity and is necessary for RNA packaging. Here we show that there are actually two in vitro RNA-binding domains of Pol (residues 172-190 and 770-819), and both are necessary for viral propagation, (but not for particle assembly). Furthermore, the N-terminal RNA-binding domain is necessary for in vivo packaging of viral (+) single-stranded RNA. We precisely define the extent of the Pol packaging domain (residues 67-213), which includes the N-terminal RNA-binding domain. This suggests that the N-terminal RNA-binding domain is responsible for binding the genomic RNA in the process of packaging and that additional surrounding residues are responsible for the specificity of binding.			RIBAS, JC (corresponding author), NIDDK,BIOCHEM PHARMACOL LAB,GENET SIMPLE EUKARYOTES SECT,BETHESDA,MD 20892, USA.		Ribas, Juan C/C-9864-2015; Fujimura, Tsutomu/K-5807-2014	Ribas, Juan C/0000-0001-6430-0895; Fujimura, Tsutomu/0000-0002-9457-6769				BARTENSCHLAGER R, 1990, J VIROL, V64, P5324, DOI 10.1128/JVI.64.11.5324-5332.1990; BLANC A, 1994, MOL CELL BIOL, V14, P2664, DOI 10.1128/MCB.14.4.2664; BROTTIER P, 1992, J GEN VIROL, V73, P1931, DOI 10.1099/0022-1317-73-8-1931; BRUENN JA, 1991, NUCLEIC ACIDS RES, V19, P217, DOI 10.1093/nar/19.2.217; CHEN D, 1990, VIROLOGY, V176, P143; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; ESTEBAN R, 1988, J VIROL, V62, P1278, DOI 10.1128/JVI.62.4.1278-1285.1988; ESTEBAN R, 1988, P NATL ACAD SCI USA, V85, P4411, DOI 10.1073/pnas.85.12.4411; FUJIMURA T, 1992, J BIOL CHEM, V267, P2708; FUJIMURA T, 1992, NATURE, V359, P746, DOI 10.1038/359746a0; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; FUJIMURA T, 1988, J BIOL CHEM, V263, P454; FUJIMURA T, 1989, J BIOL CHEM, V264, P10872; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; HATTON T, 1992, J VIROL, V66, P5232, DOI 10.1128/JVI.66.9.5232-5241.1992; HIRSCH RC, 1990, NATURE, V344, P552, DOI 10.1038/344552a0; HUA J, 1994, IN PRESS J VIROL, V68; ICHO T, 1989, J BIOL CHEM, V264, P6716; KATTOURA MD, 1992, VIROLOGY, V191, P698, DOI 10.1016/0042-6822(92)90245-K; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUBAN J, 1991, J VIROL, V65, P3203, DOI 10.1128/JVI.65.6.3203-3212.1991; MANDECKI W, 1986, GENE, V43, P131, DOI 10.1016/0378-1119(86)90016-8; MATTION NM, 1992, VIROLOGY, V190, P68, DOI 10.1016/0042-6822(92)91193-X; PETRIE BL, 1984, VIRUS RES, V1, P133, DOI 10.1016/0168-1702(84)90069-8; PONCET D, 1993, J VIROL, V67, P3159, DOI 10.1128/JVI.67.6.3159-3165.1993; RIBAS JC, 1992, P NATL ACAD SCI USA, V89, P2185, DOI 10.1073/pnas.89.6.2185; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; VALLE RPC, 1993, J VIROL, V67, P2764, DOI 10.1128/JVI.67.5.2764-2771.1993; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; WICKNER RB, 1992, ANNU REV MICROBIOL, V46, P347, DOI 10.1146/annurev.micro.46.1.347; WICKNER RB, 1976, GENETICS, V82, P429; WICKNER RB, 1995, IN PRESS FIELDS VIRO	39	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					28420	28428						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961783				2022-12-25	WOS:A1994PV77200095
J	TAKAKUWA, Y; NISHINO, H; ISHIBE, Y; ISHIBASHI, T				TAKAKUWA, Y; NISHINO, H; ISHIBE, Y; ISHIBASHI, T			PROPERTIES AND KINETICS OF MEMBRANE-BOUND ENZYMES WHEN BOTH THE ENZYME AND SUBSTRATE ARE COMPONENTS OF THE SAME MICROSOMAL MEMBRANE - STUDIES OF LATHOSTEROL 5-DESATURASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN; RAT-LIVER MICROSOMES; SUPERNATANT PROTEIN; LATERAL DIFFUSION; INTERMEMBRANE TRANSFER; BILAYER-MEMBRANES; CALF BRAIN; RECEPTORS; SQUALENE; CYCLASE	Microsomes isolated from rat liver contain an NADH-dependent lathosterol B-desaturation system that catalyzes the introduction of a Delta(5) bond into lathosterol to form 7-dehydrocholesterol. Microsomes were preloaded in vitro with liposomes composed of lathosterol and phosphatidylcholine in the presence of a high-speed supernatant (S-105) protein prior to enzyme assay. The desaturation led to a reaction that occurred in two distinct phases. That is, there was an initial burst of product formation over an approximate time scale of 5 min that fell off, thereafter to a steady state rate for over 30 min. The latter steady state phase was slower than the burst phase, because lateral diffusion of the lathosterol substrate must occur before the next reaction can take place. The total amount of the burst, which may be obtained by extrapolating the linear part of the curve in the steady state phase back to zero time, provides a means of obtaining the enzyme concentration in terms of functional active sites. It was found that the kinetics between enzyme and substrate within the same membrane also followed the usual kinetic formalism of a Michaelis-Menten type reaction as in nonaggregated homogenous solution.	HOKKAIDO UNIV,SCH MED,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University								BLOCH K, 1965, SCIENCE, V150, P19, DOI 10.1126/science.150.3692.19; BURTON P, 1985, J BIOL CHEM, V260, P7289; DELISI C, 1976, J THEOR BIOL, V62, P159, DOI 10.1016/0022-5193(76)90056-4; DEMPSEY ME, 1981, J BIOL CHEM, V256, P1867; DEMPSEY ME, 1964, J BIOL CHEM, V239, P1381; DVORNIK D, 1966, BIOCHEMISTRY-US, V5, P1060, DOI 10.1021/bi00867a035; FRIEDLANDER EJ, 1980, J BIOL CHEM, V255, P8042; GUTFREUND H, 1972, ENZYMES PHYSICAL PRI, P69; HACKENBROCK CR, 1981, TRENDS BIOCHEM SCI, V6, P151, DOI 10.1016/0968-0004(81)90056-6; HANSKI E, 1979, BIOCHEMISTRY-US, V18, P846, DOI 10.1021/bi00572a017; HONJO K, 1985, J BIOCHEM, V97, P955, DOI 10.1093/oxfordjournals.jbchem.a135137; INOUYE K, 1977, J BIOCHEM-TOKYO, V82, P961, DOI 10.1093/oxfordjournals.jbchem.a131800; ISHIBASHI T, 1983, EUR J BIOCHEM, V132, P23, DOI 10.1111/j.1432-1033.1983.tb07320.x; ISHIBASHI T, 1981, J BIOL CHEM, V256, P2962; ISHIBASHI T, 1986, LIPIDS, V21, P191, DOI 10.1007/BF02534820; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER WL, 1967, BIOCHEMISTRY-US, V6, P2673, DOI 10.1021/bi00861a005; PARRY G, 1976, FEBS LETT, V67, P123, DOI 10.1016/0014-5793(76)80348-1; REDDY VVR, 1976, EUR J BIOCHEM, V69, P577, DOI 10.1111/j.1432-1033.1976.tb10943.x; RIMON G, 1978, NATURE, V276, P394, DOI 10.1038/276394a0; RITTER MC, 1971, J BIOL CHEM, V246, P1536; SAAT YA, 1976, J BIOL CHEM, V251, P5155; SANDHOFF K, 1978, P NATL ACAD SCI USA, V75, P122, DOI 10.1073/pnas.75.1.122; SCHEEL G, 1982, EUR J BIOCHEM, V127, P245, DOI 10.1111/j.1432-1033.1982.tb06862.x; STRITTMATTER P, 1975, P NATL ACAD SCI USA, V72, P2658, DOI 10.1073/pnas.72.7.2658; TRIVEDI A, 1986, BIOCHEM CELL BIOL, V64, P1195, DOI 10.1139/o86-157; VAZ WLC, 1984, FEBS LETT, V174, P199, DOI 10.1016/0014-5793(84)81157-6; VAZ WLC, 1982, CELL SURF REV, V8, P83	28	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27889	27893						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961720				2022-12-25	WOS:A1994PV77200021
J	LAPIDOT, A; GOPHER, A				LAPIDOT, A; GOPHER, A			CEREBRAL METABOLIC COMPARTMENTATION - ESTIMATION OF GLUCOSE FLUX VIA PYRUVATE-CARBOXYLASE PYRUVATE-DEHYDROGENASE BY C-13 NMR ISOTOPOMER ANALYSIS OF D-[U-C-13]GLUCOSE METABOLITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CHROMATOGRAPHY-MASS-SPECTROMETRY; PRODUCER STREPTOMYCES-PARVULUS; RAT-BRAIN; SPECTROSCOPY; INVIVO; PATHWAYS; BIOSYNTHESIS; PRECURSORS; GLUTAMATE	A method is presented for determining the compartmentation of amino acid metabolism in the brain. C-13 NMR spectroscopy, and more specifically, homonuclear C-13-C-13 spin coupling patterns of C-13-labeled amino acids were used to measure the relative flux of label from D-[U-C-13]glucose through the anaplerotic pathway versus the oxidative pathway. Glucose flux through the pyruvate carboxylase pathway was quantitated following primed dose constant infusion of D-[U-C-13]glucose to young rabbits at a rate of 1 mg/kg body weight per min. We demonstrate, for the first time, that multiplet spectra of three adjacent C-13 isoptomers in 1,2,3-C-13(3) in glutamine and glutamate, which are derived from [1,2,3-C-13(3)]-pyruvate, present different isotopomer populations in glutamine in comparison to that in glutamate. This is due to two different metabolic compartments characterized by the presence or absence of glutamine synthetase activity and two different tricarboxylic acid cycles, one preferentially mediated by pyruvate carboxylase and the other by pyruvate dehydrogenase. Our results indicate that the anaplerotic pathway accounts for 34% of glutamine synthesis and only 16% of glutamate and gamma-aminobutyric acid syntheses in metabolic and isotopic steady state conditions. These results support the concept, and provide a quantitative measure, that glutamine and/or tricarboxylic acid cycle intermediates are supplied by astrocytes to neurons to replenish the neurotransmitter pool of gamma-aminobutyric acid and glutamate.			LAPIDOT, A (corresponding author), WEIZMANN INST SCI, DEPT ORGAN CHEM, IL-76100 REHOVOT, ISRAEL.							BADARGOFFER RS, 1990, BIOCHEM J, V266, P133, DOI 10.1042/bj2660133; BECKMANN N, 1991, BIOCHEMISTRY-US, V30, P6362, DOI 10.1021/bi00240a002; BERL S, 1969, HDB NEUROCHEMISTRY, V2, P447; BRAINARD JR, 1989, J NEUROCHEM, V53, P1285, DOI 10.1111/j.1471-4159.1989.tb07426.x; BRAND A, 1992, BIOCHIMIE, V74, P941, DOI 10.1016/0300-9084(92)90078-S; CERDAN S, 1990, J BIOL CHEM, V265, P12916; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; GARFINKEL D, 1966, J BIOL CHEM, V241, P3918; GOPHER A, 1990, P NATL ACAD SCI USA, V87, P5449, DOI 10.1073/pnas.87.14.5449; GOPHER A, 1991, 10 ANN SCI M SOC MAG, P1050; GOPHER A, 1990, 9TH ANN SCI M SOC MA, P1110; Hertz L., 1988, GLUTAMINE GLUTAMATE, P39; INBAR L, 1988, J BIOL CHEM, V263, P16014; INBAR L, 1988, J BACTERIOL, V170, P4055, DOI 10.1128/jb.170.9.4055-4064.1988; INBAR L, 1991, J BACTERIOL, V173, P7790, DOI 10.1128/jb.173.24.7790-7801.1991; INBAR L, 1987, EUR J BIOCHEM, V162, P621, DOI 10.1111/j.1432-1033.1987.tb10684.x; KALDERON B, 1986, FEBS LETT, V204, P29, DOI 10.1016/0014-5793(86)81381-3; KALDERON B, 1987, FEBS LETT, V213, P209, DOI 10.1016/0014-5793(87)81493-X; KALDERON B, 1989, P NATL ACAD SCI USA, V86, P4690, DOI 10.1073/pnas.86.12.4690; KALDERON B, 1988, BIOMED ENVIRON MASS, V16, P305, DOI 10.1002/bms.1200160158; KALDERON B, 1989, AM J PHYSIOL, V257, pE346, DOI 10.1152/ajpendo.1989.257.3.E346; LAPIDOT A, 1986, TRENDS BIOTECHNOL, V4, P2, DOI 10.1016/0167-7799(86)90126-5; LAPIDOT A, 1990, J INHERIT METAB DIS, V13, P466, DOI 10.1007/BF01799504; LAPIDOT A, 1991, 10TH ANN SCI M SOC M, P444; LAPIDOT A, 1992, 11TH ANN SCI M SOC M, P2110; LONDON RE, 1988, PROG NUCL MAG RES SP, V20, P337, DOI 10.1016/0079-6565(88)80010-4; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; McIlwain H., 1985, BIOCH CENTRAL NERVOU, V5th ed.; SHANK RP, 1993, J NEUROCHEM, V61, P315, DOI 10.1111/j.1471-4159.1993.tb03570.x	29	140	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27198	27208						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961629				2022-12-25	WOS:A1994PV77100011
J	SHIH, A; LARAMEE, GR; SCHMELZER, CH; BURTON, LE; WINSLOW, JW				SHIH, A; LARAMEE, GR; SCHMELZER, CH; BURTON, LE; WINSLOW, JW			MUTAGENESIS IDENTIFIES AMINO-TERMINAL RESIDUES OF NERVE GROWTH-FACTOR NECESSARY FOR TRK RECEPTOR-BINDING AND BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; HOMOLOG-SCANNING MUTAGENESIS; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; FACTOR FAMILY; BIOCHEMICAL-CHARACTERIZATION; PROTOONCOGENE PRODUCT; RECOMBINANT HUMAN; NGF RECEPTOR	Limited proteolysis and site-directed mutagenesis of human nerve growth factor (hNGF) was utilized to determine the role of the NH2 terminus in p140(TrkA) (TrkA) receptor function. Purified (6-118)hNGF, representing deletion of the first 5 NH2-terminal residues, is 9-fold less potent than (1-118)hNGF in displacing I-125-hNGF from TrkA. The deletion of a further 4 residues to form (10-118)hNGF is nearly 300-fold less potent. (6-118)hNGF is only 2-4-fold less potent than (1-118)hNGF in eliciting TrkA autophosphorylation and PC12 cell neurite outgrowth, suggesting that the first 5 residues of the NH2 terminus are necessary for full TrkA binding activity but may be less critical for potent receptor activation and intracellular signaling. In contrast, purified mutant H4D results in a nearly 1000-fold loss in TrkA binding at 4 degrees C relative to (1-118)hNGF, at least 10-fold less potency of TrkA autophosphorylation, and 30-fold loss of potency in PC12 cell differentiation. NH2-terminal hBDNF/hNGF and hNT3/hNGF chimeric mutants further affected these activities suggesting that the NH2-terminal sequence specificity of hNGF contributes to structural interactions necessary for TrkA receptor binding and ligand-induced signaling. The potency of binding of all hNGF variants to the low affinity NGF receptor p75 was largely unaffected indicating distinct structural contributions of the NH2-terminal region of hNGF to the binding to TrkA versus p75.	GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROC SCI,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech								BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BURTON LE, 1992, J NEUROCHEM, V59, P1937, DOI 10.1111/j.1471-4159.1992.tb11030.x; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; COLLAWN JF, 1988, J BIOL CHEM, V263, P8625; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P257; EIGENBROT C, 1992, Current Opinion in Biotechnology, V3, P333, DOI 10.1016/0958-1669(92)90160-K; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ESCANDON E, 1993, J NEUROSCI RES, V34, P601, DOI 10.1002/jnr.490340602; GIBBBS CS, 1991, J BIOL CHEM, V266, P3923; Gorman CM, 1990, DNA PROTEIN ENG TECH, V2, P1; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASHIO Y, 1990, FEBS LETT, V266, P187; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; ROSENTHAL A, 1991, ENDOCRINOLOGY, V129, P1289, DOI 10.1210/endo-129-3-1289; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHMELZER CH, 1992, J NEUROCHEM, V59, P1675, DOI 10.1111/j.1471-4159.1992.tb10998.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUTER U, 1992, J NEUROSCI, V12, P306; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TAYLOR RAV, 1992, SOC NEUR ABS, V17, P712; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VROEGOP S, 1992, J PROTEIN CHEM, V11, P71, DOI 10.1007/BF01025094; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	61	58	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27679	27686						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961687				2022-12-25	WOS:A1994PV77100081
J	VANCURA, A; HALDAR, D				VANCURA, A; HALDAR, D			PURIFICATION AND CHARACTERIZATION OF GLYCEROPHOSPHATE ACYLTRANSFERASE FROM RAT-LIVER MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SN-GLYCEROL 3-PHOSPHATE; MEMBRANE PHOSPHOLIPID-SYNTHESIS; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; ESCHERICHIA-COLI; DIHYDROXYACETONE PHOSPHATE; COENZYME-A; GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; PHOSPHATIDYLINOSITOL SYNTHASE; ENZYMES; PROTEIN	Glycerophosphate acyltransferase (GAT) catalyzes the conversion of sn-glycerol 3-phosphate to lysophospha tidic acid (LPA), the first and committed step of triacyl glycerol and phospholipid synthesis. In spite of the important regulatory roles GAT may play in this biosynthetic pathway, little information is available on the structure, biochemical properties, and regulation of GAT from eukaryotic cells. We solubilized GAT from rat Liver mitochondrial membranes and purified it to an apparent homogeneity by hydroxylapatite chromatography, preparative isoelectric focusing, and gel filtration. The enzyme is composed of a single polypeptide of 85 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and gel filtration chromatography of the native protein. The GAT activity was completely lost during the purification procedure and required addition of exogenous phospholipids for its reconstitution. Since a high phospholipid to detergent ratio was needed for full reactivation, it is concluded that GAT requires ''lipid boundary'' for reconstitution. The ability of different phospholipids to reactivate GAT decreased in the following order: phosphatidylglycerol (PG), phosphatidylethanolamine (PE), phosphatidylcholine (PC), asolectin, phosphatidylinositol (PI), phosphatidylserine (PG), and cardiolipin. 1,2-Dioleoyl derivatives of PG; and PE were more effective in reconstituting the GAT activity than corresponding dipalmitoyl derivatives. The GAT activation was further increased by using a combination of PG and PE or PG and PC. Regardless of the phospholipid used for reconstitution, palmitoyl-CoA was the best acyl donor and LPA was the only reaction product.	ST JOHNS UNIV, DEPT BIOL SCI, JAMAICA, NY 11439 USA	Saint John's University				Vancura, Ales/0000-0002-5895-1218	NIGMS NIH HHS [GM-46692] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046692] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAELEE M, 1990, J BIOL CHEM, V265, P7221; BATES EJ, 1979, BIOCHEM J, V182, P751, DOI 10.1042/bj1820751; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bell RM, 1983, ENZYMES, V16, P87; BRINDLEY DN, 1982, PHOSPHOLIPIDS NEW CO, V4, P179; Chapman D., 1984, BIOL MEMBR, VV, P1; COLEMAN RA, 1984, BIOCHEM J, V217, P391, DOI 10.1042/bj2170391; COLEMAN RA, 1983, J BIOL CHEM, V258, P450; CORTESE JD, 1982, BIOCHEMISTRY-US, V21, P3899, DOI 10.1021/bi00259a027; DAAE LNW, 1973, BIOCHIM BIOPHYS ACTA, V306, P186, DOI 10.1016/0005-2760(73)90224-5; DATTA NS, 1984, FEBS LETT, V176, P264, DOI 10.1016/0014-5793(84)80954-0; Dennis EA, 1983, ENZYMES, P307; DUROCHER V, 1990, CAN J PHYSIOL PHARM, V68, P1255, DOI 10.1139/y90-188; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; GREEN PR, 1981, J BIOL CHEM, V256, P1151; HAJRA AK, 1978, J NEUROCHEM, V31, P125, DOI 10.1111/j.1471-4159.1978.tb12440.x; HALDAR D, 1979, J BIOL CHEM, V254, P4502; HALDAR D, 1992, METHOD ENZYMOL, V209, P64; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; KELKER HC, 1979, J BIOL CHEM, V254, P5364; KIMELBERG HK, 1977, CELL SURF REV, V3, P205; KLUYTMANS JH, 1974, PREP BIOCHEM, V4, P141, DOI 10.1080/00327487408068769; LARSON TJ, 1980, J BIOL CHEM, V255, P9421; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LIGHTNER VA, 1980, J BIOL CHEM, V255, P9413; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONROY G, 1973, J BIOL CHEM, V248, P2845; MONROY G, 1972, J BIOL CHEM, V247, P6884; NIMMO HG, 1978, BIOCHEM J, V176, P607, DOI 10.1042/bj1760607; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SAGGERSON ED, 1987, BIOCHEM J, V243, P289, DOI 10.1042/bj2430289; SALEM L, 1962, J CHEM PHYS, V37, P2100, DOI 10.1063/1.1733431; SANDERMANN H, 1986, PROGR PROTEIN LIPID, V2, P197; SCHEIDELER MA, 1991, J BIOL CHEM, V266, P14321; SCHEIDELER MA, 1986, J BIOL CHEM, V261, P990; SCHEIDELER MA, 1989, J BIOL CHEM, V264, P12455; SHIN DH, 1991, J BIOL CHEM, V266, P23834; STERN W, 1978, J BIOL CHEM, V253, P8047; THOMAS PD, 1990, J BIOL CHEM, V265, P2684; TILLMAN TS, 1986, J BIOL CHEM, V261, P9144; VANCURA A, 1991, BIOCHEM BIOPH RES CO, V175, P339, DOI 10.1016/S0006-291X(05)81240-9; VANCURA A, 1992, J BIOL CHEM, V267, P14353; VANDEENEN LLM, 1965, PROGR CHEM FATS OTHE, V8; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; WILKISON WO, 1988, J BIOL CHEM, V263, P14505; WOOD R, 1969, ARCH BIOCHEM BIOPHYS, V131, P478, DOI 10.1016/0003-9861(69)90420-2; YAMASHITA S, 1972, EUR J BIOCHEM, V31, P565, DOI 10.1111/j.1432-1033.1972.tb02566.x; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029	49	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27209	27215						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961630				2022-12-25	WOS:A1994PV77100012
J	FOLETTA, VC; SONOBE, MH; SUZUKI, T; ENDO, T; IBA, H; COHEN, DR				FOLETTA, VC; SONOBE, MH; SUZUKI, T; ENDO, T; IBA, H; COHEN, DR			CLONING AND CHARACTERIZATION OF THE MOUSE FRA-2 GENE	ONCOGENE			English	Article							C-FOS; MESSENGER-RNAS; JUN COMPLEXES; TRANSCRIPTION; PROTEINS; AP-1; EXPRESSION; FAMILY; SERUM; DNA	Transcription factor AP-1 is comprised of multiple protein complexes that include members of a family of genes related to the proto-oncogene c-fos. In this report, we have extended the analysis of one member of this family, fos-related antigen-2 (fra-2), by isolating and characterising genomic and cDNA clones encoding:the mouse fra-2 homolog. The overall gene structure (number and positions of introns) was similar to that of both the chicken fra-2 gene and other members of the fos family, and the relative positions of putative enhancers in the 5' regulatory region were well conserved between the mouse and chicken fra-2 genes. High levels of fra-2 mRNA were detected in ovary, stomach, small and large intestine, brain, lung and heart. The mouse Fra-2 protein showed 94% and 87.5% conservation with human and chicken Fra-2, respectively, and mouse Fra-2, like the chicken homolog, induced transformation of chicken embryo fibroblasts. The characterisation of the mouse fra-2 gene provides a basis for analysis of Fra-2 function in the whole animal.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO,JAPAN	Australian National University; John Curtin School of Medical Research; University of Tokyo			Sonobe, Martha/I-2877-2015	Cohen, Donna/0000-0002-0419-9542				ALEXANDERBRIDGES M, 1992, J CELL BIOCHEM, V48, P129, DOI 10.1002/jcb.240480204; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1993, ONCOGENE, V8, P443; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1994, P NATL ACAD SCI USA, V91, P4372, DOI 10.1073/pnas.91.10.4372; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FUJIWARA K, 1987, J VIROL, V61, P4021; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; HADMAN M, 1993, ONCOGENE, V8, P1895; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MATSUI M, 1990, ONCOGENE, V5, P249; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MOLDERS H, 1987, ONCOGENE, V1, P377; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; THOMPSON JA, 1979, J VIROL, V31, P437, DOI 10.1128/JVI.31.2.437-446.1979; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715	38	45	48	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3305	3311						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936655				2022-12-25	WOS:A1994PM65800024
J	KERPPOLA, TK; CURRAN, T				KERPPOLA, TK; CURRAN, T			A CONSERVED REGION ADJACENT TO THE BASIC DOMAIN IS REQUIRED FOR RECOGNITION OF AN EXTENDED DNA-BINDING SITE BY MAF/NRL FAMILY PROTEINS	ONCOGENE			English	Article							NF-KAPPA-B; FOS-JUN; MAF ONCOGENE; TRANSCRIPTION; GENE; ACTIVATION; COMPLEX; EXPRESSION; ENHANCER; PROMOTER	The c-maf proto-oncogene and the neural retina specific gene nul encode members of a subfamily of bZIP proteins that form heterodimers with Fos and Jun. We have determined the DNA binding specificities of various homo- and heterodimeric combinations among Nrl, Maf, Fos and Jun. Fos-Jun heterodimers and Jun homodimers bound to a palindromic TGAC(G)TCA recognition sequence as previously demonstrated. Maf and Nrl homodimers also bound to palindromic recognition sites with the consensus sequence TGC(N)(6-7)GCA. Fos-Nrl, Jun-Nrl and Fos-Maf heterodimers bound to nonpalindromic recognition sequences with the consensus sequence TGAC(N)(3-4)GCA. These results indicate that Nrl and Maf have a DNA binding specificity distinct from that of Fos and Jun, and that each subunit in the dimer independently recognizes one half of the recognition sequence. This allows combinatorial determination of target gene specificity. Specific recognition of the extended DNA binding sequence by Maf requires an ancillary DNA binding region on the amino terminal side of the basic domain that is conserved among Maf/Nrl family members. Thus, heterodimer formation among distantly related bZIP family members can generate novel DNA binding specificities and the addition of an auxiliary DNA binding domain to the simple bZIP motif can facilitate the recognition of extended binding sites.	ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110				Kerppola, Tom/AFK-6155-2022; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011; Curran, Tom/C-1164-2008; Kerppola, Tom/AAG-4457-2022; Curran, Tom/F-5234-2018	Kerppola, Tom/0000-0002-0611-9446; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446; Curran, Tom/0000-0003-1444-7551				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERGELSON S, 1994, ONCOGENE, V9, P565; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CURRAN T, 1988, CELL, V55, P305; DICCIANNI MB, 1992, NUCLEIC ACIDS RES, V20, P5153, DOI 10.1093/nar/20.19.5153; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; PAOLELLA DN, 1994, SCIENCE, V264, P1130, DOI 10.1126/science.8178171; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RYSECK RP, 1991, ONCOGENE, V6, P533; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	36	123	124	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3149	3158						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936637				2022-12-25	WOS:A1994PM65800006
J	MASER, RL; MAGENHEIMER, BS; CALVET, JP				MASER, RL; MAGENHEIMER, BS; CALVET, JP			MOUSE PLASMA GLUTATHIONE-PEROXIDASE - CDNA SEQUENCE-ANALYSIS AND RENAL PROXIMAL TUBULAR EXPRESSION AND SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; POLYCYSTIC KIDNEY-DISEASE; IMMUNOLOGICAL INVESTIGATIONS; TISSUE DISTRIBUTION; MESSENGER-RNA; SELENIUM; ACID; GENE; SELENOCYSTEINE; IDENTIFICATION	A mouse kidney cDNA isolated by differential screening was found to be highly homologous to rat, human, and bovine plasma glutathione peroxidase (GPx) sequences. Analysis of the full-length coding region sequence demonstrated an in-frame selenocysteine-encoding opal codon and putative signal sequence, suggesting that the sequence represents the mouse homolog of plasma GPx. The level of expression of plasma GPx in various mouse tissues and during development was investigated by Northern blot analysis. Plasma GPx mRNA was observed to be very abundant in kidney compared with placenta, epididymis, intestine, lung, heart, testis, ovary, salivary gland, spleen, thymus, stomach, brain, and fetal kidney and could not be detected in pancreas or in Liver except from pregnant mice. In addition, plasma GPx mRNA levels were shown to increase during postnatal development of the kidney. In situ hybridization localized plasma GPx mRNA to proximal tubules, while primary cell culture demonstrated that plasma GPx is synthesized and secreted by proximal tubular epithelial cells. The relative abundance of plasma GPx mRNA in mouse kidney suggests that proximal tubules may be the primary source of the enzyme detectable in plasma and further suggests that plasma GPx has an important function in protecting the kidney from oxidative damage.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037100] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37100] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATSCHUL SF, 1990, J MOL BIOL, V215, P403; Ausubel FM., 1988, CURRENT PROTOCOLS MO; AVISSAR N, 1991, J NUTR, V121, P1243, DOI 10.1093/jn/121.8.1243; AVISSAR N, 1989, BLOOD, V73, P318; AVISSAR N, 1994, AM J PHYSIOL, V266, pC367, DOI 10.1152/ajpcell.1994.266.2.C367; AVISSAR N, 1994, ARCH BIOCHEM BIOPHYS, V309, P239, DOI 10.1006/abbi.1994.1108; AVISSAR N, 1989, J BIOL CHEM, V264, P15850; Bard JBL, 1992, CURR OPIN GENET DEV, V2, P589, DOI 10.1016/S0959-437X(05)80177-7; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU FF, 1992, BLOOD, V79, P3233; CHU FF, 1993, J BIOL CHEM, V268, P2571; DEAR TN, 1991, BIOCHEMISTRY-US, V30, P10376, DOI 10.1021/bi00107a003; DELEEUW WJF, 1989, NUCLEIC ACIDS RES, V17, P10137, DOI 10.1093/nar/17.23.10137; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; DORFMAN DM, 1989, BIOTECHNIQUES, V7, P568; EBERLE JR, 1993, BIOTECHNIQUES, V14, P408; ESWORTHY RS, 1991, ARCH BIOCHEM BIOPHYS, V286, P330, DOI 10.1016/0003-9861(91)90048-N; FAURE J, 1991, BIOL REPROD, V44, P13, DOI 10.1095/biolreprod44.1.13; FORSTROM JW, 1978, BIOCHEMISTRY-US, V17, P2639, DOI 10.1021/bi00606a028; GATTONE VH, 1988, LAB INVEST, V59, P231; GESEK FA, 1987, AM J PHYSIOL, V253, pF358, DOI 10.1152/ajprenal.1987.253.2.F358; GHYSELINCK NB, 1991, J REPROD FERTIL, V93, P461; GONZALEZ IL, 1986, AM J HUM GENET, V38, P419; HARDING MA, 1992, KIDNEY INT, V41, P317, DOI 10.1038/ki.1992.44; HARDING MA, 1991, DEV BIOL, V146, P483, DOI 10.1016/0012-1606(91)90249-3; HOJO Y, 1987, SCI TOTAL ENVIRON, V65, P85, DOI 10.1016/0048-9697(87)90163-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRINSKY NI, 1992, P SOC EXP BIOL MED, V200, P248; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDIPATI KR, 1987, J BIOL CHEM, V262, P17398; MARTINALONSO JM, 1993, J BIOCHEM-TOKYO, V114, P284, DOI 10.1093/oxfordjournals.jbchem.a124168; MASER R L, 1992, Journal of the American Society of Nephrology, V3, P299; PERRY ACF, 1992, BIOCHEM J, V285, P863, DOI 10.1042/bj2850863; Pertoft H., 1982, CELL SEPARATION METH, P115; RANKIN CA, 1992, J CELL PHYSIOL, V152, P578, DOI 10.1002/jcp.1041520318; ROVERI A, 1992, J BIOL CHEM, V267, P6142; Sambrook J, 1989, MOL CLONING LABORATO; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; STRIKER GE, 1985, LAB INVEST, V53, P122; SUNDE RA, 1990, ANNU REV NUTR, V10, P451, DOI 10.1146/annurev.nu.10.070190.002315; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; TAKAHASHI K, 1986, BLOOD, V68, P640; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; TAUB M, 1984, METHODS SERUM FREE C, P3; THOMAS JP, 1990, J BIOL CHEM, V265, P454; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; VENUTI SE, 1988, BIOCHIM BIOPHYS ACTA, V946, P119, DOI 10.1016/0005-2736(88)90464-6; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMAMOTO Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P541, DOI 10.1006/abbi.1993.1458; YOSHIMURA S, 1991, J BIOCHEM-TOKYO, V109, P918, DOI 10.1093/oxfordjournals.jbchem.a123480	54	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27066	27073						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929449				2022-12-25	WOS:A1994PQ93100072
J	COHEN, DM; CHIN, WW; GULLANS, SR				COHEN, DM; CHIN, WW; GULLANS, SR			HYPEROSMOTIC UREA INCREASES TRANSCRIPTION AND SYNTHESIS OF EGR-1 IN MURINE INNER MEDULLARY COLLECTING DUCT (MIMCD3) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY ALDOSE REDUCTASE; RENAL EPITHELIAL-CELLS; ZINC FINGER PROTEIN; GROWTH FACTOR-II; DNA-BINDING; INOSITOL COTRANSPORTER; MOLECULAR-CLONING; PROMOTER REGION; OSMOTIC-STRESS; GENE-PRODUCT	It was previously shown that when cells of renal epithelial origin are exposed to hyperosmotic urea in concentrations unique to the renal medulla, abundance of mRNA encoding the immediate-early gene product Egr-1 is up-regulated. This phenomenon appears restricted to cells of renal epithelial origin. In the present study, the newly isolated murine renal inner medullary cell line mIMCD3 was used to determine whether the urea-induced increase in Egr-1 mRNA abundance is associated with increased expression of functional protein product, and whether this increase is transcriptionally mediated. In Western analysis, urea (200 mM) increased Egr-1 immunoreactivity 3-fold relative to sham-treated cells. [S-35]Methionine pulse-labeling followed by immunoprecipitation confirmed that this increased immunoreactivity was associated with increased de novo Egr-1 protein synthesis. Electrophoretic mobility shift assay demonstrated that urea treatment induced a commensurate increase in specific DNA binding activity for the Egr-1 consensus sequence. In addition, the increase in Egr-1 mRNA expression accompanying urea treatment was a consequence of enhanced transcription, as determined by nuclear run-off assay. Taken together, these data indicate that hyperosmotic urea increases both Egr-1 transcription and new protein synthesis in renal epithelial cells in culture, and that this newly synthesized Egr-1 is a functional DNA-binding protein. To our knowledge, this is the first example of urea-inducible gene transcription. In addition, Egr-1 represents the first eukaryotic transcription factor transcriptionally activated by a hyperosmotic stressor.	BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST, DIV GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	COHEN, DM (corresponding author), BRIGHAM & WOMENS HOSP, DIV RENAL, 75 FRANCIS ST, BOSTON, MA 02115 USA.				NIDDK NIH HHS [DK-36031, DK-02188] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036031, K08DK002188] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOUBY N, 1985, KIDNEY INT, V28, P456, DOI 10.1038/ki.1985.152; BOUBY N, 1987, KIDNEY INT       S22, V32, pS57; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COHEN DM, 1993, AM J PHYSIOL, V264, pF601, DOI 10.1152/ajprenal.1993.264.4.F601; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COHEN DM, 1993, AM J PHYSIOL, V264, pF593, DOI 10.1152/ajprenal.1993.264.4.F593; COHEN DM, 1993, CELLULAR MOL PHYSL C, P363; COWLEY BD, 1990, AM J PHYSIOL, V258, pF154, DOI 10.1152/ajprenal.1990.258.1.F154; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; FEI HH, 1993, BIOTECHNIQUES, V15, P838; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GREENBERG ME, 1993, CURRENT PROTOCOLS MO; GSTRAUNTHALER GJA, 1988, RENAL PHYSIOL BIOCH, V11, P1; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HANDLER JS, 1993, AM J PHYSIOL, V265, pC1449, DOI 10.1152/ajpcell.1993.265.6.C1449; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; JACK RS, 1990, BIOCHEM BIOPH RES CO, V169, P840, DOI 10.1016/0006-291X(90)91969-Y; KNEPPER MA, 1991, KIDNEY, P445; KWON HM, 1992, J BIOL CHEM, V267, P6297; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P7456; LIM RW, 1987, ONCOGENE, V1, P263; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORIYAMA T, 1990, AM J PHYSIOL, V259, pF847, DOI 10.1152/ajprenal.1990.259.5.F847; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; NAKANISHI T, 1989, AM J PHYSIOL, V257, pC795, DOI 10.1152/ajpcell.1989.257.4.C795; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TOBACK FG, 1980, P NATL ACAD SCI-BIOL, V77, P6654, DOI 10.1073/pnas.77.11.6654; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; WERNER H, 1990, BIOCHEM BIOPH RES CO, V169, P1021, DOI 10.1016/0006-291X(90)91996-6; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAMAUCHI A, 1993, AM J PHYSIOL, V264, pF20; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	51	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25865	25870						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929290				2022-12-25	WOS:A1994PQ49100092
J	XIE, XS; CRIDER, BP; MA, YM; STONE, DK				XIE, XS; CRIDER, BP; MA, YM; STONE, DK			ROLE OF A 50-57-KDA POLYPEPTIDE HETERODIMER IN THE FUNCTION OF THE CLATHRIN-COATED VESICLE PROTON PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; AMINO-ACID SEQUENCE; MOLECULAR-CLONING; TRANSLOCATING COMPLEX; ADENOSINE-TRIPHOSPHATASE; SACCHAROMYCES-CEREVISIAE; CHROMAFFIN GRANULES; CDNA SEQUENCE; HIGHER-PLANT; SUBUNIT	The vacuolar-type proton-translocating ATPase of clathrin-coated vesicles is composed of an integral membrane proton channel (V-B) and a peripheral catalytic sector (V-C). Native enzyme can catalyze the hydrolysis of both MgATP and CaATP and support proton pumping when reconstituted into liposomes. In contrast, isolated V-C catalyzes only Ca2+-activated ATP hydrolysis and cannot support proton pumping when reconstituted into liposomes (Xie, X.-S., and Stone, D. K. (1988) J. Biol. Chem. 263, 9859-9867). We now report that solubilized isolated V-C can be reassembled with purified V-B to restore properties of native enzyme, including Mg2+-activated ATP hydrolysis and proton-pumping capability. Investigation of this reassembly revealed that a heterodimer, composed of polypeptides of 50 and 57 kDa, stimulates Ca2+-activated ATPase activity of isolated V, 2-fold and Mg2+-activated ATPase activity catalyzed by the reassembled pump 9-fold. Moreover, this heterodimer stimulated proton transport by the reassembled pump >20-fold. When Separated from the proton pump, the dimer has no detectable kinase activity. Maximal stimulation occurs at a molar ratio of heterodimer to reassembled pump of 3, implying a structural, nonenzymatic mechanism. These data indicate that the 50-kDa and/or the 57-kDa polypeptide likely plays an essential and potentially regulatory role in the function of the proton-translocating ATPase of clathrin-coated vesicles.			XIE, XS (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOLEC TRANSPORT,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK RO1 33627] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERN RA, 1909, KIDNEY, P318; BELTRAN C, 1992, ACTA PHYSIOL SCAND, V146, P41; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; FORGAC M, 1992, J EXP BIOL, V172, P155; GRAF R, 1994, J BIOL CHEM, V269, P3767; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HO MN, 1993, J BIOL CHEM, V268, P18286; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1987, J BIOL CHEM, V262, P3864; KEILY B, 1968, J BIOL CHEM, V243, P129; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI S, 1991, J BIOL CHEM, V266, P16078; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; MEAGHER L, 1990, NUCLEIC ACIDS RES, V18, P6712, DOI 10.1093/nar/18.22.6712; MEYERS M, 1993, J BIOL CHEM, V268, P9184; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NANDI PK, 1982, P NATL ACAD SCI-BIOL, V79, P5881, DOI 10.1073/pnas.79.19.5881; NELSON H, 1990, J BIOL CHEM, V265, P20390; NEZU J, 1992, J BIOCHEM, V112, P212, DOI 10.1093/oxfordjournals.jbchem.a123879; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PENG SB, 1994, J BIOL CHEM, V269, P11356; PENG SB, 1993, J BIOL CHEM, V268, P23519; PERCY JM, 1985, BIOCHEM J, V231, P557, DOI 10.1042/bj2310557; PERIN MS, 1991, J BIOL CHEM, V266, P3877; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1988, KIDNEY INT, V33, P403; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; SUN SZ, 1987, J BIOL CHEM, V262, P14790; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; TAKASE K, 1994, J BIOL CHEM, V269, P11037; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; WANG SY, 1988, J BIOL CHEM, V263, P17638; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1986, P NATL ACAD SCI USA, V83, P8913, DOI 10.1073/pnas.83.23.8913; XIE XS, 1988, J BIOL CHEM, V263, P9859; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	52	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25809	25815						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929286				2022-12-25	WOS:A1994PQ49100085
J	BAKER, DP; STEBBINS, JW; DESENA, E; KANTROWITZ, ER				BAKER, DP; STEBBINS, JW; DESENA, E; KANTROWITZ, ER			GLUTAMIC-ACID-86 IS IMPORTANT FOR POSITIONING THE 80S LOOP AND ARGININE-54 AT THE ACTIVE-SITE OF ESCHERICHIA-COLI ASPARTATE TRANSCARBAMOYLASE AND FOR THE STRUCTURAL STABILIZATION OF THE C1-C2 INTERFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURES; CATALYTIC CHAIN; LIGATED-T; CARBAMOYLTRANSFERASE; BINDING; RESOLUTION; MUTANTS; ANALOG; STATE	Glu-86, which interacts with the side chain of Arg-54 across the C1-C2 interface of Escherichia coli aspartate transcarbamoylase, tethers the end of the flexible 80's loop, which moves into the active site during the T to R transition. In order to determine whether this interaction is important for the correct positioning of the 80's loop and Arg-54 at the active site and also for the structural stabilization of the enzyme, a mutant version was created in which Glu-86 was replaced by Gln (Glu-86 --> Gln). Although the mutant holoenzyme exhibits almost normal homotropic cooperativity, both the holoenzyme and catalytic subunit exhibit substantial reductions in activity and affinity for aspartate and carbamyl phosphate. Furthermore, the mutant holoenzyme shows a marked decrease in the activation by ATP and by the bisubstrate analog N-(phosphonoacetyl)-L-aspartate, reduced inhibition by CTP, as well as reduced affinities for these ligands. Results from molecular dynamics simulations of the Glu-86 --> Gln and Glu-86 --> Ala enzymes suggest that the positions of the 80's loop and Arg-54 are significantly perturbed by the introduction of these mutations. Taken together, these results indicate that the interaction between Glu-86 and Arg-54 is important for the formation of the high affinity, high activity form of the enzyme by stabilizing the correct position of the 80's loop and Arg-54 at the active site. Heat inactivation experiments also demonstrated that Glu-86 plays a significant role in the structural stabilization of the C1-C2 interface, since the temperature required for loss of half of the activity of the Glu-86 --> Gln catalytic subunit is reduced by 5 degrees C relative to the wild-type catalytic subunit.	BOSTON COLL,MERKERT CHEM CTR,DEPT CHEM,CHESTNUT HILL,MA 02167	Boston College					NCRR NIH HHS [1 P41 RR06009] Funding Source: Medline; NIGMS NIH HHS [NIGMS GM26237] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER DP, 1993, BIOCHEMISTRY-US, V32, P10150, DOI 10.1021/bi00089a034; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURZ DS, 1990, BIOPHYS CHEM, V37, P31, DOI 10.1016/0301-4622(90)88005-D; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FOOTE J, 1985, J MOL BIOL, V186, P175, DOI 10.1016/0022-2836(85)90267-0; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P389, DOI 10.1021/bi00454a013; GOUAUX JE, 1988, P NATL ACAD SCI USA, V85, P4205, DOI 10.1073/pnas.85.12.4205; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; JONES ME, 1955, J AM CHEM SOC, V77, P819, DOI 10.1021/ja01608a101; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KE HM, 1984, P NATL ACAD SCI USA, V81, P4027; KIM KH, 1987, J MOL BIOL, V196, P853, DOI 10.1016/0022-2836(87)90410-4; KOSMAN RP, 1993, PROTEINS, V15, P147, DOI 10.1002/prot.340150206; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P268, DOI 10.1021/bi00401a041; MIDDLETON SA, 1989, BIOCHEMISTRY-US, V28, P1617, DOI 10.1021/bi00430a029; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PASTRALANDIS SC, 1978, J BIOL CHEM, V253, P4624; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; REICHARD P, 1956, ACTA CHEM SCAND, V10, P548, DOI 10.3891/acta.chem.scand.10-0548; ROBEY EA, 1986, P NATL ACAD SCI USA, V83, P5935; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEBBINS JW, 1989, BIOCHEMISTRY-US, V28, P2592, DOI 10.1021/bi00432a037; STEBBINS JW, 1992, PROTEIN SCI, V1, P1435, DOI 10.1002/pro.5560011105; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; WEST TP, 1985, BIOCHIM BIOPHYS ACTA, V839, P32, DOI 10.1016/0304-4165(85)90178-3; WU CW, 1973, BIOCHEMISTRY-US, V12, P1400, DOI 10.1021/bi00731a021; XU W, 1988, BIOCHEMISTRY-US, V27, P5507, DOI 10.1021/bi00415a018; XU W, 1991, BIOCHEMISTRY-US, V30, P2535, DOI 10.1021/bi00223a034; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	40	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24608	24614						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929132				2022-12-25	WOS:A1994PQ49000018
J	CHEN, XH; HARDEN, TK; NICHOLAS, RA				CHEN, XH; HARDEN, TK; NICHOLAS, RA			MOLECULAR-CLONING AND CHARACTERIZATION OF A NOVEL BETA-ADRENERGIC-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-3-ADRENERGIC RECEPTOR; HAMSTER OVARY CELLS; TURKEY ERYTHROCYTE; G-PROTEIN; BETA-1-ADRENERGIC RECEPTOR; PHOSPHOLIPASE-C; AGONIST ACTIVATION; GENE; RAT; ADRENOCEPTOR	In an attempt to isolate new G protein-coupled receptors from turkey erythrocytes, reverse transcribed polymerase chain reaction was performed on fetal turkey blood RNA using degenerate primers based on conserved sequences present in seven transmembrane receptors. An open reading frame in one of the clones, designated 4C (497 base pairs), displayed approximately 50-60% identity to all of the previously cloned beta-adrenergic receptors (beta-ARs). A lambda-DASH turkey genomic library was screened with a probe generated from the partial 4C cDNA, and the gene encoding this receptor was localized to a 3.5-kilobase pair HindIII fragment. Ribonuclease protection analysis of turkey lung mRNA indicated that the 3' end of the coding sequence of the 4C gene, like beta(3)-AR, was interrupted by an intron. To obtain the cDNA sequence of 4C, RNA-polymerase chain reaction was performed using primers complementary to regions identified by ribonuclease protection analysis to be present in 4C mRNA. Comparison of the genomic and cDNA sequences of 4C indicated that the first exon encodes 414 amino acids of the protein, the second exon (68 base pairs) encodes an additional 12 residues followed by a stop codon, and the third exon is composed of 3'-untranslated sequence. The 4C receptor was transiently expressed in COS-1 cells, and the apparent affinities of a series of beta-AR agonists and antagonists were determined using [I-125]iodocyanopindolol. As implicated by its amino acid sequence, 4C displayed a pharmacological selectivity that was consistent with that of a beta-AR but distinct from other cloned beta-ARs. Isoproterenol, epinephrine, and norepinephrine stimulated cyclic AMP accumulation in a concentration dependent manner in mouse L cells stably expressing the 4C receptor. No effect on phospholipase C activity was observed. Ribonuclease protection assays indicated that 4C mRNA exhibits a broad tissue distribution, which suggests that it may play an important role in avian physiology.	UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM38213] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; BENSAID M, 1993, FEBS LETT, V318, P223, DOI 10.1016/0014-5793(93)80516-W; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLIN N, 1993, MOL PHARMACOL, V44, P1094; BOND RA, 1987, BRIT J PHARMACOL, V91, P683, DOI 10.1111/j.1476-5381.1987.tb11262.x; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CHALLISS RAJ, 1988, BIOCHEM PHARMACOL, V37, P947, DOI 10.1016/0006-2952(88)90186-4; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; Fourney R.M., 1988, FOCUS, V10, P5; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GRANNEMAN JG, 1992, MOL PHARMACOL, V42, P964; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; GRANNEMAN JG, 1993, MOL PHARMACOL, V44, P264; HARDEN TK, 1982, MOL PHARMACOL, V21, P570; HERTEL C, 1990, J BIOL CHEM, V265, P17988; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; LAZAROWSKI ER, 1994, J BIOL CHEM, V269, P11830; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LIGGETT SB, 1992, MOL PHARMACOL, V42, P634; MACHIDA CA, 1990, J BIOL CHEM, V265, P12960; MAURICE DH, 1993, BIOCHEM J, V290, P765, DOI 10.1042/bj2900765; MAURIEGE P, 1988, J LIPID RES, V29, P587; MINNEMAN KP, 1980, MOL PHARMACOL, V17, P1; MONOPOLI A, 1989, J CARDIOVASC PHARM, V14, P114, DOI 10.1097/00005344-198907000-00020; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NAKAHATA N, 1987, BIOCHEM J, V241, P337, DOI 10.1042/bj2410337; NANTEL F, 1993, MOL PHARMACOL, V43, P548; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; ROONEY TA, 1991, J BIOL CHEM, V266, P15068; Sambrook J, 1989, MOL CLONING LABORATO; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SELDEN RF, 1993, CURRENT PROTOCOLS MO; SHORR RGL, 1982, J BIOL CHEM, V257, P2341; SIMPSON IA, 1980, FEBS LETT, V115, P113, DOI 10.1016/0014-5793(80)80738-1; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1989, J BIOL CHEM, V264, P16470; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; TATE KM, 1991, EUR J BIOCHEM, V196, P357, DOI 10.1111/j.1432-1033.1991.tb15824.x; TSUKAHARA T, 1986, STROKE, V17, P202, DOI 10.1161/01.STR.17.2.202; VAZIRI C, 1992, BIOCHEM J, V284, P917, DOI 10.1042/bj2840917; WILSON C, 1984, EUR J PHARMACOL, V100, P309, DOI 10.1016/0014-2999(84)90007-4; WITKIN KM, 1981, J CYCLIC NUCL PROT, V7, P235; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YARDEN Y, 1986, P NATL ACAD SCI USA, V83, P6795, DOI 10.1073/pnas.83.18.6795; ZAAGSMA J, 1990, TRENDS PHARMACOL SCI, V11, P3, DOI 10.1016/0165-6147(90)90032-4	58	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24810	24819						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929160				2022-12-25	WOS:A1994PQ49000047
J	ZANI, ML; POURCHER, T; LEBLANC, G				ZANI, ML; POURCHER, T; LEBLANC, G			MUTATION OF POLAR AND CHARGED RESIDUES IN THE HYDROPHOBIC NH2-TERMINAL DOMAINS OF THE MELIBIOSE PERMEASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING SEGMENTS; CATION SPECIFICITY; TRANSPORT-SYSTEM; KLEBSIELLA-PNEUMONIAE; POTASSIUM CHANNELS; BINDING-PROPERTIES; ACIDIC RESIDUES; SUGAR BINDING; CARRIER; NA+	The suggestion that acidic residues in the hydrophobic NH2-terminal domains of Mel permease (Asp-31 in helix I, Asp-51 and Asp-55 in helix II, Asp-120 in helix IV) may be essential components of a coordination network involved in cation recognition (Pourcher, T., Zani, M. L., and Leblanc, G. (1993) J. Biol. Chem. 268, 3209-3215) is further analyzed using site-directed mutagenesis. To study whether nearby polar residues also contribute to the cation recognition process, Tyr-24, Tyr-27 and Tyr-28 (aligned with Asp-31) and Tyr-109 and Tyr-116 (aligned with Asp-120) were individually converted into a phenylalanine. The effect of replacing Arg-48 (aligned with Asp-51 and Asp-55) or Asn-83 (in the middle of helix III) by an alanine was also studied. The importance of the position of the carboxylate of the residue at position 31, 51, 55, or 120 was next examined by replacing each Asp by a Glu residue. Sugar binding and/or transport activity measurements indicate that all polar --> apolar or Asp --> Glu mutants use Na+ or Li+ for active sugar transport. Moreover, two groups of mutants could be distinguished. One group, composed of Y27F, Y28F, D31E, and Y109F mutants, retains wild type permease properties. A second group (Y24F, N83A, and Y116F and also D51E, D55E, and D120E) exhibits concomitant reduction of affinity for sodium and sugars and altered sugar specificity but conserves wild type cation selectivity profile. The data reinforce the notion that Asp-51, Asp-55, and Asp-120 residues and the position of their carboxyl side chains are of primary importance for cation recognition. Finally, since Mel permease properties are predominantly modified by mutagenizing residues located in the cytoplasmic half of the permease, we propose that Mel permease has a well-like shape opened toward the periplasmic space and is closed at its cytoplasmic extremity by a gate.	CEA, DEPT BIOL CELLULAIRE & MOLEC, LAB J MAETZ, F-06230 VILLEFRANCHE MER, FRANCE	CEA				Pourcher, Thierry/0000-0003-2839-4622				BASSILANA M, 1985, BIOCHEM BIOPH RES CO, V129, P626, DOI 10.1016/0006-291X(85)91937-0; BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1989, J BIOL CHEM, V264, P11649; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOTFIELD MC, 1990, RES MICROBIOL, V141, P328, DOI 10.1016/0923-2508(90)90006-C; BOYER PD, 1988, TRENDS BIOCHEM SCI, V13, P5, DOI 10.1016/0968-0004(88)90005-9; COHN DE, 1980, BIOCHEMISTRY-US, V19, P4237, DOI 10.1021/bi00559a015; DAMIANOFORANO E, 1986, J BIOL CHEM, V261, P6893; HAMA H, 1994, J BIOL CHEM, V269, P1063; HAMA H, 1993, J BIOL CHEM, V268, P10060; HAMA H, 1992, J BIOL CHEM, V267, P18371; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Kaback H R, 1974, Methods Enzymol, V31, P698; KAWAKAMI T, 1988, J BIOL CHEM, V263, P14276; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; LEBLANC G, 1993, SOC GEN PHY, V48, P213; LEBLANC G, 1992, 7TH EUR BIOEN C; LOLKEMA JS, 1988, BIOCHEMISTRY-US, V27, P8307, DOI 10.1021/bi00422a003; LOPILATO J, 1978, J BACTERIOL, V134, P147, DOI 10.1128/JB.134.1.147-156.1978; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER C, 1993, SCIENCE, V261, P1692, DOI 10.1126/science.8397443; OLSEN SG, 1989, J BIOL CHEM, V264, P15982; POURCHER T, 1991, BIOCHEM BIOPH RES CO, V178, P1176, DOI 10.1016/0006-291X(91)91016-6; POURCHER T, 1990, PHILOS T ROY SOC B, V326, P411, DOI 10.1098/rstb.1990.0021; POURCHER T, 1993, J BIOL CHEM, V268, P3209; POURCHER T, 1990, BIOCHEMISTRY-US, V29, P690, DOI 10.1021/bi00455a014; POURCHER T, 1990, P NATL ACAD SCI USA, V87, P468, DOI 10.1073/pnas.87.1.468; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIOTA S, 1985, J BACTERIOL, V162, P106, DOI 10.1128/JB.162.1.106-109.1985; TSUCHIYA T, 1983, J BIOL CHEM, V258, P2765; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; WILSON DM, 1994, BBA-BIOMEMBRANES, V1190, P225, DOI 10.1016/0005-2736(94)90078-7; WILSON DM, 1992, J BACTERIOL, V174, P3083, DOI 10.1128/JB.174.9.3083-3086.1992; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; YAZYU H, 1984, J BIOL CHEM, V259, P4320; ZANI ML, 1993, J BIOL CHEM, V268, P3216	37	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24883	24889						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929169				2022-12-25	WOS:A1994PQ49000056
J	TANG, AH; TU, CPD				TANG, AH; TU, CPD			BIOCHEMICAL-CHARACTERIZATION OF DROSOPHILA GLUTATHIONE S-TRANSFERASES D1 AND D21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDASE-ACTIVITY; 3-DIMENSIONAL STRUCTURE; INSECTICIDE RESISTANCE; INTRONLESS GENE; MUSCA-DOMESTICA; RAT-LIVER; RESOLUTION; ENZYMES; COMPLEX; SPECIFICITIES	The genomic DNA for the two Drosophila genes, gstD1 and gstD21, were engineered for expression in Escherichia coli by polymerase chain reaction using a pair of specially designed primers. This newly designed expression system produced consistently high yields of the recombinant glutathione S-transferases (GSTs), which were purified to electrophoretic homogeneity by S-hexyl-GSH affinity chromatography. Consistent with their differences in size, GST D1 and GST D21 displayed different mobilities on SDS-polyacrylamide gel electrophoresis. Circular dichroism spectrometry revealed some differences in the protein secondary structural organization between the two GST D isozymes. Polyclonal antibodies against GST D1 and GST D21 revealed that they are immunologically distinct hom each other. The GST D1 antiserum cross-reacted weakly with GST D21, but the GST D21 antiserum had no detectable crossreactivity with GST D1. The amino acid sequences of GST D1 and GST D21 have 70% identity. GST D1 is active toward CDNB with 17% of the catalytic efficiency of the human alpha GST121, whereas CDNB is a poor substrate for GST D21. Both GST D1 and GST D21 have similar levels of GSH peroxidase activity against cumene hydroperoxide. Another major difference in substrate specificities between GST D1 and GST D21 is in the activity of 1,1,1-trichloro-2,2-bis-(p-chlorophenyl)ethane (DDT) dehydrochlorinase, which exists only in the GST D1 isozyme. This is the first definitive demonstration that DDT dehydrochlorinase activity is an intrinsic property of a Drosophila GST. Our results suggest that GST D1 may play a role in DDT metabolism in Drosophila.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, PAUL M ALTHOUSE LAB 401, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Tang, Amy/L-3226-2016	Tang, Amy/0000-0002-5772-2878	NCRR NIH HHS [2S07 RR07082] Funding Source: Medline; NIEHS NIH HHS [ES 05661] Funding Source: Medline; NIGMS NIH HHS [GM 49205] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005661] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049205] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1989, ARCH INSECT BIOCHEM, V12, P31, DOI 10.1002/arch.940120104; AHMAD S, 1987, ARCH INSECT BIOCHEM, V6, P85, DOI 10.1002/arch.940060203; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; BALABASKARAN S, 1970, BIOCHEM J, V117, P989, DOI 10.1042/bj1170989; BEALL C, 1992, BIOCHEM GENET, V30, P515, DOI 10.1007/BF01037590; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BURGESS JR, 1989, BIOCHEM BIOPH RES CO, V158, P497, DOI 10.1016/S0006-291X(89)80076-2; CHOW NWI, 1988, J BIOL CHEM, V263, P12797; CLARK AG, 1989, COMP BIOCHEM PHYS B, V92, P419, DOI 10.1016/0305-0491(89)90114-4; CLARK AG, 1984, PESTIC BIOCHEM PHYS, V22, P249, DOI 10.1016/0048-3575(84)90018-X; COCHRANE BJ, 1987, INSECT BIOCHEM, V17, P731, DOI 10.1016/0020-1790(87)90043-6; COCHRANE BJ, 1992, ACS SYM SER, V505, P53; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; FOURNIER D, 1992, J BIOL CHEM, V267, P1840; Habig W H, 1981, Methods Enzymol, V77, P398; HARTZ D, 1990, RIBOSOME, P275; HIRATSUKA A, 1990, J BIOL CHEM, V265, P11973; Innis MA, 1990, PCR PROTOCOLS GUIDE, P1, DOI [10.1016/0167-7799(90)90215-J, DOI 10.1016/0167-7799(90)90215-J]; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KIMURA T, 1965, WHO B, V32, P557; KLEPPE K, 1971, J MOL BIOL, V56, P341, DOI 10.1016/0022-2836(71)90469-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LIPKE H, 1959, J BIOL CHEM, V234, P2123; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MCCARTHY JEG, 1990, TRENDS GENET, V6, P78, DOI 10.1016/0168-9525(90)90098-Q; MORROW CS, 1990, CANCER CELL-MON REV, V2, P15; MORTON RA, 1993, GENOME, V36, P1, DOI 10.1139/g93-001; OPPENOORTH F. J., 1965, ENTOMOL EXPAPPL, V8, P293, DOI 10.1007/BF00344541; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PLAPP FW, 1984, PESTIC BIOCHEM PHYS, V22, P194, DOI 10.1016/0048-3575(84)90089-0; PRITSOS CA, 1988, COMP BIOCHEM PHYS C, V90, P423, DOI 10.1016/0742-8413(88)90021-7; PROHASKA JR, 1980, BIOCHIM BIOPHYS ACTA, V611, P87, DOI 10.1016/0005-2744(80)90045-5; REDDY CC, 1983, ARCH BIOCHEM BIOPHYS, V224, P87, DOI 10.1016/0003-9861(83)90192-3; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SIMMONS TW, 1989, COMP BIOCHEM PHYS B, V94, P323, DOI 10.1016/0305-0491(89)90350-7; Simons P C, 1981, Methods Enzymol, V77, P235; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; SOHAL RS, 1988, EXP GERONTOL, V23, P211, DOI 10.1016/0531-5565(88)90008-3; STERNBURG J, 1954, J AGR FOOD CHEM, V2, P1125, DOI 10.1021/jf60042a008; STORMO GD, 1986, MAXIMIZING GENE EXPR, P195; SUNDSETH SS, 1989, PESTIC BIOCHEM PHYS, V33, P176, DOI 10.1016/0048-3575(89)90008-4; TERRIERE LC, 1984, ANNU REV ENTOMOL, V29, P71, DOI 10.1146/annurev.en.29.010184.000443; TOUNG YPS, 1991, BIOCHEM BIOPH RES CO, V178, P1205, DOI 10.1016/0006-291X(91)91021-4; TOUNG YPS, 1993, J BIOL CHEM, V268, P9737; TOUNG YPS, 1990, P NATL ACAD SCI USA, V87, P31, DOI 10.1073/pnas.87.1.31; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; TSUKAMOTO M., 1960, Botyu-Kagaku = Scientific Insect Control, V25, P156; TU CPD, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P379; TU CPD, 1985, J BIOL CHEM, V260, P9961; WATERS LC, 1988, PESTIC BIOCHEM PHYS, V30, P214, DOI 10.1016/0048-3575(88)90036-3; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; WEINHOLD LC, 1990, COMP BIOCHEM PHYS B, V95, P355, DOI 10.1016/0305-0491(90)90088-B	60	109	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27876	27884						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961718				2022-12-25	WOS:A1994PV77200019
J	CHAE, HZ; CHUNG, SJ; RHEE, SG				CHAE, HZ; CHUNG, SJ; RHEE, SG			THIOREDOXIN-DEPENDENT PEROXIDE REDUCTASE FROM YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; FLAVOPROTEIN DISULFIDE OXIDOREDUCTASES; SACCHAROMYCES-CEREVISIAE; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; OXIDATIVE STRESS; SEQUENCE; PROTEIN; CLONING; ACIDS	A 25-kDa antioxidant enzyme that provides protection against oxidation systems capable of generating reactive oxygen and sulfur species has previously been identified. The nature of the oxidant eliminated by and the physiological source of reducing equivalents for, this enzyme, however, were not known. The 25-kDa enzyme is now shown to be a peroxidase that reduces H2O2 and alkyl hydroperoxides with the use of hydrogens provided by thioredoxin, thioredoxin reductase, and NADPH. This protein is the first peroxidase to be identified that uses thioredoxin as the immediate hydrogen donor and is thus named thioredoxin peroxidase (TPx). TPx exists as a dimer of identical 25-kDa subunits that contain 2 cysteine residues, Cys(47) and Cys(170). Cys(47)-SH appears to be the site of oxidation by peroxides, and the oxidized Cys(47) probably reacts with Cys(170)-SH of the other subunit to form an intermolecular disulfide. Mutant TPx proteins lacking either Cys(47) or Cys(170), therefore, do not exhibit thioredoxin-coupled peroxidase activity. The TPx disulfide is specifically reduced by thioredoxin, but can also be reduced (less effectively) by a small molecular size thiol. The Saccharomyces cerevisiae thioredoxin reductase gene was also cloned and sequenced, and the deduced amino sequence was shown to be 51% identical with that of the Escherichia coli enzyme.	NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; CHAUDIERE J, 1984, J BIOL CHEM, V259, P1043; CLAIBORNE A, 1992, TRENDS BIOCHEM SCI, V17, P183, DOI 10.1016/0968-0004(92)90263-9; Flohe L., 1989, GLUTATHIONE CHEM BIO, P644; FURTER R, 1986, NUCLEIC ACIDS RES, V14, P6357, DOI 10.1093/nar/14.16.6357; GAN ZR, 1991, J BIOL CHEM, V266, P1692; HALL DE, 1971, EUR J BIOCHEM, V23, P328, DOI 10.1111/j.1432-1033.1971.tb01625.x; HALLIWELL B, 1984, METHOD ENZYMOL, V105, P47; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; LIM YS, 1993, BIOCHEM BIOPH RES CO, V107, P279; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; POOLE LB, 1989, J BIOL CHEM, V264, P12330; PORQUE P G, 1970, Journal of Biological Chemistry, V245, P2363; RHEE SG, 1985, METHOD ENZYMOL, V113, P213; ROSS D, 1985, J BIOL CHEM, V260, P5028; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; SPERANZA ML, 1973, BIOCHIM BIOPHYS ACTA, V327, P274, DOI 10.1016/0005-2744(73)90410-5; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; YIM MB, 1994, J BIOL CHEM, V269, P1621	27	830	855	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27670	27678						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961686				2022-12-25	WOS:A1994PV77100080
J	ORR, JW; NEWTON, AC				ORR, JW; NEWTON, AC			REQUIREMENT FOR NEGATIVE CHARGE ON ACTIVATION LOOP OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CELLS; PHOSPHOLIPIDS; FAMILY; SITE	Increasing evidence has implicated a post-translational phosphorylation in the production of a catalytically competent protein kinase C. Here we present structural and biochemical evidence that Thr(500) of protein kinase C-beta II is the residue phosphorylated by another kinase. Modeling studies indicate that this residue is part of a ''lip'' structure at the entrance of the catalytic site; phosphorylation on this lip, or ''activation loop,'' is central to the regulation of three kinases whose structures have been elucidated (Taylor, S. S., and Radzio-Andzelm, E. (1994) Structure 2, 345-355). Biochemical data reveal that mutation of Thr(500) to an acidic residue (Glu) results in expression of catalytically active protein kinase C in COS cells. In contrast, mutation of this residue to a neutral, non-phosphorylatable residue (Val) results in expression of inactive enzyme. Thus, negative charge at position 500 is required for catalytically competent protein kinase C-beta II. These data suggest that signal processing by protein kinase C cannot occur until the enzyme is first phosphorylated by a protein kinase C kinase.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington					NIGMS NIH HHS [GM 43154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORNER C, 1989, J BIOL CHEM, V264, P13902; CAZAUBON S, 1990, EUR J BIOCHEM, V194, P799, DOI 10.1111/j.1432-1033.1990.tb19472.x; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1988, J BIOL CHEM, V263, P6927; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; STRAUS D, 1985, P NATL ACAD SCI USA, V82, P2272, DOI 10.1073/pnas.82.8.2272; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; WATANABE M, 1994, J BIOL CHEM, V269, P16829; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P6130, DOI 10.1073/pnas.90.13.6130	22	130	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27715	27718						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961692				2022-12-25	WOS:A1994PV77100086
J	TAYLOR, JM; JACOBMOSIER, GG; LAWTON, RG; REMMERS, AE; NEUBIG, RR				TAYLOR, JM; JACOBMOSIER, GG; LAWTON, RG; REMMERS, AE; NEUBIG, RR			BINDING OF AN ALPHA(2) ADRENERGIC-RECEPTOR 3RD INTRACELLULAR LOOP PEPTIDE TO G-BETA AND THE AMINO-TERMINUS OF G-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN TRANSDUCIN INTERACTIONS; GAMMA SUBUNIT COMPLEX; G-PROTEINS; SYNTHETIC PEPTIDES; CARBOXYL TERMINUS; CROSS-LINKING; BOVINE BRAIN; ADENYLATE-CYCLASE; HIGH-AFFINITY; SITE	The structural basis of receptor-G protein interactions was examined using a photoaffinity derivative of a G protein-activating receptor-derived peptide (Q peptide) from the carboxyl-terminal region of the third intracellular loop of alpha(2) adrenergic receptor. A diazopyruvoyl photoaffinity derivative of this peptide (DAP-Q) was cross-linked to purified bovine brain G(o). Specific, competable cross-linking of 750 nM DAP-Q to sites on both the alpha(o) and beta subunits was observed. No specific cross-linking was seen with non-target proteins or heat-denatured G protein subunits. I-125-DAP-Q labeled the 2-kDa amino-terminal fragment of alpha(o) as determined by protease digestion of the cross-linked G protein followed by gel electrophoresis or high pressure liquid chromatography purification and mass spectroscopy of the radiolabeled proteolysis fragment. The functional significance of incorporation into beta gamma subunit is supported by the absolute requirement of beta gamma subunit for DAP-Q stimulation of G(o)/G(i) GTPase. Thus, specific interactions of G protein-coupled receptors with the beta subunit of G protein, in addition to those with the alpha subunit, appear to be important for receptor-G protein coupling.	UNIV MICHIGAN,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED HYPERTENS,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Taylor, Joan/0000-0002-8794-5167; Remmers, Ann/0000-0002-2465-7651; Neubig, Richard/0000-0003-0501-0008	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00042] Funding Source: Medline; NHLBI NIH HHS [HLGM46417] Funding Source: Medline; NIAMS NIH HHS [P60-AR20557] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DALMAN HM, 1991, FASEB J, V5, pA1594; DERETIC D, 1987, J BIOL CHEM, V262, P10839; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GOODFELLOW VS, 1989, BIOCHEMISTRY-US, V28, P6346, DOI 10.1021/bi00441a030; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARRISON JK, 1989, BIOCHEMISTRY-US, V28, P6023, DOI 10.1021/bi00440a045; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; IM MJ, 1988, FEBS LETT, V227, P225, DOI 10.1016/0014-5793(88)80903-7; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KWON G, 1993, BIOCHEMISTRY-US, V32, P2401, DOI 10.1021/bi00060a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG JC, 1989, J RECEPTOR RES, V9, P313, DOI 10.3109/10799898909066061; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MOSIER GJ, 1995, IN PRESS J ORG CHEM; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; Roth J, 1975, Methods Enzymol, V37, P223; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRADER CD, 1987, J BIOL CHEM, V262, P16439; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TAYLOR JM, 1994, PEPTIDES, V15, P829, DOI 10.1016/0196-9781(94)90038-8; TAYLOR JM, 1993, J CELL BIOCHEM, V17, pA133; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; WADE SM, 1994, MOL PHARMACOL, V45, P1191; WAKAMATSU K, 1993, J CELL BIOCHEM, V17, pA364; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044	51	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27618	27624						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961678				2022-12-25	WOS:A1994PV77100071
J	FLETCHER, FA; CARPENTER, MK; SHILLING, H; BAUM, P; ZIEGLER, SF; GIMPEL, S; HOLLINGSWORTH, T; BOS, TV; JAMES, L; HJERRILD, K; DAVISON, BL; LYMAN, SD; BECKMANN, MP				FLETCHER, FA; CARPENTER, MK; SHILLING, H; BAUM, P; ZIEGLER, SF; GIMPEL, S; HOLLINGSWORTH, T; BOS, TV; JAMES, L; HJERRILD, K; DAVISON, BL; LYMAN, SD; BECKMANN, MP			LERK-2, A BINDING-PROTEIN FOR THE RECEPTOR-TYROSINE KINASE ELK, IS EVOLUTIONARILY CONSERVED AND EXPRESSED IN A DEVELOPMENTALLY-REGULATED PATTERN	ONCOGENE			English	Article							GROWTH-FACTOR; FAMILY; GENE; PHOSPHORYLATION; MEMBERS; CLONING; CELLS; SITES	We have isolated and characterized cDNA clones that encode the rat homologue of a binding protein, LERK-2, for the receptor tyrosine kinase, elk. The cDNAs contain an open reading frame of 1527 nucleotides capable of encoding a protein 345 amino acid residues in length. The nucleotide sequence of the present clones is >90% identical to the previously identified human LERK-2 cDNA, and the predicted proteins encoded by the rat and human clones are identical at 95% of amino acid residues. Recombinant proteins expressed from the rat cDNAs bind to elk with high affinity, similar to recombinant human LERK-2 and an endogenously-expressed rat elk-binding protein. Expression of the rat LERK-2 mRNA was detected in embryonic brain, kidney, lung, skeletal muscle, thymus, liver, and heart, and diminished in the early post-natal period. Significant LERK-2 mRNA expression in the young adult rat was restricted to the lung, kidney, heart and testes.	IMMUNEX RES & DEV CORP,SEATTLE,WA 98101									BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, IN PRESS EMBO J; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAN J, 1991, ONCOGENE, V6, P1057; COOPER JA, 1984, J BIOL CHEM, V259, P7835; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	29	29	34	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3241	3247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936648				2022-12-25	WOS:A1994PM65800017
J	WAEBER, G; THOMPSON, N; HAEFLIGER, JA; NICOD, P				WAEBER, G; THOMPSON, N; HAEFLIGER, JA; NICOD, P			CHARACTERIZATION OF THE MURINE HIGH K(M) GLUCOSE-TRANSPORTER GLUT2 GENE AND ITS TRANSCRIPTIONAL REGULATION BY GLUCOSE IN A DIFFERENTIATED INSULIN-SECRETING CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; PYRUVATE-KINASE GENE; MESSENGER-RNA; DIABETIC HYPERGLYCEMIA; RESPONSE ELEMENT; RAT ISLETS; CYCLIC-AMP; EXPRESSION; PROMOTER; BINDING	In pancreatic beta-cells, high K-m glucose transporter GLUT2 catalyzes the first step in glucose-induced insulin secretion by glucose uptake. Expression of the transporter has been reported to be modulated by glucose either at the protein or mRNA levels. In this study we used the differentiated insulinoma cell Line INS-1 which expresses high levels of GLUT2 and show that the expression of GLUT2 is regulated by glucose at the transcriptional level. By run-on transcription assays we showed that glucose induced GLUT2 gene transcription 3-4-fold in INS-1 cells which was paralleled by a 1.7-2.3-fold increase in cytoplasmic GLUT2 mRNA levels. To determine whether glucose regulatory sequences were present in the promoter region of GLUT2, we cloned and characterized a 1.4-kilobase region of mouse genomic DNA located 5' of the translation initiation site. By RNase protection assays and primer extension, we determined that multiple transcription initiation sites were present at positions -55, -64, and -115 from the first coding ATG and which were identified in liver, intestine, kidney, and beta-cells mRNAs. Plasmids were constructed with the mouse promoter region linked to the reporter gene chloramphenicol acetyltransferase (CAT), and transiently and stably transfected in the INS-1 cells. Glucose induced a concentration dependent increase in CAT activity which reached a maximum of 3.6-fold at 20 mM glucose. Similar CAT constructs made of the human GLUT2 promoter region and the CAT gene displayed the same glucose-dependent increase in transcriptional activity when transfected into INS-1 cells. Comparison of the mouse and human promoter regions revealed sequence identity restricted to a few stretches of sequences which suggests that the glucose responsive element(s) may be conserved in these common sequences.			WAEBER, G (corresponding author), CHU VAUDOIS, DEPT INTERNAL MED, 19-533, CH-1011 LAUSANNE, SWITZERLAND.			Haefliger, Jacques-Antoine/0000-0003-2732-1667; Waeber, Gerard/0000-0003-4193-788X				ASANO T, 1992, DIABETES, V41, P22, DOI 10.2337/diabetes.41.1.22; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; FERRER J, 1993, DIABETES, V42, P1273, DOI 10.2337/diabetes.42.9.1273; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; IMAFAWA M, 1987, CELL, V51, P251; INAGAKI N, 1992, DIABETES, V41, P592, DOI 10.2337/diabetes.41.5.592; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MARIE S, 1993, J BIOL CHEM, V268, P23881; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; OHNEDA M, 1993, DIABETES, V42, P1065, DOI 10.2337/diabetes.42.7.1065; ORCI L, 1990, J CLIN INVEST, V86, P1615, DOI 10.1172/JCI114883; ORCI L, 1990, P NATL ACAD SCI USA, V87, P9953, DOI 10.1073/pnas.87.24.9953; POSTIC C, 1993, BIOCHEM J, V293, P119, DOI 10.1042/bj2930119; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; SUZUE K, 1989, NUCLEIC ACIDS RES, V17, P10099, DOI 10.1093/nar/17.23.10099; TAKEDA J, 1993, DIABETES, V42, P773, DOI 10.2337/diabetes.42.5.773; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VANNICE JL, 1984, P NATL ACAD SCI-BIOL, V81, P4241, DOI 10.1073/pnas.81.14.4241; YASUDA K, 1992, DIABETES, V41, P76, DOI 10.2337/diabetes.41.1.76	37	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					26912	26919						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929431				2022-12-25	WOS:A1994PQ93100052
J	GRAHAM, LA; HILL, KJ; STEVENS, TH				GRAHAM, LA; HILL, KJ; STEVENS, TH			VMA7 ENCODES A NOVEL 14-KDA SUBUNIT OF THE SACCHAROMYCES-CEREVISIAE VACUOLAR H+-ATPASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTON-TRANSLOCATING ATPASE; ADENOSINE-TRIPHOSPHATASE; GENE ENCODES; YEAST; MEMBRANE; SEQUENCE; PROTEIN	The Saccharomyces cerevisiae vacuolar proton-translocating ATPase (V-ATPase) is composed of at least 10 subunits belonging to either the peripheral V-1 or integral membrane V-0 subcomplex. We have characterized a novel 14-kDa V-ATPase subunit (Vma7p), encoded by the VMA7 gene, which exhibits features common to both V-1 and V-0 subunit proteins. Vma7p is a hydrophilic protein of 118 amino acids with a predicted molecular mass of 13,452 Da. Vacuolar membranes isolated from a vma7 Delta null mutant contained no V-ATPase activity. Western analysis of vma7 Delta cells revealed greatly reduced levels of the remaining V-0 complex V-ATPase subunits, but normal levels of the V-1 subunits. However, the V-1 subunits failed to associate with the vacuolar membrane. Unlike the integral membrane subunits of the V-0 complex, Vma7p was easily stripped from vacuolar membranes. Density gradient fractionation revealed that Vma7p associated only with the fully assembled V-ATPase and did not associate with a separate lower density V-0 subcomplex fraction. The unique properties of the Vma7p may reflect a critical role in stabilizing the V-0 complex and bridging the V-1 and V-0 complexes to form a functional V-ATPase complex.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon				Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRE B, 1990, NUCLEIC ACIDS RES, V18, P3049, DOI 10.1093/nar/18.10.3049; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRAF R, 1994, J BIOL CHEM, V269, P3767; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; HOLZENBURG A, 1993, EUR J BIOCHEM, V213, P21, DOI 10.1111/j.1432-1033.1993.tb17730.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKASE K, 1994, J BIOL CHEM, V269, P11037; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	29	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					25974	25977						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929308				2022-12-25	WOS:A1994PQ93000009
J	GREEN, SA; LIGGETT, SB				GREEN, SA; LIGGETT, SB			A PROLINE-RICH REGION OF THE 3RD INTRACELLULAR LOOP IMPARTS PHENOTYPIC BETA(1)-VERSUS BETA(2)-ADRENERGIC RECEPTOR COUPLING AND SEQUESTRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTORS; STRUCTURAL BASIS; LIGAND-BINDING; GS; AFFINITY	beta-Adrenergic receptor (beta AR) subtypes differ not only by characteristic ligand affinities but also in the manner and extent to which they mediate agonist-promoted events such as activation of adenylyl cyclase and receptor tor sequestration. We utilized mutagenesis and recombinant expression in Chinese hamster fibroblasts to examine the effect of an unusual proline-rich 24-amino acid sequence (PARPPSPSPSPVPAPAPPPGPPRP) present in the third intracellular loop of the beta(1)AR, but not in the beta(2)AR, on the aforementioned receptor-mediated events. Cells expressing the wild type beta(2)AR stimulated adenylyl cyclase in response to the agonist isoproterenol with an EC(50) similar to 5 fold lower than that observed with the beta(1)AR (0.53 +/- 0.14 versus 2.47 +/- 0.52 nM, p < 0.01). Deletion of the proline-rich sequence from the beta(1)AR resulted in an improvement in isoproterenol-stimulated adenylyl cyclase to an EC(50) value intermediate to that observed in the wild type receptors (1.14 +/- 0.08 nM, p < 0.05 versus wild-type beta(1)AR). In contrast, insertion of this sequence into the beta(2)AR impaired its ability to mediate this process. Similar results were observed for receptor sequestration. Wild-type beta(1)- and beta(2)AR underwent maximal agonist-promoted sequestration of 25.9 +/- 4.0 and 60.0 +/- 3.3%, respectively. Deletion of the proline-rich region from the beta(1)AR improved maximal sequestration to 43.0 +/- 2.7% (p < 0.01 versus wild-type beta(1)AR), while insertion of the sequence into the beta(2)AR impaired sequestration to 39.9 +/- 2.7% (p < 0.001 versus wild-type beta(2)AR). We conclude that the distinct phenotypic patterns observed for these two agonist-promoted events in the beta(1)AR and beta(2)AR subtypes are partially due to the conformational effects of this proline-rich third intracellular loop sequence. Such regions, which are also found in some other G-protein-coupled receptors, may represent a general motif responsible for attenuating certain agonist-promoted receptor events.	UNIV CINCINNATI,MED CTR,DEPT PULM MED,CINCINNATI,OH 45267; UNIV CINCINNATI,MED CTR,DEPT MOLEC GENET,CINCINNATI,OH 45267; UNIV CINCINNATI,MED CTR,DEPT PHARMACOL,CINCINNATI,OH 45267	University of Cincinnati; University of Cincinnati; University of Cincinnati			liggett, stephen b/E-7453-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, R01HL045967] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL45967, P01 HL41496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1980, J BIOL CHEM, V255, P7108; EASON MG, 1992, J BIOL CHEM, V267, P25473; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1992, MOL PHARMACOL, V41, P889; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; KENT RS, 1980, MOL PHARMACOL, V17, P14; LEVY FO, 1993, P NATL ACAD SCI USA, V90, P10798, DOI 10.1073/pnas.90.22.10798; LICHTER JB, 1993, HUM MOL GENET, V2, P767, DOI 10.1093/hmg/2.6.767; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIGGETT SB, 1993, CATECHOLAMINES, P279; Liggett SB, 1993, REGULATION CELLULAR, P71; PERKINS JP, 1991, MECHANISMS LIGAND IN, P125; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRADER CD, 1987, J BIOL CHEM, V262, P16439; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; VANTOL HHM, 1992, NATURE, V358, P149; YU SS, 1993, J BIOL CHEM, V268, P337	23	92	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26215	26219						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929336				2022-12-25	WOS:A1994PQ93000044
J	SUPEK, F; SUPEKOVA, L; NELSON, N				SUPEK, F; SUPEKOVA, L; NELSON, N			FEATURES OF VACUOLAR H+-ATPASE REVEALED BY YEAST SUPPRESSOR MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN-GRANULE MEMBRANES; TRANSMEMBRANE ALPHA-HELICES; SACCHAROMYCES-CEREVISIAE; SUBUNIT-C; MUTATIONAL ANALYSIS; PROTON-ATPASES; MOLECULAR-GENETICS; NEUROSPORA-CRASSA; V-ATPASES; ACIDIFICATION	The yeast Saccharomyces cerevisiae serves as an excellent model for the study of the structure and function of proteins. Numerous amino acid substitutions in the proteolipid subunit of yeast vacuolar H+-ATPase have been reported. Suppressed variants for several of the inactive mutants were selected after subjecting them to chemical or polymerase chain reaction mutagenesis and screening for second site suppressors. Suppressors for the mutation GLn(90) to Lys change were intragenic and resulted from the changes: Ala(14) to Val, Val(74) to Ile, Ile(89) to Leu, and Ile(89) to Met. These residues are found on three different transmembrane segments but presumably at the same surface of the membrane. A new inactive proteolipid mutation was constructed by changing Val(138) to, Leu. This residue is situated in the middle of the fourth transmembrane segment, neighboring Glu(137) which is the potential dicyclohexylcarbodiimide-binding site. The intragenic suppressor mutations for the above amino acid replacement resulted in changes of Val(55) to Ala, Met(59) to Val, or Ile(130) to Thr. These residues are found in the second and fourth transmembrane segments, presumably on the same interface. It seems as if all those internal suppressor mutations compensate for the volume changes caused by the original displacement of the given amino acid. Five glycine residues, situated on the same face of the third transmembrane helix, were changed to valine and all these mutants were inactive. A suppressor mutation to one of those mutants (Gly(101) to Val) was identified as substitution of Ile(134) to Val. The structural and functional implications of these findings are discussed.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding								ANRAKU Y, 1992, J EXP BIOL, V172, P67; ANRAKU Y, 1991, BIOCHIM BIOPHYS ACTA, V1093, P169, DOI 10.1016/0167-4889(91)90119-I; ANRAKU Y, 1991, NEW ERA BIOENERGETIC, P133; ARAI H, 1987, J BIOL CHEM, V262, P11006; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BELTRAN C, 1992, ACTA PHYSIOL SCAND, V146, P41; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; FINBOW ME, 1991, PROTEIN ENG, V5, P7; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOURY F, 1990, J BIOL CHEM, V265, P18554; FRAGA D, 1994, J BIOL CHEM, V269, P2562; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; GIRVIN ME, 1994, BIOCHEMISTRY-US, V33, P665, DOI 10.1021/bi00169a006; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; IIDA H, 1990, J BIOL CHEM, V265, P13391; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JONES PC, 1994, IN PRESS BIOCH SOC T; KANE PM, 1992, J EXP BIOL, V172, P93; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; LAI S, 1991, J BIOL CHEM, V266, P16078; LEE JI, 1992, J BIOL CHEM, V267, P20758; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NELSON N, 1991, TRENDS PHARMACOL SCI, V12, P71, DOI 10.1016/0165-6147(91)90501-I; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Sambrook J, 1989, MOL CLONING LABORATO; STEVENS TH, 1992, J EXP BIOL, V172, P47; SUPEK F, 1992, ANN NY ACAD SCI, V671, P284, DOI 10.1111/j.1749-6632.1992.tb43803.x; SUTTON R, 1981, FEBS LETT, V130, P103, DOI 10.1016/0014-5793(81)80675-8; SZE H, 1992, J EXP BIOL, V172, P123; TAIZ L, 1991, PLANT PHYSL; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	53	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26479	26485						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929369				2022-12-25	WOS:A1994PQ93000082
J	CAI, H; WANG, CC; TSOU, CL				CAI, H; WANG, CC; TSOU, CL			CHAPERONE-LIKE ACTIVITY OF PROTEIN DISULFIDE-ISOMERASE IN THE REFOLDING OF A PROTEIN WITH NO DISULFIDE BONDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CATALYSIS; ENZYME; AGGREGATION	D-Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a protein containing no disulfide bonds; the guanidine HCl-denatured enzyme shows only a limited extent of refolding and reactivation upon dilution, and the enzyme is particularly prone to aggregation during the dilution process. With increasing GAPDH concentration, reactivation decreases and aggregation increases, The presence of protein disulfide isomerase in the dilution mixture markedly increases reactivation of GAPDH and at the same time prevents the aggregation of GAPDH as shown by light-scattering measurements. It is suggested that upon dilution, denatured GAPDH is faced with two competing processes of correct folding and assembly to yield the native enzyme and non-productive association of the partially refolded species to form aggregates. Independent of the isomerase activity as no disulfide bond is present in GAPDH, protein disulfide isomerase assists the refolding of GAPDH to its active state by suppressing aggregation in a way closely similar to the action of chaperones.	ACAD SINICA,INST BIOPHYS,NATL LAB BIOMACROMOLECULES,BEIJING 100101,PEOPLES R CHINA	Chinese Academy of Sciences; Institute of Biophysics, CAS								BUCHNER J, 1992, BIO-TECHNOL, V10, P682, DOI 10.1038/nbt0692-682; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; HU CH, 1991, FEBS LETT, V290, P87, DOI 10.1016/0014-5793(91)81232-W; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LIANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P240, DOI 10.1016/0167-4838(90)90211-W; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; MARANGOS PJ, 1974, BIOCHEMISTRY-US, V13, P904, DOI 10.1021/bi00702a012; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OTSU M, 1994, J BIOL CHEM, V269, P6874; PUIG A, 1994, J BIOL CHEM, V269, P7764; TAGUCHI H, 1994, J BIOL CHEM, V269, P15325; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P792, DOI 10.1021/bi00781a011; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YU XC, 1994, BBA-PROTEIN STRUCT M, V1207, P109, DOI 10.1016/0167-4838(94)90058-2	23	235	250	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24550	24552						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929125				2022-12-25	WOS:A1994PQ49000009
J	OGRADY, P; KRUEGER, NX; STREULI, M; SAITO, H				OGRADY, P; KRUEGER, NX; STREULI, M; SAITO, H			GENOMIC ORGANIZATION OF THE HUMAN LAR PROTEIN-TYROSINE-PHOSPHATASE GENE AND ALTERNATIVE SPLICING IN THE EXTRACELLULAR FIBRONECTIN TYPE-III DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE COMMON ANTIGEN; IMMUNOGLOBULIN SUPERFAMILY; RNA; EXPRESSION; CLONING; REGION; CONSERVATION; PROMOTER; SYSTEM; USAGE	The structure of the human leukocyte-common antigen-related molecule (LAR) protein tyrosine phosphatase gene was elucidated using phage and cosmid genomic DNA clones. The LAR gene is composed of 33 exons spanning over 85 kilobase pairs. Exon 2 encodes the signal sequence and the first four amino acids in the mature LAR protein. The three immunoglobulin-like domains are encoded by exons 3-7, and the eight fibronectin type III (Fn-III) domains by exons 8-17. Exons 18-22 encode the juxtamembrane and transmembrane domains, and exons 23-33 encode the two conserved tyrosine phosphatase domains and the entire 3'-untranslated region. Exon 1, which presumably encodes the 5'-untranslated sequence, has not been identified. Reverse transcription-polymerase chain reaction analysis revealed the alternative splicing of a mini exon (exon 13) in the Fn-III domain 5 of human LAR and other related genes (rat LAR, rat PTP sigma, and human PTP delta). RNase protection analysis showed that the human LAR mRNA in which exon 13 is spliced out is the major mRNA species in all cell lines examined. Reverse transcription-polymerase chain reaction analysis revealed further alternative splicing of LAR mRNA involving the Fn-III domains 4, 5, 6, and 7 in various combinations. These findings will facilitate the understanding of the physiological functions of the LAR extracellular domain.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689	NCI NIH HHS [CA-51132] Funding Source: Medline; NIAID NIH HHS [AI-26598] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026598] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; DUFOUR S, 1988, TRENDS GENET, V4, P198, DOI 10.1016/0168-9525(88)90076-5; GULCHER JR, 1991, P NATL ACAD SCI USA, V88, P9438, DOI 10.1073/pnas.88.21.9438; HALL LR, 1988, J IMMUNOL, V141, P2781; JOHNSON NA, 1989, J BIOL CHEM, V264, P6220; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LONGO FM, 1993, J BIOL CHEM, V268, P26503; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIZUNO K, 1993, MOL CELL BIOL, V13, P5513, DOI 10.1128/MCB.13.9.5513; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PAN MG, 1993, J BIOL CHEM, V268, P19284; POT DA, 1992, J BIOL CHEM, V267, P140; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; SAGA Y, 1988, MOL CELL BIOL, V8, P4889, DOI 10.1128/MCB.8.11.4889; Saito H, 1993, Semin Cell Biol, V4, P379, DOI 10.1006/scel.1993.1045; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZBAUER JE, 1991, BIOESSAYS, V13, P527, DOI 10.1002/bies.950131006; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TABOR S, 1989, J BIOL CHEM, V264, P6447; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WONG ECC, 1993, GENOMICS, V17, P33, DOI 10.1006/geno.1993.1279; YAN H, 1993, J BIOL CHEM, V268, P24880; YU Q, 1992, ONCOGENE, V7, P1051; ZHANG WR, 1993, L11587 GENB DAT ACC	41	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25193	25199						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929208				2022-12-25	WOS:A1994PQ49000099
J	SHWORAK, NW; SHIRAKAWA, M; COLLIECJOUAULT, S; LIU, J; MULLIGAN, RC; BIRINYI, LK; ROSENBERG, RD				SHWORAK, NW; SHIRAKAWA, M; COLLIECJOUAULT, S; LIU, J; MULLIGAN, RC; BIRINYI, LK; ROSENBERG, RD			PATHWAY-SPECIFIC REGULATION OF THE SYNTHESIS OF ANTICOAGULANTLY ACTIVE HEPARAN-SULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; ANTITHROMBIN-BINDING SEQUENCE; HIGH-AFFINITY; N-SULFOTRANSFERASE; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; CORE PROTEIN; PROTEOGLYCANS; BIOSYNTHESIS; IDENTIFICATION	L cells and endothelial cells synthesize a heparan sulfate (HS) subpopulation, HSact, that exhibits anticoagulant activity due to a specific monosaccharide sequence; the remaining heparan sulfate, HSinact, lacks this region of defined structure and is anticoagulantly inactive. HSact biosynthesis was examined in these two cell types by stably expressing epitope-tagged rat ryudocan (ryudocan(12CA5)), which possesses three glycosaminoglycan (GAG) acceptor sites. Both HSact and HSinact were present on ryudocan(12CA5) isolated from L cells and endothelial cells; thus, a core protein with a unique primary sequence initiates the synthesis of both GAGs. The expression in L cells of ryudocan(12CA5) variants containing a single functional GAG acceptor site demonstrated that each of the three acceptor regions initiates the synthesis of both types of GAGs to a similar extent. Most importantly, in both cell types total HSact generation declined as a function of ryudocan(12CA5) overexpression even though HSinact production increased linearly as a function of this variable. This discordant relationship is a general property of the biosynthetic machinery since in both cell types HSact production was reduced to an equal extent on protein cores of either exogenous or endogenous origins. The suppression of HSact generation was also observed with a secreted form of core protein lacking transmembrane and cytoplasmic domains or by a GAG acceptor site mutated form of core protein incapable of augmenting GAG synthesis. These results suggest that elevated intracellular levels of core protein saturate the capacity of a critical component of the HSact biosynthetic machinery. This critical component is not a member of the common set of biosynthetic enzymes involved in the production of HSact and HSinact since no structural changes were observed in either GAG during overexpression of core protein. Based upon the above data, we conclude that increased intracellular levels of ryudocan probably act by saturating the capacity of components which regulate HSact production by coordinating the function of biosynthetic enzymes.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02215 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043771, P01HL033014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43771, HL-33014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HORNER AA, 1982, J BIOL CHEM, V257, P8749; ISHIHARA M, 1992, ANAL BIOCHEM, V202, P310, DOI 10.1016/0003-2697(92)90111-J; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; JACOBSSON I, 1979, BIOCHEM J, V179, P77, DOI 10.1042/bj1790077; KATO M, 1991, J CELL BIOL, V115, P729; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; Lindahl U., 1989, HEPARIN, P159; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LINHARDT RJ, 1989, BIOCHEMISTRY-US, V28, P2888, DOI 10.1021/bi00433a021; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1989, HEPARIN, P275; MERTENS G, 1992, J BIOL CHEM, V267, P20435; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SHIVELY JE, 1970, BIOCHEMISTRY-US, V9, P33, DOI 10.1021/bi00803a005; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; TANTRAVAHI RV, 1986, P NATL ACAD SCI USA, V83, P9207, DOI 10.1073/pnas.83.23.9207; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	61	64	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24941	24952						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929177				2022-12-25	WOS:A1994PQ49000064
J	TONG, JJ; FEINBERG, BA				TONG, JJ; FEINBERG, BA			DIRECT SQUARE-WAVE VOLTAMMETRY OF SUPEROXIDIZED [4FE-4S](3+) ACONITASE AND ASSOCIATED 3FE/4FE CLUSTER INTERCONVERSIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; VINELANDII FERREDOXIN-I; IRON-SULFUR CLUSTERS; 4FE-4S CLUSTER; ACTIVATED ACONITASE; 3FE-4S CLUSTERS; REDUCTION; PROTEINS; BINDING; CRYSTAL	We report a direct square-wave voltammetric study of the iron-surfur enzyme, aconitase, at the pyrolytic graphite edge electrode. New and established redox driven reactions were observed and the equilibrium reduction potential for each couple was determined: E([3Fe-4S]1+/0)(0') = -268 mV, E([4Fe-4S]2+/1+) = -450 mV, E([4Fe-4S]3+/2+) = +100 mV, E(Linear Form) (0') = -281 mV, and putatively, E([3Fe-4S]0/2-)(0') similar or equal to -1000 mV, all versus normal hydrogen electrode. Most importantly we have directly observed the superoxidized [4Fe-4S](3+) form of aconitase (originally proposed by Emptage, M. H., Dreyer, J. L., Kennedy, M. C., and Beinert, H. (1983) J. Biol. Chem. 258, 11106-11111) and directly followed its conversion to the [3Fe-4S](1+) form; this intermediate is required for the deactivation of aconitase, Without exogenous ferrous iron, [3Fe-4S](0) aconitase is apparently super-reduced at very negative potentials to the [3Fe-4S](2-) form and the concomitant formation of [4Fe-4S](2+) aconitase was followed over time. It is the apparent decomposition of super-reduced [3Fe-4S](2-) aconitase that provides the source of ferrous iron for the interconversion of [3Fe-4S](0) aconitase to the [4Fe-4S](2+) form. Voltammetry of free and substrate bound [4Fe-4S]2+ aconitase showed that the latter is less susceptible to oxidation but, surprisingly, has the same E([4Fe-4S]3+/2+)(0').	UNIV WISCONSIN,DEPT CHEM,MILWAUKEE,WI 53201	University of Wisconsin System; University of Wisconsin Milwaukee			Feinberg, Bruce/AAX-9378-2021	Feinberg, Bruce/0000-0001-9267-9994	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048598] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48598] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG FA, 1989, FEBS LETT, V259, P15, DOI 10.1016/0014-5793(89)81483-8; ARMSTRONG FA, 1989, J AM CHEM SOC, V111, P9185, DOI 10.1021/ja00208a008; ARMSTRONG FA, 1990, STRUCT BOND, V72, P137; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BEINERT H, 1983, P NATL ACAD SCI-BIOL, V80, P393, DOI 10.1073/pnas.80.2.393; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; CAMMACK R, 1992, NATURE, V356, P288, DOI 10.1038/356288b0; CAMMACK R, 1973, BIOCHEM BIOPH RES CO, V54, P548, DOI 10.1016/0006-291X(73)91457-5; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; EMPTAGE MH, 1988, ACS SYM SER, V372, P343; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; GEORGE SJ, 1989, BIOCHEM J, V264, P275, DOI 10.1042/bj2640275; GEORGE SJ, 1989, BIOCHEM J, V264, P265; HENSON CP, 1967, J BIOL CHEM, V242, P3833; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; KENNEDY C, 1972, BIOCHEM BIOPH RES CO, V47, P740; KENNEDY MC, 1992, ADV INORG CHEM RAD, V38, P323, DOI 10.1016/S0898-8838(08)60067-7; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; MORENO C, 1994, J INORG BIOCHEM, V53, P219, DOI 10.1016/0162-0134(94)80006-5; OSTERYOUNG J, 1986, ELECTROANAL CHEM, V14, P209; Osteryoung JG, 1885, ANAL CHEM, V57, P101, DOI DOI 10.1021/AC00279A004; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; SMITH ET, 1991, ANAL CHIM ACTA, V251, P27, DOI 10.1016/0003-2670(91)87111-J; SUCHETA A, 1992, NATURE, V356, P361, DOI 10.1038/356361a0; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10526, DOI 10.1021/bi00498a015; YOCH DC, 1978, J BACTERIOL, V136, P822, DOI 10.1128/JB.136.2.822-824.1978; ZHUANG HY, 1992, INORG CHIM ACTA, V201, P239	29	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24920	24927						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929174				2022-12-25	WOS:A1994PQ49000061
J	DELOSMONTEROS, AE; SAWAYA, BE; GUILLOU, F; ZAKIN, MM; DEVELLIS, J; SCHAEFFER, E				DELOSMONTEROS, AE; SAWAYA, BE; GUILLOU, F; ZAKIN, MM; DEVELLIS, J; SCHAEFFER, E			BRAIN-SPECIFIC EXPRESSION OF THE HUMAN TRANSFERRIN GENE - SIMILAR ELEMENTS GOVERN TRANSCRIPTION IN OLIGODENDROCYTES AND IN A NEURONAL CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; CAMP RESPONSE ELEMENT; DNA-BINDING DOMAINS; CHOROID-PLEXUS; RAT-BRAIN; CYCLIC-AMP; PROTEIN CRE-BP1; MESSENGER-RNA; SERTOLI CELLS; ENHANCER	We have identified the regulatory sequences that govern the expression of the human transferrin gene in cultured brain cells and compared them with the data obtained with the neuronal cell line B103. Oligodendrocytes and epithelial choroid plexus cells from rat brain were cultured and used for transient expression experiments. Deletion analysis of 1.8 kilobase pairs of the 5' regulatory sequences revealed a -1530/-1140 positive-acting region in oligodendrocytes. The -164/+1 promoter region was sufficient to confer cell type-specific transcription in oligodendrocytes, epithelial choroid plexus cells, and B103 cells. DNase I footprinting experiments revealed three protected sequences, the proximal regions I and II, and the central region I. Gel retardation and antibody reactivity data allowed us to identify most of the nuclear factors present in oligodendrocytes interacting with the promoter sequences. Chicken ovalbumin upstream promoter transcription factor, a CAAT/enhancer-binding protein, and a cAMP response element-binding protein called CRI-BP interact with the proximal regions I and II and central region I sites, respectively. These data confirm the results obtained with the neuronal cell line and emphasize the importance of the three promoter elements for the transferrin gene-specific expression in the central nervous system compared with only two elements required for liver- and testis-specific expression.	UNIV CALIF LOS ANGELES,MENTAL RETARDAT RES CTR,DEPT ANAT & CELL BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,MENTAL RETARDAT RES CTR,DEPT PSYCHIAT,LOS ANGELES,CA 90024; INST PASTEUR,UNITE EXPRESS GENES EUCARYOTES,F-75724 PARIS 15,FRANCE; INRA,PHYSIOL REPROD STN,F-37380 NOUZILLY,FRANCE	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; INRAE					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD006576] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-06576] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALDRED AR, 1987, J BIOL CHEM, V262, P5293; BARTLETT WP, 1991, J NEUROCHEM, V57, P318, DOI 10.1111/j.1471-4159.1991.tb02130.x; BERNDT JA, 1992, J BIOL CHEM, V267, P14730; BLOCH B, 1987, BRAIN RES BULL, V18, P573, DOI 10.1016/0361-9230(87)90122-5; BLOCH B, 1985, P NATL ACAD SCI USA, V82, P6706, DOI 10.1073/pnas.82.19.6706; BOISSIER F, 1991, J BIOL CHEM, V266, P9822; BRUNEL F, 1988, J BIOL CHEM, V263, P10180; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; Cole R., 1989, DISSECTION TISSUE CU, P121; CONNOR JR, 1987, J NEUROSCI RES, V17, P51, DOI 10.1002/jnr.490170108; DELOSMONTEROS AE, 1990, J NEUROSCI RES, V25, P576, DOI 10.1002/jnr.490250416; DELOSMONTEROS AE, 1988, INT J DEV NEUROSCI, V6, P167, DOI 10.1016/0736-5748(88)90042-1; DELOSMONTEROS AE, 1989, J NEUROSCI RES, V24, P125, DOI 10.1002/jnr.490240202; DESMARAIS D, 1992, EMBO J, V11, P2971, DOI 10.1002/j.1460-2075.1992.tb05367.x; DICKSON PW, 1985, BIOCHEM BIOPH RES CO, V127, P890, DOI 10.1016/S0006-291X(85)80027-9; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GARABEDIAN MJ, 1986, CELL, V45, P859, DOI 10.1016/0092-8674(86)90560-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUILLOU F, 1991, J BIOL CHEM, V266, P9876; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KAHN A, 1987, ONCOGENES GENES GROW, P277; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEMAGUERESSE B, 1988, J ENDOCRINOL, V118, pR13, DOI 10.1677/joe.0.118R013; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NOMURA N, 1993, J BIOL CHEM, V268, P4259; OH TH, 1986, DEV BRAIN RES, V30, P207, DOI 10.1016/0165-3806(86)90111-2; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SCHAEFFER E, 1993, J BIOL CHEM, V268, P23399; SCHAEFFER E, 1987, GENE, V56, P109, DOI 10.1016/0378-1119(87)90163-6; SCHAEFFER E, 1989, J BIOL CHEM, V264, P7153; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SKINNER MK, 1980, J BIOL CHEM, V255, P9523; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TSUTSUMI M, 1989, J BIOL CHEM, V264, P9626; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, MOLCELL BIOL, V12, P1708; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; YUAN J, 1992, J NEUROSCI RES, V31, P68, DOI 10.1002/jnr.490310110	46	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24504	24510						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929115				2022-12-25	WOS:A1994PQ34600100
J	BECKERANDRE, M; WIESENBERG, I; SCHAERENWIEMERS, N; ANDRE, E; MISSBACH, M; SAURAT, JH; CARLBERG, C				BECKERANDRE, M; WIESENBERG, I; SCHAERENWIEMERS, N; ANDRE, E; MISSBACH, M; SAURAT, JH; CARLBERG, C			PINEAL-GLAND HORMONE MELATONIN BINDS AND ACTIVATES AN ORPHAN OF THE NUCLEAR RECEPTOR SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							9-CIS RETINOIC ACID; SIGNALING PATHWAYS; MAMMALIAN-TISSUES; RESPONSE PATHWAY; HIGH-AFFINITY; VITAMIN-D; LOCALIZATION; LIGAND; ASSAY; SITES	Nuclear orphan receptors are members of the superfamily of structurally related, ligand-inducible tran scription factors for which no ligand has yet been identified. Over the past few years many nuclear orphan receptors have been cloned, but only for the retinoid X receptor (RXR) has a natural ligand (9 cis-retinoic acid) been found. Here we report the identification of melatonin as a ligand for the recently cloned orphan receptor retinoid Z receptor beta (RZR beta). We found RZR beta expression in the rat brain nearly coincident with binding sites for the pineal gland hormone melatonin (5-methoxy-N-acetyltryptamine). We show here binding and activation of RZR beta by melatonin with K-d and EC(50) values in the low nanomolar range. A nuclear signaling pathway for melatonin may contribute to some of the diverse and profound effects of this hormone, for example, in the context of circadian rhythmicity.	HOP CANTONAL GENEVA,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND; GLAXO INST MOLEC BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND; CIBA GEIGY AG,PHARMA FORSCH,CH-4002 BASEL,SWITZERLAND; UNIV ZURICH,INST HIRNFORSCH,CH-8029 ZURICH,SWITZERLAND	University of Geneva; GlaxoSmithKline; Novartis; University of Zurich			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				ACUNACASTROVIEJ.D, 1993, RES COMMUN CHEM PATH, V2, P253; ACUNACASTROVIEJO D, 1994, J PINEAL RES, V16, P100, DOI 10.1111/j.1600-079X.1994.tb00089.x; BECKERANDRE M, 1993, METHOD ENZYMOL, V218, P420; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1993, BIOCHEM J, V295, P343, DOI 10.1042/bj2950343; DUBOCOVICH ML, 1987, P NATL ACAD SCI USA, V84, P3916, DOI 10.1073/pnas.84.11.3916; EBISAWA T, 1994, P NATL ACAD SCI USA, V91, P6133, DOI 10.1073/pnas.91.13.6133; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KENNAWAY DJ, 1992, MOL CELL ENDOCRINOL, V88, pC1, DOI 10.1016/0303-7207(92)90002-N; KRAUSE DN, 1991, ANNU REV PHARMACOL, V31, P549; LAITINEN JT, 1990, ENDOCRINOLOGY, V126, P2110, DOI 10.1210/endo-126-4-2110; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MENENDEZPELAEZ A, 1993, J PINEAL RES, V15, P59, DOI 10.1111/j.1600-079X.1993.tb00511.x; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MORGAN PJ, 1994, NEUROCHEM INT, V24, P101, DOI 10.1016/0197-0186(94)90100-7; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SUGDEN D, 1994, NEUROCHEM INT, V24, P147, DOI 10.1016/0197-0186(94)90101-5	30	373	387	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 18	1994	269	46					28531	28534						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PU168	7961794				2022-12-25	WOS:A1994PU16800003
J	MCCORMICK, ML; ROEDER, TL; RAILSBACK, MA; BRITIGAN, BE				MCCORMICK, ML; ROEDER, TL; RAILSBACK, MA; BRITIGAN, BE			EOSINOPHIL PEROXIDASE-DEPENDENT HYDROXYL RADICAL GENERATION BY HUMAN EOSINOPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN TRAPPING EVIDENCE; HUMAN-NEUTROPHILS; MONONUCLEAR PHAGOCYTES; STAPHYLOCOCCUS-AUREUS; ENDOTHELIAL-CELLS; SUPEROXIDE ANION; XANTHINE-OXIDASE; IRON; MYELOPEROXIDASE; THIOCYANATE	Eosinophil production of superoxide (O-2-radical anion) and hydrogen peroxide (H2O2) is important in host defense. The present study assessed the potential of eosinophils to generate another potent cytotoxic species, the hydroxyl radical ((OH)-O-.). (OH)-O-. formation by phorbol myristate acetate (PMA)-stimulated eosinophils was demonstrated using an alpha-(4-pyridyl-1-oxide)-N-tert-butyl nitrone/ethanol spin trapping system. Additionally, (OH)-O-. was spin trapped following the addition of purified eosinophil peroxidase (EPO) to a cell-free O-2-radical anion/H2O2 generating systems. Effects of superoxide dismutase, catalase, azide, aminotriazole, chloride-depleted buffer, and extensive metal chelation were consistent with (OH)-O-. formation via the reaction of O-2-radical anion and EPO-generated hypohalous acid. Under chloride-depleted conditions, physiologic concentrations of Br- increased (OH)-O-. formation by both PMA-stimulated eosinophils and the cell-free EPO system. Physiologic concentrations of SCN-, however, did not increase (OH)-O-. formation, and in the presence of both Br- and SCN-, (OH)-O-. formation was similar to SCN- only. Eosinophils appear to form (OH)-O-. via an EPO-dependent mechanism, the magnitude of which varies with the availability of various EPO substrates. Given the highly reactive nature of this radical and the ability of EPO to adhere to cell membranes, even small amounts of (OH)-O-. formed at such sites could contribute to eosinophil-mediated cytotoxicity.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,CTR CARDIOVASC,IOWA CITY,IA 52242; VET ADM MED CTR,RES SERV,IOWA CITY,IA 52242; VET ADM MED CTR,DEPT INTERNAL MED,IOWA CITY,IA 52242	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)					NHLBI NIH HHS [HL44275, HL07121] Funding Source: Medline; NIAID NIH HHS [AI28412] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028412] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUNE TM, 1977, EUR J BIOCHEM, V80, P209, DOI 10.1111/j.1432-1033.1977.tb11873.x; BOZEMAN PM, 1990, J IMMUNOL METHODS, V126, P125, DOI 10.1016/0022-1759(90)90020-V; BRITIGAN BE, 1992, BLOOD, V79, P699; BRITIGAN BE, 1992, J CLIN INVEST, V90, P2187, DOI 10.1172/JCI116104; BRITIGAN BE, 1988, J EXP MED, V168, P2367, DOI 10.1084/jem.168.6.2367; BRITIGAN BE, 1990, J BIOL CHEM, V265, P17533; BRITIGAN BE, 1990, J BIOL CHEM, V265, P2650; BRITIGAN BE, 1986, J BIOL CHEM, V261, P4426; BYNOE LA, 1991, BIOCHEM BIOPH RES CO, V179, P1305, DOI 10.1016/0006-291X(91)91715-O; CANDEIAS LP, 1993, FEBS LETT, V333, P151, DOI 10.1016/0014-5793(93)80394-A; CAPPELLETTI P, 1992, AM J CLIN PATHOL, V98, P615, DOI 10.1093/ajcp/98.6.615; COHEN HJ, 1978, J CLIN INVEST, V61, P1081, DOI 10.1172/JCI109007; COHEN MS, 1992, J INFECT DIS, V166, P1375, DOI 10.1093/infdis/166.6.1375; FINKELSTEIN E, 1979, MOL PHARMACOL, V16, P676; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GANNON DE, 1987, LAB INVEST, V57, P37; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HASSAN HM, 1980, J BACTERIOL, V141, P156, DOI 10.1128/JB.141.1.156-163.1980; HIMMELHOCH SR, 1969, BIOCHEMISTRY-US, V8, P914, DOI 10.1021/bi00831a022; JONG EC, 1980, J IMMUNOL, V124, P1949; JONG EC, 1980, J IMMUNOL, V124, P1378; JORG A, 1982, BIOCHIM BIOPHYS ACTA, V701, P185, DOI 10.1016/0167-4838(82)90112-1; KAUR H, 1988, ANAL BIOCHEM, V172, P360, DOI 10.1016/0003-2697(88)90456-3; KLEBANOFF SJ, 1988, ARCH BIOCHEM BIOPHYS, V264, P600, DOI 10.1016/0003-9861(88)90326-8; LOCKSLEY RM, 1982, J CLIN INVEST, V69, P1099, DOI 10.1172/JCI110545; LONG CA, 1980, J PHYS CHEM-US, V84, P555, DOI 10.1021/j100442a023; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; NAGANO T, 1985, Journal of Free Radicals in Biology and Medicine, V1, P39, DOI 10.1016/0748-5514(85)90027-3; NOGUEIRA NM, 1982, J IMMUNOL, V128, P1705; PETRECCIA DC, 1987, J LEUKOCYTE BIOL, V41, P283, DOI 10.1002/jlb.41.4.283; POU S, 1989, ANAL BIOCHEM, V177, P1, DOI 10.1016/0003-2697(89)90002-X; RAMOS CL, 1992, J BIOL CHEM, V267, P8307; RAMSEY PG, 1982, J IMMUNOL, V128, P415; REPINE JE, 1981, J BIOL CHEM, V256, P7094; ROBERTS RL, 1985, BLOOD, V65, P433; ROOT RK, 1981, REV INFECT DIS, V3, P565; SINGH S, 1988, ANAL BIOCHEM, V171, P47, DOI 10.1016/0003-2697(88)90123-6; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; THOMAS EL, 1986, J BIOL CHEM, V261, P9694; THOMAS MJ, 1986, BIOCHEMISTRY-US, V25, P8042, DOI 10.1021/bi00372a037; THOMAS MJ, 1993, FREE RADICAL BIO MED, V15, P477, DOI 10.1016/0891-5849(93)90210-L; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WINTERBOURN CC, 1986, J CLIN INVEST, V78, P545, DOI 10.1172/JCI112607; ZABUCCHI G, 1992, BLOOD, V80, P2903; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	49	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 11	1994	269	45					27914	27919						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV772	7961724				2022-12-25	WOS:A1994PV77200025
J	BRUSTOVETSKY, N; KLINGENBERG, M				BRUSTOVETSKY, N; KLINGENBERG, M			THE RECONSTITUTED ADP/ATP CARRIER CAN MEDIATE H+ TRANSPORT BY FREE FATTY-ACIDS, WHICH IS FURTHER STIMULATED BY MERSALYL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ADP ATP CARRIER; PHOSPHOLIPID-BILAYER MEMBRANES; ADENINE-NUCLEOTIDE TRANSLOCASE; BEEF-HEART MITOCHONDRIA; BROWN ADIPOSE-TISSUE; UNCOUPLING PROTEIN; SUBMITOCHONDRIAL PARTICLES; PERMEABILITY TRANSITION; PROTON CONDUCTANCE	In a reconstituted system, the participation of the ATP/ADP carrier (AAC) in the free fatty acid (FFA)-induced proton transport was demonstrated (i) by direct measuring of the proton transport through the membranes of AAC proteoliposomes and (ii) by monitoring of the transmembrane potential Delta psi in AAC-cytochrome-c oxidase (COX)-coreconstituted proteoliposomes. FFA increased the initial rate of proton transport in AAC proteoliposomes and decreased Delta psi in AAC-COX proteoliposomes. Inhibitors of AAC suppressed the effects of FFA, Without AAC or with inactive AAC, FFA cannot maintain proton leakage through the membrane. In these cases, even a small increase of Delta psi was induced by FFA These results demonstrate for the first time with purified components a participation of AAC in FFA-induced proton transport supporting an earlier suggestion (Skulachev, V. P. (1991) FEBS Lett. 294, 158-162). Mersalyl treatment of the AAC-COX proteoliposomes resulted in an increase of the AAC-mediated protonophoric action of FFA. Mersalyl also sensitized the protonophoric action of the FFA against nucleotides so that even guanine nucleotides, which are inactive in transport, become inhibitory. The effect of mersalyl is rationalized in terms of a specific interaction with cysteine 159 being attracted as anion by surrounding positive charges. This might open a gate similarly as suggested for eosin 5-maleimide interaction (Majima, E., Koike, H., Hong, Y.-M., Shinohara, Y., and Terada, Il. (1993) J. Biol. Chem. 268, 22181-22187) and, thus, transform the AAC into unidirectional transport mode.			BRUSTOVETSKY, N (corresponding author), UNIV MUNICH, INST PHYS BIOCHEM, GOETHESTR 33, D-80336 MUNICH, GERMANY.							AHMED I, 1990, BIOCHIM BIOPHYS ACTA, V1024, P298, DOI 10.1016/0005-2736(90)90358-U; ANDREYEV AY, 1988, FEBS LETT, V226, P265, DOI 10.1016/0014-5793(88)81436-4; ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x; AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; Bernardi G, 1971, METHOD ENZYMOL, V22, P325; BISACCIA F, 1988, BIOCHIM BIOPHYS ACTA, V933, P229, DOI 10.1016/0005-2728(88)90030-8; BISACCIA F, 1989, BIOCHIM BIOPHYS ACTA, V977, P171, DOI 10.1016/S0005-2728(89)80068-4; BISACCIA F, 1985, BIOCHIM BIOPHYS ACTA, V810, P362, DOI 10.1016/0005-2728(85)90222-1; BLAIR PV, 1967, METHOD ENZYMOL, V10, P78; BRANDOLIN G, 1980, BIOCHIM BIOPHYS ACTA, V592, P592, DOI 10.1016/0005-2728(80)90103-6; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BRUSTOVETSKY N, 1993, NEW PERSPECTIVES MIT, P51; BRUSTOVETSKY NN, 1990, FEBS LETT, V272, P190, DOI 10.1016/0014-5793(90)80481-W; COTY WA, 1974, J BIOL CHEM, V249, P2593; CROMPTON M, 1988, BIOCHEM J, V255, P357; DALBON P, 1988, BIOCHEMISTRY-US, V27, P5141, DOI 10.1021/bi00414a029; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEDUKHOVA VI, 1991, FEBS LETT, V295, P51, DOI 10.1016/0014-5793(91)81382-I; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; Errede B, 1978, Methods Enzymol, V53, P40; Fiske CH, 1925, J BIOL CHEM, V66, P375; FOWLER LR, 1962, BIOCHIM BIOPHYS ACTA, V64, P170, DOI 10.1016/0006-3002(62)90770-9; GAWAZ M, 1990, J BIOL CHEM, V265, P14202; GRIFFITHS D, 1961, J BIOL CHEM, V236, P1850; GRINIUS LL, 1970, BIOCHIM BIOPHYS ACTA, V216, P1, DOI 10.1016/0005-2728(70)90153-2; GUTKNECHT J, 1987, P NATL ACAD SCI USA, V84, P6443, DOI 10.1073/pnas.84.18.6443; GUTKNECHT J, 1988, J MEMBRANE BIOL, V106, P83, DOI 10.1007/BF01871769; HALESTRAP AP, 1976, BIOCHEM J, V156, P181, DOI 10.1042/bj1560181; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HARRIS EJ, 1979, BIOCHEM J, V182, P455, DOI 10.1042/bj1820455; HUTHER FJ, 1984, EUR J BIOCHEM, V143, P79, DOI 10.1111/j.1432-1033.1984.tb08343.x; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KLINGENBERG M, 1985, ENZYMES BIOL MEMBR, V4, P511; KOHNKE D, 1993, FEBS LETT, V336, P90, DOI 10.1016/0014-5793(93)81616-8; KOHNKE D, 1993, BIOL CHEM HOPPESEYLE, V374, P144; KRAMER R, 1980, FEBS LETT, V119, P257, DOI 10.1016/0014-5793(80)80266-3; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; LABONIA N, 1988, BIOCHEM J, V254, P139, DOI 10.1042/bj2540139; LEQUOC K, 1988, ARCH BIOCHEM BIOPHYS, V265, P249, DOI 10.1016/0003-9861(88)90125-7; LOWRY C, 1984, MOL CELL BIOL, V8, P4651; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macedo Denise Vaz De, 1993, European Journal of Biochemistry, V215, P595, DOI 10.1111/j.1432-1033.1993.tb18070.x; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; MARTYN A, 1991, BIOCHEM SOC T, V19, pS257; MAYINGER P, 1989, FEBS LETT, V244, P421, DOI 10.1016/0014-5793(89)80576-9; MCLAUGHLIN SGA, 1980, PHYSIOL REV, V60, P825, DOI 10.1152/physrev.1980.60.3.825; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; PALMIERI F, 1974, BIOCHIM BIOPHYS ACTA, V333, P195, DOI 10.1016/0005-2728(74)90004-8; PANDE SV, 1976, J BIOL CHEM, V251, P6683; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHONFELD P, 1992, FEBS LETT, V303, P190, DOI 10.1016/0014-5793(92)80516-J; SCHONFELD P, 1990, FEBS LETT, V264, P246, DOI 10.1016/0014-5793(90)80259-L; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; STRIELEMAN PJ, 1985, J BIOL CHEM, V260, P3402; THOMAS AP, 1981, BIOCHEM J, V196, P471, DOI 10.1042/bj1960471; TIKHONOVA IM, 1994, FEBS LETT, V337, P231, DOI 10.1016/0014-5793(94)80197-5; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; WINKLER E, 1994, J BIOL CHEM, V269, P2508; WINKLER E, 1992, EUR J BIOCHEM, V207, P135, DOI 10.1111/j.1432-1033.1992.tb17030.x; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y	63	106	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27329	27336						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961643				2022-12-25	WOS:A1994PV77100031
J	CHENG, JB; GUFFANTI, AA; KRULWICH, TA				CHENG, JB; GUFFANTI, AA; KRULWICH, TA			THE CHROMOSOMAL TETRACYCLINE RESISTANCE LOCUS OF BACILLUS-SUBTILIS ENCODES A NA+/H+ ANTIPORTER THAT IS PHYSIOLOGICALLY IMPORTANT AT ELEVATED PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; TRANSPOSON TN10; GENE; DNA; DETERMINANTS; PROTEIN; EFFLUX	The chromosomal tetB(L) gene of Bacillus subtilis encodes a transporter that catalyzes Na+/H+ antiport even more actively than tetracycline/H+ antiport, as shown by assays of membrane antiporter activity upon transformation of Na+/H+ antiporter-deficient Escherichia coli with the cloned gene; the transformation results in a substantial increase in Na+ resistance as well as detectable resistance to low tetracycline concentrations. Transpositional disruption of the chromosomal tetB(L) locus of B. subtilis led to reduced rates of electrogenic Na+ efflux and revealed a physiological role for this locus in Na+ resistance and Na+-dependent pH homeostasis at pH 8.5. The mutant phenotype was reversed by transformation with a plasmid expressing the cloned tetB(L) gene. Energy-dependent tetracycline efflux rates in the wild type were greater than in the transposition mutant but were not sufficient to confer resistance to the antibiotic. TetB(L) is also inferred to have a modest capacity for K+ efflux, since the transposition mutant is slightly impaired in K+-dependent pH homeostasis at pH 8.5 and grew better than the wild type at pH 7 on limiting K+ concentrations.	CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								AMANO H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P251, DOI 10.1016/0167-4781(91)90061-P; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; AMBUDKAR SV, 1990, BACTERIA, V12, P247; BURDETT V, 1982, J BACTERIOL, V149, P995, DOI 10.1128/JB.149.3.995-1004.1982; CAMILLI A, 1990, J BACTERIOL, V172, P3738, DOI 10.1128/jb.172.7.3738-3744.1990; DOSCH DC, 1984, J BACTERIOL, V160, P1188, DOI 10.1128/JB.160.3.1188-1190.1984; DUBNAU D, 1971, J MOL BIOL, V56, P209, DOI 10.1016/0022-2836(71)90460-8; DUBNAU D, 1984, CRIT REV BIOCH, V16, P102; GARCIA ML, 1983, J BACTERIOL, V156, P1151, DOI 10.1128/JB.156.3.1151-1157.1983; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GRIFFITH JK, 1988, J BACTERIOL, V170, P598, DOI 10.1128/jb.170.2.598-604.1988; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GUAY GG, 1993, J BACTERIOL, V175, P4927, DOI 10.1128/JB.175.15.4927-4929.1993; GUFFANTI AA, 1991, J GEN MICROBIOL, V137, P2375, DOI 10.1099/00221287-137-10-2375; HILLEN W, 1982, J BIOL CHEM, V257, P6605; IVES CL, 1990, J BACTERIOL, V172, P4936, DOI 10.1128/jb.172.9.4936-4944.1990; IVES CL, 1990, GENE, V94, P115, DOI 10.1016/0378-1119(90)90476-8; IVES CL, 1989, J BACTERIOL, V171, P1801, DOI 10.1128/jb.171.4.1801-1810.1989; IVEY DM, 1991, J BIOL CHEM, V266, P23483; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; KRULWICH TA, 1989, J BIOENERG BIOMEMBR, V21, P663, DOI 10.1007/BF00762685; KRULWICH TA, 1983, BIOCHIM BIOPHYS ACTA, V726, P245, DOI 10.1016/0304-4173(83)90011-3; KRULWICH TA, 1985, J BIOL CHEM, V260, P4055; KRULWICH TA, 1994, IN PRESS J EXP BIOL, V196; LEVY SB, 1989, J ANTIMICROB CHEMOTH, V24, P1, DOI 10.1093/jac/24.1.1; LEVY SB, 1989, ANTIMICROB AGENTS CH, V33, P1373, DOI 10.1128/AAC.33.8.1373; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; MACNAB RM, 1987, BIOPHYS J, V52, P637, DOI 10.1016/S0006-3495(87)83255-1; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MCMURRY LM, 1992, J BACTERIOL, V174, P6294, DOI 10.1128/JB.174.19.6294-6297.1992; MOJUMDAR M, 1988, J BACTERIOL, V170, P5522, DOI 10.1128/jb.170.12.5522-5528.1988; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; OHYAMA T, 1992, J BACTERIOL, V174, P7743, DOI 10.1128/JB.174.23.7743-7749.1992; PADAN E, 1993, J BIOENERG BIOMEMBR, V25, P647; PADAN E, 1989, J BIOL CHEM, V267, P11064; QUIRK PG, 1993, J BACTERIOL, V175, P647, DOI 10.1128/JB.175.3.647-654.1993; SAKAGUCHI R, 1988, BIOCHIM BIOPHYS ACTA, V949, P49, DOI 10.1016/0167-4781(88)90053-X; SALYERS AA, 1990, MOL MICROBIOL, V4, P151, DOI 10.1111/j.1365-2958.1990.tb02025.x; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS JR, 1984, BRIT MED BULL, V40, P54, DOI 10.1093/oxfordjournals.bmb.a071948; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SCHULDINER S, 1993, ALKALI CATION TRANSP, P25; SCHWARZ S, 1992, ANTIMICROB AGENTS CH, V36, P580, DOI 10.1128/AAC.36.3.580; SHERIDAN RP, 1991, MOL MICROBIOL, V5, P895, DOI 10.1111/j.1365-2958.1991.tb00763.x; SHISHIDO K, 1983, PLASMID, V10, P224, DOI 10.1016/0147-619X(83)90036-7; SPEER BS, 1992, CLIN MICROBIOL REV, V5, P387, DOI 10.1128/CMR.5.4.387-399.1992; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WILLIAMS G, 1979, MOL GEN GENET, V177, P23, DOI 10.1007/BF00267249; WILSON CR, 1985, J BACTERIOL, V163, P445, DOI 10.1128/JB.163.2.445-453.1985; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1992, FEBS LETT, V307, P229, DOI 10.1016/0014-5793(92)80773-A; YAMAGUCHI A, 1991, FEBS LETT, V282, P415, DOI 10.1016/0014-5793(91)80527-A; YAMAGUCHI A, 1991, ANTIMICROB AGENTS CH, V35, P53, DOI 10.1128/AAC.35.1.53; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; ZILBERSTEIN D, 1982, J BIOL CHEM, V257, P3687	56	74	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27365	27371						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961647				2022-12-25	WOS:A1994PV77100036
J	GIDHJAIN, M; ZHANG, YP; VANPOELJE, PD; LIANG, JY; HUANG, SH; KIM, JY; ELLIOTT, JT; ERION, MD; PILKIS, SJ; ELMAGHRABI, MR; LIPSCOMB, WN				GIDHJAIN, M; ZHANG, YP; VANPOELJE, PD; LIANG, JY; HUANG, SH; KIM, JY; ELLIOTT, JT; ERION, MD; PILKIS, SJ; ELMAGHRABI, MR; LIPSCOMB, WN			THE ALLOSTERIC SITE OF HUMAN LIVER FRUCTOSE-1,6-BISPHOSPHATASE - ANALYSIS OF 6 AMP SITE MUTANTS BASED ON THE CRYSTAL-STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T7 RNA-POLYMERASE; ESCHERICHIA-COLI; FRUCTOSE 2,6-BISPHOSPHATE; EXPRESSION; REFINEMENT	The molecular structure of human liver fructose-1,6-bisphosphatase complexed with AMP was determined by x-ray diffraction using molecular replacement, starting from the pig kidney enzyme AMP complex. Of the 34 amino acid residues which differ between these two sequences, only one interacts with AMP; Met(30) in pig kidney is Leu(30) in human liver. From this analysis, six sites in which side chains of amino acid residues are in contact with AMP Ala(24), Leu(30), Thr(31), Tyr(113), Arg(140), and Met(177), were mutated by polymerase chain reaction. The wild-type and mutant forms were expressed in Escherichia coli, purified, and their kinetic properties determined. Circular dichroism spectra of the mutants were indistinguishable from that of the wild-type enzyme. Kinetic analyses revealed that all forms had similar turnover numbers, K-m values for fructose 2,6-bisphosphate, and inhibition constants for fructose 2,6-bisphosphate. Apparent K-i values for AMP inhibition of the Leu(30) --> Phe and Met(177) --> Ala mutants were similar to those of the wild-type enzyme, but the apparent K-i values for the Arg(140) --> Ala and Ala(24) --> Phe mutants were 7-to 20-fold higher, respectively. The Thr(31) --> Ser mutant exhibited a 5-fold increase in apparent K-i for AMP, while mutation of Thr(31) to Ala increased the apparent K-i 120-fold. AMP inhibition of the Tyr(113) --> Phe mutant was undetectable even at millimolar AMP concentrations. Fructose 2,6-bisphosphate potentiated AMP inhibition of the mutants to the same extent as for the wild-type enzyme, except in the case of the Thr(31) --> Ala and Tyr(113) --> Phe mutants. Thus, the Met(177) --> Ala mutant suggests that the side chain beyond C alpha is not needed for AMP binding, and that the Leu(30) --> Phe mutant preserves the AMP contacts with these side chains. Thr(31), Tyr(113), and Arg(140) form key hydrogen bonds to AMP consistent with strong side chain interactions in the wild-type enzyme. Finally, the absence of any effect of fructose 2,6-bisphosphate on AMP inhibition observed in the Thr(31) --> Ala mutant may be an important clue relating to the mechanism of synergism of these two inhibitors.	SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; GENSIA INC,SAN DIEGO,CA 92121; HARVARD UNIV,DEPT CHEM,GIBBS CHEM LAB,CAMBRIDGE,MA 02138	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University					NIDDK NIH HHS [DK 38354] Funding Source: Medline; NIGMS NIH HHS [GM 06920] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038354, R37DK038354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM006920, R37GM006920] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABUL J, 1983, ARCH BIOCHEM BIOPHYS, V225, P944, DOI 10.1016/0003-9861(83)90109-1; BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEN M, 1994, J BIOL CHEM, V269, P5554; ELMAGHRABI MR, 1992, J BIOL CHEM, V267, P6526; ELMAGHRABI MR, 1993, J BIOL CHEM, V268, P9466; ELMAGHRABI MR, 1991, BIOCHEM BIOPH RES CO, V176, P137, DOI 10.1016/0006-291X(91)90900-R; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KE H, 1989, J MOL BIOL, V212, P513; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG JY, 1993, P NATL ACAD SCI USA, V90, P21312; LIANG JY, 1992, P NATL ACAD SCI USA, V89, P2402; LIU F, 1990, FRUCTOSE 2 6 BISPHOS, P17; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCUS F, 1990, ARCH BIOCHEM BIOPHYS, V279, P151, DOI 10.1016/0003-9861(90)90475-E; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; PILKIS SJ, 1981, J BIOL CHEM, V256, P1489; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PONTREMOLI S., 1966, BIOCHEMISTRY, V5, P3568, DOI 10.1021/bi00875a027; RAO SN, 1980, ACTA CRYSTALLOGR A, V36, P878, DOI 10.1107/S0567739480001854; SEDIVY JM, 1986, P NATLA CAD SCI US, V225, P1656; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKETA K, 1965, J BIOL CHEM, V240, P651; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P263, DOI 10.1042/bj1920263; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P1844, DOI 10.1021/bi00058a019	27	67	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27732	27738						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961695				2022-12-25	WOS:A1994PV77100089
J	JAMES, GL; BROWN, MS; COBB, MH; GOLDSTEIN, JL				JAMES, GL; BROWN, MS; COBB, MH; GOLDSTEIN, JL			BENZODIAZEPINE PEPTIDOMIMETIC BZA-5B INTERRUPTS THE MAP KINASE ACTIVATION PATHWAY IN H-RAS-TRANSFORMED RAT-1 CELLS, BUT NOT IN UNTRANSFORMED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE-2; GROWTH-FACTOR; PROTEIN FARNESYLTRANSFERASE; TYROSINE PHOSPHORYLATION; P21RAS; REQUIREMENT; INHIBITION; BINDING; MUTANTS; BRAIN	A benzodiazepine peptidomimetic, BZA-5B, inhibits farnesylation of H-Ras and normalizes the morphology of Rat-1 cells transformed with H-Ras(V12) at concentrations that do not affect the growth of untransformed Rat-1 cells. In the current experiments, we show that BZA-5B decreases the active forms of enzymes in the mitogen-activated protein (MAP) kinase signaling cascade, including Raf, MAP kinase kinase (MEK), and MAP kinase, in cells transformed with H-Ras(V12). BZA-5B had no effect on these enzymes in cells transformed with H-Ras(V12,189), which is geranylgeranylated rather than farnesylated. In cells transformed with H-Ras(V12), BZA-5B reduced the activities of enzymes in the MAP kinase pathway at concentrations that only partially blocked farnesylation of H-Ras(V12), suggesting that nonfarnesylated H-Ras(V12) is a dominant inhibitor of the action of farnesylated H-Ras(V12) in the BZA-5B treated cells. In untransformed Rat-1 cells, BZA-5B did not inhibit MAP kinase activity nor did it prevent the acute activation triggered by epidermal growth factor, even though farnesylated endogenous H-Ras was no longer detectable. These data raise the possibility that untransformed cells contain a form of Ras (K-Ras or N-Ras) whose prenylation is not inhibited by BZA-5B, thus allowing them to resist the effects of BZA-5B.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	JAMES, GL (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEWMAN CMH, 1993, BIOCHIM BIOPHYS ACTA, V1155, P79, DOI 10.1016/0304-419X(93)90023-6; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J, 1989, MOL CLONING LABORATO; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230	39	105	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27705	27714						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961691				2022-12-25	WOS:A1994PV77100085
J	INADA, M; CROWL, RM; BEKKERS, ACAPA; VERHEIJ, H; WEISS, J				INADA, M; CROWL, RM; BEKKERS, ACAPA; VERHEIJ, H; WEISS, J			DETERMINANTS OF THE INHIBITORY-ACTION OF PURIFIED 14-KDA PHOSPHOLIPASES A(2) ON CELL-FREE PROTHROMBINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY-INCREASING PROTEIN; PORCINE PANCREATIC PHOSPHOLIPASE-A2; NAJA-NIGRICOLLIS VENOM; ESCHERICHIA-COLI; SNAKE-VENOM; UNILAMELLAR VESICLES; ENZYMATIC-ACTIVITY; BINDING-SITE; FACTOR-VA; MEMBRANE	It has been suggested (Kini, R. R., and Evans, H. J. (1987) J. Biol. Chem. 262, 14402-14407) that the anticoagulant activity of members of the 14-kDa phospholipase A(2) (PLA(2)) family depends on the presence of basic residues within a variable surface region (residues 54-77) distinct from both the conserved catalytic machinery and surface sites mediating the antibacterial action of these enzymes (see Weiss, J., Inada, M., Elsbach, P., and Crowl, R. M. (1994) J. Biol. Chem. 269, 26331-26337). To further define the determinants of the anticoagulant activity of PLA(2), we have analyzed the inhibitory effects of purified native and recombinant PLA(2) on cell-free prothrombinase. Both native and recombinant wildtype pig pancreas (net charge -1) and human ''secretory'' PLA(2) (net charge +15) produced similar dose-dependent inhibition of prothrombinase activity that was significantly less potent than a toxic PLA(2) purified from snake venom. Site specific mutations that either increased or decreased PLA(2) activity toward bactericidal/permeability-increasing protein-treated Escherichia coli by up to 50-fold had no effect on antiprothrombinase activity. In contrast, substitution of Arg for Asp-59/Gly for Ser-60 in the pig PLA(2) increased antiprothrombinase activity by 5-10-fold without affecting catalytic activity toward a range of phospholipid substrates or antibacterial activity. Comparison of antiprothrombinase activity of catalytically active and inactive forms of the PLA(2) and under a range of phospholipid conditions revealed that the potent antiprothrombinase activity of native toxic venom PLA(2) and of the D59R.S60G mutant pancreatic PLA(2) reflect combined catalytic and noncatalytic actions, the latter apparently dependent on basic residues at discrete surface sites in the enzyme.	NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, NUTLEY, NJ 07110 USA; UNIV UTRECHT, CTR BIOMEMBRANES & LIPID ENZYMOL, DEPT BIOCHEM, UTRECHT, NETHERLANDS	New York University; Roche Holding; Utrecht University				Weiss, Jerrold/0000-0003-1476-4485	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018571] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18571] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CIRINO G, 1993, THROMB RES, V70, P337, DOI 10.1016/0049-3848(93)90106-X; CONDREA E, 1981, TOXICON, V19, P705, DOI 10.1016/0041-0101(81)90108-2; CONDREA E, 1983, TOXICON, V21, P209, DOI 10.1016/0041-0101(83)90005-3; CUTSFORTH GA, 1989, BIOCHEMISTRY-US, V28, P7453, DOI 10.1021/bi00444a045; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEKRUIJFF B, 1975, BIOCHIM BIOPHYS ACTA, V406, P6, DOI 10.1016/0005-2736(75)90038-3; ELSBACH P, 1991, METHOD ENZYMOL, V197, P24; ELSBACH P, 1979, J BIOL CHEM, V254, P1000; FORST S, 1986, BIOCHEMISTRY-US, V25, P4309, DOI 10.1021/bi00363a020; FORST S, 1987, BIOCHIM BIOPHYS ACTA, V920, P221, DOI 10.1016/0005-2760(87)90098-1; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FRANCK PFH, 1985, J CLIN INVEST, V75, P183, DOI 10.1172/JCI111672; GERADS I, 1990, BIOCHEMISTRY-US, V29, P7967, DOI 10.1021/bi00486a027; GILFILLAN AM, 1983, J LIPID RES, V24, P1651; GOVERSRIEMSLAG JWP, 1992, BIOCHEMISTRY-US, V31, P10000, DOI 10.1021/bi00156a020; HAMILTON KK, 1990, J BIOL CHEM, V265, P3809; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HAWROT E, 1978, J BIOL CHEM, V253, P8213; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; KINI RM, 1987, J BIOL CHEM, V262, P14402; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KINI RM, 1986, TOXICON, V24, P895; KINI RM, 1986, TOXICON, V24, P527, DOI 10.1016/0041-0101(86)90173-X; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LICHTENBERG D, 1986, J BIOL CHEM, V261, P5334; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANN KG, 1990, BLOOD, V76, P1; MENASHE M, 1986, J BIOL CHEM, V261, P5328; Nieuwenhuizen W, 1974, Methods Enzymol, V32, P147; PEI G, 1993, J BIOL CHEM, V268, P3226; ROSING J, 1980, J BIOL CHEM, V255, P274; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; STEFANSSON S, 1990, BIOCHEMISTRY-US, V29, P7742, DOI 10.1021/bi00485a024; STEFANSSON S, 1989, THROMB RES, V55, P481, DOI 10.1016/0049-3848(89)90056-X; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; VADAS P, 1992, LIFE SCI, V50, P807, DOI 10.1016/0024-3205(92)90186-S; VERHEIJ HM, 1980, EUR J BIOCHEM, V112, P25, DOI 10.1111/j.1432-1033.1980.tb04982.x; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; VOLWERK JJ, 1974, BIOCHEMISTRY-US, V13, P1446, DOI 10.1021/bi00704a020; WAITE M, 1990, BIOCH MOL BIOL PHYSL; WEISS J, 1991, J BIOL CHEM, V266, P4162; WEISS J, 1994, J BIOL CHEM, V269, P26331	47	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26338	26343						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929351				2022-12-25	WOS:A1994PQ93000061
J	SHI, MM; KUGELMAN, A; IWAMOTO, T; TIAN, L; FORMAN, HJ				SHI, MM; KUGELMAN, A; IWAMOTO, T; TIAN, L; FORMAN, HJ			QUINONE-INDUCED OXIDATIVE STRESS ELEVATES GLUTATHIONE AND INDUCES GAMMA-GLUTAMYLCYSTEINE SYNTHETASE-ACTIVITY IN RAT LUNG EPITHELIAL L2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSIVE ELEMENT; HUMAN OVARIAN-CANCER; MESSENGER-RNA; INDUCTION; KIDNEY; ACTIVATION; INCREASE; IDENTIFICATION; FIBROBLASTS; PROTECTION	Glutathione (GSH) is one of the most important physiological antioxidants involved in detoxification of hydrogen peroxide and lipid hydroperoxide. Previous studies have shown that cells can maintain and even increase cellular GSH content in response to sublethal oxidative stress. We hypothesized that gamma-glutamylcysteine synthetase (gamma GCS), the rate-limiting enzyme in de novo GSH synthesis, could be induced by oxidative stress. Rat lung epithelial L2 cells were challenged with 2,3-dimethoxy-1,4 naphthoquinone (DMNQ), which generates O-2(radical anion) and H2O2 continuously through redox cycling. Exposure of confluent L2 cells with sublethal doses of DMNQ caused sustained elevation of cellular GSH levels over a 24-h period (to 2.5-fold with 10 mu M). DMNQ caused increases in gamma GCS activity (70% at 24 h with 10 mu M), the gamma GCS catalytic heavy subunit (gamma GCS-HS) protein level, and gamma GCS-HS mRNA content (similar to 4 fold after 6 h with 10 mu M). The elevation of gamma GCS-HS mRNA by DMNQ was eliminated by co-incubation with actinomycin D. Nuclear run-on experiments demonstrated that the transcriptional rate of the gamma GCS-HS gene was increased by 3- or 6 h exposure to 10 mu M DMNQ. Our results suggested that the induction of de novo GSH synthesis by naphthoquinone-induced oxidative stress is associated with the transcriptional activation of the gamma GCS-HS gene and the subsequent elevation in gamma GCS activity. Unlike simpler quinones, DMNQ cannot form a GSH conjugate. Thus, the induction of gamma GCS-HS gene transcription does not require formation of an electrophile-glutathione conjugate.	UNIV SO CALIF,SCH PHARM,DEPT MOLEC PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; KANSAS STATE UNIV AGR & APPL SCI,DEPT BIOCHEM,MANHATTAN,KS 66506	University of Southern California; University of Southern California; University of Southern California; Kansas State University				Forman, Henry Jay/0000-0001-5838-2791	NIEHS NIH HHS [ES05511] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005511, R56ES005511] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAILEY HH, 1992, CANCER RES, V52, P5115; BANNAI S, 1989, J BIOL CHEM, V264, P18480; BORROZ KI, 1994, TOXICOL APPL PHARM, V126, P150, DOI 10.1006/taap.1994.1101; BRUNMARK A, 1989, FREE RADICAL BIO MED, V7, P435, DOI 10.1016/0891-5849(89)90126-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; DARLEYUSMAR VM, 1991, BIOCHEM J, V278, P429, DOI 10.1042/bj2780429; DENEKE SM, 1989, AM J PHYSIOL, V257, pL265, DOI 10.1152/ajplung.1989.257.4.L265; DOUGLAS WHJ, 1974, IN VITRO CELL DEV B, V10, P230; DOUGLAS WHJ, 1976, ENVIRON HEALTH PERSP, V16, P83, DOI 10.2307/3428588; EATON DL, 1994, TOXICOL APPL PHARM, V126, P145, DOI 10.1006/taap.1994.1100; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; GANT TW, 1988, CHEM-BIOL INTERACT, V65, P157, DOI 10.1016/0009-2797(88)90052-X; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; HAGEN TM, 1988, KIDNEY INT, V34, P74, DOI 10.1038/ki.1988.147; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1988, P NATL ACAD SCI USA, V85, P2464, DOI 10.1073/pnas.85.8.2464; KUGELMAN A, 1994, IN RPESS AM J RESPIR, V11; LEE FYF, 1989, BRIT J CANCER, V60, P291, DOI 10.1038/bjc.1989.273; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MOORE WR, 1989, P NATL ACAD SCI USA, V86, P1461, DOI 10.1073/pnas.86.5.1461; OGINO T, 1989, BIOCHIM BIOPHYS ACTA, V1006, P131, DOI 10.1016/0005-2760(89)90334-2; OHNO K, 1990, BIOCHEM BIOPH RES CO, V168, P551, DOI 10.1016/0006-291X(90)92356-5; POOT M, 1987, EUR J BIOCHEM, V162, P287, DOI 10.1111/j.1432-1033.1987.tb10598.x; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; SHI M, 1993, FREE RADICAL BIO MED, V15, P57, DOI 10.1016/0891-5849(93)90125-E; SHI MM, 1994, IN PRESS AM J PHYSL, V267; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; WOODS JS, 1992, ARCH BIOCHEM BIOPHYS, V296, P350, DOI 10.1016/0003-9861(92)90583-I; YAN N, 1990, J BIOL CHEM, V265, P1588	36	298	306	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26512	26517						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929374				2022-12-25	WOS:A1994PQ93000087
J	TZAGOLOFF, A; YUE, J; JANG, J; PAUL, MF				TZAGOLOFF, A; YUE, J; JANG, J; PAUL, MF			A NEW MEMBER OF A FAMILY OF ATPASES IS ESSENTIAL FOR ASSEMBLY OF MITOCHONDRIAL RESPIRATORY-CHAIN AND ATP-SYNTHETASE COMPLEXES IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME QH2-CYTOCHROME-C REDUCTASE; MEMBRANE SYSTEM; PUTATIVE ATPASES; GENE-EXPRESSION; YEAST REQUIRES; PROTEIN FAMILY; NUCLEAR; MUTANTS; DNA; IDENTIFICATION	Respiration-defective pet mutants of Saccharomyces cerevisiae, assigned to complementation group G25, are grossly deficient in mitochondrial respiratory and ATPase complexes. This phenotype is usually found in strains impaired in mitochondrial protein synthesis. The G25 mutants, however, synthesize all of the proteins encoded by mitochondrial DNA. The mutants are also able to import and process cytoplasmically derived subunits of these enzymes. These results are most compatible with the idea that the gene defined by G25 mutants (RCA1) codes for a protein essential for the assembly of functional respiratory and ATPase complexes. The RCA1 gene has been cloned by complementation of an rca1 mutant with a yeast genomic library. The sequence of the encoded product shows Rca1 protein to be a new member of a recently described family of ATPases. The Rca1 protein is a mitochondrial membrane protein and is the third known member of this family implicated to function in the biogenesis of mitochondria. The primary structure of Rca1 protein indicates several distinct domains in addition to the common purine nucleotide binding region shared by all members of this protein family. One, located in the amino-terminal half, contains two hydrophobic stretches of sufficient length to span a membrane lipid bilayer.			TZAGOLOFF, A (corresponding author), COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA.				NHLBI NIH HHS [R01 HL022174, HL22174] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022174, R01HL022174] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; Berden J.A., 1988, MOL BASIS BIOMEMBRAN, P195; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; COSTANZO MC, 1986, EMBO J, V5, P3637, DOI 10.1002/j.1460-2075.1986.tb04693.x; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DOUGLAS MG, 1976, P NATL ACAD SCI USA, V73, P1083, DOI 10.1073/pnas.73.4.1083; DUJON B, 1981, MOL BIOL YEAST SACCH, P506; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; MYERS AM, 1987, J BIOL CHEM, V262, P3388; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PILLAR T, 1983, J BIOL CHEM, V258, P7954; PON L, 1991, MOL CELLULAR BIOL YE, P333; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; REPETTO B, 1991, MOL CELL BIOL, V11, P3931, DOI 10.1128/MCB.11.8.3931; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; ten Berge A M, 1974, Mol Gen Genet, V131, P113; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; TZAGOLOFF A, 1989, EUR J BIOCHEM, V179, P365, DOI 10.1111/j.1432-1033.1989.tb14562.x; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; Tzagoloff A, 1990, Prog Nucleic Acid Res Mol Biol, V39, P129, DOI 10.1016/S0079-6603(08)60625-X; WU M, 1989, J BIOL CHEM, V264, P11122; WU M, 1987, J BIOL CHEM, V262, P12275	50	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26144	26151						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929327				2022-12-25	WOS:A1994PQ93000033
J	HIGAZI, AAR; BARGHOUTI, II				HIGAZI, AAR; BARGHOUTI, II			INACTIVATION OF HUMAN ANAPHYLATOXIN C5A AND C5A DES-ARG THROUGH CLEAVAGE BY THE PLASMINOGEN-ACTIVATOR ACTIVITY OF A HUMAN FIBROSARCOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY-CHROMATOGRAPHY; EXTRACELLULAR-MATRIX; PERITONEAL-FLUID; TUMOR INVASION; UROKINASE; PURIFICATION; CANCER; DIFFERENTIATION; FIBRINOLYSIS; DEGRADATION	The HT-1080 human fibrosarcoma cell line exhibited a plasminogen-dependent ability to inactivate recombinant anaphylatoxin C5a or zymosan-activated serum. The inactivation was obtained at physiological levels of both plasminogen (2 mu M) and C5a (1-5 nM). Inactivated C5a and zymosan activated serum were no longer able to induce chemotaxis and degranulation of neutrophils. Inactivation of C5a paralleled the emergence of plasmin activity, assayed by cleavage of the synthetic substrate H-D-valyl-L-leucyl-L-lysine-p-nitroanilide (S-2251). Both C5a inactivation and S-2251 cleavage were inhibited by the plasmin inhibitor alpha(2)-antiplasmin, the urokinase inhibitor amiloride, and by anti-urokinase antibodies. In a cell-free system, inactivation of C5a was shown to depend on the simultaneous presence of urokinase and plasminogen and was inhibited by alpha(2)-antiplasmin and by anti-urokinase antibodies. SDS-polyacrylamide electrophoresis demonstrated the cleavage of C5a by the plasminogen activation system and inhibition of the cleavage by amiloride. Amino acid sequencing of the band corresponding to the C5a degradation product revealed that C5a was cleaved at positions Lys(14)-His(15) and Arg(40)-Ile(41); cleavage at position Arg(40)-Ile(41) seemed to be responsible for the loss of activity. Since neoplastic cells extensively produce and exhibit plasminogen activator activity, the present observations suggest that plasminogen activation may, by inactivation of C5a, reduce the anti-tumor immune response and support the immunological escape phenomenon of tumors.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	HIGAZI, AAR (corresponding author), HADASSAH UNIV HOSP,DEPT CLIN BIOCHEM,POB 12000,IL-91120 JERUSALEM,ISRAEL.							AYESH SK, 1990, J IMMUNOL, V144, P3066; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DAMERAU B, 1986, MOL IMMUNOL, V23, P433, DOI 10.1016/0161-5890(86)90141-0; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ELLIS V, 1991, J BIOL CHEM, V266, P12752; FAUVE RM, 1974, P NATL ACAD SCI USA, V71, P4052, DOI 10.1073/pnas.71.10.4052; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; GERARD C, 1985, J BIOL CHEM, V260, P2613; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GOLDSTEIN IM, 1992, INFLAMMATION BASIC P, P55; HART DA, 1992, FIBRINOLYSIS, V6, P11, DOI 10.1016/0268-9499(92)90087-X; HUGLI TE, 1984, SPRINGER SEMIN IMMUN, V7, P193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHONEY MJ, 1962, CANCER RES, V22, P334; MARKUS G, 1984, SEMIN THROMB HEMOST, V10, P61, DOI 10.1055/s-2007-1004408; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATZNER Y, 1984, J LAB CLIN MED, V103, P227; MAYER M, 1990, CLIN BIOCHEM, V23, P197, DOI 10.1016/0009-9120(90)90601-P; MOORE M, 1985, IMMUNOLOGY; MULLINS DE, 1983, BIOCHIM BIOPHYS ACTA, V695, P177, DOI 10.1016/0304-419X(83)90011-2; NEUMAN T, 1989, J NEUROSCI RES, V23, P274, DOI 10.1002/jnr.490230305; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; OSSOWSKI L, 1991, CANCER RES, V51, P274; PAULI BU, 1983, CANCER METAST REV, V2, P129, DOI 10.1007/BF00048966; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; REICH R, 1988, CANCER RES, V48, P3307; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; SAKSELA O, 1985, BIOCHIM BIOPHYS ACTA, V823, P35, DOI 10.1016/0304-419X(85)90014-9; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VERSTRAETE M, 1986, BLOOD, V67, P1529; WALLEN P, 1978, PROGR CHEM FIBRINOLY, V3, P167; WARD PA, 1970, J IMMUNOL, V104, P535; WILSON EL, 1983, BLOOD, V61, P568; WOOLLEY DE, 1984, CANCER METAST REV, V3, P361, DOI 10.1007/BF00051460; WRIGHT DG, 1977, J IMMUNOL, V119, P1068; WUN TC, 1982, J BIOL CHEM, V257, P7262	40	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25529	25533						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929254				2022-12-25	WOS:A1994PQ49100047
J	CAPRANICO, G; PALUMBO, M; TINELLI, S; ZUNINO, F				CAPRANICO, G; PALUMBO, M; TINELLI, S; ZUNINO, F			UNIQUE SEQUENCE SPECIFICITY OF TOPOISOMERASE-II DNA CLEAVAGE STIMULATION AND DNA-BINDING MODE OF STREPTONIGRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REQUIREMENTS; MITOXANTRONE; CYTOTOXICITY; DERIVATIVES; RESISTANCE; AMSACRINE	Streptonigrin stimulated unique intensity patterns of topoisomerase II-mediated DNA cleavage in agarose and sequencing gels with no similarity to those of doxorubicin, VM-26, 4'(9-acridinylamino)-methanesulfon-m anisidide, genistein, and mitoxantrone. Surprisingly, a statistical analysis of 60 sites stimulated by streptonigrin in SV40 and pBR322 DNAs showed that the drug required the dinucleotide 5'-TA-3' from 2- to 3-positions at the DNA cleavage site. Streptonigrin did not intercalate into the double helix; however, a positive value of the reduced linear dichroism indicated that indeed the drug interacted with the DNA. An angle of 45 degrees was found between the major drug and local DNA axes, suggesting a minor groove binding mode. Moreover, a DNA winding assay showed that streptonigrin may tighten the helical twist of DNA, similar to the known minor groove binder distamycin. Drug competition for receptor site binding was then evaluated by drug combination in the cleavage reaction. DNA cleavage intensity patterns were altered only with the streptonigrin/mitoxantrone combination, suggesting that the two compounds may compete for ternary complex formation. The results indicate that streptonigrin may bind to the DNA in a manner similar to that of minor groove binders and that its pharmacophore, possibly different from other topoisomerase II inhibitors, may be an important determinant of its unique sequence position specificity.	UNIV PADUA, DEPT PHARMACEUT SCI, I-35100 PADUA, ITALY	University of Padua	CAPRANICO, G (corresponding author), IST NAZL STUDIO & CURA TUMORI, DIV EXPTL ONCOL B, VIA VENEZIAN 1, I-20133 MILAN, ITALY.		Capranico, Giovanni/K-1678-2014	Capranico, Giovanni/0000-0002-8708-6454; Palumbo, Manlio/0000-0002-3163-1564				[Anonymous], DEV CANC CHEMOTHERAP; BIGIONI M, 1994, NUCLEIC ACIDS RES, V22, P2274, DOI 10.1093/nar/22.12.2274; CAPRANICO G, 1992, EUR J CANCER, V28A, P2055, DOI 10.1016/0959-8049(92)90255-Z; CAPRANICO G, 1993, BIOCHEMISTRY-US, V32, P3038, DOI 10.1021/bi00063a015; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; CAPRANICO G, 1994, J MOL BIOL, V235, P1218, DOI 10.1006/jmbi.1994.1075; CHEN AY, 1993, CANCER RES, V53, P1332; CHEN AY, 1993, P NATL ACAD SCI USA, V90, P8131, DOI 10.1073/pnas.90.17.8131; COHEN MM, 1963, P NATL ACAD SCI USA, V50, P16, DOI 10.1073/pnas.50.1.16; DEISABELLA P, 1993, MOL PHARMACOL, V43, P715; DEISABELLA P, 1990, MOL PHARMACOL, V37, P11; FOSSE P, 1991, NUCLEIC ACIDS RES, V19, P2861, DOI 10.1093/nar/19.11.2861; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; LEE CH, 1981, P NATL ACAD SCI-BIOL, V78, P2838, DOI 10.1073/pnas.78.5.2838; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Macdonald T. L., 1991, DNA TOPOISOMERASES C, P199; MINFORD J, 1986, BIOCHEMISTRY-US, V25, P9, DOI 10.1021/bi00349a002; NELSON EM, 1984, P NATL ACAD SCI-BIOL, V81, P1361, DOI 10.1073/pnas.81.5.1361; NORDEN B, 1990, JERUS SYM Q, V23, P23; NORDEN B, 1978, APPL SPECTROSC REV, V14, P157, DOI 10.1080/05704927808060393; OLESON JJ, 1961, ANTIBIOT CHEMOTHER, V11, P158; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; ROWE TC, 1986, CANCER RES, V46, P2021; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; YAMASHITA Y, 1990, CANCER RES, V50, P5841; ZWELLING LA, 1992, CANCER RES, V52, P209	30	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25004	25009						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929186				2022-12-25	WOS:A1994PQ49000073
J	VANDERSTAAY, GWM; STAEHELIN, LA				VANDERSTAAY, GWM; STAEHELIN, LA			BIOCHEMICAL-CHARACTERIZATION OF PROTEIN-COMPOSITION AND PROTEIN-PHOSPHORYLATION PATTERNS IN STACKED AND UNSTACKED THYLAKOID MEMBRANES OF THE PROCHLOROPHYTE PROCHLOROTHRIX-HOLLANDICA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A/B ANTENNA; MULTIPLE EVOLUTIONARY ORIGINS; PHOTOSYSTEM-II; PHOTOSYNTHETIC PROKARYOTE; POLYACRYLAMIDE GELS; CHLAMYDOMONAS-REINHARDTII; SUPRAMOLECULAR STRUCTURE; IONIC-STRENGTH; CYANOBACTERIA; ORGANIZATION	We describe a procedure to separate stacked and unstacked membranes from the prochlorophyte Prochlorothrix hollandica that is based on methods used for the separation of grana and stroma thylakoids from chloroplasts. Stacked membranes were isolated from Triton X-100-treated whole thylakoid preparations, unstacked membranes from French press disrupted cells. Membrane fractions were isolated by differential centrifugation. The stacked membranes were enriched in photosystem (PS) II and a chlorophyll a/b-binding antenna complex, whereas the unstacked membranes contained PS I and the ATP synthase. No evidence for a PS I-associated chlorophyll a/b antenna system was obtained. The PS II-associated chlorophyll a/b antenna complex is composed of several apoproteins in the molecular mass range from 32 to 38 kDa. The 38-kDa protein of this complex becomes phosphorylated on its stromal surface by a light-activated kinase, but, unlike the light-harvesting II complex of chloroplasts, it does not migrate from grana to stroma membrane regions. Overall, the thylakoid membranes of Prochlorothrix exhibit a remarkably similar organization to those of chloroplasts, especially in terms of the non-random distribution of protein complexes between grana and stroma thylakoid membranes. However, in contrast to the rapidly reversible phosphorylation-dependent state 1-state 2 response of light-harvesting complex associated with PS II in chloroplasts, the slowly reversible phosphorylation in Prochlorothrix leads only to a functional uncoupling from PS II but not to its redistribution between stacked and unstacked membrane regions.	UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder				Staehelin, Andrew/0000-0002-0611-4346	NIGMS NIH HHS [GM 22912] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022912] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ALLEN KD, 1991, ANAL BIOCHEM, V194, P214, DOI 10.1016/0003-2697(91)90170-X; BASSI R, 1991, PLANTA, V183, P423, DOI 10.1007/BF00197742; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BULLERJAHN GS, 1990, FEMS MICROBIOL LETT, V67, P99, DOI 10.1111/j.1574-6968.1990.tb13844.x; BULLERJAHN GS, 1987, EUR J BIOCHEM, V168, P295, DOI 10.1111/j.1432-1033.1987.tb13420.x; BULLERJAHN GS, 1993, CRIT REV MICROBIOL, V19, P43, DOI 10.3109/10408419309113522; BULLERJAHN GS, 1992, PLANT PHYSL S, V99, P589; BURGERWIERSMA T, 1986, NATURE, V320, P262, DOI 10.1038/320262a0; BURGERWIERSMA T, 1989, INT J SYST BACTERIOL, V39, P250, DOI 10.1099/00207713-39-3-250; BURGERWIERSMA T, 1989, PLANT PHYSIOL, V91, P770, DOI 10.1104/pp.91.2.770; BURGESS SC, 1990, MEAS SCI TECHNOL, V1, P1, DOI 10.1088/0957-0233/1/1/001; CARTER DP, 1980, ARCH BIOCHEM BIOPHYS, V200, P364, DOI 10.1016/0003-9861(80)90366-5; CHAPMAN RL, 1986, FREEZE FRACTURE ETCH, P213; CHEETHAM PSJ, 1979, ANAL BIOCHEM, V92, P447, DOI 10.1016/0003-2697(79)90683-3; DUNAHAY TG, 1984, BIOCHIM BIOPHYS ACTA, V764, P179, DOI 10.1016/0005-2728(84)90027-6; ENGLE JM, 1991, ARCH MICROBIOL, V155, P453, DOI 10.1007/BF00244961; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GHANOTAKIS DF, 1986, FEBS LETT, V197, P244, DOI 10.1016/0014-5793(86)80335-0; GIDDINGS TH, 1980, P NATL ACAD SCI-BIOL, V77, P352, DOI 10.1073/pnas.77.1.352; GOLECKI JR, 1989, ARCH MICROBIOL, V152, P77, DOI 10.1007/BF00447015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER KR, 1988, J CELL SCI, V91, P577; MOR TS, 1993, BIOCHIM BIOPHYS ACTA, V1141, P206, DOI 10.1016/0005-2728(93)90044-G; NEALE PJ, 1991, BIOCHIM BIOPHYS ACTA, V1056, P195, DOI 10.1016/S0005-2728(05)80287-7; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OLIVE J, 1991, J ELECTRON MICR TECH, V18, P360, DOI 10.1002/jemt.1060180405; PALENIK B, 1992, NATURE, V355, P265, DOI 10.1038/355265a0; POST AF, 1993, BIOCHIM BIOPHYS ACTA, V1144, P374, DOI 10.1016/0005-2728(93)90123-W; POST AF, 1992, BIOCHIM BIOPHYS ACTA, V1100, P75, DOI 10.1016/0005-2728(92)90128-O; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SANE PV, 1970, BIOCHIM BIOPHYS ACTA, V216, P162, DOI 10.1016/0005-2728(70)90168-4; SILVERSTEIN T, 1993, FEBS LETT, V334, P101, DOI 10.1016/0014-5793(93)81690-2; SIMPSON DJ, 1986, ENCY PLANT PHYSL, V19, P665; STAEHELIN LA, 1983, J CELL BIOL, V97, P1327, DOI 10.1083/jcb.97.5.1327; STAEHELIN LA, 1986, ENCY PLANT PHYSL, V19, P1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRISSL HW, 1993, TRENDS BIOCHEM SCI, V18, P411; TURNER S, 1989, NATURE, V337, P380, DOI 10.1038/337380a0; URBACH E, 1992, NATURE, V355, P267, DOI 10.1038/355267a0; VANDERSTAAY GWM, 1989, BIOCHIM BIOPHYS ACTA, V975, P317, DOI 10.1016/S0005-2728(89)80338-X; VANDERSTAAY GWM, 1993, BIOCHIM BIOPHYS ACTA, V1142, P189, DOI 10.1016/0005-2728(93)90101-K; VANDERSTAAY GWM, 1992, BIOCHIM BIOPHYS ACTA, V1102, P220, DOI 10.1016/0167-4838(92)90513-D; VANDERSTAAY GWM, 1992, RES PHOTOSYNTHESIS, V1, P207; VANDERSTAAY GWM, 1992, THESIS U AMSTERDAM	46	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24834	24844						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929163				2022-12-25	WOS:A1994PQ49000050
J	CHAZOT, PL; COLEMAN, SK; CIK, M; STEPHENSON, FA				CHAZOT, PL; COLEMAN, SK; CIK, M; STEPHENSON, FA			MOLECULAR CHARACTERIZATION OF N-METHYL-D-ASPARTATE RECEPTORS EXPRESSED IN MAMMALIAN-CELLS YIELDS EVIDENCE FOR THE COEXISTENCE OF 3 SUBUNIT TYPES WITHIN A DISCRETE RECEPTOR MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR; ISO-OLIGOMERS; CLONED CDNAS; CHANNEL; SUBTYPES; PURIFICATION; PROTEINS	The N-methyl-D-aspartate R1 (NMDA R1), NMDA R2A, and NMDA R2C subunits were expressed transiently in double or triple combinations in human embryonic kidney (HEK) 293 cells. The biochemical and pharmacological properties of the cloned receptors were compared with those of adult mouse forebrain and cerebellum. Under conditions established for maximal expression, cotransfection of the NMDA R1 and R2C subunits yielded a protein detected immunologically with a molecular size of 780,000-850,000 daltons. No cell death was observed in the transfected cells, and the K-D for [H-3]MK801 binding to the NMDA R1/R2C receptor was 346 +/- 158 nM. This was in contrast to a value of K-D = 22 +/- 9 nM found for native cerebellar receptors. Co-transfection with NMDA R1/R2A/R2C subunits with a DNA ratio, 1:3:3, resulted in the expression of a protein with a size similar to the NMDA R1/R2C combination, but the affinity of [H-3]MK801 was now 22 +/- 5 nM, and the percentage cell death post-transfection was 89 +/- 17%. Immunoprecipitation assays of detergent-solubilized transfected cells with NMDA R1 subunit-specific antibodies co-precipitated the NMDA R2A and NMDA R2C subunits in 1/2A and 1/2C transfections, respectively. Similarly, immunoprecipitations with either NMDA R1 or NMDA R2C subunit-specific antibodies co-precipitated the NMDA R2A subunit in the R1/2A/2C triple transfections. These results show that the three NMDA receptor subunit types can co-assemble following their co-expression in mammalian cells with a pharmacological profile that is similar to that found for adult cerebellar NMDA receptors.	UNIV LONDON,SCH PHARM,DEPT PHARMACEUT CHEM,LONDON WC1N 1AX,ENGLAND	University of London; University College London; University of London School of Pharmacy				Coleman, Sarah/0000-0002-1066-8296				BROSE N, 1993, J BIOL CHEM, V268, P22663; CHAZOT PL, 1992, J NEUROCHEM, V59, P1176, DOI 10.1111/j.1471-4159.1992.tb08364.x; CHAZOT PL, 1993, BIOCHEM PHARMACOL, V45, P605, DOI 10.1016/0006-2952(93)90133-H; CIK M, 1994, EUR J PHARM-MOLEC PH, V266, pR1; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; DUGGAN MJ, 1990, J BIOL CHEM, V265, P3831; EBERT B, 1991, EUR J PHARM-MOLEC PH, V208, P49, DOI 10.1016/0922-4106(91)90050-R; FARRANT M, 1994, NATURE, V368, P335, DOI 10.1038/368335a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; ISHII T, 1993, J BIOL CHEM, V268, P2836; KOPKE AKE, 1993, PROTEIN SCI, V2, P2066; KUONEN DR, 1986, ANAL BIOCHEM, V153, P221, DOI 10.1016/0003-2697(86)90084-9; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH DR, 1994, MOL PHARMACOL, V45, P540; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; STEPHENSON FA, 1991, MOL NEUROBIOL, P183; STERN P, 1994, J PHYSIOL-LONDON, V476, P391, DOI 10.1113/jphysiol.1994.sp020140; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; WAFFORD KA, 1993, NEUROREPORT, V4, P1347, DOI 10.1097/00001756-199309150-00015; WENTHOLD RJ, 1994, J BIOL CHEM, V269, P1332; WILLIAMS K, 1991, MOL PHARMACOL, V40, P774; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; YAMAKURA T, 1993, NEUROREPORT, V4, P687, DOI 10.1097/00001756-199306000-00021	30	175	176	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 30	1994	269	39					24403	24409						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ346	7929101				2022-12-25	WOS:A1994PQ34600086
J	PAILLART, JC; MARQUET, R; SKRIPKIN, E; EHRESMANN, B; EHRESMANN, C				PAILLART, JC; MARQUET, R; SKRIPKIN, E; EHRESMANN, B; EHRESMANN, C			MUTATIONAL ANALYSIS OF THE BIPARTITE DIMER LINKAGE STRUCTURE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GENOMIC RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLONEY MURINE LEUKEMIA; PACKAGING SIGNAL; CIS ELEMENTS; VIRAL-RNA; DIMERIZATION; PROTEIN; HIV-1; SEQUENCES; RECOMBINATION; RETROVIRUSES	The genome of all retroviruses consists in two homologous RNA molecules associated near their 5' end in a region called the dimer linkage structure. Dimerization of genomic RNA is thought to be important for several functions of the retroviral cycle such as encapsidation, reverse transcription, and translation. In human immunodeficiency virus type 1 (HIV-1), a region downstream of the splice donor site was initially postulated to mediate dimerization. However, we recently showed that the dimerization initiation site is located upstream of the splice donor site and suggested that dimerization may initiate through a loop-loop interaction. Here, we show that single base mutations in the palindromic loop of the dimerization initiation site completely abolish dimerization, while introduction of compensatory mutations restores the process. Furthermore, two single nucleotide mutants that are unable to form homodimers efficiently codimerize, while the wild type RNA and the compensatory mutant, which both form homodimers, are unable to codimerize. These results unambiguously prove the interaction between the palindromic loops of each monomer. By contrast, none of the deletions that we introduced downstream of the splice donor site abolishes dimerization. However, deletions of two purine tracts located in the vicinity of the initiation codon of the gag gene significantly decrease the thermal stability of the HIV-1 RNA dimer.	INST BIOL MOLEC & CELLULAIRE, CNRS, UPR 9002, F-67084 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Paillart, Jean-Christophe/A-4171-2010	Paillart, Jean-Christophe/0000-0003-1647-8917; Marquet, Roland/0000-0002-4209-3976				ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BENDER W, 1976, CELL, V7, P595, DOI 10.1016/0092-8674(76)90210-5; BENDER W, 1978, J VIROL, V25, P888, DOI 10.1128/JVI.25.3.888-896.1978; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; CANAANI E, 1973, P NATL ACAD SCI USA, V70, P401, DOI 10.1073/pnas.70.2.401; CLAVEL F, 1990, J VIROL, V64, P5230, DOI 10.1128/JVI.64.10.5230-5234.1990; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; EHRESMANN B, 1992, B I PASTEUR, V90, P109; FU W, 1994, J VIROL, V68, P5013, DOI 10.1128/JVI.68.8.5013-5018.1994; FU W, 1993, J VIROL, V67, P5443, DOI 10.1128/JVI.67.9.5443-5449.1993; HARRISON GP, 1992, J VIROL, V66, P4144, DOI 10.1128/JVI.66.7.4144-4153.1992; HAYASHI T, 1993, FEBS LETT, V327, P213, DOI 10.1016/0014-5793(93)80172-Q; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; Maniatis T., 1982, MOL CLONING; MARQUET R, 1994, NUCLEIC ACIDS RES, V22, P145, DOI 10.1093/nar/22.2.145; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; MURTI KG, 1981, J VIROL, V37, P411, DOI 10.1128/JVI.37.1.411-419.1981; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; PRATS AC, 1990, J VIROL, V64, P774, DOI 10.1128/JVI.64.2.774-783.1990; RIPPE K, 1992, EMBO J, V11, P3777, DOI 10.1002/j.1460-2075.1992.tb05463.x; ROY C, 1990, NUCLEIC ACIDS RES, V18, P7287, DOI 10.1093/nar/18.24.7287; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; TEMIN HM, 1991, TRENDS GENET, V7, P71, DOI 10.1016/0168-9525(91)90048-U; WEISS S, 1993, NUCLEIC ACIDS RES, V21, P4879, DOI 10.1093/nar/21.21.4879	31	190	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27486	27493						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961663				2022-12-25	WOS:A1994PV77100053
J	PALEJWALA, VA; PANDYA, GA; BHANOT, OS; SOLOMON, JJ; MURPHY, HS; DUNMAN, PM; HUMAYUN, MZ				PALEJWALA, VA; PANDYA, GA; BHANOT, OS; SOLOMON, JJ; MURPHY, HS; DUNMAN, PM; HUMAYUN, MZ			UVM, AN ULTRAVIOLET-INDUCIBLE RECA-INDEPENDENT MUTAGENIC PHENOMENON IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC ETHENOCYTOSINE; EXOCYCLIC DNA ADDUCTS; M13 VIRAL-DNA; SOS MUTAGENESIS; VINYL-CHLORIDE; LIGHT MUTAGENESIS; CYCLOBUTANE DIMER; POLYMERASE-II; 2-STEP MODEL; POLB GENE	Most mutagenic DNA lesions are noninstructive in the sense that template instruction is either missing or inaccessible during DNA replication, leading to replication arrest. According to the SOS hypothesis, arrested replication induces the expression of SOS factors that force replication past stalled sites at the cost of mutagenesis. We have recently shown that prior UV irradiation of Delta recA cells, in which the SOS pathway does not function, enhances mutagenesis at an ethenocytosine residue borne on a circular gapped duplex DNA vector, indicating the existence of an SOS-independent inducible mutagenic phenomenon termed UVM (UV modulation of mutagenesis). In the previous experiments, mutation fixation was expected to occur during gap-filling DNA synthesis. To test whether UVM is observable during normal replication by DNA polymerase III, we have examined mutagenesis at an epsilon C residue borne on M13 single-stranded DNA. By analyzing mutation frequency and specificity using a multiplex sequence assay, we now show that UVM is observable in UV-irradiated recA(+), and in Delta recA cells. These data indicate that UV irradiation induces a previously unrecognized mutagenic mechanism in Escherichia coli, and that this mechanism is manifested during gap-filling DNA synthesis as well as during normal DNA replication.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103; NYU,SCH MED,DEPT MICROBIOL & MOLEC GENET,AZ LANZA RES LABS,TUXEDO PK,NY 10987	Rutgers State University New Brunswick; Rutgers State University Medical Center; New York University					NATIONAL CANCER INSTITUTE [R01CA047234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260, R01ES005694] Funding Source: NIH RePORTER; NCI NIH HHS [CA47234] Funding Source: Medline; NIEHS NIH HHS [ES05694, ES00260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANERJEE SK, 1990, J BACTERIOL, V172, P2105, DOI 10.1128/jb.172.4.2105-2112.1990; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BARRIO JR, 1972, BIOCHEM BIOPH RES CO, V46, P597, DOI 10.1016/S0006-291X(72)80181-5; BASU AK, 1993, BIOCHEMISTRY-US, V32, P12793, DOI 10.1021/bi00210a031; BATES H, 1991, MUTAT RES, V250, P199, DOI 10.1016/0027-5107(91)90176-O; BATES H, 1991, BIOCHIMIE, V73, P485, DOI 10.1016/0300-9084(91)90116-I; BATTISTA JR, 1990, P NATL ACAD SCI USA, V87, P7190, DOI 10.1073/pnas.87.18.7190; BHANOT OS, 1990, BIOCHEMISTRY-US, V29, P10357, DOI 10.1021/bi00497a010; BHANOT OS, 1992, NUCLEIC ACIDS RES, V20, P587, DOI 10.1093/nar/20.3.587; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; BRIDGES BA, 1985, P NATL ACAD SCI USA, V82, P4193, DOI 10.1073/pnas.82.12.4193; BRIDGES BA, 1984, MOL GEN GENET, V196, P364, DOI 10.1007/BF00328073; BRIDGES BA, 1992, MOL GEN GENET, V233, P331, DOI 10.1007/BF00265428; BRIDGES BA, 1985, MUTAT RES, V150, P133, DOI 10.1016/0027-5107(85)90110-1; CHEN H, 1989, J BIOL CHEM, V264, P20591; COHENFIX O, 1992, P NATL ACAD SCI USA, V89, P3300, DOI 10.1073/pnas.89.8.3300; DEFAIS M, 1971, VIROLOGY, V43, P495, DOI 10.1016/0042-6822(71)90321-7; DONNELLY CE, 1992, J BACTERIOL, V174, P3133, DOI 10.1128/jb.174.10.3133-3139.1992; DORPER T, 1983, NUCLEIC ACIDS RES, V11, P2575, DOI 10.1093/nar/11.9.2575; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; GREEN T, 1978, CHEM-BIOL INTERACT, V22, P211, DOI 10.1016/0009-2797(78)90126-6; HORSFALL MJ, 1994, J MOL BIOL, V235, P465, DOI 10.1006/jmbi.1994.1006; IWASAKI H, 1990, J BACTERIOL, V172, P6268, DOI 10.1128/jb.172.11.6268-6273.1990; JACOBSEN JS, 1990, BIOCHEMISTRY-US, V29, P496, DOI 10.1021/bi00454a025; JACOBSEN JS, 1989, GENETICS, V121, P213; KUSMIEREK JT, 1982, BIOCHEMISTRY-US, V21, P5717, DOI 10.1021/bi00265a050; LASPIA MF, 1989, J MOL BIOL, V207, P53, DOI 10.1016/0022-2836(89)90440-3; LEITHAUSER MT, 1990, CARCINOGENESIS, V11, P463, DOI 10.1093/carcin/11.3.463; LIU SK, 1990, J BACTERIOL, V172, P6135, DOI 10.1128/jb.172.10.6135-6138.1990; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; Model P., 1988, BACTERIOPHAGES, P375; MURLI S, 1993, CURR OPIN GENET DEV, V3, P719, DOI 10.1016/S0959-437X(05)80089-9; Narang S A, 1980, Methods Enzymol, V65, P610; PALEJWALA VA, 1993, BIOCHEMISTRY-US, V32, P4105, DOI 10.1021/bi00066a036; PALEJWALA VA, 1993, BIOCHEMISTRY-US, V32, P4112, DOI 10.1021/bi00066a037; PALEJWALA VA, 1991, BIOCHEMISTRY-US, V30, P8736, DOI 10.1021/bi00100a004; Radman M, 1974, MOL ENV ASPECTS MUTA, P128; Radman M., 1975, MOL MECHANISMS REPAI, P355; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; SAHASRABUDHE SR, 1991, GENETICS, V129, P981; SAMBAMURTI K, 1988, GENETICS, V120, P863; SIMHA D, 1991, BIOCHEMISTRY-US, V30, P8727, DOI 10.1021/bi00100a003; TESSMAN I, 1991, MOL GEN GENET, V227, P144, DOI 10.1007/BF00260719; TESSMAN I, 1992, P NATL ACAD SCI USA, V89, P1159, DOI 10.1073/pnas.89.4.1159; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WALKER GC, 1987, ESCHERICHIA COLI SAL, P1346; WEIGLE JJ, 1953, P NATL ACAD SCI USA, V39, P628, DOI 10.1073/pnas.39.7.628; WITKIN EM, 1991, BIOCHIMIE, V73, P133, DOI 10.1016/0300-9084(91)90196-8; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976	49	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27433	27440						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961656				2022-12-25	WOS:A1994PV77100046
J	RAMAN, B; RAO, CM				RAMAN, B; RAO, CM			CHAPERONE-LIKE ACTIVITY AND QUATERNARY STRUCTURE OF ALPHA-CRYSTALLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CALF-LENS; B-CRYSTALLIN; MOLECULAR CHAPERONE; GAMMA-CRYSTALLIN; CATARACT FORMATION; LIGHT-SCATTERING; CONFORMATION; EXPRESSION; STABILITY	alpha-Crystallin has been shown to function as a molecular chaperone in preventing thermal aggregation of crystallins and other proteins. The molecular mechanism of this protection is not yet clear. gamma-Crystallin aggregates upon exposure to UV light. We have investigated the effect of the presence of alpha-crystallin in the photoaggregation process and find that alpha-crystallin does not prevent photoaggregation at low temperatures. The protection starts around 30 degrees C and steeply increases with temperature. The plot of protection ability versus temperature is sigmoidal, indicating a structural transition. Perturbation of the quaternary structure of alpha by non-thermal mode, such as 3 M urea, also results in enhanced protection. Pyrene, a hydrophobic fluorophore, is sparingly soluble in water. alpha-Crystallin enhances the solubility of pyrene by severalfold. Temperature dependence of this solubilization shows a transition around 30 degrees C (another at about 50 degrees C). Fluorescence intensity ratio of third and first peaks of pyrene emission (I-3/I-1,), indicative of hydrophobicity of the reporting area, also shows similar transitions suggesting enhanced hydrophobicity Gel filtration experiments of irradiated samples indicate the complex formation between gamma- and alpha-crystallins. alpha-Crystallin does not prevent cold precipi tation of gamma-crystallin. On the basis of these results, we hypothesize that alpha-crystallin prevents aggregation of non-native structures by providing appropriately placed hydrophobic surfaces. A structural transition above 30 degrees C enhances the protective ability, perhaps by increasing or reorganizing the hydrophobic surfaces. A similar temperature dependence has been reported for GroEL. Whether a structural switch, either activated by temperature, solvent conditions, or small molecule binding, forms a part of the general mechanism of chaperone activity needs to be investigated.	CTR CELLULAR & MOLEC BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)								ANDLEY UP, 1988, CURR EYE RES, V7, P571, DOI 10.3109/02713688809031813; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; CHAKRABARTI B, 1986, J INDIAN CHEM SOC, V63, P131; CLARK JI, 1980, BIOCHEM BIOPH RES CO, V95, P482, DOI 10.1016/0006-291X(80)90763-9; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; De Jong W.W., 1981, MOL CELLULAR BIOL EY, P221, DOI DOI 10.1146/ANNUREV.ECOLSYS.33.020602.095451; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HUBBARD TJP, 1991, PROTEIN ENG, V4, P711, DOI 10.1093/protein/4.7.711; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P1732; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MANDAL K, 1988, PHOTOCHEM PHOTOBIOL, V47, P583, DOI 10.1111/j.1751-1097.1988.tb08848.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MERCK KB, 1993, J BIOL CHEM, V268, P1046; NAKAJIMA A, 1976, J MOL SPECTROSC, V61, P467, DOI 10.1016/0022-2852(76)90336-2; NAKAJIMA A, 1976, J LUMIN, V11, P429, DOI 10.1016/0022-2313(76)90027-2; RAO CM, 1994, INVEST OPHTH VIS SCI, V35, P1905; RAO CM, 1993, INVEST OPHTH VIS SCI, V34, P988; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; SIEZEN RJ, 1978, EUR J BIOCHEM, V91, P387, DOI 10.1111/j.1432-1033.1978.tb12691.x; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SIEZEN RJ, 1978, EUR J BIOCHEM, V91, P397, DOI 10.1111/j.1432-1033.1978.tb12692.x; SIEZEN RJ, 1985, P NATL ACAD SCI USA, V82, P1701, DOI 10.1073/pnas.82.6.1701; SPECTOR A, 1967, J BIOL CHEM, V242, P3594; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; THOMSON JA, 1985, EXP EYE RES, V40, P393, DOI 10.1016/0014-4835(85)90152-6; THOMSON JA, 1984, J BIOL CHEM, V259, P4339; THOMSON JA, 1983, EXP EYE RES, V37, P367, DOI 10.1016/0014-4835(83)90173-2; VANDENOETELAAR PJM, 1985, J BIOL CHEM, V260, P4030; WALKER ML, 1989, EXP EYE RES, V48, P375, DOI 10.1016/S0014-4835(89)80006-5; WALSH MT, 1991, J BIOL CHEM, V266, P20079	40	207	210	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 4	1994	269	44					27264	27268						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PV771	7961635				2022-12-25	WOS:A1994PV77100020
J	YOKOYAMA, K; YASUMOTO, K; SUZUKI, H; SHIBAHARA, S				YOKOYAMA, K; YASUMOTO, K; SUZUKI, H; SHIBAHARA, S			CLONING OF THE HUMAN DOPACHROME TAUTOMERASE/TYROSINASE-RELATED PROTEIN-2 GENE AND IDENTIFICATION OF 2 REGULATORY REGIONS REQUIRED FOR ITS PIGMENT CELL-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; RAT HEME OXYGENASE; MOUSE TYROSINASE; MAMMALIAN MELANOGENESIS; MALIGNANT-MELANOMA; CONVERSION FACTOR; PROMOTER ACTIVITY; BROWN LOCUS; METAL-IONS; WILD-TYPE	We have cloned and sequenced the human genomic DNA segments encoding the 5'-flanking region and the first two exons of the DOPAchrome tautomerase (DT)/tyrosinase-related protein 2 (TRP-2) gene. The DT gene is a member of the tyrosinase gene family and specifically expressed in melanin-producing cells. A transcriptional initiation site of the DT gene was identified by S1 nuclease-mapping and primer-extension analyses using RNA prepared from human pigmented melanoma cells. To study the mechanism for pigment cell-specific expression of the human DT gene, we analyzed the promoter function of its 5'-flanking region by transient expression assays. The fusion genes, containing the DT gene promoter upstream hom a firefly luciferase reporter gene, were introduced into human pigmented melanoma cells and HeLa cells, and the pigment cell-specific promoter activity was evaluated by comparing the luciferase activity expressed in both cell lines. A series of 5' deletion studies of the human DT gene promoter revealed that the 32-bp element, located between -447 and -415, is sufficient to confer pigment cell-specific expression of a reporter gene on a homologous promoter, but not on a heterologous simian virus 40 promoter, Internal deletion studies using a homologous or a heterologous promoter revealed that the pigment cell-specific expression of a reporter gene mediated by the 32-bp element is dependent on the presence of another region of the DT gene spanning from -268 to -56, which was termed the proximal region. However, the proximal region by itself is not sufficient to confer cell type-specific expression. These results indicate that the presence of two regulatory regions, the 32-bp element and the proximal region, is required for pigment cell-specific expression of the DT gene. Both regulatory regions contain a CANNTG motif, a well known binding site for a large family of transcription factors possessing a basic helix-loop-helix structure.	TOHOKU UNIV,SCH MED,DEPT APPL PHYSIOL & MOLEC BIOL,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	Tohoku University			Shibahara, Shigeki/M-3644-2014	Yasumoto, Ken-ichi/0000-0002-8090-1161				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AROCA P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P266, DOI 10.1016/0304-4165(90)90088-E; BARBER JI, 1984, J INVEST DERMATOL, V83, P145, DOI 10.1111/1523-1747.ep12263381; BENNETT DC, 1990, DEVELOPMENT, V110, P471; BOUCHARD B, 1994, EUR J BIOCHEM, V219, P127, DOI 10.1111/j.1432-1033.1994.tb19922.x; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BRUGGEN J, 1981, CANCER IMMUNOL IMMUN, V10, P121; CHAKRABORTY AK, 1992, FEBS LETT, V302, P126, DOI 10.1016/0014-5793(92)80421-C; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HASUMI K, 1978, CANCER-AM CANCER SOC, V42, P2675, DOI 10.1002/1097-0142(197812)42:6<2675::AID-CNCR2820420624>3.0.CO;2-G; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INOUE S, 1987, BIOCHEM PHARMACOL, V36, P3537, DOI 10.1016/0006-2952(87)90340-6; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JARA JR, 1990, BIOCHIM BIOPHYS ACTA, V1035, P276, DOI 10.1016/0304-4165(90)90089-F; KORNER AM, 1980, J INVEST DERMATOL, V75, P192, DOI 10.1111/1523-1747.ep12522650; KORNER AM, 1985, J INVEST DERMATOL, V85, P229, DOI 10.1111/1523-1747.ep12276688; KWON BS, 1989, J INVEST DERMATOL, V93, P589, DOI 10.1111/1523-1747.ep12319693; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MULLER RM, 1987, J BIOL CHEM, V262, P6795; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PALUMBO A, 1991, BIOCHIM BIOPHYS ACTA, V1115, P1, DOI 10.1016/0304-4165(91)90003-Y; PAWELEK JM, 1990, BIOCHEM BIOPH RES CO, V166, P1328, DOI 10.1016/0006-291X(90)91011-G; PAWELEK JM, 1991, PIGM CELL RES, V4, P53, DOI 10.1111/j.1600-0749.1991.tb00315.x; SAKAI J, 1994, J BIOL CHEM, V269, P2173; Sambrook J, 1989, MOL CLONING LABORATO; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SHIBAHARA S, 1990, EUR J BIOCHEM, V189, P455, DOI 10.1111/j.1432-1033.1990.tb15510.x; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIBAHARA S, 1991, J BIOL CHEM, V266, P15895; SHIBATA K, 1992, J BIOL CHEM, V267, P20584; SHIBATA K, 1992, BIOCHEM BIOPH RES CO, V184, P568, DOI 10.1016/0006-291X(92)90627-W; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEEL KP, 1992, DEVELOPMENT, V115, P1111; TAKEDA A, 1989, BIOCHEM BIOPH RES CO, V162, P984, DOI 10.1016/0006-291X(89)90770-5; YAMAMOTO H, 1989, JPN J GENET, V64, P121, DOI 10.1266/jjg.64.121; YOKOYAMA K, 1994, BBA-GENE STRUCT EXPR, V1217, P317, DOI 10.1016/0167-4781(94)90292-5; ZDARSKY E, 1990, GENETICS, V126, P443	42	102	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 28	1994	269	43					27080	27087						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ931	7929451				2022-12-25	WOS:A1994PQ93100074
J	ELIASSON, R; PONTIS, E; SUN, XY; REICHARD, P				ELIASSON, R; PONTIS, E; SUN, XY; REICHARD, P			ALLOSTERIC CONTROL OF THE SUBSTRATE-SPECIFICITY OF THE ANAEROBIC RIBONUCLEOTIDE REDUCTASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The reduction of ribonucleotides is catalyzed by different enzymes in aerobic and anaerobic Escherichia coli, each with a different primary and quaternary structure. Here, we describe the allosteric regulation of the substrate specificity of the anaerobic ribonucleoside triphosphate reductase. The enzyme reduced ribonucleotides at a low basal rate. Reduction was stimulated up to 10-fold by an appropriate modulator (dGTP for ATP reduction, ATP for CTP and UTP reduction, and dTTP for GTP reduction). dGTP and dTTP inhibited the reduc tion of the ''incorrect'' substrate; dATP inhibited reduction of all four. From kinetic, effector binding, and competition experiments we conclude that the enzyme has two classes of sites, one that binds ATP and dATP and regulates pyrimidine ribonucleotide reduction (''pyrimidine site''), the other that binds dATP, dGTP, and dTTP and regulates purine ribonucleotide reduction (''purine site''). This model differs slightly from the model for the aerobic reductase, but the physiological consequences remain the same and explain how a single enzyme can provide a balanced supply of the four dNTPs. The similarity of a highly sophisticated control mechanism for the aerobic and anaerobic enzymes suggests that both arose by divergent evolution from a common ancestor, in spite of their different structures.	KAROLINSKA INST, MED NOBEL INST, DEPT BIOCHEM 1, MBB, S-17177 STOCKHOLM, SWEDEN; UNIV STOCKHOLM, DEPT BIOL MOLEC, S-10691 STOCKHOLM, SWEDEN	Karolinska Institutet; Stockholm University								BECK WS, 1967, J BIOL CHEM, V242, P3148; BLAKLEY RL, 1965, J BIOL CHEM, V240, P2173; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CHEN AK, 1974, BIOCHEMISTRY-US, V13, P654, DOI 10.1021/bi00701a004; HARDER J, 1992, J BIOL CHEM, V267, P25548; KIM JJ, 1977, ARCH BIOCHEM BIOPHYS, V182, P674, DOI 10.1016/0003-9861(77)90548-3; MONOD J, 1961, COLD SPRING HARB SYM, V26, P389, DOI 10.1101/SQB.1961.026.01.048; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025	15	43	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26052	26057						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929317				2022-12-25	WOS:A1994PQ93000021
J	HEATH, RJ; JACKOWSKI, S; ROCK, CO				HEATH, RJ; JACKOWSKI, S; ROCK, CO			GUANOSINE TETRAPHOSPHATE INHIBITION OF FATTY-ACID AND PHOSPHOLIPID-SYNTHESIS IN ESCHERICHIA-COLI IS RELIEVED BY OVEREXPRESSION OF GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE (PLSB)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEIN SYNTHETASE; SN-GLYCEROL 3-PHOSPHATE; RELA GENE; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; STRINGENT RESPONSE; PPGPP; SPOT; BIOSYNTHESIS; MUTANTS; INVIVO	The accumulation of the alarmone guanosine-3',5'-bispyrophosphate (ppGpp) in response to amino acid starvation or energy source depletion mediates the coordinate inhibition of macromolecular and membrane phospholipid biosynthesis in Escherichia coli. Accumulation of ppGpp triggered by the induced expression of either the relA gene or an unregulated, truncated relA gene that encodes a constitutively active ppGpp synthetase I, inhibited both de novo fatty acid and phospholipid biosynthesis and the incorporation of exogenous fatty acids into phospholipid. ppGpp inhibition of fatty acid and phospholipid synthesis was associated with an accumulation of long-chain acyl-ACP, the end products of fatty acid biosynthesis, and substrates for the sn-glycerol-3-phosphate acyltransferase (the plsB gene product). Overexpression of the plsB gene product relieved the inhibition of fatty acid and phospholipid synthesis, prevented the accumulation of long-chain acyl-ACPs, and allowed an increase in cell size following elevation of intracellular ppGpp. However, stable RNA accumulation and cell division were still blocked by ppGpp accumulation. These data show that the sn-glycerol-3-phosphate acyltransferase mediates the ppGpp dependent regulation of fatty acid and phospholipid biosynthesis in E. coli.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429; Heath, Richard/0000-0002-1795-1254	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL RM, 1974, J BACTERIOL, V117, P1065, DOI 10.1128/JB.117.3.1065-1076.1974; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUUSCHEDE H, 1977, J BACTERIOL, V129, P1020; CASHEL M, 1969, J BIOL CHEM, V244, P3133; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CLEWELL DB, 1969, P NATL ACAD SCI USA, V69, P2110; COOPER CL, 1987, J BACTERIOL, V169, P605, DOI 10.1128/jb.169.2.605-611.1987; CRONAN JE, 1978, ANNU REV BIOCHEM, V47, P163, DOI 10.1146/annurev.bi.47.070178.001115; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; GOLDEN NG, 1972, J BIOL CHEM, V247, P6651; HASELTIN.WA, 1972, NATURE, V238, P381, DOI 10.1038/238381a0; HASELTINE WA, 1973, P NATL ACAD SCI USA, V70, P1564, DOI 10.1073/pnas.70.5.1564; HERNANDEZ VJ, 1991, J BIOL CHEM, V266, P5991; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; JUSTESEN J, 1986, BIOCHIMIE, V68, P715, DOI 10.1016/S0300-9084(86)80165-1; KAINUMAKURODA R, 1980, J BACTERIOL, V142, P362, DOI 10.1128/JB.142.1.362-365.1980; LAFFLER T, 1974, CELL, V1, P27, DOI 10.1016/0092-8674(74)90151-2; LIGHTNER VA, 1980, J BIOL CHEM, V255, P9413; LUEKING DR, 1975, J BIOL CHEM, V250, P4911; MERLIE JP, 1973, J BACTERIOL, V116, P355, DOI 10.1128/JB.116.1.355-366.1973; Miller J.H., 1972, EXPT MOL GENETICS; NUNN WD, 1976, BIOCHEMISTRY-US, V15, P2546, DOI 10.1021/bi00657a009; NUNN WD, 1976, J MOL BIOL, V102, P167, DOI 10.1016/0022-2836(76)90080-2; NUNN WD, 1974, J BIOL CHEM, V249, P3994; PEDERSEN FS, 1977, EUR J BIOCHEM, V76, P91, DOI 10.1111/j.1432-1033.1977.tb11573.x; POLAKIS SE, 1973, J BIOL CHEM, V248, P7957; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; RAY TK, 1975, J BIOL CHEM, V250, P8422; ROCK CO, 1981, J BIOL CHEM, V256, P736; ROCK CO, 1981, J BIOL CHEM, V256, P2669; ROCK CO, 1982, J BIOL CHEM, V257, P10759; ROCK CO, 1979, J BIOL CHEM, V254, P7116; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; SCHULZ H, 1975, J BIOL CHEM, V250, P2299; SEYFZADEH M, 1993, P NATL ACAD SCI USA, V90, P11004, DOI 10.1073/pnas.90.23.11004; SNIDER MD, 1979, J BIOL CHEM, V254, P7197; SOKAWA Y, 1968, BIOCHEM BIOPH RES CO, V33, P108, DOI 10.1016/0006-291X(68)90263-5; SPENCER A, 1977, J BACTERIOL, V130, P114, DOI 10.1128/JB.130.1.114-117.1977; STEIN JP, 1976, BIOCHEM BIOPH RES CO, V73, P881, DOI 10.1016/0006-291X(76)90204-7; SVITIL AL, 1993, J BIOL CHEM, V268, P2307; TEDIN K, 1992, J BIOL CHEM, V267, P2337; VALLARI DS, 1982, ARCH BIOCHEM BIOPHYS, V218, P402, DOI 10.1016/0003-9861(82)90361-7; XIAO H, 1991, J BIOL CHEM, V266, P5980	48	88	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26584	26590						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929384				2022-12-25	WOS:A1994PQ93000097
J	HEINS, L; MENTZEL, H; SCHMID, A; BENZ, R; SCHMITZ, UK				HEINS, L; MENTZEL, H; SCHMID, A; BENZ, R; SCHMITZ, UK			BIOCHEMICAL, MOLECULAR, AND FUNCTIONAL-CHARACTERIZATION OF PORIN ISOFORMS FROM POTATO MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; OUTER-MEMBRANE CHANNEL; MATRIX PROTEIN PORIN; ESCHERICHIA-COLI; PROCESSING PEPTIDASE; LIVER-MITOCHONDRIA; NEUROSPORA-CRASSA; ION SELECTIVITY; YEAST MUTANT; VDAC	The mitochondrial outer membrane of eukaryotic cells contains a voltage-dependent anion channel termed porin. In the organisms studied so far only one type of porin has been identified at the protein level. Here we present a biochemical and molecular genetic analysis of two different porin polypeptides of M(r) 34,000 and 36,000 from the outer membranes of potato mitochondria (termed POM 34 and POM 36, respectively). N-terminal sequencing and the use of labeled oligonucleotide mixtures derived from these amino acid sequences allowed the isolation of cDNA clones encoding the 34- and 36-kDa proteins. They have similar steady state protein levels and share about 75% identical amino acids suggesting that they represent isoforms. In addition, a third cDNA clone coding for a slightly different isoform of the 36-kDa protein was characterized. The polypeptides encoded by the three cDNA clones share the highest degree of sequence identity with mitochondrial porins from fungi and mammals. Tentative models of the secondary structure of the 34- and 36-kDa proteins suggest the occurrence of a 16-stranded beta-barrel typical for bacterial and mitochondrial porins. Purification of the 34-kDa protein by hydroxyapatite chromatography allowed conductance measurements in artificial bilayers. The 34-kDa protein is a voltage-dependent, channel-forming component with single channel conductances of 3.5 and 2.0 nanosiemens in 1 M KCl. In spite of the striking functional similarities to mitochondrial porins from other organisms neither the 34- nor the 36-kDa proteins are able to complement the respiratory defect of a yeast por(-) mutant.	INST GENBIOL FORSCH BERLIN GMBH,D-14195 BERLIN,GERMANY; UNIV WURZBURG,THEODOR BOVERI INST BIOZENTRUM,LEHRSTUHL BIOTECHNOL,D-97074 WURZBURG,GERMANY	University of Wurzburg				Benz, Roland/0000-0002-9510-9265				ALJAMAL JA, 1993, PLANT PHYSIOL, V102, P615, DOI 10.1104/pp.102.2.615; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1992, J BIOENERG BIOMEMBR, V24, P33, DOI 10.1007/BF00769528; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BENZ R, 1985, CRC CR REV BIOCH MOL, V19, P145, DOI 10.3109/10409238509082542; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BLUMENTHAL A, 1993, PLANT PHYSIOL, V101, P579, DOI 10.1104/pp.101.2.579; BRAUN HP, 1992, MOL GEN GENET, V231, P217, DOI 10.1007/BF00279794; BRAUN HP, 1994, PLANTA, V193, P99, DOI 10.1007/BF00191612; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P279, DOI 10.1016/0005-2736(87)90456-1; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DAUM G, 1952, J BIOL CHEM, V267, P13028; DEPINTO V, 1991, BIOCHIM BIOPHYS ACTA, V1061, P279, DOI 10.1016/0005-2736(91)90293-H; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V894, P109, DOI 10.1016/0005-2728(87)90180-0; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; DIHANICH M, 1987, EMBO J, V6, P723, DOI 10.1002/j.1460-2075.1987.tb04813.x; DIHANICH M, 1989, EUR J BIOCHEM, V181, P703, DOI 10.1111/j.1432-1033.1989.tb14780.x; EMMERMANN M, 1991, CURR GENET, V20, P405, DOI 10.1007/BF00317069; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; FIEK C, 1982, BIOCHIM BIOPHYS ACTA, V688, P429, DOI 10.1016/0005-2736(82)90354-6; FREITAG H, 1982, EUR J BIOCHEM, V123, P629; HA HJ, 1993, J BIOL CHEM, V268, P12143; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU MY, 1992, J BIOENERG BIOMEMBR, V24, P41, DOI 10.1007/BF00769529; LUDWIG O, 1989, BIOCHIM BIOPHYS ACTA, V978, P319, DOI 10.1016/0005-2736(89)90131-4; MANNELLA CA, 1992, TRENDS BIOCHEM SCI, V17, P315, DOI 10.1016/0968-0004(92)90444-E; MANNELLA CA, 1989, FEBS LETT, V253, P231, DOI 10.1016/0014-5793(89)80965-2; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; PENG SZ, 1992, J BIOENERG BIOMEMBR, V24, P27, DOI 10.1007/BF00769527; PFALLER R, 1990, EXPERIENTIA, V46, P4509; ROISE D, 1988, J BIOENERG BIOMEMBR, V63, P27; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID A, 1992, BIOCHIM BIOPHYS ACTA, V1112, P174, DOI 10.1016/0005-2736(92)90389-4; SMACK DP, 1985, PLANT PHYSIOL, V79, P1094, DOI 10.1104/pp.79.4.1094; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; TROLL H, 1992, J BIOL CHEM, V267, P21072; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242	46	80	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26402	26410						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929361				2022-12-25	WOS:A1994PQ93000071
J	SLIVA, D; WOOD, TJJ; SCHINDLER, C; LOBIE, PE; NORSTEDT, G				SLIVA, D; WOOD, TJJ; SCHINDLER, C; LOBIE, PE; NORSTEDT, G			GROWTH-HORMONE SPECIFICALLY REGULATES SERINE-PROTEASE INHIBITOR GENE-TRANSCRIPTION VIA GAMMA-ACTIVATED SEQUENCE-LIKE DNA ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE RECEPTOR SUPERFAMILY; TYROSINE PHOSPHORYLATION; INTERFERON-GAMMA; BINDING PROTEINS; SIGNAL-TRANSDUCTION; KINASE; JAK2; IDENTIFICATION; PROMOTERS; INVITRO	Growth hormone activates gene transcription of the serine protease inhibitors (SPI) 2.1 and 2.2 by an unknown mechanism. In order to define the promoter regions responsible for this effect and to characterize the transcription factors involved, we have performed gel electrophoresis mobility shift assays on nuclear extracts from cells lines transfected with growth hormone receptor cDNA. We have identified a 9-base pair DNA element, the SPI-GLE 1, which forms a complex with nuclear proteins following activation by growth hormone and which, when placed upstream of a minimal thymidine kinase promoter, drives chloramphenicol acetyltransferase expression in a growth hormone dependent fashion. This element is similar to those from several genes regulated by other cytokines including interferon. The growth hormone-induced complexes formed were dependent on tyrosine phosphorylation but did not contain the interferon-gamma-activated transcription factor Stat 91. Competition studies with oligonucleotides similar to the SPI-GLE 1 reveal the sequence of a consensus element that specifically binds growth hormone-regulated nuclear proteins.	KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN; KAROLINSKA INST,NOVUM,DEPT MED NUTR,S-14157 HUDDINGE,SWEDEN; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MOLEC MED,NEW YORK,NY 10032	Karolinska Institutet; Karolinska Institutet; Columbia University								AGUET M, 1990, J INTERFERON RES, V10, P551, DOI 10.1089/jir.1990.10.551; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AUSUBEL FM, 1990, CURRENT PROTOCOL MOL; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENBERG B, 1994, J MOL ENDOCRINOL, V12, P39, DOI 10.1677/jme.0.0120039; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATTHEWS LS, 1989, J BIOL CHEM, V264, P9905; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MOLLER C, 1994, MOL CELL ENDOCRINOL, V99, P111, DOI 10.1016/0303-7207(94)90153-8; MOLLER C, 1992, J BIOL CHEM, V267, P23403; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; PAQUEREAU L, 1992, EUR J BIOCHEM, V209, P1053, DOI 10.1111/j.1432-1033.1992.tb17381.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; WANG XZ, 1994, P NATL ACAD SCI USA, V91, P1391, DOI 10.1073/pnas.91.4.1391; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; YOON JB, 1990, J BIOL CHEM, V265, P19947; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	44	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 21	1994	269	42					26208	26214						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ930	7929335				2022-12-25	WOS:A1994PQ93000043
J	LOPASCHUK, GD; WITTERS, LA; ITOI, T; BARR, R; BARR, A				LOPASCHUK, GD; WITTERS, LA; ITOI, T; BARR, R; BARR, A			ACETYL-COA CARBOXYLASE INVOLVEMENT IN THE RAPID MATURATION OF FATTY-ACID OXIDATION IN THE NEWBORN RABBIT HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; COENZYME-A CARBOXYLASE; MALONYL-COA; ENERGY SUBSTRATE; PROTEIN-KINASE; MESSENGER-RNA; PIG HEARTS; FETAL; METABOLISM; RAT	Fatty acid oxidation rapidly increases in the rabbit heart following birth. By inhibiting carnitine palmitoyltransferase 1 (CPT1), malonyl-CoA is a potent regulator of fatty acid oxidation in the heart. We therefore addressed the hypothesis that a decrease in acetyl-CoA carboxylase (ACC) activity and/or malonyl-CoA inhibition of CPT1 could account for the increase in the ability of the heart to oxidize fatty acids following birth. ACC activity and expression, malonyl-CoA levels, and mitochondrial CPT1 activity were measured in hearts from 1-day, 7-day, and 6-week-old rabbits. CPT1 activity and sensitivity to malonyl-CoA inhibition did not differ between 1-day, 7-day, or 6-week hearts (the IC50 for malonyl-CoA was 32.0 +/- 1.5, 36.0 +/- 0.3, and 36.3 nM respectively). Western blot analysis with streptavidin showed that all hearts expressed similar amounts of both a 265-kDa (ACC-265) and 280-kDa isoform (ACC-280) of ACC. A progressive and significant decrease in malonyl-CoA levels was seen in 1-day, 7-day, and g-week hearts (47 +/- 2, 40 +/- 2, and 26 +/- 2 nmol/g dry weight, respectively), paralleling a decline in ACC activity. We hypothesized that these developmental changes could be due to changes in hormonal regulation of cardiac ACC in the postnatal period. In isolated hearts from 1-day-old rabbits, the fatty acid oxidation rate was 9.01 +/- 1.10 nmol.g dry weight(-1).min(-1). Glucagon (1 ng/ml) did not alter this rate (11.03 +/- 1.42 nmol.g dry weight(-1).min(-1)), but insulin (100 microunits/ml) resulted in a significant decrease in rate. (4.81 +/- 0.82 nmol.g dry weight(-1).min(-1)). ACC activity was markedly elevated in 1-day-old hearts perfused with insulin compared to control hearts or glucagon perfused hearts (0.415 +/- 0.052, 0.095 +/- 0.018, and 0.133 +/- 0.013 nmol of malonyl-CoA produced.g dry weight(-1).min(-1), respectively). Malonyl-CoA levels were also markedly elevated in 1-day hearts perfused with insulin (123.0 +/- 8.3, 2.0 +/- 0.4, and 1.8 +/- 0.6 nmol/g dry weight in insulin, control, and glucagon hearts, respectively). In 7-day old rabbit hearts, the basal fatty acid oxidation rate had increased to 24.5 +/- 4.8 nmol.mg(-1). min(-1). In contrast to the 1-day-old hearts, insulin had no significant effect on fatty acid oxidation, although glucagon resulted in a significant increase in rates (38.9 +/- 12.2 and 80.7 +/- 9.1 nmol.g dry weight(-1) min(-1), respectively). Both ACC activity and malonyl-CoA levels were low in 7-day-old hearts and were also not dramatically altered by insulin or glucagon. Taken together these data suggest that the increase in fatty acid oxidation following birth is not due to a decreased sensitivity of CPT1 to malonyl-CoA inhibition, but rather to a decrease in malonyl-CoA production by ACC. The decrease in circulating insulin combined with the increase in glucagon seen in rabbits immediately following birth may result in a decrease in ACC activity and malonyl-CoA levels in the newborn heart. This may relieve the inhibition of CPT1 resulting in an increase in fatty acid oxidation. Low ACC activity and lack of sensitivity to insulin activation in 7-day-old hearts may ensure that fatty acid oxidation remains an important source of ATP production in the maturing heart.	UNIV ALBERTA, DEPT PEDIAT, LIPID & LIPOPROT RES GRP, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, DEPT PHARMACOL, LIPID & LIPOPROT RES GRP, EDMONTON T6G 2S2, AB, CANADA; DARTMOUTH COLL, SCH MED, DEPT MED, DIV ENDOCRINE METAB, HANOVER, NH 03755 USA; DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, DIV ENDOCRINE METAB, HANOVER, NH 03755 USA	University of Alberta; University of Alberta; Dartmouth College; Dartmouth College	LOPASCHUK, GD (corresponding author), UNIV ALBERTA, CARDIOVASC DIS RES GRP, 423 HERITAGE MED RES BLDG, EDMONTON T6G 2S2, AB, CANADA.				NIDDK NIH HHS [DK35712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCUITTO RJ, 1989, AM J PHYSIOL, V256, pH9, DOI 10.1152/ajpheart.1989.256.1.H9; AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; BIANCHI A, 1992, J CELL BIOCHEM, V48, P86, DOI 10.1002/jcb.240480113; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1981, BIOCHIM BIOPHYS ACTA, V665, P628, DOI 10.1016/0005-2760(81)90282-4; BREUER E, 1968, BIOL NEONATORUM, V12, P54; COOK GA, 1984, J BIOL CHEM, V259, P2030; COOK GA, 1992, MOL CELL BIOCHEM, V116, P39, DOI 10.1007/BF01270567; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; ESSER V, 1993, J BIOL CHEM, V268, P5817; FISHER DJ, 1981, PEDIATR RES, V15, P843, DOI 10.1203/00006450-198115050-00003; FISHER DJ, 1980, AM J PHYSIOL, V238, pH399, DOI 10.1152/ajpheart.1980.238.3.H399; GHADIMINEJAD I, 1991, BIOCHIM BIOPHYS ACTA, V1083, P166, DOI 10.1016/0005-2760(91)90038-J; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; ITOI T, 1988, H JPN PEDIATR SOC, V92, P1879; IVERSON AJ, 1990, BIOCHEM J, V269, P365, DOI 10.1042/bj2690365; JONES CT, 1985, PHYSIOL REV, V65, P357, DOI 10.1152/physrev.1985.65.2.357; KERNER J, 1994, J BIOL CHEM, V269, P8209; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KING MT, 1988, METHOD ENZYMOL, V166, P70; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPASCHUK GD, 1990, AM J PHYSIOL, V258, pH1274, DOI 10.1152/ajpheart.1990.258.5.H1274; LOPASCHUK GD, 1991, AM J PHYSIOL, V261, pH1698, DOI 10.1152/ajpheart.1991.261.6.H1698; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LUO X, 1989, P NATL ACAD SCI USA, V86, P1511; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MEDINA JM, 1985, BIOL NEONATE, V48, P237, DOI 10.1159/000242176; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; PRIPBUUS C, 1990, BIOCHEM J, V269, P409, DOI 10.1042/bj2690409; ROLPH TP, 1983, J DEV PHYSIOL, V5, P31; SADDIK M, 1993, J BIOL CHEM, V268, P25836; SIM ATR, 1988, FEBS LETT, V233, P294, DOI 10.1016/0014-5793(88)80445-9; THAMPY KG, 1985, J BIOL CHEM, V260, P6318; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; TOMEC RJ, 1975, ARCH BIOCHEM BIOPHYS, V170, P716, DOI 10.1016/0003-9861(75)90169-1; TRUMBLE GE, 1991, LIFE SCI, V49, P39, DOI 10.1016/0024-3205(91)90577-X; WARSHAW JB, 1970, J CELL BIOL, V44, P354, DOI 10.1083/jcb.44.2.354; WERNER JC, 1981, AM J PHYSIOL, V241, pE364, DOI 10.1152/ajpendo.1981.241.5.E364; WERNER JC, 1987, PEDIATR RES, V22, P552, DOI 10.1203/00006450-198711000-00016; WERNER JC, 1989, AM J PHYSIOL, V256, pE315, DOI 10.1152/ajpendo.1989.256.2.E315; WINZ R, 1994, J BIOL CHEM, V269, P14438; WITTELS B, 1965, J CLIN INVEST, V44, P1639, DOI 10.1172/JCI105270; WITTERS LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P413, DOI 10.1006/abbi.1994.1058; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; WITTERS LA, 1988, P NATL ACAD SCI USA, V85, P5473, DOI 10.1073/pnas.85.15.5473; WOOD JM, 1975, J BIOL CHEM, V250, P3062	49	116	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25871	25878						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929291				2022-12-25	WOS:A1994PQ49100093
J	MISRA, RP; BONNI, A; MIRANTI, CK; RIVERA, VM; SHENG, M; GREENBERG, ME				MISRA, RP; BONNI, A; MIRANTI, CK; RIVERA, VM; SHENG, M; GREENBERG, ME			L-TYPE VOLTAGE-SENSITIVE CALCIUM-CHANNEL ACTIVATION STIMULATES GENE-EXPRESSION BY A SERUM RESPONSE FACTOR-DEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS TRANSCRIPTION; MULTIPLE SEQUENCE ELEMENTS; IMMEDIATE EARLY GENES; DNA-BINDING ACTIVITY; PROTEIN-KINASE; MESSENGER-RNA; HIPPOCAMPAL-NEURONS; SIGNALING PATHWAYS; PRIMARY CULTURES; MAMMALIAN-CELLS	A mechanism by which calcium-induced signals are transduced to the nucleus to activate transcription of the c-fos proto-oncogene has been characterized. The serum response element (SRE), a region of the c-fos gene which controls growth factor-induced transcription, is now shown to mediate c-fos transcription in response to activation of L-type voltage-sensitive calcium channels. Calcium-dependent transcriptional activation through the SRE is mediated by the serum response factor (SRF). Membrane depolarization induces phosphorylation of SRF at Ser-103, an event shown to enhance the ability of SRF to bind the SRE. Ca2+-induced SRF phosphorylation occurs via a pathway that may involve Ca2+/calmodulin-dependent kinases.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Miranti, Cindy/AAJ-3783-2020	Rivera, Victor/0000-0002-7258-3001	NINDS NIH HHS [NS28829] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028829, R01NS028829] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOULDEN AM, 1992, MOL CELL BIOL, V12, P4769, DOI 10.1128/MCB.12.10.4769; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HENSON PI, 1992, ANNU REV BIOCHEM, V61, P559; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; LEREA LS, 1993, NEURON, V10, P31, DOI 10.1016/0896-6273(93)90239-N; LEREA LS, 1992, J NEUROSCI, V12, P2973, DOI 10.1523/JNEUROSCI.12-08-02973.1992; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; SZEKELY AM, 1990, MOL PHARMACOL, V38, P624; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1990, CANCER BIOL, V1, P47; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191	50	143	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 14	1994	269	41					25483	25493						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ491	7929249				2022-12-25	WOS:A1994PQ49100042
J	BARON, AJ; STEVENS, C; WILMOT, C; SENEVIRATNE, KD; BLAKELEY, V; DOOLEY, DM; PHILLIPS, SEV; KNOWLES, PF; MCPHERSON, MJ				BARON, AJ; STEVENS, C; WILMOT, C; SENEVIRATNE, KD; BLAKELEY, V; DOOLEY, DM; PHILLIPS, SEV; KNOWLES, PF; MCPHERSON, MJ			STRUCTURE AND MECHANISM OF GALACTOSE-OXIDASE - THE FREE-RADICAL SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OROTIDINE-5'-PHOSPHATE DECARBOXYLASE GENE; ASPERGILLUS-NIDULANS; DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; TRANSFORMATION; RESONANCE; PROTEINS; NUCLEAR; CLONING	Crystallographic and spectroscopic studies on galactose oxidase have shown that the active site involves a free radical on tyrosine 272, one of the ligands coordinated to the Cu2+ cofactor. A novel thioether bond between tyrosine 272 and cysteine 228, and a stacking tryptophan 290, over this bond, are features of the crystal structure. The present study describes the development of a high level heterologous expression system for galactose oxidase and the construction of mutational variants at these key active site residues. The expressed wildtype enzyme and mutational variants (W290H and C228G) have been characterized by x-ray crystallography, visible spectroscopy, and catalytic activity measurements. A further variant protein, Y272F, could not be purified. The data establish that the thioether bond and stacking tryptophan are essential for activity and further support a role for tryptophan 290 as a component of the free radical site.	UNIV LEEDS, DEPT BIOCHEM & MOLEC BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; MONTANA STATE UNIV, DEPT CHEM & BIOCHEM, BOZEMAN, MT 59717 USA	University of Leeds; Montana State University System; Montana State University Bozeman				McPherson, Michael/0000-0002-0719-6427; Phillips, Simon/0000-0001-8922-0250				AMARAL D, 1963, J BIOL CHEM, V238, P2281; BABCOCK GT, 1992, J AM CHEM SOC, V114, P3727, DOI 10.1021/ja00036a023; BALLANCE DJ, 1985, GENE, V36, P321, DOI 10.1016/0378-1119(85)90187-8; BALLANCE DJ, 1983, BIOCHEM BIOPH RES CO, V112, P284, DOI 10.1016/0006-291X(83)91828-4; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; ETTINGER MJ, 1974, BIOCHEMISTRY-US, V13, P1242, DOI 10.1021/bi00703a029; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRIES DG, 1984, BIOCHEM J, V223, P551, DOI 10.1042/bj2230551; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; ITO N, 1992, FARADAY DISCUSS, V93, P75, DOI 10.1039/fd9929300075; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JUDICE JK, 1993, SCIENCE, V261, P1578, DOI 10.1126/science.8103944; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Knowles P. F., 1994, PERSPECTIVES BIO INO, V2, P207; KOSMAN DJ, 1974, ARCH BIOCHEM BIOPHYS, V165, P456, DOI 10.1016/0003-9861(74)90271-9; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; KWIATKOWSKI LD, 1981, J INORG BIOCHEM, V14, P209, DOI 10.1016/S0162-0134(00)80001-X; MCPHERSON M.J., 1992, MOL PLANT PATHOL, VI, P123; MCPHERSON MJ, 1992, J BIOL CHEM, V267, P8146; MESSER W, 1988, CELL, V54, P735, DOI 10.1016/S0092-8674(88)90911-7; OAKLEY BR, 1987, GENE, V61, P385, DOI 10.1016/0378-1119(87)90201-0; OGEL ZB, 1994, MYCOL RES, V98, P474, DOI 10.1016/S0953-7562(09)81207-0; OGEL ZB, 1993, THESIS U LEEDS UK, P81; ORMO M, 1992, J BIOL CHEM, V267, P8711; ROWLANDS RT, 1973, MOL GEN GENET, V126, P201, DOI 10.1007/BF00267531; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STURA EA, 1991, J CRYST GROWTH, V110, P270, DOI 10.1016/0022-0248(91)90896-D; WARD M, 1990, BIO-TECHNOL, V8, P435, DOI 10.1038/nbt0590-435; WHITTAKER MM, 1988, J BIOL CHEM, V263, P6074; WHITTAKER MM, 1993, BIOPHYS J, V64, P762, DOI 10.1016/S0006-3495(93)81437-1; WHITTAKER MM, 1989, J BIOL CHEM, V264, P7104; WHITTAKER MM, 1990, J BIOL CHEM, V265, P9610	39	128	131	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					25095	25105						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929198				2022-12-25	WOS:A1994PQ49000087
J	NISHIMURA, K; HIGAKI, T; OKAMURA, H; TANASE, S				NISHIMURA, K; HIGAKI, T; OKAMURA, H; TANASE, S			FUNCTIONAL-ROLE OF THE AMINO-TERMINAL MOBILE SEGMENT IN CATALYSIS BY PORCINE CYTOSOLIC ASPARTATE-AMINOTRANSFERASE - CRITICAL IMPORTANCE OF VAL(17) AND PHE(18) FOR PRODUCTIVE BINDING OF SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DOMAIN CLOSURE; ENZYME; DEHYDROGENASE; RESOLUTION; YEAST; LOOP	A notable feature of porcine cytosolic aspartate aminotransferase is the closure of the active site cleft by a mobile amino-terminal segment (residues 15-40) upon binding substrate. The functional roles of Va1(17) and Phe(18), residues that are part of the mobile loop, have been studied in the site-directed mutants in which the size and hydrophobic nature of these residues have been changed. Absorption, circular dichroism spectra, susceptibility to protease 401, and thermal stability did not differ appreciably between wild type and mutant enzymes. In the overall transamination between aspartate and 2-oxoglutarate, V17A represented a typical K-m mutant while V17I retained the substrate binding affinity fairly well. In contrast, replacement of Phe(18) by Ala resulted in a large decrease in both catalytic rate and binding affinity for substrates. F18W, F18Y, and F18H showed a moderate decrease in k(cat) and a considerable increase in K-m values. Single-turnover reactions with four individual substrates yielded analogous results to those obtained for the overall reaction and, in addition, revealed that k/K-d values of mutants F18A and F18H were over 10 times lower for C-5 substrates (glutamate and 2-oxoglutarate) than those for C-4 substrates (aspartate and oxalacetate). All mutant enzymes showed variously increased K-d values for substrate analogs such as 2-methylaspartate, succinate, and glutarate. H-1 MMR observations of F18H, in which His(18) served as a built-in probe, were in accord with the behavior that would be expected from the conformational transition. We conclude that, although Val(17) and Phe(18) may not be essential for catalysis, the presence of a bulky residue of appropriate size at each position is critical for productive binding of substrate.	KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT OBSTET & GYNECOL,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,COLL MED SCI,KUMAMOTO 862,JAPAN	Kumamoto University; Kumamoto University; Kumamoto University								Arnone A, 1985, TRANSAMINASES, P138; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; CAMPBELL ID, 1973, J MAGN RESON, V11, P172, DOI 10.1016/0022-2364(73)90004-8; Cleland W W, 1979, Methods Enzymol, V63, P103; DREUSICKE D, 1988, J MOL BIOL, V203, P1021, DOI 10.1016/0022-2836(88)90126-X; FASELLA P, 1966, BIOCHEMISTRY-US, V5, P197, DOI 10.1021/bi00865a026; FUKUMOTO Y, 1991, J BIOL CHEM, V266, P4187; GERSTEIN M, 1991, J MOL BIOL, V220, P133, DOI 10.1016/0022-2836(91)90387-L; INOUE K, 1991, BIOCHEMISTRY-US, V30, P7796, DOI 10.1021/bi00245a019; JANSONIUS JN, 1985, TRANSAMINASES, P110; JENKINS WT, 1959, J BIOL CHEM, V234, P51; JENKINS WT, 1966, J BIOL CHEM, V241, P5667; KAMITORI S, 1990, J BIOCHEM-TOKYO, V108, P175, DOI 10.1093/oxfordjournals.jbchem.a123178; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; LESK AM, 1984, J MOL BIOL, V174, P175, DOI 10.1016/0022-2836(84)90371-1; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MORINO Y, 1984, J BIOL CHEM, V259, P3877; NAGASHIMA F, 1989, BIOCHEMISTRY-US, V28, P1153, DOI 10.1021/bi00429a033; NAGASHIMA F, 1986, J BIOCHEM, V99, P1017, DOI 10.1093/oxfordjournals.jbchem.a135565; PAN QW, 1993, J BIOL CHEM, V268, P24758; Sambrook J, 1989, MOL CLONING LABORATO; SKARZYNSKI T, 1988, J MOL BIOL, V203, P1097, DOI 10.1016/0022-2836(88)90130-1; WIERENGA RK, 1992, J MOL BIOL, V224, P1115, DOI 10.1016/0022-2836(92)90473-W	23	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 7	1994	269	40					24712	24718						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PQ490	7929145				2022-12-25	WOS:A1994PQ49000032
